"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT01049009","The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension",,"Completed","Has Results","High Blood Pressure","Drug: Nebivolol|Drug: Metoprolol XL","Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks|Endothelial Function Measured by Forearm Blood Flow (FBF) at 24 Weeks","Emory University|Forest Laboratories","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 4","91","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00017946","December 2009","June 2012","June 2012","January 14, 2010","December 19, 2014","April 11, 2017","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01049009"
2,"NCT03459807","Blood Pressure Lowering in Dialysis (BOLD) Trial","BOLD","Completed","No Results Available","Blood Pressure|End Stage Renal Disease on Dialysis (Diagnosis)|Chronic Kidney Diseases|Chronic Kidney Disease Stage 5","Drug: Anti-Hypertensive medications|Procedure: Dry Weight Adjustment","Feasibility - screen:enrollment ratio|Adherence to assigned treatment arm|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]","University of California, San Francisco|University of Washington","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBD123","March 23, 2018","December 6, 2018","January 3, 2019","March 9, 2018",,"July 23, 2019","UCSF, San Francisco, California, United States|University of Washington, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT03459807/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT03459807/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03459807"
3,"NCT03629340","Metformin for Pulmonary Hypertension HFpEF",,"Active, not recruiting","No Results Available","Pulmonary Hypertension|Heart Failure","Drug: Metformin|Drug: Placebo oral capsule","The primary endpoint of the trial will be mean pulmonary artery pressure (mPAP) during submaximal exercise as compared between placebo and metformin at 12 weeks (i.e. the week 12 RHC of placebo vs week 12 RHC of metformin).","Marc A. Simon|National Institute on Aging (NIA)|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 2","32","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO18030354|R01AG058659","February 26, 2019","June 2023","December 2023","August 14, 2018",,"April 1, 2020","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03629340"
4,"NCT01779453","A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia",,"Completed","No Results Available","Hypercholesterolemia","Drug: ETC-1002|Drug: Placebo|Drug: Atorvastatin","Area under the plasma concentration versus time curve (AUC) of atorvastatin and its active metabolites|Peak plasma concentration (Cmax) of atorvastatin and its active metabolites|Number of subjects with adverse events, clinical lab abnormalities and other safety findings|Percent change in LDL-C|Percent change in other lipids and cardio-metabolic risk factors","Esperion Therapeutics","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1002-007","December 2012","August 2013","August 2013","January 30, 2013",,"March 29, 2019","Indianapolis, Indiana, United States|Louisville, Kentucky, United States|Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01779453"
5,"NCT01007994","Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients",,"Active, not recruiting","No Results Available","Hypertension Secondary to Kidney Transplant","Drug: New Medication: Enalapril, Isradipine, Propranolol","Proportion of subjects in each of the treatment arms who change from non-dipper to dipper status|Change in night-time systolic/diastolic blood pressure|Change in left ventricular mass index|Change in albumin:creatinine ratio|Change in estimated glomerular filtration rate|Change in pulse wave velocity|Association of serum adiponectin levels and SNPs of adiponectin with outcomes","Northwell Health|Children's Hospital of Philadelphia","All","5 Years to 21 Years   (Child, Adult)","Phase 2|Phase 3","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","09-054","November 2009","April 2020","April 2020","November 5, 2009",,"May 29, 2019","Cohen Children's Medical Center of NY, New Hyde Park, New York, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01007994"
6,"NCT01074918","Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients",,"Withdrawn","No Results Available","Pre-hypertension|Hypertension","Drug: Potassium, Magnesium, Citrate|Drug: Potassium Chloride","Blood Pressure","University of Texas Southwestern Medical Center","All","21 Years to 95 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","012007-080","September 2009","September 2012","December 2012","February 24, 2010",,"February 11, 2019","Dallas VA Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01074918"
7,"NCT01897727","Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment",,"Completed","Has Results","Obstructive Sleep Apnea|Resistant Hypertension|Hyperaldosteronism","Drug: Spironolactone|Drug: BP medication uptitration","Severity of Obstructive Sleep Apnea","University of Alabama at Birmingham|National Heart, Lung, and Blood Institute (NHLBI)","All","19 Years to 80 Years   (Adult, Older Adult)","Not Applicable","41","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F080821012|R01HL075614","January 2009","April 2012",,"July 12, 2013","January 15, 2014","January 15, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT01897727"
8,"NCT01806324","A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects",,"Completed","No Results Available","Hypertension|Hyperlipidemia","Drug: HL040XC|Drug: Losartan + Atorvastatin","Cmax|AUC","HanAll BioPharma Co., Ltd.","Male","19 Years to 50 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HL-040XC-US-001","April 2012","November 2012","December 2012","March 7, 2013",,"March 7, 2013","Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01806324"
9,"NCT01894217","Statin Therapy to Improve Medication Adherence",,"Completed","No Results Available","Hypercholesterolemia|HMG COA Reductase Inhibitor Adverse Reaction","Genetic: Genetic testing and reporting for SLCO1B1*5 allele","Change in Beliefs about Medicines|Change in Medication adherence|Percentage of patients who meets their National Cholesterol Education Program (NCEP) low-density lipoprotein cholesterol (LDLc)goals|Number of new statin prescriptions written|Patient reported medication utilization, as a surrogate for medication adherence","Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 1","63","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pro00029836","May 2011","December 2012","April 2014","July 10, 2013",,"January 8, 2015","Duke Center for Living, Durham, North Carolina, United States|Duke Primary Care Clinic at Pickett Road, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01894217"
10,"NCT01026311","Coenzyme Q10 in Older Athletes Treated With Statin Medications",,"Completed","No Results Available","Muscle Weakness|Myalgia|Side Effects of Statins","Drug: Coenzyme q 10|Drug: placebo","The primary objective of this study is to test if oral coenzyme Q10 is superior to placebo in improving oxygen consumption by mitochondria as measured by cardiopulmonary fitness testing for anaerobic threshold in this population","Richard Deichmann, MD|Ochsner Health System","All","50 Years and older   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","09-076","November 2009","March 2011","March 2011","December 4, 2009",,"May 3, 2012","Ochsner, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT01026311"
11,"NCT02133872","Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients",,"Recruiting","No Results Available","Hypertension","Drug: Minocycline 100mg Group|Drug: Minocycline 200mg Group","Reduction in High Blood Pressure|Renal function changes","University of Florida|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","101","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB2015005 -N|RO1HL3361028|2013-00102 Study 1|1R01HL132448-01","October 2014","May 2020","May 2020","May 8, 2014",,"June 5, 2019","UF Health Cardiovascular Clinic, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02133872"
12,"NCT02489045","Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension",,"Completed","No Results Available","Liver Diseases|Portal Hypertension","Drug: SHAPE measurement (Sonazoid ultrasoud contrast agent)","SHAPE liver pressure measurements vs catheter pressures|Correlating SHAPE results with blood work and concomitant imaging in portal hypertension patients","Thomas Jefferson University|University of Pennsylvania|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","21 Years and older   (Adult, Older Adult)","Phase 4","178","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","14F.113|R01DK098526","April 6, 2015","March 31, 2019","March 31, 2019","July 2, 2015",,"September 24, 2019","University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Dept of Radiology, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02489045"
13,"NCT01351753","Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity","REVIVE","Suspended","No Results Available","Obesity|Metabolic Syndrome X","Drug: Metformin|Drug: Orlistat|Drug: Topiramate|Drug: Placebo","Weight (change from baseline)|Brachial artery flow mediated dilatation (change from baseline)|Number of subjects with mild, moderate and serious adverse events.|Systolic and diastolic systemic arterial pressure (change from baseline)|Fasting lipids, glucose and other biomarkers of obesity risk (change from baseline)|Mood, anxiety, quality of life and cognitive function (change from baseline)|Body fat distribution (change from baseline)|Pulse wave velocity (PWV) and aortic augmentation pressure (change from baseline)|Peripheral arteriolar tonometry","University of Iowa","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 2","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201012738","March 2011","October 2019","October 2020","May 11, 2011",,"January 23, 2020","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT01351753"
14,"NCT02517697","Oral Nitrite Trial for Hypertension and Metabolic Syndrome","ONPC","Not yet recruiting","No Results Available","Metabolic Syndrome|Hypertension","Drug: 14 Nitrogen (N) Sodium Nitrite|Drug: Placebo","Change in insulin sensitivity (i.e. insulin stimulated glucose disposal)|Change in systolic blood pressure|Change in mean arterial pressure|Change in diastolic blood pressure|Change in methemoglobin level","Gladwin, Mark, MD|University of Pittsburgh","All","18 Years to 60 Years   (Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO15050540","March 2020","July 2024","July 2024","August 7, 2015",,"December 17, 2019","Montefiore Hospital of UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02517697"
15,"NCT01499134","Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure","ENCOMPASS","Completed","Has Results","Peripheral Artery Disease|Hypertension","Drug: nebivolol|Drug: Metoprolol succinate","Peak Walking Time (PWT)|Ankle-brachial Index (ABI)|Claudication Onset Time (COT)|Walking Impairment Questionnaire (WIQ) - Change Calf Pain|Walking Impairment Questionnaire (WIQ) - Change in Buttock Pain|Walking Impairment Questionnaire (WIQ) - Change in WIQ Distance Score|Walking Impairment Questionnaire (WIQ) - Change in WIQ Speed Score|Walking Impairment Questionnaire (WIQ) - Change in WIQ Stairs Score","Thomas Jefferson University|Forest Laboratories","All","18 Years and older   (Adult, Older Adult)","Phase 3","17","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11C.18","August 2011","June 2014","June 2014","December 26, 2011","December 3, 2014","December 17, 2014","Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01499134"
16,"NCT03122730","VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB",,"Completed","No Results Available","Pulmonary Hypertension","Combination Product: VentaProst","Determination of the equivalent dose of VentaProst necessary to achieve a pharmacodynamic response that is comparable to Standard of Care|Treatment-Emergent Adverse Events (TEAEs)|Effects on pulmonary vascular resistance|Effects on oxygenation status|Effects on fraction of inspired oxygen (FiO2)|Effects on cardiovascular medication usage","Aerogen Pharma Limited","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APC-VP-CLN-001","August 23, 2017","March 1, 2019","May 30, 2019","April 21, 2017",,"May 31, 2019","Stanford University Medical Center, Stanford, California, United States|Rush University Medical Center, Chicago, Illinois, United States|Tufts Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03122730"
17,"NCT01432106","The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome","SAAVE","Withdrawn","No Results Available","Hypertension|Metabolic Syndrome","Drug: Aliskerin/Valsartan and Rampiril","Mean Change in SBP from baseline to 10 weeks (2 weeks on initial dose & 6 weeks on higher dose)","University of Michigan|Novartis Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPP100AUS20T","February 2011","December 2012","December 2012","September 12, 2011",,"November 18, 2013","University of Michigan Health System, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01432106"
18,"NCT01468571","Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension",,"Unknown status","No Results Available","Pulmonary Hypertension","Drug: Spironolactone|Drug: Placebo","Change in biomarker levels in the spironolactone treated as compared to placebo treated group.|Number of adverse events in patients treated with spironolactone as compared to placebo.|Change in six-minute walk distance from baseline to week 8 and week 16.|Composite end-point","Baylor College of Medicine|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","H24178|K23HL093214","July 2011","July 2015","December 2015","November 9, 2011",,"May 8, 2015","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01468571"
19,"NCT01065350","A Comparison of Ketofol (Ketamine and Propofol Admixture) Versus Propofol as Induction Agents on Hemodynamic Parameters",,"Completed","Has Results","Blood Pressure","Drug: Propofol|Drug: Ketamine","Percent of Subjects With a Greater Than 20% Decrease in Systolic Blood Pressure (SBP) Following Induction of General Anesthesia|Percent of Subjects With a Greater Than 20% Decrease in Diastolic Blood Pressure (DBP) Following Induction of General Anesthesia|Percent of Subjects With a Greater Than 20% Decrease in Mean Arterial Pressure (MAP) Following Induction of General Anesthesia|Average Change in Cardiac Output (CO)|Average Change in Cardiac Index (CI)|Average Change in Heart Rate (HR)|Average Change in Systolic Blood Pressure (SBP)|Average Change in Diastolic Blood Pressure (DBP)|Average Change in Mean Arterial Pressure (MAP)|Average Change in Total Peripheral Resistance (TPR)|Average Change in Total Peripheral Resistance Index (TPRI)|Average Change in Stroke Volume (SV)|Average Change in Stroke Volume Index (SVI)|Average Change in Stroke Volume Variation (SVV)","Mayo Clinic|Dartmouth-Hitchcock Medical Center","All","18 Years to 60 Years   (Adult)","Not Applicable","85","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","22063","December 2010","March 2011","March 2011","February 9, 2010","May 3, 2013","May 3, 2013","Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT01065350"
20,"NCT01206062","Systolic Blood Pressure Intervention Trial","SPRINT","Active, not recruiting","Has Results","Hypertension","Drug: Intensive control of SBP|Drug: Standard control of SBP","Number of Participants With First Occurrence of a Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Stroke, Heart Failure (HF), or CVD Death|Number of Participants With All-cause Mortality|Number of CKD Participants Who Experienced a 50% Decline From Baseline eGFR|Participants Who Developed End Stage Renal Disease|Dementia|Decline in Cognitive Function|Small Vessel Cerebral Ischemic Disease","National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Aging (NIA)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Neurological Disorders and Stroke (NINDS)|Wake Forest University Health Sciences","All","50 Years and older   (Adult, Older Adult)","Not Applicable","9361","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","SPRINT|268200900040C-1-0-1","October 2010","July 2016","November 2018","September 21, 2010","December 4, 2017","October 18, 2018","Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT01206062/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT01206062/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT01206062"
21,"NCT03640312","Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension","QUARTET USA","Recruiting","No Results Available","Hypertension","Drug: QUARTET LDQT|Drug: Candesartan","Change in Mean Systolic Blood Pressure|Mean Systolic Blood Pressure|Mean 24-Hour Blood Pressure|Mean Daytime Blood Pressure|Mean Nighttime Blood Pressure|Proportion of dippers|Change in Mean Diastolic Blood Pressure|Mean Diastolic Blood Pressure|Proportion of patients with hypertension control|Proportion of patients requiring step up treatment|Proportion of patients with adverse event free hypertension control|Medication Adherence|Health-related quality of life","Northwestern University|ACCESS Community Health Network|University of Sydney","All","18 Years and older   (Adult, Older Adult)","Phase 2","365","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STU00205834","August 30, 2019","November 30, 2021","December 30, 2021","August 21, 2018",,"September 3, 2019","ACCESS Martin T. Russo Family Health Center, Bloomingdale, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03640312"
22,"NCT01120613","Post Kidney Transplant Nocturnal Hypertension Prevalence and Management Study",,"Withdrawn","No Results Available","Hypertension","Drug: Chronotherapy","Percent drop in mean SBP at night time compared to mean SBP at day time|Urine Microalbumin to creatinine ratio|Change in Glomerular filtration rate as measured by MDRD equation.|24 hour mean systolic Blood Pressure (SBP) Control","Northwell Health","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-015A","April 2010","August 2010",,"May 11, 2010",,"May 30, 2013","North Shore Long Island Jewish Hospital, Great Neck, New York, United States",,"https://ClinicalTrials.gov/show/NCT01120613"
23,"NCT01403922","To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension",,"Terminated","No Results Available","Chronic Hypertension","Drug: TC-5214","Part 1: To measure the effect of TC-5214 on sitting blood pressure in patients with chronic hypertension.|Part 2: To measure the effect of TC-5214 combined with treatment with the common classes of anti-hypertensive medication (calcium channel blockers, beta blockers, angiotensin converting enzyme inhibitors) on sitting blood pressure.|To examine the safety and tolerability of TC-5214.|The concentration of TC-5214 in plasma will be measured.","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","D4130C00010","August 2011","August 2012","August 2012","July 27, 2011",,"October 2, 2012","Research Site, Overland Park, Kansas, United States|Research Site, Willingboro, New Jersey, United States|Research Site, Berlin, Germany|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01403922"
24,"NCT00986986","Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels",,"Completed","Has Results","HIV Infections|Dyslipidemia|Endothelial Dysfunction","Drug: extended release niacin","Change in Flow-mediated Vasodilation (FMD) From Baseline to Study Week 12|Flow Mediated Vasodilation|High-density Lipoprotein Cholesterol (HDL) Change From Baseline to Study Week 12|HDL","University of Hawaii|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENDO|Department of Defense","November 2007","April 2010","April 2010","September 30, 2009","December 18, 2012","December 18, 2012","University of Hawaii - Hawaii Center for AIDS, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT00986986"
25,"NCT01979601","Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia",,"Completed","No Results Available","Hypercholesterolemia","Drug: LGT209|Drug: Placebo","Number of patients with adverse events, serious adverse events and death|Change from baseline in low density lipoprotein-cholesterol (LDL-C) concentration in healthy volunteers|Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) in healthy volunteers|Pharmacokinetics of LGT209: : Area under the serum concentration-time curve from time zero to infinity (AUC0-inf) of LGT209 in patients and healthy volunteers following intravenous administration|Pharmacokinetics of LGT209: observed maximum serum concentrations (Cmax) of LGT209 in patients and healthy volunteers following intravenous administration|Pharmacokinetics of LGT209: Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) of LGT209 in patients and healthy volunteers following intravenous administration|Pharmacokinetics of LGT209: Elimination half-life associated with the terminal slope of a semi-logarithmic concentration-time curve (T1/2) of LGT209 in patients and healthy volunteers following intravenous administration|Number of healthy volunteers with adverse events, serious adverse events and death|Pharmacokinetics of intravenous LGT209 in relationship to concentrations of PCSK9 and LDL-C in patients and healthy volunteers|Change from baseline in low density lipoprotein-cholesterol (LDL-C) concentration in patients|Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients|Pharmacokinetics of LGT209: Area under the serum concentration-time curve from time zero to time 't' (AUC0-t)|Pharmacokinetics of LGT209: Dose-normalized area under the serum concentration-time curve (AUC/D) of LGT209 in patients and healthy volunteers following intravenous administration|Pharmacokinetics of LGT209: Dose-normalized maximum serum concentrations (Cmax/D) of LGT209 in patients and healthy volunteers following intravenous administration|Pharmacokinetics of LGT209: Volume of distribution during the terminal elimination phase (Vz) of LGT209 in patients and healthy volunteers following intravenous administration|Pharmacokinetics of LGT209: Volume of distribution at steady state (Vss) of LGT209 in patients and healthy volunteers following intravenous administration|Pharmacokinetics of LGT209: Mean residence time (MRT) of LGT209 in patients and healthy volunteers following intravenous administration|Pharmacokinetics of LGT209: the systemic (or total body) clearance from serum following intravenous administration","Novartis Pharmaceuticals|Novartis","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLGT209X2101","December 2010","November 2011","November 2011","November 8, 2013",,"December 10, 2013","Novartis Investigative Site, Miami Gardens, Florida, United States|Novartis Investigative Site, Fargo, North Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01979601"
26,"NCT03814317","Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension","SAPPHIRE","Recruiting","No Results Available","Sarcoidosis|Precapillary Pulmonary Hypertension|Interstitial Lung Disease","Drug: Inhaled Treprostinil","PVR by Right heart catheterization (RHC)|mPAP by Right heart catheterization (RHC)|Change in 6-Minute Walk Test (6MWT)|Change in Cardiac MRI parameters|Change in Pulmonary Function Testing|Change in Brain Natriuretic Peptide (BNP)|Change in WHO Functional Class (WHO FC)","University of Florida|United Therapeutics","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OCR19684|20192572","January 30, 2020","September 2020","March 2021","January 24, 2019",,"February 13, 2020","University of Florida, Division of Pulmonary and Critical Care Medicine, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03814317"
27,"NCT01959971","Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol",,"Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab|Drug: Placebo","Percent change in Fractional Clearance Rate of apolipoprotein B (apoB) in Low Density Lipoproteins (pools/day) in plasma during alirocumab treatment|Change in lipids turnover parameters measured in isolated Very Low Density Lipoproteins (VLDL), Intermediate Density Lipoproteins (IDL), Low Density Lipoproteins (LDL) and High Density Lipoproteins (HDL)|Change in post-heparin hepatic lipase and lipoprotein lipase activities|Change in lipids and apolipoproteins in plasma lipids panel|Assessment of Lipoprotein particle size profiles|Assessment of serum concentrations of PCSK9|Assessment of safety parameters (clinical laboratory, ECG, vital signs)|Assessment of the serum concentration of alirocumab|Assessment of the serum concentration of anti-alirocumab antibodies","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","PDY13670|U1111-1141-4567","December 2013","May 2015","May 2015","October 10, 2013",,"May 2, 2017","Investigational Site Number 840001, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01959971"
28,"NCT01645826","Efficacy Study of Cardizem in Pulmonary Arterial Hypertension",,"Withdrawn","No Results Available","Idiopathic Pulmonary Arterial Hypertension|Primary Pulmonary Hypertension|Pulmonary Arterial Hypertension|Familial Primary Pulmonary Hypertension","Drug: Diltiazem Hydrochloride|Drug: Sugar Pill","Six Minute Walk Distance|Dyspnea Score|Quality of Life Score|Pulse Oximetry","University of South Florida","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pro00004379","July 2012","September 2014","September 2014","July 20, 2012",,"November 20, 2018","University of South Florida, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01645826"
29,"NCT02167035","Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: Combigan Two Times Daily (BID)|Drug: Simbrinza Three Times Daily (TID)","Intraocular Pressure|Ocular Symptom and Tolerability Questionaire","Cornerstone Health Care, PA|Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","43","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","TEP001","August 2014","March 2018","March 2018","June 18, 2014","October 24, 2018","October 24, 2018","Cornerstone Health Care, High Point, North Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02167035/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02167035/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02167035"
30,"NCT03359395","Pre-medication With Alfentanil vs Placebo During ECT",,"Completed","No Results Available","Blood Pressure|Electroconvulsive Therapy","Drug: Alfentanil|Drug: Placebos","Systolic blood pressure change|Diastolic blood pressure change|Heart rate|Antihypertensive medication use","Wake Forest University Health Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","IRB00045800","June 4, 2018","February 17, 2020","February 17, 2020","December 2, 2017",,"February 27, 2020","Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03359395"
31,"NCT03131167","Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma",,"Completed","Has Results","Primary Open-angle Glaucoma (POAG)|Ocular Hypertension","Drug: SHP639 (n=60)|Drug: Placebo Comparator (n=24)","Number of Participants With Treatment Emergent Adverse Event (TEAE)|Change From Baseline in Intra Ocular Pressure (IOP) at Day 29","Shire","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SHP639-101","May 10, 2017","May 30, 2018","May 30, 2018","April 27, 2017","August 7, 2019","August 7, 2019","Central Contact, Lexington, Massachusetts, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03131167/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03131167/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03131167"
32,"NCT03179163","Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans","H2SPharm","Recruiting","No Results Available","Hypertension,Essential","Drug: Captopril Pill|Drug: Enalapril Pill|Drug: Hydrochlorothiazide","laser Doppler blood flow|Systolic Blood Pressure|Diastolic Blood Pressure","Penn State University|National Heart, Lung, and Blood Institute (NHLBI)","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","70","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","STUDY3224|5R01HL093238|120058","July 20, 2016","August 31, 2020","August 31, 2020","June 7, 2017",,"November 1, 2019","Pennsylvania State University, University Park, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03179163"
33,"NCT02285634","The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.",,"Completed","Has Results","Epistaxis|Blood Pressure","Drug: Oxymetazoline 0.05%|Drug: Phenylephrine 0.25%|Drug: Lidocaine 1% plus epinephrine 1:100,000|Drug: Bacteriostatic 0.9% NaCL","Change in Mean Arterial Blood Pressure|Change in Systolic Blood Pressure|Change in Diastolic Blood Pressure|Change in Heart Rate","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14-006312|UL1TR000135","November 2014","December 22, 2016","December 22, 2017","November 7, 2014","October 2, 2018","October 2, 2018","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02285634"
34,"NCT00835120","Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance",,"Completed","Has Results","Metabolic Syndrome|Bipolar Depression|Insulin Resistance","Drug: Pioglitazone","Change in the Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR) Score|Change in Quick Inventory of Depressive Symptoms-Self Report (QIDS-SR16) Total Score|Response Rates on the IDS-CR, Montgomery Asberg Depression Rating Scale (MADRS) and Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR)|Remission Rates Based on IDS-CR, QIDS-SR, and MADRS Scores|Change in Clinical Global Impressions-Bipolar Version (CGI-BP)","University Hospitals Cleveland Medical Center|National Alliance for Research on Schizophrenia and Depression|Takeda Pharmaceuticals North America, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","34","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-08-24","March 2009","April 2013","April 2013","February 3, 2009","October 17, 2014","January 26, 2017","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00835120"
35,"NCT03091920","Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension",,"Completed","No Results Available","Diabetes Mellitus, Type 2|Hypertension","Drug: IW-1973 Oral Tablet|Drug: Placebo Oral Tablet","The number and percentage of all on-study deaths, all Serious Adverse Events (SAEs), and Treatment-Emergent Adverse Events (TEAEs).","Cyclerion Therapeutics","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 2","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","C1973-202","February 28, 2017","July 14, 2017","July 14, 2017","March 27, 2017",,"April 4, 2019","ProSciento, Inc., Chula Vista, California, United States",,"https://ClinicalTrials.gov/show/NCT03091920"
36,"NCT01748994","Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women","Apple/Pear","Completed","No Results Available","Obesity|Metabolic Syndrome","Drug: Pioglitazone|Drug: Placebo","Enrichment of DNA of adipose cells with deuterium|Differentiation of adipose-derived stromo-vascular cultures|Proliferation of adipose-derived stromo-vascular cultures|Apoptosis of adipose-derived stromo-vascular cultures|Size of adipocytes|Number of fat cells|Number of fat cell precursor cells|Body composition|Volume of abdominal fat depots|Lipid accretion in the skeletal muscle cells (intra-myo-cellular lipid)|Lipid accretion in the cells of the liver (intra-hepato-cellular lipid)|Proinflammatory state of adipose-derived stromo-vascular cultures|Glucose tolerance","Pennington Biomedical Research Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Female","18 Years to 40 Years   (Adult)","Not Applicable","49","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","PBRC 10039|5R01DK090607","February 2011","December 2016","December 2016","December 13, 2012",,"August 29, 2018","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT01748994"
37,"NCT01480531","Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm / Dissection","Clevidipine","Withdrawn","No Results Available","Aorta Aneurysm|Dissection of Aorta","Drug: Clevidipine","The use of Clevidipine to maintain clinically acceptable blood pressure.|The incidence of hypotension","Duke University|The Medicines Company","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00030060","December 2011","December 2012","December 2012","November 29, 2011",,"February 11, 2013","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01480531"
38,"NCT01859455","Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins",,"Completed","No Results Available","Hypercholesterolemia|LDL Cholesterol","Drug: LGT209 50 mg|Drug: LGT209 300 mg|Drug: Placebo|Drug: Statins (atorvastatin or simvastatin)","Number of subjects (patients and healthy volunteers) with adverse events, serious adverse events and death|Plasma concentrations of LGT209 following subcutaneous administration|Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) concentration|Change from baseline in low density lipoprotein-cholesterol (LDL-C) concentration|Plasma concentrations of atorvastatin in patients|Plasma concentrations of simvastatin in patients|Serum concentrations of PCSK9","Novartis Pharmaceuticals|Novartis","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLGT209X2105","July 2011","July 2012","July 2012","May 22, 2013",,"March 31, 2017","Novartis Investigative Site, Fort Myers, Florida, United States|Novartis Investigative Site, Miramar, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01859455"
39,"NCT00965055","Ezetimibe in Patients Hypo-responsive to Statins",,"Terminated","Has Results","High Cholesterol|Coronary Artery Disease","Drug: Ezetimibe|Drug: Atorvastatin","LDL-C Reduction|LDL-C Reduction as Well as Changes in TG, HDL, and Non-HDL Cholesterol.","University of California, San Diego|Merck Sharp & Dohme Corp.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","2","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","090948","September 2009","September 2011","September 2012","August 25, 2009","August 21, 2019","August 21, 2019","UCSD Medical Center in Hillcrest Clinical Trials Facility, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00965055"
40,"NCT01939990","Safety Study of Nebivolol for COPD Patients",,"Withdrawn","No Results Available","High Blood Pressure","Drug: Placebo|Drug: Nebivolol","to assess blood pressure control|to assess pulmonary function tests","University of Chicago|Forest Laboratories","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research","11-0720","January 2012","March 2013","March 2013","September 11, 2013",,"January 12, 2016","University of Chicago Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01939990"
41,"NCT03896633","Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt",,"Completed","No Results Available","Glaucoma|Open Angle or Ocular Hypertension","Drug: brinzolamide 1% ophthalmic suspension|Drug: Azopt 1%","Intraocular pressure (IOP)|Change in intraocular pressure (IOP)","Bausch Health Americas, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","637","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","883","February 28, 2018","November 17, 2018","November 17, 2018","April 1, 2019",,"September 6, 2019","Various, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03896633"
42,"NCT03795428","Long-Term, Open Label Extension Study of PB1046 in PAH Subjects Following Completion of Study PB1046-PT-CL-0004","VIP Extend","Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: PB1046 Injection","Incidence and Severity of Adverse Events|Incidence of Clinical Laboratory Abnormalities|Change in Diastolic Blood Pressure from baseline|Change in Systolic Blood Pressure from baseline|Change in Oral Body Temperature from baseline|Change in Respiratory Rate from baseline|Change in Heart Rate from baseline|12-Lead ECG - Incidence of clinically significant abnormal ECG findings as measured by 12 Lead ECG|Incidence of Immunogenicity|Survival|Change from baseline in 6MWD (6 minute walk distance test)|Change from baseline in NT-proBNP|Change from baseline in NYHA/WHO Functional Class (FC)|Change from baseline in emPHasis-10 (Health Related Quality of Life) score|Change from baseline in Borg Dyspnea Index (BDI)|Incidence of Clinical Worsening|Change in REVEAL Registry Risk Calculator Score","PhaseBio Pharmaceuticals Inc.","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PB1046-PT-CL-0006","April 10, 2019","January 15, 2024","February 15, 2024","January 7, 2019",,"February 25, 2020","Emory University, The Emory Clinic, Atlanta, Georgia, United States|University of Rochester Medical Center, Rochester, New York, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03795428"
43,"NCT02278471","The SCCS Polypill Pilot Trial",,"Completed","Has Results","Hypertension|Hyperlipidemia","Drug: Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)","Systolic Blood Pressure|Medication Adherence-Percentage of Pills Taken|LDL Cholesterol|Medication Adherence|Drug Metabolite Profile|Insulin Resistance|Inflammatory Profile","Vanderbilt University|Vanderbilt University Medical Center","All","45 Years to 75 Years   (Adult, Older Adult)","Phase 2","303","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","141583","December 2015","June 27, 2018","June 27, 2018","October 30, 2014","October 1, 2019","December 18, 2019","Franklin Primary Health Center, Mobile, Alabama, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02278471/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02278471"
44,"NCT03810911","Mechanisms of EPO-induced Hypertension","EPIC","Not yet recruiting","No Results Available","Chronic Kidney Disease|Blood Pressure|Anemia","Drug: Darbepoetin","Change in diastolic blood pressure in EPO treated patients compared to delayed start controls|Change in flow mediated dilatation (FMD)|Oxygen-induced change in forearm blood flow (OIC-FBF)|Predictors of change in flow mediated dilatation (FMD)|Change in systolic blood pressure in EPO treated patients|Between group change in hypertension status|Within group change in hypertension status","VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Phase 2","160","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NEPH-005-18S|052387","October 1, 2020","July 15, 2022","January 2, 2023","January 22, 2019",,"April 6, 2020","Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT03810911"
45,"NCT00988364","Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.",,"Unknown status","No Results Available","Metabolic Syndrome","Drug: Simvastatin|Drug: Vytorin|Drug: Placebo|Drug: Ezetimibe","To identify the common factor for L5 prevalence in Metabolic Syndrome patients.|To determine whether Ezetimibe, Simvastatin, and Vytorin can correct the L5- promoting factor and reduce L5 in Metabolic Syndrome.","Baylor College of Medicine|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 4","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Merck-123|MK0653A","October 2009","April 2010","July 2010","October 2, 2009",,"October 6, 2009","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00988364"
46,"NCT00831129","A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs","SIROCO","Completed","Has Results","Pre-diabetes","Drug: Rosiglitazone|Drug: Placebo Rosiglitazone|Drug: Simvastatin","Change in High-sensitivity C-reactive Protein|Change in Urinary Isoprostane|Change in Malondialdehyde|Change in Office Systolic Blood Pressure|Change in Office Diastolic Blood Pressure|Change in (Ambulatory Blood Pressure Monitoring) Systolic Blood Pressure|Change in (Ambulatory Blood Pressure Monitoring) Diastolic Blood Pressure|Change in Low-density Lipoprotein|Change in Triglycerides|Change in High-density Lipoprotein|Change in Glycosylated Haemoglobin|Change in Fasting Blood Glucose|Change in Insulin|Change in Homeostatic Model Assessment for Insulin Resistance|Change in Adiponectin|Change in Body Mass Index","University of Chicago|GlaxoSmithKline","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","53","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","14863B (SIROCO)","September 2006","March 2011","April 2011","January 28, 2009","September 12, 2013","February 10, 2017","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00831129"
47,"NCT02497235","A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935",,"Completed","Has Results","Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents","Drug: TAK-935|Drug: [18F]MNI-792 (tracer)","Cholesterol 24S-Hydroxylase (CH24H) Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 45 Minutes Post-TAK-935 Dose|CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose|CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 10 Hours Post-TAK-935 Dose|CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose|Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods|Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC)","Takeda","All","19 Years to 55 Years   (Adult)","Phase 1","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAK-935_1003|U1111-1170-0452","July 2015","December 2015","January 2016","July 14, 2015","April 11, 2017","April 11, 2017","New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02497235"
48,"NCT02767531","Orlistat for the Treatment of Type I Hyperlipoproteinemia","T1HLP","Active, not recruiting","Has Results","Hyperlipoproteinemia Type I|Hypertriglyceridemia","Drug: Orlistat","Fasting Serum Triglycerides","University of Texas Southwestern Medical Center","All","8 Years to 18 Years   (Child, Adult)","Phase 2","2","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","012013-042","December 2015","May 31, 2018","July 31, 2020","May 10, 2016","February 1, 2019","October 22, 2019","UT Southwestern Medical Center 5323 Harry Hines Blvd, Dallas, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02767531/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02767531"
49,"NCT00850460","Quality of Life in Patients With Statin-Associated Myopathy",,"Terminated","Has Results","Statin Adverse Reaction","Drug: Statins|Drug: Placebo","Individualized Neuromuscular Quality of Life (INQoL) Mean Scores From Week 0 to Week 8|Individualized Short Form-36 (SF-36) Mean Scores (Physical Component) From Week 0 to Week 8","Rockefeller University|Cornell University|Adelphi University","All","40 Years to 60 Years   (Adult)","Phase 4","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)","PAM-0655","February 2009","February 2013","February 2013","February 25, 2009","November 7, 2016","November 7, 2016","Rockefeller University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00850460"
50,"NCT01448239","Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)",,"Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Pain using present pain intensity (PPI) verbal questionnaire|Erythema at injection site by measuring diameter and qualitative assessment|Edema at injection site by measuring diameter and qualitative assessment|Assessment of PK parameter - time to maximum concentration (tmax)|Assessment of PK parameter - maximum concentration (Cmax)|Assessment of PK parameter - area under curve (AUC)|Assessment of PK parameter - cluster of differentiation (CD) biomarker (CD29)|Assessment of PK parameter - terminal elimination half-life (t1/2z)|Pharmacodynamics: Change in LDL-C from baseline|Number of participants with Adverse Events","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PKD12010|U1111-1118-2935","February 2011","May 2011","May 2011","October 7, 2011",,"June 28, 2013","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01448239"
51,"NCT01864642","Effects of a Single OMT on Intraocular Pressure (IOP) in Ocular Hypertenive or Glaucoma Suspect Subjects","OMT4OHT","Completed","No Results Available","Ocular Hypertension|Glaucoma","Procedure: osteopathic manipulative treatment (OMT)","Intraocular pressure (IOP)|pupillometry","University of Wisconsin, Madison","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","UW IRB 2012-1102","July 2013","May 2014","June 2014","May 29, 2013",,"August 18, 2014","UW Dept of Ophthalmology Clinic, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01864642"
52,"NCT02121041","Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study",,"Completed","Has Results","Hypertension","Drug: Amlodipine|Drug: Chlorthalidone|Drug: Losartan","24 Hour Blood Pressure Average at the End of 4 Month Participation.","Anthony J Viera, MD, MPH|North Carolina Translational and Clinical Sciences Institute|University of North Carolina, Chapel Hill","All","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","14-0670","May 2014","September 2015","July 2016","April 23, 2014","December 19, 2016","February 10, 2017","University of North Carolina, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02121041"
53,"NCT03405870","LIPIDS-P Trial Phase I/II","LIPIDS-P","Recruiting","No Results Available","Sepsis, Severe|Septic Shock","Drug: Smoflipid","Total Cholesterol|Maximum Tolerated Dose|Lipid Oxidation|HDL function|Organ Dysfunction|Mortality","University of Florida|Fresenius Kabi","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","84","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB201800027 - A|OCR19642","August 17, 2018","February 11, 2021","February 11, 2021","January 23, 2018",,"February 18, 2020","UF Health, Gainesville, Florida, United States|Department of Emergency Medicine, UF Health Jax ICU/MICU, Jacksonville, Florida, United States|UF Health Jacksonville, Jacksonville, Florida, United States|UF Health Jacksonville North campus, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03405870"
54,"NCT01960153","Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage","PITCH-ER","Withdrawn","No Results Available","Heart Failure|Pulmonary Hypertension","Drug: Tadalafil|Drug: Placebo","Change in renal function|Incidence of acute kidney injury (AKI) events (clinical and subclinical)|Changes in renal function stratified by diabetes/no diabetes|Incidence of AKI events stratified by diabetes/no diabetes","Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)|HealthCore-NERI","All","21 Years and older   (Adult, Older Adult)","Phase 3","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2013P001412|R01HL119155-01A1","October 2013","December 2017","May 2018","October 10, 2013",,"September 12, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01960153"
55,"NCT01894230","Genetically Guided Statin Therapy",,"Completed","Has Results","Hypercholesterolemia|Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction","Genetic: SLCO1B1*5 allele testing, results reported at randomization|Genetic: SLCO1B1*5 allele testing, results reported at end of study|Genetic: Genetic testing for SLCO1B1*5 allele","Morisky Medication Adherence Scale (MMAS) Score|Low Density Lipoprotein Cholesterol (LDLc) at Baseline, Month 3 and Month 8|Medication Possession Ratio (MPR) From Baseline to Last Patient Follow-up|Number of Participants Reporting New Statin Prescriptions|Brief Pain Inventory (BPI) Score - Pain Severity at Month 3 and Month 8|Brief Pain Inventory (BPI) Score - Pain Interference at Month 3 and Month 8|Change in Short Form -12 Item (SF-12) Health Survey - Physical Component (PC)|Change in Short Form -12 Item (SF-12) Health Survey - Mental Component (MC)|Physical Activity Scale Score|Beliefs About Medications (BMQ) Score at Baseline, Month 3 and Month 8","Duke University|David Grant U.S. Air Force Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","167","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pro00044989|Pro00045542","July 2013","April 30, 2016","April 30, 2016","July 10, 2013","June 23, 2017","June 23, 2017","David Grant US Air Force Medical Center, Travis Air Force Base, California, United States|Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01894230"
56,"NCT00947661","Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension",,"Completed","Has Results","Open Angle Glaucoma|Ocular Hypertension","Drug: SPARC0912|Drug: Reference0912","Change in Intraocular Pressure From Baseline to Week 12","Sun Pharma Advanced Research Company Limited","All","18 Years and older   (Adult, Older Adult)","Phase 3","578","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CLR_09_12","July 2010","May 2012","May 2012","July 28, 2009","May 30, 2016","October 27, 2016","SPARC study site, North Carolina, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00947661"
57,"NCT03015402","Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction","PH-HFpEF","Active, not recruiting","No Results Available","Pulmonary Hypertension Secondary|Heart Failure","Drug: Sodium Nitrite|Drug: Placebo Oral Capsule","Pulmonary artery pressure (mPAP) during submaximal exercise as compared between placebo and nitrite|Difference in 6-minute walk test|Change in right heart catheterization (RHC) hemodynamics|Change in severity of heart failure|Change in endurance exercise time","Gladwin, Mark, MD|National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 2","26","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO16110594|5P01HL103455","October 30, 2017","March 2021","March 2021","January 10, 2017",,"April 1, 2020","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03015402"
58,"NCT00834600","Renin Profiling in Selection of Initial Antihypertensive Drug",,"Completed","No Results Available","Hypertension","Drug: olmesartan, hydrochlorothiazide, amlodipine|Drug: hydrochlorothiazide (HCTZ) or olmesartan","Percent of patients with BP <140/90 mmHg and on monotherapy at the 5th visit.|Will include change in blood pressure, percent of patients with blood pressure <140/mmHg, total number of classes of antihypertensive agents taken, adverse events and discontinuation of therapy.|In addition, we will be able to determine the reproducibility of PRA determination in this clinical setting. Finally, it will be possible to demonstrate the value of ""in-treatment"" PRA as a guide to treatment modification.","The Louis & Rachel Rudin Foundation|Daiichi Sankyo, Inc.","All","40 Years to 85 Years   (Adult, Older Adult)","Not Applicable","185","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","04-074|MMC #05-02-054","December 2005","October 2011","October 2011","February 3, 2009",,"April 19, 2012","Lincoln Medical and Mental Health Center, Bronx, New York, United States|Albert Einstein College of Medicine - GCRC, Bronx, New York, United States|Jacobi Medical Center, Bronx, New York, United States|Bronx Nephrology Hypertension, PC, Bronx, New York, United States|Ralph Yung, MD, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT00834600"
59,"NCT01501929","Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients",,"Completed","Has Results","Hypertension","Drug: Metoprolol succinate|Drug: Nebivolol|Procedure: Non-invasive measurement of Cardiac Output (CO)|Procedure: Endothelial cell collection|Procedure: Microvascular perfusion assessment using Definity","Endothelial Cell Protein Expression p47phox From Endothelial Cell Collection|Microvascular Blood Flow","University of Texas Southwestern Medical Center|Forest Laboratories","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Bystolic MD52","August 2010","December 2015","December 2015","December 30, 2011","November 6, 2018","November 6, 2018","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01501929"
60,"NCT01268553","Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication",,"Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Treprostinil","Number of Participants Without Adverse Events|Number of Participants Without Clinical Worsening|Change in 6-minute Walk Distance|VE/VCO|CAMPHOR: Cambridge Pulmonary Hypertension Outcome Review; Construct = Quality of Life|N-terminal Pro BNP Level","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|United Therapeutics","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Tyvaso Switch","August 2010","October 5, 2016","October 5, 2016","December 31, 2010","September 1, 2017","September 1, 2017","University of Arizona, Tucson, Arizona, United States|University of CA, San Francisco, San Francisco, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States",,"https://ClinicalTrials.gov/show/NCT01268553"
61,"NCT00819403","Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment",,"Completed","Has Results","Metabolic Syndrome","Drug: simvastatin|Drug: ezetimibe/simvastatin","Ex Vivo Effects of Treatment With Vytorin Versus Zocor for 6 Weeks on Platelet Alpha Thrombin PAR-1 Receptor Expression|Biomarkers of Inflammation","University of Maryland, Baltimore|Merck Sharp & Dohme Corp.","All","21 Years and older   (Adult, Older Adult)","Phase 4","15","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HP-00040970|MSP-JV IISP #32031","January 2009","November 2011","November 2011","January 9, 2009","December 18, 2014","January 14, 2020","VA Maryland Health Care System, Baltimore, Maryland, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00819403"
62,"NCT02534376","Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal",,"Completed","No Results Available","Prostate Cancer","Drug: ezetimibe 10mg-simvastatin 40mg","Growth of Gleason grade 3 prostate cancer|Growth of benign prostate glands|Growth of high grade prostate cancer (e.g. Gleason grade 4/5)","Cedars-Sinai Medical Center|Roswell Park Cancer Institute","Male","18 Years and older   (Adult, Older Adult)","Early Phase 1","63","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00040945","September 2015","February 28, 2019","February 28, 2019","August 27, 2015",,"April 3, 2020","Cedars Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02534376"
63,"NCT02307565","Blood Pressure, Cerebral Blood Flow and Cognition in Spinal Cord Injury",,"Completed","No Results Available","Spinal Cord Injury","Drug: Midodrine|Drug: Placebo","Systolic Blood Pressure|Cerebral Blood Flow|Memory|Number of Hypertensive Events","James J. Peters Veterans Affairs Medical Center|Kessler Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","60","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WEC-13-066","March 2014","December 2019","December 2019","December 4, 2014",,"February 11, 2020","Kessler Foundation Research Center, West Orange, New Jersey, United States|James J Peters VAMC, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT02307565"
64,"NCT01099774","Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: Bimatoprost 0.03% Formulation B Ophthalmic Solution|Drug: Bimatoprost 0.03% Ophthalmic Solution","Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Week 12|Average Eye IOP at Week 12|Average Eye IOP at Week 6|Average Eye IOP at Week 2","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","597","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","192024-048","May 1, 2010","April 29, 2011","April 29, 2011","April 8, 2010","April 27, 2012","April 17, 2019","Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT01099774"
65,"NCT01586156","PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)","PAHTCH","Completed","Has Results","Pulmonary Hypertension","Drug: Carvedilol|Drug: placebo","Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography)|Urinary cAMP (Cyclic Adenosine Monophosphate)/Creatinine|Beta-Adrenergic Receptor (Alprenolol Binding Assay)","The Cleveland Clinic|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11-1198|R01HL115008","December 2012","July 2016","July 2016","April 26, 2012","November 30, 2017","December 5, 2018","Cleveland Clinic, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT01586156/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01586156"
66,"NCT02822222","Safety Study of RMJH-111b to Treat Essential Hypertension",,"Completed","No Results Available","Essential Hypertension","Drug: RMJH-111b|Drug: Placebo","Safety and tolerability of RMJH-111b assessed primarily based on adverse events (AEs); secondary safety assessments will include physical examination, 12-lead ECG, vital signs, patellar reflex test, and clinical safety labs.|Change from baseline office visit systolic blood pressure (SBP) and diastolic (DBP) after 7 days of treatment with RMJH-111b compared to placebo|Maximum serum concentration (Cmax) of total serum magnesium after single and repeated oral administrations of RMJH-111b compared to placebo|Time to maximum serum concentration (Tmax) of total serum magnesium after single and repeated oral administrations of RMJH-111b compared to placebo|Area under the serum concentration-time curve from time zero to time of last measureable concentration (AUC0-t) of total serum magnesium after single and repeated oral administrations of RMJH-111b compared to placebo|Area under the serum concentration-time curve from time zero extrapolated to infinity (AUC0-inf) of total serum magnesium after single and repeated oral administrations of RMJH-111b compared to placebo|Apparent serum terminal phase half-life (t1/2) of total serum magnesium after single and repeated oral administrations of RMJH-111b compared to placebo|24-hour urinary excretion of urine magnesium after single and repeated oral administrations of RMJH-111b compared to placebo|Change from baseline in mean daytime (8 AM to 4 PM) ambulatory blood pressure monitor (ABPM) SBP and DBP after 7 days of treatment with RMJH-111b compared to placebo|Change from baseline in mean nighttime (10 PM to 6 AM) ABPM SBP and DBP after 7 days of treatment with RMJH-111b compared to placebo|Change from baseline in mean 24-hour ABPM SBP and DBP after 7 days of treatment with RMJH-111b compared to placebo","RMJ Holdings, LLC","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RMJH-111b-002","June 2016","July 2016","July 2016","July 4, 2016",,"July 14, 2016","Orange County Research Center, Tustin, California, United States",,"https://ClinicalTrials.gov/show/NCT02822222"
67,"NCT03644576","Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart Rate",,"Completed","No Results Available","Healthy Volunteers","Drug: ozanimod|Drug: Pseudoephedrine|Drug: ozanimod placebo","Cardiovascular analysis|Pharmacokinetics- Cmax|Pharmacokinetics- Cmin|Pharmacokinetics- Tmax|Pharmacokinetics- AUC0-24|Pharmacokinetics- Ctrough|Adverse events (AEs)|Pharmacokinetics- % total drug related AUC0-24 for each analyte|Pharmacokinetics- % total active drug related AUC0-24 for each active analyte|Cardiovascular analysis for DBP|Cardiovascular analysis for heart rate|Cardiovascular analysis for blood pressure|Cardiovascular analysis for Heart Rate","Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","RPC01-1914|U1111-1215-6267","July 11, 2018","September 12, 2018","September 12, 2018","August 23, 2018",,"May 30, 2019","ICON Early Phase Services, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03644576"
68,"NCT00994253","Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics",,"Withdrawn","No Results Available","Hypertension|Diabetes Type 2","Drug: Aliskiren|Drug: Hydrochlorothiazide","The primary objective is to assess the effect of a multimodal drug therapy regimen including the renin inhibitor Tekturna (aliskiren), an ACE inhibitor, and a calcium channel blocker on coronary flow reserve (CFR) in hypertensive Type II diabetics.|Secondary measures include evaluation of serum and urine biomarkers related to endothelial function, the renin-angiotensin system, oxidative stress, and inflammation.","William Beaumont Hospitals|Novartis Pharmaceuticals","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-083","August 2009","December 2012","December 2012","October 14, 2009",,"October 2, 2017","William Beaumont Hospital, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00994253"
69,"NCT01306292","Safety of SonoVue on Pulmonary Hemodynamics",,"Completed","Has Results","Pulmonary Hypertension","Drug: SonoVue|Drug: Placebo","Effects of SonoVue and Placebo on Pulmonary Hemodynamics: Systolic Pulmonary Artery Pressure (mmHg) - Mean Change From Baseline|Effects of SonoVue and Placebo on Pulmonary Hemodynamics: Diastolic Pulmonary Artery Pressure (mmHg) - Mean Change From Baseline|Effects of SonoVue and Placebo on Pulmonary Hemodynamics: Pulmonary Vascular Resistance (Dyne*Sec/cm^5) - Mean Change From Baseline","Bracco Diagnostics, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","BR1-133","April 2011","November 2011","November 2011","March 1, 2011","February 8, 2016","December 7, 2016","Holy Name Medical Center, Teaneck, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01306292"
70,"NCT01948518","Effect of Sildenafil on Diffusion Capacity in Patients With PH and Parenchymal Lung Disease",,"Completed","Has Results","Diffuse Parenchymal Lung Disease|Pulmonary Hypertension","Drug: Oral sildenafil 20 mg","Change in Diffusion Capacity Measured at Baseline and One Hour.|Change in 6 Minute Walk Distance","The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","08-993","June 2009","June 2012","June 2012","September 23, 2013","September 30, 2014","September 30, 2014","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01948518"
71,"NCT01702688","Evaluation of Lysine-Specific Demethylase 1",,"Withdrawn","No Results Available","Hypertension","Drug: Para-aminohippuric Acid|Drug: Angiotensin II","Evaluating for the mechanisms by which genetic variants in the LSD1 gene contribute to salt-sensitive hypertension and cardiovascular disease","Brigham and Women's Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2012 Lysine|AHA 12CRP11690012","July 2012",,,"October 8, 2012",,"July 12, 2017","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01702688"
72,"NCT03683069","MR Antagonist and STRIATIN",,"Recruiting","No Results Available","Hypertension|Genetics Hypertension","Drug: Eplerenone vs Amlodipine","Systolic supine morning liberal salt automated blood pressure","Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2018P001888","January 15, 2019","June 1, 2022","August 31, 2022","September 25, 2018",,"March 12, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03683069"
73,"NCT02674204","STOP Heart Disease in Breast Cancer Survivors Trial","STOP","Terminated","Has Results","Breast Cancer|Heart Disease|Cardiotoxicity|Myocardial Dysfunction","Drug: Atorvastatin|Drug: Placebo","Change in Global Circumferential Strain (GCS) Measured by Cardiac MRI (CMRI)|Change in Global Longitudinal Strain as Measured by CMRI|Change in Peak Left Ventricular Twist as Measured by CMRI|Change in Peak Left Ventricular Torsion as Measured by CMRI|Change in Left Ventricular Untwisting Rate as Measured by CMRI|Change in Left Ventricular Ejection Fraction as Measured by CMRI|Change in Left Ventricular End Diastolic Volume as Measured by CMRI|Change in Left Ventricular End Systolic Volume as Measured by CMRI|Change in Cardiac Output as Measured by CMRI|Change in Left Ventricular Mass as Measured by CMRI|Change in Left Ventricular Concentricity as Measured by CMRI|Change in Native T1 as Measured by CMRI|Change in Post Contrast T1 as Measured by CMRI|Change in Extracellular Volume as Measured by CMRI|Change in Native T2 as Measured by CMRI","Cedars-Sinai Medical Center|California Breast Cancer Research Program","Female","18 Years and older   (Adult, Older Adult)","Phase 2","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IIT2015-12-Goodman-STOP","May 5, 2016","May 25, 2018","May 25, 2018","February 4, 2016","April 30, 2019","May 15, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02674204/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02674204/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02674204"
74,"NCT02625558","Riociguat for Sarcoidosis Associated Pulmonary Hypertension","RioSAPH","Unknown status","No Results Available","Sarcoidosis","Drug: Riociguat|Drug: Placebo","Time until clinical worsening|Safety: adverse events|Pulmonary function|Quality of life|Six minute walk","University of Cincinnati","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2014-7130","April 2015","April 2018","October 2018","December 9, 2015",,"December 9, 2015","University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02625558"
75,"NCT01271374","Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome","AMORE","Unknown status","No Results Available","Hypertension","Drug: amlodipine and olmesartan|Drug: losartan and HCTZ","Change in Central Aortic Pressure (CAP)|Blood pressure control","InVasc Therapeutics, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVR-2010-001","April 2010","June 2011","December 2011","January 6, 2011",,"May 5, 2011","Atlanta Clinical Research Center, Tucker, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01271374"
76,"NCT01280604","Effect of Fenofibrate Conversion on Triglyceride Levels in Patients on Statin Therapy",,"Completed","Has Results","Hyperlipidemias","Drug: Fenofibrate 54mg","Triglyceride Levels|Low-density Lipoprotein (LDL)|High-density Lipoprotein,(HDL)|Alanine Aminotransferase(ALT)|Aspartate Aminotransferase (AST)|Serum Creatinine(SCr)","Kaiser Permanente","All","18 Years and older   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KPGA-10KMani-01","October 2010","January 2013","January 2013","January 21, 2011","June 8, 2015","June 8, 2015","Kaiser Permanente of Georgia, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01280604"
77,"NCT00959842","Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia","ELLF","Completed","No Results Available","Hypertriglyceridemia","Drug: Lovaza","The primary endpoint will be the effect of treatment on lipoprotein binding to target cells.|Performance of VLDL as a substrate for lipolysis.|Plasma LpL mass and activity.|VLDL, LDL, HDL oxylipin and fatty acid content","Sanford Research|GlaxoSmithKline","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LVZ 112860|GSK - LVZ 112860","September 2009","February 2010","February 2010","August 17, 2009",,"November 18, 2014","Sanford Research/USD, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT00959842"
78,"NCT01773278","Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)",,"Recruiting","No Results Available","Smith-Lemli-Opitz Syndrome|Cone-Rod Dystrophy|Hearing Loss","Drug: Antioxidants|Drug: Cholesterol","Change in Electroretinogram (ERG) results over time|Change in ABR (Auditory Brainstem response) testing over time","University of Colorado, Denver","All","up to 65 Years   (Child, Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01-410","December 2008","December 2020","December 2020","January 23, 2013",,"October 3, 2019","Children's Hospital Colorado, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01773278"
79,"NCT03355469","Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome",,"Recruiting","No Results Available","Metabolic Syndrome","Drug: Low Intensity Exercise + Metformin|Drug: High Intensity Exercise + Metformin|Drug: Low Intensity Exercise + Placebo|Drug: High Intensity Exercise + Placebo","Change in Flow Mediated Dilation of brachial artery|Change in Metabolic Insulin Sensitivity by the Euglycemic Clamp|Change in Post Ischemic Flow Velocity in brachial artery|Change in Contrast Enhanced Ultrasound|Change in Pulse Wave Velocity|Change in Augmentation Index|Change in Ambulatory Blood Pressure","University of Virginia|National Heart, Lung, and Blood Institute (NHLBI)","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 4","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","19364|1R01HL130296-01A1","August 7, 2017","June 30, 2021","January 31, 2022","November 28, 2017",,"January 17, 2019","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03355469"
80,"NCT02558400","Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Open-angle Glaucoma|Ocular Hypertension","Drug: PG324 Ophthalmic Solution 0.02%/0.005%|Drug: Netarsudil (AR-13324) Ophthalmic Solution 0.02%|Drug: Latanoprost Ophthalmic Solution 0.005%","Intraocular Pressure (IOP)|Extent of Exposure","Aerie Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","718","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PG324-CS301","September 18, 2015","May 17, 2017","June 30, 2017","September 24, 2015","June 4, 2019","June 4, 2019","Aerie Pharmaceuticals, Bedminster, New Jersey, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02558400/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02558400/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02558400"
81,"NCT02674854","Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension",,"Completed","Has Results","Open-angle Glaucoma|Ocular Hypertension","Drug: PG324 Ophthalmic Solution 0.02%/0.005%|Drug: Netarsudil (AR-13324) ophthalmic solution 0.02%|Drug: Latanoprost ophthalmic solution 0.005%","Intraocular Pressure (IOP)","Aerie Pharmaceuticals","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","750","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PG324-CS302","February 2016","March 2017","March 2017","February 5, 2016","May 1, 2019","May 21, 2019","Aerie Pharmaceuticals, Bedminster, New Jersey, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02674854/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02674854/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02674854"
82,"NCT01448304","Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)",,"Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Pain using present pain intensity (PPI) verbal questionnaire|Erythema at injection site by measuring diameter and qualitative assessment|Edema at injection site by measuring diameter and qualitative assessment|Assessment of PK parameter - time to maximum concentration (tmax)|Assessment of PK parameter - maximum concentration (Cmax)|Assessment of PK parameter - area under curve (AUC)|Assessment of PK parameter - cluster of differentiation (CD) biomarker (CD29)|Assessment of PK parameter - terminal elimination half-life (t1/2z)|Pharmacodynamics: Change in LDL-C from baseline|Number of participants with Adverse Events","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PKD12011|U1111-1119-3056","June 2011","September 2011","September 2011","October 7, 2011",,"June 28, 2013","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01448304"
83,"NCT01443650","Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects",,"Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Pain using Present Pain Intensity (PPI) verbal questionnaire and Visual Analog Scale (VAS)|Erythema at injection site by measuring diameter and qualitative assessment|Edema at injection site by measuring diameter and qualitative assessment|Assessment of PK parameter - time to maximum concentration (tmax)|Pharmacodynamics: Change in LDL-C from baseline|Number of participants with Adverse Events|Assessment of PK parameter - maximum concentration (Cmax)|Assessment of PK parameter - area under curve (AUC)|Assessment of PK parameter - area under curve versus time curve (AUC0-D29)|Assessment of PK parameter - plasma concentration on Day 29 (C D29)|Assessment of PK parameter - terminal elimination half-life (t1/2z)","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PKD12275|U1111-1120-0670","July 2011","November 2011","November 2011","September 30, 2011",,"June 28, 2013","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01443650"
84,"NCT04200573","Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855",,"Recruiting","No Results Available","Symptomatic Neurogenic Orthostatic Hypertension|nOH","Drug: Ampreloxetine","Plasma AUC0-t|Plasma AUC0-inf|Plasma Cmax|Number of subjects with clinically significant vital sign abnormalities|Number of subjects with change in C-SSRS scores","Theravance Biopharma","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0179","January 13, 2020","August 31, 2020","August 31, 2020","December 16, 2019",,"January 28, 2020","Theravance Biopharma Investigational Site, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04200573"
85,"NCT03657550","Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects",,"Completed","No Results Available","Hypertension","Drug: Levamlodipine Malate Tablets|Drug: Amlodipine Besylate Tablets","The plasma concentration of study drugs","Conjupro Biotherapeutics|CSPC Ouyi Pharmaceutical Co., Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LAM-US-101","May 31, 2018","September 6, 2018","September 6, 2018","September 5, 2018",,"April 4, 2019","Collaborative Neuroscience Network, LLC, Long Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT03657550"
86,"NCT01527747","Effects of DPP-4 Inhibition on Triglycerides",,"Enrolling by invitation","No Results Available","Type 2 Diabetes|Hypertriglyceridemia","Drug: Saxagliptin","Change in fasting and postprandial triglyceride concentrations|Changes in glycemia","Oregon Health and Science University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","CV181-142","January 2012","November 2020","December 2020","February 7, 2012",,"November 20, 2018","Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01527747"
87,"NCT01334554","Study of Sildenafil Citrate on Insulin Resistance in African American",,"Completed","Has Results","Metabolic Syndrome|Obesity","Drug: Sildenafil|Drug: Placebo","Insulin Sensitivity|Endothelial Function","Vanderbilt University Medical Center|National Heart, Lung, and Blood Institute (NHLBI)|Pfizer","Female","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","46","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","100713|K23HL103976","April 2011","August 2013","August 2013","April 13, 2011","April 10, 2015","March 27, 2017","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01334554"
88,"NCT01934582","A Pharmacokinetic Substudy of the TDE-PH-304 Protocol",,"Completed","Has Results","Pulmonary Arterial Hypertension","Drug: UT-15C SR|Drug: treprostinil diethanolamine","To Assess the Pharmacokinetics (Mean AM Dose) in Subjects During Twice Daily (BID) Dosing (up to 14 Days Prior to Transitioning to Three Times Daily [TID] Dosing Regimen at PK Visit 1) and up to 35 Days After Transitioning to TID Dosing (at PK Visit 2).|To Assess the Pharmacokinetics (Cmax, Cmin) in Subjects During Twice Daily (BID) Dosing (up to 14 Days Prior to Transitioning to Three Times Daily [TID] Dosing Regimen at PK Visit 1) and up to 35|To Assess the Pharmacokinetics (AUClast) in Subjects During Twice Daily (BID) Dosing (up to 14 Days Prior to Transitioning to Three Times Daily [TID] Dosing Regimen at PK Visit 1) and up to 35 Days After Transitioning to TID Dosing (at PK Visit 2).|To Assess 6-minute Walk Distance for Both Groups (BID and TID) 3 to 6 Hours Post-morning Dose.|To Compare the Adverse Event (AE) Profile of BID Versus TID Dosing.","United Therapeutics","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","13","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","TDE-PH-309|TDE-PH-304","August 2013","November 2013","November 2013","September 4, 2013","October 27, 2016","October 27, 2016","University of Rochester Medical Center, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01934582"
89,"NCT03508739","Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition",,"Suspended","No Results Available","Diabetes Mellitus, Type 2|Pre-diabetic|Hypertension|Elevated Blood Pressure","Drug: Sacubitril/Valsartan 200mg (blinded)|Drug: Valsartan 160mg (blinded)","Intact glucagon like peptide-1 (GLP-1) levels after the mixed meal|Insulin levels after the mixed meal|Blood glucose levels after the mixed meal|Triglyceride levels after the mixed meal|Neprilysin enzyme (drug) activity at baseline, during sacubitril/valsartan, and during valsartan","University of Pennsylvania","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","828731","June 1, 2018","June 1, 2020","June 30, 2020","April 26, 2018",,"July 16, 2019","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03508739"
90,"NCT04019652","The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers",,"Completed","No Results Available","Hypertension|Mineralocorticoid Receptor Antagonist","Drug: CS-3150|Drug: Moxifloxacin|Drug: Placebo matching moxifloxacin tablet|Drug: Placebo matching CS-3150","Change in corrected QT (QTc) interval from baseline following oral administration of 1 of 4 treatment sequences with CS-3150|Percentage of participants reporting treatment-emergent adverse events (TEAEs) following oral administration of 1 of 4 treatment sequences with CS-3150|Change in corrected QT (QTc) interval from baseline following oral administration of 1 of 4 treatment sequences with moxifloxacin|Change in the interval between the P and R waves (PR) from baseline following oral administration of 1 of 4 treatment sequences with CS-3150|Change in QRS wave complex (QRS) from baseline following oral administration of 1 of 4 treatment sequences with CS-3150|Change in QT interval (QT) from baseline following oral administration of 1 of 4 treatment sequences with CS-3150|Change in QTc corrected by Bazett's formula (QTcB) from baseline following oral administration of 1 of 4 treatment sequences with CS-3150|Change in QTc corrected by Fridericia's formula (QTcF) from baseline following oral administration of 1 of 4 treatment sequences with CS-3150|Change in heart rate (HR) from baseline following oral administration of 1 of 4 treatment sequences with CS-3150","Daiichi Sankyo, Inc.","All","18 Years to 45 Years   (Adult)","Phase 1","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","CS3150-A-U106","November 19, 2015","December 23, 2015","December 23, 2015","July 15, 2019",,"July 15, 2019","Worldwide Clinical Trials, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04019652"
91,"NCT01076140","Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab",,"Withdrawn","No Results Available","Hypertension","Drug: Nebivolol|Drug: Lisinopril","The primary endpoint of the study will be changes in sitting systolic and diastolic blood pressure at the crossover and final visits.|The secondary endpoint of the study will be changes in heart rate at the end of the crossover and final visits.","University of Mississippi Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-0222","February 2010","January 2011","August 2011","February 25, 2010",,"April 6, 2012","University of Mississippi Medical Center, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT01076140"
92,"NCT01702987","Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS",,"Completed","Has Results","Myopathy|HMG COA Reductase Inhibitor Adverse Reaction|Hypercholesterolemia","Dietary Supplement: ubiquinol|Dietary Supplement: placebo|Drug: statin","Phosphocreatine Recovery","Beth Israel Deaconess Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","2012P000219","October 2012","October 2013","October 2013","October 10, 2012","April 17, 2017","April 17, 2017","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01702987"
93,"NCT01564485","Cardiac CT's Role in Asymptomatic Patients With Diabetes and Metabolic Syndrome","CTRAD","Completed","No Results Available","Diabetes|Metabolic Syndrome","Procedure: Cardiac CT|Drug: Usual medical care","Systolic BP pressure|Control of LDL cholesterol|Hemoglobin A1c","University of California, Irvine","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","198","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20086170","July 2008","December 2016","December 2016","March 27, 2012",,"December 8, 2016","University of California, Irvine Medical Center, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT01564485"
94,"NCT01122407","Pathophysiology of Cardiometabolic Risk Factors in African Americans",,"Completed","No Results Available","Obesity|Hypertension","Drug: L-NMMA|Drug: Trimethaphan","change in systolic blood pressure in response to trimethaphan, as a measurement of the tonic sympathetic contribution to blood pressure.|increase in systolic blood pressure induced by NOS inhibition with 250 ug/kg/min L-NMMA during autonomic withdrawal with trimethaphan.","Vanderbilt University Medical Center|National Heart, Lung, and Blood Institute (NHLBI)","Female","30 Years to 50 Years   (Adult)","Phase 1","34","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","091282|K23HL103976-06","January 2010","November 2016","November 2016","May 13, 2010",,"January 18, 2017","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01122407"
95,"NCT01420328","To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects",,"Unknown status","No Results Available","Inflammation","Drug: Vytorin","Change in nile red staining score|Change in markers of monocyte activation|Change in markers of inflammation|Change in the expression of toll like receptor","Kaleida Health","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MED7120311A","May 2011","December 2013","December 2013","August 19, 2011",,"December 18, 2012","Diabetes Endocrinology Center of WNY, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT01420328"
96,"NCT02232880","Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation",,"Terminated","Has Results","Hypertension","Drug: Abatacept|Drug: Placebo","Change in Systolic Blood Pressure From Randomization to End of Treatment|Change in Blood Pressure|Change in Brachial Artery Reactivity|Change in Inflammatory Markers","Vanderbilt University Medical Center|Bristol-Myers Squibb","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","1","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","121740","August 2014","June 2015","June 2015","September 5, 2014","August 29, 2016","February 7, 2017","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02232880"
97,"NCT01751984","A Study of the Efficacy and Safety of ETC-1002 in Subjects With Statin Intolerance",,"Completed","No Results Available","Hypercholesterolemia","Drug: ETC-1002|Drug: Placebo","Percent change from baseline in LDL-C|Percent change from baseline in other lipids and cardio-metabolic risk factors|Percent achieving LDL-C goal|Number of subjects with adverse events|Number of subjects with muscle related adverse events","Esperion Therapeutics","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1002-006","October 2012","May 2013","May 2013","December 18, 2012",,"March 29, 2019","Hartford, Connecticut, United States|Indianapolis, Indiana, United States|Raleigh, North Carolina, United States|Wilmington, North Carolina, United States|Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01751984"
98,"NCT01921010","Benefit of Elevation of HDL-C in Women",,"Completed","No Results Available","Cardiovascular Outcomes","Drug: Niaspan|Drug: Placebo","endothelial function","Cedars-Sinai Medical Center","Female","18 Years to 100 Years   (Adult, Older Adult)","Phase 4","43","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3954","June 2003","June 2005","June 2005","August 13, 2013",,"April 23, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01921010"
99,"NCT02943590","STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)",,"Recruiting","No Results Available","Heart Failure","Drug: Placebo|Drug: Atorvastatin","Left ventricular Ejection Fraction (LVEF)|Number of Cardiac Events|Myocardial Fibrosis|Troponin T and Global Longitudinal Strain","Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16-440","January 13, 2017","June 2021","May 2022","October 24, 2016",,"August 13, 2019","Massachusetts general Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02943590"
100,"NCT00995072","Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function",,"Completed","Has Results","Hypertension|Female Sexual Dysfunction","Drug: nebivolol and metoprolol succinate|Drug: metoprolol succinate and nebivolol","Change in Female Sexual Function Index|Change in Sexual Functioning Questionnaire Score","East Coast Institute for Research","Female","40 Years and older   (Adult, Older Adult)","Not Applicable","29","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SAIRB-09-0011","October 2009","April 2013","April 2013","October 14, 2009","March 29, 2019","March 29, 2019","Family Practice, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00995072"
101,"NCT01004705","A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol",,"Terminated","Has Results","Elevated LDL Cholesterol","Drug: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),|Drug: Simvastatin","The Difference in LDL Cholesterol Levels Between the Basal and the Final Visit of Each Treatment Period.|The Difference in Mean Total Cholesterol Between the Basal and the Final Visit of Each Treatment Period.","Ferrer Internacional S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","P-080647-01","September 2009","March 2011","March 2011","October 30, 2009","August 31, 2012","August 31, 2012","Mount Sinai Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01004705"
102,"NCT03331666","Impact of LDL-cholesterol Lowering on Platelet Activation",,"Recruiting","No Results Available","Familial Hypercholesterolemia","Drug: Evolocumab","Change in P2Y12 Reaction Units|Change in platelet P-selectin level","Columbia University|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","22","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","AAAR1041","November 16, 2018","July 1, 2021","November 1, 2021","November 6, 2017",,"July 2, 2019","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03331666"
103,"NCT03390426","Femoral Peri-arterial Local Anesthetic Injection Decreases Tourniquet Associated Ischemic Hypertension",,"Completed","Has Results","Tourniquet Hypertension|Intraoperative Hypertension|Total Ankle Arthroplasty|Ankle Fusion","Drug: Mepivacaine|Procedure: Perifemoral Injection of Local Anesthetic|Drug: Saline","Number of Subjects Experiencing Tourniquet Hypertension|Pain Scores as Measured by the Numeric Rating Scale (NRS-11)|Amount of Opioid Pain Medications Used by Patient|Amount of Esmolol Used Intraoperatively","Duke University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Pro00089161","May 3, 2018","October 27, 2018","October 28, 2018","January 4, 2018","October 30, 2019","November 19, 2019","Duke University Hospital, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT03390426/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03390426"
104,"NCT02169752","Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension","AMERICA-PAH","Terminated","No Results Available","Pre-Pulmonary Atrial Hypertension","Drug: Ambrisentan","Improvement in right ventricular (RV) myocardio strain > 2%","National Jewish Health","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","7","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HS-2716","September 2012","May 25, 2017","May 25, 2017","June 23, 2014",,"August 24, 2018","National Jewish Health, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02169752"
105,"NCT01530464","The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers","GQ01","Completed","Has Results","High Altitude Pulmonary Hypertension","Drug: Aminophylline|Drug: Ambrisentan|Drug: Aminophylline plus ambrisentan","Mean Number of Adverse Events Following Each Dose|Plasma Halflife of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination|Time Until Maximum Plasma Concentration (Tmax) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination|Maximum Plasma Concentration (Cmax) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination|Area Under the Curve Within 24 Hours Post Dosing (AUC_0-24 Hours) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination|Area Under the Curve Post Dosing (AUC_0-infinity) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination","Thies Schroeder|Duke University","All","18 Years to 40 Years   (Adult)","Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00028417","February 2012","April 2012","April 2012","February 10, 2012","January 16, 2014","January 16, 2014","Duke Clinical Research Unit, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01530464"
106,"NCT02056340","Statin Therapy in Acute Influenza",,"Completed","Has Results","Influenza","Drug: Atorvastatin|Drug: Placebo","Change in Inflammatory Markers From Time Zero to 72 Hours|Severity of Illness Score Baseline to 72 Hours","Beth Israel Deaconess Medical Center|National Institute of General Medical Sciences (NIGMS)","All","18 Years and older   (Adult, Older Adult)","Phase 2","116","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2013P000026|1K23GM101463-01A1|FWA00003245","October 2013","June 30, 2018","June 30, 2018","February 6, 2014","July 26, 2019","July 26, 2019","The Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02056340/Prot_SAP_000.pdf|""Informed Consent Form: Part D: Informed Consent"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02056340/ICF_001.pdf|""Informed Consent Form: Verbal Consent - Rapid Antigen Test (RAT)"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02056340/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT02056340"
107,"NCT01658657","A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension",,"Completed","Has Results","Hypertension|Plasma Renin Activity","Drug: Hydrochlorothiazide|Drug: Lisinopril|Drug: Amlodipine|Drug: metoprolol|Drug: lisinopril/hydrochlorothiazide","Blood Pressure Control, as Defined as Office BP Measurement of <140 mmHg Systolic and <90 mmHg Diastolic","University of North Carolina, Chapel Hill|Cornell University|Wake Forest University Health Sciences","All","18 Years and older   (Adult, Older Adult)","Not Applicable","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-1133","October 2012","July 2014","July 2014","August 7, 2012","June 22, 2015","August 27, 2015","UNC Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01658657"
108,"NCT02623036","The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors",,"Unknown status","No Results Available","Hypertension, Resistant to Conventional Therapy","Drug: Equivalent dose enalapril|Drug: Equivalent dose lisinopril","Change from baseline nighttime blood pressure|Change from baseline night to day blood pressure ratio (dipping status)|Change from baseline 24 Hour Blood Pressure","Memorial Health University Medical Center","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MHUMC 2015.10.01","November 2015","April 2018","April 2018","December 7, 2015",,"May 25, 2017","Memorial Family Medicine Center, Savannah, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02623036"
109,"NCT02633488","Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome","EJB044","Completed","Has Results","Metabolic Syndrome|Insulin Sensitivity","Drug: Placebos|Drug: metformin","Flow Mediated Dilation - Endothelial Function","University of Virginia","All","18 Years to 60 Years   (Adult)","Not Applicable","19","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","16121","June 2014","July 2016","July 2016","December 17, 2015","March 23, 2020","March 23, 2020","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02633488"
110,"NCT03057028","Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Anakinra","Change in exercise capacity, as determined by peak oxygen consumption and ventilatory efficiency on cardiopulmonary exercise testing|Effect of anakinra on serum high sensitivity C-reactive protein|Effect of anakinra on serum NT-pro-BNP.|Effect of anakinra on serum interleukin-6|Change in symptoms of heart failure (as assessed by questionnaire with the Duke Activity Status Index and Minnesota Living With Heart Failure Questionnaire).|Correlate between biomarkers (serum high sensitivity C reactive protein, interluekin-6, and NT-pro BNP) and measures of exercise capacity (peak oxygen consumption and ventilatory efficiency on cardiopulmonary exercise testing)|Number of patients with treatment related adverse events related to anakinra in patients with pulmonary arterial hypertension","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM20005870","April 2016","June 7, 2018","June 7, 2018","February 17, 2017",,"April 5, 2019","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03057028"
111,"NCT01140308","CoEnzyme Q10 in Statin Myopathy",,"Unknown status","No Results Available","Statin Myopathy","Drug: CoEnzyme Q10|Drug: Placebo","To test the hypothesis that CoQ10 supplementation compared to placebo in patients with documented statin myalgia reduces the intensity of pain during statin treatment.","Hartford Hospital","All","20 Years and older   (Adult, Older Adult)","Not Applicable","135","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","1RC1AT005836-01","September 2009","September 2013","September 2013","June 9, 2010",,"September 7, 2012","Hartford Hospital, Hartford, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01140308"
112,"NCT03308578","Statins and CPAP in Adipose Tissue of OSA","SCAT-OSA","Enrolling by invitation","No Results Available","Sleep Apnea, Obstructive","Drug: Atorvastatin|Drug: Placebo oral capsule","Changes in prevalence of dual positive p16IND4A and gamma H2AX cells in adipose tissue|Changes in prevalence of phosphorylated p53 (pp53) in adipose tissue|Changes in 24- h mean arterial pressure|Changes in vascular endothelial function|Changes in insulin sensitivity|Changes in body composition","Mayo Clinic|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","90","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","17-005119|R01HL065176|UL1TR000135","January 8, 2018","October 1, 2022","July 2023","October 12, 2017",,"February 24, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03308578"
113,"NCT01502787","Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients",,"Completed","Has Results","Hypertension","Drug: Metoprolol succinate|Drug: Nebivolol|Procedure: Forearm blood flow|Procedure: Microneurography|Procedure: Rhythmic handgrip exercise|Procedure: Lower body negative pressure|Drug: Angiotensin II","Forearm Blood Flow|Blood Pressure During Exercise|Blood Pressure During Angiotensin II Infusion","University of Texas Southwestern Medical Center|Forest Laboratories","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","46","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Bystolic MD19","April 2009","June 2013","June 2013","January 2, 2012","December 31, 2014","June 8, 2018","UT Southwestern Medical Center, Dallas, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT01502787/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01502787"
114,"NCT01330108","Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension","SCOBA-PH","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: ambrisentan","Number of Subjects Not Able to Tolerate Ambrisentan|Mean Change in Distance for a Six Minute Walk at 12 Weeks Post Start of Ambrisentan","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Phase 4","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCOBA-PH","May 2011","June 2012","June 2012","April 6, 2011","August 11, 2014","August 11, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT01330108"
115,"NCT01038921","Melatonin and the Metabolic Syndrome","MetSyn","Completed","Has Results","Metabolic Syndrome","Drug: Melatonin|Drug: Placebo","Metabolic Syndrome Components","Emory University","All","30 Years to 79 Years   (Adult, Older Adult)","Phase 2","39","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00014784|R21AT004220-01A2","July 2009","June 2012","July 2013","December 24, 2009","May 1, 2014","February 27, 2015","Emory Hospital, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01038921"
116,"NCT02992301","Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab",,"Active, not recruiting","No Results Available","Atherosclerosis|Hyperlipidemia","Drug: Alirocumab","Changes in carotid atherosclerotic plaque characteristics as evidenced by effect on the volume transfer constant( Ktrans) and lipid-rich necrotic core (LRNC) size.|Associations between reductions in atherogenic lipids and changes in atherosclerotic plaque characteristics","Westside Medical Associates of Los Angeles|University of Washington|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","35","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WMALA-99-032","November 2016","November 2019","November 2019","December 14, 2016",,"April 26, 2019","Westside Medical Associates of Los Angeles, Beverly Hills, California, United States",,"https://ClinicalTrials.gov/show/NCT02992301"
117,"NCT00972829","Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia",,"Unknown status","No Results Available","Hypercholesterolemia","Drug: Rosuvastatin|Drug: Ezetimibe","Low-density lipoprotein (LDL) cholesterol|The ability to remain on Crestor for the study period","Bronx VA Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","BAR-09-07","September 2009","December 2010","March 2011","September 9, 2009",,"September 10, 2009","Bronx VA Medical Center, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT00972829"
118,"NCT02059278","Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension",,"Completed","Has Results","Primary Open Angle Glaucoma|Ocular Hypertension","Drug: T-2345|Drug: Xalatan","Intraocular Pressure|Visual Acuity|Slit Lamp Examination|Ophthalmoscopy|Mean Deviation in Visual Field","Nephron Pharmaceuticals Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","335","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","T-2345-001","January 2014","January 2015","January 2015","February 11, 2014","August 22, 2018","August 22, 2018","El Paso, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02059278"
119,"NCT02102243","Neural Mechanism of Aldosterone-induced Insulin Resistance",,"Recruiting","No Results Available","Hypertension","Drug: DEFINITY® infusion|Drug: Human Recombinant Regular Insulin infusion|Drug: Dextrose infusion|Procedure: Flow mediated vasodilation|Procedure: Endothelial cell collection|Procedure: Microvascular perfusion assessment using Definity|Procedure: Microneurography","Increase in muscle sympathetic nerve activity during hyperinsulinemic euglycemic clamp|Change in microvascular blood flow during hyperinsulinemic euglycemic clamp.|Change in microvascular blood flow during saline infusion.|Change in endothelial cell protein expression after hyperinsulinemic euglycemic clamp|Change in endothelial cell protein expression after saline infusion|Increase in muscle sympathetic nerve activity during saline infusion","University of Texas Southwestern Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","2","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STU 102010-063","November 2010","December 2020","December 2020","April 2, 2014",,"April 10, 2020","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02102243"
120,"NCT01292694","Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure",,"Terminated","No Results Available","Hypertension|Pure Autonomic Failure|Multiple System Atrophy","Drug: Losartan|Drug: Captopril|Drug: Placebo","Changes in plasma renin activity and subsequent components of the circulating renin-angiotensin system|Changes in blood pressure|Changes in heart rate, cardiac output, stroke volume and systemic vascular resistance","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","101618","March 2011","March 2017","March 2017","February 9, 2011",,"August 24, 2018","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01292694"
121,"NCT01279083","Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Open-angle Glaucoma|Ocular Hypertension","Drug: DE-112|Drug: DE-112 Vehicle Solution|Drug: Timolol Maleate Solution","Intraocular pressure (IOP)","Santen Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","147","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","29-001","January 2011","November 2011","February 2012","January 19, 2011",,"December 17, 2012","Austin, Texas, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01279083"
122,"NCT03011567","Hypertension In Postpartum Preeclampsia Study","HIPPS","Unknown status","No Results Available","Hypertension, Pregnancy-Induced","Drug: Acetaminophen|Drug: Ibuprofen","Average Mean Arterial Blood Pressure|Proportion of participants with at least one episode of severe blood pressure postpartum (systolic >=160 or diastolic >=105mmHg) during inpatient postpartum hospitalization|Wong-Baker Facial Grimace Pain Scale Scores During Inpatient Postpartum Hospital Stay|Outpatient Blood Pressure Measurement|Patient Satisfaction/Side Effects|Length of Hospital Stay|Diuresis","MemorialCare Health System","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","202","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","663-15","January 2017","September 2019","November 2019","January 5, 2017",,"January 25, 2019","Miller Children and Women Hospital Long Beach, Long Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT03011567"
123,"NCT01966302","Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: BPS-314d-MR","Number of participants experiencing Adverse Events","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Lung Biotechnology PBC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Compassionate use BPS-314d-MR","November 2013","June 2, 2019","June 2, 2019","October 21, 2013",,"June 19, 2019","Los Angeles Biomedical research Institute, Torrance, California, United States",,"https://ClinicalTrials.gov/show/NCT01966302"
124,"NCT01479010","Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension",,"Terminated","Has Results","Pulmonary Hypertension","Drug: Anakinra 100 mg subcutaneously daily","Median Interval Change From Baseline in Peak VO2|Median Interval Change From Baseline in the Minute Ventilation and Carbon Dioxide Production (VE/VCO2 Slope)|Interval Change From Baseline in Biomarkers (High-sensitivity C-reactive Protein, Whole Blood Assay, Brain Natriuretic Peptide)|Interval Change From Baseline in Heart Failure Symptoms as Measured by Duke Activity Status Index (DASI)|Correlation Between Interval Changes in Biomarkers, Peak VO2, and VE/VCO2|Rate of Adverse Events and Hospitalizations|Total Exercise Time|Oxygen Uptake Efficiency Slope","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM13729","November 2011","November 2013","November 2013","November 24, 2011","June 8, 2015","November 13, 2017","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01479010"
125,"NCT00825396","An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension",,"Completed","No Results Available","Ocular Hypertension","Drug: C-KAD Ophthalmic Solution","Mean change in intraocular pressure from baseline","Chakshu Research, Inc.","All","50 Years to 90 Years   (Adult, Older Adult)","Not Applicable","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCK-0106","April 2007","April 2009","April 2009","January 21, 2009",,"June 11, 2009","Charlotte Eye, Ear, Nose & Throat Associates, Charlotte, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00825396"
126,"NCT02424695","Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome",,"Unknown status","No Results Available","Restless Legs Syndrome","Drug: Gabapentin Enacarbil (GEn)|Drug: Placebo","The mean change from baseline to week 4 in intensity of cortical arousals associated with periodic limb movements (PLMs)|The mean change from baseline to week 4 in heart rate variability associated with arousals secondary to periodic limb movements (PLMs)|The mean change from baseline to week 4 in blood pressure associated with arousals secondary to periodic limb movements (PLMs)|The mean change from baseline to week 4 in periodic limb movement (PLM) intensity|The mean change from Baseline to week 4 in Rechtschaffen and Kales polysomnography parameters|The mean change from baseline to week 4 in International Restless Legs Syndrome (IRLS) Rating Scale total score|The mean change from Baseline to week 4 in proportion of responders (""much""/ ""very much"" improved) on the investigator-rated Clinical Global Impression-Improvement (CGI-I) scale|The mean change from Baseline to week 4 in proportion of responders (""moderately better"" to ""a great deal better"") on the patient Global Impression of Change (PGIC) scale|The mean change from Baseline to week 4 in Post Sleep Questionnaire (PSQ)scores|The mean change from Baseline to week 4 in Subjective Sleep Questionnaire (SSQ) scores|The mean change from Baseline to week 4 in Restless Legs Syndrome Quality of Life Questionnaire (RLSQoL) scores|The mean change from Baseline to week 4 in Restless Legs Syndrome- Next Day Impact Questionnaire (RLS-NDI) scores|The mean change from Baseline to week 4 in the Epworth Sleepiness Scale (ESS) scores|Number of subjects with treatment emergent adverse events|Number of subjects with mild, moderate and severe adverse events","Cleveland Sleep Research Center|XenoPort, Inc.|YRT Limited","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","XP-IIT-0031","June 2015","June 2016","July 2016","April 23, 2015",,"April 23, 2015","Cleveland Sleep Research Center, Middleburg Heights, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02424695"
127,"NCT00825266","Insulin Resistance in Pulmonary Arterial Hypertension",,"Terminated","Has Results","Hypertension, Pulmonary","Drug: bosentan|Drug: Pioglitazone","Insulin Resistance Profile Change - Triglyceride:HDL Cholesterol Ratio|6 Minute Walk Test|NYHA (New York Heart Association Classification) Changes","Stanford University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SU-09052008-1295|IRB#7432","September 2008","May 2010","May 2010","January 21, 2009","March 31, 2017","March 31, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00825266"
128,"NCT02412761","Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension",,"Completed","Has Results","Essential Hypertension","Drug: Lisinopril|Drug: Amlodipine|Drug: Hydrochlorothiazide","The Number of Patients for Whom Each Drug is Selected as the Preferred Therapy","The University of Texas Health Science Center, Houston","All","9 Years to 22 Years   (Child, Adult)","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-13-0287|5KL2TR000370","June 2013","July 2016","July 2016","April 9, 2015","November 15, 2018","November 15, 2018","University of Texas at Houston Medical School; Pediatric Nephrology and Hypertension Clinics, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02412761"
129,"NCT03781739","MANP in Hypertension and Metabolic Syndrome","MANP-HTN-MS","Completed","No Results Available","Hypertension|Metabolic Syndrome","Drug: MANP","cardiovascular outcome|second messenger|metabolic outcome|secondary cardiovascular outcome|secondary metabolic outcome","Mayo Clinic|American Heart Association","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB # 16-005813","August 18, 2017","November 14, 2019","December 10, 2019","December 20, 2018",,"April 8, 2020","Mayo Foundation, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03781739"
130,"NCT02901067","STAT-STatin and Aspirin in Trauma","STAT","Recruiting","No Results Available","Wounds and Injuries|Venous Thromboembolism","Drug: Aspirin and Rosuvastatin|Drug: Placebo (for Aspirin and Rosuvastatin)","Incidence of VTE|Fibrinolysis phenotypes|Plasminogen activator inhibitor (PAI) - 1 and tissue plasminogen activator (tPA) levels in plasma|Incidence of acute lung injury (ALI)|Ventilator days|Incidence of arterial thrombotic complications: myocardial infarction (MI) and cerebrovascular accident (CVA).|All-cause mortality|Intensive care unit (ICU) days|Incidence of multiple organ failure (MOF)","Denver Health and Hospital Authority","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COMIRB 16-0391","February 3, 2017","December 2021","December 2021","September 15, 2016",,"June 3, 2019","Denver Health Medical Center, Denver, Colorado, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02901067/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02901067/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02901067"
131,"NCT04121299","Mechanism of Masked Hypertension - Intervention",,"Not yet recruiting","No Results Available","Masked Hypertension","Drug: Carvedilol|Drug: Amlodipine","Out of clinic 24 hour ambulatory blood pressure|Out of clinic awake blood pressure|Out of clinic asleep blood pressure|Out of clinic blood pressure variability|Out of clinic heart rate variability|Out of clinic 24-hour urinary catecholamines|Out of clinic 24-hour urinary metanephrines","University of Alabama at Birmingham","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB-300004152","September 2020","August 2025","August 2025","October 9, 2019",,"February 11, 2020","Hypertension Research Clinic at UAB, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04121299"
132,"NCT01328769","Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)",,"Completed","Has Results","Hypertension","Drug: Febuxostat|Drug: Placebo","Change in Renal Plasma Flow in Response to Infused Angiotensin II|Change in Endothelial Function","Paul N. Hopkins|University of Utah","All","18 Years to 60 Years   (Adult)","Phase 4","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","42916","March 2011","September 2013","January 2014","April 5, 2011","September 17, 2015","September 17, 2015","Cardiovascular Genetics, University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01328769"
133,"NCT02991118","Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk","CLEAR Wisdom","Completed","Has Results","Hypercholesterolemia|Atherosclerotic Cardiovascular Disease","Drug: bempedoic acid|Drug: placebo","Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)|Percent Change From Baseline to Week 24 in LDL-C|Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)|Percent Change From Baseline to Week 12 in Total Cholesterol (TC)|Percent Change From Baseline to Week 12 in Apolipoprotein b (Apo B)|Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)|Change From Baseline to Week 12 in LDL-C|Change From Baseline to Week 24 in LDL-C","Esperion Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","779","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1002-047|2016-003486-26","November 18, 2016","August 22, 2018","August 22, 2018","December 13, 2016","April 27, 2020","April 27, 2020","Clearwater, Florida, United States|Georgetown, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02991118/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02991118/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02991118"
134,"NCT00849810","Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate",,"Terminated","Has Results","Hypertension","Drug: Metoprolol|Drug: Nebivolol","Primary Outcome is Pre- and Post-treatment Ambulatory Blood Pressure.","University of Mississippi Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-0002","January 2009","November 2010","November 2010","February 24, 2009","March 19, 2013","March 19, 2013","University of Mississippi Medical Center, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT00849810"
135,"NCT00927459","Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol",,"Terminated","No Results Available","Hypercholesterolemia","Drug: PRO-040201|Drug: Placebo","Safety and tolerability of PRO-040201|Pharmacokinetics of PRO-040201 in Humans|Pharmacodynamics of PRO-040201 in Humans","Arbutus Biopharma Corporation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TKM-ApoB-001","June 2009","December 2009","January 2010","June 25, 2009",,"January 22, 2010","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00927459"
136,"NCT01157234","Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients",,"Completed","Has Results","Hypertension","Drug: Nebivolol|Drug: Metoprolol","Plasma Nitric Oxide Level Change From Baseline to Month 12 Between the Groups.|Estimated Glomerular Filtration Rate (ml/Minute) Change From Baseline to Month-12 Between the Groups|Systolic Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 of Treatment Between the Groups|Diastolic Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 Between the Groups|Mean Arterial Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 Between the Groups|Number of Antihypertensive Drug Classes Change From Baseline to Month-12 Between the Groups.|Plasma Asymmetric Dimethylarginine (ADMA) Change From Baseline to Month 12 Between the Groups|Plasma Arginine (ARG) Level Change From Baseline to Month-12 Between Groups","University of Florida|Forest Laboratories","All","18 Years and older   (Adult, Older Adult)","Phase 4","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BYS-MD-42","July 2010","July 2014","July 2014","July 5, 2010","March 24, 2016","March 24, 2016","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01157234"
137,"NCT02331095","Statin Use in Patients With Acute VTE",,"Unknown status","No Results Available","Venous Thromboembolism","Drug: Atorvastatin|Drug: Warfarin","The reduction of thrombin peak concentration|The composite rate of recurrent VTE and VTE related mortality|The rate of arterial thrombotic events|The rate of residual vein obstruction by doppler ultrasound|The rate of clinical post-thrombotic syndrome (PTS), as objectively evaluated with Villalta scoring system|The rate of major, non-major, and all hemorrhages defined by the ISTH (International Society on Thrombosis and Haemostasis) criteria|The levels of d-dimer, hs-CRP, liver function tests (AST, ALT, bilirubin), fasting lipid panel (total cholesterol, TG, HDL, LDL), inflammatory cytokines (IL-6, 8, and tissue necrosis factor-alpha)","Ohio State University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014H0262","January 2015","April 2019","October 2019","January 6, 2015",,"April 6, 2018","The Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02331095"
138,"NCT01414881","Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects",,"Completed","No Results Available","Healthy Volunteer","Drug: mipomersen|Drug: Placebo","Percent change in the production rate (PR) of very low density lipoprotein (VLDL) apolipoprotein B (apo B)|Fractional clearance rate (FCR) of VLDL Triglyceride (TG), VLDL apo B, intermediate density lipoprotein (IDL) apo B, and low-density lipoprotein (LDL) apo B|Production rate (PR) of VLDL-TG, IDL apo B, LDL apo B|Conversion of VLDL apo B to low-density lipoprotein (LDL) apo B|Direct removal of VLDL apo B from plasma|Post-heparin hepatic lipase and lipoprotein lipase activities in serum|Fasting plasma levels of fatty acids and beta-hydroxybutyrate|Incidence of adverse events (AEs) and serious adverse events (SAEs)","Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)","MIPO1600810","September 2011","June 2012","November 2012","August 11, 2011",,"August 3, 2016","Columbia-Presbyterian Medical Center, MS Care Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01414881"
139,"NCT02425566","Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension",,"Suspended","No Results Available","Hypertension","Drug: Trimethaphan|Drug: Nitroglycerin","Splanchnic venous capacitance|Systolic Blood Pressure|Stroke volume","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","141218","April 2015","July 2021","August 2021","April 24, 2015",,"April 10, 2020","Autonomic Dysfunction Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02425566"
140,"NCT03657797","Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Glaucoma, Open-Angle|Hypertension, Ocular","Drug: NCX 470|Drug: Latanoprost 0.005%","Reduction from baseline in mean diurnal IOP at the Week 4 Visit in the study eye|Number of subjects with adverse events as a measure of safety and tolerability","Nicox Ophthalmics, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","656","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NCX-470-17001","August 1, 2018","August 23, 2019","August 23, 2019","September 5, 2018",,"January 13, 2020","Texan Eye, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03657797"
141,"NCT03604289","Angiotensin 1-7 in Obesity Hypertension",,"Recruiting","No Results Available","Obesity|Hypertension","Drug: Angiotensin-(1-7)|Drug: Saline","Change in brachial artery diameter with reactive hyperemia|Heart Rate Variability|Circulating catecholamines|Change in coronary blood velocity to the cold pressor test|Change in systolic and diastolic blood pressure to the cold pressor test|Change in muscle sympathetic nerve activity to the cold pressor test","Amy Arnold|American Heart Association|Milton S. Hershey Medical Center","All","18 Years to 60 Years   (Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","STUDY00008170|18POST33960087","April 1, 2019","June 2022","June 2022","July 27, 2018",,"April 20, 2020","Penn State College of Medicine, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03604289"
142,"NCT00999752","Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension","NASAA","Completed","No Results Available","Hypertension","Drug: Nebivolol|Drug: Hydrochlorothiazide","Changes in systolic and diastolic blood pressure after treatment with nebivolol and reaching normal blood pressure <140/90|Differences after nebivolol treatment on diastolic function as measured by tissue doppler imaging (ECHO), arterial compliance and stiffness and vascular nitric oxide availability determined by neutrophil function","InVasc Therapeutics, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AVR-2009-02 (BYS-MD-27)","October 2009","February 2010","May 2010","October 22, 2009",,"May 5, 2011","Atlanta Vascular Research Foundation, Tucker, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00999752"
143,"NCT01170884","Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution|Drug: bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops","Mean Diurnal Intraocular Pressure (IOP) at Week 12","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","GMA-COM-09-013","December 2009","September 2010","September 2010","July 27, 2010","January 12, 2012","April 24, 2019","Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01170884"
144,"NCT01212874","Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery",,"Completed","Has Results","Hypertension","Drug: nitroglycerin|Drug: esmolol","Diastolic Blood Pressure Excursions Beyond Predetermined Lower Limits, Normalized Per Hour|Title: Systolic Hypertension","Loma Linda University","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5100218","December 2010","June 2014","June 2014","October 1, 2010","August 17, 2016","March 1, 2019","Loma Linda University, Loma Linda, California, United States",,"https://ClinicalTrials.gov/show/NCT01212874"
145,"NCT02253394","The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study",,"Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: Ambrisentan plus Spironolactone|Drug: Ambrisentan plus Placebo","Effect of Combination Ambrisentan + Spironolactone on Peak Volume of Oxygen Consumption (pVO2) and Cardiac Output","Brigham and Women's Hospital|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","2","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","CAPS_PAH","September 2015","February 2018","February 2018","October 1, 2014","November 15, 2019","November 15, 2019","Brigham & Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02253394/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02253394"
146,"NCT02507011","Beta-blockers in Pulmonary Arterial Hypertension",,"Terminated","No Results Available","Pulmonary Arterial Hypertension","Drug: Carvedilol|Drug: Placebo","Mean change in Right Ventricular Ejection Fraction as measured by cardiac MRI","University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1504M69361","January 31, 2016","July 1, 2019","July 1, 2019","July 23, 2015",,"April 24, 2020","University of Minnesota Medical Center, Minneapolis, Minnesota, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02507011/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02507011"
147,"NCT01009944","Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study",,"Terminated","No Results Available","Hypertension","Drug: Lisinopril, Atenolol","One type of blood pressure medication will better treat individuals with certain genetic backgrounds.","Brigham and Women's Hospital|University of Utah","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007p002290","January 2007","March 19, 2019","March 19, 2019","November 9, 2009",,"March 21, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01009944"
148,"NCT01005290","A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure",,"Terminated","Has Results","Hypertension","Drug: Combination pill|Drug: Ramipril","Difference in the Adjusted Mean 24-h Systolic Pressure Results (Using ABPM) Between the Basal and the Final Visit of Each Treatment Period.|Difference in the Adjusted Mean 24-h Diastolic Pressure Results Between the Basal and the Final Visit of Each Treatment Period","Ferrer Internacional S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 2","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","P-080646-01","October 2009","October 2010","October 2010","October 30, 2009","July 26, 2012","July 26, 2012","Mount Sinai Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01005290"
149,"NCT04116112","Blood Pressure After Endovascular Stroke Therapy-II","BEST-II","Recruiting","No Results Available","Acute Stroke|Endovascular Thrombectomy","Drug: Nicardipine|Drug: Labetalol|Drug: Hydralazine","Final Infarct Volume|Utility-weighted modified Rankin Score|Number of participants with any hemorrhagic transformation|Number of participants with symptomatic hemorrhagic transformation|Number of participants with neurological worsening associated with antihypertensive treatment","Vanderbilt University Medical Center|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","191520|K23NS113858","January 17, 2020","March 30, 2023","March 30, 2023","October 4, 2019",,"January 22, 2020","Vanderbilt Univeristy Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04116112"
150,"NCT01324388","A Study of the Effect of LY2189265 on Two Blood Pressure Drugs",,"Completed","Has Results","Diabetes Mellitus, Type 2","Biological: LY2189265|Drug: Metoprolol|Drug: Lisinopril|Drug: Placebo","Pharmacokinetics, Area Under the Concentration Curve (AUC) of Lisinopril|Pharmacokinetics, Maximum Concentration (Cmax) of Lisinopril|Mean, 24-hour Heart Rate (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol|Mean, 24-hour Blood Pressure (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol|Mean, 24-hour Heart Rate (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Lisinopril|Mean, 24-hour Blood Pressure (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Lisinopril|Pharmacokinetics, Area Under the Concentration Curve (AUC) of Metoprolol When Administered With LY2189265|Pharmacokinetics, Maximum Concentration (Cmax) of Metoprolol When Administered With LY2189265","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 1","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","11552|H9X-MC-GBCO","March 2011","August 2011","August 2011","March 29, 2011","October 8, 2014","October 8, 2014","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01324388"
151,"NCT01671085","A Study of LY3015014 in Healthy Participants With High Cholesterol",,"Completed","Has Results","Healthy Volunteers|Hypercholesterolemia","Drug: LY3015014|Drug: Placebo","Number of Participants With One or More Other Non-Serious Adverse Events (AEs) or Any Serious AEs (SAEs)|Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3015014|PK: Area Under the Concentration Curve During One Dosing Interval (AUCt) of LY3015014|PK: Time of Maximum Concentration (Tmax) of LY3015014|Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","14938|I5S-EW-EFJD","August 2012","March 2013","March 2013","August 23, 2012","February 25, 2019","March 15, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miramar, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01671085"
152,"NCT03270332","Effect of Inhaled Albuterol in Pulmonary Hypertension",,"Recruiting","No Results Available","Pulmonary Hypertension","Drug: albuterol first then placebo|Drug: placebo first then albuterol","Mean Pulmonary Artery Pressure|Pulmonary Vascular Resistance","University of Miami","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20170552","October 12, 2017","June 30, 2020","September 30, 2020","September 1, 2017",,"November 8, 2019","Pulmonary Human Research Laboratory, University of Miami, Miller School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03270332"
153,"NCT03245970","Impedance Cardiography to Decrease the Risk of Preeclampsia",,"Recruiting","No Results Available","Chronic Hypertension Complicating Pregnancy (Diagnosis)|Preeclampsia","Drug: Labetalol Hydrocholoride 200 mg orally every 12 hours|Drug: Nifedipine 60 mg orally daily|Drug: Atenolol 25 mg daily","Rates of preeclampsia in chronically hypertensive pregnant women","High Risk Obstetrical Consultants","Female","18 Years to 51 Years   (Adult)","Early Phase 1","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","4222","April 24, 2017","December 31, 2019","April 24, 2020","August 10, 2017",,"February 27, 2019","HIgh Risk Obstetrical Consultants, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03245970"
154,"NCT02108743","Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension",,"Withdrawn","No Results Available","Idiopathic Pulmonary Arterial Hypertension.","Drug: Albuterol.|Drug: Normal saline placebo","End-expiratory lung volume:total lung capacity (EELV/TLC) ratio at matched metabolic isowork.|Change in peak oxygen consumption with albuterol|Change in O2 pulse with albuterol.|Exercise time|Borg dyspnea score","American Medical Association Foundation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB8603","June 2014","July 2016","October 2016","April 9, 2014",,"December 30, 2015","LSUHSC Interim Louisiana Hospital, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT02108743"
155,"NCT01758744","Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1","TAPIT-1","Completed","No Results Available","Pulmonary Hypertension|COPD","Drug: Inhaled Treprostinil Therapy","To assess the safety of Tyvaso ® as assessed by changes or stability of acute oxygenation (pulse oximetry) and spirometry (FEV1).|New York Heart Association (NYHA) functional class|Six minute walk distance|Clinical Worsening|Peripheral Blood Mononuclear Cells (PBMC) phagocytic index (PI) and PBMC gene expression|St. George's Chronic Obstructive Pulmonary Disease (COPD) questionnaire","University of Colorado, Denver","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-0560","December 2012","July 2016","July 2016","January 1, 2013",,"July 20, 2016","University of Colorado Denver, Aurora, Colorado, United States|University of Florida College of Medicine, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01758744"
156,"NCT00887653","Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy",,"Completed","Has Results","HIV|Hyperlipidemia|Hypertriglyceridemia|HIV Infections","Drug: raltegravir","Change From Baseline Triglycerides|Proportion of Patients With Plasma Viral Load Below the Limit of Detection","The Miriam Hospital|Tufts Medical Center|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 3","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-09","May 2009","June 2012","April 2014","April 24, 2009","October 10, 2014","October 10, 2014","Tufts University, Boston, Massachusetts, United States|Miriam Hospital Immunology Clinic, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT00887653"
157,"NCT02417246","Open-Labeled PK-PD Studies of Metoprolol ER",,"Completed","Has Results","Blood Pressure","Drug: brand name metoprolol ER|Drug: Generic A|Drug: Generic B","Area Under the Plasma Concentration Versus Time Curve (AUC)|Peak Plasma Concentration (Cmax) of Metoprolol Succinate|The Heart Rate Variability (HRV) Response to Brand Name Metoprolol ER Versus Each Generic Formulation of Metoprolol Succinate.|Blood Pressure Values (Systolic and Diastolic) Compared Between Brand Name Metoprolol ER and Each Generic Metoprolol Formulation (Generic B, Generic A)|Heart Rate (HR) Response Compared Between Brand Name Metoprolol ER and Each Generic (Generic B, Generic A) Formulation of Metoprolol Succinate","University of Florida|Food and Drug Administration (FDA)","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 4","61","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB201500092|FD14-024|OCR15985","August 2015","June 6, 2018","June 6, 2018","April 15, 2015","November 8, 2019","February 10, 2020","Family Medicine at Hampton Oaks Medical Plaza, Gainesville, Florida, United States|Oak Hammock at the University of Florida, Gainesville, Florida, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02417246/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02417246"
158,"NCT01712620","Spironolactone for Pulmonary Arterial Hypertension",,"Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Spironolactone|Drug: Placebo","Change in placebo corrected 6-minute walk distance|Change in placebo corrected VO2 max|Change in right ventricular function|Biomarkers of vascular inflammation|Rate of study drug discontinuation due to hyperkalemia, renal insufficiency, or other side effects such as breast pain and gynecomastia","National Institutes of Health Clinical Center (CC)|National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pennsylvania|University of Maryland, College Park|Washington Hospital Center|New England Medical Center, Tufts University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","120211|12-CC-0211","January 10, 2014","October 1, 2021","October 1, 2021","October 23, 2012",,"May 1, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01712620"
159,"NCT01523548","Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension","CO in PAH","Withdrawn","No Results Available","Hypertension, Pulmonary","Drug: Carbon Monoxide","Evidence of a 20% decrease in pulmonary vascular resistance post-therapy when compared to pre-therapy value|Effect of 16-weeks CO inhalation on other pulmonary and systemic hemodynamic parameters|Effect of 16-weeks CO inhalation on functional capacity assessed by six-minute walk test|Effect of 16-weeks CO inhalation on Brain Natriuretic Peptide levels|Effect of 16-weeks CO inhalation on right ventricular echocardiographic parameters|Effect of 16-weeks CO inhalation on acute pulmonary vasoreactivity","University of Illinois at Chicago|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-06425|K23HL098454","July 2012","December 2018","December 2018","February 1, 2012",,"June 9, 2017","University of Illinois at Chicago Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01523548"
160,"NCT01114360","Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study",,"Completed","Has Results","Hypertension","Drug: Melatonin|Drug: Placebo","Mean Nighttime Systolic Blood Pressure (SBP)|Mean Nighttime Diastolic Blood Pressure (DBP)|Mean Nighttime Mean Arterial Pressure (MAP)|Mean Nighttime Heart Rate (HR)|Mean Daytime Systolic Blood Pressure (SBP)|Mean Daytime Diastolic Blood Pressure (DBP)|Mean Daytime Mean Arterial Pressure (MAP)|Mean Daytime Heart Rate (HR)|Urinary Dopamine Excretion Rate|Urinary Noradrenaline Excretion Rate|Urinary Adrenaline Excretion Rate|Plasma E-Selectin|Plasma P-Selectin|Total Sleep Time|Nocturnal Dipping of Blood Pressure|Percentage of Participants With Melatonin-related Side Effect.","Emory University|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years to 64 Years   (Adult)","Phase 2","37","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00021300|1R21AT004509-01A2","March 2010","September 2013","September 2014","May 3, 2010","December 18, 2015","December 18, 2015","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01114360"
161,"NCT01114373","Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study",,"Completed","Has Results","Hypertension","Drug: Melatonin|Drug: Placebo","Mean Nighttime Systolic Blood Pressure (SBP)|Mean Nighttime Diastolic Blood Pressure (DBP)|Mean Nighttime Mean Arterial Pressure (MAP)|Mean Nighttime Heart Rate (HR)|Mean Daytime Systolic Blood Pressure (SBP)|Mean Daytime Diastolic Blood Pressure (DBP)|Mean Daytime Mean Arterial Pressure (MAP)|Mean Daytime Heart Rate (HR)|Urinary Dopamine Excretion Rate|Urinary Noradrenaline Excretion Rate|Urinary Adrenaline Excretion Rate|Plasma E-Selectin|Plasma P-Selectin|Total Sleep Time","Emory University|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years to 64 Years   (Adult)","Phase 2","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00021300a|3R21AT004509-01A2S1","June 2010","September 2013","September 2014","May 3, 2010","December 18, 2015","February 26, 2016","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01114373"
162,"NCT00931710","Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension","EXALT","Completed","Has Results","Stage 2 Systolic Hypertension","Drug: valsartan, amlodipine, HCTZ|Drug: Losartan, HCTZ followed by valsartan, amlodipine, HCTZ","Change in Mean Sitting Systolic Blood Pressure After 6 Weeks|Change in Mean Sitting Diastolic Blood Pressure After 6 Weeks|Cumulative Percentage of Patients Achieving Blood Pressure Control|Cumulative Percentage of Treatment Responders|Change in Mean Sitting Systolic and Diastolic Blood Pressure After 12 Weeks|Cumulative Percentage of Patients With Incidence of Peripheral Edema Before or at the Corresponding Visit","Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 4","488","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CVEA489AUS01","July 2009","January 2010","January 2010","July 2, 2009","February 4, 2011","March 7, 2011","sites in USA, East Hanover, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00931710"
163,"NCT03522935","Subcutaneous Elafin in Healthy Subjects",,"Active, not recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Elafin|Drug: Placebo","Incidence of Treatment-Emergent Adverse Events in healthy controls.|Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: AUC0-last","Roham T. Zamanian|Duke University|SRI International|Stanford University","All","18 Years to 55 Years   (Adult)","Phase 1","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","42336","March 18, 2019","April 1, 2020","July 1, 2020","May 14, 2018",,"March 25, 2020","Duke Early Phase Research Unit (DEPRU), Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03522935"
164,"NCT03885661","Vascepa to Accelerate Lipoprotein Uptake and Elimination","VALUE","Active, not recruiting","No Results Available","Lipid Disorder|Triglycerides High|Dyslipidemias","Drug: Icosapent Ethyl 1000 MG [Vascepa]","Change in VLDL-apoB100 production rate","University of Pennsylvania|Amarin Pharma Inc.","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 1",,"Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other","823489|AMR-01-01-0024","January 11, 2016","December 2019","December 2019","March 21, 2019",,"March 21, 2019","Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03885661"
165,"NCT01701622","The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study",,"Terminated","Has Results","Blood Pressure|Gout","Drug: febuxostat","BP Differences While on Allopurinol and Febuxostat by Clinic Blood Pressure Readings and 24-hour Ambulatory Blood Pressure Readings|If Patients With Hypertension Receive a Greater Reduction in Blood Pressure (BP) While on Febuxostat (Versus Allopurinol)","University of Mississippi Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-0186","January 2010","October 2011","October 2011","October 5, 2012","February 11, 2013","January 12, 2018","University of Mississippi Medical Center General Medicine/Hypertension and Family Medicine Clinics, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT01701622"
166,"NCT01961453","Effect of Isosorbide Mononitrate on Hypertension to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function","ISMN","Withdrawn","No Results Available","Hypertension","Drug: Isosorbide Mononitrate, sustained release|Drug: Placebo capsule","Change in left ventricular mass|Change in extracellular volume fraction|Change in peak myocardial systolic longitudinal strain measured by MRI|Change in peak early diastolic intraventricular pressure gradient measured by MRI|Change in late systolic hypertension derived from pulse wave analysis","Corporal Michael J. Crescenz VA Medical Center","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 2","0","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01442","August 2013","January 2016","January 2016","October 11, 2013",,"August 11, 2016","Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01961453"
167,"NCT03223272","Mechanisms of Refractory Hypertension (Reserpine)",,"Recruiting","No Results Available","Refractory Hypertension","Drug: Reserpine","Ambulatory Systolic Blood Pressure","University of Alabama at Birmingham","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","130822008","July 23, 2015","March 31, 2020","October 30, 2020","July 21, 2017",,"February 19, 2020","UAB, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03223272"
168,"NCT01180062","Safety Study of Latanoprost Slow Release Insert","Latanoprost SR","Terminated","No Results Available","Primary Open Angle Glaucoma (POAG)|Ocular Hypertension (OHT)","Drug: Latanoprost|Drug: Arm 2|Drug: Latanoprost SR insert","Intraocular Pressure|Intraocular pressure parameters i.e. mean IOP, IOP range, percentage reduction in IOP, IOP fluctuation.","Daniel Moore|Pfizer|University of Kentucky","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-0476-F1V|IND# 109,182","January 2011","June 2014","June 2014","August 11, 2010",,"December 8, 2014","Univ of Ky Dept of Ophthalmology and Visual Sciences, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT01180062"
169,"NCT01961323","Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart",,"Completed","Has Results","Hypertension|Left Ventricular Diastolic Dysfunction","Drug: Nebivolol","Improvement in Exercise Tolerance|E Velocity Indexed to e' (E/e' Ratio) of the Left Ventricle|Untwist Rate of the Left Ventricle","Icahn School of Medicine at Mount Sinai|Forest Laboratories","All","18 Years and older   (Adult, Older Adult)","Phase 4","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 12-0493","March 2012","March 2016","March 2016","October 11, 2013","November 24, 2017","November 24, 2017","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01961323"
170,"NCT02891174","The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy",,"Completed","Has Results","Hypertension, Pregnancy-Induced|Pre-eclampsia","Drug: Ibuprofen|Drug: Acetaminophen","Difference in Systolic Blood Pressure (SBP)|Change in Self-reported Pain Score 2 Hours After First Intervention|Mean Pain Score by Nursing Assessment|Satisfaction With Pain Control During 24 Hours of Exposure Each to Ibuprofen and Acetaminophen","University of Michigan","Female","18 Years to 45 Years   (Adult)","Phase 4","74","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HUM00117154","December 1, 2016","March 31, 2018","June 20, 2018","September 7, 2016","May 23, 2019","May 23, 2019","University of Michigan, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02891174/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02891174"
171,"NCT03556761","Furosemide for Accelerated Recovery of Blood Pressure Postpartum","ForBP","Recruiting","No Results Available","Hypertension, Pregnancy-Induced","Drug: Oral furosemide|Drug: Placebo Oral Tablet","Persistently elevated blood pressures 7 days postpartum|Time to resolution|Postpartum readmission|Frequency of severe hypertension|Postpartum length of stay|Complications during hospitalization|Adverse effects","University of Pennsylvania","Female","18 Years to 55 Years   (Adult)","Phase 2","385","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","829444","June 20, 2018","March 2020","May 2020","June 14, 2018",,"June 18, 2019","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03556761"
172,"NCT00999102","Nebivolol Versus Metoprolol: Comparative Effects on Fatigue and Quality of Life",,"Completed","Has Results","Hypertension","Drug: Metoprolol|Drug: Nebivolol","Multidimensional Assessment of Fatigue (MAF) Questionnaire: Global Fatigue Score After 4 Weeks of Treatment on Each Drug/Dose Combination.|Treadmill Exercise Time After 4 Weeks of Treatment on Each Drug/Dose Combination.","Weill Medical College of Cornell University|Forest Laboratories","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 4","37","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0901010162","October 2009","January 2011","January 2011","October 21, 2009","October 19, 2018","October 19, 2018","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00999102"
173,"NCT00851929","Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension",,"Completed","No Results Available","Sarcoidosis|Pulmonary Hypertension","Drug: Ambrisentan","Change in 6 minute walk distance.","Medical University of South Carolina|Gilead Sciences","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2|Phase 3","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17747","November 2008","April 2011","November 2011","February 26, 2009",,"August 2, 2018","University of North Carolina Medical Center, Chapel Hill, North Carolina, United States|Medical Univerrsity of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00851929"
174,"NCT01681810","Oral Nitrite in Adults With Metabolic Syndrome and Hypertension","ONTX","Completed","Has Results","Metabolic Syndrome|Hypertension","Drug: 14Nitrogen Sodium Nitrite","Change in Insulin Stimulated Glucose Disposal Over 12 Week Study Period|Peak Change in Systolic Blood Pressure Over 12 Week Study Period|Peak Change in Diastolic Blood Pressure Over 12 Week Study Period|Peak Change in Mean Arterial Pressure Over 12 Week Study Period|Peak Change in Methemoglobin Over 12 Week Study Period","Gladwin, Mark, MD|University of Pittsburgh","All","18 Years to 60 Years   (Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO11030131","October 2012","February 8, 2018","March 8, 2018","September 10, 2012","April 16, 2019","April 16, 2019","Montefiore Hospital of University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT01681810/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT01681810/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT01681810"
175,"NCT04062565","Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH",,"Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Treprostinil Injectable Product|Drug: Riociguat Pill","Change in stroke volume/end systolic volume (SV/ESV)|Change in pulmonary and cardiac pressures|Change in pulmonary blood flow|Change in end-systolic elastance/arterial elastance (Ees/Ea)|Change in Right Ventricle (RV) diastolic stiffness (Beta)|Change in 6 minute walk distance|Change in brain natriuretic peptide (BNP)|Change in magnetic resonance imaging (MRI) right ventricle volumes|Change in Cardio pulmonary Exercise Testing (CPET)|Change in derived VO2 max|Change in derived Ve/VCO2|Change in adverse event profile|Change in composite time to clinical worsening","University of Arizona","All","18 Years and older   (Adult, Older Adult)","Phase 3","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1812168816","March 25, 2019","December 2020","December 2021","August 20, 2019",,"August 20, 2019","University of Arizona, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04062565"
176,"NCT00845299","Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: Latanoprost punctal plug|Drug: artificial tears preserved with Benzalkonium Chloride","IOP change from baseline","Mati Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPL GLAU 04","January 2009","December 2009","December 2009","February 18, 2009",,"September 19, 2013","Menlo Park, California, United States",,"https://ClinicalTrials.gov/show/NCT00845299"
177,"NCT03044314","Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension","OVATION","Recruiting","No Results Available","Pulmonary Hypertension","Drug: Illoprost and nitric oxide administration","Change in invasively measured pulmonary artery pressures after challenge with NO and iloprost|Change in echocardiographic and invasively measured parameters after vasodilator challenge|Change in PA pressure and mean pressure determined invasively after vasodilator challenge|Clinical response to vasodilator challenge by echo|Association of change in pressures after vasodilator challenge with clinical outcomes","Duke University|Actelion","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00075840","July 21, 2017","December 1, 2020","December 1, 2020","February 7, 2017",,"February 20, 2020","Duke University Health System, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03044314"
178,"NCT00899977","TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension",,"Terminated","No Results Available","Refractory Hypertension","Drug: Placebo|Drug: TC-5214","Mean difference between TC-5214 and placebo in change at 3 hours from baseline SBP|Safety and tolerability of TC-5214 in patients with refractory hypertension and obtain preliminary dose-response estimates","Targacept Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TC-5214-23-CRD-002","May 2009","August 2009","December 2009","May 12, 2009",,"September 13, 2013","Piedmont Medical Research, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00899977"
179,"NCT01202175","Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension",,"Completed","Has Results","Pre-hypertension|Hypertension","Drug: Nebivolol","Aortic Systolic Blood Pressure (SBP)|Aortic Diastolic Blood Pressure (DBP)|Aortic Mean Arterial Pressure (MAP)|Aortic Pulse Pressure|Aortic Augmentation Pressure|Aortic Augmentation Index for Heart Rate|Pulse Wave Velocity|Heart Rate, Beats Per a Minute|Urinary Nitric Oxide Excretion|Urinary Isoprostane Excretion|Urinary Hydrogen Peroxide Excretion|Plasma Interleukin Levels","University of California, San Diego|Forest Laboratories","All","18 Years to 50 Years   (Adult)","Phase 4","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","100353","July 2010","June 2012","June 2013","September 15, 2010","August 21, 2019","August 21, 2019","University of California, San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT01202175"
180,"NCT01873885","Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension",,"Completed","No Results Available","Essential Hypertension","Drug: Placebo Single IV (Intravenous) Infusion|Drug: Experimental: Single IV Infusion Vasomera (PB1046)","Safety and Tolerability|Pharmacokinetic Profile|Hemodynamic Parameters|Immunogenicity Assessment","PhaseBio Pharmaceuticals Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PB1046-PT-CL-0002","June 2013","March 2014","March 2014","June 10, 2013",,"April 10, 2014","New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01873885"
181,"NCT03349775","Cardiometabolic Disease and Pulmonary Hypertension",,"Recruiting","No Results Available","Obesity","Drug: Metformin|Drug: Placebo","Pulmonary vascular hemodynamics (rest)|Pulmonary vascular hemodynamics (exercise)|Effect on pulmonary artery endothelial cell phenotypes","Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)","All","30 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","75","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","2017P001020|1R01HL134893-01A1","November 27, 2017","September 1, 2022","September 1, 2024","November 22, 2017",,"February 19, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03349775"
182,"NCT00820300","A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: Latanoprost-PPDS","IOP change from baseline","Mati Therapeutics Inc.","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","113","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPL GLAU 03","January 2009","December 2009","December 2009","January 12, 2009",,"September 19, 2013","Menlo Park, California, United States",,"https://ClinicalTrials.gov/show/NCT00820300"
183,"NCT02304705","Sildenafil in Heart Failure With Reactive Pulmonary Hypertension","Sildenafil-HF","Terminated","Has Results","Heart Failure With Reactive Pulmonary Hypertension","Drug: Sildenafil|Drug: Placebo","Change in Exercise Tolerance","Maya Guglin|University of Kentucky","All","18 Years and older   (Adult, Older Adult)","Phase 4","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14-0628-F3R","January 2015","June 2017","June 2017","December 2, 2014","March 13, 2019","November 7, 2019","University of Kentucky Medical Center, Lexington, Kentucky, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02304705/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02304705"
184,"NCT01682837","Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension",,"Completed","Has Results","Hypertension","Drug: Potassium chloride powder|Drug: Potassium citrate powder|Drug: Potassium magnesium citrate powder|Drug: Placebo","24-hour Average Systolic Blood Pressure|24-hour Average Diastolic Blood Pressure|Office Systolic Blood Pressure|Office Diastolic Blood Pressure|Serum C-terminal Telopeptide (CTX)|24-hour Urinary Calcium|Carotid to Femoral Pulse Wave Velocity|Central Aortic Systolic Blood Pressure|Central Aortic Diastolic Blood Pressure","University of Texas Southwestern Medical Center","All","21 Years and older   (Adult, Older Adult)","Phase 2","35","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LiqKMgCit-1208-01","October 2012","March 2015","March 2015","September 11, 2012","April 28, 2017","April 28, 2017","Hypertension Clinic - UT Southwestern Medical Center at Dallas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01682837"
185,"NCT01366976","Inhibition of Lipid Peroxidation During Cardiac Surgery",,"Completed","Has Results","Cardiopulmonary Bypass Induced Lipid Peroxidation","Drug: Acetaminophen","Plasma Isofuran Concentrations|Plasma F2-isoprostane Concentrations|Urinary NGAL (Neutrophil Gelatinase-associated Lipocalin)|Serum Creatinine","Vanderbilt University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","67","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","110423","July 2011","June 2013","June 2013","June 6, 2011","January 14, 2015","January 27, 2015","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01366976"
186,"NCT02634606","Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood","TRF","Terminated","Has Results","Hypercholesterolemia","Drug: Gamma Delta Tocotrienols - Low Dose|Drug: Gamma Delta Tocotrienols - High Dose|Drug: Sugar Pill","Change in LDL Cholesterol Over Time Between the 3 Groups","University of California, Los Angeles","All","35 Years to 70 Years   (Adult, Older Adult)","Phase 3","13","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","TOCO 11-000665","March 22, 2011","November 13, 2015","November 13, 2015","December 18, 2015","February 12, 2019","February 12, 2019","UCLA Center for Human Nutrition, 900 Veteran Avenue, WH 14-187, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02634606"
187,"NCT02030314","The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone",,"Withdrawn","No Results Available","Resistant Hypertension in Kidney Transplant Patients","Drug: Chlorthalidone","Change from mean baseline systolic blood pressure (by ABPM) between week 0, 1 and 7, ANOVA ABPM at baseline, week 1 and end of the study, Least-squares mean and standard error of the mean for changes in blood pressure measures,","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM20002960","July 2013","April 12, 2017","April 12, 2017","January 8, 2014",,"June 15, 2017","Virginia Commonwealtlh University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02030314"
188,"NCT00952081","A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients",,"Completed","Has Results","Hypertension|Brain Tumor|Epilepsy","Drug: Clevidipine","The Primary Endpoint of This Trial is the Proportion of Patients Who Did Not Require Rescue Antihypertensive Medication to Maintain SBP Below 130 mmHg (i.e. Clevidipine is a Sole Antihypertensive Agent Used for Blood Pressure Control)","NYU Langone Health|The Medicines Company","All","21 Years and older   (Adult, Older Adult)","Phase 4","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-745","July 2009","December 2009","February 2010","August 4, 2009","October 30, 2013","February 9, 2015","NYU Langone Medical Center, Department of Anesthesiology, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00952081"
189,"NCT03938389","The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans",,"Recruiting","No Results Available","PreDiabetes|Impaired Glucose Tolerance|Obesity|Blood Pressure","Drug: Sacubitril-Valsartan Tab 97-103 MG|Drug: Valsartan 160mg|Drug: Placebo Oral Tablet","Change from Baseline to 26 weeks in β-cell function (first-phase insulin secretion)|Change in Central Aortic Pressure (mmHg) from Baseline to 26 weeks","Ohio State University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","90","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2018H0061|K23DK117041","February 25, 2020","August 2021","December 2021","May 6, 2019",,"February 20, 2020","The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03938389"
190,"NCT01034540","Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia",,"Completed","Has Results","Hypertriglyceridemia","Drug: POM3|Drug: Placebo","Difference Between Treatments in Liquid Meal Tolerance Test (LMTT) Matsuda Insulin Sensitivity Index (MISI).|Difference Between Treatments in LMTT Insulin Secretion Index and Disposition Index.","Provident Clinical Research|GlaxoSmithKline","All","18 Years to 79 Years   (Adult, Older Adult)","Not Applicable","23","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PRV-09009","March 2010","December 2010","February 2011","December 17, 2009","October 22, 2013","October 22, 2013","Provident Clinical Research (now Biofortis), Addison, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01034540"
191,"NCT00964678","Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension",,"Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Carvedilol","Absolute Change in Right Ventricular Ejection Fraction|Change in Right Ventricular End Systolic Volume|Change in 6 Minute Walk Distance|Change in Tricuspid Annular Plane Systolic Excursion","Virginia Commonwealth University|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM12120","June 2010","May 2014","May 2014","August 25, 2009","June 8, 2017","June 8, 2017","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00964678"
192,"NCT01862536","Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease","TADA-PHILD","Active, not recruiting","No Results Available","Pulmonary Hypertension|Chronic Obstructive Pulmonary Disease (COPD)","Drug: Tadalafil|Drug: placebo","Change in 6 minute walk test|Maximum volume of oxygen extraction on exercise testing|Pulmonary vascular resistance|Mean pulmonary artery pressure|Tricuspid annular plane excursion (TAPSE)|Dyspnea and health related quality of life (HRQL)|N-type brain natriuretic peptide (BNP) concentration|Resting Hypoxemia|Exercise-induced hypoxemia","VA Office of Research and Development","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 2","64","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLIN-008-12F","October 1, 2013","August 31, 2019","June 30, 2020","May 24, 2013",,"December 13, 2019","VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|VA Eastern Colorado Health Care System, Denver, CO, Denver, Colorado, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States|Providence VA Medical Center, Providence, RI, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01862536"
193,"NCT03762395","Anti Inflammatory Lipid Mediators in Asthma","ALMA","Recruiting","No Results Available","Asthma|Obesity","Drug: CXA-10|Drug: Matching Placebo","Change in Methacholine challenge dose per spirometry","University of Colorado, Denver|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","19-0510|5R01HL132550-03","September 10, 2019","August 2021","August 2021","December 3, 2018",,"February 28, 2020","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03762395"
194,"NCT02220634","Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension","RHINO","Terminated","No Results Available","Pulmonary Hypertension","Drug: Regadenoson","Number of people","National Jewish Health|Astellas Pharma Inc","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS-2820","August 2014","May 25, 2017","May 25, 2017","August 20, 2014",,"August 24, 2018","National Jewish Health, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02220634"
195,"NCT02885012","Crossover Study From Macitentan or Bosentan Over to Ambrisentan","Letairis","Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: Ambrisentan","Change in Stroke Volume|Change in EmPHasis-10 Score|Disease Status as Measured by Change in Biomarker","Medical University of South Carolina|Ochsner Health System","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00046009","June 2016","July 7, 2017","July 7, 2017","August 31, 2016","April 8, 2019","April 8, 2019","Ochsner Medical Center, New Orleans, Louisiana, United States|Medical University of South Carolina, Charleston, South Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02885012/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02885012"
196,"NCT01687426","Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Glaucoma and Ocular Hypertension","Drug: Brimonidine Tartrate 0.025%|Drug: Vehicle","IOP","Eye Therapies, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12-150-0001","September 2012","December 2012","December 2012","September 19, 2012",,"December 25, 2012","Clinical Site, Winchester, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01687426"
197,"NCT01757808","A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Ranolazine|Drug: Placebo","Change in pulmonary vascular resistance (PVR)|Change in CPET (VE/VCO2, PETCO2, peak VO2, peak HR, peak RER, work max (MET or Watt), sub maximum exercise time|Change in RV echo parameters: 2D, 3D|Change in 6MWD|Safety/SAE","University of Chicago","All","18 Years to 72 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11-0301","August 2011","January 2015","January 2015","December 31, 2012",,"March 3, 2017","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01757808"
198,"NCT01833455","Premature Ventricular Contractions (PVCs) and Blood Pressure Control",,"Terminated","Has Results","Ventricular Premature Complexes|Blood Pressure","Drug: PVC Suppression using Flecainide|Drug: No PVC Suppression using Placebo","Change in Mean Arterial Pressure|Change in Muscle Sympathetic Nerve Activity","University of Wisconsin, Madison","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","UW-PVC-2012-0510","February 2013","June 2016","June 2016","April 16, 2013","February 22, 2019","February 22, 2019","University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01833455"
199,"NCT00927394","Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus","ViVID","Completed","Has Results","Hypertension","Drug: Aliskiren|Drug: Valsartan|Drug: Placebo for Aliskiren|Drug: Placebo for Valsartan","Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (MASBP) at Week 8|Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)|Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (MADBP) at Week 8|Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure (MAPP) at Week 8|Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)|Change From Baseline in Mean Sitting Pulse Pressure (MSPP) at Week 8|Percentage of Patients Achieving Blood Pressure Control|Percentage of Responders|Change From Baseline in Plasma Renin Activity (PRA) at Week 8|Change From Baseline in Plasma Renin Concentration (PRC) at Week 8|Change From Baseline in Plasma Aldosterone at Week 8|Number of Patients With Adverse Events, Serious Adverse Events and Death","Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 4","1143","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CSPV100AUS02","May 2009","October 2011","October 2011","June 25, 2009","October 31, 2012","December 6, 2012","Investigative Site, Newark, Delaware, United States|Investigative Site, Kansas, Missouri, United States|Investigative Site, Camden, New Jersey, United States|Investigative Site, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00927394"
200,"NCT01022398","Vitamin D Replacement: The Effect on Statin-Related Myalgias",,"Terminated","Has Results","HMG-CoA Reductase Inhibitors-related Myalgias","Drug: cholecalciferol/placebo","Determine if the Replacement of Vitamin D 10,000 IU Weekly Will Decrease the Discontinuation Rate of Statin Therapy and Decrease the Incidence of Statin-related Myalgia in Patients Requiring Statin Therapy","Creighton University","All","19 Years to 89 Years   (Adult, Older Adult)","Not Applicable","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","09-15532","February 2010","June 2011","June 2011","December 1, 2009","May 20, 2013","May 20, 2013","The Cardiac Center at Creighton University, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01022398"
201,"NCT01072643","Sedation With Dexmedetomidine During Cardiac Catheterization",,"Terminated","Has Results","Pulmonary Hypertension","Drug: Dexmedetomidine","The Primary Endpoint Will be the Change in PVR in Wood Units|Efficacy of Sedation With DEX|Quantify the Effect of DEX on PVR in Pediatric Subjects With Pulmonary Hypertension (PHTN) and Its Dependence on Baseline PVR|Obtain Pharmacokinetic Data in This Population|Demonstrate That DEX is a Safe Sedative in Pediatric Subjects With PHTN","Aruna Nathan|Children's Hospital of Philadelphia","All","8 Years to 21 Years   (Child, Adult)","Phase 2|Phase 3","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-007076","March 2010","March 2013","April 2013","February 22, 2010","September 8, 2014","April 16, 2019","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01072643"
202,"NCT01324999","Tadalafil for Sarcoidosis Associated Pulmonary Hypertension","SAPH","Completed","Has Results","Pulmonary Hypertension","Drug: Tadalafil","6 Minute Walk Distance|Resting Oxygen Saturation|Oxygen Desaturation During 6 Minute Walk Test|Maximum Borg Dyspnea Score During 6 Minute Walk Test|Brain Natriuretic Peptide Level|Short Form-36 Global Score|St. George's Respiratory Questionnaire (SGRQ) Score|Number of Participants With Change in WHO Functional Class (WHO FC)","University of North Carolina, Chapel Hill|Eli Lilly and Company|United Therapeutics|University of Cincinnati","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-2326","March 2011","July 2013","October 2013","March 29, 2011","July 24, 2017","July 24, 2017","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01324999"
203,"NCT02926027","Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy","EVAPORATE","Active, not recruiting","No Results Available","Hypertriglyceridemia","Drug: Vascepa|Drug: placebo","Progression rates of low attenuation plaque under influence of Vascepa as compared to placebo.|The morphology of non-calcified coronary atherosclerotic plaque (NCP)|markers of inflammation (Lp-PLA2)|changes in markers of LDL and HDL cholesterol|The composition of non-calcified coronary atherosclerotic plaque (NCP)","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Intermountain Research and Medical Foundation","All","30 Years to 85 Years   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","21733-01","March 28, 2017","May 15, 2020","August 15, 2020","October 6, 2016",,"April 9, 2020","Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), Torrance, California, United States|Intermountain Medical Center, Intermountain Heart Institute, Murray, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02926027"
204,"NCT02047656","To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension",,"Terminated","No Results Available","Part 1 - Healthy Volunteers|Part 2 - Patients With Hypertension","Drug: LFF269|Drug: Placebo to LFF269","Number of healthy volunteers reported with adverse events as an assessment of safety and tolerability (Part 1)|Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau)[Part 1- Healthy volunteers]|Observed maximum plasma concentration following drug administration (Cmax) at day 1 [Part 1- Healthy volunteers]|Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) [Part 2- Patients with hypertension]|Observed maximum plasma concentration following drug administration (Cmax) at day 1 [Part 2 - Patients with hypertension]|Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau at steady state (AUCtau,ss) [Part 1- Healthy volunteers]|Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau at steady state (AUCtau,ss) [Part 2 - Patients with hypertension]|Observed maximum plasma concentration following drug administration at steady state (Cmax,ss) [Part 2 - Patients with hypertension]|Observed maximum plasma concentration following drug administration at steady state (Cmax,ss) [Part 1- Healthy volunteers]|Number of patients reported with adverse events as an assessment of safety and tolerability (Part - 2, Patient with Hypertension)","Novartis Pharmaceuticals|Novartis","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","93","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLFF269X2105","August 2013","August 2014","August 2014","January 28, 2014",,"April 1, 2016","Novartis Investigative Site, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02047656"
205,"NCT01446003","A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)",,"Completed","Has Results","Hypertension","Drug: MK-8457|Drug: Placebo for MK-8457","Change From Baseline to Day 10 in 24-hour Mean Ambulatory Systolic Blood Pressure (SBP)|Number of Participants Who Experienced at Least One Adverse Event (AE)|Number of Participants Who Discontinued the Study Medication Due to an AE|Change From Baseline to Day 10 in 24-hour Mean Ambulatory Diastolic Blood Pressure (DBP)|Change From Baseline to Day 10 in Maximum Moving Average (maxMAΔ) Blood Pressure Measured Over 4 Hours|Area Under the Plasma Concentration-time Curve From Time 0 to 12 Hours (AUC0-12hr) of MK-8457|Maximum Concentration (Cmax) of MK-8457|Time to Maximum Concentration (Tmax) of MK-8457|Trough Plasma Concentration (Ctrough) of MK-8457","Merck Sharp & Dohme Corp.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","8457-004","October 25, 2011","February 18, 2012","March 3, 2012","October 4, 2011","May 2, 2017","February 5, 2019","Call for Information, Miramar, Florida, United States|Call for Information, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01446003"
206,"NCT01748123","EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network",,"Withdrawn","No Results Available","Hypertension","Drug: Chlorthalidone|Drug: Hydrochlorothiazide","Mean systolic 24 Hour Ambulatory Blood Pressure|Subjective Medication Side Effects","Johns Hopkins University","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCORI-EGID 4231|00041242","August 2016","June 2017","June 2018","December 12, 2012",,"August 18, 2017","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01748123"
207,"NCT02981082","Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension",,"Terminated","No Results Available","Systemic Sclerosis|Pulmonary; Hypertension","Drug: Dimethyl Fumarate (DMF)|Drug: Placebo Oral Tablet","6 minute walk distance (6MWD).|Clinical Worsening|Borg Dyspnea Index (BDI)|Serum markers of oxidative stress|Proteomic biomarkers","Robert Lafyatis|Biogen|University of Pittsburgh","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","6","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO16070614","December 2016","February 10, 2020","February 10, 2020","December 2, 2016",,"April 7, 2020","National Jewish, Denver, Colorado, United States|John Hopkins, Baltimore, Maryland, United States|Boston University, Boston, Massachusetts, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02981082"
208,"NCT01041287","Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells",,"Completed","Has Results","Hypertension","Drug: Nebivolol|Drug: Metoprolol succinate","Pulse Wave Velocity (Measure of Arterial Stiffness)","Emory University|Forest Laboratories","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 4","96","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00013262|BYD-MD-20","December 2009","December 2013","December 2013","December 31, 2009","December 19, 2014","December 19, 2014","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01041287"
209,"NCT01472692","Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure",,"Completed","Has Results","Prehypertension|Gout|Pulse Wave Velocity|Hypertension|24 Hour Blood Pressure","Drug: Febuxostat","Changes in 24 Hour Blood Pressure|Changes in Pulse Wave Velocity","University of California, San Diego","All","18 Years to 50 Years   (Adult)","Phase 4","47","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","110806","October 2011","March 2014","March 2014","November 16, 2011","December 16, 2019","December 16, 2019","Univerisity Of California San Diego, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT01472692"
210,"NCT01051960","Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan",,"Completed","No Results Available","Systemic Sclerosis|Shortness of Breath|Pulmonary Hypertension","Drug: Ambrisentan","Change in multipoint exercise total pulmonary resistance (TPR)from baseline to week 24.|Change in distance walked in six minutes from baseline to 24 week|SF-36 (short form 36)|HAQ-DI (health assessment questionnaire disability index)|St. George's respiratory questionnaire","University of California, Los Angeles|Gilead Sciences","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-000567","March 2009","June 2010","January 2011","January 20, 2010",,"March 7, 2018","David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01051960"
211,"NCT01707381","BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension","Constellation","Completed","Has Results","Ocular Hypertension|Open Angle Glaucoma","Drug: BOL-303259-X|Drug: Timolol maleate","24 Hour IOP|24-hour Ocular Perfusion Pressure|IOP Area Under the Curve Over 24 Hours","Bausch & Lomb Incorporated","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","803","November 2012","December 2013","February 2014","October 16, 2012","September 4, 2018","September 4, 2018","University of California San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT01707381"
212,"NCT01037036","A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG",,"Completed","No Results Available","Ocular Hypertension|Open-Angle Glaucoma","Drug: Latanoprost Punctal Plug Delivery System|Drug: Xalatan","Change from baseline in IOP measurements","Mati Therapeutics Inc.|QLT Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPL GLAU 08","December 2009","April 2010","July 2010","December 21, 2009",,"January 10, 2014","Menlo Park, Menlo Park, California, United States",,"https://ClinicalTrials.gov/show/NCT01037036"
213,"NCT02312544","Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: OTX-TP|Drug: Timolol","Difference in the mean change from baseline average diurnal IOP between treatment groups at the Day 60 Visit|Difference in the mean change from baseline average diurnal IOP between treatment groups at the Day 90 Visit|Difference in the mean change from baseline IOP between treatment groups to each individual time point at the Day 60 and 90 Visits|Difference in mean IOP between treatment groups for the average diurnal IOP and to each individual time point at the Day 60 and 90 Visits|Difference in the mean percent change from baseline IOP between treatment groups for the average diurnal IOP and to each individual time point at the Day 60 and 90 Visits","Ocular Therapeutix, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","OTX-13-004","November 2014","September 2015","December 2015","December 9, 2014",,"December 14, 2016","Vold Vision, Fayetteville, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT02312544"
214,"NCT02129725","Effect of Prolonged PDE-5 Inhibition on Insulin Signaling in Skeletal Muscle.",,"Completed","Has Results","Metabolic Syndrome","Drug: Sildenafil citrate|Drug: Placebo Oral Capsule","Insulin-stimulated AKT Phosphorylation","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","110206-substudy","April 2014","October 2016","December 2016","May 2, 2014","April 19, 2017","April 19, 2017","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02129725"
215,"NCT01939496","Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents",,"Completed","Has Results","Diabetes Mellitus, Type 2|Hypertension","Drug: Canagliflozin|Drug: Placebo","Change From Baseline in the Mean 24-Hour Systolic Blood Pressure (SBP) to Week 6|Change From Baseline in Mean 24-Hour Systolic Blood Pressure (SBP) to Day 2|Change From Baseline in the Mean 24-Hour Diastolic Blood Pressure (DBP) to Day 2 and to Week 6|Change From Baseline in Mean Daytime Systolic Blood Pressure (SBP) to Day 2 and to Week 6|Change From Baseline in Mean Daytime Diastolic Blood Pressure (DBP) to Day 2 and to Week 6|Change From Baseline in Mean Nighttime Systolic Blood Pressure (SBP) to Day 2 and to Week 6|Change From Baseline in Mean Nighttime Diastolic Blood Pressure (DBP) to Day 2 and to Week 6|Change From Baseline in Fasting Plasma Glucose (FPG) to Week 6|Change From Baseline in Body Weight to Week 6|Change From Baseline in Seated Office Blood Pressure (BP) to Day 2, to Week 3, and to Week 6|Change From Baseline in Standing Office Blood Pressure (BP) to Day 2, to Week 3, and to Week 6|Change From Baseline in Seated Heart Rate (HR) to Day 2, to Week 3, and to Week 6|Change From Baseline in Standing Heart Rate (HR) to Day 2, to Week 3, and to Week 6|Change From Baseline in the Difference in Seated Office Blood Pressure (BP) and Standing Office BP to Day 2, to Week 3, and to Week 6|Change From Baseline in the Difference in Seated Heart Rate (HR) and Standing HR to Day 2, to Week 3, and to Week 6","Janssen Scientific Affairs, LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","171","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR102208|28431754DIA4002","October 2013","April 2015","April 2015","September 11, 2013","April 6, 2016","March 3, 2017","Birmingham, Alabama, United States|Gulf Shores, Alabama, United States|Avondale, Arizona, United States|Phoenix, Arizona, United States|Glendale, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Pismo Beach, California, United States|Rancho Cucamonga, California, United States|Roseville, California, United States|Sacramento, California, United States|Spring Valley, California, United States|Tustin, California, United States|Denver, Colorado, United States|Brandon, Florida, United States|Doral, Florida, United States|Fort Lauderdale, Florida, United States|Lake Worth, Florida, United States|Lauderdale Lakes, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Pembroke Pines, Florida, United States|Port Orange, Florida, United States|West Palm Beach, Florida, United States|Perry, Georgia, United States|Rincon, Georgia, United States|Indianapolis, Indiana, United States|Topeka, Kansas, United States|Lexington, Kentucky, United States|Mandeville, Louisiana, United States|Marrero, Louisiana, United States|Metairie, Louisiana, United States|Auburn, Maine, United States|Elkridge, Maryland, United States|Dearborn, Michigan, United States|Kalamazoo, Michigan, United States|Jackson, Mississippi, United States|St. Louis, Missouri, United States|Morganville, New Jersey, United States|Whiting, New Jersey, United States|Albuquerque, New Mexico, United States|Raleigh, North Carolina, United States|Oklahoma City, Oklahoma, United States|Altoona, Pennsylvania, United States|Jenkintown, Pennsylvania, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Plano, Texas, United States|Sugar Land, Texas, United States|Salt Lake City, Utah, United States|Renton, Washington, United States|Carolina, Puerto Rico|Ponce Pr, Puerto Rico|Trujillo Alto, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01939496"
216,"NCT01863953","A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: Fixed-Combination Bimatoprost/Brimonidine|Drug: Bimatoprost Ophthalmic Solution 0.01%|Drug: Vehicle Ophthalmic Solution|Drug: Brimonidine Tartrate Ophthalmic Solution 0.2%","Change From Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP)|Change From Baseline in Average Eye Mean Diurnal IOP|Average Eye Mean Diurnal IOP","Allergan","All","40 Years and older   (Adult, Older Adult)","Phase 2","112","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","192024-082","June 2013","December 2013","December 2013","May 29, 2013","January 26, 2015","January 26, 2015","Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT01863953"
217,"NCT01932606","Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction",,"Completed","Has Results","Heart Disease|Heart Failure With Preserved Ejection Fraction|Exercise Intolerance|Pulmonary Hypertension","Drug: Nitrite|Drug: Saline Placebo for Nitrite","Exercise Pulmonary Capillary Wedge Pressure (PCWP)|Change in Central Pressures After Study Drug (Resting)|Change in Heart Rate After Study Drug (Resting)|Change in Blood Pressure After Study Drug (Resting)|Change in Pulmonary Vascular Resistance (PVR) After Study Drug (Resting)|Change in Pulmonary Artery (PA) Compliance After Study Drug (Resting)|Change in Systemic Vascular Resistance (SVR) After Study Drug (Resting)|Change in Left Ventricular Stroke Work (LVSW) After Study Drug (Resting)|Change in Oxygen Consumption (VO_2) After Study Drug (Resting)|Change in Arteriovenous Oxygen Content Difference After Study Drug (Resting)|Change in Cardiac Output After Study Drug (Resting)|Change in Stroke Volume After Study Drug (Resting)|Change in Central Pressures After Study Drug (Exercise)|Change in Heart Rate After Study Drug (Exercise)|Change in Blood Pressure After Study Drug (Exercise)|Change in PVR After Study Drug (Exercise)|Change in PA Compliance After Study Drug (Exercise)|Change in SVR After Study Drug (Exercise)|Change in LVSW After Study Drug (Exercise)|Change in Oxygen Consumption (VO_2) After Study Drug (Exercise)|Change in Arteriovenous Oxygen Difference After Study Drug (Exercise)|Change in Cardiac Output After Study Drug (Exercise)|Change in Stroke Volume After Study Drug (Exercise)","Barry Borlaug|Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13-004077","August 2013","October 2014","October 2014","August 30, 2013","February 15, 2016","March 14, 2016","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01932606"
218,"NCT03043365","Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults",,"Completed","No Results Available","Lipoprotein Metabolism|PCSK9|Proteomics","Drug: control fish oil|Drug: LCMUFA-rich saury oil","Changes in the lipid profile (TC, TG, HDL-C and LDL-C)|changes lipoprotein particle number, composition and size","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","37","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","170050|17-H-0050","June 15, 2017","May 29, 2019","November 21, 2019","February 6, 2017",,"November 29, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03043365"
219,"NCT02948569","Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome",,"Completed","No Results Available","Metabolic Syndrome","Drug: 3-V Bioscience-2640","Change in hepatic lipogenesis|Change in liver fat measured by MRI|Change in skin sebum production","University of Missouri-Columbia|Sagimet Biosciences Inc.","Male","35 Years to 60 Years   (Adult)","Phase 1|Phase 2","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006432","February 1, 2017","December 18, 2017","December 18, 2017","October 28, 2016",,"January 4, 2018","University of Missouri, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02948569"
220,"NCT04125745","Oral CXA-10 in Pulmonary Arterial Hypertension","PAH","Active, not recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: CXA-10","Number of Treatment-Related Adverse Events as assessed by CTCAE v4.0 in 12 Weeks|Change from Baseline in Pulmonary Vascular Resistance is measured at baseline and 12 weeks by Right Heart Catheterization|Change from Baseline in Mean Pulmonary Artery Pressure is measured at baseline and 12 weeks by Right Heart Catheterization|Change from baseline in RV function as measured by tricuspid annular plane systolic excursion (TAPSE) as assessed by echocardiograms at 12 weeks|Changes from baseline in functional exercise capacity by assessing 6 minute walk distance test|Change from Baseline in levels of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) at 12 Weeks|Change from Baseline in Functional Status of Patients as Assessed by New York Heart Association Functional Class|Change from Baseline in Daily Physical Activity as Measured by a Accelerometer","Gladwin, Mark, MD|National Heart, Lung, and Blood Institute (NHLBI)|Complexa, Inc.|University of Pittsburgh","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY19010004|P01HL103455","October 31, 2019","June 30, 2023","December 31, 2023","October 14, 2019",,"April 3, 2020","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04125745"
221,"NCT01830140","A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: Bimatoprost 0.01%|Drug: Bimatoprost 0.03%","Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","466","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","192024-081","July 2013","May 2014","May 2014","April 12, 2013","May 6, 2015","May 6, 2015","Artesia, California, United States|El Paso, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01830140"
222,"NCT00990834","Muscle Characteristics Associated With Statin Therapy",,"Withdrawn","No Results Available","Hydroxymethylglutaryl-CoA Reductase Inhibitors|Myopathy","Drug: simvastatin","Atrogin-1 expression.|Intramuscular Ras level.|Intramuscular Coenzyme Q10 level.|Intramuscular mitochondrial to nuclear DNA ratio.|Intramuscular geranylgeranylpyrophosphate.|PPAR-gamma coactivator-1-alpha expression.","Scripps Health","All","21 Years to 90 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","MCAST","November 2009","June 2011","June 2011","October 7, 2009",,"May 22, 2015","Scripps-Mercy Hospital, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00990834"
223,"NCT01001195","Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: AGN-210669 ophthalmic solution, 0.1%|Drug: AGN-210669 ophthalmic solution, 0.075%|Drug: AGN-210669 ophthalmic solution, 0.05%|Drug: bimatoprost ophthalmic solution 0.03%","Change From Baseline in Average Eye Intraocular Pressure (IOP)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","165","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","210669-010","November 2009","April 2010","April 2010","October 26, 2009","October 18, 2013","October 18, 2013","Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01001195"
224,"NCT02038179","Center of Research Translation (CORT) Project 2",,"Completed","Has Results","Pre-hypertension|JNC 7 Stage I Hypertension","Drug: Allopurinol|Drug: Placebo","Change in Systolic Blood Pressure (SBP)|Change in Flow-mediated Arterial Vasodilation|Change in Serum Levels of High Sensitivity C-reactive Protein","University of Alabama at Birmingham|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","All","18 Years to 40 Years   (Adult)","Phase 2|Phase 3","99","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","F130408004|P50AR060772","July 2014","August 2018","August 2018","January 16, 2014","February 26, 2020","March 17, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02038179/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02038179"
225,"NCT01880866","(-)-Epicatechin and Pulmonary Arterial Hypertension",,"Withdrawn","No Results Available","Pulmonary Arterial Hypertension","Drug: (-)-Epicatechin","Pulmonary Vascular Resistance Index|Endothelial function and hemodynamics","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPI","July 2013","January 2014","January 2014","June 19, 2013",,"September 10, 2014","UCSF, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01880866"
226,"NCT01203852","Pharmacogenomic Evaluation of Antihypertensive Responses 2","PEAR2","Completed","Has Results","Hypertension","Drug: Metoprolol|Drug: Chlorthalidone","Change in Blood Pressure From Baseline to Treatment|Adverse Metabolic Effects","University of Florida|National Institute of General Medical Sciences (NIGMS)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","839","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201700661-N|U01GM074492-06","August 2010","April 2014","April 2014","September 16, 2010","May 19, 2015","April 6, 2018","University of Florida, Gainesville, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Mayo Clinic, Division of Hypertension, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01203852"
227,"NCT01603758","Physiological Study of Human Cholesterol Metabolism and Excretion",,"Completed","No Results Available","Coronary Heart Disease|Cardiovascular Disease|Dyslipidemia|Disorder of Cholesterol Metabolism","Drug: Ezetimibe","Fractional Excretion of Endogenous Cholesterol","Richard E. Ostlund Jr., MD|National Heart, Lung, and Blood Institute (NHLBI)|Washington University School of Medicine","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","132","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","201110042|R01HL108160","January 2014","June 2015","June 2015","May 23, 2012",,"May 6, 2016","Washington University School of Medicine, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01603758"
228,"NCT03574363","Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease","BLOCKCKD","Recruiting","No Results Available","Chronic Kidney Diseases|Hypertension","Drug: KBP-5074","Systolic blood pressure|Diastolic blood pressure|ABPM|UACR","KBP Biosciences|Worldwide Clinical Trials","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","240","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","KBP5074-2-001","April 25, 2018","August 11, 2020","October 30, 2020","July 2, 2018",,"January 29, 2020","KBP Biosciences USA Inc, Princeton, New Jersey, United States|Worldwide Clinical Trials, Morrisville, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03574363"
229,"NCT01782027","Mendelian Reverse Cholesterol Transport Study",,"Suspended","No Results Available","Cholesterol, HDL|Lipid Metabolism, Inborn Errors|Tangier Disease|LCAT Deficiency|Cholesteryl Ester Transfer Protein (CETP) Deficiency","Drug: 3H-cholesterol bound to albumin","determination of 3H cholesterol in plasma and lipoproteins|determination of 3H cholesterol and its metabolites in red blood cells over time","University of Pennsylvania","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","815075","October 2012","December 2020","December 2020","February 1, 2013",,"April 24, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01782027"
230,"NCT00869141","Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma",,"Completed","Has Results","Glaucoma","Drug: glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)","Rate of Hypertensive Phase After Ahmed Valve Implantation for Glaucoma|Intraocular Pressure Control After Ahmed Valve Implantation for Glaucoma|Intraocular Pressure of Eyes With Hypertensive Phase Versus Without Hypertensive Phase","University of California, Los Angeles","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCLA IRB#08-10-110-01","March 2009","March 2013","March 2013","March 25, 2009","June 17, 2015","December 30, 2015","Juels Stein Eye Institute, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00869141"
231,"NCT02841280","Chlorthalidone in Chronic Kidney Disease","CLICK","Recruiting","No Results Available","Renal Insufficiency, Chronic|Hypertension","Drug: Chlorthalidone|Drug: Placebo","Change from baseline to 12 weeks in systolic ambulatory blood pressure in the chlorthalidone group compared to placebo.|Changes in albuminuria from baseline at each 4 week visit in the log transformed albumin/creatinine ratio in the chlorthalidone group compared to placebo, as measured by overnight urine collection.|Change from baseline at each 4 week visit in log of aldosterone to renin ratio in the chlorthalidone group compared to placebo. No adjustments will be made for multiple comparisons.|Change from baseline at each 4 week visit in log of B-type natriuretic peptide in the chlorthalidone group compared to placebo. No adjustments will be made for multiple comparisons.|Change from baseline at each 4 week visit in body volume in the chlorthalidone group compared to placebo. No adjustments will be made for multiple comparisons.","Indiana University","All","18 Years and older   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1507540384","July 2016","January 2021","January 2022","July 22, 2016",,"January 24, 2019","Indiana University School of Medicine, Division of Nephrology, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02841280"
232,"NCT01496469","Effect of Febuxostat on Blood Pressure",,"Completed","Has Results","Hypertension","Drug: Febuxostat|Drug: Placebo","Change From Baseline in 24-hour Mean Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring at Week 6|Change From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring at Week 6|Change From Baseline in Serum Urate Levels at Week 6","Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 2","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TMX-67_206|U1111-1124-4638","February 2012","August 2014","August 2014","December 21, 2011","August 31, 2015","August 31, 2015","Foley, Alabama, United States|Buena Park, California, United States|Carmichael, California, United States|Fresno, California, United States|Irvine, California, United States|Lomita, California, United States|Paramount, California, United States|Sacramento, California, United States|San Diego, California, United States|Wildomar, California, United States|Milford, Connecticut, United States|Fort Lauderdale, Florida, United States|Miami, Florida, United States|Tallahassee, Florida, United States|Tampa, Florida, United States|Dunwoody, Georgia, United States|Roswell, Georgia, United States|Suwanee, Georgia, United States|Avon, Indiana, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|Biddeford, Maine, United States|Saint Peters, Missouri, United States|St. Louis, Missouri, United States|St. Peters, Missouri, United States|Henderson, Nevada, United States|Las Vegas, Nevada, United States|Albuquerque, New Mexico, United States|Glens Falls, New York, United States|Greensboro, North Carolina, United States|Salisbury, North Carolina, United States|Shelby, North Carolina, United States|Fargo, North Dakota, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Lyndhurst, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Tipton, Pennsylvania, United States|Carrollton, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Burke, Virginia, United States|Manassas, Virginia, United States|Port Orchard, Washington, United States|Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01496469"
233,"NCT02514070","Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults",,"Completed","No Results Available","Lipoprotein Metabolism|PCSK9|Proteomics","Drug: EPA-rich fish oil|Drug: DHA-rich fish oil","Change in plasma PCSK9 levels|To investigate the effects of age, gender, BMI, and other factors on change in triglycerides, LDL-C, lipoprotein and HDL values by using a linear model","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","150173|15-H-0173","October 30, 2015","July 23, 2019","July 23, 2019","August 3, 2015",,"January 27, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02514070"
234,"NCT01804777","Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes",,"Terminated","No Results Available","Proteinuria|Hypertension|Type II Diabetes","Drug: Amiloride|Drug: HCTZ","Blood Pressure|Hypertension","University of New Mexico|Dialysis Clinic, Inc.|University of Pittsburgh","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","9","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research","13-017","March 2013","December 2014","December 2014","March 5, 2013",,"May 11, 2018","University of New Mexico Hospital; Clinical & Translational Science Center, Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT01804777"
235,"NCT02763735","Right Ventricular Metabolism in Pulmonary Arterial Hypertension",,"Completed","No Results Available","Pulmonary Arterial Hypertension|Healthy","Drug: 11C acetate","Right ventricular oxygen consumption divided by the rate pressure product|Right ventricular oxygen consumption (kmono)|Right ventricular glucose uptake (standardized uptake value)|Percent myocardial triglyceride content|Correlation of kmono, kmono/RPP, FDG uptake, and myocardial triglyceride content with right ventricular function|Correlation of kmono, kmono/RPP, FDG uptake, and myocardial triglyceride content with six minute walk distance|Correlation of kmono, kmono/RPP, FDG uptake, and myocardial triglyceride content with plasma metabolic profile","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","131271","June 2014","June 2019","June 2019","May 5, 2016",,"July 17, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02763735"
236,"NCT04140279","A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension",,"Not yet recruiting","No Results Available","Ocular Hypertension","Drug: Latanoprostene Bunod|Drug: Placebo","Change From Baseline in Episcleral Venous Pressure (EVP) at Intervals on Days 1 and 8|Change From Baseline in Diurnal (Daytime) EVP at Days 1 and 8|Change From Baseline in Trabecular Outflow Facility at Intervals on Days 1 and 8|Change From Baseline in Diurnal (Daytime) Trabecular Outflow Facility at Days 1 and 8","Bausch & Lomb Incorporated","All","18 Years and older   (Adult, Older Adult)","Phase 4","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","899","July 2020","July 1, 2020","July 1, 2020","October 25, 2019",,"April 2, 2020","Bausch Site 001, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04140279"
237,"NCT02906579","A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension",,"Completed","Has Results","Diabetes Mellitus, Type 2|Hypertension","Drug: Matching Placebo|Drug: IW-1973","Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to TEAEs|Certain Clinical Chemistry Laboratory Parameters: Overall Changes From Study Baseline in Cholesterol, Glucose, HDL-C, LDL-C, and Triglycerides at Discharge Day (Day 19)|Certain Clinical Chemistry Laboratory Parameters: Overall Changes From Study Baseline in Cholesterol, Glucose, HDL-C, LDL-C, and Triglycerides at Follow-Up (Day 32)|Certain Clinical Chemistry Laboratory Parameters: Overall Changes From Study Baseline in Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase at Discharge Day (Day 19)|Certain Clinical Chemistry Laboratory Parameters: Overall Changes From Study Baseline in GGT and Lactate Dehydrogenase at Follow-Up (Day 32)|Certain Clinical Chemistry Laboratory Parameters: Overall Changes From Study Baseline in Hemoglobin A1c at Discharge Day (Day 19)|Certain Clinical Chemistry Laboratory Parameters: Overall Changes From Study Baseline in Hemoglobin A1c at Follow-Up (Day 32)|Certain Clinical Chemistry Laboratory Parameters: Overall Changes From Study Baseline in Insulin at Discharge Day (Day 19)|Certain Clinical Chemistry Laboratory Parameters: Overall Changes From Study Baseline in Insulin at Follow-Up (Day 32)|Change From Time-Matched Baseline in Fasting Blood Glucose on Day 2 of Each Dose Cycle|Change From Time-Matched Baseline in Serum Insulin on Day 2 of Each Dose Cycle|Number of Participants With Notable Changes in Post Baseline Vital Signs Values|Number of Participants With Notable Post Baseline Orthostatic Vital Signs Values|Change From Baseline Over Time in Respiratory Rate|Change From Baseline Over Time in Temperature|Change From Baseline Over Time in Weight|Number of Participants With Clinically Significant Findings or Shifts in Baseline in Electrocardiograms (ECGs)|Number of Participants With Clinically Significant Findings or Shifts in Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF)|Change From Study Baseline Over Time in Supine Pulse|Change From Time-Matched Baseline (Placebo Cycle) Over Time in Supine Pulse|Change From Study Baseline Over Time in Supine Systolic Blood Pressure|Change From Time-Matched Baseline (Placebo Cycle) Over Time in Supine Systolic Blood Pressure|Change From Study Baseline Over Time in Supine Diastolic Blood Pressure|Change From Time-Matched Baseline (Placebo Cycle) Over Time in Supine Diastolic Blood Pressure|Orthostatic Pulse Over Time|Orthostatic Systolic Blood Pressure Over Time|Orthostatic Diastolic Blood Pressure Over Time|Change From Time-Matched Baseline (Placebo Cycle) Over Time in Ambulatory Blood Pressure Monitoring (ABPM) 4-Hour Averages of Systolic Blood Pressure|Change From Time-Matched Baseline (Placebo Cycle) Over Time in ABPM 30 Minute Averages of Systolic Blood Pressure|Change From Time-Matched Baseline (Placebo Cycle) Over Time in ABPM Daytime (12-Hour) Averages of Systolic Blood Pressure|Change From Time-Matched Baseline (Placebo Cycle) Over Time in ABPM 4-Hour Averages of Diastolic Blood Pressure|Change From Time-Matched Baseline (Placebo Cycle) Over Time in ABPM 30 Minute Averages of Diastolic Blood Pressure|Change From Time-Matched Baseline (Placebo Cycle) Over Time in ABPM Daytime (12-Hour) Averages of Diastolic Blood Pressure|Change From Time-Matched Baseline (Placebo Cycle) Over Time in ABPM 4-Hour Averages of Mean Arterial Pressure|Change From Time-Matched Baseline (Placebo Cycle) Over Time in ABPM 30 Minute Averages of Mean Arterial Pressure|Change From Time-Matched Baseline (Placebo Cycle) Over Time in ABPM Daytime (12-Hour) Averages of Mean Arterial Pressure|Change From Time-Matched Baseline (Placebo Cycle) Over Time in ABPM 4-Hour Averages of Pulse|Change From Time-Matched Baseline (Placebo Cycle) Over Time in ABPM 30 Minute Averages of Pulse|Change From Time-Matched Baseline (Placebo Cycle) Over Time in ABPM Daytime (12-Hour) Averages of Pulse|Change From Pre- to Post-Nitroglycerin Dose Assessment in Supine Pulse|Change From Pre- to Post-Nitroglycerin Dose Assessment in Supine Systolic Blood Pressure|Change From Pre- to Post-Nitroglycerin Dose Assessment in Supine Diastolic Blood Pressure|Change From Study Baseline Over Time in Endothelial Function: Reactive Hyperemia Index (RHI)|Change From Time-Matched Baseline (Placebo Cycle) Over Time in Endothelial Function: RHI|Change From Pre- to Post-Nitroglycerin Dose Assessment in Endothelial Function: RHI|Change From Time-Matched Baseline (Placebo Cycle) in Platelet Function Assessments: Collagen/Epinephrine Time to Aggregation","Cyclerion Therapeutics","All","30 Years to 65 Years   (Adult, Older Adult)","Phase 2","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C1973-201","September 2016","March 17, 2017","March 17, 2017","September 20, 2016","April 16, 2020","April 16, 2020","ICON Early Phase Unit, San Antonio, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02906579/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02906579/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02906579"
238,"NCT01025492","Study of Trilipix Effects on Lipids and Arteries",,"Terminated","Has Results","Dyslipidemia","Drug: Trilipix|Drug: placebo","Apolipoprotein A-I Serum Concentration","University of Utah|Abbott","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 4","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","00030151","November 2009","March 2011","March 2011","December 3, 2009","September 1, 2016","September 1, 2016","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01025492"
239,"NCT00872599","The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans",,"Completed","Has Results","Hypertension","Drug: fenofibrate|Drug: Placebo","Change in Blood Pressure During High Salt Intake and Fenofibrate Treatment Compared to High Salt Intake and Placebo Treatment|HDL-cholesterol Measured During High Salt Fenofibrate in Salt-resistant and Salt-sensitive Hypertension","Vanderbilt University|National Institutes of Health (NIH)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","75","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PPAR Alpha Agonist|Grant# DK38226-21","September 2009","January 2012","January 2012","March 31, 2009","June 20, 2013","June 28, 2013","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00872599"
240,"NCT04024072","To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes",,"Active, not recruiting","No Results Available","Glaucoma, Open-Angle|Ocular Hypertension","Drug: Brinzolamide 1% ophthalmic suspension|Drug: Azopt 1% Ophthalmic Suspension","Mean change in intra-ocular pressure","Perrigo Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","495","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRG-NY-19-001","June 24, 2019","February 26, 2020","June 2020","July 18, 2019",,"April 21, 2020","James D. Branch Ophthalmology, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04024072"
241,"NCT02120339","Carvedilol PAH A Pilot Study of Efficacy and Safety",,"Terminated","No Results Available","Pulmonary Hypertension|Cardiac MRI <40","Drug: Carvedilol","Mean change in RVEF|Absence of Adverse Events","University of Minnesota","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PAH","May 2014","June 2015","June 2016","April 22, 2014",,"July 12, 2019","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02120339"
242,"NCT01123785","A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: INO-8875|Drug: Placebo","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Number of Participants with decreased Intra-ocular pressure","Inotek Pharmaceuticals Corporation","All","18 Years to 77 Years   (Adult, Older Adult)","Phase 1|Phase 2","144","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IPC-10-2009","May 2010","December 2011","January 2012","May 14, 2010",,"October 15, 2012","Lugene Eye Institute, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT01123785"
243,"NCT01150981","Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue","RAPA","Completed","Has Results","Metabolic Syndrome|Insulin Resistance","Drug: Rosiglitazone|Drug: Placebo","Adipose Tissue Capillary Sprout Formation|Serum Adiponectin","University of Massachusetts, Worcester|GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 2","35","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","12196","November 2006","April 2010","April 2010","June 25, 2010","March 26, 2012","March 26, 2012","UMass Medical School, Worcester, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01150981"
244,"NCT01305252","A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).",,"Completed","Has Results","Hypertension, Pulmonary","Drug: treprostinil inhalations|Drug: tadalafil","Change in Right Ventricular Ejection Fraction|6 Minute Walk Distance|N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)|Change in NYHA/WHO Class|B-type Natriuretic Peptide (BNP)","Stanford University|Northwestern University","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 4","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SU-07152010-6565|IRB protocol # 18305","July 2010","September 2014","September 2014","February 28, 2011","June 2, 2017","June 2, 2017","Stanford University School of Medicine, Stanford, California, United States|Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01305252"
245,"NCT02603770","Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers",,"Completed","No Results Available","Lipid Metabolism Disorder","Drug: XueZhiKang|Drug: Lovastatin","AUC for the Pharmacokinetics (PK) of XZK","Luye Pharma Group Ltd.","Male","18 Years to 50 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LY02405/CT-USA-102","November 2015","January 2016","February 2016","November 13, 2015",,"December 5, 2016","NRC Research Institute, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT02603770"
246,"NCT02651272","Macitentan in Pulmonary Hypertension of Sickle Cell Disease","MENSCH","Completed","No Results Available","Pulmonary Hypertension|Sickle Cell Disease","Drug: macitentan","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Assess change in Right atrial pressure (RAP), Right ventricular pressure (RVP), Systolic pulmonary artery pressure (SPAP), and Diastolic pulmonary artery pressure (PADP), measured in mmHg.|Assess change in Cardiac output (CO) measured in L/min|Assess change in Cardiac index (CI) measured in L/min/m^2|Assess change in systemic vascular resistance measured by the following formula: Systemic Vascular Resistance (SVR) = 80x(Mean Arterial Pressure - Mean Venous Pressure or CVP) / Cardiac Output|Assess change in Right ventricular function assessed by pressure-volume loop measurements|Assess change in 6 minute walk test|Assess change of Borg Dyspnea Index|Assess change in NYHA/WHO functional classification|Assess change in cardiac biomarkers (BNP, NT-pro-BNP)","Boston University|Actelion","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","H-33165","July 2015","December 18, 2019","December 18, 2019","January 8, 2016",,"February 11, 2020","Boston University School of Medicine, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02651272"
247,"NCT01258764","Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril","1HAT","Completed","No Results Available","Hypertension, Grade 1|Hypertension Treatment|N of 1 Study Design|Hypertension","Drug: Lisinopril|Drug: Hydrochlorothiazide","Blood pressure control defined as 24-hour ambulatory systolic and diastolic pressure average below 135/85 mmHg.|Blood Pressure (BP) load, treatment of non-dippers, side effects, and compliance.","Scripps Translational Science Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","STSI 10-5486","November 2010","March 2014","March 2014","December 13, 2010",,"May 20, 2015","Scripps Clinic, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT01258764"
248,"NCT01654276","Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome",,"Completed","Has Results","Gout","Drug: Febuxostat","BMI|Serum Uric Acid|Serum Creatinine|Ambulatory Systolic Blood Pressure|Ambulatory Diastolic Blood Pressure|Serum Glucose|Serum Insulin|Insulin Sensitivity Measured by HOMA (HOmeostasis Model Assessment)|Seum Total Cholesterol|Serum HDL-cholesterol|Serum Triglycerides|Urine Uric Acid|Urine Creatinine|Fractional Excretion UA|Urine pH","University of Texas Southwestern Medical Center","All","21 Years and older   (Adult, Older Adult)","Phase 4","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSA-FEB-137","May 2012","March 2015","March 2015","July 31, 2012","January 13, 2017","June 18, 2018","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01654276"
249,"NCT01660191","A Study Comparing CoQ10 Levels While Taking 3 Different Statins","SPARQ","Completed","Has Results","Hypercholesterolemia","Drug: Pitavastin 4mg|Drug: Atorvastatin 20mg|Drug: Rosuvastatin 5mg","Changes in Plasma CoQ10 Levels|Changes in Major Lipid Parameters - VLDL Size|Changes to Glucose Metabolism - HbA1c and Insulin|Changes in HDL and LDL Size|Changes to Glucose Metabolism - Fructosamine|Changes HDL Particle Number and LDL Particle Number","University of Kansas Medical Center|Kowa Pharmaceuticals America, Inc.|Eli Lilly and Company","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","134","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12943","December 2011","August 2013","October 2013","August 8, 2012","January 18, 2017","January 18, 2017","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01660191"
250,"NCT01174173","Ranolazine and Pulmonary Hypertension",,"Completed","Has Results","Angina|Pulmonary Arterial Hypertension","Drug: Ranolazine","Improve Angina Symptoms|6-Minute Walk Test|Improve Quality of Life|RV Perfusion on Cardiac MRI|Absolute RV Longitudinal Strain|Right Ventricular Hemodynamics","Northwestern University|Gilead Sciences","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU00030314","June 2010","January 2014","October 2014","August 3, 2010","April 23, 2015","May 11, 2018","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01174173"
251,"NCT02245230","Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension",,"Recruiting","No Results Available","Hypertension|Hypertension, Essential","Drug: Angiotensin (1-7)|Drug: Trimethaphan|Drug: Phenylephrine","Systolic Blood Pressure|Hemodynamic Measures|Circulating Renin-Angiotensin System Components","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years to 60 Years   (Adult)","Phase 1","34","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","140958","January 2015","December 2021","December 2021","September 19, 2014",,"February 7, 2020","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02245230"
252,"NCT01156597","Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: pioglitazone","Increased HDL-Cholesterol and Decreased Triglycerides|HDL Apolipoprotein Levels at Study End-point|Cholesterol Efflux Capacity of HDL","University of Miami|Takeda Pharmaceuticals North America, Inc.","All","35 Years to 70 Years   (Adult, Older Adult)","Phase 3","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","06-009A","April 2008","September 2010","September 2010","July 5, 2010","November 11, 2014","November 21, 2014","Diabetes Research Institute, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01156597"
253,"NCT02133352","Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction",,"Completed","Has Results","Pulmonary Hypertension|Diastolic Left Ventricular Dysfunction","Drug: Ranolazine","Percent Change in mPAP, PAOP and Pulmonary Vascular Resistance (PVR)|Percent Change in Other Hemodynamic Parameters|6 Minute Walk Test (6MWT)|Change in Cardiac Size and Function|Change in Echocardiogram Parameters (LVEF)|Change in BNP Cardiac Biomarker","Boston University|Gilead Sciences","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","30217","July 2011","May 2013","May 2014","May 8, 2014","May 17, 2017","May 17, 2017","Boston University Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02133352"
254,"NCT00944229","The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure",,"Terminated","Has Results","Heart Failure","Drug: LOVAZA (Omega-3)|Drug: Placebo","Change in Peak VO2|Change in Reactive Hyperemia Peripheral Arterial Tonometry (RH-PAT) After 8 Weeks of Omega 3 Supplementation.|Change in Base Line Oxidized Low Density Lipoprotein (LDL) Level and in Response to Exercise","Columbia University|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","58","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AAAD7501|LVZ112854","January 2010","March 2014","March 2014","July 23, 2009","April 22, 2016","May 25, 2016","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00944229"
255,"NCT01431313","Inhaled Nitrite in Subjects With Pulmonary Hypertension",,"Completed","Has Results","Pulmonary Hypertension|Heart Failure, Diastolic","Drug: Inhaled Nitrite","Change in Pulmonary Vascular Resistance (PVR)|Time to Maximum Pulmonary Vascular Resistance (PVR) Decrease|Change in Systemic Blood Pressure (Mean Arterial Pressure, MAP)|Change in Systemic Vascular Resistance (SVR)|Change in Pulmonary Vascular Impedance / Wave Intensity|Change in Plasma Nitrite Concentrations in Mixed Venous Blood|Change in Pulmonary Artery Occlusion (Capillary) Pullback Nitrite|Change in Mitochondrial Oxygen Consumption Compared to Baseline After Each Dose of Nitrite","Schmidhofer, Mark, MD|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO11080686","June 2012","October 2017","October 2017","September 9, 2011","March 12, 2019","March 28, 2019","University of Pittsburgh, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT01431313/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01431313"
256,"NCT02436512","Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide","EAGLE","Withdrawn","No Results Available","Pulmonary Arterial Hypertension","Drug: Inhaled Nitric Oxide","Wean Success vs Wean Failure","Geno LLC","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P-2014-001","June 2015","August 2015","August 2015","May 6, 2015",,"September 7, 2015","University of Alabama, Birmingham, Alabama, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02436512"
257,"NCT03663049","The Impact of Statin Holiday in Dialysis Patients Over 70 Years Old on Mental Function, Physical Function and Frailty",,"Recruiting","No Results Available","ESRD|Cardiovascular Diseases","Drug: discontinue statin","Change in quality of life|Change in handgrip strength","Loyola University","All","70 Years and older   (Older Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","210890","August 17, 2018","May 2021","May 2021","September 10, 2018",,"April 23, 2019","Loyola University Medical Center, Maywood, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03663049"
258,"NCT04098003","Investigation of the Gut Microbiome and Statin Response","INGEST","Active, not recruiting","No Results Available","Healthy Volunteers","Drug: Rosuvastatin|Drug: Placebo","Change in bacterial abundance|Change in LDL-C","Sony Tuteja|University of Pennsylvania","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","832874","February 6, 2020","April 2022","April 2022","September 20, 2019",,"March 24, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04098003"
259,"NCT01247090","Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease",,"Completed","Has Results","Hypertension|End Stage Renal Disease","Drug: Vasopressin - Very Low Dose|Drug: Vasopressin - Low Dose|Drug: Placebo Comparator","Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period","Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AAAE0454 - pilot","October 2010","August 2018","August 2018","November 24, 2010","April 28, 2011","November 18, 2019","Columbia University Medical Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT01247090/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01247090"
260,"NCT01545336","Anastrozole in Patients With Pulmonary Arterial Hypertension","AIPH","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Anastrozole|Drug: Placebo","Plasma Estradiol (E2) Level|Tricuspid Annular Plane Systolic Excursion (TAPSE)|Six Minute Walk Distance","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","815035","October 2012","June 2015","September 2015","March 6, 2012","August 9, 2016","October 27, 2016","University of Pennsylvania - Penn Presbyterian, Philadelphia, Pennsylvania, United States|University of Pennsylvania - Perelman Center, Philadelphia, Pennsylvania, United States|Brown University - Rhode Island Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01545336"
261,"NCT01330979","24-hour Efficacy of AR-12286",,"Completed","No Results Available","Open Angle Glaucoma|Ocular Hypertension","Drug: AR-12286 0.5% Ophthalmic Solution","Intraocular pressure","Aerie Pharmaceuticals","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AR-12286-CS204","May 2011","August 2012","August 2012","April 7, 2011",,"April 21, 2014","University of California, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT01330979"
262,"NCT02656394","Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101",,"Active, not recruiting","No Results Available","Ocular Surface Disease","Drug: GL101|Drug: Placebo","Glaucoma medication ocular side effect symptoms|Glaucoma medication ocular side effect signs|Other signs","Glia, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GL-1","January 22, 2016","December 4, 2017","December 30, 2019","January 15, 2016",,"July 30, 2019","New York Eye & Ear Infirmary of Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02656394"
263,"NCT01254370","Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease",,"Completed","No Results Available","Glaucoma|Ocular Hypertension|Ocular Surface Disease","Drug: Latanoprost|Drug: Travatan Z","Efficacy of Catioprost versus Travatan Z","Santen SAS","All","18 Years and older   (Adult, Older Adult)","Phase 2","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","NVG10E118","November 2010","June 2011","June 2011","December 6, 2010",,"June 6, 2016","Ora (Ophthalmic Research Associates), Andover, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01254370"
264,"NCT02726711","Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic",,"Active, not recruiting","No Results Available","Multiple System Atrophy|Orthostatic Hypotension|Supine Hypertension","Drug: Trimethaphan|Drug: Placebo","The percentage of increase of the y intercept of the P-V relationship","Vanderbilt University|Vanderbilt University Medical Center","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1","2","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","151947","April 2016","March 2021","March 2021","April 4, 2016",,"February 11, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02726711"
265,"NCT00821002","A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)",,"Completed","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Drug: Latanoprost","Intraocular pressure change from baseline (mmHg)|Number of subjects with adverse events","Mati Therapeutics Inc.|QLT Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPL GLAU 05","January 2009","November 2009","November 2009","January 12, 2009",,"September 19, 2013","Menlo Park, California, United States",,"https://ClinicalTrials.gov/show/NCT00821002"
266,"NCT02024386","Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude",,"Completed","Has Results","Hypertension, Pulmonary|Altitude Sickness","Drug: Riociguat","Mean Pulmonary Artery Pressure|Mean Radial Arterial Pressure|Mean Arterial Oxygen Saturation (SaO2)|Mean Ventilation Rate|Mean Work Rate at Exhaustion|Cardiac Output","Richard Moon|Duke University","All","18 Years to 40 Years   (Adult)","Phase 4","28","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro00049150","January 2014","December 2015","December 2015","December 31, 2013","April 12, 2017","April 12, 2017","Duke Center for Hyperbaric Medicine and Environmental Physiology, Trent Drive, Building CR2, Room 0584, Box 3823,, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02024386"
267,"NCT01253902","Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma, Open-Angle|Ocular Hypertension","Drug: bimatoprost ophthalmic solution 0.01%|Drug: travoprost ophthalmic solution 0.004%|Drug: latanoprost ophthalmic solution 0.005%","Mean Conjunctival Hyperemia at Week 12|Mean Corneal Staining With Fluorescein at Week 12|Mean Tear Break Up Time (TBUT) at Week 12","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","GMA-LUM-09-014","December 2010","October 2011","October 2011","December 6, 2010","November 7, 2012","November 7, 2012","Rogers, Arkansas, United States|Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT01253902"
268,"NCT00938405","Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1|Hyperlipidemias","Drug: Colesevelam HCl|Drug: Placebo","To demonstrate a 10% LDL reduction in type 1 diabetic subjects with initial LDL > 100 after twelve weeks in the colesevelam group.|To evaluate colesevelam use for glucose control as measured by A1c using a 0.4% confidence interval at baseline and after one, two, and three months of therapy.|To evaluate colesevelam use for non-inferiority of percent of target range glucose values and time spent in hyper- and hypoglycemic ranges as determined by CGM readings at baseline and after one, two, and three months of therapy.|In addition change in insulin dose at one, two and three months from baseline will be evaluated.","University of Colorado Denver School of Medicine Barbara Davis Center|Daiichi Sankyo, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","45","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DSI-WCH-100","July 2009","December 2009","December 2009","July 13, 2009",,"May 20, 2014","Barbara Davis Center for Diabetes, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT00938405"
269,"NCT03653663","NIRS to Diagnose SAMS",,"Active, not recruiting","No Results Available","Statin Adverse Reaction|Skeletal Myopathy","Drug: Simvastatin 20 mg|Drug: Placebo Oral Tablet","Near infrared spectroscopy|Creatine kinase","Hartford Hospital|University of Connecticut","All","40 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Grant-In-Aid #17GRNT33661247","January 1, 2018","February 29, 2020","July 30, 2020","August 31, 2018",,"February 13, 2020","Hartford Hospital, Hartford, Connecticut, United States|University of Connecticut, Storrs, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03653663"
270,"NCT03583866","Adiposity and Endothelin Receptor Function","END-RF","Recruiting","No Results Available","Hypertension","Drug: Candesartan|Drug: Placebo","Percentage Change in Flow-Mediated Dilation (FMD)","Augusta University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 40 Years   (Adult)","Early Phase 1","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1148277|5P01HL069999","May 21, 2018","June 2020","June 2021","July 12, 2018",,"October 8, 2019","Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03583866"
271,"NCT01223378","Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension","Voyager","Completed","Has Results","Intraocular Pressure","Drug: BOL-303259-X|Drug: Latanoprost","Change in Mean Diurnal IOP at Visit 6 (Day 28)|Change in Mean Diurnal IOP at Visits 4,5, and 7|IOP </=18mm Hg|Change in IOP at Specified Time Points (8 AM, 12 PM, 4 PM) at Visit 6 (Day 28)|Change in IOP at Specified Time Points (8 AM, 12 PM, 4 PM) at Visits 4, 5, and 7 (Days 7, 14, and 29)","Bausch & Lomb Incorporated","All","18 Years and older   (Adult, Older Adult)","Phase 2","413","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Screening","659","December 13, 2010","December 20, 2011","June 22, 2012","October 19, 2010","July 24, 2018","July 24, 2018","Bausch & Lomb, Inc, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01223378"
272,"NCT02053246","Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure",,"Active, not recruiting","No Results Available","Pulmonary Hypertension|Diastolic Heart Failure|Heart Failure With Preserved Ejection Fraction","Drug: Nebivolol","Changes in pulmonary vascular pressure|Changes in 6-minute walk distance","University of Florida|National Institute of General Medical Sciences (NIGMS)","All","18 Years and older   (Adult, Older Adult)","Phase 4","7","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201501144 -N|K23GM112014","January 2014","March 2021","March 2021","February 3, 2014",,"March 17, 2020","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02053246"
273,"NCT01304095","Ranolazine, Ethnicity and the Metabolic Syndrome","REMS","Unknown status","No Results Available","Coronary Artery Disease|Angina|Metabolic Syndrome","Drug: Ranolazine","Exercise Duration|fasting glucose|Angina|Concomitant medications|lipid profile|HgbA1c","Atlanta Heart Specialists, LLC|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","160","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AHS-REMS-001","January 2011","July 2013","November 2013","February 25, 2011",,"July 11, 2013","Atlanta Heart Specialist, LLC, Cumming, Georgia, United States|Atlanta Heart Specialists, LLC, Tucker, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01304095"
274,"NCT04040959","Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD",,"Recruiting","No Results Available","Vascular Diseases|Kidney Disease|Blood Pressure|Oxidative Stress","Drug: Nicotinamide riboside","carotid-femoral pulse wave velocity|Systolic blood pressure","University of Colorado, Denver|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","35 Years to 80 Years   (Adult, Older Adult)","Phase 2","118","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19-0149|R01DK121516-01","November 19, 2019","May 15, 2024","September 15, 2024","August 1, 2019",,"November 26, 2019","UColorado, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04040959"
275,"NCT02684786","A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension",,"Withdrawn","No Results Available","Pulmonary Artery Hypertension","Drug: reserpine|Procedure: stellate ganglion block|Drug: lidocaine","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Number of participants with successful stellate ganglion block|Effect of stellate ganglion block on heart rate|Change in 6 minute walk distance from one month of reserpine therapy|Change in brain natriuretic peptide (BNP) from one month of reserpine therapy|Change in Doppler derived mean pulmonary artery pressure from one month of reserpine therapy|Change in blood pressure from one month of reserpine therapy|Change in Minnesota Living with heart failure questionnaire from one month of reserpine therapy|Hemodynamic effect of stellate ganglion block|Change in heart rate from one month of reserpine therapy","Mayo Clinic","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-000928","July 2016","July 2016","July 2016","February 18, 2016",,"May 22, 2019","Mayo Clinic Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02684786"
276,"NCT01534910","Effect of Aged Garlic Extract on Atherosclerosis","Garlic4","Completed","Has Results","Metabolic Syndrome","Drug: aged garlic extract|Drug: placebo","CT Angiography Plaque|Coronary Calcium","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Wakunaga Pharmaceutical Co., Ltd.","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 4","65","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","21567-01","May 2012","December 2014","December 2014","February 17, 2012","April 3, 2015","April 20, 2017","Los Angeles Biomedical Research Institute, Torrance, California, United States",,"https://ClinicalTrials.gov/show/NCT01534910"
277,"NCT03787082","Chlorhexidine Mouthwash and Oral Nitrate in Adults With Pulmonary Hypertension",,"Not yet recruiting","No Results Available","Pulmonary Hypertension|Heart Failure With Normal Ejection Fraction|Pulmonary Heart Disease and Diseases of Pulmonary Circulation","Drug: Nitrates|Drug: Chlorhexidine Gluconate Mouthwash|Drug: Placebo Mouthwash","Change in Plasma Nitrate|Change in Urine Nitrate|Change in Pulmonary Vascular Resistance (PVR)","Gladwin, Mark, MD|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 1","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRO18080517|5P01HL103455","July 2020","February 2021","February 2021","December 26, 2018",,"April 6, 2020","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03787082"
278,"NCT01153386","Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Treprostinil diethanolamine","Treprostinil pharmacokinetics|Clinical laboratories|Adverse event monitoring","United Therapeutics","All","18 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-PH-122","July 2010","August 2010","August 2010","June 30, 2010",,"August 23, 2010","PPD Development, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01153386"
279,"NCT02813551","ToRsemide for pOstpartum HYpertension","TROPHY","Completed","Has Results","Preeclampsia","Drug: Torsemide|Drug: Placebo","Number of Participants With Persistent Postpartum Hypertension Defined as Systolic Blood Pressure ≥ 150 and/or Diastolic Blood Pressure ≥ 100 mmHg|Number of Participants With Severe Postpartum Hypertension Requiring Acute Antihypertensives (Systolic Blood Pressure ≥160 and/or Diastolic Blood Pressure ≥ 110 mmHg)|Number of Participants Requiring Postpartum Readmission|Length of Hospital Stay After Delivery|Weight Change|Change in Lower Extremity Edema|Number of Participants With Persistent Postpartum Hypertension (Systolic Blood Pressure ≥140 and/or Diastolic Blood Pressure ≥ 90 mmHg)|Number of Participants With Side Effects of Therapy - Hypokalemia (Low Blood Potassium Levels)|Number of Participants With Side Effects of Therapy - Decreased Breast Milk|Number of Participants With Severe Composite Maternal Morbidity","The University of Texas Health Science Center, Houston","Female","18 Years and older   (Adult, Older Adult)","Phase 2","118","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HSC-MS-16-0198","August 2016","July 28, 2017","September 9, 2017","June 27, 2016","April 10, 2019","April 10, 2019","The University of Texas Health Science Center, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02813551/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02813551"
280,"NCT01248234","Does Administration of Etomidate and Propofol of the Anesthetic Induction of Elderly Hypertensive Patient Provide Superior Blood Pressure Stability in Response to Direct Laryngoscopy When Compared to Propofol or Etomidate Alone?",,"Withdrawn","No Results Available","Hypertension","Drug: propofol|Drug: Etomidate|Drug: Propofol and Etomidate","Blood pressure stability during anesthetic induction","University of Mississippi Medical Center","All","65 Years to 90 Years   (Older Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","2010-0097","July 2012","July 2012","July 2012","November 25, 2010",,"July 16, 2012","University of Mississippi Medical Center, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT01248234"
281,"NCT01980979","Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension",,"Withdrawn","No Results Available","Congenital Heart Disease","Drug: Remodulin","Improved cardiopulmonary exercise test|Improved overall cardiopulmonary variables","University of California, Los Angeles|United Therapeutics","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Remodulin in ACHD|IRB#12-001968","November 2013","December 2015","December 2015","November 11, 2013",,"September 21, 2017","UCLA Medical Center, Los Angeles, California, United States|Ohio State University/Nationwide Children's Hospital, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01980979"
282,"NCT01752842","Lipid Biomarkers for Diabetic Heart Disease",,"Completed","Has Results","Type II Diabetes Mellitus|Diabetes Complications","Drug: Fenofibrate|Drug: Placebo for fenofibrate","Change in Cardiac Diastolic Function as Measured by E' (cm/s)|Change in Cardiac Systolic Function as Measured by Fractional Shortening Percent|Change in C24:0/C16:0 Ceramide Ratio","Washington University School of Medicine|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|Leducq Foundation","All","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","70","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","201112122|P20HL113444-01","March 2013","February 23, 2018","February 23, 2018","December 19, 2012","February 26, 2019","March 15, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT01752842/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT01752842/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01752842"
283,"NCT03528902","Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension","T3PAH","Recruiting","No Results Available","Hypertension|Pulmonary Arterial Hypertension|Familial Primary Pulmonary Hypertension|Primary Pulmonary Hypertension|Lung Diseases|Tamoxifen|Estrogen Receptor Antagonist|Hormone Antagonists|Estrogens","Drug: Tamoxifen|Drug: Placebo Oral Tablet","Transthoracic echocardiogram (ECHO)-based change in the Tricuspid Annular Plane Systolic Excursion (TAPSE) measurement|Six minute walk test distance (6MWTD)|Quality of life will be assessed using the SF36 questionnaire. This will be administered at baseline and 12 and 24 weeks.|Quality of life will be assessed using emPHasis-10 questionnaire. This will be administered at baseline and 12 and 24 weeks.","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","180241","October 1, 2018","June 30, 2022","June 30, 2023","May 18, 2018",,"January 18, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03528902"
284,"NCT01145066","Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects",,"Completed","Has Results","Diabetes|Metabolic Syndrome x","Drug: borage/echium oil combination|Dietary Supplement: fish oil|Dietary Supplement: corn oil","Fasting Insulin|hsCRP|Leptin|Serum Fatty Acids|Pro and Anti-inflammatory Cytokines|Fasting Glucose|Hemoglobin Levels|Adipose Derived Cytokines|PBMC Gene Expression|SNPs in DNA of Selected Genes|PBMC Leukotriene Stimulation","Wake Forest University Health Sciences|Brigham and Women's Hospital","All","21 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","IRB00007488|P50 AT 0027820","May 2009","March 2011","March 2011","June 16, 2010","December 26, 2018","July 18, 2019","Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01145066"
285,"NCT00827775","Mechanisms and Treatment of Intradialytic Hypertension","MATCH","Completed","No Results Available","Intradialytic Hypertension","Drug: Carvedilol","Endothelial progenitor cells|flow mediated vasodilation","University of Texas Southwestern Medical Center|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","59","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","102008-042|NIH K23 HL092297","June 2009","September 2010","September 2010","January 23, 2009",,"January 29, 2014","UTSW Oakcliff Davita Dialysis, Dallas, Texas, United States|UTSW Dallas East Davita Dialysis (Buckner unit), Dallas, Texas, United States|UTS Dallas Dialysis (Elmbrook), Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00827775"
286,"NCT02116335","Endothelin Receptor Function and Acute Stress","End-Stress","Recruiting","No Results Available","Hypertension","Drug: Bosentan|Drug: Placebo","Flow-Mediated Dilation (FMD)|Arterial Stiffness Evaluation (PWV)|Physio Flow|Femoral blood flow|Blood Pressure","Augusta University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 50 Years   (Adult)","Not Applicable","320","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","End-Stress|5P01HL069999","June 2015","April 2020","April 2020","April 16, 2014",,"October 8, 2019","Georgia Regents University, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02116335"
287,"NCT01750294","A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD",,"Completed","Has Results","Chronic Kidney Disease|Poorly-Controlled Hypertension","Drug: Chlorthalidone","Change of Systolic Ambulatory Blood Pressure From Baseline to 12 Weeks","Indiana University","All","18 Years and older   (Adult, Older Adult)","Phase 4","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1206009002","August 2012","August 2013","August 2013","December 17, 2012","May 10, 2016","June 13, 2016","Richard L. Roudebush VAMC, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01750294"
288,"NCT00992056","Nebivolol Versus Metoprolol: Sodium Sensitivity",,"Completed","Has Results","Hypertension","Drug: nebivolol|Drug: Metoprolol","Change in 24-hour Mean Systolic Blood Pressure by ABPM From Day 5 of Low Sodium to Day 10 of High Sodium","University of Miami|Forest Laboratories","Female","46 Years and older   (Adult, Older Adult)","Phase 4","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090654","December 2010","February 2012","May 2012","October 8, 2009","June 23, 2014","June 8, 2017","Division of Clinical Pharmacology Clinical Pharmacology Research Unit (CPRU) 1500 NW 12th Ave 15-West., Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00992056"
289,"NCT02466399","POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma",,"Completed","No Results Available","Glaucoma","Drug: POLAT-001|Drug: Latanoprost ophthalmic solution","Mean change from baseline in intraocular pressure","Peregrine Ophthalmic","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LipoLat-CS202","July 2015","April 2016","April 2016","June 9, 2015",,"April 22, 2016","Professional Research Network, Goose Creek, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02466399"
290,"NCT03070483","Blood Pressure in Blacks and Calcium (BBC) and Vitamin D Study","BBC","Completed","No Results Available","Hypertension|Vitamin D Deficiency","Drug: Cholecalciferol","Change in mean blood pressure from baseline to 12 weeks|Change in total 25-hydroxyvitamin D from baseline to 12 weeks|Change in free 25-hydroxyvitamin D levels from baseline to 12 weeks|Change in intact parathyroid hormone levels from baseline to 12 weeks|Change in 1,25-dihydroxyvitamin D from baseline to 12 weeks|Change in 24-hour urine calcium excretion from baseline to 12 weeks","Loyola University","All","25 Years to 45 Years   (Adult)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","209476","January 8, 2018","November 1, 2018","November 1, 2018","March 3, 2017",,"April 11, 2019","Loyola Medical Center, Maywood, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03070483"
291,"NCT02357004","Mechanisms of Refractory Hypertension (Carvedilol)",,"Active, not recruiting","No Results Available","Hypertensive","Drug: Carvedilol|Drug: Chlorthalidone","% of subjects who achieve BP control (<140/90 mm Hg)","University of Alabama at Birmingham","All","19 Years to 70 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","A000502641","February 2015","January 30, 2020","March 30, 2020","February 6, 2015",,"March 25, 2019","David A. Calhoun, MD, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT02357004"
292,"NCT01607294","A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes",,"Completed","No Results Available","Hyperlipidemia|Type 2 Diabetes","Drug: ETC-1002|Drug: Placebo","assess the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes|assess the effect of ETC-1002 versus placebo on glycemic parameters including fasting plasma and postprandial glucose and insulin|assess the effect of ETC-1002 versus placebo on measures of insulin sensitivity in subjects with type 2 diabetes|assess safety using adverse event reports, physical exams, vital signs, ECGs and clinical laboratory parameters","Esperion Therapeutics","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1002-005","April 2012","October 2012","October 2012","May 30, 2012",,"March 29, 2019","Miramar, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01607294"
293,"NCT00978822","Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage","CLASH","Unknown status","No Results Available","Subarachnoid Hemorrhage|Hypertension","Drug: Clevidipine butyrate injectable emulsion","Ability to control and maintain blood pressure within a certain range by the drug infusion.","Henry Ford Health System|The Medicines Company","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLV-0904-001|PCF Varelas 5605","September 2009","April 2010","June 2010","September 17, 2009",,"September 18, 2009","Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00978822"
294,"NCT01556906","Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor",,"Completed","Has Results","Homozygous Familial Hypercholesterolemia","Drug: Lomitapide","LDL-C|Absolute Change From Baseline in Alanine Aminotransferase (ALT)|Absolute Change From Baseline in Aspartate Aminotransferase (AST)|Absolute Change From Baseline in Total Bilirubin|Absolute Change From Baseline in Hepatic Fat Percent|Absolute Change From Baseline in Forced Expiratory Volume During 1 Second (FEV1)|Absolute Change From Baseline in Carbon Monoxide Lung Diffusing Capacity (DLCO)(a Pulmonary Function Test)|Absolute Change From Baseline in Vitamin A|Absolute Change From Baseline in Vitamin E|Absolute Change From Baseline in Vitamin D|Absolute Change From Baseline in Ratio of Vitamin E to Total Lipids|Absolute Change From Baseline in Alpha Linoleic Acid (ALA)|Absolute Change From Baseline in Eicosapentaenoic Acid (EPA)|Absolute Change From Baseline in Docosahexaenoic Acid (DHA)|Absolute Change From Baseline in Linoleic Acid (LA)","Aegerion Pharmaceuticals, Inc.|University of Pennsylvania|Doris Duke Charitable Foundation","All","13 Years and older   (Child, Adult, Older Adult)","Phase 2","6","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UP1001","June 2003","February 2004","February 2004","March 19, 2012","February 22, 2013","April 10, 2013","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01556906"
295,"NCT02829034","Targeting Right Ventricle in Pulmonary Hypertension Gilead",,"Completed","Has Results","Pulmonary Hypertension","Drug: Ranolazine|Drug: Placebo","Absolute Change From Baseline Right Ventricular Ejection Fraction (the Unit is Percentage)|Percent Change in 6min-walk-test Distance|Change in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)","University of Pennsylvania|Brigham and Women's Hospital|University of Maryland, College Park|Gilead Sciences","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","22","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","824808","July 2016","December 2017","January 2018","July 12, 2016","February 26, 2019","February 26, 2019","University of Maryland, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02829034/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02829034"
296,"NCT02980068","A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction","PMED","Recruiting","No Results Available","Pulmonary; Hypertension|Heart Failure|Preserved Ejection Fraction","Drug: 15N Nitrate|Drug: 14N Nitrate","Change in nitrate level in urine|Change in nitrate level in plasma|Bacterial content of gut microbiome|Bacterial content of the oral microbiome|Change in nitrite level in urine|Change in nitrite level in plasma|Change in blood pressure|Change in heart rate|Change in respiratory rate|Change in hemoglobin concentration","Gladwin, Mark, MD|National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 1","120","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO16090149|5P01HL103455","August 28, 2017","July 2020","July 2021","December 2, 2016",,"November 13, 2019","University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02980068"
297,"NCT01212900","Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression",,"Completed","Has Results","Atherosclerosis|Hypercholesterolemia","Drug: Statins, HMG CoA","Change in Mean of Wall Volume of Internal Carotid Arteries","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","50 Years to 99 Years   (Adult, Older Adult)","Phase 4","230","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","100214|10-H-0214","September 30, 2010","November 30, 2016","February 22, 2017","October 1, 2010","October 31, 2018","November 30, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT01212900/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01212900"
298,"NCT02634034","A Comparison Study to Evaluate the Pharmacokinetics and Safety of NK-104-CR in Healthy Adult Volunteers",,"Completed","No Results Available","Hyperlipidemia","Drug: A: NK-104-CR 8 mg|Drug: B: Pitavastatin IR 4 mg|Drug: C: Pitavastatin IR 8 mg","Area Under the Curve","Kowa Research Institute, Inc.","All","18 Years to 45 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","NK-104-CR-1.01US","December 2015","December 2015","December 2015","December 17, 2015",,"January 11, 2016","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02634034"
299,"NCT01426412","A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol",,"Completed","Has Results","Hyperlipidemia","Drug: LY3015014 IV|Drug: Placebo IV|Drug: LY3015014 SC|Drug: Placebo SC","Number of Participants With Clinically Significant Effects|Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time 0 to the Last Time Point With a Measurable Concentration of LY3015014 [AUC(0-tlast)]|PK: Maximum Concentration (Cmax) of LY3015014|Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)|Number of Participants With Detectable Levels of Anti-LY3015014 Antibodies","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","69","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","13980|I5S-EW-EFJA","September 2011","June 2013","June 2013","August 31, 2011","April 5, 2019","April 5, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01426412"
300,"NCT01896180","Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost",,"Completed","No Results Available","Primary Open Angle Glaucoma|Ocular Hypertension|Elevated Intraocular Pressure","Drug: ALZ-1101|Drug: Latanoprost","Goldmann applanation tonometry|Safety","Alleanza Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ALZ-1101-101","July 2013","January 2014","January 2014","July 11, 2013",,"September 30, 2014","Morrow, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01896180"
301,"NCT01668524","ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects",,"Completed","No Results Available","Primary Open Angle Glaucoma|Ocular Hypertension","Drug: ATS907","Evaluate local ocular safety and tolerability: change from baseline in ocular tolerability signs and symptoms (hyperemia, irritation, pain, tearing) using ocular tolerability and hyperemia grading scales; and change from baseline for vital signs","Altheos, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATS907-205","August 2012","August 2012","August 2012","August 20, 2012",,"September 7, 2012","Sall Research Medical Center, Artesia, California, United States",,"https://ClinicalTrials.gov/show/NCT01668524"
302,"NCT01917383","A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma",,"Completed","No Results Available","Primary Open-Angle Glaucoma (POAG)|Ocular Hypertension (OHT)","Drug: Trabodenoson|Drug: Latanoprost|Drug: Timolol","Intraocular Pressure (IOP)","Inotek Pharmaceuticals Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","101","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IPC-01-2013","August 2013","August 2014","September 2014","August 6, 2013",,"December 2, 2017","Chiltern, Bristol, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01917383"
303,"NCT02129673","A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Open Angle Glaucoma|Ocular Hypertension","Drug: VS101 Insert Dose A|Drug: VS101 Insert Dose B|Drug: VS101 Insert Dose C|Drug: Latanoprost 0.005% eye drops","Intra-ocular pressure","ViSci Ltd.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","VS101-CS201","May 2014","May 2017","August 2017","May 2, 2014",,"March 14, 2018","Speciality Eyecare Centre, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02129673"
304,"NCT01847014","Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument","SYMPHONYext","Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: Macitentan","Incident Rate of Adverse Events (AEs).","Actelion","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","4","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-055-402","September 1, 2013","October 1, 2015","November 30, 2017","May 6, 2013","August 22, 2018","August 22, 2018","Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|The Carl & Edyth Lindner Center for Research & Education at The Christ Hospital, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01847014"
305,"NCT01749904","Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension","APOLLO","Completed","Has Results","Open-Angle Glaucoma|Ocular Hypertension","Drug: BOL-303259-X|Drug: Timolol","Mean IOP|Response Rate - IOP ≤ 18 mm Hg|Response Rate - IOP Reduction ≥ 25%","Bausch & Lomb Incorporated","All","18 Years and older   (Adult, Older Adult)","Phase 3","420","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","769","January 31, 2013","June 2, 2015","September 30, 2015","December 17, 2012","November 7, 2018","November 7, 2018","Bausch & Lomb Inc., Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01749904"
306,"NCT01036802","Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease",,"Terminated","Has Results","Pulmonary Hypertension","Drug: Warfarin|Drug: Placebo","Effect of Anticoagulation on Pulmonary Artery Systolic Pressure Was Obtained by Doppler Echocardiography|6-minute Walk Test|Thrombin Generation|Platelet Activation|Endothelial Activation|All-cause Mortality|Major and Minor Bleeding Complications","University of North Carolina, Chapel Hill|National Heart, Lung, and Blood Institute (NHLBI)","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","3","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","09-1596|R01HL094592-01A1","December 2009","September 2012","September 2012","December 21, 2009","February 21, 2014","May 9, 2016","University of North Carolina, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01036802"
307,"NCT00910988","Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone",,"Completed","Has Results","Hyperglycemia|Hyperlipidemia","Drug: Olanzapine|Drug: Ziprasidone","Whole Body Insulin Sensitivity|Hepatic Insulin Sensitivity|Peripheral Insulin Sensitivity|Adipose Tissue Insulin Sensitivity","Washington University School of Medicine|Pfizer","Male","18 Years to 45 Years   (Adult)","Not Applicable","46","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","08-0540","February 2009","June 2012","June 2012","June 1, 2009","January 15, 2014","July 18, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00910988"
308,"NCT01749930","Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension","LUNAR","Completed","Has Results","Open-Angle Glaucoma|Ocular Hypertension","Drug: BOL-303259-X|Drug: Timolol","Mean IOP|IOP ≤ 18 mm Hg|IOP Reduction ≥ 25%","Bausch & Lomb Incorporated","All","18 Years and older   (Adult, Older Adult)","Phase 3","420","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","770","January 2013","May 2015","May 2015","December 17, 2012","November 21, 2018","November 21, 2018","Bausch & Lomb Inc., Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01749930"
309,"NCT01839110","Targeting the Right Ventricle in Pulmonary Hypertension",,"Completed","Has Results","Pulmonary Hypertension","Drug: Ranolazine|Drug: Placebo","Changes in Right Ventricular Ejection Fraction","University of Pennsylvania|The Cardiovascular Medical Research and Education Fund|Brigham and Women's Hospital|University of Maryland, College Park|Yale University|Washington University School of Medicine","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","817785","July 2013","January 2018","January 2018","April 24, 2013","December 19, 2018","February 5, 2019","University of Maryland, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT01839110/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01839110"
310,"NCT00934219","Triglyceride Lowering Study","TGLL","Unknown status","No Results Available","Hypertriglyceridemia","Drug: Omega-3-Acid Ethyl Esters","triglycerides level","Jewish Hospital, Cincinnati, Ohio|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 4","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TgLL8506","July 2009","July 2012","December 2012","July 8, 2009",,"July 8, 2009","Jewish Hospital Cholesterol Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00934219"
311,"NCT00817635","A Study to Evaluate the Effects of LCI699 on Safety and Efficacy in Subjects With Resistant Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic",,"Completed","No Results Available","Hypertension","Drug: LCI699|Drug: Placebo|Drug: Eplerenone","Change in mean sitting systolic blood pressure (MSSBP) as measured by office blood pressure (OBP)|Change in mean sitting diastolic blood pressure (MSDBP) at 8 weeks as measured by OBP|Proportion of patients achieving a successful BP response and BP control (MSSBP and MSDBP), as measured by OBP|Dose/exposure BP response relationship of LCI699, as measured by OBP|Changes from baseline in mean 24 hours, mean daytime and mean nighttime SBP and DBP, as measured by ABPM|To evaluate safety and tolerability of LCI699","Novartis|Great Lakes Drug Development, Inc.|Integrium","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","155","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLCI699A2216|EudraCT 2008-007338-23","December 2008","October 2009","October 2009","January 6, 2009",,"December 4, 2012","Horizon Research Group, Inc, Mobile, Alabama, United States|Cochise Clinical Research, Sierra Vista, Arizona, United States|Clinical Solutions Advantage, Buena Park, California, United States|Michael Waldman, MD, Irvine, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|Clinical Trials Research, Roseville, California, United States|Orange County Research Center, Tustin, California, United States|Metro Clinical Research, Littleton, Colorado, United States|Meridien Research, Bradenton, Florida, United States|Clinical Research of So. Florida, Coral Gables, Florida, United States|Jacksonville Heart Center, Jacksonville Beach, Florida, United States|FPA Clinical Research, Kissimmee, Florida, United States|Accelovance, Melbourne, Florida, United States|Cardio-Pulminary Associates, Plantation, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Northwest Clinical Trials, Boise, Idaho, United States|Provident Clinical Research, Addison, Illinois, United States|Cedar-Crosse Research Centereet, Chicago, Illinois, United States|Provident Clinical Research, Bloomington, Indiana, United States|Accelovance, South Bend, Indiana, United States|Peter A. Holt, Baltimore, Maryland, United States|MD Medical Research, Oxon Hill, Maryland, United States|Chelsea Internal Medicine, Chelsea, Michigan, United States|New York Cardiovascular Associates, New York, New York, United States|Charlotte Clinical Research, Charlotte, North Carolina, United States|Northstate Clinical Research, Lenior, North Carolina, United States|Community Research, Cincinnati, Ohio, United States|Tipton Medical & Diagnostic Center, Tipton, Pennsylvania, United States|Medical Research South, Charleston, South Carolina, United States|Mountain View Clinical Research Associates, Greer, South Carolina, United States|Clinical Research Associates, Inc, Nashville, Tennessee, United States|Punzi Medical Center, Carrollton, Texas, United States|KRK Medical Research, Dallas, Texas, United States|DCOL Center for Clinical Research, Longview, Texas, United States|Daniel Gottlieb, MD, Burien, Washington, United States|Rainier Clinical Research Center, Renton, Washington, United States|Gemini Scientific, Madison, Wisconsin, United States|Encode Clinic, Reykjavik, SA, Iceland",,"https://ClinicalTrials.gov/show/NCT00817635"
312,"NCT02957682","Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo",,"Active, not recruiting","No Results Available","Hypercholesterolemia","Drug: Praluent (Alirocumab)|Drug: Placebo","Change in Cambridge Neuropsychological Test Automated Battery (CANTAB) cognitive domain Spatial Working Memory (SWM) strategy score|Percent change in calculated low-density lipoprotein cholesterol (LDL-C)|Percent change in apolipoprotein (Apo) B|Percent change in non-high-density lipoprotein cholesterol (non-HDL-C),|Percent change in total cholesterol (Total-C)|Percent change in lipoprotein a [Lp(a)]|Percent change in HDL-C|Percent change in triglyceride (TG)|Percent change in apolipoprotein (Apo) A-1|Proportion of participants reaching LDL-C <70 mg/dL (1.81 mmol/L)|Proportion of participants reaching LDL-C <50 mg/dL (1.29 mmol/L)","Regeneron Pharmaceuticals|Sanofi","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 4","2176","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1532|2016-003189-16","November 2, 2016","March 5, 2020","March 5, 2020","November 8, 2016",,"February 28, 2020","Regeneron Study Site, Auburn, Alabama, United States|Regeneron Study Site, Birmingham, Alabama, United States|Regeneron Study Site, Mobile, Alabama, United States|Regeneron Study Site, Beverly Hills, California, United States|Regeneron Study Site, Los Gatos, California, United States|Regeneron Study Site, North Hollywood, California, United States|Regeneron Study Site, Port Hueneme, California, United States|Regeneron Study Site, Westminster, California, United States|Regeneron Study Site 1, Aurora, Colorado, United States|Regeneron Study Site 2, Aurora, Colorado, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Lake Worth, Florida, United States|Regeneron Study Site, Lake Worth, Florida, United States|Regeneron Study Site, Miami Springs, Florida, United States|Regeneron Study Site, Covington, Georgia, United States|Regeneron Study Site, Champaign, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Rock Island, Illinois, United States|Regeneron Study Site, Evansville, Indiana, United States|Regeneron Study Site, Indianapolis, Indiana, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Waterloo, Iowa, United States|Regeneron Study Site, Hutchinson, Kansas, United States|Regeneron Study Site, Newton, Kansas, United States|Regeneron Study Site, Overland Park, Kansas, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, Bangor, Maine, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Oxon Hill, Maryland, United States|Regeneron Study Site, Minneapolis, Minnesota, United States|Regeneron Study Site, Olive Branch, Mississippi, United States|Regeneron Study Site, Washington, Missouri, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, New Hyde Park, New York, United States|Regeneron Study Site, Cary, North Carolina, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Greensboro, North Carolina, United States|Regeneron Study Site, Hickory, North Carolina, United States|Regeneron Study Site, High Point, North Carolina, United States|Regeneron Study Site, Raleigh, North Carolina, United States|Regeneron Study Site, Rocky Mount, North Carolina, United States|Regeneron Study Site, Salisbury, North Carolina, United States|Regeneron Study Site, Statesville, North Carolina, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Winston-Salem, North Carolina, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Cleveland, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Duncansville, Pennsylvania, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Greenville, South Carolina, United States|Regeneron Study Site, Summerville, South Carolina, United States|Regeneron Study Site, Rapid City, South Dakota, United States|Regeneron Study Site, Bristol, Tennessee, United States|Regeneron Study Site, Knoxville, Tennessee, United States|Regeneron Study Site, Knoxville, Tennessee, United States|Regeneron Study Site, Knoxville, Tennessee, United States|Regeneron Study Site, Powell, Tennessee, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Schertz, Texas, United States|Regeneron Study Site, Shavano Park, Texas, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Winchester, Virginia, United States|Regeneron Study Site, Burien, Washington, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Tacoma, Washington, United States|Regeneron Study Site, Walla Walla, Washington, United States|Regeneron Study Site, Manitowoc, Wisconsin, United States|Regeneron Study Site, Pleven, Bulgaria|Regeneron Study Site, Plovdiv, Bulgaria|Regeneron Study Site, Plovdiv, Bulgaria|Regeneron Study Site, Sofia, Bulgaria|Regeneron Study Site, Sofia, Bulgaria|Regeneron Study Site, Sofia, Bulgaria|Regeneron Study Site, Stara Zagora, Bulgaria|Regeneron Study Site 1, Varna, Bulgaria|Regeneron Study Site 2, Varna, Bulgaria|Regeneron Study Site, Osorno, Chile|Regeneron Study Site, San Miguel, Chile|Regeneron Study Site, Santiago, Chile|Regeneron Study Site, Santiago, Chile|Regeneron Study Site, Santiago, Chile|Regeneron Study Site, Santiago, Chile|Regeneron Study Site, Temuco, Chile|Regeneron Study Site, Temuco, Chile|Regeneron Study Site, Viña del Mar, Chile|Regeneron Study Site, Paide, Estonia|Regeneron Study Site, Tallinn, Estonia|Regeneron Study Site, Tallinn, Estonia|Regeneron Study Site 1, Tallinn, Estonia|Regeneron Study Site 2, Tallinn, Estonia|Regeneron Study Site, Tallinn, Estonia|Regeneron Study Site, Tallinn, Estonia|Regeneron Study Site, Tartu, Estonia|Regeneron Study Site, Nishinomiya, Hogo, Japan|Regeneron Study Site, Kahoku-gun, Ishikawa, Japan|Regeneron Study Site, Kawasaki, Kanagawa, Japan|Regeneron Study Site, Yokohama, Kanagawa, Japan|Regeneron Study Site, Uji-shi, Kyoto, Japan|Regeneron Study Site, Nakagami-gun, Okinawa, Japan|Regeneron Study Site, Iruma-gun, Saitama, Japan|Regeneron Study Site, Bunkyō-Ku, Tokyo, Japan|Regeneron Study Site, Chuo Ku, Tokyo, Japan|Regeneron Study Site, Hachiōji, Tokyo, Japan|Regeneron Study Site, Itabashi-ku, Tokyo, Japan|Regeneron Study Site, Shinagawa-Ku, Tokyo, Japan|Regeneron Study Site, Aguascalientes, Mexico|Regeneron Study Site, Cuernavaca, Mexico|Regeneron Study Site, Culiacán, Mexico|Regeneron Study Site, Distrito Federal, Mexico|Regeneron Study Site, Durango, Mexico|Regeneron Study Site, Guadalajara, Mexico|Regeneron Study Site, Guadalajara, Mexico|Regeneron Study Site, Guadalajara, Mexico|Regeneron Study Site, Merida, Mexico|Regeneron Study Site, Mexico City, Mexico|Regeneron Study Site, Mexico City, Mexico|Regeneron Study Site, Mexico City, Mexico|Regeneron Study Site 1, Monterrey, Mexico|Regeneron Study Site 2, Monterrey, Mexico|Regeneron Study Site, Monterrey, Mexico|Regeneron Study Site, Pachuca, Mexico|Regeneron Study Site, Querétaro, Mexico|Regeneron Study Site, San Juan Del Río, Mexico|Regeneron Study Site, Torreon, Mexico|Regeneron Study Site, Ivanovo, Russian Federation|Regeneron Study Site, Kirov, Russian Federation|Regeneron Study Site, Moscow, Russian Federation|Regeneron Study Site, Moscow, Russian Federation|Regeneron Study Site, Moscow, Russian Federation|Regeneron Study Site, Novosibirsk, Russian Federation|Regeneron Study Site, Rostov-on-Don, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Study Site, Saratov, Russian Federation|Regeneron Study Site, Tyumen', Russian Federation|Regeneron Study Site, Yaroslavl, Russian Federation|Regeneron Study Site, Yaroslavl, Russian Federation|Regeneron Study Site 1, Yaroslavl, Russian Federation|Regeneron Study Site 2, Yaroslavl, Russian Federation|Regeneron Study Site, Kuils River, Cape Town, South Africa|Regeneron Study Site, Port Elizabeth, Eastern Cape, South Africa|Regeneron Study Site, Halfway House, Gauteng, South Africa|Regeneron Study Site, Pretoria West, Gauteng, South Africa|Regeneron Study Site, Pretoria, Gauteng, South Africa|Regeneron Study Site, Pretoria, Gauteng, South Africa|Regeneron Study Site, Kempton Park, Johannesburg, South Africa|Regeneron Study Site, Soweto, Johannesburg, South Africa|Regeneron Study Site, Soweto, Johannesburg, South Africa|Regeneron Study Site, Middelburg, Mpumalanga, South Africa|Regeneron Study Site, Cape Town, Western Cape, South Africa|Regeneron Study Site, Cape Town, Western Cape, South Africa|Regeneron Study Site, Paarl, Western Cape, South Africa|Regeneron Study Site, Somerset West, Western Cape, South Africa|Regeneron Study Site, Worcester, Western Cape, South Africa|Regeneron Study Site 1, Bloemfontein, South Africa|Regeneron Study Site 2, Bloemfontein, South Africa|Regeneron Study Site, Claremont, South Africa|Regeneron Study Site, Úzhgorod, Transcarpathian Region, Ukraine|Regeneron Study Site, Kharkiv, Ukraine|Regeneron Study Site, Kharkiv, Ukraine|Regeneron Study Site, Kharkov, Ukraine|Regeneron Study Site 1, Kiev, Ukraine|Regeneron Study Site 2, Kiev, Ukraine|Regeneron Study Site, Kyiv, Ukraine|Regeneron Study Site 1, Kyiv, Ukraine|Regeneron Study Site 2, Kyiv, Ukraine|Regeneron Study Site, Kyiv, Ukraine|Regeneron Study Site 1, Kyiv, Ukraine|Regeneron Study Site 2, Kyiv, Ukraine|Regeneron Study Site 1, Kyiv, Ukraine|Regeneron Study Site 2, Kyiv, Ukraine|Regeneron Study Site, Kyiv, Ukraine|Regeneron Study Site, Kyiv, Ukraine|Regeneron Study Site, L'viv, Ukraine|Regeneron Study Site 1, Vinnitsa, Ukraine|Regeneron Study Site 2, Vinnitsa, Ukraine|Regeneron Study Site, Vinnitsa, Ukraine",,"https://ClinicalTrials.gov/show/NCT02957682"
313,"NCT01755858","Study to Assess the Effects of Intravenous Bendavia in Patients Undergoing Percutaneous Transluminal Angioplasty of the Renal Artery (PTRA)","EVOLVE","Terminated","No Results Available","Renal Artery Obstruction|Hypertension, Renovascular|Ischemia Reperfusion Injury","Drug: Bendavia|Drug: Placebo","Comparison between treatment groups in the change in the glomerular filtration rate (GFR), as measured by iothalamate clearance, from before percutaneous renal artery angioplasty (PTRA) to 8 weeks post-PTRA.|Mean change in renal volume (ml) as measured using Multi-Detector Computed Tomography (MDCT) from pre-PTRA to 8 weeks post-PTRA with and without Bendavia.|Mean change in regional perfusion (medulla) (ml/minute/ml of tissue) as measured using Multi-Detector Computed Tomography (MDCT) from pre-PTRA to 8 weeks post-PTRA with and without Bendavia.|Mean change in regional perfusion (cortex) (ml/minute/ml of tissue) as measured using Multi-Detector Computed Tomography (MDCT) from pre-PTRA to 8 weeks post-PTRA with and without Bendavia.|Mean change in glomerular flow rate (ml/minute) as measured using Multi-Detector Computed Tomography (MDCT) from pre-PTRA to 8 weeks post-PTRA with and without Bendavia.|Mean change in renal blood flow (ml/minute) as measured using Multi-Detector Computed Tomography (MDCT) from pre-PTRA to 8 weeks post-PTRA with and without Bendavia.|Mean change in renal oxygenation between pre-PTRA, 27 hours post-PTRA and 8 weeks post-PTRA as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging, with and without Bendavia.|Mean change in plasma 8-isoprostane (8-iso prostaglandin F2-alpha) levels (pg/ml) from pre-PTRA and then immediately post-PTRA and 8 weeks post-PTRA, with and without Bendavia.|Mean change in Monocyte Chemotactic Protein-1 (MCP-1) levels (pg/ml) from pre-PTRA and then immediately post-PTRA and 8 weeks post-PTRA, with and without Bendavia.|Mean change in Tumor Necrosis Factor-alpha (TNF-a) levels (pg/ml) from pre-PTRA and then immediately post-PTRA and 8 weeks post-PTRA, with and without Bendavia.|Mean change in Interferon-Gamma (IFN-gamma) levels (pg/ml) from pre-PTRA and then immediately post-PTRA and 8 weeks post-PTRA, with and without Bendavia.|Mean change in Interleukin-10 (IL-10) levels (pg/ml) from pre-PTRA and then immediately post-PTRA and 8 weeks post-PTRA, with and without Bendavia.|Mean change in Neutrophil Gelatinase-Associated Lipocalin (NGAL) levels (pg/ml) from pre-PTRA to immediately post-PTRA, 3, 9, 15, 21, and 27 hours post-PTRA and then 8 weeks post-PTRA, with and without Bendavia.|Mean change in High Sensitivity C-Reactive Protein (hs-CRP) levels (mg/L) from pre-PTRA to immediately post-PTRA and 15 hours, 27 hours and 8 weeks post-PTRA, with and without Bendavia.|Mean change in partial pressure of blood oxygen (PO2) values (mmHg) from pre-PTRA and then immediately post-PTRA and 8 weeks post-PTRA, with and without Bendavia.|Mean change in Plasma Renin Activity (PRA) levels (ng/ml/hr) from pre-PTRA and then immediately post-PTRA and 8 weeks post-PTRA, with and without Bendavia.|Mean Change in Systolic Blood Pressure (SBP) values (mmHg) from pre-PTRA, immediately post-PTRA, 27 hours and 8 weeks post-PTRA, with and without Bendavia.|Mean Change in Diastolic Blood Pressure (DBP) values (mmHg) from pre-PTRA, immediately post-PTRA, 27 hours and 8 weeks post-PTRA, with and without Bendavia.|Number of adverse events observed with and without Bendavia|Mean change in serum sodium levels (mmol/l) from pre-study drug administration (and pre-PTRA), and then at 3, 9, 15, 21, and 27 hours post-PTRA, with and without Bendavia.|Mean change in urine sodium levels (mmol/l) from pre-study drug administration (and pre-PTRA), and then at 3, 9, 15, 21, and 27 hours post-PTRA, with and without Bendavia.|Mean change in serum osmolality levels (mOsm/kg) from pre-study drug administration (and pre-PTRA), and then at 3, 9, 15, 21, and 27 hours post-PTRA, with and without Bendavia.|Mean change in urine osmolality levels (mOsm/kg) from pre-study drug administration (and pre-PTRA), and then at 3, 9, 15, 21, and 27 hours post-PTRA, with and without Bendavia.|Mean change in plasma Arginine Vasopressin (AVP) levels (pg/ml) from pre-study drug administration (and pre-PTRA), and then at 3, 9, 15, 21, and 27 hours post-PTRA , with and without Bendavia.|Mean difference in Bendavia Area Under the Curve(0-infinity) (AUC) when Bendavia is administered in patients undergoing PTRA and healthy volunteers (historical data will be used to provide AUC for Bendavia in healthy volunteers).|Change in KIM-1 levels from pre-PTRA to immediately post-PTRA, 3, 9 (±1), 15 (±2), 21 (±2), and 27 (±4) hours post-PTRA, and 8 (+4) weeks post-PTRA.","Stealth BioTherapeutics Inc.","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","SPIRI-225","December 2012","December 2015","May 2016","December 24, 2012",,"June 7, 2016","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01755858"
314,"NCT02217683","Use of Inhaled Nitric Oxide to Prevent Pulmonary Hypertension Associated to Stored Blood Transfusion",,"Withdrawn","No Results Available","Hypertension, Pulmonary|Hemolysis","Drug: Nitric Oxide","Pulmonary vascular resistance index|Hemolysis|Nitric oxide metabolites|Inflammation","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BloodiNO","March 2016","December 2016","April 2017","August 15, 2014",,"March 18, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02217683"
315,"NCT01780974","Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention",,"Completed","Has Results","Treated Hypertension","Drug: Lipoic Acid plus Omega-3 Fatty Acids|Drug: Placebo","Trails Making Test Part B (Executive Function)|White Matter Hyperintensity Volume (Brain MRI)","Oregon Health and Science University","All","55 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SFF01","April 2013","October 2015","October 2015","January 31, 2013","April 7, 2017","April 7, 2017","Lynne Shinto, ND, MPH, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01780974"
316,"NCT03464864","Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Treprostinil Inhalation Powder","Incidence and severity of treatment-related adverse events (safety and tolerability) of single ascending doses of Treprostinil Inhalation Powder|Systemic exposure and pharmacokinetics of treprostinil administered as Treprostinil Inhalation Powder in healthy normal volunteers|Dose proportionality","Mannkind Corporation","All","18 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","MKC-475-001","March 9, 2018","June 5, 2018","June 5, 2018","March 14, 2018",,"October 30, 2018","Investigational Site 441, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03464864"
317,"NCT00872170","Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension",,"Completed","Has Results","Thalassemia|Hypertension, Pulmonary","Drug: Sildenafil","Change in Six-minute Walk Test (6MWT) Distance From Baseline to Week 12 Among Sildenafil Group|Change in Tricuspid Regurgitant Jet Velocity (TRV) From Baseline to Week 12 Among Sildenafil Group|Change in Echo Left Ventricular End Systolic Volume (LVESV) From Baseline to Week 12 Among Sildenafil Group|Change in Echo Left Ventricular End Diastolic Volume (LVEDV) From Baseline to Week 12 Among Sildenafil Group|Change in Plasma Arginine From Baseline to Week 12 Among Sildenafil Group|Change in Red Blood Cell (RBC) Arginine From Baseline to Week 12 Among Sildenafil Group|Change in Soluble Platelet Selectin (sP-SELECTIN) From Baseline to Week 12 Among Sildenafil Group|Change in Lactate Dehydrogenase (LDH) From Baseline to Week 12 Among Sildenafil Group|Change in Cell Free Hemoglobin From Baseline to Week 12 Among Sildenafil Group|Change in Arginase Concentration From Baseline to Week 12 Among Sildenafil Group|Change in Arginase Activity From Baseline to Week 12 Among Sildenafil Group","HealthCore-NERI|National Heart, Lung, and Blood Institute (NHLBI)","All","7 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","27","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","638|U01HL065238","March 2009","June 2010","November 2010","March 31, 2009","February 21, 2014","February 21, 2014","Children's Hospital and Research Institute Oakland, Oakland, California, United States",,"https://ClinicalTrials.gov/show/NCT00872170"
318,"NCT01983462","Vascular Dysfunction in Human Obesity Hypertension","VANISH","Recruiting","No Results Available","Obesity|Prehypertension|Hypertension","Drug: Clonidine|Drug: Hydrochlorothiazide|Drug: Placebo","Forearm endothelium-dependent dilation (EDD)|Forearm endothelium-independent dilation (EID)|Muscle sympathetic nerve activity|Endothelial cell oxidative stress and RAS proteins","Gary L. Pierce|American Heart Association|University of Iowa","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","201307779","October 2013","December 2019","June 2020","November 14, 2013",,"August 20, 2019","University of Iowa, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT01983462"
319,"NCT02358369","Dose-Ranging Study of the Bimatoprost Ocular Insert",,"Completed","No Results Available","Primary Open-Angle Glaucoma|Ocular Hypertension","Drug: Bimatoprost|Drug: Timolol","Change in IOP from baseline|Safety assessed by ophthalmic examination including best-corrected visual acuity, slit lamp exam, automated visual field, and dilated fundus exam.","ForSight Vision5, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","156","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FSV5-004","January 2015","August 2015","November 2015","February 9, 2015",,"October 25, 2016","Sall Medical Research Center, Artesia, California, United States",,"https://ClinicalTrials.gov/show/NCT02358369"
320,"NCT00829296","Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries","EFFORT","Completed","Has Results","Hypertension|Diabetes","Drug: nebivolol|Drug: Metoprolol","Change in Central Systolic Blood Pressure (SBP)|Change in Pulse Wave Velocity (PWV)|Change in Augmentation Index|Change in Pulse Pressure Amplification","University of Chicago|Forest Laboratories","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","16310B (EFFORT trial)","January 2009","April 2012","April 2013","January 27, 2009","November 5, 2014","February 5, 2016","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00829296"
321,"NCT01984164","CAndesartan vs LIsinopril Effects on the BRain","CALIBREX","Completed","No Results Available","Hypertension|Mild Cognitive Impairment","Drug: Candesartan|Drug: Lisinopril","Executive function|Memory|Language|Attention|White Matter Hyperintensity (WMH) Volume|rs-fMRI|Cerebral Perfusion and Vasoreactivity (VR)","Emory University|National Institute on Aging (NIA)","All","55 Years and older   (Adult, Older Adult)","Phase 2","176","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","IRB00070087|R01AG042127","August 2014","December 3, 2018","December 3, 2018","November 14, 2013",,"January 10, 2020","Emory Univeristy, Atlanta, Georgia, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT01984164/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT01984164"
322,"NCT03315507","A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: PB1046 Subcutaneous Injection","Adverse Events|Vital Signs (Blood pressure)|Vital Signs (Heart rate)|Laboratory Parameters (Lipids)|Laboratory Parameters (Serum chemistry)|Laboratory Parameters (Urinalysis)|Laboratory Parameters (NT-pro-BNP)|Mean Pulmonary Artery Pressure|Cardiac Index|Total pulmonary resistance|Laboratory Parameters (Fasting Plasma Glucose)|Laboratory Parameters (Hematology)|Pharmacokinetic Dose Exposures (AUC (0-t))|Pharmacokinetic Dose Exposures (AUC (0-tmax))|Pharmacokinetic Dose Exposures (Cmax)|Pharmacokinetic Dose Exposures (Tmax)|Pharmacokinetic Dose Exposures (Ctrough)|Pharmacokinetic Dose Exposures (t1/2)|Pharmacokinetic Dose Exposures (Lambda z)|Pharmacokinetic Dose Exposures (Cl/F)|Pharmacokinetic Dose Exposures (Vd/F)|Immunogenicity","PhaseBio Pharmaceuticals Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","3","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PB1046-PT-CL-0005","October 20, 2017","August 8, 2019","August 8, 2019","October 20, 2017",,"October 8, 2019","The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03315507"
323,"NCT02911701","Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features",,"Unknown status","No Results Available","Pre-Eclampsia|HELLP Syndrome|Eclampsia","Drug: Acetaminophen|Drug: Ibuprofen","Duration of severe-range hypertension after delivery|Length of hospitalization|Mean arterial pressure over the entire postpartum hospitalization|Mean arterial pressure, stratified by postpartum day 1, 2, 3, etc.|mean total number of severe range blood pressure measurements in each study arm.|Proportion of study participants in each study arm who have any severe range|Mean maximum measured blood pressure for entire postpartum hospitalization (in mm Hg)|Proportion of study participants requiring the use of scheduled oral antihypertensives at discharge|Number of scheduled oral antihypertensive agents required at discharge|Number of doses of antihypertensives (either oral or intravenous) given for acute lowering of blood pressure|The proportion of study participants requiring the use of intravenous antihypertensives|Mean daily pain level, as reported by patient on scale from 1-10, stratified by postpartum day|Use of opioid analgesics, measured in morphine milligram equivalents per day, stratified by postpartum day|Serum creatinine trend from day of delivery to day of discharge|Mean drop in hematocrit from pre-delivery to the nadir prior to discharge|Composite of adverse events|Proportion of study participants in each study arm with new onset postpartum elevation of liver function tests (AST, ALT) above twice the normal limit|Proportion of study participants in each study arm with new onset postpartum acute kidney injury|Proportion of study participants in each study arm with delayed postpartum hemorrhage","University of New Mexico","Female","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16-147","September 2016","December 18, 2017","June 2018","September 22, 2016",,"October 31, 2017","University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT02911701"
324,"NCT03595982","Is Procardia XL 60 mg Q Daily Equivalent to 30 mg XL Given Twice Daily?",,"Terminated","No Results Available","Hypertension in Pregnancy|Hypertension in Postpartum","Drug: Procardia XL 30Mg|Drug: Procardia XL 60Mg","Procardia plasma level|Blood pressure (Systolic/Diastolic)|Survey of Side effects","Icahn School of Medicine at Mount Sinai","Female","18 Years to 55 Years   (Adult)","Phase 4","5","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 18-0959","September 15, 2018","February 20, 2020","February 20, 2020","July 23, 2018",,"March 27, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03595982"
325,"NCT04039464","Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension","MoD","Not yet recruiting","No Results Available","Pediatric Hypertension","Drug: Mono-Therapy with Sildenafil|Drug: Duo-Therapy with Sildenafil + Bosentan","Change in WHO functional class (FC) of Mono vs. Dual Therapy|Change in serum NT-proBNP level (pg/ml)|Change in right ventricular function as assessed by systolic pressure (mmHg)|Change in Quality of life as assessed by Pediatric Quality of Life Inventory (PedsQL)","Johns Hopkins University","All","4 Months to 18 Years   (Child, Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Kids Mono vs. Duo Therapy PAH","July 2021","December 2025","December 2025","July 31, 2019",,"April 10, 2020","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04039464"
326,"NCT00946166","Impact of Statins on Cytokine Expression in Pneumonia",,"Withdrawn","No Results Available","Community Acquired Pneumonia|Cardiovascular Risk Factors","Drug: simvastatin|Drug: Placebo","Cytokine (TNF alpha, IL-1beta, IL-6, IL-8, IL-10) levels|30-day mortality","The University of Texas Health Science Center at San Antonio","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","HSC2009-183H","July 2009","August 2011","August 2011","July 24, 2009",,"April 22, 2015","Audie L Murphy Memorial Veterans Hospital, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00946166"
327,"NCT00819910","Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)","RAFAEL","Terminated","Has Results","Hypertriglyceridemia in Type 4 Hyperlipidemia|Non Diabetic Subjects With Normoglycemia","Drug: Rosiglitazone|Drug: Placebo (Rosiglitazone)|Drug: Placebo (Fenofibrate)|Drug: Fenofibrate","Percent Change in Triglyceride (TG) Levels Post Treatment|Post-treatment Percent Change in High-Density Lipoprotein (HDL) Levels|Post-treatment Percent Change in Low-Density Lipoprotein (LDL) Levels|Post-treatment Percent Change in Apolipoprotein A-I (Apo AI), Apolipoprotein A-II (Apo AII) and Apolipoprotein C-III (Apo CIII) Levels|Mean Levels of Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) at Initial Visit and Final Visit","Ahmad Slim|GlaxoSmithKline|Brooke Army Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","41","U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","C.2007.122","September 2008","May 2010","May 2010","January 9, 2009","February 26, 2014","April 24, 2014","Brooke Army Medical Center, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00819910"
328,"NCT00980031","Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension","Aldosterone","Terminated","No Results Available","Myocardial Remodeling","Drug: Eplerenone|Drug: Lactose Tablet","Myocardial Remodeling (cardiac chamber sizes, wall thickness, left ventricular ejection fraction, left atrial volumes, and diastolic function) assessed by transthoracic echocardiogram|Blood Pressure","Creighton University","All","19 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","07-14634","April 2007","September 2011","September 2011","September 18, 2009",,"March 28, 2014","Creighton University Medical Center (including ambulatory centers), Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT00980031"
329,"NCT01712113","Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted Conditions",,"Completed","No Results Available","Hypertension","Drug: Irbesartan|Drug: Avapro","bioequivalence determined by statistical comparison Cmax","Roxane Laboratories|West-Ward Pharmaceutical","All","18 Years to 45 Years   (Adult)","Not Applicable","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRBE-T300-PVFS-1","August 2007","August 2007","August 2007","October 23, 2012",,"January 23, 2018","Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01712113"
330,"NCT01172496","A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: treprostinil diethanolamine","Plasma treprostinil concentrations|vital sign measurements, clinical laboratory parameters, electrocardiograms (ECGs) and adverse events (AEs)","United Therapeutics","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-PH-123","August 2010","August 2010",,"July 29, 2010",,"October 13, 2010","PPD Development, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01172496"
331,"NCT01165476","Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Treprostinil diethanolamine","Treprostinil pharmacokinetics|Clinical lab values|Adverse event monitoring","United Therapeutics","All","18 Years to 55 Years   (Adult)","Phase 1","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-PH-121","July 2010","August 2010","August 2010","July 19, 2010",,"April 19, 2011","PPD Development, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01165476"
332,"NCT01267227","Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress",,"Completed","Has Results","Hyperlipidemia|Blood Pressure|Oxidative Stress","Drug: Pterostilbene 50 mg twice daily|Drug: Placebo|Drug: Grape Extract|Drug: Pterostilbene 125 mg twice daily","LDL|Blood Pressure|Subjective Adverse Effects","University of Mississippi Medical Center","All","18 Years to 88 Years   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2010-0225","December 2010","February 2012","February 2012","December 28, 2010","May 3, 2013","January 10, 2018","University of Mississippi Medical Center, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT01267227"
333,"NCT03298802","Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide",,"Recruiting","No Results Available","Pre-Eclampsia|Gestational Hypertension|Superimposed Pre-Eclampsia|Hypertension, Pregnancy-Induced|Postpartum Pregnancy-Induced Hypertension|Postpartum Preeclampsia","Drug: Hydrochlorothiazide 50mg Tablet|Drug: Placebo Tablet","Rate of readmission and/or triage visits|Need for additional antihypertensive therapy|Length of hospital stay|Total Additional doses of anti-hypertensive therapy|Elevation of blood pressure >150/90|Severe composite maternal morbidity|Use of resources|Adverse Events","The University of Texas Medical Branch, Galveston","Female","18 Years to 50 Years   (Adult)","Phase 3","612","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","16-0280","November 21, 2017","April 30, 2021","May 30, 2021","October 2, 2017",,"April 29, 2020","St. David's North Austin Medical Center, Austin, Texas, United States|Luis Monsivais, Galveston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03298802"
334,"NCT03273413","Statin Therapy in Patients With Early Stage ADPKD",,"Recruiting","No Results Available","ADPKD|Autosomal Dominant Polycystic Kidney","Drug: Pravastatin|Drug: Placebo","Change in Total Kidney Volume|Change in Renal Blood Flow|Change in Kidney Function|Change in Circulating Inflammatory Markers|Change in Circulating Markers of Oxidative Stress|Change in Urinary Epithelial Cells","University of Colorado, Denver","All","25 Years to 60 Years   (Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17-0678","August 31, 2017","December 2021","December 2021","September 6, 2017",,"October 22, 2019","University of Colorado Denver Anschutz Medical Campus, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03273413"
335,"NCT03380000","Effect of Beetroot Juice on Blood Pressure Regulation in Post Menopausal Women",,"Active, not recruiting","No Results Available","Postmenopausal Women","Drug: Beetroot juice|Drug: Beetroot juice placebo","Resting blood pressures|Blood measures of nitrate absorption and conversion|Resting arterial stiffness/wave properties|Handgrip exercise blood pressure responses|Handgrip exercise tolerance","Penn State University","Female","55 Years to 80 Years   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","00043633","September 12, 2014","September 2019","September 2020","December 20, 2017",,"October 14, 2019","Penn State University, University Park, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03380000"
336,"NCT03611010","Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients",,"Completed","No Results Available","Hypercholesterolemia|Dyslipidemias","Drug: Atorvastatin injection","Efficacy, Low-density lipoprotein cholesterol (LDL-C)|Efficacy, High -density lipoprotein cholesterol (HDL-C)|Mean change, LDL-C|Cmax IV|AUCinf IV|AUC0-24 IV|T-1/2 IV|VDss IV|Kel IV|Cl IV|Cmax SC|AUCinf SC|T-1/2 SC|VDss SC|Kel SC|Cl/F SC|Cl SC","Cumberland Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPI-1103-002","August 7, 2018","February 17, 2020","February 24, 2020","August 2, 2018",,"March 5, 2020","Frontage Clinical Services, Secaucus, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03611010"
337,"NCT00879112","Study of MB07811 in Subjects With Hypercholesterolemia",,"Withdrawn","No Results Available","Hypercholesterolemia","Drug: MB07811|Drug: Placebo","Evaluate the effects of MB07811 compared to placebo on LDL-C|Evaluate the effects of MB07811 on other lipid markers compared to placebo|Assess the safety and tolerability of MB07811","Ligand Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MB07811-201","April 2009","December 2009","December 2009","April 9, 2009",,"August 12, 2011","Scripps Clinic, Clinical Research, San Diego, California, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|University Clinical Research, Pembroke Pines, Florida, United States|Radiant Research, Chicago, Illinois, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Commonwealth Biomedical Research, Madisonville, Kentucky, United States|Troy Internal Medicine, Troy, Michigan, United States|Coastal Carolina Research Center, Inc., Goose Creek, South Carolina, United States|Research Across America, Dallas, Texas, United States|National Clinical Research - Norfolk, Norfolk, Virginia, United States|National Clinical Research, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00879112"
338,"NCT01822860","Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function",,"Withdrawn","No Results Available","Hypertension","Drug: Chlorthalidone 12.5 mg|Drug: Hydrochlorothiazide 25 mg|Drug: Placebo","Flow mediated vasodilatation","Creighton University","All","19 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13-16628","March 2013","February 2015","February 2015","April 2, 2013",,"March 25, 2015","Creighton University, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01822860"
339,"NCT02217345","Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease","NAFLD","Recruiting","No Results Available","Nonalcoholic Fatty Liver Disease (NAFLD)","Drug: Growth hormone|Drug: Placebo","Intrahepatic lipid content as measured by 1H-MRS|Inflammatory Markers","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2014P001680","September 2015","January 2021","January 2021","August 15, 2014",,"February 17, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02217345"
340,"NCT01525173","A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: 0.1% brimonidine tartrate ophthalmic solution|Drug: 0.01% bimatoprost ophthalmic solution|Drug: 0.2% hypromellose lubricant eye drops|Drug: latanoprost 0.005% ophthalmic solution","Change From Baseline in Mean Diurnal Intraocular Pressure (IOP)","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","137","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GMA-LUM-11-019","January 2012","October 2012","October 2012","February 2, 2012","December 4, 2013","December 4, 2013","Deerfield Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01525173"
341,"NCT02252081","Metformin in Kidney Disease",,"Recruiting","No Results Available","Chronic Kidney Disease|Cardiovascular Disease|Metabolic Syndrome","Drug: metformin|Drug: Placebo","leptin to adiponectin ratio (LAR)|estimated glomerular filtration rate (eGFR)","VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ENDA-014-13F|1I01CX000982-01A1","October 1, 2014","December 31, 2019","December 31, 2019","September 29, 2014",,"February 18, 2019","Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02252081"
342,"NCT03593785","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.",,"Active, not recruiting","No Results Available","Hypercholesterolemia","Drug: AZD8233","Number of subjects with adverse events (AEs) due to AZD8233 SC SAD treatment|Vital sign: Blood pressure [BP]|Vital sign: Pulse rate|Vital sign: Oral body temperature|Number of patients with abnormal findings in Resting 12-lead Electrocardiogram (ECG)|Physical examination|Laboratory assessments: Haematology - Blood cells count|Laboratory assessments: Haematology - Hemoglobin (Hb)|Laboratory assessments: Haematology - Haematocrit (HCT)|Laboratory assessments: Haematology - Mean corpuscular volume (MCV)|Laboratory assessments: Haematology - Mean corpuscular hemoglobin (MCH)|Laboratory assessments: Haematology - Mean corpuscular hemoglobin concentration (MCHC)|Laboratory assessments: Haematology - Differential count|Laboratory assessments: Haematology - Platelets|Laboratory assessments: Haematology - Reticulocytes absolute count|Laboratory assessments: Serum clinical chemistry - Electrolytes|Laboratory assessments: Serum clinical chemistry - Urea|Laboratory assessments: Serum clinical chemistry - Creatinine|Laboratory assessments: Serum clinical chemistry - Glucose (fasting)|Laboratory assessments: Serum clinical chemistry - Liver enzymes|Laboratory assessments: Serum clinical chemistry - Total Bilirubin|Laboratory assessments: Serum clinical chemistry - Cell enzymes|Laboratory assessments: Coagulation|Laboratory assessments: Lipid Panel|Laboratory assessments: Clinical Urinalysis - Glucose|Laboratory assessments: Clinical Urinalysis - Protein|Laboratory assessments: Clinical Urinalysis - Blood|Laboratory assessments: Clinical Urinalysis - Creatinine|Laboratory assessments: Clinical Urinalysis - Microscopy evaluation|Renal Safety Biomarkers - Serum Creatinine|Renal Safety Biomarkers - Urine protein|Renal Safety Biomarkers - Estimated glomerular filtration rate (eGFR)|Renal Safety Biomarkers -Urine Kidney Injury Molecule-1 (KIM-1)|Renal Safety Biomarkers - Urine Neutrophil gelatinase-associated lipocalin (NGAL)|Renal Safety Biomarkers - Urine Alpha-glutathione S-transferase (Alpha-GST)|Immune Activation Response: High Sensitivity - C-reactive protein (hs-CRP)|Complement Activation panel|Injection Site Reaction Examinations|Number of patients with abnormal findings in Telemetry|Laboratory assessments: Serum clinical chemistry - Creatine kinase|Laboratory assessments: Serum clinical chemistry - Bicarbonate|Laboratory assessments: Serum clinical chemistry - Direct bilirubin|Laboratory assessments: Serum clinical chemistry -Uric acid|Plasma PK analysis: Time delay between drug administration and the first observed concentration in plasma (tlag)|Plasma PK analysis: Time to reach peak or maximum observed concentration following drug administration (tmax)|Plasma PK analysis: Maximum observed plasma concentration (Cmax)|Plasma PK analysis: Area under the plasma concentration-curve from time zero to the time of last quantifiable analyte concentration (AUC[0-last])|Plasma PK analysis: Area under the concentration-time curve from time zero to 48 hours post-dose (AUC[0-48])|Plasma PK analysis: Area under the concentration-time curve from time zero extrapolated to infinity (AUC)|Plasma PK analysis: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)|Plasma PK analysis: Apparent volume of distribution for parent drug at terminal phase (extravascular administration) (Vz/F)|Plasma PK analysis: Half-life associated with the terminal slope (λz) of a semi-logarithmic concentration-time curve (t½z)|Plasma PK analysis: Mean Residence Time (MRT)|Urine PK analysis: Amount of analyte excreted unchanged in urine from time t1 to t2 (Ae[t1-t2])|Urine PK analysis: Cumulative amount of analyte excreted at the last sampling interval (Ae[0-last])|Urine PK analysis: Fraction of analyte excreted unchanged in urine from t1 to t2 (fe[t1-t2])|Urine PK analysis: Cumulative fraction of dose excreted unchanged into the urine from time zero to the last measured time-point for an analyte (fe[0-last])|Urine PK analysis: Percentage of dose excreted unchanged into the urine from time zero to the last measured time-point for an analyte (%fe[0-last])|Urine PK analysis: Renal clearance of drug from plasma (CLR)|PD analysis: The effect of AZD8233 on cholesterol and related biomarkers","AstraZeneca|Parexel","Male","18 Years to 60 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","D7990C00001","August 3, 2018","August 17, 2020","August 17, 2020","July 20, 2018",,"February 18, 2020","Research Site, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT03593785"
343,"NCT00965185","Statin Therapy to Improve Atherosclerosis in HIV Patients",,"Completed","Has Results","Cardiovascular Disease|HIV|Atherosclerosis|Inflammation|Statins, HMG-CoA|HIV Infections","Drug: atorvastatin|Drug: Placebo","Coronary and Aortic Plaque Inflammation|Plaque Progression|Endothelial Function|Immune Function|Lipid Profile|C-reactive Protein (CRP)|Adipocytokines|Liver Function Tests (LFTs)","Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 60 Years   (Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2008-P-000257|R01HL095123|HL 095123","September 2009","January 2014","January 2014","August 25, 2009","February 26, 2015","December 11, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00965185"
344,"NCT01712139","Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions",,"Completed","No Results Available","Hypertension","Drug: Irbesartan and Hydrochlorothiazide|Drug: Avalide","bioequivalence determined by statistical comparison Cmax","Roxane Laboratories|West-Ward Pharmaceutical","All","18 Years to 45 Years   (Adult)","Not Applicable","37","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRHY-T300-PVFS-1","September 2007","September 2007","September 2007","October 23, 2012",,"January 23, 2018","Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01712139"
345,"NCT01774591","Effect of Azilsartan on Aldosterone in Postmenopausal Females",,"Completed","Has Results","Hypertension","Drug: Azilsartan medoximil|Drug: Placebo","24-hour BP (Systolic)|24-hour BP (Diastolic)|Difference in 24-hour Urine Aldosterone Change From Baseline","University of Chicago|Takeda","Female","45 Years to 70 Years   (Adult, Older Adult)","Not Applicable","21","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12-1179","January 2013","November 2015","January 2016","January 24, 2013","November 9, 2017","November 9, 2017","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01774591"
346,"NCT01319045","Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease",,"Terminated","Has Results","Pulmonary Arterial Hypertension|Congenital Heart Disease|Eisenmenger's Syndrome","Drug: Iloprost","Safety and Tolerability|Exercise Capacity|Serum Brain Natriuretic Peptide (BNP)|Quality of Life","University of California, Los Angeles|Actelion","All","18 Years and older   (Adult, Older Adult)","Not Applicable","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Iloprost ACHD","June 2011","May 2013","May 2013","March 21, 2011","December 29, 2014","January 26, 2015","Ronald Reagan UCLA Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01319045"
347,"NCT01346371","The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer",,"Completed","Has Results","Allergic Conjunctivitis","Drug: Refresh Tears 0.5% Lubricant Eye Drops|Drug: Bepreve 1.5% Ophthalmic Solution","Tear Osmolarity","Minnesota Eye Consultants, P.A.|Bausch & Lomb Incorporated","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MAC-01-11","May 2011","August 2012","September 2012","May 3, 2011","March 31, 2020","March 31, 2020","Minnesota Eye Consultants, P.A., Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01346371"
348,"NCT00980785","Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's","SEAIRA","Completed","No Results Available","Alzheimer's Disease|Hypertension","Drug: Ramipril|Drug: Placebo","To determine the effects of 4 months of ramipril therapy on CSF Aβ levels in mildly hypertensive, non-demented adult children of persons with AD when compared to subjects taking placebo.|To evaluate the effects of 4 months of ramipril on CSF ACE levels in mildly hypertensive, non-demented adult children of persons with AD when compared to subjects taking placebo.|To determine the effects of 4 months of ramipril therapy on the cardiovascular outcome variables of brachial reactivity and aortic augmentation index in non-demented adult children of persons with AD when compared to subjects taking placebo.","University of Wisconsin, Madison","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 4","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","H-2014-1353|H-2009-0036","April 2009","July 2011","July 2011","September 21, 2009",,"March 29, 2017","Wisconisn Alzheimer's Disease Research Center, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00980785"
349,"NCT02746237","Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: KAR5585 Capsules|Drug: Placebo Capsules","Number of participants with abnormal physical exam results|Number of participants with abnormal hematology values|Number of participants with abnormal electrocardiogram results|Number of participants with abnormal clinical chemistry values|Number of participants with abnormal urinalysis values|Plasma area under the curve (AUC0-24) of prodrug KAR5585 and active inhibitor KAR5417 from time zero to 24 hours after dosing|Time to reach maximum observed plasma concentration (Tmax) of prodrug KAR5585 and active inhibitor KAR5417|Plasma terminal elimination half- life (T1/2) of prodrug KAR5585 and active inhibitor KAR5417|Apparent volume of distribution (Vz/F) of prodrug KAR5585 and active inhibitor KAR5417|Maximum peak concentration (Cmax) of prodrug KAR5585 and active inhibitor KAR5417|Serum levels of serotonin (ng/mL)|Urinary levels of 5-hydroxyindoleacetic acid(mg/24 hrs)|Urinary levels of creatinine (gm/24 hrs)|Urinary levels of 5-hydroxyindoleacetic acid normalized to creatinine (mg/gm)|Plasma levels of 5-hydroxyindoleacetic acid (ng/mL)|Plasma terminal elimination half-life (T1/2) of prodrug KAR5585 and active inhibitor KAR5417","Karos Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","KAR5585-101","November 2015","May 2016","August 2016","April 21, 2016",,"August 30, 2016","Spaulding Clinical, West Bend, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02746237"
350,"NCT02403284","The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans",,"Active, not recruiting","No Results Available","Insulin Resistance","Drug: Liraglutide|Drug: Sugar Pill","Whole Body Insulin Sensitivity (insulin suppression test)|Postprandial lipid changes (area under the curve difference in triglyceride,total apolipoprotein B100, apolipoprotein B48, and apolipoprotein C3.|Postprandial changes in glucose metabolism (total and incremental area under the curve differences in glucose, insulin and glucagon)|Changes in adipose tissue insulin signaling pathway activation (compare insulin signaling pathway activity (e.g., Akt and insulin receptor phosphorylation)|subcutaneous adipose tissue lipid intermediates (e.g., ceramide, diacylglycerol, acylcarnitine concentrations)|skeletal muscle tissue lipid intermediates (e.g., ceramide, diacylglycerol, acylcarnitine concentrations)|Adipose tissue inflammation measures (e.g., interleukin (IL)-6, and -8, adiponectin, TNF-alpha, nuclear factor-kappa b, gene and protein expression)|Skeletal muscle inflammation measures (e.g., IL-6,8, TNF-alpha, nuclear factor-kappa b gene and protein expression)|Adipose tissue arteriole function (vasodilation measurement)|Changes in skeletal muscle insulin signaling pathway","Phoenix VA Health Care System|Novo Nordisk A/S","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 4","35","U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","028","March 2013","December 2020","May 2021","March 31, 2015",,"March 13, 2020","Carl T. Hayden VA Medical Hospital, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02403284"
351,"NCT01528709","Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)","ACTIVE","Completed","Has Results","Saphenous Vein Graft Disease","Drug: Atorvastatin 80 mg daily|Drug: Atorvastatin 10 mg daily","Saphenous Vein Graft Occlusion (Percentage of Vein Grafts Occluded) Based on CT Coronary Angiography at 1 Year|Vein Graft Stenosis 1 Year After CABG Based on CT Coronary Angiography","Boca Raton Regional Hospital|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","173","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2011.02","March 2012","January 2017","January 2017","February 8, 2012","August 9, 2018","September 7, 2018","Lynn Heart and Vascular Institute, Boca Raton Regional Hospital, Boca Raton, Florida, United States|University of Ottawa Heart Institute, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01528709"
352,"NCT00963027","Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil",,"Completed","No Results Available","Hypertension, Pulmonary|Pulmonary Arterial Hypertension","Drug: Treprostinil diethanolamine|Drug: Esomeprazole","Treprostinil pharmacokinetics in healthy volunteers following a single oral dose of a 1 mg treprostinil diethanolamine sustained release tablet before and after repeated dosing with esomeprazole.|Adverse event monitoring|Clinical laboratories","United Therapeutics","All","18 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-PH-116","September 2009","October 2009","October 2009","August 20, 2009",,"March 8, 2010","PPD Development, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00963027"
353,"NCT01065051","Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics","HEARTWORK","Terminated","Has Results","Hypertension, Pulmonary|Ventricular Dysfunction, Left","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo","Change in Peak Power Index at Rest|Change in Left Ventricular Stroke Work Index (LVSWI) at Rest|Change in Left Ventricular Ejection Fraction (LVEF) at Rest|Change in End-systolic Elastance at Rest|Change in Peak Power Index During the Cardiopulmonary Exercise Tests|Change in Lateral Mitral Annular Peak Systolic Velocity (Sm) During the Cardiopulmonary Exercise Tests|Change in Peak Systolic Tricuspid Annular Velocity (RV-Sm) During the Cardiopulmonary Exercise Tests|Change in Tricuspid Annular Plane Systolic Excursion (TAPSE) During the Cardiopulmonary Exercise Tests|Change in Lateral Mitral Annular Peak Early Diastolic Velocity (E') During the Cardiopulmonary Exercise Tests|Change in the Slope of the Relationship Between Work Rate and Mean Pulmonary Arterial Pressure (PAPmean) During the Cardiopulmonary Exercise Tests|Change in the Ventilatory Efficiency (V'E/V'CO2) Measured From Baseline to the Anaerobic Threshold (AT) During the Cardiopulmonary Exercise Tests (CPET)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14549","November 2010","January 2011","January 2011","February 9, 2010","January 6, 2014","January 6, 2014","Boston, Massachusetts, United States|Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01065051"
354,"NCT01522950","A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function","EVIDENCE","Completed","Has Results","Hypertension","Drug: Nebivolol|Drug: atenolol|Drug: placebo","Change in Small Artery Elasticity|Change in Large Artery Elasticity|Change in Systolic Blood Pressure|Change in Diastolic Blood Pressure","University of Minnesota|Forest Laboratories","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","76","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1004M81135","May 2010","October 2016","October 2016","February 1, 2012","January 21, 2020","January 21, 2020","University of Minnesota, Minneapolis, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT01522950/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01522950"
355,"NCT00945958","Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension",,"Completed","Has Results","Open Angle Glaucoma|Ocular Hypertension","Drug: SPARC0913","Number of Subjects With AEs|Mean Change in IOP From Baseline to Visit 7 (End of Evaluations Visit)","Sun Pharma Advanced Research Company Limited","All","18 Years and older   (Adult, Older Adult)","Phase 3","161","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLR_09_13","November 2010","June 2012","June 2012","July 24, 2009","May 5, 2016","June 24, 2016","SPARC study site, NC, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00945958"
356,"NCT00967811","A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: Formulation E1 of L-PPDS|Drug: Formulation E2 of L-PPDS","IOP change from baseline","Mati Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","83","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPL GLAU 07","August 2009","May 2010","May 2010","August 28, 2009",,"September 19, 2013","Menlo Park, California, United States",,"https://ClinicalTrials.gov/show/NCT00967811"
357,"NCT00825188","A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives",,"Terminated","No Results Available","Obesity|Hypertension","Drug: eplerenone, amlodipine|Drug: eplerenone|Drug: amlodipine","Basal metabolic rate","University of Mississippi Medical Center","All","21 Years to 100 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-0035","January 2009","March 2014","March 2014","January 19, 2009",,"May 29, 2018","The University of Mississippi Clinical Research Program, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT00825188"
358,"NCT01712100","Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions",,"Completed","No Results Available","Hypertension","Drug: Irbesartan|Drug: Avapro","bioequivalence determined by statistical comparison Cmax","Roxane Laboratories|West-Ward Pharmaceutical","All","18 Years to 45 Years   (Adult)","Not Applicable","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRBE-T300-PVFD-1","August 2007","August 2007","August 2007","October 23, 2012",,"January 23, 2018","Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01712100"
359,"NCT01013155","Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fed Conditions",,"Completed","No Results Available","Essential Hypertension","Drug: perindopril erbumine","bioequivalence determined by statistical comparison Cmax","Roxane Laboratories|West-Ward Pharmaceutical","All","18 Years to 45 Years   (Adult)","Not Applicable","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PERI-T8-PVFD-1","May 2007","May 2007","May 2007","November 13, 2009",,"January 23, 2018","Novum Pharmaceutical Research Services, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01013155"
360,"NCT01012687","Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions",,"Completed","No Results Available","Essential Hypertension","Drug: perindopril erbumine","bioequivalence determined by statistical comparison Cmax","Roxane Laboratories|West-Ward Pharmaceutical","All","18 Years to 45 Years   (Adult)","Not Applicable","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PERI-T8-PVFS-1","April 2007","May 2007","May 2007","November 13, 2009",,"January 23, 2018","Novum Pharmaceutical Research Services, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01012687"
361,"NCT02100462","Chlorthalidone and HCTZ Impacts on Platelet Activation",,"Unknown status","No Results Available","Hypertension","Drug: Chlorthalidone 12.5 mg|Drug: Hydrochlorothiazide 25 mg|Drug: Aspirin 81 mg","Change in mean fluorescence intensity of PAC-1|Change in CD62P expression|Change in platelet aggregation","Creighton University|Dialysis Clinic, Inc.","All","19 Years and older   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13-16785","March 2014","December 2016","December 2016","April 1, 2014",,"December 14, 2015","Creighton University, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT02100462"
362,"NCT03121092","ACEI/ARB Study in Ambulatory and Day of Surgery Admission Patients","ACE/ARB","Terminated","No Results Available","Hypertension|Hypotension","Drug: ACEI or ARB","Presence of moderate hypotension|Presence of severe hypotension|The prevalence of cancellation of surgery secondary to unstable BP|The number and dose of medications to treat BP|prevalence of adverse effects (increased length of stay in the PACU, unanticipated hospitalizations, myocardial ischemia, stroke, death)","State University of New York - Downstate Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","188","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","303066-1","May 16, 2012","March 7, 2017","March 7, 2017","April 19, 2017",,"April 19, 2017","SUNY Downstate Medical Center, Brooklyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT03121092"
363,"NCT02591173","Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure",,"Recruiting","No Results Available","Autonomic Nervous System Disorders|Pure Autonomic Failure|Shy-Drager Syndrome|Orthostatic Hypotension, Dysautonomic","Drug: Angiotensin-(1-7)|Drug: Saline","Blood Pressure|Heart Rate|Cardiac Output|Stroke Volume|Systemic Vascular Resistance|Renin Activity|Angiotensin Peptides|Aldosterone","Vanderbilt University Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","151461","February 2016","December 2021","December 2021","October 29, 2015",,"February 7, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02591173"
364,"NCT02153983","Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome",,"Completed","Has Results","Obesity|Metabolic Disease","Drug: Colchicine 0.6Mg Cap|Drug: Placebo capsules given|Drug: Colchicine 0.6Mg Tab","Change in Insulin Sensitivity From FSIVGTT|Change in HOMA-IR Index|Changes in C-reactive Protein","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1|Phase 2","77","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","140119|14-CH-0119|ZIAHD000641-23","May 31, 2014","August 15, 2018","August 15, 2018","June 3, 2014","August 13, 2019","August 13, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02153983/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02153983/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02153983"
365,"NCT02069379","Endogenous Opioid Activity and Affective State in Insulin Resistant Women",,"Completed","Has Results","Depression|Insulin Resistance|Metabolic Syndrome","Drug: Metformin|Drug: Placebo","Mu-opioid Receptor Binding Potential in Left Nucleus Accumbens, Resting State|Mu-opioid Receptor Binding Potential in Right Nucleus Accumbens, Resting State|Mu-opioid Receptor Binding Potential in Left Amygdala, Resting State|Mu-opioid Receptor Binding Potential in Right Amygdala, Resting State|Positive and Negative Affect Schedule - Positive Affective State|Positive and Negative Affect Schedule - Negative Affective State|Profile of Mood States - Overall Negative Mood|Beck Depression Index","University of Michigan|National Institute of Mental Health (NIMH)","Female","18 Years to 40 Years   (Adult)","Phase 4","42","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","HUM00066696|K01MH095920","July 2014","March 24, 2017","September 2017","February 24, 2014","November 8, 2018","November 8, 2018","University of Michigan Medical School, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02069379/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02069379"
366,"NCT01927406","The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.",,"Withdrawn","No Results Available","Thyroid Eye Disease|Ocular Hypertension|Glaucoma","Drug: Prostaglandin Analog|Drug: Timolol","Change from baseline in appearance of facial periorbital region at 6 months.|Change from baseline in Hertel exophthalmometry at 3, 6, 9 and 12 months.|Change from baseline in intraocular pressure at 3, 6, 9 and 12 months.|Change from baseline in appearance of facial periorbital region at 3, 6, 9 and 12 months.","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","26654","June 2014","December 2016","December 2016","August 22, 2013",,"May 15, 2018","Stanford Hospital and Clinics, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01927406"
367,"NCT01647945","FK506 (Tacrolimus) in Pulmonary Arterial Hypertension","TransformPAH","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Placebo|Drug: FK506 level < 2 ng/ml|Drug: FK506 level 2-3 ng/ml|Drug: FK506 level 3-5 ng/ml","Safety of Low-dose FK-506 in PAH|Number of Combined Clinical Events|Efficacy of Low-dose FK-506 in Pulmonary Arterial Hypertension (PAH) Measured by Change in 6-min Walk Distance (6MWD)","Edda Spiekerkoetter|Stanford University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PAH-70522","July 2012","May 2014","August 2014","July 24, 2012","October 5, 2016","October 5, 2016","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01647945"
368,"NCT03480568","Alirocumab in Patients on a Stable Dialysis Regimen",,"Recruiting","No Results Available","Hemodialysis|Peritoneal Dialysis|Hypercholesterolemia|Atherosclerotic Disease","Drug: Alirocumab 150 MG/ML [Praluent]","Change in LDL cholesterol levels|Change in HDL-cholesterol levels|Change in apoprotein B levels","Baylor Research Institute|Regeneron Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","018-038","May 1, 2018","August 31, 2020","December 31, 2020","March 29, 2018",,"February 12, 2020","Baylor Soltero CV Research, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03480568"
369,"NCT01712126","Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions",,"Completed","No Results Available","Hypertension","Drug: Irbesartan and Hydrochlorothiazide|Drug: Avalide","bioequivalence determined by statistical comparison Cmax","Roxane Laboratories|West-Ward Pharmaceutical","All","18 Years to 45 Years   (Adult)","Not Applicable","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRHY-T300-PVFD-1","September 2007","September 2007","September 2007","October 23, 2012",,"January 23, 2018","Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01712126"
370,"NCT02265952","Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)",,"Completed","Has Results","Homozygous Familial Hypercholesterolemia","Drug: REGN1500 250 mg SC/15 mg/kg IV/450 mg SC","Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) to Week 4 in the Main Study Period|Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) to Week 4 in the Main Study Period|Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Week 2 to Week 4 in the Main Study Period|Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Week 2 to Week 4 in the Main Study Period|Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) Over Time in the Main Study Period|Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) Over Time in the Main Study Period|Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period|Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period|Absolute Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) From Baseline (Week 0) up to Week 26 in the Main Study Period|Percent Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) From Baseline (Week 0) up to Week 26 in the Main Study Period|Absolute Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period|Percent Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period|Percentage of Participants Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of ≥ 25% From Baseline (Week 0) in the Main Study Period|Percentage of Participants Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of ≥ 25% From Baseline (Week 26) in the Open Label Extension (OLE) Period|Percentage of Participants Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of ≥ 50% From Baseline (Week 0) in the Main Study Period|Percentage of Participants Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of ≥ 50% From Baseline (Week 26) in the Open Label Extension (OLE) Period|Absolute Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) From Baseline (Week 0) Over Time in the Main Study Period|Percent Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) From Baseline (Week 0) Over Time in the Main Study Period|Percent Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period|Absolute Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period|Absolute Change in Apolipoprotein CIII (Apo CIII) From Baseline (Week 0) Over Time in the Main Study Period|Percent Change in Apolipoprotein CIII (Apo CIII) From Baseline (Week 0) Over Time in the Main Study Period","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R1500-CL-1331|2016-000411-32","February 4, 2015","November 21, 2016","July 23, 2018","October 16, 2014","December 9, 2019","December 9, 2019","Los Angeles, California, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|Chicoutimi, Quebec, Canada|Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02265952"
371,"NCT01931527","Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status","UA","Completed","Has Results","Obesity|Metabolic Syndrome|Hyperuricemia","Drug: Rasburicase","Percent Increase in Insulin-stimulated Glucose Uptake|The Effect of Reducing Uric Acid on Oxidative Status|Baseline Carbonylated Protein Ratio|AFTER Rasburicase Carbonylated Protein Ratio|Baseline Plasma TRAP|AFTER Rasburicase Plasma TRAP|Baseline Plasma FRAP|AFTER Rasburicase Plasma FRAP (Fe⁺² · Lˉ¹)","Washington University School of Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","31","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","06-0509 / 201104189","July 2006","June 2008","November 2012","August 29, 2013","May 15, 2015","August 14, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01931527"
372,"NCT00878878","Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).",,"Completed","Has Results","Pulmonary Hypertension","Drug: Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)|Drug: Dextrose","Observed the Change of Pulmonary Artery Systolic Pressure (PASP) Measured by Millimeters of Mercury (mm hg) Within Certain Time Periods. This is Per Sequence and Not a Cross-over Study.|Observed the Change of Pulmonary Vascular Resistance (PVR) Measured by Wood Units Within Certain Time Periods. This is Per Sequence and Not a Cross-over Study.|Recorded Any Adverse Events From the Optison and Control Solution (5% Dextrose) Used in Subjects With Normal and Elevated Pulmonary Artery Systolic Pressure (PASP. This is Per Sequence and Not a Cross-over Study.","GE Healthcare|ICON Clinical Research","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","GE-191-004","March 2009","July 2010","July 2010","April 9, 2009","August 24, 2012","August 24, 2012","ICON Development Solutions, Elliott City, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00878878"
373,"NCT01216852","Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fasted Conditions",,"Completed","No Results Available","Hypertension","Drug: Losartan Potassium","bioequivalence determined by statistical comparison Cmax","Roxane Laboratories|West-Ward Pharmaceutical","All","18 Years to 45 Years   (Adult)","Not Applicable","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LOSA-01","August 2004","August 2004","August 2004","October 7, 2010",,"January 23, 2018","Bio-Kinetic Clinical Applications, Inc., Springfield, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01216852"
374,"NCT00902304","Valsartan Intensified Primary Care Reduction of Blood Pressure Study","VIPER-BP","Completed","Has Results","Hypertension","Drug: Valsartan and hydrochlorothiazide (HCTZ) - monotherapy|Drug: Valsartan and amlodipine|Drug: Usual care|Drug: Valsartan|Drug: Valsartan and hydrochlorothiazide (HCTZ) - combination arm","Percentage of Patients Who Have Achieved Their Pre-specified (Individualized National Heart Foundation of Australia Criteria) Blood Pressure (BP) Target|Change in Mean Sitting Systolic Blood Pressure|Change in Mean Sitting Diastolic Blood Pressure|Change in Absolute Cardiovascular Risk Score|Number of Patients With at Least One Adverse Events Attributable to Anti-hypertensive Therapy|Number of 'Early Responder' Patients Who Achieve Individualized Blood Pressure Control After 1 or 2 Adjustments|Change in the EQ-5D Score|Number of Patients With Depression|Change in Center for Epidemiologic Studies Depression (CES-D) Score From Baseline to Week 26|Participants With End Organ Disease at Baseline and Week 26|Change in Self-care Behavior Score From Baseline to Week 26|Rate of Treatment Compliance|Number of Patients With Major Clinical Endpoints","Novartis Pharmaceuticals|Baker IDI Heart and Diabetes Institute|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 4","2337","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CVAL489AAU01","July 2009","July 2011","July 2011","May 15, 2009","August 30, 2012","December 4, 2012","Novartis Pharmaceuticals, East Hanover, New Jersey, United States|Professor Garry Jennings-Co Principal Investigator, Melbourne, Australia|Professor Simon Stewart-Principal Investigator, Melbourne, Australia",,"https://ClinicalTrials.gov/show/NCT00902304"
375,"NCT01800292","Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.","LV strain","Completed","No Results Available","Hypertension, Pulmonary Artery|Ventricular Dysfunction, Left","Drug: sildenafil","exercise capacity not on/on sildenafil therapy|Echo parameters:left ventricular septal and lateral wall longitudinal strain and strain rate, RV strain and strain rate, and LV lateral wall/septal strain and strain rate","University of Arizona","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13-0006-01|986-12","February 2013","December 2013","December 2014","February 27, 2013",,"November 4, 2015","University of Arizona Medical Center, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01800292"
376,"NCT01215019","Osmotic Therapy for Treatment of Intracranial Hypertension for Traumatic Brain Injury",,"Withdrawn","No Results Available","Traumatic Brain Injury","Drug: Mannitol|Drug: NaCl","Assess efficacy of 20% mannitol versus 3% MaCl in controlling elevated intracranial pressure in acute traumatic brain injury","Indiana University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","1004-10","October 2010","October 2020","October 2020","October 5, 2010",,"April 4, 2013","Wishard Memorial Hospital, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01215019"
377,"NCT01240512","DAYLIGHT: Vitamin D Therapy in Individuals at High Risk of Hypertension","DAYLIGHT","Completed","No Results Available","Hypertension|Vitamin D Deficiency|Pre-Hypertension","Drug: Cholecalciferol","The primary endpoint is defined as the change in mean 24-hour ambulatory systolic blood pressure.|Change in mean 24-hour ambulatory diastolic blood pressure|Change in mean daytime and nighttime ambulatory systolic and diastolic blood pressure|Change in mean clinic systolic and diastolic blood pressure|Change in mean clinic pulse pressure|Relation of vitamin D status to changes in clinic and 24-hour ambulatory blood pressure measurements","Massachusetts General Hospital|Hartford Hospital|Allina Health System","All","18 Years to 50 Years   (Adult)","Not Applicable","534","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2010P001612","December 2010","October 2013","October 2013","November 15, 2010",,"March 9, 2017","Hartford Hospital, Hartford, Connecticut, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01240512"
378,"NCT00978419","Pilot Trial of Statin Use in Burn Patients","BURNSTAT","Completed","Has Results","Burns","Drug: Rosuvastatin|Drug: Placebo","Primary Endpoint: Reduction in CRP Level Over Time, Compared to Placebo Measured at Baseline and Days 3, 7, 14. The Mean CRP Levels at Specified Days Will be the Endpoints.|Mortality Compared to Placebo|Mortality Compared to Placebo, Adjusted for Cardiovascular Co-morbidities|Reduction in the Incidence of Septic Shock (See Definition) Compared to Placebo|Reduction in the Incidence of Septic Shock (See Definition) Compared to Placebo, Adjusted for Cardiovascular Co-morbidities|A Reduction in CK Levels Over Time, Compared to Placebo Measured at Baseline and Days 3, 7, 14, 21, 28|A Reduction in ALT Levels Over Time, Compared to Placebo, Measured at Baseline, Days 1, 7, 14, 21, 28|Determine the Safety of Rosuvastatin Compared to Placebo in Burn Patients by Comparing the Frequency, Type and Severity of Adverse Events|Determine Which Are Appropriate Attainable Endpoints for Future Trials and the Number of Participants Required to Reach Significance in Analysis of a Variety of Variables|Determine the Prevalence of Delirium in the Two Subgroup of Patients|Determine the Prevalence of De-novo Long-term Neurocognitive Impairment in Burn Patients and by Study Group.|Determine the Prevalence of Functional Impairment in Burn Patients and by Study Group","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","091060","March 2010","February 2011","May 2011","September 16, 2009","June 1, 2018","June 1, 2018","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00978419"
379,"NCT01936389","A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma","ROCK","Completed","Has Results","Exfoliation Syndrome|Ocular Hypertension|Open Angle Glaucoma","Drug: AR-12286","Evaluate the Ocular Hypotensive Efficacy of Rho Kinase Inhibitor (AR-12286 0.5% and 0.7%)","Robert Ritch, MD, LLC.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12286","September 2013","October 2014","October 2014","September 6, 2013","April 24, 2015","November 16, 2018","Glaucoma Associates of New York, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01936389"
380,"NCT01653678","Vitamin D and Omega-3 Hypertension Trial (VITAL Hypertension)",,"Active, not recruiting","No Results Available","Hypertension","Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU|Drug: Omega-3 fatty acids (fish oil)|Dietary Supplement: Vitamin D placebo|Drug: Fish oil placebo","Change in blood pressure|Incident hypertension|Changes in 25-hydroxy-vitamin D levels|Changes in fatty acid levels|Changes in biomarkers related to blood pressure","Brigham and Women's Hospital|National Heart, Lung, and Blood Institute (NHLBI)","All","50 Years and older   (Adult, Older Adult)","Not Applicable","25875","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2010-P-002880|1R01HL102122","November 2011","February 2020","November 2020","July 31, 2012",,"July 15, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01653678"
381,"NCT01082588","Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia",,"Completed","Has Results","Schizophrenia|Schizoaffective Disorders|Schizophreniform Disorders","Drug: Pravastatin|Drug: Placebo","Change in LDL-cholesterol Between Baseline and Week 12|Change in C-Reactive Protein (CRP) From Baseline to Week 12|Change in MATRICS Neuropsychological Battery Composite Score From Baseline to Week 12|Change in Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 12|Change in Positive and Negative Syndrome Scale (PANSS) Positive Score From Baseline to Week 12|Change in Positive and Negative Syndrome Scale (PANSS) Negative Score From Baseline to Week 12|Change in Positive and Negative Syndrome Scale (PANSS) General Score From Baseline to Week 12","Massachusetts General Hospital|Stanley Medical Research Institute|North Suffolk Mental Health Association","All","18 Years to 68 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2009-P-002524|09T-1296","June 2010","September 2012","September 2012","March 8, 2010","April 28, 2014","April 28, 2014","Freedom Trail Clinic, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01082588"
382,"NCT02919176","Brown Fat Activation Study",,"Completed","No Results Available","Obese|Metabolic Syndrome","Drug: Mirabegron|Drug: Pioglitazone|Drug: Mirabegron and Pioglitazone","Change in beige adipose tissue|Change in brown adipose tissue|Change in insulin sensitivity|Change in body mass index|Change in glucose tolerance","Philip Kern|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Kentucky","All","35 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","39","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16-0642-F1V|R01DK112282","September 1, 2016","February 4, 2019","February 4, 2019","September 29, 2016",,"February 7, 2020","Center for Clinical and Translational Science, Lexington, Kentucky, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02919176/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02919176"
383,"NCT03858894","Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6",,"Completed","No Results Available","Primary Open-angle Glaucoma and Ocular Hypertension","Drug: DE-117 Ophthalmic Solution QD|Drug: DE-117 Ophthalmic Solution BID","Intraocular Pressure (IOP)","Santen Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","98","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","011712IN","January 28, 2019","June 20, 2019","June 20, 2019","March 1, 2019",,"July 26, 2019","East West Eye Institute, Los Angeles, California, United States|Danbury Eye Specialist, Danbury, Connecticut, United States|Hernando Eye Institute, Brooksville, Florida, United States|Levenson Eye Associates, Jacksonville, Florida, United States|Seidenberg Protzko Eye Associates, Havre De Grace, Maryland, United States|Tekwani Vision Center, Saint Louis, Missouri, United States|Eye Associates/SurgiCenter of Vineland, Vineland, New Jersey, United States|Ophthalmic Consultants of Long Island, Lynbrook, New York, United States|Apex Eye Clinical Research, LLC, Cincinnati, Ohio, United States|Abrams Eye Center, Cleveland, Ohio, United States|Scott & Christie and Associates PC, Cranberry Township, Pennsylvania, United States|University Eye Specialist, Maryville, Tennessee, United States|Advanced Vision Research, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03858894"
384,"NCT02431936","Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress",,"Completed","No Results Available","Hypertension|Stress, Psychological|Blood Pressure","Drug: Prazosin|Drug: Placebo","Urinary sodium excretion rate|Hemodynamics: change in systolic blood pressure","Augusta University|The University of Texas at Arlington","All","18 Years to 50 Years   (Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","611851","April 2015","April 16, 2019","April 16, 2019","May 1, 2015",,"June 20, 2019","Augusta University, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02431936"
385,"NCT01161082","Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin",,"Completed","No Results Available","Hypercholesterolemia","Drug: REGN727(SAR236553)","The primary endpoint in the study is to assess the incidence and severity of treatment-emergent adverse events in hyperlipidemic patients treated with REGN727 or placebo receiving stable doses of atorvastatin.|To assess the pharmacodynamic effect of REGN727 added to atorvastatin on lipids|To assess the pharmacodynamic effect of monotherapy REGN727 in hyperlipidemic patients|To assess the pharmacokinetics of REGN727 in hyperlipidemic patients with or without atorvastatin","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R727-CL-1001","June 2010","May 2011","May 2011","July 13, 2010",,"January 27, 2015","Site 1, Cincinnati, Ohio, United States|Site 2, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01161082"
386,"NCT02927184","Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease",,"Completed","No Results Available","Hyperlipidemia|NAFLD","Drug: VK2809|Drug: Placebo","Change in LDL-C in patients receiving VK2809 compared to placebo","Viking Therapeutics, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VK2809-201","September 28, 2016","March 26, 2019","March 26, 2019","October 6, 2016",,"November 25, 2019","Radiant Research, Inc., Chandler, Arizona, United States|SC Clinical Research, Garden Grove, California, United States|ACTCA, Los Angeles, California, United States|Catalina Research Institute, Montclair, California, United States|North America Research, Inc, Pomona, California, United States|Orange County Research Center, Tustin, California, United States|Research Institute of South Florida, Miami, Florida, United States|Research Institute of South Florida, Miami, Florida, United States|Avant Research Associates, LLC, Crowley, Louisiana, United States|HCI- MetroMedic Walk-in, New Bedford, Massachusetts, United States|HCI- MetroMedic Walk-in, New Bedford, Massachusetts, United States|Flint Clinical Research, PLLC, Flint, Michigan, United States|CHEAR Center, LLC, Bronx, New York, United States|Mid Hudson Medical, Hopewell Junction, New York, United States|Wake Research Associcates, LLC., Raleigh, North Carolina, United States|Avant Research, Beaumont, Texas, United States|Clinical Trials of Texas, INC, San Antonio, Texas, United States|Radiant Research, Inc., San Antonio, Texas, United States|Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02927184"
387,"NCT01206439","An Advanced Echocardiographic Evaluation of Nebivolol",,"Terminated","Has Results","Hypertension","Drug: nebivolol","Change in Systolic and Diastolic Myocardial Function|Exercise Tolerance","Jack Rubinstein|Forest Laboratories|University of Cincinnati","All","20 Years to 60 Years   (Adult)","Phase 4","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UC- 09-12-31-04","September 2010","August 2012","August 2012","September 21, 2010","November 25, 2015","February 15, 2018","University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01206439"
388,"NCT01102478","Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg/25 mg Tablet Under Fasted Conditions",,"Completed","No Results Available","Hypertension","Drug: losartan potassium / hydrochlorothiazide","Bioequivalence determined by statistical comparison Cmax","Roxane Laboratories|West-Ward Pharmaceutical","All","18 Years to 45 Years   (Adult)","Not Applicable","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LOHY-T100/25-PVFS-1","February 2005","March 2005","March 2005","April 13, 2010",,"January 23, 2018","CEDRA Clinical Research, LLC, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01102478"
389,"NCT02029534","Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF)",,"Unknown status","No Results Available","Cardiothoracic Surgery|Post-operative Atrial Fibrillation","Drug: Atorvastatin 20 mg|Drug: Atorvastatin 80 mg","Occurrence of atrial fibrillation by hospital discharge|Length of hospital stay|Incidence of major adverse cardiac and cardiovascular events (MACCE) at 30 days","Creighton University","All","19 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","13-16729","August 2013","June 2017","June 2017","January 8, 2014",,"June 16, 2016","Creighton University, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT02029534"
390,"NCT03978767","Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial","PANDA","Recruiting","No Results Available","Preeclampsia Severe|Preeclampsia Postpartum","Drug: Ibuprofen 600 mg|Drug: Ketorolac|Drug: Acetaminophen|Drug: Oxycodone","postpartum antihypertensive requirements|Postpartum pain scores|Postpartum opioid use|Mean arterial blood pressure|End organ damage|Hospital readmission|Continued anti-hypertensive requirement","Washington University School of Medicine","Female","Child, Adult, Older Adult","Phase 2","286","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201901202","June 10, 2019","May 27, 2021","July 27, 2021","June 7, 2019",,"June 11, 2019","Barnes Jewish Hospital, Saint Louis, Missouri, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03978767/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03978767/Prot_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03978767/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03978767"
391,"NCT01600170","Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)",,"Completed","No Results Available","HIV Dementia","Drug: Atorvastatin (generic Lipitor)|Drug: placebo","Effects of Atorvastatin on peripheral blood monocytes|Effects of Atorvastatin on T cell and CSF activation markers","University of Pennsylvania","All","18 Years to 60 Years   (Adult)","Phase 4","11","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB Protocol # 815512","January 2013","October 2017","October 2017","May 16, 2012",,"November 22, 2019","University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01600170"
392,"NCT01274481","Iloprost Effects on Gas Exchange and Pulmonary Mechanics",,"Completed","No Results Available","Acute Respiratory Distress Syndrome|Acute Lung Injury|Pulmonary Hypertension","Drug: Iloprost","Arterial oxygenation|Lung compliance","University of Oklahoma|Actelion","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15123","March 2011","July 2012","July 2012","January 11, 2011",,"August 10, 2012","OU Medical Center, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT01274481"
393,"NCT03753204","Salt-Sensitivity and Immunity Cell Activation",,"Not yet recruiting","No Results Available","High Blood Pressure|Salt; Excess|Inflammation","Drug: Furosemide 40 mg","The percent of participants with salt sensitive blood pressure|Percent of participants with immune cell activation","Vanderbilt University Medical Center","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","182038","March 2020","March 1, 2020","March 15, 2020","November 26, 2018",,"April 5, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03753204"
394,"NCT03372733","Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults",,"Recruiting","No Results Available","Cardiovascular Disease","Drug: control olive oil (COO)|Drug: palmitoleate-rich oil (PLO)","Changes in the LDL-cholesterol levels|Changes in TC, TG, HDL-C, and other lipids, lipoprotein particle number, HDL functional test (i.e. efflux study) composition and size,changes in apetite and/or satiety","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","70","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","180019|18-H-0019","July 31, 2018","July 31, 2020","July 31, 2020","December 14, 2017",,"January 13, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03372733"
395,"NCT02938949","Alirocumab in Patients With Acute Myocardial Infarction",,"Completed","Has Results","Myocardial Infarction|Hypercholesterolemia","Drug: alirocumab|Drug: placebo","Changes in Low-density Lipoprotein (LDL) Cholesterol|Change in Inflammatory Markers (hsCRP)","Virginia Commonwealth University|Regeneron Pharmaceuticals|Sanofi","All","21 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HM20008008","January 2017","August 2018","August 16, 2018","October 19, 2016","September 6, 2019","September 6, 2019","Virginia Commonwealth University, Richmond, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02938949/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02938949"
396,"NCT01567826","Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy","YELLOW","Completed","Has Results","Coronary Artery Disease","Drug: standard of care lipid therapy|Drug: Aggressive lipid therapy","Lipiscan - Lipid Core Burden Index (LCBI)|LCBI4mm Max|Change in LCBI4mm Max|Change in LCBI, Lesion|Intravascular Ultrasound (IVUS) Parameters|Fractional Flow Reserve (FFR) Value|Diameter Stenosis|Post PCI Cardiac Enzymes|Major Adverse Cardiac Events (MACE)|Blood Chemistry - HsCRP","Annapoorna Kini|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Phase 4","87","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","GCO 09-1294|IF1292822","May 2010","February 2012","February 2012","March 30, 2012","February 27, 2017","May 19, 2017","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01567826"
397,"NCT01048905","Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension",,"Completed","No Results Available","Pulmonary Hypertension|Sickle Cell Disease|Thalassemia","Drug: L-Glutamine","Change in erythrocyte glutamine/glutamate ratio, a novel biomarker of oxidative stress,post therapy compared to pre-therapy steady-state values.|Plasma Glutamine|Tricuspid Regurgitant Jet velocity on Doppler Echocardiography|6 minute walk distance|Liver function tests|Renal function tests","UCSF Benioff Children’s Hospital Oakland","All","4 Years and older   (Child, Adult, Older Adult)","Phase 2","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R01FD003531-01|IRB 2008-059","March 2009","March 2014","March 2014","January 14, 2010",,"July 18, 2014","Children's Hospital & Research Center Oakland, Oakland, California, United States",,"https://ClinicalTrials.gov/show/NCT01048905"
398,"NCT01794455","Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression",,"Terminated","Has Results","Depression|Hypertension","Drug: Sertraline|Drug: Candesartan","MRI Arterial Spin Labeling|Montgomery Asberg Depression Rating Scale (MADRS)|Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16)|Montgomery-Asberg Depression Rating Scale","Vanderbilt University","All","60 Years and older   (Adult, Older Adult)","Phase 4","1","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","VR5642","May 2013","March 2015","March 2015","February 18, 2013","October 20, 2016","October 20, 2016","Vanderbilt Psychiatric Hospital, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01794455"
399,"NCT01895972","Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT","JUPITER","Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: Latanoprostene bunod","Change From Baseline in Intraocular Pressure|Clinical Safety","Bausch & Lomb Incorporated","All","20 Years and older   (Adult, Older Adult)","Phase 3","130","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","811","July 5, 2013","April 2, 2015","April 14, 2015","July 11, 2013","June 6, 2018","July 26, 2018","Bausch & Lomb Incorporated, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01895972"
400,"NCT01096771","The Effect of Intravenous Lipids on Lung Function in Acute Respiratory Distress Syndrome (ARDS)",,"Terminated","Has Results","Acute Respiratory Distress Syndrome","Drug: ClinOleic 20%|Drug: Intralipid 20%","Bronchoalveolar Lavage Fluid Interleukin-8 Concentrations|Ventilator Days|PaO2:FiO2 Ratio|30 Day Mortality|New Infection|Organ Failures|Biomarkers (C-reactive Protein)|Hospital Length of Stay|Allergic Reactions|Hypertriglyceridemia","Methodist Research Institute, Indianapolis","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Lipids for ARDS","June 2010","November 2012","November 2012","March 31, 2010","May 26, 2014","May 26, 2014","Methodist Hospital, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01096771"
401,"NCT02920593","A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy",,"Unknown status","No Results Available","Gestational Hypertension|Toxemia|Superimposed Preeclampsia|Eclampsia|HELLP Syndrome","Drug: Vitamin D3","Vitamin D prophylaxis in pregnant women and incidence of hypertensive disorders of pregnancy|Adverse neonatal outcome in those who received Vitamin D prophylaxis compared to those who did not receive Vitamin D prophylaxis|Placental pathology in those who received Vitamin D prophylaxis compared to those who did not receive Vitamin D prophylaxis|Placental TNF-alpha in those who received Vitamin D prophylaxis compared to those who did not receive Vitamin D prophylaxis|Placental inflammatory marker IL-6 in those who received Vitamin D prophylaxis compared to those who did not receive Vitamin D prophylaxis|Placental inflammatory marker IFN-gamma in those who received Vitamin D prophylaxis compared to those who did not receive Vitamin D prophylaxis|Placental inflammatory marker GMSCF-2 in those who received Vitamin D prophylaxis compared to those who did not receive Vitamin D prophylaxis|Placental inflammatory marker endometrial growth factor in those who received Vitamin D prophylaxis compared to those who did not receive Vitamin D prophylaxis|Maternal Vitamin D level in those who received Vitamin D prophylaxis compared to those who did not receive Vitamin D prophylaxis|Cord blood Vitamin D level in those who received Vitamin D prophylaxis compared to those who did not receive Vitamin D prophylaxis","Stony Brook University","Female","18 Years and older   (Adult, Older Adult)","Phase 4","412","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","875799-3","October 2016","July 31, 2018","March 31, 2019","September 30, 2016",,"October 5, 2017","SUNY Stony Brook Hospital, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT02920593"
402,"NCT02353806","Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation",,"Completed","Has Results","Chronic Hypertension in Pregnancy","Drug: Amlodipine besylate","Area Under the Curve for Amlodipine in the Maternal Serum|Time to Maximal Concentration in the Maternal Serum.|Maximal Amlodipine Maternal Serum Concentration|Half-life of Amlodipine in Maternal Plasma|Clearance Rate of Plasma Amlodipine|Drug Levels/Concentration in Cord Blood (Amlodipine Levels/Concentrations)|Amlodipine Concentration in Breastmilk|Drug Level/Concentration in Infant Blood (Amlodipine Level/Concentration)|Neonatal Birth Weight|Infant Gestational Age at Delivery.|Infant Length of Stay.|Major Infant Complications","University of Texas Southwestern Medical Center|National Center for Advancing Translational Science (NCATS)","Female","18 Years to 50 Years   (Adult)","Phase 4","16","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","042014-059|UL1TR001105","January 2015","July 2016","September 2016","February 3, 2015","February 6, 2019","February 6, 2019","Parkland Health and Hospital System, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02353806"
403,"NCT03847974","Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003",,"Active, not recruiting","No Results Available","Hypercholesterolemia","Drug: LIB003","The incidence and severity of treatment emergent adverse events (TEAEs)|Percent reduction in Low Density Lipoprotein Cholesterol (LDL-C) at week 52","LIB Therapeutics LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LIB003-010","February 14, 2019","March 7, 2020","May 31, 2020","February 20, 2019",,"April 24, 2020","Sterling Research Group, Cincinnati, Ohio, United States|The Lindner Research Center, Cincinnati, Ohio, United States|Metabolic & Atherosclerosis Research Center (MARC), Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03847974"
404,"NCT02372955","Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes",,"Unknown status","No Results Available","Diabetes Mellitus Type 2","Drug: dapagliflozin|Drug: glimpiride","systolic blood pressure by ambulatory blood pressure monitoring (ABPM)|arterial stiffness|urinary sodium excretion|composite intravascular volume status","Gulf Regional Research & Educational Services, LLC","All","21 Years and older   (Adult, Older Adult)","Phase 4","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ESR-14-10022/D1690L00020","February 2015","February 2016","December 2016","February 26, 2015",,"February 26, 2015","Gulf Regional Research & Educational Services, LLC, Metairie, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT02372955"
405,"NCT01392469","Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Imatinib","Measure: To evaluate the effect of QTI571 on pharmacokinetics of of sildenafil and bosentan in terms of the changes in AUCtau and Cmax in patients with Pulmonary Arterial Hypertension|Measure: Number of patients with adverse events as a measure of the safety and tolerability of QTI571 when co-administered with sildenafil and bosentan.|Measure: To evaluate the pharmacokinetics of QTI571 and its active metabolite in terms of AUCtau and Cmax in patients with Pulmonary Arterial Hypertension","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CQTI571A2102|2010-021344-17","April 20, 2011","October 25, 2012","October 25, 2012","July 12, 2011",,"June 13, 2018","Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Weston, Florida, United States|Novartis Investigative Site, Mineola, New York, United States|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01392469"
406,"NCT01131845","The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil",,"Completed","No Results Available","Pulmonary Arterial Hypertension|Renal Dysfunction","Drug: UT-15C SR (treprostinil diethanolamine)","Treprostinil pharmacokinetics in volunteers with varying degrees of renal function following a single oral dose of a 1 mg treprostinil diethanolamine sustained release.","United Therapeutics","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-PH-120","May 2010","September 2010","September 2010","May 27, 2010",,"May 17, 2012","Orlando Clinical Research Center, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01131845"
407,"NCT00939822","Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease","SHARP","Completed","Has Results","Alzheimer's Disease","Drug: Simvastatin|Drug: Placebo","Changes in Cerebrospinal Fluid (CSF) Beta-amyloid-42 Levels Compared to Baseline as Measured by xMAP|Changes in CSF Beta-amyloid-40 Levels as Measured by xMAP (Multi-Analyte Profiling) )|Changes in CSF Soluble Alpha Precursor Proteins (sAPP-alpha) and Soluble Beta Precursor Proteins (sAPP-beta) as Measured by Duplex|Changes in CSF Total Tau (T-tau) and Phosphorylated Tau (P-tau) as Measured by xMAP","University of Wisconsin, Madison|National Institute on Aging (NIA)","All","40 Years to 72 Years   (Adult, Older Adult)","Phase 2","88","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2015-0038|R01AG031790-01A1|H-2009-0030|H-2008-0275","March 2009","September 2013","September 2013","July 15, 2009","August 9, 2019","August 9, 2019","Karen Lazar, Fitchburg, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00939822"
408,"NCT02406586","Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)","FFAADA","Completed","Has Results","Hypertension|Diabetes","Drug: Salsalate|Drug: Carvedilol|Drug: Placebo|Drug: Intralipid 20%","Change in Systolic Blood Pressure.|Change in Systolic Blood Pressure|Change in Flow-mediated Dilation|Change in Diastolic Blood Pressure From Baseline to 6 Weeks|Change in Oxidative Stress Markers.|Change in Augmentation Index (AIx)|Change in Expression of Inflammatory Biomarker Interleukin-6 (IL-6)|Change in FFA (Free Fatty Acid) Levels From Baseline to 6 Weeks|Change in Pulse Wave Velocity (PWV)|Change in Expression of Inflammatory Biomarker C-Reactive Protein (CRP)","Emory University|American Diabetes Association","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","IRB00009277a","July 2009","March 2011","March 2011","April 2, 2015","May 28, 2015","January 8, 2019","Grady Memorial Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02406586"
409,"NCT01670266","Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma",,"Completed","No Results Available","Ocular Hypertension (OHT)|Mild Open Angle-glaucoma (OAG)","Drug: ONO-9054|Drug: Placebo","Safety and tolerability of ONO-9054|Characterization of PK profiles|Evaluation of PD measurements|Comparison of safety, tolerability between once daily morning and once daily evening","Ono Pharma USA Inc|Ono Pharmaceutical Co. Ltd","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ONO-9054IOU002","August 2012","May 2013",,"August 22, 2012",,"June 3, 2013","Costa Mesa Clinical Site, Costa Mesa, California, United States|Newport Beach (satellite site), Newport Beach, California, United States|Santa Ana (satellite site), Santa Ana, California, United States",,"https://ClinicalTrials.gov/show/NCT01670266"
410,"NCT01044693","Nebivolol in the Supine Hypertension of Autonomic Failure",,"Completed","Has Results","Hypertension|Pure Autonomic Failure|Multiple System Atrophy","Drug: Placebo|Drug: Nebivolol 5 mg|Drug: metoprolol tartrate 50 mg|Drug: Sildenafil25 mg","Change in Systolic Blood Pressure During the Night|Nocturnal Urinary Sodium Excretion|Orthostatic Tolerance the Following Morning|Change in Heart Rate During the Night","Vanderbilt University|Forest Laboratories","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)","091252","January 2010","July 2014","August 2014","January 8, 2010","May 1, 2015","May 1, 2015","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01044693"
411,"NCT01216878","Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fed Conditions",,"Completed","No Results Available","Hypertension","Drug: losartan potassium","bioequivalence determined by statistical comparison Cmax","Roxane Laboratories|West-Ward Pharmaceutical","All","18 Years to 45 Years   (Adult)","Not Applicable","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LOSA-02","September 2004","September 2004","September 2004","October 7, 2010",,"January 23, 2018","BioKinetic Clinical Applications, Inc., Springfield, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01216878"
412,"NCT01568255","Is Treatment of Vitamin D Deficiency Associated With Resolution of Statin-Induced Muscular Symptoms",,"Recruiting","No Results Available","Myopathic Symptoms","Drug: Ergocalciferol|Drug: Placebo","Myopathic pain|Quality of life|Vitamin 25 OH D levels|Statin tolerability|Parathyroid hormone (PTH)|Calcium|Lipid profile","Cedars-Sinai Medical Center","Female","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","23187","March 2012","March 2021","March 2021","April 2, 2012",,"April 11, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01568255"
413,"NCT01968785","Renal Denervation in Patients With Uncontrolled Blood Pressure",,"Completed","No Results Available","Blood Pressure","Radiation: Radiation Dose 25 Gy|Radiation: Radiation Dose 50 Gy","Safety|Efficacy|Angiographic|Effects on Blood Pressure|eGFR or New Stenosis|Medication changes|Serious Adverse Events","Rebecca Torguson|Medstar Health Research Institute","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Renal Denervation","August 2013","January 2017","January 2017","October 24, 2013",,"January 2, 2020","MedStar Washington Hospital Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT01968785"
414,"NCT01097785","Targeting Sympathetic Overactivity in Heart Failure Patients With Statins",,"Completed","Has Results","Heart Failure","Drug: Simvastatin|Drug: Placebo","Change in Muscle Sympathetic Nerve Activity in Bursts Per 100 Heartbeats|Change in Measures of Reactive Oxygen Species in the Blood","University of Missouri-Columbia|University of Nebraska","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","IRB-1135098","March 2009","July 2014","July 2014","April 2, 2010","November 21, 2016","November 21, 2016","University of Missouri, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01097785"
415,"NCT01605773","Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes",,"Completed","No Results Available","Diabetes|Diabetes Mellitus, Type 2","Drug: repaglinide|Drug: glyburide","Triglyceride levels post standardised fat tolerance test|Incidence of hypoglycemic episodes|Change in HbA1c (glycosylated haemoglobin A1c)|Change in FPG (fasting plasma glucose)","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)","Phase 4","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGEE-2137","November 8, 2001","March 13, 2003","March 13, 2003","May 25, 2012",,"February 20, 2017","Novo Nordisk Investigational Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01605773"
416,"NCT01067339","Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans",,"Completed","Has Results","Endothelial Dysfunction","Drug: darapladib|Drug: placebo","Percentage Change in Coronary Artery Diameter|Percentage Change in Coronary Blood Flow (CBF)","Mayo Clinic|GlaxoSmithKline|National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Aging (NIA)","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","70","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","10-000044|5R01HL092954|5R01AG031750","February 4, 2010","November 2015","November 2015","February 11, 2010","March 15, 2017","April 18, 2017","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01067339"
417,"NCT01144494","Aqueous Humor Dynamics and Brimonidine","Brimonidine","Completed","Has Results","Intraocular Pressure","Drug: Brimonidine|Drug: Artificial tears","Seated Day-time IOP 9 am and 11 am, Supine Day-time IOP 9 am and 11 am, and Seated Night-time IOP 9 pm and 11 pm|Supine Night-time & Day-time Seated Episcleral Venous Pressure (EVP)|Aqueous Flow|Uveoscleral Outflow|Outflow Facility","University of Nebraska","All","19 Years and older   (Adult, Older Adult)","Not Applicable","35","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","220-10-FB","June 2010","January 2011","January 2012","June 15, 2010","April 24, 2019","May 22, 2019","University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01144494"
418,"NCT03180593","Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH","BVreduce","Completed","No Results Available","Hypertension Complicated|Hypertrophy, Left Ventricular|Blood Pressure","Drug: Valsartan 80 mg","LVH reduction at 4 weeks.|24hr-ABPM measurement Change from baseline in mean 24 hour ABPM SBP|LVH reduction at 8 weeks.|24hr-Systolic ABPM measurement|24hr- DBP ABPM measurements|Office Blood Pressure measurements","Trinity Hypertension & Metabolic Research Institute|Allergan Sales, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","BYS-IT-78","February 7, 2017","January 25, 2018","January 25, 2018","June 8, 2017",,"April 11, 2018","Trinity Hypertension & Metabolic Research Institute, Carrollton, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03180593"
419,"NCT01511016","Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome",,"Completed","Has Results","HIV Lipodystrophy","Drug: Human recombinant leptin (""metreleptin"")|Drug: Placebo","Rate of Total Lipolysis|Rate of Net Lipolysis|Rates of Fatty Acid Oxidation|Fasting Plasma Non-HDL-C|Glucose Levels After Glucose Challenge|Insulin Levels After Oral Glucose Challenge.","Baylor College of Medicine","Male","18 Years to 64 Years   (Adult)","Not Applicable","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","H-13372","February 2003","June 2011","October 2011","January 18, 2012","January 27, 2016","January 27, 2016","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01511016"
420,"NCT01102465","Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg /25 mg Tablet Under Fed Conditions",,"Completed","No Results Available","Hypertension","Drug: losartan potassium hydrochlorothiazide","Bioequivalence determined by statistical comparison Cmax","Roxane Laboratories|West-Ward Pharmaceutical","All","18 Years to 45 Years   (Adult)","Not Applicable","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LOHY-T100/25-PVFD-2","February 2005","March 2005","March 2005","April 13, 2010",,"January 23, 2018","CEDRA Clinical Research, LLC, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01102465"
421,"NCT02757872","Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives",,"Active, not recruiting","No Results Available","Hypertension|Kidney Diseases","Dietary Supplement: Vitamin D3|Drug: Omega-3 Fatty acids|Dietary Supplement: Vitamin D3 placebo|Dietary Supplement: Fish oil placebo","Change in estimated glomerular filtration rate|Prevalence of Albuminuria","Albert Einstein College of Medicine|Brigham and Women's Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","50 Years and older   (Adult, Older Adult)","Phase 3","2612","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2015P002330/BWH|R01DK102952","April 2016","December 2019","March 2020","May 2, 2016",,"January 23, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02757872"
422,"NCT02646475","Metabolic Effects of Angiotensin-(1-7)",,"Recruiting","No Results Available","Obesity|Insulin Resistance|Hypertension|Metabolic Cardiovascular Syndrome","Drug: Angiotensin-(1-7)|Drug: Saline","Whole-Body Insulin Sensitivity|Blood Pressure|Heart Rate|Cardiac Output|Stroke Volume|Systemic Vascular Resistance","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years to 60 Years   (Adult)","Phase 1","19","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","151699","February 2016","December 2021","December 2021","January 5, 2016",,"February 7, 2020","Vanderbilt University School of Medicine, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02646475"
423,"NCT03014830","Alirocumab and Reverse Cholesterol Transport",,"Completed","No Results Available","Atherosclerosis|Coronary Heart Disease","Drug: Alirocumab|Drug: Placebos","Change from baseline in percent cholesterol excretion per day.|Change from baseline in removal rate of esterified cholesterol from plasma per day.|Change from baseline in LDL cholesterol|Change from baseline in percent cholesterol absorption","Washington University School of Medicine","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","201612021","June 1, 2017","June 4, 2018","July 30, 2018","January 9, 2017",,"November 7, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03014830"
424,"NCT01441570","The Impact of Nebivolol Versus Metoprolol on Quality of Life",,"Terminated","Has Results","Transplant; Failure, Kidney|Hypertension","Drug: Nebivolol|Drug: Metoprolol succinate","Quality of Life|Blood Pressure","Brigham and Women's Hospital|Forest Laboratories|Lahey Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","11","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2011P001638","February 2012","July 2013","July 2013","September 27, 2011","April 20, 2017","April 20, 2017","Brigham and Women's Hospital, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01441570"
425,"NCT01324245","Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet","Salt","Completed","No Results Available","Salt-sensitive Hypertension","Drug: Fenoldopam","Urinary sodium excretion|Renal Plasma Flow","Georgetown University|University of Virginia","All","18 Years to 55 Years   (Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","2003-142|RR 17613","November 2002","December 2005","May 2006","March 28, 2011",,"March 28, 2011","Georgetown University Medical Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT01324245"
426,"NCT02841774","High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV","HILLCLIMBER","Recruiting","No Results Available","HIV Infection|Coronary Heart Disease","Drug: Pravastatin|Drug: Rosuvastatin","Mean percent change in fasting LDL-cholesterol|Treatment-emergent adverse events|Mean percent change in fasting HDL-cholesterol|Mean percent change in fasting Total Cholesterol|Mean percent change in fasting Triglycerides","Matthew Feinstein|Northwestern University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSC01","November 2016","March 2020","March 2020","July 22, 2016",,"May 17, 2019","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02841774"
427,"NCT01349114","Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects",,"Terminated","Has Results","Diabetes|Pre-hypertension|Hypertension","Drug: aliskiren 300 mg once daily|Drug: Placebo/sugar pill","Change in Flow-mediated Dilation|Mean Central Aortic Pressure at 3 Months","University of Alabama at Birmingham|Novartis","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 4","21","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research","F110124007","June 2011","January 2012","January 2012","May 6, 2011","June 30, 2014","May 11, 2017","UAB, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT01349114"
428,"NCT02137408","Docosahexaenoic Acid Supplementation of Women With Hypertension in Pregnancy to Improve Endothelial Health","DHA-2","Withdrawn","No Results Available","Hypertension in Pregnancy","Dietary Supplement: Docosahexaenoic acid 200 mg|Drug: Docosahexaenoic acid 1000 mg","Improve maternal endothelial health|Improve immune homeostasis","Children's Hospital Medical Center, Cincinnati|Nationwide Children's Hospital","Female","18 Years to 45 Years   (Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2013-7329","December 2014","November 2015","April 2016","May 13, 2014",,"September 18, 2014","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02137408"
429,"NCT02081638","Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study",,"Completed","No Results Available","Human Immunodeficiency Virus","Drug: Aspirin|Drug: Lipitor","Changes in sCD14 after 9 months of treatment with aspirin or rosuvastatin, in Elite Controller and Treated Progressor (ART <50) groups combined.|Changes in soluble biomarkers including sCD14, IL-6, D- dimer, hsCRP, sTF, sCD163 and other related markers of inflammation and coagulation in EC and ART <50 groups treated with aspirin orrosuvastatin.","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","140039|14-I-0039","April 18, 2014","October 16, 2019","October 16, 2019","March 7, 2014",,"April 30, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Hennipen County Medical Center, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02081638"
430,"NCT01037660","Effects of Lipemia and Metformin on Endothelial Function",,"Completed","No Results Available","Cardiovascular Disease","Drug: Metformin","Brachial artery flow-mediated dilation|blood lipid levels","Boston University","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","139","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","H-23660","September 2005","December 1, 2015","December 1, 2016","December 23, 2009",,"March 10, 2017","Boston Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01037660"
431,"NCT01071993","Efficacy of Statins In Prevention of CIN","SCIN","Terminated","Has Results","Nephropathy","Drug: placebo|Drug: atorvastatin","Primary Endpoint. Development of CIN (Contrast-induced Nephropathy) Defined as a Postprocedure Increase in Serum Creatinine of > 0.5 mg/dL or >25% Increase From Baseline at 24 & at 48 Hours.","University of Oklahoma","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","15097","March 2010","July 2013","July 2013","February 19, 2010","September 13, 2017","December 4, 2017","Oklahoma University Health Science Center, Oklahoma City, Oklahoma, United States|Veterans Affairs Medical Center, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT01071993"
432,"NCT01837823","YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering",,"Completed","Has Results","Obstructive Coronary Artery Disease|Coronary Artery Disease","Drug: rosuvastatin","Correlation Between Plaque Morphology and HDL Functionality|Correlation Between the Change in Fibrous Cap Thickness and Hs-CRP|Maximal 4mm Lipid Core Burden Index (LCBI 4mm Max)|Fibrous Cap Thickness (FCT) by OCT|IVUS Imaging Measures|Inflammatory and Lipid Parameters|Lesion LCBI|LCBI 4mm at Same Anatomical Site|Change in Atheroma Volume|Biomarker Release|Correlation of Baseline Lipid Parameters With Baseline LCBI4mm Max|Plaque Morphology as Related to Haptoglobin|Mechanism of Reverse Cholesterol Transport|Correlation of Changes in Plaque Morphology|MACE","Icahn School of Medicine at Mount Sinai|Texas Heart Institute (Wafic Said Molecular Cardiology Research Lab)|AstraZeneca|InfraReDx (indirect)","All","18 Years and older   (Adult, Older Adult)","Phase 2","91","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 12-1507|HS#: 12-00741","July 2013","April 2015","April 2015","April 23, 2013","February 13, 2018","February 13, 2018","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01837823"
433,"NCT01988571","Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)",,"Active, not recruiting","No Results Available","Breast Cancer","Drug: Atorvastatin|Drug: Placebo","Determine if Atorvastatin (Lipitor) administration preserves LV Function|Document the effect of atorvastatin on cognitive function|Document effect of Atorvastatin on self-reported quality of life","Wake Forest University Health Sciences|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)","Female","30 Years to 80 Years   (Adult, Older Adult)","Phase 2","279","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB00038639|U10CA081851|1R01HL118740-01|REBACCCWFU 98213","February 2014","May 2020","June 2020","November 20, 2013",,"April 7, 2020","Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Wisconsin Carbon Cancer Center, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01988571"
434,"NCT01186289","Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery",,"Withdrawn","No Results Available","Neurocognitive Dysfunction","Drug: atorvastatin","Neurocognitive Dysfunction","Duke University|Pfizer","All","50 Years and older   (Adult, Older Adult)","Not Applicable","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","PRO00020165","October 2010","October 2011","October 2012","August 23, 2010",,"October 14, 2015","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01186289"
435,"NCT02213094","Phase I Study of Nicotinamide for Early Onset Preeclampsia",,"Completed","Has Results","Pregnancy Induced Hypertension|Superimposed Preeclampsia|Hypertension","Drug: Nicotinamide 500 mg|Drug: Nicotinamide 1000 mg","Number of Participants With Adverse Events","University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute","Female","18 Years to 45 Years   (Adult)","Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","13-2203","January 1, 2014","December 3, 2015","December 3, 2015","August 11, 2014","November 2, 2018","November 2, 2018","University of North Carolina Women's Hospital, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02213094"
436,"NCT03460470","Sildenafil in US Heart Failure Patients (SilHF-US)","SilHF-US","Unknown status","No Results Available","Heart Failure|Pulmonary Hypertension","Drug: Sildenafil|Drug: Placebo oral capsule","Six minute walk test|Patient Global Assessment (PGA)|1.Quality of Life (QoL) evaluation by EuroQol5D|Kansas City Cardiomyopathy Questionnaire (KCCQ)|New York Heart Association (NYHA) function class","Hartford Hospital|Helse Stavanger HF","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HHC-2016-0152","February 14, 2018","December 2018","December 2018","March 9, 2018",,"March 9, 2018","Hartford Hospital 80 Seymour street, Hartford, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03460470"
437,"NCT01195662","A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication",,"Completed","Has Results","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Placebo matching Dapagliflozin","Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure for 12 Week Double-Blind Treatment Period - Randomized Participants|Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) for 12 Week Double-Blind Treatment Period - Randomized Participants|Adjusted Mean Change From Baseline in 24-hour Ambulatory Systolic Blood Pressure at Week 12 Last Observation Carried Forward (LOCF)|Adjusted Mean Change From Baseline in Seated Diastolic Blood Pressure (DBP) for 12 Week Double-Blind Treatment Period - Randomized Participants|Adjusted Mean Change From Baseline in 24-hr Ambulatory Diastolic Blood Pressure at Week 12 (LOCF)|Adjusted Mean Change From Baseline in Serum Uric Acid at Week 12 in Double-Blind Treatment Period - Randomized Participants|Number of Participants With Deaths,Serious Adverse Events (SAEs), Adverse Events (AEs), Hypoglycemia Events, Discontinuation Due to AEs, SAEs and Hypoglycemia, During the 12 Week Double Blind Period, Including Data After Rescue|Number of Participants With Marked Chemistry Laboratory Abnormalities in 12 Week Double Blind Treatment Period, Including Data After Rescue|Number of Participants With Elevated Liver Laboratory Tests in Participants Treated With Double Blind 10 mg Dapagliflozin or Placebo , Including Data After Rescue|Number of Participants With Normal or Abnormal Electrocardiogram Summary Tracing at Week 12 (LOCF), Including Data After Rescue|Proportion of Participants With Orthostatic Hypotension at Baseline and Week 12, Including Data After Rescue","AstraZeneca|Bristol-Myers Squibb","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 3","2245","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MB102-077 ST|2010-019798-13","October 2010","February 2013","February 2013","September 6, 2010","May 23, 2014","December 29, 2016","University Of Alabama At Birmingham, Birmingham, Alabama, United States|Medical Affiliated Research Center, Inc., Huntsville, Alabama, United States|Wilmax Clinical Research, Inc., Mobile, Alabama, United States|43rd Medical Associates, Phoenix, Arizona, United States|Central Phoenix Medical Center, Tempe, Arizona, United States|Clinical Research Advantage, Inc./Mesa Family Med Ctr, Pc, Tempe, Arizona, United States|Clinical Research Advantage/Desert Clinical Research, Tempe, Arizona, United States|Visions Clinical Research - Tucson, Tucson, Arizona, United States|Eclipse Clinical Research, Tucson, Arizona, United States|Aureus Research, Inc., Little Rock, Arkansas, United States|Preferred Research Partners, Inc., Little Rock, Arkansas, United States|Cmp Research, Anaheim, California, United States|Catalina Research Institute, Llc, Chino, California, United States|Southland Clinical Research Center, Inc., Fountain Valley, California, United States|Marin Endocrine Care & Research, Inc., Greenbrae, California, United States|Del Rosario Medical Clinic, Inc., Huntington Park, California, United States|Time Clinical Research Inc., Huntington Park, California, United States|Clinica Medica San Miguel, Los Angeles, California, United States|American Institute Of Research, Los Angeles, California, United States|Randall G. Shue, D.O., Los Angeles, California, United States|Mcs Clinical Trials, Los Angeles, California, United States|National Research Inst, Los Angeles, California, United States|Diabetes Medical Center Of California, Northridge, California, United States|Valley Clinical Trials, Northridge, California, United States|Lucita M. Cruz,Md.,Inc., Norwalk, California, United States|Sds Clinical Trials, Orange, California, United States|Bayview Research Group, Llc, Paramount, California, United States|San Diego Managed Care Group, Poway, California, United States|Integrated Research Group, Inc., Riverside, California, United States|Quality Control Research, Inc, Sacramento, California, United States|Wetlin Research Associates, Inc., San Diego, California, United States|Crest Clinical Trials, Inc., Santa Ana, California, United States|Neurological Research Institute, Santa Monica, California, United States|Orrin M. Troum, Md And Medical Associates, Santa Monica, California, United States|Torrance Clinical Research, Torrance, California, United States|Orange County Research Center, Tustin, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Chase Medical Research, Llc, Waterbury, Connecticut, United States|Christiana Care Health Services, Inc, Newark, Delaware, United States|Zasa Clinical Research, Boynton Beach, Florida, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Innovative Research Of West Florida, Inc, Clearwater, Florida, United States|Clinical Research Of South Florida, Coral Gables, Florida, United States|Avail Clinical Research, Llc, Deland, Florida, United States|International Research Associates, Llc, Hialeah, Florida, United States|Palm Springs Research Institute, Hialeah, Florida, United States|The Community Research Of South Florida, Hialeah, Florida, United States|Central Florida Internists, Kissimmee, Florida, United States|Newphase Clinical Trials, Inc., Miami Beach, Florida, United States|Ocean Blue Medical Research Center, Inc., Miami Springs, Florida, United States|Flcri Global Research, Llc, Miami, Florida, United States|Clinical Research Of Miami, Inc., Miami, Florida, United States|Pharmax Research Clinic, Inc., Miami, Florida, United States|Apf Research, Llc, Miami, Florida, United States|Community Research Foundation, Inc., Miami, Florida, United States|Baptist Diabetes Associates, Pa, Miami, Florida, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, United States|Florida Institute For Clinical Research, Llc, Orlando, Florida, United States|Michele A. Morrison Internal Medicine, Inc., Pembroke Pines, Florida, United States|Medsol Clinical Research Center, Port Charlotte, Florida, United States|Meridien Research, Tampa, Florida, United States|Perimeter Institute For Clinical Research, Atlanta, Georgia, United States|Bainbridge Medical Associates, Bainbridge, Georgia, United States|River Birch Research Alliance, Llc, Blue Ridge, Georgia, United States|In-Quest Medical Research, Llc, Duluth, Georgia, United States|Middle Georgia Drug Study Center, Llc, Perry, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|So. Illinois Clin Res Ctr @ Div Of Kevin L Pritchett Md, Pc, O?Fallon, Illinois, United States|Springfield Diabetes And Endocrine Center, Springfield, Illinois, United States|American Health Network Of Indiana Llc, Avon, Indiana, United States|Investigators Research Group, Llc, Brownsburg, Indiana, United States|American Health Network Of In Llc, Franklin, Indiana, United States|Laporte County Institute For Clinical Research, Inc., Michigan City, Indiana, United States|American Health Network Of In Llc, Muncie, Indiana, United States|Medical Development Centers, Llc, Baton Rouge, Louisiana, United States|Omega Clinical Research, Llc, Metairie, Louisiana, United States|Acadia Clinical Research, Llc, Bangor, Maine, United States|Alternative Primary Care, Silver Spring, Maryland, United States|Hci-Metromedic Walk-In Medical Office, New Bedford, Massachusetts, United States|Neurocare, Inc., Newton, Massachusetts, United States|Atlantic Clinical Trials, Llc, Watertown, Massachusetts, United States|Providence Park Clinical Research, Novi, Michigan, United States|The Center For Clinical Trials, Biloxi, Mississippi, United States|Phillips Medical Services, Pllc, Jackson, Mississippi, United States|Jefferson City Medical Group, Jefferson City, Missouri, United States|Kcumb Dybedal Clinical Research Center, Kansas City, Missouri, United States|Clin Research Advantage, Inc. James Meli, Do Family Pracice, Henderson, Nevada, United States|Office Of Ted Thorp, Md, Las Vegas, Nevada, United States|Independent Clinical Researchers@ Wolfson Medical Center, Las Vegas, Nevada, United States|Clinical Research Advantage, Inc., Las Vegas, Nevada, United States|Palm Medical Research Center, Las Vegas, Nevada, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Premier Research, Trenton, New Jersey, United States|Medex Healthcare Research, Inc., New York, New York, United States|Digiovanna Institute For Medical Education & Research, North Massapequa, New York, United States|Southgate Medical Group, West Seneca, New York, United States|Diabetes & Endocrinology Consultants, Morehead City, North Carolina, United States|Burke Primary Care, Morganton, North Carolina, United States|Lillestol Research, Fargo, North Dakota, United States|Community Health Care, Inc., Canal Fulton, Ohio, United States|Community Research, Cincinnati, Ohio, United States|Parsons Avenue Medical Clinical, Columbus, Ohio, United States|Clinical Research Source, Inc, Perrysburg, Ohio, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Integris Family Care Yukon, Yukon, Oklahoma, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Southeastern Pa Medical Institute, Broomall, Pennsylvania, United States|Abington Memorial Hos/Feasterville Family Health Care Center, Feasterville, Pennsylvania, United States|The Clinical Trial Center, Llc, Jenkintown, Pennsylvania, United States|Arcuri Clinical Research Llc, Philadelphia, Pennsylvania, United States|Philadelphia Health Associates - Adult Medicine, Philadelphia, Pennsylvania, United States|Research Across America, Reading, Pennsylvania, United States|Pish Medical Associates, Uniontown, Pennsylvania, United States|Greater Providence Clinical Research, Llc, Warwick, Rhode Island, United States|Medical Research South, Charleston, South Carolina, United States|Southeastern Research Associates, Inc., Greenville, South Carolina, United States|North Myrtle Beach Family Practice, North Myrtle Beach, South Carolina, United States|Pawleys Pediatrics And Adult Medicine, Pawleys Island, South Carolina, United States|Hillcrest Clinical Reseach, Llc, Simpsonville, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Southwind Medical Specialists, Memphis, Tennessee, United States|Tn Medical Research, Spring Hill, Tennessee, United States|Arlington Family Research Center, Inc., Arlington, Texas, United States|3rd Coast Research Associates, Corpus Christi, Texas, United States|Krk Medical Research, Dallas, Texas, United States|Research Institute Of Dallas, Dallas, Texas, United States|Internal Medicine Clinical Reaseach, Dallas, Texas, United States|Renaissance Clinical Research And Hypertension Pllc, Dallas, Texas, United States|Sergio F. Rovner, M.D., El Paso, Texas, United States|Pioneer Research Solutions, Inc., Houston, Texas, United States|Village Family Practice, Houston, Texas, United States|Dependable Clinical Research, Llc, Houston, Texas, United States|Southwest Clinical Trials, Houston, Texas, United States|Bellaire Medical Care Group, Houston, Texas, United States|Excel Clinical Research, Llc, Houston, Texas, United States|Hill Country Medical Associates, New Braunfels, Texas, United States|North Hills Medical Research, Inc., North Richland Hills, Texas, United States|Med-Olam Clinical Research, Pasadena, Texas, United States|Lisa E. Medwedeff, Md, Pa, Plano, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Abbott Clinical Research Group, Inc., San Antonio, Texas, United States|Covenant Clinical Research, Pa, San Antonio, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Breco Research, Ltd, Sugarland, Texas, United States|Exodus Healthcare Network, Magna, Utah, United States|Wasatch Endocrinology And Diabetes Specialists, Salt Lake City, Utah, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|Alexandria Health Care Center, Alexandria, Virginia, United States|Millennium Clinical Trials Llc, Arlington, Virginia, United States|Burke Internal Medicine And Research, Burke, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Hampton Roads Center For Clinical Research, Inc., Suffolk, Virginia, United States|Larry D. Stonesifer, Md, Federal Way, Washington, United States|Sound Medical Research, Port Orchard, Washington, United States|Clinical Investigation Specialists, Inc., Kenosha, Wisconsin, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Kelowona, British Columbia, Canada|Local Institution, Victoria, British Columbia, Canada|Local Institution, Monction, New Brunswick, Canada|Local Institution, Brampton, Ontario, Canada|Local Institution, Granby, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Armenia, Quindio, Colombia|Local Institution, Bucaramanga, Santander, Colombia|Local Institution, Barranquilla, Colombia|Local Institution, Barranquilla, Colombia|Local Institution, Bogota, Colombia|Local Institution, Beroun, Czech Republic|Local Institution, Cheb, Czech Republic|Local Institution, Havirov, Czech Republic|Local Institution, Krnov, Czech Republic|Local Institution, Liberec, Czech Republic|Local Institution, Ostrava, Czech Republic|Local Institution, Prague 1, Czech Republic|Local Institution, Praha 4, Czech Republic|Local Institution, Copenhagen, Denmark|Local Institution, Frederiksberg, Denmark|Local Institution, Gentofte, Denmark|Local Institution, Slagelse, Denmark|Local Institution, Helsinki, Finland|Local Institution, Kerava, Finland|Local Institution, Kokkola, Finland|Local Institution, Oulu, Finland|Local Institution, Aschaffenburg, Bavaria, Germany|Local Institution, Augsburg, Bavaria, Germany|Local Institution, Duisburg, Nordrhein-Westfalen, Germany|Local Institution, Bad Kreuznach, Germany|Local Institution, Berlin, Germany|Local Institution, Dortmund, Germany|Local Institution, Dresden, Germany|Local Institution, Karlsruhe, Germany|Local Institution, Kothen, Germany|Local Institution, Kronshagen, Germany|Local Institution, Langenfeld, Germany|Local Institution, Lueneburg, Germany|Local Institution, Magdeburg, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Saarbruecken, Germany|Local Institution, Wuestensachsen, Germany|Local Institution, Gyongyos, Heves, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Eger, Hungary|Local Institution, Kisvarda, Hungary|Local Institution, Miskolc, Hungary|Local Institution, Nyiregyhaza, Hungary|Local Institution, Satoraljaujhely, Hungary|Local Institution, Sopron, Hungary|Local Institution, Szeged, Hungary|Local Institution, Szekszard, Hungary|Local Institution, Hyderabad, Andhra Pradesh, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Mangalore, Karnataka, India|Local Institution, Belgaum, Karnatka, India|Local Institution, Indore, Madhya Pradesh, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Delhi, New Delhi, India|Local Institution, Jaipur, Rajasthan, India|Local Institution, Chennai, Tamil Nadu, India|Local Institution, Coimbatore, Tamil Nadu, India|Local Institution, Madurai, Tamilnadu, India|Local Institution, Chennai Tamilnadu, India|Local Institution, Hyderabad, India|Local Institution, Nagpur, India|Local Institution, Trivandrum, India|Local Institution, Dublin 15, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Torreon, Coahuila, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Cuautla, Morelos, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Culiacan, Sinaloa, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, Del. Benito Juarez, Mexico|Local Institution, Delegacion Tlalpan, Mexico|Local Institution, Distrito Federal, Mexico|Local Institution, San Luis Potosi, Mexico|Local Institution, Bialystok, Poland|Local Institution, Bialystok, Poland|Local Institution, Chrzanow, Poland|Local Institution, Elblag, Poland|Local Institution, Gdansk, Poland|Local Institution, Gdynia, Poland|Local Institution, Kamieniec Zabkowicki, Poland|Local Institution, Katowice, Poland|Local Institution, Kielce, Poland|Local Institution, Krakow, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Lodz, Poland|Local Institution, Lublin, Poland|Local Institution, Ostroda, Poland|Local Institution, Poznan, Poland|Local Institution, Warsaw, Poland|Local Institution, Warsaw, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Wroclaw, Poland|Local Institution, Zabrze, Poland|Local Institution, Fajard, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Oradea, Bihor, Romania|Local Institution, Oradea, Jud. Bihor, Romania|Local Institution, Timisoara, Jud. Timis, Romania|Local Institution, Targu Mures, Mures, Romania|Local Institution, Targu Mures, Mures, Romania|Local Institution, Ploiesti, Prahova, Romania|Local Institution, Ploiesti, Prahova, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Satu Mare, Romania|Local Institution, Sibiu, Romania|Local Institution, Sibiu, Romania|Local Institution, Irvine, Ayrshire, United Kingdom|Local Institution, Ely, Cambridgeshire, United Kingdom|Local Institution, Birmingham, West Midlands, United Kingdom|Local Institution, Bath, Wiltshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01195662"
438,"NCT02489019","Fentanyl Effect on Blood Pressure in Elderly Patients After Induction of General Anesthesia","Fentanyl","Recruiting","No Results Available","Hypotension","Drug: Sodium chloride|Drug: Fentanyl","Development of hypotension","Loyola University","All","60 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","204821","February 19, 2018","July 2020","December 2022","July 2, 2015",,"June 5, 2019","Loyola University Medical Center, Maywood, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02489019"
439,"NCT01733953","Statin Therapy in Young Adult Survivors of Childhood Cancer",,"Completed","Has Results","Cardiovascular Disease|Childhood ALL|Childhood NHL","Drug: Atorvastatin|Drug: Sugar Pill (Placebo)","Change From Baseline in Brachial Artery Flow-Mediated Dilation at 6-months|Change From Baseline in Carotid Artery Compliance at 6-Months|Change From Baseline in Carotid Artery Distensibility at 6-Months|Change From Baseline in Pulse Wave Velocity at 6-Months|Change From Baseline in Augmentation Index at 6-Months|Change From Baseline in Carotid Intima-Media Thickness at 6-Months","University of Minnesota","All","18 Years to 39 Years   (Adult)","Phase 2","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1207M17202","November 2012","November 2015","March 2016","November 27, 2012","October 14, 2016","December 14, 2016","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01733953"
440,"NCT01114893","Travoprost Five Day Posology Study",,"Completed","Has Results","Open-angle Glaucoma (OAG)|Ocular Hypertension","Drug: Travoprost 0.004%|Drug: Travoprost Vehicle|Drug: Travoprost (Groups A, B and C)","Mean Intraocular Pressure (IOP) Change From Baseline at 8 AM on Day 5|IOP Change From Baseline at 8 PM on Day 5","Alcon Research","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","C-09-075","April 2010","May 2010",,"May 3, 2010","June 23, 2011","June 23, 2011","Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01114893"
441,"NCT03680976","Anti-Inflammatory Lipid Mediators in Asthma","ALMA","Withdrawn","No Results Available","Asthma","Drug: CXA-10|Drug: Placebo","Change in airway responsiveness after treatment with CXA-10 using a methacholine challenge test|Treatment with CXA-10 compared to baseline: Change in the concentration of Nitrite/Nitrate (NO2/NO3). and NO2-Conjugated Linoleic Acid (CLA) in plasma and urine|Treatment with CXA-10 compared to baseline: Characterization of the pharmacokinetic (PK) profile of CXA-10 in plasma and urine|Treatment with CXA-10 compared to baseline: Changes in airway epithelial gene expression","Sally E. Wenzel MD|University of Pittsburgh","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRO16020149",,"April 2021","April 2021","September 21, 2018",,"September 21, 2018","The University of Pittsburgh Asthma Institute at UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03680976"
442,"NCT03115853","The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function",,"Completed","Has Results","High Blood Pressure","Drug: Aliskiren 150 mg|Drug: Placebo|Drug: HCTZ|Drug: Aliskiren 300 mg","Difference in Peak Plasma PAI-1 Level|Difference in Mean Plasma PAI-1 Level|Difference in Mean Plasma Aldosterone Levels|Difference in Mean Changes in Plasma Renin Activity.|Difference in Mean Plasma Peak Aldosterone Levels","Vanderbilt University Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","31","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","090738","June 2009","January 2012","January 2012","April 14, 2017","August 25, 2017","August 25, 2017","VUMC, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03115853"
443,"NCT02681055","Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects",,"Completed","No Results Available","Non-alcoholic Steatohepatitis|Hypertriglyceridemia|Non-alcoholic Fatty Liver Disease|Hypercholesterolemia","Drug: MN-001","To measure the change from baseline at 12 weeks of MN-001 on Cholesterol Efflux Capacity in NASH subjects with hypertriglyceridemia|To measure the change from baseline at 12 weeks of MN-001 on serum triglyceride levels in NASH subjects with hypertriglyceridemia|To measure the safety and tolerability of MN-001 by assessing the number of treatment-related adverse events.|To measure blood the concentration of MN-001/MN-002 (metabolite) change from pre-dose after 24 hours|To measure the effect of MN-001 on serum lipid panel|To measure the effect of MN-001/002 on liver enzymes|To measure the effect of MN-001/002 on percentage of fat in the liver by MRI from baseline to Week 12","MediciNova","All","18 Years and older   (Adult, Older Adult)","Phase 2","19","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MN-001-NATG-201","March 2016","May 30, 2018","October 1, 2019","February 12, 2016",,"October 24, 2019","Southern California Research Center, Coronado, California, United States|Scripps Research, La Jolla, California, United States|Harborview Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02681055"
444,"NCT03380624","Tear Lipid Layer Thickness With Emollient Eye Drops",,"Completed","No Results Available","Dry Eye Syndromes","Drug: Refresh Optive|Drug: Refresh Optimum OMEGA 3","Lipid Layer Thickness","Ohio State University|Allergan","All","30 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2016H0354","March 1, 2017","June 30, 2018","June 30, 2018","December 21, 2017",,"May 23, 2019","The Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03380624"
445,"NCT01260454","The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain",,"Completed","Has Results","Pulmonary Hypertension|Pulmonary Arterial Hypertension","Drug: Qutenza (8% capsaicin)","Pain Score on a Visual Analogue Scale|Number of Participants Who Experienced Greater Than 6 Pain Level Using the 10 Point Visual Analog Score|Number of Participants Who Used of Narcotics Following a Treprostinil Infusion Site Change","University of Rochester|United Therapeutics","All","15 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Qutenza White","November 2010","December 2011","April 2012","December 15, 2010","February 22, 2016","April 21, 2016","Mary M. Parkes Asthma Center, University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01260454"
446,"NCT01271686","24-hour IOP-lowering Effect of 0.01% Bimatoprost",,"Completed","Has Results","Intraocular Pressure|Glaucoma|Ocular Hypertension","Drug: 0.01% bimatoprost","Nocturnal Intraocular Pressure (IOP) Change","University of California, San Diego","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 4","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCSD 101705 bimatoprost","January 2011","October 2012","October 2012","January 7, 2011","June 19, 2014","June 19, 2014","UCSD Shiley Eye Center, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT01271686"
447,"NCT03129542","Midodrine Hydrochloride in Early Sepsis",,"Recruiting","No Results Available","Sepsis|Blood Pressure","Drug: Midodrine Hydrochloride 10 milligrams|Drug: Placebo capsule","Duration of Vasopressor Use|Mean arterial blood pressure (MAP)|Cumulative Fluid Balance|ICU and hospital length of stay, central venous access use and organ failure|Incidence of potential side effects attributable to Midodrine|Cumulative Vasopressor Dose","Mayo Clinic|Cleveland Clinic Abu Dhabi","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16-002444","August 30, 2017","July 31, 2020","December 31, 2020","April 26, 2017",,"October 4, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03129542"
448,"NCT01695954","Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz",,"Unknown status","No Results Available","Hyperlipidemia|HIV","Drug: Pitavastatin|Drug: Darunavir|Drug: Ritonavir|Drug: Efavirenz","AUC of pitavastatin after coadministration of efavirenz. AUC of pitavastatin after coadministration of darunavir with ritonavir. AUC of efavirenz after coadministration of pitavastatin. AUC of darunavir after coadministration of pitavastatin.|Other pharmacokinetic parameters of pitavastatin and efavirenz and of pitavastatin and darunavir+ritonavir. Lipid measurements at days 0,4,14 and 18.","NYU Langone Health|Bellevue/NYU AIDS Clinical Trials Unit|Kowa Pharmaceuticals America, Inc.|University at Buffalo","All","18 Years to 60 Years   (Adult)","Phase 1","28","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","NYU 11-01787","May 2012","October 2012","October 2012","September 28, 2012",,"September 28, 2012","Bellevue/NYU AIDS Clinical Trials Unit, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01695954"
449,"NCT01740817","A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling",,"Completed","Has Results","Diabetes|Obesity","Drug: Intralipid 20%|Drug: Saline","Muscle Insulin Sensitivity-M Value|TLR4 Messenger Ribonucleic Acid (mRNA) in Muscle|Extracellular Signal-regulated Kinase (ERK) Phosphorylation in Muscle","The University of Texas Health Science Center at San Antonio|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 60 Years   (Adult)","Not Applicable","12","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HSC20080015H|5R01DK080157","January 2008","December 2013","September 2015","December 4, 2012","January 25, 2016","January 25, 2016","Audie L. Murphy VA Hospital, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01740817"
450,"NCT01398423","INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria",,"Completed","No Results Available","Hypertension|Diabetes Mellitus, Type 2","Drug: Active Control|Drug: INV-144","Safety|Efficacy","InVasc Therapeutics, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","INV144-201","June 2011","July 2012","July 2012","July 20, 2011",,"August 7, 2012","Garden Grove, California, United States|La Mesa, California, United States|Northridge, California, United States|Riverside, California, United States|Tustin, California, United States|Kissimmee, Florida, United States|Miami, Florida, United States|Macon, Georgia, United States|Tucker, Georgia, United States|Reisterstown, Maryland, United States|Brooklyn Center, Minnesota, United States|Cary, North Carolina, United States|Greenville, North Carolina, United States|New Bern, North Carolina, United States|Raleigh, North Carolina, United States|Aiken, South Carolina, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01398423"
451,"NCT02432339","Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress","MMF","Recruiting","No Results Available","Psychological Stress|Hypertension, Renal","Drug: mycophenolate mofetil (MMF)|Drug: Placebo","Urinary sodium excretion rate|Hemodynamics- change in systolic blood pressure compared to changes in sodium excretion","Augusta University","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","611878","April 22, 2014","November 2019","November 30, 2019","May 4, 2015",,"June 20, 2019","Augusta University, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02432339"
452,"NCT01764451","Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins",,"Completed","No Results Available","Cavernous Angioma, Familial|Cerebral Cavernous Malformations|Cerebral Cavernous Hemangioma","Drug: Simvastatin","Change in blood brain barrier permeability over three months for the treatment group compared to the control group.|Correlation of physiologic permeability data with anatomic lesion data","University of New Mexico|National Institute of Neurological Disorders and Stroke (NINDS)|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","12","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","BVMC 6205|U54NS065705","March 2012","January 2016","January 2016","January 9, 2013",,"April 11, 2016","University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT01764451"
453,"NCT01348880","Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study",,"Completed","No Results Available","Erectile Dysfunction","Drug: Vardenafil ODT, (Staxyn, BAY38-9456)|Drug: Placebo","The primary pharmacodynamic variable (endpoint) is the placebo-corrected mean maximal decrease in supine systolic blood pressure from baseline (1 hour before dose) to within 8 hours of dosing with 10 mg ODT formulation of vardenafil HCl and nifedipine.|Mean maximal decrease in standing SBP|Mean maximal decrease in standing diastolic blood pressure (DBP)|Mean maximal decrease in supine DBP|Mean maximal orthostatic change in SBP (the supine SBP minus the standing SBP)|Mean maximal increase in supine and standing heart rate|Mean area under effect curve (AUEC) in standing and supine systolic and diastolic blood pressure, and heart rate|Safety parameters|Pharmacokinetics parameter","Bayer|GlaxoSmithKline|Merck Sharp & Dohme Corp.","Male","65 Years to 80 Years   (Older Adult)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","15345","May 2011","December 2011","December 2011","May 6, 2011",,"May 19, 2014","Miami, Florida, United States|Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01348880"
454,"NCT01327014","Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia",,"Completed","No Results Available","Hyperlipidemia","Drug: XueZhiKang (XZK), a botanic product with multiple components|Drug: Placebo","Mean percentage change from baseline at week 12 (or the last assessment) on serum low-density lipoprotein cholesterol (LDL-C) level.|Mean percentage change from baseline at week 12 (or the last assessment on serum total cholesterol (TC) level.|Mean percentage change from baseline at week 12 (or the last assessment) on serum high-density lipoprotein cholesterol (HDL-C) level|Mean percentage change from baseline at week 12 (or the last assessment) on serum triglyceride (TG) level.|Mean percentage change from baseline at week 12 (or the last assessment) on serum non-HDL cholesterol level.|Mean percentage change from baseline at week 12 (or the last assessment) on serum apolipoprotein A-I (Apo A-I) and serum apolipoprotein-B (Apo-B) and the Apo-B/Apo A-I ratio.|Mean percentage change from baseline at week 12 (or the last assessment) on the serum TC/HDL-C ratio.|Percentage of patients who show a LDL-C level of <130 mg/dl or <100 mg/dl at end of the study.|Safety will be assessed by the incidence of adverse events (AEs), discontinuation due to the AEs, clinically relevant changes on laboratory test results, vital signs, physical examinations, and 12-lead electrocardiograms (ECG).","Beijing Peking University WBL Biotech Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","116","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WPU-201","April 2011","December 2012","December 2012","April 1, 2011",,"July 23, 2014","Robert Karns, MD A Medical Corporation, Beverly Hills, California, United States|Jellinger and Lerman, MD, Hollywood, Florida, United States|Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, United States|Harold E Bays, MD, Louisville, Kentucky, United States|Eli M Roth, MD, Cincinnati, Ohio, United States|Cardiovascular Medical Associates, Philadelphia, Pennsylvania, United States|Osvaldo Brusco, MD, Corpus Christi, Texas, United States|Clinical Trial Network, Houston, Texas, United States|Chinese PLA General Hospital, Beijing, Beijing, China|Wuhan Union Hospital, Wuhan, Hubei, China|Second Xiangya Hospital of Central-South Univ, Changsha, Hunan, China|Shanghai Ruijin Hospital, Shanghai, Shanghai, China|Shanghai First People's Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01327014"
455,"NCT01860911","Plasma Triglyceride Extraction by The Muscle",,"Active, not recruiting","No Results Available","Obesity|Insulin Resistance","Drug: Insulin|Drug: NG-monomethyl-L-arginine","Triglyceride extraction across the forearm|Muscle microvascular blood volume","Mayo Clinic|American Diabetes Association","All","18 Years to 50 Years   (Adult)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","12-005173","April 2013","September 19, 2019","August 21, 2020","May 23, 2013",,"October 28, 2019","Mayo Clinic in Arizona, Scottsdale, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01860911"
456,"NCT01400256","Blood Pressure Lowering in Acute Stroke Trial","BLAST","Withdrawn","No Results Available","Stroke, Acute","Drug: Valsartan",,"Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","CVAL489A US71","August 2007","February 2009","February 2009","July 22, 2011",,"May 9, 2016","Stanford University Medical Center, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01400256"
457,"NCT01725256","A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)",,"Terminated","No Results Available","Pulmonary Arterial Hypertension","Drug: AIR001 (sodium nitrite inhalation solution)","Change in pulmonary vascular resistance (PVR)from baseline to week 16 assessed at peak AIR001|Time to Clinical Worsening (TTCW), other hemodynamics, and safety","Aires Pharmaceuticals, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIR001-CS05","November 2012","February 2014","February 2014","November 12, 2012",,"April 9, 2014","UCSD Medical Center, La Jolla, California, United States|UCLA Medical Center, Torrance, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Gottsegen Gyorgy Hungarian, Budapest, Hungary|Semmelweis Karlocai, Budapest, Hungary|University of Debrecen, Debrecen, Hungary|University of Szeged, Szeged, Hungary",,"https://ClinicalTrials.gov/show/NCT01725256"
458,"NCT02321111","The Role of TLR4 on Lipid-induced Insulin Resistance","Eritoran1","Completed","Has Results","Insulin Sensitivity","Drug: Eritoran|Drug: D5W (5% Dextrose in water)","Effect of Eritoran on Muscle Insulin Sensitivity|Effect of Eritoran on Hepatic Insulin Sensitivity|Effect of Eritoran on TLR4 Expression on Peripheral Blood Monocytes|Effect of Eritoran on Plasma Cytokine Concentration|Effect of Eritoran on Intramyocellular Diacylglycerol and Ceramide Content","The University of Texas Health Science Center at San Antonio","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC20140497H","January 2015","September 2018","September 2018","December 22, 2014","October 8, 2019","October 8, 2019","Audie L. Murphy VA Hospital, STVHCS, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02321111/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02321111"
459,"NCT01675154","Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia",,"Active, not recruiting","No Results Available","Type 1 Hyperlipoproteinemia","Drug: SLx-4090 placebo|Drug: Orlistat Placebo|Drug: Orlistat|Drug: Slx-4090","Change in serum triglycerides from baseline for each crossover arm phase of placebo/placebo, orlistat/placebo, orlistat/SLx-4090, SLx-4090/placebo","University of Texas Southwestern Medical Center","All","12 Years to 100 Years   (Child, Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3940|FD-R-003940","November 2015","July 31, 2020","December 31, 2020","August 29, 2012",,"November 5, 2019","UT Southwestern Medical Center 5323 Harry Hines Blvd, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01675154"
460,"NCT01496430","Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes",,"Terminated","Has Results","Hypertension|Diabetes","Drug: Placebo|Drug: Azilsartan medoxomil","Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure|Change From Baseline in Glycosylated Hemoglobin (HbA1c)|Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure|Change From Baseline in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring|Change From Baseline in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring|Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring|Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring|Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring|Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring|Change From Baseline in the 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring|Change From Baseline in the 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring|Change From Baseline in the Trough (22 to 24 Hours After Dosing) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring|Change From Baseline in the Trough (22 to 24 Hours After Dosing) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring|Percentage of Participants Requiring Rescue Glycemic Therapy|Time to First Glycemic Rescue|Change From Baseline in HbA1c|Change From Baseline in Fasting Plasma Glucose|Change From Baseline to Week 6 and Week 24 in 2h Glucose During Oral Glucose Tolerance Testing (OGTT)|Change From Baseline to Week 6 and Week 24 in the Area Under the Plasma Concentration-time Curve (AUC) for Glucose During OGTT|Change From Baseline to Week 6 and Week 24 in AUC for Insulin During OGTT|Change From Baseline to Week 6 and Week 24 in AUC for C-peptide During OGTT|Change From Baseline to Week 6 and Week 24 in AUC for Insulin/Glucose Ratio During OGTT|Change From Baseline to Week 6 and Week 24 in AUC for Glucagon During OGTT","Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 3","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-491_304|U1111-1125-1197","January 2012","May 2013","May 2013","December 21, 2011","May 6, 2015","May 6, 2015","Birmingham, Alabama, United States|Green Valley, Arizona, United States|Tempe, Arizona, United States|Tucson, Arizona, United States|Buena Park, California, United States|Hawaiian Gardens, California, United States|Norwalk, California, United States|Paramount, California, United States|Rancho Cucamonga, California, United States|Sacramento, California, United States|San Diego, California, United States|Tustin, California, United States|Denver, Colorado, United States|Bradenton, Florida, United States|Brooksville, Florida, United States|Hallandale Beach, Florida, United States|Jupiter, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Pembroke Pines, Florida, United States|St Petersburg, Florida, United States|Tampa, Florida, United States|Winter Park, Florida, United States|Roswell, Georgia, United States|Chicago, Illinois, United States|Evergreen Park, Illinois, United States|Gurnee, Illinois, United States|Avon, Indiana, United States|Greenfield, Indiana, United States|Lexington, Kentucky, United States|Paducah, Kentucky, United States|Baltimore, Maryland, United States|Columbia, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Margate, New Jersey, United States|Albuquerque, New Mexico, United States|Brooklyn, New York, United States|Calabash, North Carolina, United States|Greensboro, North Carolina, United States|Lenoir, North Carolina, United States|Morehead City, North Carolina, United States|Salisbury, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Centerville, Ohio, United States|Cincinnati, Ohio, United States|Oklahoma City, Oklahoma, United States|Downingtown, Pennsylvania, United States|Fleetwood, Pennsylvania, United States|Reading, Pennsylvania, United States|Providence, Rhode Island, United States|Anderson, South Carolina, United States|Chattanooga, Tennessee, United States|Kingsport, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|Irving, Texas, United States|North Richland Hills, Texas, United States|Pearland, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Burke, Virginia, United States|Manassas, Virginia, United States|Richmond, Virginia, United States|Virginia Beach, Virginia, United States|Wauwatosa, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01496430"
461,"NCT01811693","Field Administration of Stroke Therapy-Blood Pressure Lowering","FAST-BP","Unknown status","No Results Available","Intracerebral Hemorrhage|Ischemic Stroke","Drug: Glycerly Trinitrate","Mean blood pressure change","University of California, Los Angeles","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FBP001","April 2013","December 2015",,"March 14, 2013",,"June 4, 2015","Los Alamitos Medical Center, Los Alamitos, California, United States|FAST-MAG Clinical Trial Coordinating Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01811693"
462,"NCT02754570","The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure",,"Completed","Has Results","Glaucoma, Open-angle|Hypertension, Ocular","Drug: Pilocarpine","Change in Intraocular Pressure From Baseline at Visit 3|Change in Ocular Perfusion Pressure","University of Colorado, Denver","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-1972|UL1TR001082","July 2016","December 2017","February 21, 2018","April 28, 2016","November 7, 2019","November 7, 2019","University of Colorado Denver Eye Hospital, Denver, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT02754570/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02754570"
463,"NCT03868124","Clinical Study Comparing Two Models of a Travoprost Intraocular Implant",,"Recruiting","No Results Available","Glaucoma, Open-Angle|Ocular Hypertension","Combination Product: G2TR intraocular implant containing travoprost|Drug: Sham surgery + active-comparator eye drops","Mean IOP (Control Group vs. Each Implant Group) through 3 months postoperative|Mean IOP (Control Group vs. Each Implant Group) through 12 months postoperative","Glaukos Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","1000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","GC-012","August 2, 2018","June 2021","June 2023","March 8, 2019",,"March 8, 2019","Center for Sight, Las Vegas, Nevada, United States",,"https://ClinicalTrials.gov/show/NCT03868124"
464,"NCT03519386","Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%",,"Recruiting","No Results Available","Glaucoma, Open-Angle|Ocular Hypertension","Combination Product: G2TR intraocular implant containing travoprost|Drug: Sham surgery + active-comparator eye drops","Mean IOP (Control Group vs. Each Implant Group) through 3 months postoperative|Mean IOP (Control Group vs. Each Implant Group) through 12 months postoperative","Glaukos Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","1000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","GC-010","May 22, 2018","June 2021","June 2023","May 9, 2018",,"March 8, 2019","Vance Thompson Vision, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT03519386"
465,"NCT02066649","Carvedilol vs Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding",,"Withdrawn","No Results Available","Portal Hypertension Related to Cirrhosis","Drug: Carvedilol|Procedure: Variceal band ligation","Incidence of first variceal bleed|Bleed-related mortality|Overall mortality|Recurrence of varices","Rutgers, The State University of New Jersey","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro2013003729","July 2018","March 2019","September 2021","February 19, 2014",,"July 24, 2018","Rutgers NJ Medical School, Newark, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02066649"
466,"NCT00974922","Vitamin D Deficiency in Patients With Hypertension",,"Terminated","Has Results","Vitamin D Deficiency|Hypertension","Drug: Aliskiren|Dietary Supplement: Cholecalciferol|Dietary Supplement: Placebo","Change From Baseline in Ambulatory Diastolic Blood Pressure|Change From Baseline Blood Pressure Measurement in 24-hour Systolic BP, Changes in Awake and Sleep Systolic and Diastolic BP, and Changes From Baseline in Clinic Systolic and Diastolic BP.","UConn Health|Novartis","All","21 Years and older   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","09-166-1|20090713","August 2009","December 2011","December 2011","September 11, 2009","March 9, 2018","March 9, 2018","University of Connecticut Health Center, Farmington, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00974922"
467,"NCT01275352","CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression",,"Withdrawn","No Results Available","Hypertension","Drug: Eplerenone|Drug: placebo","Change in LV mass index (g/m2) in ClC-Ka Gly/Gly83 patients and ClC-Ka Gly/Gly83 patients|Change in LV relative wall thickness|Change in N-terminal pro-brain natriuretic peptide (NT-proBNP)|Change in LV mass index (g/m2)","Washington University School of Medicine|University of Pennsylvania","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLNCKA-1","December 2011","December 2014","June 2015","January 12, 2011",,"June 3, 2015","Barnes Jewish Hospital, St. Louis, Missouri, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01275352"
468,"NCT01975935","Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients",,"Completed","Has Results","Diabetes Mellitus Type 2|Non-alcoholic Fatty Liver Disease|Obesity","Drug: Amlexanox|Drug: Placebo","Difference in Hemoglobin A1c Values|Hepatic Steatosis as Measured by MRI|Change in Weight","University of Michigan","All","18 Years and older   (Adult, Older Adult)","Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HUM00079381","January 2014","April 25, 2016","August 18, 2017","November 5, 2013","May 9, 2017","November 7, 2018","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01975935"
469,"NCT04061044","A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert",,"Active, not recruiting","No Results Available","Open Angle Glaucoma and Ocular Hypertension","Drug: Ophthalmic Insert","Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Subject ocular comfort assessment|Best corrected visual acuity (BCVA)|Slit lamp biomicroscopy including assessment and grade of ocular hyperemia (at slit lamp) and punctum exam|Measurement of Intraocular pressure (IOP)|Fundus examination|Optical Coherence Tomography of optic nerve on nerve fiber layer|Automated perimetry|Number of subjects who need rescue therapy over the study period","Ocular Therapeutix, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLN-Protocol-0047","July 10, 2018","February 2020","February 2020","August 19, 2019",,"August 21, 2019","ApexEye, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04061044"
470,"NCT01722604","Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt",,"Completed","No Results Available","Glaucoma|Open Angle or Ocular Hypertension","Drug: brinzolamide 1% ophthalmic suspension|Drug: Azopt 1%","Intraocular pressure (IOP) at baseline (Eligibility Visit 2) weeks and after treatment.|Reduction in intraocular pressure (IOP) from baseline (Eligibility Visit 2) and after treatment.","Bausch Health Americas, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","258","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","CD-11-265","January 2012","September 2012","September 2012","November 7, 2012",,"April 9, 2019","US01, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT01722604"
471,"NCT01285908","Intravenous Norepinephrine for Orthostatic Hypotension",,"Completed","Has Results","Orthostatic Hypertension","Drug: Intravenous Norepinephrine Infusion","Blood Pressure (Systolic)|Blood Pressure (Diastolic)|Blood Pressure (Mean)|Heart Rate|Cardiac Stroke Volume|Cardiac Output|Total Peripheral Resistance|Arterial Plasma Levels of Norepinephrine|Arterial Plasma Levels of Dihydroxyphenylglycol (DHPG)","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","6","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110085|11-N-0085","January 2011","September 2012","September 2012","January 28, 2011","March 26, 2014","October 10, 2014","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01285908"
472,"NCT03387579","Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates",,"Recruiting","No Results Available","Cholestasis of Parenteral Nutrition","Drug: Lipid Emulsions, Intravenous|Drug: Intralipid, 20% Intravenous Emulsion","Cholestasis|Growth velocity|Maximum total calories from enteral intake|Essential fatty acid deficiency|Difference in liver enzymes|Complications of prematurity|Triglyceride concentration|Length of stay|Two year development","Indiana University","All","Child, Adult, Older Adult","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1708745276","November 30, 2018","March 2020","March 2022","January 2, 2018",,"February 27, 2019","Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT03387579"
473,"NCT01239004","Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy","CERTAIN","Completed","No Results Available","Dyslipidemia|Hyperlipidemia|Hyperglycemia","Drug: Placebo|Drug: Colesevelam","Low-density lipoprotein cholesterol (LDL-C)|Fasting Plasma Glucose (FPG)|NMR Lipid subfractions and lipoprotein-IR score|Hemoglobin A1C (HbA1C)|Fructosamine|High sensitivity c-reactive protein (hs-CRP)|Niacin-related flushing|Homeostasis model assessment of insulin resistance (HOMA-IR) score|High-density lipoprotein cholesterol (HDL-C)|Non-high-density lipoprotein cholesterol (non-HDL-C)|Total Cholesterol (TC)|Triglycerides (TG)|Fasting Insulin","Radiant Research","All","18 Years and older   (Adult, Older Adult)","Phase 4","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Welchol-Niaspan 001","November 2010","August 2011","August 2011","November 11, 2010",,"January 6, 2012","Radiant Research, Chicago, Illinois, United States|Kansas City, Kansas, United States|Minneapolis, Minnesota, United States|St Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01239004"
474,"NCT01489319","Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)","ELI-ROAS","Terminated","No Results Available","Polycystic Ovary Syndrome","Drug: Salsalate","White blood cell nuclear factor kappa B (NFkappaB) activation in response to oral lipid ingestion and ovarian androgen secretion in response to human chorionic gonadotropin (HCG) stimulation.|White blood cell NFkappaB activation following oral lipid ingestion in response to 12 weeks of salsalate or PCE administration.|Ovarian androgen secretion following HCG administration in response to 12 weeks of salsalate or PCE administration.|Body composition status measured by DEXA in response to 12 weeks of salsalate or PCE administration.|Insulin sensitivity derived from an OGTT in response to 12 weeks of salsalate or PCE administration.|Ovulation rates documented by serum progesterone in response to 12 weeks of salsalate or PCE administration","Indiana University","Female","18 Years to 40 Years   (Adult)","Phase 1","47","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IU-PCOS-0112","February 2012","June 2015","June 2015","December 9, 2011",,"February 10, 2017","Indiana University Hospital, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01489319"
475,"NCT01426529","Caveolin-1 and Vascular Dysfunction",,"Active, not recruiting","No Results Available","Hypertension|Insulin Resistance","Drug: Para-aminohippuric Acid|Drug: Angiotensin II|Drug: Norepinephrine","Genetic Variation at the Caveolin-1 Locus","Brigham and Women's Hospital|National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health (NIH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","120","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2010P002187|1R01HL104032-01","October 1, 2010","October 15, 2017","October 15, 2019","August 31, 2011",,"July 17, 2018","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01426529"
476,"NCT02450773","Prevention of Severe Postpartum Hypertension",,"Active, not recruiting","No Results Available","Hypertension","Drug: Furosemide|Drug: Potassium chloride|Drug: Placebo #1|Drug: Placebo #2","Composite maternal morbidity|Adverse events associated with furosemide","Indiana University","Female","Child, Adult, Older Adult","Phase 2","248","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","201501157","August 2015","May 2022","May 2022","May 21, 2015",,"March 6, 2020","Indiana University School of Medicine, Indianapolis, Indiana, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02450773"
477,"NCT04055168","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects",,"Recruiting","No Results Available","Dyslipidemia","Drug: AZD6615|Drug: Placebo","Number of subjects with adverse events (AEs) and serious adverse events (SAEs)|Number of subjects with abnormal findings in systolic and diastolic blood pressure (BP)|Number of subjects with abnormal findings in pulse rate|Number of subjects with abnormal findings in body temperature|Number of subjects with abnormal findings in resting 12-lead electrocardiogram (ECG)|Number of subjects with abnormal findings in telemetry|Number of subjects with abnormal findings in physical examination|Number of subjects with abnormal findings in hematology - Blood cells count|Number of subjects with abnormal findings in hematology - Hemoglobin (Hb)|Number of subjects with abnormal findings in hematology - Hematocrit (HCT)|Number of subjects with abnormal findings in hematology - Mean corpuscular volume (MCV)|Number of subjects with abnormal findings in hematology - Mean corpuscular hemoglobin (MCH)|Number of subjects with abnormal findings in hematology - Mean corpuscular hemoglobin concentration (MCHC)|Number of subjects with abnormal findings in hematology - Differential count|Number of subjects with abnormal findings in hematology - Platelets|Number of subjects with abnormal findings in serum clinical chemistry - Electrolytes|Number of subjects with abnormal findings in serum clinical chemistry - Blood urea nitrogen|Number of subjects with abnormal findings in serum clinical chemistry - Creatinine|Number of subjects with abnormal findings in serum clinical chemistry - Glucose (fasting)|Number of subjects with abnormal findings in serum clinical chemistry - Total Bilirubin|Number of subjects with abnormal findings in serum clinical chemistry - Cell enzymes|Number of subjects with abnormal findings in serum clinical chemistry - Creatine kinase|Number of subjects with abnormal findings in serum clinical chemistry - Liver enzymes|Number of subjects with abnormal findings in serum clinical chemistry - Bicarbonate|Number of subjects with abnormal findings in serum clinical chemistry - Uric acid|Number of subjects with abnormal findings in bile acid (serum and urine)|Number of subjects with abnormal findings in serum clinical chemistry - Direct bilirubin|Number of subjects with abnormal findings in coagulation - Partial thrombin time and prothrombin time|Number of subjects with abnormal findings in coagulation - International normalized ratio|Number of subjects with abnormal findings in lipid panel|Number of subjects with abnormal findings in clinical urinalysis - Protein|Number of subjects with abnormal findings in clinical urinalysis - Glucose|Number of subjects with abnormal findings in clinical urinalysis - Blood|Number of subjects with abnormal findings in clinical urinalysis - Creatinine|Number of subjects with abnormal findings in renal safety biomarkers - Serum Creatinine|Number of subjects with abnormal findings in renal safety biomarkers - Urine protein|Number of subjects with abnormal findings in renal safety biomarkers - Estimated glomerular filtration rate (eGFR)|Number of subjects with abnormal findings in renal safety biomarkers - Urine Kidney Injury Molecule1 (KIM1)|Number of subjects with abnormal findings in renal safety biomarkers - Urine Neutrophil gelatinase-associated lipocalin (NGAL)|Number of subjects with abnormal findings in renal safety biomarkers - Urine Clusterin|Number of subjects with abnormal findings in renal safety biomarkers - Urine N-acetyl-beta-D-glucosaminidase (NAG)|Number of subjects with abnormal findings in renal safety biomarkers - Urine Cystatin-C|Number of subjects with abnormal findings in renal safety biomarkers - Urine Osteopontin|Number of subjects with abnormal findings in complement activation panel|Number of subjects with abnormal findings in immune activation response: High Sensitivity - C-reactive protein (hs-CRP)|Plasma PK analysis: Maximum observed concentration (Cmax)|Plasma PK analysis: Time to reach maximum observed concentration (tmax)|Plasma PK analysis: Terminal half-life (t½λz)|Plama PK analysis: Terminal elimination rate constant (λz)|Plasma PK analysis: Area under the plasma concentration-curve from time zero to the time of last quantifiable analyte concentration (AUClast)|Plasma PK analysis: Area under the plasma concentration-time curve from time zero to 24 hours after dosing (AUC0-24)|Plasma PK analysis: Area under the concentration-time curve from time zero extrapolated to infinity (AUC)|Plasma PK analysis: Apparent volume of distribution (Vz/F)|Plasma PK analysis: Apparent total body clearance (CL/F)|Plasma PK analysis: Area under the plasma concentration-time curve from time zero extrapolated to infinity divided by the dose administered (AUC/D)|Plasma PK analysis: Area under the plasma concentration-time curve from time zero to 24 hours after dosing divided by the dose administered (AUC0-24/D)|Plasma PK analysis: Area under the plasma concentration-time curve from time zero to time of last quantifiable analyte concentration divided by the dose administered (AUClast/D)|Plama PK analysis: Mean Residence Time from time 0 to infinity (MRT)|Plasma PK analysis: Observed maximum concentration divided by the dose administered (Cmax/D)|PD analysis: Levels of dyslipidemia related biomarkers","AstraZeneca|Parexel","All","20 Years to 60 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","D7991C00001","July 24, 2019","August 6, 2021","August 6, 2021","August 13, 2019",,"April 7, 2020","Research Site, Glendale, California, United States|Research Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04055168"
478,"NCT02087917","A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia",,"Completed","No Results Available","Primary Hypercholesterolemia","Drug: HS-25|Drug: Placebo","Percent change from baseline in LDL-C after 4 weeks of double-blind treatment|Percentage of participants with reported adverse events during a 4-week period of treatment as a measure of safety and tolerability of HS-25|Percent change from baseline in LDL-C after a 1 and 2-week period of double-blind treatment|Percent change from baseline in apoprotein B, non-high density lipoprotein-cholesterol, total cholesterol, triglycerides, high density lipoprotein-cholesterol and apoprotein A1 levels after a 1, 2 and 4-week period of treatment|Mean concentration of HS-25 dose and its major metabolite (HS-25-M1) during treatment with HS-25 5, 10, 20 or 30 mg.|Correlation between trough HS-25 and HS-25-M1 levels and percent change in LDL-C, apoA1, apoB, non-HDL-C, TC, TG, and HDL-C during a 4-week period of HS-25 treatment.","Zhejiang Hisun Pharmaceutical Co. Ltd.|Covance","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","376","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HS-25-III","March 2014","September 2014","December 2014","March 14, 2014",,"January 6, 2015","Chandler, Arizona, United States|Phoenix, Arizona, United States|West Hills, California, United States|Doral, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|South Miami, Florida, United States|Chicago, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Overland Park, Kansas, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Bethesda, Maryland, United States|Methuen, Massachusetts, United States|Trenton, New Jersey, United States|Rochester, New York, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Tulsa, Oklahoma, United States|Penndel, Pennsylvania, United States|Greensboro, South Carolina, United States|Dallas, Texas, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02087917"
479,"NCT04051957","Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury",,"Recruiting","No Results Available","Kidney Injury|Proteinuria|Hypertension","Drug: Isosorbide Mononitrate|Drug: Placebo oral tablet","Number of participants with a reduction in Urine Protein Creatinine ratio (UPC )of > 500 mg/day from that measured before enrollment|Number of participants with a reduction in UPC of > 500 mg/day from that measured before enrollment|Number of participants with improvement in estimated Glomerular Filtration Rate (eGFR)≥25% from before enrollment|Number of participants with reduction in systolic blood pressure (SBP) of ≥ 10 mm Hg and/or diastolic blood pressure (DBP) ≥ 5 mm Hg from before enrollment","The University of Texas Health Science Center, Houston|National Kidney Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HSC-MS-19-0429","September 26, 2019","March 31, 2020","June 30, 2020","August 9, 2019",,"September 26, 2019","The University Of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04051957"
480,"NCT01539473","A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge",,"Completed","No Results Available","Healthy Volunteers","Drug: TR-701 FA with Tyramine|Drug: Placebo-controlled withTyramine","Systolic Blood Pressure","Trius Therapeutics LLC","All","18 Years to 45 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)","1986-032|TR701-105","February 2012","May 2012","May 2012","February 27, 2012",,"May 3, 2016","Trius Investigator Site 001, Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01539473"
481,"NCT02448446","The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates",,"Completed","No Results Available","Diabetic Macular Edema|Hard Lipid Exudates","Drug: ranibizumab 0.3mg","Best Corrected Visual Acuity as measured by ETDRS at 6 and 12 months|Percentage of patients with improvement of lipid deposits in the central subfield as measured on OCT and fundus photography|Percentage of patients with complete resolution of lipid deposits in the central subfield as measured on OCT and fundus photography|Time to complete resolution of lipid deposits in the central subfield as measured on OCT and fundus photography|Percentage of patients with improvement in lipid deposits throughout the macular grid as measured by OCT and fundus photography|Percentage of patients with complete resolution of lipid deposits throughout the macular grid as measured on OCT and fundus photography|Time to complete resolution of lipid deposits throughout the macular grid as measured by OCT and fundus photography|Incidence and severity of ocular adverse events as a measure of safety and tolerability|Incidence and severity of other adverse events as a measure of safety and tolerability","South Coast Retina Center; Carson, McBeath, Boswell, Inc.|Genentech, Inc.|Doheny Image Reading Center|Retina Partners","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML259577","August 2015","May 2018","May 2018","May 19, 2015",,"September 27, 2019","South Coast Retina Center; Carson, McBeath, Boswell, Inc, Huntington Beach, California, United States|South Coast Retina Center; Carson, McBeath, and Boswell, Inc, Long Beach, California, United States|Retina Partners, Santa Monica, California, United States|South Coast Retina Center; Carson, McBeath, Boswell, Inc, Torrance, California, United States",,"https://ClinicalTrials.gov/show/NCT02448446"
482,"NCT02512718","Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation",,"Recruiting","No Results Available","Hematopoietic Stem Cell Transplantation","Drug: Omegaven|Drug: Soybean oil lipid emulsion","Incidence of adverse events|Essential fatty acid levels|Triglyceride levels","Alexandra N. Carey|Boston Children’s Hospital","All","6 Years to 18 Years   (Child, Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","P00016641","June 2016","March 2021","June 2021","July 31, 2015",,"May 22, 2019","Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02512718"
483,"NCT03351998","Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity",,"Recruiting","No Results Available","Mitochondrial Diseases","Drug: Lipitor 20Mg Tablet|Drug: Lipitor 80Mg Tablet|Drug: Placebo Oral Tablet","Difference in mitochondrial respiratory function|VO2 max|Insulin sensitivity|Citrate synthase activity","University of Kansas Medical Center|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","All","35 Years to 65 Years   (Adult, Older Adult)","Phase 4","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","STUDY00140789|R01AR071263","February 22, 2018","July 1, 2022","July 1, 2022","November 24, 2017",,"November 6, 2019","University of Kansas Medical Center, Kansas City, Kansas, United States|East Carolina University, Greenville, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03351998"
484,"NCT04149899","Safety and IOP-Lowering Effects of WB007",,"Recruiting","No Results Available","Glaucoma, Primary Open Angle|Ocular Hypertension","Drug: Study Treatment 1 WB007|Drug: Study Treatment 2 WB007|Drug: Study Treatment 3 WB007|Drug: Timolol 0.5%","Mean change from Baseline in intraocular pressure (IOP) at Day 14|Mean IOP at Day 14","Whitecap Biosciences, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WB007-001","November 2019","June 2020","December 2020","November 4, 2019",,"November 4, 2019","Eye Research Foundation, Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT04149899"
485,"NCT02471183","Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension","TRANSIT-1","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Selexipag","Percentage of Subjects With Sustained Treatment Transition|Percentage of Subjects With Treatment-emergent Adverse Events (AEs),|Number of Subjects With Adverse Events Leading to Premature Discontinuation of Selexipag|Absolute Change From Baseline Over Time in Blood Pressure|Absolute Change From Baseline Over Time in Heart Rate (HR)|Maximal Tolerated Dose|Time to Discontinuation of Inhaled Treprostinil.|Percentage of Subjects With WHO Functional Class (FC) Change From Baseline|Absolute Change in 6-minute Walk Distance (6MWD) at Trough|Percentage of Patients With Change in 6-minute Walk Distance (6MWD)|Geometric Mean of the Ratio in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) of Week 16 to Baseline","Actelion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","34","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-065A304","October 12, 2015","December 5, 2016","December 5, 2016","June 15, 2015","December 28, 2017","January 23, 2018","UCSD Medical Center -La Jolla, La Jolla, California, United States|UCSF Medical Center, San Francisco, California, United States|Harbor UCLA Medical Center, Torrance, California, United States|Emory University, Atlanta, Georgia, United States|Piedmont Healthcare Research Institute, Austell, Georgia, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Duke Unversity, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|UT Southwestern, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Sentara Cardiovascular Research Instistute, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02471183"
486,"NCT02097719","Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: bimatoprost 0.01%|Drug: travoprost 0.004%|Drug: timolol 0.5%|Drug: hypromellose 0.3%","Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","GMA-LUM-12-022","May 2014","December 2014","December 2014","March 27, 2014","January 14, 2016","January 14, 2016","Racine, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02097719"
487,"NCT01441908","Longitudinal Study of Multi-Analyte Profile for Dyslipidemia",,"Unknown status","No Results Available","Dyslipidemia","Drug: Pravastatin","Comparison of 29 specific cardiovascular related lab assays from baseline through a period of 6 months in a control population with dyslipidemia vs a study group with dyslipidemia receiving an FDA approved Statin (Pravastatin).|Limited time-course of different stages of disease regression","MaiHealth Inc","All","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","MAI-001|6R44HL082382-0|6R44HL082382","June 2011","April 2012","April 2012","September 28, 2011",,"April 16, 2012","Wake Research Associates, Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01441908"
488,"NCT02989025","Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia","PROGRESS","Recruiting","No Results Available","Pregnancy","Drug: 17 OHPC","Improvement of maternal and perinatal outcomes|Change is being assessed in Maternal Outcomes","Babbette Lamarca|University of Mississippi Medical Center","Female","18 Years to 45 Years   (Adult)","Phase 3","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0029","May 22, 2017","January 31, 2020","January 31, 2020","December 12, 2016",,"May 6, 2019","Winfred L. Wiser Hospital, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT02989025"
489,"NCT01319916","Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue",,"Completed","No Results Available","Healthy","Drug: ATX-101","Effects of ATX-101 on serum lipid and deoxycholate|Adipokine levels following subcutaneous administration of ATX-101","Kythera Biopharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATX-101-10-18","December 2010","January 2011","January 2011","March 22, 2011",,"March 22, 2011","Robert Cooper, M.D. Cetero Research, Fargo, North Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01319916"
490,"NCT02168803","A Study of Evacetrapib in Participants With Abnormal Cholesterol",,"Completed","Has Results","Dyslipidemia","Drug: Evacetrapib","Pharmacokinetics (PK) Parameters of Evacetrapib: Area Under the Concentration Versus Time Curve From Time Zero to the Last Time Point With a Measurable Concentration (AUC[0-tlast])|PK Parameters of Evacetrapib: Maximum Concentration (Cmax)|PK Parameters of Evacetrapib: Terminal Half-life|PD Parameters of Evacetrapib: High Density Lipoprotein Cholesterol (HDL-C) Level|PD Parameters of Evacetrapib: Low-Density Lipoprotein Cholesterol (LDL-C) Level|PD Parameters of Evacetrapib: Total Cholesterol Level|PD Parameters of Evacetrapib: Triglyceride Level","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 1","101","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","15340|I1V-MC-EIBM","May 2014","December 2015","December 2015","June 20, 2014","October 3, 2018","October 3, 2018","Covance Clinical Research Inc, Daytona Beach, Florida, United States|Covance, Dallas, Texas, United States|Covance Clinical Research Inc, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02168803"
491,"NCT02665117","Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate",,"Recruiting","No Results Available","Hypertension","Drug: Potassium Magnesium Citrate (KMgCit)|Drug: Potassium Chloride (KCl)|Drug: Chlorthalidone","Change in fasting plasma glucose|Hepatic fat|Muscle magnesium content|Serum Aldosterone|FGF23|Urinary Isoprostanes","University of Texas Southwestern Medical Center","All","21 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","STU 092015-058","January 2015","January 2023","January 2023","January 27, 2016",,"March 11, 2020","University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02665117"
492,"NCT02730871","Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®",,"Terminated","Has Results","Open-angle Glaucoma|Ocular Hypertension","Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|Drug: Brinzolamide/brimonidine vehicle|Drug: Travoprost 0.004%/timolol 0.5% solution","Mean Change From Baseline in Diurnal Intraocular Pressure (IOP) (Mean of Changes at 09:00 and 11:00 Time Points) at Week 6|Mean Diurnal IOP at Week 6|Mean Percentage Change From Baseline in Diurnal IOP at Week 6|Mean Change From Baseline in IOP (09:00, 11:00) at Week 6|Mean Percentage Change From Baseline in IOP (09:00, 11:00) at Week 6","Alcon Research","All","18 Years and older   (Adult, Older Adult)","Phase 4","173","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GLJ576-P001|2016-000176-20","June 24, 2016","July 13, 2018","July 13, 2018","April 7, 2016","May 17, 2019","May 29, 2019","Contact Alcon for Locations (Europe, Asia, and Latin America), Fort Worth, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02730871/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02730871/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02730871"
493,"NCT01656382","Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex",,"Completed","No Results Available","Invasive Cryptococcosis","Drug: ABLC","Survival|Time to Sterilization of CSF|Infusion related and renal toxicity","Medstar Health Research Institute|Enzon Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","18","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-273","January 2007","January 2010","January 2010","August 3, 2012",,"August 3, 2012","Washington Hospital Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT01656382"
494,"NCT03726398","CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH","CRUSADE","Recruiting","No Results Available","Interstitial Lung Disease|Scleroderma|Pulmonary Hypertension","Drug: Opsumit 10 Mg Tablet","Change in exercise pulmonary vascular resistance (PVR)|Change in right ventricular pulmonary vascular hemodynamic coupling (RVPA).|Change in maximal oxygen consumption (V02 max).|Change in pulmonary impedance.","Franz Rischard, DO|National Jewish Health|University of Pittsburgh|University of Arizona","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IIS-02801","September 1, 2018","January 31, 2020","December 1, 2020","October 31, 2018",,"April 2, 2019","University of Arizona, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03726398"
495,"NCT03198793","Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins","NEW-HOPE","Completed","No Results Available","Hypertension","Drug: QGC001","Change in office systolic blood pressure from baseline to Week 8 (Day 56 Visit)|Change in office diastolic blood pressure from baseline to Week 8 (Day 56 Visit)|Change in office systolic blood pressure and diastolic blood pressure from baseline to Week 4 (Day 28 Visit)|Change in mean 24-hour ambulatory systolic blood pressure, diastolic blood pressure, and mean office blood pressure from baseline to Week 8 (Day 56 Visit)|Percentage of responders (defined as subjects with normalized office blood pressure, ie, less than or equal to 140-90 mmHg at Week 8 - Day 56 Visit)|Predictive factors for responders at Week 8 (Day 56 Visit)","Quantum Genomics SA","All","18 Years and older   (Adult, Older Adult)","Phase 2","256","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QGC001-2QG3","October 13, 2017","October 16, 2018","November 12, 2018","June 26, 2017",,"December 11, 2018","Progressive Medical Research, Port Orange, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03198793"
496,"NCT03651089","SP16 SERPIN-like Peptide Administration in Healthy Individuals",,"Active, not recruiting","No Results Available","Healthy Participants","Drug: SP16|Drug: Placebos","Preliminary Safety Assessment: Occurence of adverse events|Volume of distribution of SP16 in healthy subjects|Clearance of SP16 in healthy subjects","Serpin Pharma, LLC|George Mason University|Virginia Commonwealth University","All","18 Years to 59 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","01-SP16","July 16, 2018","February 2, 2019","August 1, 2019","August 29, 2018",,"January 15, 2019","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03651089"
497,"NCT01315574","Effects of Anti-Glaucoma Medications on the Ocular Surface","BAK","Terminated","Has Results","Glaucoma","Drug: Travoprost|Drug: Latanoprost","Effectiveness in Lowering Intraocular Pressure|Corneal Fluorescein Staining Score|Tear Film Break-Up Time","Massachusetts Eye and Ear Infirmary|Alcon Research","All","18 Years and older   (Adult, Older Adult)","Phase 4","14","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11-007H","February 2011","December 2013","December 2013","March 15, 2011","February 3, 2017","March 16, 2017","Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01315574"
498,"NCT03961360","Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida","ASPREO","Recruiting","No Results Available","Pre-Eclampsia|Hypertension in Pregnancy|Obesity","Drug: Aspirin 81 mg|Drug: Aspirin 162 mg","Preeclampsia diagnosis|Maternal Outcomes-Incidence of preterm preeclampsia|Maternal Outcomes-Gestational Hypertension|Maternal Outcomes-Placenta Abruption|Maternal Outcomes-Eclampsia|Maternal Outcomes-HELLP syndrome|Maternal Outcomes-Postpartum Hemorrhage|Maternal Outcomes-Other maternal bleeding|Maternal Outcomes-Need for blood transfusion|Neonatal Outcomes- Gestational age at delivery|Neonatal Outcomes-Delivery at < 37 weeks|Neonatal Outcomes-Apgar score at 5 min ≤ 5|Neonatal Outcomes-Small for gestational age|Neonatal Outcomes-Neonatal Intensive Care Unit (NICU) length of stay|Neonatal Outcomes-Intraventricular Hemorrhage Grade III-IV|Neonatal Outcomes-Bronchopulmonary Dysplasia|Neonatal Outcomes-Necrotizing Enterocolitis","The University of Texas Health Science Center, Houston","Female","18 Years to 45 Years   (Adult)","Phase 2|Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-18-1073","May 6, 2019","May 1, 2020","May 1, 2020","May 23, 2019",,"May 23, 2019","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03961360"
499,"NCT01842399","Resveratrol and Cardiovascular Health in the Elderly",,"Recruiting","No Results Available","Vascular Resistance|Hypertension","Dietary Supplement: Resveratrol|Drug: Placebo","To determine if oral resveratrol administered for 12 months will blunt the aging associated increase in vascular stiffness as measured by Pulse Wave Velocity (PWV).","National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC)","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","300","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","130078|13-AG-0078","February 9, 2013","September 1, 2021","September 1, 2021","April 29, 2013",,"March 23, 2020","National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01842399"
500,"NCT03602781","Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric",,"Withdrawn","No Results Available","Pulmonary Arterial Hypertension","Drug: Placebo|Drug: iNO","Time to clinical worsening during iNO withdrawal for up to 8 weeks|Difference in clinical worsening events that occur during iNO withdrawal for up to 8 weeks between those treated with iNO ≥ 10 months prior to the start of withdrawal of iNO vs. those treated < 10 months prior to initiation of withdrawal to iNO.","Bellerophon Pulse Technologies|Worldwide Clinical Trials|Bellerophon","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PULSE-PAH-007","August 2018","June 2019","June 2020","July 27, 2018",,"August 10, 2018","Bluhm Cardiovascular Institute, Clinical Trials Unit, Chicago, Illinois, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Peter Lougheed Centre, Calgary, Alberta, Canada|Toronto General Hospital, University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03602781"
501,"NCT01951950","Nicardipine vs Esmolol Craniotomy Emergence",,"Completed","Has Results","Brain Tumors","Drug: Nicardipine|Drug: Esmolol","Failure of Drug to Control Systolic Blood Pressure (SBP) < 140 mmHg","Northwestern University","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU00083793","September 2013","May 2014","May 2014","September 27, 2013","August 29, 2014","August 29, 2014","Northwestern Memorial Hospital, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01951950"
502,"NCT03067441","Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)",,"Completed","No Results Available","Hypercholesterolemia|Atherosclerotic Cardiovascular Disease","Drug: bempedoic acid","Number of participants with treatment-related adverse events as assessed by MedDRA 18.1|Percent change in Low-Density Lipoprotein Cholesterol (LDL-C)|Change in Low-Density Lipoprotein Cholesterol (LDL-C)|Percent change in non-High-Density Lipoprotein Cholesterol (non-HDL-C)|Percent change in Total Cholesterol|Percent change in Apolipoprotein B (ApoB)|Percent change in High-Sensitivity C-Reactive Protein (hs-CRP)|Percent change in Trigycerides|Percent change in High-Density Lipoprotein Cholesterol (HDL-C)","Esperion Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","1452","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1002-050|2016-004115-12","February 3, 2017","November 5, 2019","November 5, 2019","March 1, 2017",,"April 6, 2020","Jedidiah Clinical Research, Tampa, Florida, United States|L-MARC Research Center, Louisville, Kentucky, United States|Sentral Clinical Research Services, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03067441"
503,"NCT01117987","Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)","IMPRES Extn","Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: Imatinib|Drug: Placebo","Number of Participants With Adverse Events, Serious Adverse Events and Deaths|Change From Core Study Baseline in Six-Minute Walk Distance (6MWD)|Percentage of Participants With Incidence of Clinical Worsening Events","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","144","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CQTI571A2301E1|2009-018167-26","April 2010","April 2014","April 2014","May 6, 2010","May 21, 2015","August 13, 2015","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Weston, Florida, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Rochester, Minnesota, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Mineola, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Tualatin, Oregon, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Milwaulkee, Wisconsin, United States|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Clamart Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Köln, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Regensburg, Germany|Novartis Investigative Site, Würzburg, Germany|Novartis Investigative Site, Pavia, (pv), Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, Okayama-city, Okayama, Japan|Novartis Investigative Site, Hamamatsu, Shizuoka, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Mitaka-city, Tokyo, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Santander, Cantabria, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, St. Gallen, Switzerland|Novartis Investigative Site, Cambridge, Cambridgeshire, United Kingdom|Novartis Investigative Site, Newcastle Upon Tyne, Newcastle, United Kingdom|Novartis Investigative Site, Sheffield, South Yorkshire, United Kingdom|Novartis Investigative Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01117987"
504,"NCT04164888","Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy",,"Active, not recruiting","No Results Available","Hypercholesterolemia","Drug: CIVI 007","Assessment of CIVI 007 adverse events|Assessment of CIVI 007 safety laboratory abnormalities|Assessment of the pharmacodynamic effect of CIVI 007|Assessment of the pharmacodynamic (PD) effect of CIVI 007|Assessment of the lipid efficacy of CIVI 007","Civi Biopharma, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CIVI 007-02-01","November 11, 2019","June 30, 2020","September 30, 2020","November 15, 2019",,"January 22, 2020","Research Site, Jacksonville, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Munroe Falls, Ohio, United States|Research Site, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04164888"
505,"NCT03323164","Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study",,"Active, not recruiting","No Results Available","Glaucoma; Drugs|Normal Tension Glaucoma|Primary Open-angle Glaucoma","Drug: Timolol Maleate|Drug: Brimonidine Tartrate","Changes in peripapillary blood flow assessed by OCT angiography","Wills Eye|Optovue","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","31","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","17-636E","July 10, 2017","December 31, 2018","May 30, 2020","October 26, 2017",,"July 26, 2019","Glaucoma Research Center - Wills Eye Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03323164"
506,"NCT03370848","Effects of Psyllium on Niacin Tolerability",,"Completed","No Results Available","Flushing|Hyperlipidemias|Dyslipidemias","Dietary Supplement: Psyllium|Drug: Aspirin","Global Flushing Severity Score|HDL|LDL","VA Greater Los Angeles Healthcare System","All","18 Years and older   (Adult, Older Adult)","Phase 4","26","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","039","March 2009","July 2011","July 2011","December 12, 2017",,"December 12, 2017","VA West Los Angeles Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03370848"
507,"NCT02829996","Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG",,"Completed","Has Results","Primary Open-Angle Glaucoma (POAG)|Ocular Hypertension (OHT)","Drug: trabodenoson 6.0% / latanoprost 0.005% QD|Drug: trabodenoson 3.0% / latanoprost 0.005% QD|Drug: trabodenoson 6.0% / latanoprost 0.0025% QD|Drug: latanoprost 0.005% QD|Drug: latanoprost 0.0025% QD","Mean Intraocular Pressure (IOP)","Inotek Pharmaceuticals Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","201","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IPC-02-2015","August 19, 2016","May 24, 2017","May 31, 2017","July 12, 2016","February 15, 2018","February 15, 2018","Inotek Pharmaceuticals Corporation, Lexington, Massachusetts, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02829996/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02829996/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02829996"
508,"NCT03686657","Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients","RESILIENCE","Not yet recruiting","No Results Available","Type 2 Diabetes|High Blood Pressure|Arthritis|Obesity","Drug: Metformin|Drug: Val, Cel and Met XR Low|Drug: Val, Cel and Met XR High","Change in glycosylated Hemoglobin (HbA1c) for metformin background patients|Change in glycosylated Hemoglobin (HbA1c) for treatment naive patients|Change from baseline in acute insulin response to glucose (AIRg) for metformin background patients|Change from baseline in acute insulin response to glucose (AIRg) for treatment naive patients|Change in glycosylated Hemoglobin (HbA1c) to <7.0%|Change from baseline in Body weight|Change from baseline in fasting plasma glucose|Change from baseline in Beta-cell function Index|Change from baseline in insulin sensitivity index (ISI or Si)|Change from baseline in glycosylated albumin (GA): glycosylated Hemoglobin A1c (HbA1c) ratio|Change from baseline in HOMA2-b%|Change from baseline in HOMA-IR|Leptin/Adiponectin ratio|Change from baseline in Atherogenic Index (AI)|Change from baseline in glycosylated albumin (GA)|Change from baseline in Leptin|Change from baseline in Adiponectin","ARKAY Therapeutics|Albany Medical College","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","115","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","RK-01 Prototype","August 5, 2020","November 30, 2021","January 31, 2022","September 27, 2018",,"October 9, 2019","Albany Medical College, Albany, New York, United States",,"https://ClinicalTrials.gov/show/NCT03686657"
509,"NCT02236520","Tissue Sodium in Pre-hypertensive Patients",,"Completed","Has Results","Hypertension","Drug: Spironolactone|Drug: Chlorthalidone|Dietary Supplement: Diet|Drug: Placebo","Change in Tissue Sodium Concentration Measured Using Sodium Magnetic Resonance Imaging (NaMRI)","Vanderbilt University|American Heart Association|Vanderbilt University Medical Center","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","71","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","141382","September 2014","May 1, 2018","May 1, 2018","September 10, 2014","May 22, 2019","May 22, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02236520/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02236520"
510,"NCT02374047","A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects",,"Completed","No Results Available","Hypercholesterolemia","Drug: CAT-2054|Drug: Placebo|Drug: CAT-2054-C|Drug: Atorvastatin","Frequency and severity of adverse events|AUCinf of CAT-2054|Cmax of CAT-2054|Changes from baseline for hematology, chemistry, coagulation and urinalysis|Assess the pharmacodynamic effects of multiple doses of CAT-2054 on serum lipids LDL-C, non-HDL-C, total cholesterol, triglycerides, HDL-C, apoB, and PCSK9.|AUC48 of Atorvastatin","Catabasis Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","118","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","CAT-2054-101","January 2015","July 2015","July 2015","February 27, 2015",,"March 22, 2016","Spaulding Clinical Research, West Bend, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02374047"
511,"NCT02531152","28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Open Angle Glaucoma -Ocular Hypertension","Drug: Latanoprost|Drug: SAR366234","Number of adverse events (including local tolerance and ophthalmological examinations)|Assessment of IOP using Goldman applanation tonometry","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","TDR13459|U1111-1153-3544","September 2015","April 2016","April 2016","August 24, 2015",,"April 27, 2016","Investigational Site Number 840001, Inglewood, California, United States|Investigational Site Number 840003, Cape Coral, Florida, United States|Investigational Site Number 840005, Roswell, Georgia, United States|Investigational Site Number 840004, St Joseph, Michigan, United States|Investigational Site Number 840002, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02531152"
512,"NCT02747602","Evaluation of PK of AC1204 v Caprylic Triglyceride Oil Incl Food Effect on Ketone Body Production",,"Completed","No Results Available","Healthy","Drug: AC-1204|Drug: caprylic triglyceride oil (standard breakfast)|Drug: caprylic triglyceride oil (high fat breakfast)","total ketones AUC0-t|total ketones AUC0-inf|total ketones AUC%extap|total ketones Cmax|total ketones Kel|total ketones T 1/2|total ketones Tmax|β-hydroxybutyrate AUC0-t|β-hydroxybutyrate AUC0-inf|β-hydroxybutyrate AUC%extap|β-hydroxybutyrate Cmax|β-hydroxybutyrate Tmax|β-hydroxybutyrate Kel|β-hydroxybutyrate T 1/2","Cerecin|Celerion","Male","18 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","AC-16-011_BE","April 2016","May 2016","October 2016","April 22, 2016",,"October 28, 2016","Celerion, Inc, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02747602"
513,"NCT02360826","Statin Distribution",,"Completed","No Results Available","Drug Distribution","Drug: Pravastatin|Drug: Simvastatin","Evaluate effect of genotype (SLCO1B1) on Cmax pravastatin|Evaluate effect of genotype (SLCO1B1) on AUC pravastatin|Evaluate effect of genotype (SLCO1B1) on Cmax Simvastatin|Evaluate effect of genotype on AUC Simvastatin|Evalaute the effect of age on Cmax of pravastatin|Evalaute the effect of gender on Cmax of pravastatin|Evalaute the effect of race Cmax of pravastatin|Evaluate the effect of sexual maturity on Cmax of pravastatin based|Evaluate the effect of age on Cmax of simvastatin|Evaluate the effect of gender on Cmax of simvastatin|Evaluate the effect of race on Cmax of simvastatin|Evaluate the effect of sexual maturity on Cmax of simvastatin|Evaluate the effect of age on AUC of pravastatin|Evaluate the effect of gender on AUC of pravastatin|Evaluate the effect of race on AUC of pravastatin|Evaluate the effect of sexual maturity on AUC of pravastatin|Evaluate the effect of age on AUC of simvastatin|Evaluate the effect of gender on AUC of simvastatin|Evaluate the effect of race on AUC of simvastatin|Evaluate the effect of sexual maturity on AUC of simvastatin|Evaluate the effect of age on Ka of pravastatin|Evaluate the effect of gender on Ka of pravastatin|Evaluate the effect of race on Ka of pravastatin|Evaluate the effect of sexual maturity on Ka of pravastatin|Evaluate the effect of age on Ka of simvastatin|Evaluate the effect of gender on Ka of simvastatin|Evaluate the effect of race on Ka of simvastatin|Evaluate the effect of sexual maturity on Ka of simvastatin","Children's Mercy Hospital Kansas City|American Heart Association","All","8 Years to 21 Years   (Child, Adult)","Phase 1","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13CRP1711002","June 17, 2014","July 5, 2016","July 5, 2016","February 11, 2015",,"July 19, 2017","Children's Mercy Hospital, Kansas City, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02360826"
514,"NCT01881971","Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center","SPARC","Completed","No Results Available","HIV Seropositivity","Drug: Placebo|Drug: Rouvastatin calcium","change in inflammatory markers - hsCRP|effect of rosuvastatin on pulmonary and cardiac status by use of cIMT/FMD/ Vascular studies are a measure of preclinical atherosclerosis and predicts future cardiovascular events and mortality","Alison Morris|University of Pittsburgh","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PRO12100503|RFA-HL-12-034","May 2013","November 2015","January 2016","June 20, 2013",,"August 14, 2019","University of California, Los Angelos, Los Angeles, California, United States|University of California, SF, San Francisco, California, United States|University of Pittsburgh department of medicine division of Pulmonary, Allergy and Critical Care medicine, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01881971"
515,"NCT00846872","Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance",,"Withdrawn","No Results Available","Insulin Resistance|Endothelial Dysfunction","Drug: GHRP-3 low dose|Drug: GHRP-3 high dose|Drug: Saline","Determine the relative effects of 0.1µg/kg/h and 0.5µg/kg/h GHRP-3 as compared to placebo in inducing physiological secretion of the GH-IGF-I system after continuous sc delivery in healthy older men and women with insulin resistance|Determine the relative interrelated effects of 0.1 and 0.5µg/kg/h GHRP-3 infusion and placebo on various hormonal and non hormonal aspects of insulin resistance.","Tulane University Health Sciences Center|Tulane University","All","45 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)","65-08","July 2008","March 2012","March 2012","February 19, 2009",,"December 5, 2016","Clinical and Translational Research center Tulane Hospital, New Orleans, Louisiana, United States|Clinical and Translational Research Center, University Hospital, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT00846872"
516,"NCT01336569","Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol",,"Completed","Has Results","Glaucoma","Drug: Travoprost 0.004%/timolol maleate 0.5% fixed combination","Mean Intraocular Pressure (IOP) Change at the Final Visit From Baseline (Prior Beta-blocker Monotherapy)","Alcon Research","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SMA-09-26","February 2011","March 2012","March 2012","April 18, 2011","July 8, 2013","July 8, 2013","Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01336569"
517,"NCT02023918","Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes","PEGIR","Completed","Has Results","Diabetes|Metabolic Syndrome|Insulin Resistance","Drug: pegvisomant","Insulin Sensitivity|Lipolysis","University of California, San Francisco|San Francisco General Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WI178028","January 2014","August 2015","December 2015","December 30, 2013","March 13, 2017","April 24, 2017","San Francisco General Hospital, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT02023918"
518,"NCT00852787","Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease",,"Unknown status","No Results Available","Hypertension|Hemodialysis","Drug: Digoxin immune fab|Drug: Placebo","Blood pressure|Marinobufagenin levels","National Institute on Aging (NIA)|University of Toledo Health Science Campus","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","30","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AG0115|263-MA-707136-1","April 2009","May 2012","May 2012","February 27, 2009",,"May 25, 2012","University of Toledo Medical Center, Toledo, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00852787"
519,"NCT01119417","The Role of Endothelin in the Supine Hypertension of Autonomic Failure",,"Suspended","No Results Available","Hypertension|Pure Autonomic Failure|Multiple System Atrophy","Drug: BQ123|Drug: Bq123|Drug: Saline","Change in Systolic BP|Change in cardiac output, stroke volume and systemic vascular resistance","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","091344","May 2010","December 2021","December 2021","May 7, 2010",,"April 10, 2020","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01119417"
520,"NCT03924154","A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)",,"Terminated","No Results Available","Pulmonary Arterial Hypertension","Drug: RVT-1201|Drug: Placebo","Adverse events (AEs) and discontinuations due to AEs|Concentration of biomarkers of serotonin biosynthesis in plasma|Concentration of biomarkers of serotonin biosynthesis in urine|Study drug (RVT-1201) and active metabolite (KAR5417) plasma concentrations|Area under the plasma concentration versus time curve (AUC) of KAR5417 (the active metabolite of RVT-1201)|Relationship between KAR5417 exposure and percent change from baseline in plasma concentrations of the serotonin-related biomarkers|Relationship between KAR5417 exposure and percent change from baseline in urine concentrations of the serotonin-related biomarkers","Altavant Sciences GmbH|Altavant Sciences, Inc.|PPD","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","3","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RVT-1201-2001","August 1, 2019","February 24, 2020","February 24, 2020","April 23, 2019",,"March 9, 2020","Pulmonary Associates, PA, Phoenix, Arizona, United States|University of California Davis Medical Center, Sacramento, California, United States|SBPA Research LLC, Santa Barbara, California, United States|University of Colorado, Aurora, Colorado, United States|George Washington Medical Faculty Associates - Pulmonary Hypertension Program, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|San Marcus Research Clinic, Inc., Miami Lakes, Florida, United States|Central Florida Pulmonary Group, P.A., Orlando, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Kentuckiana Pulmonary Research Center, Louisville, Kentucky, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Pulmonary Research Institute of Southeast Michigan, Farmington Hills, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, United States|University of Calgary, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|London Health Sciences Centre, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03924154"
521,"NCT00942994","Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension","ASCENT","Completed","Has Results","Hypertension","Drug: Aliskiren/Amlodipine|Drug: Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)","Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8|Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8|Percentage of Patients Achieving Blood Pressure Control (Defined as MSSBP < 140 mmHg and MSDBP < 90 mmHg) During 8 Weeks|Percentage of Responders (Defined as Patients With MSSBP < 140 mmHg or a Reduction From Baseline in MSSBP of ≥20 mmHg) During 8 Weeks.","Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 4","412","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CSPA100AUS02","June 2009","March 2010",,"July 21, 2009","April 27, 2011","June 8, 2011","K and S Research Services, Little Rock, Arkansas, United States|Well Pharma Medical Research, South Miami, Florida, United States|Hyde Park Health Associates, Mattapan, Massachusetts, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Scriber Kidney Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00942994"
522,"NCT03109795","Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System","ATLAS","Active, not recruiting","No Results Available","Anxiety|Hypertension","Drug: Clonidine Pill|Drug: Hydrochlorothiazide","Aortic stiffness","Seth Holwerda|University of Iowa","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","201701762","April 10, 2017","June 30, 2023","December 31, 2023","April 12, 2017",,"February 19, 2019","University of Iowa, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT03109795"
523,"NCT03187678","Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension",,"Completed","Has Results","Pulmonary Arterial Hypertension","Drug: i.v. selexipag|Drug: oral selexipag (Uptravi)","Number of Participants With at Least One Adverse Event (AE)|Number of Participants With Prostacyclin-associated Adverse Events|Number of Participants With Adverse Event Related to Injection Site Reactions|Number of Participants With Prostacyclin-associated AEs Leading to Study Treatment Discontinuation|Number of Participants With PAH-related Adverse Events","Actelion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-065A309|2016-004035-21","December 4, 2017","May 29, 2018","May 29, 2018","June 15, 2017","May 21, 2019","May 21, 2019","University of California San Diego Medical center - PULM VASCULAR DIV, La Jolla, California, United States|TUFTS New England Medical Center - PULM / CRITICAL CARE & SLEEP, Boston, Massachusetts, United States|Cleveland Clin Foundation - Dept of Pulm & Critical Care Med, Cleveland, Ohio, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Universitätsklinikum Giessen und Marburg GmbH, Medizinische Klinik und Poliklinik II, Pneumologie, Giessen, Germany|Universitätsmedizin Greifswald, Klinik und Poliklinik für Innere Medizin B, Greifswald, Germany|Universitätsklinikum Hamburg-Eppendorf, II. Medizinische Klinik und Poliklinik, Pneumologie, Hamburg, Germany|Universitätsklinikum Leipzig / Medizinischen Klinik und Poliklinik I, Pneumologie, Leipzig, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03187678/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03187678/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03187678"
524,"NCT01508026","Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension",,"Completed","No Results Available","Stage 1 Hypertension|Stage 2 Hypertension","Drug: Nebivolol and Valsartan 1|Drug: Nebivolol and Valsartan 2|Drug: Nebivolol and Valsartan 3|Drug: Nebivolol 1|Drug: Nebivolol 2|Drug: Valsartan 1|Drug: Valsartan 2|Drug: Placebo","Change in Sitting Diastolic Blood Pressure (DBP)|Change in Sitting Systolic Blood Pressure (SBP)","Forest Laboratories","All","18 Years and older   (Adult, Older Adult)","Phase 3","4161","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NAC-MD-01","January 2012","March 2013","May 2013","January 11, 2012",,"April 25, 2014","Forest Investigative Site 1750, Birmingham, Alabama, United States|Forest Investigative Site 1038, Birmingham, Alabama, United States|Forest Investigative Site 1308, Birmingham, Alabama, United States|Forest Investigative Site 1192, Birmingham, Alabama, United States|Forest Investigative Site 1005, Birmingham, Alabama, United States|Forest Investigative Site 1047, Foley, Alabama, United States|Forest Investigative Site 1717, Gulf Shores, Alabama, United States|Forest Investigative Site 1056, Mobile, Alabama, United States|Forest Investigative Site 1719, Muscle Shoals, Alabama, United States|Forest Investigative Site 1145, Glendale, Arizona, United States|Forest Investigative Site 1703, Goodyear, Arizona, United States|Forest Investigative Site 1757, Mesa, Arizona, United States|Forest Investigative Site 1170, Phoenix, Arizona, United States|Forest Investigative Site 1238, Phoenix, Arizona, United States|Forest Investigative Site 1204, Phoenix, Arizona, United States|Forest Investigative Site 1755, Phoenix, Arizona, United States|Forest Investigative Site 1259, Phoenix, Arizona, United States|Forest Investigative Site 1001, Phoenix, Arizona, United States|Forest Investigative Site 1078, Scottsdale, Arizona, United States|Forest Investigative Site 1225, Tempe, Arizona, United States|Forest Investigative Site 1712, Tempe, Arizona, United States|Forest Investigative Site 1089, Tempe, Arizona, United States|Forest Investigative Site 1065, Tucson, Arizona, United States|Forest Investigative Site 1340, Tucson, Arizona, United States|Forest Investigative Site 1331, Tucson, Arizona, United States|Forest Investigative Site 1290, Little Rock, Arkansas, United States|Forest Investigative Site 1138, Little Rock, Arkansas, United States|Forest Investigative Site 1371, Pine Bluff, Arkansas, United States|Forest Investigative Site 1220, Searcy, Arkansas, United States|Forest Investigative Site 1063, Buena Park, California, United States|Forest Investigative Site 1743, Burbank, California, United States|Forest Investigative Site 1006, Carmichael, California, United States|Forest Investigative Site 1384, Chino, California, United States|Forest Investigative Site 1190, Chula Vista, California, United States|Forest Investigative Site 1178, Costa Mesa, California, United States|Forest Investigative Site 1043, Diamond Bar, California, United States|Forest Investigative Site 1362, Encinitas, California, United States|Forest Investigative Site 1144, Fresno, California, United States|Forest Investigative Site 1095, Fresno, California, United States|Forest Investigative Site 1710, Garden Grove, California, United States|Forest Investigative Site 1022, Greenbrae, California, United States|Forest Investigative Site 1370, Huntington Beach, California, United States|Forest Investigative Site 1704, Huntington Park, California, United States|Forest Investigative Site 1725, Huntington Park, California, United States|Forest Investigative Site 1742, La Mesa, California, United States|Forest Investigative Site 1381, Lomita, California, United States|Forest Investigative Site 1706, Long Beach, California, United States|Forest Investigative Site 1248, Los Angelas, California, United States|Forest Investigative Site 1785, Los Angelas, California, United States|Forest Investigative Site 1029, Los Angeles, California, United States|Forest Investigative Site 1361, Los Angeles, California, United States|Forest Investigative Site 1102, Los Angeles, California, United States|Forest Investigative Site 1054, Mission Hills, California, United States|Forest Investigative Site 1386, Moreno Valley, California, United States|Forest Investigative Site 1756, Newport Beach, California, United States|Forest Investigative Site 1181, Northridge, California, United States|Forest Investigative Site 1212, Orange, California, United States|Forest Investigative Site 1101, Palm Springs, California, United States|Forest Investigative Site 1014, Paramount, California, United States|Forest Investigative Site 1150, Pismo Beach, California, United States|Forest Investigative Site 1009, Riverside, California, United States|Forest Investigative Site 1241, Roseville, California, United States|Forest Investigative Site 1046, Sacramento, California, United States|Forest Investigative Site 1193, Sacramento, California, United States|Forest Investigative Site 1296, Sacramento, California, United States|Forest Investigative Site 1716, Sacramento, California, United States|Forest Investigative Site 1096, San Bernardino, California, United States|Forest Investigative Site 1189, San Diego, California, United States|Forest Investigative Site 1279, San Diego, California, United States|Forest Investigative Site 1354, San Diego, California, United States|Forest Investigative Site 1724, San Diego, California, United States|Forest Investigative Site 1106, San Diego, California, United States|Forest Investigative Site 1027, San Francisco, California, United States|Forest Investigative Site 1017, San Marino, California, United States|Forest Investigative Site 1158, San Ramon, California, United States|Forest Investigative Site 1318, Santa Ana, California, United States|Forest Investigative Site 1239, Spring Valley, California, United States|Forest Investigative Site 1792, Stockton, California, United States|Forest Investigative Site 1301, Sylmar, California, United States|Forest Investigative Site 1066, Temecula, California, United States|Forest Investigative Site 1729, Tustin, California, United States|Forest Investigative Site 1783, Westlake Village, California, United States|Forest Investigative Site 1162, Colorado Springs, Colorado, United States|Forest Investigative Site 1270, Denver, Colorado, United States|Forest Investigative Site 1711, Denver, Colorado, United States|Forest Investigative Site 1013, Northglenn, Colorado, United States|Forest Investigative Site 1400, Thornton, Colorado, United States|Forest Investigative Site 1324, Bridgeport, Connecticut, United States|Forest Investigative Site 1045, Cromwell, Connecticut, United States|Forest Investigative Site 1059, Stamford, Connecticut, United States|Forest Investigative Site 1072, Waterbury, Connecticut, United States|Forest Investigative Site 1159, Boca Raton, Florida, United States|Forest Investigative Site 1007, Bradenton, Florida, United States|Forest Investigative Site 1042, Brandon, Florida, United States|Forest Investigative Site 1702, Brooksville, Florida, United States|Forest Investigative Site 1764, Clearwater, Florida, United States|Forest Investigative Site 1182, Coral Gables, Florida, United States|Forest Investigative Site 1249, Coral Gables, Florida, United States|Forest Investigative Site 1221, Cutler Bay, Florida, United States|Forest Investigative Site 1793, Daytona Beach, Florida, United States|Forest Investigative Site 1266, Deerfield Beach, Florida, United States|Forest Investigative Site 1100, DeFuniak Springs, Florida, United States|Forest Investigative Site 1734, Deland, Florida, United States|Forest Investigative Site 1775, Doral, Florida, United States|Forest Investigative Site 1378, Doral, Florida, United States|Forest Investigative Site 1237, Edgewater, Florida, United States|Forest Investigative Site 1068, Fort Lauderdale, Florida, United States|Forest Investigative Site 1330, Fort Lauderdale, Florida, United States|Forest Investigative Site 1026, Ft. Lauderdale, Florida, United States|Forest Investigative Site 1794, Gainsville, Florida, United States|Forest Investigative Site 1261, Hallandale Beach, Florida, United States|Forest Investigative Site 1240, Hialeah, Florida, United States|Forest Investigative Site 1260, Hialeah, Florida, United States|Forest Investigative Site 1155, Hollywood, Florida, United States|Forest Investigative Site 1233, Jacksonville, Florida, United States|Forest Investigative Site 1253, Jacksonville, Florida, United States|Forest Investigative Site 1264, Jacksonville, Florida, United States|Forest Investigative Site 1256, Jacksonville, Florida, United States|Forest Investigative Site 1077, Jupiter, Florida, United States|Forest Investigative Site 1041, Kissimmee, Florida, United States|Forest Investigative Site 1399, Kissimmee, Florida, United States|Forest Investigative Site 1297, Miami Springs, Florida, United States|Forest Investigative Site 1784, Miami, Florida, United States|Forest Investigative Site 1364, Miami, Florida, United States|Forest Investigative Site 1206, Miami, Florida, United States|Forest Investigative Site 1397, Miami, Florida, United States|Forest Investigative Site 1180, Miami, Florida, United States|Forest Investigative Site 1396, Miami, Florida, United States|Forest Investigative Site 1154, Miami, Florida, United States|Forest Investigative Site 1788, Miami, Florida, United States|Forest Investigative Site 1223, Miami, Florida, United States|Forest Investigative Site 1707, Miami, Florida, United States|Forest Investigative Site 1282, Miami, Florida, United States|Forest Investigative Site 1708, New Port Richey, Florida, United States|Forest Investigative Site 1176, North Miami Beach, Florida, United States|Forest Investigative Site 1284, Oldsmar, Florida, United States|Forest Investigative Site 1232, Opa-Locka, Florida, United States|Forest Investigative Site 1802, Orlando, Florida, United States|Forest Investigative Site 1049, Orlando, Florida, United States|Forest Investigative Site 1235, Orlando, Florida, United States|Forest Investigative Site 1741, Ormond Beach, Florida, United States|Forest Investigative Site 1003, Oviedo, Florida, United States|Forest Investigative Site 1369, Palm Harbor, Florida, United States|Forest Investigative Site 1079, Pembroke Pines, Florida, United States|Forest Investigative Site 1053, Pembroke Pines, Florida, United States|Forest Investigative Site 1055, Pembroke Pines, Florida, United States|Forest Investigative Site 1161, Pembroke Pines, Florida, United States|Forest Investigative Site 1166, Pembroke Pines, Florida, United States|Forest Investigative Site 1224, Pembroke Pines, Florida, United States|Forest Investigative Site 1075, Pembroke Pines, Florida, United States|Forest Investigative Site 1368, Pinellas Park, Florida, United States|Forest Investigative Site 1023, Plant City, Florida, United States|Forest Investigative Site 1737, Ponte Vedra, Florida, United States|Forest Investigative Site 1749, Port Orange, Florida, United States|Forest Investigative Site 1739, South Miami, Florida, United States|Forest Investigative Site 1069, St. Cloud, Florida, United States|Forest Investigative Site 1315, St. Cloud, Florida, United States|Forest Investigative Site 1243, St. Petersburg, Florida, United States|Forest Investigative Site 1723, St. Petersburg, Florida, United States|Forest Investigative Site 1730, St. Petersburg, Florida, United States|Forest Investigative Site 1076, Tamarack, Florida, United States|Forest Investigative Site 1032, Tampa, Florida, United States|Forest Investigative Site 1302, Tampa, Florida, United States|Forest Investigative Site 1120, Winter Haven, Florida, United States|Forest Investigative Site 1281, Atlanta, Georgia, United States|Forest Investigative Site 1745, Atlanta, Georgia, United States|Forest Investigative Site 1080, Blue Ridge, Georgia, United States|Forest Investigative Site 1236, Lilburn, Georgia, United States|Forest Investigative Site 1389, Marietta, Georgia, United States|Forest Investigative Site 1002, Marietta, Georgia, United States|Forest Investigative Site 1390, Oakwood, Georgia, United States|Forest Investigative Site 1333, Sandy Springs, Georgia, United States|Forest Investigative Site 1332, Savannah, Georgia, United States|Forest Investigative Site 1252, Snellville, Georgia, United States|Forest Investigative Site 1353, Snellville, Georgia, United States|Forest Investigative Site 1740, Stockbridge, Georgia, United States|Forest Investigative Site 1173, Woodstock, Georgia, United States|Forest Investigative Site 1018, Honolulu, Hawaii, United States|Forest Investigative Site 1398, Blackfoot, Idaho, United States|Forest Investigative Site 1727, Boise, Idaho, United States|Forest Investigative Site 1387, Hayden Lake, Idaho, United States|Forest Investigative Site 1004, Meridian, Idaho, United States|Forest Investigative Site 1039, Nampa, Idaho, United States|Forest Investigative Site 1790, Addison, Illinois, United States|Forest Investigative Site 1093, Arlington Heights, Illinois, United States|Forest Investigative Site 1747, Chicago, Illinois, United States|Forest Investigative Site 1071, Chicago, Illinois, United States|Forest Investigative Site 1752, Chicago, Illinois, United States|Forest Investigative Site 1403, Hazel Crest, Illinois, United States|Forest Investigative Site 1126, Morton, Illinois, United States|Forest Investigative Site 1283, O'Fallon, Illinois, United States|Forest Investigative Site 1091, Evansville, Indiana, United States|Forest Investigative Site 1103, Evansville, Indiana, United States|Forest Investigative Site 1147, Muncie, Indiana, United States|Forest Investigative Site 1107, Augusta, Kansas, United States|Forest Investigative Site 1345, Hutchinson, Kansas, United States|Forest Investigative Site 1805, Lenexa, Kansas, United States|Forest Investigative Site 1255, Mission, Kansas, United States|Forest Investigative Site 1092, Newton, Kansas, United States|Forest Investigative Site 1801, Crestview Hills, Kentucky, United States|Forest Investigative Site 1366, Lexington, Kentucky, United States|Forest Investigative Site 1770, Louisville, Kentucky, United States|Forest Investigative Site 1177, Madisonville, Kentucky, United States|Forest Investigative Site 1251, Baton Rouge, Louisiana, United States|Forest Investigative Site 1215, Covington, Louisiana, United States|Forest Investigative Site 1274, Eunice, Louisiana, United States|Forest Investigative Site 1323, Metairie, Louisiana, United States|Forest Investigative Site 1795, Metairie, Louisiana, United States|Forest Investigative Site 1285, New Orleans, Louisiana, United States|Forest Investigative Site 1779, New Orleans, Louisiana, United States|Forest Investigative Site 1769, Auburn, Maine, United States|Forest Investigative Site 1125, Baltimore, Maryland, United States|Forest Investigative Site 1263, Baltimore, Maryland, United States|Forest Investigative Site 1128, Lutherville, Maryland, United States|Forest Investigative Site 1726, Haverhill, Massachusetts, United States|Forest Investigative Site 1061, Hyannis, Massachusetts, United States|Forest Investigative Site 1728, North Dartmouth, Massachusetts, United States|Forest Investigative Site 1356, Watertown, Massachusetts, United States|Forest Investigative Site 1336, Chelsea, Michigan, United States|Forest Investigative Site 1097, Flint, Michigan, United States|Forest Investigative Site 1165, Kalamazoo, Michigan, United States|Forest Investigative Site 1337, Stevensville, Michigan, United States|Forest Investigative Site 1768, Traverse City, Michigan, United States|Forest Investigative Site 1064, Troy, Michigan, United States|Forest Investigative Site 1025, Belzoni, Mississippi, United States|Forest Investigative Site 1057, Jackson, Mississippi, United States|Forest Investigative Site 1034, Olive Branch, Mississippi, United States|Forest Investigative Site 1271, Picayune, Mississippi, United States|Forest Investigative Site 1782, Kansas City, Missouri, United States|Forest Investigative Site 1250, St. Louis, Missouri, United States|Forest Investigative Site 1326, Missoula, Montana, United States|Forest Investigative Site 1028, Bellevue, Nebraska, United States|Forest Investigative Site 1388, Fremont, Nebraska, United States|Forest Investigative Site 1313, Fremont, Nebraska, United States|Forest Investigative Site 1035, Omaha, Nebraska, United States|Forest Investigative Site 1016, Omaha, Nebraska, United States|Forest Investigative Site 1254, Omaha, Nebraska, United States|Forest Investigative Site 1148, Omaha, Nebraska, United States|Forest Investigative Site 1044, Henderson, Nevada, United States|Forest Investigative Site 1052, Henderson, Nevada, United States|Forest Investigative Site 1011, Las Vegas, Nevada, United States|Forest Investigative Site 1376, Las Vegas, Nevada, United States|Forest Investigative Site 1019, Las Vegas, Nevada, United States|Forest Investigative Site 1807, Las Vegas, Nevada, United States|Forest Investigative Site 1048, Las Vegas, Nevada, United States|Forest Investigative Site 1709, Edison, New Jersey, United States|Forest Investigative Site 1132, Haddon Heights, New Jersey, United States|Forest Investigative Site 1141, Linden, New Jersey, United States|Forest Investigative Site 1227, Paramus, New Jersey, United States|Forest Investigative Site 1169, Trenton, New Jersey, United States|Forest Investigative Site 1338, Union, New Jersey, United States|Forest Investigative Site 1761, Albuquerque, New Mexico, United States|Forest Investigative Site 1796, Brooklyn, New York, United States|Forest Investigative Site 1151, Buffalo, New York, United States|Forest Investigative Site 1021, Glen Falls, New York, United States|Forest Investigative Site 1115, Rochester, New York, United States|Forest Investigative Site 1040, Asheboro, North Carolina, United States|Forest Investigative Site 1073, Burlington, North Carolina, United States|Forest Investigative Site 1142, Cary, North Carolina, United States|Forest Investigative Site 1733, Charlotte, North Carolina, United States|Forest Investigative Site 1067, Charlotte, North Carolina, United States|Forest Investigative Site 1342, Dunn, North Carolina, United States|Forest Investigative Site 1088, Greensboro, North Carolina, United States|Forest Investigative Site 1385, Greensboro, North Carolina, United States|Forest Investigative Site 1309, Greensboro, North Carolina, United States|Forest Investigative Site 1306, Hickory, North Carolina, United States|Forest Investigative Site 1098, Hickory, North Carolina, United States|Forest Investigative Site 1110, Lenoir, North Carolina, United States|Forest Investigative Site 1272, Mooresville, North Carolina, United States|Forest Investigative Site 1024, Raleigh, North Carolina, United States|Forest Investigative Site 1789, Raleigh, North Carolina, United States|Forest Investigative Site 1715, Salisbury, North Carolina, United States|Forest Investigative Site 1123, Shelby, North Carolina, United States|Forest Investigative Site 1081, Wilmington, North Carolina, United States|Forest Investigative Site 1705, Wilmington, North Carolina, United States|Forest Investigative Site 1319, Winston-Salem, North Carolina, United States|Forest Investigative Site 1405, Winston-Salem, North Carolina, United States|Forest Investigative Site 1778, Winston-Salem, North Carolina, United States|Forest Investigative Site 1203, Akron, Ohio, United States|Forest Investigative Site 1210, Canal Fulton, Ohio, United States|Forest Investigative Site 1012, Cincinnati, Ohio, United States|Forest Investigative Site 1721, Cincinnati, Ohio, United States|Forest Investigative Site 1280, Cincinnati, Ohio, United States|Forest Investigative Site 1798, Cincinnati, Ohio, United States|Forest Investigative Site 1732, Cincinnati, Ohio, United States|Forest Investigative Site 1718, Cincinnati, Ohio, United States|Forest Investigative Site 1062, Cincinnati, Ohio, United States|Forest Investigative Site 1050, Cincinnati, Ohio, United States|Forest Investigative Site 1084, Cleveland, Ohio, United States|Forest Investigative Site 1765, Columbus, Ohio, United States|Forest Investigative Site 1395, Columbus, Ohio, United States|Forest Investigative Site 1209, Delaware, Ohio, United States|Forest Investigative Site 1201, Lyndhurst, Ohio, United States|Forest Investigative Site 1246, Maumee, Ohio, United States|Forest Investigative Site 1135, Mt. Gilead, Ohio, United States|Forest Investigative Site 1322, Perrysburg, Ohio, United States|Forest Investigative Site 1231, Willoughby, Ohio, United States|Forest Investigative Site 1713, Zanesville, Ohio, United States|Forest Investigative Site 1195, Norman, Oklahoma, United States|Forest Investigative Site 1184, Oklahoma City, Oklahoma, United States|Forest Investigative Site 1305, Oklahoma City, Oklahoma, United States|Forest Investigative Site 1759, Oklahoma City, Oklahoma, United States|Forest Investigative Site 1392, Yukon, Oklahoma, United States|Forest Investigative Site 1116, Ashland, Oregon, United States|Forest Investigative Site 1379, Eugene, Oregon, United States|Forest Investigative Site 1780, Eugene, Oregon, United States|Forest Investigative Site 1108, Hillsboro, Oregon, United States|Forest Investigative Site 1294, Portland, Oregon, United States|Forest Investigative Site 1109, Bensalem, Pennsylvania, United States|Forest Investigative Site 1291, Bensalem, Pennsylvania, United States|Forest Investigative Site 1090, Broomall, Pennsylvania, United States|Forest Investigative Site 1218, Carnegie, Pennsylvania, United States|Forest Investigative Site 1163, Downington, Pennsylvania, United States|Forest Investigative Site 1118, Erie, Pennsylvania, United States|Forest Investigative Site 1171, Erie, Pennsylvania, United States|Forest Investigative Site 1383, Holland, Pennsylvania, United States|Forest Investigative Site 1720, Jenkintown, Pennsylvania, United States|Forest Investigative Site 1207, Lansdale, Pennsylvania, United States|Forest Investigative Site 1314, Norristown, Pennsylvania, United States|Forest Investigative Site 1198, Penndel, Pennsylvania, United States|Forest Investigative Site 1293, Philadelphia, Pennsylvania, United States|Forest Investigative Site 1137, Pittsburgh, Pennsylvania, United States|Forest Investigative Site 1247, Red Lion, Pennsylvania, United States|Forest Investigative Site 1791, Tipton, Pennsylvania, United States|Forest Investigative Site 1196, Upper St. Clair, Pennsylvania, United States|Forest Investigative Site 1172, Warminster, Pennsylvania, United States|Forest Investigative Site 1278, West Chester, Pennsylvania, United States|Forest Investigative Site 1375, Warwick, Rhode Island, United States|Forest Investigative Site 1760, Charleston, South Carolina, United States|Forest Investigative Site 1363, Charleston, South Carolina, United States|Forest Investigative Site 1122, Columbia, South Carolina, United States|Forest Investigative Site 1133, Greenville, South Carolina, United States|Forest Investigative Site 1809, Greenville, South Carolina, United States|Forest Investigative Site 1327, Greer, South Carolina, United States|Forest Investigative Site 1127, Mt. Pleasant, South Carolina, United States|Forest Investigative Site 1310, Murrells Inlet, South Carolina, United States|Forest Investigative Site 1152, Pelzer, South Carolina, United States|Forest Investigative Site 1114, Simpsonville, South Carolina, United States|Forest Investigative Site 1149, Spartanburg, South Carolina, United States|Forest Investigative Site 1113, Summerville, South Carolina, United States|Forest Investigative Site 1806, Union, South Carolina, United States|Forest Investigative Site 1185, Dakota Dunes, South Dakota, United States|Forest Investigative Site 1753, Rapid City, South Dakota, United States|Forest Investigative Site 1402, Bristol, Tennessee, United States|Forest Investigative Site 1037, Chattanooga, Tennessee, United States|Forest Investigative Site 1031, Clarksville, Tennessee, United States|Forest Investigative Site 1074, Collierville, Tennessee, United States|Forest Investigative Site 1033, Fayetteville, Tennessee, United States|Forest Investigative Site 1763, Kingsport, Tennessee, United States|Forest Investigative Site 1744, Knoxville, Tennessee, United States|Forest Investigative Site 1358, Memphis, Tennessee, United States|Forest Investigative Site 1082, Memphis, Tennessee, United States|Forest Investigative Site 1094, Arlington, Texas, United States|Forest Investigative Site 1245, Austin, Texas, United States|Forest Investigative Site 1311, Austin, Texas, United States|Forest Investigative Site 1174, Beaumont, Texas, United States|Forest Investigative Site 1762, Boerne, Texas, United States|Forest Investigative Site 1244, Bryan, Texas, United States|Forest Investigative Site 1776, Carrollton, Texas, United States|Forest Investigative Site 1205, Corpus Christi, Texas, United States|Forest Investigative Site 1268, Corsicana, Texas, United States|Forest Investigative Site 1213, Dallas, Texas, United States|Forest Investigative Site 1228, Houston, Texas, United States|Forest Investigative Site 1372, Houston, Texas, United States|Forest Investigative Site 1777, Houston, Texas, United States|Forest Investigative Site 1157, Houston, Texas, United States|Forest Investigative Site 1360, Houston, Texas, United States|Forest Investigative Site 1230, Houston, Texas, United States|Forest Investigative Site 1774, Houston, Texas, United States|Forest Investigative Site 1262, Irving, Texas, United States|Forest Investigative Site 1229, Longview, Texas, United States|Forest Investigative Site 1199, New Braunfels, Texas, United States|Forest Investigative Site 1214, Plano, Texas, United States|Forest Investigative Site 1129, San Antonio, Texas, United States|Forest Investigative Site 1766, San Antonio, Texas, United States|Forest Investigative Site 1797, San Antonio, Texas, United States|Forest Investigative Site 1295, San Antonio, Texas, United States|Forest Investigative Site 1167, San Antonio, Texas, United States|Forest Investigative Site 1186, San Antonio, Texas, United States|Forest Investigative Site 1257, San Antonio, Texas, United States|Forest Investigative Site 1317, San Antonio, Texas, United States|Forest Investigative Site 1758, San Antonio, Texas, United States|Forest Investigative Site 1334, Sugar Land, Texas, United States|Forest Investigative Site 1269, Tomball, Texas, United States|Forest Investigative Site 1349, Waco, Texas, United States|Forest Investigative Site 1015, Clinton, Utah, United States|Forest Investigative Site 1187, Draper, Utah, United States|Forest Investigative Site 1226, Draper, Utah, United States|Forest Investigative Site 1086, Magna, Utah, United States|Forest Investigative Site 1216, Ogden, Utah, United States|Forest Investigative Site 1219, Orem, Utah, United States|Forest Investigative Site 1328, Riverton, Utah, United States|Forest Investigative Site 1771, Salt Lake City, Utah, United States|Forest Investigative Site 1175, Salt Lake City, Utah, United States|Forest Investigative Site 1197, Salt Lake City, Utah, United States|Forest Investigative Site 1194, Salt Lake City, Utah, United States|Forest Investigative Site 1202, South Jordan, Utah, United States|Forest Investigative Site 1773, St. George, Utah, United States|Forest Investigative Site 1786, Arlington, Virginia, United States|Forest Investigative Site 1130, Arlington, Virginia, United States|Forest Investigative Site 1020, Burke, Virginia, United States|Forest Investigative Site 1343, Danville, Virginia, United States|Forest Investigative Site 1164, Manassas, Virginia, United States|Forest Investigative Site 1767, Norfolk, Virginia, United States|Forest Investigative Site 1292, Petersburg, Virginia, United States|Forest Investigative Site 1131, Suffolk, Virginia, United States|Forest Investigative Site 1099, Virginia Beach, Virginia, United States|Forest Investigative Site 1119, Port Orchard, Washington, United States|Forest Investigative Site 1394, Seattle, Washington, United States|Forest Investigative Site 1085, Spokane, Washington, United States|Forest Investigative Site 1335, Walla Walla, Washington, United States|Forest Investigative Site 1377, Charleston, West Virginia, United States|Forest Investigative Site 1367, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01508026"
525,"NCT01042574","The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy",,"Withdrawn","No Results Available","Hypertension|Intracranial Hemorrhage|Subarachnoid Hemorrhage","Drug: Clevidipine butyrate","The primary endpoint of this trial is the time to achieve the pre-specified SBP target range (110-140) within 30 minutes of the initiation of Cleviprex infusion.|The percentage of patients whose SBP is <90 mmHg within 30 minutes of the initiation of Cleviprex infusion","Methodist Healthcare|The Medicines Company","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cleviprex Use In ICB Patients","May 2010","December 31, 2010","December 31, 2010","January 5, 2010",,"August 14, 2019","Methodist Healthcare, University Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01042574"
526,"NCT01719185","The Effect of Phentermine and B12 on Weight Loss Among Obese Patients",,"Completed","No Results Available","Obesity|Hypertension","Drug: Phentermine and B12|Drug: Phentermine","Weight Change|Blood Pressure|Waist Circumference|Waist to hip ratio","Dr. Michael Lang|East Carolina University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12-001323","September 2012","January 2013","April 2013","November 1, 2012",,"August 13, 2015","Brody Outpatient of Brody Medical Sciences Module D, Greenville, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01719185"
527,"NCT01095822","Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics",,"Unknown status","No Results Available","Diabetes Mellitus","Drug: Aliskiren + Valsartan","How therapy with valsartan (160mg/daily) in combination with aliskiren (150-300mg/daily) affects platelet/coagulation/fibrinolytic biomarkers in recently diagnosed hypertensive patients with type 2 diabetes mellitus.|Whether combination therapy is superior over monotherapy with aliskiren with regard to the improvement of hemostatic biomarkers (platelet aggregation, expression of GP IIb/IIIa, and plasma levels of antithrombin-III).","HeartDrug Research LLC|Novartis","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 4","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","DT-NOV-09-37918","March 2010","December 2010","March 2011","March 30, 2010",,"March 30, 2010","Dr. Pokov's Polyclinic. 6821 Reisterstown Road Suite 206, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01095822"
528,"NCT01354613","Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)",,"Completed","No Results Available","Heart Failure With Preserved Ejection Fraction|Pulmonary Disease|Left Ventricular Hypertrophy/Hypertension","Drug: Dobutamine|Drug: Amlodipine","Change in ejection fraction with 5mcg/kg/min dobutamine|Change in pulse wave velocity","University of Wisconsin, Madison|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","14","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","H-2010-0061|R21HL106103-01","April 2011","December 2013","December 2013","May 17, 2011",,"April 11, 2019","UW - Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01354613"
529,"NCT03556020","Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC PB1046 in Subjects With Symptomatic PAH","VIP","Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: PB1046","Incidence and severity of AEs|Incidence of Clinical Laboratory Abnormalities|Changes in Diastolic Blood Pressure|Changes in Systolic Blood Pressure|Changes in Oral Body Temperature|Changes in Respiratory Rate|Changes in Heart Rate|12-Lead ECG - Incidence of clinically significant findings|Immunogenicity|Change in baseline in pulmonary vascular resistance (PVR)|Change from baseline in 6MWD|Change from baseline in NT-proBNP|Change from baseline in cardiac index (CI)|Change from baseline in mean pulmonary artery pressure (mPAP)|Change from baseline in mean right atrial pressure (mRAP)|Change from baseline in wedge pressure|Change from baseline in mixed venous oxygen saturation (SvO2)|Change from baseline in pulmonary artery compliance","PhaseBio Pharmaceuticals Inc.","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PB1046-PT-CL-0004","July 15, 2018","December 31, 2021","December 31, 2021","June 14, 2018",,"February 25, 2020","IMC - Diagnostic & Medical Clinic, LLC, Mobile, Alabama, United States|University of California, San Diego (UCSD), La Jolla, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|University of California-Davis, Sacramento, California, United States|University of Colorado Denver, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|The University Miami Health Hospital, Miami, Florida, United States|The Emory Clinic, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics, Dept of Internal Medicine, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Tufts University, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYU Langone Health, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|The Linder Center for Resarch and Education at The Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Memorial Hermann Hospital CRU affiliated with University of Texas Health Science Center at Houston - McGovern Medical School, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03556020"
530,"NCT02565173","Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma","MATrX-1","Completed","No Results Available","Primary Open-Angle Glaucoma (POAG)|Ocular Hypertension (OHT)","Drug: trabodenoson 4.5% BID|Drug: trabodenoson 6.0% QD|Drug: trabodenoson 3.0% QD|Drug: timolol 0.5% BID|Drug: placebo BID","Mean Intraocular Pressure (IOP)","Inotek Pharmaceuticals Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","303","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IPC-01-2015","September 2015","November 2016","November 2016","October 1, 2015",,"December 6, 2016","Inotek Pharmaceuticals Corporation, Lexington, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02565173"
531,"NCT04005079","Pilocarpine After Combined Cataract/Trabectome Surgery","PACCT","Recruiting","No Results Available","Open Angle Glaucoma|Ocular Hypertension","Drug: Pilocarpine|Drug: Ofloxacin|Drug: Prednisolone","Percentage of intraocular lowering from baseline|Number of IOP lowering agents required to achieve goal IOP|Rate of progression to further glaucoma surgeries.|Frequency of pilocarpine related side effects|Frequency of drug discontinuation due to pilocarpine related side effects","Montefiore Medical Center","All","30 Years to 100 Years   (Adult, Older Adult)","Phase 3","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-8704","June 5, 2019","July 2022","July 2029","July 2, 2019",,"July 2, 2019","Montefiore Medical Center, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT04005079"
532,"NCT03814187","Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C","ORION-8","Active, not recruiting","No Results Available","ASCVD|Elevated Cholesterol|Heterozygous Familial Hypercholesterolemia|Homozygous Familial Hypercholesterolemia","Drug: Inclisiran Sodium","Proportion of subjects reaching on treatment LDL-C targets of <70 mg/dL|Proportion of subjects reaching on treatment LDL-C targets of <100 mg/dL|Evaluate the effect of inclisiran on LDL-C levels|Evaluate the effect of inclisiran on total cholesterol (TC), triglycerides, LDL-C, and high density lipoprotein cholesterol (HDL-C)","The Medicines Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","2991","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MDCO-PCS-17-05","April 16, 2019","August 2023","December 2023","January 23, 2019",,"March 13, 2020","Research Site 10001-015, Birmingham, Alabama, United States|Research Site 10001-138, Foley, Alabama, United States|Research Site 10001-113, Huntsville, Alabama, United States|Research Site 10001-058, Mobile, Alabama, United States|Research Site 10001-037, Montgomery, Alabama, United States|Research Site 10001-076, Saraland, Alabama, United States|Research Site 10001-013, Chandler, Arizona, United States|Research Site 10001-077, Mesa, Arizona, United States|Research Site 10001-136, Phoenix, Arizona, United States|Research Site 10001-051, Surprise, Arizona, United States|Research Site 10001-019, Tucson, Arizona, United States|Research Site 10001-004, Tucson, Arizona, United States|Research Site 10001-132, Tucson, Arizona, United States|Research Site 10001-073, Beverly Hills, California, United States|Research Site 10001-050, Canoga Park, California, United States|Research Site 10001-011, Carlsbad, California, United States|Research Site 10001-065, El Cajon, California, United States|Research Site 10001-150, Los Angeles, California, United States|Research Site 90001-005, Mission Viejo, California, United States|Research Site 10001-043, Northridge, California, United States|Research Site 10001-022, Northridge, California, United States|Research Site 10001-033, Sacramento, California, United States|Research Site 10001-105, San Ramon, California, United States|Research Site 10001-008, Santa Rosa, California, United States|Research Site 10001-153, Spring Valley, California, United States|Research Site 90001-015, Stanford, California, United States|Research Site 10001-044, Torrance, California, United States|Research Site 90001-047, Boca Raton, Florida, United States|Research Site 10001-084, Clearwater, Florida, United States|Research Site 10001-155, Clearwater, Florida, United States|Research Site 10001-099, Clearwater, Florida, United States|Research Site 10001-127, Daytona Beach, Florida, United States|Research Site 10001-119, Fleming Island, Florida, United States|Research Site 10001-070, Fort Lauderdale, Florida, United States|Research Site 10001-067, Hialeah, Florida, United States|Research Site 10001-139, Jacksonville, Florida, United States|Research Site 10001-039, Jacksonville, Florida, United States|Research Site 10001-098, Jacksonville, Florida, United States|Research Site 10001-080, Miami Springs, Florida, United States|Research Site 10001-081, Miami, Florida, United States|Research Site 10001-140, Miami, Florida, United States|Research Site 10001-142, Miami, Florida, United States|Research Site 10001-030, Miami, Florida, United States|Research Site 10001-116, Miami, Florida, United States|Research Site 10001-027, Pembroke Pines, Florida, United States|Research Site 10001-115, Pembroke Pines, Florida, United States|Research Site 10001-048, Pembroke Pines, Florida, United States|Research Site 10001-147, Pembroke Pines, Florida, United States|Research Site 10001-003, Pinellas Park, Florida, United States|Research Site 10001-104, Ponte Vedra, Florida, United States|Research Site 10001-090, Saint Augustine, Florida, United States|Research Site 10001-102, Saint Petersburg, Florida, United States|Research Site 10001-123, Sarasota, Florida, United States|Research Site 10001-038, Tampa, Florida, United States|Research Site 10001-143, Tampa, Florida, United States|Research Site 10001-069, Atlanta, Georgia, United States|Research Site 10001-137, Dunwoody, Georgia, United States|Research Site 10001-092, Macon, Georgia, United States|Research Site 10001-059, Arlington Heights, Illinois, United States|Research Site 10001-158, Chicago, Illinois, United States|Research Site 10001-036, Evanston, Illinois, United States|Research Site 10001-082, Indianapolis, Indiana, United States|Research Site 10001-040, Valparaiso, Indiana, United States|Research Site 10001-074, West Des Moines, Iowa, United States|Research Site 10001-028, Hutchinson, Kansas, United States|Research Site 10001-125, Lexington, Kentucky, United States|Research Site 10001-108, Lexington, Kentucky, United States|Research Site 10001-107, Owensboro, Kentucky, United States|Research Site 10001-144, Crowley, Louisiana, United States|Research Site 10001-041, Lake Charles, Louisiana, United States|Research Site 10001-101, Monroe, Louisiana, United States|Research Site 90001-004, Boston, Massachusetts, United States|Research Site 10001-024, Flint, Michigan, United States|Research Site 10001-095, Grandville, Michigan, United States|Research Site 10001-078, Sterling Heights, Michigan, United States|Research Site 10001-034, Troy, Michigan, United States|Research Site 10001-018, Edina, Minnesota, United States|Research Site 90001-056, Saint Paul, Minnesota, United States|Research Site 10001-156, Saint Louis, Missouri, United States|Research Site 10001-007, Saint Louis, Missouri, United States|Research Site 90001-012, Butte, Montana, United States|Research Site 10001-053, Omaha, Nebraska, United States|Research Site 10001-021, Omaha, Nebraska, United States|Research Site 90001-112, Las Vegas, Nevada, United States|Research Site 10001-124, Las Vegas, Nevada, United States|Research Site 10001-060, Bridgewater, New Jersey, United States|Research Site 90001-014, Summit, New Jersey, United States|Research Site 10001-055, Warren, New Jersey, United States|Research Site 10001-054, Albany, New York, United States|Research Site 10001-122, Binghamton, New York, United States|Research Site 10001-128, Endwell, New York, United States|Research Site 10001-042, New Windsor, New York, United States|Research Site 10001-129, Poughkeepsie, New York, United States|Research Site 10001-110, Williamsville, New York, United States|Research Site 10001-063, Cary, North Carolina, United States|Research Site 10001-064, Greensboro, North Carolina, United States|Research Site 10001-145, Mooresville, North Carolina, United States|Research Site 10001-046, Shelby, North Carolina, United States|Research Site 10001-016, Akron, Ohio, United States|Research Site 10001-120, Cincinnati, Ohio, United States|Research Site 90001-002, Cincinnati, Ohio, United States|Research Site 10001-010, Cincinnati, Ohio, United States|Research Site 10001-134, Cincinnati, Ohio, United States|Research Site 10001-014, Columbus, Ohio, United States|Research Site 10001-141, Dayton, Ohio, United States|Research Site 10001-148, Marion, Ohio, United States|Research Site 10001-109, Wyomissing, Pennsylvania, United States|Research Site 10001-001, Anderson, South Carolina, United States|Research Site 10001-006, Greer, South Carolina, United States|Research Site 10001-075., Greer, South Carolina, United States|Research Site 10001-111, Myrtle Beach, South Carolina, United States|Research Site 10001-133, Pelzer, South Carolina, United States|Research Site 10001-103, Rapid City, South Dakota, United States|Research Site 10001-146, Athens, Tennessee, United States|Research Site 10001-130, Kingsport, Tennessee, United States|Research Site 10001-118, Knoxville, Tennessee, United States|Research Site 10001-106, Knoxville, Tennessee, United States|Research Site 10001-100, Amarillo, Texas, United States|Research Site 10001-087, Austin, Texas, United States|Research Site 10001-117, Austin, Texas, United States|Research Site 10001-009, Dallas, Texas, United States|Research Site 10001-068, Edinburg, Texas, United States|Research Site 10001-031, Houston, Texas, United States|Research Site 10001-088, Houston, Texas, United States|Research Site 10001-091, Houston, Texas, United States|Research Site 10001-061, Houston, Texas, United States|Research Site 10001-032, Houston, Texas, United States|Research Site 10001-025, Lubbock, Texas, United States|Research Site 10001-057, New Braunfels, Texas, United States|Research Site 10001-079, Round Rock, Texas, United States|Research Site 10001-071, San Antonio, Texas, United States|Research Site 10001-083, Schertz, Texas, United States|Research Site 10001-149, Shavano Park, Texas, United States|Research Site 10001-045, Tomball, Texas, United States|Research Site 10001-005, Layton, Utah, United States|Research Site 10001-002, Salt Lake City, Utah, United States|Research Site 10001-052, Salt Lake City, Utah, United States|Research Site 10001-093, Falls Church, Virginia, United States|Research Site 10001-085, Manassas, Virginia, United States|Research Site 10001-094, Midlothian, Virginia, United States|Research Site 10001-023, Richmond, Virginia, United States|Research Site 10001-029, Suffolk, Virginia, United States|Research Site 10001-114, Tacoma, Washington, United States|Research Site 90011-005, Chicoutimi, Quebec, Canada|Research Site 90011-001, Montréal, Quebec, Canada|Research Site 90011-002, Québec, Quebec, Canada|Research Site 11420-002, Chomutov, Czechia|Research Site 90420-001, Praha, Czechia|Research Site 90420-006, Praha, Czechia|Research Site 11420-003, Uherské Hradiště, Czechia|Research Site 90045-001, Aalborg, Nordjylland, Denmark|Research Site 90045-004, Esbjerg, Denmark|Research Site 90045-003, Herning, Denmark|Research Site 90045-006, Hvidovre, Denmark|Research Site 90045-002, Roskilde, Denmark|Research Site 90045-005, Viborg, Denmark|Research Site 11049-006, Berlin, Germany|Research Site 11049-002, Bochum, Germany|Research Site 11049-003, Frankfurt, Germany|Research Site 11049-001, Heidelberg, Germany|Research Site 11049-007, Heidelberg, Germany|Research Site 11036-001, Budapest, Hungary|Research Site 11036-004, Debrecen, Hungary|Research Site 11036-002, Hatvan, Hungary|Research Site 11036-003, Zalaegerszeg, Hungary|Research Site 90031-001, Amersfoort, Netherlands|Research Site 90031-003, Amsterdam, Netherlands|Research Site 90031-006, Goes, Netherlands|Research Site 90031-009, Hoorn, Netherlands|Research Site 90031-005, Utrecht, Netherlands|Research SIte 11048-016, Brzozowie, Poland|Research Site 11048-018, Bydgoszcz, Poland|Research Site 11048-011, Bydgoszcz, Poland|Research Site 11048-004, Gdańsk, Poland|Research Site 11048-005, Gdynia, Poland|Research Site 11048-007, Katowice, Poland|Research SIte 11048-012, Katowice, Poland|Research Site 11048-003, Kraków, Poland|Research SIte 11048-014, Kraków, Poland|Research Site 11048-008, Lublin, Poland|Research Site 11048-001, Poznań, Poland|Research Site 11048-019, Ruda Śląska, Poland|Research SIte 11048-013, Rzeszów, Poland|Research SIte 11048-015, Tarnów, Poland|Research Site 11048-006, Warsaw, Poland|Research Site 11048-009, Warsaw, Poland|Research Site 11048-002, Wrocław, Poland|Research Site 11048-010, Wrocław, Poland|Research Site 90027-008, Bellville, Cape Town, South Africa|Research Site 90027-007, Lyttelton, Cape Town, South Africa|Research Site 90027-003, Bloemfontein, Free State, South Africa|Research Site 90027-010, Johannesburg, Gauteng, South Africa|Research Site 11027-005, Kempton Park, Gauteng, South Africa|Research Site 90027-006, Pretoria, Gauteng, South Africa|Research Site 90027-009, Witbank, Gauteng, South Africa|Research Site 90027-001, Cape Town, Western Cape, South Africa|Research Site 11027-007, Kuilsrivier, Western Cape, South Africa|Research Site 11027-013, Paarl, Western Cape, South Africa|Research Site 90027-004, Somerset West, Western Cape, South Africa|Research Site 90027-005, Somerset West, Western Cape, South Africa|Research Site 90034-004, Córdoba, Andalucia, Spain|Research Site 90034-002, Zaragoza, Aragon, Spain|Research Site 90034-005, Barcelona, Cataluna, Spain|Research Site 90034-006, Barcelona, Cataluna, Spain|Research Site 90034-001, Reus, Cataluna, Spain|Research Site 90034-003, La Coruña, Galicia, Spain|Research Site 90046-002, Göteborg, Sweden|Research Site 90046-001, Stockholm, Sweden|Research Site 90046-003, Stockholm, Sweden|Research Site 11380-005, Cherkasy, Ukraine|Research Site 11380-008, Kharkiv, Ukraine|Research Site 11380-001, Kyiv, Ukraine|Research Site 11380-002, Kyiv, Ukraine|Research Site 11380-003, Kyiv, Ukraine|Research Site 11380-004, Kyiv, Ukraine|Research Site 11380-009, Zaporizhzhya, Ukraine|Research Site 11380-006, Úzhgorod, Ukraine|Research Site 11044-028, Bollington, Cheshire, United Kingdom|Research Site 11044-026, Bury, United Kingdom|Research Site 11044-024, Cheadle Hulme, United Kingdom|Research Site 11044-014, Chorley, United Kingdom|Research Site 11044-012, Cornwell, United Kingdom|Research Site 11044-010, Derby, United Kingdom|Research Site 11044-006, Edgbaston, United Kingdom|Research Site 11044-009, Exeter, United Kingdom|Research Site 11044-001, Glasgow, United Kingdom|Research Site 11044-008, Hexham, United Kingdom|Research SIte 11044-020, Macclesfield, United Kingdom|Research Site 11044-005, Manchester, United Kingdom|Research Site 11044-025, Manchester, United Kingdom|Research Site 11044-027, Manchester, United Kingdom|Research Site 11044-029, Manchester, United Kingdom|Research Site 11044-019, Plymouth, United Kingdom|Research Site 11044-003, Reading, United Kingdom|Research Site 11044-022, Sale, United Kingdom|Research Site 11044-023, Sale, United Kingdom|Research Site 11044-002, Stockton-on-Tees, United Kingdom|Research Site 11044-021, Timperley, United Kingdom|Research Site 11044-007, Wales, United Kingdom|Research Site 11044-004, Waterloo, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03814187"
533,"NCT04029584","Drug-Drug Interaction Between Rifampin and Fluvastatin",,"Recruiting","No Results Available","Drug-drug Interaction","Drug: Intravenous Rifampin","AUC|Cmax|Tmax","University of California, San Francisco","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","18-27008","April 25, 2019","April 25, 2020","April 25, 2020","July 23, 2019",,"July 23, 2019","University of California San Francisco, San Francisco, California, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT04029584/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04029584"
534,"NCT02789150","Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg",,"Completed","No Results Available","Hepatorenal Syndrome","Drug: Norepinephrine (Levophed)","Urine output|serum creatinine|Cardiac events|ischemic events","University of Louisville","All","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14.1190","January 2015","January 11, 2018","January 11, 2018","June 2, 2016",,"January 16, 2018","University of Louisville, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT02789150"
535,"NCT01434745","SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation",,"Terminated","Has Results","Smith-Lemli-Opitz Syndrome","Drug: Simvastatin|Dietary Supplement: Lactose","Development Quotient (DQ)|Whole Body Cholesterol Pool Size, Synthesis & Absorption Using Stable Isotope Testing|Plasma Marker of Sterol Metabolism|ADC|MVA|MRS Lipids|FA","Oregon Health and Science University|National Heart, Lung, and Blood Institute (NHLBI)","All","1 Year to 89 Years   (Child, Adult, Older Adult)","Not Applicable","1","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","R01HL073980","September 2011","October 2014","October 2014","September 15, 2011","October 1, 2019","October 1, 2019","Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01434745"
536,"NCT01633814","Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women",,"Terminated","Has Results","Menopause|Aging|Blood Pressure","Drug: Transdermal estradiol|Drug: Placebo","Change in Carotid Baroreflex Sensitivity (Bpm/mmHg)|Change in Exercise Pressor Reflex Responsiveness (Mean Blood Pressure Response (mmHg) and Muscle Sympathetic Nerve Activity Response (Burst Frequency) During Post Handgrip Ischemia.)","University of Missouri-Columbia","Female","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","4","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","1133919","September 2011","August 2015","August 2015","July 4, 2012","August 10, 2017","August 10, 2017","University of Missouri, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01633814"
537,"NCT01077297","Tezosentan in Pulmonary Arterial Hypertension",,"Terminated","No Results Available","Pulmonary Arterial Hypertension","Drug: Tezosentan","Change in PVR from Baseline to 30 minutes expresses as percent of the Baseline value.|Change in mean right arterial pressure (mRAP) from Baseline to 30 minutes|Change in mPAP from Baseline to 30 min|Change in total pulmonary resistance (TPR) from Baseline to 30 min|Change in PCWP from Baseline to 30 min|Change in cardiac output (CO) from Baseline to 30 min|Change in cardiac index (CI) from Baseline to 30 min","Idorsia Pharmaceuticals Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","3","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-051-206","August 2010","November 2010","September 2011","March 1, 2010",,"July 9, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States|Baylor College of Medicine, Houston, Texas, United States|Hopital Antoine Béclère, Paris, Clamart, France|University Hospital of Basel, Clinic of Pneumology, Basel, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland",,"https://ClinicalTrials.gov/show/NCT01077297"
538,"NCT01840540","MSC for Occlusive Disease of the Kidney",,"Completed","No Results Available","Atherosclerotic Renal Artery Stenosis|Ischemic Nephropathy|Renovascular Hypertension","Drug: Arterial infusion of autologous mesenchymal stem cells","Renal blood flow and function in the treated kidneys.|Level of kidney function.","Mayo Clinic","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-009298","April 2013","March 2014","April 2017","April 25, 2013",,"August 7, 2017","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01840540"
539,"NCT03310580","Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension",,"Completed","Has Results","Primary Open Angle Glaucoma or Ocular Hypertension","Drug: AR-13324 Ophthalmic Solution 0.02%|Drug: AR-13324 Ophthalmic Solution 0.04%|Drug: AR-13324 Ophthalmic Solution Placebo","Mean Diurnal IOP (Intraocular Pressure) (mmHg)|Extent of Exposure","Aerie Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AR-13324-CS205","November 15, 2017","October 25, 2018","October 25, 2018","October 16, 2017","November 15, 2019","December 23, 2019","Arizona Eye Center, Chandler, Arizona, United States|Arizona Glaucoma Specialists, Phoenix, Arizona, United States|Milton M. Hom, OD FAAO FACAAISc, Azusa, California, United States|Havana Research Institute, Burbank, California, United States|Global Research Management, Glendale, California, United States|Southern California Eye Physicians & Surgeons, Los Alamitos, California, United States|East West Eye Institute, Los Angeles, California, United States|USC Roski Eye Institute University of Souther California, Los Angeles, California, United States|Global Research Foundation, Los Angeles, California, United States|The Eye Research Foundation, Newport Beach, California, United States|Southern California Eye Physicians Surgeons, Pasadena, California, United States|North Bay Eye Associates Inc., Petaluma, California, United States|Martel Eye, Rancho Cordova, California, United States|University of California, San Diego, California, United States|AdvanceMed Clinical Research, San Diego, California, United States|Glaucoma Center of San Francisco, San Francisco, California, United States|Samsum Clinic, Santa Barbara, California, United States|MCB Clinical Research Centers LLC, Colorado Springs, Colorado, United States|Clayton Eye Clinical Research, LLC, Morrow, Georgia, United States|Jenkins Eye Care, Honolulu, Hawaii, United States|Winward Eye Physicians and Eye Surgeons, Kailua, Hawaii, United States|Island Eye Care, Inc., Kailua, Hawaii, United States|They Eye Care Institute, Louisville, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Emil A. Stein MD Ltd, Las Vegas, Nevada, United States|AdvanceMed Clinical Research, Las Vegas, Nevada, United States|New York Eye Infirmary of Mount Sinai, New York, New York, United States|The Shimmyo Group, New York, New York, United States|Manhattan Eye Ear and Throat Hospital, New York, New York, United States|Optimed Research, Marysville, Ohio, United States|Glaucoma Consultants and Center for Eye Research, PA, Mount Pleasant, South Carolina, United States|University Eye Specialists, Maryville, Tennessee, United States|VRF Eye Speciality Group, Memphis, Tennessee, United States|Lake Travis Eye and Laser Center, Lakeway, Texas, United States|DCT - Shah Research LLC dba Discovery Clinical Trials, Mission, Texas, United States|Round Rock Eye Consultants, Round Rock, Texas, United States|San Antonio Eye Center, San Antonio, Texas, United States|R and R Eye Research LLC, San Antonio, Texas, United States|Emerson Clinical Research Institute, Falls Church, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03310580/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03310580/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03310580"
540,"NCT02500147","Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)",,"Suspended","No Results Available","Polycystic Ovary Syndrome|Non-Alcoholic Fatty Liver Disease|Metabolic Syndrome","Drug: Metformin|Drug: Placebo","Difference in percentage liver fat between Metformin arm and Placebo arm in adolescents and young adults with PCOS and with elevated percentage liver fat (>/=4.8%)|Proportion of PCOS subjects with the PNPLA3 allele comparing those with elevated percentage liver fat (>/=4.8%) and those with normal percentage liver fat (<4.8%) by magnetic resonance spectroscopy|The association of percentage liver fat by magnetic resonance spectroscopy with insulin resistance as measured by HOMA-IR in adolescents with PCOS|The association of percentage liver fat with triglycerides|The association of percentage liver fat with visceral adipose tissue|The association of percentage liver fat with total body adipose tissue|The association of percentage liver fat with pancreatic polypeptide|The association of percentage liver fat with M30, a hepatic apoptosis marker","Columbia University","Female","13 Years to 25 Years   (Child, Adult)","Phase 4","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AAAF4452","September 8, 2011","November 30, 2021","November 30, 2021","July 16, 2015",,"February 5, 2020","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02500147"
541,"NCT03496623","A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With PH Due to COPD",,"Recruiting","No Results Available","Pulmonary Hypertension|Chronic Obstructive Pulmonary Disease","Drug: Inhaled treprostinil solution|Drug: Placebo solution","Change in 6-Minute Walk Distance (6MWD) from Baseline to Week 12|Change in Borg dyspnea score from Baseline to Week 12|Change in quality of life (QOL) measured by St. George's Respiratory Questionnaire (SGRQ) from Baseline to Week 12|Change in QOL measured by the University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ) from Baseline to Week 12|Change in plasma concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) levels from Baseline to Week 12","United Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","314","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RIN-PH-304","June 27, 2018","September 30, 2020","September 30, 2020","April 12, 2018",,"February 13, 2020","The University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner University Medical Center, Phoenix, Arizona, United States|University of Arizona Clinical and Translational Science (CATS) Research Center, Tucson, Arizona, United States|Loma Linda University Medical Center, Loma Linda, California, United States|University of Southern California, Los Angeles, California, United States|West Los Angeles VA Healthcare Center, Los Angeles, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Santa Barbara Pulmonary Associates, Santa Barbara, California, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|South Denver Cardiology, Littleton, Colorado, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|St. Francis Medical Institute, Clearwater, Florida, United States|University of Florida Clinical Research Center, Gainesville, Florida, United States|St. Vincent's Lung, Sleep, and Critical Care Specialists, Jacksonville, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Pulmonary Disease Specialists, Kissimmee, Florida, United States|University of Miami Hospital, Miami, Florida, United States|Pulmonary & Critical Care of Atlanta, Atlanta, Georgia, United States|Georgia Clinical Research, Austell, Georgia, United States|Advocate Aurora Health Care, Elmhurst, Illinois, United States|Advocate Condell Medical Center, Libertyville, Illinois, United States|Advocate Heart Institute & Pulmonology, Normal, Illinois, United States|Edward Heart Hospital, Oakbrook Terrace, Illinois, United States|Indiana University Healh North Hospital, Indianapolis, Indiana, United States|St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Louisville Research Foundation, Louisville, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beaumont Health, Troy, Michigan, United States|Albany Medical College, Albany, New York, United States|The Mount Sinai Hospital, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|The Carl and Edyth Lindner Research Center at the Christ Hospital, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Temple Lung Center, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center - Montefiore, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Statcare Pulmonary Consultants, Knoxville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Tech, El Paso, Texas, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Carilion Clinic, Roanoke, Virginia, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|CardioPulmonary Research Center, Guaynabo, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03496623"
542,"NCT01523067","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension",,"Completed","No Results Available","Essential Hypertension","Drug: Vasomera (PB1046)|Drug: 0.9% Sodium Chloride","Safety/Tolerability|Pharmacokinetics|Pharmacodynamics|Immunogenicity","PhaseBio Pharmaceuticals Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PB1046-PT-CL-0001","January 2012","December 2012","December 2012","February 1, 2012",,"January 4, 2013","Pinnacle Research, Anniston, Alabama, United States|Diablo Clinical Research, Walnut Creek, California, United States|Prism Research Inc., Saint Paul, Minnesota, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, United States|Rainier Clinical Research, Renton, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01523067"
543,"NCT00989963","Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Beraprost Sodium Modified Release","Right Heart Catheterization|Exercise Capacity|World Health Organization(WHO)Functional Class.|Clinical Laboratory Parameters|Electrocardiogram (ECG) Findings","Lung Biotechnology PBC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BPS-MR-PAH-203","November 2009","December 2011","December 2011","October 6, 2009",,"April 24, 2013","Harbor-UCLA Medical Center, Torrance, California, United States|Edward Heart Hospital, Naperville, Illinois, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Beth Israel Medical Center, New York, New York, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Universite Libre de Bruxelles, Bruxellas, Belgium|Catholic University of Leuven, Leuven, Belgium|General Teaching Hospital, Praha, Czech Republic|Klinikum der Universitat zu Koln, Cologne, Germany|Medizinische Klinik und Poliklinik, Dresden, Germany|Abt. Innere Medizin III, Medizinische Universitatsklinik, Heidelberg, Germany|Universitatsklinik Leipzig Abteilung Pulmologie, Leipzig, Germany|Mater Misericordiae University Hospital Ltd., Dublin, Ireland|Institutul de Urgenta pentru Boli, Bucuresti, Romania|Institutul National de Pneumologie, Bucuresti, Romania|Institutul de Boli Cardiovasculare, Lasi, Romania",,"https://ClinicalTrials.gov/show/NCT00989963"
544,"NCT01773512","The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques","PREDICT","Unknown status","No Results Available","Coronary Artery Disease","Drug: Rosuvastatin","The prediction of plaque volume and plaque composition.|Prediction of changes in plaque volume and plaque composition","General University Hospital, Prague|Ministry of Health, Czech Republic|Czech Ministry of Education|University of Iowa|Loyola University Chicago","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UK2012|IGA 2012 NT/13224","June 2012","December 2014","June 2015","January 23, 2013",,"January 23, 2013","Loyola University Hospital, Maywood, Illinois, United States|The University of Iowa, Iowa City, Iowa, United States|General University Hospital, Prague, Czech Republic",,"https://ClinicalTrials.gov/show/NCT01773512"
545,"NCT00833976","Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia",,"Completed","Has Results","High Triglycerides|Hypercholesterolemia|Schizophrenia|Schizoaffective Disorder|Bipolar Disorder","Drug: Lovaza","Change in Triglycerides From Baseline to 16 Weeks|Change in Total Cholesterol From Baseline to 16 Weeks|Tolerability of Omega-3 Fatty Acid Capsules (Lovaza)","Massachusetts General Hospital|GlaxoSmithKline","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","65","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-P-002219","July 2009","March 2013","March 2013","February 2, 2009","April 4, 2016","July 2, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00833976"
546,"NCT01761877","NSAID Effects on Clinical and Imaging Breast Biomarkers",,"Active, not recruiting","No Results Available","Inflammation|Cancer|Pain|Hypertension","Drug: Sulindac","Change in breast density measured as fat to water ratio by magnetic resonance imaging|Muscle and joint pain and stiffness","Stony Brook University","Female","up to 75 Years   (Child, Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1RO1 CA1615301A1|12-0080-04|676847","December 2012","June 2019","June 2019","January 7, 2013",,"November 30, 2018","University of Arizona Cancer Center, Tucson, Arizona, United States|Stony Brook University Cancer Center, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT01761877"
547,"NCT01419535","Mifepristone for Metabolic Syndrome",,"Completed","No Results Available","Endocrine Disease|Diabetes","Drug: Mifepristone|Drug: Placebo","To change in insulin sensitivity index based on the effect of insulin on glucose during frequently sampled IV glucose tolerance test (FSIVGTT)|Change in fasting plasma glucose and insulin levels","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","35 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","19","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","110208|11-CH-0208","August 17, 2011","November 29, 2017","November 29, 2017","August 18, 2011",,"April 30, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT01419535/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT01419535/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT01419535"
548,"NCT01524653","Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)","DISOLVE","Completed","No Results Available","Venous Thromboembolism|Deep Vein Thrombosis|Neoplasms","Drug: Rosuvastatin|Drug: Placebo","To determine if rosuvastatin therapy reduces the risk of VTE in patients with cancer receiving chemotherapy, as measured by a decrease in D-dimer level with treatment compared to placebo|To investigate the impact of rosuvastatin therapy on other established biomarkers of VTE risk in cancer patients receiving chemotherapy as measured by the change in Factor VIII|To investigate the impact of rosuvastatin therapy on other established biomarkers of VTE risk in cancer patients receiving chemotherapy as measured by the change in soluble P-selectin|To investigate the impact of rosuvastatin therapy on other established biomarkers of VTE risk in cancer patients receiving chemotherapy as measured by the change in C-reactive protein|To investigate the impact of rosuvastatin therapy on other established biomarkers of VTE risk in cancer patients receiving chemotherapy as measured by the change in Peak thrombin generation|Adverse Events (CTCAE v4) associated with rosuvastatin therapy|Venous thromboembolism|To investigate the impact of rosuvastatin therapy on other established biomarkers of VTE risk in cancer patients receiving chemotherapy as measured by the change in Plasminogen activator inhibitor-1 activity|To investigate the impact of rosuvastatin therapy on other established biomarkers of VTE risk in cancer patients receiving chemotherapy as measured by the change in Plasminogen activator inhibitor-1 protein concentration|To investigate the impact of rosuvastatin therapy on other established biomarkers of VTE risk in cancer patients receiving chemotherapy as measured by the change in tissue factor|To investigate the impact of rosuvastatin therapy on other established biomarkers of VTE risk in cancer patients receiving chemotherapy as measured by the change in Factor XIa","University of Vermont","All","18 Years and older   (Adult, Older Adult)","Phase 2","38","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","VCC 1110","March 2012","July 1, 2016","September 1, 2016","February 2, 2012",,"July 10, 2018","Fletcher Allen Health Care, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT01524653"
549,"NCT01477333","Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®",,"Completed","Has Results","Pulmonary Arterial Hypertension","Drug: UT-15C SR|Drug: Tyvaso Inhalation Solution","Change in Hemodynamic Parameters From Baseline to Week 24.|Change in Hemodynamic Parameter (Heart Rate) From Baseline to Week 24.|Change in Hemodynamic Parameters (Arterial and Venous Oxygen Saturation) From Baseline to Week 24.|Change in Hemodynamic Parameter (Cardiac Output) From Baseline to Week 24.|Change in Hemodynamic Parameter (Cardiac Index) From Baseline to Week 24.|Change in Hemodynamic Parameter (Pulmonary Vascular Resistance Index) From Baseline to Week 24.|Change in Exercise Capacity as Measured by the 6-minute Walk Test (6MWT) Over the 24-week Treatment Period.|Time to Clinical Worsening Over the Treatment Period.|Shift From Baseline in World Health Organization (WHO) Functional Class Over the 24-week Treatment Period.|N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Over the 24-week Treatment Period.","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-PH-203","October 2011","November 2013","November 2013","November 22, 2011","March 6, 2017","March 6, 2017","The University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Allegheny General Hospital, Pittsburg, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01477333"
550,"NCT00995670","Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins",,"Completed","Has Results","Hyperglycemia","Drug: 5% dextrose|Drug: Vitamin C|Drug: Simvastatin|Drug: Sevoflurane","Forearm Blood Flow","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years to 35 Years   (Adult)","Not Applicable","59","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CARA-023-09S","March 2010","September 2013","September 2013","October 15, 2009","March 17, 2015","March 17, 2015","Zablocki VA Medical Center, Milwaukee, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00995670"
551,"NCT00818883","Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension",,"Completed","Has Results","Essential Hypertension","Drug: Azilsartan medoxomil and chlorthalidone|Drug: Azilsartan medoxomil and hydrochlorothiazide","Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure|Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure|Change From Baseline in Mean Trough Systolic Blood Pressure (22 to 24 Hours After Dosing) as Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline in Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing) as Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline in 24-hour Mean Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing as Measured by Ambulatory Blood Pressure Monitoring|Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing as Measured by Ambulatory Blood Pressure Monitoring.|Percentage of Participants Who Reached Their Trough, Sitting, Clinic Systolic Blood Pressure Targets, Defined as <140 mm Hg for Participants Without Diabetes or Chronic Kidney Disease or <130 mm Hg for Participants With Diabetes or Chronic Kidney Disease|Percentage of Participants Who Reached Their Trough, Sitting, Clinic Diastolic Blood Pressure Target, Defined as <90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease or <80 mm Hg for Participants With Diabetes or Chronic Kidney Disease.|Percentage of Participants Who Reached Their Trough, Sitting, Clinic Systolic and Diastolic Blood Pressure Targets, Defined as <140/90 mm Hg Without Diabetes or Chronic Kidney Disease or <130/80 mm Hg With Diabetes or Chronic Kidney Disease","Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 3","609","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-491CLD_306|U1111-1112-7119","February 2009","November 2009","November 2009","January 8, 2009","February 7, 2012","February 7, 2012","Birmingham, Alabama, United States|Gulf Shores, Alabama, United States|Scottsboro, Alabama, United States|Gilbert, Arizona, United States|Sierra Vista, Arizona, United States|Paramount, California, United States|Sacramento, California, United States|San Diego, California, United States|Colorado Springs, Colorado, United States|Wheat Ridge, Colorado, United States|Milford, Connecticut, United States|Adventura, Florida, United States|Aventura, Florida, United States|Brooksville, Florida, United States|Crystal River, Florida, United States|DeLand, Florida, United States|Doral, Florida, United States|Miami, Florida, United States|Naranja, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Winter Haven, Florida, United States|Atlanta, Georgia, United States|Stockbridge, Georgia, United States|Suwanee, Georgia, United States|Huntsville, Illinois, United States|Bloomington, Indiana, United States|Valparaiso, Indiana, United States|Crestview Hills, Kentucky, United States|Lexington, Kentucky, United States|West Yarmouth, Massachusetts, United States|Ann Arbor, Michigan, United States|St. Louis, Missouri, United States|St. Peters, Missouri, United States|New Windsor, New York, United States|Asheboro, North Carolina, United States|Cincinnati, Ohio, United States|Kettering, Ohio, United States|Downingtown, Pennsylvania, United States|Lancaster, Pennsylvania, United States|Lansdale, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Goose Creek, South Carolina, United States|Taylors, South Carolina, United States|Bryan, Texas, United States|San Antonio, Texas, United States|Ettrick, Virginia, United States|Seattle, Washington, United States|Madison, Wisconsin, United States|Moscow, Russian Federation|Perm, Russian Federation|St. Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00818883"
552,"NCT00931879","Lovaza® and Microvascular Function in Type 2 Diabetes",,"Completed","Has Results","Hypertriglyceridemia|Diabetic Neuropathy","Drug: omega-3-ethyl esters|Drug: Placebo","Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Conduction Amplitude.|Measurements of Indices of Large and Small Fiber Nerve Function Including Heart Rate Variation Measures.|Measurements of Indices of Large and Small Fiber Nerve Function Using Vibration and Thermal Thresholds.|Percent Change in Measurements of Indices of Large and Small Fiber Nerve Function Including Vibration Thresholds|Measurements of Indices of Large and Small Fiber Nerve Function Including Markers of Inflammation and Oxidative Stress.|Efficacy Measures Are Nerve Conduction Studies; Specifically, Increases in Conduction Velocity.|Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Latency.|Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in F-wave Conduction|Efficacy Measures Examining Increased Vascular Response to Ischemic Block and to Local Warming at the Dorsum of the Foot.","Eastern Virginia Medical School|GlaxoSmithKline","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","44","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","LVZ111903","October 2009","July 2012","July 2012","July 2, 2009","May 9, 2017","May 9, 2017","Strelitz Diabetes Center, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00931879"
553,"NCT02138825","Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)","RISE-IIP","Terminated","Has Results","Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo","Mean Change in 6 Minute Walking Distance (6MWD) From Baseline to Week 26|Number of Participants With Clinical Worsening","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","147","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13605|2010-024332-42","June 4, 2014","May 5, 2016","September 14, 2016","May 15, 2014","June 5, 2017","December 4, 2017","University of California, Los Angeles, Los Angeles, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Miami, Florida, United States|Orlando, Florida, United States|Via Christi Clinic, Wichita, Kansas, United States|Louisville, Kentucky, United States|Columbia University Medical Center, New York, New York, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Falls Church, Virginia, United States|Mar del Plata, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Godoy Cruz, Mendoza, Argentina|San Miguel de Tucumán, Tucuman, Argentina|Camperdown, New South Wales, Australia|Darlinghurst, New South Wales, Australia|Sydney, New South Wales, Australia|Chermside, Queensland, Australia|Adelaide, South Australia, Australia|Prahran, Victoria, Australia|Murdoch, Western Australia, Australia|Leuven, Belgium|Vancouver, British Columbia, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Quebec, Canada|Bogotá, Distrito Capital de Bogotá, Colombia|Floridablanca-Bucaramanga, Santander, Colombia|Cali, Valle del Cauca, Colombia|Bogotá, Colombia|Santafe de Bogotá, Colombia|Aarhus N, Denmark|Bron, France|Lille Cedex, France|Marseille, France|Paris Cedex 15, France|München, Bayern, Germany|München, Bayern, Germany|Würzburg, Bayern, Germany|Gießen, Hessen, Germany|Hannover, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Grosshansdorf, Germany|Athens, Greece|Haidari, Greece|Ioannina, Greece|Thessaloniki, Greece|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Forlì-Cesena, Emilia-Romagna, Italy|Roma, Lazio, Italy|Monza-Brianza, Lombardia, Italy|Palermo, Sicilia, Italy|Siena, Toscana, Italy|Seto, Aichi, Japan|Yokohama, Kanagawa, Japan|Sakai, Osaka, Japan|Shibuya-ku, Tokyo, Japan|Chiba, Japan|Auckland, New Zealand|Christchurch, New Zealand|Coimbra, Portugal|Porto, Portugal|Vila Nova de Gaia, Portugal|Moscow, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|Vladimir, Russian Federation|Riyadh, Saudi Arabia|Riyadh, Saudi Arabia|Riyadh, Saudi Arabia|Barcelona, Spain|Barcelona, Spain|Valencia, Spain|Bern, Switzerland|Genève, Switzerland|Zürich, Switzerland|Denizli, Turkey|Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Clydebank, West Dunbartonshire, United Kingdom|London, United Kingdom|Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02138825"
554,"NCT00865228","Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia",,"Terminated","No Results Available","Hypercholesterolemia","Drug: Lapaquistat acetate|Drug: Placebo","Percent change from Baseline in the Fasting Plasma Low-Density Lipoprotein Cholesterol concentration|Change from Baseline in Total Cholesterol|Percent change from Baseline in apolipoprotein B|Percent change from Baseline in apolipoprotein A1|Change from Baseline in Triglycerides|Percent change from Baseline in High-Density Lipoprotein Cholesterol|Percent change from Baseline in Very Low-Density Lipoprotein Cholesterol|Percent change from Baseline in non- High-Density Lipoprotein Cholesterol|Percent change from Baseline in derived ratio of Low-Density Lipoprotein Cholesterol / High-Density Lipoprotein Cholesterol|Percent change from Baseline in derived ratio of Total Cholesterol / High-Density Lipoprotein Cholesterol|Percent change from Baseline in derived ratio of apolipoprotein B / apolipoprotein A1|Change from Baseline in high sensitivity C-Reactive Protein.","Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 2","224","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-475_201|U1111-1122-8404","July 2007","November 2007","November 2007","March 19, 2009",,"May 24, 2012","Long Beach, California, United States|Sacramento, California, United States|San Diego, California, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|New Port Richey, Florida, United States|Chicago, Illinois, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Margate, New Jersey, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Statesville, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Medford, Oregon, United States|Perkasie, Pennsylvania, United States|Sellerville, Pennsylvania, United States|Bristol, Tennessee, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00865228"
555,"NCT01033071","Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.",,"Completed","Has Results","Essential Hypertension","Drug: Azilsartan medoxomil and chlorthalidone|Drug: Olmesartan medoxomil and hydrochlorothiazide","Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.|Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure.|Change From Baseline in Mean Trough Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.|Change From Baseline in Mean Trough Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.|Change From Baseline in 24-hour Mean Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.|Change From Baseline in 24-hour Mean Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.|Change From Baseline in Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.|Change From Baseline in Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.|Change From Baseline in Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.|Change From Baseline in Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.|Change From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.|Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.|Change From Baseline in the Mean Systolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.|Change From Baseline in the Mean Diastolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.|Percentage of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline.|Percentage of Participants Who Reached Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.|Percent of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline and Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.","Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 3","1071","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-491CLD_303|U1111-1112-4298","January 2010","October 2010","November 2010","December 16, 2009","February 7, 2012","February 7, 2012","Gulf Shores, Alabama, United States|Litchfield Park, Arizona, United States|Mesa, Arizona, United States|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Buena Park, California, United States|Carmichael, California, United States|Greenbrae, California, United States|Irvine, California, United States|Paramount, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|Spring Valley, California, United States|Wildomar, California, United States|Colorado Springs, Colorado, United States|Milford, Connecticut, United States|Waterbury, Connecticut, United States|Newark, Delaware, United States|Aventura, Florida, United States|Clearwater, Florida, United States|Deland, Florida, United States|Fort Lauderdale, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Plant City, Florida, United States|Tallahassee, Florida, United States|Tampa, Florida, United States|West Palm beach, Florida, United States|Winter Haven, Florida, United States|Dunwoody, Georgia, United States|Roswell, Georgia, United States|Suwanee, Georgia, United States|Chicago, Illinois, United States|Melrose Park, Illinois, United States|Naperville, Illinois, United States|Avon, Indiana, United States|Indianapolis, Indiana, United States|Valparaiso, Indiana, United States|Crestview Hills, Kentucky, United States|Lexington, Kentucky, United States|Auburn, Maine, United States|Brockton, Massachusetts, United States|Hyannis, Massachusetts, United States|West Yarmouth, Massachusetts, United States|Ann Arbor, Michigan, United States|St Louis, Missouri, United States|St Peters, Missouri, United States|Henderson, Nevada, United States|Margate, New Jersey, United States|Wildwood Crest, New Jersey, United States|Albuquerque, New Mexico, United States|Glens Falls, New York, United States|Boiling Springs, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Willoughby Hills, Ohio, United States|Oklahoma City, Oklahoma, United States|Yukon, Oklahoma, United States|Ashland, Oregon, United States|Portland, Oregon, United States|Bensalem, Pennsylvania, United States|Feasterville, Pennsylvania, United States|Lansdale, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Reading, Pennsylvania, United States|Tipton, Pennsylvania, United States|Cranston, Rhode Island, United States|Cumberland, Rhode Island, United States|Mt Pleasant, South Carolina, United States|Simpsonville, South Carolina, United States|Beaumont, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|North Richland Hills, Texas, United States|San Antonio, Texas, United States|Magna, Utah, United States|Manassas, Virginia, United States|Lakewood, Washington, United States|Port Orchard, Washington, United States|Madison, Wisconsin, United States|Menomonee Falls, Wisconsin, United States|Abbotsford, British Columbia, Canada|Powell River, British Columbia, Canada|Mount Pearl, Newfoundland and Labrador, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Sarnia, Ontario, Canada|Vaughan, Ontario, Canada|Whitby, Ontario, Canada|Woodstock, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01033071"
556,"NCT01211860","Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects",,"Completed","No Results Available","Hypertriglyceridmia","Drug: Diazoxide Choline Controlled-Release Tablet","Steady-state Pharmacokinetic profile of DCCR|Concentration-Time profile of major metabolite","Essentialis, Inc.|Cetero Research, San Antonio","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","9","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","PK015","October 2010","November 2010","November 2010","September 30, 2010",,"January 10, 2014","Cetero, Fargo, North Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01211860"
557,"NCT03691662","A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study",,"Active, not recruiting","No Results Available","Glaucoma and Ocular Hypertension","Drug: DE-117 Ophthalmic Solution|Drug: Timolol Maleate Ophthalmic Solution 0.5%","Intraocular pressure","Santen Inc.","All","12 Months and older   (Child, Adult, Older Adult)","Phase 3","409","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","011710IN","September 27, 2018","December 31, 2019","December 31, 2019","October 2, 2018",,"December 16, 2019","Arizona Eye Center, Chandler, Arizona, United States|M & M Eye Institute, Prescott, Arizona, United States|Global Research Management, Glendale, California, United States|United Medical Research Inst, Inglewood, California, United States|Eye Research Foundation, Newport Beach, California, United States|North Bay Eye Associates Inc., Petaluma, California, United States|Sacramento Eye Consultants, Sacramento, California, United States|AdvanceMed Clinical Research, San Diego, California, United States|Michael K. Tran, MD, Inc., Westminster, California, United States|Haas Vision Center, Colorado Springs, Colorado, United States|Florida Ophthalmic Institute, Gainesville, Florida, United States|St. Michaels Eye Laser Institute, Largo, Florida, United States|International Eye Associates PA, Ormond Beach, Florida, United States|East Florida Eye Institute, Stuart, Florida, United States|Clayton Eye Clinical Research, LLC, Morrow, Georgia, United States|Seidenberg Protzko Eye Associates, Havre De Grace, Maryland, United States|Great Lakes Eye Care P.C, Saint Joseph, Michigan, United States|Discover Vision Centers, Independence, Missouri, United States|Silverstein Eye Centers, Kansas City, Missouri, United States|Comprehensive Eye Care Ltd., Washington, Missouri, United States|AdvanceMed Clinical Research, Las Vegas, Nevada, United States|Rochester Ophthalmological Group, PC, Rochester, New York, United States|Asheville Eye Associates, Asheville, North Carolina, United States|Abrams Eye Center, Cleveland, Ohio, United States|Total Eye Care PA, Memphis, Tennessee, United States|VRF Eye Specialty Group, Memphis, Tennessee, United States|Glaucoma Associates of Texas, Dallas, Texas, United States|Houston Eye Associates HEA - Gramercy Location, Houston, Texas, United States|Baylor College of Medicine Alkek Eye Center, Houston, Texas, United States|The Eye Clinic of Texas, League City, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Stacy R. Smith M.D. P.C., Salt Lake City, Utah, United States|Vistar Eye Center, Roanoke, Virginia, United States|Tidewater Clinical Research, Virginia Beach, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03691662"
558,"NCT03691649","A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study",,"Active, not recruiting","No Results Available","Glaucoma and Ocular Hypertension","Drug: DE-117 Ophthalmic Solution|Drug: Timolol Maleate Ophthalmic Solution 0.5%","Intraocular pressure","Santen Inc.","All","12 Months and older   (Child, Adult, Older Adult)","Phase 3","427","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","011709IN","September 14, 2018","December 31, 2019","October 30, 2020","October 2, 2018",,"December 16, 2019","Arizona Glaucoma Specialists, Phoenix, Arizona, United States|DocTrials Walman Eye Center, Sun City, Arizona, United States|Havana Research Institute, Burbank, California, United States|Macy Eye Center, Los Angeles, California, United States|North Valley Eye Medical Group, Mission Hills, California, United States|North Bay Eye Associates, Inc, Petaluma, California, United States|Martel Eye Medical Group, Rancho Cordova, California, United States|Samsum Clinic (DocTrials), Santa Barbara, California, United States|MCB Clinical Research Centers LLC, Colorado Springs, Colorado, United States|Hernando Eye Institute, Brooksville, Florida, United States|Eye Associates of Fort Myers, Fort Myers, Florida, United States|Bowden Eye & Associates, Jacksonville, Florida, United States|Shettle Eye Research, Largo, Florida, United States|Dixophthal PC Dba. Dixon Eye Care, Albany, Georgia, United States|Coastal Research Associates, Alpharetta, Georgia, United States|Clayton Eye Clinical Research, LLC, Morrow, Georgia, United States|Indiana University, Bloomington, Indiana, United States|Heart of America Eye Care, P.A., Shawnee Mission, Kansas, United States|Clinical Eye Research of Boston, LLC, Winchester, Massachusetts, United States|Tauber Eye Center, Kansas City, Missouri, United States|Nevada Eye Care Professionals, Las Vegas, Nevada, United States|Wellish Vision Institute, Las Vegas, Nevada, United States|AdvanceMed Clinical Research-Las Vegas, Las Vegas, Nevada, United States|Northern New Jersey Eye Institute, South Orange, New Jersey, United States|NY Eye & ear Infirmary of Mt Sinai (NYEE), New York, New York, United States|South Shore Eye Care, LLP, Wantagh, New York, United States|Asheville Eye Associates, Asheville, North Carolina, United States|Charlotte Eye Ear Nose & Throat Associates, PA, Charlotte, North Carolina, United States|Cornerstone Eye Care, High Point, North Carolina, United States|Apex Eye Clinical Research, LLC, Cincinnati, Ohio, United States|Ophthalmic Surgeons & Consultants of Ohio, Inc., Columbus, Ohio, United States|Office of Mark J. Weiss MD, Tulsa, Oklahoma, United States|Scott & Christie and Associates PC, Cranberry Township, Pennsylvania, United States|Glaucoma Consultants and Center for Eye Research PA, Mount Pleasant, South Carolina, United States|Black Hills Regional Eye Institute, LLP, Rapid City, South Dakota, United States|University Eye Specialists, Maryville, Tennessee, United States|Total Eye Care PA, Memphis, Tennessee, United States|Keystone Research Ltd. Texan Eye PA, Austin, Texas, United States|The Cataract and Glaucoma Center, El Paso, Texas, United States|Ophthalmology Associates, Fort Worth, Texas, United States|Shah Research LLC dba Discovery Clinical Trials, Mission, Texas, United States|San Antonio Eye Center, San Antonio, Texas, United States|R and R Eye Research LLC, San Antonio, Texas, United States|Delay Winter Eye Consultants LLC, San Antonio, Texas, United States|Stacy R. Smith M.D. P.C., Salt Lake City, Utah, United States|Emerson Clinical Research Institute, Falls Church, Virginia, United States|Specialty Eye Care Centre, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03691649"
559,"NCT01103245","Aldosterone and the Metabolic Syndrome",,"Completed","Has Results","Metabolic Diseases|Diabetes Mellitus|Endocrine System Diseases|Glucose Metabolism Disorders","Drug: Hydrochlorothiazide (HCTZ)|Drug: Aliskiren 150 mg (ALI 150)|Drug: Spironolactone (SPL 25)|Drug: Aliskiren 300 mg (ALI 300)|Drug: Spironolactone 50 mg (SPL 50)","Plasma Insulin|Plasma Glucose","Vanderbilt University Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","69","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","091072|09CRP2261428","March 2010","July 2012","September 2013","April 14, 2010","November 5, 2018","November 5, 2018","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01103245"
560,"NCT01487460","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients",,"Completed","No Results Available","Dyslipidemia|Healthy Volunteers","Drug: TAP311","Safety and tolerability of single and multiple doses of TAP311 in healthy subjects and patients with dyslipidemia|TAP311 concentrations in blood and urine following administration of single and multiple doses in healthy subjects and in patients with dyslipidemia.|Effect of TAP311 administration on simvastatin (and metabolite) blood concentration in healthy subjects.|Effect of food on TAP311 blood concentration in healthy subjects.|Effects of TAP311 on total cholesterol in patients with dyslipidemia|Effects of TAP311 on Low Density Lipoprotein (LDL-C) in patients with dyslipidemia|Effects of TAP311 on high density lipoprotein (HDL-C)in patients with dyslipidemia.|Effects of TAP311 on triglycerides in patients with Dyslipidemia","Novartis Pharmaceuticals|Novartis","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","137","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","CTAP311X2101","November 2011","June 2012","June 2012","December 7, 2011",,"April 19, 2016","Novartis Investigative Site, Miramar, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01487460"
561,"NCT02178098","Evaluation of ETC-1002 in Patients With Hypercholesterolemia and Hypertension",,"Completed","No Results Available","Hypercholesterolemia|Hypertension","Drug: ETC-1002|Drug: Placebo","Percent change in calculated LDL-cholesterol (LDL-C)|Change in 24-hour, day-time and night-time mean systolic blood pressure|Change in 24-hour, day-time and night-time mean diastolic blood pressure|Percent change in high-sensitivity C-reactive protein (hsCRP)","Esperion Therapeutics|Medpace, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","143","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1002-014","June 2014","July 2015","July 2015","June 30, 2014",,"March 29, 2019","Birmingham, Alabama, United States|Chandler, Arizona, United States|Phoenix, Arizona, United States|DeLand, Florida, United States|Fort Lauderdale, Florida, United States|Hialeah, Florida, United States|Pembroke Pines, Florida, United States|Pembroke Pines, Florida, United States|Port Orange, Florida, United States|Gurnee, Illinois, United States|Indianapolis, Indiana, United States|Kansas City, Kansas, United States|Paducah, Kentucky, United States|Auburn, Maine, United States|Olive Branch, Mississippi, United States|Butte, Montana, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Endwell, New York, United States|Wilmington, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Willoughby Hills, Ohio, United States|Eugene, Oregon, United States|Downingtown, Pennsylvania, United States|Charleston, South Carolina, United States|Simpsonville, South Carolina, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Kenosha, Wisconsin, United States|Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02178098"
562,"NCT03773172","Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism",,"Recruiting","No Results Available","Cardiovascular Diseases","Drug: MEDI6012|Drug: Placebo","Percent Change in FCR of LDL-apoB100 (pools/day)|PR of LDL apoB100 (mg/kg/day)","Columbia University|MedImmune LLC|AstraZeneca","All","35 Years to 80 Years   (Adult, Older Adult)","Phase 2","8","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AAAS0459","January 31, 2019","October 2019","May 2020","December 12, 2018",,"April 1, 2019","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03773172"
563,"NCT02833012","Evaluation of PK of Caprylic Triglyceride Oil, AC-1202, AC-1204, and Axona on Ketone Body Production",,"Completed","No Results Available","Healthy","Drug: Caprylic Triglyceride Oil|Drug: AC-1202|Drug: Axona|Drug: AC-1204","total ketones AUC0-t|total ketones AUC0-inf|total ketones AUC%extap|total ketones Cmax|total ketones Kel|total ketones T 1/2|total ketones Tmax|β hydroxybutyrate AUC0-t|β hydroxybutyrate AUC0-inf|β hydroxybutyrate AUC%extap|β hydroxybutyrate Cmax|β hydroxybutyrate Kel|β hydroxybutyrate T 1/2|β hydroxybutyrate Tmax|estimate of acetoacetate AUC0-t|estimate of acetoacetate AUC0-inf|estimate of acetoacetate AUC%extap|estimate of acetoacetate Cmax|estimate of acetoacetate Kel|estimate of acetoacetate T 1/2|estimate of acetoacetate Tmax","Cerecin|Celerion","Male","18 Years to 55 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","AC-16-012_BE","July 2016","September 2016","December 2016","July 14, 2016",,"April 11, 2017","Celerion, Inc, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02833012"
564,"NCT03657095","BPS-314d-MR-PAH-303 (BEAT OLE)","BEAT OLE","Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Beraprost Sodium 314d Modified Release tablets","Incidence of treatment-related adverse events|Severity of treatment-related adverse events|6 Minute Walk Distance (6MWD)|Borg Dyspnea Score|World Health Organization (WHO) Functional Class (FC)|N-terminal pro-brain natriuretic peptide (NT-pro-BNP)","Lung Biotechnology PBC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","112","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BPS-314d-MR-PAH-303","December 10, 2018","July 20, 2019","July 20, 2019","September 4, 2018",,"November 4, 2019","The University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Beverly Hills, California, United States|University of California San Diego Medical Center, La Jolla, California, United States|University of California Los Angeles UCLA, Los Angeles, California, United States|West Los Angeles VA Healthcare Center, Los Angeles, California, United States|Santa Barbara Pulmonary Associates, Santa Barbara, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|Allianz Research Institute, Westminster, California, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|Aurora Denver Cardiology Associates, Denver, Colorado, United States|South Denver Cardiology Associates, Littleton, Colorado, United States|Bay Area Cardiology Research, Brandon, Florida, United States|University of Florida Clinical Research Center, Gainesville, Florida, United States|Florida Hospital, Orlando, Florida, United States|South Miami Heart Specialists, South Miami, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University, Atlanta, Georgia, United States|Pulmonary & Critical Care of Atlanta, Atlanta, Georgia, United States|Georgia Clinical Research, Austell, Georgia, United States|Indiana University Health North Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Louisville Research Foundation, Louisville, Kentucky, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beaumont Health, Troy, Michigan, United States|Albany Medical Center, Albany, New York, United States|The Mount Sinai Hospital, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|The University of Toledo, Toledo, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Anderson Pharmaceutical Research, LLC, Anderson, South Carolina, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Scott & White Memorial Hospital, Temple, Texas, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Rabin Medical Center, Petah Tikva, Israel|The Chaim Sheba Medical Center, Tel Hashomer, Israel",,"https://ClinicalTrials.gov/show/NCT03657095"
565,"NCT01241903","Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions",,"Completed","Has Results","Acute Coronary Syndrome|Angioplasty, Transluminal, Percutaneous Coronary|Hydroxymethylglutaryl-CoA Reductase Inhibitors|Blood Platelets","Drug: rosuvastatin|Drug: placebo","Platelet - Leukocyte Aggregates|Biomarkers of Platelet Function and Myocardial Necrosis","Susan Smyth|University of Kentucky","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10-208-F1V","June 2011","August 2013","February 2014","November 16, 2010","June 24, 2014","March 28, 2017","University of Kentucky Dept of Cardiology, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT01241903"
566,"NCT00979121","Statins for Acutely Injured Lungs From Sepsis","SAILS","Terminated","Has Results","Sepsis|Acute Lung Injury","Drug: Rosuvastatin|Drug: Placebo","Hospital Mortality to Day 60.|Ventilator Free Days at Study Day 28","National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","745","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","670|N01HR056179","January 2010","November 2013","November 2013","September 17, 2009","October 3, 2014","May 16, 2016","University of San Francisco-Fresno Medical Center, Fresno, California, United States|University of California, Davis Medical Center, Sacramento, California, United States|UCSF-Moffitt Hospital, San Francisco, California, United States|University of California, San Francisco (UCSF)-Moffitt Hospital, San Francisco, California, United States|Centura St. Anthony Central Hospital, Denver, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|University of Colorado Health Sciences Center, Denver, Colorado, United States|Washington Hospital Center, Washington DC, District of Columbia, United States|Baton Rouge General Hospital-Blue Bonnet, Baton Rouge, Louisiana, United States|Baton Rouge General Hospital-Midcity, Baton Rouge, Louisiana, United States|Earl K. Long Medical Center, Baton Rouge, Louisiana, United States|Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States|Medical Center of Louisiana, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|University of Maryland Shock Trauma Center, Baltimore, Maryland, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Rochester Methodist Hospital, Rochester, Minnesota, United States|St. Mary's Hospital, Mayo Clinic, Rochester, Minnesota, United States|Duke University Medical Center, Durham, North Carolina, United States|Durham Regional Medical Center, Durham, North Carolina, United States|Moses Cone Health System, Greensboro, North Carolina, United States|Wesley Long Community Hospital, Greensboro, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston Salem, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|McKay-Dee Hospital, Ogden, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|University of Virginia Medical Center, Charlottesville, Virginia, United States|Providence Hospital, Everett, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00979121"
567,"NCT03397121","Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)","ORION-9","Active, not recruiting","No Results Available","Heterozygous Familial Hypercholesterolemia|Elevated Cholesterol","Drug: Inclisiran|Drug: Placebo","Percentage Change In LDL-C from Baseline To Day 510|Time-adjusted Percentage Change in LDL-C from Baseline After Day 90 and up to Day 540 Levels|Absolute Change in LDL-C from Baseline to Day 510|Time-adjusted Absolute Change in LDL-C from Baseline After Day 90 and up to Day 540|Percentage Change in Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) from Baseline to Day 510|Percentage Change in Total Cholesterol from Baseline to Day 510|Percentage Change in Apolipoprotein B (ApoB) from Baseline To Day 510|Percentage Change in Non-high-density Lipoprotein (HDL)-C from Baseline To Day 510","The Medicines Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","482","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","MDCO-PCS-17-03|2017-002472-30","November 28, 2017","September 27, 2019","September 27, 2019","January 11, 2018",,"September 17, 2019","Site 90001-005, Mission Viejo, California, United States|Site 90001-001, Newport Beach, California, United States|Site 90001-015, Stanford, California, United States|Site 90001-047, Boca Raton, Florida, United States|Site 90001-004, Boston, Massachusetts, United States|Site 90001-056, Saint Paul, Minnesota, United States|Site 90001-012, Butte, Montana, United States|Site 90001-112, Las Vegas, Nevada, United States|Site 90001-014, Summit, New Jersey, United States|Site 90001-002, Cincinnati, Ohio, United States|Site 90011-005, Chicoutimi, Quebec, Canada|Site 90011-001, Montréal, Quebec, Canada|Site 90011-002, Quebec City, Quebec, Canada|Site 90420-001, Prague, Czechia|Site 90420-006, Prague, Czechia|Site 90420-005, Trutnov, Czechia|Site 90045-001, Aalborg, Denmark|Site 90045-004, Esbjerg, Denmark|Site 90045-003, Herning, Denmark|Site 90045-006, Hvidovre, Denmark|Site 90045-002, Roskilde, Denmark|90045-005, Viborg, Denmark|Site 90031-001, Amersfoort, Netherlands|Site 90031-003, Amsterdam, Netherlands|Site 90031-009, Hoorn, Netherlands|Site 90031-006, Tilburg, Netherlands|Site 90031-005, Utrecht, Netherlands|Site 90027-004, Cape Town, Western Cape, South Africa|Site 90027-003, Bloemfontein, South Africa|Site 90027-005, Cape Town, South Africa|Site 90027-001, Cape Town, South Africa|Site 90027-008, Cape Town, South Africa|Site 90027-010, Johannesburg, South Africa|Site 90027-007, Pretoria, South Africa|Site 90027-006, Pretoria, South Africa|Site 90027-009, Witbank, South Africa|Site 90034-003, A Coruña, Spain|Site 90034-005, Barcelona, Spain|Site 90034-004, Córdoba, Spain|Site 90034-006, L'Hospitalet De Llobregat, Spain|Site 90034-001, Reus, Spain|Site 90034-002, Zaragoza, Spain|Site 90046-002, Göteborg, Sweden|Site 90046-001, Stockholm, Sweden|Site 90046-003, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03397121"
568,"NCT01604824","A Study of Alirocumab (REGN727/SAR236553) in Patients With ADH and GOFm of the PCSK9 Gene or LOFm of the apoB Gene",,"Unknown status","No Results Available","Hypercholesterolemia","Drug: alirocumab|Drug: placebo","Percent change in serum LDL-C|TEAEs|Percent change in ApoB100|Percent change in non-HDL-C|Percent change in total cholesterol|Percent change in ApoB100/ApoA1 ratio|Trough concentrations of total alirocumab|Immunogenicity of repeat SC dosing","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1018","September 2012","May 2014","September 2016","May 24, 2012",,"January 30, 2015","Salt Lake City, Utah, United States|Lille, Cedex, France|Nante, Cedex, France|Paris, France",,"https://ClinicalTrials.gov/show/NCT01604824"
569,"NCT02364258","Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients","SD2","Completed","No Results Available","Dyslipidemia","Drug: Rosuvastatin|Drug: Atorvastatin","Evaluate effect of genotype (SLCO1BI) on Cmax rosuvastatin|Evaluate effect of genotype (SLCO1B1) on AUC rosuvastatin|Evaluate effect of genotype (SLCO1BI) on Cmax atorvastatin|Evaluate effect of genotype (SLCO1B1) on AUC atorvastatin|Evaluate the effect of age on Cmax of rosuvastatin|Evaluate the effect of gender on Cmax of rosuvastatin|Evaluate the effect of race on Cmax of rosuvastatin|Evaluate the effect of sexual maturity on Cmax of rosuvastatin|Evaluate the effect of age on Cmax of atorvastatin|Evaluate the effect of age on AUC of atorvastatin|Evaluate the effect of gender on AUC of atorvastatin|Evaluate the effect of race on AUC of atorvastatin|Evaluate the effect of sexual maturity on AUC of atorvastatin|Evaluate the effect of age on AUC of rosuvastatin|Evaluate the effect of gender on AUC of rosuvastatin|Evaluate the effect of race on AUC of rosuvastatin|Evaluate the effect of sexual maturity on AUC of rosuvastatin|Evaluate the effect of age on Ka of atorvastatin|Evaluate the effect of gender on Ka of atorvastatin|Evaluate the effect of race on Ka of atorvastatin|Evaluate the effect of sexual maturity on Ka of atorvastatin|Evaluate the effect of age on Ka of rosuvastatin|Evaluate the effect of gender on Ka of rosuvastatin|Evaluate the effect of race on Ka of rosuvastatin|Evaluate the effect of sexual maturity on Ka of rosuvastatin","Children's Mercy Hospital Kansas City","All","8 Years to 21 Years   (Child, Adult)","Phase 1","28","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13020063","July 2014","December 27, 2017","December 27, 2017","February 18, 2015",,"January 31, 2019","Children's Mercy Hospital, Kansas City, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02364258"
570,"NCT01106014","Selexipag (ACT-293987) in Pulmonary Arterial Hypertension","GRIPHON","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Selexipag|Drug: Placebo","Time From Randomization to the First Morbidity Event or Death (All Causes) up to 7 Days After the Last Study Drug Intake|Change From Baseline to Week 26 in 6-minute Walk Distance (6MWD) at Trough|Absence of Worsening From Baseline to Week 26 in Modified NYHA/WHO Functional Class (WHO FC)","Actelion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","1156","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-065A302","December 1, 2009","April 1, 2014","October 1, 2014","April 19, 2010","March 1, 2016","January 11, 2018","University of South Alabama, Mobile, Alabama, United States|The University of Arizona, Clinical and Translational Science (CATS) Research Center, Tucson, Arizona, United States|University of California San Diego Medical Center (La Jolla), La Jolla, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|GLVA Healthcare Center, Los Angeles, California, United States|University of California, Davis, UC Davis Medical Center, Sacramento, California, United States|LIU Center for Pulmonary Hypertension, Torrance, California, United States|Lung Health & Sleep Emhancement Center, LLC, Newark, Delaware, United States|Emory University School of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Atlanta, Georgia, United States|Georgia Health Sciences University, Augusta, Georgia, United States|Georgia Clinical Research, Austell, Georgia, United States|Clarian North Hospital, Carmel, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|LSU Health Science Center - New Orleans, New Orleans, Louisiana, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital - Pulmonary Critical Care Unit, Boston, Massachusetts, United States|Massachusetts General Hospital-Pulmonary Critical Care Unit, Boston, Massachusetts, United States|Boston University School of Medicine / Boston University Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Beaumont Hospital, Troy, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Newark Beth Isreal Medical Center-Department of Pulmonary Medicine, Newark, New Jersey, United States|Montefiore Medical Center, Weiler Division, Bronx, New York, United States|Columbia University Medical Center, Pediatric Cardiology, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Oregon Pulmonary Associates, PC, Portland, Oregon, United States|Central Bucks Specialists, Doylestown, Pennsylvania, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas-Houston Health Center Department of Pulmonary & Critical Care, Houston, Texas, United States|University of Wisconsin Hospital-Department of Medicine, Madison, Wisconsin, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Froedtert Hospital - Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Centro de Investigacion y Prevencion Cardiovascular (CIPREC), Buenos Aires, Argentina|Sanatorio Otamendi y Miroli S.A., Buenos Aires, Argentina|Hospital Britanico-Pneumology, Buenos Aires, Argentina|Sanatorio San Jose, Buenos Aires, Argentina|Hospital Privado Centro Medico de Cordoba S.A., Cordoba, Argentina|Instituto De Cardiologia de Corrientes, Corrientes, Argentina|St. Vincent's Hospital / Heart and Lung Transplant Unit, Darlinghurst, New South Wales, Australia|Prince Charles Hospital Lung Transplant, Thoracic Department, Chermside, Queensland, Australia|Royal Adelaide Hospital, Cardiovascular Investigation Unit (CVIU), Adelaide, South Australia, Australia|Flinders Medical Centre, Pulmonary Hypertension, c/- Cardiology, Bedford Park, South Australia, Australia|St Vincent's Hospital, Fitzroy, Victoria, Australia|Royal Hobart Hospital, Centre for Clinical Research, Hobart, Australia|John Hunter Hospital Autoimmune Resource and Research Centre, New Lambton, Australia|Royal Melbourne Hospital, Department of Respiratory and Sleep Medicine, Parkville, Australia|Royal Perth Hospital, Perth, Australia|Medizinische Universität Graz, Graz, Austria|Medical University of Vienna and AKH Cardiology, Vienna, Austria|The Republican Scientific-Practical Center ""Cardiology"", Minsk, Belarus|Minsk City Hospital No. 9, Minsk, Belarus|Minsk Regional Clinical Hospital of the Red Banner of Labour, Minsk, Belarus|Ulb Erasme, Cardiology, Brussels, Belgium|University Hospital Gasthuisberg - Pneumologie, Leuven, Belgium|University of Alberta Hospital - Children's Centre, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Hopital General Juif (Jewish General Hospital), Montreal, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec City, Quebec, Canada|Instituto Nacional del Torax Teaching Dept, Santiago, Chile|Clinica Tabancura- Cardiology Unit, Santiago, Chile|Pontificia Universidad Catolica de Chile-Departmento De Enfermedades Cardiovasculares, Santiago, Chile|Peking Union Medical College Hospital, Rheumatology Department, Beijing, China|Cardiovascular Institute & Fuwai Hospital-Pulmonary Vascular Center, Beijing, China|Beijing Shijitan Hospital, Beijing, China|Guangdong General Hospital, Cardiology Department, Guangzhou, China|Renji Hospital, Rheumatology Department, Shanghai, China|Renji Hospital, Cardiology Department, Shanghai, China|Shanghai Pulmonary Hospital, Department of Pulmonary Circulation, Shanghai, China|Fundacion Cardio Infantil, Bogota, Colombia|Fundacion Clinica Shaio, Bogota, Colombia|Gen Faculty Hosp Prague Cardiology Clin, Praha 2, Czechia|Aarhus University Hospital , Cardiology, Arhus, Denmark|Rigshospitalet, Hjertemedicinsk klinik - Cardiology, Copenhagen, Denmark|Hosp Pradel Lyon - Dpt Pneumology, Bron cedex, France|Hosp Cote de Nacre - Dpt Pneumology, Caen Cedex, France|Hosp A. Beclere - Dept Pulmo & Resp Intensive Care, Clamart, France|Hosp Huriez - Dpt Internal Medecine, Lille Cedex, France|Hosp Civil - Dpt Pneumology, Strasbourg, France|Hosp Larrey - Dpt Pneumology, Toulouse Cedex 9, France|DRK Kliniken Köpenick, Berlin, Germany|Universitätsklinikum Carl Gustav Carus, Medizinische Klinik1-Pneumologie/MK1-A13, Dresden, Germany|""Justus-Liebig-Universität Gießen Zentrum für Innere Medizin Medizinische Klinik II"", Giessen, Germany|Universität Greifswald / Klinik für Innere Medizin B, Greifswald, Germany|Medizinische Hochschule Hannover / Klinik für Pneumologie, Hannover, Germany|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|""Universitätsklinikum Köln Herzzentrum / Klinik III für Innere Medizin (Kardiologie, Pneumologie, Angiologie und Intensivmedizin)"", Köln, Germany|Praxis für Pneumologie und Allergologie, Leipzig, Germany|Klinik Löwenstein gGmbH, Medizinische Klinik 1, Pneumologie - Kardiologie, Löwenstein, Germany|Universitätsklinkum Regensburg / Innere Medizin II, Regensburg, Germany|Onasseio Cardiosurgical Hospital, Athens, Greece|""Gottsegen György Országos Kardiológiai Intézet, Felnőtt kardiológiai osztály"", Budapest, Hungary|""Semmelweis Egyetem, Pulmonológiai Klinika"", Budapest, Hungary|Egészségügyi Járóbeteg Központ Kardiológiai Intézete - Debrecen, Debrecen, Hungary|""Pécsi Tudományegyetem Klinikai Központ,, Pécs, Hungary|""Szegedi Tudományegyetem ÁOK Szent-Györgyi Albert Klinikai Központ, II. sz. Belgyógyászati klinika és Kardiológiai központ"", Szeged, Hungary|Sanjivani Hospitals - Department of Cardiology, Ahmedabad, India|Apollo Hospitals, Chennai, Chennai, India|Frontier Lifeline Hospitals, Dr KM Cherian Heart Foundation, Chennai, Chennai, India|CARE Hospitals Nampally, Cardiology Dep. Hyderabad, Hyderabad, India|Apollo Indraprastha Hospitals, New Delhi, India|Mater Miscordiae University Hospital, Dublin, Ireland|Carmel Medical Center, Pulmonary Unit, Haifa, Israel|Pulmonology Institute, Hadassah University Hospital at Ein Karem, Jerusalem, Israel|Rabin Medical Centre - Pulmonology, Petach Tikvah, Israel|Kaplan Medical - Pulmonary Institute, Rehovot, Israel|The Chaim Sheba Med Ctr -Pulmonology, Tel-Hashomer, Israel|Policlinico S. Orsola-Malpighi - Dipartimento Cardio-Toraco-Vascolare, Bologna, Italy|Seconda Università Degli Studi di Napoli - Azienda Universitaria Policlinico - Dipartimento Assistenziale di medicina Generale, Angiologia, Endocrinologia, Epatogastroenterologia e Reumatologia - Unità Operativa di Reumatologia, Napoli, Italy|ISMETT - Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione - Dipartimento di Medicina - Divisione di Pneumologia, Palermo, Italy|Gil Medical Centre, Incheon, Korea, Republic of|Seoul Nathional University Hospital, Seoul, Korea, Republic of|Yonsei University Health System Dept of Cardiology, Seoul, Korea, Republic of|Samsung Medical Center, Division of Cardiology, Seoul, Korea, Republic of|""The Catholic University of Korea, Seoul St. Mary's Hospital Department of Cardiology"", Seoul, Korea, Republic of|Institut Jantung Negara (National Heart Institute), Kuala Lumpur, Malaysia|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubrian, Mexico City, Mexico|Instituto Nacional de Cardiologia (INC) Ignacio Chavez, Mexico City, Mexico|VU Medisch Centrum / Afdeling longziekten, secretariaat 4A 48, Amsterdam, Netherlands|Academisch Ziekenhuis Maastricht / Department of Pulmonary Diseases, Maastricht, Netherlands|St. Antonius Ziekenhuis afdeling Longziekten, Nieuwegein, Netherlands|Erasmus Medisch Centrum Rotterdam afdeling longziekten, Rotterdam, Netherlands|Hospital Nacional Edgardo Rebagliati / Unidad de Investigacion Cardiologia 2, Lima, Peru|Instituto de Enfermedades Respiratorias Clinica San Gabriel, Lima, Peru|""Uniwersyteckie Centrum Kliniczne II Klinika Kardiologii i Elektroterapii Serca"", Gdańsk, Poland|""Instytut Kardiologii Collegium Medium UJ Krakowski Szpital Specjalistyczny im Jana Pawła II Klinika Chorób Serca i Naczyń"", Krakow, Poland|""Instytut Gruźlicy i Chorób Płuc Klinika Chorób Wewnętrznych Klatki Piersiowej"", Warszawa, Poland|""Wojewódzki Specjalistyczny Szpital im. dr Władysława Biegańskiego Oddział Kardiologiczny, II Katedra i Klinika Kardiologii UM"", Łódź, Poland|""Institutul de Pneumologie ""Marius Nasta"", I. Clinica de Pneumoftiziologie"", Bucharest, Romania|""Spitalul Clinic de Pneumoftiziologie Iasi Sectia Clinica I de Pneumoftiziologie"", Iasi, Romania|Municipal Medical Institution City Hospital #5, Barnaul, Russian Federation|Regional Clinical Hospital # 1, Ekaterinburg, Russian Federation|Kemerovo Cardiology Dispensary / Kemerovo Regional Hospital, Kemerovo, Russian Federation|Scientific Research Institute of Pulmonology of the Federal Medical and Biological Agency of Russia, Moscow, Russian Federation|State Institution, ""Institute fo Rheumatology of RAMS"", Moscow, Russian Federation|The Institution of the Clinical Cardiology named after A. L. Myaskinov, Moscow, Russian Federation|Limited liability company, Consultative diagnostic centre Healthy Joints, Novosibirsk, Russian Federation|V. A. Almazov Institute of Cardiology, Russian Ministry of Healthcare and Social Development / Medical Treatment and Rehabilitation Complex, St Petersburg, Russian Federation|Cardiology Scientific Research Institute of Tomsk Scientific Center of RAMs, Siberian Branch / Cardiovascular Surgery Department, Tomsk, Russian Federation|Tomsk Regional Clinical Hospital/ Pulmonology Unit, Tomsk, Russian Federation|""Klinički Centar Srbije, Klinika za pulmologiju"", Belgrade, Serbia|""Kliničko-bolnički centar Zemun, Kardiološko odeljenje"", Belgrade, Serbia|National Heart Centre (NHC) Singapore, Singapore, Singapore|Národný ústav srdcových a cievnych chorôb, a.s. - NÚSCH a.s., Bratislava, Slovakia|Hosp Vall D'Hebron - Barcelona - Pneumology, Barcelona, Spain|Clinic-Barcelona, Barcelona, Spain|Hospital 12 Octubre, Madrid, Spain|Sahlgrenska Universitetssjukhuset, Kardiologi, Goteborg, Sweden|Linköping University Hospital, Cardiology, Linköping, Sweden|Umeå University Hospital, Cardiology (Umeå), Umea, Sweden|Uppsala Akademiska Sjukhuset, Kardiologkliniken 50F, Uppsala, Sweden|University Hospital Basel Division of Pneumology, Basel, Switzerland|Universitätsspital Bern, Clinic for Pneumology (Inselspital), Bern, Switzerland|HUG Hôpitaux Universitaires de Genève; Pneumology, PAH, Genève 14, Switzerland|Kantonsspital St. Gallen Klinik für Pneumologie, St. Gallen, Switzerland|Kaohsiung Veterans General Hospital (KVGH), Kaohsiung, Taiwan|National Taiwan University Hospital / Department of Surgery, Taipei, Taiwan|Srinagarind Hospital, Khon Kaen University, Division of Allergy-Immunology and Rheumatology, Department of Medicine, Khon Kaen, Thailand|Çukurova Üniversitesi Tıp Fakültesi Kardiyoloji Anabilim Dalı, Adana, Turkey|Istanbul Üniversitesi Kardiyoloji Enstitisü, Istanbul, Turkey|Marmara Üniversitesi Tip Fakultesi Kardiyoloji Anabilim Dali, Istanbul, Turkey|Dokuz Eylül Üniversitesi Tıp Fakültesi Kardiyoloji Anabilim Dalı, İzmir, Turkey|""Dnipropetrovsk State Medical Academy, Municipal Institution """"Dnipropetrovsk Regional Clinic Diagnostic Center"""", Dnipropetrovsk, Ukraine|Health Care Municipal Institution, City Clinical Hospital #13, Kharkiv, Ukraine|Public Institution ""F.H. Yanovski Phthisiology and Pulmonology National Institute Under Ukrainian Academy of Medical Sciences"", Kyiv, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Golden Jubilee - Pulm Vascular Unit, Glasgow, United Kingdom|Royal Free & Ucms Rheumatology Unit, London, United Kingdom|Hammersmith, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01106014"
571,"NCT01236365","Statins in Children With Type 1 Diabetes and Hypercholesterolemia",,"Completed","Has Results","Diabetes Mellitus, Insulin-Dependent|Hypercholesterolemia","Drug: Atorvastatin|Drug: Atorvastatin Placebo","LDL-C Levels Assessed at Randomization and 6 Months|Hs-CRP Levels Assessed at Randomization and 6 Months|MAGE|RAGE|Descending Aortic Strain","Nemours Children's Clinic|Pfizer|Medtronic|Quest Diagnostics","All","10 Years to 20 Years   (Child, Adult)","Phase 3","42","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB# 185500","October 2010","October 2013","November 2014","November 8, 2010","May 21, 2015","June 25, 2019","Alfred I duPont Hospital, Wilmington, Delaware, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Nemours Children's Clinic, Orlando, Florida, United States|Nemours Children's Clinic, Pensacola, Florida, United States|Nemours Children's Clinic-Jefferson, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01236365"
572,"NCT00846365","Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension",,"Completed","Has Results","Essential Hypertension","Drug: Azilsartan medoxomil and chlorthalidone|Drug: Olmesartan medoxomil-hydrochlorothiazide","Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.|Change From Baseline to Week 4 in Trough, Sitting, Clinic Systolic Blood Pressure.|Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure|Change From Baseline in Trough Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline in Trough Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline in Daytime Mean (6am to 10pm) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline in Daytime Mean (6am to 10pm) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline in Nighttime Mean (12am to 6am) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring|Change From Baseline in Nighttime Mean (12am to 6am) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline in 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline in 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.|Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as <140 mm Hg for Participants Without Diabetes or CKD or <130 mm Hg for Participants With Diabetes or CKD|Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as Defined as <90 mm Hg for Participants Without Diabetes or CKD or <80 mm Hg for Participants With Diabetes or CKD|Percentage of Participants Who Achieve a Clinic Diastolic AND Systolic Blood Pressure Response, Defined as <140/90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease (CKD) or <130/80 mm Hg for Participants With Diabetes or CKD","Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 3","1085","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-491CLD_301|U1111-1112-4287","March 2009","June 2010","June 2010","February 18, 2009","March 13, 2012","March 13, 2012","Birmingham, Alabama, United States|Haleyville, Alabama, United States|Hueytown, Alabama, United States|Jasper, Alabama, United States|Tallassee, Alabama, United States|Green Valley, Arizona, United States|Phoenix, Arizona, United States|Long Beach, California, United States|National City, California, United States|Roseville, California, United States|San Francisco, California, United States|San Jose, California, United States|Newark, Delaware, United States|Clearwater, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Pembroke Pines, Florida, United States|Plant City, Florida, United States|Tallahassee, Florida, United States|Arlington Heights, Illinois, United States|Chicago, Illinois, United States|Gurnee, Illinois, United States|Avon, Indiana, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Baltimore, Maryland, United States|Brockton, Massachusetts, United States|Haverhill, Massachusetts, United States|North Dartmouth, Massachusetts, United States|Bingham Farms, Michigan, United States|Stevensville, Michigan, United States|Olive Branch, Mississippi, United States|Kansas City, Missouri, United States|New York, New York, United States|Burlington, North Carolina, United States|Charlotte, North Carolina, United States|Hickory, North Carolina, United States|Shelby, North Carolina, United States|Akron, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Marion, Ohio, United States|Middleburg Heights, Ohio, United States|Willoughby Hills, Ohio, United States|Norman, Oklahoma, United States|Bensalem, Pennsylvania, United States|Erie, Pennsylvania, United States|Reading, Pennsylvania, United States|Cranston, Rhode Island, United States|Cumberland, Rhode Island, United States|North Charleston, South Carolina, United States|Jackson, Tennessee, United States|Kingsport, Tennessee, United States|Milan, Tennessee, United States|Austin, Texas, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Arlington, Virginia, United States|Burke, Virginia, United States|Charlottesville, Virginia, United States|Manassas, Virginia, United States|Lakewood, Washington, United States|Port Orchard, Washington, United States|Menomonee Falls, Wisconsin, United States|Temuco, Cautín, Chile|La Serena, Elqui, Chile|Vina del Mar, Valparaíso, Chile|Osorno, Chile|Santiago, Chile|Tijuana, Baja California, Mexico|Leon, Guanajuato, Mexico|Guadalajara, Jalisco, Mexico|Chihuahua, Mexico|San Luis Potosi, Mexico",,"https://ClinicalTrials.gov/show/NCT00846365"
573,"NCT03029247","Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)",,"Recruiting","No Results Available","Anaemia","Drug: Daprodustat|Drug: Epoetin alfa","Average of 6-hour post dose systolic blood pressure (SBP) at Day 57|Average of 6-hour post dose SBP and diastolic BP (DBP) at Day 1 (millimeter of mercury [mmHg])|Average of mean arterial blood pressure (MAP) over 6-hour post dose at Day 1|Average heart rate over 6-hour post dose at Day 1|Area under the effect curve (AUEC) of SBP over 24-hour post-dose at Day 1|AUEC of DBP over 24-hour post-dose at Day 1|AUEC of MAP over 24-hour post-dose at Day 1|AUEC of heart rate over 24-hour post-dose at Day 1|Average of 6- hour post dose DBP at Day 57|Average of MAP over 6-hour post dosing at Day 57|Average of heart rate over 6-hour post dosing at Day 57|AUEC of SBP over 24-hour post-dose at Day 57|AUEC of DBP over 24-hour post-dose at Day 57|AUEC of MAP over 24-hour post-dose at Day 57|AUEC of heart rate over 24-hour post-dose at Day 57|Change from pre-dose in SBP, DBP, and MAP on Day 1 (mmHg)|Change from pre-dose in heart rate at each timepoint on Day 1|Maximum plasma concentration (Cmax) of daprodustat|Cmax of metabolite GSK2391220|Cmax of metabolite GSK2531403|Cmax of metabolite GSK2487818|Cmax of metabolite GSK2506102|Cmax of metabolite GSK2531398|Cmax of metabolite GSK2531401|Time to occurrence of Cmax (Tmax) of daprodustat|Tmax of metabolite GSK2391220|Tmax of metabolite GSK2531403|Tmax of metabolite GSK2487818|Tmax of metabolite GSK2506102|Tmax of metabolite GSK2531398|Tmax of metabolite GSK2531401|Terminal phase half-life (T1/2) of daprodustat|T1/2 of metabolite GSK2391220|T1/2 of metabolite GSK2531403|T1/2 of metabolite GSK2487818|T1/2 of metabolite GSK2506102|T1/2 of metabolite GSK2531398|T1/2 of metabolite GSK2531401|Area under concentration-time curve from time zero to 24 hours (AUC [0-24]) of daprodustat|AUC(0-24) of metabolite GSK2391220|AUC(0-24) of metabolite GSK2531403|AUC(0-24) of metabolite GSK2487818|AUC(0-24) of metabolite GSK2506102|AUC(0-24) of metabolite GSK2531398|AUC(0-24) of metabolite GSK2531401","GlaxoSmithKline|ERT: Clinical Trial Technology Solutions|Q2 Solutions|Quintiles, Inc.|HemoCue","All","40 Years and older   (Adult, Older Adult)","Phase 2","62","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","205665","July 27, 2017","July 31, 2020","July 31, 2020","January 24, 2017",,"April 8, 2020","GSK Investigational Site, La Mesa, California, United States|GSK Investigational Site, Lakewood, Colorado, United States|GSK Investigational Site, Coral Gables, Florida, United States|GSK Investigational Site, DeLand, Florida, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03029247"
574,"NCT02230891","Biomarker Guided Therapies in Stage A/B Heart Failure",,"Active, not recruiting","No Results Available","Hypertension|Diabetes|Cardiovascular Disease","Drug: Carvedilol|Drug: Spironolactone","Cardiac Strain|Change in biomarkers|arterial stiffness","VA Office of Research and Development|Baylor College of Medicine","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 2","210","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CLNB-009-13F","October 1, 2014","July 1, 2020","December 31, 2020","September 3, 2014",,"April 7, 2020","Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02230891"
575,"NCT01788358","Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension",,"Completed","Has Results","Hypertension","Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)","Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 28|Number of Subjects With Treatment-emergent Adverse Events (TEAEs) of Special Interest up to Week 28|Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 52/End of Study (EOS)|Number of Subjects With Treatment-emergent Adverse Events (TEAEs) of Special Interest up to Week 52/End of Study (EOS)|Number of Subjects With Clinically Relevant Changes in Laboratory Parameters|Change From Baseline In Mean Seated Systolic Blood Pressure (MSSBP) At Weeks 28 And 52|Change From Baseline in Mean Seated Diastolic Blood Pressure (MSDBP) at Weeks 28 and 52|Blood Pressure Control Rate at Weeks 28 and 52|Blood Pressure Response Rate at Weeks 28 and 52","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","508","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14801|2012-004515-32","February 14, 2013","May 1, 2014","May 1, 2014","February 11, 2013","August 17, 2015","October 24, 2017","Foley, Alabama, United States|Carmichael, California, United States|Los Angeles, California, United States|Spring Valley, California, United States|Milford, Connecticut, United States|Coral Gables, Florida, United States|Hallandale Beach, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Valparaiso, Indiana, United States|Newton, Kansas, United States|Wichita, Kansas, United States|Lexington, Kentucky, United States|New Orleans, Louisiana, United States|Auburn, Maine, United States|Elkridge, Maryland, United States|Brockton, Massachusetts, United States|Saint Louis, Missouri, United States|Shelby, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Greenville, South Carolina, United States|Mount Pleasant, South Carolina, United States|Rapid City, South Dakota, United States|Nashville, Tennessee, United States|New Tazewell, Tennessee, United States|Beaumont, Texas, United States|Bryan, Texas, United States|Carrollton, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Kenosha, Wisconsin, United States|Moorsel, Oost-Vlaanderen, Belgium|Wetteren, Oost-Vlaanderen, Belgium|Steenokkerzeel, Vlaams Brabant, Belgium|Deurne, Belgium|HAM, Belgium|Burnaby, British Columbia, Canada|Langley, British Columbia, Canada|Vancouver, British Columbia, Canada|Brampton, Ontario, Canada|Burlington, Ontario, Canada|Etobicoke, Ontario, Canada|London, Ontario, Canada|Newmarket, Ontario, Canada|Sarnia, Ontario, Canada|Stayner, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Woodstock, Ontario, Canada|Pointe-Claire, Quebec, Canada|Ste-Foy, Quebec, Canada|Frankfurt, Hessen, Germany|Bochum, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Görlitz, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Dresden, Germany|Gdynia, Poland|Katowice, Poland|Warszawa, Poland|Wroclaw, Poland|Reading, Berkshire, United Kingdom|Chesterfield, Derbyshire, United Kingdom|Blackpool, Lancashire, United Kingdom|Bath, Somerset, United Kingdom|Bury St Edmonds, Suffolk, United Kingdom|Coventry, Warwickshire, United Kingdom|Birmingham, West Midlands, United Kingdom|Cardiff, United Kingdom|Chorley, United Kingdom|Glasgow, United Kingdom|Liverpool, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01788358"
576,"NCT03078907","Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.","TRACE","Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Selexipag|Drug: Placebo","Change from baseline to Week 24 in daily time spent in non-sedentary activity|Change from baseline to Week 24 in percentage of daily time spent in non-sedentary activity|Change from baseline to Week 24 in total daily life physical activity|Change from baseline to Week 24 in total sleep time (TST)|Change from baseline to Week 24 in wake after sleep onset (WASO)|Change from baseline to Week 24 in number of awakenings|Change from baseline to Week 24 in sleep efficiency (SE)|Change from baseline to Week 24 in World Health Organization Functional Class (WHO FC)|Change from baseline to Week 24 in 6-minute walk distance (6MWD)|Change from baseline to Week 24 in Borg dyspnea score|Change from baseline to Week 24in N-terminal pro-brain natriuretic peptide (NT-proBNP)|Change from baseline to Week 24 in cardiovascular symptom domain score of PAH-SYMPACT®|Change from baseline to Week 24 in cardiopulmonary symptom domain score of PAH-SYMPACT®|Change from baseline to Week 24 in physical impact domain score of PAH-SYMPACT®|Change from baseline to Week 24 in cognitive/emotional impact domain score of PAH-SYMPACT®","Actelion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","108","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","AC-065A404","November 8, 2017","February 10, 2020","February 10, 2020","March 14, 2017",,"March 18, 2020","LA Biomedical Research Institute, Torrance, California, United States|Northside Hospital, Atlanta, Georgia, United States|Kentuckiana Pulmonary Research Center, Louisville, Kentucky, United States|Tufts Medical Center, Pulmonary/Critical Care & Sleep, Boston, Massachusetts, United States|University of Nebraska Medical Center, Pulmonary, Critical Care & Sleep Medicine Division, Omaha, Nebraska, United States|NYU Winthrop Hospital, Mineola, New York, United States|UNC Pulmonary Speciality Clinic, Chapel Hill, North Carolina, United States|Duke University School of Medicine, Duke Pulmonary Vascular Disease center, Durham, North Carolina, United States|University of Cincinnati, Heart, Lung and Vascular Institute, Cincinnati, Ohio, United States|CCF- Akron General Medical Hospital, Cleveland, Ohio, United States|Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States|University of Pennsylvania, Pulmonary Vascular Disease Program, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Care Medicine, Nashville, Tennessee, United States|Methodist Clinical Trials, San Antonio, Texas, United States|University of Texas Health Science Center (San Antonio), San Antonio, Texas, United States|Medizinische Universität Innsbruck (MUI), Abt. für Pneumologie, Haus 2, Innsbruck, Austria|Krankenhaus der Elisabethinen, Servicestelle Klinische Studien, Linz, Austria|Hôpital Bicêtre, ervice de Pneumologie et Réanimation respiratoire, Le Kremlin-Bicêtre, France|CHRU de Lille - Hôpital Albert Calmette, Service de cardiologie, Lille, France|Hospital Larrey CHU de Toulouse, Toulouse, France|Universitätsklinikum Giessen, Giessen, Germany|Herzzentrum der Universität zu Köln, Klinik III für Innere Medizin, Köln, Germany|Universitätsklinikum Leipzig AöR, Abteilung Pneumologie, Leipzig, Germany|Katholisches Klinikum Lünen/Werne GmbH, Haus E, Lünen, Germany|Mater Misericordiae University Hospital, Dublin, Ireland|Oslo University Hospital, dept of cardiology, Oslo, Norway|Centro Hospitalar e Universitário de Coimbra, Serviço de Cardiologia, Coimbra, Portugal|Hospital Geral de Santo António-DEFI, Porto, Portugal|Sahlgrenska University Hospital, Gothenburg, Gothenburg, Sweden|Skåne University Hospital, VO Hjärt och Lungmedicin, Lund, Sweden|Kantonsspital St. Gallen, Klinik für Pneumologie und Schlafmedizin, St. Gallen, Switzerland|Universitaetsspital Zurich, Klinik für Pneumologie C HOER 11, Zurich, Switzerland|Papworth Hospital, Pulmonary Vascular Disease Unit, Cambridge, United Kingdom|Golden Jubilee National Hospital, Scottish Pulmonary Vascular Unit, Clydebank, United Kingdom|The Royal Free Hospital, Cardiology Department, London, United Kingdom|Royal Brompton Hospital, Hypertension, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Freeman Hospital, Cardiothoracic Department, Newcastle Upon Tyne, United Kingdom|Royal Hallamshire Hospital, Pulmonary Vascular Medicine, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03078907"
577,"NCT03337308","A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy",,"Completed","Has Results","Hyperlipidemias","Combination Product: Bempedoic Acid + Ezetimibe Fixed-Dose Combination|Drug: Bempedoic Acid|Drug: Ezetimibe|Drug: Placebos","Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)|Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)|Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)|Percent Change From Baseline to Week 12 in Total Cholesterol (TC)|Percent Change From Baseline to Week 12 in Apolipoprotein B (Apo B)|Percent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C)|Percent Change From Baseline to Week 12 in Triglycerides (TGs)","Esperion Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","382","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1002FDC-053","October 23, 2017","June 18, 2018","July 18, 2018","November 8, 2017","April 8, 2020","April 8, 2020","PMG Research of McFarland, Ames, Iowa, United States|Foundation Cardiology, Nashua, New Hampshire, United States|PMG Research of Piedmont Healthcare, Statesville, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|PMG Research of Knoxville, Knoxville, Tennessee, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03337308/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03337308/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03337308"
578,"NCT02007629","Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor","RESPITE","Completed","No Results Available","Hypertension, Pulmonary","Drug: Riociguat (Adempas, BAY63-2521)","Change from baseline in 6 Minute Walking Distance (6MWD)","Bayer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","61","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16719|2013-001759-10","February 18, 2014","December 29, 2016","December 29, 2016","December 11, 2013",,"February 21, 2019","La Jolla, California, United States|Sacramento, California, United States|Iowa City, Iowa, United States|Boston, Massachusetts, United States|Saint Louis, Missouri, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Bruxelles - Brussel, Belgium|Leuven, Belgium|Montreal, Quebec, Canada|Praha 2, Czechia|GRENOBLE Cedex 09, France|Le Kremlin Bicetre Cedex, France|Marseille, France|Heidelberg, Baden-Württemberg, Germany|Regensburg, Bayern, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Roma, Lazio, Italy|Pavia, Lombardia, Italy|Zürich, Switzerland|Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Clydebank, West Dunbartonshire, United Kingdom|London, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02007629"
579,"NCT03714776","A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Subjects With Controlled Blood Pressure",,"Completed","No Results Available","Mild Hypertension","Drug: IONIS-AGT-LRx|Drug: Placebo","Percent change in plasma angiotensinogen from Baseline to Study Day 43 (Week 7) compared to placebo|Change on in-clinic SBP from Baseline to each scheduled, post-Baseline visit|Percent change in plasma angiotensinogen from Baseline to each scheduled, post-baseline visit","Ionis Pharmaceuticals, Inc.","All","18 Years to 72 Years   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ISIS 757456-CS2","January 3, 2019","November 13, 2019","November 13, 2019","October 22, 2018",,"February 13, 2020","Orange County Research Center, Tustin, California, United States|Progressive Medical Research, Port Orange, Florida, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Ohio Clinical Research - Lyndhurst, Lyndhurst, Ohio, United States|Juno Research, LLC - Northwest Site, Houston, Texas, United States|York Clinical Research LLC, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03714776"
580,"NCT01176565","Antihypertensive Treatment of Acute Cerebral Hemorrhage-II","ATACH-II","Terminated","Has Results","Intracerebral Hemorrhage","Drug: Intravenous nicardipine hydrochloride","Death or Disability According to Modified Rankin Scale Score at 90 Days (3 Months) From Randomization|Quality of Life at 90 Days Using EuroQol (EQ) Measures: EQ-5D (EuroQol Five Dimension), Consisting of Standardized EQ-5D-3L (EuroQol Five Dimension, Three-Level) Questionnaire and EQ VAS (EuroQol Visual Analog Scale) Scores|Hematoma Expansion (Number of Patients With Hematoma Expansion of 33% or Greater Between the Baseline and 24 +/- 6 Hours Head CTs, as Measured by the Central Reader for Patients With Readable Scans for Both Time Points Submitted by Data Lock.)","University of Minnesota|National Institute of Neurological Disorders and Stroke (NINDS)|Medical University of South Carolina|Johns Hopkins University|University of Michigan|Neurocritical Care Research Network|National Cerebral and Cardiovascular Center|Japan Cardiovascular Research Foundation|Beijing Tiantan Hospital|China Medical University Hospital|University Hospital Heidelberg|Seoul National University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","1000","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1207M17921|U01NS062091|U01NS061861|U01NS059041|U01NS056975|H23-4-3","May 15, 2011","December 21, 2015","March 8, 2016","August 6, 2010","April 25, 2017","April 25, 2017","UAB Comprehensive Stroke Center, Birmingham, Alabama, United States|Maricopa Medical Center, Phoenix, Arizona, United States|Mayo Clinic Pheonix, Scottsdale, Arizona, United States|Banner University Medical Center - South Campus, Tuscon, Arizona, United States|Banner University Medical Center - University Campus, Tuscon, Arizona, United States|Community Regional Medical Center of Fresno, Fresno, California, United States|University of California San Diego, La Jolla, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Ronald Regan UCLA Medical Center, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Stanford University, Palo Alto, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Good Samaritan Hospital, San Jose, California, United States|Santa Clara Valley Medical Center, Santa Clara, California, United States|Colorado Neurological Institute, Englewood, Colorado, United States|Yale - New Haven Hospital, New Haven, Connecticut, United States|Christiana Hospital, Newark, Delaware, United States|University of Florida Gainesville, Gainesville, Florida, United States|Baptist Medical Center Jacksonville, Jacksonville, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|University of South Florida, Tampa General Hospital, Tampa, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Eastern Idaho Medical Consultants, Idaho Falls, Idaho, United States|Loyola University Medical Center, Maywood, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Southern Illinois University Memorial Medical Center, Springfield, Illinois, United States|Lutheran Hospital Indiana, Fort Wayne, Indiana, United States|Parkview Hospital, Fort Wayne, Indiana, United States|Kansas University Medical Center, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|West Jefferson Medical Center, Marrero, Louisiana, United States|Interim LSU Hospital, New Orleans, Louisiana, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center, Shreveport, Shreveport, Louisiana, United States|Maine Medical Center, South Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Wayne State University - Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Sinai-Grace Hospital, Detroit, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Essentia Health St. Mary's Medical Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|St. Cloud Hospital, St. Cloud, Minnesota, United States|Regions Hospital, St.Paul, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Neuroscience Institute, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|Cooper University Hospital, Camden, New Jersey, United States|St. Joseph's Regional Medical Center, Clifton, New Jersey, United States|New Jersey Neuroscience Institute, JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|New York City Health and Hospitals Corp. / Kings County Hospital, Brooklyn, New York, United States|Mamoides Medical Center, Brooklyn, New York, United States|Sister of Charity/Buffalo Mercy Hospital, Catholic Health System, Buffalo, New York, United States|UHS Wilson Medical Center, Johnson City, New York, United States|North Shore University Hospital, Manhasset, New York, United States|SUNY Downstate, New York, New York, United States|Columbia University, New York, New York, United States|Lincoln Medical and Mental Health Center, New York, New York, United States|Rochester General Hospital, Rochester, New York, United States|Strong Stroke Center, Rochester, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Guilford Neurologic Associates, Greenboro, North Carolina, United States|Vidant Medical Center, Greenville, North Carolina, United States|Novant Clinical Research Institute/Forsyth Medical Center, Winston-Salem, North Carolina, United States|Wake Forest Baptist Medical Center (Wake Forest School of Medicine), Winston-Salem, North Carolina, United States|Akron General Hospital, Akron, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Ohio State University - Wexner Medical Center, Columbus, Ohio, United States|University of Toledo Medical Center, Toledo, Ohio, United States|Oklahoma University Health Sciences Center (OUHSC), Oklahoma City, Oklahoma, United States|Providence Brain and Spine Institute, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Penn State Univ/ Hershey Med Center, Hershey, Pennsylvania, United States|Hahnemann University Hospital, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Mercy Hospital, Pittsburgh, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Wellspan York Hospital, York, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Palmetto Health, Columbia, South Carolina, United States|Vanderbilt Stroke Center, Nashville, Tennessee, United States|Seton Medical Center Austin, Austin, Texas, United States|St. David's Medical Center, Austin, Texas, United States|University Medical Center Brackenridge, Austin, Texas, United States|UT Southwestern - Parkland Hospital, Dallas, Texas, United States|Texas Tech University Health Sciences Center, El Paso, Texas, United States|Valley Baptist Medical Center, Harlingen, Texas, United States|Memorial Herman - Texas Medical Center, Houston, Texas, United States|Baylor College of Medicine - Ben Taub Community Hospital, Houston, Texas, United States|Baylor College of Medicine - St. Luke's Episcopal Hospital, Houston, Texas, United States|Methodist Hospital - The Neurological Institute, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|West Virginia University - Ruby Memorial Hospital, Morgantown, West Virginia, United States|Medical College of Wisconsin, Milwakee, Wisconsin, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|University of Alberta, Edmonton, Alberta, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|The Second Hospital of Hebei Medical University, Shijiazhuang City, Hebei, China|The Second Hospital of Shanxi Medical University, Taiyuan City, Shanxi, China|Baotou Central Hospital, Baotou, China|Beijing Tiantan Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|Datong Third People's Hospital, Datong, China|The First Hospital of Shanxi Medical University, Taiyuan City, China|The First People's Hospital of Taizhou, Taizhou City, China|Tianjin Fourth Central Hospital, Tianjin, China|Wuhan Brain Hospital, Wuhan, China|Renmin Hospital of Wuhan University, Wuhan, China|People's Hopital of Zhengzhou, Zhengzhou, China|Charité Universtity Medicine Berlin, Berlin, Germany|University of Bonn, Bonn, Germany|University Hospital Dresden, Dresden, Germany|Clinic Frankfurt Hoechst, Frankfurt, Germany|University Hospital Halle, Halle (Saale), Germany|University Hospital Heidelberg, Heidelberg, Germany|University Hospital Leipzig, Leipzig, Germany|University Hospital Mannheim, Mannheim, Germany|University Hospital Meunster, Munster, Germany|University of Tubingen, Tubingen, Germany|Nagoya Medical Center, Nagoya City, Aichi, Japan|Nakamura Memorial Hospital, Sapporo, Hokkaido, Japan|Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Kanagowa, Japan|Saiseikai Kumamoto Hospital, Kumamoto City, Kumamoto, Japan|Kyushu Medical Center, Fukuoka, Japan|Gifu University Hospital, Gifu, Japan|St. Marianna - Toyoko, Kawasaki, Japan|St. Marianna University Hospital, Kawasaki, Japan|Kobe City Medical Center General Hospital, Kobe City, Japan|Kawasaki Medical School, Okayama, Japan|National Cerebral and Cardiovascular Center, Osaka, Japan|Kohnan Hospital, Sendai, Japan|Toranomon Hospital, Tokyo, Japan|Saiseikai Central Hospital - Tokyo, Tokyo, Japan|Keio University Hospital, Tokyo, Japan|Kyorin University, Tokyo, Japan|Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kyung Hee University Hospital, Seoul, Korea, Republic of|Seoul National University Boramae Hospital, Seoul, Korea, Republic of|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hopital, Taichung City, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Taipei Veteran's Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01176565"
581,"NCT03399370","Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol","ORION-10","Active, not recruiting","No Results Available","ASCVD|Elevated Cholesterol","Drug: Inclisiran Sodium|Drug: Placebo","Percentage Change in LDL-C from Baseline to Day 510|Time-adjusted Percentage Change in LDL-C Levels from Baseline after Day 90 and up to Day 540|Absolute Change in LDL-C from Baseline to Day 510|Time-adjusted Absolute Change in LDL-C from Baseline after Day 90 and up to Day 540|Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) from Baseline to Day 510|Percentage Change in Total Cholesterol from Baseline to Day 510|Percentage Change in Apolipoprotein B (ApoB) from Baseline to Day 510|Percentage Change in Non-HDL-C from Baseline to Day 510","The Medicines Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","1561","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","MDCO-PCS-17-04","December 21, 2017","October 2019","December 2019","January 16, 2018",,"April 17, 2019","Research Site 10001-015, Birmingham, Alabama, United States|Research Site 10001-138, Foley, Alabama, United States|Research Site 10001-113, Huntsville, Alabama, United States|Research Site 10001-058, Mobile, Alabama, United States|Research Site 10001-037, Montgomery, Alabama, United States|Research Site 10001-076, Saraland, Alabama, United States|Research Site 10001-013, Chandler, Arizona, United States|Research Site 10001-077, Mesa, Arizona, United States|Research Site 10001-136, Phoenix, Arizona, United States|Research Site 10001-051, Surprise, Arizona, United States|Research Site 10001-019, Tucson, Arizona, United States|Research Site 10001-004, Tucson, Arizona, United States|Research Site 10001-132, Tucson, Arizona, United States|Research Site 10001-073, Beverly Hills, California, United States|Research Site 10001-050, Canoga Park, California, United States|Research Site 10001-011, Carlsbad, California, United States|Research Site 10001-065, El Cajon, California, United States|Research Site 10001-150, Los Angeles, California, United States|Research Site 10001-043, Northridge, California, United States|Research Site 10001-022, Northridge, California, United States|Research Site 10001-033, Sacramento, California, United States|Research Site 10001-105, San Ramon, California, United States|Research Site 10001-008, Santa Rosa, California, United States|Research Site 10001-153, Spring Valley, California, United States|Research Site 10001-044, Torrance, California, United States|Research Site 10001-047, Boca Raton, Florida, United States|Research Site 10001-084, Clearwater, Florida, United States|Research Site 10001-155, Clearwater, Florida, United States|Research Site 10001-099, Clearwater, Florida, United States|Research Site 10001-127, Daytona Beach, Florida, United States|Research Site 10001-119, Fleming Island, Florida, United States|Research Site 10001-070, Fort Lauderdale, Florida, United States|Research Site 10001-067, Hialeah, Florida, United States|Research Site 10001-139, Jacksonville, Florida, United States|Research Site 10001-039, Jacksonville, Florida, United States|Research Site 10001-098, Jacksonville, Florida, United States|Research Site 10001-080, Miami Springs, Florida, United States|Research Site 10001-081, Miami, Florida, United States|Research Site 10001-140, Miami, Florida, United States|Research Site 10001-142, Miami, Florida, United States|Research Site 10001-030, Miami, Florida, United States|Research Site 10001-089, Miami, Florida, United States|Research Site 10001-116, Miami, Florida, United States|Research Site 10001-027, Pembroke Pines, Florida, United States|Research Site 10001-115, Pembroke Pines, Florida, United States|Research Site 10001-048, Pembroke Pines, Florida, United States|Research Site 10001-147, Pembroke Pines, Florida, United States|Research Site 10001-003, Pinellas Park, Florida, United States|Research Site 10001-104, Ponte Vedra, Florida, United States|Research Site 10001-090, Saint Augustine, Florida, United States|Research Site 10001-102, Saint Petersburg, Florida, United States|Research Site 10001-123, Sarasota, Florida, United States|Research Site 10001-038, Tampa, Florida, United States|Research Site 10001-143, Tampa, Florida, United States|Research Site 10001-069, Atlanta, Georgia, United States|Research Site 10001-137, Dunwoody, Georgia, United States|Research Site 10001-092, Macon, Georgia, United States|Research Site 10001-059, Arlington Heights, Illinois, United States|Research Site 10001-158, Chicago, Illinois, United States|Research Site 10001-035, Chicago, Illinois, United States|Research Site 10001-036, Evanston, Illinois, United States|Research Site 10001-082, Indianapolis, Indiana, United States|Research Site 1001-020, Sellersburg, Indiana, United States|Research Site 10001-040, Valparaiso, Indiana, United States|Research Site 10001-074, West Des Moines, Iowa, United States|Research Site 10001-028, Hutchinson, Kansas, United States|Research Site 10001-125, Lexington, Kentucky, United States|Research Site 10001-108, Lexington, Kentucky, United States|Research Site 10001-107, Owensboro, Kentucky, United States|Research Site 10001-144, Crowley, Louisiana, United States|Research Site 10001-041, Lake Charles, Louisiana, United States|Research Site 10001-101, Monroe, Louisiana, United States|Research Site 10001-024, Flint, Michigan, United States|Research Site 10001-095, Grandville, Michigan, United States|Research Site 10001-078, Sterling Heights, Michigan, United States|Research Site 10001-034, Troy, Michigan, United States|Research Site 10001-018, Edina, Minnesota, United States|Research Site 10001-056, Saint Paul, Minnesota, United States|Research Site 10001-156, Saint Louis, Missouri, United States|Research Site 10001-007, Saint Louis, Missouri, United States|Research Site 10001-053, Omaha, Nebraska, United States|Research Site 10001-021, Omaha, Nebraska, United States|Research Site 10001-112, Las Vegas, Nevada, United States|Research Site 10001-124, Las Vegas, Nevada, United States|Research Site 10001-060, Bridgewater, New Jersey, United States|Research Site 10001-055, Raritan, New Jersey, United States|Research Site 10001-054, Albany, New York, United States|Research Site 10001-122, Binghamton, New York, United States|Research Site 10001-128, Endwell, New York, United States|Research Site 10001-042, New Windsor, New York, United States|Research Site 10001-129, Poughkeepsie, New York, United States|Research Site 10001-110, Williamsville, New York, United States|Research Site 10001-063, Cary, North Carolina, United States|Research Site 10001-064, Greensboro, North Carolina, United States|Research Site 10001-145, Mooresville, North Carolina, United States|Research Site 10001-046, Shelby, North Carolina, United States|Research Site 10001-016, Akron, Ohio, United States|Research Site 10001-120, Cincinnati, Ohio, United States|Research Site 10001-154, Cincinnati, Ohio, United States|Research Site 10001-010, Cincinnati, Ohio, United States|Research Site 10001-134, Cincinnati, Ohio, United States|Research Site 10001-014, Columbus, Ohio, United States|Research Site 10001-012, Columbus, Ohio, United States|Research Site 10001-141, Dayton, Ohio, United States|Research Site 10001-148, Marion, Ohio, United States|Research Site 10001-017, Edmond, Oklahoma, United States|Research Site 10001-109, Wyomissing, Pennsylvania, United States|Research Site 10001-001, Anderson, South Carolina, United States|Research Site 10001-006, Greer, South Carolina, United States|Research Site 10001-075., Greer, South Carolina, United States|Research Site 10001-111, Myrtle Beach, South Carolina, United States|Research Site 10001-133, Pelzer, South Carolina, United States|Research Site 10001-026, Spartanburg, South Carolina, United States|Research Site 10001-103, Rapid City, South Dakota, United States|Research Site 10001-146, Athens, Tennessee, United States|Research Site 10001-130, Kingsport, Tennessee, United States|Research Site 10001-118, Knoxville, Tennessee, United States|Research Site 10001-100, Amarillo, Texas, United States|Research Site 10001-087, Austin, Texas, United States|Research Site 10001-117, Austin, Texas, United States|Research Site 10001-009, Dallas, Texas, United States|Research Site 10001-068, Edinburg, Texas, United States|Research Site 10001-126, Fort Worth, Texas, United States|Research Site 10001-031, Houston, Texas, United States|Research Site 10001-088, Houston, Texas, United States|Research Site 10001-091, Houston, Texas, United States|Research Site 10001-061, Houston, Texas, United States|Research Site 10001-032, Houston, Texas, United States|Research Site 10001-025, Lubbock, Texas, United States|Research Site 10001-057, New Braunfels, Texas, United States|Research Site 10001-106, Powell, Texas, United States|Research Site 10001-079, Round Rock, Texas, United States|Research Site 10001-071, San Antonio, Texas, United States|Research Site 10001-083, Schertz, Texas, United States|Research Site 10001-149, Shavano Park, Texas, United States|Research Site 10001-045, Tomball, Texas, United States|Research Site 10001-005, Layton, Utah, United States|Research Site 10001-002, Salt Lake City, Utah, United States|Research Site 10001-052, Salt Lake City, Utah, United States|Research Site 10001-093, Falls Church, Virginia, United States|Research Site 10001-085, Manassas, Virginia, United States|Research Site 10001-094, Midlothian, Virginia, United States|Research Site 10001-023, Richmond, Virginia, United States|Research Site 10001-029, Suffolk, Virginia, United States|Research Site 10001-114, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03399370"
582,"NCT01105091","Epoprostenol for Injection in Pulmonary Arterial Hypertension","EPITOME-1","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: ACT-385781A (Actelion Epoprostenol)|Drug: Flolan®","Dose Normalized Pharmacokinetics of 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha at 2 ng/kg/Min|Dose Normalized Pharmacokinetics of 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha at 4 ng/kg/Min|Dose Normalized Pharmacokinetics of 6-keto-Prostacyclin F1alpha at 2 ng/kg/Min|Dose Normalized Pharmacokinetics of 6-keto-Prostacyclin F1alpha at 4 ng/kg/Min|Six-minute Walk Distance (6MWD) - Baseline and Day 28|Patients With New York Heart Association (NYHA) Functional Class Change (Improved or Worsened) From Baseline to Day 28|Percentage Central Venous Blood Oxygen Saturation (ScVO2) - Baseline and Day 28|Blood Pressure - Baseline and Day 28|Heart Rate - Baseline and Day 28|Body Weight - Baseline and Day 28","Actelion","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-066A401","March 2010","May 2011","July 2011","April 16, 2010","August 23, 2012","December 3, 2012","University of California - San Diego, La Jolla, California, United States|University of Colorado - Denver, Aurora, Colorado, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01105091"
583,"NCT02266394","Hypoxia and Inflammatory Injury in Human Renovascular Hypertension",,"Active, not recruiting","No Results Available","Renal Artery Stenosis|Ischemic Nephropathy|Renovascular Disease|Chronic Kidney Disease","Drug: Mesenchymal stem cell|Procedure: Mesenchymal stem cell delivery with stent placement","Change in Kidney function|Safety of Mesenchymal stem cell infusion|Decrease in Kidney inflammation","Mayo Clinic|University of Mississippi Medical Center|University of Alabama at Birmingham","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1","42","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-002799","October 2014","March 2020","March 2020","October 17, 2014",,"June 14, 2019","University of Alabama, Birmingham, Alabama, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT02266394"
584,"NCT01105117","Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401","EPITOME-1 Ext","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: ACT-385781A (Actelion Epoprostenol)|Drug: Flolan®","Safety and Tolerability of ACT-385781A and Flolan in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) - Number of Patients With Adverse Events Leading Discontinuation of Study Treatment|Safety and Tolerability of ACT-385781A and Flolan in Injectable Prostanoid Treatment-naïve Patients With PAH - Number of Deaths","Actelion","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","2","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-066A402","May 2010","July 2011","December 2011","April 16, 2010","August 23, 2012","December 3, 2012","University of California - San Diego, La Jolla, California, United States|University of Colorado - Denver, Aurora, Colorado, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania-Penn Presybyterian Medical Center, Philadelphia, Pennsylvania, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01105117"
585,"NCT02634151","A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins","ROYAL-1","Completed","No Results Available","Hypercholesteremia","Drug: Gemcabene 600 mg|Drug: Placebo","LDL-C","NeuroBo Pharmaceuticals Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GEM-301","November 2016","June 2017","August 2017","December 17, 2015",,"March 31, 2020","Central Research Associates, Inc., Birmingham, Alabama, United States|Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|National Research Institute, Huntington Park, California, United States|National Research Institute, Los Angeles, California, United States|Atlantic Clinical Research Collaborative- Cardiology, Atlantis, Florida, United States|Excel Medical Clinical Trials, Boca Raton, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Health Awareness, Inc., Jupiter, Florida, United States|Meridien Research, Inc., Maitland, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Varkey Medical, Tampa, Florida, United States|Evanston Premier Healthcare Research, LLC, Evanston, Illinois, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|L-MARC, Louisville, Kentucky, United States|Mid-Hudson Medical Research, New Windsor, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Sentral Clinical Research Services, Cincinnati, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Associates in Medicine, Houston, Texas, United States|Diagnostics Research Grup, San Antonio, Texas, United States|Sugar Lakes Family Practice, Sugar Land, Texas, United States|National Research Institute, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02634151"
586,"NCT02939599","Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients",,"Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: QCC374","Number of Participants Who Experienced Adverse Events (AEs), Serious Adverse Events (SAEs) in Patients With PAH Over a Two Year Period|Maximum Observed Plasma Concentration (Cmax)|Time to Reach the Maximum Plasma Concentration (Tmax)|Area Under the Plasma Concentration-time Curve From 0 to the Last Measurable Concentration (AUClast)|Area Under the Plasma Concentration Time Curve From 0 to the End of a Dosing Interval (AUCtau)|Change From Baseline in Six Minute Walk Distance (6MWD)|Change in Tricuspid Annular Peak Systolic Velocity (TA S') at Week 16 (Day 112) Using Echocardiography|Change From Baseline in RV Tei Index at Week 16 (Day 112) Using Echocardiography|Change From Baseline in RV Fractional Area Change at Week 16 (Day 112) Using Echocardiography","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CQCC374X2201E1","February 1, 2018","November 6, 2018","November 6, 2018","October 20, 2016","February 28, 2020","February 28, 2020","Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Cambridge, Cambridgeshire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02939599/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02939599/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02939599"
587,"NCT01063283","Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC","AVF4759","Completed","Has Results","Advanced Non-squamous Non-Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Carboplatin|Drug: Bevacizumab 7.5 mg/kg|Drug: Bevacizumab 15 mg/kg","Change in 24 Hour Diastolic Blood Pressure (DBP)|Response Rate|Change in Tumor Size From Baseline|Progression Free Survival","University of Chicago|Genentech, Inc.","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-014-B","March 2010","June 2016","June 2016","February 5, 2010","November 18, 2019","November 18, 2019","The University of Chicago Medical Center, Chicago, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01063283"
588,"NCT00887978","Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension","FREEDOM-C2","Completed","Has Results","Pulmonary Hypertension","Drug: UT-15C SR|Drug: Placebo","6-minute Walk Distance (6MWD)|Clinical Worsening Assessment|Borg Dyspnea Score|World Health Organization (WHO) Functional Class|Symptoms of PAH|Dyspnea Fatigue Index|N-terminal proBNP (NT-proBNP)|Quality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","310","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TDE-PH-308","June 2009","July 2011","July 2011","April 24, 2009","January 15, 2013","January 15, 2013","University of Alabama-Birmingham, Birmingham, Alabama, United States|Arizona Pulmonary Specialist, LTD, Phoenix, Arizona, United States|University of California, San Francisco-Fresno, Fresno, California, United States|UCSD Medical Center, La Jolla, California, United States|West Los Angeles VA Healthcare Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Health Science Center, Aurora, Colorado, United States|University of Florida-Jacksonville, Jacksonville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|University of Chicago Hospitals, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Kansas University Medical Center, Kansas City, Kansas, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Maine Medical Center, Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Pulmonary Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University Hospital, St. Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Winthrop University Hospital, Mineola, New York, United States|Columbia University Presbyterian Medical Center, New York, New York, United States|Mary M Parkes Center for Asthma, Allergy and Pulmonary Care, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Lindner Center, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|The University of Toledo, Toledo, Ohio, United States|Legacy Pulmonary Northwest, Portland, Oregon, United States|OHSU, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|UT Southwestern, Dallas, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Inova Transplant Center, Falls Church, Virginia, United States|University Hospital Gasthuisberg, Leuven, Belgium|University of Calgary, Calgary, Alberta, Canada|University of Alberta Hospitals, Edmonton, Alberta, Canada|Vancouver Coastal Health Respiratory Clinic, Vancouver, British Columbia, Canada|London Health Sciences Center, London, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Hospital Claude Huriez, Lille, Cedex, France|Hospital Haut Leveque, Pessac, Cedex, France|Hospital Cavale Blanche, Brest, France|Universitaetsklinikum Dresden, Dresden, Germany|University Hospital Greifswald, Greifswald, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Pulmonology Department Rambam Medical Center, Haifa, Israel|Lady Davis Carmel Medical Centre, Haifa, Israel|Pulmonary institute, Ramat Gan, Israel|Azienda Ospedaliera Universitaria, Naples, Italy|VUMC, Amsterdam, Netherlands|Hospital de Santa Marta, Lisboa, Portugal|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Lund University Hospital, Lund, Sweden|Royal Free Hospital NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00887978"
589,"NCT03689244","A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery","SELECT","Recruiting","No Results Available","Chronic Thromboembolic Pulmonary Hypertension","Drug: Selexipag|Drug: Placebo","Percent of baseline Pulmonary vascular resistance (PVR) at Week 20|Change from baseline to Week 26 in 6-minute walk distance (6MWD)|Rate of pulmonary hypertension-related hospitalizations or death up to Week 52|Time to clinical worsening up to Week 52|Percentage of subjects with World Health Organization Functional Class (WHO FC) improvement at Week 26|Change from baseline to Week 26 in PAH-SYMPACT™ scores|Change from baseline to Week 26 in Borg dypnea index|Change from baseline to Week 26 in N-terminal pro b-type natriuretic peptide (NT pro-BNP)","Actelion","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","236","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-065B302|2018-002823-41","January 23, 2019","March 26, 2021","October 31, 2024","September 28, 2018",,"March 18, 2020","Mayo Clinic Arizona, Phoenix, Arizona, United States|University of California San Diego Medical Center, La Jolla, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|UCSF, San Francisco, California, United States|University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States|Colorado Springs Pulmonary Consultants, Colorado Springs, Colorado, United States|South Denver Cardiology Associates PC, Littleton, Colorado, United States|St Vincents Lung, Sleep And Critical Care, Jacksonville, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago Hospitals - Chicago, Chicago, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|University of Maryland, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Sparrow Clinical Research Institute, Lansing, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|St. Mary's Cardiology, Reno, Nevada, United States|University of New Mexico Clinical & Translational Science Center, Albuquerque, New Mexico, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Allegheny, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor Scott & White Research Institute at The Heart Hospital Baylor Plano, Plano, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Cardiovascular Center, Salt Lake City, Utah, United States|Inova Heart and Vascular Institute, Falls Church, Virginia, United States|University of Washington, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Medical College of Wisconsin-Froedtert Hospital, Milwaukee, Wisconsin, United States|Aurora Saint Lukes Medical Center, Milwaukee, Wisconsin, United States|Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Caba, Argentina|Sanatorio Ramon Cereijo, Caba, Argentina|Instituto de Cardiología y Cirugía Cardiovascular - Fundación Favaloro, Caba, Argentina|Hospital General de Agudos Dr Cosme Argerich, Caba, Argentina|Hospital Britanico de Buenos Aires, Caba, Argentina|Hospital General de Agudos Dr. Juan A. Fernández, Caba, Argentina|Centro Médico Dra. De Salvo, Ciudad Autónoma de Buenos Aires, Argentina|Royal Adelaide Hospital, Adelaide, Australia|Queensland Lung Transplant Service, Chermside, Australia|St Vincent's hospital, Darlinghurst, Australia|Pulmonary Arterial Hypertension Clinic, Hobart, Australia|The Alfred Hospital, Melbourne, Australia|Westmead Hospital, Westmead, Australia|Ordensklinikum Linz GmbH Elisabethinen, Linz, Austria|Medical University Vienna, Vienna, Austria|ULB Hôpital Erasme, Brussels, Belgium|UZ Leuven, Leuven, Belgium|Hospital das Clínicas - Universidade Federal de Minas Gerais, Belo Horizonte, Brazil|Instituto das Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa, Belo Horizonte, Brazil|Faculdade de Medicina de Botucatu - Universidade Estadual Paulista, Botucatu, Brazil|Hospital de Messejana dr. Carlos Alberto Studart Gomes, Fortaleza, Brazil|Hospital das Clinicas - UFG, Goiania, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Hospital São Lucas PUCRS, Porto Alegre, Brazil|Faculdade de Medicina Do Abc, Santo André, Brazil|Hospital São Paulo-UNIFESP, São Paulo, Brazil|Instituto do Coracao (INCOR) - HCFMUSP, São Paulo, Brazil|UMHAT 'Heart and Brain Center for Excellence', Pleven, Bulgaria|National Cardiology Hospital, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment- UMHAT Sveta Anna AD, Sofia, Bulgaria|University Of Calgary - Peter Lougheed Centre, Calgary, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|University Health Network - Toronto General Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Institut Universitaire De Cardiologie Et De Pneumologie De Québec, Quebec, Canada|China-Japan Friendship Hospital, Beijing, China|Cardiovascular institute & Fuwai Hospital- Thrombus Center, Beijing, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|Shanghai Pulmonary Hospital, Shanghai, China|The General Hospital of Northern Theater Command, Shenyang, China|Wuhan Asia Heart Hospital, Wuhan, China|General University Hospital II.department of Internal Medicine-cardiology and angiology, Praha 2, Czechia|Århus Universitetshospital, Skejby, Hjertemedicinsk Afdeling B, Arhus, Denmark|Rigshospitalet Kardiologisk Klinisk, Copenhagen, Denmark|Universitätsklinikum Carl Gustav Carus Medizinische Klinik und Poliklinik 1-Pneumologie, Dresden, Germany|Universitätsklinikum Giessen Medizinische Klinik Und Poliklinik Ii, Pneumologie, Giessen, Germany|Universität Greifswald - Klinik Für Innere Medizin Bereich Pneumologie/Infektiologie, Greifswald, Germany|Universitätsklinikum Hamburg-Eppendorf - Pneumologie, Hamburg, Germany|Medizinische Hochschule Hannover Zentrum Innere Medizin Klinik für Pneumologie, Hannover, Germany|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätskliniken des Saarlandes / Medizinische Klinik und Poliklinik, Innere Medizin V, Homburg/Saar, Germany|Universitätsklinikum Leipzig / Medizinischen Klinik und Poliklinik I, Abteilung für Pneumologie, Leipzig, Germany|Klinikum Würzburg Mitte gGmbH Standort Missioklinik, Würzburg, Germany|Semmelweis Egyetem,Pulmonológiai Klinika, Budapest, Hungary|Gottsegen György Országos Kardiológiai Intézet, Felnőtt kardiológiai osztály, Budapest, Hungary|SE Pulmonológiai Klinika, Budapest, Hungary|Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont, Pecs, Hungary|Szegedi Tudományegyetem, Általános Orvostudományi Kar, Családorvosi Intézet és rendelő, Szeged, Hungary|Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel|The Chaim Sheba Medical Center, Tel-Hashomer, Israel|Azienda Ospedaliera Policlinico S. Orsola-Malpighi, Bologna, Italy|ISMETT Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione, Palermo, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Policlinico Umberto I, Roma, Italy|Ospedale di Cattinara - Struttura complessa di Pneumologia, Trieste, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Instituto Nacional de Cardiologia Dr. Ignacio Chavez, Ciudad de Mexico, Mexico|CICUM San Miguel, Guadalajara, Mexico|Unidad de Investigacion Clinica en Medicina S.C. (UDICEM), Monterrey, Mexico|VUMC Amsterdam, Amsterdam, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Krakowski Szpital Specjalistyczny im Jana Pawla II, Krakow, Poland|Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego SPZOZ, Lublin, Poland|NZOZ Europejskie Centrum Zdrowia Otwock, Otwock, Poland|Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|Warszawski Uniwersytet Medyczny, Szpital Kliniczny Dzieciątka Jezus, Warszawa, Poland|Wojewodzki Szpital Specjalist, Osrodek Badawczo-Rozwojowy, Wrocław, Poland|Hospital Garcia de Orta, Almada, Portugal|Hospitais da universidade de Coimbra, Coimbra, Portugal|Centro Hospitalar de Lisboa Norte, Lisbon, Portugal|Hospital Geral de Santo Antonio, Porto, Portugal|Altay Regional Cardiological Dispensary, Barnaul, Russian Federation|Irkutsk Regional Clinical Hospital, Irkutsk, Russian Federation|Cardiovascular Pathology Research Institute of Siberian Branch of RAMS, Kemerovo, Russian Federation|Moscow City Clinical Hospital #1 n.a. N.I.Pirogov, Moscow, Russian Federation|Moscow City Clinical Hospital No.51, Moscow, Russian Federation|National Medical Research Center of Cardiology of MoH of Russian Federation, Moscow, Russian Federation|Novosibirsk Research Institution of Circulation Pathology n.a. E.N. Meshalkin, Novosibirsk, Russian Federation|Omsk Regional Clinical Hospital, Omsk, Russian Federation|State Autonomous Healthcare Organization of Permsky Region ""City Clinical Hospital #4"", Perm, Russian Federation|National medical Research Center n.a. V.A.Almazov of MoH of Russian Federation, Saint-Petersburg, Russian Federation|Samara Regional Clinical Cardiological Dispensary, Samara, Russian Federation|Voronezh Regional Clinical Hospital #1, Voronezh, Russian Federation|National University Heart Centre, Singapore, Singapore, Singapore|National Heart Centre (NHC) Singapore, Singapore, Singapore|Narodny ustav srdcovych a cievnych chorob, Bratislava, Slovakia|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hosp. Univ. Marques de Valdecilla, Santander, Spain|Hosp. Virgen Del Rocio, Sevilla, Spain|Hosp. Univ. I Politecni La Fe, Valencia, Spain|Norrlands Universitetssjukhus, Umea, Sweden|Uppsala Akademiska Sjukhuset, Kardiologkliniken, Uppsala, Sweden|Universitatsspital Zurich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Ramathibodi Hospital, Mahidol University, Bangkok, Thailand|Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand|Hacettepe University Medical Faculty, Ankara, Turkey|Ankara University Medical Faculty, Ankara, Turkey|Istanbul University Istanbul Medical Faculty, Istanbul, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey|Marmara University Medical Faculty, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Kartal Kosuyolu Yuksek Ihtisas Egitim Ve Arastirma Hastanesi, Kartal-Istanbul, Turkey|CI 'Dnipropetrovsk Regional Clinical Center of Cardiology and Cardiosurgery', Dnipro, Ukraine|Clinic of SI 'NSC 'The M.D.Strazhesko Institute of Cardiology' of NAMS of Ukraine', Kyiv, Ukraine|SI 'National Institute of Phtisiology and Pulmonology n.a. F.G. Yanovsky of NAMS of Ukraine', Kyiv, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Papworth Hospital NHS Trust, Cambridge, United Kingdom|National Waiting Times Centre Board Golden Jubilee National Hospital, Glasgow, United Kingdom|Royal Free Hospital, London, United Kingdom|Royal Brompton Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03689244"
590,"NCT03944577","Impact of Evolocumab in Cardiac Transplant Patients With CAV",,"Recruiting","No Results Available","Heart Transplant","Drug: Evolocumab (Repatha)","To measure the effect of evolocumab on serum LDL as measured in mL/dL after 12 weeks of therapy in heart transplant patients.","University of Nebraska|Amgen","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20177584","July 15, 2019","July 1, 2021","September 1, 2021","May 9, 2019",,"July 29, 2019","University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT03944577"
591,"NCT02197065","Pilot Study of Atorvastatin for Orthopedic Surgery Patients","POST-OP Pilot","Completed","Has Results","Hip Fracture|Myocardial Ischemia|Inflammation","Drug: Atorvastatin|Drug: Placebo","Percentage of All Enrolled Patients With a Peri-operative Rise in High-sensitivity Cardiac Troponin I|Peri-operative Rise in High Sensitivity C-reactive Protein (Hs-CRP)|Peri-operative Rise in Interleukin-6 (IL-6) Levels","Hospital for Special Surgery, New York|Weill Medical College of Cornell University|Washington University School of Medicine|University of Utah","All","65 Years to 99 Years   (Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","EPAR4398|UL1TR000457-06","September 2014","July 2016","January 2017","July 22, 2014","July 2, 2017","July 2, 2017","Hospital for Special Surgery, New York, New York, United States|New York Presbyterian Hospital (Cornell), New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02197065"
592,"NCT01842113","Quality of Life and Nutritional Improvements in Cirrhotic Patients",,"Terminated","No Results Available","Liver Cirrhosis|Hepatic Encephalopathy|Portal Hypertension","Drug: Rifaximin|Drug: Lactulose|Drug: Lactulose Placebo|Drug: Rifaximin Placebo","Outcomes of Change in Quality of Life Assessment Between the Two Groups|Nutritional Improvement Between the Two Groups|Markers of improvement in general health","Tampa General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Rifaximin and Nutrition","April 2013","May 2014",,"April 29, 2013",,"September 23, 2013","Tampa General Medical Group, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01842113"
593,"NCT01910389","Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure","PITCH-HF","Terminated","Has Results","Heart Failure|Pulmonary Hypertension","Drug: Tadalafil|Drug: Placebo for tadalafil","Composite Outcome of Cardiovascular (CV) Mortality or Heart Failure (HF) Hospitalization|Cardiovascular Mortality|Heart Failure Hospitalization|All-cause Mortality|Composite Outcome of All-cause Mortality or CV Hospitalization (Myocardial Infarction, Acute Coronary Syndrome, Stroke, Arrhythmia, or Heart Failure)|Frequency of CV Hospitalizations|Frequency of HF Hospitalizations|Change in 6 Minute Walk Distance From Baseline to 3 Months|Change in MLHFQ Score From Baseline to 3 Months|Change in 6 Minute Walk Distance From Baseline to 18 Months|Trend in 6 Minute Walk Distance From Baseline Through 18 Months|Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score From Baseline to 18 Months|Trend in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score From Baseline Through 18 Months","HealthCore-NERI|National Heart, Lung, and Blood Institute (NHLBI)|Massachusetts General Hospital","All","21 Years and older   (Adult, Older Adult)","Phase 3","23","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","U01HL105463","November 2013","February 2014","February 2014","July 29, 2013","May 4, 2015","May 4, 2015","Heart Center Inc - Research, Huntsville, Alabama, United States|Baptist Health Transplant Institute, Little Rock, Arkansas, United States|Allianz Medical and Research Center, Fountain Valley, California, United States|Christiana Care Health System, Newark, Delaware, United States|Broward Health, Ft. Lauderdale, Florida, United States|Miller School of Medicine University of Miami, Miami, Florida, United States|Orlando Health, Orlando, Florida, United States|Charlotte Heart Group Research Center, Port Charlotte, Florida, United States|Brevard Cardiovascular Research Associates, Rockledge, Florida, United States|University Cardiology Associates LLC, Augusta, Georgia, United States|Eisenhower Army Medical Center, Fort Gordon, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Illinois Hospital, Chicago, Illinois, United States|Methodist Medical Group Cardiology, Peoria, Illinois, United States|Baptist Hospital East, Louisville, Kentucky, United States|Research Integrity LLC, Owensboro, Kentucky, United States|LSU Health Sciences Center, New Orleans, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Primary Care Cardiology Research, Inc., Ayer, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|MGH West, Waltham, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Covenant Center for the Heart, Saginaw, Michigan, United States|Essentia Health East, Duluth, Minnesota, United States|Metropolitan Heart and Vascular Institute, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Missouri Cardiovascular Specialists, Columbia, Missouri, United States|St. Luke's Health System, Kansas City, Missouri, United States|Glacier View Research Institute, Kalispell, Montana, United States|Advanced Heart Care, LLC, Bridgewater, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Heart & Vascular Center of NJ/Cardio Metabolic Institute, Somerset, New Jersey, United States|Bronx - Lebanon Hospital Center, Bronx, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|Columbia University Medical Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Cardiology Associates of Schenectady, Schenectady, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|LeBauer Cardiovascular Research Foundation, Greensboro, North Carolina, United States|The Lindner Center for Research & Education at The Christ Hospital, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Dayton VA Medical Center, Dayton, Ohio, United States|Oklahoma City VA, Oklahoma City, Oklahoma, United States|Warren Cancer Research Foundation, Tulsa, Oklahoma, United States|Lancaster Heart and Stroke Foundation, Lancaster, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Grand View - Lehigh Valley Health Service, Sellersville, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Stern Cardiovascular Foundation, Inc., Germantown, Tennessee, United States|CIVA/CArdiovascular Research Institute of Dallas, Dallas, Texas, United States|Michael E. Debakey VA Medical Center, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Aspirus Wausau Hospital, Wausau, Wisconsin, United States|Jewish General Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01910389"
594,"NCT01112306","ACT-293987 in Pulmonary Arterial Hypertension",,"Active, not recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: ACT-293987","Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Actelion","All","18 Years and older   (Adult, Older Adult)","Phase 3","1193","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-065A303|2009-014992-31","July 7, 2010","December 31, 2020","October 31, 2023","April 28, 2010",,"March 18, 2020","Mobile, Alabama, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|La Jolla, California, United States|Los Angeles, California, United States|Sacramento, California, United States|Torrance, California, United States|Newark, Delaware, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Austell, Georgia, United States|Carmel, Indiana, United States|Iowa City, Iowa, United States|Kansas, Kansas, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Troy, Michigan, United States|Rochester, Minnesota, United States|Chesterfield, Missouri, United States|Saint Louis, Missouri, United States|Newark, New Jersey, United States|Bronx, New York, United States|Islandia, New York, United States|New York, New York, United States|Durham, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Bend, Oregon, United States|Portland, Oregon, United States|Doylestown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|York, Pennsylvania, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Madison, Wisconsin, United States|Milwaukee, Wisconsin, United States|Buenos Aires, Argentina|Cordoba, Argentina|Corrientes, Argentina|Adelaide, Australia|Bedford Park, Australia|Chermside, Australia|Concord, Australia|Darlinghurst, Australia|Fitzroy, Australia|Hobart, Australia|Murdoch, Australia|New Lambton, Australia|Parkville, Australia|Graz, Austria|Vienna, Austria|Minsk, Belarus|Brussels, Belgium|Leuven, Belgium|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Quebec, Canada|Santiago De Chile, Chile|Beijing, China|Guangzhou, China|Shanghai, China|Bogota, Colombia|Bogotá, Colombia|Praha 2, Czechia|Arhus, Denmark|Copenhagen, Denmark|Bron Cedex, France|Le Kremlin-Bicêtre Cedex, France|Lille Cedex, France|Toulouse Cedex 9, France|Berlin, Germany|Dresden, Germany|Giessen, Germany|Greifswald, Germany|Hannover, Germany|Heidelberg, Germany|Köln, Germany|Leipzig, Germany|Löwenstein, Germany|Regensburg, Germany|Alexandroupoli, Greece|Athens, Greece|Thessaloniki, Greece|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Szeged, Hungary|Ahmedabad, India|Chennai, India|Hyderabad, India|Dublin, Ireland|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel|Tel-Hashomer, Israel|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Kuala Lumpur, Malaysia|Ciudad de Mexico, Mexico|Amsterdam, Netherlands|Maastricht, Netherlands|Rotterdam, Netherlands|Lima, Peru|Gdańsk, Poland|Krakow, Poland|Otwock, Poland|Łódź, Poland|Bucharest, Romania|Iasi, Romania|Barnaul, Russian Federation|Ekaterinburg, Russian Federation|Kemerovo, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|St Petersburg, Russian Federation|Tomsk, Russian Federation|Belgrade, Serbia|Singapore, Singapore|Bratislava, Slovakia|Košice, Slovakia|Barcelona, Spain|Madrid, Spain|Göteborg, Sweden|Linköping, Sweden|Umea, Sweden|Uppsala, Sweden|Basel, Switzerland|Bern, Switzerland|Genève 14, Switzerland|Lausanne, Switzerland|Kaohsiung, Taiwan|Taipei, Taiwan|Khon Kaen, Thailand|Adana, Turkey|Istanbul, Turkey|İzmir, Turkey|Dnipro, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Glasgow, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01112306"
595,"NCT01546454","Relationship Between the Menstrual Cycle and Heart Disease in Women",,"Completed","Has Results","Coronary Heart Disease","Drug: Ethinyl Estradiol-Levonorgestrel combination|Drug: leuprolide acetate|Drug: Estradiol|Drug: Progesterone","Total to HDL Cholesterol Ratio","Oregon Health and Science University|Medical Research Foundation, Oregon","Female","21 Years to 40 Years   (Adult)","Not Applicable","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB8023","February 2012","June 2012","January 2013","March 7, 2012","October 23, 2014","March 22, 2017","Oregon Health & Sciences University, Department of Obstetrics and Gynecology, Women's Health Research Unit, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01546454"
596,"NCT02430077","Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients",,"Recruiting","No Results Available","Familial Partial Lipodystrophy","Drug: Obeticholic Acid|Drug: Placebo","Change in the Liver Triglycerides(TG).","University of Texas Southwestern Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","062014-033","June 2016","June 2020","December 2020","April 29, 2015",,"September 24, 2019","UT Southwestern Medical Center 5323 Harry Hines Blvd, Dallas, Texas, United States|UT Southwestern Medical Center 5323 Harry Hines Blvd, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02430077"
597,"NCT02587325","ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension",,"Recruiting","No Results Available","Pulmonary Hypertension","Drug: ABI-009, nab-rapamycin, albumin-bound rapamycin","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","Aadi, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PAH-001","April 1, 2017","December 2020","December 2020","October 27, 2015",,"December 10, 2019","University of Arizona, Tucson, Arizona, United States|Harbor-UCLA Medical Center, Torrance, California, United States|Indiana University, Indianapolis, Indiana, United States|National Institutes of Health, Bethesda, Maryland, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02587325"
598,"NCT03216902","A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study",,"Completed","No Results Available","Open-angle Glaucoma, Ocular Hypertension","Drug: Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution|Drug: Topical ultra-low dose of DE-126 Ophthalmic Solution|Drug: Topical low dose of DE-126 Ophthalmic Solution|Drug: Topical medium dose of DE-126 Ophthalmic Solution|Drug: Topical high dose of DE-126 Ophthalmic Solution|Drug: 0.005% Latanoprost Ophthalmic Solution","Intraocular Pressure in the study eye at 3 time-points throughout the day|Intraocular Pressure in the study eye at 3 time-points throughout the day at week 6|Intraocular Pressure in the study eye at 3 time-points throughout the day at weeks 1 and 2|Mean diurnal Intraocular Pressure in the study eye at weeks 1, 2, 6 and month 3|Change and percent change from baseline (CFB) in mean diurnal Intraocular Pressure in the study eye at each post-baseline visit|Change and percent change from baseline (CFB) in Intraocular Pressure in the study eye at three time points at each post-baseline visit|Proportion of subjects with mean diurnal Intraocular Pressure reduction from baseline ≥ 20%, 25% and 30% in the study eye at each post-baseline visit|Proportion of subjects with mean diurnal Intraocular Pressure ≤ 18 mmHg in the study eye at each post-baseline visit","Santen Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","241","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","012601IN","July 25, 2017","February 27, 2018","February 27, 2018","July 13, 2017",,"January 27, 2020","Sall Research Medical Center, Inc, Artesia, California, United States|North Valley Eye Medical Group, Mission Hills, California, United States|Eye Research Foundation, INC, Newport Beach, California, United States|North Bay Eye Associates, Inc., Petaluma, California, United States|Shettle Eye Research, Inc., Largo, Florida, United States|Clayton Eye Clinical Research, LLC, Morrow, Georgia, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|Rochester Ophthalmological Group, PC, Rochester, New York, United States|Mundorf Eye Center, Charlotte, North Carolina, United States|Cornerstone Health Care, LLC, High Point, North Carolina, United States|Keystone Research Ltd SMO/Texan Eye, PA, Austin, Texas, United States|Keystone Research LTD SMO/Medical Center Ophthalmology Assoc., San Antonio, Texas, United States|Murakami Karindoh Hospital, Fukuoka-shi, Fukuoka, Japan|Nagasaka Eye Clinic, Nagoya-shi, Aichi, Japan|Sugiura Eye Clinic, Osaka-shi, Osaka, Japan|Sapporo Katoh Ophthalmology Clinic, Sapporo-shi, Hokkaido, Japan|Dogenzaka Kato Eye Clinic, Shibuya-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT03216902"
599,"NCT01481051","A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma",,"Completed","No Results Available","Glaucoma|Ocular Hypertension (OH)","Drug: Latanoprost-PPDS","IOP change from baseline","Mati Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","57","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPL GLAU 12","November 2011","September 2012","September 2012","November 29, 2011",,"September 26, 2013","Sall Research Medical Center, Inc, Artesia, California, United States|Wolstan & Goldberg Eye Associates, Los Angeles, California, United States|West Coast Eye Care Associates, San Diego, California, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|R and R Eye Associates, San Antonio, Texas, United States|Rocky Mountain Eye Care Associates, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01481051"
600,"NCT00920985","US Cycle Control and Blood Pressure Study",,"Completed","No Results Available","Contraception","Drug: Gestodene/EE (FC Patch Low, BAY86-5016)|Drug: Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A","Cycle control parameters and bleeding pattern indices|Number of pregnancies while on treatment up to 14 days after removal of the last patch|Evaluation of blood pressure changes during the dosing-free interval","Bayer","Female","18 Years to 45 Years   (Adult)","Phase 3","346","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","91556","June 2009","August 2010","September 2010","June 16, 2009",,"October 9, 2015","Chandler, Arizona, United States|Glendale, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|San Diego, California, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Lake Worth, Florida, United States|Leesburg, Florida, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Metairie, Louisiana, United States|Kalamazoo, Michigan, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|New Brunswick, New Jersey, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Wexford, Pennsylvania, United States|Columbia, South Carolina, United States|Richmond, Virginia, United States|Renton, Washington, United States|Seattle, Washington, United States|La Crosse, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00920985"
601,"NCT01462565","Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)",,"Completed","Has Results","Hypertension, Pulmonary","Drug: current marketed FLOLAN (epoprostenol sodium)|Drug: new thermo stable formulation of epoprostenol sodium","Change From Baseline in Medical Outcomes Study Short Form 36 (SF-36)|Change From Baseline in Study Specific Participant Acceptance Survey|Change From Baseline in Dose of Thermo Stable Epoprostenol Sodium at Week 4|Number of Participants With Any Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events(SAEs)|Number of Participants With Infusion Site Reactions During Treatment Period|Change From Baseline in Vital Signs at Week 4 : Systolic and Diastolic Blood Pressure|Change From Baseline in Vital Signs at Week 4: Heart Rate|Number of Participants With Abnormal Clinical Chemistry|Number of Participants With Abnormal Hematology|Number of Participants With Abnormal Urinalysis|Change From Baseline in Six Minute Walk Distance Test (6MWD) After 4-weeks of Treatment|Breathlessness After 6MWD - Borg Dyspnoea Index (BDI)|World Health Organization [WHO] Functional Class at Baseline and After 4- Weeks of Treatment|Mean Oxygen Saturation in Blood Over Time|Number of Participants With Urine Pregnancy Test Positive","GlaxoSmithKline","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","16","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","115332","November 1, 2011","May 16, 2012","November 8, 2012","October 31, 2011","October 16, 2017","October 16, 2017","GSK Investigational Site, Miami Beach, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01462565"
602,"NCT02666664","Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)",,"Completed","Has Results","Hypercholesterolemia|Atherosclerotic Cardiovascular Diseases","Drug: ETC-1002|Drug: Placebo","Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)|Percentage of Participants With Adjudicated Major Adverse Cardiovascular Event|Percentage of Participants With the Indicated Event of Special Interest: Creatine Kinase Elevations|Percentage of Participants With the Indicated Event of Special Interest: Hepatic Disorders|Percentage of Participants With the Indicated Event of Special Interest: Hypoglycemia|Percentage of Participants With the Indicated Event of Special Interest: Metabolic Acidosis|Percentage of Participants With the Indicated Event of Special Interest: Muscular Disorder|Percentage of Participants With the Indicated Event of Special Interest: Neurocognitive Disorder|Percentage of Participants With the Indicated Event of Special Interest: New Onset or Worsening Diabetes Mellitus|Percentage of Participants With the Indicated Event of Special Interest: Renal Disorder|Change From Baseline to Week 52 in Uric Acid (Urate) Level|Change From Baseline to Week 52 in Creatinine Level|Change From Baseline to Week 52 in Hemoglobin Level|Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)|Absolute Change From Baseline to Week 12 in LDL-C","Esperion Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","2230","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1002-040|2015-004136-36","January 21, 2016","February 21, 2018","March 28, 2018","January 28, 2016","April 20, 2020","April 20, 2020","Huntsville, Alabama, United States|Cottonwood, Arizona, United States|Phoenix, Arizona, United States|Canoga Park, California, United States|Santa Rosa, California, United States|Bridgeport, Connecticut, United States|Hartford, Connecticut, United States|Atlantis, Florida, United States|Boca Raton, Florida, United States|Crestview, Florida, United States|Crystal River, Florida, United States|Daytona Beach, Florida, United States|Lake Worth, Florida, United States|Miami Lakes, Florida, United States|Tampa, Florida, United States|Park Ridge, Illinois, United States|Iowa City, Iowa, United States|Overland Park, Kansas, United States|Covington, Kentucky, United States|Louisville, Kentucky, United States|Minden, Louisiana, United States|Monroe, Louisiana, United States|Shreveport, Louisiana, United States|Auburn, Maine, United States|Midland, Michigan, United States|Saginaw, Michigan, United States|Saint Cloud, Minnesota, United States|Tupelo, Mississippi, United States|Jefferson City, Missouri, United States|Nashua, New Hampshire, United States|Bridgewater, New Jersey, United States|Cary, North Carolina, United States|Mount Airy, North Carolina, United States|Raleigh, North Carolina, United States|Rocky Mount, North Carolina, United States|Wilmington, North Carolina, United States|Cincinnati, Ohio, United States|Sandusky, Ohio, United States|Willoughby, Ohio, United States|Hillsboro, Oregon, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Katy, Texas, United States|Kingwood, Texas, United States|Orem, Utah, United States|Richmond, Virginia, United States|Puyallup, Washington, United States|Tacoma, Washington, United States|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Gatineau, Ontario, Canada|Mississauga, Ontario, Canada|Oshawa, Ontario, Canada|Peterborough, Ontario, Canada|Scarborough, Ontario, Canada|Chicoutimi, Quebec, Canada|Gatineau, Quebec, Canada|Longueuil, Quebec, Canada|Montréal, Quebec, Canada|Québec, Quebec, Canada|Saint-Jean-Sur-Richelieu, Quebec, Canada|St-Charles-Borromee, Quebec, Canada|Berlin, Germany|Bochum, Germany|Dresden, Germany|Essen, Germany|Frankfurt, Germany|Leipzig, Germany|Muenchen, Germany|Amsterdam, Netherlands|Arnhem, Netherlands|Eindhoven, Netherlands|Goes, Netherlands|Groningen, Netherlands|Hardenberg, Netherlands|Leiden, Netherlands|Rotterdam, Netherlands|Tilburg, Netherlands|Venlo, Netherlands|Zutphen, Netherlands|Gdansk, Poland|Gdynia, Poland|Katowice, Poland|Kraków, Poland|Poznań, Poland|Puławy, Poland|Toruń, Poland|Wroclaw, Poland|Łowicz, Poland|Łódź, Poland|Bexhill-on-Sea, United Kingdom|Birmingham, United Kingdom|Cardiff, United Kingdom|Chesterfield, United Kingdom|Chichester, United Kingdom|Chippenham, United Kingdom|Chorley, United Kingdom|Glasgow, United Kingdom|Hexham, United Kingdom|Hull, United Kingdom|Ipswich, United Kingdom|Liverpool, United Kingdom|Manchester, United Kingdom|Reading, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02666664/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02666664/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02666664"
603,"NCT01714609","Pilot Study of Effect of Sorafenib on Portal Pressure",,"Completed","Has Results","Clinically Significant Portal Hypertension","Drug: Placebo|Drug: Sorafenib","Patients With Change in HVPG From Baseline","Yale University|Onyx Therapeutics, Inc.","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HIC # 1002006266","August 2011","September 2013","September 2014","October 26, 2012","December 9, 2015","December 9, 2015","Yale Cancer Center, New Haven, Connecticut, United States|VA Medical Center West Haven, West Haven, Connecticut, United States|Brigham & Womens, Boston, Massachusetts, United States|New York University Langone Medical Center, New York, New York, United States|University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01714609"
604,"NCT01968720","Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia",,"Completed","No Results Available","Hyperlipidemias|Hypertriglyceridemia|Dyslipidemias|Lipid Metabolism Disorders|Metabolic Diseases","Drug: CAT-2003|Drug: Placebo","Percent change from baseline in fasting triglycerides in patients with severe hypertriglyceridemia|Frequency of adverse events|Absolute and percent change from baseline on postprandial total and chylomicron triglyceride levels","Catabasis Pharmaceuticals","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 2","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CAT-2003-202","October 2013","April 2014","April 2014","October 24, 2013",,"August 14, 2015","Miami, Florida, United States|Indianapolis, Indiana, United States|Auburn, Maine, United States|Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01968720"
605,"NCT03037580","Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction",,"Terminated","No Results Available","Pulmonary Hypertension|Heart Failure With a Preserved Ejection Fraction","Drug: Oral treprostinil|Drug: Placebo","Change in 6-Minute Walk Distance (6MWD) from Baseline to Week 24|Change in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Levels from Baseline to Week 24|Time to the First Clinical Worsening Event Over the 24-week Treatment Period|Change in WHO Functional Class from Baseline to Week 24","United Therapeutics","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TDE-HF-301","August 15, 2017","December 3, 2019","December 3, 2019","January 31, 2017",,"April 20, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner University Medical Center Phoenix, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|VA Healthcare System of Greater Los Angeles, Los Angeles, California, United States|University of California Los Angeles Pulmonary Division, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California - Davis Medical Center, Sacramento, California, United States|Santa Barbara Cottage Hospital, Santa Barbara, California, United States|Aurora Denver Cardiology Associates, Aurora, Colorado, United States|University of Colorado Denver, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|South Denver Cardiology, Littleton, Colorado, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Medical Faculty Associates, George Washington University, Washington, District of Columbia, United States|Bay Area Cardiology Associates, Brandon, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|St. Vincent's Lung, Sleep, and Critical Care Specialists, Jacksonville, Florida, United States|Central Florida Pulmonary Group, P.A., Orlando, Florida, United States|Florida Hospital, Orlando, Florida, United States|University of South Florida ; Tampa General Hospital, Tampa, Florida, United States|Cleveland Clinic of Florida, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Piedmont Physicians Georgia Lung, Austell, Georgia, United States|WellStar Medical Group, Marietta, Georgia, United States|University of Illinois at Chicago Hospital, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|OSF HealthCare, Peoria, Illinois, United States|Indiana University Health Methodist Research Institute, INC, Indianapolis, Indiana, United States|Community Physician Network, Heart and Vascular Care, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Services, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Iowa Heart Center, West Des Moines, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Louisville Physicians Outpatient Center, Louisville, Kentucky, United States|Chest Medicine Associates, South Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|St. Elizabeth's Medical Center, Brighton, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Spectrum Health Medical Group, Grand Rapids, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|St. Luke's Hospital, Chesterfield, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Barnabas Health Lung Center, Newark, New Jersey, United States|Albany Medical College, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Pulmonary Health Physicians, PC, Syracuse, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Pinehurst Medical Clinic, Pinehurst, North Carolina, United States|The Lindner Research Center The Christ Hospital Health Network, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|University of Toledo Medical Center, Toledo, Ohio, United States|The Oregon Clinic, Portland, Oregon, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|AnMed Health Pulmonary and Sleep Medicine, Anderson, South Carolina, United States|VitaLink Research - Anderson, Anderson, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Stern Cardiovascular Foundation, Germantown, Tennessee, United States|Summit Medical Group, Knoxville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|Houston Methodist Research Institute, Houston, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|Texas Tech University Health Sciences Center, Lubbock, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Inova Heart and Vascular Institute, Falls Church, Virginia, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Carilion Clinic, Roanoke, Virginia, United States|Providence Medical Research Center, Spokane, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03037580"
606,"NCT01475825","A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol","FOCUS FH","Completed","Has Results","Hypercholesterolemia|Heterozygous Familial","Drug: mipomersen sodium 200 mg|Drug: Placebo|Drug: mipomersen sodium 70 mg","Percent Change From Baseline To Primary Endpoint Visit (PET) In LDL-C In Cohort 1|Percent Change From Baseline To PET In LDL-C In Cohort 2|Percent Change From Baseline To PET In Apolipoprotein B (Apo B) In Cohort 1|Percent Change From Baseline To PET In Apolipoprotein B (Apo B) In Cohort 2|Percent Change From Baseline To PET in Lipoprotein (a) In Cohort 1|Percent Change From Baseline To PET in Lipoprotein (a) In Cohort 2","Kastle Therapeutics, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","309","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MIPO3801011|2011-001480-42|EFC12875","December 2011","December 29, 2015","December 29, 2015","November 21, 2011","March 14, 2019","March 26, 2019","Mission Viejo, California, United States|Aurora, Colorado, United States|Cooper City, Florida, United States|Winter Park, Florida, United States|Indianapolis, Indiana, United States|Kansas City, Kansas, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Grandville, Michigan, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Summit, New Jersey, United States|North Massapequa, New York, United States|Portland, Oregon, United States|Lancaster, Pennsylvania, United States|Charleston, South Carolina, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Norfolk, Virginia, United States|Ciudad Autonoma de Buenos Aires, Argentina|Cordoba, Argentina|Perth, Australia|South Brisbane, Australia|Edegem, Belgium|Haine St. Paul, Belgium|Leuven, Belgium|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|Sainte-Foy, Quebec, Canada|Osijek, Croatia|Zagreb, Croatia|Hradec Kralove, Czechia|Praha 1, Czechia|Aarhus, Denmark|Viborg, Denmark|Aachen, Germany|Berlin, Germany|Freiburg, Germany|Hamburg, Germany|Heidelberg, Germany|Koeln, Germany|Magdeburg, Germany|Ioannina, Greece|Kallithea, Greece|Hong Kong, Hong Kong|Baja, Hungary|Budapest, Hungary|Debrecen, Hungary|New Delhi, India|Holon, Israel|Kfar Saba, Israel|Ofakim, Israel|Bologna, Italy|Napoli, Italy|Padova, Italy|Palermo, Italy|Pisa, Italy|Roma, Italy|Seoul, Korea, Republic of|Kuala Lumpur, Malaysia|Kubang Kerian, Malaysia|Alkmaar, Netherlands|Amsterdam, Netherlands|Maastricht, Netherlands|Nijmegen, Netherlands|Utrecht, Netherlands|Waalwijk, Netherlands|Christchurch, New Zealand|Bodo, Norway|Oslo, Norway|Sandefjord, Norway|Bialystok, Poland|Gdansk, Poland|Katowice, Poland|Krakow, Poland|Naleczow, Poland|Poznan, Poland|Sopot, Poland|Szczecin, Poland|Warszawa, Poland|Wroclaw, Poland|Barnaul, Russian Federation|Kemerovo, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Petrozavodsk, Russian Federation|Ryazan, Russian Federation|Saint Petersburg, Russian Federation|St-Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Yaroslavl, Russian Federation|Cape Town, South Africa|Pretoria, South Africa|Madrid, Spain|Stockholm, Sweden|New Taipei City, Taiwan|Taipei, Taiwan|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Sivas, Turkey|Ivano-Frankivsk, Ukraine|Kiev, Ukraine|Kyiv, Ukraine|Odesa, Ukraine|Odessa, Ukraine|Birmingham, United Kingdom|Cardiff, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Oldham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01475825"
607,"NCT01560637","An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension",,"Enrolling by invitation","No Results Available","Pulmonary Arterial Hypertension","Drug: UT-15C (treprostinil diethanolamine)","Safety (e.g.number and frequency of adverse events, changes in laboratory parameters from Baseline)","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","850","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-PH-311","May 2012","May 2021","August 2021","March 22, 2012",,"April 7, 2020","Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|University of California, San Francisco-Fresno, Fresno, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California-Davis Medical Group, Advanced Lung Disease/Transplant Program, Sacramento, California, United States|David Geffen School of Medicine, Torrance, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Florida College of Medicine Jacksonville- Division of Pulmonary & Critical Medicine, Jacksonville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Piedmont - Georgia Lung Associates, Austell, Georgia, United States|HeartCare Midwest, Peoria, Illinois, United States|Indiana University Hospital, Carmel, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Maryland, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Beaumont Health, Troy, Michigan, United States|Nebraska Medical Center, Omaha, Nebraska, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|University of Rochester, Rochester, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospital, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Legacy Research Institute, Portland, Oregon, United States|Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center - Presbyterian Cardiovascular Institute, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Sanatorio San José, Caba, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Distrito Federal, Argentina|Hospital Italiano Garibaldi, Rosario, Santa Fe, Argentina|Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina|Hospital Dr. José María Cullen, Santa Fe, Argentina|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|Saint Vincents Hospital, Sydney, New South Wales, Australia|Macquarie University, Sydney, New South Wales, Australia|Prince Charles Hospital, Chermside, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Krankenhaus Elisabethinen Linz, Linz, Upper Austria, Austria|Medizinische Universität Wien, Wien, Austria|Hospital das Clinicas da Universidade Federal de Goias, Goiania, Goias, Brazil|Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Hospital Madre Teresa, Belo Horizonte, Minas Gerais, Brazil|Complexo Hospitalar Santa Casa de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital das Clínicas da Faculdade de Medicina de Botucatu- UNESP, Botucatu, SAO Paulo, Brazil|Hospital da Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SAO Paulo, Brazil|Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SAO Paulo, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Respiratory Research Foundation, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Vancouver Coastal Health, Vancouver, British Columbia, Canada|Lawson Health Research Institute, London, Ontario, Canada|Centro de Investigaciones TASOL, Santiago, Region Metropolitana, Chile|Clínica Tabancura, Vitacura, Santiago, Chile|Beijing Chao-Yang Hospital, Beijing, Beijing, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Wuhan Asia Heart Hospital, Wuhan, Hubei, China|Xiangya Hospital, Changsha, Hunan, China|The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|The Second Affiliated Hospital of Nanchang Medical University, Nanchang, Jiangxi, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, China|Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|West China Hospital, Chengdu, Sichuan, China|Peking Union Medical College Hospital, Beijing, China|Beijing Shijitan Hospital, Beijing, China|Chinese PLA General Hospital, Beijing, China|The Affiliated Hospital of Qingdao University, Qingdao, China|Renji Hospital of Shanghai Jiaotong University, Shanghai, China|Shanghai Pulmonary Hospital of Tongji University, Shanghai, China|Shenyang General Hospital of Shenyang Military Command, Shenyang, China|Aarhus Universitetshospital, Skejby, Aarhus, Denmark|Rigshospitalet-Copenhagen University Hospital, Copenhagen, Denmark|Hopital Haut-Leveque, CHU Bordeaux, Pessac, Aquitaine, France|Hopital Jean Minjoz Centre Hospitalier Universitaire Besancon, Besancon, Franche-comte, France|CHU de Montpellier, Montpellier cedex 5, Languedoc-roussillon, France|Hopital Brabois, Vandoeuvre-Les-Nancy, Limousin, Lorraine, France|Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez, Lille, NORD Pas-de-calais, France|Centre Hospitalier Universitaire Hopital Nord, Marseille, Provence Alpes COTE D'azur, France|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Baden-wuerttemberg, Germany|Ludwig-Maximilians-Universitat Munchen, Munchen, Bayern, Germany|Universitätsklinikum Regensburg, Regensburg, Bayern, Germany|Missionsarztliche Klinik Wurzburg gGmbH, Wurzburg, Bayern, Germany|Universitätsmedizin Greifswald, Greifswald, Mecklenburg-vorpommern, Germany|Bergmannsheil Berufsgenossenschaftliche Universitätsklinik GmbH, Bochum, Nordrhein-westfalen, Germany|Herzzentrum Duisburg, Duisburg, Nordrhein-westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-westfalen, Germany|Universitätsmedizin der Johannes Gutenberg Universität, Mainz, Rheinland-pfalz, Germany|Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany|Technische Universität Dresden, Dresden, Sachsen, Germany|Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany|Universitätskrankenhaus Hamburg-Eppendorf, Hamburg, Germany|University General Hospital of Attikon, Athens, Attica, Greece|General Hospital of Thessaloniki, ""G.Papanikolaou"", Thessaloniki, Macedoni, Greece|CARE Hospital, Hyderabad, Andhra Pradesh, India|Mediciti Hospital, Hyderabad, Andhra Pradesh, India|Sir Ganga Ram Hospital, New Delhi, Delhi, India|Indraprastha Apollo Hospital, New Delhi, Delhi, India|Care Institute Medical Sciences, Ahmedabad, Gujarat, India|Apollo Hospitals International, Ltd., Gandhinagar, Gujarat, India|Medanta - The Medicity, Gurgaon, Haryana, India|Narayana Institute of Cardiac Sciences, Bangalore, Karnataka, India|KEM Hospital, Mumbai, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Apollo Hospital, Chennai, Tamil NADU, India|G. Kuppuswamy Naidu Memorial Hospital, Coimbatore, Tamil NADU, India|Rabin Medical Center, Petach Tikvah, Petah Tiqwa, Israel|The Chaim Sheba Medical Center at Tel Hashomer, Tel Hashomer, Tel Aviv, Israel|Rambam Health Corp., Haifa, Israel|Carmel Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Azienda Ospedaliera Universitaria, Napoli, Italy|Istituto Mediterraneo Trapianti e Terapia Alta Specializzazione (ISMETT), Palermo, Italy|Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy|Azienda Policlinico Umberto I di Roma, Roma, Italy|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Instituto Nacional de Cardiologia Ignacio Chavez, Tlalpan, Distrito Federal, Mexico|Unidad de Investigacion Clinica en Medicina S.C., Monterrey, Nuevo LEON, Mexico|Universitair Medisch Centrum Sint Radboud, Nijmegen, Gelderland, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Noord-holland, Netherlands|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im K. Marcinkowskiego w Poznaniu, Krakow, Poland|Krakowski Szpital Specjalistyczny im. Jana Pawla II, Malogoskie, Poland|Europejskie Centrum Zdrowia Otwock, Szpital im. Fryderyka Chopina, Otwock, Poland|National University Hospital, Singapore, Singapore|National Heart Centre Singapore, Singapore, Singapore|Sahlgrenska University Hospital, Göteborg, Vastra Gotaland, Sweden|Karolinska University Hospital Solna, Stockholm, Sweden|National Cheng Kung University Hospital, Tainan, Tainan CITY, Taiwan|Veterans General Hospital-Kaohsiung, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Papworth Hospital, Papworth Everard, Cambridgshire, United Kingdom|Royal Free Hospital, London, England, United Kingdom|Freeman Hospital, Newcastle upon Tyne, England, United Kingdom|Royal Hallamshire Hospital, Sheffield, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01560637"
608,"NCT03590821","Timed Aspirin Chronobiome Study",,"Not yet recruiting","No Results Available","Healthy","Drug: Aspirin 81 mg|Drug: Celecoxib 200mg capsule","Blood pressure [mmHg]|Mean arterial pressure (MAP)","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","829532","November 2020","May 2021","May 2022","July 18, 2018",,"April 7, 2020","Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03590821"
609,"NCT01647308","Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes",,"Terminated","No Results Available","Type 2 Diabetes","Drug: ISIS-APOCIIIRX|Drug: Placebo","Total apoC-III|Insulin Sensitivity","Ionis Pharmaceuticals, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ISIS 304801-CS4","July 2012","January 2014","March 2014","July 23, 2012",,"June 28, 2018","Profil Institute for Clinical Research, Chula Vista, California, United States",,"https://ClinicalTrials.gov/show/NCT01647308"
610,"NCT01637623","Study of Cardiovascular Disease and Obstructive Sleep Apnea","CVD/OSA","Completed","No Results Available","Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour)|Hypertension","Drug: Losartan|Drug: Allopurinol|Drug: Placebo","Muscle sympathetic nerve activity responses during hypoxia|Aortic Pulse Wave Velocity|Cerebral Blood Flow|Forearm Blood Flow|Minute ventilation at rest and during hypoxia|Aortic Augmentation Index|% Vasodilation|Apnea Threshold|Apnea-Hypopnea Index|% Time Spent Below 90% Oxygen Saturation|Mean Blood Pressure","University of Wisconsin, Madison|National Heart, Lung, and Blood Institute (NHLBI)","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 2","90","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012-0026|U01HL105365","June 2012","June 2015","June 2015","July 11, 2012",,"June 2, 2017","Aurora Bay Care, Green Bay, Wisconsin, United States|Gundersen Lutheran, La Crosse, Wisconsin, United States|University of Wisconsin Madison, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01637623"
611,"NCT01078376","A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults",,"Terminated","Has Results","Hypertension","Drug: Azilsartan medoxomil (TAK-491)","Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536|Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536 Metabolite M-II.|Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536|Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536 Metabolite M-II|Maximum Observed Plasma Concentration (Cmax) for TAK-536|Maximum Observed Plasma Concentration (Cmax) for TAK-536 Metabolite M-II|Time to Reach Cmax (Tmax) for TAK-536|Time to Reach Cmax (Tmax) for TAK-536 Metabolite M-II|Terminal Elimination Half-life (T1/2) for TAK-536|Terminal Elimination Half-life (T1/2) for TAK-536 Metabolite M-II|Apparent Oral Clearance (CL/F) for TAK-536|Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)|Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)|Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)|Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)|Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)|Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)","Takeda","All","1 Year to 45 Years   (Child, Adult)","Phase 1","29","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","TAK-491_109|2009-013165-25|U1111-1113-4416","May 2010","July 2013","September 2013","March 2, 2010","July 25, 2014","July 25, 2014","Little Rock, Arkansas, United States|Atlanta, Georgia, United States|Louisville, Kentucky, United States|Toledo, Ohio, United States|Birmingham, England, United Kingdom|Bristol, England, United Kingdom|London, England, United Kingdom|Manchester, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01078376"
612,"NCT02326220","Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy","ODYSSEY ESCAPE","Completed","Has Results","Heterozygous Familial Hypercholesterolemia","Drug: Placebo|Drug: Alirocumab","Change in Standardized Rate of Apheresis Treatments From Week 7 to Week 18|Percent Change From Baseline in Calculated LDL-C (Pre-apheresis) at Week 6|Change in Standardized Rate of Apheresis Treatments From Week 15 to Week 18|Percent Change From Baseline in Apolipoprotein B (Apo B) (Pre-apheresis) to Week 6|Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) (Pre-apheresis) to Week 6|Percent Change From Baseline in Total Cholesterol (Pre-apheresis) to Week 6|Percent Change From Baseline in Apolipoprotein A (Apo A1) (Pre-apheresis) to Week 6|Percentage of Participants With At Least (>=) 30% Reduction in Calculated LDL-C (Pre-apheresis) at Week 6|Percentage of Participants With At Least (>=) 50% Reduction in Calculated LDL-C (Pre-apheresis) at Week 6|Percent Change From Baseline in Calculated LDL-C (Pre-Apheresis) to Week 18|Percent Change From Baseline in Apolipoprotein B (Apo B) (Pre-apheresis) to Week 18|Percent Change From Baseline in Non-HDL-C (Pre-apheresis) to Week 18|Percent Change From Baseline in Total Cholesterol (Pre-apheresis) to Week 18|Percent Change From Baseline in Apo A1 (Pre-apheresis) to Week 18|Percentage of Participants With At Least (>=) 30% Reduction in Calculated LDL-C (Pre-apheresis) at Week 18|Percentage of Participants With At Least (>=) 50% Reduction in Calculated LDL-C (Pre-apheresis) at Week 18|Change From Baseline in W-BQ22 (Well-being Questionnaire) Index Score at Week 18|Percent Change From Baseline in Lipoprotein (a) (Lp [a]) (Pre-apheresis) to Week 6|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) (Pre-apheresis) to Week 6|Percent Change From Baseline in Triglyceride (TG) Levels (Pre-apheresis) to Week 6|Percent Change From Baseline in Lp (a) (Pre-apheresis) to Week 18|Percent Change From Baseline in HDL-C (Pre-apheresis) to Week 18|Percent Change From Baseline in TG Levels (Pre-apheresis) to Week 18","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1216","March 31, 2015","January 31, 2016","April 30, 2016","December 29, 2014","May 1, 2020","May 1, 2020","Aurora, Colorado, United States|Hartford, Connecticut, United States|Kansas City, Kansas, United States|Scarborough, Maine, United States|Rochester, Minnesota, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Dresden, Sachsen, Germany|Berlin, Germany|Göttingen, Germany|Muenchen (2 locations), Germany|Passau, Germany|Rostock, Germany",,"https://ClinicalTrials.gov/show/NCT02326220"
613,"NCT01229566","Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia",,"Unknown status","No Results Available","Severe Hypertriglyceridemia","Drug: AKR-963","Difference between AKR963 and Control [placebo or active control] treatment groups in triglyceride lowering effect [ Time Frame: 12 weeks ]","Trygg Pharma, Inc.","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TRGG-963-002","October 2010","July 2012","July 2012","October 27, 2010",,"November 24, 2011","Illinois Recruiting, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01229566"
614,"NCT03270644","A Study of Lasmiditan and Propranolol in Healthy Participants",,"Completed","Has Results","Healthy","Drug: Lasmiditan|Drug: Propranolol","Change From Baseline (Day 8) in Mean Hourly Heart Rate Following Propranolol Administered Alone and When Coadministered With Lasmiditan|Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan Alone and When Coadministered With Propranolol|Pharmacokinetic: Maximum Observed Drug Concentration (Cmax) of Propranolol Alone and When Coadministered With Lasmiditan|Pharmacokinetic: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Last Measurable Concentration [AUC(0-tlast)] of Lasmiditan Alone and When Administered With Propranolol|Pharmacokinetic: Area Under the Concentration Versus Time Curve (AUC) of Propranolol During One Dosing Interval Alone and When Administered With Lasmiditan|Change From Baseline (Day 8) in PR Interval Following Propranolol Administered Alone and When Coadministered With Lasmiditan|Change From Baseline (Day 8) in Systolic Blood Pressure Following Propranolol Administered Alone and When Coadministered With Lasmiditan|Change From Baseline (Day 8) in Diastolic Blood Pressure Following Propranolol Administered Alone and When Coadministered With Lasmiditan","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","44","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16857|H8H-MC-LAHD","August 31, 2017","November 22, 2017","November 22, 2017","September 1, 2017","December 2, 2019","December 16, 2019","Covance Daytona Beach, Daytona Beach, Florida, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03270644/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03270644/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03270644"
615,"NCT01104870","A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension",,"Completed","Has Results","Pulmonary Hypertension","Drug: UT-15C","Change in Peak Total Pulmonary Resistance Index (TPRI) During Exercise From Baseline to Week 12|Change in Mean Pulmonary Artery Pressure (PAPm) From Baseline to Week 12|Change in Cardiac Index (CI) From Baseline to Week 12|Change in 6-minute Walk Distance (6MWD) From Baseline to Week 12|Change in Borg Dyspnea Score (Following 6MWT) From Baseline to Week 12|Change in PH Symptoms From Baseline to Week 12|Number of Participants With a Change From Baseline World Health Organization (WHO) Functional Classification at Week 12|Change in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) Concentrations From Baseline to Week 12","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","TDE-PH-202","April 2010","January 2013","January 2013","April 16, 2010","December 30, 2015","May 27, 2016","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|University of California Los Angeles Pulmonary Division, Los Angeles, California, United States|University of California Davis Medical Center, Sacramento, California, United States|University of Rochester Medical Center, Mary Parkes Center, Rochester, New York, United States|The Carl and Edyth Lindner Research Center at The Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01104870"
616,"NCT01842282","Amlexanox for Type 2 Diabetes and Obesity",,"Active, not recruiting","No Results Available","Diabetes Mellitus Type 2|Non Alcoholic Fatty Liver Disease|Obesity","Drug: Amlexanox","HbA1c|hepatic steatosis by MRI|Weight","University of Michigan","All","18 Years to 59 Years   (Adult)","Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HUM00065177","July 19, 2013","December 2020","July 2021","April 29, 2013",,"November 29, 2019","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01842282"
617,"NCT03043651","Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)",,"Terminated","No Results Available","Pulmonary Hypertension Associated With HFpEF","Drug: Oral Treprostinil","Long-term Safety of Oral Treprostinil in Subjects with PH Associated with HFpEF as assessed by number of subjects with treatment-related adverse events|Long-term Safety of Oral Treprostinil in Subjects with PH Associated with HFpEF as assessed by clinical laboratory parameters|Long-term Safety of Oral Treprostinil in Subjects with PH Associated with HFpEF as assessed by number of subjects with heart failure signs and symptoms|Effect of Continued Long-term Oral Treprostinil Therapy on the 6-Minute Walk Distance (6MWD)|Effect of Continued Long-term Oral Treprostinil Therapy on the Borg Dyspnea Score|Effect of Continued Long-term Oral Treprostinil Therapy on World Health Organization (WHO) Functional Class|Effect of Continued Long-term Oral Treprostinil Therapy on the N-Terminal Pro-brain Natriuretic Peptide (NT-proBNP)","United Therapeutics","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 3","48","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-HF-302","August 15, 2017","March 2, 2020","March 2, 2020","February 6, 2017",,"April 20, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner University Medical Center Phoenix, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|VA Healthcare System of Greater Los Angeles, Los Angeles, California, United States|University of California Los Angeles Pulmonary Division, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California - Davis Medical Center, Sacramento, California, United States|Santa Barbara Cottage Hospital, Santa Barbara, California, United States|Aurora Denver Cardiology Associates, Aurora, Colorado, United States|University of Colorado Denver, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|South Denver Cardiology, Littleton, Colorado, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Medical Faculty Associates, George Washington University, Washington, District of Columbia, United States|Bay Area Cardiology Associates, Brandon, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|St. Vincent's Lung, Sleep, and Critical Care Specialists, Jacksonville, Florida, United States|Central Florida Pulmonary Group, P.A., Orlando, Florida, United States|Florida Hospital, Orlando, Florida, United States|University of South Florida ; Tampa General Hospital, Tampa, Florida, United States|Cleveland Clinic of Florida, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Piedmont Physicians Georgia Lung, Austell, Georgia, United States|WellStar Medical Group, Marietta, Georgia, United States|University of Illinois at Chicago Hospital, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|OSF HealthCare, Peoria, Illinois, United States|Indiana University Health Methodist Research Institute, INC, Indianapolis, Indiana, United States|Community Heart and Vascular Hospital, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Services, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Iowa Heart Center, West Des Moines, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Louisville Physicians Outpatient Center, Louisville, Kentucky, United States|Chest Medicine Associates, South Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|St. Elizabeth's Medical Center, Brighton, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Spectrum Health Medical Group, Grand Rapids, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|St. Luke's Hospital, Chesterfield, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Barnabas Health Lung Center, Newark, New Jersey, United States|Albany Medical College, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Pulmonary Health Physicians, PC, Syracuse, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Pinehurst Medical Clinic, Pinehurst, North Carolina, United States|The Lindner Research Center The Christ Hospital Health Network, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|University of Toldedo Medical Center, Toledo, Ohio, United States|The Oregon Clinic, Portland, Oregon, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|AnMed Health Pulmonary and Sleep Medicine, Anderson, South Carolina, United States|VitaLink Research - Anderson, Anderson, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Stern Cardiovascular Foundation, Germantown, Tennessee, United States|Summit Medical Group, Knoxville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|Houston Methodist Research Institute, Houston, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|Texas Tech University Health Sciences Center, Lubbock, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Inova Heart and Vascular Institute, Falls Church, Virginia, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Carilion Clinic, Roanoke, Virginia, United States|Providence Medical Research Center, Spokane, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03043651"
618,"NCT02729025","Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))","ANITSCHKOW","Completed","Has Results","Subjects With Hyperlipidemia, Dyslipidemia","Drug: Evolocumab|Drug: Placebo","Percent Change From Baseline in Maximum Target-to-background Ratio in the Most Diseased Segment of the Index Vessel at Week 16|Percent Change From Baseline in Lipoprotein(a) Concentration at Week 16|Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Concentration at Week 16|Percent Change From Baseline in Apolipoprotein B Concentration at Week 16","Amgen","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 3","129","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20130293|2015-003731-35","April 14, 2016","April 5, 2018","April 5, 2018","April 6, 2016","April 23, 2019","April 23, 2019","Research Site, Miami, Florida, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Hurst, Texas, United States|Research Site, Newmarket, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Amsterdam, Netherlands|Research Site, Apeldoorn, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Venlo, Netherlands|Research Site, Waalwijk, Netherlands","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02729025/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02729025/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02729025"
619,"NCT01280994","Hyperpolarized 129Xe MRI for Imaging Pulmonary Function",,"Suspended","No Results Available","Interstitial Lung Disease|Cystic Fibrosis|Pulmonary Hypertension|NSIP","Drug: Xenon","Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Bastiaan Driehuys|Duke University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","445","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00025110","January 2011","December 2020","December 2021","January 21, 2011",,"April 27, 2020","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01280994"
620,"NCT02373241","Preventing Sickle Cell Kidney Disease",,"Recruiting","No Results Available","Anemia, Sickle Cell|Sickle Cell Disease|Kidney Disease|Hypertension|Proteinuria","Drug: Losartan","Feasibility as measured by the number of patients that accept enrollment, remain adherent to losartan, and remain adherent to study procedures.|Feasibility as measured by number of patients with adverse events to losartan.|To prospectively evaluate the incidence of hypertension (clinic and ambulatory) in patients with SCD and number of patients with abnormal blood pressure biomarkers.|Feasibility as measured by the number of patients with improvement in nocturnal blood pressure while receiving losartan.","University of Alabama at Birmingham|National Heart, Lung, and Blood Institute (NHLBI)","All","5 Years to 25 Years   (Child, Adult)","Phase 2","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F141107009|1K23HL127100-01","April 2015","April 2020","April 2020","February 26, 2015",,"May 10, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT02373241"
621,"NCT01560624","Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy","FREEDOM-EV","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Treprostinil Diolamine|Drug: Placebo","Time to First Clinical Worsening Event|Change in 6-Minute Walk Distance|Change in Plasma N-Terminal Pro-brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 24|Change in World Health Organization Functional Class (WHO FC) From Baseline to Week 48","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","690","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TDE-PH-310","June 26, 2012","June 24, 2018","June 24, 2018","March 22, 2012","February 13, 2020","February 13, 2020","Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|University of California, San Francisco-Fresno, Fresno, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California-Davis Medical Group, Advanced Lung Disease/Transplant Program, Sacramento, California, United States|David Geffen School of Medicine, Torrance, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Florida College of Medicine Jacksonville- Division of Pulmonary & Critical Medicine, Jacksonville, Florida, United States|University of Florida College of Medicine Jacksonville, Jacksonville, Florida, United States|University of Florida College of Medicine, Jacksonville, Jacksonville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Piedmont - Georgia Lung Associates, Austell, Georgia, United States|HeartCare Midwest, Peoria, Illinois, United States|Indiana University Hospital, Carmel, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Maryland, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Beaumont Health, Troy, Michigan, United States|Nebraska Medical Center, Omaha, Nebraska, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|University of Rochester, Rochester, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospital, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Legacy Research Institute, Portland, Oregon, United States|Perelman Center for Advanced Medicine; University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center - Presbyterian Cardiovascular Institute, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Sanatorio San José, Caba, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Distrito Federal, Argentina|Hospital Italiano Garibaldi, Rosario, Santa Fe, Argentina|Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina|Hospital Dr. José María Cullen, Santa Fe, Argentina|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|Saint Vincents Hospital, Sydney, New South Wales, Australia|Macquarie University, Sydney, New South Wales, Australia|Prince Charles Hospital, Chermside, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Krankenhaus Elisabethinen Linz, Linz, Upper Austria, Austria|Medizinische Universität Wien, Wien, Austria|Hospital das Clinicas da Universidade Federal de Goias, Goiania, Goias, Brazil|Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Hospital Madre Teresa, Belo Horizonte, Minas Gerais, Brazil|Complexo Hospitalar Santa Casa de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital das Clínicas da Faculdade de Medicina de Botucatu- UNESP, Botucatu, SAO Paulo, Brazil|Hospital da Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SAO Paulo, Brazil|Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SAO Paulo, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Respiratory Research Foundation, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Vancouver Coastal Health, Vancouver, British Columbia, Canada|Lawson Health Research Institute, London, Ontario, Canada|Centro de Investigaciones TASOL, Santiago, Region Metropolitana, Chile|Clínica Tabancura, Vitacura, Santiago, Chile|Beijing Chao-Yang Hospital, Beijing, Beijing, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Wuhan Asia Heart Hospital, Wuhan, Hubei, China|Xiangya Hospital, Changsha, Hunan, China|The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|The Second Affiliated Hospital of Nanchang Medical University, Nanchang, Jiangxi, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, China|Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|West China Hospital, Chengdu, Sichuan, China|Peking Union Medical College Hospital, Beijing, China|Beijing Shijitan Hospital, Beijing, China|Chinese PLA General Hospital, Beijing, China|The Affiliated Hospital of Qingdao University, Qingdao, China|Renji Hospital of Shanghai Jiaotong University, Shanghai, China|Shanghai Pulmonary Hospital of Tongji University, Shanghai, China|Shenyang General Hospital of Shenyang Military Command, Shenyang, China|Aarhus Universitetshospital, Skejby, Aarhus, Denmark|Rigshospitalet-Copenhagen University Hospital, Copenhagen, Denmark|Hopital Haut-Leveque, CHU Bordeaux, Pessac, Aquitaine, France|Hopital Jean Minjoz Centre Hospitalier Universitaire Besancon, Besancon, Franche-comte, France|CHU de Montpellier, Montpellier Cedex 5, Languedoc-roussillon, France|Hopital Brabois, Vandoeuvre-Les-Nancy, Limousin, Lorraine, France|Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez, Lille, NORD Pas-de-calais, France|Centre Hospitalier Universitaire Hopital Nord, Marseille, Provence Alpes COTE D'azur, France|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Baden-wuerttemberg, Germany|Ludwig-Maximilians-Universitat Munchen, Munchen, Bayern, Germany|Universitätsklinikum Regensburg, Regensburg, Bayern, Germany|Missionsarztliche Klinik Wurzburg gGmbH, Wurzburg, Bayern, Germany|Universitätsmedizin Greifswald, Greifswald, Mecklenburg-vorpommern, Germany|Bergmannsheil Berufsgenossenschaftliche Universitätsklinik GmbH, Bochum, Nordrhein-westfalen, Germany|Herzzentrum Duisburg, Duisburg, Nordrhein-westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-westfalen, Germany|Universitätsmedizin der Johannes Gutenberg Universität, Mainz, Rheinland-pfalz, Germany|Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany|Technische Universität Dresden, Dresden, Sachsen, Germany|Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany|Universitätskrankenhaus Hamburg-Eppendorf, Hamburg, Germany|Technische Universität Dresden, Sachsen, Germany|University General Hospital of Attikon, Athens, Attica, Greece|General Hospital of Thessaloniki, ""G.Papanikolaou"", Thessaloniki, Macedoni, Greece|CARE Hospital, Hyderabad, Andhra Pradesh, India|Mediciti Hospital, Hyderabad, Andhra Pradesh, India|Sir Ganga Ram Hospital, New Delhi, Delhi, India|Indraprastha Apollo Hospital, New Delhi, Delhi, India|Care Institute Medical Sciences, Ahmedabad, Gujarat, India|Apollo Hospitals International, Ltd., Gandhinagar, Gujarat, India|Medanta - The Medicity, Gurgaon, Haryana, India|Narayana Institute of Cardiac Sciences, Bangalore, Karnataka, India|KEM Hospital, Mumbai, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Apollo Hospital, Chennai, Tamil NADU, India|G. Kuppuswamy Naidu Memorial Hospital, Coimbatore, Tamil NADU, India|Rabin Medical Center, Petach Tikvah, Petah Tiqwa, Israel|The Chaim Sheba Medical Center at Tel Hashomer, Tel Hashomer, Tel Aviv, Israel|Rambam Health Corp., Haifa, Israel|Carmel Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Azienda Ospedaliera Universitaria, Napoli, Italy|Istituto Mediterraneo Trapianti e Terapia Alta Specializzazione (ISMETT), Palermo, Italy|Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy|Azienda Policlinico Umberto I di Roma, Roma, Italy|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Instituto Nacional de Cardiologia Ignacio Chavez, Tlalpan, Distrito Federal, Mexico|Unidad de Investigacion Clinica en Medicina S.C., Monterrey, Nuevo LEON, Mexico|Universitair Medisch Centrum Sint Radboud, Nijmegen, Gelderland, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Noord-holland, Netherlands|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im K. Marcinkowskiego w Poznaniu, Krakow, Poland|Krakowski Szpital Specjalistyczny im. Jana Pawla II, Malogoskie, Poland|Europejskie Centrum Zdrowia Otwock, Szpital im. Fryderyka Chopina, Otwock, Poland|National University Hospital, Singapore, Singapore|National Heart Centre Singapore, Singapore, Singapore|Sahlgrenska University Hospital, Göteborg, Vastra Gotaland, Sweden|Karolinska University Hospital Solna, Stockholm, Sweden|National Cheng Kung University Hospital, Tainan, Tainan CITY, Taiwan|Veterans General Hospital-Kaohsiung, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Papworth Hospital, Papworth Everard, Cambridgshire, United Kingdom|Royal Free Hospital, London, England, United Kingdom|Freeman Hospital, Newcastle upon Tyne, England, United Kingdom|Royal Hallamshire Hospital, Sheffield, England, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT01560624/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT01560624/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01560624"
622,"NCT02083289","A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)",,"Completed","No Results Available","Ocular Hypertension|Open Angle-glaucoma","Drug: ONO-9054|Drug: Latanoprost","Mean change in diurnal IOP (average of four time points) from baseline|Evaluating the safety parameters per protocol|Diurnal IOP|Mean change from baseline in IOP at each measured time point|Treatment response rates|Percent change from baseline in IOP at each measured time point","Ono Pharmaceutical Co. Ltd","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","123","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ONO-9054IOU003","May 2014","December 2014",,"March 11, 2014",,"February 25, 2016","Los Angeles Clinical Site, Los Angeles, California, United States|Mission Hills Clinical Site, Mission Hills, California, United States|Newport Beach Clinical Site, Newport Beach, California, United States|Pasadena Clinical Site, Pasadena, California, United States|Petaluma Clinical Site, Petaluma, California, United States|Morrow Clinical Site, Morrow, Georgia, United States|Roswell Clinical Site, Roswell, Georgia, United States|New York Clinical Site, New York, New York, United States|High Point Clinical Site, High Point, North Carolina, United States|Cranberry Township Clinical Site, Cranberry Township, Pennsylvania, United States|Philadelphia Clinical Site, Philadelphia, Pennsylvania, United States|Austin Clinical Site, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02083289"
623,"NCT02152774","A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma","ROCK - CACG","Unknown status","No Results Available","Chronic Angle-closure Glaucoma","Drug: Rho-Kinase Inhibitor","Long Lasting effect of study drug to reduce IOP|Secondary Outcome","New York Glaucoma Research Institute","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14.12","May 2014","February 2015",,"June 2, 2014",,"April 24, 2015","Glaucoma Associates of New York, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02152774"
624,"NCT01262638","A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides",,"Completed","No Results Available","Dyslipidemia","Drug: ETC-1002|Drug: Placebo","To assess the LDL-C lowering efficacy of ETC-1002 versus placebo|To assess the efficacy of ETC-1002 to modulate TG and other lipid and cardio-metabolic biomarkers|To assess safety using adverse event reports, physical exams, vital signs, ECGs and clinical laboratory parameters","Esperion Therapeutics","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","177","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ETC-1002-003","December 2010","October 2011","October 2011","December 17, 2010",,"March 29, 2019","Chandler, Arizona, United States|Greenbrae, California, United States|Santa Rosa, California, United States|Jacksonville, Florida, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Louisville, Kentucky, United States|Kalamazoo, Michigan, United States|Raleigh, North Carolina, United States|Houston, Texas, United States|Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01262638"
625,"NCT00986999","Effect of Rosuvastatin on Endothelial Function",,"Terminated","Has Results","HIV Infections|Cardiovascular Disease","Drug: rosuvastatin","Change in Flow Mediated Dilatation (FMD) of the Brachial Artery|Change in HIV Biomarkers of Immune Activation to Include CD38 and CD69 Expression on T Cells and CD16 and CD69 Expression on Monocytes|Change in Mitochondrial-specific Oxidative Stress (Mt-specific 8-oxo-dG) and Oxidative Phosphorylation (OXPHOS) Protein/Enzyme Activity [Complex I and Complex IV] Levels|Change in Glucose Homeostasis and Insulin Resistance as Assessed by Oral Glucose Tolerance Testing|Change in Total, HDL and LDL Cholesterol and Triglyceride Levels|Change in hsCRP","University of Hawaii","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H002|R01HL095135","September 2009","January 2015",,"September 30, 2009","January 29, 2015","January 29, 2015","Hawaii Center for AIDS, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT00986999"
626,"NCT02173223","A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt",,"Unknown status","No Results Available","Advanced Glaucoma","Drug: Rho-Kinase Inhibitor","Effect of study drug to reduce IOP|IOP Reduction","New York Glaucoma Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14.14","June 2014","February 2015",,"June 24, 2014",,"April 24, 2015","Glaucoma Associates of New York, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02173223"
627,"NCT00902174","Imatinib (QTI571) in Pulmonary Arterial Hypertension","IMPRES","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: imatinib mesylate|Drug: Placebo","Difference in Six-minute Walk Distance Test (6MWD) Between Imatinib and Placebo at 24 Weeks|Clinical Worsening Comparing Imatinib Versus Placebo for Adjudicated Cases|Change From Baseline in Right Atrial Pressure|Change From Baseline in Mean Pulmonary Arterial Pressure|Change From Baseline in Mean Pulmonary Capillary Wedge Pressure|Change From Baseline in Systemic Vascular Resistance|Change From Baseline in Pulmonary Vascular Resistance|Change From Baseline in Pulmonary Resistance Index|Change From Baseline in Cardiac Output|Change From Baseline in Systolic Arterial Blood Pressure|Change From Baseline in Diastolic Arterial Blood Pressure|Change From Baseline in Heart Rate|Change in Borg Dyspnea Score During 6-minute Walk Test|Covariance of End of Study CAMPHOR Score|Plasma Concentration of QTI571 200 mg and Its Metabolite (GCP74588) Pre-dose and Between 0 Hour to 3 Hour Post-dose Per Participant|Plasma Concentration of QTI571 400 mg and Its Metabolite (GCP74588) Pre-dose and Between 0 Hour to 3 Hour Post-dose Per Participant","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","202","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CQTI571A2301","September 2009","May 2011","May 2011","May 15, 2009","July 16, 2013","February 17, 2016","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Clearwater, Florida, United States|Novartis Investigative Site, Miami Beach, Florida, United States|Novartis Investigative Site, Weston, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Rochester, Minnesota, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Minneola, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis investigative site, Innsbruck, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Calgary, Canada|Novartis Investigative Site, Edmonton, Canada|Novartis Investigative Site, London, Canada|Novartis Investigative Site, Montreal, Canada|Novartis Investigative Site, Ottawa, Canada|Novartis investigative site, Toronto, Canada|Novartis Investigative Site, Vancouver, Canada|Novartis Investigative Site, Clamart Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Giessen, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Koln, Germany|Novartis investigative site, Lowenstein, Germany|Novartis Investigative Site, Munchen, Germany|Novartis Investigative Site, Regensberg, Germany|Novartis Investigative Site, Wurzberg, Germany|Novartis Investigative Site, Bologna, Italy|Novartis Investigative Site, Pavia, Italy|Novartis Investigative Site, Pisa, Italy|Novartis Investigative Site, Roma, Italy|Novartis Investigative Site, Bunkyo-ku, Japan|Novartis Investigative Site, Hamamatsu, Japan|Novartis Investigative Site, Mitaka, Japan|Novartis Investigative Site, Okayama, Japan|Novartis Investigative Site, Sendai, Japan|Novartis Investigative Site, Suita, Japan|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Caceras, Spain|Novartis Investigative Site, La Coruna, Spain|Novartis investigative site, La Laguna, Spain|Novartis Investigative Site, Las Palmas de Gran Canarias, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Malaga, Spain|Novartis Investigative Site, Santa Cruz de Tenerife, Spain|Novartis Investigative Site, Santander, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis investigative site, Valencia, Spain|Novartis Investigative Site, Valladolid, Spain|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Umea, Sweden|Novartis Investigative Site, Uppsala, Sweden|University Hospital Basel, Basel, Switzerland|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, St. Gallen, Switzerland|Novartis Investigative Site, Cambridge, United Kingdom|Novartis Investigative Site, Clydebank, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00902174"
628,"NCT00990314","Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients",,"Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Beraprost Sodium Modified Release","Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE)|Number of Reported Treatment-Emergent Adverse Events|Change in Six-Minute-Walk Distance (6MWD)|Change in Borg Dyspnea Score|Number of Participants That Experienced Clinical Worsening|Number of Participants With a Change in WHO Functional Class","Lung Biotechnology PBC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","31","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BPS-MR-PAH-204","November 30, 2009","November 30, 2013","November 30, 2013","October 6, 2009","September 16, 2019","September 16, 2019","Harbor-UCLA Medical Center, Torrance, California, United States|Midwest Heart Foundation - Advocate Medical Group, Oakbrook Terrace, Illinois, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Beth Israel Medical Center, New York, New York, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Universite Libre de Bruxelles, Bruxelles, Belgium|Catholic University of Leuven, Leuven, Belgium|General Teaching Hospital, Praha, Czechia|Klinikum der Universitat zu Koln, Cologne, Germany|Medizinische Klinik und Poliklinik, Dresden, Germany|Abt Innere Medizin III, Medizinische Universitatsklinik, Heidelberg, Germany|Universitatsklinik Leipzig Abteilung Pulmologie, Leipzig, Germany|Mater Misericordiae University Hospital Ltd., Dublin, Ireland|Institutul de Urgenta pentru Boli, Bucuresti, Romania|Institutul National de Pneumologie, Bucuresti, Romania|Institutul de Boli Cardiovasculare, Lasi, Romania",,"https://ClinicalTrials.gov/show/NCT00990314"
629,"NCT01302444","Treprostinil Combined With Tadalafil for Pulmonary Hypertension","T2","Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: Tadalafil|Drug: Placebo","All Cause Mortality|Adverse Events Are no Greater Than With Treprostinil Infusion Alone|WHO Functional Class Will Improve or Remain Stable|Hospitalizations|6 Minute Walking Distance Change Will Improve|Tei Index Change by Transthoracic Echocardiography|Plasma BNP (Brain Natriuretic Peptide)Level Change|Change From Baseline in Pulmonary Arterial Systolic Pressure (PASP)as Assessed by Transthoracic Echocardiography Using Doppler Ultrasound","Rhode Island Hospital|United Therapeutics","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","1","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","T2 Trial","March 2011","March 2012","March 2012","February 24, 2011","July 18, 2013","July 26, 2013","Maine Medical Center, Portland, Maine, United States|Tuft's New England Medical Center, Boston, Massachusetts, United States|Brigham & Womens Hospital, Boston, Massachusetts, United States|Saint Barnabas Health Care System, Newark Beth Israel Medical Center, Newark, New Jersey, United States|Beth Israel Medical Center, new York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01302444"
630,"NCT01884675","Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.","AMBER I","Terminated","Has Results","Hypertension","Drug: Ambrisentan 5 mg|Drug: Placebo","Change From Baseline in Six Minutes Walking Distance (6MWD) at Week 16|Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 16|Change From Baseline in WHO Functional Class (FC) at Weeks 4, 8, 12 and 16/Early Withdrawal|Change From Baseline in Borg CR10 Scale (BCR10S) Immediately Following Exercise at Weeks 4, 8, 12 and 16/Early Withdrawal|Number of Participants With Clinical Worsening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|Change From Baseline in Mean Right Atrial Pressure (mRAP) and Mean Pulmonary Artery Pressure (mPAP) at Week 16|Change From Baseline in Cardiac Index at Week 16|Percent Change From Baseline in Plasma N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)|Change From Baseline in Quality of Life as Measured by Short Form 36 Health Survey (SF-36)|Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change From Baseline in Haemoglobin Levels at Weeks 4, 8, 12, and 16/Early Withdrawal|Change From Baseline in Haematocrit Levels at Weeks 4, 8, 12, and 16/Early Withdrawal|Number of Participants With Significant Liver Events at Weeks 4, 8, 12, and 16/Early Withdrawal|Change From Baseline in Supine Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Assessed at Weeks 4, 8, 12, and 16/Early Withdrawal|Change From Baseline in Heart Rate Assessed at Weeks 4, 8, 12, and 16/Early Withdrawal|Number of Participants With Clinical Chemistry Parameters of Potential Clinical Concern Any Time Post Baseline|Number of Participants With Hematology Parameters of Potential Clinical Concern Any Time Post Baseline|Number of Participants With Testicular Function (Males Only) of Potential Clinical Concern Any Time Post Baseline","GlaxoSmithKline","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","115811","September 2013","March 2015","March 2015","June 24, 2013","December 16, 2015","March 6, 2017","GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Corrientes, Argentina|GSK Investigational Site, Santa Fe, Argentina|GSK Investigational Site, Graz, Austria|GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Wuhan, Hubei, China|GSK Investigational Site, Xian, Shaanxi, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Praha 2, Czech Republic|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Homburg, Saarland, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Ashkelon, Israel|GSK Investigational Site, Zrifin, Israel|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Miyagi, Japan|GSK Investigational Site, Tochigi, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Monterrey NL, Nuevo León, Mexico|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, Tomsk, Russian Federation|GSK Investigational Site, Riyadh, Saudi Arabia|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Clydebank, United Kingdom|GSK Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01884675"
631,"NCT03419364","Study of Nicotinamide in Early Onset Preeclampsia",,"Recruiting","No Results Available","Preeclampsia","Drug: nicotinamide","Change in Mean Arterial blood Pressure (MAP)|Number of participants with alanine aminotransferase (ALT) =/> 3x Upper Limit of Normal (ULN)|Number of participants with aspartate aminotransferase (AST) =/> 3x Upper Limit of Normal (ULN)|Number of participants with Maternal side effects|Proportion of women maternal abdominal tenderness|Proportion of women with headache unrelieved by oral analgesics|Proportion of women with hematocrit decrease of more than 3%|Proportion of women with less than 500 cc urine output in 24 hours|Proportion of fetuses with Category III non stress test results|Proportion of fetuses with biophysical profile < 6","University of North Carolina, Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","18 Years to 55 Years   (Adult)","Phase 2","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-0693|1R03HD092370-01","November 1, 2017","July 31, 2020","July 31, 2020","February 1, 2018",,"March 13, 2020","UNC at Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03419364"
632,"NCT01717586","Pravastatin for Prevention of Preeclampsia","Statin","Active, not recruiting","No Results Available","Preeclampsia","Drug: Pravastatin|Drug: Placebo","Number and type of maternal adverse events|Number and type of fetal/neonatal adverse events|Pharmacokinetic parameters of pravastatin sodium during pregnancy","The University of Texas Medical Branch, Galveston|University of Pittsburgh|Northwestern University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","18 Years and older   (Adult, Older Adult)","Phase 1","48","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","12-097 OPRU/OPRC Pravastatin|U54HD047891","August 2012","December 2020","December 2021","October 30, 2012",,"June 11, 2019","Northwestern University, Chicago, Illinois, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas Medical Branch, Galveston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01717586"
633,"NCT00934089","A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329",,"Completed","No Results Available","Glaucoma, Open-Angle|Ocular Hypertension","Drug: PF-04217329|Drug: latanoprost vehicle|Drug: latanoprost","Intraocular pressure (IOP) change from baseline|Plasma concentrations of the active metabolite of PF-04217329|Diastolic ocular perfusion pressure and mean change from baseline|Conjunctival hyperemia scores and change from baseline|Corneal staining scores and mean change from baseline|Mean corneal thickness change from baseline|Mean change in corneal endothelial cell counts from baseline","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","A0191002","January 2010","June 2010","June 2010","July 8, 2009",,"July 1, 2011","Pfizer Investigational Site, Cypress, California, United States|Pfizer Investigational Site, Garden Grove, California, United States|Pfizer Investigational Site, Gardena, California, United States|Pfizer Investigational Site, Long Beach, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, Pasadena, California, United States",,"https://ClinicalTrials.gov/show/NCT00934089"
634,"NCT01941836","Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients",,"Completed","No Results Available","Hypercholesterolemia","Drug: ETC-1002|Drug: Ezetimibe","Percent change in calculated low density lipoprotein-cholesterol (LDL-C)|Percent change in other lipid measures non high density lipoprotein cholesterol (nonHDL-C)|Safety using adverse event reports; vital signs|Percent change in Apolipoprotein B (ApoB)|Percent change in high sensitivity C-reactive protein (hsCRP)|Safety using adverse event reports; clinical laboratory results|Safety using adverse event reports; rates of muscle-related adverse","Esperion Therapeutics|Medpace, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","349","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1002-008","September 2013","October 2014","November 2014","September 13, 2013",,"March 29, 2019","Birmingham, Alabama, United States|Muscle Shoals, Alabama, United States|Chandler, Arizona, United States|Beverly Hills, California, United States|Chino, California, United States|Lincoln, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Thousand Oaks, California, United States|Vista, California, United States|Denver, Colorado, United States|Hartford, Connecticut, United States|Atlantis, Florida, United States|Brandon, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Oviedo, Florida, United States|Ponte Vedra, Florida, United States|Port Orange, Florida, United States|Saint Petersburg, Florida, United States|West Palm Beach, Florida, United States|Decatur, Georgia, United States|Marietta, Georgia, United States|Meridian, Idaho, United States|Evansville, Indiana, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Lincoln, Nebraska, United States|Clifton, New Jersey, United States|Albuquerque, New Mexico, United States|New Windsor, New York, United States|Rochester, New York, United States|Williamsville, New York, United States|Greensboro, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Wilmington, North Carolina, United States|Beachwood, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Franklin, Ohio, United States|Lyndhurst, Ohio, United States|Marion, Ohio, United States|Willoughby Hills, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Eugene, Oregon, United States|Mount Pleasant, South Carolina, United States|Kingsport, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Round Rock, Texas, United States|Orem, Utah, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Olympia, Washington, United States|Renton, Washington, United States|Seattle, Washington, United States|Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01941836"
635,"NCT03229499","Pulmonary Hypertension and Anastrozole Trial","PHANTOM","Active, not recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Anastrozole|Drug: Placebo Oral Tablet","Difference in changes in distance walked in six minutes between anastrozole and placebo groups|Difference in right ventricular function between anastrozole and placebo groups|Difference in changes in plasma NT-proBNP level between anastrozole and placebo groups|Difference in changes in biomarkers between anastrozole and placebo groups|Difference in changes in SF36 between anastrozole and placebo groups|Difference in changes in emPHasis-10 between anastrozole and placebo groups|Difference in changes in actigraphy-measured physical activity between anastrozole and placebo groups|Difference in time-to-clinical worsening (TTCW) between anastrozole and placebo groups|Difference in changes in bone mineral density between anastrozole and placebo groups|Difference in side effects between anastrozole and placebo groups at twelve months","University of Pennsylvania|National Heart, Lung, and Blood Institute (NHLBI)|Johns Hopkins University|University of Colorado, Denver|Rhode Island Hospital|Stanford University|Vanderbilt University|Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","84","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","827486|R01HL134905","December 7, 2017","September 2021","September 2021","July 25, 2017",,"April 24, 2020","Stanford University, Stanford, California, United States|University of Colorado - Denver, Aurora, Colorado, United States|Johns Hopkins University, Baltimore, Maryland, United States|Washington University, Saint Louis, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, East Providence, Rhode Island, United States|Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03229499"
636,"NCT03626662","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)",,"Active, not recruiting","No Results Available","Cardiovascular Disease","Drug: AMG 890|Drug: Placebo","Subject incidence of treatment-emergent adverse events|Changes in blood pressure|Changes in heart rate|Changes in respiratory rate|Changes in temperature|Changes in QRS interval|Changes in PR interval|Changes in QT interval|Changes in RR interval|Changes in red blood cells|Changes in platelets|Changes in white blood cells|Changes in prothrombin time (PT)|Changes in international normalized ratio (INR)|Changes in activated partial thromboplastin time (aPTT)|Changes in Thrombin time (TT)|Changes in aspartate aminotransferase (AST) levels (units: U/L)|Changes in alanine aminotransferase (ALT) levels (units: U/L)|Changes in total bilirubin levels (units: μmol/L)|Changes in direct bilirubin levels (units: μmol/L)|Changes in alkaline phosphatase levels (units: U/L)|Changes in total protein levels (units: g/L)|Changes in albumin levels (units: g/L)|Pharmacokinetics parameter of maximum observed concentration (Cmax)|Pharmacokinetics parameter of time of maximum observed concentration (tmax)|Pharmacokinetics parameter of area under the concentration time curve (AUC)|Change in plasma Lp(a) over time|Percent change in plasma Lp(a) over time","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","20170544","July 30, 2018","November 27, 2021","November 27, 2021","August 13, 2018",,"April 24, 2020","Research Site, Tustin, California, United States|Research Site, Boca Raton, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, Kansas City, Kansas, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Nedlands, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT03626662"
637,"NCT01108744","Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increased Intracranial Pressure (ICP).",,"Withdrawn","No Results Available","Elevated Intracranial Pressure","Drug: hypertonic saline|Drug: Mannitol","Percent reduction of ICP from baseline|Time from study drug administration completion to ICP < 25 mmHg|Cumulative duration of ICP below 25 mmHg|Cumulative duration of cerebral perfusion pressure (CPP) above 60 mmHg|Cumulative duration of regional oxygen partial pressure (pbtO2) > 20%|Total dose of medications given|Frequency of treatment failure|Frequency of rebound intracranial hypertension|Frequency of composite Major Adverse Events|Difference in inflammatory response|Difference in average pre-discharge stroke scale score","Beth Israel Deaconess Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2009P000313","January 2012","January 2014","January 2014","April 22, 2010",,"March 16, 2017","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01108744"
638,"NCT00853957","Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension","AACESS","Completed","Has Results","Hypertension","Drug: Aliskiren/Amlodipine|Drug: Amlodipine","Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)|Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)|Percentage of Patients Achieving Blood Pressure (BP) Control (<140/90 mmHg)|Percentage of Responders (Patients With MSSBP < 140 mmHg or Decrease From Baseline of Greater Than or Equal to 20 mmHg)|Change From Baseline in MSSBP at Week 1 and 4|Percentage of Patients With Peripheral Edema by Visit","Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 4","443","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CSPA100AUS01","February 2009","August 2009","August 2009","March 2, 2009","January 21, 2011","April 30, 2012","Investigative Site, Chicago, Illinois, United States|Investigative Site, Baltimore, Maryland, United States|Investigative Site, Oxon Hill, Maryland, United States|Investigative Site, Detroit, Michigan, United States|Investigative Site, Trenton, New Jersey, United States|Investigative Site, Brooklyn, New York, United States|Investigative Site, Springfield Gardens, New York, United States|Investigative Site, Philadelphia, Pennsylvania, United States|Investigative Site, Milwaukeee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00853957"
639,"NCT01057251","Nebivolol in Patients With Systolic Stage 2 Hypertension","NEB-MD-20","Completed","Has Results","Hypertension","Drug: Nebivolol|Drug: Placebo","Change From Baseline in Mean Seated Systolic Blood Pressure After 6 Weeks of Nebivolol Monotherapy|Change From Baseline in Mean Seated Diastolic Blood Pressure After 6 Weeks of Nebivolol Monotherapy","Forest Laboratories","All","18 Years to 64 Years   (Adult)","Phase 4","433","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NEB-MD-20","March 2010","December 2010","January 2011","January 27, 2010","January 11, 2012","January 11, 2012","Forest Investigative Site 008, Foley, Alabama, United States|Forest Investigative Site 021, Montgomery, Alabama, United States|Forest Investigative Site 006, Chino, California, United States|Forest Investigative Site 002, Long Beach, California, United States|Forest Investigative Site 004, Los Angeles, California, United States|Forest Investigative Site 020, Temecula, California, United States|Forest Investigative Site 028, Coral Gables, Florida, United States|Forest Investigative Site 014, Daytona Beach, Florida, United States|Forest Investigative Site 037, Fort Lauderdale, Florida, United States|Forest Investigative Site 001, Ft. Lauderdale, Florida, United States|Forest Investigative Site 033, Hialeah, Florida, United States|Forest Investigative Site 026, Jacksonville, Florida, United States|Forest Investigative Site 017, Miami, Florida, United States|Forest Investigative Site 010, Miami, Florida, United States|Forest Investigative Site 030, Orlando, Florida, United States|Forest Investigative Site 009, Atlanta, Georgia, United States|Forest Investigative Site 031, Augusta, Georgia, United States|Forest Investigative Site 039, Meridian, Idaho, United States|Forest Investigative Site 007, Auburn, Maine, United States|Forest Investigative Site 038, Baltimore, Maryland, United States|Forest Investigative Site 011, Baltimore, Maryland, United States|Forest Investigative Site 029, Prince Frederick, Maryland, United States|Forest Investigative Site 023, Paw Paw, Michigan, United States|Forest Investigative Site 005, Florissant, Missouri, United States|Forest Investigative Site 041, Las Vegas, Nevada, United States|Forest Investigative Site 040, New York, New York, United States|Forest Investigative Site 012, Hickory, North Carolina, United States|Forest Investigative Site 027, Salisbury, North Carolina, United States|Forest Investigative Site 024, Harleysville, Pennsylvania, United States|Forest Investigative Site 013, Charleston, South Carolina, United States|Forest Investigative Site 035, Greenville, South Carolina, United States|Forest Investigative Site 018, Mt. Pleasant, South Carolina, United States|Forest Investigative Site 022, Simpsonville, South Carolina, United States|Forest Investigative Site 003, Memphis, Tennessee, United States|Forest Investigative Site 032, Corpus Christi, Texas, United States|Forest Investigative Site 025, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01057251"
640,"NCT03171480","Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia","NOPE","Recruiting","No Results Available","Preeclampsia|Labor, Premature","Drug: Monoket Pill","Cesarean delivery rate|Time from start of induction to delivery|Incidence of placental abruption, use of anti-hypertensives, maternal hypotension and uterine hyperstimulation, atony, meconium stained fluid","Ohio State University","Female","18 Years to 42 Years   (Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2017H0195","October 30, 2017","August 2020","August 2020","May 31, 2017",,"February 25, 2020","The Ohio State Medical Center Labor and Delivery Unit, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03171480"
641,"NCT02639286","Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension",,"Completed","No Results Available","Lipodystrophy","Drug: ISIS 304801|Drug: Placebo","To evaluate the efficacy of 16 weeks of ISIS 304801compared to placebo on the change inlog10 fasting triglycerides (TG).|To evaluate the efficacy of 16 weeks of ISIS 304801 as compared to placebo (between group comparison) on additional lipid, glycemic, hepatic, and cardiovascular parameters, as well as safety and tolerability of ISIS 304801.","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","160038|16-DK-0038","December 23, 2015","September 26, 2019","September 26, 2019","December 24, 2015",,"January 7, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02639286"
642,"NCT01977859","BNP Pharmacodynamics and Effects on Metabolism in Lean and Obese Subjects",,"Completed","No Results Available","Obesity|Cardiovascular Disease|Hypertension|Diabetes","Drug: Nesiritide|Drug: Saline","Difference in level of B-type Natriuretic Peptide (BNP)|Differences in the expression of NPRC|Determine whether short term infusion of rhBNP increases metabolic rate and/or fat oxidation|determine whether short term infusion of rhBNP alters gene expression in subcutaneous adipose tissue and skeletal muscle in a pattern consistent with activation of thermogenic pathways|Difference in responses of lean and obese subjects","Translational Research Institute for Metabolism and Diabetes, Florida|Sanford-Burnham Medical Research Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","TRIMDFH 472930","November 2013","February 15, 2016","February 28, 2017","November 7, 2013",,"February 14, 2018","Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01977859"
643,"NCT01926782","Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)",,"Completed","Has Results","Hypercholesterolemia","Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Statin","Percent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Calculated LDL-C in Participants Receiving Concomitant Statin Therapy - Intent-to-Treat (ITT Analysis)|Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - On-treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - On-treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Total-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL (Without Concomitant Statin Therapy) at Week 24 - ITT Analysis|Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (With Concomitant Statin Therapy) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL(2.59 mmol/L) (Without Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL(1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL(2.59 mmol/L) (With Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis|Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","803","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1308","September 2013","September 2014","April 2015","August 21, 2013","March 21, 2017","March 21, 2017","Chandler, Arizona, United States|Goodyear, Arizona, United States|Carmichael, California, United States|Fresno, California, United States|West Hills, California, United States|Wildomar, California, United States|Colorado Springs, Colorado, United States|Golden, Colorado, United States|Boynton Beach, Florida, United States|Jacksonville, Florida, United States|Safety Harbor, Florida, United States|Atlanta, Georgia, United States|Boise, Idaho, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Gurnee, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|Monroe, Louisiana, United States|Auburn, Maine, United States|Methuen, Massachusetts, United States|Minneapolis, Minnesota, United States|St. Louis, Missouri, United States|Rochester, New York, United States|Farmville, North Carolina, United States|Greensboro, North Carolina, United States|Greenville, North Carolina, United States|Raleigh, North Carolina, United States|Wilson, North Carolina, United States|Cincinnati, Ohio, United States|Marion, Ohio, United States|Tulsa, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Wyomissing, Pennsylvania, United States|Knoxville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Orem, Utah, United States|Salt Lake City, Utah, United States|South Jordan, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Kenosha, Wisconsin, United States|Sofia, Bulgaria|Varna, Bulgaria|Victoria, British Columbia, Canada|Oshawa, Ontario, Canada|Toronto, Ontario, Canada|Woodstock, Ontario, Canada|Montreal, Quebec, Canada|Trois-Rivieres, Quebec, Canada|Quebec, Canada|Budapest, Becsi ut, Hungary|Debrecen, HBM, Hungary|Nyiregyhaza, Sz-sz-b_m, Hungary|Ajka, VeszprÃ©m, Hungary|Nagykanizsa, Zala, Hungary|Zalaegerszeg, Zala, Hungary|Tel Hashomer, IL, Israel|Safed, ISR, Israel|Ofakim, South, Israel|Holon, Israel|Tel Hashomer, Israel|Skedsmokorset, Akershus, Norway|Oslo, Norway|Svidnik, Presov, Slovakia|Bratislava, SK, Slovakia|Bratislava, SR, Slovakia|Lucenec, Slovakia|PovaÅ¾skÃ¡ Bystrica, Slovakia|Worton Grange, Reading, Berkshire, United Kingdom|Edgbaston, Birmingham, United Kingdom|Llanishen, Cardiff, United Kingdom|Choley, Lancashire, United Kingdom|Waterloo, Liverpool, United Kingdom|Lloyd Street North, Manchester, United Kingdom|Glasgow, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01926782"
644,"NCT01185067","Physiological Effects of Grape Seed Extract in Diastolic Heart Failure","GRAPEVINE-HF","Completed","No Results Available","Diastolic Heart Failure|Hypertensive Heart Disease|Heart Failure With Preserved Ejection Fraction|Hypertension|Oxidative Stress","Drug: grape seed extract (MegaNatural BP, Polyphenolics, Inc.)","Brachial artery flow-mediated dilation (FMD)|24-hour blood pressure|EndoPAT arterial endothelial function|Carotid-femoral pulse wave velocity|Maximal exercise capacity and oxygen consumption|Resting and post-exercise ventricular systolic and diastolic function|Urinary 8-isoprostanes|Heart failure related quality of life","University of Michigan","All","50 Years and older   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HUM00029626","October 2010","November 4, 2013","February 24, 2014","August 19, 2010",,"June 6, 2017","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01185067"
645,"NCT01975194","Rosuvastatin in African Americans With Cerebrovascular Disease","RIAA","Terminated","No Results Available","Stroke|Transient Ischemic Attack","Drug: Rosuvastatin","LDL value","Wayne State University","All","30 Years and older   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0481540","January 2012","August 2013","August 2013","November 3, 2013",,"November 5, 2013","Detroit Medical Center, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01975194"
646,"NCT02802228","Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients",,"Completed","No Results Available","Portal Hypertension|Liver Cirrhosis","Drug: Ifetroban|Drug: Placebo","Safety (incidence and severity of adverse events)|Hepatic venous pressure gradient (HVPG)|Aspartate Aminotransferase (AST)|Alanine Aminotransferase (ALT)|APRI|Variceal bleeds (occurrence of variceal bleeds)","Cumberland Pharmaceuticals","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CPI-IFE-005","March 6, 2017","July 17, 2018","July 17, 2018","June 16, 2016",,"June 24, 2019","Tampa General Medical Group, Tampa, Florida, United States|Indiana University, Indianapolis, Indiana, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Baylor University Medical Center, Dallas, Texas, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02802228"
647,"NCT04023552","Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD","Lp(a)HORIZON","Recruiting","No Results Available","Cardiovascular Disease and Lipoprotein(a)","Drug: TQJ230|Drug: Placebo","Time to first occurrence of clinical endpoint committee confirmed expanded major adverse cardiovascular events in patients with elevated Lp(a) ≥ 70 mg/dL|Time to the first occurrence of clinical endpoint committee confirmed expanded major adverse cardiovascular events in a population of patients with elevated Lp(a) ≥ 90 mg/dL.|Time to the first occurrence of the clinical endpoint committee confirmed composite endpoint of major adverse cardiovascular events (CV death, non-fatal MI, and non-fatal stroke)|Time to the first occurrence of the clinical endpoint committee confirmed composite endpoint of coronary heart disease: coronary heart disease death, non-fatal MI, urgent coronary re-vascularization requiring hospitalization|Number of participants with confirmed all-cause death","Novartis Pharmaceuticals|Novartis","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","7680","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CTQJ230A12301|2019-001076-11","December 12, 2019","March 1, 2024","March 1, 2024","July 17, 2019",,"April 10, 2020","Novartis Investigative Site, Andalusia, Alabama, United States|Novartis Investigative Site, Cottonwood, Arizona, United States|Novartis Investigative Site, Surprise, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, West Hills, California, United States|Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, Bradenton, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Naples, Florida, United States|Novartis Investigative Site, Port Charlotte, Florida, United States|Novartis Investigative Site, Covington, Louisiana, United States|Novartis Investigative Site, Hammond, Louisiana, United States|Novartis Investigative Site, Houma, Louisiana, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Livingston, Texas, United States|Novartis Investigative Site, Tomball, Texas, United States|Novartis Investigative Site, Bountiful, Utah, United States|Novartis Investigative Site, Layton, Utah, United States|Novartis Investigative Site, Falls Church, Virginia, United States|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Loehne, Germany|Novartis Investigative Site, Mannheim, Germany",,"https://ClinicalTrials.gov/show/NCT04023552"
648,"NCT01484951","AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure",,"Completed","Has Results","Glaucoma","Drug: Brinzolamide 1% and timolol 0.5% fixed combination eye drops","Change in Intraocular Pressure (IOP) at the Final Visit From Prior Beta-blocker Monotherapy (Timolol 0.5% Only)|Percentage of Patients With Target IOP (≤18 mmHg), Regardless of Prior Therapy","Alcon Research","All","20 Years and older   (Adult, Older Adult)","Phase 4","74","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SMA-10-11","May 2011","March 2012","March 2012","December 5, 2011","April 26, 2013","May 1, 2013","Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01484951"
649,"NCT00879229","ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis","ARTEMIS-PH","Terminated","Has Results","Idiopathic Pulmonary Fibrosis|Pulmonary Hypertension","Drug: Ambrisentan|Drug: Placebo","Change From Baseline in Six-minute Walk Distance (6MWD).|Long-term Survival|Transition Dyspnea Index (TDI)|Change From Baseline in WHO Functional Class|Change From Baseline in Forced Vital Capacity (FVC) Percent Predicted|Change From Baseline in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)|Change From Baseline in the Borg Dyspnea Index (BORG) Immediately Following Exercise|Hemoglobin-corrected Diffusing Capacity for Carbon Monoxide (DLCO) Percent Predicted|Change in Quality of Life (QOL) Score as Assessed by the Short-Form 36® (SF-36)|Change in QOL Score as Assessed by the St. George's Respiratory Questionnaire (SRGQ)","Gilead Sciences","All","35 Years to 80 Years   (Adult, Older Adult)","Phase 3","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GS-US-300-0128","July 2009","February 2011","February 2011","April 9, 2009","April 22, 2014","May 15, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|University of California Davis, Davis, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|University of California San Diego Medical Center, San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|University of Colorado Heatlh Sciences Center, Aurora, Colorado, United States|Bay Area Chest Physicians, Clearwater, Florida, United States|University of Florida, Gainesville, Florida, United States|University of Miami Medical Center, Miami, Florida, United States|Suncoast Lung Center, Sarasota, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Atlanta Institute for Medical Research, Decatur, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Kentuckiana Pulmonary Association, Louisville, Kentucky, United States|Maine Medical Center, Portland, Maine, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|Beth Israel Deacones Medical Center, Boston, Massachusetts, United States|University of Michigan Health Systems, Ann Arbor, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Washington University, St Louis, Missouri, United States|Creighton University Center for Allergy & Asthma, Omaha, Nebraska, United States|Dartmouth Medical School, Lebanon, New Hampshire, United States|Albany Medical Center, Albany, New York, United States|Winthrop University Hospital, Mineola, New York, United States|North Shore Health System, New Hyde Park, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|The Lindner Center for Research & Education at The Christ Hospital, Cincinnati, Ohio, United States|University Hospitals of Cleveland Case Western, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Alleghany General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Inova Heart Institiute and Vascular Institute, Falls Church, Virginia, United States|Virginia Commonwealth University Health System, Richmond, Virginia, United States|Providence Everett Medical Center, Everett, Washington, United States|St. Vincents Hospital, Sydney, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Medizinische Universität Graz, Graz, Austria|Universitatsklinikum Innsbruck, Innsbruck, Austria|Medizinische Universität Wien, Vienna, Austria|Peter Loughheed Center- Calgary General Hospital, Calgary, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|London Health Sciences Centre, London, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite de Montreal, Montreal, Quebec, Canada|Sir Mortimer B. Davis Jewish General Center, Montreal, Quebec, Canada|Centre de Pneumologie de L'Hospital Laval, Sainte foy, Quebec, Canada|Evangelische Lungenklinik Berlin, Berlin, Germany|Charite-Universitatsmedizin Berlin, Berlin, Germany|Krankenhaus Donaustauf der LVA, Donaustauf, Germany|Universitatsklinikum Freiburg, Freiburg, Germany|Universitat Greifswald, Greifswald, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Thorax Klinik, Heidelberg, Germany|LMU Klinikum der Universitat, Munchen, Germany|Azienda Ospedaliero Universitaria, Catania, Italy|Presidio Ospedaliero G.B. Morgagni, Forli, Italy|Unita Funzionale di Pneumologia e Fisiopatologia Respiratoria, Milano, Italy|Ospedale S.Giuseppe Fatebenefratelli, Milan, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Instituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, Italy|Policlinico Universitario Tor Vergata, Rome, Italy|Azienda Ospedaliera Universitaria Senese, Siena, Italy|Centro delle Interstiziopatie Polmonari e Malattie Rare del Polmone, Torino, Italy|Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom|University Hospital Aintree, Liverpool, United Kingdom|University College Hosptial, London, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00879229"
650,"NCT02563860","Pharmacological Treatment of Rett Syndrome With Statins","Statins","Completed","Has Results","Rett Syndrome","Drug: Lovastatin","Gait Velocity as Measured by GAITRite System|Visual Memory Novelty Score as Assessed by TobiiTX 300 Eyetracking System","Montefiore Medical Center|Rett Syndrome Research Trust","Female","3 Years and older   (Child, Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-4253","July 2015","July 2016","July 2016","September 30, 2015","May 7, 2019","July 12, 2019","Montefiore Medical center, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT02563860"
651,"NCT02743598","Liraglutide for HIV-associated Neurocognitive Disorder",,"Suspended","No Results Available","HIV Infection|Diabetes Mellitus Type 2|Obesity|Overweight|Metabolic Syndrome","Drug: Liraglutide","Neurocognitive performance- change in global cognitive scores on a standard neuropsychological profile|Neurocognitive performance- change in domain averages on a standard neuropsychological profile|Change from baseline high sensitivity C-reactive protein|Change from baseline d-dimer|Change from baseline Interleukin 6|Change from baseline plasma soluble cluster of differentiation 14 (CD14)|Change from baseline BMI|Change from baseline weight|Change from baseline waist circumference|Change from baseline blood pressure|Change from baseline serum triglycerides|Change from baseline insulin resistance by homeostasis model assessment (HOMA-IR) in subjects not on insulin|Change from baseline liver enzymes aspartate aminotransferase and alanine aminotransferase|Change from baseline Hemoglobin A1c|Change from baseline fructosamine|Number of Adverse events|Number of subjects with Adverse events|Change from baseline serum LDL","Temple University|The Comprehensive NeuroAIDS Center (CNAC) at Temple University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","23284","September 2016","April 2020","May 2020","April 19, 2016",,"February 24, 2020","Cherie Vaz, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02743598"
652,"NCT02072161","Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy",,"Completed","No Results Available","Hypercholesterolemia","Drug: ETC-1002|Drug: Placebo|Drug: Statin Therapy","Percent change from baseline in calculated low density lipoprotein-cholesterol (LDL-C)|Percent change in non-high-density lipoprotein cholesterol (non-HDL-C)|Percent change in apolipoprotein B (ApoB)|Percent change in total cholesterol (TC)|Percent change in high-sensitivity C-reactive protein (hsCRP)|Percent change in triglycerides (TG)|Percent change in lipoprotein particle number|Safety using adverse event reports; clinical laboratory results|Safety using adverse event reports; vital signs|Pharmacokinetic plasma trough concentrations of ETC-1002 and metabolite 15228","Esperion Therapeutics|Medpace, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","133","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1002-009","March 2014","January 2015","January 2015","February 26, 2014",,"March 29, 2019","Muscle Shoals, Alabama, United States|Chandler, Arizona, United States|Chino, California, United States|Los Angeles, California, United States|Sacramento, California, United States|Walnut Creek, California, United States|Denver, Colorado, United States|Hartford, Connecticut, United States|Brandon, Florida, United States|Jacksonville, Florida, United States|Oviedo, Florida, United States|Ponte Vedra, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Marietta, Georgia, United States|Boise, Idaho, United States|Meridian, Idaho, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Port Gibson, Mississippi, United States|Rochester, New York, United States|Salisbury, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Franklin, Ohio, United States|Lyndhurst, Ohio, United States|Marion, Ohio, United States|Tulsa, Oklahoma, United States|Greer, South Carolina, United States|Mount Pleasant, South Carolina, United States|Summerville, South Carolina, United States|Kingsport, Tennessee, United States|Houston, Texas, United States|Bountiful, Utah, United States|Orem, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02072161"
653,"NCT03794583","Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)","PERFECTOLE","Enrolling by invitation","No Results Available","Pulmonary Hypertension|Chronic Obstructive Pulmonary Disease","Drug: Inhaled treprostinil solution","Incidence of treatment-related adverse events|Severity of treatment-related adverse events|6 Minute Walk Distance (6MWD)|Borg Dyspnea Score|N-terminal pro-brain natriuretic peptide (NT-pro-BNP)|Pulse Oximetry","United Therapeutics|Lung Biotechnology PBC","All","18 Years and older   (Adult, Older Adult)","Phase 3","136","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RIN-PH-305","December 21, 2018","December 31, 2020","December 31, 2020","January 7, 2019",,"April 30, 2020","St. Vincent's Lung, Sleep, and Criticial Care Specialists, Jacksonville, Florida, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Albany Medical Center, Albany, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|The Carl and Edyth Lindner Research Center at The Christ Hospital, Cincinnati, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03794583"
654,"NCT01279590","Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)",,"Completed","No Results Available","Myalgia|Hypercholesterolemia|Hyperlipidemia","Drug: PPD10558|Drug: Atorvastatin|Drug: Placebo","Incidence of stopping treatment with double-blinded study drug due to statin-associated myalgia.|Change from Baseline in fasting lipid profile components (low density lipoprotein-cholesterol(LDL-C), high density lipoprotein-cholesterol(HDL-C), triglyceride(TG), total cholesterol(TC), Apolipoprotein B(ApoB), HDL-TG, LDL/HDL ratio and TC/HDL ratio)|Change from baseline in muscle strength measurements (Sit-to-stand(STS) performance and hand grip strength by Jamar Hydraulic Hand Dynamometer)|Frequency of pain rescue medication|Change from Baseline in inflammatory markers (Tumor necrosis factor α (TNF-α), C-reactive protein (CRP), and lipoprotein-associated phospholipase A2 (Lp-PLA2))|Change in patients' functional health and well-being as measured by the Short Form-36v2 Health Survey (SF-36)|Time to onset of statin -associated myalgia (SAM)|Time to stopping treatment with study drug due to SAM","Furiex Pharmaceuticals, Inc","All","40 Years and older   (Adult, Older Adult)","Phase 2","282","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PPD10558-010","March 2011","November 2011","November 2011","January 19, 2011",,"December 22, 2011","Furiex research site, Anniston, Alabama, United States|Furiex research site, Phoenix, Arizona, United States|Furiex research site, Phoenix, Arizona, United States|Furiex research site, Huntington Park, California, United States|Furiex research site, Long Beach, California, United States|Furiex research site, Pismo Beach, California, United States|Furiex research site, San Diego, California, United States|Furiex research site, West Lake Village, California, United States|Furiex research site, Colorado Springs, Colorado, United States|Furiex research site, Golden, Colorado, United States|Furiex research site, Hartford, Connecticut, United States|Furiex research site, Boynton Beach, Florida, United States|Furiex research site, Coral Gables, Florida, United States|Furiex research site, Deerfield Beach, Florida, United States|Furiex research site, Fort Lauderdale, Florida, United States|Furiex research site, Gainesville, Florida, United States|Furiex research site, Opa Locka, Florida, United States|Furiex research site, Pembroke, Florida, United States|Furiex research site, Pembroke, Florida, United States|Furiex research site, Sanford, Florida, United States|Furiex research site, West Palm Beach, Florida, United States|Furiex research site, Honolulu, Hawaii, United States|Furiex Research site, Boise, Idaho, United States|Furiex research site, Nampa, Idaho, United States|Furiex research site, Chicago, Illinois, United States|Furiex research site, Mission, Kansas, United States|Furiex research site, Madisonville, Kentucky, United States|Furiex research site, Covington, Louisiana, United States|Furiex research site, Auburn, Maine, United States|Furiex research site, Oxon Hill, Maryland, United States|Furiex research site, Bay City, Michigan, United States|Furiex research site, St. Louis, Missouri, United States|Furiex research site, Billings, Montana, United States|Furiex research site, Butte, Montana, United States|Furiex research site, Missoula, Montana, United States|Furiex research site, Omaha, Nebraska, United States|Furiex research site, Great Neck, New York, United States|Furiex research site, Asheville, North Carolina, United States|Furiex research site, Cary, North Carolina, United States|Furiex research site, Charlotte, North Carolina, United States|Furiex research site, Harrisburg, North Carolina, United States|Furiex research site, Hickory, North Carolina, United States|Furiex research site, Hickory, North Carolina, United States|Furiex research site, High Point, North Carolina, United States|Furiex research site, Raleigh, North Carolina, United States|Furiex research site, Raleigh, North Carolina, United States|Furiex research site, Wilmington, North Carolina, United States|Furiex research site, Carlisle, Ohio, United States|Furiex research site, Cincinnati, Ohio, United States|Furiex research site, Columbus, Ohio, United States|Furiex research site, Kettering, Ohio, United States|Furiex research site, Springfield, Ohio, United States|Furiex research site, Altoona, Pennsylvania, United States|Furiex research site, Johnstown, Pennsylvania, United States|Furiex research site, Cumberland, Rhode Island, United States|Furiex research site, East Providence, Rhode Island, United States|Furiex research site, Anderson, South Carolina, United States|Furiex research site, Greenville, South Carolina, United States|Furiex research site, Greer, South Carolina, United States|Furiex research site, Mt. Pleasant, South Carolina, United States|Furiex research site, Pawley's Island, South Carolina, United States|Furiex research site, Bristol, Tennessee, United States|Furiex research site, Tomball, Texas, United States|Furiex research site, Salt Lake City, Utah, United States|Furiex research site, Norfolk, Virginia, United States|Furiex research site, Richmond, Virginia, United States|Furiex, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01279590"
655,"NCT03738878","Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1",,"Recruiting","No Results Available","Hypertension","Drug: Valsartan|Drug: LCZ696|Drug: Bradykinin|Drug: Substance P|Drug: BNP|Drug: Sitagliptin","forearm blood flow|tissue-type plasminogen activator release|norepinephrine release","Vanderbilt University Medical Center","All","18 Years to 60 Years   (Adult)","Phase 4","32","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB#170762","November 15, 2018","July 1, 2020","December 31, 2020","November 13, 2018",,"February 5, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03738878"
656,"NCT01588405","Remodulin® to Oral Treprostinil Transition",,"Completed","Has Results","Pulmonary Arterial Hypertension","Drug: UT-15C SR","Number of Participants That Were Succesfully Transitioned From Parenteral Remodulin to UT-15C.|Change From Baseline in Six-minute Walk Distance at Week 24|Change in Borg Dyspnea Score (Following 6MWT) From Baseline to Week 24|Change in Quality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) From Baseline to Week 24|Change in World Health Organization (WHO) Functional Classification From Baseline to Week 24|Change in Dyspnea-fatigue Index From Baseline to Week 24|Change From Baseline to Week 24 in Pharmacokinetic Parameters: Peak Plasma Concentration (Cmax), Average Plasma Concentration (Cavg), and Trough Plasma Concentration (Cmin)|Change From Baseline to Week 24 in Pharmacokinetics Parameter: Peak Time to Reach Peak Plasma Concentration [Tmax (h)]|Change From Baseline to Week 24 in Pharmacokinetics Parameters: Area Under the Plasma Concentration Curve (AUC) [h(ng/mL)]|Change From Baseline to Week 24 in Hemodynamics Parameters: Mean Pulmonary Artery Pressure (PAPm), Mean Right Atrial Pressure (RAPm) and Mean Pulmonary Capillary Wedge Pressure (PCWPm)|Change From Baseline to Week 24 in Hemodynamics Parameters: Arterial Oxygen Saturation (SaO2) (%) and Mixed Venous Oxygen Saturation (SvO2) (%)|Change From Baseline to Week 24 in Hemodynamics Parameters: Cardiac Output (CO) (L/Min)|Change From Baseline to Week 24 in Hemodynamics Parameters: Cardiac Index (CI) (L/Min/m^2)|Change From Baseline to Week 24 in Hemodynamics Parameters: Pulmonary Vascular Resistance Index (PVRI) (mmHg*Min*m^2/L)|Change From Baseline to Week 24 in Hemodynamics Parameters: Pulmonary Vascular Resistance (PVR) (mmHg*Min/L)","United Therapeutics","All","15 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2","33","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-PH-205","April 2012","July 2014","December 2014","May 1, 2012","May 16, 2016","May 16, 2016","Arizona Pulmonary Specialists, Phoenix, Arizona, United States|University of Arizona Clinical and Translational Science (CATS) Research Center, Tucson, Arizona, United States|Washington University School of Medicine, St. Louis, Missouri, United States|University of Rochester, Rochester, New York, United States|The Ohio State University, Columbus, Ohio, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01588405"
657,"NCT01908699","Beraprost-314d Added-on to Tyvaso® (BEAT)","BEAT","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Beraprost Sodium 314d Modified Release Tablets|Drug: Placebo","Number of Participants That Experienced Clinical Worsening|Mean Change From Baseline in Borg Dyspnea Score at Week 24|Mean Change From Baseline in NT-pro-BNP Levels at Week 24|Change in WHO Functional Class From Baseline to Week 24|Mean Change From Baseline in Six Minutes Walk Distance (6MWD) at Week 24|Number of Participants With TEAEs, Serious TEAEs, Investigations SOC TEAEs, and Serious Investigations SOC TEAEs","Lung Biotechnology PBC","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","273","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BPS-314d-MR-PAH-302","May 31, 2013","February 19, 2019","February 19, 2019","July 26, 2013","February 28, 2020","February 28, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars-Sinai Medical Center Heart Institute, Beverly Hills, California, United States|Allianz Research Institute Inc., Fountain Valley, California, United States|University of California San Francisco - Fresno, Fresno, California, United States|University of California - San Diego, La Jolla, California, United States|University of California Los Angeles, Los Angeles, California, United States|Keck Medical Center of USC, Los Angeles, California, United States|Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States|Center for Advanced Pulmonary Medicine, Rancho Mirage, California, United States|University of California - San Francisco, San Francisco, California, United States|Cottage Pulmonary Hypertension Center, Santa Barbara, California, United States|Stanford University, Stanford, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Aurora Denver Cardiology Associates, Denver, Colorado, United States|South Denver Cardiology Associates P.C., Littleton, Colorado, United States|Yale School of Medicine, New Haven, Connecticut, United States|Bay Area Cardiology Associates, P.A., Brandon, Florida, United States|Florida Lung, Asthma, and Sleep Institute, Celebration, Florida, United States|University of Florida, Gainesville, Florida, United States|University of Florida College of Medicine, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|Orlando Health Heart Institute, Orlando, Florida, United States|South Miami Heart Specialists, South Miami, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University, Atlanta, Georgia, United States|Pulmonary & Critical Care of Atlanta, Atlanta, Georgia, United States|Georgia Clinical Research, Austell, Georgia, United States|Gwinnett Biomedical Research, Lawrenceville, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago Medicine, Chicago, Illinois, United States|Advocate Health and Hospitals Corporation, Oakbrook Terrace, Illinois, United States|Indiana University - Health Physicians, Carmel, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Louisville Department of Medicine, Louisville, Kentucky, United States|John Ochsner Heart & Vascular Institute, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beaumont Health Systems, Troy, Michigan, United States|Rutgers University Hospital, Newark, New Jersey, United States|Albany Medical College, Albany, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Beth Israel Medical Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Pulmonary Health Physicians, PC, Syracuse, New York, United States|University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Toledo Medical Center, Toledo, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Anderson Pharmaceutical Research, Anderson, South Carolina, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Methodist Healthcare Clinical Trials Office, San Antonio, Texas, United States|Scott & White Memorial Hospital, Temple, Texas, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Soroka Medical Center, Beer-sheva, Israel|The Lady Davis Carmel Medical Center, Haifa, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, Israel|Rabin Medical Center-Beilinson Campus, Petach Tikva, Israel|Chaim Sheba Medical Center, Ramat-Gan, Israel|Kaplan Medical Center, Rechovot, Israel","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT01908699/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT01908699/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01908699"
658,"NCT03950739","Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso","BREEZE","Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Treprostinil Inhalation Powder","Number of subjects with treatment-emergent adverse events [Safety and Tolerability]|Analysis of treprostinil plasma concentration (pharmacokinetics [PK])|Change in 6-Minute Walk Distance (6MWD) from Baseline to Week 3|Number of subjects with treatment-emergent adverse events [Long-term Safety and Tolerability] during an Optional Extension Phase|Subject satisfaction with and preference for inhaled treprostinil devices|Patient-reported PAH symptoms and impact","United Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TIP-PH-101","September 17, 2019","May 2020","August 2020","May 15, 2019",,"March 2, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|USC, Department of Medicine, Los Angeles, California, United States|Department of Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States|University of Florida Clinical Research Center, Gainesville, Florida, United States|Ascension/ St. Vincent's Lung Institute, Jacksonville, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville Pulmonary Research, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03950739"
659,"NCT01681576","Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension",,"Completed","Has Results","Salt-sensitive Hypertension","Drug: Valsartan|Drug: LCZ696","Cumulative Sodium Excretion (Natriuresis) at Day 1|Cumulative Sodium Excretion (Natriuresis) at Day 28|Urine Volume (Diuresis) Over Time|Seated Office Blood Pressure (BP) (Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)) Over Time|Mean Sitting Pulse Pressure (PP) Over Time","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","CLCZ696A2222","August 2012","October 2013","October 2013","September 10, 2012","October 9, 2015","November 10, 2015","Novartis Investigative Site, Anaheim, California, United States|Novartis Investigative Site, Cypress, California, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, Hong Kong, Shatin, NT, Hong Kong|Novartis Investigative Site, Bucheon, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Koyang-si, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01681576"
660,"NCT02532218","Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia","REASCEND","Unknown status","No Results Available","Hyperlipidemia","Drug: ARI-3037MO","LDL-c|HDL-c|TG|HbA1C","Arisaph Pharmaceuticals Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","176","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ARI-3037MO-005","August 2015","September 2016","December 2016","August 25, 2015",,"August 8, 2016","Catalina Reserch Institute, LLC, Chino, California, United States|S&W Clinical Reserch, Ft Lauderdale, Florida, United States|Jacksonville Center for Clinical Research, Jacksonvile, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Sestron Clinical Research 833 Campbell Hill Street Suite 230, Marietta, Georgia, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, United States|Rochester clinical Research,Inc, Rochester, New York, United States|Sterling Research Group Ltd, Cincinnati, Ohio, United States|The Carl and Edyth Lindner Center for Reserch and education at the Christ Hospital, Cincinnati, Ohio, United States|Metabolic and atherosclerosis Research center, Cincinnati, Ohio, United States|IVA reserch, Cincinnati, Ohio, United States|Sterling Research group, Ltd, Cincinnati, Ohio, United States|Ohio Clinical Research-Lyndhurst, Lyndhurst, Ohio, United States|COR Clinical Research, Oklahoma City, Oklahoma, United States|Willamette Valley Clinical studies, Eugene, Oregon, United States|Health Research of Hampton Roads - Norfolk, Norfolk, Virginia, United States|National Clinical Research inc, Richmond, Virginia, United States|Raninier Clinical Reserach, Renton, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02532218"
661,"NCT01789736","A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days",,"Completed","No Results Available","Open Angle Glaucoma|Ocular Hypertension","Drug: PG286 Ophthalmic Solution 0.5%|Drug: AR-12286 Ophthalmic Solution 0.5%|Drug: Travoprost Ophthalmic Solution 0.004%","Mean diurnal IOP|IOP","Aerie Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","234","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PG286-CS202","February 2013","June 2013","June 2013","February 12, 2013",,"March 17, 2014","Kenneth Sall, M.D., Artesia, California, United States|United Medical Research Institute, Inglewood, California, United States|Aesthetic Eye Care Institute, Newport Beach, California, United States|Bacharach practice, Petaluma, California, United States|Centre For Health Care, Poway, California, United States|Clayton Eye Center, Morrow, Georgia, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|Bradley Kwapiszeski, MD, Shawnee Mission, Kansas, United States|Taustine Eye Center, Louisville, Kentucky, United States|Alan L Robin, M.D., Baltimore, Maryland, United States|Seidenberg Protzko Eye Associates, Havre de Grace, Maryland, United States|Great Lakes Eye Care, St Joseph, Michigan, United States|Jeffrey Schultz, M.D., Bronx, New York, United States|Ophthalmic Consultants of Long Island, Lynbrook, New York, United States|Rochester Ophthalmological Group, Rochester, New York, United States|Charlotte Eye Ear Nose & Throat Associates, P.A., Belmont, North Carolina, United States|The Eye Institute, Tulsa, Oklahoma, United States|Texan Eye, Austin, Texas, United States|Medical Center Ophth. Associates, San Antonio, Texas, United States|Stacy R. Smith, M.D., Salt Lake City, Utah, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01789736"
662,"NCT02512042","Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes",,"Completed","Has Results","Glaucoma","Drug: Test-Brinzolamide 1% Ophthalmic suspension|Drug: Reference-Brinzolamide 1% Ophthalmic suspension","Mean Difference in Intraocular Pressure (IOP) of Both Eyes Between the Two Treatment Groups at Four Time Points","Actavis Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","973","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","WAT/BNZL/2014","April 2015","April 2016","May 2016","July 30, 2015","March 2, 2020","March 2, 2020","David Wirta, MD, Newport Beach, California, United States|Shettle Eye Research, Inc., Largo, Florida, United States|AMB Research Center, Inc., Miami, Florida, United States|Eye Care Centers Management, Inc., Morrow, Georgia, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|Heart of America Eye Care PA, Shawnee Mission, Kansas, United States|Ophthalmology Associates, Saint Louis, Missouri, United States|Las Vegas Physicians Research Group, Henderson, Nevada, United States|Keystone Research Ltd., Austin, Texas, United States|Keystone Research Ltd., San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02512042"
663,"NCT01178073","A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)","AMBITION","Completed","Has Results","Hypertension, Pulmonary","Drug: ambrisentan|Drug: tadalafil","Number of Participants With First Adjudicated Clinical Failure (CF) Event, Death, Hospitalisation for Worsening PAH, Disease Progression, Unsatisfactory Long-term Clinical Response, All Through FAV|Percent Change From Baseline in the N-Terminal Pro-B-Type Natriuretic Peptide at Week 24|Percentage of Participants With a Satisfactory Clinical Response at Week 24|Change From Baseline in the 6 Minute Walk Distance Test at Week 24|Change From Baseline in the World Health Organization Functional Class at Week 24|Change From Baseline in Borg Dyspnea Index at Week 24","GlaxoSmithKline|Gilead Sciences","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","610","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","112565","October 1, 2010","July 31, 2014","July 31, 2014","August 9, 2010","April 28, 2015","September 13, 2017","GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, La Jolla, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Aurora, Colorado, United States|GSK Investigational Site, Gainesville, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Kissimmee, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Weston, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Decatur, Georgia, United States|GSK Investigational Site, Oakbrook Terrace, Illinois, United States|GSK Investigational Site, Carmel, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Kansas City, Kansas, United States|GSK Investigational Site, New Orleans, Louisiana, United States|GSK Investigational Site, Portland, Maine, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Springfield, Massachusetts, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Troy, Michigan, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Morristown, New Jersey, United States|GSK Investigational Site, Newark, New Jersey, United States|GSK Investigational Site, New Hyde Park, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Asheville, North Carolina, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Temple, Texas, United States|GSK Investigational Site, Murray, Utah, United States|GSK Investigational Site, Charlottesville, Virginia, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Camperdown, New South Wales, Australia|GSK Investigational Site, Darlinghurst, New South Wales, Australia|GSK Investigational Site, Chermside, Queensland, Australia|GSK Investigational Site, Hobart, Tasmania, Australia|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Perth, Western Australia, Australia|GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Vancouver, British Columbia, Canada|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Quebec City, Quebec, Canada|GSK Investigational Site, Brest, France|GSK Investigational Site, Bron, France|GSK Investigational Site, La Tronche, France|GSK Investigational Site, Le Kremlin-Bicêtre cedex, France|GSK Investigational Site, Lille, France|GSK Investigational Site, Marseille cedex 20, France|GSK Investigational Site, Montpellier cedex 5, France|GSK Investigational Site, Pessac cedex, France|GSK Investigational Site, Saint Pierre cedex, France|GSK Investigational Site, Toulouse cedex 9, France|GSK Investigational Site, Vandoeuvre-les-Nancy, France|GSK Investigational Site, Freiburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Loewenstein, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Giessen, Hessen, Germany|GSK Investigational Site, Greifswald, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Bonn, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Homburg, Saarland, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Alexandroupolis, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Cagliari, Sardegna, Italy|GSK Investigational Site, Catania, Sicilia, Italy|GSK Investigational Site, Pisa, Toscana, Italy|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Shizuoka, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Maastricht, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Córdoba, Spain|GSK Investigational Site, L'Hospitalet de Llobregat, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, Malaga, Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Santander, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Toledo, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Linköping, Sweden|GSK Investigational Site, Lund, Sweden|GSK Investigational Site, Umeå, Sweden|GSK Investigational Site, Uppsala, Sweden|GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom|GSK Investigational Site, Clydebank, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01178073"
664,"NCT03070782","Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Patients With Hyperlipoproteinemia(a) and Cardiovascular Disease",,"Completed","No Results Available","Elevated Lipoprotein(a)|Cardiovascular Disease","Drug: ISIS 681257|Drug: Placebo","Percent change in plasma Lp(a) from baseline at the primary analysis time point for ISIS 681257 treatment groups compared to placebo.|Safety and tolerability of different doses and dosing regimens of ISIS 681257 as measured by proportion of patients with treatment-related adverse events by severity, and number of patients meeting safety stopping rules|Evaluate the effect of ISIS 681257 on the percent change from baseline in LDL-C.|Evaluate the effect of ISIS 681257 on the proportion of patients who achieve plasma Lp(a) ≤ 50 mg/dL.|Evaluate the effect of ISIS 681257 on the percent change from baseline in plasma levels of apolipoprotein B (apoB).|Evaluate the effect of ISIS 681257 on the percent change from baseline in plasma levels of oxidized phospholipids (OxPL) on apolipoprotein (a) [apo(a)] [OXPL-apo(a)].|Evaluate the effect of ISIS 681257 on the percent change from baseline in plasma levels of oxidized phospholipids (OxPL) on apoB (OXPL-apoB).","Akcea Therapeutics|Ionis Pharmaceuticals, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","286","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ISIS 681257-CS6","March 7, 2017","July 18, 2018","November 13, 2018","March 6, 2017",,"December 13, 2018","Clinical Site, Cottonwood, Arizona, United States|Clinical Site, Huntington Beach, California, United States|Clinical Site, La Jolla, California, United States|Clinical Site, Los Angeles, California, United States|Clinical Site, Stanford, California, United States|Clinical Site, Colorado Springs, Colorado, United States|Clinical Site, Boca Raton, Florida, United States|Clinical Site, Jacksonville, Florida, United States|Clinical Site, Kansas City, Kansas, United States|Clinical Site, Baltimore, Maryland, United States|Clinical Site, Boston, Massachusetts, United States|Clinical Site, Cooperstown, New York, United States|Clinical Site, New York, New York, United States|Clinical Site, New York, New York, United States|Clinical Site, Cleveland, Ohio, United States|Clinical Site, Portland, Oregon, United States|Clinical Site, Lancaster, Pennsylvania, United States|Clinical Site, Philadelphia, Pennsylvania, United States|Clinical Site, Providence, Rhode Island, United States|Clinical Site, Houston, Texas, United States|Clinical Site, Falls Church, Virginia, United States|Clinical Site, Milwaukee, Wisconsin, United States|Clinical Site, Chicoutimi, Quebec, Canada|Clinical Site, Montreal, Quebec, Canada|Clinical Site, Montréal, Quebec, Canada|Clinical Site, Québec, Quebec, Canada|Clinical Site, Ottawa, Canada|Clinical Site, Herlev, Denmark|Clinical Site, Viborg, Denmark|Clinical Site, Berlin, Germany|Clinical Site, Cologne, Germany|Clinical Site, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT03070782"
665,"NCT01894022","A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)","AMBER II","Terminated","Has Results","Hypertension","Drug: Ambrisentan 5 mg","Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)|Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points|Change From Study AMB115811 Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at the Indicated Time Points|Change From Study AMB115811 Baseline in Hematocrit at the Indicated Time Points|Change From Study AMB115811 Baseline in Mean Corpuscle Volume at the Indicated Time Points|Change From Study AMB115811 Baseline in Red Blood Cell Count and Reticulocytes at the Indicated Time Points|Number of Participants With Clinical Chemistry Parameters of Potential Clinical Concern at Any Time Post Entry Visit|Number of Participants With Creatinine Values of Potential Clinical Concern at Any Time Post Entry Visit|Change From Study AMB115811 Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Assessed at the Indicated Time Points|Change From Study AMB115811 Baseline in Heart Rate at the Indicated Time Points|Change From Study AMB115811 Baseline in Weight at the Indicated Time Points|Time to First Change in Dose of Open-label Ambrisentan Due to Tolerability Issues in Any Participant|Change From Study AMB115811 Baseline in the 6 Minutes Walking Distance (6MWD) at the Indicated Time Points|Change From Study AMB115811 Baseline (BL) in World Health Organization (WHO) Functional Class (FC) at the Indicated Time Points|Change From Study AMB115811 Baseline in Borg CR10 Scale (BCR10S) Immediately Following Exercise at the Indicated Time Points|Number of Participants With Clinical Worsening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|Change From Study AMB115811 Baseline in Quality of Life as Measured by Short Form 36 Health Survey (SF-36)|Percent Change From Study AMB115811 Baseline in Plasma N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)|Change From Start of Ambrisentan Treatment in 6 Minutes Walking Distance at the Indicated Time Points|Change From Start of Ambrisentan Treatment in World Health Organization (WHO) Functional Class (FC) at the Indicated Time Points|Change From Start of Ambrisentan Treatment in Borg CR10 Scale (BCR10S) Immediately Following Exercise at the Indicated Time Points|Percent Change From Start of Ambrisentan Treatment in Plasma N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)|Time to First Change in Dose of Open-label Ambrisentan Due to Deterioration of Clinical Conditions in Any Participant|Time to First Addition of Another Targeted PAH Therapeutic Agent Due to Deterioration of Clinical Condition or Lack of Beneficial Effect With Previous Therapy in Any Participant","GlaxoSmithKline","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","19","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","116457","January 23, 2014","November 18, 2015","November 18, 2015","July 9, 2013","June 8, 2017","September 11, 2017","GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Corrientes, Argentina|GSK Investigational Site, Santa Fe, Argentina|GSK Investigational Site, Graz, Austria|GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Wuhan, Hubei, China|GSK Investigational Site, Xian, Shaanxi, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Homburg, Saarland, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Ashkelon, Israel|GSK Investigational Site, Zrifin, Israel|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Miyagi, Japan|GSK Investigational Site, Tochigi, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Monterrey NL, Nuevo León, Mexico|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Tomsk, Russian Federation|GSK Investigational Site, Riyadh, Saudi Arabia|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Clydebank, United Kingdom|GSK Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01894022"
666,"NCT03850782","Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-angle Glaucoma or Ocular Hypertension",,"Recruiting","No Results Available","Glaucoma, Open-Angle|Ocular Hypertension","Drug: Bimatoprost (SR)","Retreatment or rescue administered for IOP|Number of patients experiencing a treatment emergent adverse event.","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1698-301-007|2018-002574-52","February 28, 2019","July 17, 2023","July 17, 2023","February 22, 2019",,"February 27, 2020","Walman Eye Center, Sun City, Arizona, United States|Atlantis Eyecare, Huntington Beach, California, United States|Lakeside Vision Center, Irvine, California, United States|Southern Califonria Kaiser Permanente, West Los Angeles, Los Angeles, California, United States|Global Research Foundation, Los Angeles, California, United States|Tayani Institute / American Institute of Research, Mission Viejo, California, United States|Eye Research Foundation, Newport Beach, California, United States|Byers Eye Institute, Stanford, Palo Alto, California, United States|Foothill Eye Institute, Pasadena, California, United States|Martel Eye Medical Group, Rancho Cordova, California, United States|Danbury Eye Physicians and Surgeons PC, Danbury, Connecticut, United States|Bruce Segal, MD, Delray Beach, Florida, United States|International Research Center, Tampa, Florida, United States|Specialty Retina Center, Weston, Florida, United States|Thomas Eye Group, P.C., Sandy Springs, Georgia, United States|Indiana University - Glick Eye Institute, Indianapolis, Indiana, United States|Midwest Eye Institute, Indianapolis, Indiana, United States|Tulane University Medical Center, New Orleans, Louisiana, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Clinical Eye Research of Boston, LLC, Winchester, Massachusetts, United States|Kellogg Eye Center, Ann Arbor, Michigan, United States|Fraser Eye Care Center, Fraser, Michigan, United States|Silverstein Eye Center, Kansas City, Missouri, United States|Moyes Eye Center, Kansas City, Missouri, United States|Clinical Research Center of Nevada LLC, Las Vegas, Nevada, United States|Alterman, Modi & Wolter, Poughkeepsie, New York, United States|The Ohio State University, Columbus, Ohio, United States|AMA Eyes Research Institute, Marysville, Ohio, United States|Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States|Drs. Fine, Hoffman and Sims, LLC, Eugene, Oregon, United States|Vantage EyeCare, LLC, Bala-Cynwyd, Pennsylvania, United States|Scott & Christie and Associates, PC, Cranberry Township, Pennsylvania, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Vance Thompson Vision, Sioux Falls, South Dakota, United States|Eye Specialty Group, Memphis, Tennessee, United States|Nashville Vision Associates, Nashville, Tennessee, United States|Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States|Keystone Eye Research, Austin, Texas, United States|Medical Center Opthalmology Associates - Keystone Medical Research, LTD, San Antonio, Texas, United States|Southern Utah Medical Research, Saint George, Utah, United States|UMHAT Sveti Georgi, Plovdiv, Bulgaria|Sliven, MHAT ""Hadzhi Dimitar"", Sliven, Bulgaria|MHAT Dr. Bratan Shukerov, Smolyan, Bulgaria|Medical Center for eye healt ""Focus"" Ltd, Sofia, Bulgaria|Pentagram Eye Hospital, Sofia, Bulgaria|University Hospital - Lozenets, Sofia, Bulgaria|Specialized Hospital for Active Treatment in Ocular Diseases ""Zrenie"", Sofia, Bulgaria|Diagnostic Consultative Center Alexandrovska, Sofia, Bulgaria|St. Sofia Hospital, Sofia, Bulgaria|Mbal-Trakia, Stara Zagora, Bulgaria|Medical Center -Verea, Stara Zagora, Bulgaria|Medical Center Zara - Med, Stara Zagora, Bulgaria|Specialized Ophthalmological Hospital for Active Treatment - Varna, Varna, Bulgaria|FN Hradec Kralove, Hradec Kralove, Czechia|Ocni klinika Pardubice, Pardubice, Czechia|University Hospital Královské Vinohrady, Prague, Czechia|VFN, Prague, Czechia|Rigshospitalet-Glostrup, Glostrup, Denmark|CHU de Bordeaux Hopital Pellegrin, Bordeaux, Gironde, France|CHU Angers, Angers, France|Ophthalmologie, Polyclinique de la Baie, Avranches, France|Clinique Honore Cave, Montauban, France|Universitaetsklinikum Freiburg, Klinik fuer Augenheilkunde, Freiburg, Baden-Württemberg, Germany|Augenzentrum Dr Hamacher, Starnberg, Bavaria, Germany|Städtisches Klinikum Dresden, Augenklinik, Dresden, Germany|Asklepios Augenklink Nord-Heidberg, Hamburg, Germany|Franziskus Hospital Muenster, Munster, Germany|Bugat Pal Hospital, Gyongyos, Heves, Hungary|Jahn Ferenc Dél-pesti Kórház és Rendelőintézet, Budapest, Hungary|Budapest Retina Associates, Budapest, Hungary|Markusovszky Egyetemi Oktatokorhaz, Szombathely, Hungary|Royal Victoria Eye and Ear Research Foundation, Dublin, Ireland|Institute of Eye Surgery, Waterford, Ireland|University of Bari Aldo Moro, Bari, Italy|Eye Clinic, University of Catania, Catania, Italy|Universita Magna Graecia di Catanzaro, Catanzaro, Italy|University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Fiorini di Terracina, Roma, Italy|Fondazione Bietti - Ospedale Britannico, Rome, Italy|Profesorskie Centrum Okulistyki, Gdańsk, Poland|Gabinet Okulistyczny Edward Wylegala, Katowice, Poland|Medical Center Julianow, Lodz, Poland|Military Institute of Medicine Warsaw, Warsaw, Poland|Pretoria Eye Institute, Pretoria, Gauteng, South Africa|Somerset Eye Specialist Medical & Surgical Centre, Cape Town, South Africa|Dr Lynette Venter, Westdene, South Africa|Norrlands Universitetessjukhus, Umea, Sweden|Mid Essex Hospitals NHS Trust, Cambridge, Cambridgeshire, United Kingdom|Hinchingbrooke Hospital, Huntingdon, Cambridgeshire, United Kingdom|Colchester Eye Centre, Colchester General Hospital, Colchester, Essex, United Kingdom|Birmingham & Midland Eye Center, Birmingham, United Kingdom|Mid-Cheshire Hospitals NHS Trust, Crewe, United Kingdom|Aintree University Hospital NHS Foundation Trust, Liverpool, United Kingdom|Royal Liverpool Hospital St Paul's Clinical Eye Research Centre, Liverpool, United Kingdom|Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom|Oxford University Hospitals, Oxford, United Kingdom|Peterborough City Hospital, Peterborough, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03850782"
667,"NCT01234649","Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)",,"Completed","Has Results","Gestational Diabetes Mellitus|Type 2 Diabetes Mellitus|Metabolic Syndrome|Impaired Glucose Tolerance|Disorder of Glucose Regulation","Drug: Metformin XR plus placebo|Drug: Metformin XR plus liraglutide","Insulin Secretion-Sensitivity Index (IS-SI)|Fasting Blood Glucose (FBG)|Mean Glucose During OGTT (MBG)|Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)|Matsuda Insulin Sensitivity Index Derived From OGTT|Insulinogenic Index (IGI) /HOMA-IR|Absolute Body Weight|Change in Body Weight From Baseline to End of Study (Expressed as % Compared to Baseline)|Body Mass Index (BMI)|Waist Circumference (WC)|Waist-to-Hip Ratio (WHR)|Waist to Height Ratio (WHtR)|Total Cholesterol (CHOL) Levels|High Density Lipoprotein Cholesterol (HDL-C) Levels|Low Density Lipoprotein Cholesterol (LDL-C) Levels|Triglyceride (TRG) Levels|Triglyceride to High Density Lipoprotein Cholesterol Ratio TRG/HDL-C)|Systolic Blood Pressure|Diastolic Blood Pressure|Alanine Aminotransferase (ALT) Levels|Aspartate Aminotransferase (AST)|Alanine Aminotransferase /Aspartate Aminotransferase (ALT/AST) Ratio","Woman's|Novo Nordisk A/S","Female","18 Years to 45 Years   (Adult)","Phase 3","153","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","RP10-012","August 11, 2011","April 24, 2019","June 14, 2019","November 4, 2010","July 26, 2019","July 26, 2019","Woman's Hospital, Baton Rouge, Louisiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT01234649/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT01234649/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT01234649"
668,"NCT00817414","An Evaluation of the Effects of LCI699 on Cortisol in Patients With Hypertension",,"Completed","No Results Available","Hypertension","Drug: Placebo|Drug: LCI699","To determine the maximum tolerated dose (MTD) of LCI699 with respect to effect on the ACTH-stimulated cortisol response following ACTH stimulation in hypertensive patients.|To characterize the LCI699 exposure-response relationship on cortisol levels following ACTH stimulation in hypertensive patients.|To characterize the pharmacokinetics of LCI699 in hypertensive patients|To assess the safety and tolerability of LCI699 in hypertensive patients|To explore the proportion of patients achieving a successful BP response and BP control in all treatment groups for 23-26 hour post dose (11-14 hour post dose for BID regimen) MSSBP and MSDBP","Novartis|Great Lakes Drug Development, Inc.|Integrium","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLCI699A2215|EudraCT 2008-007337-49","December 2008","July 2009","August 2009","January 6, 2009",,"December 4, 2012","Impact Clinical Trials, Beverly Hills, California, United States|Associated Pharmaceutical Research Center, Inc, Buena Park, California, United States|Innovative Clinical Research, Inc, Harbor City, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|Metro Clinical Research, Littleton, Colorado, United States|Clinical Study Center of Asheville, LLC, Asheville, North Carolina, United States|Northstate Clinical Research, Lenior, North Carolina, United States|Tipton Medical & Diagnostic Center, Tipton, Pennsylvania, United States|Punzi Medical Center, Carollton, Texas, United States|dgd Research, Inc, San Antonio, Texas, United States|Encode Clinic, Reykjavik, SA, Iceland",,"https://ClinicalTrials.gov/show/NCT00817414"
669,"NCT00853905","Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?",,"Completed","Has Results","Glaucoma","Drug: Triesence|Drug: balanced salt solution BSS","Intraocular Pressure (IOP)|Anterior Chamber Inflammation (Flare)|Bleb Appearance|Patient Comfort|Ocular Hypotensive Medications","Wills Eye|Alcon Research","All","21 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","77","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-827","February 2009","December 2011","January 2012","March 2, 2009","March 21, 2016","July 10, 2018","Wills Eye Institute, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00853905"
670,"NCT02603068","Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis",,"Withdrawn","No Results Available","Pulmonary Hypertension|Pulmonary Fibrosis","Drug: Oral treprostinil","Change in pulmonary vascular resistance (PVR)|Change in Six-minute walk distance (6MWD)|Change in N-terminal pro-brain natriuretic peptide (NT-ProBNP)","United Therapeutics","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-PH-204","February 2016","April 2018","July 2018","November 11, 2015",,"February 9, 2016","Banner University Medical Center Phoenix Advanced Lung Disease, Phoenix, Arizona, United States|University of California, Los Angeles - Pulmonary Division, Los Angeles, California, United States|University of California - Davis Medical Group, Sacramento, California, United States|Emory University Hospital, Atlanta, Georgia, United States|Johns Hopkins University, Baltiomore, Maryland, United States|Oregon Health and Science University, Portland, Oregon, United States|CLC Pulmonary Hypertension Clinic Division of Pulmonary, Allergy and Critical Care Medicine UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02603068"
671,"NCT02993406","Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo","CLEAR Outcomes","Active, not recruiting","No Results Available","Cardiovascular Diseases|Statin Adverse Reaction","Drug: Bempedoic acid 180 mg tablet|Drug: Matching placebo tablet","Time from randomization to first occurrence of one of the following adjudicated composite endpoints: CV death, nonfatal myocardial infarction (MI), nonfatal stroke, or coronary revascularization.","Esperion Therapeutics|The Cleveland Clinic","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","12600","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1002-043","November 18, 2016","December 2021","March 2022","December 15, 2016",,"February 7, 2020","Birmingham, Alabama, United States|Birmingham, Alabama, United States|Huntsville, Alabama, United States|Mobile, Alabama, United States|Mobile, Alabama, United States|Pell City, Alabama, United States|Tuscumbia, Alabama, United States|Chandler, Arizona, United States|Cottonwood, Arizona, United States|Fountain Hills, Arizona, United States|Gilbert, Arizona, United States|Glendale, Arizona, United States|Glendale, Arizona, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Beverly Hills, California, United States|Carlsbad, California, United States|Huntington Beach, California, United States|Lincoln, California, United States|Long Beach, California, United States|Long Beach, California, United States|Northridge, California, United States|Oceanside, California, United States|Rancho Cucamonga, California, United States|San Diego, California, United States|Santa Ana, California, United States|Santa Rosa, California, United States|Torrance, California, United States|Vista, California, United States|Aurora, Colorado, United States|Colorado Springs, Colorado, United States|Colorado Springs, Colorado, United States|Golden, Colorado, United States|Littleton, Colorado, United States|Loveland, Colorado, United States|Hamden, Connecticut, United States|Hartford, Connecticut, United States|North Haven, Connecticut, United States|Stamford, Connecticut, United States|Boca Raton, Florida, United States|Boynton Beach, Florida, United States|Boynton Beach, Florida, United States|Bradenton, Florida, United States|Clearwater, Florida, United States|Crystal River, Florida, United States|Fleming Island, Florida, United States|Fort Lauderdale, Florida, United States|Fort Lauderdale, Florida, United States|Green Acres, Florida, United States|Hialeah, Florida, United States|Hialeah, Florida, United States|Inverness, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Center for Advanced Research Excellence LLC, Hialeah, Jupiter, Florida, United States|Jupiter, Florida, United States|Lake Worth, Florida, United States|Largo, Florida, United States|Largo, Florida, United States|Melbourne, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Pharmax Research Clinic, Miami, Florida, United States|Miami, Florida, United States|Elite Clinical Research, Miami, Florida, United States|Miami, Florida, United States|Future Care Solution, LLC, Miami, Florida, United States|Med-Care Research, Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|South Florida Research Group, LLC, Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Naples, Florida, United States|New Port Richey, Florida, United States|North Miami Beach, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Ormond Beach, Florida, United States|Pembroke Pines, Florida, United States|Family Clinical Trials, LLC., Pembroke Pines, Florida, United States|Pembroke Pines, Florida, United States|Pembroke Pines, Florida, United States|Pinellas Park, Florida, United States|Ponte Vedra, Florida, United States|Port Charlotte, Florida, United States|Safety Harbor, Florida, United States|Saint Petersburg, Florida, United States|Tampa, Florida, United States|Wellington, Florida, United States|Atlanta, Georgia, United States|Columbus, Georgia, United States|Covington, Georgia, United States|Cumming, Georgia, United States|Dunwoody, Georgia, United States|Gainesville, Georgia, United States|Macon, Georgia, United States|Savannah, Georgia, United States|Tucker, Georgia, United States|Woodstock, Georgia, United States|Meridian, Idaho, United States|Champaign, Illinois, United States|Chicago, Illinois, United States|Gurnee, Illinois, United States|Jerseyville, Illinois, United States|Olympia Fields, Illinois, United States|Rock Island, Illinois, United States|Rockford, Illinois, United States|Anderson, Indiana, United States|Elkhart, Indiana, United States|Evansville, Indiana, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Munster, Indiana, United States|Richmond, Indiana, United States|Council Bluffs, Iowa, United States|Lipid Research Clinic - University of Iowa, Iowa City, Iowa, United States|Iowa City, Iowa, United States|Waterloo, Iowa, United States|West Des Moines, Iowa, United States|Hutchinson, Kansas, United States|Kansas City, Kansas, United States|Wichita, Kansas, United States|Elizabethtown, Kentucky, United States|Lexington, Kentucky, United States|L-MARC Research Center, Louisville, Kentucky, United States|Louisville, Kentucky, United States|Paducah, Kentucky, United States|Eunice, Louisiana, United States|Lake Charles, Louisiana, United States|New Orleans, Louisiana, United States|New Orleans, Louisiana, United States|West Monroe, Louisiana, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Medstar Cardiology Group at Franklin Square, Baltimore, Maryland, United States|Columbia, Maryland, United States|Optimal Research, LLC, Rockville, Maryland, United States|Salisbury, Maryland, United States|CPG Baltimore Research, Towson, Maryland, United States|Haverhill, Massachusetts, United States|Hyannis, Massachusetts, United States|Buckley, Michigan, United States|Cadillac, Michigan, United States|Caro, Michigan, United States|Grand Blanc, Michigan, United States|Grand Rapids, Michigan, United States|Kalamazoo, Michigan, United States|Lansing, Michigan, United States|Lansing, Michigan, United States|Mount Clemens, Michigan, United States|Petoskey, Michigan, United States|Saginaw, Michigan, United States|Sterling Heights, Michigan, United States|Troy, Michigan, United States|Minneapolis, Minnesota, United States|Richfield, Minnesota, United States|Saint Cloud, Minnesota, United States|Saint Paul, Minnesota, United States|Saint Paul, Minnesota, United States|Tupelo, Mississippi, United States|Bridgeton, Missouri, United States|Saint Louis, Missouri, United States|Saint Louis, Missouri, United States|Kalispell, Montana, United States|Fremont, Nebraska, United States|Lincoln, Nebraska, United States|Omaha, Nebraska, United States|Henderson, Nevada, United States|Las Vegas, Nevada, United States|Foundation Cardiology, Nashua, New Hampshire, United States|Nashua, New Hampshire, United States|Bridgeton, New Jersey, United States|Bridgewater, New Jersey, United States|Flemington, New Jersey, United States|Haddon, New Jersey, United States|Linden, New Jersey, United States|Sewell, New Jersey, United States|Teaneck, New Jersey, United States|Albany, New York, United States|Binghamton, New York, United States|Bronxville, New York, United States|Buffalo Heart Group, Buffalo, New York, United States|Endwell, New York, United States|Jackson Heights, New York, United States|Jamaica, New York, United States|Manhasset, New York, United States|New Windsor, New York, United States|New York, New York, United States|New York, New York, United States|Poughkeepsie, New York, United States|Saratoga Springs, New York, United States|Southampton, New York, United States|Asheboro, North Carolina, United States|Burlington, North Carolina, United States|Cary, North Carolina, United States|PMG Research of Cary, Cary, North Carolina, United States|Cary, North Carolina, United States|Charlotte, North Carolina, United States|Greensboro, North Carolina, United States|Medication Management, LLC, Greensboro, North Carolina, United States|Greensboro, North Carolina, United States|Greensboro, North Carolina, United States|PMG Research of Hickory, Hickory, North Carolina, United States|Hickory, North Carolina, United States|Lenoir, North Carolina, United States|Mooresville, North Carolina, United States|Morehead City, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|PMG Research of Raleigh, Raleigh, North Carolina, United States|Raleigh, North Carolina, United States|PMG Research of Rocky Mount, Rocky Mount, North Carolina, United States|Rocky Mount, North Carolina, United States|Sanford, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Fargo, North Dakota, United States|Akron, Ohio, United States|Akron, Ohio, United States|Canton, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Synexus Clinical Research, Columbus, Ohio, United States|Dayton, Ohio, United States|Franklin, Ohio, United States|Marion, Ohio, United States|Maumee, Ohio, United States|Middleburg Heights, Ohio, United States|Norman, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Abington Medical Specialists, Abington, Pennsylvania, United States|Beaver, Pennsylvania, United States|Camp Hill, Pennsylvania, United States|Johnstown, Pennsylvania, United States|McMurray, Pennsylvania, United States|Natrona Heights, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Smithfield, Pennsylvania, United States|Uniontown, Pennsylvania, United States|York, Pennsylvania, United States|Cumberland, Rhode Island, United States|Providence, Rhode Island, United States|Anderson, South Carolina, United States|Anderson, South Carolina, United States|Charleston, South Carolina, United States|Charleston, South Carolina, United States|Greer, South Carolina, United States|Indian Land, South Carolina, United States|Little River, South Carolina, United States|Summerville, South Carolina, United States|Rapid City, South Dakota, United States|Rapid City, South Dakota, United States|Fayetteville, Tennessee, United States|Greeneville, Tennessee, United States|Jackson, Tennessee, United States|Knoxville, Tennessee, United States|Allen, Texas, United States|Pharma Tex Research, LLP, Amarillo, Texas, United States|Amarillo, Texas, United States|Seton Heart Institute, Austin, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|DeSoto, Texas, United States|Fort Worth, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Katy, Texas, United States|Kerrville, Texas, United States|Lubbock, Texas, United States|McKinney, Texas, United States|Odessa, Texas, United States|Pearland, Texas, United States|Plano, Texas, United States|Plano, Texas, United States|San Angelo, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Schertz, Texas, United States|Sugar Land, Texas, United States|Tomball, Texas, United States|Tyler, Texas, United States|Victoria, Texas, United States|Farmington, Utah, United States|Layton, Utah, United States|Murray, Utah, United States|Orem, Utah, United States|Burke, Virginia, United States|Charlottesville, Virginia, United States|Danville, Virginia, United States|Falls Church, Virginia, United States|Hampton, Virginia, United States|York Clinical Research, LLC, Norfolk, Virginia, United States|Roanoke, Virginia, United States|Hampton Roads Center for Clinical Research, Suffolk, Virginia, United States|Suffolk, Virginia, United States|Woodbridge, Virginia, United States|Bellevue, Washington, United States|Green Bay, Wisconsin, United States|Kenosha, Wisconsin, United States|La Crosse, Wisconsin, United States|Madison, Wisconsin, United States|Bahia Blanca, Buenos Aires, Argentina|Bahía Blanca, Buenos Aires, Argentina|Bahía Blanca, Buenos Aires, Argentina|Berazategui, Buenos Aires, Argentina|Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|Coronel Suárez, Buenos Aires, Argentina|Haedo, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|Mar Del Plata, Buenos Aires, Argentina|Mar Del Plata, Buenos Aires, Argentina|Mar del Plata, Buenos Aires, Argentina|Mar Del Plata, Buenos Aires, Argentina|Moron, Buenos Aires, Argentina|San Martín, Buenos Aires, Argentina|Vicente López, Buenos Aires, Argentina|Zárate, Buenos Aires, Argentina|Villa Luro, Ciudad Autonoma Buenos Aires, Argentina|Caba, Ciudad Autonoma, Argentina|Ciudad Autónoma de Buenos Aire, Ciudad Autonoma, Argentina|Ciudad Autónoma de Buenos Aire, Ciudad Autonoma, Argentina|Ciudad Autónoma de Buenos Aire, Ciudad Autonoma, Argentina|Ciudad Autónoma de Buenos Aire, Ciudad Autonoma, Argentina|Ciudad Autónoma de Buenos Aire, Ciudad Autonoma, Argentina|Córdoba, Cordoba, Argentina|Córdoba, Cordoba, Argentina|Córdoba, Cordoba, Argentina|San Vicente, Cordoba, Argentina|Godoy Cruz, Mendoza, Argentina|San Rafael, Mendoza, Argentina|Temperley, Partido De Lomas De Zamora, Argentina|San Fernando, Provincia De Buenos AIres, Argentina|Rosario, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Rosario, Sante Fe, Argentina|San Miguel De Tucumán, Tucuman, Argentina|San Miguel de Tucumán, Tucumán, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Ciudad Autonoma Buenos Aires, Argentina|Ciudad Autonoma Buenos Aires, Argentina|Ciudad Autonoma de Buenos Aires, Argentina|Ciudad Autonoma de Buenos Aires, Argentina|Ciudad Autonoma de Buenos Aires, Argentina|Ciudad Autonoma de Buenos Aires, Argentina|Ciudad Autónoma de Buenos Aires, Argentina|Cordoba, Argentina|Cordoba, Argentina|Cordoba, Argentina|Cordoba, Argentina|Cordoba, Argentina|Cordoba, Argentina|Corrientes, Argentina|Córdoba, Argentina|La Plata, Argentina|La Plata, Argentina|Lanús, Argentina|Morón, Argentina|Pilar, Argentina|Quilmes, Argentina|Ramos Mejía, Argentina|Rosario, Argentina|Rosario, Argentina|Salta, Argentina|San Lorenzo, Argentina|San Miguel de Tucuman, Argentina|Santa Fe, Argentina|Santa Fe, Argentina|Tucuman, Argentina|Adamstown, New South Wales, Australia|Camperdown, New South Wales, Australia|Gosford, New South Wales, Australia|Liverpool, New South Wales, Australia|Merewether, New South Wales, Australia|Tumbi Umbi, New South Wales, Australia|Wollongong, New South Wales, Australia|Auchenflower, Queensland, Australia|Bundaberg, Queensland, Australia|Chermside, Queensland, Australia|Milton, Queensland, Australia|Sherwood, Queensland, Australia|Sippy Downs, Queensland, Australia|Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Adelaide, South Australia, Australia|Ashford, South Australia, Australia|Fullarton, South Australia, Australia|Hobart, Tasmania, Australia|Ballarat, Victoria, Australia|Box Hill, Victoria, Australia|Clayton, Victoria, Australia|Fitzroy, Victoria, Australia|Frankston, Victoria, Australia|Langwarrin, Victoria, Australia|Melbourne, Victoria, Australia|Mildura, Victoria, Australia|Joondalup, Western Australia, Australia|Murdoch, Western Australia, Australia|Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Perth, Western Australia, Australia|Subiaco, Western Australia, Australia|Feldkirch, Austria|Graz, Austria|Innsbruck, Austria|Linz, Austria|Linz, Austria|Vienna, Austria|Wiener Neustadt, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Aalst, Belgium|Antwerpen, Belgium|Antwerpen, Belgium|Brasschaat, Belgium|Brugge, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|De Pinte, Belgium|Dendermonde, Belgium|Edegem, Belgium|Genk, Belgium|Gent, Belgium|Halen, Belgium|Liège, Belgium|Mechelen, Belgium|Merksem, Belgium|Mons, Belgium|Tienen, Belgium|Turnhout, Belgium|Wetteren, Belgium|Yvoir, Belgium|Salvador, Bahia, Brazil|Fortaleza, Ceará, Brazil|Fortaleza, Ceará, Brazil|ICE-HUWC - Instituto Cearense de Endocrinologia do Hospital Universitário Walter Cantídio, Fortaleza, Ceará, Brazil|Fortaleza, Ceará, Brazil|Fortaleza, Ceará, Brazil|Brasília, Distrito Federal, Brazil|Brasília, Distrito Federal, Brazil|Brasília, Distrito Federal, Brazil|Vitória, Espírito Santo, Brazil|Goiânia, Goiás, Brazil|Goiânia, Goiás, Brazil|Campo Grande, Mato Grosso Do Sul, Brazil|Belo Horizonte, Minas Gerais, Brazil|Belo Horizonte, Minas Gerais, Brazil|Belo Horizonte, Minas Gerais, Brazil|Uberlândia, Minas Gerais, Brazil|Curitiba, Paraná, Brazil|Curitiba, Paraná, Brazil|Curitiba, Paraná, Brazil|Curitiba, Paraná, Brazil|Belém, Pará, Brazil|Recife, Pernambuco, Brazil|Boa Vista, Recife, Brazil|Natal, Rio Grande Do Norte, Brazil|Passo Fundo, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Santa Maria, Rio Grande Do Sul, Brazil|Caxias Do Sul, Rio Grande Du Sul, Brazil|Porto Alegre, Rio Grande Du Sul, Brazil|Balneário Camboriú, Santa Catarina, Brazil|Blumenau, Santa Catarina, Brazil|Campinas, Sao Paulo, Brazil|Campinas, Sao Paulo, Brazil|Campinas, Sao Paulo, Brazil|Cotia, Sao Paulo, Brazil|Jaú, Sao Paulo, Brazil|Marília, Sao Paulo, Brazil|Santo André, Sao Paulo, Brazil|Santo André, Sao Paulo, Brazil|Santo André, Sao Paulo, Brazil|São José Do Rio Preto, Sao Paulo, Brazil|São José dos Campos, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Tatuí, Sao Paulo, Brazil|Votuporanga, Sao Paulo, Brazil|Sao Paulo, Sau Paulo, Brazil|Paraíso, São Paulo, Brazil|São José Do Rio Preto, São Paulo, Brazil|Bela Vista, Brazil|Belo Horizonte, Brazil|Belo Horizonte, Brazil|Belo Horizonte, Brazil|Bento Gonçalves, Brazil|Brasília, Brazil|Curitiba, Brazil|Curitiba, Brazil|Curitiba, Brazil|Goiânia, Brazil|Joinville, Brazil|Maceió, Brazil|Marilia, Brazil|Maringá, Brazil|Porto Alegre, Brazil|Porto Alegre, Brazil|Rio de Janeiro, Brazil|Salvador, Brazil|Salvador, Brazil|Salvador, Brazil|Salvador, Brazil|Santa Maria, Brazil|São José, Brazil|São Luís, Brazil|São Paulo, Brazil|São Paulo, Brazil|Blagoevgrad, Bulgaria|Byala, Bulgaria|Dimitrovgrad, Bulgaria|Haskovo, Bulgaria|MHAT - Pazardzhik AD, Pazardzhik, Bulgaria|Pazardzhik, Bulgaria|Pernik, Bulgaria|MHAT ""Sv. Pantaleymon - Pleven"", OOD, Pleven, Bulgaria|Pleven, Bulgaria|Plovdiv, Bulgaria|Plovdiv, Bulgaria|Ruse, Bulgaria|Ruse, Bulgaria|Sandanski, Bulgaria|Sliven, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Varna, Bulgaria|Varna, Bulgaria|Veliko Tarnovo, Bulgaria|Yambol, Bulgaria|Victoria, British Columbia, Canada|Mount Pearl, Newfoundland and Labrador, Canada|Brampton, Ontario, Canada|Brampton, Ontario, Canada|Cambridge, Ontario, Canada|Cambridge, Ontario, Canada|London, Ontario, Canada|Newmarket, Ontario, Canada|Oakville, Ontario, Canada|Peterborough, Ontario, Canada|Sarnia, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Longueuil, Quebec, Canada|Longueuil, Quebec, Canada|Montréal, Quebec, Canada|Montréal, Quebec, Canada|Pointe-Claire, Quebec, Canada|Saint-Georges, Quebec, Canada|St-Jérôme, Quebec, Canada|St. Jean sur Richelieu, Quebec, Canada|Victoriaville, Quebec, Canada|Quebec, Canada|Québec, Canada|San Bernardo, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Temuco, Chile|Viña del Mar, Chile|Barranquilla, Colombia|Barranquilla, Colombia|Centro de Diabetes Cardiovascular, Barranquilla, Colombia|Barranquilla, Colombia|Bogota, Colombia|Bogota, Colombia|Bogotá, Colombia|Bogotá, Colombia|Bogotá, Colombia|Bucaramanga, Colombia|Bucaramanga, Colombia|Cali, Colombia|Cali, Colombia|Cartagena, Colombia|Cartagena, Colombia|Espinal, Colombia|Ibagué, Colombia|Manizales, Colombia|Medellin, Colombia|Medellin, Colombia|Pereira, Colombia|San Gil, Colombia|Zipaquirá, Colombia|Dubrovnik, Croatia|Koprivnica, Croatia|Krapinske Toplice, Croatia|Opatija, Croatia|Osijek, Croatia|Rijeka, Croatia|Slavonski Brod, Croatia|Varazdin, Croatia|Virovitica, Croatia|Zabok, Croatia|Zadar, Croatia|Zagreb, Croatia|Čakovec, Croatia|Benátky Nad Jizerou, Czechia|Beroun, Czechia|Brandýs Nad Labem, Czechia|Brno, Czechia|Brno, Czechia|Brno, Czechia|Brno, Czechia|Brno, Czechia|Broumov, Czechia|Choceň, Czechia|Chrudim, Czechia|Frýdek-Místek, Czechia|Havirov, Czechia|Havlíčkův Brod, Czechia|Hodonín, Czechia|Hradec Kralove, Czechia|Hradec Králové, Czechia|Kolín, Czechia|Náchod, Czechia|Olomouc, Czechia|Ostrava, Czechia|Pardubice, Czechia|Prague 5, Czechia|Prague, Czechia|Praha 10, Czechia|Praha 1, Czechia|Praha 2, Czechia|Praha 4 - Krc, Czechia|Praha 4, Czechia|Praha, Czechia|Přerov, Czechia|Slaný, Czechia|Teplice, Czechia|Trutnov, Czechia|Uherské Hradiště, Czechia|Aalborg, Denmark|Aalborg, Denmark|Ballerup, Denmark|Copenhagen NV, Denmark|Esbjerg, Denmark|Glostrup, Denmark|Hellerup, Denmark|Holbæk, Denmark|Nykøbing Falster, Denmark|Vejle, Denmark|Viborg, Denmark|Århus N, Denmark|Tallinn, Estonia|Tallinn, Estonia|Tallinn, Estonia|Tallinn, Estonia|Bad Krozingen, Baden Wuerttemberg, Germany|Dresden, Baden Wuerttemberg, Germany|Heidelberg, Baden Wuerttemberg, Germany|Munich, Bayern, Germany|Wallerfing, Bayern, Germany|Bad Homburg, Hessen, Germany|Frankfurt am Main, Hessen, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Kassel, Hessen, Germany|Rodgau, Hessen, Germany|Mainz, Hesse, Germany|Schwerin, Mecklenburg Vorpommern, Germany|Bochum, Nordrhein Westfalen, Germany|Dortmund, Nordrhein Westfalen, Germany|Essen, Nordrhein Westfalen, Germany|Goch, Nordrhein Westfalen, Germany|Koeln, Nordrhein Westfalen, Germany|Koeln, Nordrhein Westfalen, Germany|Siegen, Nordrhein Westfalen, Germany|Soest, Nordrhein Westfalen, Germany|Witten, Nordrhein Westfalen, Germany|Bielefeld, North Rhine-Westphalia, Germany|Dortmund, North Rhine-Westphalia, Germany|Essen, North Rhine-Westphalia, Germany|Mainz, Rheinland Pfalz, Germany|Bohlen, Sachsen, Germany|Dippoldiswalde, Sachsen, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Markkleeberg, Sachsen, Germany|Wermsdorf, Sachsen, Germany|Zwenkau, Sachsen, Germany|Altenburg, Saxony, Germany|Bad Homburg, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Bielefeld, Germany|Falkensee, Germany|Frankfurt, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hannover, Germany|Heidelberg, Germany|Mainz, Germany|Reinfeld, Germany|Orosháza, Szentetornya, Hungary|Baja, Hungary|Balatonfüred, Hungary|Balatongyörök, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Békéscsaba, Hungary|Debrecen, Hungary|Debrecen, Hungary|Dombovar, Hungary|Gyula, Hungary|Gyöngyös, Hungary|Győr, Hungary|Hajdúszoboszló, Hungary|Kalocsa, Hungary|Kecskemét, Hungary|Kiskunhalas, Hungary|Miskolc, Hungary|Mosonmagyaróvár, Hungary|Nagykanizsa, Hungary|Nyíregyháza, Hungary|Nyíregyháza, Hungary|Orosháza, Hungary|Polgar, Hungary|Pécs, Hungary|Pécs, Hungary|Szekszard, Hungary|Szentendre, Hungary|Szentes, Hungary|Szombathely, Hungary|Székesfehérvár, Hungary|Zalaegerszeg, Hungary|Hyderabad, Andhra Pradesh, India|Guwahati, Assam, India|New Delhi, Delhi, India|New Delhi, Delhi, India|New Delhi, Delhi, India|Ahmedabad, Gujarat, India|Nadiād, Gujarat, India|Surat, Gujarat, India|Sūrat, Gujarat, India|Sūrat, Gujarat, India|Vadodara, Gujarat, India|Faridabad, Haryana, India|Gurgaon, Haryana, India|Bangalore, Karnataka, India|Bangalore, Karnataka, India|Belgaum, Karnataka, India|Bengaluru, Karnataka, India|Hubli, Karnatak, India|Aurangabad, Maharashtra, India|Aurangabad, Maharashtra, India|Nagpur, Maharashtra, India|Nagpur, Maharashtra, India|Nagpur, Maharashtra, India|Nashik, Maharashtra, India|Nashik, Maharashtra, India|Pune, Maharashtra, India|Pune, Maharashtra, India|Pune, Maharashtra, India|Jaipur, Rajasthan, India|Jaipur, Rajasthan, India|Chennai, Tamilnadu, India|Coimbatore, Tamilnadu, India|Lucknow, Uttar Pradesh, India|Noida, Uttar Pradesh, India|Kolkata, West Bengal, India|Delhi, India|Daugavpils, Latvia|Kuldiga, Latvia|Ogre, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Tukums, Latvia|Ventspils, Latvia|Alytus, Lithuania|Kaunas, Lithuania|Kaunas, Lithuania|Kaunas, Lithuania|Kaunas, Lithuania|Kaunas, Lithuania|Kaunas, Lithuania|Klaipėda, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|Šiauliai, Lithuania|Tijuana, Baja California Norte, Mexico|Chihuahua, Chihuahua C.P., Mexico|Monclova, Coahuila, Mexico|Torreon, Coahuila, Mexico|Mexico, Distrito Federal, Mexico|Mexico, Distrito Federal, Mexico|Mexico, Distrito Federal, Mexico|Mexico, Distrito Federal, Mexico|Mexico, Distrito Federal, Mexico|Pachuca, Hidalgo, Mexico|Guadalajara, Jalisco, Mexico|Guadalajara, Jalisco, Mexico|Monterrey, Nuevo León, Mexico|Querétaro, Qro., Mexico|Querétaro, Queretaro, Mexico|Culiacan, Sinaloa, Mexico|Culiacán, Sinaloa, Mexico|Mazatlán, Sinaloa, Mexico|Mérida, Yucatán, Mexico|Aguascalientes, Mexico|Aguascalientes, Mexico|Aguascalientes, Mexico|Chihuahua, Mexico|Chihuahua, Mexico|Chihuahua, Mexico|Cuernavaca, Mexico|Durango, Mexico|Guadalajara, Mexico|Guadalajara, Mexico|Guadalajara, Mexico|Guadalajara, Mexico|Juarez, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Bioné-IPHARMA, Monterrey, Mexico|SBHI ""Penza Regional Clinical Hospital n.a. N.N. Burdenko"", Monterrey, Mexico|Monterrey, Mexico|Monterrey, Mexico|Monterrey, Mexico|Pachuca, Mexico|Puerto Vallarta, Mexico|Querétaro, Mexico|Tamaulipas, Mexico|Veracruz, Mexico|Alkmaar, Netherlands|Almelo, Netherlands|Almere, Netherlands|Amersfoort, Netherlands|Amstelveen, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Apeldoorn, Netherlands|Apeldoorn, Netherlands|Arnhem, Netherlands|Beverwijk, Netherlands|Blaricum, Netherlands|Delft, Netherlands|Den Haag, Netherlands|Den Haag, Netherlands|Den Haag, Netherlands|Dirksland, Netherlands|Doetinchem, Netherlands|Dordrecht, Netherlands|Ede, Netherlands|Eindhoven, Netherlands|Enschede, Netherlands|Goes, Netherlands|Gorinchem, Netherlands|Gouda, Netherlands|Gouda, Netherlands|Hardenberg, Netherlands|Hardenberg, Netherlands|Harderwijk, Netherlands|Heerlen, Netherlands|Helmond, Netherlands|Hilversum, Netherlands|Hoogeveen, Netherlands|Hoogezand, Netherlands|Hoorn, Netherlands|Leeuwarden, Netherlands|Leiden, Netherlands|Leiderdorp, Netherlands|Maastricht, Netherlands|Nijmegen, Netherlands|Nijmegen, Netherlands|Purmerend, Netherlands|Roosendaal, Netherlands|Rotterdam, Netherlands|Rotterdam, Netherlands|Rotterdam, Netherlands|Rotterdam, Netherlands|Rotterdam, Netherlands|Schiedam, Netherlands|Sneek, Netherlands|Tiel, Netherlands|Tilburg, Netherlands|Utrecht, Netherlands|Utrecht, Netherlands|Utrecht, Netherlands|Venlo, Netherlands|Zutphen, Netherlands|Zwijndrecht, Netherlands|Zwijndrecht, Netherlands|Zwolle, Netherlands|Auckland, New Zealand|Auckland, New Zealand|Auckland, New Zealand|Auckland, New Zealand|Christchurch, New Zealand|Christchurch, New Zealand|Grafton, New Zealand|Hamilton, New Zealand|Hastings, New Zealand|New Plymouth, New Zealand|Papamoa, New Zealand|Rotorua, New Zealand|Tauranga, New Zealand|Tauranga, New Zealand|Wellington, New Zealand|Legnica, Dolnoslaskie, Poland|Wrocław, Dolnoslaskie, Poland|Wrocław, Dolnoslaskie, Poland|Włocławek, Kujawsko-Pomorskie, Poland|Lublin, Lubelski, Poland|Kraków, Małopolskie, Poland|Tarnów, Małopolskie, Poland|Katowice, Slaskie, Poland|Katowice, Sląskie, Poland|Katowice, Sląskie, Poland|Ruda Śląska, Sląskie, Poland|Białystok, Poland|Brzozów, Poland|Bydgoszcz, Poland|Bydgoszcz, Poland|Chełm, Poland|Częstochowa, Poland|Elbląg, Poland|Gdańsk, Poland|Gdańsk, Poland|Gdynia, Poland|Grodzisk Mazowiecki, Poland|Katowice, Poland|Katowice, Poland|Kielce, Poland|Krakow, Poland|Krakow, Poland|Kraków, Poland|Kraków, Poland|Legnica, Poland|Lublin, Poland|Lublin, Poland|Nałęczów, Poland|Nowa Sól, Poland|Nowy Targ, Poland|Oświęcim, Poland|Poznań, Poland|Poznań, Poland|Poznań, Poland|Pulawy, Poland|Puławy, Poland|Płock, Poland|Ruda Śląska, Poland|Ruda Śląska, Poland|Rzeszów, Poland|Rzeszów, Poland|Rzeszów, Poland|Siedlce, Poland|Skierniewice, Poland|Sopot, Poland|Staszów, Poland|Szczecin, Poland|Szczecin, Poland|Tarnów, Poland|Tczew, Poland|Toruń, Poland|Warsaw, Poland|Warsaw, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Wroclaw, Poland|Wrocław, Poland|Wrocław, Poland|Włocławek, Poland|Zamość, Poland|Łódź, Poland|Łódź, Poland|Łódź, Poland|Łódź, Poland|Łódź, Poland|Łódź, Poland|Łódź, Poland|Łódź, Poland|Pitesti, Arges, Romania|Baia Mare, Maramures County, Romania|Satu Mare, Satu Mare County, Romania|Timişoara, Timis County, Romania|Alba Iulia, Romania|Baia Mare, Romania|Baia Mare, Romania|Baloteşti, Romania|Braila, Romania|Braşov, Romania|Braşov, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Calarasi, Romania|Cluj-Napoca, Romania|Craiova, Romania|Deva, Romania|Galaţi, Romania|Galaţi, Romania|Oradea, Romania|S.C Grandmed S.R.L, Oradea, Romania|Oradea, Romania|Oradea, Romania|Oradea, Romania|Paşcani, Romania|Pitesti, Romania|Ploieşti, Romania|Satu Mare, Romania|Timisoara, Romania|Timişoara, Romania|Timişoara, Romania|Târgu-Mureş, Romania|Târgu-Mureş, Romania|Târgu-Mureş, Romania|Târgu-Mureş, Romania|Zalău, Romania|Barnaul, Altayskiy Kray, Russian Federation|Arkhangel'sk, Russian Federation|Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Chelyabinsk, Russian Federation|Chelyabinsk, Russian Federation|Ekaterinburg, Russian Federation|Ekaterinburg, Russian Federation|Ekaterinburg, Russian Federation|Ivanovo, Russian Federation|Kazan, Russian Federation|Kemerovo, Russian Federation|Kemerovo, Russian Federation|Kemerovo, Russian Federation|Kirovsk, Russian Federation|Kirov, Russian Federation|Kirov, Russian Federation|Krasnoyarsk, Russian Federation|Kursk, Russian Federation|Kursk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhniy Novgorod, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Omsk, Russian Federation|Omsk, Russian Federation|Orenburg, Russian Federation|Perm, Russian Federation|Rostov-on-Don, Russian Federation|Ryazan', Russian Federation|Ryazan', Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|North-West Federal Medical Research Center n.a. V.A. Almazov, Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Saratov, Russian Federation|Sestroretsk, Russian Federation|Smolensk, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Tomsk, Russian Federation|Yaroslavl, Russian Federation|Yaroslavl, Russian Federation|Yaroslavl, Russian Federation|Belgrade, Serbia|Belgrade, Serbia|Belgrade, Serbia|Kragujevac, Serbia|Niš, Serbia|Pančevo, Serbia|Smederevo, Serbia|Sremska Mitrovica, Serbia|Užice, Serbia|Valjevo, Serbia|Zaječar, Serbia|Bratislava 2, Ružinov, Slovakia|Bardejov, Slovakia|Bratislava, Slovakia|Bratislava, Slovakia|Bratislava, Slovakia|Bratislava, Slovakia|Dolný Kubín, Slovakia|Komarno, Slovakia|Košice, Slovakia|Košice, Slovakia|Košice, Slovakia|Košice, Slovakia|Levice, Slovakia|Levice, Slovakia|Lucenec, Slovakia|Lučenec, Slovakia|Lučenec, Slovakia|Moldava Nad Bodvou, Slovakia|Nitra, Slovakia|Nove Zamky, Slovakia|Nové Zámky, Slovakia|Prešov, Slovakia|Rožňava, Slovakia|Sahy, Slovakia|Svidnik, Slovakia|Svidník, Slovakia|Ľubochňa, Slovakia|Štúrovo, Slovakia|Žilina, Slovakia|Port Elizabeth, Eastern Cape, South Africa|Port Elizabeth, Eastern Cape, South Africa|Bloemfontein, Free State, South Africa|Bloemfontein, Free State, South Africa|Centurion, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Kempton Park, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Alberton, Guateng, South Africa|Pretoria, Guateng, South Africa|Pretoria, Guateng, South Africa|Durban, KwaZulu-Natal, South Africa|Durban, KwaZulu-Natal, South Africa|Durban, KwaZulu-Natal, South Africa|Merebank, KwaZulu-Natal, South Africa|Thabazimbi, Limpopo, South Africa|Middelburg, Mpumalanga, South Africa|Moloto, Mpumalanga, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa|Santiago De Compostela, La Coruña, Spain|A Coruña, Spain|Almeria, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Girona, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Sevilla, Spain|Sevilla, Spain|Sevilla, Spain|Adana, Turkey|Ankara, Turkey|Antalya, Turkey|Edirne, Turkey|Eskisehir, Turkey|Istanbul, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Kocaeli, Turkey|Mersin, Turkey|Sivas, Turkey|Brovary, Ukraine|Cherkasy, Ukraine|Chernivtsi, Ukraine|Dnipro, Ukraine|Dnipro, Ukraine|Dnipro, Ukraine|Dnipro, Ukraine|Ivano-Frankivs'k, Ukraine|Ivano-Frankivs'k, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Kyiv, Ukraine|Kyiv, Ukraine|Kyiv, Ukraine|Kyiv, Ukraine|Kyiv, Ukraine|Kyiv, Ukraine|Kyiv, Ukraine|Kyiv, Ukraine|Kyiv, Ukraine|SI NSC M.D. Strazhesko Institute of Cardiology of NAMSU, Kyiv, Ukraine|Kyiv, Ukraine|Kyiv, Ukraine|Kyiv, Ukraine|Luts'k, Ukraine|Lviv, Ukraine|Lviv, Ukraine|Mykolaiv, Ukraine|Odesa, Ukraine|Sumy, Ukraine|Ternopil, Ukraine|Vinnytsia, Ukraine|Vinnytsia, Ukraine|Vinnytsia, Ukraine|Vinnytsia, Ukraine|Vinnytsia, Ukraine|Vinnytsya, Ukraine|Zaporizhzhia, Ukraine|Zaporizhzhia, Ukraine|Zaporizhzhia, Ukraine|Zaporizhzhia, Ukraine|Zaporizhzhia, Ukraine|Zaporizhzhia, Ukraine|Zhytomyr regional clinical hospital n.a. O.F. Gerbachevskyy, Zhytomyr, Ukraine|Zhytomyr, Ukraine|Úzhgorod, Ukraine|Reading, Berkshire, United Kingdom|Soham, Cambridgeshire, United Kingdom|Fowey, Cornwall, United Kingdom|Hayle, Cornwall, United Kingdom|Torpoint, Cornwall, United Kingdom|Exmouth, Devon, United Kingdom|Plymouth, Devon, United Kingdom|Plymouth, Devon, United Kingdom|Stockton on Tees, Durham, United Kingdom|Basildon, Essex, United Kingdom|London, Greater London, United Kingdom|Manchester, Greater Manchester, United Kingdom|East Kilbride, Lanarkshire, United Kingdom|Blackpool, Lancashire, United Kingdom|Chorley, Lancashire, United Kingdom|Edinburgh, Lothian Region, United Kingdom|Liverpool, Merseyside, United Kingdom|Airdrie, North Lanarkshire, United Kingdom|Hexham, Northumberland, United Kingdom|Axbridge, Somerset, United Kingdom|Bath, Somerset, United Kingdom|Cardiff, South Glamorgan, United Kingdom|Glasgow, Strathclyde, United Kingdom|Chertsey, Surrey, United Kingdom|Dundee, Tayside Region, United Kingdom|Birmingham, West Midlands, United Kingdom|Wakefield, Yorkshire And The Humber, United Kingdom|Wakefield, Yorkshire, United Kingdom|Blackpool, United Kingdom|Chesterfield, United Kingdom|Crownhill, United Kingdom|Leamington Spa, United Kingdom|Lincoln, United Kingdom|Oldham, United Kingdom|Sandbach, United Kingdom|Whitby, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02993406"
672,"NCT02014142","A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma",,"Completed","No Results Available","Ocular Hypertension|Open-Angle Glaucoma","Drug: Latanoprost Punctal Plug Delivery System (L-PPDS)","IOP change from baseline and the primary analysis time point will be the IOP assessment at Week 12","Mati Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PPL GLAU M1","December 2013","December 2016","December 2016","December 18, 2013",,"January 18, 2017","Arizona Eye Center, Chandler, Arizona, United States|Arizona Glaucoma Specialists, Phoenix, Arizona, United States|Wolstan & Goldberg Eye Associates, Torrance, California, United States|Argus Research at Cape Coral Eye Center, Cape Coral, Florida, United States|Eye Associates of Fort Myers, Fort Myers, Florida, United States|Indiana Universtiy - Eugene and Marilyn Glick Eye Institute Ophthalmology Center, Indianapolis, Indiana, United States|Cincinnati Eye Institute, Edgewood, Kentucky, United States|Great Lakes Eye Care, St. Joseph, Michigan, United States|Chu Vision Institute, Bloomington, Minnesota, United States|Ophthalmology Associates, St. Louis, Missouri, United States|Comprehensive Eye Care, Ltd., Washington, Missouri, United States|Abrams Eye Institute, Las Vegas, Nevada, United States|Ophthalmic Consultants of Long Island, Lynbrook, New York, United States|Dr. Steven T. Simmons, Slingerlands, New York, United States|Philadelphia Eye Associates, Philadelphia, Pennsylvania, United States|Wills Eye Hospital, Phildelphia, Pennsylvania, United States|University Eye Surgeons, Maryville, Tennessee, United States|Total Eye Care, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02014142"
673,"NCT01377909","HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity",,"Terminated","No Results Available","Chronic Hepatitis C","Drug: statin","Improvement in peginterferon response as measured by change in HCV RNA levels|The response of interferon stimulated genes","Bader, Ted, M.D.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Bader 15859","March 2012","August 2013","August 2013","June 22, 2011",,"August 22, 2013","Veterans Administration Medical Center (VAMC), Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT01377909"
674,"NCT01370512","Droxidopa / Pyridostigmine in Orthostatic Hypotension",,"Recruiting","No Results Available","Orthostatic Hypotension","Drug: Droxidopa|Drug: Pyridostigmine Bromide","The primary endpoint is the improvement in diastolic BP fall at the end of 5 minutes of standing.|Evaluate the effect of Droxidopa alone versus Droxidopa combined with pyridostigmine versus placebo on supine NE and its orthostatic increment.|Evaluate the effect of Droxidopa alone versus Droxidopa combined with pyridostigmine on orthostatic symptoms.","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10-008810","November 2011","June 2020","June 2020","June 10, 2011",,"August 13, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01370512"
675,"NCT02515331","Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients",,"Completed","Has Results","Patients, Resistant Hypertension","Drug: LHW090|Drug: Placebo","Number of Participants With Reported Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths|Change From Baseline in Mean Daytime Blood Pressure|Pharmacokinetics of LHW090/LHV527 in Plasma: Observe Maximum Plasma Concentration Following LHW090 at Steady State in Patients (Cmax)|Pharmacokinetics of LHW090/LHV527 in Plasma: Time to Reach the Maximum Concentration After Administration of LHW090 (Tmax)|Pharmacokinetics of LHW090/LHV527 in Plasma: Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast)|Pharmacokinetics of LHW090/LHV527 in Plasma: Last Measurable Plasma Concentration (Clast)|Pharmacokinetics of LHW090/LHV527 in Plasma:Tlast","Novartis Pharmaceuticals|Novartis","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 2","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CLHW090X2202|2015-001890-42","November 4, 2015","August 17, 2017","August 17, 2017","August 4, 2015","July 5, 2018","July 5, 2018","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, North Hollywood, California, United States|Novartis Investigative Site, Atlantis, Florida, United States|Novartis Investigative Site, Daytona Beach, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Gentofte, Denmark|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Meibergdreef 9, Netherlands|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Lausanne, Switzerland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02515331/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02515331/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02515331"
676,"NCT02009865","Epanova® for Lowering Very High Triglycerides II (EVOLVE II)","EVOLVEII","Completed","Has Results","Hypertriglyceridemia","Drug: Epanova|Drug: Olive Oil","Percent Change in Triglyceride for All Subjects|Percent Change in Triglycerides for Subjects With at Least 1 Qualifying Triglyceride >885 mg/dL|Percent Change in Non-High-Density Lipoprotein Cholesterol (mg/dL)|Percent Change in High-Density Lipoprotein Cholesterol (mg/dL)|Percent Change in Triglyceride(mg/dL) in Subjects With Biochemically Defined Fredrickson Type V (Triglyceride/Very-Low-Density Lipoprotein Cholesterol ≥6)","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","379","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D5880C00001|OM-EPA-011","December 16, 2013","December 23, 2014","December 23, 2014","December 12, 2013","January 15, 2016","September 10, 2019","Research Site, Los Angeles, California, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Addison, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Lyndhurst, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Bristol, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Katy, Texas, United States|Research Site, Chicoutimi, Quebec, Canada|Research Site, Hradec Kralova, Czechia|Research Site, Trutnov, Czechia|Research Site, Zlín, Czechia|Research Site, Esbjerg, Denmark|Research Site, Gentofte, Denmark|Research Site, Herlev, Denmark|Research Site, Viborg, Denmark|Research Site, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Debrecen, Hungary|Research Site, Szikszó, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Sátoraljaújhely, Hungary|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02009865"
677,"NCT02179008","Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension","SEE-1","Completed","No Results Available","Open-angle Glaucoma|Ocular Hypertension","Drug: DE-117 Low Dose ophthalmic solution|Drug: DE-117 Low/Middle Dose ophthalmic solution|Drug: DE-117 Middle Dose ophthalmic solution|Drug: DE-117 Middle/High Dose ophthalmic solution|Drug: DE-117 High Dose ophthalmic solution|Drug: latanoprost ophthalmic solution 0.005%","Intraocular pressure (mmHg)|Number of Subjects with Adverse Events as a Measure of Safety and Tolerability","Santen Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","184","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","33-003","June 2014","January 2015","January 2015","July 1, 2014",,"April 18, 2018","Chandler, Arizona, United States|Artesia, California, United States|Glendale, California, United States|Long Beach, California, United States|Newport Beach, California, United States|Largo, Florida, United States|Morrow, Georgia, United States|Roswell, Georgia, United States|Rochester, New York, United States|High Point, North Carolina, United States|Cleveland, Ohio, United States|Austin, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02179008"
678,"NCT01437878","Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)",,"Terminated","Has Results","Chronic Obstructive Pulmonary Disease|Pulmonary Hypertension","Drug: Iloprost|Drug: Placebo","Change in Endurance Time|Participants With Treatment-emergent Adverse Events|Change in Systolic Pulmonary Arterial Pressure|Change in Diastolic Pulmonary Arterial Pressure|Change in Mean Pulmonary Arterial Pressure|Change in Mean Right Atrial Pressure|Change in Cardiac Output|Change in Right Ventricular Pressure|Change in Pulmonary Vascular Resistance|Change in End Tidal Partial Pressure of Carbon Dioxide|Change in End Tidal Partial Pressure of Oxygen|Change in Oxygen Uptake|Change in Carbon Dioxide Output|Change in Oxygen Uptake Per Heartbeat|Change in Heart Rate|Change in Arterial Oxygen Saturation as Indicated by Pulse Oximetry|Change in Tidal Volume|Change in Minute Ventilation","Actelion","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 2","2","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AC-063B201","March 2012","November 2012","November 2012","September 21, 2011","January 6, 2015","November 20, 2015","Los Angeles Biomedical Research Institute, Torrance, California, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Northwestern University, Chicago, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Hopital d'adultes de Brabois, Vandoeuvre-lès-Nancy, France|Hospital Clinic i Provincial, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01437878"
679,"NCT01202110","Early Propranolol After Traumatic Brain Injury: Phase II","EPAT: Phase II","Terminated","Has Results","Traumatic Brain Injury","Drug: Propranolol","Determine in Patients With Traumatic Brain Injury (TBI) the Safe Dosing of Early Propranolol.","Cedars-Sinai Medical Center","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00020850","June 2010","February 2015","February 2015","September 15, 2010","May 13, 2016","May 13, 2016","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01202110"
680,"NCT02736149","Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)","LIBERTY2","Terminated","No Results Available","Pulmonary Arterial Hypertension","Drug: ubenimex","Treatment-emergent adverse events recorded on the Adverse Event Case Report Form|Change in pulmonary vascular resistance (PVR)|Change in exercise capacity as measured by 6-minute walk distance (6MWD)|Change in World Health Organization/New York Heart Association Functional Classification|Change in disease biomarkers brain natriuretic peptide (BNP) /N-terminal pro-brain natriuretic peptide (NT-proBNP )","Eiger BioPharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","51","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EIG-UBX-002","December 2016","March 2018","August 2018","April 13, 2016",,"July 18, 2019","California Heart Center Foundation, An Affiliate of Cedars-Sinai Heart Institute, Cedars-Sinai Medical Care Foundation, Beverly Hills, California, United States|UCSD Medical Center, La Jolla, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Cleveland Clinic, Florida, Weston, Florida, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Chest Medicine Associates, South Portland, Maine, United States|Johns Hopkins University, Pulmonary and Critical Care Medicine, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic College of Medicine, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Weill Cornell Medicine, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Respiratory Institute, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pennsylvania Medical Center, Pittsburgh, Pennsylvania, United States|Alpert Medical School of Brown University Rhode Island Hospital, Providence, Rhode Island, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University Texas Health Science Center, San Antonio, Texas, United States|London Health Sciences Centre, London, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02736149"
681,"NCT01300858","A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients",,"Terminated","No Results Available","Colorectal Cancer","Drug: EGEN-001-301","Progression-free survival|Overall survival|Tumor Growth Assessment by X-ray/CT|Number of study subjects with adverse events","EGEN, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","4","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EGEN-001-301","June 2011","July 2014","July 2014","February 23, 2011",,"July 13, 2015","Midwestern Regional Medical Center, Zion, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01300858"
682,"NCT02988245","Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension","PGEN for HTN","Completed","No Results Available","Hypertension","Drug: Geneticure Panel for HTN therapy|Drug: JNC-8","Time to Blood Pressure Control|Change in Blood Pressure|Number of Blood Pressure Medicines|Number of Medication Changes","Geneticure, LLC|Fairview Health Services|University of Minnesota","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 2","425","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Geneticure","January 23, 2017","March 31, 2019","March 31, 2019","December 9, 2016",,"April 2, 2019","Fairview Health Clinics - Andover, Andover, Minnesota, United States|Fairview Health Clinics - Blaine, Blaine, Minnesota, United States|Fairview Health Clinics - Bloomington, Oxboro, Bloomington, Minnesota, United States|Fairview Clinics - Brooklyn Park, Brooklyn Park, Minnesota, United States|Fairview Clinics- Burnsville, Burnsville, Minnesota, United States|Fairview Clinics - Columbia Heights, Columbia Heights, Minnesota, United States|Fairview Health Clinics - Edina, Edina, Minnesota, United States|Fairview Health Clinics - Elk River, Elk River, Minnesota, United States|Fairview Clinics - Fridley, Fridley, Minnesota, United States|Fairview Clinics - Lino Lakes, Lino Lakes, Minnesota, United States|Fairview Clinics - Hiawatha, Minneapolis, Minnesota, United States|Fairview Clinics - North Branch, N. Branch, Minnesota, United States|Fairview Clinic - New Brighton, New Brighton, Minnesota, United States|Fairview Clinics - Wyoming, Wyoming, Minnesota, United States|Fairview Health Services - Zimmerman, Zimmerman, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02988245"
683,"NCT02659397","A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg",,"Completed","No Results Available","Hyperlipidemia","Drug: ETC-1002|Drug: Atorvastatin|Drug: Placebo","Peak plasma concentration (Cmax) pharmacokinetics of atorvastatin and its active metabolites|24-hour area under the curve (AUC) pharmacokinetics of atorvastatin and its active metabolites|Percent change in LDL-cholesterol|Percent change in hsCRP|Percent change in total cholesterol|Percent change in non-HDL-cholesterol|Percent change in apolipoprotein B|24-hour post dose plasma concentration pharmacokinetics of ETC-1002 and its active metabolite","Esperion Therapeutics","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1002-035","December 2015","July 2016","July 2016","January 20, 2016",,"March 29, 2019","Anaheim, California, United States|Los Angeles, California, United States|Northridge, California, United States|Clearwater, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Port Orange, Florida, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Springfield, Illinois, United States|Louisville, Kentucky, United States|Berlin, New Jersey, United States|Rapid City, South Dakota, United States|Carrollton, Texas, United States|West Jordan, Utah, United States|Arlington, Virginia, United States|Lynchburg, Virginia, United States|Richmond, Virginia, United States|Renton, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02659397"
684,"NCT03496207","A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)","PULSAR","Active, not recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Placebo|Drug: Sotatercept","Change from baseline in Pulmonary Vascular Resistance (PVR) as measured by right heart catheterization|Change from baseline in 6-Minute Walk Distance (6MWD)|Change from baseline in amino-terminal brain natriuretic propeptide (NT-proBNP)|Change from baseline in tricuspid annular plane systolic excursion (TAPSE) by echocardiography (ECHO)|Change from baseline in Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) patient-reported outcome (PRO) score|Change from baseline in 36-Item Short Form Health Survey (SF-36) patient-reported outcome (PRO) score","Acceleron Pharma, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A011-09|2017-004738-27","June 27, 2018","March 2020","November 2021","April 12, 2018",,"August 28, 2019","Pulmonary Associates, PA, Phoenix, Arizona, United States|Arizona Pulmonary Specialists, Phoenix, Arizona, United States|Banner-University Medical Center Phoenix, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|University of California, San Francisco Medical Center, San Francisco, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|UF Health Shands Hospital, Gainesville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Michigan, Ann Arbor, Michigan, United States|Center for Outpatient Health, Saint Louis, Missouri, United States|Lindner Clinical Trial Center, Cincinnati, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Houston Methodist Hospital, Houston, Texas, United States|St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|John Hunter Hospital, New Lambton, New South Whales, Australia|Prince Charles Hospital, Chermside, Queensland, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Hospital Madre Teresa, Belo Horizonte, Minas Gerais, Brazil|Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Riogrande Do Sul, Brazil|Hospital Dia do Pulmão, Blumenau, Santa Catarina, Brazil|Hospital São Paulo, Sao Paulo, Brazil|Hôpital Arnaud de Villeneuve, Montpellier, Hérault, France|Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-Bicêtre, France|Centre Hospitalier Universitaire de Saint Etienne, Saint-Étienne, France|Klinikum der Universität Regensburg, Regensburg, Bayern,, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universitatsklinikum Halle (Saale), Halle, Sachsen-Anhalt, Germany|Otto-von-Guericke-Universität Magdeburg, Magdeburg, Sachsen-Anhalt, Germany|Universitatsklinikum Leipzig, Leipzig, Sachsen, Germany|DRK Kliniken Berlin Westend, Berlin, Germany|Barzilai Medical Center, Ashkelon, Israel|Lady Davis Carmel Medical Center, Haifa, Israel|Rabin Medical Center - PPDS, Petach-Tikva, Israel|ZIV Medical Center, Safed, Israel|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain|Hospital Complejo Hospitalario Universitario de Pontevedra, Santander, Pontevedra, Spain|Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital de Montecel, Pontevedra, Spain|Royal Free London NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03496207"
685,"NCT01179737","Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)",,"Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: Nilotinib|Drug: Placebo to nilotinib","Change in Pulmonary Vascular Resistance (PVR)|Change in Six-Minute Walk Distance (6MWD) From Baseline|Total Number of Adverse Events and Serious Adverse Events","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CAMN107X2201|2010-019883-36","July 2010","January 2013","January 2013","August 11, 2010","February 27, 2014","May 1, 2014","Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT01179737"
686,"NCT02234141","Selonsertib in Adults With Pulmonary Arterial Hypertension","ARROW","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Placebo|Drug: Selonsertib","Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24, as Measured by Right Heart Catheterization (RHC)|Change From Baseline at Week 24 in Other Cardiopulmonary Hemodynamic Measures: Cardiac Index|Change From Baseline at Week 24 in Other Cardiopulmonary Hemodynamic Measures: mPAP|Change From Baseline at Week 24 in Other Cardiopulmonary Hemodynamic Measures: mRAP|Change From Baseline at Week 24 in Other Cardiopulmonary Hemodynamic Measures: Mixed Venous Oxygen Saturation (SVO2) (%)|Change From Baseline at Week 24 in Other Cardiopulmonary Hemodynamic Measures: Right Ventricular Cardiac Power (RVCP)|Change From Baseline at Week 24 in 6MWD Test|Change From Baseline at Week 24 in BDI After the 6MWD Test|Number of Participants Experiencing Change From Baseline at Week 24 in WHO Functional Class|Change From Baseline at Week 24 in NT-proBNP|Change From Baseline at Week 24 in Short Form (SF-36) Physical Functioning Scale|Change From Baseline at Week 24 in emPHasis-10 Questionnaire Score|Change From Baseline at Week 24 in Heart Rate Recovery (HRR) After the 6MWD Test|Kaplan-Meier Estimate of Time to Clinical Worsening (TTCW) Evaluated in Period 1|Change From Baseline in Echocardiographic Measures of Right Ventricular Function at Week 24: TAPSE|Change From Baseline in Echocardiographic Measures of Right Ventricular Function at Week 24: Right Ventricular Myocardial Strain (%)|Change From Baseline in Echocardiographic Measures of Right Ventricular Function at Week 24: Tricuspid Annular Peak Sys Myocard Velocity (TAS)|Change From Baseline in Echocardiographic Measures of Right Ventricular Function at Week 24: Right Ventricular Tei Index (RVTI)|Change From Baseline in Echocardiographic Measures of Right Ventricular Function at Week 24: Right Ventricular Fractional Area Change (RVFAC)","Gilead Sciences","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GS-US-357-1394|2014-002131-34","November 2014","April 2016","December 2016","September 9, 2014","April 10, 2019","April 10, 2019","University of South Alabama Medical Center, Mobile, Alabama, United States|Advanced Lung Disease Institute, Phoenix, Arizona, United States|Arizona Pulmonary Specialist, Ltd, Phoenix, Arizona, United States|University of Arizona Clinical and Translational Science (CATS) Research Center, Tucson, Arizona, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|University of California, Davis, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|LA Biomedical Research Institute Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Cardiac and Vascular Center, Anschutz Inpatient Pavillion, Aurora, Colorado, United States|The Emory Clinic, Atlanta, Georgia, United States|University of Chicago Medicine, Chicago, Illinois, United States|Boston University Medical Center, Boston, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mary M. Parkes Center // University of Rochester Medical Center, Rochester, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Martha Morehouse Medical Pavilion, Columbus, Ohio, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|Peter Lougheed Center, Calgary, Alberta, Canada|Vancouver General Hospital, The Lung Centre // Vancouver Coastal Health, Vancouver General Hospital, Vancouver, British Columbia, Canada|Victoria Hospital - London Health Sciences Centre, London, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Institut Universitaire de caridologie et de pneumologie de Quebee (IUCPQ), Sainte Foy, Quebec, Canada|CHU de Grenoble Clinique Universitaire de Pneumologie, Grenoble Cedex 9, France|CHU de Bicetre, Service de Pneumologie-Reanimation Respiratoire, Le Kremlin Bicetre Cedex, France|Hopital Cardiologique-CHRU Lille, Service de cardiologie, Lille Cedex, France|Universitatsklinikul Giessen und Marburg GmbH, Giessen, Hessen, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Klinik III fur Innere Medizin, Herzzentrum Uniklinik Koln, Koln, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Klinik und Poliklinik fur Innere Medizin II, Universitatsklinikum Regensburg, Regensburg, Germany|Universita ""Sapienza""-Azienda Policlinico Umberto 1, Rome, Italy|VU University Medical Center, Amsterdam, Netherlands|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Doce (12) de Octubre, Madrid, Spain|Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Clydebank, West Dunbartonshire, United Kingdom|Royal Free Hampstead NHS Trust, London, United Kingdom|Clinical Research Facility, Royal Hallamshrie Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02234141"
687,"NCT02444767","Bimatoprost Ocular Insert Pharmacokinetic Study",,"Completed","No Results Available","Healthy Volunteers","Drug: 13mg Bimatoprost Ocular Insert","Whole blood concentrations of bimatoprost and bimatoprost acid","ForSight Vision5, Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","FSV5-006","March 2015","April 2015","April 2015","May 14, 2015",,"May 14, 2015","Sall Medical Research Center, Artesia, California, United States",,"https://ClinicalTrials.gov/show/NCT02444767"
688,"NCT01266876","Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo","Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12 - On-treatment Analysis|Percentage of Participants Achieving LDL-C < 70 mg/dL (1.81 mmol/L) at Week 12 - On-treatment Analysis|Percent Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 - On-treatment Analysis|Absolute Change From Baseline in HDL-C at Week 12 - On-treatment Analysis|Percent Change From Baseline in Triglycerides at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Triglycerides at Week at 12 - On-treatment Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis|Percent Change From Baseline in Apo Lipoprotein B (Apo-B) at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Apo-B at Week 12 - On-treatment Analysis|Percent Change From Baseline in Apolipoprotein - A1 (Apo-A1) at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Apo-A1 at Week 12 - On-treatment Analysis|Absolute Change in the Ratio ApoB/ApoA-1 From Baseline to Week 12 - On-treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1003","January 2011","November 2011","November 2011","December 24, 2010","September 22, 2015","September 22, 2015","Huntsville, Alabama, United States|Mission Viejo, California, United States|Newport Beach, California, United States|Bridgeport, Connecticut, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Port Orange, Florida, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Biddeford, Maine, United States|St. Louis, Missouri, United States|Concord, New Hampshire, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Winnipeg, Manitoba, Canada|London, Ontario, Canada|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|St. Foy, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01266876"
689,"NCT02279160","Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: APD811|Drug: Placebo","Change from baseline in pulmonary vascular resistance (PVR)|Change from baseline in 6-min walk distance (6MWD) in patients with PAH","Arena Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APD811-003","December 2014","June 2017","June 2017","October 30, 2014",,"December 11, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCLA Medical Center, Torrance, California, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Maryland, Baltimore, Maryland, United States|Boston University Medical Center, Boston, Massachusetts, United States|University of Cincinnati, Cincinnati, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|University of Pittsburg Medical Center, Pittsburgh, Pennsylvania, United States|UT Southwestern, Dallas, Texas, United States|University of Texas, Houston Center for Clinical and Translational Sciences, Houston, Texas, United States|The Prince Charles Hospital, Chermside, Australia|St Vincent's Hospital, Darlinghurst NSW, Australia|St Vincent's Hospital, Fitzroy, Australia|Royal Hobart Hospital, Hobart, Australia|Fiona Stanley Hospital, Murdoch, Australia|""Многопрофилната болница за активно лечение ""Национална кардиологична болница """" ЕАД, Sofia, Bulgaria|Многопрофилна болница за активно лечение ""Света Анна"" София АД, Клиника по кардиология, Sofia, Bulgaria|II. interní klinika - klinika kardiologie a angiologie, 1. lékařská fakulta, Univerzita Karlova v Praze a Všeobecná fakultní nemocnice v Praze, Prague, Czechia|Gottsegen György Országos Kardiologiai Intézet, Felnőtt Kardiológia, Budapest, Hungary|Semmelweis Egyetem Pulmonológiai Klinika, Budapest, Hungary|Pécsi Tudományegyetem Klinikai Központ, Szívgyógyászati Klinika, Pecs, Hungary|Uniwersytecki Szpital Kliniczny w Białymstoku, Bialystok, Poland|Krakowski Szpital Specjalistyczny im. Jana Pawła II w Krakowie, Krakow, Poland|Wojewódzki Szpital Specjalistyczny im. W. Biegańskiego w Łodzi, Lodz, Poland|Institutul de Urgență pentru Boli Cardiovasculare, Secția Clinică Cardiologie III, Bucharest, Romania|Institutul de Pneumoftiziologie ""Marius Nasta"", Secția Clinică Pneumoftiziologie IV, Bucharest, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie, Sectia Clinica Pneumologie II, Timisoara, Romania|Klinički Centar Srbije (KCS), Klinika za kardiologiju, Belgrade, Serbia|Kliničko-bolnički centar (KBC) Zemun,Klinika za internu medicinu,Sluzba kardiologije, Belgrade, Serbia|Institut za plućne bolesti Vojvodine Sremska Kamenica (IPBVSK),, Sremska Kamenica, Serbia|Hospital Universitari General Vall d'Hebron, Servicio de Neumología, Barcelona, Spain|Hospital Clinic de Barcelona, Departamento de Pneumologia, Barcelona, Spain|Hospital 12 de Octubre, Departamento de Cardiologia, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02279160"
690,"NCT02371746","Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma",,"Completed","Has Results","Glaucoma and Ocular Hypertension","Drug: ENV515-3 Travoprost XR|Drug: ENV515-1 Travoprost XR|Drug: ENV515-3-2 Travoprost XR","Summary of Change From Baseline Average Intraocular Pressure Diurnal Measurement by Treatment Group Population (Cohort 1)","Envisia Therapeutics","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENV515-01","January 1, 2015","February 13, 2019","February 13, 2019","February 26, 2015","October 17, 2019","October 17, 2019","Chandler, Arizona, United States|Garden Grove, California, United States|Inglewood, California, United States|Redding, California, United States|Morrow, Georgia, United States|Indianapolis, Indiana, United States|Chesterfield, Missouri, United States|Kansas City, Missouri, United States|Cincinnati, Ohio, United States|Portland, Oregon, United States|Sioux Falls, South Dakota, United States|Austin, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02371746/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02371746/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02371746"
691,"NCT01481077","A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma",,"Completed","No Results Available","Glaucoma|Ocular Hypertension (OH)","Drug: Latanoprost-PPDS","IOP change from baseline","Mati Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPL GLAU 13","November 2011","September 2012","September 2012","November 29, 2011",,"September 26, 2013","Vold Vision, Springdale, Arkansas, United States|Glaucoma Consultants of Colorado, PC, Denver, Colorado, United States|Danbury Eye Physicians & Surgeons, Danbury, Connecticut, United States|Ophthalmology Consultants Inc., Des Peres, Missouri, United States|Ophthalmology Associates, St. Louis, Missouri, United States|Comprehensive Eye Care, Ltd, Washington, Missouri, United States|Las Vegas Physicians Research Group, Henderson, Nevada, United States|Abrams Eye Institute, Las Vegas, Nevada, United States|Philadelphia Eye Associates, Philadelphia, Pennsylvania, United States|University Eye Surgeons, Maryville, Tennessee, United States|Total Eye Care, P.A., Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01481077"
692,"NCT01288443","Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Atorvastatin","Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and <70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol, High-density Lipoprotein Cholesterol (HDL-C), Non-HDL-C and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Fasting Triglycerides and Lipoprotein(a) at Week 12 - On-Treatment Analysis|Absolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 12 - On-Treatment Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","183","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DFI11565|U1111-1116-5252","January 2011","December 2011","December 2011","February 2, 2011","September 24, 2015","September 24, 2015","Investigational Site Number 840525, Tempe, Arizona, United States|Investigational Site Number 840516, Los Angeles, California, United States|Investigational Site Number 840528, Mission Viejo, California, United States|Investigational Site Number 840509, Newport Beach, California, United States|Investigational Site Number 840523, Palm Springs, California, United States|Investigational Site Number 840534, Westlake Village, California, United States|Investigational Site Number 840530, Colorado Springs, Colorado, United States|Investigational Site Number 840504, Aventura, Florida, United States|Investigational Site Number 840519, Aventura, Florida, United States|Investigational Site Number 840514, Jacksonville, Florida, United States|Investigational Site Number 840539, Jupiter, Florida, United States|Investigational Site Number 840502, Miami, Florida, United States|Investigational Site Number 840520, Pembroke Pines, Florida, United States|Investigational Site Number 840524, Ponte Vedra, Florida, United States|Investigational Site Number 840536, Port Orange, Florida, United States|Investigational Site Number 840507, St. Petersburg, Florida, United States|Investigational Site Number 840527, Chicago, Illinois, United States|Investigational Site Number 840506, Evansville, Indiana, United States|Investigational Site Number 840529, Indianapolis, Indiana, United States|Investigational Site Number 840515, Wichita, Kansas, United States|Investigational Site Number 840532, Madisonville, Kentucky, United States|Investigational Site Number 840535, Auburn, Maine, United States|Investigational Site Number 840503, Brockton, Massachusetts, United States|Investigational Site Number 840512, Las Vegas, Nevada, United States|Investigational Site Number 840505, Edison, New Jersey, United States|Investigational Site Number 840538, Rochester, New York, United States|Investigational Site Number 840508, Raleigh, North Carolina, United States|Investigational Site Number 840522, Statesville, North Carolina, United States|Investigational Site Number 840511, Cincinnati, Ohio, United States|Investigational Site Number 840526, Cincinnati, Ohio, United States|Investigational Site Number 840510, Lyndhurst, Ohio, United States|Investigational Site Number 840533, Tulsa, Oklahoma, United States|Investigational Site Number 840537, Eugene, Oregon, United States|Investigational Site Number 840521, Bristol, Tennessee, United States|Investigational Site Number 840531, Bountiful, Utah, United States|Investigational Site Number 840517, Norfolk, Virginia, United States|Investigational Site Number 840518, Richmond, Virginia, United States|Investigational Site Number 840513, Olympia, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01288443"
693,"NCT00846989","Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: RKI983A|Drug: Latanoprost","Mean reduction of the daily average intraocular pressure (IOP) .|Mean IOP reduction at each assessment time-point|Mean reduction of the daily average IOP|Frequency of adverse events","Novartis Pharmaceuticals|Novartis","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","276","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","CRKI983A2201","January 2009","April 2009","April 2009","February 19, 2009",,"February 13, 2013","Novartis Investigative Site, Artesia, California, United States|Novartis Investigative Site, Inglewood, California, United States|Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, Poway, California, United States|Novartis Investigative Site, Stockton, California, United States|Novartis Investigative Site, Danbury, Connecticut, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Morrow, Georgia, United States|Novartis Investigative Site, Roswell, Georgia, United States|Novartis Investigative Site, Kaneohe, Hawaii, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Bossier City, Louisiana, United States|Novartis Investigative Site, Cambridge, Massachusetts, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Bethpage, New York, United States|Novartis Investigative Site, Lynbrook, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Mt. Pleasant, South Carolina, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, El Paso, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00846989"
694,"NCT03156621","Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)","ODYSSEY HoFH","Completed","No Results Available","Homozygous Familial Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo","Percent change in LDL-C from baseline to Week 12 (Intent-to-Treat (ITT) population)|Percent change in apolipoprotein (Apo) B from baseline to week 12|Percent change in non-high-density lipoprotein cholesterol (non-HDL-C) from baseline to week 12|Percent change in total cholesterol (TC) from baseline to week 12|Proportion of participants with ≥15% reduction in LDL-C at week 12|Proportion of participants with ≥30% reduction in LDL-C at week 12|Percent change in lipoprotein(a) [Lp(a)] from baseline to week 12|Proportion of participants with ≥50% reduction in LDL-C at week 12|Percent change in HDL-C from baseline to week 12|Percent change in fasting triglycerides (TG) from baseline to week 12|Percent change in Apo A-1 from baseline to week 12|Percent change in LDL-C from baseline to week 12 (Modified Intent-to-Treat (m)ITT population)|Percent change in Apo B from baseline to week 12|Percent change in non-HDL-C from baseline to week 12|Percent change in TC from baseline to week 12|Percent change in Lp(a) from baseline to week 12|Percent change in fasting TG from baseline to week 12|Proportion of patients with ≥15% reduction, ≥30% reduction, and ≥50% reduction in LDL-C at week 12|Absolute change in the ratio of Apo B/Apo A-1 from baseline to week 12|Incidence of Adverse Events (AEs)","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","69","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1628|2017-000351-95","October 3, 2017","September 27, 2019","February 13, 2020","May 17, 2017",,"May 1, 2020","Regeneron Research Site, Boca Raton, Florida, United States|Regeneron Research Site, New York, New York, United States|Regeneron Research Site, Cincinnati, Ohio, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Research Site, Innsbruck, Tirol, Austria|Regeneron Research Site, Chicoutimi, Quebec, Canada|Regeneron Research Site, Québec, Quebec, Canada|Regeneron Research Site, Praha, Czechia|Regeneron Research Site, Marseille, France|Regeneron Research Site, Paris, France|Regeneron Research Site, Berlin, Germany|Regeneron Research Site, Athens, Greece|Regeneron Research Site, Ioánnina, Greece|Regeneron Research Site, Napoli, Italy|Regeneron Research Site, Roma, Italy|Regeneron Research Site, Nishinomiya, Hyogo, Japan|Regeneron Research Site, Kanazawa, Ishikawa, Japan|Regeneron Research Site, Suita, Osaka, Japan|Regeneron Research Site, Parktown, Johannesburg, South Africa|Regeneron Research Site, Cape Town, Western Cape, South Africa|Regeneron Study Site, Taipei, Taiwan|Regeneron Research Site, Besevler, Ankara, Turkey|Regeneron Research Site, İzmir, Bornova, Turkey|Regeneron Research Site, Ivano-Frankivs'k, Ukraine|Regeneron Research Site, Kharkiv, Ukraine|Regeneron Research Site, Kharkiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT03156621"
695,"NCT03060577","An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol",,"Active, not recruiting","No Results Available","Atherosclerotic Cardiovascular Disease|Symptomatic Atherosclerosis|Type2 Diabetes|Familial Hypercholesterolemia","Drug: Inclisiran|Drug: Evolocumab","Percentage Change in LDL-C at Day 210 Compared to Day 1 of the ORION_1 Study (Inclisiran Arm)|Percentage Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in LDL-C|Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in LDL-C|Percentage Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in PCSK9 Levels|Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in PCSK9 Levels|Percentage Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in Total Cholesterol, Triglycerides, HDL-C, non-HDL-C, VLDL-C, Apo-A1, Apo-B, and Lp(a)|Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in Total Cholesterol, Triglycerides, HDL-C, non-HDL-C, VLDL-C, Apo-A1, Apo-B, and Lp(a)|Proportion of Participants in the Inclisiran Group and the Evolocumab Group Who Attain Global Lipid Modification Targets for Their Level of ASCVD Risk|Proportion of Participants in the Evolocumab Group Who Attain Global Lipid Modification Targets for Their Level of ASCVD Risk at Day 570 (210 Days After Starting Inclisiran)|Proportion of Participants in the Inclisiran Group and the Evolocumab Group with ≥50% LDL-C Reduction|Number of Participants in the Inclisiran Group and the Evolocumab Group Reaching on Treatment LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL|Time to Lipid Lowering Effect in Participants in the Inclisiran Group and the Evolocumab Group|Change from Day 1 to Day 360 in LDL-C (Beta Quantification) of Participants in the Evolocumab Group|Change from Day 30 to Day 360 in Participant-Reported Scores Using the Treatment Satisfaction Questionnaire for Medication (TSQM) Questionnaire of Participants in the Inclisiran Group and the Evolocumab Group|Change from Day 450 to Day 720 in Participant-Reported Scores Using the TSQM Questionnaire of Participants in the Inclisiran Group|Participant-Reported Adherence to Self-Injectable Evolocumab","The Medicines Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","490","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MDCO-PCS-16-01","March 24, 2017","August 29, 2018","January 2022","February 23, 2017",,"June 19, 2019","Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Midwest Institute For Clinical Research, Indianapolis, Indiana, United States|Mount Sinai Icahn School of Medicine, New York, New York, United States|Metabolic And Atherosclerosis Research Center, Cincinnati, Ohio, United States|Sterling Research Group, Cincinnati, Ohio, United States|Wellmont CVA Heart Institute, Greeneville, Tennessee, United States|Amarillo Heart Clinical Research Institute, Inc., Amarillo, Texas, United States|National Clinical Research, Inc., Richmond, Virginia, United States|St. Paul's Hospital, Vancouver, British Columbia, Canada|St. Boniface Hospital, Winnipeg, Manitoba, Canada|Eastern Regional Health Authority, Patient Research Centre, Saint John's, Newfoundland and Labrador, Canada|Brampton Research Associates, Brampton, Ontario, Canada|Lawson Health Research Institute, London, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|ECOGENE-21 Clinical Trials Center, Chicoutimi, Quebec, Canada|Institut de Recherches Cliniques de Montreal, Montreal, Quebec, Canada|Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, Quebec, Canada|Université Laval Quebec, Quebec, Canada|Clinique des maladies lipidique Quebec, Quebec, Canada|Medical University Berlin, Berlin, Germany|Medical Center Essen, Essen, Germany|University Hospital Frankfurt, Frankfurt, Germany|Medical University Hospital Heidelberg, Internal Medicine III, Heidelberg, Germany|Technical University Munich, German Heart Center, Munich, Germany|Amsterdam Medical Center, Amsterdam, Netherlands|Haga Hospital, Den Haag, Netherlands|Deventer Ziekenhuis, Deventer, Netherlands|Andromed Eindoven, Eindhoven, Netherlands|Admiraal de Ruyter Hospital, Cardiology, Goes, Netherlands|Bethesda Diabetes Research Center, Hoogeveen, Netherlands|Medisch Centrum Gorecht, Hoogezand, Netherlands|VOC Hoorn, Hoorn, Netherlands|Leids Universitair Medisch Centrum (LUMC), Leiden, Netherlands|Andromed Rotterdam, Rotterdam, Netherlands|Diakonesseshuis, Vascular Policlinic, Utrecht, Netherlands|UMC Utrecht, Utrecht, Netherlands|VieCurie Venlo, Cardiology, Venlo, Netherlands|Albert Schweitzer Hospital, Cardiology, Zwijndrecht, Netherlands|Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Edinburgh Royal Infirmary, Edinburgh, United Kingdom|The Royal Devon and Exeter NHS Trust, Exeter, United Kingdom|Fowey River Practice, Fowey, United Kingdom|Buckinghamshire NHS Trust, High Wycombe, United Kingdom|Oak Tree Surgery, Liskeard, United Kingdom|Royal Free Hospital, London, United Kingdom|Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, United Kingdom|The Alverton Practice, Penzance, United Kingdom|Knowle House Surgery, Plymouth, United Kingdom|Brannel Surgery, Saint Austell, United Kingdom|Rame Medical Ltd (Rame Research), Torpoint, United Kingdom|Worcestershire Acute NHS Trust, Worcester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03060577"
696,"NCT03497689","EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension",,"Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Intravenous/Subcutaneous Treprostinil; Oral Treprostinil","Oral treprostinil dose|Prostanoid Adverse Events (AEs)|Echocardiograms|Change in 6-minute walk distance (6MWD)|Change in Borg dyspnea score|Change in World Health Organization (WHO) functional class (FC)|Change in serum N-terminal pro-brain natriuretic peptide (NT-proBNP) levels|Impact of pulmonary hypertension on a person's life (health-related quality of life)|Treatment satisfaction","United Therapeutics","All","17 Years to 85 Years   (Child, Adult, Older Adult)","Phase 4","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-PH-402","September 21, 2018","July 2020","July 2020","April 13, 2018",,"March 6, 2020","University of California San Francisco - Fresno, Fresno, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|Florida Hospital, Orlando, Florida, United States|Piedmont Healthcare Pulmonary and Critical Care Research, Austell, Georgia, United States|St. Vincent Medical Group, Indianapolis, Indiana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University of Cincinnati Health, Cincinnati, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States|UPMC Presbytarian Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03497689"
697,"NCT02833844","Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia",,"Completed","No Results Available","Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection","Drug: Repatha (Evolocumab)|Drug: Placebo","Effect of Repatha (Evolocumab) on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in human immunodeficiency virus (HIV)-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on change from baseline in LDL-C in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent of subjects attaining LDL-C < 70 mg/dL (1.8 mmol/L) in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent of subjects attaining a 50% reduction in LDL-C from baseline in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in ApoB in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in TC in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent chang from baseline in Lp(a) in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in triglycerides in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in HDL-C in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in non-HDL-C in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in VLDL-C in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","467","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20130286|2015-004735-12","May 22, 2017","July 9, 2019","January 27, 2020","July 14, 2016",,"February 5, 2020","Research Site, Los Angeles, California, United States|Research Site, Hartford, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Miami, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Berkley, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Camden, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Bronx, New York, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Falls Church, Virginia, United States|Research Site, Darlinghurst, New South Wales, Australia|Research Site, East Sydney, New South Wales, Australia|Research Site, Sydney, New South Wales, Australia|Research Site, Fortitude Valley, Queensland, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Antwerp, Belgium|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Bordeaux, France|Research Site, Lyon cedex 04, France|Research Site, Montpellier cedex 5, France|Research Site, Nantes Cedex 1, France|Research Site, Paris Cedex 10, France|Research Site, Paris Cedex 12, France|Research Site, Paris Cedex 13, France|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Bologna, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Modena, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Warszawa, Poland|Research Site, Almada, Portugal|Research Site, Aveiro, Portugal|Research Site, Coimbra, Portugal|Research Site, Porto, Portugal|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Constanta, Romania|Research Site, Timisoara, Romania|Research Site, Pretoria, Gauteng, South Africa|Research Site, Westdene, Gauteng, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lugano, Switzerland|Research Site, Zuerich, Switzerland|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02833844"
698,"NCT03452033","H-1337 Ophthalmic Solution Phase 1/2",,"Completed","No Results Available","Glaucoma, Open-Angle","Drug: H-1337 Placebo|Drug: H-1337 [1]|Drug: H-1337 [2]|Drug: H-1337 [3]","Intraocular pressure|Adverse events","Allysta Pharmaceutical","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","87","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALY337-201","March 15, 2018","August 15, 2018","August 15, 2018","March 2, 2018",,"September 4, 2018","PRN, Goose Creek, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03452033"
699,"NCT01410188","Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Primary Open-angle Glaucoma|Ocular Hypertension","Drug: OPA-6566|Drug: Placebo|Drug: Latanoprost","Safety: incidence of treatment emergent adverse events (TEAEs), vital signs, physical exam, ocular exams, electrocardiogram, ocular symptoms, laboratory tests on whole blood, serum and urine.|Composite of Pharmacokinetics|Efficacy: measurement of change in intraocular pressure from baseline.","Acucela Inc.|Otsuka Pharmaceutical Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","OPA-6566-101","September 2011","October 2012","October 2012","August 5, 2011",,"March 11, 2014","Artesia, California, United States|Glendale, California, United States|Roswell, Georgia, United States|Louisville, Kentucky, United States|Washington, Missouri, United States|High Point, North Carolina, United States|Maryville, Tennessee, United States|Austin, Texas, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01410188"
700,"NCT01731002","Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure",,"Completed","Has Results","Ocular Hypertension|Open Angle Glaucoma","Drug: AR-13324 Ophthalmic Solution 0.01%|Drug: AR-13324 Ophthalmic Solution 0.02%|Drug: Latanoprost ophthalmic solution 0.005%","Intraocular Pressure (IOP)|Extent of Exposure","Aerie Pharmaceuticals","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","224","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AR-13324-CS202","November 2012","May 2013","May 2013","November 21, 2012","April 17, 2018","April 17, 2018","Kenneth Sall, M.D., Artesia, California, United States|United Medical Research Institute, Inglewood, California, United States|Aesthetic Eye Care Institute, Newport Beach, California, United States|North Bay Eye Associates, Petaluma, California, United States|Centre For Health Care, Poway, California, United States|Clayton Eye Center, Morrow, Georgia, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|Bradley Kwapiszeski, MD, Shawnee Mission, Kansas, United States|Taustine Eye Center, Louisville, Kentucky, United States|Alan L Robin, M.D., Baltimore, Maryland, United States|Seidenberg Protzko Eye Associates, Havre De Grace, Maryland, United States|Great Lakes Eye Care, Saint Joseph, Michigan, United States|Ophthalmic Consultants of Long Island, Lynbrook, New York, United States|Rochester Ophthalmological Group, Rochester, New York, United States|Charlotte Eye Ear Nose and Throat, Charlotte, North Carolina, United States|Michael E. Tepedino, M.D., High Point, North Carolina, United States|The Eye Institute, Tulsa, Oklahoma, United States|Wills Eye Hospital, Philadelphia, Pennsylvania, United States|Texan Eye, Austin, Texas, United States|Cataract & Glaucoma Center, El Paso, Texas, United States|Medical Center Ophth. Associates, San Antonio, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01731002"
701,"NCT02070991","Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction","MELODY-1","Completed","Has Results","Pulmonary Hypertension","Drug: Macitentan|Drug: Placebo","Number of Participants Experiencing Significant Fluid Retention or Worsening in NYHA Functional Class (FC) up to End-of-treatment|NT-proBNP at Week 12 Expressed as Percent of Baseline NT-proBNP at Rest|PVR at Rest at Week 12 Expressed as Percent of Baseline PVR at Rest|Change From Baseline to Week 12 in Mean Pulmonary Arterial Pressure (mPAP)|Change From Baseline to Week 12 in Mean Right Atrial Pressure (mRAP)|Change From Baseline to Week 12 in Pulmonary Artery Wedge Pressure (PAWP)|Change From Baseline to Week 12 in Cardiac Index (CI)|Change From Baseline to Week 12 in Diastolic Pulmonary Vascular Pressure Gradient (DPG)","Actelion","All","18 Years and older   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-055G201","July 1, 2014","November 1, 2015","November 1, 2015","February 25, 2014","May 15, 2019","May 15, 2019","Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan Internal Medicine Cardiology, Pulmonary Hypertension Program, Ann Arbor, Michigan, United States|Washington University School of Medicine - Center for Advanced Med, Saint Louis, Missouri, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|Houston Methodist Hospital - Heart Failure/Pulm Hypertension, Houston, Texas, United States|Krankenhaus der Elisabethinen Linz, 2. Interne Abteilung, Linz, Austria|Medical University of Vienna and AKH Cardiology, Vienna, Austria|Hôpital Erasme, Cliniques Universitaires de Bruxelles, Cardiologie, Brussels, Belgium|University Hospital Gasthuisberg / Interne Geneeskunde - I.G. Pneumologie, Leuven, Belgium|Vancouver General Hospital - The Lung, Vancouver, Canada|FN Brno-Bohunice, I. interní kardiologická klinika, Brno, Czechia|FN Olomouc, 1. Interní klinika - kardiologická, Olomouc, Czechia|IKEM (Institut klinické a experimentální medicíny, Institute for Clinical and Experimental Medicine), Praha, Czechia|Lékařská fakulta a Všeobecná fakultní nemocnice v Praze, II. Interní klinika kardiologie a angiologie, Praha, Czechia|Hôpital Charles Nicolle Service de Cardiologie, Rouen cedex, France|DRK Klinken Berlin Kopenick Klinik für Innere Medizin Kardiologie, Berlin, Germany|Universitätsklinik Schleswig-Holstein Campus Kiel Klinik für Innere Medizin III Kardiologie und Angiologie, Kiel, Germany|Universitätsklinikum Köln Herzzentrum / Klinik III für Innere Medizin (Kardiologie, Pneumologie, Angiologie und Intensivmedizin), Köln, Germany|Klinikum der Universität München Medizinische Klinik und Poliklinik 1 - Großhadern Schwerpunkt Pneumologie, Munich, Germany|Carmel Medical Center, Pulmonary Unit, Haifa, Israel|Institute of Pulmonology Hadassah Medical Centre : Ein Karem, Jerusalem, Israel|Kaplan Medical Centre / Pulmonary Institute and Department of Medicine, Rehovot, Israel|The Chaim Sheba Medical Center / The Institute of Pulmonology, Physiology and Exercise, Tel-Hashomer, Israel|A.O. Universitaria Policlinico S. Orsola-Malpighi - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale - Unità Operativa di Cardiologia, Bologna, Italy|Ospedali Riuniti Di Trieste, Trieste, Italy|Hospital Vall d´Hebron Servicio de Cardiologia, Barcelona, Spain|Hospital Clinic Servicio de Cardiologia, Barcelona, Spain|Hospital Reina Sofia Servicio de Cardiologia, Cordoba, Spain|Hospital Universitario 12 Octubre Servicio de Cardiología, Madrid, Spain|Universitätsklinik für Kardiologie Schweizer Herz- und Gefässzentrum Bern, Bern, Switzerland|Centre Hospitalier Universitaire Vaudois Service de Cardiologie, Lausanne, Switzerland",,"https://ClinicalTrials.gov/show/NCT02070991"
702,"NCT00926289","Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension",,"Completed","Has Results","Hypertension","Drug: Telmisartan|Drug: Hydrochlorothiazide","Change From Baseline in Mean Seated Trough Cuff Systolic Blood Pressure (SBP) to Week 7|Change From Baseline in Mean Seated Trough Cuff SBP to Week 5|Change From Baseline in Mean Seated Trough Cuff SBP to Week 3|Change From Baseline in Mean Seated Trough Cuff Diastolic Blood Pressure (DBP) to Week 7|Number of Patients With SBP Control (SBP < 140 mmHg) at Week 7|Number of Patients With SBP Control (SBP < 140 mmHg) at Week 5|Number of Patients With SBP Control (SBP < 140 mmHg) at Week 3|Number of Patients With DBP Control (DBP < 90 mmHg) at Week 7|Number of Patients With DBP Control (DBP < 90 mmHg) at Week 5|Number of Patients With DBP Control (DBP < 90 mmHg) at Week 3|Number of Patients With Blood Pressure (BP) Control at Week 7|Number of Patients With BP Control at Week 7|Number of Patients With Systolic Blood Pressure (SBP) Response at Week 7|Number of Participants With DBP Response at Week 7|BP Categories at Week 7","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 4","894","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","502.550|2008-007711-32","June 2009","April 2010",,"June 23, 2009","May 24, 2011","June 27, 2014","502.550.01008 Boehringer Ingelheim Investigational Site, Athens, Alabama, United States|502.550.01019 Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States|502.550.01015 Boehringer Ingelheim Investigational Site, Lomita, California, United States|502.550.01003 Boehringer Ingelheim Investigational Site, Colorado Springs, Colorado, United States|502.550.01014 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States|502.550.01002 Boehringer Ingelheim Investigational Site, Louisville, Kentucky, United States|502.550.01011 Boehringer Ingelheim Investigational Site, New Iberia, Louisiana, United States|502.550.01009 Boehringer Ingelheim Investigational Site, New Orleans, Louisiana, United States|502.550.01018 Boehringer Ingelheim Investigational Site, Olive Branch, Mississippi, United States|502.550.01006 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States|502.550.01016 Boehringer Ingelheim Investigational Site, Charlotte, North Carolina, United States|502.550.01007 Boehringer Ingelheim Investigational Site, Greensboro, North Carolina, United States|502.550.01005 Boehringer Ingelheim Investigational Site, Cincinnati, Ohio, United States|502.550.01001 Boehringer Ingelheim Investigational Site, Cleveland, Ohio, United States|502.550.01017 Boehringer Ingelheim Investigational Site, Houston, Texas, United States|502.550.01020 Boehringer Ingelheim Investigational Site, Houston, Texas, United States|502.550.01012 Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|502.550.01004 Boehringer Ingelheim Investigational Site, Arlington, Virginia, United States|502.550.35901 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|502.550.35902 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|502.550.35903 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|502.550.35904 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|502.550.35905 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|502.550.35908 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|502.550.35909 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|502.550.35910 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|502.550.35911 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|502.550.35906 Boehringer Ingelheim Investigational Site, Stara Zagora, Bulgaria|502.550.86004 Boehringer Ingelheim Investigational Site, Changsha, China|502.550.86003 Boehringer Ingelheim Investigational Site, Guangzhou, Guangdong Province, China|502.550.86008 Boehringer Ingelheim Investigational Site, QingDao, China|502.550.86001 Boehringer Ingelheim Investigational Site, Shanghai, China|502.550.86002 Boehringer Ingelheim Investigational Site, Shanghai, China|502.550.86009 Boehringer Ingelheim Investigational Site, Shenyang, China|502.550.86007 Boehringer Ingelheim Investigational Site, Tianjin, China|502.550.86010 Boehringer Ingelheim Investigational Site, Zhengzhou, China|502.550.3302D Boehringer Ingelheim Investigational Site, Aigrefeuille S/Maine, France|502.550.3305I Boehringer Ingelheim Investigational Site, Aix-en-Provence, France|502.550.3305G Boehringer Ingelheim Investigational Site, Aubagne, France|502.550.3301H Boehringer Ingelheim Investigational Site, Briollay, France|502.550.3301K Boehringer Ingelheim Investigational Site, Cholet, France|502.550.3302I Boehringer Ingelheim Investigational Site, Corsept, France|502.550.3302C Boehringer Ingelheim Investigational Site, Donges, France|502.550.3302B Boehringer Ingelheim Investigational Site, La Montagne, France|502.550.3306A Boehringer Ingelheim Investigational Site, Louvigné de Bais, France|502.550.3303A Boehringer Ingelheim Investigational Site, Marseille, France|502.550.3303D Boehringer Ingelheim Investigational Site, Marseille, France|502.550.3303F Boehringer Ingelheim Investigational Site, Marseille, France|502.550.3304A Boehringer Ingelheim Investigational Site, Marseille, France|502.550.3304D Boehringer Ingelheim Investigational Site, Marseille, France|502.550.3304F Boehringer Ingelheim Investigational Site, Marseille, France|502.550.3304J Boehringer Ingelheim Investigational Site, Marseille, France|502.550.3305A Boehringer Ingelheim Investigational Site, Marseille, France|502.550.3301A Boehringer Ingelheim Investigational Site, Murs Erigne, France|502.550.3301I Boehringer Ingelheim Investigational Site, Murs-Erigne, France|502.550.3302A Boehringer Ingelheim Investigational Site, Nantes, France|502.550.3302E Boehringer Ingelheim Investigational Site, Nantes, France|502.550.3301E Boehringer Ingelheim Investigational Site, Parcay-les-Pins, France|502.550.3303C Boehringer Ingelheim Investigational Site, Roquevaire, France|502.550.3301F Boehringer Ingelheim Investigational Site, Segre, France|502.550.3302G Boehringer Ingelheim Investigational Site, St Aubin les Châteaux, France|502.550.3306F Boehringer Ingelheim Investigational Site, St Jouan des Guerets, France|502.550.3307A Boehringer Ingelheim Investigational Site, Thouars, France|502.550.3301J Boehringer Ingelheim Investigational Site, Vihiers, France|502.550.99501 Boehringer Ingelheim Investigational Site, Tbilisi, Georgia|502.550.99502 Boehringer Ingelheim Investigational Site, Tbilisi, Georgia|502.550.99503 Boehringer Ingelheim Investigational Site, Tbilisi, Georgia|502.550.99504 Boehringer Ingelheim Investigational Site, Tbilisi, Georgia|502.550.99505 Boehringer Ingelheim Investigational Site, Tbilisi, Georgia|502.550.99506 Boehringer Ingelheim Investigational Site, Tbilisi, Georgia|502.550.99507 Boehringer Ingelheim Investigational Site, Tbilisi, Georgia|502.550.99508 Boehringer Ingelheim Investigational Site, Tbilisi, Georgia|502.550.82008 Boehringer Ingelheim Investigational Site, Cheonan, Korea, Republic of|502.550.82009 Boehringer Ingelheim Investigational Site, Daegu, Korea, Republic of|502.550.82001 Boehringer Ingelheim Investigational Site, Goyang, Korea, Republic of|502.550.82003 Boehringer Ingelheim Investigational Site, Gwangju, Korea, Republic of|502.550.82002 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|502.550.82005 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|502.550.82006 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|502.550.82007 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|502.550.82011 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|502.550.82012 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|502.550.82013 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|502.550.82004 Boehringer Ingelheim Investigational Site, Suwon, Korea, Republic of|502.550.82010 Boehringer Ingelheim Investigational Site, Wonju, Korea, Republic of|502.550.40002 Boehringer Ingelheim Investigational Site, Baia Mare Maramures, Romania|502.550.40003 Boehringer Ingelheim Investigational Site, Braila, Romania|502.550.40001 Boehringer Ingelheim Investigational Site, Bucharest, Romania|502.550.40010 Boehringer Ingelheim Investigational Site, Bucharest, Romania|502.550.40012 Boehringer Ingelheim Investigational Site, Bucharest, Romania|502.550.40009 Boehringer Ingelheim Investigational Site, Cluj Napoca, Romania|502.550.40011 Boehringer Ingelheim Investigational Site, Cluj Napoca, Romania|502.550.40006 Boehringer Ingelheim Investigational Site, Iasi, Romania|502.550.40004 Boehringer Ingelheim Investigational Site, Oradea, Romania|502.550.40005 Boehringer Ingelheim Investigational Site, Sibiu, Romania|502.550.40008 Boehringer Ingelheim Investigational Site, Tg. Mures, Romania|502.550.07001 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|502.550.07002 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|502.550.07003 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|502.550.07004 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|502.550.07005 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|502.550.07006 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|502.550.07007 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|502.550.07008 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|502.550.07009 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|502.550.07010 Boehringer Ingelheim Investigational Site, St.Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00926289"
703,"NCT02657356","Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST",,"Active, not recruiting","No Results Available","Connective Tissue Disease-Associated Pulmonary Arterial Hypertension","Drug: Placebo capsules|Drug: Bardoxolone methyl capsules","Change from baseline in six-minute-walk distance (6MWD)","Reata Pharmaceuticals, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","202","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RTA 402-C-1504","October 4, 2016","May 2020","June 2020","January 15, 2016",,"December 4, 2019","Banner University Medical Center, Phoenix Advanced Lung Disease Institute, Phoenix, Arizona, United States|Arizona Pulmonary Specialists, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Beverly Hills, California, United States|Regents of The University of California, Fresno, California, United States|University of California San Diego, La Jolla, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Pacific Pulmonary Research, Inc., San Diego, California, United States|Santa Barbara Pulmonary Associates, Santa Barbara, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|Georgetown University Medical Center - Department of Rheumatology, Washington, District of Columbia, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Augusta University, Augusta, Georgia, United States|Piedmont-Georgia Lung, Austell, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University of New Mexico, Albuquerque, New Mexico, United States|NYU Langone Health, New York, New York, United States|University of Rochester - University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Wexner Medical Center at The Ohio State University, Columbus, Ohio, United States|Integris Nazih Zuhdi Transplant Institute, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Fundación Favaloro, Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina|Hospital Británico de Buenos Aires, Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina|Centro Médico Dra de Salvo, Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina|Instituto de Investigaciones Clínicas Mar Del Plata, Buenos Aires, Mar Del Plata, Argentina|Instituto De Enfermedades Respiratorias E Investigacion Medica, Buenos Aires, Villa Vatteone, Argentina|Hospital Cordoba, Cordoba, Argentina|Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina|Instituto de Cardiologia de Corrientes Juana Francisca Cabral, Corrientes, Argentina|Hospital de Alta Complejidad ""Pte. J. D. Perón"", Formosa, Argentina|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|John Hunter Hospital, New Lambton, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|UZ Leuven, Leuven, Vlaams Brabant, Belgium|Hôpital Erasme, Brussels, Belgium|Hospital de Messejana, Fortaleza, Ceara, Brazil|Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Dia do Pulmão, Blumenau, Santa Catarina, Brazil|Hospital São Paulo, Sao Paulo, Brazil|Instituto do Coração - HCFMUSP, São Paulo, Brazil|Peter Lougheed Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|London Health Sciences Centre, London, Ontario, Canada|Centre Hospitalier de l'Université Laval, Sainte Foy, Quebec, Canada|Vseobecna fakultni nemocnice v Praze, Prague, Czechia|Institut klinicke a experimentalni mediciny, Prague, Czechia|Universitätsklinikum Freiburg, Freiburg im Breisgau, Baden-Württemberg, Germany|Universitatsklinkum Erlangen, Erlangen, Bayern, Germany|Universität Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany|DRK Kliniken Berlin Westend, Berlin, Germany|Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany|Thorax Klinik, Heidelberg, Germany|Universitätsklinikum Köln, Köln, Germany|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Nippon Medical School Hospital, Tokyo, Bunkyo-ku, Japan|Kitasato University Hospital, Sagamihara, Kanagawa, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|National Hospital Organization Okayama Medical Center, Okayama-shi, Okayama, Japan|Chiba University Hospital, Chiba, Japan|Gunma University School of Medicine, Gunma, Japan|Kobe University Hospital, Kobe, Japan|Nagoya Medical Center, Nagoya, Japan|Hokkaido University Hospital, Sapporo, Japan|Kurume University Medical Center, Sendai-shi, Japan|National Cerebral and Cardiovascular Center, Suita, Japan|Fujita Health University Hospital, Toyoake, Japan|Instituto Nacional de Cardiologia Dr. Ignacio Chavez, Ciudad de Mexico, Distrito Federal, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico|Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio González, Monterrey, Nuevo Leon, Mexico|Unidad de Investigación Clínica En Medicina SC, Monterrey, Nuevo Leon, Mexico|Vrije Universiteit Amsterdam, Amsterdam, Noord-Holland, Netherlands|Angeles University Foundation Medical Center (AUFMC), Angeles City, Philippines|Mary Mediatrix Medical Center (MMMC), Lipa, Philippines|Makati Medical Center (MMC), Makati, Philippines|Philippine General Hospital (PGH), Manila, Philippines|Philippine Heart Center (PHC), Quezon City, Philippines|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Hospital Virgen de La Salud, Toledo, Spain|Golden Jubilee National Hospital, Glasgow, United Kingdom|Royal Free Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02657356"
704,"NCT01263223","A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: Placebo","Maximum and Mean Change From Baseline in Ambulatory Heart Rate on Day 1|Maximum and Mean Change From Baseline in Ambulatory Heart Rate on Day 4|Maximum and Mean Change From Baseline in Ambulatory Systolic and Diastolic Blood Pressure During Treatment With 18-mg LY2216684 or Placebo on Day 1|Maximum and Mean Change From Baseline in Ambulatory Systolic and Diastolic Blood Pressure During Treatment With 18-mg LY2216684 or Placebo on Day 4|Maximum and Mean Change From Baseline in ABPM Heart Rate During Treatment With 36-mg LY2216684 or Placebo on Day 4|Maximum and Mean Change From Baseline in ABPM Systolic and Diastolic Blood Pressure During Treatment With 36-mg LY2216684 or Placebo on Day 4|Maximum and Mean Change From Baseline in ABPM Heart Rate During Treatment With 18-mg LY2216684 or 36-mg LY2216684 on Day 4|Maximum and Mean Change From Baseline in ABPM Systolic and Diastolic Blood Pressure During Treatment With 18-mg LY2216684 or 36-mg LY2216684 on Day 4","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12607|H9P-EW-LNCP","December 2010","March 2011","March 2011","December 20, 2010","October 23, 2018","October 23, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01263223"
705,"NCT01137474","A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker",,"Completed","Has Results","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Placebo-matching dapagliflozin","Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (BP) at Week 12|Adjusted Mean Change From Baseline in Hemoglobin (HbA1c) at Week 12|Adjusted Mean Change From Baseline in 24-Hour Ambulatory Systolic Blood Pressure at Week 12 (Last Observation Carried Forward)|Adjusted Mean Change From Baseline in Seated Diastolic Blood Pressure at Week 12|Adjusted Mean Change in 24-Hour Ambulatory Diastolic Blood Pressure at Week 12 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Serum Uric Acid Levels at Week 12","AstraZeneca|Bristol-Myers Squibb","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 3","2996","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MB102-073 ST|2010-019797-32","July 2010","February 2013","February 2013","June 4, 2010","May 1, 2014","January 26, 2017","University Of Alabama At Birmingham, Birmingham, Alabama, United States|Horizon Research Group, Inc., Mobile, Alabama, United States|Iicr, Inc. (International Institute Of Clinical Research), Ozark, Alabama, United States|Hope Research Institute, Phoenix, Arizona, United States|43rd Medical Associates, Phoenix, Arizona, United States|Central Phoenix Medical Clinic, Llc, Tempe, Arizona, United States|Clinical Research Advantage/Desert Clinical Research, Tempe, Arizona, United States|Visions Clinical Research - Tucson, Tucson, Arizona, United States|Eclipse Clinical Research, Tucson, Arizona, United States|Aureus Research, Inc., Little Rock, Arkansas, United States|Preferred Research Partners, Inc., Little Rock, Arkansas, United States|Orange County Research Institute, Anaheim, California, United States|Cmp Research, Anaheim, California, United States|Med Center, Carmichael, California, United States|Catalina Research Institute, Llc, Chino, California, United States|Southland Clinical Research Center, Inc., Fountain Valley, California, United States|Marin Endocrine Care & Research, Inc., Greenbrae, California, United States|Del Rosario Medical Clinic, Inc., Huntington Park, California, United States|Time Clinical Research Inc., Huntington Park, California, United States|Marina Raikhel, M.D., F.A.A.F.P, Lomita, California, United States|Clinica Medica San Miguel, Los Angeles, California, United States|American Institute Of Research, Los Angeles, California, United States|Randall G. Shue, D.O., Los Angeles, California, United States|National Research Inst, Los Angeles, California, United States|Quest Diagnostics West Hills, Los Angeles, California, United States|Diabetes Medical Center Of California, Northridge, California, United States|Valley Clinical Trials, Northridge, California, United States|Lucita M. Cruz,Md.,Inc., Norwalk, California, United States|Sds Clinical Trials, Orange, California, United States|Integrated Research Group, Inc., Riverside, California, United States|Quality Control Research, Inc, Sacramento, California, United States|Crest Clinical Trials, Inc., Santa Ana, California, United States|Orrin M. Troum, Md And Medical Associates, Santa Monica, California, United States|Orange County Research Center, Tustin, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Infosphere Clinical Research, Inc., West Hills, California, United States|Aurora Family Medicine, P.C., Aurora, Colorado, United States|Horizons Clinical Research Center, Llc, Denver, Colorado, United States|Chase Medical Research, Llc, Waterbury, Connecticut, United States|Zasa Clinical Research, Boynton Beach, Florida, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Family Care Associates Of Nw Fl, Chipley, Florida, United States|Innovative Research Of West Florida, Inc, Clearwater, Florida, United States|Clinical Research Of South Florida, Coral Gables, Florida, United States|Avail Clinical Research, Llc, Deland, Florida, United States|In Vivo Clinical Research, Doral, Florida, United States|Palm Springs Research Institute, Hialeah, Florida, United States|The Community Research Of South Florida, Hialeah, Florida, United States|Newphase Clinical Trials, Inc., Miami Beach, Florida, United States|Ocean Blue Medical Research Center, Inc., Miami Springs, Florida, United States|San Marcus Research Clinic, Inc., Miami, Florida, United States|Flcri Global Research, Llc, Miami, Florida, United States|International Research Associates, Llc, Miami, Florida, United States|Clinical Research Of Miami, Inc., Miami, Florida, United States|Apf Research, Llc, Miami, Florida, United States|Community Research Foundation, Inc., Miami, Florida, United States|Medical Research Marseilles, Miami, Florida, United States|Baptist Diabetes Associates, Pa, Miami, Florida, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, United States|Compass Research, Llc, Orlando, Florida, United States|Florida Institute For Clinical Research, Llc, Orlando, Florida, United States|South Miami Clinical Research, Llc, South Miami, Florida, United States|Meridien Research, St Petersburg, Florida, United States|Meridien Research, Tampa, Florida, United States|Perimeter Institute For Clinical Research, Atlanta, Georgia, United States|Bainbridge Medical Associates, Bainbridge, Georgia, United States|River Birch Research Alliance, Llc, Blue Ridge, Georgia, United States|In-Quest Medical Research, Llc, Duluth, Georgia, United States|Middle Georgia Clinical Research Center, Llc, Perry, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|James R. Herron, Md, Ltd, Chicago, Illinois, United States|So. Illinois Clin Res Ctr @ Div Of Kevin L Pritchett Md, Pc, O?Fallon, Illinois, United States|Springfield Diabetes And Endocrine Center, Springfield, Illinois, United States|American Health Network Of Indiana Llc, Avon, Indiana, United States|Investigators Research Group, Llc, Brownsburg, Indiana, United States|American Health Network Of In Llc, Franklin, Indiana, United States|Laporte County Institute For Clinical Research, Inc., Michigan City, Indiana, United States|American Health Network Of In Llc, Muncie, Indiana, United States|Medical Development Centers, Llc, Baton Rouge, Louisiana, United States|Crescent City Clinical Research Center, Metairie, Louisiana, United States|Acadia Clinical Research, Llc, Bangor, Maine, United States|Alternative Primary Care, Silver Spring, Maryland, United States|Neurocare, Inc., Brookline, Massachusetts, United States|Genesis Clinical Research, Llc, Fall River, Massachusetts, United States|Hci-Metromedic Walk-In Medical Office, New Bedford, Massachusetts, United States|Atlantic Clinical Trials, Llc, Watertown, Massachusetts, United States|Providence Park Clinical Research, Novi, Michigan, United States|The Center For Clinical Trials, Biloxi, Mississippi, United States|Phillips Medical Services, Pllc, Jackson, Mississippi, United States|Jackson Clinic, Rolling Fork, Mississippi, United States|Jefferson City Medical Group, Jefferson City, Missouri, United States|St. Louis Center For Clinical Research, St. Louis, Missouri, United States|Kcumb Dybedal Clinical Research Center, Kansas City, Montana, United States|Clin Research Advantage, Inc. James Meli, Do Family Pracice, Henderson, Nevada, United States|Office Of Ted Thorp, Md, Las Vegas, Nevada, United States|Independent Clinical Researchers@ Wolfson Medical Center, Las Vegas, Nevada, United States|Clinical Research Advantage, Inc., Las Vegas, Nevada, United States|Palm Medical Research Center, Las Vegas, Nevada, United States|Joslin Diabetes Center Affiliate Of Snhmc, Nashua, New Hampshire, United States|Central Jersey Medical Research Center, Elizabeth, New Jersey, United States|Premier Research, Trenton, New Jersey, United States|Medex Healthcare Research, Inc., New York, New York, United States|Digiovanna Institute For Medical Education & Research, North Massapequa, New York, United States|Southgate Medical Group, West Seneca, New York, United States|Barat Research Group, Inc., Charlotte, North Carolina, United States|Pharmquest, Greensboro, North Carolina, United States|Burke Primary Care, Morganton, North Carolina, United States|Pmg Research Of Wilmington Llc, Wilmington, North Carolina, United States|Lillestol Research, Fargo, North Dakota, United States|Community Health Care, Inc., Canal Fulton, Ohio, United States|Community Research, Cincinnati, Ohio, United States|Cleveland Sleep Research Center, Middleburg Heights, Ohio, United States|Clinical Research Source, Inc, Perrysburg, Ohio, United States|Integris Family Care Central, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Integris Family Care Yukon, Yukon, Oklahoma, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Fanno Creek Clinic, Portland, Oregon, United States|Southeastern Pa Medical Institute, Broomall, Pennsylvania, United States|Abington Memorial Hos/Feasterville Family Health Care Center, Feasterville Trevose, Pennsylvania, United States|The Clinical Trial Center, Llc, Jenkintown, Pennsylvania, United States|Arcuri Clinical Research Llc, Philadelphia, Pennsylvania, United States|Philadelphia Health Associates - Adult Medicine, Philadelphia, Pennsylvania, United States|Banksville Medical Pc, Pittsburgh, Pennsylvania, United States|Research Across America, Reading, Pennsylvania, United States|Pish Medical Associates, Uniontown, Pennsylvania, United States|Greater Providence Clinical Research, Llc, Warwick, Rhode Island, United States|Southeastern Research Associates, Inc., Anderson, South Carolina, United States|Southeastern Research Associates, Inc., Greenville, South Carolina, United States|Hillcrest Clinical Reseach, Llc, Simpsonville, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Chattanooga Research & Medicine, Pllc, Chattanooga, Tennessee, United States|Complete Family Care Of Knoxville, Pllc, Knoxville, Tennessee, United States|Premier Internal Medicine, Memphis, Tennessee, United States|Arlington Family Research Center, Inc., Arlington, Texas, United States|Krk Medical Research, Dallas, Texas, United States|Research Institute Of Dallas, Dallas, Texas, United States|Internal Medicine Clinical Research, Dallas, Texas, United States|Renaissance Clinical Research And Hypertension Pllc, Dallas, Texas, United States|Sergio F. Rovner, M.D., El Paso, Texas, United States|Mercury Clinical Research, Houston, Texas, United States|Southwest Clinical Trials, Houston, Texas, United States|Excel Clinical Research, Llc, Houston, Texas, United States|Lone Star Clinical Research, Houston, Texas, United States|Hill Country Medical Associates, New Braunfels, Texas, United States|North Hills Medical Research, Inc., North Richland Hills, Texas, United States|Med-Olam Clinical Research, Pasadena, Texas, United States|Lisa E. Medwedeff, Md, Pa, Plano, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Abbott Clinical Research Group, Inc., San Antonio, Texas, United States|Covenant Clinical Research, Pa, San Antonio, Texas, United States|Breco Research, Ltd, Sugarland, Texas, United States|Pioneer Research Solutions, Inc., Sugarland, Texas, United States|Exodus Healthcare Network, Magna, Utah, United States|Wasatch Endocrinology And Diabetes Specialists, Salt Lake City, Utah, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|Millennium Clinical Trials Llc, Arlington, Virginia, United States|Burke Internal Medicine And Research, Burke, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Hampton Roads Center For Clinical Research, Inc., Suffolk, Virginia, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Sound Medical Research, Port Orchard, Washington, United States|Local Institution, Kelowona, British Columbia, Canada|Local Institution, Victoria, British Columbia, Canada|Local Institution, Brampton, Ontario, Canada|Local Institution, Granby, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Medellin, Antioquia, Colombia|Local Institution, Bogota, Cundinamarca, Colombia|Local Institution, Armenia, Quindio, Colombia|Local Institution, Cali, Valle, Colombia|Local Institution, Barranquilla, Colombia|Local Institution, Barranquilla, Colombia|Local Institution, Bogota, Colombia|Local Institution, Beroun, Czech Republic|Local Institution, Cheb, Czech Republic|Local Institution, Havirov, Czech Republic|Local Institution, Liberec, Czech Republic|Local Institution, Ostrava, Czech Republic|Local Institution, Prague 1, Czech Republic|Local Institution, Praha 4, Czech Republic|Local Institution, Copenhagen, Denmark|Local Institution, Copenhagen, Denmark|Local Institution, Frederiksberg, Denmark|Local Institution, Slagelse, Denmark|Local Institution, Kokkola, Finland|Local Institution, Oulu, Finland|Local Institution, Aschaffenburg, Bavaria, Germany|Local Institution, Vellmar, Hessen, Germany|Local Institution, Duisburg, Nordrhein-Westfalen, Germany|Local Institution, Bad Kreuznach, Germany|Local Institution, Berlin, Germany|Local Institution, Karlsruhe, Germany|Local Institution, Kothen, Germany|Local Institution, Kronshagen, Germany|Local Institution, Langenfeld, Germany|Local Institution, Lueneburg, Germany|Local Institution, Magdeburg, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Pirna, Germany|Local Institution, Saarbruecken, Germany|Local Institution, Gyongyos, Heves, Hungary|Local Institution, Eger, Hungary|Local Institution, Hatvan, Hungary|Local Institution, Miskolc, Hungary|Local Institution, Nagykanizsa, Hungary|Local Institution, Nyiregyhaza, Hungary|Local Institution, Satoraljaujhely, Hungary|Local Institution, Sopron, Hungary|Local Institution, Szeged, Hungary|Local Institution, Szekszard, Hungary|Local Institution, Szentes, Hungary|Local Institution, Hyderabad, Andhra Pradesh, India|Local Institution, Vijayawada, Andhra Pradesh, India|Local Institution, New Delhi, Delhi, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Belgaum, Karnatka, India|Local Institution, Indore, Madhya Pradesh, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Delhi, New Delhi, India|Local Institution, Jaipur, Rajasthan, India|Local Institution, Jaipur, Rajasthan, India|Local Institution, Jaipur, Rajasthan, India|Local Institution, Coimbatore, Tamil Nadu, India|Local Institution, Madurai, Tamilnadu, India|Local Institution, Bangalore, India|Local Institution, Hyderabad, India|Local Institution, Manipal, India|Local Institution, Nagpur, India|Local Institution, Torreon, Coahuila, Mexico|Local Institution, Del. Benito Juarez, Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico, Df, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Cuautla, Morelos, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Culiacan, Sinaloa, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, Durango, Mexico|Local Institution, Guadalajara, Mexico|Local Institution, Puebla, Mexico|Local Institution, Queretaro, Mexico|Local Institution, Veracruz, Mexico|Local Institution, Chiclayo, Lambayeque, Peru|Local Institution, Lince, Lima, Peru|Local Institution, Arequipa, Peru|Local Institution, Arequipa, Peru|Local Institution, Cusco, Peru|Local Institution, Ica, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Piura, Peru|Local Institution, Bialystok, Poland|Local Institution, Bydgoszcz, Poland|Local Institution, Chrzanow, Poland|Local Institution, Gdansk, Poland|Local Institution, Gdynia, Poland|Local Institution, Golub-Dobrzyn, Poland|Local Institution, Kamieniec Zabkowicki, Poland|Local Institution, Katowice, Poland|Local Institution, Krakow, Poland|Local Institution, Krakow, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Lodz, Poland|Local Institution, Lodz, Poland|Local Institution, Ostroda, Poland|Local Institution, Poznan, Poland|Local Institution, Szczecin, Poland|Local Institution, Warsaw, Poland|Local Institution, Warsaw, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroc#Aw, Poland|Local Institution, WrocB Aw, Poland|Local Institution, Zamosc, Poland|Local Institution, Cidra, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Oradea, Bihor, Romania|Local Institution, Oradea, Jud. Bihor, Romania|Local Institution, Timisoara, Jud. Timis, Romania|Local Institution, Targu Mures, Mures, Romania|Local Institution, Targu Mures, Mures, Romania|Local Institution, Ploiesti, Prahova, Romania|Local Institution, Ploiesti, Prahova, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Satu Mare, Romania|Local Institution, Sibiu, Romania|Local Institution, Sibiu, Romania|Local Institution, Dzerzhinskiy, Russian Federation|Local Institution, Krasnoyarsk, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, Smolensk, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St.Petersburg, Russian Federation|Local Institution, Yaroslavl, Russian Federation|Local Institution, Yaroslavl, Russian Federation|Local Institution, Yaroslav, Russian Federation|Local Institution, Santiago De Compostela, A Coruna, Spain|Local Institution, Barcelona, Spain|Local Institution, La Roca Del Valles, Spain|Local Institution, Peralada, Spain",,"https://ClinicalTrials.gov/show/NCT01137474"
706,"NCT03113994","Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk","RoBaCO","Recruiting","No Results Available","Spinal Cord Injuries|Osteoporosis|Metabolic Syndrome","Drug: Rosuvastatin Calcium|Drug: Placebo Oral Tablet|Dietary Supplement: Coenzyme Q10|Dietary Supplement: Calcium Carbonate|Dietary Supplement: Vitamin D","Change from Baseline in areal BMD of the knee region|Change from Baseline in Low density lipoprotein cholesterol (LDL)|Change from Baseline in high density lipoprotein cholesterol (HDL)|Change from Baseline in triglycerides (TG)|Change from Baseline in total cholesterol|Change from Baseline in High sensitivity C-reactive Protein (hsCRP)|Change from Baseline in Interleukin-1ß (IL-1ß)|Change from Baseline in interleukin-6 (IL-6)|Change from Baseline in tumor necrosis factor - alpha (TNF-alpha)|Change from Baseline in erythrocyte sedimentation rate (ESR)|Change from Baseline in Bone Specific Alkaline Phosphatase (BALP)|Change from Baseline in C-telopeptide (CTX)|Change from Baseline in Sclerostin|Change from Baseline in RANK Ligand (RANK-L)|Change from Baseline in volumetric BMD of the tibia (pQCT)|Change from Baseline in volumetric BMD of the tibia (HR-pQCT)","Dr. B. Catharine. Craven|The Craig H. Neilsen Foundation|Toronto Rehabilitation Institute|University Health Network, Toronto|University of Miami|Rick Hansen Institute","All","18 Years to 60 Years   (Adult)","Phase 2","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2016-350642","February 26, 2018","December 2020","December 2020","April 14, 2017",,"November 1, 2018","University Of Miami Miller School of Medicine, Miami, Florida, United States|University Health Network - Toronto Rehab Lyndhurst Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03113994"
707,"NCT02597127","Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)","ORION-1","Completed","Has Results","Atherosclerotic Cardiovascular Disease|Familial Hypercholesterolemia|Diabetes","Drug: ALN-PCSSC|Drug: Normal Saline","Percentage Change in LDL-C From Baseline to Day 180|Percentage Change in LDL-C From Baseline to Day 90|Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210|Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210|Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180|Number of Participants With Greater Or Equal To 50% LDL-C Reduction From Baseline At Day 180|Percentage Change in PCSK9 Levels From Baseline at Day 180|Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180|Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk|Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180","The Medicines Company","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","501","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MDCO-PCS-15-01","January 2016","June 7, 2017","June 7, 2017","November 5, 2015","May 17, 2019","May 17, 2019","Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Midwest Institute For Clinical Research, Indianapolis, Indiana, United States|Mount Sinai Icahn School of Medicine, New York, New York, United States|Metabolic And Atherosclerosis Research Center, Cincinnati, Ohio, United States|Sterling Research Group, Cincinnati, Ohio, United States|Wellmont CVA Heart Institute, Greeneville, Tennessee, United States|Amarillo Heart Clinical Research Institute, Inc., Amarillo, Texas, United States|National Clinical Research, Inc., Richmond, Virginia, United States|St. Paul's Hospital, Vancouver, British Columbia, Canada|St. Boniface Hospital, Winnipeg, Manitoba, Canada|Eastern Regional Health Authority, Patient Research Centre, St. Johns, Newfoundland and Labrador, Canada|Brampton Research Associates, Brampton, Ontario, Canada|Lawson Health Research Institute, London, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|ECOGENE-21 Clinical Trials Center, Chicoutimi, Quebec, Canada|Clinic Sante Cardio MC, Montreal, Quebec, Canada|Institut de Recherches Cliniques de Montreal, Montreal, Quebec, Canada|Université Laval Quebec, Quebec City, Quebec, Canada|Clinique des maladies lipidique Quebec, Quebec City, Quebec, Canada|Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, Quebec, Canada|Medical University Berlin, Berlin, Germany|Medical Center Essen, Essen, Germany|University Hospital Frankfurt, Frankfurt, Germany|University Heart Center Hamburg, Hamburg, Germany|Medical University Hospital Heidelberg, Internal medicine III, Heidelberg, Germany|Technical University Munich, German Heart Center, Munich, Germany|Amsterdam Medical Center, Amsterdam, Netherlands|Haga Hospital, Den Haag, Netherlands|Deventer Ziekenhuis, Deventer, Netherlands|Andromed Eindhoven, Eindhoven, Netherlands|Admiraal de Ruyter Hospital, Cardiology, Goes, Netherlands|Bethesda Diabetes Research Center, Hoogeveen, Netherlands|Medisch Centrum Gorecht, Hoogezand, Netherlands|VOC Hoorn, Hoorn, Netherlands|Leids Universitair Medisch Centrum (LUMC), Leiden, Netherlands|Andromed Rotterdam, Rotterdam, Netherlands|Diakonessenhuis, Vascular Policlinic, Utrecht, Netherlands|UMC Utrecht, Utrecht, Netherlands|VieCurie Venlo, Cardiology, Venlo, Netherlands|Albert Schweitzer Hospital, Cardiology, Zwijndrecht, Netherlands|Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Edinburgh Royal Infirmary, Edinburgh, United Kingdom|The Royal Devon and Exeter NHS Trust, Exeter, United Kingdom|Fowey River Practice, Fowey, United Kingdom|Buckinghamshire NHS Trust, High Wycombe, United Kingdom|Oak Tree Surgery, Liskeard, United Kingdom|Royal Free Hospital, London, United Kingdom|Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, United Kingdom|The Alverton Practice, Penzance, United Kingdom|Knowle House Surgery, Plymouth, United Kingdom|Brannel Surgery, St. Austell, United Kingdom|Rame Medical Ltd (Rame Research), Torpoint, United Kingdom|Worcestershire Acute NHS Trust, Worcester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02597127/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02597127/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02597127"
708,"NCT01570686","8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension",,"Completed","Has Results","Hypertension","Drug: Aliskiren","Change From Baseline (Visit 3) to End of Study (Week 8) in Mean 24 Hour Ambulatory Systolic Blood Pressure (maSBP)|Change From Baseline (Visit 3) to End of Study (Week 8) in Mean 24 Hour Ambulatory Diastolic Blood Pressure (maDBP)|Percentage of Patients Achieving Blood Pressure Control|Change From Baseline (Visit 3) to End of Study (8 Weeks) in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP)|Percentage of Patients Achieving a Successful Response in Systolic Blood Pressure Reduction|Pharmacokinetic (PK) of Aliskiren: The Observed Maximum Plasma Concentration (Cmax) Following Drug Administration in Fasted vs. Fed|Pharmacokinetic of Aliskiren: The Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) in Fasted vs. Fed|Pharmacokinetic of Aliskiren: Time to Reach the Maximum Concentration (Tmax) After Drug Administration in Fasted vs. Fed|Change From Baseline to Week 8 in Plasma Renin Activity (PRA)|Change From Baseline to Week 8 in Plasma Renin Concentration (PRC)|Number of Patients With Adverse Events, Serious Adverse Events and Death","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 4","589","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSPP100A2413|2011-005297-36","April 2012","November 2012","November 2012","April 4, 2012","January 1, 2014","January 22, 2014","Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Riverside, California, United States|Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, Walnut Creek, California, United States|Novartis Investigative Site, Westlake Village, California, United States|Novartis Investigative Site, Coral Gables, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, South Miami, Florida, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Evansville, Indiana, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Opelousas, Louisiana, United States|Novartis Investigative Site, Chaska, Minnesota, United States|Novartis Investigative Site, Edina, Minnesota, United States|Novartis Investigative Site, St. Paul, Minnesota, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Picayune, Mississippi, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Salisbury, North Carolina, United States|Novartis Investigative Site, Shelby, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Lyndhurst, Ohio, United States|Novartis Investigative Site, Marion, Ohio, United States|Novartis Investigative Site, Norman, Oklahoma, United States|Novartis Investigative Site, Eugene, Oregon, United States|Novartis Investigative Site, Oregon City, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Beaumont, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Lake Jackson, Texas, United States|Novartis Investigative Site, Pasadena, Texas, United States|Novartis Investigative Site, Centerville, Utah, United States|Novartis Investigative Site, Arlington, Virginia, United States|Novartis Investigative Site, Ettrick, Virginia, United States|Novartis Investigative Site, Midlothian, Virginia, United States|Novartis Investigative Site, Port Orchard, Washington, United States|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, St. John's, Newfoundland and Labrador, Canada|Novartis Investigative Site, Brampton, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Mirabel, Quebec, Canada|Novartis Investigative Site, Sainte-Foy, Quebec, Canada|Novartis Investigative Site, Pozzilli, IS, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Sassari, SS, Italy|Novartis Investigative Site, Carolina, Puerto Rico|Novartis Investigative Site, Cidra, Puerto Rico|Novartis Investigative Site, Manati, Puerto Rico|Novartis Investigative Site, Banská Bystrica, Slovak republic, Slovakia|Novartis Investigative Site, Bratislava, Slovak republic, Slovakia|Novartis Investigative Site, Kosice, Slovak Republic, Slovakia|Novartis Investigative Site, Kosice, Slovak republic, Slovakia|Novartis Investigative Site, Nitra, Slovak republic, Slovakia|Novartis Investigative Site, Rimavska Sobota, Slovak republic, Slovakia|Novartis Investigative Site, Senec, Slovak republic, Slovakia|Novartis Investigative Site, Snina, Slovak republic, Slovakia|Novartis Investigative Site, Svidnik, Slovak Republic, Slovakia|Novartis Investigative Site, Trnava, Slovak republic, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Martin, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Sala, Slovakia|Novartis Investigative Site, Zvolen, Slovakia|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Centelles, Cataluña, Spain|Novartis Investigative Site, Corbera de Llobregat, Cataluña, Spain|Novartis Investigative Site, Hostalets de Balenya, Cataluña, Spain|Novartis Investigative Site, Vic, Cataluña, Spain|Novartis Investigative Site, Alzira, Comunidad Valenciana, Spain|Novartis Investigative Site, Quart de Poblet, Comunidad Valenciana, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01570686"
709,"NCT04083222","A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx",,"Active, not recruiting","No Results Available","Hypertension","Drug: IONIS-AGT-LRx|Drug: Placebo","Percent Change in Plasma Angiotensinogen (AGT) from Baseline to Study Day 57 (Study Week 9) Compared to Placebo|Change in Systolic Blood Pressure (SBP) from Baseline to Each Scheduled, Post-Baseline Visit|Percent Change in Plasma AGT from Baseline to Each Scheduled, Post-Baseline Visit","Ionis Pharmaceuticals, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ISIS 757456-CS3","November 13, 2019","October 2020","January 2021","September 10, 2019",,"April 29, 2020","Central Alabama Research, Birmingham, Alabama, United States|National Research Institute - Wilshire, Los Angeles, California, United States|Orange County Research Center, Tustin, California, United States|Excel Medical Clinical Trials, Boca Raton, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Ohio Clinical Research - Lyndhurst, Lyndhurst, Ohio, United States|Juno Research, LLC, Houston, Texas, United States|York Clinical Research LLC, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04083222"
710,"NCT02927366","Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients",,"Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: QCC374|Drug: Placebo Matching","Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 16 (Day 111)|Change From Baseline in Six Minute Walk Distance (6MWD) Over Time|Change From Baseline in Cardiac Output (CO) at Week 16 (Day 111)|Change From Baseline in Cardiac Index at Week 16 (Day 111)|Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 16 (Day 111)|Change From Baseline in Systemic Vascular Resistance (SVR) at Week 16 (Day 111)|Change From Baseline in RV Fractional Area Change and RV Free Wall Average Peak Long Strain at Week 16 (Day 111) Using Echocardiography|Change From Baseline in RV Tei Index at Week 16 (Day 111) Using Echocardiography|Change From Baseline in Tricuspid Annular Peak Systolic Velocity (TA S') at Week 16 (Day 111) Using Echocardiography|Change From Baseline in Tricuspid Annular Plane Sys Excursion (TAPSE) at Week 16 (Day 111) Using Echocardiography|Maximum Observed Plasma Concentration (Cmax) for QCC374 and Its Metabolite QCM441|Time to Reach the Maximum Plasma Concentration (Tmax) for QCC374 and Its Metabolite QCM441|Area Under the Plasma Concentration-time Curve From 0 to the Last Measurable Concentration (AUClast) for QCC374 and Its Metabolite QCM441|Area Under the Plasma Concentration Time Curve From 0 to the End of a Dosing Interval (AUCtau) for QCC374 and Its Metabolite QCM441","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CQCC374X2201|2016-001412-38","September 19, 2017","June 7, 2018","June 7, 2018","October 7, 2016","August 7, 2019","February 28, 2020","Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Cambridge, Cambridgeshire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02927366/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02927366/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02927366"
711,"NCT02191137","Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)",,"Completed","Has Results","Hypertension, Pulmonary","Drug: Riociguat (Adempas, BAY63-2521)","Change From Baseline to Week 24 in the Living With Pulmonary Hypertension (LPH) Questionnaire Total Score|Change From Baseline to Weeks 4 and 16 in the LPH Total Score|Change From Week 16 to Week 24 in the LPH Total Score (Completers Analysis Set Only)|Change From Baseline to Weeks 4, 16, and 24 in the LPH Physical Dimension Score|Change From Week 16 to Week 24 in the LPH Physical Dimension Score (Completers Analysis Set Only)|Change From Baseline to Weeks 4, 16, and 24 in the LPH Emotional Dimension Score|Change From Week 16 to Week 24 in the LPH Emotional Dimension Score (Completers Analysis Set Only)|Percentage of Patients With a Minimal Clinically Significant Important Difference (MCID) From Baseline in LPH Total Score at Weeks 4, 16, and 24|Percentage of Patients With an MCID From Baseline in LPH Physical Dimension Score at Weeks 4, 16, and 24|Percentage of Patients With an MCID From Baseline in LPH Emotional Dimension Score at Weeks 4, 16, and 24|Percentage of Patients With an MCID From Week 16 in LPH Total Score at Week 24 (Completers Analysis Set Only)|Percentage of Patients With an MCID From Week 16 in Physical Dimension Score at Week 24 (Completers Analysis Set Only)|Percentage of Patients With an MCID From Week 16 in Emotional Dimension Score at Week 24 (Completers Analysis Set Only)|Change From Baseline to Weeks 4, 16, and 24 in the WLQ Time Management, Physical Demands, Mental-Interpersonal Demands and Output Demands Scores|Change From Baseline to Weeks 4, 16, and 24 in the WLQ Percentage of Productivity Loss|Change From Week 16 to Week 24 in the WLQ Time Management, Physical Demands, Mental-Interpersonal Demands, and Output Demands Scores (Completers Analysis Set Only)|Change From Week 16 to Week 24 in the WLQ Percentage of Productivity Loss (Completers Analysis Set Only)|Change From Baseline to Weeks 4, 16, and 24 in the Short Form-12 Health Survey (SF-12) Physical Component Summary (PCS) Score and Mental Component Summary (MCS) Score|Change From Week 16 to Week 24 in the SF-12 PCS Score and MCS Score (Completers Analysis Set Only)|Change From Baseline to Weeks 4, 16, and 24 in the WHO Functional Class|Change From Week 16 to Week 24 in the WHO Functional Class (Completers Analysis Set Only)|Change From Baseline to Weeks 16 and 24 in the Modified Borg Dyspnea Scale|Change From Week 16 to Week 24 in the Modified Borg Dyspnea Scale (Completers Analysis Set Only)|Change From Baseline to Weeks 16 and 24 in the 6MWD|Change From Week 16 to Week 24 in the 6MWD (Completers Analysis Set Only)","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","75","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17407","September 23, 2014","July 16, 2016","July 16, 2016","July 16, 2014","October 13, 2017","October 13, 2017","Tucson, Arizona, United States|La Jolla, California, United States|Moreno Valley, California, United States|Pomona, California, United States|Sacramento, California, United States|San Juan Capistrano, California, United States|Santa Barbara, California, United States|Aurora, Colorado, United States|Hartford, Connecticut, United States|Celebration, Florida, United States|Jacksonville, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Weston, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Austell, Georgia, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|North Dartmouth, Massachusetts, United States|Detroit, Michigan, United States|Troy, Michigan, United States|Pascagoula, Mississippi, United States|Lincoln, Nebraska, United States|Omaha, Nebraska, United States|Newark, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Brooklyn, New York, United States|Liverpool, New York, United States|Mineola, New York, United States|New Hyde Park, New York, United States|Stony Brook, New York, United States|Syracuse, New York, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Sioux Falls, South Dakota, United States|El Paso, Texas, United States|Houston, Texas, United States|Temple, Texas, United States|Milwaukee, Wisconsin, United States|Milwaukee, Wisconsin, United States|Guaynabo, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02191137"
712,"NCT01556997","Perindopril Amlodipine for the Treatment of Hypertension","PATH","Completed","Has Results","Essential Hypertension","Drug: XOMA 985|Drug: Amlodipine Besylate|Drug: Perindopril Erbumine","Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Diastolic Blood Pressure (DBP).|Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Systolic Blood Pressure (SBP).","Symplmed Pharmaceuticals LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","837","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","X985400","February 2012","February 2013","February 2013","March 19, 2012","August 25, 2015","September 28, 2015","Huntsville, Alabama, United States|Muscle Shoals, Alabama, United States|Glendale, Arizona, United States|Greenbrae, California, United States|Los Angeles, California, United States|Santa Ana, California, United States|Denver, Colorado, United States|Deland, Florida, United States|Ft. Lauderdale, Florida, United States|Miami, Florida, United States|Palm Harbor, Florida, United States|Port Orange, Florida, United States|Marietta, Georgia, United States|Gurnee, Illinois, United States|Indianapolis, Indiana, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Metairie, Louisiana, United States|Auburn, Maine, United States|Baltimore, Maryland, United States|Olive Branch, Mississippi, United States|Butte, Montana, United States|Berlin, New Jersey, United States|Greensboro, North Carolina, United States|Hickory, North Carolina, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Kettering, Ohio, United States|Lyndhurst, Ohio, United States|Marion, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Eugene, Oregon, United States|Mount Pleasant, South Carolina, United States|Simpsonville, South Carolina, United States|Bristol, Tennessee, United States|Austin, Texas, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Ft. Worth, Texas, United States|Houston, Texas, United States|Katy, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01556997"
713,"NCT01437007","TKM 080301 for Primary or Secondary Liver Cancer",,"Completed","No Results Available","Colorectal Cancer With Hepatic Metastases|Pancreas Cancer With Hepatic Metastase|Gastric Cancer With Hepatic Metastase|Breast Cancer With Hepatic Metastase|Ovarian Cancer With Hepatic Metastase","Drug: TKM-080301","To evaluate feasibility of administering TKM-080301 via HAI, and establish MTD and DLT.|Characterize PK &amp; pharmacodynamics of TKM 080301|Eval biological effects of TKM-080301 on biopsies performed before &amp; after 1 cycle of tx|To evaluate the potential conversion rate from unresectable to resectable disease.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","1","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110240|11-C-0240","August 26, 2011","June 21, 2012","June 21, 2012","September 20, 2011",,"August 3, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01437007"
714,"NCT01858935","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects",,"Completed","No Results Available","Healthy","Drug: ND-L02-s0201 Injection|Drug: Placebo","Incidence, nature, and severity of adverse events and abnormal clinical laboratory tests|Pharmacokinetic profile and parameters","Bristol-Myers Squibb|Nitto Denko Corporation","Male","18 Years to 55 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","ND-L02-s0201-001","May 2013","February 2014","February 2014","May 21, 2013",,"May 11, 2017","Quintiles Phase One Services, LLC, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01858935"
715,"NCT03960541","CD24Fc Administration to Decrease LDL and Inflammation in HIV Patients (CALIBER)","CALIBER","Recruiting","No Results Available","HIV Infections|Dyslipidemias","Drug: CD24Fc (human CD24 extracellular domain and human IgG1 Fc fusion protein)|Drug: Saline Solution","To evaluate the change in LDL during 6-week dosing period of CD24Fc.|Levels of total cholesterol, HDL, and triglycerides|Markers of immune activation (CD4 and CD8 T cells, IFN, TNF, sCD14)|Size of HIV reservoirs|Myocardial damage (measured by Troponin I)|Hepatic steatosis, as determined by transient elastography|Level of leptin|Hemoglobin A1c|Area under the plasma concentration versus time curve (AUC) of CD24Fc in first 6 patients.|The number of patients who develop Anti-drug antibody in 28 weeks of study period","OncoImmune, Inc.|University of Maryland, Baltimore|National Heart, Lung, and Blood Institute (NHLBI)","All","50 Years and older   (Adult, Older Adult)","Phase 2","64","Industry|Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HP-00086029|CD24Fc-003|R44HL145964","January 30, 2020","October 2021","October 2022","May 23, 2019",,"February 18, 2020","Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03960541"
716,"NCT01373086","LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension",,"Terminated","No Results Available","Hypertension","Drug: LFF269|Drug: Eplerenone|Drug: Placebo","Change from baseline in mean 24-hour systolic blood pressure (SBP) as measured by ambulatory blood pressure monitoring (ABPM) after 4 weeks treatment|Change from baseline in mean 24-hour diastolic blood pressure (DBP) as measured by ABPM after 4 weeks of treatment|Change from baseline in mean 24-hour SBP and DBP as measured by ABPM after 4 weeks treatment|Percentage of patients experiencing adverse events during the study as measure of safety and tolerability|Change from baseline in mean sitting SBP and DBP after 4 weeks treatment|Percentage of patients achieving a successful BP response (> placebo) and BP control (SBP < 140 mmHg at trough)|change from baseline in mean daytime and mean nighttime SBP and DBP as measured by ABPM after 4 weeks treatment|Pharmacokinetics of LFF269: Plasma concentrations of LFF269","Novartis Pharmaceuticals|Novartis","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLFF269X2201","May 2011","October 2011","October 2011","June 14, 2011",,"December 4, 2012","Advanced Clinical Research Institute-Phase I, Anaheim, California, United States|Comprehensive Phase I, Fort Myers, Florida, United States|Comprehensive Phase One®,, Miramar, Florida, United States|Comprehensive NeuroScience, St Petersburg, Florida, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Clinical Research Advantage/ Prairie Fields Family Medicine, PC, Fremont, Nebraska, United States|Internal Medicine Physicians, Omaha, Nebraska, United States|ICON Developmental Solutions, Omaha, Nebraska, United States|Clinical Research Advantage/ Aloha Medical, Las Vegas, Nevada, United States|ICON Development Solutions,, San Antonio, Texas, United States|Comprehensive Clinical Development NW, Inc., Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01373086"
717,"NCT01841762","Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument",,"Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Macitentan","Development and Refinement of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT)|Validation of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT), With Reliability Assessed Via Test-retest Reliability.|Validation of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT), Assessing Internal Consistency Reliability.|Number of Participants With Treatment-emergent Adverse Events, Serious Adverse Events, and Adverse Events Resulting in Patient Study Drug Discontinuation Between Time Periods, BL to End of Study Visit (EoS, Week 16+30 Days for Follow-up Safety Visits)","Actelion","All","18 Years and older   (Adult, Older Adult)","Phase 3","284","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-055-401","April 1, 2013","November 1, 2015","November 1, 2015","April 29, 2013","October 31, 2018","February 26, 2019","Cardiovascular Associates of the Southeast, LLC, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Pulmonary Associates, PA, Phoenix, Arizona, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|Cedars-Sinai Medical Center, Beverly Hills, California, United States|UCSF Fresno, Fresno, California, United States|UCSD Medical Center, Pulmonary Department, La Jolla, California, United States|VAGLAHS, VA Greater LA Healthcare System, Los Angeles, California, United States|University of California Los Angeles, Los Angeles, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Los Angeles Biomedical Research Institute, Torrance, California, United States|University of Colorado, Aurora, Colorado, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|Bay Area Cardiology Associates, P.A., Brandon, Florida, United States|University of Florida Academic Health Center, Gainesville, Florida, United States|University of Florida College of Medicine, Jacksonville, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Georgia Regents University, Augusta, Georgia, United States|Georgia Clinical Research, Austell, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago Medical, Chicago, Illinois, United States|Advocate Health and Hospitals Corporation, Oakbrook Terrace, Illinois, United States|Chest Infectious Diseases and Critical Care Associates, PC, Des Moines, Iowa, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Iowa City Heart Center, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Veritas Clinical Specialties, Topeka, Kansas, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Beaumont Hospital, Troy, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Midwest Pulmonary Consultants, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Clinic Pulmonology, Saint Louis, Missouri, United States|Clayton Sleep Institute, Saint Louis, Missouri, United States|Ferrell-Duncan Clinic, Springfield, Missouri, United States|Nebraska Pulmonary Specialties, Lincoln, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Pulmonary and Critical Care Associates, Union, New Jersey, United States|Montefiore Medical Center, Weiler Division, Bronx, New York, United States|Buffalo General Medical Center, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|North Shore-LIJ/Advance Lung Disease Clinic, New Hyde Park, New York, United States|Beth Israel Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Novant Health Pulmonary and Critical Care, Matthews, North Carolina, United States|The Christ Hospital, Cincinnati, Ohio, United States|UC Health/University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Davis Heart & Lung Research Institute, Columbus, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|The Oregon Clinic, Portland, Oregon, United States|CDA for Oregon Pulmonary Associate, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Thomas Jefferson University, Division on Pulmonary and Critical Care, Philadelphia, Pennsylvania, United States|Temple Lung Center, Philadelphia, Pennsylvania, United States|UPMC, Pittsburgh, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Berks Schuylkill Respiratory Specialists, Ltd., Wyomissing, Pennsylvania, United States|Wellspan Lung, Sleep and Critical Care, York, Pennsylvania, United States|Sioux Falls Cardiovascular, PC, Sioux Falls, South Dakota, United States|Baylor Research Institute (BRI), Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|Scott & White Memorial Hospital, Temple, Texas, United States|Inova Heart and Vascular Institue / Inova Fairfax Hospital, Falls Church, Virginia, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Pulmonary & Sleep Research, Spokane, Washington, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Aurora Cardiovascular Services, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01841762"
718,"NCT01693315","Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma",,"Completed","No Results Available","Glaucoma|Ocular Hypertension|Eye Disease","Drug: AMA0076|Drug: Placebo","intraocular pressure change from baseline.|Adverse events as a measure of safety/tolerability|IOP assessments at weekly visits","Amakem, NV","All","30 Years to 85 Years   (Adult, Older Adult)","Phase 2","82","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AMA0076-201","September 2012","July 2013","July 2013","September 26, 2012",,"July 17, 2013","Artesia Clinical Site - Site 02, Artesia, California, United States|Inglewood Clinical Site - Site 03, Inglewood, California, United States|Petaluma Clinical Site - Site 05, Petaluma, California, United States|New Haven Clinical Site - Site 01, New Haven, Connecticut, United States|Atlanta Clinical Site - Site 04, Atlanta, Georgia, United States|High Point Clinical Site - Site 06, High Point, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01693315"
719,"NCT00832507","Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)",,"Terminated","No Results Available","Pulmonary Arterial Hypertension","Drug: Cicletanine|Drug: Cicletanine Placebo","Change from baseline in six-minute walk distance (6MWD) evaluated after 12 weeks of treatment|Change from baseline in BDI, WHO Functional Class, BNP, cardiac hemodynamics and SF-36 physical functioning scale following 12 weeks of treatment. In addition, time to clinical worsening (TTCW) will be evaluated.","Gilead Sciences","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2","162","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GS-US-235-0101","January 2009","October 2011","March 2012","January 30, 2009",,"February 4, 2014","University of South Alabama, Mobile, Alabama, United States|Arizona Pulmonary Specialists, Phoenix, Arizona, United States|VA Greater LA Healthcare System, Los Angeles, California, United States|University of California San Diego Medical Center, San Diego, California, United States|Harish H. K. Murthy, MD, San Jose, California, United States|UCLA Medical Center, Torrance, California, United States|University of Colorado Denver, Aurora, Colorado, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|Cleveland Clinic, Ft. Lauderdale, Florida, United States|University of Florida, Gainesville, Florida, United States|Emory University, Atlanta, Georgia, United States|Medical College of Georgia, Augusta, Georgia, United States|University of Chicago Hospital, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Louisiana State University, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Tufts-New England Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Beth Israel Medical Center, New York, New York, United States|Cornell University, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|New York Presbyterian Hospital, New York, New York, United States|University of Rochester, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|Case Medical Center, Cleveland, Ohio, United States|Davis Heart and Lung Research Institute, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University Of Virginia, Charlottesville, Virginia, United States|St Vincent's Hospital, Darlinghurst, New South Wales, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|University Klinik Graz, Graz, Austria|University Klinik Wien, Wien, Austria|ULB Hôpital Erasme, Bruxelles, Belgium|Peter Lougheed Centre, Calgary, Alberta, Canada|London Health Sciences Centre, London, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Ludwig-Maximilians-Universitaet, Muenchen, BY, Germany|Universitaetsklinikum Giessen und Marburg, Giessen, HE, Germany|Rabin Medical Center, Petach Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Unidad de Investigación Clínica en Medicina S.C., Monterrey, NL, Mexico|Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico|H Clinic i Provincial, Barcelona, Spain|HU 12 de Octubre, Madrid, Spain|Royal Free Hospital, London, Gt Lon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00832507"
720,"NCT01725269","Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05",,"Terminated","No Results Available","Pulmonary Arterial Hypertension","Drug: AIR001","To evaluate the intermediate/long-term safety of inhaled nebulized AIR001|To assess the effect of inhaled AIR001 on Time to Clinical Worsening, 6MWD, Functional Class, and Quality of Life","Aires Pharmaceuticals, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","17","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIR001-CS06","March 2013","April 2014","April 2014","November 12, 2012",,"April 9, 2014","UCSD Medical Center, La Jolla, California, United States|UCLA Medical Center, Torrance, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Adaani Frost, M.D., Houston, Texas, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Gottsegen Gyorgy Hungarian, Budapest, Hungary|Semmelweis University, Budapest, Hungary|University of Debrecen, Debrecen, Hungary|University of Szeged, Szeged, Hungary",,"https://ClinicalTrials.gov/show/NCT01725269"
721,"NCT03068130","Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER","RANGER","Recruiting","No Results Available","Pulmonary Hypertension","Drug: Bardoxolone methyl","Long-term Safety","Reata Pharmaceuticals, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","414","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RTA 402-C-1602","April 18, 2017","December 2021","December 2021","March 1, 2017",,"August 28, 2019","Banner University Medical Center, Phoenix Advanced Lung Disease Institute, Phoenix, Arizona, United States|Arizona Pulmonary Specialists, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Beverly Hills, California, United States|University of California San Diego, La Jolla, California, United States|VA Healthcare System of Greater Los Angeles, Los Angeles, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|University of California Davis Medical Center - Division of Pulmonary and Critical Care, Sacramento, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|University of Colorado Denver - Division of Pulmonary Sciences, Aurora, Colorado, United States|Georgetown University Medical Center - Department of Rheumatology, Washington, District of Columbia, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Cleveland Clinic of Florida, Weston, Florida, United States|Augusta University, Augusta, Georgia, United States|Piedmont-Georgia Lung, Austell, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Maine Medical Center - Division of Pulmonary and Critical Care Medicine, Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|Winthrop University Hospital, Mineola, New York, United States|NYU Langone Medical Center, New York, New York, United States|University of Rochester - University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|University of Cincinnati - Department of Internal Medicine Pulmonary, Critical Care & Sleep Medicine, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oklahoma Heart Hospital, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|BreatheAmerica El Paso, El Paso, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|The University of Texas - Health Science Center & Medical School at Houston, Houston, Texas, United States|University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Aurora Health Care, Milwaukee, Wisconsin, United States|Centro Médico Dra de Salvo, Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina|Instituto de Investigaciones Clínicas Mar Del Plata, Buenos Aires, Mar Del Plata, Argentina|Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina|Instituto de Cardiologia de Corrientes Juana Francisca Cabral, Corrientes, Argentina|Instituto Cardiovascular de Rosario, Rosario, Argentina|Hospital Provincial Dr Jose Maria Cullen, Santa Fe, Argentina|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|John Hunter Hospital, New Lambton, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|UZ Leuven, Leuven, Vlaams Brabant, Belgium|Hospital Erasme, Brussels, Belgium|Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Dia do Pulmão, Blumenau, Santa Catarina, Brazil|Instituto do Coração - HCFMUSP, São Paulo, Brazil|Peter Lougheed Centre, Calgary, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|London Health Sciences Centre, London, Ontario, Canada|Centre Hospitalier de l'Université Laval, Sainte Foy, Quebec, Canada|Vseobecna fakultni nemocnice v Praze, Prague, Czechia|Institut klinicke a experimentalni mediciny, Prague, Czechia|Universitatsklinkum Carl Gustav Carus an der Tu, Dresden, Germany|Universitatsklinikum Hamburg Eppendorf, Hamburg, Germany|Thorax Klinik, Heidelberg, Germany|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Nippon Medical School Hospital, Tokyo, Bunkyo-ku, Japan|Kobe University Hospital, Kobe, Hyogo, Japan|Kitasato University Hospital, Sagamihara, Kanagawa, Japan|Kyorin University Hospital, Tokyo, Mitaka-shi, Japan|National Hospital Organization Okayama Medical Center, Okayama-shi, Okayama, Japan|Chiba University Hospital, Chiba, Japan|Hokkaido University Hospital, Sapporo, Japan|Kurume University Medical Center, Sendai-shi, Japan|National Cerebral and Cardiovascular Center, Suita, Japan|Instituto Nacional de Cardiologia Dr. Ignacio Chavez, Ciudad de Mexico, Distrito Federal, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Nuevo León, Monterrey, Mexico|Unidad de Investigación Clínica En Medicina SC, Monterrey, Nuevo Leon, Mexico|Vrije Universiteit Amsterdam, Amsterdam, Noord-Holland, Netherlands|Philippine Heart Center, Quezon City, Metro Manila, Philippines|Makati Medical Center, Makati, Philippines|Philippine General Hospital (PGH), Manila, Philippines|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Hospital Virgen de La Salud, Toledo, Spain|Golden Jubilee National Hospital, Glasgow, United Kingdom|Royal Free Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03068130"
722,"NCT01010399","Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects","BuLLET","Completed","Has Results","Hypertriglyceridemia|HIV Infection","Dietary Supplement: Lovaza|Drug: fosamprenavir/ritonavir","Proportion of Subjects With Triglycerides <200 mg/dL|Proportion of Subjects With HIV-1 RNA <50 Copies/mL","Felizarta, Franco, M.D.|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 4","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COL112948","September 2009","November 2010","November 2010","November 10, 2009","April 18, 2012","April 18, 2012","Franco Felizarta, MD, Bakersfield, California, United States",,"https://ClinicalTrials.gov/show/NCT01010399"
723,"NCT02057575","Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure",,"Completed","Has Results","Open Angle Glaucoma|Ocular Hypertension","Drug: PG324 Ophthalmic Solution 0.01%|Drug: PG324 Ophthalmic Solution 0.02%|Drug: Netarsudil (AR-13324) Ophthalmic Solution 0.02%|Drug: Latanoprost Ophthalmic Solution 0.005%","Intraocular Pressure (IOP)","Aerie Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","298","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PG324-CS201","January 2014","June 2014","June 2014","February 7, 2014","June 4, 2019","June 4, 2019","Kenneth Sall, M.D., Artesia, California, United States|United Medical Research Institute, Inglewood, California, United States|Aesthetic Eye Care Institute, Newport Beach, California, United States|Bacharach practice, Petaluma, California, United States|Centre For Health Care, Poway, California, United States|Clayton Eye Center, Morrow, Georgia, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|Bradley Kwapiszeski, MD, Shawnee Mission, Kansas, United States|Taustine Eye Center, Louisville, Kentucky, United States|Seidenberg Protzko Eye Associates, Havre De Grace, Maryland, United States|Great Lakes Eye Care, Saint Joseph, Michigan, United States|Comprehensive Eye Care, Saint Louis, Missouri, United States|Ophthalmic Consultants of Long Island, Lynbrook, New York, United States|Rochester Ophthalmological Group, Rochester, New York, United States|Charlotte Eye Ear Nose & Throat Associates, P.A., Belmont, North Carolina, United States|Michael E. Tepedino, M.D., High Point, North Carolina, United States|The Eye Institute, Tulsa, Oklahoma, United States|Texan Eye, Austin, Texas, United States|Glaucoma Associates of Texas - Dallas Office, Dallas, Texas, United States|Cataract & Glaucoma Center, El Paso, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Stacy R. Smith, M.D., Salt Lake City, Utah, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02057575"
724,"NCT01415531","Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)",,"Completed","Has Results","Hypertension","Drug: Nebivolol|Drug: Placebo","Trough Seated Diastolic Blood Pressure (DBP)|Trough Seated Systolic Blood Pressure (SBP)","Forest Laboratories","All","18 Years to 54 Years   (Adult)","Phase 4","641","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NEB-MD-28","August 2011","March 2012","April 2012","August 12, 2011","May 16, 2013","May 16, 2013","Forest Investigative Site 065, Phoenix, Arizona, United States|Forest Investigative Site 067, Phoenix, Arizona, United States|Forest Investigative Site 070, Phoenix, Arizona, United States|Forest Investigative Site 049, Buena Park, California, United States|Forest Investigative Site 034, Burbank, California, United States|Forest Investigative Site 039, Costa Mesa, California, United States|Forest Investigative Site 024, Fountain Valley, California, United States|Forest Investigative Site 020, Fresno, California, United States|Forest Investigative Site 021, Fresno, California, United States|Forest Investigative Site 040, Greenbrae, California, United States|Forest Investigative Site 047, La Mesa, California, United States|Forest Investigative Site 073, Los Angeles, California, United States|Forest Investigative Site 077, Roseville, California, United States|Forest Investigative Site 060, San Bernardino, California, United States|Forest Investigative Site 054, San Francisco, California, United States|Forest Investigative Site 018, Spring Valley, California, United States|Forest Investigative Site 028, Denver, Colorado, United States|Forest Investigative Site 059, Brooksville, Florida, United States|Forest Investigative Site 033, Ft. Lauderdale, Florida, United States|Forest Investigative Site 006, Hallandale Beach, Florida, United States|Forest Investigative Site 044, Longwood, Florida, United States|Forest Investigative Site 001, Miami, Florida, United States|Forest Investigative Site 012, Miami, Florida, United States|Forest Investigative Site 032, Miami, Florida, United States|Forest Investigative Site 055, Miami, Florida, United States|Forest Investigative Site 045, Oviedo, Florida, United States|Forest Investigative Site 031, St. Petersburg, Florida, United States|Forest Investigative Site 009, Atlanta, Georgia, United States|Forest Investigative Site 007, Chicago, Illinois, United States|Forest Investigative Site 004, Morton, Illinois, United States|Forest Investigative Site 072, Evansville, Indiana, United States|Forest Investigative Site 069, Newburgh, Indiana, United States|Forest Investigative Site 025, Augusta, Kansas, United States|Forest Investigative Site 029, Louisville, Kentucky, United States|Forest Investigative Site 068, Madisonville, Kentucky, United States|Forest Investigative Site 061, Metairie, Louisiana, United States|Forest Investigative Site 057, New Orleans, Louisiana, United States|Forest Investigative Site 058, New Orleans, Louisiana, United States|Forest Investigative Site 008, Lutherville, Maryland, United States|Forest Investigative Site 062, Fall River, Massachusetts, United States|Forest Investigative Site 075, Paw Paw, Michigan, United States|Forest Investigative Site 019, Brooklyn Center, Minnesota, United States|Forest Investigative Site 017, Chaska, Minnesota, United States|Forest Investigative Site 038, Belzoni, Mississippi, United States|Forest Investigative Site 035, Olive Branch, Mississippi, United States|Forest Investigative Site 023, Las Vegas, Nevada, United States|Forest Investigative Site 048, Las Vegas, Nevada, United States|Forest Investigative Site 052, Las Vegas, Nevada, United States|Forest Investigative Site 014, Elizabeth, New Jersey, United States|Forest Investigative Site 051, Trenton, New Jersey, United States|Forest Investigative Site 003, Asheboro, North Carolina, United States|Forest Investigative Site 010, Charlotte, North Carolina, United States|Forest Investigative Site 011, Raleigh, North Carolina, United States|Forest Investigative Site 016, Raleigh, North Carolina, United States|Forest Investigative Site 005, Wilmington, North Carolina, United States|Forest Investigative Site 036, Winston-Salem, North Carolina, United States|Forest Investigative Site 002, Columbus, Ohio, United States|Forest Investigative Site 050, Norman, Oklahoma, United States|Forest Investigative Site 030, Portland, Oregon, United States|Forest Investigative Site 056, Downingtown, Pennsylvania, United States|Forest Investigative Site 022, Pelzer, South Carolina, United States|Forest Investigative Site 053, Beaumont, Texas, United States|Forest Investigative Site 066, Boerne, Texas, United States|Forest Investigative Site 076, Corpus Christi, Texas, United States|Forest Investigative Site 037, Dallas, Texas, United States|Forest Investigative Site 043, Haltom City, Texas, United States|Forest Investigative Site 015, Houston, Texas, United States|Forest Investigative Site 026, Houston, Texas, United States|Forest Investigative Site 027, Houston, Texas, United States|Forest Investigative Site 074, Houston, Texas, United States|Forest Investigative Site 071, Orem, Utah, United States|Forest Investigative Site 042, Sandy, Utah, United States|Forest Investigative Site 063, Norfolk, Virginia, United States|Forest Investigative Site 064, Norfolk, Virginia, United States|Forest Investigative Site 046, Port Orchard, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01415531"
725,"NCT02279745","Long Term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension",,"Active, not recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Ralinepag","Long-term safety assessed by adverse events up to 28 days following discontinuation of study drug","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APD811-007","July 2015","May 2020","May 2020","October 31, 2014",,"December 4, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Beverly Hills, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Cardiac and Vascular Center, Anschutz Inpatient Pavilion, Aurora, Colorado, United States|Cleveland Clinic Florida, Weston, Florida, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Chest Medicine Associates, Portland, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Boston University Medical Center General Clinical Research Unit (GCRU), Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|UC Health, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center - Martha Morehouse Medical Pavilion, Columbus, Ohio, United States|UPMC, Presbytarian, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Memorial Hermann Hospital - Texas Medical Center, Houston, Texas, United States|The Prince Charles Hospital, Chermside, Australia|St. Vincent's Hospital/Lung Transplant Unit, Darlinghurst, Australia|St Vincent's Hospital, Fitzroy, Australia|Royal Hobart Hospital, Hobart, Australia|Fiona Stanley Hospital, Murdoch, Australia|Multiprofile Hospital for Active Treatment in Cardiology EAD, Department of Cardiology, Pleven, Bulgaria|Multiprofile Hospital for Active Treatment ""National Heart Hospital"" EAD, Clinic of Cardiology, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment "" St. Anna"", Sofia AD, Cardiology Clinic, Sofia, Bulgaria|Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czechia|Second Internal Clinic - Clinic of Cardiology and Angiology, 1st Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Prague, Czechia|Gottsegen Gyorgy Orszagos Kardiológiai lntézet National Institute of Cardiology, Department of Adult Cardiology, Budapest, Hungary|Semmelweis University, Department of Pulmonology - Semmelweis Egyetem Pulmonológiai Klinika, Budapest, Hungary|University of Derecen Clinical Research Center Cardiology and Cardiac Surgery Department - Debreceni Egyetem Klinikai Kozpont Kardiologiai es Szivsebeszeti Klinika, Debrecen, Hungary|University of Pecs, Medical School, Heart Institute - Pécsi Tudományegyetem, Klinikai Központ, Szívgyógyászati Klinika, Pécs, Hungary|University of Szeged Faculty of Medicine, 2nd Department of Medicine and Cardiology Center, Albert Szent-Györyi Clinical Center - SZTE ÁOK Szent-Györgyi A lbert Klinikai Központ I I. sz. Belgyógyászati Klini ka és Kard ilógiai Központ, Szeged, Hungary|Medical University of Bialystok Clinical Hospital Cardiology Clinic - Uniwersytecki Szpital Kliniczny, Klinika Kardiologii z Oddziałem Intensywnego Nadzoru Kardiologicznego, Białystok, Poland|John Paul II Hospital in Cracov Department of Cardiac and Vascular Diseases - Krakowski Szpital Specjalistyczny im. Jana Pawła II, Oddział Kliniczny Chorób Serca i Naczyń, Krakow, Poland|Biegański Provincial Specialist Hospital Department of Cardiology - Wojewódzki Szpital Specjalistyczny im. dr Wł. Biegańskiego w Lodzi, Oddział Kardiologiczny, Lodz, Poland|""Prof. Dr. C.C. Iliescu"" Institute of Cardiovascular Diseases, Department of Clinic Cardiology III - Institutul de Urgenţă pentru Boli Cardiovasculare ""Prof. Dr. C.C. Iliescu"", Secţia Clinica Cardiologie fIJ, Bucharest, Romania|""Marius Nasta"" Institute of Pneumoftiziology, Department of Pneumoftiziology IV - Institutul de Pneumoftiziologie ""Marius Nasta"", Sectia Clinica Pneumoftiziologie IV, Bucharest, Romania|""Dr. Victor Babes"" Clinic Hospital for Infesctious Diseases and Pneumoftiziology, Department of Clinic Pneumology II, Timisoara, Romania|Clinical Centre of Serbia (CCS), Cardiology Clinic - Klinicki Centar SrЬije, Klinika za kardiologiju, Belgrade, Serbia|Кlinjcko-bolnicki centar Zemun, Кlinika za internu medicmu, Sluzba za kardiologiju, Belgrade, Serbia|Institute of Pulmonary Diseases of Vojvodina Sremska Kamenica (IPDVSK), The Clinic for Urgent Pulmonology, ICU - Intensive Care Unit - Klinicki Centar SrЬije, Klinika za kardiologiju, Sremska Kamenica, Serbia|Department of Heart Failure and Transplantation, National Institute of Cardiovascular Diseases - Oddelenie zlyhávania a transplantácie srdca, Národný ústav srdcových a cievnych chorôb, a.s., Bratislava, Slovakia|Cardiology department, East Slovak Institute for Cardiovascular Diseases - Kardiologické oddelenie Klinika kardiológie , Východoslovenský ústav srdcových a cievnych chorôb, a.s, Košice, Slovakia|General Universitary Hospital Vall d'Hebron, Department of Pneumology, Barcelona, Spain|Clinic Hospital of Barcelona, Department of Pneumology, Barcelona, Spain|Hospital 12th of October, Department of Cardiology, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02279745"
726,"NCT01576484","Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia",,"Completed","No Results Available","Hypercholesterolemia","Drug: REGN727 (SAR236553)","Incidence of AEs from baseline to end of study|Percent change in LDL-C: Baseline to weeks 12, 24, 52 and 218|Changes in other lipids and other lipoproteins","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","58","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R727-CL-1032","March 2012","December 2016","December 2016","April 12, 2012",,"February 9, 2018","Mission Viejo, California, United States|Newport Beach, California, United States|Thousand Oaks, California, United States|Miami, Florida, United States|Port Orange, Florida, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Saint Louis, Missouri, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Houston, Texas, United States|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|Sainte-Foy, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01576484"
727,"NCT01854918","Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia","OSLER-2","Completed","Has Results","Hyperlipidemia and Mixed Dyslipidemia","Biological: Evolocumab|Drug: Standard of Care","Number of Participants With Adverse Events|Percent Change From Baseline in LDL-C at Weeks 48 and 104|Change From Baseline in LDL-C at Weeks 48 and 104","Amgen","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","3681","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120138|2012-004357-83","April 23, 2013","May 31, 2018","May 31, 2018","May 16, 2013","June 11, 2019","June 11, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Beverly Hills, California, United States|Research Site, Carmichael, California, United States|Research Site, Encinitas, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Newport Beach, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Spring Valley, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Torrance, California, United States|Research Site, Tustin, California, United States|Research Site, Ventura, California, United States|Research Site, Littleton, Colorado, United States|Research Site, Daytona Beach, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Sanford, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Sterling, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Monroe, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Bethesda, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Ayer, Massachusetts, United States|Research Site, Quincy, Massachusetts, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Edina, Minnesota, United States|Research Site, Olive Branch, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Endwell, New York, United States|Research Site, Manlius, New York, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Cadiz, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Mansfield, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Lansdale, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Suffolk, Virginia, United States|Research Site, Renton, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Maroubra, New South Wales, Australia|Research Site, Sydney, New South Wales, Australia|Research Site, Sydney, New South Wales, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Carina Heights, Queensland, Australia|Research Site, Sherwood, Queensland, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Heidelberg Heights, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Salzburg, Austria|Research Site, Anthée, Belgium|Research Site, Blankenberge, Belgium|Research Site, Bruxelles, Belgium|Research Site, Bruxelles, Belgium|Research Site, Chênée, Belgium|Research Site, Gent, Belgium|Research Site, Gozee, Belgium|Research Site, Gribomont, Belgium|Research Site, Halen, Belgium|Research Site, Ham, Belgium|Research Site, Hasselt, Belgium|Research Site, La Louvière, Belgium|Research Site, Linkebeek, Belgium|Research Site, Oostende, Belgium|Research Site, Tessenderlo, Belgium|Research Site, Tremelo, Belgium|Research Site, Vilvoorde, Belgium|Research Site, Burnaby, British Columbia, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Bay Roberts, Newfoundland and Labrador, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Granby, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Chomutov, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Kladno, Czechia|Research Site, Litomerice, Czechia|Research Site, Moravske Budejovice, Czechia|Research Site, Olomouc, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 3, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Slany, Czechia|Research Site, Svitavy, Czechia|Research Site, Aalborg, Denmark|Research Site, Aarhus N, Denmark|Research Site, Ballerup, Denmark|Research Site, Glostrup, Denmark|Research Site, Vejle, Denmark|Research Site, Brest Cedex 2, France|Research Site, Bron, France|Research Site, Caen Cedex 9, France|Research Site, Dijon, France|Research Site, Montpellier cedex 05, France|Research Site, Nantes Cedex 1, France|Research Site, Paris Cedex 12, France|Research Site, Paris Cedex 13, France|Research Site, Vénissieux, France|Research Site, Bad Krozingen, Germany|Research Site, Berlin (Hellersdorf), Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Heppenheim, Germany|Research Site, Homburg, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Magdeburg, Germany|Research Site, Messkirch, Germany|Research Site, München, Germany|Research Site, Witten, Germany|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Baja, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Eger, Hungary|Research Site, Gyongyos, Hungary|Research Site, Hodmezovasarhely, Hungary|Research Site, Jaszbereny, Hungary|Research Site, Komarom, Hungary|Research Site, Mosonmagyarovar, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Bologna, Italy|Research Site, Cagliari, Italy|Research Site, Chieti, Italy|Research Site, Cinisello Balsamo (MI), Italy|Research Site, Ferrara, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Pisa, Italy|Research Site, Trieste, Italy|Research Site, Noda-shi, Chiba, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kitakyusyu-shi, Fukuoka, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Takasaki-shi, Gunma, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Tsuchiura-shi, Ibaraki, Japan|Research Site, Morioka-shi, Iwate, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Tomigusuku-shi, Okinawa, Japan|Research Site, Ibaraki-shi, Osaka, Japan|Research Site, Toyonaka-shi, Osaka, Japan|Research Site, Koshigaya-shi, Saitama, Japan|Research Site, Niiza-shi, Saitama, Japan|Research Site, Arakawa-ku, Tokyo, Japan|Research Site, Chiyoda-ku, Tokyo, Japan|Research Site, Chofu-shi, Tokyo, Japan|Research Site, Edogawa-ku, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Katsushika-ku, Tokyo, Japan|Research Site, Koto-ku, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Ota-ku, Tokyo, Japan|Research Site, Setagaya-ku, Tokyo, Japan|Research Site, Shibuya-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Toshima-ku, Tokyo, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Den Helder, Netherlands|Research Site, Groningen, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Waalwijk, Netherlands|Research Site, Zwijndrecht, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Oslo, Norway|Research Site, Ålesund, Norway|Research Site, Lodz, Poland|Research Site, Barnaul, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Centurion, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Midrand, Gauteng, South Africa|Research Site, Sunninghill, Gauteng, South Africa|Research Site, Amanzimtoti, KwaZulu-Natal, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Paarl, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, L'Hospitalet de Llobregat, Cataluña, Spain|Research Site, Reus, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Göteborg, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uddevalla, Sweden|Research Site, Örebro, Sweden|Research Site, Bellinzona, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lugano, Switzerland|Research Site, Muensterlingen, Switzerland|Research Site, Reinach, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Zurich, Switzerland|Research Site, Zurich, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Birmingham, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Doncaster, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Telford, United Kingdom|Research Site, Wakefield, United Kingdom|Research Site, West Bromwich, United Kingdom|Research Site, Whitby, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01854918/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01854918/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01854918"
728,"NCT02174991","A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention",,"Unknown status","No Results Available","Glaucoma","Drug: Rho-Kinase Inhibitor (AR-12286)","IOP Reduction|Tolerance and Lasting IOP Effect","New York Glaucoma Research Institute","All","Child, Adult, Older Adult","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","14.15","June 2014","February 2015",,"June 26, 2014",,"April 24, 2015","Glaucoma Associates of New York, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02174991"
729,"NCT01031680","Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension",,"Completed","Has Results","Type 2 Diabetes Mellitus|Cardiovascular Disease|Hypertension|Inadequate Glycaemic Control","Drug: Dapagliflozin|Drug: Placebo","Adjusted Mean Change in HbA1c Levels|Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit|Adjusted Mean Change in Seated Systolic Blood Pressure (SBP)|Adjusted Mean Percent Change in Body Weight|Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 24 (LOCF)|Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²","AstraZeneca|Bristol-Myers Squibb","All","45 Years and older   (Adult, Older Adult)","Phase 3","922","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1690C00018","February 2010","May 2011","December 2012","December 14, 2009","August 23, 2013","October 29, 2013","Research Site, Gulf Shores, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Burbank, California, United States|Research Site, Garden Grove, California, United States|Research Site, Huntington Park, California, United States|Research Site, Lancaster, California, United States|Research Site, Salinas, California, United States|Research Site, San Marino, California, United States|Research Site, San Ramon, California, United States|Research Site, Tustin, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Clearwater, Florida, United States|Research Site, Deerfield Beach, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Columbus, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Stone Mountain, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Chicago, Illinois, United States|Research Site, Wichita, Kansas, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, West Monroe, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Kansas City, Missouri, United States|Research Site, St Louis, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Brick, New Jersey, United States|Research Site, Oradell, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Phoenixville, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Reading, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Carrollton, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, North Richland Hills, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Danville, Virginia, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Buenos Aires, Caba, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Mendoza, Argentina|Research Site, Santa Fe, Argentina|Research Site, Calgary, Alberta, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Carbonear, Newfoundland and Labrador, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Courtice, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Smiths Falls, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saint-marc-des-carrieres, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Potsdam, BR, Germany|Research Site, Bad Nauheim, Germany|Research Site, Berlin, Germany|Research Site, Erdmannhausen, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Heilbronn, Germany|Research Site, Hildesheim, Germany|Research Site, Mainz, Germany|Research Site, Munster, Germany|Research Site, Potsdam, Germany|Research Site, Speyer, Germany|Research Site, Wahlstedt, Germany|Research Site, Braila, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Constanta, Romania|Research Site, Iasi, Romania|Research Site, Sibiu, Romania|Research Site, Suceava, Romania|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Dolny Kubin, Slovakia|Research Site, Komarno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kysucke Nove Mesto, Slovakia|Research Site, Liptovsky Hradok, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Nitra, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Prievidza, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Ruzomberok, Slovakia|Research Site, Zilina, Slovakia|Research Site, Cordoba, Andalucia, Spain|Research Site, Granada, Andalucia, Spain|Research Site, Sevilla, Andalucia, Spain|Research Site, Oviedo, Asturias, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Lerida, Cataluna, Spain|Research Site, Olot (girona), Cataluna, Spain|Research Site, Majadahonda, Comunidad de Madrid, Spain|Research Site, San Juan (alicante), Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A Coruna, Galicia, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Palma de Mallorca, Islas Baleares, Spain|Research Site, Changhua, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan County, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-yuan, Taiwan|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT01031680"
730,"NCT01302249","AR-12286 in Combination With Latanoprost",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: Latanoprost 0.005%|Drug: AR-12286 Ophthalmic Solution 0.5%|Drug: Timolol maleate ophthalmic solution 0.5%","Intraocular pressure|Ocular safety|Systemic safety","Aerie Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AR-12286-CS203","February 2011","December 2011","December 2011","February 24, 2011",,"May 8, 2014","David Silverstone, M.D., New Haven, Connecticut, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|Heart of America Eye Care, P.A., Shawnee Mission, Kansas, United States|Taustine Eye Center, Louisville, Kentucky, United States|Alan L Robin, M.D., Baltimore, Maryland, United States|Comprehensive Eye Care, St Louis, Missouri, United States|Rochester Ophthalmology Group, Rochester, New York, United States|Glaucoma Consultants of the Capital Region, Slingerlands, New York, United States|Thomas K. Mundorf, M.D., Charlotte, North Carolina, United States|Charlotte Eye Ear Nose and Throat, Charlotte, North Carolina, United States|The Eye Institute, Tulsa, Oklahoma, United States|Wills Eye Hospital, Philadelphia, Pennsylvania, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Cataract & Glaucoma Center, El Paso, Texas, United States|Stacy R. Smith, M.D., Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01302249"
731,"NCT00863681","BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension","PATENT-2","Completed","No Results Available","Hypertension, Pulmonary","Drug: Riociguat (BAY63-2521)","Safety (adverse events collection) and tolerability|Change in 6MWD (6 minute walking distance) from baseline","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","396","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12935|2008-003610-94","March 12, 2009","August 19, 2019","August 19, 2019","March 18, 2009",,"September 11, 2019","Los Angeles, California, United States|Sacramento, California, United States|Aurora, Colorado, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Omaha, Nebraska, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Fairfield, Ohio, United States|Dallas, Texas, United States|El Paso, Texas, United States|Capital Federal, Argentina|Darlinghurst, New South Wales, Australia|Auchenflower, Queensland, Australia|Chermside, Queensland, Australia|Hobart, Tasmania, Australia|Prahran, Victoria, Australia|Linz, Oberösterreich, Austria|Innsbruck, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Leuven, Belgium|Porto Alegre, Rio Grande Do Sul, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Calgary, Alberta, Canada|Montreal, Quebec, Canada|Guangzhou, Guangdong, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Praha 2, Czechia|Aarhus N, Denmark|Besancon, France|Brest, France|GRENOBLE Cedex 09, France|Lille Cedex, France|Montpellier, France|Pessac, France|Rouen, France|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|Gießen, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Chaidari, Greece|Trieste, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Nagoya, Aichi, Japan|Kobe, Hyogo, Japan|Toride, Ibaraki, Japan|Tsukuba, Ibaraki, Japan|Kanazawa, Ishikawa, Japan|Sendai, Miyagi, Japan|Tomigusuku, Okinawa, Japan|Bunkyo-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Ota-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Hiroshima, Japan|Okayama, Japan|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Antiguo Hospital Civil de Guadalajara ""Fray Antonio Alcalde"", Guadalajara, Jalisco, Mexico|Pulmocritic, Guadalajara, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Culiacan, Sinaloa, Mexico|Mexico D.F., Mexico|Querétaro, Mexico|Otwock, Poland|Coimbra, Portugal|Lisboa, Portugal|Centro Hospitalar de Lisboa Norte - Hospital Santa Maria, Lisboa, Portugal|Moscow, Russian Federation|St. Petersburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Umeå, Sweden|Zürich, Switzerland|Kaoshiung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Chiang Mai, Thailand|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Clydebank, West Dunbartonshire, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00863681"
732,"NCT00868894","Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Drug: DE-104 medium concentration|Drug: DE-104 high concentration|Drug: Placebo|Drug: 0.005% latanoprost","To compare the safety and efficacy of two concentrations of DE-104 ophthalmic solution with placebo and 0.005% latanoprost in Japanese and Non-Japanese subjects with primary open-angle glaucoma or ocular hypertension.|To investigate the dose-response relationship of DE-104 in lowering intraocular pressure in Japanese and Non-Japanese subjects with primary open-angle glaucoma or ocular hypertension.","Santen Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","27-003","March 2009","May 2010","June 2010","March 25, 2009",,"November 3, 2011","Artesia, California, United States|Pasadena, California, United States|San Francisco, California, United States|Honolulu, Hawaii, United States|Kailua, Hawaii, United States|New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00868894"
733,"NCT02608697","A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia",,"Completed","No Results Available","Hypercholesterolemia","Drug: CAT-2054|Drug: Placebo|Drug: Atorvastatin","Percent change in LDL-C from baseline in patients with hypercholesterolemia.|Frequency of adverse events|Percent change in TG, non-HDL-C, total cholesterol, HDL-C, apoB from baseline in patients with hypercholesterolemia","Catabasis Pharmaceuticals","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 2","153","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAT-2054-201","October 2015","May 2016","June 2016","November 20, 2015",,"June 20, 2017","Muscle Shoals, Alabama, United States|Huntington Park, California, United States|Lomita, California, United States|Los Angeles, California, United States|Brooksville, Florida, United States|Hialeah, Florida, United States|Jupiter, Florida, United States|Pembroke Pines, Florida, United States|Winter Park, Florida, United States|Chicago, Illinois, United States|Evanston, Illinois, United States|Indianapolis, Indiana, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Troy, Michigan, United States|Las Vegas, Nevada, United States|New York, New York, United States|Rochester, New York, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Franklin, Ohio, United States|Lyndhurst, Ohio, United States|Marion, Ohio, United States|Willoughby Hills, Ohio, United States|Mount Pleasant, South Carolina, United States|Summerville, South Carolina, United States|Houston, Texas, United States|Houston, Texas, United States|Orem, Utah, United States|Richmond, Virginia, United States|Olympia, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02608697"
734,"NCT00910429","BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension","CHEST-2","Completed","No Results Available","Pulmonary Hypertension","Drug: Riociguat (Adempas, BAY63-2521)","Safety and tolerability (e.g. adverse event collection)|Change in 6-Minute Walking Distance (6MWD) from baseline","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","237","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11349|2008-003539-19","July 1, 2009","August 19, 2019","August 19, 2019","May 29, 2009",,"August 29, 2019","La Jolla, California, United States|Sacramento, California, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Dallas, Texas, United States|Corrientes, Argentina|Prahran, Victoria, Australia|Wien, Austria|Bruxelles - Brussel, Belgium|Leuven, Belgium|Porto Alegre, Rio Grande Do Sul, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Calgary, Alberta, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Beijing, China|Beijing, China|Shanghai, China|Praha 2, Czechia|Aarhus N, Denmark|Brest, France|Le Kremlin Bicetre Cedex, France|Rouen, France|Vandoeuvre Les Nancy, France|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|Würzburg, Bayern, Germany|Gießen, Hessen, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Hamburg, Germany|Rabin Medical Center - Beilinson Campus, Petach Tikva, Israel|Pavia, Lombardia, Italy|Nagoya, Aichi, Japan|Kitakyushu, Fukuoka, Japan|Komatsu, Ishikawa, Japan|Fujisawa, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Sendai, Miyagi, Japan|Suwa, Nagano, Japan|Bunkyo-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Chiba, Japan|Fukuoka, Japan|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Monterrey, Nuevo Leon, Mexico|Mexico D.F., Mexico|Querétaro, Mexico|Krakow, Poland|Otwock, Poland|Coimbra, Portugal|Centro Hospitalar de Lisboa Norte - Hospital Santa Maria, Lisboa, Portugal|Novosibirsk, Russian Federation|St. Petersburg, Russian Federation|Bratislava 37, Slovakia|Barcelona, Spain|Zürich, Switzerland|Taipei, Taiwan|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Glasgow, West Dunbartonshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00910429"
735,"NCT01256476","Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia","PREVAIL-US","Completed","Has Results","Primary Dyslipidemia|Mixed Dyslipidemia","Drug: pitavastatin|Drug: pravastatin","Mean Percent Change in Low Density Lipoprotein Cholesterol(LDL-C) From Baseline to Week 12","Kowa Research Institute, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","328","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NK-104-4.04US","October 2010","June 2011","June 2011","December 8, 2010","April 30, 2012","May 8, 2012","Huntsville, Alabama, United States|Muscle Shoals, Alabama, United States|Chandler, Arizona, United States|Goodyear, Arizona, United States|Phoenix, Arizona, United States|Beverly Hills, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Colorado Springs, Colorado, United States|Clearwater, Florida, United States|Deland, Florida, United States|Fort Luaderdale, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Ovido, Florida, United States|Pembroke Pines, Florida, United States|Ponte Vedra, Florida, United States|Addison, Illinois, United States|Chicago, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Kansas City, Kansas, United States|Erlanger, Kentucky, United States|Baltimore, Maryland, United States|Brockton, Massachusetts, United States|Edina, Minnesota, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Rochester, New York, United States|Statesville, North Carolina, United States|Cincinnati, Ohio, United States|Lyndhurst, Ohio, United States|Willoughby Hills, Ohio, United States|Tulsa, Oklahoma, United States|Eugene, Oregon, United States|Greer, South Carolina, United States|Mt. Pleasant, South Carolina, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Olympia, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01256476"
736,"NCT03697811","DE-117 Spectrum 5 Study",,"Recruiting","No Results Available","Primary Open-angle Glaucoma and Ocular Hypertension","Drug: DE-117 Ophthalmic Solution","Intraocular pressure","Santen Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","150","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","011711IN","September 27, 2018","December 31, 2020","December 31, 2020","October 5, 2018",,"January 10, 2020","Arizona Eye Center, Chandler, Arizona, United States|Global Research Management, Glendale, California, United States|North Valley Eye Medical Group, Mission Hills, California, United States|Eye Research Foundation, Newport Beach, California, United States|North Bay Eye Associates, Petaluma, California, United States|Martel Eye Medical Group, Rancho Cordova, California, United States|Danbury Eye Physicians & Surgeons, Danbury, Connecticut, United States|Shettle Eye Research, Inc., Largo, Florida, United States|International Eye Associates, PA, Ormond Beach, Florida, United States|Dixon Eye Care, Albany, Georgia, United States|Clayton Eye Clinical Research, LLC, Morrow, Georgia, United States|Coastal Research Associates, LEC, Roswell, Georgia, United States|Heart of America Eye Care, P.A., Shawnee Mission, Kansas, United States|Tekwani Vision Center, Saint Louis, Missouri, United States|Comprehensive Eye Care Ltd, Washington, Missouri, United States|Rochester Ophthalmological Group, PC, Rochester, New York, United States|South Shore Eye Center, Wantagh, New York, United States|Asheville Eye Associates, PLLC, Asheville, North Carolina, United States|Mundorf Eye Center, Charlotte, North Carolina, United States|Cornerstone Health Care, High Point, North Carolina, United States|Apex Eye Clinical Research, LLC, Cincinnati, Ohio, United States|Abrams Eye Center, Cleveland, Ohio, United States|The Eye Institute, Tulsa, Oklahoma, United States|Scott & Christie and Associates PC, Cranberry Township, Pennsylvania, United States|Glaucoma Consultants and Center for Eye Research, PA, Mount Pleasant, South Carolina, United States|Total Eye Care PA, Memphis, Tennessee, United States|VRF Eye Specialty Group, Memphis, Tennessee, United States|Nashville Vision Associates, Nashville, Tennessee, United States|Texas Eye, PA, Austin, Texas, United States|Eye Clinic of Texas, League City, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03697811"
737,"NCT01413542","Pharmacogenetics of Ace Inhibitor-Associated Angioedema",,"Completed","Has Results","Hypertension|Diabetes Type 2","Drug: Sitagliptin (DPP4 inhibitor)|Drug: Substance P,|Drug: bradykinin|Drug: enalaprilat (ACE inhibitor)|Drug: Glucagon-like peptide 1|Drug: brain natriuretic peptide","The Effect of Enalaprilat (ACE Inhibition), Sitagliptin (DPP4 Inhibition), or the Combination on the Vasodilator Response (Forearm Blood Flow) to Substance P (SP) and Bradykinin (Group 1) or Glucagon Like Peptide-1 and Brain Naturetic Peptide (Group 2).|Assess Tissue Type Plasminogen Activator (tPA) Release|Assess Effect of ACE and/or DPP4 Inhibition on Heart Rate Response to Substance P (SP)|Effect of Treatment (ACE or DPP4 Inhibition, or Combined) on Norepinephrine (NE) Release (Arterial Venous Gradient) in Response to Substance P (SP)|Effect of Treatment (DPP4 Inhibition vs. Placebo) on Venous GLP-1 Levels in Response to Arterial GLP-1 Infusion","Vanderbilt University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HL079184","November 2011","July 2013","July 2014","August 10, 2011","November 4, 2015","November 4, 2015","Vanderbilt University- General Clinic Research Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01413542"
738,"NCT01448824","A Study of LY2484595 on Pharmacokinetics in Healthy Participants",,"Completed","Has Results","Healthy Participants","Drug: LY2484595|Drug: Placebo|Drug: Ketoconazole","Part 1: Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs|Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2484595|Pharmacokinetics: Time of Maximum Observed Plasma Concentration (Tmax) of LY2484595|Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of LY2484595|Pharmacodynamics: Change From Baseline to Day 21 in Cholesteryl Ester Transfer Protein (CETP) Activity|Pharmacodynamics: Change From Baseline to Day 21 in High-density Lipoprotein Cholesterol (HDL-C), Low-density Lipoprotein Cholesterol (LDL-C), and Triglycerides (TG)","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","82","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","14460|I1V-MC-EIAL","October 2011","February 2012","February 2012","October 7, 2011","April 2, 2019","April 2, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01448824"
739,"NCT02922426","An Insulin Sensitivity Study in Healthy Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: ALKS 3831|Drug: Olanzapine|Drug: Placebo","Changes in blood glucose concentrations|Changes in insulin concentrations|Incidence of treatment-emergent adverse events (AEs)","Alkermes, Inc.","All","18 Years to 40 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALK3831-A108","September 2016","July 20, 2017","July 20, 2017","October 4, 2016",,"August 22, 2017","Alkermes Investigational Site, Chula Vista, California, United States",,"https://ClinicalTrials.gov/show/NCT02922426"
740,"NCT00847626","Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension",,"Completed","Has Results","Hypertension","Drug: Azilsartan medoxomil and chlorthalidone|Drug: Chlorthalidone|Drug: Azilsartan medoxomil","Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)|Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pairwise Analysis)|Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure|Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pooled Analysis)|Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pairwise Analysis)|Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure|Change From Baseline to Week 8 in the Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing), as Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring|Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring|Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline to Week 8 in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.|Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.|Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response at Week 8, as Defined by Clinic Systolic Blood Pressure <140 mm Hg and/or a Reduction of ≥20 mm Hg From Baseline.|Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response at Week 8, Defined as Clinic Diastolic Blood Pressure <90 mm Hg and/or a Reduction of ≥10 mm Hg From Baseline.|Percentage of Participants Who Achieve Both a Clinic Systolic and Diastolic Blood Pressure Response at Week 8.","Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 3","1711","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-491CLD_302|2008-004218-28|U1111-1113-8735","January 2009","May 2010","July 2010","February 19, 2009","February 7, 2012","February 7, 2012","Birmingham, Alabama, United States|Columbiana, Alabama, United States|Tuscaloosa, Alabama, United States|Chandler, Arizona, United States|Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Little Rock, Arkansas, United States|Buena Park, California, United States|Carmichael, California, United States|Costa Mesa, California, United States|Irvine, California, United States|Palm Springs, California, United States|Riverside, California, United States|Sacramento, California, United States|San Diego, California, United States|Vista, California, United States|Walnut Creek, California, United States|Middletown, Delaware, United States|Bradenton, Florida, United States|Deerfield Beach, Florida, United States|Fort Lauderdale, Florida, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Longwood, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Ormond Beach, Florida, United States|St Petersburg, Florida, United States|Atlanta, Georgia, United States|Buffalo Grove, Illinois, United States|Libertyville, Illinois, United States|Melrose Park, Illinois, United States|Fishers, Indiana, United States|Indianapolis, Indiana, United States|Erlanger, Kentucky, United States|Madisonville, Kentucky, United States|Paducah, Kentucky, United States|Rockville, Maryland, United States|Ann Arbor, Michigan, United States|Chesterfield, Michigan, United States|St Louis, Missouri, United States|Omaha, Nebraska, United States|Henderson, Nevada, United States|Brick, New Jersey, United States|Margate, New Jersey, United States|Albuquerque, New Mexico, United States|Endwell, New York, United States|Cary, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Lyndhurst, Ohio, United States|Willoughby Hills, Ohio, United States|Oklahoma City, Oklahoma, United States|Ashland, Oregon, United States|Altoona, Pennsylvania, United States|Bensalem, Pennsylvania, United States|Feasterville, Pennsylvania, United States|Jenkintown, Pennsylvania, United States|Sellersville, Pennsylvania, United States|Warminster, Pennsylvania, United States|Charleston, South Carolina, United States|Florence, South Carolina, United States|Murrells Inlet, South Carolina, United States|Simpsonville, South Carolina, United States|Spartanburg, South Carolina, United States|Clarksville, Tennessee, United States|New Tazewell, Tennessee, United States|Austin, Texas, United States|Bellaire, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|McKinney, Texas, United States|Richardson, Texas, United States|San Antonio, Texas, United States|Magna, Utah, United States|West Jordan, Utah, United States|Arlington, Virginia, United States|Virginia Beach, Virginia, United States|Oregon, Wisconsin, United States|Santiago, Chile|Temuco, Chile|Aguascalientes, Mexico|Merida, Mexico|Mexico DF, Mexico|Bellavista, Peru|Chiclayo, Peru|Jesus Maria, Peru|Miraflores, Peru|San Borja, Peru|San Martin de Porres, Peru|Trujillo, Peru|Umacollo, Peru|Moscow, Russian Federation|St. Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00847626"
741,"NCT01687257","Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation",,"Completed","Has Results","Hepatitis C|Cirrhosis|Portal Hypertension|With or Without Liver Decompensation","Drug: SOF|Drug: RBV","Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)|Percentage of Participants With SVR at 4, 24, and 48 Weeks After Discontinuation of Therapy (SVR4, SVR24, and SVR48)|Percentage of Participants Experiencing On-Treatment Virologic Failure|Percentage of Participants Experiencing Viral Relapse|Change From Baseline in Hepatic Venous Pressure Gradient (HVPG) at End of Treatment|Change From Baseline in Child-Pugh-Turcotte (CPT) Score|Change From Baseline in Model for End Stage Liver Disease (MELD) Scores","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-334-0125|2012-002457-29","July 2012","January 2015","October 2015","September 18, 2012","February 24, 2016","September 16, 2016","Aurora, Colorado, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Philadelphia, Pennsylvania, United States|Newtown, New South Wales, Australia|Leclerc, Clichy, France|Grafton, Auckland, New Zealand|Majadahonda, Madrid, Spain|Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01687257"
742,"NCT00860262","Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension",,"Completed","Has Results","Hypertension","Drug: amlodipine|Drug: telmisartan|Drug: telmisartan and amlodipine","Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8|Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6|Change From Baseline in Trough Seated Systolic Blood Pressure at Week 4|Change From Baseline in Trough Seated Systolic Blood Pressure at Week 2|Change From Baseline in Trough Seated Systolic Blood Pressure at Week 1|Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) at Week 8|Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6|Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 4|Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 2|Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 1|Patients Achieving Diastolic Blood Pressure Control at Week 1|Patients Achieving Diastolic Blood Pressure Control at Week 2|Patients Achieving Blood Pressure Control at Week 1|Patients Achieving Blood Pressure Control at Week 2|Patients Achieving Diastolic Blood Pressure Response at Week 1|Patients Achieving Diastolic Blood Pressure Response at Week 2|Patients Achieving Systolic Blood Pressure Response at Week 1|Patients Achieving Systolic Blood Pressure Response at Week 2|Number of Patients Achieving Various Blood Pressure Response Levels at Week 1|Number of Patients Achieving Various Blood Pressure Response Levels at Week 2|Patients Achieving Diastolic Blood Pressure Control at Week 4|Patients Achieving Diastolic Blood Pressure Control at Week 6|Patients Achieving Diastolic Blood Pressure Control at Week 8|Patients Achieving Blood Pressure Control at Week 4|Patients Achieving Blood Pressure Control at Week 6|Patients Achieving Blood Pressure Control at Week 8|Patients Achieving Diastolic Blood Pressure Response at Week 4|Patients Achieving Diastolic Blood Pressure Response at Week 6|Patients Achieving Diastolic Blood Pressure Response at Week 8|Patients Achieving Systolic Blood Pressure Response at Week 4|Patients Achieving Systolic Blood Pressure Response at Week 6|Patients Achieving Systolic Blood Pressure Response at Week 8|Patients Achieving Normal Blood Pressure Response at Week 4|Patients Achieving Normal Blood Pressure Response at Week 6|Patients Achieving Normal Blood Pressure Response at Week 8","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","858","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1235.20|2008-000873-40","March 2009","December 2009",,"March 12, 2009","January 4, 2011","May 20, 2014","1235.20.525 Boehringer Ingelheim Investigational Site, Buena Park, California, United States|1235.20.503 Boehringer Ingelheim Investigational Site, Long Beach, California, United States|1235.20.507 Boehringer Ingelheim Investigational Site, Long Beach, California, United States|1235.20.529 Boehringer Ingelheim Investigational Site, Roseville, California, United States|1235.20.518 Boehringer Ingelheim Investigational Site, Tustin, California, United States|1235.20.521 Boehringer Ingelheim Investigational Site, Westlake Village, California, United States|1235.20.508 Boehringer Ingelheim Investigational Site, DeLand, Florida, United States|1235.20.506 Boehringer Ingelheim Investigational Site, Hialeah, Florida, United States|1235.20.519 Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States|1235.20.523 Boehringer Ingelheim Investigational Site, Port Orange, Florida, United States|1235.20.528 Boehringer Ingelheim Investigational Site, Blue Ridge, Georgia, United States|1235.20.516 Boehringer Ingelheim Investigational Site, North Dartmouth, Massachusetts, United States|1235.20.527 Boehringer Ingelheim Investigational Site, Bay City, Michigan, United States|1235.20.510 Boehringer Ingelheim Investigational Site, Las Vegas, Nevada, United States|1235.20.512 Boehringer Ingelheim Investigational Site, Albuquerque, New Mexico, United States|1235.20.509 Boehringer Ingelheim Investigational Site, Bronx, New York, United States|1235.20.511 Boehringer Ingelheim Investigational Site, Kettering, Ohio, United States|1235.20.515 Boehringer Ingelheim Investigational Site, Tulsa, Oklahoma, United States|1235.20.534 Boehringer Ingelheim Investigational Site, Medford, Oregon, United States|1235.20.526 Boehringer Ingelheim Investigational Site, Erie, Pennsylvania, United States|1235.20.513 Boehringer Ingelheim Investigational Site, Tipton, Pennsylvania, United States|1235.20.517 Boehringer Ingelheim Investigational Site, Providence, Rhode Island, United States|1235.20.522 Boehringer Ingelheim Investigational Site, Carrollton, Texas, United States|1235.20.520 Boehringer Ingelheim Investigational Site, Houston, Texas, United States|1235.20.530 Boehringer Ingelheim Investigational Site, Killeen, Texas, United States|1235.20.535 Boehringer Ingelheim Investigational Site, Draper, Utah, United States|1235.20.533 Boehringer Ingelheim Investigational Site, Magna, Utah, United States|1235.20.505 Boehringer Ingelheim Investigational Site, Saratoga Springs, Utah, United States|1235.20.537 Boehringer Ingelheim Investigational Site, Tacoma, Washington, United States|1235.20.501 Boehringer Ingelheim Investigational Site, Madison, Wisconsin, United States|1235.20.001 Boehringer Ingelheim Investigational Site, Bourgas, Bulgaria|1235.20.002 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|1235.20.003 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|1235.20.005 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|1235.20.006 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|1235.20.007 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|1235.20.008 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|1235.20.009 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|1235.20.004 Boehringer Ingelheim Investigational Site, Stara Zagora, Bulgaria|1235.20.052 Boehringer Ingelheim Investigational Site, Benatky nad Jizerou, Czech Republic|1235.20.059 Boehringer Ingelheim Investigational Site, Cesky Krumlov, Czech Republic|1235.20.051 Boehringer Ingelheim Investigational Site, Plzen, Czech Republic|1235.20.053 Boehringer Ingelheim Investigational Site, Praha 5, Czech Republic|1235.20.054 Boehringer Ingelheim Investigational Site, Pribram, Czech Republic|1235.20.055 Boehringer Ingelheim Investigational Site, Slany, Czech Republic|1235.20.057 Boehringer Ingelheim Investigational Site, Strakonice, Czech Republic|1235.20.058 Boehringer Ingelheim Investigational Site, Tabor, Czech Republic|1235.20.101A Boehringer Ingelheim Investigational Site, Albens, France|1235.20.102F Boehringer Ingelheim Investigational Site, Arles, France|1235.20.103A Boehringer Ingelheim Investigational Site, Beziers, France|1235.20.103C Boehringer Ingelheim Investigational Site, Beziers, France|1235.20.103F Boehringer Ingelheim Investigational Site, Beziers, France|1235.20.106A Boehringer Ingelheim Investigational Site, Bourg des cptes, France|1235.20.109B Boehringer Ingelheim Investigational Site, Brive, France|1235.20.108E Boehringer Ingelheim Investigational Site, Carbonne, France|1235.20.101D Boehringer Ingelheim Investigational Site, Chambery, France|1235.20.103E Boehringer Ingelheim Investigational Site, Cournonterral, France|1235.20.108C Boehringer Ingelheim Investigational Site, Cugnaux, France|1235.20.106D Boehringer Ingelheim Investigational Site, Etrelles, France|1235.20.108F Boehringer Ingelheim Investigational Site, Fenouillet, France|1235.20.102A Boehringer Ingelheim Investigational Site, Gemenos, France|1235.20.102C Boehringer Ingelheim Investigational Site, Gemenos, France|1235.20.101C Boehringer Ingelheim Investigational Site, Gresy Sur Aix, France|1235.20.108A Boehringer Ingelheim Investigational Site, Labarthe Sur Leze, France|1235.20.108B Boehringer Ingelheim Investigational Site, Labarthe sur Leze, France|1235.20.106F Boehringer Ingelheim Investigational Site, Louvigne De bais, France|1235.20.102E Boehringer Ingelheim Investigational Site, Marseille, France|1235.20.106B Boehringer Ingelheim Investigational Site, Mordelles, France|1235.20.107A Boehringer Ingelheim Investigational Site, Ortez, France|1235.20.107B Boehringer Ingelheim Investigational Site, Orthez, France|1235.20.107E Boehringer Ingelheim Investigational Site, Orthez, France|1235.20.107G Boehringer Ingelheim Investigational Site, Orthez, France|1235.20.109A Boehringer Ingelheim Investigational Site, Rosiers d'Egletons, France|1235.20.109F Boehringer Ingelheim Investigational Site, Saint Aulaire, France|1235.20.104A Boehringer Ingelheim Investigational Site, Saint Etienne, France|1235.20.104D Boehringer Ingelheim Investigational Site, Saint Etienne, France|1235.20.107F Boehringer Ingelheim Investigational Site, Salies de Bearn, France|1235.20.105A Boehringer Ingelheim Investigational Site, Toulon, France|1235.20.105D Boehringer Ingelheim Investigational Site, Toulon, France|1235.20.152 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1235.20.156 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1235.20.158 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1235.20.159 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1235.20.161 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1235.20.153 Boehringer Ingelheim Investigational Site, Gyongyos, Hungary|1235.20.154 Boehringer Ingelheim Investigational Site, Miskolc, Hungary|1235.20.157 Boehringer Ingelheim Investigational Site, Miskolc, Hungary|1235.20.155 Boehringer Ingelheim Investigational Site, Mosonmagyarovar, Hungary|1235.20.207 Boehringer Ingelheim Investigational Site, Busan, Korea, Republic of|1235.20.206 Boehringer Ingelheim Investigational Site, Chunan, Korea, Republic of|1235.20.205 Boehringer Ingelheim Investigational Site, Koyang, Korea, Republic of|1235.20.201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1235.20.202 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1235.20.203 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1235.20.204 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1235.20.252 Boehringer Ingelheim Investigational Site, Braila, Romania|1235.20.259 Boehringer Ingelheim Investigational Site, Bucharest, Romania|1235.20.262 Boehringer Ingelheim Investigational Site, Bucharest, Romania|1235.20.254 Boehringer Ingelheim Investigational Site, Iasi, Romania|1235.20.261 Boehringer Ingelheim Investigational Site, Oradea, Romania|1235.20.256 Boehringer Ingelheim Investigational Site, Sibiu, Romania|1235.20.251 Boehringer Ingelheim Investigational Site, Targu-Mures, Romania|1235.20.260 Boehringer Ingelheim Investigational Site, Tg. Mures, Romania|1235.20.253 Boehringer Ingelheim Investigational Site, Timisoara, Romania|1235.20.301 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1235.20.302 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1235.20.303 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1235.20.304 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1235.20.310 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1235.20.305 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1235.20.306 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1235.20.307 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1235.20.308 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1235.20.309 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1235.20.311 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1235.20.355 Boehringer Ingelheim Investigational Site, Galanta, Slovakia|1235.20.353 Boehringer Ingelheim Investigational Site, Kosice, Slovakia|1235.20.352 Boehringer Ingelheim Investigational Site, Povazska Bystrica, Slovakia|1235.20.354 Boehringer Ingelheim Investigational Site, Rimavska Sobota, Slovakia|1235.20.356 Boehringer Ingelheim Investigational Site, Trnava, Slovakia|1235.20.351 Boehringer Ingelheim Investigational Site, Vrable, Slovakia|1235.20.406 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1235.20.408 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1235.20.402 Boehringer Ingelheim Investigational Site, Granada, Spain|1235.20.403 Boehringer Ingelheim Investigational Site, Sevilla, Spain|1235.20.409 Boehringer Ingelheim Investigational Site, Valencia, Spain|1235.20.451 Boehringer Ingelheim Investigational Site, Kharkov, Ukraine|1235.20.458 Boehringer Ingelheim Investigational Site, Kharkov, Ukraine|1235.20.460 Boehringer Ingelheim Investigational Site, Kharkov, Ukraine|1235.20.453 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1235.20.454 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1235.20.455 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1235.20.456 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1235.20.457 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1235.20.461 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1235.20.452 Boehringer Ingelheim Investigational Site, Lvov, Ukraine|1235.20.459 Boehringer Ingelheim Investigational Site, Odessa, Ukraine",,"https://ClinicalTrials.gov/show/NCT00860262"
743,"NCT02558231","The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension","TRITON","Active, not recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Macitentan|Drug: Tadalafil|Drug: Selexipag","Pulmonary vascular resistance","Actelion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","247","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-065A308","May 1, 2016","August 29, 2019","March 31, 2020","September 23, 2015",,"February 19, 2020","Arizona Pulmonary Specialists, LTD, Phoenix, Arizona, United States|UCSD Health Sciences, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Piedmont Pulmonary and Critical Care Research, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|LSU Health Sciences Center, New Orleans, Louisiana, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Michigan, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|The Christ Hospital, Cincinnati, Ohio, United States|Allegheny General Hospital of Research, Pittsburgh, Pennsylvania, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Royal Prince Albert Hospital, Camperdown, New South Wales, Australia|St. Vincents Hospital Sydney, Darlinghurst, New South Wales, Australia|LKH -Universität Klinkum Graz, Graz, Austria|Krankenhaus der Elisabethinen Linz, Linz, Austria|AKH Wien, Wien, Austria|Hôpital Erasme, Brussels, Belgium|UZ Leuven - Campus Gasthuisberg, Leuven, Belgium|Vancouver General Hospital, Vancouver, British Columbia, Canada|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Quebec, Canada|University of Calgary, Calgary, Canada|University of Ottawa Heart Institute, Ottawa, Canada|Aarhus University Hospital Skejby, Aarhus, Denmark|Rigshospitalet Copenhagen, Copenhagen, Denmark|CHU de Bicêtre, Le Kremlin-Bicêtre, France|Unversitätsklinikum Carl Gustav Carus, Dresden, Germany|Universitätsklinikum Giessen, Giessen, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum Köln, Köln, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Mater Misericordiae University Hospital, Dublin, Ireland|Ospedale Sant'Orsola, Bologna, Italy|VUmc Amsterdam, Amsterdam, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Skånes universitetssjukhus Lund, Lund, Sweden|Norrlands universitetssjukhus, Umeå, Sweden|Kardiologkliniken, Uppsala, Sweden|Universiätsspital Zürich, Zürich, Switzerland|Golden Jubilee National Hospital, Clydebank, United Kingdom|The Royal Free Hospital, London, United Kingdom|Royal Brompton Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02558231"
744,"NCT03541174","A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety","PRECISION","Recruiting","No Results Available","Resistant Hypertension","Drug: Aprocitentan 12.5 mg|Drug: Aprocitentan 25 mg|Drug: Placebo","Change from baseline to Week 4 of DB treatment in trough Sitting Systolic BP (SiSBP) measured by AOBPM|Change from Week 36 (i.e., start of DB-WD) to Week 40 in trough SiSBP as measured by AOBPM|Change from baseline to Week 4 of DB treatment in trough Sitting Diastolic BP (SiDBP) measured by AOBPM|Changes from baseline to Week 4 of DB treatment in 24-h mean SBP and DBP measured by ABPM|Change from Week 36 to Week 40 of DB-WD treatment in trough SiDBP measured by AOBPM|Changes from Week 36 to Week 40 of DB-WD treatment in 24-h mean SBP and DBP measured by ABPM","Idorsia Pharmaceuticals Ltd.|Janssen Biotech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ID-080A301|2017-004393-33","June 18, 2018","February 8, 2021","February 8, 2021","May 30, 2018",,"March 26, 2020","Advanced Cardiovascular, LLC, Alexander City, Alabama, United States|University of Alabama at Birmingham Vascular Biology and Hypertension Program, Birmingham, Alabama, United States|Chrishard Medical Group, Inglewood, California, United States|Clinical Trials Research, Lincoln, California, United States|Academic Medical Research Institute, Los Angeles, California, United States|Entertainment Medical Group, Inc., Los Angeles, California, United States|Amicis Research Center, Northridge, California, United States|Empire Clinical Research, Pomona, California, United States|North America Research Institute, San Dimas, California, United States|Orange County Research Center, Tustin, California, United States|Alfieri Cardiology, Wilmington, Delaware, United States|Bay Area Cardiology Associates, P.A., Brandon, Florida, United States|West Broward Research, Coral Springs, Florida, United States|Century Clinical Research, Inc, Daytona Beach, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Canvas Clinical Research, LLC, Lake Worth, Florida, United States|East Coast Institute for Research, Saint Augustine, Florida, United States|Premier Medical Associates, The Villages, Florida, United States|Northwest Heart Clinical Research, LLC., Arlington Heights, Illinois, United States|SIU School of Medicine Center for Clinical Research, Springfield, Illinois, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Cardiovascular Research of Northwest Indiana, L.L.C., Munster, Indiana, United States|Reid Physician Associates, Richmond, Indiana, United States|Alexandria Cardiology Clinic, Alexandria, Louisiana, United States|Grace Research, LLC, Bossier City, Louisiana, United States|Horizon Research Group of Opelousas, LLC, Eunice, Louisiana, United States|DelRicht Research, Gretna, Louisiana, United States|Capital Nephrology, Greenbelt, Maryland, United States|MedStar Health Research Institute, Hyattsville, Maryland, United States|Washington Nephrology Associates, Takoma Park, Maryland, United States|St Clair Nephrology Research, Roseville, Michigan, United States|Clinical Research Consultants, LLC, Kansas City, Missouri, United States|Renal Medicine Associates, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|Scott Research Inc, Laurelton, New York, United States|Great Lakes Medical Research LLC, Westfield, New York, United States|Metrolina Internal Medicine/Internal Medicine Research, Charlotte, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Physician's East Endocrinology, Greenville, North Carolina, United States|Carteret Medical Group, Morehead City, North Carolina, United States|Sterling Research Group, Ltd, Cincinnati, Ohio, United States|Sentral Clinical Research Services, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center - Neurological Institute, Cleveland, Ohio, United States|Aventiv Research Inc., Columbus, Ohio, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Doylestown Health Cardiology, Doylestown, Pennsylvania, United States|Aventiv Research, Inc, Erie, Pennsylvania, United States|Allegheny Valley Hospital, Natrona Heights, Pennsylvania, United States|Drexel University Dept of Nephrology, Philadelphia, Pennsylvania, United States|TLM Medical Services LLC, Columbia, South Carolina, United States|DeGarmo Institute of Medical Research, Greer, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Stern Cardiovascular Foundation, Inc, Germantown, Tennessee, United States|The University of Tennessee, Memphis, Tennessee, United States|LifeDOC Research PLLC, Memphis, Tennessee, United States|San Antonio Kidney Disease Center, PLLC, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Mercury Clinical Research, Webster, Texas, United States|St. George Kidney Care, Saint George, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Salem Veterans Affairs Medical Center, Salem, Virginia, United States|Central Coast Local Health District, Gosford, New South Wales, Australia|Renal Research, Gosford, New South Wales, Australia|St. George Hospital, Dept. Renal Medicine, Kogarah, New South Wales, Australia|Western Sydney Local Health District, Westmead, New South Wales, Australia|Sunshine Coast University Private Hospital, Birtinya, Queensland, Australia|Core Research Group Pty Ltd, Milton, Queensland, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|CCRE Clinical Trial Centre, SPHPM, Monash University, Caulfield, Victoria, Australia|St Vincent's Hospital (Melbourne), Fitzroy, Victoria, Australia|Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia|Curtin University, Faculty of Health Sciences, School of Public Health, Bentley, Western Australia, Australia|Royal Perth Hospital Unit - The University of Western Australia, Perth, Western Australia, Australia|Grand Hôpital de Charleroi, Site St-Joseph, Gilly, Charleroi, Belgium|Hospital Erasme _Cardiology department, Brussels, Belgium|UZ Brussel, Brussels, Belgium|Clinique Universitaires de Saint Luc, Departement cardio-vasculaires intensives, Brussels, Belgium|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Centre Hospitalier Universitaire du Sart-Tilman, Liège, Belgium|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|Lakeridge Health, Oshawa, Ontario, Canada|The Ottawa Hospital, Renal Hypertension Program, Ottawa, Ontario, Canada|Manna Research (Stoney Creek), Stoney Creek, Ontario, Canada|Canadian Phase Onward Inc., Toronto, Ontario, Canada|Stephen S. Chow Medicine Professional Corporation, Toronto, Ontario, Canada|Jewish General Hospital - Cardiovascular Prevention Center, Montreal, Quebec, Canada|Hopital MaisonNeuve-Rosemont, Montréal, Quebec, Canada|Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada|The First Affiliated Hospital of Baotou Medical College of Inner Mongolia, Baotou, China|The Third Xiangya Hospital of Central South University, Changsha, China|Guangdong General Hospital, Guangzhou, China|Zhejiang Province People's Hospital, Hangzhou, China|Lanzhou University Second Hospital, Lanzhou, China|Hainan NO.3 Provincial people's Hospital, Sanya, China|Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|FN U Sv.Anny Brno, kardiologická klinika, Brno, Czechia|Krajska zdravotni, a.s. - Nemocnice Decin, o.z., Děčín, Czechia|Fakultní nemocnice Plzeň, Pilsen, Czechia|Všeobecní fakultní nemocnice Praha, Prague, Czechia|Nefromed s.r.o., Prague, Czechia|Fakultní nemocnice Královské Vinohrady, Praha 10, Czechia|Thomayerova nemocnice, Praha 4, Czechia|Kardio Václavík s.r.o, Přerov, Czechia|Aalborg University Hospital Cardiology, Aalborg, Denmark|Regional Hospital Holstebro Department of Medicine University Clinic in Nephrology and Hypertension at Holstebro, Holstebro, Denmark|University of Oulu, Medical Research Center, Oulu, Finland|TAYS RDI center (Tampere University Hospital,Specialist Internal Medicine, Rare Diseases), Tampere, Finland|Turku University Central Hospital - Turun yliopistollinen keskussairaala Sisätautien klinikka, Turku, Finland|Centre de Recherche Clinique, Bobigny, France|Hôpital Saint-André - Service de Cardiologie et Hypertension Artérielle, Bordeaux cedex, France|CHU Grenoble - Alpes, Grenoble cedex 9, France|Institut Cœur Poumon CHRU LILLE, Lille Cedex, France|Hôpital de la Croix-Rousse - Rhône, Lyon, France|GHRMSA - Hôpital Emile Muller, Mulhouse, France|Hôpital Européen Georges Pompidou- Centre d' Investigation Clinique, Paris, France|Centre Hospitalier Intercommunal Toulon La Seyne sur Mer, Toulon, France|Medic Trials STUG, Berlin, Germany|Universitätsklinikum Düsseldorf Klinik für Nephrologie, Düsseldorf, Germany|Universitätsklinikum Erlangen Klinische Forschungsstation (CRC), Erlangen, Germany|University Medical Centre Goettingen - Universitätsmedizin Göttingen Klinik für Nephrologie und Rheumatologie, Göttingen, Germany|Clinical Trial Center North GmbH & Co. KG, Hamburg, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, Germany|Herzzentrum der Uniklinik Köln, Köln, Germany|Herzzentrum Leipzig Universitätsklinik für Kardiologie, Leipzig, Germany|Sana Kliniken Lüebeck, Cardiology, Lubeck, Germany|Universitätsklinikum Nürnberg Süd, Nürnberg, Germany|Euroclinic Athens, Athens, Greece|General Hospital of Athens, Ippokrateio, Athens, Greece|National and Kapodistrian University of Athens, School of Medicine Third Department of Medicine, Sotiria Hospital, Athens, Greece|General Hospital of Athens Georgios Gennimatas, Athens, Greece|University Hospital of Heraklion, Heraklion, Greece|General Hospital Konstantopouleio -Patision, Nea Ionia, Greece|AHEPA University Hospital, Thessaloniki, Greece|Asklepeion General Hospital, Voula, Greece|Principal SMO Kft., Baja, Hungary|DRC Gyógyszervizsgáló Központ Kft., Balatonfüred, Hungary|Gottsegen György Országos Kardiológiai Intézet, Budapest, Hungary|Debreceni Egyetem - Klinikai Központ, Debrecen, Hungary|Pécsi Tudományegyetem Klinikai Központ, Pécs, Hungary|University of Szeged, 1st Dept. of Medicine, Szeged, Hungary|HaEmek M.C, Afula, Israel|Assuta Medical Center Ashdod, Ashdod, Israel|Cardiovascular Institute, Ashkelon, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|University Brescia Department Clinical and Experimental Science, Brescia, Italy|Division of Internal Medicine & Nephrology University of L'Aquila - San Salvatore Hospital V.le San Salvatore, L'Aquila, Italy|Ospedale San Gerardo, Clinica Medica, Monza, Italy|Azienda Ospedaliera S. Andrea di Roma - Division of Cardiology and of Cardiothoracic and Vascular Science Department -, Pisa, Italy|Azienda Ospedaliero Universitaria PisanA - Department Clinical and Experimental Medicine, Pisa, Italy|SCU Medicina Interna e Centro Ipertensione arteriosa. Dipartimento di Scienze Mediche Università di Torino, Aou Citta' Salute E Scienza Torino, Torino, Italy|Veterans Health Service Medical Center Division of Cardiology - Dep. of Internal Medicine, Seoul, Gangdong-gu, Korea, Republic of|Gangnueng Asan Hospital University of Ulsan College of Medicine, Seoul, Gangwon-do, Korea, Republic of|Yonsei University Wonju Severance Christian Hospital Division of Cardiology - Dept. of Internal Medicine, Wonju, Ganwon-do, Korea, Republic of|Seoul National University Hospital Division of Cardiology, Department of Internal Medicine, Seoul, Korea, Republic of|Kaunas Clinical Hospital, Kaunas, Lithuania|JSC ""InMedica"", Kaunas, Lithuania|Clinic of Cardiology and Rehabilitation, Klaipeda, Lithuania|Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania|Academic Medical Center Amsterdam, Amsterdam, Netherlands|Zuyderland Medical Center, Geleen, Netherlands|Maastricht University Medical Center, Dept. of Medicine, Maastricht, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Haga Ziekenhuizen-Internal Medicine, The Hague, Netherlands|Klinika Nadciśnienia Tętniczego i Diabetologii, Gdańsk, Poland|Mazowieckie Centrum Badań Klinicznych, Grodzisk-Mazowiecki, Poland|Samodzielny Publiczny Szpital Kliniczny im. Andrzeja Mielęckiego Śląskiego Uniwersytetu Medycznego w Katowicach, Katowice, Poland|Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w, Kraków, Poland|Diamond Clinic, Kraków, Poland|Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1w Lublinie, Lublin, Poland|KO-MED. CentraKliniczne Sp. Z o.o. Ośrodek Badań Klinicznych w Lublinie II, Lublin, Poland|ETG Lublin, Lublin, Poland|Etyka Ośrodek Badań Klinicznych, Olsztyn, Poland|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|KO-MED. Centra Kliniczne Sp. Z o.o. Ośrodek Badań Klinicznych w Puławach, Puławy, Poland|ETG Skierniewice, Skierniewice, Poland|Medycyna Kliniczna, Warszawa, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Warszawa, Poland|ETG Warszawa, Warszawa, Poland|Instytut Kardiologii im. Prymasa Tysiąclecia Stefana Kardynała Wyszyńskiego, Warszawa, Poland|Samodzielny Publiczny Szpital Wojewódzki im. Papieża Jana Pawła II w Zamościu, Zamość, Poland|ETG Zgierz, Zgierz, Poland|State Budgetary Healthcare Institution of Arkhangelsk Region ""First City Clinical Hospital n.a. E.E. Volosevich"", Arkhangelsk, Russian Federation|Municipal Autonomous Healthcare Institution City Clinical Hospital #6, Gastroenterology Department, Chelyabinsk, Russian Federation|Federal State Autonomous Institution of Higher Education ""Kazan (Volga Region) Federal University"", Kazan, Russian Federation|Federal State Budget Scientific Institution ""Scientific Research Institute for Complex Issues of Cardiovascular Diseases"", Kemerovo, Russian Federation|Scientific Research Institute - Regional Clinical Hospital №1, Krasnodar, Russian Federation|Regional State Budget Healthcare Institution ""Krasnoyarsk Interdistrict Clinical Hospital for Emergency Medical Care n.a. N.S Karpovich"", Nephrology Department, Krasnoyarsk, Russian Federation|Regional Budget Healthcare Institution ""Kursk City Clinical Hospital for Emergency Medical Care"" of Healthcare Committee of Kursk Region/Therapeutic, Kursk, Russian Federation|State budget healthcare institution of Novosibirsk region ""City clinical hospital #34"", Novosibirsk, Russian Federation|Federal State Budget Scientific Institution ""Federal Research Center Institute of Cytology and Genetics of Siberian Department of Russian Academy of Sciences"", Novosibirsk, Russian Federation|International Medical Center ""SOGAZ"", LLC, Saint Petersburg, Russian Federation|Federal State Military Educational Institution of Higher Professional Education, Military Medical Academy named for S. M. Kirov of the Ministry of Defense of the Russian Federation, Saint Petersburg, Russian Federation|State Healthcare Institution ""Regional Clinical Cardiology Dispensary"", Saratov, Russian Federation|Federal State Budget Educational Institution of Higher Education ""Saratov State Medical University n.a. V.I. Razumovskiy"" of the Ministry of Healthcare of the Russian Federation, Saratov, Russian Federation|State Budgetary Educational Institution of Higher Professional Education Smolensk State Medical Academy, Smolensk, Russian Federation|Federal State Budget Institution ""National Medical Research Center n.a. V.A. Almazov"" of the Ministry of healthcare of the Russian Federation, St. Petersburg, Russian Federation|Federal State Budget Scientific Institution ""Tomsk National Research Medical Center of the Russian Academy of Sciences"", Tomsk, Russian Federation|Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science, Tyumen, Russian Federation|Hospital Universitari Germans Trias i Pujol de Badalona, Badalona, Spain|Hospital del Mar, Barcelona, Spain|Fundació Puigvert, Barcelona, Spain|Hipertensión Clinic, Internal Medicine, Hospital Clinico, University of Barcelona, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|Hospital Virgen de las Nieves - Internal Medicine Department, Granada, Spain|Hospital Clinico San Carlos - Istituto de Investigacion Sanitaria San Carlos (IdISSC), Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Virgen del Rocio Departamento de Medicina Interna, Sevilla, Spain|Hypertension Clinic, Internal Medicine, Hospital Clinico, University of Valencia, Valencia, Valencia, Spain|Municipal non-profit enterprise ""Clinical hospital of emergency medicine"" of the Dniрro city council, Dnipro, Ukraine|State Institution ""L.T. Malaya Therapy National Institute of the NAMS of Ukraine"", Kharkiv, Ukraine|Municipal non-profit enterprise ""Clinical Hospital # 8""of Kharkiv City Council, Kharkiv, Ukraine|Kyiv City Clinical Hospital # 1, Kyiv, Ukraine|Kyiv Municipal Clinical Emergency Hospital, Kyiv, Ukraine|State Institution ""National Scientific Center ""M.D. Strazhesko Institute of Cardiology"" of the National Academy of Medical Sciences of Ukraine"", Kyiv, Ukraine|State Institution ""D.F. Chebotarev Institute of Gerontology, National Academy of Medical Science of Ukraine"", Kyiv, Ukraine|State Institution ""Institute of Gerontology named after D.F. Chebotarev of National Academy of Medical Sciences of Ukraine"", Kyiv, Ukraine|Municipal Enterprise ""Lutsk City Clinical Hospital"", Volyn Regional Center for Cardiovascular Pathology, Lutsk, Ukraine|Municipal Noncommercial Enterprise ""Lviv City Clinical Hospital #5"", Lviv, Ukraine|Communal Non-profit Enterprise ""Vinnytsya regional Clinical Hospital named after. N.I. Pirogov Vinnytsia Regional Council""/ National Pirogov Memorial Medical University, Vinnytsya, Vinnytsya, Ukraine|Municipal non-profit enterprise ""Regional Clinical Hospital named after AF Gerbachevsky"" of Zhytomyr Regional Council, Zhytomyr, Ukraine|James Paget University Hospitals Foundation Trust, Great Yarmouth, Norfolk, United Kingdom|Aberdeen Royal Infirmary, Clinical Pharmacology Unit, Aberdeen, United Kingdom|Clinical Research Centre The University of Edinburgh Centre for Cardiovascul, Edinburgh, United Kingdom|Glasgow Clinical Research Facility (CRF), Glasgow, United Kingdom|University Hospitals of Leicester NHS Trust Dept of Chemical Pathology and Metabolic Diseases, Leicester, United Kingdom|Altnagelvin Area Hospital, Londonderry, United Kingdom|Queen Mary University of London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03541174"
745,"NCT02670434","Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia",,"Terminated","No Results Available","Hyperlipidemia|Dyslipidemia","Drug: NK-104-CR|Drug: Placebo|Drug: Livalo","Percent change in LDL-C from baseline|The percent change from baseline in fasting serum total cholesterol (TC )","Kowa Research Institute, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NK-104-CR-3.01US","January 2016","July 2017","October 2017","February 1, 2016",,"June 9, 2016","Beverly Hills, California, United States|Chino, California, United States|Lincoln, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|North Hollywood, California, United States|Thousand Oaks, California, United States|Vista, California, United States|Brooksville, Florida, United States|Ft. Lauderdale, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Miami, Florida, United States|Pembroke Pines, Florida, United States|Port Orange, Florida, United States|Marietta, Georgia, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Evanston, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Newton, Kansas, United States|Wichita, Kansas, United States|Auburn, Maine, United States|Elkridge, Maryland, United States|Edina, Minnesota, United States|Jackson, Mississippi, United States|Butte, Montana, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Endwell, New York, United States|Rochester, New York, United States|Greensboro, North Carolina, United States|Cincinnati, Ohio, United States|Kettering, Ohio, United States|Lyndhurst, Ohio, United States|Marion, Ohio, United States|Willoughby Hills, Ohio, United States|Dowingtown, Pennsylvania, United States|Charleston, South Carolina, United States|Mount Pleasant, South Carolina, United States|Kingsport, Tennessee, United States|Houston, Texas, United States|Hurst, Texas, United States|Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02670434"
746,"NCT01426438","Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate",,"Completed","Has Results","HIV-1 Infection","Drug: Niacin|Drug: Aspirin|Drug: Fenofibrate","Absolute Change in Relative FMD (%)|Change in Cholesterol|Change in Triglycerides|Men: Change in HDL Cholesterol|Women: Change in HDL Cholesterol|Change in HDL Particles|Change in Non-HDL Cholesterol|Change in LDL Cholesterol|Change in Small LDL Particles|Change in Large HDL Particles|Change in HOMA-IR|Change in IL-6|Change in C-reactive Protein (CRP)|Change in D-Dimer","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 2","99","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG A5293|1U01AI068636","November 2011","October 2013","October 2013","August 31, 2011","October 21, 2014","February 3, 2016","Alabama Therapeutics CRS (5801), Birmingham, Alabama, United States|University of Southern California (1201), Los Angeles, California, United States|UCLA CARE Center CRS (601), Los Angeles, California, United States|Harbor-UCLA Med. Ctr. CRS (603), Torrance, California, United States|University of Colorado Hospital CRS (6101), Aurora, Colorado, United States|Northwestern University CRS (2701), Chicago, Illinois, United States|New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477), Newark, New Jersey, United States|NY Univ. HIV/AIDS CRS (401), New York, New York, United States|Unc Aids Crs (3201), Chapel Hill, North Carolina, United States|Duke Univ. Med. Ctr. Adult CRS (1601), Durham, North Carolina, United States|Moses H. Cone Memorial Hospital CRS (3203), Greensboro, North Carolina, United States|Univ. of Cincinnati CRS (2401), Cincinnati, Ohio, United States|Case CRS (2501), Cleveland, Ohio, United States|University of Washington AIDS CRS (1401), Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01426438"
747,"NCT00847483","Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-Weeks, Masked Evaluator, Phase IV Multi-Center Study in the US","XLT","Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: latanoprost 0.005% ophthalmic solution|Drug: Travoprost 004% sterile ophthalmic solution|Drug: Bimatoprost .03% sterile ophthalmic solution","To compare the IOP reducing effect of latanoprost (Xalatan) versus travoprost (Travatan) versus bimatoprost (Lumigan) over a twelve-week period.|The mean change since baseline of Week 12 IOP measured at the time of peak (8:00AM) drug effect.|To study the safety variables within and between all treatment groups over 12 weeks|The mean change since baseline of Week 12 IOP measured at the time of trough (8:00PM) drug effect. The mean percentage change since baseline of diurnal IOP at Week 12.|The mean change since baseline of Week 12 IOP measured at the times of peak (8:00AM) and trough (8:00PM) drug effects evaluated by race. The percentage of patient withdrawals from the study","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","375","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","XALA-0091-157|A6111081","January 2002","August 2002","August 2002","February 19, 2009",,"February 19, 2009","Pfizer Investigational Site, Belleflower, California, United States|Pfizer Investigational Site, Inglewood, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Lakeland, Florida, United States|Pfizer Investigational Site, Ormond Beach, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Bloomingdale, Illinois, United States|Pfizer Investigational Site, Evansville, Indiana, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Shreveport, Louisiana, United States|Pfizer Investigational Site, Bangor, Maine, United States|Pfizer Investigational Site, Kansas City, Missouri, United States|Pfizer Investigational Site, Kansas City, Missouri, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Bloomfield, New Jersey, United States|Pfizer Investigational Site, Willingboro, New Jersey, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Streetsboro, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, Maryville, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, El Paso, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Layton, Utah, United States|Pfizer Investigational Site, Norfolk, Virginia, United States|Pfizer Investigational Site, Norfolk, Virginia, United States|Pfizer Investigational Site, Virginia Beach, Virginia, United States|Pfizer Investigational Site, Wenatchee, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00847483"
748,"NCT01912560","Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia","PATHWAYS I","Completed","No Results Available","Dyslipidemia|Hypercholesterolemia|Hypertriglyceridemia","Drug: CAT-2003|Drug: Placebo|Drug: Statin","Absolute and percent change from baseline in plasma triglycerides in patients with hypertriglyceridemia|Absolute and percent change from baseline in plasma low density lipoprotein-cholesterol in patients with hypercholesterolemia|Absolute and percent change from baseline in plasma non-high-density lipoprotein cholesterol|Pharmacodynamic effects of CAT-2003 on other lipid biomarkers in patients with hyperlipidemia|Frequency of adverse events","Catabasis Pharmaceuticals","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 2","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAT-2003-201","July 2013","December 2013","December 2013","July 31, 2013",,"July 28, 2016","Muscle Shoals, Alabama, United States|Los Angeles, California, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Winter Park, Florida, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Raleigh, North Carolina, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Sainte-Foy, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01912560"
749,"NCT01964326","Actual Use Trial of Atorvastatin Calcium 10 mg",,"Completed","Has Results","Hypercholesterolemia","Drug: Atorvastatin calcium 10 mg","Percentage of Participants Who Complied With the Direction to Check Their Low-density Lipoprotein Cholesterol (LDL-C) Level|Percentage of Participants Who Took Appropriate Action Based on Their LDL-C Results|Percentage of Participants Taking an ""Ask a Doctor or Pharmacist Before Use"" Medication Who Followed the Labeling and Contacted a Doctor or Pharmacist Before Using Study Medication|Percentage of Participants Who Stopped Study Medication Use and Asked a Doctor if They Experienced Any of the Labeled ""Stop Use and Ask a Doctor"" Symptoms","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","1311","Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","A2581189","October 2013","December 2014","December 2014","October 17, 2013","January 27, 2016","May 18, 2016","Robert's Discount Pharmacy, Hoover, Alabama, United States|Pharmacy at the Pig, McCalla, Alabama, United States|Pinson Discount Drugs, Pinson, Alabama, United States|Community Clinical Pharmacy, Mesa, Arizona, United States|Melrose Pharmacy, Phoenix, Arizona, United States|Bi-Rite Quality Pharmacies, La Habra, California, United States|Parkview Compounding Pharmacy, Rancho Cucamonga, California, United States|Garden Drug, Fort Lauderdale, Florida, United States|Pill Box Pharmacy and Medical Supply, Pembroke Pines, Florida, United States|Summerfield Pharmacy, Riverview, Florida, United States|Sutton Family Pharmacy, Dalton, Georgia, United States|Wynn's Pharmacy Inc., Griffin, Georgia, United States|Catonsville Pharmacy, Baltimore, Maryland, United States|Kemper Drug, Elk River, Minnesota, United States|Goodrich Pharmacy, Fridley, Minnesota, United States|Northfield Pharmacy, Northfield, Minnesota, United States|Cub Pharmacy, Rosemount, Minnesota, United States|Goodrich Pharmacy, St Francis, Minnesota, United States|Albers' Medical Pharmacy, Kansas City, Missouri, United States|Countryside Pharmacy, Savannah, Missouri, United States|Texas Road Pharmacy, Monroe, New Jersey, United States|Duran Central Pharmacy, Albuquerque, New Mexico, United States|Sam's Regent Pharmacy, Albuquerque, New Mexico, United States|Family Prescription Center, Bethlehem, Pennsylvania, United States|T.B. Bond Pharmacy, Hillsboro, Texas, United States|Inwood Pharmacy, Houston, Texas, United States|Brick Street Pharmacy, Tyler, Texas, United States|Mountain West Apothecary, Bountiful, Utah, United States|Ridgeview Pharmacy, Roy, Utah, United States|The Apothecary Shoppe, Salt Lake City, Utah, United States|The Medicine Center, Salt Lake City, Utah, United States|Family Plaza Pharmacy, West Jordan, Utah, United States|Montpelier Pharmacy, Inc., Montpelier, Virginia, United States|Lafayette Pharmacy, Richmond, Virginia, United States|Jim's Pharmacy, Enuwclaw, Washington, United States|Ostrom Drugs, Kenmore, Washington, United States|Katterman's Sand Point Professional Pharmacy, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01964326"
750,"NCT02250105","Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia",,"Completed","No Results Available","Hypertriglyceridemia","Drug: ARI-3037MO|Drug: Placebo","Change in Triglyceride levels|Change in LDL cholesterol|Change in HDL cholesterol","Arisaph Pharmaceuticals Inc|Baim Institute for Clinical Research","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ARI-3037MO-004","September 2014","June 2016","June 2016","September 26, 2014",,"August 8, 2016","Orange County Research Center, Tustin, California, United States|Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, United States|Maine Research Associates, Auburn, Maine, United States|Sterling Clinical Research Inc, Cincinnati, Ohio, United States|National Clinical Research inc, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02250105"
751,"NCT00855465","A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.","CHEST-1","Completed","Has Results","Pulmonary Hypertension","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo","6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 16|Pulmonary Vascular Resistance (PVR) - Change From Baseline to Week 16|N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) - Change From Baseline to Week 16|World Health Organization (WHO) Functional Class - Change From Baseline to Week 16|Percentage of Participants With Clinical Worsening|Borg CR 10 Scale - Change From Baseline to Week 16|EQ-5D Utility Score - Change From Baseline to Week 16|Living With Pulmonary Hypertension (LPH) Questionnaire - Change From Baseline to Week 16","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","262","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11348|2007-000072-16","February 2009","June 2012","June 2012","March 4, 2009","March 11, 2014","November 28, 2016","Birmingham, Alabama, United States|La Jolla, California, United States|Sacramento, California, United States|Aurora, Colorado, United States|Gainesville, Florida, United States|Miami, Florida, United States|Weston, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Rochester, New York, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Fairfield, Ohio, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Dallas, Texas, United States|Houston, Texas, United States|Murray, Utah, United States|Milwaukee, Wisconsin, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Capital Federal, Argentina|Corrientes, Argentina|Camperdown, New South Wales, Australia|Auchenflower, Queensland, Australia|Chermside, Queensland, Australia|Prahran, Victoria, Australia|Innsbruck, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Leuven, Belgium|Porto Alegre, Rio Grande do Sul, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|São Paulo, Brazil|Calgary, Alberta, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Qingdao, Shandong, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Vseobecna fakultni nemocnice, Praha 2, Czech Republic|Aarhus N, Denmark|Besancon, France|Brest, France|Caen, France|Hopital Antoine Beclere, Clamart Cedex, France|GRENOBLE Cedex 09, France|Lille Cedex, France|Montpellier, France|Nice, France|Pessac, France|Rouen, France|Tours, France|Vandoeuvre Les Nancy, France|Heidelberg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Würzburg, Bayern, Germany|Gießen, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Hamburg, Germany|Dublin, Ireland|Petah Tikva, Israel|Roma, Lazio, Italy|Pavia, Lombardia, Italy|Nagoya, Aichi, Japan|Seto, Aichi, Japan|Kitakyushu, Fukuoka, Japan|Komatsu, Ishikawa, Japan|Fujisawa, Kanagawa, Japan|Isehara, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Sendai, Miyagi, Japan|Suwa, Nagano, Japan|Suita, Osaka, Japan|Bunkyo-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Chiba, Japan|Fukuoka, Japan|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Guadalajara, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Monterrey, Nuevo Leon, Mexico|Mexico D.F., Mexico|Querétaro, Mexico|Amsterdam, Netherlands|Amsterdam, Netherlands|Nieuwegein, Netherlands|Krakow, Poland|Otwock, Poland|Wroclaw, Poland|Coimbra, Portugal|Lisboa, Portugal|Porto, Portugal|Novosibirsk, Russian Federation|St. Petersburg, Russian Federation|Bratislava 37, Slovakia|Barcelona, Spain|Madrid, Spain|Zürich, Switzerland|Kaohsiung, Taiwan|Taipei, Taiwan|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Glasgow, West Dunbartonshire, United Kingdom|London, United Kingdom|London, United Kingdom|Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00855465"
752,"NCT01492361","A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.","REDUCE-IT","Completed","No Results Available","Cardiovascular Diseases","Drug: AMR101|Drug: Placebo","Composite of CV death, nonfatal MI (including silent MI), nonfatal stroke, coronary revascularization, and unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization.|Composite of CV death, nonfatal MI (including silent MI), or nonfatal stroke.|Composite of CV death or nonfatal MI (including silent MI).|Fatal or nonfatal MI (including silent MI).|Non-elective coronary revascularization represented as the composite of emergent or urgent classifications.|CV death.|Unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization.|Fatal or nonfatal stroke.|Total mortality, nonfatal MI (including silent MI), or nonfatal stroke.|Total mortality.","Amarin Pharma Inc.","All","45 Years and older   (Adult, Older Adult)","Phase 3","8179","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AMR-01-01-0019","November 2011","May 2018","May 2018","December 15, 2011",,"June 6, 2019","Amarin Investigational Site, Birmingham, Alabama, United States|Amarin Investigational Site, Birmingham, Alabama, United States|Amarin Investigational Site, Huntsville, Alabama, United States|Amarin Investigational Site, Mobile, Alabama, United States|Amarin Investigational Site, Muscle Shoals, Alabama, United States|Amarin Investigational Site, Mesa, Arizona, United States|Amarin Investigational Site, Phoenix, Arizona, United States|Amarin Investigational Site, Tucson, Arizona, United States|Amarin Investigational Site, Little Rock, Arkansas, United States|Amarin Investigational Site, Beverly Hills, California, United States|Amarin Investigational Site, Chino, California, United States|Amarin Investigational Site, Concord, California, United States|Amarin Investigational Site, El Cajon, California, United States|Amarin Investigational Site, Encino, California, United States|Amarin Investigational Site, Fair Oaks, California, United States|Amarin Investigational Site, Hawaiian Gardens, California, United States|Amarin Investigational Site, Lancaster, California, United States|Amarin Investigational Site, Lincoln, California, United States|Amarin Investigational Site, Los Angeles, California, United States|Amarin Investigational Site, Los Angeles, California, United States|Amarin Investigational Site, Los Angeles, California, United States|Amarin Investigational Site, National City, California, United States|Amarin Investigational Site, Orange, California, United States|Amarin Investigational Site, Paramount, California, United States|Amarin Investigational Site, Roseville, California, United States|Amarin Investigational Site, San Diego, California, United States|Amarin Investigational Site, Torrance, California, United States|Amarin Investigational Site, Ventura, California, United States|Amarin Investigational Site, Walnut Creek, California, United States|Amarin Investigational Site, Aurora, Colorado, United States|Amarin Investigational Site, Colorado Springs, Colorado, United States|Amarin Investigational Site, Golden, Colorado, United States|Amarin Investigational Site, Guilford, Connecticut, United States|Amarin Investigational Site, Hartford, Connecticut, United States|Amarin Investigational Site, Newark, Delaware, United States|Amarin Investigational Site, Wilmington, Delaware, United States|Amarin Investigational Site, Washington, District of Columbia, United States|Amarin Investigational Site, Boynton Beach, Florida, United States|Amarin Investigational Site, Bradenton, Florida, United States|Amarin Investigational Site, Clearwater, Florida, United States|Amarin Investigational Site, Edgewater, Florida, United States|Amarin Investigational Site, Fleming Island, Florida, United States|Amarin Investigational Site, Fort Lauderdale, Florida, United States|Amarin Investigational Site, Fort Lauderdale, Florida, United States|Amarin Investigational Site, Inverness, Florida, United States|Amarin Investigational Site, Jacksonville, Florida, United States|Amarin Investigational Site, Jacksonville, Florida, United States|Amarin Investigational Site, Jacksonville, Florida, United States|Amarin Investigational Site, Jacksonville, Florida, United States|Amarin Investigational Site, Miami Beach, Florida, United States|Amarin Investigational Site, Miami Lakes, Florida, United States|Amarin Investigational Site, Miami, Florida, United States|Amarin Investigational Site, Miami, Florida, United States|Amarin Investigational Site, Ocala, Florida, United States|Amarin Investigational Site, Orlando, Florida, United States|Amarin Investigational Site, Pembroke Pines, Florida, United States|Amarin Investigational Site, Plantation, Florida, United States|Amarin Investigational Site, Safety Harbor, Florida, United States|Amarin Investigational Site, Saint Petersburg, Florida, United States|Amarin Investigational Site, Sarasota, Florida, United States|Amarin Investigational Site, Vero Beach, Florida, United States|Amarin Investigational Site, West Palm Beach, Florida, United States|Amarin Investigational Site, Conyers, Georgia, United States|Amarin Investigational Site, Covington, Georgia, United States|Amarin Investigational Site, Cumming, Georgia, United States|Amarin Investigational Site, Roswell, Georgia, United States|Amarin Investigational Site, Honolulu, Hawaii, United States|Amarin Investigational Site, Addison, Illinois, United States|Amarin Investigational Site, Chicago, Illinois, United States|Amarin Investigational Site, Norman, Illinois, United States|Amarin Investigational Site, North Chicago, Illinois, United States|Amarin Investigational Site, Peoria, Illinois, United States|Amarin Investigational Site, Winfield, Illinois, United States|Amarin Investigational Site, Evansville, Indiana, United States|Amarin Investigational Site, Iowa City, Iowa, United States|Amarin Investigational Site, Wichita, Kansas, United States|Amarin Investigational Site, Wichita, Kansas, United States|Amarin Investigational Site, Louisville, Kentucky, United States|Amarin Investigational Site, Alexandria, Louisiana, United States|Amarin Investigational Site, Eunice, Louisiana, United States|Amarin Investigational Site, Marrero, Louisiana, United States|Amarin Investigational Site, Auburn, Maine, United States|Amarin Investigational Site, Baltimore, Maryland, United States|Amarin Investigational Site, Lutherville, Maryland, United States|Amarin Investigational Site, Takoma Park, Maryland, United States|Amarin Investigational Site, Boston, Massachusetts, United States|Amarin Investigational Site, Boston, Massachusetts, United States|Amarin Investigational Site, Fall River, Massachusetts, United States|Amarin Investigational Site, Lansing, Michigan, United States|Amarin Investigational Site, Marquette, Michigan, United States|Amarin Investigational Site, Troy, Michigan, United States|Amarin Investigational Site, Saint Cloud, Minnesota, United States|Amarin Investigational Site, Biloxi, Mississippi, United States|Amarin Investigational Site, Tupelo, Mississippi, United States|Amarin Investigational Site, Chesterfield, Missouri, United States|Amarin Investigational Site, Florissant, Missouri, United States|Amarin Investigational Site, Jefferson City, Missouri, United States|Amarin Investigational Site, Kansas City, Missouri, United States|Amarin Investigational Site, Saint Louis, Missouri, United States|Amarin Investigational Site, Saint Peters, Missouri, United States|Amarin Investigational Site, Hastings, Nebraska, United States|Amarin Investigational Site, Omaha, Nebraska, United States|Amarin Investigational Site, Omaha, Nebraska, United States|Amarin Investigational Site, Henderson, Nevada, United States|Amarin Investigational Site, Las Vegas, Nevada, United States|Amarin Investigational Site, Ocean City, New Jersey, United States|Amarin Investigational Site, Albuquerque, New Mexico, United States|Amarin Investigational Site, Albany, New York, United States|Amarin Investigational Site, Brooklyn, New York, United States|Amarin Investigational Site, Great Neck, New York, United States|Amarin Investigational Site, Liverpool, New York, United States|Amarin Investigational Site, New York, New York, United States|Amarin Investigational Site, New York, New York, United States|Amarin Investigational Site, North Massapequa, New York, United States|Amarin Investigational Site, Smithtown, New York, United States|Amarin Investigational Site, Vestal, New York, United States|Amarin Investigational Site, West Seneca, New York, United States|Amarin Investigational Site, Charlotte, North Carolina, United States|Amarin Investigational Site, Durham, North Carolina, United States|Amarin Investigational Site, Gastonia, North Carolina, United States|Amarin Investigational Site, Kernersville, North Carolina, United States|Amarin Investigational Site, Raleigh, North Carolina, United States|Amarin Investigational Site, Winston-Salem, North Carolina, United States|Amarin Investigational Site, Fargo, North Dakota, United States|Amarin Investigational Site, Cincinnati, Ohio, United States|Amarin Investigational Site, Dayton, Ohio, United States|Amarin Investigational Site, Lorain, Ohio, United States|Amarin Investigational Site, Sandusky, Ohio, United States|Amarin Investigational Site, Tulsa, Oklahoma, United States|Amarin Investigational Site, Bend, Oregon, United States|Amarin Investigational Site, Portland, Oregon, United States|Amarin Investigational Site, Beaver, Pennsylvania, United States|Amarin Investigational Site, Doylestown, Pennsylvania, United States|Amarin Investigational Site, Jersey Shore, Pennsylvania, United States|Amarin Investigational Site, Newport, Pennsylvania, United States|Amarin Investigational Site, Philadelphia, Pennsylvania, United States|Amarin Investigational Site, Phoenixville, Pennsylvania, United States|Amarin Investigational Site, Sellersville, Pennsylvania, United States|Amarin Investigational Site, Tipton, Pennsylvania, United States|Amarin Investigational Site, Wyomissing, Pennsylvania, United States|Amarin Investigational Site, Yardley, Pennsylvania, United States|Amarin Investigational Site, Lancaster, South Carolina, United States|Amarin Investigational Site, Simpsonville, South Carolina, United States|Amarin Investigational Site, Rapid City, South Dakota, United States|Amarin Investigational Site, Bristol, Tennessee, United States|Amarin Investigational Site, Columbia, Tennessee, United States|Amarin Investigational Site, Germantown, Tennessee, United States|Amarin Investigational Site, Jackson, Tennessee, United States|Amarin Investigational Site, Knoxville, Tennessee, United States|Amarin Investigational Site, Smyrna, Tennessee, United States|Amarin Investigational Site, Austin, Texas, United States|Amarin Investigational Site, Beaumont, Texas, United States|Amarin Investigational Site, Carrollton, Texas, United States|Amarin Investigational Site, Dallas, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Hurst, Texas, United States|Amarin Investigational Site, New Braunfels, Texas, United States|Amarin Investigational Site, Plano, Texas, United States|Amarin Investigational Site, San Antonio, Texas, United States|Amarin Investigational Site, San Antonio, Texas, United States|Amarin Investigational Site, Splendora, Texas, United States|Amarin Investigational Site, Tomball, Texas, United States|Amarin Investigational Site, West Jordan, Utah, United States|Amarin Investigational Site, Falls Church, Virginia, United States|Amarin Investigational Site, Manassas, Virginia, United States|Amarin Investigational Site, Midlothian, Virginia, United States|Amarin Investigational Site, Newport News, Virginia, United States|Amarin Investigational Site, Burien, Washington, United States|Amarin Investigational Site, Tacoma, Washington, United States|Amarin Investigational Site, Huntington, West Virginia, United States|Amarin Investigational Site, Camperdown, New South Wales, Australia|Amarin Investigational Site, Lismore, New South Wales, Australia|Amarin Investigational Site, Brisbane, Queensland, Australia|Amarin Investigational Site, Chermside, Queensland, Australia|Amarin Investigational Site, Bedford Park, South Australia, Australia|Amarin Investigational Site, Launceston, Tasmania, Australia|Amarin Investigational Site, Fitzroy, Victoria, Australia|Amarin Investigational Site, Geelong, Victoria, Australia|Amarin Investigational Site, Heidelberg Heights, Victoria, Australia|Amarin Investigational Site, Melbourne, Victoria, Australia|Amarin Investigational Site, Fremantle, Western Australia, Australia|Amarin Investigational Site, Joondalup, Western Australia, Australia|Amarin Investigational Site, Murdoch, Western Australia, Australia|Amarin Investigational Site, Nedlands, Western Australia, Australia|Amarin Investigational Site, Perth, Western Australia, Australia|Amarin Investigational Site, Edmonton, Alberta, Canada|Amarin Investigational Site, Coquitlam, British Columbia, Canada|Amarin Investigational Site, Vancouver, British Columbia, Canada|Amarin Investigational Site, Vancouver, British Columbia, Canada|Amarin Investigational Site, Brampton, Ontario, Canada|Amarin Investigational Site, Collingwood, Ontario, Canada|Amarin Investigational Site, Corunna, Ontario, Canada|Amarin Investigational Site, Newmarket, Ontario, Canada|Amarin Investigational Site, Sarnia, Ontario, Canada|Amarin Investigational Site, Strathroy, Ontario, Canada|Amarin Investigational Site, Laval, Quebec, Canada|Amarin Investigational Site, Montreal, Quebec, Canada|Amarin Investigational Site, Montreal, Quebec, Canada|Amarin Investigational Site, Sherbrooke, Quebec, Canada|Amarin Investigational Site, St. Charles-Borromée, Quebec, Canada|Amarin Investigational Site, Québec, Canada|Amarin Investigational Site, Québec, Canada|Amarin Investigational Site, Hyderabad, Andhra Pradesh, India|Amarin Investigational Site, Hyderabad, Andhra Pradesh, India|Amarin Investigational Site, Secunderabad, Andhra Pradesh, India|Amarin Investigational Site, Visakhapatnam, Andhra Pradesh, India|Amarin Investigational Site, New Delhi, Delhi, India|Amarin Investigational Site, New Delhi, Delhi, India|Amarin Investigational Site, Bangalore, Karnataka, India|Amarin Investigational Site, Bangalore, Karnataka, India|Amarin Investigational Site, Bangalore, Karnataka, India|Amarin Investigational Site, Mysore, Karnataka, India|Amarin Investigational Site, Mysore, Karnataka, India|Amarin Investigational Site, Kottayam, Kerala, India|Amarin Investigational Site, Mumbai, Maharashtra, India|Amarin Investigational Site, Nashik, Maharashtra, India|Amarin Investigational Site, Pune, Maharashtra, India|Amarin Investigational Site, Chennai, Tamil Nadu, India|Amarin Investigational Site, Coimbatore, Tamil Nadu, India|Amarin Investigational Site, Almelo, Netherlands|Amarin Investigational Site, Amersfoort, Netherlands|Amarin Investigational Site, Blaricum, Netherlands|Amarin Investigational Site, Capelle aan den Ijssel, Netherlands|Amarin Investigational Site, Den Haag, Netherlands|Amarin Investigational Site, Den Helder, Netherlands|Amarin Investigational Site, Deventer, Netherlands|Amarin Investigational Site, Ede, Netherlands|Amarin Investigational Site, Eindhoven, Netherlands|Amarin Investigational Site, Enschede, Netherlands|Amarin Investigational Site, Goes, Netherlands|Amarin Investigational Site, Gorinchem, Netherlands|Amarin Investigational Site, Gouda, Netherlands|Amarin Investigational Site, Groningen, Netherlands|Amarin Investigational Site, Haarlem, Netherlands|Amarin Investigational Site, Harderwijk, Netherlands|Amarin Investigational Site, Heerenveen, Netherlands|Amarin Investigational Site, Heerlen, Netherlands|Amarin Investigational Site, Hoofddorp, Netherlands|Amarin Investigational Site, Leeuwarden, Netherlands|Amarin Investigational Site, Leiderdorp, Netherlands|Amarin Investigational Site, Nijmegen, Netherlands|Amarin Investigational Site, Roosendaal, Netherlands|Amarin Investigational Site, Rotterdam, Netherlands|Amarin Investigational Site, Rotterdam, Netherlands|Amarin Investigational Site, Rotterdam, Netherlands|Amarin Investigational Site, s'Hertogenbosch, Netherlands|Amarin Investigational Site, Schiedam, Netherlands|Amarin Investigational Site, Sneek, Netherlands|Amarin Investigational Site, Tilburg, Netherlands|Amarin Investigational Site, Tilburg, Netherlands|Amarin Investigational Site, Uden, Netherlands|Amarin Investigational Site, Veldhoven, Netherlands|Amarin Investigational Site, Zoetermeer, Netherlands|Amarin Investigational Site, Zutphen, Netherlands|Amarin Investigational Site, Takapuna, Auckland, New Zealand|Amarin Investigational Site, Christchurch, New Zealand|Amarin Investigational Site, Dunedin, New Zealand|Amarin Investigational Site, Hamilton, New Zealand|Amarin Investigational Site, Hastings, New Zealand|Amarin Investigational Site, Nelson, New Zealand|Amarin Investigational Site, New Plymouth, New Zealand|Amarin Investigational Site, Takapuna, Auckland, New Zealand|Amarin Investigational Site, Tauranga, New Zealand|Amarin Investigational Site, Whangarei, New Zealand|Amarin Investigational Site, Bialystok, Poland|Amarin Investigational Site, Bialystok, Poland|Amarin Investigational Site, Katowice, Poland|Amarin Investigational Site, Katowice, Poland|Amarin Investigational Site, Kraków, Poland|Amarin Investigational Site, Mikolów, Poland|Amarin Investigational Site, Skierniewice, Poland|Amarin Investigational Site, Tarnów, Poland|Amarin Investigational Site, Warszawa, Poland|Amarin Investigational Site, Warszawa, Poland|Amarin Investigational Site, Warszawska, Poland|Amarin Investigational Site, Wroclaw, Poland|Amarin Investigational Site, Wroclaw, Poland|Amarin Investigational Site, Zgierz, Poland|Amarin Investigational Site, Argeş, Romania|Amarin Investigational Site, Brăila, Romania|Amarin Investigational Site, Bucharest, Romania|Amarin Investigational Site, Bucharest, Romania|Amarin Investigational Site, Bucharest, Romania|Amarin Investigational Site, Bucuresti, Romania|Amarin Investigational Site, Bucuresti, Romania|Amarin Investigational Site, Bucuresti, Romania|Amarin Investigational Site, Cluj-Napoca, Romania|Amarin Investigational Site, Constanţa, Romania|Amarin Investigational Site, Craiova, Dolj, Romania|Amarin Investigational Site, Iaşi, Romania|Amarin Investigational Site, Maramureş, Romania|Amarin Investigational Site, Mureş, Romania|Amarin Investigational Site, Sibiu, Romania|Amarin Investigational Site, Timişoara, Romania|Amarin Investigational Site, Târgu Mureş, Romania|Amarin Investigational Site, Arkhangelsk, Russian Federation|Amarin Investigational Site, Arkhangelsk, Russian Federation|Amarin Investigational Site, Arkhangelsk, Russian Federation|Amarin Investigational Site, Ekaterinburg, Russian Federation|Amarin Investigational Site, Ekaterinburg, Russian Federation|Amarin Investigational Site, Kazan, Russian Federation|Amarin Investigational Site, Kazan, Russian Federation|Amarin Investigational Site, Kemerovo, Russian Federation|Amarin Investigational Site, Kemerovo, Russian Federation|Amarin Investigational Site, Kirovsk, Leningradskaya Region, Russian Federation|Amarin Investigational Site, Krasnodar, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Nizhny Novgorod, Russian Federation|Amarin Investigational Site, Novosibirsk, Russian Federation|Amarin Investigational Site, Novosibirsk, Russian Federation|Amarin Investigational Site, Novosibirsk, Russian Federation|Amarin Investigational Site, Petrozavodsk, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saratov, Russian Federation|Amarin Investigational Site, Saratov, Russian Federation|Amarin Investigational Site, Sestroretsk, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Tomsk, Russian Federation|Amarin Investigational Site, Tomsk, Russian Federation|Amarin Investigational Site, Volgograd, Russian Federation|Amarin Investigational Site, Voronezh, Russian Federation|Amarin Investigational Site, Voronezh, Russian Federation|Amarin Investigational Site, Yaroslavl, Russian Federation|Amarin Investigational Site, Yaroslavl, Russian Federation|Amarin Investigational Site, Bloemfontein, Freestate, South Africa|Amarin Investigational Site, Benoni, Gauteng, South Africa|Amarin Investigational Site, Pretorio, Gauteng, South Africa|Amarin Investigational Site, Soweto, Gauteng, South Africa|Amarin Investigational Site, Witbank, Gauteng, South Africa|Amarin Investigational Site, Durban, KwaZulu-Natal, South Africa|Amarin Investigational Site, Newlands, KwaZulu-Natal, South Africa|Amarin Investigational Site, Bellville, Western Cape, South Africa|Amarin Investigational Site, Cape Town, Western Cape, South Africa|Amarin Investigational Site, Durbanville, Western Cape, South Africa|Amarin Investigational Site, Goodwood, Western Cape, South Africa|Amarin Investigational Site, Kraaifontein, Western Cape, South Africa|Amarin Investigational Site, Paarl, Western Cape, South Africa|Amarin Investigational Site, Panorama, Western Cape, South Africa|Amarin Investigational Site, Parow, Western Cape, South Africa|Amarin Investigational Site, Pinelands, Western Cape, South Africa|Amarin Investigational Site, Somerset West, Western Cape, South Africa|Amarin Investigational Site, Worcester, Western Cape, South Africa|Amarin Investigational Site, Lutsk, Volyn Region, Ukraine|Amarin Investigational Site, Cherkasy, Ukraine|Amarin Investigational Site, Chernivtsi, Ukraine|Amarin Investigational Site, Dnipropetrovsk, Ukraine|Amarin Investigational Site, Dnipropetrovsk, Ukraine|Amarin Investigational Site, Dnipropetrovsk, Ukraine|Amarin Investigational Site, Donetsk, Ukraine|Amarin Investigational Site, Donetsk, Ukraine|Amarin Investigational Site, Ivano-Frankivsk, Ukraine|Amarin Investigational Site, Ivano-Frankivsk, Ukraine|Amarin Investigational Site, Kharkiv, Ukraine|Amarin Investigational Site, Kharkiv, Ukraine|Amarin Investigational Site, Kharkiv, Ukraine|Amarin Investigational Site, Kharkiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Luhansk, Ukraine|Amarin Investigational Site, Lutsk, Ukraine|Amarin Investigational Site, Lviv, Ukraine|Amarin Investigational Site, Odesa, Ukraine|Amarin Investigational Site, Odesa, Ukraine|Amarin Investigational Site, Odesa, Ukraine|Amarin Investigational Site, Poltava, Ukraine|Amarin Investigational Site, Ternopil, Ukraine|Amarin Investigational Site, Uzhgorod, Ukraine|Amarin Investigational Site, Uzhgorod, Ukraine|Amarin Investigational Site, Vinnytsya, Ukraine|Amarin Investigational Site, Vinnytsya, Ukraine|Amarin Investigational Site, Zaporizhzhia, Ukraine|Amarin Investigational Site, Zaporizhzhia, Ukraine|Amarin Investigational Site, Zaporizhzhia, Ukraine|Amarin Investigational Site, Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT01492361"
753,"NCT03245255","Noninvasive Real-time Intracardiac Pressure Measurements Using Subharmonic Ultrasound",,"Recruiting","No Results Available","Cardiac Catheterization|Blood Pressure|Heart Ventricles|Echocardiography|Heart Failure","Drug: Sonazoid","Agreement between SHAPE and pressure catheter measurements|Error between SHAPE and pressure catheter measurements|Accuracy of ventricular relaxation rate and relaxation time constant","Thomas Jefferson University|National Heart, Lung, and Blood Institute (NHLBI)|GE Healthcare","All","21 Years and older   (Adult, Older Adult)","Phase 2","80","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R21HL130899","December 4, 2017","March 31, 2021","March 31, 2021","August 10, 2017",,"April 1, 2020","Thomas Jefferson University and Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03245255"
754,"NCT03243942","Noninvasive, Subharmonic Intra-Cardiac Pressure Measurement",,"Completed","No Results Available","Cardiac Catheterization|Blood Pressure|Heart Ventricles|Echocardiography|Heart Failure","Drug: Definity","Agreement between SHAPE and pressure catheter measurements|Error between SHAPE and pressure catheter measurements","Thomas Jefferson University|American Heart Association|Lantheus Medical Imaging","All","21 Years and older   (Adult, Older Adult)","Phase 2","56","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15SDG25740015","June 1, 2017","June 26, 2019","June 26, 2019","August 9, 2017",,"July 10, 2019","Thomas Jefferson University and Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03243942"
755,"NCT03891446","Long-term Safety and Efficacy Extension Trial of Bimatoprost SR",,"Recruiting","No Results Available","Open-Angle Glaucoma|Ocular Hypertension","Drug: Bimatoprost SR","Duration of effect of Bimatoprost SR|Number of patients experiencing a treatment emergent adverse event.","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1698-302-007|2018-003597-26","March 27, 2019","January 21, 2024","January 21, 2024","March 27, 2019",,"April 28, 2020","Trinity Research Group, Dothan, Alabama, United States|Arizona Eye Center Phoenix, Phoenix, Arizona, United States|Arizona Glaucoma Specialists, Phoenix, Arizona, United States|M&M Eye Institute, Prescott, Arizona, United States|Walman Eye Center, Sun City, Arizona, United States|Lugene Eye Institute, Glendale, California, United States|Lakeside Vision Center, Irvine, California, United States|Hamilton Glaucoma Center, Shiley Eye Center UCSD, La Jolla, California, United States|Eye Research Foundation, Newport Beach, California, United States|Martel Eye Medical Group, Rancho Cordova, California, United States|Shasta Eye Medical Group, Inc, Redding, California, United States|Pacific Eye Associates, San Francisco, California, United States|Wolstan & Goldberg Eye Associates, Torrance, California, United States|Specialty Retina Center, Coral Springs, Florida, United States|Nature Coast Clinical Research - Crystal River, Crystal River, Florida, United States|Bruce Segal MD PA, Delray Beach, Florida, United States|Eye Associates of Fort Myers, Fort Myers, Florida, United States|Levenson Eye Associates, Jacksonville, Florida, United States|The Eye Institute for Medicine and Surgery, Melbourne, Florida, United States|MedEye Associates, South Miami, Florida, United States|International Research Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|Chicago Eye Specialists, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|The Eye Care Institute, Louisville, Kentucky, United States|Tulane University, New Orleans, Louisiana, United States|Clinical Eye Research of Boston, LLC, Winchester, Massachusetts, United States|Fraser Eye Care Center, Fraser, Michigan, United States|Tekwani Vision Center, Saint Louis, Missouri, United States|Rutgers, The State University of New Jersey, New Jersey Medi, Newark, New Jersey, United States|Vision Research Center Eye Associates of New Mexico, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Ophthalmic Consultants Long Island, Lynbrook, New York, United States|Mt. Sinai School of Medicine, New York, New York, United States|Rochester Ophthalmological Group PC, Rochester, New York, United States|Glaucoma Consultants of the Capital Region, Slingerlands, New York, United States|Asheville Eye Associates, Asheville, North Carolina, United States|Charlotte Eye Ear Nose & Throat Associates, PA, Charlotte, North Carolina, United States|Albemarle Clinical Trials, LLC, Elizabeth City, North Carolina, United States|James D. Branch, Winston-Salem, North Carolina, United States|Bergstrom Eye Research, LLC, Fargo, North Dakota, United States|Legacy Devers Eye Institute, Portland, Oregon, United States|Scott & Christie and Associates, PC, Cranberry Township, Pennsylvania, United States|Carolinas Center for Sight, PC, Florence, South Carolina, United States|VRF Eye Specialty Group, Memphis, Tennessee, United States|Advancing Vision Research, LLC, Nashville, Tennessee, United States|Keystone Research Ltd, Austin, Texas, United States|Glaucoma Associates of Texas, Dallas, Texas, United States|Houston Eye Associates, Houston, Texas, United States|DCT-Shah Research, LLC dba Discovery Clinical Trials, Mission, Texas, United States|Plano Office, Plano, Texas, United States|San Antonio Eye Center, San Antonio, Texas, United States|R and R Eye Research LLC, San Antonio, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Piedmont Eye Center, Lynchburg, Virginia, United States|Vistar Eye Center, Roanoke, Virginia, United States|West Virginia University Eye Institute, Morgantown, West Virginia, United States|The Eye Centers of Racine & Kenosha, Racine, Wisconsin, United States|Clinica Privada de Ojos, Mar del Plata, Buenos Aires Province, Argentina|Hospital Universitario Austral, Pilar, Buenos Aires Province, Argentina|Oftalmologia Global, Rosario, Santa Fe, Argentina|Consultorio Oftalmologico Dr. Fabian Lerner, Buenos Aires, Argentina|University of Graz, Graz, Austria|University Hospitals Leuven, Leuven, Belgium|CHU Sart Tilman, Liege, Belgium|Universidade Federal de Goias, Goiania, Goias, Brazil|Nova Campinas Oftalmologia, Campinas, Sao Paulo, Brazil|Hospital Oftalmologico Medicina dos Olhos, Osasco, Sao Paulo, Brazil|Hospital de Olhos de Mato Grosso Do Sul, Campo Grande, Brazil|Hospital Sao Paulo, Sao Paulo, Brazil|Dalhousie University, Halifax, Nova Scotia, Canada|St Joseph's Healthcare, Hamilton, Ontario, Canada|Ophthalmic Consultant Centres, Mississauga, Ontario, Canada|Montreal Glaucoma Institute, Montreal, Quebec, Canada|Clinica de Oftalmologia Sandiego S.A., Medellin, Antioquia, Colombia|Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Santander, Colombia|Fundacion Oftalmologica Nacional, Bogota, Colombia|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia|OFTEX s.r.o., Pardubice, Czechia|Glostrup Hospital, Glostrup, Denmark|Menoufia University Hospital, Shibin Al Kawm, Al Minufiyah, Egypt|Bostan Diagnostic Eye Center, Cairo, Egypt|Ain Shams University Hospital, Cairo, Egypt|CHU de NICE, Nice, Alpes-Maritimes, France|CHU de Bordeaux Hopital Pellegrin, Bordeaux, Gironde, France|Centre Opthalmologie Pole Vision, Ecully, France|CHU de Limoges - Service d'Ophthalmologie, Limoges, France|CHU Purpan, Toulouse Cedex 9, France|Charite-Universtitaetsmedizin Berlin, Berlin, Germany|Internationale Innovative Ophthalmochirurgie, Dusseldorf, Germany|Universitatsaugenklinik Magdeburg, Magdeburg, Germany|Universitatsklinikum Munster, Munster, Germany|The Chinese University of Hong Kong, Hong Kong, Hong Kong|Bnai Zion M. C., Haifa, Israel|Rambam Health Care Campus, Haifa, Israel|Carmel Medical Center, Haifa, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Catania, Italy|Azienda Sanitaria Locale (ASL) Chieti, Chieti, Italy|IRCCS Azienda Ospedaliera Universitaria San Martino, Genoa, Italy|Ospedale San Raffaele S.r.l. - PPDS, Milan, Italy|Azienda Ospedaliero Universitaria di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy|Universita Degli Studi di Pisa - Ospedale di Cisanello Pisa, Pisa, Italy|University of Udine - Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy|Samsung Medical Center, Sungkyunkwan University, Seoul, Korea, Republic of|University of Ulsan, Asan Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Capital Eye Specialist - Wellington, Te Aro, Wellington N, New Zealand|Centro Oftalmologico Macula Diagnostico and Tratamiento, Lima, Peru|Asian Eye Institute, Makati City, Philippines|Peregrine Eye and Laser Institute, Makati City, Philippines|OFTALMIKA Sp. z o.o., Bydgoszcz, Poland|Optimum Profesorskie Centrum Okulistyki, Gdansk, Poland|Klinkita Diagnostyki i Mikrochirugii Jaskry, Lublin, Poland|Centrum Diagnostyki i Mikrochirurgii Oka LENS, Olsztyn, Poland|Clinical Ophthalmology Hospital n.a. V.P. Vihodtsev, Omsk, Russian Federation|Samara State Medical University, Samara, Russian Federation|St. Petersburg State Medical University, St. Petersburg, Russian Federation|Singapore National Eye Centre, Singapore, Singapore|Pretoria Eye Institute - Private Practice, Pretoria, South Africa|Dr Lynette Venter, Westdene, South Africa|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Eskisehir Osmangazi University Medical Faculty, Eskisehir, Turkey|Marmara University Hospital, Istanbul, Turkey|Huntingdon Glaucoma Diagnostic & Research Centre, Huntingdon, Cambridgeshire, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Royal Derby Hospital, Derby, United Kingdom|Princess Alexandra Eye Pavilion, Edinburgh, United Kingdom|Addenbrookes Hospital, Huntingdon, United Kingdom|Moorfield Eye Hospital, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03891446"
756,"NCT01426464","Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy",,"Unknown status","No Results Available","Glaucoma","Drug: 0.005% Latanoprost dosed once.","Intraocular Pressure","Nanduri, Padma, M.D., FACS","All","21 Years and older   (Adult, Older Adult)","Phase 2","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Brown Rabbit 2011-0001","September 2011","November 2011","December 2011","August 31, 2011",,"August 31, 2011","Eye Surgical and Medical Associates, Visalia, California, United States",,"https://ClinicalTrials.gov/show/NCT01426464"
757,"NCT00943306","Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia",,"Completed","Has Results","Familial Hypercholesterolemia","Drug: lomitapide","Percent Change in Low Density Lipoprotein Cholesterol (LDL-C)|Percent Change in Total Cholesterol|Percent Change in Apolipoprotein B (Apo B)|Percent Change in Triglycerides|Percent Change in Non High Density Lipoprotein Cholesterol (Non-HDL-C)|Percent Change in Very Low Density Lipoprotein Cholesterol (VLDL-C)|Percent Change in Lp(a)|Percent Change in High Density Lipoprotein Cholesterol (HDL-C)|Percent Change in Apolipoprotein AI (Apo AI)","Aegerion Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","19","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AEGR-733-012","October 29, 2009","September 17, 2012","December 1, 2014","July 22, 2009","May 11, 2018","June 13, 2018","Cedars-Sinai Medical Center, Los Angeles, California, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Robarts Research Institute, London, Ontario, Canada|Lipid Clinic and University of Montreal Community Genomic Medicine Center, Chicoutimi, Quebec, Canada|Medicina Interna Universitaria, Ferrara, Sicily, Italy|Dipartimento di Medicina Clinica e Delle Patologie Emergenti, Palermo, Sicily, Italy|Centro Universitario Dislipidemie, Milano, Italy|DAI Ematologia, Oncologia, Anatomia Patologica e Medicina, Roma, Italy|Cardiology Research, Bloemfontein, South Africa|University of Capetown, Cape town, South Africa",,"https://ClinicalTrials.gov/show/NCT00943306"
758,"NCT01493271","A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma",,"Completed","No Results Available","Hypertension, Glaucoma, Open-Angle","Drug: Placebo|Drug: RO5093151","Change in mean intraocular pressure (IOP) at 1 hour post-dose following 7 days of treatment|Change in mean daily intraocular pressure (IOP)|Change in mean intraocular pressure (IOP) at each assessment time-points|Change in intraocular pressure (IOP) during a placebo lead-in phase|Pharmacokinetics (area under the concentration time curve)|Urinary ratio of tetrahydrocortisol to tetrahydrocortisone|Safety (incidence of adverse events)","Hoffmann-La Roche","All","21 Years and older   (Adult, Older Adult)","Phase 2","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BP25466","December 2011","November 2012","November 2012","December 15, 2011",,"November 2, 2016","Morrow, Georgia, United States|High Point, North Carolina, United States|Mt. Pleasant, South Carolina, United States|Sofia, Bulgaria|Hradec Kralove, Czech Republic|Litomysi, Czech Republic|Praha, Czech Republic|Usti Nad Labem, Czech Republic|Zlin, Czech Republic|Budapest, Hungary|Budapest, Hungary|Esztergom, Hungary",,"https://ClinicalTrials.gov/show/NCT01493271"
759,"NCT02310672","REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension","REPAIR","Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Macitentan","To evaluate the effect of macitentan on right ventricular and hemodynamic properties in patients with symptomatic pulmonary arterial hypertension (PAH).|To investigate the effect of macitentan on ventriculo-arterial coupling in patients with symptomatic PAH.|To evaluate the safety and tolerability of macitentan in patients with symptomatic PAH.","Actelion","All","18 Years to 64 Years   (Adult)","Phase 4","89","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-055-403","June 1, 2015","September 10, 2019","September 10, 2019","December 8, 2014",,"October 2, 2019","Massachussetts General Hospital, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Rudgers New Jersey Medical School, New Brunswick, New Jersey, United States|Cornell University, New York, New York, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical, Dallas, Texas, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, United States|The Prince Charles Hospital, Chermside, Queensland, Australia|Hopital Gabriel Montpied, Clermont-Ferrand, France|Hôpital Michallon, La Tronche, France|""CHRU de Lille - Hôpital Albert Calmette "", Lille Cedex, France|Hopital de Brabois, Nancy, France|Hôpital Laennec, Nantes Cedex 01, France|Hôpital Pasteur, Nice, France|Hôpital Européen Georges-Pompidou, Paris, France|Medizinische Klinik und Poliklinik II Universitätsklinik Bonn, Bonn, Germany|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum Köln Herzzentrum / Klinik III für Innere Medizin, Köln, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz Centrum für Thrombose und Hämostase, Mainz, Germany|Grantham Hospital, Cardiac Medical Unit, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|United Christian Hospital, Hong Kong, Hong Kong|Pulmonology institute, Soroka Medical Center, Beer-Sheva, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Fondazione IRCCS Policlinico San Matteo Ambulatorio Scompenso Cardiaco e Trapianti, Pavia, Italy|Hospital Pulau Pinang, George Town, Malaysia|Institut Jantung Negara (National Heart Institute), Kuala Lumpur, Malaysia|VU University Medical Center (VUMC), Amsterdam, Netherlands|Maastricht UMC+, Maastricht, Netherlands|St. Antonius Ziekenhuis, Nieuwegein, Netherlands|Radboud UMC, Nijmegen, Netherlands|Erasmus University medical Center, Rotterdam, Netherlands|Russian Cardiology Scientific and Production Complex, Moscow, Russian Federation|Almazov Federal North-West Medical Research Centre of Department of Health, Saint Petersburg, Russian Federation|National University Hospital - The Heart Institute - Cardiac Department, Singapore, Singapore|National Heart Centre (NHC) Singapore, Singapore, Singapore|Golden Jubilee National Hospital, Glasgow, United Kingdom|The Royal Free Hospital, London, United Kingdom|""Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital"", Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02310672"
760,"NCT01529502","Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting",,"Completed","Has Results","Blood Transfusion|Endothelial Physiopathology|Nitric Oxide|Pulmonary Hypertension","Procedure: Red blood Cells auto-transfusion|Drug: Inhaled Nitric Oxide (iNO) administration","Systolic Pulmonary Artery Pressure|Endothelial Function: Reactive Hyperemia Index","Massachusetts General Hospital","All","18 Years to 60 Years   (Adult)","Phase 2","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","Blood Study Overweight","March 2012","December 2013","December 2013","February 8, 2012","March 29, 2017","May 22, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01529502"
761,"NCT02537015","An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert","OLE2","Completed","Has Results","Primary Open-Angle Glaucoma|Ocular Hypertension","Drug: Bimatoprost","Percentage of Participants With Ocular and Non-ocular Adverse Events (AE) by Severity","ForSight Vision5, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","81","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FSV5-005 OLE 2","August 10, 2015","August 11, 2016","August 11, 2016","September 1, 2015","February 26, 2019","April 2, 2019","Vold Vision, Fayetteville, Arkansas, United States|Sall Medical Research Center, Artesia, California, United States|Eye Research Foundation, Newport Beach, California, United States|Clayton Eye Center, Morrow, Georgia, United States|Mundorf Eye Center, Charlotte, North Carolina, United States|Cornerstone Health Care; Cornerstone Eye Care, High Point, North Carolina, United States|University Eye Specialists, Maryville, Tennessee, United States|Total Eye Care, Memphis, Tennessee, United States|R&R Eye Research, LLC, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02537015"
762,"NCT02143843","An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product",,"Completed","Has Results","Primary Open-Angle Glaucoma|Ocular Hypertension","Drug: Bimatoprost","Percentage of Participants With Ocular and Non-ocular Adverse Events (AE) by Severity|Change From Baseline in Mean Intraocular Pressure (IOP)","ForSight Vision5, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FSV5-003","June 5, 2014","December 31, 2015","January 31, 2016","May 21, 2014","February 26, 2019","February 26, 2019","Sall Medical Research Center, Artesia, California, United States|Scripps Clinic Torrey Pines, La Jolla, California, United States|Eye Research Foundation, Newport Beach, California, United States|UC Davis Dept of Ophthalmology & Vision Science, Sacramento, California, United States|Coastal Research Associates, Atlanta, Georgia, United States|Clayton Eye Center, Morrow, Georgia, United States|Ophthalmology Consultants, Saint Louis, Missouri, United States|UNC Kittner Eye Center, Chapel Hill, North Carolina, United States|Apex Eye, Madeira, Ohio, United States|Ophthalmology Associates PC, Fort Worth, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02143843"
763,"NCT03071263","Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease","AMBER","Completed","Has Results","Hyperkalemia|Resistant Hypertension","Drug: Patiromer|Drug: Placebo|Drug: Spironolactone","Number of Participants Remaining on Spironolactone at Week 12|Change in AOBP SBP From Baseline to Week 12 or Last Available AOBP SBP Prior to Addition of Any New BP Medications or Increase From Any Baseline BP Medications","Relypsa, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","295","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RLY5016-207|2016-002657-38","January 23, 2017","November 27, 2018","November 27, 2018","March 6, 2017","January 27, 2020","January 27, 2020","Investigator Site 1012, Hollywood, Florida, United States|Investigator Site 1023, Miami Lakes, Florida, United States|Investigator Site 1022, Chicago, Illinois, United States|Investigator Site 1402, Sofia, Bulgaria|Investiagor Site 2205, Zagreb, Croatia|Investigator Site 2201, Zagreb, Croatia|Investigator Site 2202, Zagreb, Croatia|Investigator Site 2203, Zagreb, Croatia|Investigator Site 3806, Tbilisi, Georgia|Investigator Site 3811, Tbilisi, Georgia|Investigator Site 3802, Tbilisi, Georgia|Investigator Site 3801, Tbilisi, Georgia|Investigator Site 3804, Tbilisi, Georgia|Investigator Site 3805, Tbilisi, Georgia|Investigator Site 3807, Tbilisi, Georgia|Investigator Site 3808, Tbilisi, Georgia|Investigator Site 3810, Tbilisi, Georgia|Investigator Site 3812, Tbilisi, Georgia|Investigator Site 3813, Tbilisi, Georgia|Investigator Site 3809, Tbilisi, Georgia|Investigator Site 4202, Gottingen, Germany|Investigator Site 4607, Balatonfured, Hungary|Investigator Site 4606, Budapest, Hungary|Investigator Site 4611, Debrecen, Hungary|Investigator Site 4601, Hatvan, Hungary|Investigator Site 4605, Kistarcsa, Hungary|Investigator Site 4602, Miskolc, Hungary|Investigator Site 4610, Miskolc, Hungary|Investigator Site 4608, Mosonmagyarovar, Hungary|Investigator Site 7403, Johannesburg, South Africa|Investigator Site 7803, Khar'kov, Ukraine|Investiagor Site 7809, Kharkiv, Ukraine|Investigator Site 7808, Kharkiv, Ukraine|Investigator Site 7802, Kharkiv, Ukraine|Investigator Site 7805, Kiev, Ukraine|Investigator Site 7801, Kiev, Ukraine|Investigator Site 7804, Zaporizhzhia, Ukraine|Investigator Site 7807, Zaporizhzhia, Ukraine|Investigator Site 8202, Leicester, United Kingdom|Investigator Site 8205, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT03071263/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT03071263/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03071263"
764,"NCT04034485","Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH",,"Enrolling by invitation","No Results Available","Homozygous Familial Hypercholesterolemia","Drug: LIB003|Drug: evolocumab","Percent reduction in Low Density Lipoprotein Cholesterol (LDL-C) at week 24|The incidence and severity of treatment emergent adverse events (TEAEs)","LIB Therapeutics LLC","All","10 Years and older   (Child, Adult, Older Adult)","Phase 3","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LIB003-003","November 7, 2019","March 31, 2021","June 30, 2021","July 26, 2019",,"April 22, 2020","NorthShore University Health System, Evanston, Illinois, United States|Metabolic & Atherosclerosis Research Center (MARC), Cincinnati, Ohio, United States|Department of Medicine, Hadassah University Hospital, Jerusalem, Israel|Rabin Medical Center, Beilinson Hospital,, Petah Tikva, Israel|Lipid Clinic, Oslo University Hospital, Oslo, Norway|Carbohydrate and Lipid Metabolism Research Unit, Johannesburg, Gauteng, South Africa|Division of Lipidology, Department of Medicine University of Cape Town, Cape Town, Western Province, South Africa|Ege University Medical School, İzmir, Bornova, Turkey",,"https://ClinicalTrials.gov/show/NCT04034485"
765,"NCT03492177","A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension",,"Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: selexipag (Uptravi)","Area under the plasma concentration-time curve over a dose interval at steady state of selexipag and its metabolite ACT-333679 combined (AUCτ,ss, combined)|Area under the plasma concentration-time curve over a dose interval at steady state (AUCτ,ss) of selexipag|Area under the plasma concentration-time curve over a dose interval at steady state (AUCτ,ss) of ACT-333679|Maximum observed plasma concentration (Cmax,ss) of selexipag at steady state|Maximum observed plasma concentration (Cmax,ss) of ACT-333679 at steady state|Time to the maximum observed plasma concentration (tmax,ss) of selexipag at steady state|Time to the maximum observed plasma concentration (tmax,ss) of ACT-333679 at steady state|Trough concentration of selexipag at steady state (Ctrough,ss)|Trough concentration of ACT-333679 at steady state (Ctrough,ss)|Treatment-emergent adverse events (TEAEs)|Change from baseline in Tanner stage up to end of treatment (EOT + 3 days)|Change from baseline over time in body mass index (BMI) up to end of treatment (EOT + 3 days)|Change from baseline in thyroid stimulating hormone (TSH) up to end of treatment (EOT + 3 days)","Actelion","All","2 Years to 18 Years   (Child, Adult)","Phase 2","55","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-065A203|2018-000145-39","July 23, 2018","February 11, 2026","May 31, 2026","April 10, 2018",,"April 24, 2020","Children'S Hospital Cardiac Care Center University Of Colorado, Aurora, Colorado, United States|University of Iowa Hospital, Iowa City, Iowa, United States|Mayo Clinic, Rochester, Minnesota, United States|Columbia University Medical Center, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Seattle Children's Hospital, Seattle, Washington, United States|State Institution Republican Scientific And Practical Center For Pediatric Surgery, Minsk, Belarus|Health Institution 4Th City Children'S Clinical Hospital, Minsk, Belarus|Centre Hospitalier Sainte Justine, Montreal, Quebec, Canada|Stollery Children's Hospital, Edmonton, Canada|Beijing Anzhen Hospital, Beijing, China|Cardiovascular institute & Fuwai Hospital- Thrombus Center, Beijing, China|Guangdong Provincial People's Hospital, Guangzhou, China|Shanghai Children's Medical Center, Shanghai, China|Wuhan Asia Heart Hospital, Wuhan, China|CHU Arnaud de Villeneuve, Montpellier Cedex 5, France|Hôpital Necker - Enfants Malades, Paris, France|Chu Hopital Des Enfants, Toulouse Cedex 9, France|Universitätsklinikum Freiburg Zentrum, Freiburg, Germany|Justus-Liebig-Universität Gießen, Kinderherzzentrum, Giessen, Germany|Universitäres Herzzentrum Hamburg, Hamburg, Germany|Universitätsklinikum Münster, Münster, Germany|Gottsegen György Országos Kardiológiai Intézet, Felnőtt kardiológiai osztály, Budapest, Hungary|Schneider Children's Medical Center, Petach Tikvah, Israel|Sheba Medical Center, Ramat Gan, Israel|Sarawak General Hospital, Kota Samarahan, Malaysia|Institut Jantung Negara (National Heart Institute), Kuala Lumpur, Malaysia|Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland|Uniwersytecki Szpital Dzieciecy w Krakowie, Kraków, Poland|Szpital Kliniczny im. Karola Jonschera, Poznan, Poland|Wojewódzki Szpital Specjalistyczny We Wrocławiu, Wrocław, Poland|Kazan State Medical University, Kazan, Russian Federation|Federal State Budget Scientific Institution, Kemerovo, Russian Federation|Moscow Scientific Research Institute For Pediatrics And Childrens Surgery Of Rosmedtechnologies, Moscow, Russian Federation|Samara Regional Clinical Cardiological Dispensary, Samara, Russian Federation|Federal State Budgetary Institution, St Petersburg, Russian Federation|Univerzitetska Dečja Klinika, Belgrade, Serbia|Institut Za Zdravstvenu Zaštitu Majke I Deteta Srbije ''Dr Vukan Čupić'', Belgrade, Serbia|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Municipal Enterprise Of The Dnipropetrovsk Regional Council, Dnipro, Ukraine|State Institution Of The Ministry Of Health Of Ukraine, Kiev, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Municipal Institution Of The Zaporizhzhya Regional Council, Zaporizhzhya, Ukraine|Great Ormond Street Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03492177"
766,"NCT03694197","Long Term Safety Study of PRALUENT",,"Active, not recruiting","No Results Available","Heterozygous Familial Hypercholesterolemia|Non-familial Hypercholesterolemia","Drug: Praluent","Incidence of adverse events (AEs) after first administration of study drug through the last dose of study drug plus 2 weeks|Calculated low-density lipoprotein cholesterol (LDL-C) values from baseline over time|Percent change in LDL-C from baseline over time|Total cholesterol (Total-C) values from baseline over time|Non-high-density lipoprotein cholesterol (non-HDL-C) values from baseline over time|High-density lipoprotein cholesterol (HDL-C) values from baseline over time|Triglyceride (TG) values from baseline over time|Percent change from baseline in Total-C over time|Percent change from baseline in non-HDL-C over time|Percent change from baseline in HDL-C over time|Percent change from baseline in TGs over time|Gonadal hormone values from baseline over time|Gonadotropin values from baseline over time|Percent change from baseline in gonadal hormones over time|Percent change from baseline in gonadotropins over time|Alanine transaminase values from baseline over time|Aspartate transferase values from baseline over time|Alkaline phosphatase values from baseline over time|Total bilirubin values from baseline over time|Percent change from baseline in alanine transaminase over time|Percent change from baseline in aspartate transferase over time|Percent change from baseline in alkaline phosphatase over time|Percent change from baseline in total bilirubin over time","Regeneron Pharmaceuticals|Sanofi","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 4","1600","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R727-CL-1609|2018-002810-11","September 28, 2018","November 23, 2023","November 23, 2023","October 3, 2018",,"February 7, 2020","Regeneron Research Site, Auburn, Alabama, United States|Regeneron Research Site, Mobile, Alabama, United States|Regeneron Research Site, Beverly Hills, California, United States|Regeneron Research Site, Los Gatos, California, United States|Regeneron Research Site, North Hollywood, California, United States|Regeneron Research Site, Port Hueneme, California, United States|Regeneron Research Site, Aurora, Colorado, United States|Regeneron Research Site, Colorado Springs, Colorado, United States|Regeneron Research Site, Lake Worth, Florida, United States|Regeneron Research Site, Miami Springs, Florida, United States|Regeneron Research Site, Champaign, Illinois, United States|Regeneron Research Site, Evansville, Indiana, United States|Regeneron Research Site, Indianapolis, Indiana, United States|Regeneron Research Site, Ames, Iowa, United States|Regeneron Research Site, Iowa City, Iowa, United States|Regeneron Research Site, Waterloo, Iowa, United States|Regeneron Research Site, Newton, Kansas, United States|Regeneron Research Site, Louisville, Kentucky, United States|Regeneron Research Site, Bangor, Maine, United States|Regeneron Research Site, Baltimore, Maryland, United States|Regeneron Research Site, Oxon Hill, Maryland, United States|Regeneron Research Site, Olive Branch, Mississippi, United States|Regeneron Research Site, Washington, Missouri, United States|Regeneron Research Site, Buffalo, New York, United States|Regeneron Research Site, New Hyde Park, New York, United States|Regeneron Research Site, Cary, North Carolina, United States|Regeneron Research Site, Charlotte, North Carolina, United States|Regeneron Research Site, Charlotte, North Carolina, United States|Regeneron Research Site, Greensboro, North Carolina, United States|Regeneron Research Site, Hickory, North Carolina, United States|Regeneron Research Site, Raleigh, North Carolina, United States|Regeneron Research Site, Rocky Mount, North Carolina, United States|Regeneron Research Site, Salisbury, North Carolina, United States|Regeneron Research Site, Statesville, North Carolina, United States|Regeneron Research Site, Wilmington, North Carolina, United States|Regeneron Research Site, Winston-Salem, North Carolina, United States|Regeneron Research Site, Cincinnati, Ohio, United States|Regeneron Research Site, Cleveland, Ohio, United States|Regeneron Research Site, Dayton, Ohio, United States|Regeneron Research Site, Charleston, South Carolina, United States|Regeneron Research Site, Summerville, South Carolina, United States|Regeneron Research Site, Rapid City, South Dakota, United States|Regeneron Research Site, Bristol, Tennessee, United States|Regeneron Research Site 2, Knoxville, Tennessee, United States|Regeneron Research Site 3, Knoxville, Tennessee, United States|Regeneron Research Site, Knoxville, Tennessee, United States|Regeneron Research Site, Powell, Tennessee, United States|Regeneron Research Site, Dallas, Texas, United States|Regeneron Research Site, Houston, Texas, United States|Regeneron Research Site, Schertz, Texas, United States|Regeneron Research Site, Shavano Park, Texas, United States|Regeneron Research Site, Shavano Park, Texas, United States|Regeneron Research Site, Falls Church, Virginia, United States|Regeneron Research Site, Winchester, Virginia, United States|Regeneron Research Site, Tacoma, Washington, United States|Regeneron Research Site, Walla Walla, Washington, United States|Regeneron Research Site, Manitowoc, Wisconsin, United States|Regeneron Research Site, Pleven, Bulgaria|Regeneron Research Site, Plovdiv, Bulgaria|Regeneron Research Site, Sofia, Bulgaria|Regeneron Research Site, Sofia, Bulgaria|Regeneron Research Site #2, Sofia, Bulgaria|Regeneron Research Site, Stara Zagora, Bulgaria|Regeneron Research Site, Varna, Bulgaria|Regeneron Research Site, Tallinn, Harjumaa, Estonia|Regeneron Research Site, Paide, Estonia|Regeneron Research Site #2, Tallinn, Estonia|Regeneron Research Site, Tallinn, Estonia|Regeneron Research Site, Tartu, Estonia|Regeneron Research Site, Ekaterinburg, Russian Federation|Regeneron Research Site, Ivanovo, Russian Federation|Regeneron Research Site, Kirov, Russian Federation|Regeneron Research Site, Moscow, Russian Federation|Regeneron Research Site, Moscow, Russian Federation|Regeneron Research Site, Moscow, Russian Federation|Regeneron Research Site, Novosibirsk, Russian Federation|Regeneron Research Site, Rostov-na-Donu, Russian Federation|Regeneron Research Site, Saint Petersburg, Russian Federation|Regeneron Research Site, Saint-Petersburg, Russian Federation|Regeneron Research Site, Saint-Petersburg, Russian Federation|Regeneron Research Site, Saratov, Russian Federation|Regeneron Research Site #2, St. Petersburg, Russian Federation|Regeneron Research Site, St. Petersburg, Russian Federation|Regeneron Research Site, St. Petersburg, Russian Federation|Regeneron Research Site, St. Petersburg, Russian Federation|Regeneron Research Site, St. Petersburg, Russian Federation|Regeneron Research Site, Sverdlovskaya, Russian Federation|Regeneron Research Site, Tyumen, Russian Federation|Regeneron Research Site 1, Yaroslavl, Russian Federation|Regeneron Research Site 2, Yaroslavl, Russian Federation|Regeneron Research Site, Kuilsrivier, Cape Town, South Africa|Regeneron Research Site, Parow, Cape Town, South Africa|Regeneron Research Site, Port Elizabeth, Eastern Cape, South Africa|Regeneron Research Site, Halfway House, Gauteng, South Africa|Regeneron Research Site, Pretoria West, Gauteng, South Africa|Regeneron Research Site, Pretoria, Gauteng, South Africa|Regeneron Research Site, Pretoria, Gauteng, South Africa|Regeneron Research Site, Pretoria, Gauteng, South Africa|Regeneron Research Site, Kempton Park, Johannesburg, South Africa|Regeneron Research Site, Soweto, Johannesburg, South Africa|Regeneron Research Site, Cape Town, Western Cape, South Africa|Regeneron Research Site, Cape Town, Western Cape, South Africa|Regeneron Research Site, George, Western Cape, South Africa|Regeneron Research Site, Paarl, Western Cape, South Africa|Regeneron Research Site, Somerset West, Western Cape, South Africa|Regeneron Research Site, Worcester, Western Cape, South Africa|Regeneron Research Site, Bloemfontein, South Africa|Regeneron Research Site, Claremont, South Africa|Regeneron Research Site, Johannesburg, South Africa|Regeneron Research Site #2, Kharkiv, Ukraine|Regeneron Research Site, Kharkov, Ukraine|Regeneron Research Site, Kiev, Ukraine|Regeneron Research Site, Kyiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine|Regeneron Research Site #2, Kyiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine|Regeneron Research Site, Lviv, Ukraine|Regeneron Research Site, Uzhorod, Ukraine|Regeneron Research Site, Vinnitsa, Ukraine|Regeneron Research Site, Vinnitsya, Ukraine|Regeneron Research Site, Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT03694197"
767,"NCT01763918","Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2","RUTHERFORD-2","Completed","Has Results","Hyperlipidemia","Biological: Evolocumab|Drug: Placebo","Percent Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)|Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12|Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12|Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein (a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12|Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in VLDL-C at Week 12","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","331","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110117|2012-001365-32","February 7, 2013","November 27, 2013","December 19, 2013","January 9, 2013","December 22, 2015","June 17, 2019","Research Site, Scottsdale, Arizona, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Vancouver, British Columbia, Canada|Research Site, London, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Bron, France|Research Site, Nantes Cedex 1, France|Research Site, Paris Cedex 13, France|Research Site, Köln, Germany|Research Site, New Territories, Hong Kong|Research Site, Amersfoort, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Gouda, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Oslo, Norway|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Midrand, Gauteng, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Reus, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Reinach, Switzerland|Research Site, Coventry, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01763918"
768,"NCT02227784","A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol","ACCENTUATE","Terminated","Has Results","Hyperlipidemia","Drug: Evacetrapib|Drug: Atorvastatin|Drug: Ezetimibe|Drug: Placebo","Percent Change From Baseline to 3 Months in Low-Density Lipoprotein Cholesterol (LDL-C)|Percent Change From Baseline to 3 Months in High-Density Lipoprotein Cholesterol (HDL-C)|Percent Change From Baseline to 3 Months in Apolipoprotein AI (apoAI)|Percent Change From Baseline to 3 Months in Non-HDL-C|Percent Change From Baseline to 3 Months in Apolipoprotein B (apoB)|Percent Change From Baseline to 3 Months in Cholesterol Efflux Capacity|Percent Change From Baseline to 3 Months in Lipoprotein(a) (Lp[a])","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","366","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14502|I1V-MC-EIBH","October 2014","December 2015","December 2015","August 28, 2014","March 22, 2018","October 8, 2019","Heart Center Research, LLC, Huntsville, Alabama, United States|Desert Clinical Research, Mesa, Arizona, United States|Central Phoenix Med Clinic LLC, Phoenix, Arizona, United States|Advanced Clinical Research, Carmichael, California, United States|Tooraj Joseph Raoof M.D., Inc., Encino, California, United States|Irvine Clinical Research Center, Irvine, California, United States|VA Long Beach Healthcare System, Long Beach, California, United States|Rancho Cucamonga Clinical, Rancho Cucamonga, California, United States|Encompass Clinical Research, Spring Valley, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|Cardiac Research, Colorado Springs, Colorado, United States|ZASA Clinical Research, Boynton Beach, Florida, United States|Cardiology Research Assoc., Daytona Beach, Florida, United States|Avail Clinical Research LLC, DeLand, Florida, United States|Alan Graff, MD, PA, Fort Lauderdale, Florida, United States|Nature Coast Clinical Research, LLC, Inverness, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Cardiology Partners Clinical Research Institute, LLC, Wellington, Florida, United States|Georgia Heart Specialists, Covington, Georgia, United States|United Osteoporosis Center, Gainesville, Georgia, United States|East West Medical Institute, Honolulu, Hawaii, United States|Solaris Clinical Research, Meridian, Idaho, United States|Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|Midwest CRC, Crystal Lake, Illinois, United States|Indiana Heart Physicians Inc, Indianapolis, Indiana, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Hutchinson Clinic, Hutchinson, Kansas, United States|Community Medical Associates, Louisville, Kentucky, United States|Grace Research, Bossier City, Louisiana, United States|Maryland Cardiovascular Specialists, Baltimore, Maryland, United States|Overlea Personal Physicians, Baltimore, Maryland, United States|Cape Cod Research Institute, Hyannis, Massachusetts, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Medex Healthcare Research, Inc., Saint Louis, Missouri, United States|Palm Research Center, Las Vegas, Nevada, United States|Heart and Vascular Center of New Brunswick LLC, Somerset, New Jersey, United States|Medex Healthcare Research, Inc., New York, New York, United States|Saratoga Clinical Research LLC, Saratoga Springs, New York, United States|Buffalo Cardiology and Pulmonary Associates, P.C., Williamsville, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|Metrolina Internal Medicine, P.A., Charlotte, North Carolina, United States|High Point Clinical Trials Center, High Point, North Carolina, United States|Boice Willis Clinic, PA, Rocky Mount, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Aventiv Research, Columbus, Ohio, United States|South Oklahoma Heart Research, LLC, Oklahoma City, Oklahoma, United States|Portland Preventive Cardiology, LLC, Portland, Oregon, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|PMG Research of Charleston, LLC, Mount Pleasant, South Carolina, United States|Black Hills Cardiovascular Research Group, Rapid City, South Dakota, United States|Holston Medical Group Clinical Research, Kingsport, Tennessee, United States|Northwest Houston Heart Center, Tomball, Texas, United States|National Clinical Research - Richmond, Richmond, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Kootenai Heart Clinics, LLC, Spokane, Washington, United States|Clinical Investigation Specialists Inc, Kenosha, Wisconsin, United States|Research and Cardiovascular Corp., Ponce, Puerto Rico|Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02227784"
769,"NCT02882373","Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury",,"Withdrawn","No Results Available","Drug-Induced Nephropathy|Hypertension|Proteinuria","Dietary Supplement: Arginine|Drug: Placebo","Reduction in proteinuria as measured by protein-creatinine ratio (UPC) > 500 mg/day|Improved glomerular filtration rate (GFR) >= 25%|Reduction in systolic blood pressure (SBP) >= 10 mmHg and/or diastolic blood pressure >= 5 mmHg","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2015-1105|NCI-2018-02537|P30CA016672","October 23, 2018","May 15, 2019","May 15, 2019","August 29, 2016",,"May 21, 2019","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02882373"
770,"NCT02685462","Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin",,"Completed","No Results Available","Healthy","Drug: Rosuvastatin|Drug: Atorvastatin|Drug: Simvastatin|Drug: Digoxin|Drug: Caffeine","Pharmacokinetic Assessment of ROS, ATO and Digoxin alone and in the presence of CVC, as measured by maximum plasma concentration (Cmax)|Pharmacokinetic Assessment of SIM alone and in the presence of CVC, as measured by maximum plasma concentration (Cmax)|Pharmacokinetic Assessment of Caffeine alone and in the presence of CVC, as measured by maximum plasma concentration (Cmax)|Pharmacokinetic Assessment of ROS, ATO and Digoxin alone and in the presence of CVC, as measured by minimum plasma concentration (Cmin)|Pharmacokinetic Assessment of ROS, ATO and Digoxin alone and in the presence of CVC, as measured by area under the plasma concentration-time curve (AUC)|Pharmacokinetic Assessment of SIM alone and in the presence of CVC, as measured by minimum plasma concentration (Cmin)|Pharmacokinetic Assessment of SIM alone and in the presence of CVC, as measured by area under the plasma concentration-time curve (AUC)|Pharmacokinetic Assessment of Caffeine alone and in the presence of CVC, as measured by minimum plasma concentration (Cmin)|Pharmacokinetic Assessment of Caffeine alone and in the presence of CVC, as measured by area under the plasma concentration-time curve (AUC)|Evaluation of Adverse Events|Changes from Baseline in Clinical Laboratory Tests|Changes from Baseline in 12-lead ECGs|Changes from Baseline in Vital Signs|Changes from Baseline in Physical Examinations","Tobira Therapeutics, Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","652-124","January 31, 2016","February 23, 2016","February 23, 2016","February 18, 2016",,"November 24, 2017","Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02685462"
771,"NCT03399786","Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia",,"Completed","No Results Available","Homozygous Familial Hypercholesterolemia","Drug: evinacumab|Drug: Placebo","Percent change in calculated LDL-C from baseline to week 24|Percent change in Apolipoprotein B (Apo B) from baseline to week 24|Percent change in non-High-density lipoprotein cholesterol (HDL-C) from baseline to week 24|Percent change in Total cholesterol (TC) from baseline to week 24|Proportion of patients with ≥30% reduction in calculated LDL-C|Proportion of patients with ≥50% reduction in calculated LDL-C|Proportion of patients with LDL-C <100 mg/dL [2.59 mmol/L]|Change in calculated LDL-C from baseline to week 24|Proportion of patients who meet European Union (EU) apheresis eligibility criteria (see German Apheresis Working Group)|Proportion of patients who meet United States (US) apheresis eligibility criteria (see US [National Lipid Association] Lipid Apheresis Criteria)|Percent change in Triglyceride (TG) from baseline to week 24|Change in Apo B from baseline to week 24|Change in non-HDL-C from baseline to week 24|Change in TC from baseline to week 24|Percent change in lipoprotein a [Lp(a)] from baseline to week 24|Proportion of patients with LDL-C <70 mg/dL [1.81 mmol/L]|Percent change in apolipoprotein CIII (Apo CIII) from baseline to week 24|Total evinacumab concentration in serum|Incidence of anti-drug antibody (ADA)","Regeneron Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","65","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1500-CL-1629|2017-001388-19","January 18, 2018","June 10, 2019","March 17, 2020","January 16, 2018",,"April 30, 2020","Regeneron Research Site, Boca Raton, Florida, United States|Regeneron Research Site, Boston, Massachusetts, United States|Regeneron Research Site, New York, New York, United States|Regeneron Research Site, Cincinnati, Ohio, United States|Regeneron Research Site, Portland, Oregon, United States|Regeneron Research Site, Dallas, Texas, United States|Regeneron Research Site, Camperdown, New South Wales, Australia|Regeneron Research Site, Perth, Western Australia, Australia|Regeneron Research Site, Innsbruck, Austria|Regeneron Research Site, Chicoutimi, Quebec, Canada|Regeneron Research Site, Québec, Quebec, Canada|Regeneron Research Site, Paris, Cedex, France|Regeneron Research Site, Marseille, France|Regeneron Research Site, Ioánnina, Ioannina, Greece|Regeneron Research Site, Athens, Greece|Regeneron Research Site # 2, Napoli, Italy|Regeneron Research Site, Kurume, Fukuoka, Japan|Regeneron Research Site, Nishinomiya, Hyogo, Japan|Regeneron Research Site, Kanazawa, Ishikawa, Japan|Regeneron Research Site #3, Suita, Osaka, Japan|Regeneron Research Site, Suita, Osaka, Japan|Regeneron Research Site, Osaka, Japan|Regeneron Research Site, Amsterdam, Netherlands|Regeneron Research Site, Rotterdam, Netherlands|Regeneron Research Site, Parktown, Johannesburg, South Africa|Regeneron Research Site, Ivano-Frankivs'k, Ukraine|Regeneron Research Site, Kharkiv, Ukraine|Regeneron Research Site #2, Kharkiv, Ukraine|Regeneron Research Site #2, Kyiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT03399786"
772,"NCT02060487","Effects of Oral Sildenafil on Mortality in Adults With PAH","AFFILIATE","Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: sildenafil citrate","Overall Survival (OS)|Time to first clinical worsening (TTCW) event|6 Minute Walk Distance (6MWD) at Months 6 & 12","Pfizer","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 4","429","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A1481324|2013-004362-34|AFFILIATE","September 22, 2014","June 30, 2023","June 30, 2023","February 12, 2014",,"February 21, 2020","Emory University Investigational Drug Services, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|Frederik Meijer Heart & Vascular Institute Cardiovascular Research, Grand Rapids, Michigan, United States|Spectrum Health Butterworth Hospital IDS Pharmacy, Grand Rapids, Michigan, United States|Spectrum Health Heart & Lung Specialized Care Clinic, Grand Rapids, Michigan, United States|Spectrum Health Hospitals, Grand Rapids, Michigan, United States|Spectrum Health Medical Group - Pulmonary Division, Grand Rapids, Michigan, United States|Spectrum Health, Grand Rapids, Michigan, United States|Robert V. Sibilia MD, Inc., Wooster, Ohio, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Australian Respiratory and Sleep Medicine Institute, Bedford Park, South Australia, Australia|University Hospital of Mont-Godinne, Yvoir, Belgium|BH Heart Center Tuzla, Tuzla, B&h/canton Tuzla, Bosnia and Herzegovina|University Clinical Center of the Republic of Srpska, Banja Luka, B&h/republic OF Srpska, Bosnia and Herzegovina|Clinical Center University of Sarajevo, Sarajevo, Bosnia AND Herzegovina/canton Sarajevo, Bosnia and Herzegovina|Clinical Center University Sarajevo, Sarajevo, Bosnia AND Herzegovina/canton Sarajevo, Bosnia and Herzegovina|University Clinical Hospital Mostar, Mostar, Herzegovina-neretva Canton, Bosnia and Herzegovina|University Hospital Center Zagreb, Zagreb, Croatia|University Hospital Dubrava, Zagreb, Croatia|Fakultni nemocnice Olomouc, Olomouc, Czech Republic, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czech Republic, Czechia|Institut klinicke a experimentalni mediciny, Praha 4, Czechia|DRK Kliniken Berlin, Westend, Berlin, Germany|Universitaetsklinikum der TU Dresden, Dresden, Germany|Universitaetsmedizin Greifswald, Greifswald, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Thoraxklinik am Universitaetsklinikum Heidelberg, Heidelberg, Germany|Universitaetsklinikum Schleswig-Holstein, Luebeck, Germany|University General Hospital of Athens ""Attikon"", Athens, Attiki, Greece|University General Hospital of Alexandroupolis, Alexandroupolis, Evros, Greece|University General Hospital of Patras, Patras, Greece|University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece|Queen Mary Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Shatin, New Territories, Hong Kong|The Chaim Sheba Medical Center, Tel-Hashomer, Israel|Pauls Stradins Clinical University Hospital, Riga, Latvia|Sultanah Aminah Hospital, Johor Bahru, Johor, Malaysia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Serdang, Kajang, Selangor, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Centro De Prevencion Y Rehabilitacion De Enfermedades Pulmonares Crónicas, Monterrey, Nuevo LEÓN, Mexico|Centro de Desarrollo Biomedico, Merida, Yucatan, Mexico|Centro de Estudios Clinicos de Queretaro S.C., Queretaro, Mexico|Samodzielny Publiczny Szpital Kliniczny nr 4, Lublin, Poland|Institutul Inimii ,,Niculae Stancioiu"" Cluj Napoca, Cluj-Napoca, Romania|Institutul de Urgenta pentru Boli Cardiovasculare si Transplant Targu-Mures, Targu-Mures, Romania|FSBI ""Research Institute of complex problems of cardiovascular diseases"", Kemerovo, Russian Federation|FSBI Scientific Research Institute of Pulmonology of FMBA, Moscow, Russian Federation|FSBI ""E.Meshalkin National medical research center"", Novosibirsk, Russian Federation|FSBI ""V.A. Almazov National Medical Research Center"", St. Petersburg, Russian Federation|Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Vojvodina/serbia, Serbia|Institute for Cardiovascular disease of Vojvodina, Sremska Kamenica, Vojvodina, Serbia|Clinical Center of Serbia, Belgrade, Serbia|University Medical Center Zvezdara, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|National University Heart Centre, National University Hospital Singapore (NUHS), Singapore, Singapore|Khoo Teck Puat Hospital, Singapore, Singapore|Center of Chest Diseases, Johannesburg, Gauteng, South Africa|Dr PG Williams Practice, Johannesburg, Gauteng, South Africa|Hospital Universitario Val d´Hebrón, Barcelona, Cataluña, Spain|King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, Thailand|Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Sripoom Sub-district, Muang, Chiang MAI, Thailand|Division of Cardiology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Muang District, KHON KAEN , Thailand, Thailand|Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Muang District, Khon Kaen, Thailand|Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Bakirkoy, Turkey|Ege Üniversitesi Tıp Fakültesi Kardiyoloji Bilim Dalı, Izmir, Bornova, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Fatih, Turkey|Istanbul University Haseki Cardiology Institute, Istanbul, Fatih, Turkey|Uludağ Universitesi Tıp Fakültesi Kardiyoloji Bilim Dalı, Bursa, Görükle, Turkey|Dokuz Eylul Üniversitesi Tıp Fakültesi Kardiyoloji Bilim Dalı, Izmir, Inciralti, Turkey|Marmara University Pendik Training and Research Hospital, Istanbul, Pendik, Turkey|KZ ""Dnipropetrovskyi oblasnyi klinichnyi tsentr kardiolohii ta kardiokhirurhii"" DOR"", viddilennia ka, Dnipropetrovsk, Ukraine|Komunalnyi zaklad okhorony zdorovia, Kharkiv, Ukraine|Oleksandrivska klinichna likarnia m. Kyieva, Kyiv, Ukraine|Kyivska miska klinichna likarnia No 5, kardiolohichne viddilennia, Kyiv, Ukraine|Derzhavna ustanova ""Natsionalnyi naukovyi tsentr ""Instytut kardiolohii, Kyiv, Ukraine|Zakarpatskyi oblasnyi klinichnyi kardiolohichnyi dyspanser, infarktne viddilennia, m. Uzhhorod, Uzhhorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT02060487"
773,"NCT01890967","A Study of LY3015014 in Participants With High Cholesterol",,"Completed","Has Results","Hypercholesterolemia","Drug: LY3015014|Drug: Placebo|Drug: Statin|Drug: Ezetimibe","Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)|Percentage Change From Baseline in LDL-C, Total Cholesterol (TC), High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), Non-HDL-C|Percentage Change From Baseline in Apolipoprotein A1 (Apo A1), Apolipoprotein B (Apo B)|Percentage Change From Baseline in Lipoprotein(a) [Lp(a)]|Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP)|Number of Participants Who Develop Treatment Emergent Anti-LY3015014 Antibodies|Percentage Change From Baseline in Total Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (PCSK9) Levels|Percentage Change From Baseline in Free Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (PCSK9) Levels|Pharmacokinetics (PK): Area Under the Concentration-Time Curve at Steady-State (AUC,ss) for LY3015014|Number of Participants With an Injection Site Reaction","Eli Lilly and Company","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","527","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14853|I5S-MC-EFJE","June 2013","April 2014","June 2014","July 2, 2013","June 21, 2017","September 18, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Encino, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lancaster, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spring Valley, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Safety Harbor, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iowa City, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Louisville, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bossier City, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlotte, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toledo, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Knoxville, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kamloops, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brampton, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gatineau, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Marc Des Carrieres, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cesky Krumlov, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hodonin, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prague, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Svitavy, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalborg, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Copenhagen, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Esbjerg, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hellerup, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hvidovre, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Breda, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goes, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Groningen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Maastricht, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nijmegen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Utrecht, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bialystok, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01890967"
774,"NCT02113163","PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA",,"Unknown status","No Results Available","Diabetes Mellitus, Non-Insulin-Dependent|Hypertriglyceridemia","Drug: Metformin Eicosapentaenoate|Drug: Metformin HCl and Vascepa","AUC following single and repeat single oral administration of metformin eicosapentaenoate, metformin hydrochloride and Vascepa","Thetis Pharmaceuticals LLC","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TP-101-CS01","March 2014","June 2014","July 2014","April 14, 2014",,"April 14, 2014","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT02113163"
775,"NCT02960204","Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension","ENCORE-PH","Completed","No Results Available","Cirrhosis|Portal Hypertension|Non-alcoholic Steatohepatitis","Drug: Emricasan|Drug: Placebo","Mean Change in Hepatic Venous Pressure Gradient (HVPG)|Improvement of HVPG response using a 20% reduction from baseline|Caspase 3/7|Alanine aminotransferase (ALT)|The Number of Subjects with Treatment Emergent Adverse Events","Conatus Pharmaceuticals Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IDN-6556-14","October 17, 2016","October 2, 2018","May 7, 2019","November 9, 2016",,"August 19, 2019","California Liver Research Institute, Pasadena, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|IMIC Inc., Palmetto Bay, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Iowa Digestive Disease Center, Clive, Iowa, United States|Digestive and Liver Disease Specialists; Mercy Medical Center, Baltimore, Maryland, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Minnesota Gastroenterology, PA, Saint Paul, Minnesota, United States|Kansas City Gastroenterology and Hepatology, Kansas City, Missouri, United States|Duke University Medical Center, Duke South Clinics, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Einstein Healthcare Network, Philadelphia, Pennsylvania, United States|Gastro One, Germantown, Tennessee, United States|Texas Clinical Research Institute, Arlington, Texas, United States|Advanced Liver Therapies - Baylor College of Medicine, Houston, Texas, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Pinnacle Clinical Research, San Antonio, Texas, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Bon Secours Liver Institute of Virginia, Richmond, Virginia, United States|McGuire VA Medical Center, Richmond, Virginia, United States|University of Washington Harborview Medical Center, Seattle, Washington, United States|Universitätsklinikum Bonn, Bonn, Germany|Universitatsklinikum Halle (Saale), Halle (Saale), Germany|Eugastro GmbH, Leipzig, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Münster, Münster, Germany|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Spain|Hospital Universitario de Donostia, San Sebastian, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02960204"
776,"NCT03267108","A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed iNO in Subjects With Pulmonary Fibrosis",,"Active, not recruiting","No Results Available","Pulmonary Fibrosis|Pulmonary Hypertension","Drug: iNO|Drug: Placebo","Change in 6-Minute Walking Distance|Clinically meaningful reduction in 6MWD|Change in right ventricular function|Change in left ventricular function|Change in Nadir SpO2 during 6MWT|Change in Oxygen desaturation during 6MWT|Patients who remain above 88% SPO2 during 6MWT|Change in Oxygen during the 6MWT|Increase in supplemental oxygen|Change in Distance Saturation Product (DSP)|Decrease in Distance Saturation Product (DSP)|Change in Integral Distance Saturation Product (IDSP)|Decrease in Integral Distance Saturation Product (IDSP)|Change in Activity Monitoring Measurement|Decrease in Activity Monitoring Measurment|Difference in Dyspnea|Change in St. George Respiratory Questionnaire (SGRQ)|Change in Disease-specific quality of life|Change in Borg Dyspnea Score|Change in Composite of Borg Dyspnea and 6MWD|Change in Pulmonary Hemodynamics|Pulmonary Hemodynamics Change ≥20%|Change in NT-ProBNP|Time to Clinical Improvement|Time to Clinical Worsening|Percent of Responders|Change in REVEAL RISK","Bellerophon Pulse Technologies|Bellerophon","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PULSE-PHPF-001","December 29, 2017","November 2021","May 2022","August 30, 2017",,"January 14, 2020","Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|University of California Davis Health, Sacramento, California, United States|UC Denver Anschutz Medical Center, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|University of Miami, Miami, Florida, United States|Avanza Medical Research Center, Pensacola, Florida, United States|Emory University, Atlanta, Georgia, United States|Piedmont Healthcare, Austell, Georgia, United States|Wellstar Medical Group - Pulmonary Medicine, Marietta, Georgia, United States|Loyola University, Chicago, Illinois, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|The Lung Research Center, LLC, Chesterfield, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|The University of North Carolina at Chapel Hill Marsico Clinical Research Center, Chapel Hill, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Thomas Jefferson University Korman Respiratory Institute, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Utah Health Sciences, Salt Lake City, Utah, United States|Inova Heart and Vascular Institute Advanced Lung Disease Clinic, Falls Church, Virginia, United States|Pulmonary Associates of Richmond, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03267108"
777,"NCT02725372","Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH","INOvation-1","Terminated","No Results Available","Pulmonary Arterial Hypertension","Drug: Inhaled Nitric Oxide 75 mcg/kg IBW/hr|Drug: Placebo","Six Minute Walk Distance (6MWD) - Change from baseline 6MWD at 18 Weeks|Time to Clinical Worsening (TTCW)|Change in World Health Organization (WHO) Functional Class","Bellerophon Pulse Technologies|Worldwide Clinical Trials|Bellerophon","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","162","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PULSE-PAH-004","April 2016","August 2018","August 2018","April 1, 2016",,"August 6, 2019","Arizona Pulmonary Specialists, Ltd, Phoenix, Arizona, United States|University of Arizona Sarver Heart Center, Tucson, Arizona, United States|Cedars-Sinai Medical Center, Beverly Hills, California, United States|UC San Diego / Pulmonary, Critical Care and Sleep Medicine Division, La Jolla, California, United States|West Los Angeles VA Healthcare Center, Los Angeles, California, United States|University of California, Davis Medical Center, Sacramento, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Pulmonary Disease Specialists, PA, Kissimmee, Florida, United States|Central Florida Pulmonary Group, PA, Orlando, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Pulmonary and Critical Care of Atlanta, Atlanta, Georgia, United States|Piedmont Healthcare Pulmonary and Critical Care Research, Austell, Georgia, United States|Wellstar Medical Group - Pulmonary Medicine, Marietta, Georgia, United States|Bluhm Cardiovascular Institute, Clinical Trials Unit, Chicago, Illinois, United States|HeartCare Midwest, Peoria, Illinois, United States|Kentuckiana Pulmonary Associates (KPA), Inc. - Louisville, Louisville, Kentucky, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Albany Medical Center, Albany, New York, United States|Montefiore Medical Center - Weiler Division, Bronx, New York, United States|New York Presbyterian Brooklyn Methodist Hospital - Division of Pulmonary/Critical Care/Sleep, Brooklyn, New York, United States|Winthrop University Hospital, Clinical Trials Center, Mineola, New York, United States|NYU Medical Center, Division Pulmonary, Critical Care and Sleep Medicine, New York, New York, United States|University of Cincinnati Medical Ctr, Dept of Internal Medicine / Pulmonary, Critical Care & Sleep Medicine, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Legacy Medical Group - Pulmonary Clinic, Portland, Oregon, United States|The Oregon Clinic, PC, Portland, Oregon, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Allegheny Singer Research Institute, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|MedTrial, LLC, Columbia, South Carolina, United States|Sioux Falls Cardiovascular, Sioux Falls, South Dakota, United States|University of Texas Southwestern Medical Center of Dallas, Dallas, Texas, United States|Pulmonary Associates of Richmond, Richmond, Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|St Vincent's Public Hospital, Darlinghurst, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|Macquarie University Hospital, Sydney, New South Wales, Australia|Concord Repatriation General Hospital, Sydney, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Innsbruck Medical University, University Hospital for Internal Medicine VI, Pneumology, Innsbruck, Tirol, Austria|AKH-Vienna, Medical University of Vienna, Wien, Austria|Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg -, Leuven, Brabant, Belgium|Hopital Erasme - Service de Cardiologie, Bruxelles, Belgium|Faculty of Medicine / Peter Lougheed Center / Respiratory Research, Calgary, Alberta, Canada|Lawson Clinical Research Services / London Health Sciences Centre - VH, London, Ontario, Canada|Toronto General Hospital, University Health Network, Toronto, Ontario, Canada|Fundación Abood Shaio, Bogotá, Bogotá D.C., Colombia|University Hospital centre Zagreb, Zagreb, Croatia|Vseobecna Fakultni Nemocnice v Praze (VFN), Praha 2, Bohemia, Czechia|Centre Hospitalier Universitaire (CHU) Hopitaux de Rouen - Hopital Charles Nicolle, Rouen, Normandy, France|Centre Hospitalier Universitaire de Grenoble (CHU Grenoble) - Clinique de Pneumologie, Grenoble, Rhone, France|Centre Hospitalier Universitaire de Saint Etienne, St Priest en Jarez, Rhone, France|Hôpital Arnaud De Villeneuve - Service des Maladies Respiratoires, Montpellier, France|CHU de Nice Hôpital Pasteur - Pavillon H - Service Pneumologie, Nice, France|""Universitätsklinikum Freiburg - Medizinische Universitätsklinik, Freiburg, Baden-Württemberg, Germany|Thoraxklinik am Universitätsklinikum Heidelberg-Zentrum für Pulmonale Hypertension, Heidelberg, Baden-Württemberg, Germany|Waldburg-Zeil Kliniken - Fachkliniken Wangen Klinik für Pneumologie, Wangen, Baden-Württemberg, Germany|Klinikum der Universität Regensburg - Klinik und Poliklinik für Innere Medizin II, Regensburg, Bayern, Germany|Universitätsmedizin Greifswald Zentrum für innere Medizin Klinik und Poliklinik für Innere Medizin B, Greifswald, Mecklenburg-Vorpommern, Germany|Medizinische Hochschule Hannover-Abteilung für Pneumologie, Hannover, Niedersachsen, Germany|Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus - Medizinische Klinik und Poliklinik I, Dresden, Sachsen, Germany|Universitätsklinikum Leipzig-Dept. für Innere MedizinAbteilung für Pneumologie, Leipzig, Sachsen, Germany|Helios Klinikum Erfurt, Erfurt, Thüringen, Germany|Unfallkrankenhaus Berlin-Klinik für Innere Medizin/Kardiologie, Berlin, Germany|Barzilai University Medical Center, Ashqelon, Israel|Soroka Medical Center, Beer Sheba, Israel|Carmel Medical Center, Haifa, Israel|The Edith Wolfson Medical Center, Holon, Israel|Hadassah University Medical Center, Jerusalem, Israel|Meir Medical Center - Pulmonology Dept., Kfar Saba, Israel|Rabin Medical Center, Petaẖ Tiqwa, Israel|Sheba Medical Center, Ramat Gan, Israel|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, BG, Italy|Azienda Ospedaliera San Gerardo - Monza, Monza, MI, Italy|Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, PA, Italy|A.O.U. Policlinico Umberto I- Università La Sapienza, Roma, RM, Italy|Vrije Universiteit Medisch Centrum (VUMC), Amsterdam, Netherlands|Hospital Garcia de Orta, Almada, Lisbon, Portugal|Universidade de Coimbra - Hospitais da Universidade de Coimbra (H.U.C), Coimbra, Mondego, Portugal|Centro Hospitalar de Lisboa Norte - Hospital de Santa Maria, Lisbon, Portugal|Clinical Center of Serbia Department of Cardiology and Polyclinic, Belgrade, Serbia|Clinical Center of Serbia, Polyclinic, Pulomology Department, Belgrade, Serbia|Clinical-Hospital Center Zemun, Belgrade, Serbia|Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia|Clinical Center of Nis, Clinic for Cardiovascular Diseases, Nis, Serbia|Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain|Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Canarias, Spain|Hospital Universitario Marques de Valdecilla (HUMV), Santander, Cantabria, Spain|Hospital Virgen de la Salud (HVS), Toledo, Castile - La Mancha, Spain|Hospital Universitario Puerta de Hierro - Madrid, Majadahonda, Madrid, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Mallorca, Spain|Hospital Universitario Vall d'hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario de Valladolid, Valladolid, Spain|Dnipropetrovsk Regional Clinical Center of Cardiology and Cardiac Surgery of Dnipropetrovsk Regional Council, Department of Cardiology, Dnepropetrovsk, Ukraine|Municipal Institution of health care ""Kharkiv City Clinical Hospital №13"", Pulmonology Department №1, Kharkiv, Ukraine|Government Institution ""L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine"", Cardiopulmonology Department, Kharkiv, Ukraine|National institute of phthisiology and pulmonology, Kyiv, Ukraine|National Scientific Centre ""M.D. STRAZHESKO INSTITUTE OF CARDIOLOGY, MAS OF UKRAINE"", Kyiv, Ukraine|Lviv Regional Clinical Hospital, Department of Intesive Care #2, Lviv, Ukraine|Freeman Hospital, Newcastle Upon Tyne, Newcastle, United Kingdom|Golden Jubilee National Hospital, Clydebank, West Dunbartonshire, United Kingdom|Royal Free Hospital, London, United Kingdom|Royal Brompton Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02725372"
778,"NCT01149421","A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 2","Drug: LY2189265|Drug: Placebo","Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)|Change From Baseline to 26 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)|Change From Baseline to 16 and 26 Weeks in Mean 24-hour Diastolic Blood Pressure (DBP)|Change From Baseline to 16 and 26 Weeks in Mean 24-Hour Heart Rate (HR)|Change From Baseline to 16 and 26 Weeks in Mean 24-hour Pulse Pressure|Change From Baseline to 16 and 26 Weeks in Mean 24-hour Mean Arterial Pressure (MAP)|Change From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Systolic Blood Pressure (SBP)|Change From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Diastolic Blood Pressure (DBP)|Change From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Heart Rate (HR)|Change From Baseline to 16 and 26 Weeks in Mean Daytime and Nighttime Pulse Pressure|Change From Baseline to 16 and 26 Weeks in Mean Daytime and Nighttime Mean Arterial Pressure (MAP)|Change From Baseline to 16 and 26 Weeks in Glycosylated Hemoglobin (HbA1c)|Change From Baseline to 16 and 26 Weeks in Fasting Blood Glucose (FBG)|Percentage of Participants Achieving an Glycosylated Hemoglobin (HbA1c) of <7% or ≤6.5%|Number of Participants With Treatment Emergent Adverse Events at 26 Weeks|Change From Baseline to 16 and 26 Weeks on Pancreatic Enzymes|Change From Baseline to 16 and 26 Weeks on Serum Calcitonin|Change From Baseline to 16 Weeks in High-Sensitivity C-Reactive Protein (Hs-CRP)|Change From Baseline to 16 and 26 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval|Number of Events of Adjudicated Pancreatitis up to 26 Weeks|Number of Participants With Adjudicated Cardiovascular Events up to 26 Weeks|Anti-LY2189265 Antibodies|Rate of Hypoglycemic Episodes|Change From Baseline to 16 and 26 Weeks in Body Weight|Measurement of LY2189265 Drug Concentration for Pharmacokinetics - Area Under the Concentration Time Curve (AUC)","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","755","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13631|H9X-MC-GBDN|CTRI/2010/091/001444","June 2010","September 2011","January 2012","June 23, 2010","February 2, 2015","February 2, 2015","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Anaheim, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenbrae, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lancaster, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sacramento, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spring Valley, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coral Gables, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winter Haven, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cartersville, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucker, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bloomington, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Louisville, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paducah, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Metairie, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Auburn, Maine, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haverhill, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Detroit, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jackson, Mississippi, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jefferson City, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Garden City, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dayton, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jefferson Hills, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Johnstown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Georgetown, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Renton, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mar Del Plata, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mendoza, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fe, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Calgary, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Red Deer, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Victoria, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winnipeg, Manitoba, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Johns, Newfoundland and Labrador, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamilton, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oakville, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Laval, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ville St-Laurent, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ceske Budejovice, Czech Republic|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cesky Krumlov, Czech Republic|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prague, Czech Republic|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prerov, Czech Republic|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalborg, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ballerup, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vejle, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ahmedabad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coimbatore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jaipur, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ludhiana, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio Piedras, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santurce, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01149421"
779,"NCT03368066","Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?",,"Completed","No Results Available","Adrenal Insufficiency|Cirrhosis|Spur Cell Anemia|Lecithin Acyltransferase Deficiency","Drug: Cosyntropin","Cholesterol Esterification Deficiency|Spur Cell Anemia|Adrenal Insufficiency|HDL Deficiency|Free Cortisol Deficiency","University of Virginia","All","18 Years to 110 Years   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20212","January 29, 2018","March 12, 2019","March 12, 2019","December 11, 2017",,"September 13, 2019","University of Virginia Health System, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03368066"
780,"NCT01763905","Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2","GAUSS-2","Completed","Has Results","Hyperlipidemia","Biological: Evolocumab|Drug: Placebo to Evolocumab|Drug: Ezetimibe|Drug: Placebo to Ezetimibe","Percent Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)|Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12|Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12|Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein (a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12|Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at the Mean of Weeks 10 and 12|Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at Week 12","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","307","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110116|2012-001364-30","January 24, 2013","November 19, 2013","November 19, 2013","January 9, 2013","December 22, 2015","June 14, 2019","Research Site, Carmichael, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Auburn, Maine, United States|Research Site, Traverse City, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, New York, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Houston, Texas, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Milton, Queensland, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, La Louvière, Belgium|Research Site, Newmarket, Ontario, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Lille Cedex, France|Research Site, Paris Cedex 13, France|Research Site, Vénissieux, France|Research Site, Bad Krozingen, Germany|Research Site, Dresden, Germany|Research Site, Heppenheim, Germany|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Midrand, Gauteng, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Reus, Cataluña, Spain|Research Site, Lugano, Switzerland|Research Site, Reinach, Switzerland|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Telford, United Kingdom|Research Site, West Bromwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01763905"
781,"NCT00877929","Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus",,"Completed","Has Results","Hypertension","Drug: Telmisartan 80|Drug: Amlodipine 10","Change From Baseline in Trough Seated Systolic Blood Pressure to Week 8|Change From Baseline in Trough Seated Systolic Blood Pressure to Week 6|Change From Baseline in Trough Seated Systolic Blood Pressure to Week 4|Change From Baseline in Trough Seated Systolic Blood Pressure to Week 2|Change From Baseline in Trough Seated Systolic Blood Pressure to Week 1|Blood Pressure (BP) Control (SBP<140 mmHg, DBP<90 mmHg) at Eight Weeks|BP Control (SBP<140 mmHg, DBP<90 mmHg) at Six Weeks|BP Control (SBP<140 mmHg, DBP<90 mmHg) at Four Weeks|BP Control (SBP<140 mmHg, DBP<90 mmHg) at Two Weeks|BP Control (SBP<140 mmHg, DBP<90 mmHg) at One Week|BP Control (SBP<130 mmHg, DBP<80 mmHg) at Eight Weeks|BP Control (SBP<130 mmHg, DBP<80 mmHg) at Six Weeks|BP Control (SBP<130 mmHg, DBP<80 mmHg) at Four Weeks|BP Control (SBP<130 mmHg, DBP<80 mmHg) at Two Weeks|BP Control (SBP<130 mmHg, DBP<80 mmHg) at One Week|Systolic Blood Pressure (SBP) Control 140 at Eight Weeks|SBP Control 140 at Six Weeks|SBP Control 140 at Four Weeks|SBP Control 140 at Two Weeks|SBP Control 140 at One Week|SBP Control 130 at Eight Weeks|SBP Control 130 at Six Weeks|SBP Control 130 at Four Weeks|SBP Control 130 at Two Weeks|SBP Control 130 at One Week|SBP Response 140 at Eight Weeks|SBP Response 140 at Six Weeks|SBP Response 140 at Four Weeks|SBP Response 140 at Two Weeks|SBP Response 140 at One Week|SBP Response 130 at Eight Weeks|SBP Response 130 at Six Weeks|SBP Response 130 at Four Weeks|SBP Response 130 at Two Weeks|SBP Response 130 at One Week|DBP Response at Eight Weeks|DBP Response at Six Weeks|DBP Response at Week Four|DBP Response at Week Two|DBP Response at Week One|Change From Baseline in Urine Albumin:Creatinine Ratio (UACR)","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","706","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1235.21|2008-000874-19","February 2009","May 2010",,"April 8, 2009","June 7, 2011","March 12, 2014","1235.21.901 Boehringer Ingelheim Investigational Site, Long Beach, California, United States|1235.21.907 Boehringer Ingelheim Investigational Site, Tustin, California, United States|1235.21.913 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States|1235.21.910 Boehringer Ingelheim Investigational Site, Hollywood, Florida, United States|1235.21.903 Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States|1235.21.905 Boehringer Ingelheim Investigational Site, Tucker, Georgia, United States|1235.21.916 Boehringer Ingelheim Investigational Site, Olive Branch, Mississippi, United States|1235.21.915 Boehringer Ingelheim Investigational Site, Hickory, North Carolina, United States|1235.21.906 Boehringer Ingelheim Investigational Site, Winston-Salem, North Carolina, United States|1235.21.902 Boehringer Ingelheim Investigational Site, Oklahoma City, Oklahoma, United States|1235.21.904 Boehringer Ingelheim Investigational Site, Penndel, Pennsylvania, United States|1235.21.908 Boehringer Ingelheim Investigational Site, Carrollton, Texas, United States|1235.21.909 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States|1235.21.912 Boehringer Ingelheim Investigational Site, Killeen, Texas, United States|1235.21.911 Boehringer Ingelheim Investigational Site, Ettrick, Virginia, United States|1235.21.102 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|1235.21.103 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|1235.21.107 Boehringer Ingelheim Investigational Site, Ramos Mejía, Argentina|1235.21.101 Boehringer Ingelheim Investigational Site, Santa Fe, Argentina|1235.21.105 Boehringer Ingelheim Investigational Site, Zárate, Argentina|1235.21.202 Boehringer Ingelheim Investigational Site, Incheon, Korea, Republic of|1235.21.201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1235.21.203 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1235.21.204 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1235.21.205 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1235.21.302 Boehringer Ingelheim Investigational Site, Acapulco, Mexico|1235.21.304 Boehringer Ingelheim Investigational Site, Aguascalientes, Mexico|1235.21.301 Boehringer Ingelheim Investigational Site, Guadalajara, Mexico|1235.21.303 Boehringer Ingelheim Investigational Site, Guadalajara, Mexico|1235.21.305 Boehringer Ingelheim Investigational Site, Guadalajara, Mexico|1235.21.306 Boehringer Ingelheim Investigational Site, Guadalajara, Mexico|1235.21.408 Boehringer Ingelheim Investigational Site, Beek en Donk, Netherlands|1235.21.406 Boehringer Ingelheim Investigational Site, Den Haag, Netherlands|1235.21.401 Boehringer Ingelheim Investigational Site, Hoogwoud, Netherlands|1235.21.405 Boehringer Ingelheim Investigational Site, Musselkanaal, Netherlands|1235.21.404 Boehringer Ingelheim Investigational Site, Nijverdal, Netherlands|1235.21.403 Boehringer Ingelheim Investigational Site, Oude Pekela, Netherlands|1235.21.409 Boehringer Ingelheim Investigational Site, Roelofarensveen, Netherlands|1235.21.407 Boehringer Ingelheim Investigational Site, Voerendaal, Netherlands|1235.21.402 Boehringer Ingelheim Investigational Site, Wildervank, Netherlands|1235.21.501 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|1235.21.502 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|1235.21.503 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|1235.21.504 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|1235.21.507 Boehringer Ingelheim Investigational Site, Dunajska Streda, Slovakia|1235.21.509 Boehringer Ingelheim Investigational Site, Martin, Slovakia|1235.21.505 Boehringer Ingelheim Investigational Site, Nitra, Slovakia|1235.21.506 Boehringer Ingelheim Investigational Site, Nitra, Slovakia|1235.21.508 Boehringer Ingelheim Investigational Site, Rimavska Sobota, Slovakia|1235.21.27005 Boehringer Ingelheim Investigational Site, Cape Town, South Africa|1235.21.27007 Boehringer Ingelheim Investigational Site, Cape Town, South Africa|1235.21.27004 Boehringer Ingelheim Investigational Site, Durban, South Africa|1235.21.27006 Boehringer Ingelheim Investigational Site, Johannesburg, South Africa|1235.21.27002 Boehringer Ingelheim Investigational Site, Krugersdorp, South Africa|1235.21.27001 Boehringer Ingelheim Investigational Site, Lenasia, South Africa|1235.21.27003 Boehringer Ingelheim Investigational Site, Pretoria, South Africa|1235.21.702 Boehringer Ingelheim Investigational Site, Castellón, Spain|1235.21.705 Boehringer Ingelheim Investigational Site, Centelles, Spain|1235.21.703 Boehringer Ingelheim Investigational Site, Sant Adrià del Besós, Spain|1235.21.704 Boehringer Ingelheim Investigational Site, Santa Coloma de Gramanet (Barcelona), Spain|1235.21.706 Boehringer Ingelheim Investigational Site, Santa Coloma de Gramanet, Spain|1235.21.801 Boehringer Ingelheim Investigational Site, Göteborg, Sweden|1235.21.803 Boehringer Ingelheim Investigational Site, Helsingborg, Sweden|1235.21.804 Boehringer Ingelheim Investigational Site, Lund, Sweden|1235.21.802 Boehringer Ingelheim Investigational Site, Västerås, Sweden",,"https://ClinicalTrials.gov/show/NCT00877929"
782,"NCT00871234","Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study",,"Completed","Has Results","Endothelial Function|Lipids|Insulin Resistance|Inflammation|HIV Infections","Drug: Etravirine","Flow-mediated Dilation (FMD) of the Brachial Artery|Lipid Fractions|Insulin Sensitivity [(Homeostasis Model Assessment-Insulin Resistance (HOMA-IR)]|Blood Pressure|Inflammatory Biomarkers|Endothelial Activation Biomarkers","Indiana University|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","0812-18 (TMC125HIV4003)","April 2009","March 2010","July 2010","March 30, 2009","January 5, 2011","January 7, 2011","Infectious Diseases Research Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00871234"
783,"NCT02185417","Diuretic Comparison Project","DCP","Recruiting","No Results Available","Hypertension","Drug: Hydrochlorothiazide (HCTZ)|Drug: Chlorthalidone","Time to major cardiovascular event|Time to event for each component of the composite primary outcome and additional cardiovascular events|All Deaths|Urgent revascularization because of unstable angina|Hospitalization for acute congestive heart failure|Non-cancer death|The primary composite outcome substituting 'all deaths' for 'non-cancer deaths'|Possibly Vascular Deaths|The primary composite outcome substituting 'possibly vascular deaths' for 'non-cancer deaths'|Any revascularization of any artery|Erectile dysfunction (ED)","VA Office of Research and Development","All","65 Years and older   (Older Adult)","Phase 3","13500","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","597","June 15, 2016","October 15, 2022","April 15, 2023","July 9, 2014",,"February 12, 2020","Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States|Alaska VA Healthcare System, Anchorage, AK, Anchorage, Alaska, United States|Veterans Health Care System of the Ozarks, Fayetteville, AR, Fayetteville, Arkansas, United States|VA Central California Health Care System, Fresno, CA, Fresno, California, United States|VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States|VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Grand Junction VA Medical Center, Grand Junction, CO, Grand Junction, Colorado, United States|VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States|Wilmington VA Medical Center, Wilmington, DE, Wilmington, Delaware, United States|Washington DC VA Medical Center, Washington, DC, Washington, District of Columbia, United States|Bay Pines VA Healthcare System, Pay Pines, FL, Bay Pines, Florida, United States|North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|VA Pacific Islands Health Care System, Honolulu, HI, Honolulu, Hawaii, United States|Boise VA Medical Center, Boise, ID, Boise, Idaho, United States|VA Illiana Health Care System, Danville, IL, Danville, Illinois, United States|Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States|Maine VA Medical Center, Augusta, ME, Togus, Maine, United States|Rehabilitation R&D Service, Baltimore, MD, Baltimore, Maryland, United States|Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, Bedford, Massachusetts, United States|VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States|Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States|Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States|St. Cloud VA Health Care System, St. Cloud, MN, Saint Cloud, Minnesota, United States|VA Gulf Coast Veterans Health Care System, Biloxi, MS, Biloxi, Mississippi, United States|Kansas City VA Medical Center, Kansas City, MO, Kansas City, Missouri, United States|St. Louis VA Medical Center John Cochran Division, St. Louis, MO, Saint Louis, Missouri, United States|Manchester VA Medical Center, Manchester, NH, Manchester, New Hampshire, United States|New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico, United States|Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York, United States|Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States|Fargo VA Healthcare System, Fargo, ND, Fargo, North Dakota, United States|Cincinnati VA Medical Center, Cincinnati, OH, Cincinnati, Ohio, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States|Dayton VA Medical Center, Dayton, OH, Dayton, Ohio, United States|Jackson C. Montgomery VA Medical Center, Muskogee, OK, Muskogee, Oklahoma, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|VA Roseburg Healthcare System, Roseburg, OR, Roseburg, Oregon, United States|VA Southern Oregon Rehabilitation Center and Clinics, White City, OR, White City, Oregon, United States|Coatesville VA Medical Center, Coatesville, PA, Coatesville, Pennsylvania, United States|Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States|VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, United States|Wilkes-Barre VA Medical Center, Wilkes-Barre, PA, Wilkes-Barre, Pennsylvania, United States|Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States|Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC, Columbia, South Carolina, United States|VA Black Hills Health Care System Fort Meade Campus, Fort Meade, SD, Fort Meade, South Dakota, United States|Memphis VA Medical Center, Memphis, TN, Memphis, Tennessee, United States|Memphis VA Medical Center, Memphis, TN, Memphis, Tennessee, United States|Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States|White River Junction VA Medical Center, White River Junction, VT, White River Junction, Vermont, United States|Hampton VA Medical Center, Hampton, VA, Hampton, Virginia, United States|Huntington VA Medical Center, Huntington, WV, Huntington, West Virginia, United States|William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States|Clement J. Zablocki VA Medical Center, Milwaukee, WI, Milwaukee, Wisconsin, United States|Tomah VA Medical Center, Tomah, WI, Tomah, Wisconsin, United States|Sheridan VA Medical Center, Sheridan, WY, Sheridan, Wyoming, United States|VA Caribbean Healthcare System, San Juan, PR, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02185417"
784,"NCT01332331","Efficacy and Safety of Ambrisentan in Children 8-18yrs",,"Terminated","Has Results","Hypertension, Pulmonary","Drug: Ambrisentan - low dose|Drug: Ambrisentan - high dose","Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Treatment-emergent Adverse Events (SAEs)|Number of Participants With Post Baseline Potential Clinical Importance (PCI) Value for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin and Creatinine|Number of Participants With Post Baseline PCI Value for Hematology Parameter: Hemoglobin|Number of Participants With Post Baseline PCI Value for Hematology Parameter: Hematocrit|Number of Participants With Post Baseline PCI Value for Hematology Parameter: Platelet Count|Number of Participants With Abnormal Value for Physical Examination Parameter: Liver Size|Number of Participants With Abnormal Value for Physical Examination Parameter: Jugular Venous Pressure|Number of Participants With Abnormal Value for Physical Examination Parameter: Peripheral Edema|Number of Participants With Abnormal Value for Physical Examination Parameter: Ascites|Percentage of Physical Examination Parameter: Saturated Oxygen Level|Number of Participants With Post Baseline PCI Value for Vital Signs Parameter: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Number of Participants With Post Baseline PCI Value for Vital Signs Parameter: Heart Rate|Number of Participants With Post Baseline PCI Value for Vital Signs Parameter: Weight|Change From Baseline of Pubertal Development: Men- Testicular Volume (TV) at Weeks 12 and 24|Change From Baseline in Plasma Endocrine Parameter - Female : Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) at Weeks 12 and 24|Change From Baseline in Plasma Endocrine Parameter - Female : Inhibin B at Weeks 12 and 24|Change From Baseline in Plasma Endocrine Parameter - Female : Sex Hormone Binding Globulin at Weeks 12 and 24|Change From Baseline in the 6 Minutes Walking Distance (6MWD) Test|Time to the First Clinical Worsening of Pulmonary Arterial Hypertension (PAH)|Change From Baseline in Subject Global Assessment to Week 24 Using the SF-10 Health Survey for Children|Change From Baseline in World Health Organization (WHO) Functional Class to Week 24|Ratio to Baseline in Plasma N-terminal Pro-B Type Natriuretic Peptide (NT-Pro BNP) Concentration at Week 24","GlaxoSmithKline","All","8 Years to 18 Years   (Child, Adult)","Phase 2","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","112529|2010-019547-19","January 4, 2011","November 12, 2013","November 12, 2013","April 11, 2011","October 8, 2019","October 8, 2019","GSK Investigational Site, Aurora, Colorado, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Guymallen, Mendoza, Argentina|GSK Investigational Site, Ciudad de Buenos Aires, Argentina|GSK Investigational Site, Córdoba, Argentina|GSK Investigational Site, Paris cedex 15, France|GSK Investigational Site, Pessac cedex, France|GSK Investigational Site, Toulouse cedex 9, France|GSK Investigational Site, Erlangen, Bayern, Germany|GSK Investigational Site, Giessen, Hessen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, San Donato Milanese (MI), Lombardia, Italy|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, Madrid, Spain","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT01332331/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT01332331/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01332331"
785,"NCT01345448","Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy",,"Unknown status","No Results Available","Glaucoma","Drug: Brimonidine|Drug: Placebo Lotion","Intraocular Pressure|Heart Rate|Blood Pressure","Nanduri, Padma, M.D., FACS","All","21 Years and older   (Adult, Older Adult)","Phase 2","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","White Rabbit 2010-0001","April 2011","July 2011","July 2011","May 2, 2011",,"May 2, 2011","Eye Surgical and Medical Associates, Visalia, California, United States",,"https://ClinicalTrials.gov/show/NCT01345448"
786,"NCT01515813","Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation",,"Withdrawn","No Results Available","HIV-1 Infection","Drug: Pravastatin sodium|Drug: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate","Change in brachial artery FMD|Change in IL-6|Change in hs-CRP|Change in D-dimer|Change in non-HDL cholesterol|Change in fasting triglycerides|Change in demographically corrected standard scores (T-scores) for each neuropsychological performance domain and the overall global deficit score (GDS)","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG A5292|1U01AI068636","November 2011","July 2014","December 2014","January 24, 2012",,"February 1, 2016","UCLA CARE Center CRS (601), Los Angeles, California, United States|Harbor-UCLA Med. Ctr. CRS (603), Torrance, California, United States|Washington University CRS (2101), St. Louis, Missouri, United States|Unc Aids Crs (3201), Chapel Hill, North Carolina, United States|Duke University Medical Center Adult CRS (1601), Durham, North Carolina, United States|Regional Center for Infectious Disease, Wendover Medical Center CRS (3203), Greensboro, North Carolina, United States|The Ohio State University AIDS CRS (2301), Colombus, Ohio, United States|Vanderbilt Therapeutics CRS (3652), Nashville, Tennessee, United States|Houston AIDS Research Team CRS (31473), Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01515813"
787,"NCT02230683","A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension","PH","Completed","Has Results","Liver Cirrhosis|Hepatic Cirrhosis|Portal Hypertension","Drug: IDN-6556","Hepatic Venous Pressure Gradient (HVPG)|cCK18/M30|Change in cCK18/M30|Change in Alanine Aminotransferase (ALT)|Change in Aspartate Aminotransferase (AST)|Concentration of Caspase 3/7 RLU","Conatus Pharmaceuticals Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IDN-6556-11","August 2014","May 2015","June 2015","September 3, 2014","December 21, 2016","December 21, 2016","VA Connecticut Healthcare System, West Haven, Connecticut, United States|Johns Hopkins Sibley Memorial Hospital, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|North Shore University Hospital, Manhasset, New York, United States|New York University Lagone Medical Center, NYC, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|St. Luke's Health Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah Hospital, Salt Lake City, Utah, United States|Bon Secours Mary Immaculate Hospital, Newport News, Virginia, United States|Bon Secours St. Mary's Hospital, Richmond, Virginia, United States|McGuire DVAMC, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02230683"
788,"NCT03177603","A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)",,"Completed","Has Results","Hypertension, Pulmonary","Drug: GSK2586881","Change From Baseline in Pulmonary Vascular Resistance (PVR)|Change From Baseline in Cardiac Output (CO)|Change From Baseline in Mean Pulmonary Artery Pressure (mPAP)|Number of Participants With Non-serious Adverse Events (AEs)|Number of Participants With Serious Adverse Events (SAEs)|Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphatase, Alanine Amino Transferase and Aspartate Amino Transferase|Change From Baseline in Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin and Creatinine|Change From Baseline in Clinical Chemistry Parameters: Calcium, Glucose, Potassium, Sodium and Blood Urea Nitrogen (BUN)|Change From Baseline in Clinical Chemistry Parameter: Total Protein|Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count and White Blood Cell (WBC) Count|Change From Baseline in Hematology Parameter: Hemoglobin|Change From Baseline in Hematology Parameter: Hematocrit|Change From Baseline in Hematology Parameter: Mean Corpuscle Hemoglobin|Change From Baseline in Hematology Parameter: Mean Corpuscle Volume|Change From Baseline in Hematology Parameter: Red Blood Cell (RBC) Count|Change From Baseline in Hematology Parameter: Reticulocytes|Number of Participants With Urinalysis Results by Dipstick Method|Change From Baseline in Pulse Rate|Change From Baseline in Respiratory Rate|Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)|Number of Participants With Abnormal Electrocardiogram (ECG) Findings|Change From Baseline in Pulse Oximetry Parameter: Percent Oxygen in Blood|Number of Participants With Positive Immunogenicity Results|Change From Baseline in Systemic Renin-Angiotensin System (RAS) Peptides: Angiotensin II, Angiotensin (1-5) and Angiotensin (1-7)|Change From Baseline in Pulmonary Wedge RAS Peptides: Angiotensin II, Angiotensin (1-5) and Angiotensin (1-7)|Systemic RAS Peptide: Angiotensin II/Angiotensin (1-7) Ratio at Indicated Time Points|Pulmonary Wedge RAS Peptide: Angiotensin II/Angiotensin (1-7) Ratio at Indicated Time Points|Change From Baseline in Disease Biomarkers: N-terminal Pro B-type Natriuretic Peptide (NT Pro-BNP)|Change From Baseline in Nitrite, Nitrate and Endogenous Nitrite (Biomarkers of Nitric Oxide [NO])|Change From Baseline in Disease Biomarker: Cardiac Troponin-I|Maximum Observed Plasma Concentration (Cmax) of GSK2586881|Time to Cmax (Tmax) of GSK2586881|Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-t]) of GSK2586881|Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK2586881|Last Observed Quantifiable Concentration (Ct) of GSK2586881|Time of the Last Quantifiable Concentration (Tlast) of GSK2586881|Plasma Clearance (CL) of GSK2586881|Apparent Volume of Distribution of GSK2586881|Apparent Terminal Phase Half-life (t1/2) of GSK2586881","GlaxoSmithKline","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","206246|2017-000212-41","February 21, 2018","May 7, 2019","May 7, 2019","June 6, 2017","April 21, 2020","April 21, 2020","GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03177603/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03177603/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03177603"
789,"NCT00824824","Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)",,"Completed","Has Results","Glaucoma","Drug: Dorzolamide 2%-timolol 0.5%|Drug: Brimonidine 0.2%-0.5% timolol 0.5","Presence of Retinal Vascular Dysregulation (RVD)","Massachusetts Eye and Ear Infirmary","All","40 Years to 80 Years   (Adult, Older Adult)","Not Applicable","21","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","08-12-057","January 2009","August 2012","August 2012","January 19, 2009","October 28, 2016","April 4, 2017","Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00824824"
790,"NCT02136940","Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Glaucoma|Ocular Hypertension|Eye Disease","Drug: AMA0076|Drug: Placebo","Mean change from baseline in mean diurnal intraocular pressure|Mean, mean change and percent change from baseline in intraocular pressure in both mean diurnal intraocular pressure and intraocular pressure at equivalent diurnal time points.|Compare the safety and tolerability of topically administered AMA0076 compared to vehicle, by evaluation of safety variables","Amakem, NV","All","30 Years to 85 Years   (Adult, Older Adult)","Phase 2","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AMA0076-S-202","April 2014","November 2014","December 2014","May 13, 2014",,"January 21, 2015","Artesia Clinical - Site 11, Artesia, California, United States|Inglewood Clinical Site - Site 15, Inglewood, California, United States|Petaluma Clinical Site - Site 17, Petaluma, California, United States|Morrow Clinical Site - Site13, Morrow, Georgia, United States|Roswell Clinical Site - Site 18, Roswell, Georgia, United States|Rochester Clinical Site - Site 12, Rochester, New York, United States|Slingerlands Clinical Site - Site 19, Slingerlands, New York, United States|Charlotte Clinical Site - Site 14, Charlotte, North Carolina, United States|High Point Clinical Site - Site 16, High Point, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02136940"
791,"NCT01689623","A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants",,"Completed","No Results Available","Healthy Participants","Drug: TMC435|Drug: Atorvastatin|Drug: Simvastatin","Effect of steady-state (constant concentration of medication in the blood) concentrations of TMC435 on the single dose pharmacokinetics (what the body does to the drug) of simvastatin and the active metabolite simvastatin acid|Effect of steady-state concentrations of TMC435 on the single dose pharmacokinetics of atorvastatin and the active metabolites ortho- and parahydroxylated atorvastatin|Plasma hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitory activity after a single dose of atorvastatin or simvastatin, either alone or in combination with TMC435|To evaluate the steady-state pharmacokinetics of TMC435 in the presence of atorvastatin or simvastatin|Number of participants with adverse events as a measure of safety and tolerability","Janssen Research & Development, LLC","All","19 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR100873|TMC435HPC1006","June 2012","August 2012","August 2012","September 21, 2012",,"March 4, 2013","Lincoln, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01689623"
792,"NCT03667326","Postpartum Low-Dose Aspirin and Preeclampsia",,"Recruiting","No Results Available","Preeclampsia Postpartum","Drug: Aspirin|Drug: Placebo oral capsule","Change in Flow-Mediated Dilation (FMD)|Change in Systolic blood pressure|Change in Diastolic blood pressure|Number of subjects with presentation of disease postpartum (symptoms, severe range BPs, lab abnormalities)|Magnesium sulfate re-administration|Number of subjects with initiation of, increase in or addition of blood pressure medication|Rate of hospital readmissions for postpartum preeclampsia","Columbia University","Female","18 Years and older   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","AAAR9439","July 22, 2019","April 2020","June 2020","September 12, 2018",,"January 18, 2020","Columbia University Irving Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03667326"
793,"NCT01288469","Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Atorvastatin|Drug: Placebo (for atorvastatin)","Percent Change From Baseline in Calculated LDL-C at Week 8 - On-treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 8 - On-treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 8 - On-treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and < 70 mg/dL (1.81 mmol/L) at Week 8 - On-treatment Analysis|Percent Change From Baseline in Total Cholesterol, Fasting Triglycerides, Non-high-Density Lipoprotein Cholesterol (Non-HDL-C), Apolipoprotein B (Apo-B) and Lipoprotein(a) at Week 8 - On-treatment Analysis|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 8 - On-treatment Analysis|Absolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 8 - On-treatment Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DFI11566|U1111-1117-9994","January 2011","September 2011","September 2011","February 2, 2011","September 24, 2015","September 24, 2015","Investigational Site Number 840616, Mesa, Arizona, United States|Investigational Site Number 840601, Tucson, Arizona, United States|Investigational Site Number 840610, Los Angeles, California, United States|Investigational Site Number 840608, Newport Beach, California, United States|Investigational Site Number 840603, Doral, Florida, United States|Investigational Site Number 840611, Jacksonville, Florida, United States|Investigational Site Number 840618, Jupiter, Florida, United States|Investigational Site Number 840612, Miami, Florida, United States|Investigational Site Number 840614, Miami, Florida, United States|Investigational Site Number 840607, St. Petersburg, Florida, United States|Investigational Site Number 840605, Chicago, Illinois, United States|Investigational Site Number 840619, Chicago, Illinois, United States|Investigational Site Number 840604, Edison, New Jersey, United States|Investigational Site Number 840606, Rochester, New York, United States|Investigational Site Number 840615, Cincinnati, Ohio, United States|Investigational Site Number 840617, Cincinnati, Ohio, United States|Investigational Site Number 840602, Eugene, Oregon, United States|Investigational Site Number 840621, Richmond, Virginia, United States|Investigational Site Number 840609, Olympia, Washington, United States|Investigational Site Number 840613, Oregon, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01288469"
794,"NCT02182830","24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension",,"Completed","Has Results","Diabetes Mellitus, Type 2|Hypertension","Drug: Empagliflozin low dose|Drug: placebo|Drug: Empagliflozin high dose","Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks|Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (SBP) at Week 12|Changes From Baseline in Trough Mean Ambulatory SBP at Week 12|Change From Baseline in Body Weight at Week 24|Change From Baseline in Trough Seated SBP at Week 12|Change From Baseline in Mean 24-hour Ambulatory SBP (mmHg) at Week 24|Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (DBP) at Week 12|Change From Baseline in Mean 24-hour Ambulatory DBP (mmHg) at Week 24|Change From Baseline in Trough Seated SBP (mmHg) at Week 24|Change From Baseline in Trough Seated DBP (mmHg) at Week 12|Change From Baseline in Trough Seated DBP (mmHg) at Week 24","Boehringer Ingelheim|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","166","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1245.29","July 25, 2014","May 18, 2017","May 18, 2017","July 8, 2014","July 31, 2018","July 31, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC, Birmingham, Alabama, United States|Longwood Research, Huntsville, Alabama, United States|Internal Medicine Center, LLC, Mobile, Alabama, United States|Mobile Medical and Diagnostic Center, Mobile, Alabama, United States|University of South Alabama, Mobile, Alabama, United States|Cardiology and Medicine Clinic, Little Rock, Arkansas, United States|Larry Watkins, M .D., Little Rock, Arkansas, United States|eStudySite, Chula Vista, California, United States|Torrance Clinical Research Institute Inc., Lomita, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|MD Clinical Trials, Los Angeles, California, United States|Office of Dr. Alexander Ford, M.D., Los Angeles, California, United States|Diabetes Associates Medical Group, Orange, California, United States|Integrated Research Group, Inc., Riverside, California, United States|Clinical Trials Research, Sacramento, California, United States|Orange County Research Center, Tustin, California, United States|Lynn Institute of Denver, Denver, Colorado, United States|Pines Clinical Research Inc., Hollywood, Florida, United States|UF Health Jacksonville, Jacksonville, Florida, United States|Care Partners Clinical Research LLC, Jacksonville, Florida, United States|Sunshine Research Center, Opa-locka, Florida, United States|Central Florida Internist, Orlando, Florida, United States|Accord Clinical Research, LLC, Port Orange, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Alternative Solutions Medical Research and Prevention Center, Saint Petersburg, Florida, United States|International Clinical Research - US, LLC, Sanford, Florida, United States|Meridien Research, Tampa, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Morehouse School of Medicine, Atlanta, Georgia, United States|Atlanta Center, Atlanta, Georgia, United States|Atlanta Clinical Research Centers, Atlanta, Georgia, United States|Albert F. Johary MD, PC, Dunwoody, Georgia, United States|Sestron Clinical Research, Marietta, Georgia, United States|Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC, Marietta, Georgia, United States|WR-Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia, United States|Eagle's Landing Diabetes and Endocrinology, Stockbridge, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|John H. Stroger Jr. Hospital of Cook Country, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Investigators Research Group, LLC, Brownsburg, Indiana, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Gulf Regional Research and Education Services, LLC, Metairie, Louisiana, United States|New Orleans Center for Clinical Research, New Orleans, Louisiana, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|American Institute of Research Studies, Baltimore, Maryland, United States|Phillips Medical Services, PLLC, Jackson, Mississippi, United States|Mercy Research, Washington, Missouri, United States|Quality Clinical Research Inc, Omaha, Nebraska, United States|Accent Clinical Trials, Las Vegas, Nevada, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|Offic of Dr. Eric Cheng, Brooklyn, New York, United States|Healthwise Medical Associates, Brooklyn, New York, United States|Modern Medical, Brooklyn, New York, United States|Erie County Medical Center, Buffalo, New York, United States|Scott Research, Inc., Laurelton, New York, United States|Medex Healthcare Research, Inc., New York, New York, United States|Laurelton Heart Specialist, PC, Rosedale, New York, United States|Metrolina Internal Medicine, PA, Charlotte, North Carolina, United States|PhysiqueMed Clinical Trials, Greensboro, North Carolina, United States|Triad Clinical Trials, Greensboro, North Carolina, United States|Peters Medical Research, High Point, North Carolina, United States|High Point Clinical Trials Center, High Point, North Carolina, United States|Coastal Carolina Health Care, P.A., New Bern, North Carolina, United States|Hometown Urgent Care, Columbus, Ohio, United States|Dayton Clinical Research, Dayton, Ohio, United States|Today Clinical Research, Oklahoma City, Oklahoma City, Oklahoma, United States|Suburban Research Associates, Media, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Medical Research South, Charleston, South Carolina, United States|TLM Medical Services, LLC, Columbia, South Carolina, United States|Amistad Clinical Research Center, Columbia, South Carolina, United States|Greenville Pharmaceutical Rsch, Greenville, South Carolina, United States|Mountain View Clinical Research, Greer, South Carolina, United States|Berkley Family Practice, Moncks Corner, South Carolina, United States|Carolina Cardiology Clinical Research Institute, LLC, Rock Hill, South Carolina, United States|Community Research Partners, Inc, Varnville, South Carolina, United States|Memphis Veterans Affairs Medical Center, Memphis, Tennessee, United States|The Green Clinic PC, Memphis, Tennessee, United States|Southwind Medical Specialists, Memphis, Tennessee, United States|University of Tennessee, Memphis, Tennessee, United States|Diagnostic Clinic of Houston, Houston, Texas, United States|Cullen Family Practice, PLLC, Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Kelsey-Seybold Clinic, Houston, Texas, United States|Hillcrest Family Health Center, Waco, Texas, United States|Millennium Clinical Trials LLC, Arlington, Virginia, United States|York Clinical Research, LLC, Norfolk, Virginia, United States|Dominion Medical Associates, Inc., Richmond, Virginia, United States|Clinical Research Partners, LLC, Richmond, Virginia, United States|Family Medical Clinic, Milwaukee, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02182830/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02182830/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02182830"
795,"NCT01262118","Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis",,"Completed","Has Results","Rheumatoid Arthritis","Drug: CP-690,550 (tasocitinib)","High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline|High-density Lipoprotein Cholesterol (HDL-C) Concentration at Week 6|Cholesterol Ester Production Rate at Baseline|Cholesterol Ester Production Rate at Week 6|Low-density Lipoprotein Cholesterol (LDL-C) and Total Cholesterol Concentration|Cholesterol Ester Fractional Catabolic Rate|Low-density Lipoprotein Associated With Apolipoprotein B (LDL-apoB) Production Rate|Low-density Lipoprotein Associated With Apolipoprotein B (LDL-apoB) Fractional Catabolic Rate|High-density Lipoprotein Associated With Apolipoprotein A1 (HDL-apoA1) Production Rate|High-density Lipoprotein Associated With Apolipoprotein A1 (HDL-apoA1) Fractional Catabolic Rate|Cholesterol Efflux Rate","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","69","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","A3921130","May 2011","January 2012","February 2012","December 17, 2010","January 23, 2013","January 23, 2013","Pfizer Investigational Site, Anniston, Alabama, United States|Pfizer Investigational Site, Anniston, Alabama, United States|Pfizer Investigational Site, Little Rock, Arkansas, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Daytona Beach, Florida, United States|Pfizer Investigational Site, Ormond Beach, Florida, United States|Pfizer Investigational Site, South Miami, Florida, United States|Pfizer Investigational Site, Bingham Farms, Michigan, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Balatonfured, Hungary|Pfizer Investigational Site, Budapest, Hungary",,"https://ClinicalTrials.gov/show/NCT01262118"
796,"NCT03409744","Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia",,"Enrolling by invitation","No Results Available","Homozygous Familial Hypercholesterolemia","Drug: evinacumab","Incidence and severity of treatment-emergent adverse events (TEAEs)|Percent change in Low-Density Lipoprotein Cholesterol (LDL-C) over time|Absolute change in LDL-C over time|Percent change in Apolipoprotein B (Apo B) over time|Absolute change in Apo B over time|Percent change in non-High-Density Lipoprotein Cholesterol (HDL-C) over time|Absolute change in non-HDL-C over time|Percent change in Total Cholesterol (TC) over time|Absolute change in TC over time|Percent change in Triglycerides (TGs) over time|Absolute change in TGs over time|Presence of anti-evinacumab antibodies","Regeneron Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R1500-CL-1719|2017-003170-13","March 13, 2018","April 11, 2022","April 11, 2022","January 24, 2018",,"December 17, 2019","Clinical Trial Site, Los Angeles, California, United States|Clinical Trial Site, Boca Raton, Florida, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, Cincinnati, Ohio, United States|Clinical Trial Site, Portland, Oregon, United States|Clinical Trial Site, Philadelphia, Pennsylvania, United States|Clinical Trial Site, Dallas, Texas, United States|Clinical Trial Site, Dallas, Texas, United States|Clinical Trial Site, Camperdown, New South Wales, Australia|Clinical Trial Site, Perth, Western Australia, Australia|Regeneron Study Site, Vienna, Wien, Austria|Regeneron Study Site, Innsbruck, Austria|Clinical Trial Site, Chicoutimi, Quebec, Canada|Clinical Trial Site, Quebec, Canada|Regeneron Study Site, Praha 2, Kateřinská, Czechia|Clinical Trial Site, Paris, Cedex 13, France|Clinical Trial Site, Marseille, Cedex 5, France|Clinical Trial Site, Dijon, Cedex, France|Regeneron Study Site, Kallithea, Athens, Greece|Clinical Trial Site, Ioannina, Greece|Clinical Trial Site, Napoli, Campania, Italy|Clinical Trial Site, Roma, Rome, Italy|Regeneron Study Site, Kurume, Fukuoka, Japan|Regeneron Study Site, Nishinomiya, Hyogo, Japan|Regeneron Study Site, Kanazawa, Ishikawa, Japan|Regeneron Study Site, Kita-ku, Osaka, Japan|Regeneron Study Site, Suita, Osaka, Japan|Regeneron Study Site, Suita, Osaka, Japan|Clinical Trial Site, Amsterdam, Netherlands|Regeneron Study Site, Johannesburg, Gauteng, South Africa|Regeneron Study Site, Cape Town, Western Cape, South Africa|Clinical Trial Site, Ivano-Frankivsk, Ukraine|Clinical Trial Site #1, Kharkiv, Ukraine|Clinical Trial Site #2, Kharkiv, Ukraine|Clinical Trial Site, Kyiv, Ukraine|Rgeneron Study Site, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT03409744"
797,"NCT01813422","GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound","GLAGOV","Completed","Has Results","Hypercholesterolemia","Biological: Evolocumab|Drug: Placebo","Change From Baseline in Percent Atheroma Volume at Week 78|Change From Baseline in Total Atheroma Volume at Week 78|Percentage of Participants With Regression in Percent Atheroma Volume|Percentage of Participants With Regression in Total Atheroma Volume","Amgen","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","970","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20120153|2012-004208-37","April 18, 2013","July 12, 2016","July 29, 2016","March 19, 2013","January 4, 2018","February 20, 2019","Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, La Jolla, California, United States|Research Site, La Jolla, California, United States|Research Site, Long Beach, California, United States|Research Site, Newport Beach, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Monica, California, United States|Research Site, Torrance, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Atlantis, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Safety Harbor, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Hammond, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Bay City, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Marquette, Michigan, United States|Research Site, Midland, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Columbia, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, Buffalo, New York, United States|Research Site, Johnson City, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Springfield, Oregon, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Concord, New South Wales, Australia|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Liverpool, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Chermside, Queensland, Australia|Research Site, Herston, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Epping, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Antwerpen, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Edegem, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Lodelinsart, Belgium|Research Site, Cariacica, Espírito Santo, Brazil|Research Site, Goiania, Goiás, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Zlin, Czechia|Research Site, Aarhus N, Denmark|Research Site, Odense C, Denmark|Research Site, Besançon Cedex, France|Research Site, Chambray les Tours, France|Research Site, Creteil, France|Research Site, Marseille cedex 5, France|Research Site, Paris, France|Research Site, Pessac Cedex, France|Research Site, Aachen, Germany|Research Site, Essen, Germany|Research Site, München, Germany|Research Site, Neuss, Germany|Research Site, Regensburg, Germany|Research Site, Ulm, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Reykjavik, Iceland|Research Site, Dublin, Ireland|Research Site, Galway, Ireland|Research Site, Hadera, Israel|Research Site, Jerusalem, Israel|Research Site, Rehovot, Israel|Research Site, Novara, Italy|Research Site, Roma, Italy|Research Site, Rozzano MI, Italy|Research Site, Sesto San Giovanni (MI), Italy|Research Site, Torino, Italy|Research Site, Daejeon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kuantan, Pahang, Malaysia|Research Site, Penang, Malaysia|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Queretaro, Querétaro, Mexico|Research Site, San Luis Potosi, San Luis Potosí, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Aguascalientes, Mexico|Research Site, Puebla, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Venlo, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Oslo, Norway|Research Site, Tromso, Norway|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Chrzanow, Poland|Research Site, Kedzierzyn Kozle, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Singapore, Singapore|Research Site, Boksburg, Gauteng, South Africa|Research Site, Centurion, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Kuils River, Western Cape, South Africa|Research Site, Pinelands, Cape Town, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Malaga, Andalucía, Spain|Research Site, Gijon, Asturias, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, L Hospitalet De Llobregat, Cataluña, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Göteborg, Sweden|Research Site, Helsingborg, Sweden|Research Site, Lund, Sweden|Research Site, Solna, Sweden|Research Site, Stockholm, Sweden|Research Site, Örebro, Sweden|Research Site, Geneva 14, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01813422"
798,"NCT02194465","A Study of LY2623091 in Participants With High Blood Pressure",,"Completed","No Results Available","Primary Hypertension","Drug: LY2623091|Drug: Tadalafil|Drug: Spironolactone|Drug: Placebo","Change from Baseline to 4 Weeks in Seated Systolic Blood Pressure (SBP)|Change from Baseline to 4 Weeks in Seated Diastolic Blood Pressure (DBP)|Change from Baseline to 4 Weeks in Ambulatory Blood Pressure Monitoring (ABPM)|Change from Baseline to 4 Weeks in Serum Potassium|Pharmacokinetics: Maximum Concentration (Cmax) of LY2623091","Eli Lilly and Company","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","306","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15525|I7T-MC-RMAH","August 2014","March 2015","March 2015","July 18, 2014",,"May 25, 2015","Clinical Research Advantage, Glendale, Arizona, United States|John Muir Health Network - The Osteoporosis Center, Concord, California, United States|Encompass Clinical Research, Encinitas, California, United States|Avail Clinical Research LLC, Deland, Florida, United States|Alan Graff, MD, PA, Fort Lauderdale, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Cardiovascular Center of Sarasota, Sarasota, Florida, United States|East West Medical Institute, Honolulu, Hawaii, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Community Clinical Research Center, Muncie, Indiana, United States|Heartland Research Associates, Wichita, Kansas, United States|Grace Research, Bossier, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|AB Clinical Trials, Las Vegas, Nevada, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Metrolina Internal Medicine, P.A., Charlotte, North Carolina, United States|PharmQuest, Greensboro, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Sterling Research Group, LTD, Cincinnati, Ohio, United States|Rapid Medical Research Inc, Cleveland, Ohio, United States|Columbus Clinical Research, Columbus, Ohio, United States|Dayton Clinical Research, Dayton, Ohio, United States|Cor Clinical Research LLC, Oklahoma City, Oklahoma, United States|Oklahoma Foundation For Cardiovascular Research, Oklahoma City, Oklahoma, United States|Mountain View Clinical Research, Inc, Greer, South Carolina, United States|Texas Diabetes and Endocrinology, Austin, Texas, United States|Tekton Research, Inc, Austin, Texas, United States|Texas Diabetes and Endocrinology, P.A., Round Rock, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Universal Research Group, LLC, Tacoma, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brampton, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Peterborough, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pointe Claire, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Quebec City, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Red Deer, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Canada|Research and Cardiovascular Corp., Ponce, Puerto Rico|Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02194465"
799,"NCT02366065","Does Oral Acetaminophen Lower Intraocular Pressure?",,"Completed","No Results Available","Glaucoma","Drug: Acetaminophen","Lowering Eye Pressure","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIR00006973","January 2015","May 2016","May 2016","February 19, 2015",,"June 7, 2016","Johns Hopkins - The Wilmer Eye Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02366065"
800,"NCT02630316","Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE",,"Completed","No Results Available","Pulmonary Hypertension|Interstitial Lung Disease|Combined Pulmonary Fibrosis and Emphysema","Drug: Inhaled Treprostinil|Drug: Placebo","Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure from Baseline to Week 16|Change in Peak 6-minute Walk Distance (6MWD) from Baseline to Week 12|Change in Trough 6-minute Walk Distance (6MWD) from Baseline to Week 15|Change in plasma concentration of N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) from Baseline to Week 16","United Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","326","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RIN-PH-201","May 2016","December 23, 2019","December 23, 2019","December 15, 2015",,"February 28, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|IMC-Diagnostic & Medical Clinic, Mobile, Alabama, United States|Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Cedars-Sinai Medical Center, Beverly Hills, California, United States|University of California San Francisco - Fresno, Fresno, California, United States|University of California San Diego, La Jolla, California, United States|VA Long Beach Healthcare System, Long Beach, California, United States|University of Southern California, Los Angeles, California, United States|Department of Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States|Pacific Pulmonary Medical Group, Riverside, California, United States|Kaiser Permanente - Roseville, Roseville, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Kaiser Permanente, San Francisco, California, United States|University of Colorado Hospital - Cardiac and Vascular Center, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|MedStar Heart & Vascular Institute, Washington, District of Columbia, United States|Florida Lung, Asthma & Sleep Specialists, P.A., Celebration, Florida, United States|St. Francis Sleep, Allergy and Lung Institute, Clearwater, Florida, United States|University of Florida Clinical Research Center, Gainesville, Florida, United States|University of Florida College of Medicine, Jacksonville, Jacksonville, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|St. Vincent's Lung, Sleep, and Critical Care Specialists, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Florida Hospital, Orlando, Florida, United States|South Miami Heart Specialists, South Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|The Emory Clinic, Atlanta, Georgia, United States|Piedmont - Georgia Lung Associates, Austell, Georgia, United States|Wellstar Medical Group, Marietta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois at Chicago Hospital, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Hospital, Indianapolis, Indiana, United States|Community Heart and Vascular Hospital, Indianapolis, Indiana, United States|St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|University of Louisville Physicians Outpatient Center, Louisville, Kentucky, United States|Louisiana State University Health Sciences Center New Orleans, New Orleans, Louisiana, United States|Maine Medical Center, South Portland, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Spectrum Health Medical Center, Grand Rapids, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|The University of New Mexico, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|Northwell Health, New Hyde Park, New York, United States|NYU Langone Medical Center, New York, New York, United States|The Mount Sinai Hospital, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Pinehurst Medical Clinic, Inc., Pinehurst, North Carolina, United States|The Carl and Edyth Lindner Research Center at The Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati Health, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States|Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|AnMed Health Pulmonary and Sleep Medicine, Anderson, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Statcare Pulmonary Consultants, Knoxville, Tennessee, United States|Baylor University Medical Center at Dallas, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Tech University Health Sciences Center, El Paso, Texas, United States|Houston Methodist, Houston, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Vermont, Vermont Lung Center, Colchester, Vermont, United States|Inova Fairfax Hospital, Fairfax, Virginia, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Pulmonary Associates of Richmond, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States|Alliance Cardio Pulmonary Research Group, Inc., Guaynabo, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02630316"
801,"NCT02633956","Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)","CONTROL","Completed","Has Results","Nonalcoholic Steatohepatitis","Drug: Obeticholic Acid|Drug: Atorvastatin|Drug: Placebo","The Effect of Obeticholic Acid on Low-density Lipoprotein (LDL) Concentration (Least Squares Mean Change From Baseline at Week 16)|The Effect of Obeticholic Acid on LDL Particle Size (Least Squares Mean Change From Baseline at Week 16)|The Effect of Obeticholic Acid on LDL Particle Concentration (Total) (Least Squares Mean Change From Baseline at Week 16)","Intercept Pharmaceuticals","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","747-209","December 4, 2015","March 21, 2017","March 12, 2018","December 17, 2015","June 4, 2018","June 4, 2018","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Scripps Clinic, La Jolla, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|Nature Coast Clinical Research, Inverness, Florida, United States|University of Miamai, Schiff Center for Liver Diseases, Miami, Florida, United States|South Florida Center of Gastroenterology, Wellington, Florida, United States|Florida Medical Clinic, P.A., Zephyrhills, Florida, United States|The Queen's Medical Center - Liver Center, Honolulu, Hawaii, United States|Mercy Medical Center, Institute for Digestive Health & Liver Disease, Baltimore, Maryland, United States|Kansas City Research Institute, Kansas City, Missouri, United States|St. Louis University, Saint Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Consultants for Clinical Research, Cincinnati, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University Gastroenterology Liver Center, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|ClinSearch, Chattanooga, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|Liver Associates of Texas, P.A., Houston, Texas, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|McGuire DVAMC, Richmond, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02633956/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02633956/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02633956"
802,"NCT01177098","Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",,"Completed","Has Results","Glaucoma|Ocular Hypertension","Drug: bimatoprost /timolol formulation A fixed combination ophthalmic solution|Drug: bimatoprost/timolol fixed combination ophthalmic solution","Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12|Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 2|Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 6|Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12|Change From Baseline in Worse Eye IOP at Each Hour Evaluated at Week 12|Change From Baseline in Average Eye IOP at Each Hour Evaluated at Week 12","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","561","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","192024-050|2010-021507-24","October 2010","February 2012","February 2012","August 6, 2010","March 12, 2013","March 29, 2013","Artesia, California, United States|Sydney, New South Wales, Australia|Brno, Czech Republic|Leipzig, Germany|Budapest, Hungary|Tel Aviv, Israel|Saint-Petersburg, Russian Federation|Valencia, Spain|London, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01177098"
803,"NCT01208961","Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation","ECLIPSE","Completed","Has Results","Severe Hypertriglyceridemia","Drug: Epanova (4 g) and Lovaza (4 g)|Drug: Lovaza (4 g) and Epanova (4 g)","AUC(0-t): Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (the Final Time With a Concentration ≥ LOQ)|AUC(Inf): Area Under the Plasma Concentration-time Curve From 0 to Infinity|C(Max): Maximum Plasma Concentration","AstraZeneca|Radiant Research","All","18 Years and older   (Adult, Older Adult)","Phase 2","54","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OM-EPA-001","September 2010","November 2010","November 2010","September 24, 2010","January 6, 2014","July 15, 2015","Radiant Research, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01208961"
804,"NCT02852057","Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses",,"Recruiting","No Results Available","Glaucoma","Drug: timolol maleate and dorzolamide hydrochloride","IOP","University of Florida","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201602390|OCR19613","January 18, 2018","October 2020","October 2020","August 2, 2016",,"November 25, 2019","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02852057"
805,"NCT01342952","Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529",,"Active, not recruiting","No Results Available","Hypertension, Pulmonary","Drug: Ambrisentan","Serious Adverse Events|Adverse Events|Liver Function Tests|Clinical Chemistries|Haematology|Physical examination|Vital signs|12-lead ECG|Endocrinology assessments|Pubertal Development|6 minute walk distance|WHO functional class|Health outcomes assessments|Echocardiogram|Plasma NT-Pro-BNP|Time to clinical worsening","GlaxoSmithKline","All","8 Years to 18 Years   (Child, Adult)","Phase 2","66","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","114588|2010-021572-29","June 21, 2011","June 13, 2022","October 25, 2024","April 27, 2011",,"April 7, 2020","GSK Investigational Site, Aurora, Colorado, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Guymallen, Mendoza, Argentina|GSK Investigational Site, Ciudad de Buenos Aires, Argentina|GSK Investigational Site, Córdoba, Argentina|GSK Investigational Site, Paris cedex 15, France|GSK Investigational Site, Pessac cedex, France|GSK Investigational Site, Toulouse cedex 9, France|GSK Investigational Site, Giessen, Hessen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, San Donato Milanese (MI), Lombardia, Italy|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01342952"
806,"NCT02227459","Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)",,"Completed","No Results Available","Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)","Drug: ND-L02-s0201 Injection","Number of participants with serious and non-serious adverse events","Bristol-Myers Squibb|Nitto Denko Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ND-L02-s0201-002","October 2014","May 2016","May 2016","August 28, 2014",,"May 11, 2017","Texas Liver Institute, Austin, Texas, United States|Tokuda Hospital, Sofia, Bulgaria",,"https://ClinicalTrials.gov/show/NCT02227459"
807,"NCT03541603","Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF","HELP","Completed","No Results Available","Hypertension Pulmonary Secondary|Heart Failure, Right Sided|Heart Failure With Normal Ejection Fraction","Drug: Levosimendan|Drug: Matching Placebo","Change from baseline Pulmonary Capillary Wedge Pressure (PCWP) with bicycle exercise|Change in Cardiac Index (CI) at rest and with exercise|Change in Pulmonary Vascular Resistance (PVR) effect at rest and with exercise|Change in PCWP when supine and legs elevated|Patient global assessment|Exercise duration via 6 minute walk test|Physician's assessment of functional class|Composite incidence of death or hospitalization","Tenax Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TNX-LVO-04","November 14, 2018","April 7, 2020","April 7, 2020","May 30, 2018",,"April 10, 2020","Stanford Healthcare, Stanford, California, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|North Shore University Hospital, Manhasset, New York, United States|New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, United States|Ichan School of Medicine at Mount Sinai, New York, New York, United States|Christ Hospital, Cincinnati, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|UW Health University Hospital, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03541603"
808,"NCT02855450","Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma","NGF-Glaucoma","Completed","No Results Available","Glaucoma","Drug: rhNGF|Drug: Vehicle","IOP|BCDVA|HVF 24-2 or 10-2|Dilated fundus ophthalmoscopy|ERG|AE","Dompé Farmaceutici S.p.A|Cromsource","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NGF0314","December 2016","May 2018","May 2018","August 4, 2016",,"June 25, 2019","Byers Eye Institute at Stanford University, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT02855450"
809,"NCT01105065","Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma",,"Completed","Has Results","Glaucoma","Drug: brimonidine 0.15%","Presence of Retinal Blood Flow Autoregulation|Frequency Doubling Perimetry","Massachusetts Eye and Ear Infirmary","All","35 Years to 80 Years   (Adult, Older Adult)","Not Applicable","46","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-03-019 (75643)","March 2010","September 2012","September 2012","April 16, 2010","October 27, 2016","April 4, 2017","Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01105065"
810,"NCT01281306","An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension",,"Completed","Has Results","Systolic Hypertension","Drug: LCZ696|Drug: Valsartan|Drug: AHU377|Drug: Placebo","Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)|Change From Baseline in Mean Diastolic Blood Pressure (msDBP)|Change From Baseline in Mean 24 Hour Ambulatory SBP (maSBP) and Mean 24 Hour Ambulatory DBP (maDBP)|Change From Baseline in Daytime maSBP and maDBP|Change From Baseline in Nighttime maSBP and maDBP|Change From Baseline in Mean Sitting Pulse Pressure|Change From Baseline in Mean Ambulatory Pulse Pressure|Change From Baseline in maSBP and maDBP in Dippers|Change From Baseline in maSBP and maDBP in Non-dippers|Change From Baseline in msSBP and msDBP in Participants < 65 Years of Age|Change From Baseline in msSBP and msDBP in Participants >= 65 Years of Age|Change From Baseline in maSBP and maDBP in Participants < 65 Years of Age|Change From Baseline in maSBP and maDBP in Participants >= 65 Years of Age|Number of Participants Who Achieved Blood Pressure Control and Blood Pressure Response|Number of Participants With Adverse Events, Serious Adverse Events and Death","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","910","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLCZ696A2223|2010-022326-32","January 2011","December 2011","December 2011","January 21, 2011","August 18, 2015","January 29, 2016","Novartis Investigative Site, Clearwater, Florida, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Metairie, Louisiana, United States|Novartis Investigative Site, Belzoni, Mississippi, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, Henderson, Nevada, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Shelby, North Carolina, United States|Novartis Investigative Site, Erie, Pennsylvania, United States|Novartis Investigative Site, Bryan, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Lanus, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Capital Federal, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Tucuman, Argentina|Novartis Investigative Site, Buenos aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Mount Pearl, Newfoundland and Labrador, Canada|Novartis Investigative Site, Mirabel, Quebec, Canada|Novartis Investigative Site, Ste-Foy, Quebec, Canada|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Csongrad, Hungary|Novartis Investigative Site, Erd, Hungary|Novartis Investigative Site, Miskolc, Hungary|Novartis Investigative Site, Miskolc, Hungary|Novartis Investigative Site, Nyiregyháza, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Torokbalint, Hungary|Novartis Investigative Site, Vishakhapatnam, Andhra Pradesh, India|Novartis Investigative Site, Ahmedabad, Gujarat, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Ludhiana, Punjab, India|Novartis Investigative Site, Jaipur, Rajasthan, India|Novartis Investigative Site, Lucknow, Uttar Pradesh, India|Novartis Investigative Site, Lucknow, Uttar Pradesh, India|Novartis Investigative Site, Bucheon, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Goyang, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Uijeongbu-Si, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Koyang, Kyunggi, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Bucharest, District 1, Romania|Novartis Investigative Site, Bucharest, District 1, Romania|Novartis Investigative Site, Bucharest, District 1, Romania|Novartis Investigative Site, Bucharest, District 2, Romania|Novartis Investigative Site, Oradea, Jud. Bihor, Romania|Novartis Investigative Site, Craiova, Jud. Dolj, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Nitra, Slovak Republic, Slovakia|Novartis Investigative Site, Presov, Slovak Republic, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Liptovsky Mikulas, Slovakia|Novartis Investigative Site, Nitra, Slovakia|Novartis Investigative Site, Nitra, Slovakia|Novartis Investigative Site, Nove Zamky, Slovakia|Novartis Investigative Site, Partizanske, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Ruzomberok, Slovakia|Novartis Investigative Site, Sala, Slovakia|Novartis Investigative Site, Sered, Slovakia|Novartis Investigative Site, Zvolen, Slovakia|Novartis Investigative Site, Granada, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Badalona, Cataluña, Spain|Novartis Investigative Site, Centelles, Cataluña, Spain|Novartis Investigative Site, Tarragona, Cataluña, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Alzira, Comunidad Valenciana, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01281306"
811,"NCT01474135","AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure",,"Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: 0.25% AR-12286 / 0.004% travoprost|Drug: 0.5% AR-12286, 0.004% travoprost|Drug: 0.004% Travoprost","Mean IOP across subjects within treatment group on Days 1 and 7 at each post-treatment timepoint.|Ocular and systemic safety","Aerie Pharmaceuticals","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","93","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PG286-CS201","December 2011","April 2012","April 2012","November 18, 2011",,"September 23, 2016","United Medical Research Institute, Inglewood, California, United States|Aesthetic Eye Care Institute, Newport Beach, California, United States|Bacharach practice, Petaluma, California, United States|Centre For Health Care, Poway, California, United States|Comprehensive Eye Care, St Louis, Missouri, United States|Rochester Ophthalmology Group, Rochester, New York, United States|Glaucoma Consultants of the Capital Region, Slingerlands, New York, United States|Abrams Eye Center, Cleveland, Ohio, United States|Cataract & Glaucoma Center, El Paso, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01474135"
812,"NCT02370251","Compassionate Use of Omegaven in Children",,"Completed","Has Results","Total Parenteral Nutrition-induced Cholestasis|Cholestasis|Short Bowel Syndrome|Gastroschisis|Intestinal Atresia|Infant, Premature, Diseases|Cholestasis of Parenteral Nutrition","Drug: Omegaven","Resolution of Cholestasis for Subjects Who Received Omegaven|Safety Issues for Infants Who Received Omegaven|Essential Fatty Acid Deficiency in Infants Who Received Omegaven","University of Oklahoma|OU Medical Center","All","up to 18 Years   (Child, Adult)","Phase 2|Phase 3","63","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5451","June 2015","September 27, 2018","September 27, 2019","February 24, 2015","November 25, 2019","November 25, 2019","OU Children's Hospital, Oklahoma City, Oklahoma, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02370251/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02370251"
813,"NCT02658175","The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome",,"Active, not recruiting","No Results Available","Familial Chylomicronemia Syndrome|Lipoprotein Lipase Deficiency|Hyperlipoproteinemia Type 1","Drug: Volanesorsen","Efficacy of extended dosing of volanesorsen as measured by the percent change in fasting triglycerides from baseline.","Ionis Pharmaceuticals, Inc.|Akcea Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","69","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISIS 304801-CS7","December 31, 2015","June 2020","October 2020","January 18, 2016",,"January 10, 2020","IONIS Investigative Site, Huntington Beach, California, United States|IONIS Investigative Site, San Francisco, California, United States|IONIS Investigative Site, Boca Raton, Florida, United States|IONIS Investigative Site, Boston, Massachusetts, United States|IONIS Investigative Site, Philadelphia, Pennsylvania, United States|IONIS Investigative Site, Houston, Texas, United States|IONIS Investigative Site, Norfolk, Virginia, United States|IONIS Investigative Site, Seattle, Washington, United States|IONIS Investigative Site, Sao Paulo, Brazil|IONIS Investigative Site, Sao Paulo, Brazil|IONIS Investigative Site, Vancouver, British Columbia, Canada|IONIS Investigative Site, Chicoutimi, Quebec, Canada|IONIS Investigative Site, Montreal, Quebec, Canada|IONIS Investigative Site, Quebec, Canada|IONIS Investigative Site, Paris, Cedex 13, France|IONIS Investigative Site, Marseille Cedex 05, France|IONIS Investigative Site, Nantes cedex 1, France|IONIS Investigative Site, Berlin, Germany|IONIS Investigative Site, Safed, Israel|IONIS Investigative Site, Palermo, Italy|IONIS Investigative Site, Roma, Italy|IONIS Investigative Site, Rome, Italy|IONIS Investigative Site, Amsterdam-Zuidoost, Netherlands|IONIS Investigative Site, Cape Town, South Africa|IONIS Investigative Site, Barcelona, Spain|IONIS Investigative Site, La Coruna, Spain|IONIS Investigative Site, Madrid, Spain|IONIS Investigative Site, Sevilla, Spain|IONIS Investigative Site, Zaragoza, Spain|IONIS Investigative Site, Birmingham, United Kingdom|IONIS Investigative Site, London, United Kingdom|IONIS Investigative Site, Manchester, United Kingdom|IONIS Investigative Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02658175"
814,"NCT01749878","Study to Assess the Safety and Tolerability of Single Doses of REGN1500",,"Completed","No Results Available","Hypertriglyceridemia","Drug: REGN1500|Drug: placebo","Safety|Serum concentration of REGN1500","Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1500-HV-1214","December 2012","January 2016","January 2016","December 17, 2012",,"May 12, 2016","Philadelphia, Pennsylvania, United States|Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01749878"
815,"NCT01865812","Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis",,"Completed","Has Results","Primary Biliary Cirrhosis","Drug: obeticholic acid (OCA)","Absolute Change From Baseline in High-density Lipoprotein (HDL) Cholesterol Concentration|Absolute Change From Baseline in High-density Lipoprotein (HDL) Particle Size|Absolute Change From Baseline in High-density Lipoprotein (HDL) Particle Concentration","Intercept Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","747-205","November 2013","August 2014","September 2016","May 31, 2013","October 19, 2016","March 14, 2018","Scripps Clinic, La Jolla, California, United States|University of California, Davis Medical Center, Sacramento, California, United States|University of Miami, Miami, Florida, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Beth Israel Medical Center, New York, New York, United States|McGuire DVAMC, Richmond, Virginia, United States|Swedish Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01865812"
816,"NCT02739984","Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia","BANTING","Completed","Has Results","Hypercholesterolemia|Mixed Dyslipidemia|Type 2 Diabetes","Biological: Evolocumab|Drug: Placebo to Evolocumab","Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in LDL-C at Week 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12|Percent Change From Baseline in Total Cholesterol at Week 12|Percentage of Participants With Mean LDL-C at Weeks 10 and 12 Less Than 70 mg/dL (1.8 mmol/L)|Percentage of Participants With LDL-C at Week 12 Less Than 70 mg/dL (1.8 mmol/L)|Percentage of Participants With at Least a 50% Reduction From Baseline in Mean LDL-C at Weeks 10 and 12|Percentage of Participants With at Least a 50% Reduction From Baseline in LDL-C at Week 12|Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein(a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12|Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in VLDL-C at Week 12","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","424","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20130287|2015-004711-21","May 17, 2016","August 3, 2017","August 3, 2017","April 15, 2016","August 31, 2018","August 31, 2018","Research Site, Tuscumbia, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Lomita, California, United States|Research Site, Los Angeles, California, United States|Research Site, Roseville, California, United States|Research Site, San Ramon, California, United States|Research Site, Spring Valley, California, United States|Research Site, Tarzana, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Denver, Colorado, United States|Research Site, Lakewood, Colorado, United States|Research Site, Wilmington, Delaware, United States|Research Site, Boca Raton, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Fleming Island, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Inverness, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Dunwoody, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Auburn, Maine, United States|Research Site, Scarborough, Maine, United States|Research Site, Salisbury, Maryland, United States|Research Site, Methuen, Massachusetts, United States|Research Site, Bay City, Michigan, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Shelby, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Suffolk, Virginia, United States|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Vancouver, British Columbia, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St-Jérôme, Quebec, Canada|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Verona, Italy|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Chihuahua, Mexico|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Almeria, Andalucía, Spain|Research Site, Granada, Andalucía, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02739984/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02739984/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02739984"
817,"NCT03071692","Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)","PROMINENT","Active, not recruiting","No Results Available","Type2 Diabetes|Dyslipidemia","Drug: K-877|Drug: Placebo","Number of patients with first occurrence of nonfatal MI, nonfatal ischemic stroke, hospitalization for unstable angina requiring unplanned coronary revascularization, or CV death.|Time to first occurrence of any component of the 3-component composite endpoint of non-fatal MI, non-fatal stroke, or cardiovascular death|Time to first occurrence of any component of the primary endpoint or hospitalization for Heart failure (HF)|Time to first occurrence of any component of the primary endpoint or all-cause mortality|Time to first occurrence of any component of the primary endpoint, any coronary revascularization, or hospitalization for HF|Time to first occurrence of any new or worsening Peripheral artery disease (PAD)|Lipid Endpoints|Nonfasting Remnant Cholesterol Endpoint","Kowa Research Institute, Inc.|Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","10391","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","K-877-302","March 23, 2017","April 2022","May 2022","March 7, 2017",,"March 11, 2020","Synexus Clinical Research US, Inc., Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|VA Medical Center - Birmingham, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States|Fundamental Research, LLC, Gulf Shores, Alabama, United States|Mobile Heart Specialists, PC, Mobile, Alabama, United States|Terence T. Hart, MD, Tuscumbia, Alabama, United States|Synexus Clinical Research US, Inc., Chandler, Arizona, United States|Synexus Clinical Research US, Inc., Mesa, Arizona, United States|Arizona Arthritis & Rheumatology Research, PLLC, Peoria, Arizona, United States|Phoenix Veterans Adminstration Health Care System, Phoenix, Arizona, United States|Synexus Clinical Research US, Inc., Phoenix, Arizona, United States|Clinical Research Institute of Arizona, LLC, Surprise, Arizona, United States|Synexus Clinical Research US, Inc., Tucson, Arizona, United States|Eclipse Clinical Research, Tucson, Arizona, United States|Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|Clinical Research Alliance, Inc, Alhambra, California, United States|Aurora Care Clinic, Costa Mesa, California, United States|AMCR Institute, Inc., Escondido, California, United States|National Institute of Clinical Research, Huntington Beach, California, United States|VA Loma Linda Healthcare System, Loma Linda, California, United States|VA Long Beach Healthcare System, Long Beach, California, United States|Eastside Clinical Research Associates, Los Angeles, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|Richard S. Cherlin, MD, Los Gatos, California, United States|Northridge Clinical Research Inc., Northridge, California, United States|Palo Alto Division, Palo Alto, California, United States|Huntington Hospital - Research Department, Pasadena, California, United States|Rancho Cucamonga Clinical Research, Rancho Cucamonga, California, United States|MD Strategies Research Centers, San Diego, California, United States|Alex Harrison, MD Inc., Santa Maria, California, United States|Santa Rosa Cardiology Medical Group, Inc., Santa Rosa, California, United States|Blue Coast Cardiology, Vista, California, United States|Lynn Institute of Denver, Aurora, Colorado, United States|New West Physicians, PC, Golden, Colorado, United States|Southwest Family Medicine, Littleton, Colorado, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|VA Connecticut Healthcare Sys, West Haven, Connecticut, United States|Cardiology Physicians, PA, Newark, Delaware, United States|Bay Pines VA Healthcare System, Bay Pines, Florida, United States|Meridien Research, Bradenton, Florida, United States|Clinical Research Of Brandon, LLC, Brandon, Florida, United States|Clearwater Cardiovascular Consultants, Clearwater, Florida, United States|Daytona Heart Group, Daytona Beach, Florida, United States|Cohen Medical Research Associates, LLC, Delray Beach, Florida, United States|Malcom Randall VA Medical Center, Gainesville, Florida, United States|Pines Clinical Research, Inc., Hollywood, Florida, United States|Homestead Cardiac & Vein Center, Homestead, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Health Awareness, Inc., Jupiter, Florida, United States|Meridien Research, Lakeland, Florida, United States|Clearwater Cardiovascular & Interventional Consultants, Largo, Florida, United States|University of Miami, Miami, Florida, United States|Advanced Medical Research Institute, Miami, Florida, United States|Ocala Research Institute, Inc., Ocala, Florida, United States|Morgan Medical Management & Consultants Inc., Ocala, Florida, United States|Endocrine Associates of Florida, Ocoee, Florida, United States|Research Physicians Network Alliance, Orlando, Florida, United States|Andres Patron, D.O., P.A, Pembroke Pines, Florida, United States|DBC Research, Corp, Pembroke Pines, Florida, United States|Langhorne Cardiology Consultants, Inc., Pensacola, Florida, United States|Clearwater Cardiovascular Consultants, Safety Harbor, Florida, United States|Professional Health Care of Pinellas, Saint Petersburg, Florida, United States|James A. Haley VA Medical Center, Tampa, Florida, United States|Clinical Research of Central Florida, Winter Haven, Florida, United States|Emory University, Atlanta, Georgia, United States|Atlanta Heart Specialists, LLC, Cumming, Georgia, United States|VA Medical Center - Atlanta, Decatur, Georgia, United States|Alta Pharmaceutical Research Center, Inc., Dunwoody, Georgia, United States|Atlanta Heart Specialists, LLC, Tucker, Georgia, United States|Christie Clinic, LLC, Champaign, Illinois, United States|Apex Medical Research, AMR, Inc., Chicago, Illinois, United States|Clinical Investigation Specialists, Inc., Gurnee, Illinois, United States|Edward Hines Jr. VA Hospital, Hines, Illinois, United States|Advocate Health and Hospitals Corp, Normal, Illinois, United States|Captain James A. Lovell Federal Health Care Center, North Chicago, Illinois, United States|Specialty Physicians of Illinois, Olympia Fields, Illinois, United States|Community Hospital of Anderson and Madison County, Inc., Anderson, Indiana, United States|Synexus Clinical Research US, Inc., Evansville, Indiana, United States|Deaconess Clinic, Evansville, Indiana, United States|VA Medical Center - Indianapolis, Indianapolis, Indiana, United States|Cardiovascular Research of Northwest Indiana, LLC, Munster, Indiana, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|West Broadway Clinic, Council Bluffs, Iowa, United States|Iowa Diabetes and Endocrinology Research Center, PLC, Des Moines, Iowa, United States|The Iowa Clinic, PC, West Des Moines, Iowa, United States|University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States|VA Eastern Kansas Health Care, Leavenworth, Kansas, United States|The Research Group of Lexington, LLC, Lexington, Kentucky, United States|Robley Rex VA Medical Center, Louisville, Kentucky, United States|Cambridge Medical Trials, Alexandria, Louisiana, United States|Cardiovascular Associates Research, LLC, Covington, Louisiana, United States|Centex Studies Inc., Lake Charles, Louisiana, United States|Overton Brooks VA Medical Center, Shreveport, Louisiana, United States|Southern Maine Health Care, Biddeford, Maine, United States|Baltimore VA medical centre, Baltimore, Maryland, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Maryland Cardiovascular Specialists, Baltimore, Maryland, United States|Medstar Health Research Institute, Hyattsville, Maryland, United States|Delmarva Heart Research Foundation, Inc., Salisbury, Maryland, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Pentucket Medical Associates, Haverhill, Massachusetts, United States|South Shore Internal Medicine Associates, Milton, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan, United States|Northern Pines Health Center, Buckley, Michigan, United States|Cadillac Clinical Research, LLC, Cadillac, Michigan, United States|AA MRC LLC Ahmed Arif Medical Research Center, Flint, Michigan, United States|Sparrow Clinical Research Institute, Lansing, Michigan, United States|Covenant Medical Center, Inc., Saginaw, Michigan, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Synexus Clinical Research US, Inc., Richfield, Minnesota, United States|CentraCare Heart & Vascular, Saint Cloud, Minnesota, United States|HealthEast Medical Research Institute, Saint Paul, Minnesota, United States|GV Montgomery VA Medical Center, Jackson, Mississippi, United States|Kansas City VA Medical Center, Kansas City, Missouri, United States|Synexus Clinical Research US, Inc., Saint Louis, Missouri, United States|Kalispell Regional Medical Center dba Glacier View Research Institute, Kalispell, Montana, United States|VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Synexus Clinical Research US, Inc., Papillion, Nebraska, United States|Synexus Clinical Research US, Inc., Henderson, Nevada, United States|Red Rock Clinical Research LLC, Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|Monmouth Cardiology Associates, Eatontown, New Jersey, United States|NJ Heart, Linden, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Raymond G. Murphy VA Medical Center, Albuquerque, New Mexico, United States|Endocrine Group, L.L.P., Albany, New York, United States|Stratton Veterans Affairs Medical Center - Albany, Albany, New York, United States|Buffalo VA Medical Center, Buffalo, New York, United States|Winthrop Cardiology Associates, Mineola, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|VA Medical Center - Syracuse, Syracuse, New York, United States|Randolph Medical Associates, Asheboro, North Carolina, United States|OnSite Clinical Solutions, LLC, Asheville, North Carolina, United States|Kernodle Clinic, Inc., Dept. of the Private Diagnostic Clinic, PLLC, Burlington, North Carolina, United States|Cary Research Group, LLC, Cary, North Carolina, United States|PMG Research of Cary, LLC, Cary, North Carolina, United States|Novant Health - Heart and Vascular Institute, Charlotte, North Carolina, United States|The Presbyterian Hospital, Charlotte, North Carolina, United States|Focus Clinical Research Solutions, Charlotte, North Carolina, United States|Medication Management, LLC, Greensboro, North Carolina, United States|Triad Clinical Trials, LLC, Greensboro, North Carolina, United States|Clinical Trials of America-NC, LLC, Hickory, North Carolina, United States|PMG Research of Hickory, LLC, Hickory, North Carolina, United States|Research Institute of the Carolinas, PLC, Mooresville, North Carolina, United States|Diabetes and Endocrinology Consultants, Morehead City, North Carolina, United States|Pinehurst Medical Clinic Inc, Pinehurst, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|PMG Research of Salisbury, LLC, Salisbury, North Carolina, United States|Carolina Research Center, Inc., Shelby, North Carolina, United States|Synexus Clinical Research US, Inc., Akron, Ohio, United States|OhioHealth Heart & Vascular Physicians (Heartcare, Inc.) - Athens, Athens, Ohio, United States|Aultman Hospital, Canton, Ohio, United States|Hometown Urgent Care & Occupational Health, Cincinnati, Ohio, United States|Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio, United States|Louis Stokes Cleveland Dept of VA Medical Center, Cleveland, Ohio, United States|Prestige Clinical Research Center, Franklin, Ohio, United States|Craig S Thompson MD LLC, Marion, Ohio, United States|Intend Research, Norman, Oklahoma, United States|Lynn Institute of Norman, Norman, Oklahoma, United States|Oklahoma City Clinic - Central, Oklahoma City, Oklahoma, United States|South Oklahoma Heart Research Group, Oklahoma City, Oklahoma, United States|Heart Clinic of Southern Oregon, Medford, Oregon, United States|Chambersburg Hospital, Chambersburg, Pennsylvania, United States|AMH Feasterville Family Health Care Center, Feasterville, Pennsylvania, United States|Family Medical Associates, Levittown, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Fay West Family Practice, Scottdale, Pennsylvania, United States|Montgomery Medical Inc., Smithfield, Pennsylvania, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|Ocean State Clinical Research Partners, Lincoln, Rhode Island, United States|Providence Veteran Administration Medical Center, Providence, Rhode Island, United States|Synexus Clinical Research US, Inc., Anderson, South Carolina, United States|Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States|Mountain View Clinical Research, Inc., Greer, South Carolina, United States|Piedmont Research Partners, Indian Land, South Carolina, United States|Main Street Physician's Care - Waterway, Little River, South Carolina, United States|Family Medicine of Sayebrook, Myrtle Beach, South Carolina, United States|Palmetto Research Center, LLC, Spartanburg, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|PMG Research of Bristol, LLC, Bristol, Tennessee, United States|Chattanooga Medical Research, LLC, Chattanooga, Tennessee, United States|Chattanooga Research and Medicine (CHARM), Chattanooga, Tennessee, United States|University Diabetes & Endocrine Consultants, Chattanooga, Tennessee, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States|Holston Medical Group, P.C., Kingsport, Tennessee, United States|Metro Knoxville HMA, LLC, Knoxville, Tennessee, United States|VA Medical Center - Memphis, Memphis, Tennessee, United States|Tennessee Valley Healthcare System, Nashville, Tennessee, United States|Central Texas Clinical Research, LLC, Austin, Texas, United States|Protenium Clinical Research, Dallas, Texas, United States|VA Medical Center - Dallas, Dallas, Texas, United States|North Texas Endocrine Center, Dallas, Texas, United States|Research Institute of Dallas, P.A., Dallas, Texas, United States|Synexus Clinical Research US, Inc., Dallas, Texas, United States|Doctors Hospital at Renaissance, Edinburg, Texas, United States|Texas Health Research & Education Institute, Fort Worth, Texas, United States|Texas Health Physicians Group, Fort Worth, Texas, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Diabetes and Thyroid Center of Fort Worth, Fort Worth, Texas, United States|Rockwood Medical Clinic, Fort Worth, Texas, United States|East Texas Cardiology PA, Houston, Texas, United States|Endocrine Associates, LLC, Houston, Texas, United States|Heights Doctors Clinic, Houston, Texas, United States|Associates in Medicine, Houston, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States|Southwest Clinical Trials, Houston, Texas, United States|Protenium Clinical Research, Hurst, Texas, United States|Houston Methodist Research Institute - CCAT Pearland, Pearland, Texas, United States|Clinical Investigations of Texas, Plano, Texas, United States|Consano Clinical Research, LLC, San Antonio, Texas, United States|Sant Antonio Premiere Internal Medicine, San Antonio, Texas, United States|Briggs Clinical Research, LLC., San Antonio, Texas, United States|Schnitzler Cardiovascular Consultants (SCC), PLLC, San Antonio, Texas, United States|Bandera Family Healthcare Research LLC, San Antonio, Texas, United States|Northeast Clinical Research of San Antonio, Schertz, Texas, United States|Spring Family Practice Associates, Spring, Texas, United States|Northwest Houston Heart Center, Tomball, Texas, United States|Victoria Heart & Vascular Center, Victoria, Texas, United States|Hillcrest Family Health Clinics, Waco, Texas, United States|Utah Cardiology, P.C. (Davis), Farmington, Utah, United States|VA Medical Center, White River Junction, Vermont, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Virginia Endocrinology Research, Chesapeake, Virginia, United States|Carient Heart and Vascular, Manassas, Virginia, United States|Clinical Research Partners, LLC, Richmond, Virginia, United States|McGuire DVA Medical Center, Richmond, Virginia, United States|Roanoke Heart Institute, Roanoke, Virginia, United States|Suffolk Multispecialty Research, Suffolk, Virginia, United States|Corporation Lane Internal Medicine, Virginia Beach, Virginia, United States|Cardiology Associates of Bellin Health, Green Bay, Wisconsin, United States|Clinical Investigation Specialists Inc, Kenosha, Wisconsin, United States|Mayo Clinic Health System, La Crosse, Wisconsin, United States|Meriter Medical Group, Inc., Madison, Wisconsin, United States|Zablocki VA Medical Center, Milwaukee, Wisconsin, United States|Hospital Interzonal General de Agudos Dr Jose Penna, Bahia Blanca, Buenos Aires, Argentina|Hospital Italiano Regional del Sur, Bahia Blanca, Buenos Aires, Argentina|Hospital Italiano, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|CICLO, La Plata, Buenos Aires, Argentina|Centro de Investigaciones Medicas Mar del Plata, Mar del Plata, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas, Mar del Plata, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas San Nicolas, San Nicolas, Buenos Aires, Argentina|Instituto Clinico Metabolico, San Nicolas, Buenos Aires, Argentina|Clinica Olivos, Vicente Lopez, Buenos Aires, Argentina|Hospital Sirio Libanes, Caba, Ciudad Autonoma Buenos Aires, Argentina|Sanatorio Güemes, Ciudad Autonoma de Bs. As., Ciudad Autonoma Buenos Aires, Argentina|Centro Medico Viamonte SRL, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|CEMEDIC - Centro de Especialidades Medicas, Villa Luro, Ciudad Autonoma Buenos Aires, Argentina|Centro Medico Luquez, San Vicente, Cordoba, Argentina|Axismed S.R.L.- Clínica Mayo, San Miguel de Tucuman, Tucuman, Argentina|Consultorio Dr. Litvak Bruno, Ciudad Autonoma Buenos Aires, Argentina|Fundacion Favaloro, Ciudad Autonoma Buenos Aires, Argentina|CIPREC, Ciudad Autonoma Buenos Aires, Argentina|Investigaciones Medicas IMOBA S.R.L, Ciudad Autonoma Buenos Aires, Argentina|Centro Medico Dra Laura Maffei Investigacion Clinica Aplicada, Ciudad Autonoma Buenos Aires, Argentina|CEDIC Centro de Investigaciones Clinicas, Ciudad Autonoma Buenos Aires, Argentina|Instituto Cardiovascular Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|CCBR - Buenos Aires - AR, Ciudad Autonoma Buenos Aires, Argentina|Inst. Privado de Inv. Clinicas de Cordoba, Cordoba, Argentina|Instituto Medico DAMIC, Cordoba, Argentina|Hospital Privado Centro Medico de Cordoba S.A, Cordoba, Argentina|Clinica del Prado, Cordoba, Argentina|Instituto de Cardiologia de Corrientes, Corrientes, Argentina|Prevencion Cardiovascular Salta, Salta, Argentina|L2IP - Instituto de Pesquisas Clínicas Ltda., Brasília, Distrito Federal, Brazil|Hospital do Coração do Brasil, Brasília, Distrito Federal, Brazil|CECAP - Centro de Cardiologia Clínica, Brasília, Distrito Federal, Brazil|Hospital Universitário de Brasília, Brasília, Distrito Federal, Brazil|Clínica de Endocrinologia e Metabologia Ltda., Brasília, Distrito Federal, Brazil|CARDIOINTERV Centro de Pesquisa S/S, Goiânia, Goiás, Brazil|Via Médica, Goiânia, Goiás, Brazil|HC-UFG - Hospital das Clínicas da Universidade Federal de Goiás, Goiânia, Goiás, Brazil|Hospital Felício Rocho, Belo Horizonte, Minas Gerais, Brazil|CARDRESEARCH - Cardiologia Assistencial, Belo Horizonte, Minas Gerais, Brazil|Sociedade Hospitalar Angelina Caron, Campina Grande do Sul, Paraná, Brazil|Cline Research Center (Leite PS Consultoria Medica LTDA), Curitiba, Paraná, Brazil|Núcleo de Pesquisa Clínica S/S, Curitiba, Paraná, Brazil|Paraná Medical Research Center, Maringá, Paraná, Brazil|HUJBB-UFPA - Hospital Universitário João de Barros Barreto - Universidade Federal do Pará, Belém, Pará, Brazil|CCBR Brasil Centro de Pesquisas e Análises Clínicas Ltda., Rio de Janeiro, Rio Do Janeiro, Brazil|Eurolatino Natal Pesquisas Médicas Ltda., Natal, Rio Grande Do Norte, Brazil|Hospital Universitário, Canoas, Rio Grande Do Sul, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Santa Casa de Misericórdia de Pelotas, Pelotas, Rio Grande Do Sul, Brazil|Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Pesquisas em Diabetes Ltda., Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Pesquisa Clínica Maimônides - Maimônides Day Hospital, Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Pesquisa Médica Santa Maria Ltda., Santa Maria, Rio Grande Do Sul, Brazil|Maestri e Kormann Consultoria Medico Científica LTDA, Blumenau, Santa Catarina, Brazil|Loema - Instituto de Pesquisa Clínica, Campinas, Sao Paulo, Brazil|IPCC - Instituto de Pesquisa Clínica de Campinas, Campinas, Sao Paulo, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clínicos, São Bernardo do Campo, Sao Paulo, Brazil|Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto, Sao Paulo, Brazil|ISPEM - Instituto São José dos Campos em Pesquisas Médicas, São José dos Campos, Sao Paulo, Brazil|CPQuali Pesquisa Clínica Ltda., São Paulo, Sao Paulo, Brazil|CPCLIN - Centro de Pesquisas Clínicas Ltda., São Paulo, Sao Paulo, Brazil|Clínica Paulista de Doenças Cardiovasculares Ltda., São Paulo, Sao Paulo, Brazil|Dr. Consulta, São Paulo, Sao Paulo, Brazil|CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos, São Paulo, Sao Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Sao Paulo, Brazil|Incor - Instituto do Coração - HCFMUSP, São Paulo, Sao Paulo, Brazil|IMC - Instituto de Moléstias Cardiovasculares Tatuí, Tatuí, Sao Paulo, Brazil|Santa Casa de Votuporanga, Votuporanga, Sao Paulo, Brazil|MHAT 'Puls' AD, Blagoevgrad, Bulgaria|MHAT - Blagoevgrad, EOOD, Blagoevgrad, Bulgaria|MHAT ""Yuliya Vrevska - Byala"", EOOD, Byala, Bulgaria|MHAT-Haskovo, AD, Haskovo, Bulgaria|MHAT ""Higia"", AD - Pazardzhik, Pazardzhik, Bulgaria|MHAT - Pazardzhik AD, Pazardzhik, Bulgaria|MHAT ""Sv. Pantaleymon - Pleven"", OOD, Pleven, Bulgaria|SHATC Pleven EAD, Pleven, Bulgaria|UMHAT 'Dr. Georgi Stranski', EAD, Pleven, Bulgaria|UMHAT ""Sv. Georgi"", EAD, Plovdiv, Bulgaria|UMHAT ""Kaspela"", EOOD, Plovdiv, Bulgaria|MC Rusemed ltd., Ruse, Bulgaria|Diagnostic Consultative Center II - Sofia OOD, Sofia, Bulgaria|Fifth MHAT - Sofia EAD, Sofia, Bulgaria|NMTH ""Tsar Boris III"", Sofia, Bulgaria|MHAT - ""National Heart Hospital"" EAD, Sofia, Bulgaria|MHAT ""Lyulin"", EAD, Sofia, Bulgaria|Acibadem City Clinic Tokuda Hospital Ead, Sofia, Bulgaria|MC Start - d-r Todor Dimitrov EOOD, Sofia, Bulgaria|DCC ""Alexandrovska"", EOOD, Sofia, Bulgaria|UMHAT ""Alexandrovska"" EAD, Sofia, Bulgaria|UMHAT 'Tsaritsa Yoanna - ISUL', EAD, Sofia, Bulgaria|Fourth MHAT - Sofia EAD, Sofia, Bulgaria|Diagnostic Consultation Center CONVEX EOOD, Sofia, Bulgaria|Medical Center Kalimat, Sofia, Bulgaria|UMHAT 'Sveta Anna' AD, Sofia, Bulgaria|MC ""Synexus - Sofia"", EOOD, Sofia, Bulgaria|UMHAT ""SofiaMed"", OOD, Sofia, Bulgaria|MC ""Orfey"", EOOD, Stara Zagora, Bulgaria|SHATC ""Cardiolife"", OOD, Varna, Bulgaria|SHATC - Varna, EOOD, Varna, Bulgaria|MHAT ""Sv. Panteleymon"", AD, Yambol, Bulgaria|LMC Clinical Research Inc. (Calgary), Calgary, Alberta, Canada|ALTA Clinical Research Inc., Edmonton, Alberta, Canada|Royal Alexandra Hospital, CK Hui Heart Centre, Edmonton, Alberta, Canada|The Bailey Clinic, Red Deer, Alberta, Canada|Fraser Clinical Trials Inc., New Westminster, British Columbia, Canada|Surrey Memorial Hospital, Surrey, British Columbia, Canada|BC Diabetes As Operated by Dr. TG Elliott, Inc., Vancouver, British Columbia, Canada|Discovery Clinical Services Ltd., Victoria, British Columbia, Canada|Saint Boniface General Hospital, Winnipeg, Manitoba, Canada|Rivergrove Medical Clinic, Winnipeg, Manitoba, Canada|Winnipeg Clinic, Winnipeg, Manitoba, Canada|Health Sciences Centre, St. John's, Newfoundland and Labrador, Canada|LMC Clinical Research Inc. (Barrie), Barrie, Ontario, Canada|LMC Clinical Research Inc. (Brampton), Brampton, Ontario, Canada|Aggarwal and Associates Ltd, Brampton, Ontario, Canada|JBN Medical Diagnostic Services Inc., Burlington, Ontario, Canada|LMC Clinical Research dba Manna Research Inc. Burlington North, Burlington, Ontario, Canada|Cambridge Cardiac Care Centre, Cambridge, Ontario, Canada|Joanne F. Liutkus Medicine Professional Corporation, Cambridge, Ontario, Canada|Saul Vizel Professional Medicine Corporation, Cambridge, Ontario, Canada|LMC Clinical Research Inc. (Thornhill), Concord, Ontario, Canada|LMC Clinical Research Inc. (Etobicoke), Etobicoke, Ontario, Canada|Dawson Road Family Medical Clinic, Guelph, Ontario, Canada|LMC Clinical Research Inc. (Ottawa), Nepean, Ontario, Canada|LMC Clinical Research Inc. (Oakville), Oakville, Ontario, Canada|James Cha, MD, Oshawa, Ontario, Canada|The Ottawa Hospital - Riverside Campus, Ottawa, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|Scarborough Cardiology Research, Scarborough, Ontario, Canada|Janik Research, Sudbury, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|LMC Clinical Research Inc. (Bayview), Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|LMC Clinical Research dba Manna Research Inc. Toronto, Toronto, Ontario, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|ViaCar Recherche Clinique Inc, Greenfield Park, Quebec, Canada|Centre de Dépistage et Recherche Cardiovasculaire Rive-Sud, Longueuil, Quebec, Canada|Clinique de Cardiologie de Levis, Lévis, Quebec, Canada|LMC Clinical Research dba Manna Research Inc. Mirabel, Mirabel, Quebec, Canada|CHUM Hôtel-Dieu, Montreal, Quebec, Canada|Applied Medical Informatics Research Inc., Montreal, Quebec, Canada|Clinique Santé Cardio MC, Montréal, Quebec, Canada|Recherche Clinique Sigma Inc., Québec, Quebec, Canada|Clinique Médicale St-Louis (Recherche) inc d/b/a/ Centre de Recherche Saint-Louis, Québec, Quebec, Canada|ALPHA Recherche Clinique, Québec, Quebec, Canada|LMC Clinical Research Inc. (Montreal), Saint-Laurent, Quebec, Canada|Recherche Médicale St-Jérôme Inc., St-Jérôme, Quebec, Canada|Centre Medical des Carrieres, St-Marc-des-Carrieres, Quebec, Canada|DIEX Recherche Quebec Inc., Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec, Canada|Clinique des maladies Lipidiques de Quebec, Quebec, Canada|Centro de Investigacion Medico Asistencial S.A.S, Barranquilla, Colombia|IPS Centro Cientifico Asistencial S.A.S, Barranquilla, Colombia|Dexa Diab Servicios Médicos Limitada., Bogota, Colombia|Solano y Terront Servicios Médicos Ltda., Bogota, Colombia|Centro Cardiovascular Aristides Sotomayor Santa Lucia S.A.S. - IPS ASTALUC S.A.S. IPS, Cartagena, Colombia|Fundación Centro de Investigaciones Biomédicas Riescard, Espinal, Colombia|Fundación Oftalmológica de Santander - FOSCAL, Floridablanca, Colombia|Centro de Investigación Clínica CIC, Medellin, Colombia|Medicentrum Beroun spol. s.r.o., Beroun, Czechia|Nemocnice Milosrdnych bratri, Brno, Czechia|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|EDUMED s.r.o, Broumov, Czechia|Poliklinika Chocen a.s., Chocen, Czechia|Ordinace pro choroby srdce s.r.o., Chomutov, Czechia|MUDr. Jan Hubac s.r.o., Chrudim, Czechia|Nemocnice Havlickuv Brod p.o., Havlickuv Brod, Czechia|Kardio-Pisova s.r.o., Hradec Kralove, Czechia|MUDr. Tomas Edelsberger, Krnov, Czechia|EDUMED s.r.o, Nachod, Czechia|Agentura Science Pro Spol. s.r.o., Olomouc, Czechia|PreventaMed s.r.o., Olomouc, Czechia|CCR Ostrava s.r.o., Ostrava, Czechia|Corintez s.r.o., Prague, Czechia|MUDr. Jan KVASNICKA CSc. Angiologie kardiologie a interna, Praha 10, Czechia|Nemocnice na Frantisku, Praha 1, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|ResTrial s.r.o., Praha 8, Czechia|Synexus Czech s.r.o., Praha, Czechia|MUDr.Eva Mandakova MBA, Rakovnik, Czechia|Nemocnice Slany, Slany, Czechia|AeskuLab k.s., Teplice, Czechia|Kardiologicka ambulance MUDr. Ferkl s.r.o., Trutnov, Czechia|Clinical Trials Services s.r.o, Uherske Hradiste, Czechia|MUDr. Nina Zemkova s.r.o., Uherske Hradiste, Czechia|Bioclinica, Aalborg, Denmark|Ålborg Universitets Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Bioclinica, Ballerup, Denmark|Amager-Hvidovre Hospital, Copenhagen S, Denmark|Sydvestjyds Sygehus Esbjerg, Esbjerg, Denmark|Amager-Hvidovre Hospital, Glostrup, Denmark|Herlev og Gentofte Hospital, Hellerup, Denmark|Herlev og Gentofte Hospital, Herlev, Denmark|Regionshospitalet Herning-Hospitalsenheden Vest, Herning, Denmark|Holbæk Sygehus, Holbæk, Denmark|Sjællands Universitetshospital, Roskilde, Denmark|OUH, Svendborg, Denmark|Bioclinica, Vejle, Denmark|CHU Tours - Hôpital Trousseau, Chambray Les Tours, Indre Et Loire, France|CHU Nantes - Hopital Nord Laënnec, Nantes cedex 01, Loire Atlantique, France|Hôpital Bichat - Claude Bernard, Paris cedex 18, Paris, France|Universitaetsklinikum Freiburg, Freiburg, Baden Wuerttemberg, Germany|Praxis fuer Praevention und Therapie, Villingen-Schwenningen, Baden Wuerttemberg, Germany|Gemeinschaftspraxis Dr. Klein/ Minnich, Kuenzing, Bayern, Germany|Klinikum der Universitaet Muenchen, Muenchen, Bayern, Germany|Deutsches Herzzentrum Muenchen, Muenchen, Bayern, Germany|GP Dr. Haggenmiller, PD Dr. Michael Jeserich, Naumburg, Bayern, Germany|ZKS-Südbrandenburg -center for clinical studies Südbrandenburg GmbH, Elsterwerda, Brandenburg, Germany|Neurologische Praxis Dr. Schoell & Kollegen, Bad Homburg, Hessen, Germany|Synexus Clinical Research GmbH, Frankfurt, Hessen, Germany|ClinPhenomics GmbH & Co KG, Frankfurt, Hessen, Germany|Klinische Forschung Schwerin GmbH, Schwerin, Mecklenburg Vorpommern, Germany|Synexus Clinical Research GmbH, Bochum, Nordrhein Westfalen, Germany|Gemeinschaftspraxis Diabeteszentrum Dortmund Dr.med. Klaus Busch, Dortmund, Nordrhein Westfalen, Germany|Kardiologische Praxis Gemeinschaftspraxis, Dortmund, Nordrhein Westfalen, Germany|St. Johannes Hospital, Dortmund, Nordrhein Westfalen, Germany|Klinikum Bielefeld gem. GmbH, Dortmund, Nordrhein Westfalen, Germany|Zentrum fuer Praevention und Rehabilitation, Siegen, Nordrhein Westfalen, Germany|Synexus Clinical Research GmbH, Leipzig, Sachsen, Germany|Gemeinschaftspraxis Dr. Taeschner / Dr. Bonigut, Leipzig, Sachsen, Germany|Dr. Uwe Böckmann / Birgit Jacobs - Diabeteszentrum Neumünster, Neumünster, Schleswig Holstein, Germany|RED - Institut GmbH, Oldenburg, Schleswig Holstein, Germany|Katholisches Krankenhaus ""St. Johann Nepomuk"", Erfurt, Thueringen, Germany|Diabetespraxis Prenzlauer Allee, Berlin, Germany|Institut fuer klinische Forschung und Entwicklung Berlin GmbH, Berlin, Germany|Studienzentrum Rankestrasse, Berlin, Germany|Synexus Clinical Research GmbH, Berlin, Germany|Gemeinschaftspraxis fuer innere Medizin und Diabetologie, Hamburg, Germany|Lausmed Kft., Baja, Hungary|Principal SMO Kft., Baja, Hungary|DRC Gyogyszervizsgalo Kozpont Kft., Balatonfured, Hungary|Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz, Bekescsaba, Hungary|Belgyogyaszati es Kardiologiai Maganrendelo, Bekescsaba, Hungary|Clinexpert Kft., Budapest, Hungary|Synexus Magyarorszag Kft., Budapest, Hungary|CSALADGYOGYASZ Kft., Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Borvo Clinic Kft., Debrecen, Hungary|Debreceni Egyetem, Debrecen, Hungary|Meditoll Kft., Godollo, Hungary|Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza, Gyula, Hungary|Synexus Magyarorszag Egeszsegugyi Szolgaltato Kft.- Gyula DRS, Gyula, Hungary|BKS Research Kft., Hatvan, Hungary|Z+P MED Egeszsegugyi, Kereskedelmi es Szolgaltato Bt., Kalocsa, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz, Kaposvar, Hungary|Selye Janos Korhaz, Komarom, Hungary|IPR Hungary Kft., Miskolc, Hungary|Kanizsai Dorottya Korhaz, Nagykanizsa, Hungary|Medifarma-98 Kft., Nyiregyhaza, Hungary|BORBANYA PRAXIS Kft., Nyiregyhaza, Hungary|Dr. Nagy Laszlo Kardiologiai Maganrendeles, Oroshaza, Hungary|Da Vinci Maganklinika, Pecs, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Szekesfehervar, Hungary|Tolna Megyei Balassa Janos Korhaz, Szekszard, Hungary|Csolnoky Ferenc Korhaz, Veszprem, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Hungary|Vijaya Super Speciality Hospital, Nellore, Andhra Pradesh, India|GNRC Hospital, Guwahati, Assam, India|Loknayak Hospital, New Delhi, Delhi, India|Sir Gangaram Hospital, New Delhi, Delhi, India|Fortis Flight Lieutenant Rajan Dhall Hospital, New Delhi, Delhi, India|Ahmedabad Bariatrics and Cosmetics Pvt Ltd., Ahmedabad, Gujarat, India|S. A. L. Hospital & Medical Institute, Ahmedabad, Gujarat, India|DDMM Heart Institute, Nadiad, Gujarat, India|Shri B. D. Mehta Mahavir Heart Institute, Surat, Gujarat, India|BAPS Pramukhswami Hospital, Surat, Gujarat, India|Sterling Hospital, Vadodara, Gujarat, India|Rhythm Heart Institute, Vadodara, Gujarat, India|Medanta The Medicity, Gurgaon, Haryana, India|Fortis Hospitals Ltd., Bangalore, Karnataka, India|K.L.E. Society's Dr. Prabhakar Kore Hospital and Medical Research Centre, Belgaum, Karnataka, India|JSS Hospital, Mysuru, Karnataka, India|Medical College, Thiruvananthapuram, Kerala, India|Meditrina Institute Of Medical Sciences, Nagpur, Maharashtra, India|Supe Heart & Diabetes Hospital & Research Centre, Nashik, Maharashtra, India|7-Orange Hospital, Pimpri-Chinchwad, Maharashtra, India|Shree Multispecialty Hospital, Pune, Maharashtra, India|King Edward Memorial Hospital Research Centre, Pune, Maharashtra, India|Aashirwad Hospital, Ulhasnagar, Maharashtra, India|Institute of Medical Sciences and SUM Hospital, Bhubaneshwar, Orissa, India|Eternal Heart Care Centre, Jaipur, Rajasthan, India|SRM Institutes for Medical Sciences, Chennai, Tamilnadu, India|Institute of Cardiovascular Diseases Madras Medical Mission, Chennai, Tamilnadu, India|KRM Hospital & Research Centre, Lucknow, Uttar Pradesh, India|Galaxy Hospital, Varanasi, Uttar Pradesh, India|IPGMER and SSKM Hospital, Kolkata, West Bengal, India|Maharaja Agrasen Hospital, Delhi, India|HaEmek Medical Center, Afula, Israel|Bnai Zion Medical Center, Haifa, Israel|Rambam Health Care Center, Haifa, Israel|The Lady Davis Carmel Medical Center, Haifa, Israel|Wolfson Medical Center, Holon, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, Israel|Galilee Medical Center, Nahariya, Israel|Rabin Medical Center-Beilinson Campus, Petach Tikva, Israel|Chaim Sheba Medical Center, Ramat-Gan, Israel|Kaplan Medical Center, Rechovot, Israel|Ziv Medical Center, Safed, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Diabetes Medical Center, Tel Aviv, Israel|Aichi Medical University Hospital, Nagakute-shi, Aichi-Ken, Japan|JOHAS Chubu Rosai Hospital, Nagoya-shi, Aichi-Ken, Japan|Kojunkai Daido Clinic, Nagoya-shi, Aichi-Ken, Japan|NHO Nagoya Medical Center, Nagoya-shi, Aichi-Ken, Japan|National Center For Geriatrics And Gerontology, Obu-shi, Aichi-Ken, Japan|Fujita Health University Hospital, Toyoake-shi, Aichi-Ken, Japan|Chiba University Hospital, Chiba-shi, Chiba-Ken, Japan|Kioroshikai Chibanishi General Hospital, Matsudo-shi, Chiba-Ken, Japan|Seikeikai New Tokyo Heart Clinic, Matsudo-shi, Chiba-Ken, Japan|Ehime Prefectural Central Hospital, Matsuyama-shi, Ehime-Ken, Japan|Fukuoka University Hospital, Fukuoka-shi, Fukuoka-Ken, Japan|Fukuoka Tokushukai Hospital, Kasuga-shi, Fukuoka-Ken, Japan|Steel Memorial Yawata Hospital, Kitakyushu-shi, Fukuoka-Ken, Japan|NHO Fukuoka Higashi Medical Center, Koga-shi, Fukuoka-Ken, Japan|Chiyukai Fukuoka Shinmizumaki Hospital, Onga-gun, Fukuoka, Japan|Southern Tohoku Medical Clinic, Koriyama-shi, Fukushima-Ken, Japan|Hoshi General Hospital, Koriyama-shi, Fukushima-Ken, Japan|Nakahama Heart Clinic, Fuchu-shi, Hiroshima-Ken, Japan|Nippon Kokan Fukuyama Hospital, Fukuyama-shi, Hiroshima-Ken, Japan|NHO Higashihiroshima Medical Center, Higashihiroshima-shi, Hiroshima-Ken, Japan|Miyanosawa Clinic of Internal Medicine and Cardiology, Sapporo-shi, Hokkaido, Japan|Tanaka Cardiology Clinic, Hitachinaka-shi, Ibaraki-Ken, Japan|Nakakinen Clinic Medical Corporation Kensei-kai, Naka-shi, Ibaraki-Ken, Japan|Public Central Hospital of Matto Ishikawa, Hakusan-shi, Ishikawa-Ken, Japan|NHI Komatsu Municipal Hospital, Komatsu-shi, Ishikawa-Ken, Japan|Kuonkai Kamata Medical Clinic, Morioka-shi, Iwate-Ken, Japan|Iwate Medical University Uchimaru Medical Center Hospital, Morioka-shi, Iwate-Ken, Japan|Josuikai Olive Takamatsu Medical Clinic, Takamatsu-shi, Kagawa-Ken, Japan|Sohken Yamamoto Clinic, Sagamihara-shi, Kanagawa-Ken, Japan|NHO Yokohama Medical Center, Yokohama-shi, Kanagawa-Ken, Japan|Kumamoto University Hospital, Kumamoto-shi, Kumamoto-Ken, Japan|Ryubokai Higashi Diabetes and Cardiovascular Clinic, Tamana-shi, Kumamoto-Ken, Japan|Ijinkai Takeda General Hospital, Kyoto-shi, Kyoto-Fu, Japan|Kyoto University Hospital, Kyoto-shi, Kyoto-Fu, Japan|Rakuwakai Otowa Hospital, Kyoto-shi, Kyoto-Fu, Japan|Sato Hospital, Osaki-shi, Miyagi-Ken, Japan|Tohoku Kosai Hospital, Sendai-shi, Miyagi-Ken, Japan|Sendai Kousei Hospital, Sendai-shi, Miyagi-Ken, Japan|Keiwakai Oita Oka Hospital, Oita-shi, Oita-Ken, Japan|Okayama University Hospital, Okayama-shi, Okayama-Ken, Japan|Okinawa Tokushukai Chubu Tokushukai Hospital, Nakagami-gun, Okinawa-Ken, Japan|Iwasaki Naika Clinic, Higashiosaka-shi, Osaka-Fu, Japan|Takekawa Naika Clinic, Higashiosaka-shi, Osaka-Fu, Japan|Rinku General Medical Center, Izumisano-shi, Osaka-Fu, Japan|Shiraiwa Medical Clinic, Kashiwara-shi, Osaka-Fu, Japan|Tokushukai Kishiwada Tokushukai Hospital, Kishiwada-shi, Osaka-Fu, Japan|Kansai Electric Power Hospital, Osaka-shi, Osaka-Fu, Japan|National Cerebral and Cardiovascular Center, Suita-shi, Osaka-Fu, Japan|Senrichuo Ekimae Clinic, Toyonaka-shi, Osaka-Fu, Japan|IMS Miyoshi General Hospital, Iruma-gun, Saitama-Ken, Japan|Sugiura Clinic, Kawaguchi-shi, Saitama-Ken, Japan|Sanyukai Saino Clinic, Tokorozawa-shi, Saitama-Ken, Japan|NHO Saitama National Hospital, Wako-shi, Saitama-Ken, Japan|Shiga University of Medical Science Hospital, Otsu-shi, Shiga-Ken, Japan|NHO Hamada Medical Center, Hamada-shi, Shimane-Ken, Japan|Jichi Medical University Hospital, Shimotsuke-shi, Tochigi-Ken, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo-To, Japan|Fukuwa Clinic, Chuo-ku, Tokyo-To, Japan|Tokyo-Eki Center-Building Clinic, Chuo-Ku, Tokyo-To, Japan|Nomura Clinic, Itabashi-ku, Tokyo-To, Japan|Hosoda Clinic, Katsushika-ku, Tokyo-To, Japan|Toyukai Yutenji Medical Clinic (Yutenji Naika), Meguro-ku, Tokyo-To, Japan|Shinjuku Research Park Clinic, Shinjuku-ku, Tokyo-To, Japan|Yamaguchi University Hospital, Ube-shi, Yamaguchi-Ken, Japan|Centro de Investigacion Cardiovascular y Metabolica, Tijuana, Baja California Norte, Mexico|Phytomedicamenta S.A. de C.V., Mexico, Distrito Federal, Mexico|Health Pharma Professional Research S.A. de C.V., Mexico, Distrito Federal, Mexico|Centro de Atención e Investigación en Factores de Riesgo Cardiovascular Omega S.C., Mexico, Distrito Federal, Mexico|Instituto Nacional de Ciencias Médicas y Nutricion Dr. Salvador Zubiran, Mexico, Distrito Federal, Mexico|Mentrials S.A. de C.V., Mexico, Distrito Federal, Mexico|Centro de Investigacion Clinica del Pacifico, S.A. de C.V., Acapulco de Juárez, Guerrero, Mexico|Cardiologia Clinica e Intervencionista, Guadalajara, Jalisco, Mexico|Centro de Investigacion Medica de Occidente, S.C., Zapopan, Jalisco, Mexico|Instituto de Diabetes, Obesidad y Nutrición S.C., Cuautla, Morelos, Mexico|Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico|Centro Medico San Francisco, Monterrey, Nuevo León, Mexico|Unidad Medica para la Salud Integral, San Nicolas de los Garza, Nuevo León, Mexico|Centro Integral Medico SJR S.C., San Juan del Rio, Queretaro, Mexico|Centro de Estudios de Investigacion Metabolicos y Cardiovasculares S.C., Madero, Tamaulipas, Mexico|Centro de Investigacion Cardiometabolica de Aguascalientes S.A de C.V, Aguascalientes, Mexico|Investigacion En Salud Y Metabolismo S.C., Chihuahua, Mexico|Sociedad de Metabolismo y Corazon S.C, Veracruz, Mexico|Noordwest Ziekenhuisgroep, Alkmaar, Netherlands|Ziekenhuisgroep Twente, Almelo, Almelo, Netherlands|Meander Medisch Centrum, Amersfoort, Netherlands|Ziekenhuis Amstelland, Amstelveen, Netherlands|BovenlJ Ziekenhuis, Amsterdam, Netherlands|Amsterdam UMC, Locatie AMC, Amsterdam, Netherlands|Gelre ziekenhuizen, locatie Lukas, Apeldoorn, Netherlands|Rijnstate, Arnhem, Netherlands|Haga Ziekenhuis, Den Haag, Netherlands|Deventer Ziekenhuis, Deventer, Netherlands|Albert Schweitzer Ziekenhuis, Dordwijk, Dordrecht, Netherlands|Gelderse Vallei Ziekenhuis, Ede, Ede, Netherlands|Catharina Ziekenhuis Eindhoven, Eindhoven, Netherlands|Spaarne Gasthuis, Hoofddorp, Haarlem, Netherlands|Zuyderland Medisch Centrum - Heerlen, Heerlen, Netherlands|Huisartsenpraktijk Gorecht, Hoogezand, Netherlands|Quality Care Research, Kloosterhaar, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Bravis Ziekenhuis, Roosendaal, Roosendaal, Netherlands|Maasstad Ziekenhuis, Zuider, Rotterdam, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands|Albert Schweitzer Ziekenhuis, Zwijndrecht, Sliedrecht, Netherlands|Bernhoven Uden, Uden, Netherlands|UMC Utrecht, Utrecht, Netherlands|Diakonessenhuis, Utrecht, Utrecht, Netherlands|Maxima Medisch Centrum, Veldhoven, Netherlands|VieCuri Medisch Centrum, Venlo, Netherlands|NZOZ Centrum Medyczne KERmed, Bydgoszcz, Poland|KARDIOMED Janczska Kociwska Ostki PodckaRekrzSp, Elblag, Poland|Poradnia Kardiologiczna Jarosław Jurowiecki, Gdansk, Poland|Synexus Polska SCM Sp. z o.o. Gdansku, Gdansk, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Indywidualna Specjalistyczna Praktyka Lekarska w Dziedzinie Kardiologii lek. med. Krzysztof Cymerman, Gdynia, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdyni, Gdynia, Poland|Samodzielny Publiczny Specjalistyczny Szpital Zachodni im. Jana Pawla II, Grodzisk Mazowiecki, Poland|Synexus Polska Sp. z o.o. Oddzial w Katowicach, Katowice, Poland|Centrum Medyczne Pratia Katowice II, Katowice, Poland|SPSK Nr 7 SUM w Katowicach Gornoslaskie CM im. prof. Leszka Gieca, Katowice, Poland|Specjalistyczna Poradnia Kardiologiczna i Nadciśnienia Tętniczego, Kielce, Poland|Augustyn Monika, Krakow, Poland|Krakowskie Centrum Medyczne Sp. z o.o., Krakow, Poland|Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi, Lodz, Poland|NZOZ ALL-MED Centrum Medyczne Specjalistyczne Gabinety Lekarskie, Lodz, Poland|Indywidualna Specjalistyczna Praktyka Lekarska, Lodz, Poland|KO-MED Centra Kliniczne Lublin II, Lublin, Poland|Clinical Best Solutions, Lublin, Poland|NZOZ Twoja Przychodnia, Lublin, Poland|NZOZ Osrodek Kardiologii Inwazyjnej -Ikardia, Naleczow, Poland|Medicome Sp. z o.o., Oswiecim, Poland|Synexus Polska sp. z o.o. Oddzial w Poznaniu, Poznan, Poland|Praktyka Lekarska Ewa Krzyzagorska, Poznan, Poland|KO-MED Centra Kliniczne Pulawy, Pulawy, Poland|NZOZ Przychodnia Specjalistyczna H. Rudzki, A. Wittek, Ruda Slaska, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|Clinmed Research, Skierniewice, Poland|NZOZ Pro-Cordis Sopockie Centrum Bad. Kardiolog., Sopot, Poland|NSZOZ Medicus, Sroda Wielkopolska, Poland|KO-MED Centra Kliniczne Staszow, Staszow, Poland|Indywidualna Specjalistyczna Praktyka Lekarska dr n. med. Agnieszka Karczmarczyk Specjalista Chorob, Szczecin, Poland|NBR Polska, Warsaw, Poland|Centrum Medyczne Świat Pacjenta, Warszawa, Poland|Synexus Polska Sp. z o.o. Oddział w Warszawie, Warszawa, Poland|Centrum Zdrowia Tuchow Sp. z o.o., Wierzchosławice, Poland|Synexus Polska Sp. z o.o. Oddział we Wroclawiu, Wroclaw, Poland|KO-MED Centra Kliniczne Zamosc, Zamosc, Poland|VA Medical Center - San Juan, San Juan, Puerto Rico|S.C. CMI Dr. Pletea Noemi S.R.L, Bacau, Romania|Cabinet Medical Individual Diabet, Nutritie, Boli Metabolice Dr. Pop Lavinia, Baia Mare, Romania|S.C Centrul Medical de Diagnostic si Tratament Ambulator Neomed S.R.L, Brasov, Romania|Institutul de Urgenta pentru Boli Cardiovasculare ""Prof. Dr. C.C. Iliescu"", Bucharest, Romania|S.C Clinica Medicala Data Plus S.R.L, Bucuresti, Romania|Spitalul Clinic Colentina, Bucuresti, Romania|Spitalul Clinic de Urgenta ""Sfantul Pantelimon"", Bucuresti, Romania|S.C. Health Net S.R.L, Bucuresti, Romania|S.C Policlinica CCBR S.R.L, Bucuresti, Romania|CMI Dr. Stolea T. Violeta - Medic specialist diabet zaharat, nutritie si boli metabolice, Bucuresti, Romania|S.C. Medcon S.R.L., Buzau, Romania|S.C Grandmed S.R.L, Oradea, Romania|S.C Pelican Impex S.R.L, Oradea, Romania|S.C. Bella Praxis S.R.L, Pașcani, Romania|S.C. Diabmed Dr. Popescu Alexandrina S.R.L, Ploiesti, Romania|CMI Dr Busegeanu Mihaela Magdalena, Ploiesti, Romania|S.C Mediab S.R.L, Targu Mures, Romania|S.C Medicali's S.R.L, Timisoara, Romania|Spitalul Clinic Judetean de Urgenta ""Pius Brinzeu"", Timisoara, Romania|SBIH of Arkhangelsk region "" First City Clinical hospital n.a. E. E. Volosevich"", Arkhangelsk, Russian Federation|TSHI ""Altay Territorial Cardiologocal dispensary"", Barnaul, Russian Federation|SEIHPE ""Ural SMA of RosZdrav"" b.o. LLC ""City Hospital #41"", Ekaterinburg, Russian Federation|FSHI ""MSU of MoIA of RF of Kemerovo Region"", Kemerovo, Russian Federation|FSBI ""Scientific-research Institute for Complex Problems of cardiovascular disease"", Kemerovo, Russian Federation|NSIH ""Departmental Hospital on Station Kemerovo of OJSC ""Russian Railways"", Kemerovo, Russian Federation|SAIH ""Kemerovo Regional Clinical Hospital"", Kemerovo, Russian Federation|TSBIH ""Krasnoyarsk Interdistrict Clinical Hospital of Emergency Medical Care n.a. N.S. Karpovich, Krasnoyarsk, Russian Federation|SBIH of Moscow ""City Clinical Hospital n.a.Bakhrushinykh"", Moscow, Russian Federation|SBHI ""City Polyclinic #2 of Healthcare department of city of Moscow"", Moscow, Russian Federation|FSBIH ""Central Clinical Hospital of Russian Academy of Sciences"", Moscow, Russian Federation|FSBI ""Central Clinical Hospital with Polyclinic of the Department for Presidential Affairs of the RF, Moscow, Russian Federation|SBEI HPE ""Moscow State Medical and Dentistry University n.a. A. I. Evdokimov"" of the MoH of the RF, Moscow, Russian Federation|SBEI HPE ""Moscow State Medical and Dentistry University n.a. A. I. Evdokimov"" of the MoH of the RF, Moscow, Russian Federation|Murmansk Regional Clinical Hospital named after Bayandin, Murmansk, Russian Federation|SBIH of Novosibirsk Region ""Clinical Emergency Hospital #2"", Novosibirsk, Russian Federation|SBIH of Novosibirsk region ""City Clinical Hospital # 19"", Novosibirsk, Russian Federation|FSBSI ""Scientific Research Institute of Therapy and Preventive Medicine"", Novosibirsk, Russian Federation|LLC ""RC Medical"", Novosibirsk, Russian Federation|BIH of Omsk region ""Clinical Medico-Sanitary Unit # 9, Omsk, Russian Federation|Llc Ultramed, Omsk, Russian Federation|SBIH of Perm territory "" City Clinical Hospital # 2 n.a. Fedor Khristoforovich Gral"", Perm, Russian Federation|State Budgetary Healthcare Institution Clinical Medical Sani, Perm, Russian Federation|SHI ""Perm Regional Hospital of War Veterans"", Perm, Russian Federation|City Emergency Hospital #2, Rostov-on-Don, Russian Federation|CJSC Clinic complex, Saint-Petersburg, Russian Federation|FSBI North-West Federal Medical Research Center n.a. V.A. Almazov of MoH RF, Saint-Petersburg, Russian Federation|Saint-Petersburg SBHI ""City outpatient clinic #28"", Saint-Petersburg, Russian Federation|Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russian Federation|SPb SBIH ""City Pokrovskaya Hospital"", Saint-Petersburg, Russian Federation|LLC Medical Center Mart, Saint-Petersburg, Russian Federation|SIH ""Saratov City Clinical Hospital # 2 n.a. V.I. Razumovskiy"", Saratov, Russian Federation|SPb SBIH ""City Hospital # 40 of Kurortnyi region"", Sestroretsk, Russian Federation|SPb SBIH ""City Multy-field Hospital # 2"", St. Petersburg, Russian Federation|LLC ""Institute of Medical Examinations"", St. Petersburg, Russian Federation|Llc ""Medinet"", St. Petersburg, Russian Federation|SPb SBIH ""Nikolaevskaya Hospital"", St. Petersburg, Russian Federation|FSBI ""Research Institute for Cardiology"" of Siberian Branch RAMS, Tomsk, Russian Federation|SHI ""Regional Clinical Hospital"", Tver, Russian Federation|SHI Ulyanovsk Reg Clinical Hospital, Ulyanovsk, Russian Federation|Yaroslavl Regional Clinical Hospital of War Veterans, Yaroslavl, Russian Federation|Alian s.r.o., Bardejov, Slovakia|Thyreomedical s.r.o., Bardejov, Slovakia|Metabol KLINIK s.r.o., Bratislava, Slovakia|Galenum, s.r.o., Bratislava, Slovakia|DIAFA s.r.o., Bratislava, Slovakia|Diabet, spol. s.r.o., Bratislava, Slovakia|Kardiovaskularne centrum, s.r.o., Bratislava, Slovakia|Kardiologicka, interna a sonograficka amb. Kardio-Sanus, sro, Bratislava, Slovakia|MEDISPEKTRUM PLUS s.r.o., Bratislava, Slovakia|MUDr. Vladimir Gergel, s.r.o., Bratislava, Slovakia|ENDIAMED, s.r.o., Dolny Kubin, Slovakia|MEDICUS plus s.r.o., Komarno, Slovakia|Human-Care s.r.o., Kosice, Slovakia|Sukromna interna a kardiologicka ambulancia, Kosice, Slovakia|DIA- Kontrol s.r.o., Levice, Slovakia|CELL B, s.r.o., Levice, Slovakia|KARDIO 1 s.r.o., Lucenec, Slovakia|IN-DIA s.r.o., Lucenec, Slovakia|MUDr. Zuzana Ochodnicka,, Nitra, Slovakia|Fakultna nemocnica s poliklinikou Nove Zamky, Nove Zamky, Slovakia|DIABETOL s.r.o., Presov, Slovakia|Medispol s.r.o., Presov, Slovakia|Nemocnica s poliklinikou sv. Barbory Roznava a.s., Roznava, Slovakia|Peter Farkas MD, s.r.o., Sahy, Slovakia|Interna SK s.r.o., Svidnik, Slovakia|Nemocnica arm. generala L. Svobodu Svidnik, a.s.,, Svidnik, Slovakia|Diabetes centrum, s.r.o., Trencin, Slovakia|JAL s.r.o., Trnava, Slovakia|MEDIVASA s.r.o., Zilina, Slovakia|Cardiology Clinical Research, Alberton, Gauteng, South Africa|Johese Clinical Research: Unitas, Centurion, Gauteng, South Africa|Medicross Roodepoort Clinical Research, Johannesburg, Gauteng, South Africa|Lenasia Clinical Trial Centre, Johannesburg, Gauteng, South Africa|Wits Clinical Research, Johannesburg, Gauteng, South Africa|Clinresco Centres (Pty) Ltd, Kempton Park, Gauteng, South Africa|Synexus SA - Stanza Clinical Research Centre, Mamelodi East, Gauteng, South Africa|Seeber, M, Pretoria, Gauteng, South Africa|Emmed Research, Pretoria, Gauteng, South Africa|Synexus SA Watermeyer Clinical Research Centre, Pretoria, Gauteng, South Africa|Johese Clinical Research: Midstream, Pretoria, Gauteng, South Africa|Limpopo Clinical Research Initiative, Thabazimbi, Limpopo, South Africa|Dr AA Mahomed Medical Centre, Moloto, Mpumalanga, South Africa|Synexus Helderberg Clinical Research Centre, Cape Town, Western Cape, South Africa|Corbod Research, Cape Town, Western Cape, South Africa|Tread Research, Cape Town, Western Cape, South Africa|Tiervlei Trial Centre, Cape Town, Western Cape, South Africa|Cape Town Medical Research Centre, Cape Town, Western Cape, South Africa|Paarl Research Centre, Cape Town, Western Cape, South Africa|Groote Schuur Hospital Lipid Laboratory, Cape Town, Western Cape, South Africa|Dr JM Engelbrecht Practice, Somerset West, Western Cape, South Africa|Helderberg Research Institute, Somerset West, Western Cape, South Africa|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Virgen del Camino, Sanlucar de Barrameda, Cádiz, Spain|Hospital Universitario Reina Sofia, Cordoba, Córdoba, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, La Coruña, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain|Hospital Virgen del Mar, Almeria, Spain|Hospital del Mar, Barcelona, Spain|Hospital Quironsalud Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Regional Universitario de Malaga, Málaga, Spain|Nuevas tecnologías en Diabetes y Endocrinología, Sevilla, Spain|Hospital Quironsalud Infanta Luisa, Sevilla, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Cherkasy Regional Cardiological Center, Cherkasy, Ukraine|CI Cherkasy RH of Cherkasy Regional Council, Cherkasy, Ukraine|CMI CCH#3 Dep of Ther# w the beds of card profile HSEI of UBSMU, Chernivtsi, Ukraine|RCI Chernivtsi Regional Endocrinology Center Policlinic Dept SHEI of UBSMU, Chernivtsi, Ukraine|CI Dnipropetrovsk City Cl Hosp #9 of Dniprop Reg Council SI DMA of MOH of Ukr Ch of Endocrinology, Dnipro, Ukraine|Medical Center of Limited Liability Company Medical Center Clinic of Family Medicine, Dnipro, Ukraine|Regional CH Dept of Endocrinology SHEI Ivano-Frankivsk NMU, Ivano-Frankivsk, Ukraine|CI Ivano-Frankivsk Reg Cl Card Center Dept of Chronic Ischemic Heart Dis SHEI Ivano-Frank NMU, Ivano-Frankivsk, Ukraine|Ivano-Frankivsk CCH Dept of Therapy #1 SHEI Ivano-Frankivsk NMU, Ivano-Frankivsk, Ukraine|CHI Kharkiv City Student Hosp Therap dept Nat Pharm Univer, Kharkiv, Ukraine|CNE Prof. O.O. Shalimov Kharkiv City Clinical Hospital #2 KCC, Kharkiv, Ukraine|GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine, Kharkiv, Ukraine|State Institution LT Malaya Inst. of Ther. of AMS of Ukraine, Kharkiv, Ukraine|Railway Transport Kharkiv CH #1 of Healthcare Center Branch of PJSC Ukr Railway, Kharkiv, Ukraine|Railway Transport Kharkiv CH#1 of Healthcare Center Branch of PJSC Ukrainian Railway, Kharkiv, Ukraine|MC Doctor Alex Dept of General Practice-Family Medicine Kharkiv MA of PGE, Kharkiv, Ukraine|CNE City Clin Hosp #8 of KCC Dept of Therapy Kharkiv MA of PGE of MOHU, Kharkiv, Ukraine|CI Ye.Ye.Karabelesh Kherson City Clinical Hosp., Kherson, Ukraine|KCCC of Endocr Dept of General Endocrine Pathology O. O. Bogomolets NMU, Kyiv, Ukraine|Kyiv CCH #12 Dept of Therapy O.O.Bogomolets NMU, Kyiv, Ukraine|LLC Treatment and Diagnostic Center Adonis Plus, Kyiv, Ukraine|MC of PHEI Institute of General Practice - Family Medicine, Kyiv, Ukraine|Medical Center Blagomed Plus LLC, Kyiv, Ukraine|Med Center 'Ok!Clinic+' of International Institute of Clinical Trials LLC, Kyiv, Ukraine|MC of Subsidiary Production Unit Med Scient Pract Union Medbud of PJSc Holding Company Kyivmiskbud, Kyiv, Ukraine|Kyiv CH on Railway Transport #2 of Branch Center of Healthcare Public Company Ukr Railway, Kyiv, Ukraine|Med Center of Eurolab LLC Policlinic Outpatient Dept O.O.Bogomolets NMU, Kyiv, Ukraine|SI National Scientific Centre of Radiation Medicine of NAMSU, Kyiv, Ukraine|SI NSC M.D. Strazhesko Institute of Cardiology of NAMSU, Kyiv, Ukraine|SI NSС M.D. Strazhesko Institute of Cardiology of NAMSU, Kyiv, Ukraine|Department of Medical Services and Rehabilitation of State Joint Stock Holding Company Artem, Kyiv, Ukraine|Medical Center of Limited Liability Company Medical Center Concilium Medical, Kyiv, Ukraine|CI of Kyiv RC Regional Clinical Hospital #2, Kyiv, Ukraine|SI V.P.Komisarenko Institute of E&M of NAMSU, Kyiv, Ukraine|SI V.P.Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, Ukraine|Lviv Reg St Clin Treatment - Diagnostic Endocrin Center, Dept of Polyclinic, D.Galytskyy Lviv NMU, Lviv, Ukraine|Lviv Communal 4th City Clinical Hospital, Lviv, Ukraine|Center of Reconstructive & Restorative Medicine (University Clinic) of Odessa National Medical Uni, Odesa, Ukraine|CI Sumy City Clinical Hospital #1 Dept of Therapy Sumy SU Med Inst, Sumy, Ukraine|Ternopil City Municipal Hospital #2 Dept of Gastroenterology Ternopil I.Ya. Gorbachevskyi SMU, Ternopil, Ukraine|Transcarpathian Regional Clinical Cardiology Dispansery, Uzhgorod, Ukraine|Private Small Enterprise Medical Center Pulse, Vinnytsia, Ukraine|Vinnytsia RC Highly Special.Endocr.Center Dept of Therapy #2 M.I. Pyrogov NMU, Vinnytsia, Ukraine|National Pirogov Memorial Medical University, Vinnytsia, Ukraine|SRI of Invalid Rehabilitation (EST Complex) of Vinnytsia M.I.Pyrogov NMU MOHU, Vinnytsia, Ukraine|CI Zapor CCH#10 SI ZMA PGE Ch of therapy clin pharmacol & endocrin, Zaporizhzhia, Ukraine|CI Central City Hospital #1 of Zhytomyr, Zhytomyr, Ukraine|Zhytomyr regional clinical hospital n.a. O.F. Gerbachevskyy, Zhytomyr, Ukraine|Synexus Thames, Reading, Berkshire, United Kingdom|Mounts Bay Medical Ltd, Hayle, Cornwall, United Kingdom|Oak Tree Surgery, Liskeard, Cornwall, United Kingdom|The Alverton Practice, Penzance, Cornwall, United Kingdom|Rame Medical Limited, Torpoint, Cornwall, United Kingdom|Knowle House Surgery, Plymouth, Devon, United Kingdom|Torbay Hospital, Torquay, Devon, United Kingdom|Synexus Clinical Research North Tees, Stockton on Tees, Durham, United Kingdom|Broomfield Hospital, Chelmsford, Essex, United Kingdom|Barts Hospital, London, Greater London, United Kingdom|Manchester Royal Infirmary, Manchester, Greater Manchester, United Kingdom|Synexus Manchester Clinical Research Centre, Manchester, Greater Manchester, United Kingdom|Waterloo Medical Centre, Blackpool, Lancashire, United Kingdom|Synexus Lancashire Clinical Research Centre, Chorley, Lancashire, United Kingdom|Synexus Merseyside Clinical Research Centre, Liverpool, Merseyside, United Kingdom|Synexus Hexham General Hospital, Hexham, Northumberland, United Kingdom|Synexus Wales Clinical Research Centre, Cardiff, South Glamorgan, United Kingdom|Synexus Scotland Clinical Research Centre, Glasgow, Strathclyde, United Kingdom|Ninewells Hospital, Dundee, Tayside Region, United Kingdom|Synexus Birmingham Clinical Research Centre, Birmingham, West Midlands, United Kingdom|Morriston Hospital, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03071692"
818,"NCT02633293","An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE",,"Enrolling by invitation","No Results Available","Pulmonary Hypertension|Interstitial Lung Disease|Combined Pulmonary Fibrosis and Emphysema","Drug: Inhaled Treprostinil","Change in Peak 6-Minute Walk Distance (6MWD) from Baseline to the Week 48 Visit|Change in plasma concentration of N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) from Baseline to the Week 48 Visit|Change in Forced Expiratory Volume (FEV1) in One Second from Baseline to Week 48|Change in Forced Vital Capacity (FVC) from Baseline to Week 48|Change in Total Lung Capacity (TLC) from Baseline to Week 48|Change in Lung Diffusion Capacity (DLCO) from Baseline to Week 48|Incidence of Adverse Events Among Participants through Week 108","United Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","266","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RIN-PH-202","September 2016","November 2022","November 2022","December 17, 2015",,"February 28, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|IMC-Diagnostic & Medical Clinic, Mobile, Alabama, United States|Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Cedars-Sinai Medical Center, Beverly Hills, California, United States|University of California, San Francisco-Fresno, Fresno, California, United States|University of California San Diego, La Jolla, California, United States|VA Long Beach Healthcare System, Long Beach, California, United States|University of Southern California, Los Angeles, California, United States|Department of Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States|Pacific Pulmonary Medical Group, Riverside, California, United States|Kaiser Permanente - Roseville, Roseville, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Kaiser Permanente, San Francisco, California, United States|University of Colorado Hospital - Cardiac and Vascular Center, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|Georgetown University Hospital, Washington, District of Columbia, United States|MedStar Heart & Vascular Institute, Washington, District of Columbia, United States|Florida Lung, Asthma & Sleep Specialists, P.A., Celebration, Florida, United States|St. Francis Sleep, Allergy and Lung Institute, Clearwater, Florida, United States|University of Florida Clinical Research Center, Gainesville, Florida, United States|University of Florida College of Medicine, Jacksonville, Jacksonville, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|St. Vincent's Lung, Sleep, and Critical Care Specialists, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Florida Hospital, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|The Emory Clinic, Atlanta, Georgia, United States|Piedmont - Georgia Lung Associates, Austell, Georgia, United States|Wellstar Medical Group, Marietta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois at Chicago Hospital, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Hospital, Indianapolis, Indiana, United States|Community Heart and Vascular Hospital, Indianapolis, Indiana, United States|St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville Physicians Outpatient Center, Louisville, Kentucky, United States|Louisiana State University Health Sciences Center New Orleans, New Orleans, Louisiana, United States|Maine Medical Center, South Portland, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Spectrum Health Medical Center, Grand Rapids, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Washington University Hospital, Saint Louis, Missouri, United States|The University of New Mexico, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|Northwell Health, New Hyde Park, New York, United States|NYU Langone Medical Center, New York, New York, United States|The Mount Sinai Hospital, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Pinehurst Medical Clinic, Inc., Pinehurst, North Carolina, United States|The Carl and Edyth Lindner Research Center at The Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati Health, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States|Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|AnMed Health Pulmonary and Sleep Medicine, Anderson, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Statcare Pulmonary Consultants, Knoxville, Tennessee, United States|Baylor University Medical Center at Dallas, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Tech University Health Sciences Center, El Paso, Texas, United States|Houston Methodist, Houston, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Vermont, Vermont Lung Center, Colchester, Vermont, United States|Inova Fairfax Hospital, Fairfax, Virginia, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Pulmonary Associates of Richmond, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States|Alliance Cardio Pulmonary Research Group, Inc., Guaynabo, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02633293"
819,"NCT02507687","Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension",,"Active, not recruiting","No Results Available","Glaucoma, Open-Angle|Ocular Hypertension","Drug: Bimatoprost SR|Drug: Sham Bimatoprost SR|Procedure: Selective Laser Trabeculoplasty|Procedure: Sham Selective Laser Trabeculoplasty","Change from Baseline in Intraocular Pressure (IOP) at Week 24|Change from Baseline in IOP at Week 4|Change from Baseline in IOP at Week 12|IOP change from baseline at Week 8|IOP change from baseline at Week 15|IOP change from baseline at Week 20|Time to initial use of nonstudy IOP-lowering treatment as determined by the investigator|Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 4|Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 12|Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 24|Percentage of SLT eyes achieving ≥ 20% reduction at Week 4|Percentage of SLT eyes achieving ≥ 20% reduction at Week 12|Percentage of SLT eyes achieving ≥ 20% reduction at Week 24","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-093|2015-002131-18","August 27, 2015","October 31, 2021","October 31, 2021","July 24, 2015",,"April 16, 2020","Arizona Glaucoma Specialists, Phoenix, Arizona, United States|M&M Eye Institute, Prescott, Arizona, United States|Acuity Eye Group, Arcadia, California, United States|Orange County Ophthalmology, Garden Grove, California, United States|Specialty Eye Care, Glendale, California, United States|Lugene Eye Institute, Glendale, California, United States|California Eye Specialists Medical Group, Inc., Pasadena, California, United States|North Bay Eye Associates Inc., Petaluma, California, United States|Pacific Eye Associates, San Francisco, California, United States|Eye Associates of South West Florida, Fort Myers, Florida, United States|Levenson Eye Associates, Jacksonville, Florida, United States|Ocala Eye, P.A., Ocala, Florida, United States|Logan Ophthalmic Research, LLC, Tamarac, Florida, United States|Sabates Eye Centers, Leawood, Kansas, United States|Stiles Eyecare and Glaucoma Institute, Overland Park, Kansas, United States|Advanced Glaucoma Specialists, Reading, Massachusetts, United States|Midwest Vision Research Foundation/ Pepose Vision Institute, Chesterfield, Missouri, United States|Northern New Jersey Eye Institute, PA, South Orange, New Jersey, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|Albemarle Clinical Trials, LLC, Elizabeth City, North Carolina, United States|BaganStrinden Vision, Fargo, North Dakota, United States|Cincinnati Eye Institute, Cincinnati, Ohio, United States|Wills Eye Hospital, Philadelphia, Pennsylvania, United States|Carolinas Centers for Sight, PC, Florence, South Carolina, United States|Keystone Research Ltd., Austin, Texas, United States|Houston Eye Associates, Houston, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|R and R Eye Research LLC, San Antonio, Texas, United States|Emerson Clinical Research Institute, Falls Church, Virginia, United States|Piedmont Eye Center, Inc., Lynchburg, Virginia, United States|West Virginia University Eye Institute, Morgantown, West Virginia, United States|Bendigo Eye Clinic, Bendigo, Victoria, Australia|Eye Surgery Associates East Melbourne, East Melbourne, Victoria, Australia|Essendon Eye Clinic, Essendon, Victoria, Australia|Melbourne Eye Specialists, Fitzroy, Victoria, Australia|Geelong Eye Clinic, Geelong, Victoria, Australia|Waverley Eye Clinic, Glen Waverley, Victoria, Australia|Vision Eye Institute, Melbourne, Victoria, Australia|The University of Western Australia - Lions Eye Institute, Crawley, Western Australia, Australia|Nova Scotia Health Authority, Halifax, Nova Scotia, Canada|St. Joseph's Hamilton Healthcare Hospital, Hamilton, Ontario, Canada|Institut de loeil des Laurentides, Boisbriand, Quebec, Canada|Clinique d'ophthalmologie Bellvue Montreal, Montreal, Quebec, Canada|Ophthalmic Consultant Centres, Mississauga, Canada|Glostrup Hospital, Glostrup, Denmark|Charité Universitätsmedizin Berlin, Berlin, Germany|Internationale Innovative Ophthalmochirurgie, Dusseldorf, Germany|Universitaetsaugenklinik, Magdeburg, Germany|Universitaets-Augenklinik, Munster, Germany|Rambam Health Care Campus, Haifa, Israel|Carmel Medical Center, Haifa, Israel|The Rabin Medical Center, Petach Tiqva, Israel|Tel-Aviv Medical Centre, Tel Aviv, Israel|Auckland Eye Limited, Remuera, New Zealand|Capital Eye Specialist - Wellington, Wellington, New Zealand|Asian Eye Institute, Makati City, Metro Manila, Philippines|Peregrine Eye and Laser Institute, Makati City, Metro Manila, Philippines|Centrum Diagnostykii Mikrochirurgii Oka LENS ul., Olsztyn, Poland|S..Fyodorov Eye Microsurgery Federal State Institution, Novosibirsk, Russian Federation|Clinical ophthalmology hospital n.a. V.P. Vihodtsev, Omsk, Russian Federation|Samara State Medical University, Samara, Russian Federation|Queen Elisabeth Hospital Birmingham, Birmingham, United Kingdom|Sussex Eye Hospital, Brighton, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|Royal Derby Hospital, Derby, United Kingdom|Princess Alexandra Eye Pavilion, Edinburgh, United Kingdom|Moorfields Eye hospital, London, United Kingdom|Western Eye Hospital, London, United Kingdom|St Thomas' Hospital, London, United Kingdom|Manchester Royal Eye Hospital, Manchester, United Kingdom|Queen Mary's Hospital Sidcup, Sidcup, United Kingdom|Epsom & St Helier University Hospitals NHS Trust, Sutton, United Kingdom|York teaching Hospital NHS Foundation Trust, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02507687"
820,"NCT02835339","Magnesium Sulfate in Obese Preeclamptics",,"Completed","No Results Available","Preeclampsia","Drug: Magnesium sulfate 4g loading dose, 1g/hr infusion|Drug: Magnesium sulfate 6g loading dose, 2g/hr infusion","Maternal serum magnesium level at 4 hours after administration|Maternal serum magnesium level at time of delivery|Maternal side effects","Oregon Health and Science University","Female","18 Years to 45 Years   (Adult)","Phase 4","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OHSU IRB 15809","July 12, 2016","June 30, 2019","June 30, 2019","July 18, 2016",,"November 15, 2019","Oregon Health & Science Univerity, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02835339"
821,"NCT01488734","Bioavailability and Biological Effects of Vitamin D2 Contained in Mushroom",,"Completed","No Results Available","Vitamin D Deficiency|Metabolic Syndrome|Prediabetes","Dietary Supplement: Mushroom with 600 IU vitamin D2|Dietary Supplement: Mushroom with 4000 IU Vitamin D2|Dietary Supplement: 600 IU Vitamin D3 and untreated mushroom|Dietary Supplement: 4000 IU Vitamin D3 and untreated mushroom|Drug: Placebo","25OH Vitamin D level|Serum calcium|Markers of inflammation and metabolic control","Icahn School of Medicine at Mount Sinai","All","30 Years to 90 Years   (Adult, Older Adult)","Not Applicable","47","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","GCO 11-0899|11-01366","November 2011","September 2013","September 2013","December 8, 2011",,"April 14, 2017","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01488734"
822,"NCT02025426","Phenylephrine Versus Ephedrine in Pre-eclampsia",,"Terminated","No Results Available","Pre-eclampsia","Drug: Phenylephrine|Drug: Ephedrine","Cerebral tissue oxygen saturation|Cardiac output","Duke University","Female","18 Years to 50 Years   (Adult)","Phase 4","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00032812","September 2012","July 8, 2016","July 8, 2016","January 1, 2014",,"January 10, 2020","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02025426"
823,"NCT00949884","Olmesartan Comparison to Losartan in Hypertensive Subjects",,"Completed","Has Results","Hypertension","Drug: olmesartan medoxomil|Drug: Placebo|Drug: losartan potassium","Change From Baseline to Week 8 in Trough, Cuff, Seated Diastolic Blood Pressure (SDBP)|Change From Baseline to Week 4 in Trough, Cuff, Seated Systolic Blood Pressure (SSBP)|Change From Baseline to Week 8 in Trough, Cuff, Seated Systolic Blood Pressure (SSBP)|Change From Baseline to Week 4 in Trough, Cuff, Seated Diastolic Blood Pressure (SDBP)","Daiichi Sankyo, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","941","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CS0866-A-U452","August 2009","January 2010","January 2010","July 30, 2009","February 28, 2011","March 9, 2011","Mesa, Arizona, United States|Phoenix, Arizona, United States|Harbor City, California, United States|Tustin, California, United States|Westlake Village, California, United States|Pueblo, Colorado, United States|Deerfield Beach, Florida, United States|DeLand, Florida, United States|South Bend, Indiana, United States|Wichita, Kansas, United States|Metairie, Louisiana, United States|Albuquerque, New Mexico, United States|Binghamton, New York, United States|Charlotte, North Carolina, United States|Cincinnati, Ohio, United States|Greenville, South Carolina, United States|Bristol, Tennessee, United States|New Tazewell, Tennessee, United States|Dallas, Texas, United States|Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00949884"
824,"NCT02328768","Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children",,"Completed","No Results Available","Total Parenteral Nutrition-Induced Cholestasis","Drug: Omegaven","Primary efficacy outcome will be normalized direct bilirubin, defined as three consecutive direct bilirubin results < 2mg/dL or a direct bilirubin < 2mg/dL and weaned from total parenteral nutrition (TPN).","Brian Jones, MD|Children's Hospital and Medical Center, Omaha, Nebraska|University of Nebraska","All","up to 18 Years   (Child, Adult)","Phase 2","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","O-2014-BJ","April 3, 2015","November 10, 2017","September 5, 2018","December 31, 2014",,"October 15, 2018","Children's Hospital & Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT02328768"
825,"NCT02799758","Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia",,"Terminated","No Results Available","Hyperlipidemia|Dyslipidemia","Drug: NK-104-CR|Drug: Livalo® IR|Drug: Placebo (for NK-104-CR)|Drug: Placebo (for Livalo® IR)","Percent change in Low-density lipoprotein cholesterol (LDL-C)","Kowa Research Institute, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","2","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NK-104-CR-3.02US","February 2016","July 2017","November 2017","June 15, 2016",,"June 15, 2016","Foley, Alabama, United States|Huntsville, Alabama, United States|Montgomery, Alabama, United States|Muscle Shoals, Alabama, United States|Little Rock, Arkansas, United States|Greenbrae, California, United States|Huntington Park, California, United States|Lomita, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Santa Ana, California, United States|Spring Valley, California, United States|Tustin, California, United States|Walnut Creek, California, United States|Milford, Connecticut, United States|Atlantis, Florida, United States|Cooper City, Florida, United States|Coral Springs, Florida, United States|Fleming Island, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Oviedo, Florida, United States|Dawnsonville, Georgia, United States|Macon, Georgia, United States|Suwanee, Georgia, United States|Addison, Illinois, United States|Chicago, Illinois, United States|Gurnee, Illinois, United States|Morton, Illinois, United States|Evansville, Indiana, United States|Topeka, Kansas, United States|Louisville, Kentucky, United States|Owensboro, Kentucky, United States|Oxon Hill, Maryland, United States|Biloxi, Mississippi, United States|Olive Branch, Mississippi, United States|Jefferson City, Missouri, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Manlius, New York, United States|High Point, North Carolina, United States|Sailsbury, North Carolina, United States|Wilmington, North Carolina, United States|Winston Salem, North Carolina, United States|Fargo, North Dakota, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Franklin, Ohio, United States|Oklahoma City, Oklahoma, United States|Medford, Oregon, United States|Beaver, Pennsylvania, United States|Harleysville, Pennsylvania, United States|Jersey Shore, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Moncks Corner, South Carolina, United States|Simpsonville, South Carolina, United States|Summerville, South Carolina, United States|Austin, Texas, United States|Houston, Texas, United States|Katy, Texas, United States|Plano, Texas, United States|Round Rock, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Richmond, Virginia, United States|Suffolk, Virginia, United States|Seattle, Washington, United States|Kenosha, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02799758"
826,"NCT04053543","CXA-10 Study in Subjects With Pulmonary Arterial Hypertension",,"Recruiting","No Results Available","PAH","Drug: CXA-10","Incidence of AEs|Changes in respiration|Changes in heart rate|Changes in blood pressure|PAH-specific medication changes|6 Minute Walk Distance|Who Classification of Functional Status|Clinical worsening","Complexa, Inc.|Medpace, Inc.|Innovative Analytics|Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","All","18 Years and older   (Adult, Older Adult)","Phase 2","96","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CXA-10-2302","August 9, 2019","February 28, 2021","February 28, 2021","August 12, 2019",,"January 6, 2020","University of Alabama, Birmingham, Alabama, United States|University of Arizona, Tucson, Arizona, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|University of California San Diego, La Jolla, California, United States|University of California San Francisco, San Francisco, California, United States|National Jewish Health, Denver, Colorado, United States|Washington Hospital (Medstar), Washington, District of Columbia, United States|George Washington Medical Faculty Associates, Washington, District of Columbia, United States|University of Florida Health, Gainesville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|University of Chicago, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas, Kansas City, Kansas, United States|University of Minnesotta, Minneapolis, Minnesota, United States|Washington University and Barnes Jewish Hospital, Saint Louis, Missouri, United States|NYU Langone Medical Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|Christ Hospital-Lindner Research Center, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Vanderbuilt University, Nashville, Tennessee, United States|UT Southwestern, Dallas, Texas, United States|Texas Tech, El Paso, Texas, United States|Houston Methodist, Houston, Texas, United States|University of Virginia School of Medicine, Charlottesville, Virginia, United States|Inova Medical Campus, Falls Church, Virginia, United States|Sentara Medical Group, Norfolk, Virginia, United States|Froedert Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Golden Jubilee National Hospital, Glasgow, United Kingdom|Royal Free, London, United Kingdom|Royal Brompton, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04053543"
827,"NCT02636946","A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension",,"Active, not recruiting","No Results Available","Glaucoma|Open-Angle Ocular Hypertension","Drug: Bimatoprost SR|Drug: Sham Bimatoprost SR|Procedure: Selective Laser Trabeculoplasty|Procedure: Sham Selective Laser Trabeculoplasty","Change from Baseline in Intraocular Pressure (IOP) at Week 24|Change from Baseline in IOP at Week 4|Change from Baseline in IOP at Week 12|IOP change from baseline at Week 8|IOP change from baseline at Week 15|IOP change from baseline at Week 20|Time to initial use of nonstudy IOP-lowering treatment as determined by the investigator|Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 4|Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 12|Percentage of Bimatoprost SR eyes achieving ≥ 20% reduction at Week 24|Percentage of SLT eyes achieving ≥ 20% reduction at Week 4|Percentage of SLT eyes achieving ≥ 20% reduction at Week 12|Percentage of SLT eyes achieving ≥ 20% reduction at Week 24","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 3","144","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","192024-095|2015‐003631‐34","February 24, 2016","February 28, 2021","February 28, 2021","December 22, 2015",,"April 14, 2020","Eye Center South, Dothan, Alabama, United States|Arizona Eye Center Phoenix, Chandler, Arizona, United States|Walman Eye Center, Sun City, Arizona, United States|Shasta Eye Medical Group, Inc, Redding, California, United States|Wolstan & Goldberg Eye Associates, Torrance, California, United States|Eye Associates of Colorado Springs, Colorado Springs, Colorado, United States|Nature Coast Clinical Research, Crystal River, Florida, United States|The Eye Institute for Medicine and Surgery, Melbourne, Florida, United States|East Florida Eye Institute, Stuart, Florida, United States|Emory University Eye Center, Atlanta, Georgia, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|The Eye Care Institute, Louisville, Kentucky, United States|The Ophthalmology Group, LLC, Paducah, Kentucky, United States|Fraser Eye Care Center, Fraser, Michigan, United States|Ophthalmic Consultants of Long Island, Lynbrook, New York, United States|Glaucoma Consultants of Capital Region, Slingerlands, New York, United States|Asheville Eye Associates, Asheville, North Carolina, United States|Charlotte Eye Ear Nose and Throat Associates PA, Charlotte, North Carolina, United States|James D. Branch MD, Winston-Salem, North Carolina, United States|Bergstrom Eye Research, LLC, Fargo, North Dakota, United States|Scott & Christie and Associates, PC, Cranberry Township, Pennsylvania, United States|Glaucoma Associates of Texas, Dallas, Texas, United States|DCT- Shah Research, LLC dba Discovery Clinical Trials, Mission, Texas, United States|San Antonio Eye Center, San Antonio, Texas, United States|Vistar Eye Center, Roanoke, Virginia, United States|University of Washington Eye Institute, Seattle, Washington, United States|Adjunct Clinic Head University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium|CHU Sart-tilman, Liege, Belgium|Glostrup Hospital, Glostrup, Denmark|CHU de Bordeaux Hopital Pellegrin Service Ophtalmologie, Bordeaux, France|Centre ophtalmologie Pole vision, Ecully, France|CHU Dupuytren - Service d'ophtalmologie, Limoges, France|CHU de Nice - Hopital Pasteur 2 - Service Ophtalmologie, Nice, France|Hôpital Pierre-Paul Riquet, Toulouse, France|Universit degli Studi di Chieti-Pescara, Chieti, Italy|Clinica Oculistica Di.N.O.G.M.I., Genova, Italy|Università degli Studi di Parma, Parma, Italy|University of Pisa (Azienda Ospedaliero-Universitaria Pisana Cisanello Hospital), Pisa, Italy|Azienda Ospedaliera Perugia, San Sisto, Italy|University of Udine, Udine, Italy|OFTALMIKA Sp. z o.o., ul., Bydgoszcz, Poland|Centrum Diagnostykii Mikrochirurgii Oka LENS ul., Olsztyn, Poland|Research Institute of Ocular Diseases, Moscow, Russian Federation|S. Fyodorov Eye Microsurgery Federal State Institution, Novosibirsk, Russian Federation|GBOU VPO ""Omsk state medical University"" of Ministry of Health of Russia, Omsk, Russian Federation|Academician I.P. Pavlov First St. Petersburg state medical university, Saint Petersburg, Russian Federation|Samara State Medical University, Samara, Russian Federation|Singapore National Eye Centre - Singapore Eye Research Institute, Singapore, Singapore|Institut Catala de la Retina, Barcelona, Spain|Centro de Oftalmologia Barraquer, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Clinico San Carlos, Madrid, Spain|CHU de Nantes, Nantes, Spain|Hospital Universitario, Sevilla, Spain|Pio del Rio Hortega University Hospital, Valladolid, Spain|Phramongkutklao Hospital, Bangkok, Thailand|Siriraj Hospital, Bangkok, Thailand|Chiang Mai University CMU - Maharaj Nakhon Chiang Mai Hospital Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|Thammasat University Hospital, Pathumthani, Thailand",,"https://ClinicalTrials.gov/show/NCT02636946"
828,"NCT02036970","Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT",,"Completed","No Results Available","Pulmonary Arterial Hypertension|Pulmonary Hypertension|Interstitial Lung Disease|Idiopathic Interstitial Pneumonia|Idiopathic Pulmonary Fibrosis|Sarcoidosis|Respiratory Bronchiolitis Associated Interstitial Lung Disease|Desquamative Interstitial Pneumonia|Cryptogenic Organizing Pneumonia|Acute Interstitial Pneumonitis|Idiopathic Lymphoid Interstitial Pneumonia|Idiopathic Pleuroparenchymal Fibroelastosis","Drug: Bardoxolone methyl|Drug: Placebo","Change from baseline in 6-Minute Walk Distance (6MWD)","Reata Pharmaceuticals, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","166","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RTA 402-C-1302","May 2014","January 19, 2018","May 16, 2018","January 15, 2014",,"January 3, 2019","Banner University Medical Center, Phoenix Advanced Lung Disease Institute, Phoenix, Arizona, United States|Arizona Pulmonary Specialists, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Beverly Hills, California, United States|VA Healthcare System of Greater Los Angeles, Los Angeles, California, United States|University of California Davis Medical Center - Division of Pulmonary and Critical Care, Sacramento, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|University of Colorado Denver - Division of Pulmonary Sciences, Aurora, Colorado, United States|South Denver Cardiology Associates, P.C, Littleton, Colorado, United States|Georgetown University Medical Center - Department of Rheumatology, Washington, District of Columbia, United States|Cleveland Clinic of Florida, Weston, Florida, United States|University of Chicago, Chicago, Illinois, United States|Maine Medical Center - Division of Pulmonary and Critical Care Medicine, Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Winthrop University Hospital, Mineola, New York, United States|Mount Sinai, Beth Israel Medical Center, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|University of Rochester - University of Rochester Medical Center, Rochester, New York, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|University of Cincinnati - Department of Internal Medicine Pulmonary, Critical Care & Sleep Medicine, Cincinnati, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oklahoma Heart Hospital, Oklahoma City, Oklahoma, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|BreatheAmerica El Paso, Inc., El Paso, Texas, United States|Houston Methodist Research Institute, Houston, Texas, United States|The University of Texas - Health Science Center & Medical School at Houston, Houston, Texas, United States|University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University Clinic Carl Gustav Carus, Dresden, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT02036970"
829,"NCT02791958","Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy",,"Unknown status","No Results Available","Hypertension","Drug: Cardiovascular Fixed Dose Combination Pill AAR|Drug: Atorvastatin 40 mg|Drug: Ramipril 10 mg","Difference in the adjusted mean 24-h systolic blood pressure results using ABPM between the baseline (week 0) and the final visit (week 8).|Difference in LDL cholesterol levels between the baseline (week 4) and the final visit (week 8).|Difference in the adjusted mean 24-h diastolic blood pressure results (using ABPM) between the basal and the final visits.|Difference in the adjusted mean 24-h mean arterial pressure results (using ABPM) between the basal and the final visits.|Difference in the adjusted mean 24-h heart rate results (using ABPM) between the basal and the final visits.|Difference in Very Low-Density Lipoprotein (VLDL) cholesterol levels between the basal and the final visits.|Difference in HDL cholesterol levels between the basal and the final visits.|Difference in total cholesterol levels between the basal and the final visits.|Difference in triglyceride levels between the basal and the final visits.|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]","Ferrer Internacional S.A.","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 2","528","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FCD-PP-1501","March 2016","October 2017","October 2017","June 7, 2016",,"April 10, 2017","Central Alabama Research, Birmingham, Alabama, United States|National Research Institute, Los Angeles, California, United States|Clinical Trials Research, Sacramento, California, United States|Clinical Trials Investigators, Inc, Tustin, California, United States|Infoshpere Clinical Research, Inc, West Hills, California, United States|Meridien Research, Bradenton, Florida, United States|PAB Clinical Research, Brandon, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Clinical Therapeutics Corporation, Coral Gables, Florida, United States|Moonshine Research Center, Inc, Doral, Florida, United States|Riverside Clinical Research, Edgewater, Florida, United States|Nova Clinical Research Center inc, Hialeah, Florida, United States|Dr. John C. Gutleber Weight Loss, Beauty, and Family Practice, Homestead, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Health Awareness, Inc., Jupitor, Florida, United States|The Chappel Group Research, Kissimmee, Florida, United States|Sunrise Medical Center, Lauderdale Lakes, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Louisville Metabolic and Atherosclerosis Research, Louisville, Kentucky, United States|Clinical Trials of America LA, LLC, Monroe, Louisiana, United States|DelRicht Research, New Orleans, Louisiana, United States|Bay State Clinical Trials, Inc, Watertown, Massachusetts, United States|Clinical Research Source, Perrysburg, Ohio, United States|Einstein Clinical Research, Lancaster, South Carolina, United States|Punzi Medical Center, Carrollton, Texas, United States|Cullen Research, LLC, Houston, Texas, United States|Research Trials Worldwide LLC, Humble, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Deleon Research, PLLC, Plano, Texas, United States|Physician PrimeCare Research Institute, PLLC dba H, San Antonio, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|Sylvana Research, San Antonio, Texas, United States|Chysalis Clinical Research, St. George, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02791958"
830,"NCT02855177","A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: Placebo|Drug: PF-06427878","Number of Treatment Emergent Treatment-Related Adverse Events (AEs)|Change from baseline in clinical laboratory tests|Change from baseline in vital signs|Change from baseline in cardiac conduction intervals assessed via 12-lead electrocardiogram|Maximum Observed Plasma Concentration (Cmax) for PF-06427878 on day 1|Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06427878 on day 1|Area Under the Curve for PF-06427878 during the dosing interval (AUCtau) on day 1|Maximum Observed Plasma Concentration (Cmax) for PF-06427878 on day 14|Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06427878 on day 14|Area Under the Curve for PF-06427878 during the dosing interval (AUCtau) on day 14|Plasma Decay Half-Life (t1/2) for PF-06427878 on day 14|Apparent Volume of Distribution (Vz/F) of PF-06427878 on day 14|Apparent Oral Clearance (CL/F) of PF-06427878 on day 14|Minimum Observed Plasma Concentration (Cmin) for PF-06427878 on day 14|Peak:Trough ratio of PF-06427878 on day 14|Accumulation ratio for Area Under the Curve during the dosing interval (Rac(AUCtau)) for PF-06427878 on day 14 relative to day 1|Accumulation ratio for Maximum Observed Plasma Concentration (Rac(Cmax)) for PF-06427878 on day 14 relative to day 1|Amount of PF-06427878 excreted in urine (Ae) on day 14|Percent of dose excreted in urine as PF-06427878 (Ae%) on day 14|Renal clearance of PF-06427878 (CLr) on day 14","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","B7871005","August 24, 2016","April 12, 2017","April 12, 2017","August 4, 2016",,"May 4, 2017","California Clinical Trials Medical Group, Glendale, California, United States|Qps-Mra, Llc, South Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02855177"
831,"NCT01218100","Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension",,"Completed","Has Results","Stage 2 Diastolic Hypertension","Drug: nebivolol and lisinopril (free combination)|Drug: nebivolol monotherapy|Drug: lisinopril monotherapy|Drug: placebo","The Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6.|The Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6.","Forest Laboratories","All","18 Years to 64 Years   (Adult)","Phase 4","664","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NEB-MD-25","October 2010","May 2011","June 2011","October 11, 2010","June 21, 2012","June 21, 2012","Forest Investigative Site #58, Scottsdale, Arizona, United States|Forest Investigative site 080, Tempe, Arizona, United States|Forest Investigative site 096, Tucson, Arizona, United States|Forest Investigative site 038, Buena Park, California, United States|Forest Investigative site 075, Burbank, California, United States|Forest Investigative site 042, Costa Mesa, California, United States|Forest Investigative site 028, Fountain Valley, California, United States|Forest Investigative site 064, Fresno, California, United States|Forest Investigative site 079, Lancaster, California, United States|Forest Investigative site 097, Long Beach, California, United States|Forest Investigative site 049, Los Angeles, California, United States|Forest Investigative site 081, Riverside, California, United States|Forest Investigative site 040, San Marino, California, United States|Forest Investigative site 059, San Ramon, California, United States|Forest Investigative site 074, Santa Ana, California, United States|Forest Investigative site 072, Tustin, California, United States|Forest Investigative site 077, Colorado Springs, Colorado, United States|Forest Investigative site 050, Waterbury, Connecticut, United States|Forest Investigative site 019, Boca Raton, Florida, United States|Forest Investigative site 056, Brandon, Florida, United States|Forest Investigative site 043, Brooksville, Florida, United States|Forest Investigative site 035, Fort Lauderdale, Florida, United States|Forest Investigative site 002, Hialeah, Florida, United States|Forest Investigative site 003, Miami, Florida, United States|Forest Investigative site 067, Miami, Florida, United States|Forest Investigative site 057, Miami, Florida, United States|Forest Investigative site 068, Miami, Florida, United States|Forest Investigative site 007, Miami, Florida, United States|Forest Investigative site 009, New Port Richey, Florida, United States|Forest Investigative site 036, Pembroke Pines, Florida, United States|Forest Investigative site 005, Pembroke Pines, Florida, United States|Forest Investigative site 001, St. Petersburg, Florida, United States|Forest Investigative site 004, Tampa, Florida, United States|Forest Investigative site 046, Tampa, Florida, United States|Forest Investigative site 076, Atlanta, Georgia, United States|Forest Investigative site 055, Stockbridge, Georgia, United States|Forest Investigative Site 070, Honolulu, Hawaii, United States|Forest Investigative site 008, Meridian, Idaho, United States|Forest Investigative site 016, Chicago, Illinois, United States|Forest Investigative site 085, Chicago, Illinois, United States|Forest Investigative site 082, Chicago, Illinois, United States|Forest Investigative site 039, Morton, Illinois, United States|Forest Investigative site 087, Louisville, Kentucky, United States|Forest Investigative site 099, Madisonville, Kentucky, United States|Forest Investigative site 060, Owensboro, Kentucky, United States|Forest Investigative site 030, New Orleans, Louisiana, United States|Forest Investigative site 069, Balitmore, Maryland, United States|Forest Investigative site 021, Baltimore, Maryland, United States|Forest Investigative site 014, Baltimore, Maryland, United States|Forest Investigative site 054, Brockton, Massachusetts, United States|Forest Investigative site 095, St. Louis, Missouri, United States|Forest Investigative site 010, Las Vegas, Nevada, United States|Forest Investigative site 012, Las Vegas, Nevada, United States|Forest Investigative site 020, Elizabeth, New Jersey, United States|Forest Investigative site 065, Asheboro, North Carolina, United States|Forest Investigative site 034, Charlotte, North Carolina, United States|Forest Investigative site 086, Charlotte, North Carolina, United States|Forest Investigative site 089, Hickory, North Carolina, United States|Forest Investigative site 094, Hickory, North Carolina, United States|Forest Investigative site 027, Lenoir, North Carolina, United States|Forest Investigative site 101, Raleigh, North Carolina, United States|Forest Investigative site 024, Raleigh, North Carolina, United States|Forest Investigative site 013, Shelby, North Carolina, United States|Forest Investigative site 022, Winston-Salem, North Carolina, United States|Forest Investigative site 098, Cincinnati, Ohio, United States|Forest Investigative site 084, Columbus, Ohio, United States|Forest Investigative site 026, Dayton, Ohio, United States|Forest Investigative site 051, Zanesville, Ohio, United States|Forest Investigative site 053, Norman, Oklahoma, United States|Forest Investigative site 062, Ashland, Oregon, United States|Forest Investigative site 011, Broomall, Pennsylvania, United States|Forest Investigative site 061, Philadelphia, Pennsylvania, United States|Forest Investigative site 015, Tipton, Pennsylvania, United States|Forest Investigative site 045, Cranston, Rhode Island, United States|Forest Investigative site 066, Charleston, South Carolina, United States|Forest Investigative site 048, Greer, South Carolina, United States|Forest Investigative site 093, Mount Pleasant, South Carolina, United States|Forest Investigative site 052, Fayetteville, Tennessee, United States|Forest Investigative site 025, Carrollton, Texas, United States|Forest Investigative site 006, Houston, Texas, United States|Forest Investigative site 029, Houston, Texas, United States|Forest Investigative site 047, San Antonio, Texas, United States|Forest Investigative site 071, San Antonio, Texas, United States|Forest Investigative site 018, Salt Lake City, Utah, United States|Forest Investigative site 100, Salt Lake City, Utah, United States|Forest Investigative site 023, St. George, Utah, United States|Forest Investigative site 031, Norfolk, Virginia, United States|Forest Investigative site 041, Norfolk, Virginia, United States|Forest Investigative site 078, Tacoma, Washington, United States|Forest Investigative site 044, Caguas, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01218100"
832,"NCT03398005","A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)","TRILOGY 1","Completed","No Results Available","Hypertriglyceridemia","Drug: CaPre|Drug: Placebo","Percent change in fasting TG levels from baseline (average of Week -2, -1, and 0) to Week 12 (average of Week 11 and 12) in patients with fasting TG levels ≥500 mg/dL and ≤1500 mg/dL (≥5.7 mmol/L and ≤17.0 mmol/L).|Percent change from baseline (average of Week -2, -1, and 0) to Week 12 (average of Week 11 and 12) in non-HDL-C.|Percent change from baseline (Week -1 and 0) to Week 12 (average of Week 11 and 12) in VLDL-C (β-quantification).|Percent change from baseline (average of Week -2, -1, and 0) to Week 12 (average of Week 11 and 12) in HDL-C.|Percent change from baseline (average of Week -1 and 0) to Week 12 (average of Week 11 and 12) in LDL-C (β-quantification).","Acasti Pharma Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","256","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACA-CAP-001","January 23, 2018","July 21, 2019","November 20, 2019","January 12, 2018",,"January 18, 2020","Research site, Birmingham, Alabama, United States|Research site, Tucson, Arizona, United States|Research site, Conway, Arkansas, United States|Research site, El Cajon, California, United States|Research site, Fresno, California, United States|Research site, Garden Grove, California, United States|Research site, Lomita, California, United States|Research site, Newport Beach, California, United States|Research site, Tustin, California, United States|Research site, Boca Raton, Florida, United States|Research site, Clearwater, Florida, United States|Research site, Fort Myers, Florida, United States|Research site, Hialeah, Florida, United States|Research site, Homestead, Florida, United States|Research site, Jacksonville, Florida, United States|Research site, Kendall, Florida, United States|Research site, Lake Worth, Florida, United States|Research site, Miami Springs, Florida, United States|Research site, Miami, Florida, United States|Research site, Miami, Florida, United States|Research site, Miami, Florida, United States|Research site, Miami, Florida, United States|Research site, Miami, Florida, United States|Research site, Miami, Florida, United States|Research site, Miami, Florida, United States|Research site, North Miami Beach, Florida, United States|Research site, Orlando, Florida, United States|Research site, Pembroke Pines, Florida, United States|Research site, Tamarac, Florida, United States|Research site, Tampa, Florida, United States|Research site, Wellington, Florida, United States|Research site, West Palm Beach, Florida, United States|Research site, West Palm Beach, Florida, United States|Research site, Atlanta, Georgia, United States|Research site, Gainesville, Georgia, United States|Research site, Savannah, Georgia, United States|Research site, Snellville, Georgia, United States|Research site, Sugar Hill, Georgia, United States|Research site, Meridian, Idaho, United States|Research site, Meridian, Idaho, United States|Research site, Gurnee, Illinois, United States|Research site, Anderson, Indiana, United States|Research site, Louisville, Kentucky, United States|Research site, Eunice, Louisiana, United States|Research site, Cadillac, Michigan, United States|Research site, Jackson, Mississippi, United States|Research site, Olive Branch, Mississippi, United States|Research site, Saint Louis, Missouri, United States|Research site, Omaha, Nebraska, United States|Research site, Greensboro, North Carolina, United States|Research site, Mooresville, North Carolina, United States|Research site, Canton, Ohio, United States|Research site, Marion, Ohio, United States|Research site, Maumee, Ohio, United States|Research site, Norman, Oklahoma, United States|Research site, Beaver, Pennsylvania, United States|Research site, Spartanburg, South Carolina, United States|Research site, Chattanooga, Tennessee, United States|Research site, Memphis, Tennessee, United States|Research site, Arlington, Texas, United States|Research site, Houston, Texas, United States|Research site, Houston, Texas, United States|Research site, Lampasas, Texas, United States|Research site, San Antonio, Texas, United States|Research site, Salt Lake City, Utah, United States|Research site, West Jordan, Utah, United States|Research site, Danville, Virginia, United States|Research site, Bellevue, Washington, United States|Research site, Kenosha, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03398005"
833,"NCT03361501","A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)","TRILOGY 2","Active, not recruiting","No Results Available","Hypertriglyceridemia","Drug: CaPre|Drug: Placebo","Percent change in fasting TG levels from baseline (average of Week -2, -1, and 0) to Week 12 (average of Week 11 and 12) in patients with fasting TG levels ≥500 mg/dL and ≤1500 mg/dL (≥5.7 mmol/L and ≤17.0 mmol/L).|Percent change from baseline (average of Week -2, -1, and 0) to Week 12 (average of Week 11 and 12) in non-HDL-C.|Percent change from baseline (Week -1 and 0) to Week 12 (average of Week 11 and 12) in VLDL-C (β-quantification).|Percent change from baseline (average of Week -2, -1, and 0) to Week 12 (average of Week 11 and 12) in HDL-C.|Percent change from baseline (average of Week -1 and 0) to Week 12 (average of Week 11 and 12) in LDL-C (β-quantification).","Acasti Pharma Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","245","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACA-CAP-002","February 1, 2018","September 24, 2019","January 2020","December 5, 2017",,"January 18, 2020","Research site, Birmingham, Alabama, United States|Research site, Childersburg, Alabama, United States|Research site, Encino, California, United States|Research site, Long Beach, California, United States|Research site, San Diego, California, United States|Research site, Thousand Oaks, California, United States|Research site, Torrance, California, United States|Research site, Monument, Colorado, United States|Research site, Clearwater, Florida, United States|Research site, Coral Gables, Florida, United States|Research site, DeLand, Florida, United States|Research site, Fort Lauderdale, Florida, United States|Research site, Jacksonville, Florida, United States|Research site, Jacksonville, Florida, United States|Research site, Miami Lakes, Florida, United States|Research site, Miami, Florida, United States|Research site, Miami, Florida, United States|Research site, Miami, Florida, United States|Research site, Dunwoody, Georgia, United States|Research site, Peachtree Corners, Georgia, United States|Research site, Savannah, Georgia, United States|Research site, Boise, Idaho, United States|Research site, Wauconda, Illinois, United States|Research site, Iowa City, Iowa, United States|Research site, Overland Park, Kansas, United States|Research site, Biddeford, Maine, United States|Research site, Baltimore, Maryland, United States|Research site, Hyattsville, Maryland, United States|Research site, Flint, Michigan, United States|Research site, Tupelo, Mississippi, United States|Research site, Norfolk, Nebraska, United States|Research site, Las Vegas, Nevada, United States|Research site, Las Vegas, Nevada, United States|Research site, Albany, New York, United States|Research site, Bronx, New York, United States|Research site, Laurelton, New York, United States|Research site, New Windsor, New York, United States|Research site, New York, New York, United States|Research site, Morganton, North Carolina, United States|Research site, Marion, Ohio, United States|Research site, Oklahoma City, Oklahoma, United States|Research site, Lansdale, Pennsylvania, United States|Research site, Gaffney, South Carolina, United States|Research site, Summerville, South Carolina, United States|Research site, Union, South Carolina, United States|Research site, Georgetown, Texas, United States|Research site, Houston, Texas, United States|Research site, Houston, Texas, United States|Research site, Houston, Texas, United States|Research site, Kerrville, Texas, United States|Research site, Clinton, Utah, United States|Research site, Ogden, Utah, United States|Research site, Manassas, Virginia, United States|Research site, Winnipeg, Manitoba, Canada|Research site, Halifax, Nova Scotia, Canada|Research site, Brampton, Ontario, Canada|Research site, Burlington, Ontario, Canada|Research site, London, Ontario, Canada|Research site, Newmarket, Ontario, Canada|Research site, Sarnia, Ontario, Canada|Research site, Québec, Quebec, Canada|Research site, Sherbrooke, Quebec, Canada|Research site, Ciudad de mexico, Mexico City, Mexico|Research site, Culiacán, Sinaloa, Mexico|Research site, Aguascalientes, Mexico|Research site, Chihuahua, Mexico|Research site, Mexico City, Mexico|Research site, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT03361501"
834,"NCT02390284","Stop Retinal Ganglion Cell Dysfunction Study","STOP-RGCD","Recruiting","No Results Available","Glaucoma","Drug: Latanoprost|Drug: Bimatoprost|Drug: Travoprost|Drug: Timolol|Drug: Dorzolamide|Drug: Brinzolamide|Drug: Acetazolamide|Drug: Methazolamide","Retinal Nerve Fiber Layer Thickness change through Optical Coherence Tomography evaluation|Pattern Electroretinogram Changes","University of Miami|National Eye Institute (NEI)","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","500","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20140587|R01EY014957","September 2015","July 2024","July 2024","March 17, 2015",,"December 9, 2019","Bascom Palmer Eye Institute - University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02390284"
835,"NCT01644474","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia","ODYSSEY MONO","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Ezetimibe|Drug: Placebo (for Alirocumab)|Drug: Placebo (for Ezetimibe)","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC11716|U1111-1124-1167|2011-001424-38","July 2012","July 2013","July 2013","July 19, 2012","November 6, 2015","November 6, 2015","Investigational Site Number 840603, Overland Park, Kansas, United States|Investigational Site Number 840601, Cincinnati, Ohio, United States|Investigational Site Number 840602, Richmond, Virginia, United States|Investigational Site Number 056601, Antwerpen, Belgium|Investigational Site Number 246601, Helsinki, Finland|Investigational Site Number 528602, Groningen, Netherlands|Investigational Site Number 528601, Rotterdam, Netherlands|Investigational Site Number 528603, Velp, Netherlands",,"https://ClinicalTrials.gov/show/NCT01644474"
836,"NCT02622334","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).",,"Completed","No Results Available","Glaucoma","Drug: Latanoprost|Drug: Placebo|Drug: RO5093151","Incidence of adverse events|Changes in vital signs, electrocardiogram (ECG), opthalmologic assessments, and clinical laboratory results|Change in mean IOP after 7 days treatment vs baseline: change from baseline for RO5093151 and latanoprost and difference in change from baseline between RO5093151 and latanoprost|Change in IOP at matched clock-times after 7 days of treatment vs baseline (diurnal IOP) and between RO5093151 and latanoprost|Maximum observed plasma concentration (Cmax)|Time to maximum observed plasma concentration (Tmax)|Concentration at the end of a dosing interval before the next dose administration (Ctrough)|Area under the plasma concentration versus time curve from zero to 24 h post-dose (AUC0-24)|Area under the plasma concentration versus time curve up to the last measurable concentration (AUClast)|Apparent terminal half-life (T1/2)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BP30002","December 29, 2015","July 28, 2016","July 28, 2016","December 4, 2015",,"March 14, 2018","Sall Research Medical Center, Artesia, California, United States|Rocky Mountain Lions Eye Inst, Aurora, Colorado, United States|Eye Care Centers Management, Inc. (Clayton Eye Center), Morrow, Georgia, United States|New York Eye and Ear Infirmary of Mt. Sinai; New York Glaucoma Research Institute, New York, New York, United States|Cornerstone Eye Care, Div of Cornerstone Health Care, High Point, North Carolina, United States|West Virginia University Eye Institute, Morgantown, West Virginia, United States|Singapore National Eye Centre; Glaucoma Department, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02622334"
837,"NCT02104817","Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia","STRENGTH","Active, not recruiting","No Results Available","Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)","Drug: Epanova® (omega-3 carboxylic acids)|Drug: corn oil control","The primary outcome measure is the time to the first occurrence of any component of the composite of MACE.|The composite measure of CV events that include the first occurrence of cardiovascular death, non-fatal MI and non-fatal stroke.|The composite measure of coronary events that include the first occurrence of cardiac death.|The first occurrence of individual components of MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, emergent/elective coronary revascularization, or hospitalization for unstable angina.|Time to CV death","AstraZeneca|The Cleveland Clinic|IQVIA RDS Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","13086","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5881C00004|2014-001069-28","October 30, 2014","May 15, 2020","May 15, 2020","April 4, 2014",,"February 7, 2020","Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Muscle Shoals, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Gilbert, Arizona, United States|Research Site, Glendale, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Carlsbad, California, United States|Research Site, Fresno, California, United States|Research Site, Fresno, California, United States|Research Site, Greenbrae, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Milpitas, California, United States|Research Site, Newport Beach, California, United States|Research Site, Northridge, California, United States|Research Site, Palm Springs, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Tarzana, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Boca Raton, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Davie, Florida, United States|Research Site, Delray Beach, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Homestead, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Pinellas Park, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Spring Hill, Florida, United States|Research Site, Tamarac, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Sandy Springs, Georgia, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Blue Island, Illinois, United States|Research Site, Champaign, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Oakbrook Terrace, Illinois, United States|Research Site, Sterling, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Avon, Indiana, United States|Research Site, Elkhart, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Franklin, Indiana, United States|Research Site, Greenfield, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Augusta, Kansas, United States|Research Site, Overland Park, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Elkridge, Maryland, United States|Research Site, Hyannis, Massachusetts, United States|Research Site, Quincy, Massachusetts, United States|Research Site, Bay City, Michigan, United States|Research Site, Cadillac, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Edina, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Port Gibson, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Bridgeton, Missouri, United States|Research Site, Hazelwood, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, Camden, New Jersey, United States|Research Site, Elmer, New Jersey, United States|Research Site, Sewell, New Jersey, United States|Research Site, Sicklerville, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Albany, New York, United States|Research Site, Binghamton, New York, United States|Research Site, Laurelton, New York, United States|Research Site, Lawrence, New York, United States|Research Site, New York, New York, United States|Research Site, Saratoga Springs, New York, United States|Research Site, Southampton, New York, United States|Research Site, Troy, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Cary, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Morganton, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Grand Forks, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Maumee, Ohio, United States|Research Site, Middleburg Hts, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Corvallis, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Beaver, Pennsylvania, United States|Research Site, Danville, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Ephrata, Pennsylvania, United States|Research Site, Flourtown, Pennsylvania, United States|Research Site, Johnstown, Pennsylvania, United States|Research Site, Natrona Heights, Pennsylvania, United States|Research Site, Newport, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Port Matilda, Pennsylvania, United States|Research Site, Tipton, Pennsylvania, United States|Research Site, Wilkes-Barre, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Simpsonville, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Bristol, Tennessee, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Mission, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Victoria, Texas, United States|Research Site, Clinton, Utah, United States|Research Site, Ogden, Utah, United States|Research Site, Orem, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burke, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Herndon, Virginia, United States|Research Site, Lynchburg, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Port Orchard, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, La Crosse, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Wausau, Wisconsin, United States|Research Site, Adelaide, Australia|Research Site, Blacktown, Australia|Research Site, Box Hill, Australia|Research Site, Cowra, Australia|Research Site, Forbes, Australia|Research Site, Herston, Australia|Research Site, Joondalup, Australia|Research Site, Maroubra, Australia|Research Site, Milton, Australia|Research Site, South Brisbane, Australia|Research Site, Southport, Australia|Research Site, Tumbi Umbi, Australia|Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Genk, Belgium|Research Site, Halen, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Mol, Belgium|Research Site, New Westminster, British Columbia, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Thornhill, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Granby, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Mirabel, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Haerbin, China|Research Site, Haikou, China|Research Site, Hohhot, China|Research Site, Jilin, China|Research Site, Lanzhou, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Suzhou, China|Research Site, Taiyuan, China|Research Site, Tianjin, China|Research Site, Tianjin, China|Research Site, Urumqi, China|Research Site, Xian, China|Research Site, Xuzhou, China|Research Site, Yanji, China|Research Site, Yinchuan, China|Research Site, Yueyang, China|Research Site, Zhanjiang, China|Research Site, Zhenjiang, China|Research Site, Beroun, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Chocen, Czechia|Research Site, Chrudim, Czechia|Research Site, Hodonin, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jindrichuv Hradec, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 10 - Strasnice, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 8, Czechia|Research Site, Praha, Czechia|Research Site, Prerov, Czechia|Research Site, Slany, Czechia|Research Site, Tremosna, Czechia|Research Site, Trutnov, Czechia|Research Site, Zlin, Czechia|Research Site, Hellerup, Denmark|Research Site, Herlev, Denmark|Research Site, København Ø, Denmark|Research Site, Svendborg, Denmark|Research Site, Viborg, Denmark|Research Site, Ålborg, Denmark|Research Site, Århus N, Denmark|Research Site, Pärnu, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Balatongyorok, Hungary|Research Site, Ballasagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Békéscsaba, Hungary|Research Site, Csorna, Hungary|Research Site, Debrecen, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Godollo, Hungary|Research Site, Gödöllő, Hungary|Research Site, Hajdúszoboszló, Hungary|Research Site, Hatvan, Hungary|Research Site, Kalocsa, Hungary|Research Site, Kiskunhalas, Hungary|Research Site, Komarom, Hungary|Research Site, Mohacs, Hungary|Research Site, Nagykanizsa, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Szeged, Hungary|Research Site, Szeged, Hungary|Research Site, Szekszárd, Hungary|Research Site, Szentes, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Veszprem, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Brescia, Italy|Research Site, Cinisello Balsamo, Italy|Research Site, Cona, Italy|Research Site, L'Aquila, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, San Giovanni Rotondo, Italy|Research Site, Trieste, Italy|Research Site, Adachi-ku, Japan|Research Site, Adachi-ku, Japan|Research Site, Akishima-shi, Japan|Research Site, Akita-shi, Japan|Research Site, Amagasaki-shi, Japan|Research Site, Chikushino-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Fujisawa-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Hakusan-shi, Japan|Research Site, Ichikawa-shi, Japan|Research Site, Imabari-shi, Japan|Research Site, Itoshima-shi, Japan|Research Site, Kasugai-shi, Japan|Research Site, Kawanishi-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kitakyushu-shi, Japan|Research Site, Kochi-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Maebashi-shi, Japan|Research Site, Matsudo-shi, Japan|Research Site, Matsumoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Meguro-ku, Japan|Research Site, Minato-ku, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nakagami-gun, Japan|Research Site, Niigata-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Onga-gun, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Tokorozawa-shi, Japan|Research Site, Toshima-ku, Japan|Research Site, Tsuchiura-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Ulsan, Korea, Republic of|Research Site, Alytus, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Siauliai, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Chihuahua, Mexico|Research Site, Cuautitlan Izcalli, Mexico|Research Site, Culiacan, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Merida, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Almelo, Netherlands|Research Site, Almere, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Apeldoorn, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Beek, Netherlands|Research Site, Delft, Netherlands|Research Site, EDE, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Harderwijk, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Hilversum, Netherlands|Research Site, Hoofddorp, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Schiedam, Netherlands|Research Site, Sneek, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Venlo, Netherlands|Research Site, Zwijndrecht, Netherlands|Research Site, Auckland, New Zealand|Research Site, Auckland, New Zealand|Research Site, Auckland, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Havelock North, New Zealand|Research Site, Rotorua, New Zealand|Research Site, Wellington, New Zealand|Research Site, Białystok, Poland|Research Site, Chorzów, Poland|Research Site, Elbląg, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Kraków, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Oświęcim, Poland|Research Site, Parczew, Poland|Research Site, Piaseczno, Poland|Research Site, Poznań, Poland|Research Site, Poznań, Poland|Research Site, Puławy, Poland|Research Site, Ruda Śląska, Poland|Research Site, Rzeszów, Poland|Research Site, Sobótka, Poland|Research Site, Sopot, Poland|Research Site, Staszów, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Zamość, Poland|Research Site, Zgierz, Poland|Research Site, Łódź, Poland|Research Site, Barnaul, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Orenburg, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Rostov-na-Donu, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, St-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bloemfontein, South Africa|Research Site, Breyton, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Centurion, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, George, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Krugersdorp, South Africa|Research Site, Kuilsrivier, South Africa|Research Site, Mamelodi East, South Africa|Research Site, Middelburg, South Africa|Research Site, Moloto, South Africa|Research Site, Paarl, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Potchefstroom, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Somerset West, South Africa|Research Site, Stanger, South Africa|Research Site, Verulam, South Africa|Research Site, Worcester, South Africa|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Cherkasy, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Mykolaiv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zhytomyr, Ukraine|Research Site, Airdrie, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Chelmsford, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, East Kilbride, United Kingdom|Research Site, Edgbaston, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Exeter, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Hexham, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Romford, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Torquay, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02104817"
838,"NCT01711879","Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma",,"Completed","No Results Available","Neovascular Glaucoma","Drug: Aflibercept","Incidence and Severity of Adverse Events|Comparison Between Groups","University of Colorado, Denver","All","21 Years to 90 Years   (Adult, Older Adult)","Not Applicable","7","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-1526","January 2013","October 2015","October 2015","October 22, 2012",,"January 24, 2017","Rocky Mountain Lions Eye Institute, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01711879"
839,"NCT00967694","Effect of Nitrous Oxide (N2O) on Intraocular Pressure in Healthy Volunteers",,"Completed","Has Results","Glaucoma|Sedation","Drug: Nitrous oxide","Change in Intraocular Pressure During Nitrous Oxide Sedation","Oregon Health and Science University|Robert L. Bacon Medical Foundation|Research to Prevent Blindness","All","18 Years to 40 Years   (Adult)","Phase 4","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","IRB00005402","August 2009","October 2011","October 2011","August 28, 2009","September 23, 2014","September 23, 2014","OHSU, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00967694"
840,"NCT02207634","Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects","EBBINGHAUS","Completed","Has Results","Dyslipidemia","Biological: Evolocumab|Drug: Placebo|Drug: Background Statin Therapy","Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score|Mean Change From Baseline in Spatial Working Memory (SWM) Between-errors Z Score|Mean Change From Baseline in Paired Associated Learning (PAL) Total Errors Adjusted Z Score|Mean Change From Baseline in Reaction Time (RTI) Median 5-choice Reaction Time Z Score","Amgen","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 3","1974","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","20130385|2014-001976-75","September 10, 2014","November 11, 2016","November 11, 2016","August 4, 2014","January 16, 2018","January 16, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Alhambra, California, United States|Research Site, Banning, California, United States|Research Site, Harbor City, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Oceanside, California, United States|Research Site, Oxnard, California, United States|Research Site, Palm Springs, California, United States|Research Site, Roseville, California, United States|Research Site, Sacramento, California, United States|Research Site, San Pedro, California, United States|Research Site, Tarzana, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Deerfield Beach, Florida, United States|Research Site, Fleming Island, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Suwanee, Georgia, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Addison, Illinois, United States|Research Site, Belleville, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Jerseyville, Illinois, United States|Research Site, Hammond, Indiana, United States|Research Site, Waterloo, Iowa, United States|Research Site, Hutchinson, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Hammond, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Biddeford, Maine, United States|Research Site, Salisbury, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Newton, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Grandville, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Muskegon, Michigan, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Great Falls, Montana, United States|Research Site, Kalispell, Montana, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Westwood, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New Windsor, New York, United States|Research Site, Rochester, New York, United States|Research Site, Troy, New York, United States|Research Site, West Seneca, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Calabash, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Grand Forks, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Pryor, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Chambersburg, Pennsylvania, United States|Research Site, Feasterville, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Fort Mill, South Carolina, United States|Research Site, Moncks Corner, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, North Myrtle Beach, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, West Jordan, Utah, United States|Research Site, Burke, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Hopewell, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Suffolk, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Woden, Australian Capital Territory, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Hobart, Tasmania, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Epping, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Aalst, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Brussels, Belgium|Research Site, Gozee, Belgium|Research Site, Ieper, Belgium|Research Site, La Louvière, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, St Jean sur Richelieu, Quebec, Canada|Research Site, St-Jérôme, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Beroun, Czechia|Research Site, Bilovec, Czechia|Research Site, Brandys nad Labem, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Chomutov, Czechia|Research Site, Havlickuv Brod, Czechia|Research Site, Hodonin, Czechia|Research Site, Klatovy IV, Czechia|Research Site, Liberec, Czechia|Research Site, Litomysl, Czechia|Research Site, Mohelnice, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava - Vitkovice, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 3, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5 - Smichov, Czechia|Research Site, Prerov, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Esbjerg, Denmark|Research Site, Hvidovre, Denmark|Research Site, København S, Denmark|Research Site, Køge, Denmark|Research Site, Vejle, Denmark|Research Site, Paide, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Helsinki, Finland|Research Site, Helsinki, Finland|Research Site, Jyväskylä, Finland|Research Site, Kuopio, Finland|Research Site, Oulu, Finland|Research Site, OYS, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Besançon Cedex, France|Research Site, Le Coudray, France|Research Site, Montepellier Cedex, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Pessac Cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Bad Krozingen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Dresden, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Stuttgart, Germany|Research Site, Witten, Germany|Research Site, Wuppertal, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Ioannina, Greece|Research Site, Larissa, Greece|Research Site, Piraeus, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Bekescsaba, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Szekszard, Hungary|Research Site, Szikszo, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Pavia, Italy|Research Site, Ichinomiya-shi, Aichi, Japan|Research Site, Kasugai-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Toyohashi-shi, Aichi, Japan|Research Site, Matsudo-shi, Chiba, Japan|Research Site, Saijo-shi, Ehime, Japan|Research Site, Chikushi-gun, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Itoshima-shi, Fukuoka, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Himeji-shi, Hyogo, Japan|Research Site, Toride-shi, Ibaraki, Japan|Research Site, Tsukuba-city, Ibaraki, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Okinawa-shi, Okinawa, Japan|Research Site, Shimajiri-gun, Okinawa, Japan|Research Site, Urasoe-shi, Okinawa, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Kawaguchi-shi, Saitama, Japan|Research Site, Komatsushima-shi, Tokushima, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Daugavpils, Latvia|Research Site, Kuldiga, Latvia|Research Site, Liepaja, Latvia|Research Site, Ogre, Latvia|Research Site, Ogre, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Vilnius, Lithuania|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Arnhem, Netherlands|Research Site, Ede, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Uden, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Hamar, Norway|Research Site, Lierskogen, Norway|Research Site, Oslo, Norway|Research Site, Skedsmokorset, Norway|Research Site, Skien, Norway|Research Site, Stavanger, Norway|Research Site, Ålesund, Norway|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Olsztyn, Poland|Research Site, Poznan, Poland|Research Site, Pulawy, Poland|Research Site, Ruda Slaska, Poland|Research Site, Staszow, Poland|Research Site, Swidnik, Poland|Research Site, Tarnow, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wloclawek, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Zamosc, Poland|Research Site, Almada, Portugal|Research Site, Carnaxide, Portugal|Research Site, Coimbra, Portugal|Research Site, Covilha, Portugal|Research Site, Ekaterinburg, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kirov, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Pushkin, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Bardejov, Slovakia|Research Site, Brezno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Moldava nad Bodvou, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Roznava, Slovakia|Research Site, Snina, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trencin, Slovakia|Research Site, Trnava, Slovakia|Research Site, Centurion, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Pretoria west, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Paarl, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Worcester, Western Cape, South Africa|Research Site, Cape Town, South Africa|Research Site, Kempton Park, South Africa|Research Site, Zaragoza, Aragón, Spain|Research Site, L'Hospitalet de Llobregat, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Vigo, Galicia, Spain|Research Site, Galdakao, País Vasco, Spain|Research Site, Madrid, Spain|Research Site, Helsingborg, Sweden|Research Site, Linköping, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uddevalla, Sweden|Research Site, Västerås, Sweden|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Gaziantep, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kocaeli, Turkey|Research Site, Belfast, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Chippenham, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, Doncaster, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Hexham, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newport, United Kingdom|Research Site, Nuneaton, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Sandbach, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, West Bromwich, United Kingdom|Research Site, Whitby, United Kingdom|Research Site, Worcester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02207634"
841,"NCT02091362","A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: LY2409021|Drug: Placebo|Drug: Metformin","Change From Baseline to 6 Weeks in Mean 24-Hour Systolic Blood Pressure|Change From Baseline to 6 Weeks in Mean 24-Hour Diastolic Blood Pressure|Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Peripheral Pulse Rate|Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Pulse Pressures|Change From Baseline to 6 Weeks in Mean 24-Hour, Daytime, and Nighttime Mean Arterial Pressures (MAP)|Change From Baseline in Hemoglobin A1c (HbA1c)|Population Pharmacokinetics: Apparent Clearance of LY2409021|Population Pharmacokinetics: Apparent Volume of Distribution of LY2409021","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","15261|I1R-MC-GLDI|2013-003834-33","March 2014","January 2015","January 2015","March 19, 2014","July 19, 2018","July 19, 2018","Advanced Clinical Research Institute, Anaheim, California, United States|National Research Institute, Los Angeles, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Orange County Research Center, Tustin, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Berma Research, Fort Lauderdale, Florida, United States|East Coast Clinical Research, Jacksonville, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|L-Marc Research Center, Louisville, Kentucky, United States|Maine Research Associates, Auburn, Maine, United States|Alzohaili Medical Consultants, Dearborn, Michigan, United States|Premier Research, Trenton, New Jersey, United States|Manhattan Medical Research, New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Holesov, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krnov, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pardubice, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prague, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coatzacoalcos, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szczecin, Poland|Manati Center for Clinical Research Inc, Manati, Puerto Rico|Consultorio Medico, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02091362"
842,"NCT01764633","Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk","FOURIER","Completed","Has Results","Dyslipidemia","Biological: Evolocumab|Drug: Placebo","Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization|Time to Cardiovascular Death, Myocardial Infarction, or Stroke|Time to Cardiovascular Death|Time to All Cause Death|Time to First Myocardial Infarction|Time to First Stroke|Time to First Coronary Revascularization|Time to Cardiovascular Death or First Hospitalization for Worsening Heart Failure|Time to First Ischemic Fatal or Non-Fatal Stroke or Transient Ischemic Attack","Amgen","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 3","27564","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110118|2014/01/004324|2012-001398-97","February 8, 2013","November 11, 2016","November 11, 2016","January 9, 2013","February 15, 2018","August 21, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Anchorage, Alaska, United States|Research Site, Glendale, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Alhambra, California, United States|Research Site, Banning, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Encino, California, United States|Research Site, Escondido, California, United States|Research Site, Glendale, California, United States|Research Site, Harbor City, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, Oceanside, California, United States|Research Site, Oxnard, California, United States|Research Site, Palm Springs, California, United States|Research Site, Roseville, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Pedro, California, United States|Research Site, Santa Ana, California, United States|Research Site, Tarzana, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Torrance, California, United States|Research Site, Torrance, California, United States|Research Site, Valley Village, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Greeley, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Longmont, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Seaford, Delaware, United States|Research Site, Wilmington, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Atlantis, Florida, United States|Research Site, Aventura, Florida, United States|Research Site, Bay Pines, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Bradenton, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Deerfield Beach, Florida, United States|Research Site, Delray Beach, Florida, United States|Research Site, Edgewater, Florida, United States|Research Site, Fleming Island, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Safety Harbor, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Sanford, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Wellington, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Dunwoody, Georgia, United States|Research Site, East Point, Georgia, United States|Research Site, Eatonton, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Suwanee, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Boise, Idaho, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Meridian, Idaho, United States|Research Site, Nampa, Idaho, United States|Research Site, Addison, Illinois, United States|Research Site, Belleville, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Jerseyville, Illinois, United States|Research Site, Quincy, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Ames, Iowa, United States|Research Site, Des Moines, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Waterloo, Iowa, United States|Research Site, Hutchinson, Kansas, United States|Research Site, Kansas City, Kansas, United States|Research Site, Overland Park, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Covington, Louisiana, United States|Research Site, Hammond, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Natchitoches, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Annapolis, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Charlotte Hall, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Hollywood, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Ayer, Massachusetts, United States|Research Site, Billerica, Massachusetts, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Hyannis, Massachusetts, United States|Research Site, Newton, Massachusetts, United States|Research Site, Quincy, Massachusetts, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Watertown, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Dearborn, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Grandville, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Muskegon, Michigan, United States|Research Site, Novi, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Traverse City, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Olive Branch, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Columbia, Missouri, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Billings, Montana, United States|Research Site, Great Falls, Montana, United States|Research Site, Kalispell, Montana, United States|Research Site, Missoula, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Elizabeth, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Westwood, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, Kingston, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Troy, New York, United States|Research Site, West Seneca, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Asheville, North Carolina, United States|Research Site, Calabash, North Carolina, United States|Research Site, Cary, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Lenoir, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Grand Forks, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Garfield Heights, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Westlake, Ohio, United States|Research Site, Willoughby, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Pryor, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Chambersburg, Pennsylvania, United States|Research Site, Feasterville, Pennsylvania, United States|Research Site, Indiana, Pennsylvania, United States|Research Site, Jersey Shore, Pennsylvania, United States|Research Site, Norristown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Sellersville, Pennsylvania, United States|Research Site, Uniontown, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Cranston, Rhode Island, United States|Research Site, Cumberland, Rhode Island, United States|Research Site, Johnston, Rhode Island, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Fountain Inn, South Carolina, United States|Research Site, Indian Land, South Carolina, United States|Research Site, Moncks Corner, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, North Myrtle Beach, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Germantown, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Grapevine, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Kerrville, Texas, United States|Research Site, Longview, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Layton, Utah, United States|Research Site, Murray, Utah, United States|Research Site, West Jordan, Utah, United States|Research Site, White River Junction, Vermont, United States|Research Site, Burke, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Hopewell, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Suffolk, Virginia, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Federal Way, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Selah, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Marshfield, Wisconsin, United States|Research Site, Bahia Blanca, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, La Plata, Buenos Aires, Argentina|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Salta, Argentina|Research Site, Salta, Argentina|Research Site, Woden, Australian Capital Territory, Australia|Research Site, Camperdown, New South Wales, Australia|Research Site, Concord, New South Wales, Australia|Research Site, Kogarah, New South Wales, Australia|Research Site, Liverpool, New South Wales, Australia|Research Site, Woolloongabba, New South Wales, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Herston, Queensland, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Hobart, Tasmania, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Epping, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Antwerpen, Belgium|Research Site, Blankenberge, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Gozee, Belgium|Research Site, Ieper, Belgium|Research Site, La Louviere, Belgium|Research Site, La Louvière, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, Lodelinsart, Belgium|Research Site, Natoye, Belgium|Research Site, Turnhout, Belgium|Research Site, Fortaleza, Ceará, Brazil|Research Site, Brasília, Distrito Federal, Brazil|Research Site, Vitória, Espírito Santo, Brazil|Research Site, Goiania, Goiás, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Campina Grande do Sul, Paraná, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Canoas, Rio Grande Do Sul, Brazil|Research Site, Passo Fundo, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Campinas, São Paulo, Brazil|Research Site, Campinas, São Paulo, Brazil|Research Site, Sao Jose do Rio Preto, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Rio De Janeiro, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Haskovo, Bulgaria|Research Site, Kazanlak, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Strathroy, Ontario, Canada|Research Site, Thunder Bay, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Granby, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Québec, Quebec, Canada|Research Site, St Jean sur Richelieu, Quebec, Canada|Research Site, St-Charles-Borromee, Quebec, Canada|Research Site, St-Jérôme, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Westmout, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Temuco, Cautín, Chile|Research Site, Osorno, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Beijing, Beijing, China|Research Site, Beijing, Beijing, China|Research Site, Guangzhou, Guangdong, China|Research Site, Harbin, Heilongjiang, China|Research Site, Zhengzhou, Henan, China|Research Site, Wuhan, Hubei, China|Research Site, Wuhan, Hubei, China|Research Site, Changde, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Xiangtan, Hunan, China|Research Site, Zhuzhou, Hunan, China|Research Site, Baotou, Inner Mongolia, China|Research Site, Hohhot, Inner Mongolia, China|Research Site, Suzhou, Jiangsu, China|Research Site, Wuxi, Jiangsu, China|Research Site, Xuzhou, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, Changchun, Jilin, China|Research Site, Changchun, Jilin, China|Research Site, Siping, Jilin, China|Research Site, Dalian, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, Yinchuan, Ningxia, China|Research Site, Qingdao, Shandong, China|Research Site, Taiyuan, Shanxi, China|Research Site, Tianjin, Tianjin, China|Research Site, Tianjin, Tianjin, China|Research Site, Urumqi, Xinjiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Linhai, Zhejiang, China|Research Site, Ningbo, Zhejiang, China|Research Site, Wenzhou, Zhejiang, China|Research Site, Beijing, China|Research Site, Tianjin, China|Research Site, Medellin, Antioquia, Colombia|Research Site, Medellin, Antioquia, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Cartagena, Bolívar, Colombia|Research Site, Manizales, Caldas, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Armenia, Quindío, Colombia|Research Site, Floridablanca, Santander, Colombia|Research Site, Santiago de Cali, Valle Del Cauca, Colombia|Research Site, Benatky nad Jizerou, Czechia|Research Site, Benesov, Czechia|Research Site, Beroun, Czechia|Research Site, Bilovec, Czechia|Research Site, Brandys nad Labem, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Ceske Budejovice, Czechia|Research Site, Cesky Krumlov, Czechia|Research Site, Chomutov, Czechia|Research Site, Havlickuv Brod, Czechia|Research Site, Hodonin, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Hranice na Morave, Czechia|Research Site, Jihlava, Czechia|Research Site, Kladno, Czechia|Research Site, Klatovy IV, Czechia|Research Site, Kutna Hora, Czechia|Research Site, Liberec, Czechia|Research Site, Litomerice, Czechia|Research Site, Litomysl, Czechia|Research Site, Milevsko, Czechia|Research Site, Mlada Boleslav, Czechia|Research Site, Mohelnice, Czechia|Research Site, Moravske Budejovice, Czechia|Research Site, Nymburk, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava - Zabreh, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Ostrava, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen, Czechia|Research Site, Policka, Czechia|Research Site, Prachatice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 3, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5 - Smichov, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 5, Czechia|Research Site, Prerov, Czechia|Research Site, Pribram VIII, Czechia|Research Site, Svitavy, Czechia|Research Site, Teplice, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Znojmo, Czechia|Research Site, Aalborg, Denmark|Research Site, Aarhus N, Denmark|Research Site, Ballerup, Denmark|Research Site, Esbjerg, Denmark|Research Site, Glostrup, Denmark|Research Site, Hvidovre, Denmark|Research Site, København S, Denmark|Research Site, København, Denmark|Research Site, Køge, Denmark|Research Site, Odense, Denmark|Research Site, Roskilde, Denmark|Research Site, Svendborg, Denmark|Research Site, Vejle, Denmark|Research Site, Viborg, Denmark|Research Site, Harjumaa, Estonia|Research Site, Paide, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Helsinki, Finland|Research Site, Helsinki, Finland|Research Site, Hämeenlinna, Finland|Research Site, Jyväskylä, Finland|Research Site, Kokkola, Finland|Research Site, Kuopio, Finland|Research Site, Oulo, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Besançon Cedex, France|Research Site, Brest Cedex 2, France|Research Site, Chambray les Tours, France|Research Site, Clermont Ferrand, France|Research Site, Créteil, France|Research Site, Dijon cedex, France|Research Site, Le Coudray, France|Research Site, Lille Cedex, France|Research Site, Lyon, France|Research Site, Marseille Cedex 08, France|Research Site, Metz cedex 03, France|Research Site, Montpellier cedex 05, France|Research Site, Montpellier cedex 5, France|Research Site, Nantes Cedex 1, France|Research Site, Nantes Cedex 2, France|Research Site, Nice, France|Research Site, Nimes, France|Research Site, Orleans, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pau, France|Research Site, Perpignan Cedex, France|Research Site, Pessac Cedex, France|Research Site, Poitiers, France|Research Site, Reims cedex, France|Research Site, Rennes, France|Research Site, Saint Priest en Jarez, France|Research Site, Strasbourg, France|Research Site, Toulouse Cedex 9, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Vesoul, France|Research Site, Bad Krozingen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Demmin, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Düsseldorf, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Giessen, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Ingelheim, Germany|Research Site, Kassel, Germany|Research Site, Köln, Germany|Research Site, Lahr, Germany|Research Site, Leipzig, Germany|Research Site, Limburg, Germany|Research Site, Magdeburg, Germany|Research Site, Mainz, Germany|Research Site, Mannheim, Germany|Research Site, Marburg, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Regensburg, Germany|Research Site, Stuttgart, Germany|Research Site, Ulm, Germany|Research Site, Witten, Germany|Research Site, Wuppertal, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Chalkida, Greece|Research Site, Heraklion, Greece|Research Site, Ioannina, Greece|Research Site, Larissa, Greece|Research Site, Nikaia, Piraeus, Greece|Research Site, Piraeus, Greece|Research Site, Rhodes, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Balatonfured, Hungary|Research Site, Bekescsaba, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Cegled, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyongyos, Hungary|Research Site, Gyula, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kecskemet, Hungary|Research Site, Komarom, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Szekszard, Hungary|Research Site, Szolnok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Kopavogur, Iceland|Research Site, Reykjavik, Iceland|Research Site, Vijayawada, Andhra Pradesh, India|Research Site, New Delhi, Delhi, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Vadodara, Gujarat, India|Research Site, Gurgaon, Haryana, India|Research Site, Belgaum, Karnataka, India|Research Site, Mysore, Karnataka, India|Research Site, Mumbai, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Lucknow, Uttar Pradesh, India|Research Site, Kolkata, West Bengal, India|Research Site, Ballinasloe, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Galway, Ireland|Research Site, Hadera, Israel|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Herzliya-on-sea, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Nahariya, Israel|Research Site, Netanya, Israel|Research Site, Rehovot, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel Hashomer, Israel|Research Site, Ascoli Piceno, Italy|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Chieti, Italy|Research Site, Colleferro RM, Italy|Research Site, Cortona AR, Italy|Research Site, Firenze, Italy|Research Site, L' Aquila, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Palermo, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Sanremo (IM), Italy|Research Site, Siena, Italy|Research Site, Ichinomiya-shi, Aichi, Japan|Research Site, Kasugai-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Toyohashi-shi, Aichi, Japan|Research Site, Chiba-shi, Chiba, Japan|Research Site, Matsudo-shi, Chiba, Japan|Research Site, Niihama-shi, Ehime, Japan|Research Site, Saijo-shi, Ehime, Japan|Research Site, Chikushi-gun, Fukuoka, Japan|Research Site, Chikushino-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Itoshima-shi, Fukuoka, Japan|Research Site, Koga-shi, Fukuoka, Japan|Research Site, Kurume-shi, Fukuoka, Japan|Research Site, Kurume-shi, Fukuoka, Japan|Research Site, Okawa-shi, Fukuoka, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Kure-shi, Hiroshima, Japan|Research Site, Otake-shi, Hiroshima, Japan|Research Site, Asahikawa-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Himeji-shi, Hyogo, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Toride-shi, Ibaraki, Japan|Research Site, Tsukuba-city, Ibaraki, Japan|Research Site, Kanazawa-shi, Ishikawa, Japan|Research Site, Sanuki-shi, Kagawa, Japan|Research Site, Fujisawa-shi, Kanagawa, Japan|Research Site, Odawara-shi, Kanagawa, Japan|Research Site, Sagamihara-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Higashisonogi-gun, Nagasaki, Japan|Research Site, Nagasaki-shi, Nagasaki, Japan|Research Site, Omura-shi, Nagasaki, Japan|Research Site, Oita-shi, Oita, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Okinawa-shi, Okinawa, Japan|Research Site, Shimajiri-gun, Okinawa, Japan|Research Site, Urasoe-shi, Okinawa, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Kawaguchi-shi, Saitama, Japan|Research Site, Kusatsu-shi, Shiga, Japan|Research Site, Hamada-shi, Shimane, Japan|Research Site, Sunto-gun, Shizuoka, Japan|Research Site, Komatsushima-shi, Tokushima, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Musashimurayama-shi, Tokyo, Japan|Research Site, Tachikawa-shi, Tokyo, Japan|Research Site, Chuo-shi, Yamanashi, Japan|Research Site, Busan, Seo-gu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Daugavpils, Latvia|Research Site, Daugavpils, Latvia|Research Site, Kuldiga, Latvia|Research Site, Liepaja, Latvia|Research Site, Ogre, Latvia|Research Site, Ogre, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Johor Bahru, Johor, Malaysia|Research Site, Taiping, Perak, Malaysia|Research Site, Kota Kinabalu, Sabah, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Georgetown, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Melaka, Malaysia|Research Site, Penang, Malaysia|Research Site, Torreon, Coahuila, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Leon, Guanajuato, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Queretaro, Querétaro, Mexico|Research Site, San Luis Potosi, San Luis Potosí, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Tampico, Tamaulipas, Mexico|Research Site, Xalapa, Veracruz, Mexico|Research Site, Aguascalientes, Mexico|Research Site, Chihuahua, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Almelo, Netherlands|Research Site, Amstelveen, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Beverwijk, Netherlands|Research Site, Den Helder, Netherlands|Research Site, Deventer, Netherlands|Research Site, Doetinchem, Netherlands|Research Site, Ede, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Goes, Netherlands|Research Site, Gorinchem, Netherlands|Research Site, Gouda, Netherlands|Research Site, Harderwijk, Netherlands|Research Site, Helmond, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Leiden, Netherlands|Research Site, Leiden, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Purmerend, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Sneek, Netherlands|Research Site, Tiel, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Uden, Netherlands|Research Site, Veldhoven, Netherlands|Research Site, Venlo, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Papatoetoe, Auckland, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Bekkestua, Norway|Research Site, Bodø, Norway|Research Site, Hamar, Norway|Research Site, Lierskogen, Norway|Research Site, Oslo, Norway|Research Site, Skedsmokorset, Norway|Research Site, Skien, Norway|Research Site, Stavanger, Norway|Research Site, Ålesund, Norway|Research Site, Davao City, Davao, Philippines|Research Site, Angeles, Philippines|Research Site, Baguio City, Philippines|Research Site, Dasmariñas Cavite, Philippines|Research Site, Iloilo, Philippines|Research Site, Makati City, Philippines|Research Site, Manila, Philippines|Research Site, Marikiina, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Bielsko-Biala, Poland|Research Site, Bydgoszcz, Poland|Research Site, Gdansk, Poland|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Gizycko, Poland|Research Site, Jelenia Gora, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Nowa Sol, Poland|Research Site, Nysa, Poland|Research Site, Olsztyn, Poland|Research Site, Plock, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Pszczyna, Poland|Research Site, Pulawy, Poland|Research Site, Ruda Slaska, Poland|Research Site, Skierniewice, Poland|Research Site, Starogard Gdanski, Poland|Research Site, Staszow, Poland|Research Site, Swidnik, Poland|Research Site, Tarnow, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wloclawek, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Zamosc, Poland|Research Site, Almada, Portugal|Research Site, Amadora, Portugal|Research Site, Carnaxide, Portugal|Research Site, Coimbra, Portugal|Research Site, Covilha, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Setubal, Portugal|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Oradea, Romania|Research Site, Timisoara, Romania|Research Site, Timisoara, Romania|Research Site, Timisoara, Romania|Research Site, Barnaul, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kirov, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Pushkin, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tyumen, Russian Federation|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Banovce nad Bebravou, Slovakia|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Brezno, Slovakia|Research Site, Dolny Kubin, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Martin, Slovakia|Research Site, Moldava nad Bodvou, Slovakia|Research Site, Nitra, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Presov, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Roznava, Slovakia|Research Site, Snina, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trencin, Slovakia|Research Site, Trnava, Slovakia|Research Site, Port Elizabeth, Eastern Cape, South Africa|Research Site, Bloemfontein, Free State, South Africa|Research Site, Alberton, Gauteng, South Africa|Research Site, Alberton, Gauteng, South Africa|Research Site, Boksburg, Gauteng, South Africa|Research Site, Centurion, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Midrand, Gauteng, South Africa|Research Site, Pretoria west, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Soweto, Gauteng, South Africa|Research Site, Sunninghill, Gauteng, South Africa|Research Site, Amanzimtoti, KwaZulu-Natal, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Tongaat, KwaZulu-Natal, South Africa|Research Site, Kuils River, Western Cape, South Africa|Research Site, Paarl, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Worcester, Western Cape, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Kempton Park, South Africa|Research Site, Almeria, Andalucía, Spain|Research Site, Cordoba, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, L'Hospitalet de Llobregat, Cataluña, Spain|Research Site, San Juan de Alicante, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Vigo, Galicia, Spain|Research Site, El Palmar, Murcia, Spain|Research Site, Galdakao, País Vasco, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Bollnäs, Sweden|Research Site, Eksjö, Sweden|Research Site, Eskilstuna, Sweden|Research Site, Falun, Sweden|Research Site, Helsingborg, Sweden|Research Site, Jönköping, Sweden|Research Site, Linköping, Sweden|Research Site, Luleå, Sweden|Research Site, Lund, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uddevalla, Sweden|Research Site, Umeå, Sweden|Research Site, Västerås, Sweden|Research Site, Örebro, Sweden|Research Site, Östersund, Sweden|Research Site, Baden, Switzerland|Research Site, Basel, Switzerland|Research Site, Bern, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lugano, Switzerland|Research Site, Sion, Switzerland|Research Site, Winterthur, Switzerland|Research Site, Zurich, Switzerland|Research Site, New Taipei City, Taipei, Taiwan|Research Site, Changhua, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung City, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Kocaeli, Turkey|Research Site, Konya, Turkey|Research Site, Sivas, Turkey|Research Site, Cherkasy, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lugansk, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Aberdeen, United Kingdom|Research Site, Addlestone, United Kingdom|Research Site, Arnsley, United Kingdom|Research Site, Basildon, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Bury St Edmunds, United Kingdom|Research Site, Canterbury, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Chippenham, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, Colchester, United Kingdom|Research Site, Cottingham, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harrow, United Kingdom|Research Site, Haxey, Doncaster, United Kingdom|Research Site, Hayle, United Kingdom|Research Site, Hexham, United Kingdom|Research Site, Hitchin, United Kingdom|Research Site, Inverness, United Kingdom|Research Site, Leamington Spa, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Luton, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Middlesbrough, United Kingdom|Research Site, Newport, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Nuneaton, United Kingdom|Research Site, Penzance, United Kingdom|Research Site, Penzance, United Kingdom|Research Site, Penzance, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Portsmouth, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Rotherham, United Kingdom|Research Site, Rugby, United Kingdom|Research Site, Sandbach, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, St Austell, United Kingdom|Research Site, St. Leonards-on-Sea, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Stoke-on-Trent, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Telford, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, Welwyn Garden City, United Kingdom|Research Site, West Bromwich, United Kingdom|Research Site, Whitby, United Kingdom|Research Site, Wiltshire, United Kingdom|Research Site, Wirral, United Kingdom|Research Site, Wolverhampton, United Kingdom|Research Site, Worcester, United Kingdom|Research Site, Wrexham, United Kingdom|Research Site, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01764633"
843,"NCT01047501","Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","ANCHOR","Completed","No Results Available","Hypertriglyceridemia","Drug: AMR101 (ethyl icosapentate)|Drug: Placebo","Difference between AMR101 (ethyl icosapentate) and placebo treatment groups in triglyceride lowering effect|Difference between AMR101 (ethyl icosapentate) and placebo treatment groups in other lipid and biomarker levels","Amarin Pharma Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","702","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AMR-01-01-0017|The ANCHOR Study","December 2009","February 2011",,"January 13, 2010",,"November 27, 2013","Amarin Investigational Site, Muscle Shoals, Alabama, United States|Amarin Investigational Site, Scottsboro, Alabama, United States|Amarin Investigational Site, Phoenix, Arizona, United States|Amarin Investigational Site, Tucson, Arizona, United States|Amarin Investigational Site, Anaheim, California, United States|Amarin Investigational Site, Burbank, California, United States|Amarin Investigational Site, Chino, California, United States|Amarin Investigational Site, Encinitas, California, United States|Amarin Investigational Site, Irvine, California, United States|Amarin Investigational Site, Los Angeles, California, United States|Amarin Investigational Site, Los Angeles, California, United States|Amarin Investigational Site, Spring Valley, California, United States|Amarin Investigational Site, Westlake Village, California, United States|Amarin Investigational Site, Golden, Colorado, United States|Amarin Investigational Site, Wheat Ridge, Colorado, United States|Amarin Investigational Site, Aventura, Florida, United States|Amarin Investigational Site, Clearwater, Florida, United States|Amarin Investigational Site, Coral Gables, Florida, United States|Amarin Investigational Site, Hialeah, Florida, United States|Amarin Investigational Site, Jacksonville, Florida, United States|Amarin Investigational Site, Jacksonville, Florida, United States|Amarin Investigational Site, Miami, Florida, United States|Amarin Investigational Site, New Port Richey, Florida, United States|Amarin Investigational Site, New Port Richey, Florida, United States|Amarin Investigational Site, Orlando, Florida, United States|Amarin Investigational Site, Port Orange, Florida, United States|Amarin Investigational Site, West Palm Beach, Florida, United States|Amarin Investigational Site, Augusta, Georgia, United States|Amarin Investigational Site, Augusta, Georgia, United States|Amarin Investigational Site, Addison, Illinois, United States|Amarin Investigational Site, Morton, Illinois, United States|Amarin Investigational Site, Indianapolis, Indiana, United States|Amarin Investigational Site, Kansas City, Kansas, United States|Amarin Investigational Site, Newton, Kansas, United States|Amarin Investigational Site, Wichita, Kansas, United States|Amarin Investigational Site, Louisville, Kentucky, United States|Amarin Investigational Site, Munfordville, Kentucky, United States|Amarin Investigational Site, Auburn, Maine, United States|Amarin Investigational Site, Baltimore, Maryland, United States|Amarin Investigational Site, Elkridge, Maryland, United States|Amarin Investigational Site, Troy, Michigan, United States|Amarin Investigational Site, Olive Branch, Mississippi, United States|Amarin Investigational Site, St. Louis, Missouri, United States|Amarin Investigational Site, Butte, Montana, United States|Amarin Investigational Site, Concord, New Hampshire, United States|Amarin Investigational Site, Endwell, New York, United States|Amarin Investigational Site, New Windsor, New York, United States|Amarin Investigational Site, Syracuse, New York, United States|Amarin Investigational Site, Charlotte, North Carolina, United States|Amarin Investigational Site, Durham, North Carolina, United States|Amarin Investigational Site, Hickory, North Carolina, United States|Amarin Investigational Site, Raleigh, North Carolina, United States|Amarin Investigational Site, Statesville, North Carolina, United States|Amarin Investigational Site, Wilmington, North Carolina, United States|Amarin Investigational Site, Winston-Salem, North Carolina, United States|Amarin Investigational Site, Cincinnati, Ohio, United States|Amarin Investigational Site, Cincinnati, Ohio, United States|Amarin Investigational Site, Cleveland, Ohio, United States|Amarin Investigational Site, Kettering, Ohio, United States|Amarin Investigational Site, Norman, Oklahoma, United States|Amarin Investigational Site, Tulsa, Oklahoma, United States|Amarin Investigational Site, Beaver, Pennsylvania, United States|Amarin Investigational Site, Harleysville, Pennsylvania, United States|Amarin Investigational Site, Jersey Shore, Pennsylvania, United States|Amarin Investigational Site, Lansdale, Pennsylvania, United States|Amarin Investigational Site, Philadelphia, Pennsylvania, United States|Amarin Investigational Site, Mt. Pleasant, South Carolina, United States|Amarin Investigational Site, Rapid City, South Dakota, United States|Amarin Investigational Site, Dallas, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Lake Jackson, Texas, United States|Amarin Investigational Site, San Antonio, Texas, United States|Amarin Investigational Site, San Antonio, Texas, United States|Amarin Investigational Site, Temple, Texas, United States|Amarin Investigational Site, Ettrick, Virginia, United States|Amarin Investigational Site, Norfolk, Virginia, United States|Amarin Investigational Site, Richmond, Virginia, United States|Amarin Investigational Site, Richmond, Virginia, United States|Amarin Investigational Site, Wauwatosa, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01047501"
844,"NCT04070573","Low Doses of Aspirin in the Prevention of Preeclampsia","ASAPP","Recruiting","No Results Available","Preeclampsia","Drug: acetylsalicylic acid","Incidence of preterm (<37 weeks) preeclampsia|Incidence of preeclampsia with severe features|Aspirin adherence|Maternal and Fetal Outcomes|Time-to-event for preeclampsia|Aspirin compliance","Weill Medical College of Cornell University","Female","18 Years to 60 Years   (Adult)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","19-05020160","October 21, 2019","August 2024","August 2024","August 28, 2019",,"November 20, 2019","New York Presbyterian - Weill Cornell, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04070573"
845,"NCT03735433","The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia",,"Recruiting","No Results Available","Preeclampsia","Drug: 162mg aspirin dose","Incidence of Diagnosis of preeclampsia|Incidence of aspirin resistance based on incomplete inhibition of TBx2","Ohio State University","Female","18 Years to 45 Years   (Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OBASA","January 15, 2019","January 2021","January 2021","November 8, 2018",,"February 25, 2020","The Ohio State Medical Center Labor and Delivery Unit, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03735433"
846,"NCT00914017","Statins and Breast Cancer Biomarkers",,"Unknown status","No Results Available","Breast Cancer","Drug: Atorvastatin|Drug: Placebo","To evaluate change in percent mammographic density after one year of statin administration in pre-menopausal women at high risk for breast cancer.|To evaluate changes in IGF1 levels after 12 months of statin administration in pre-menopausal women at high-risk for breast cancer.|To correlate changes in breast density with changes in molecular markers.|To explore changes in breast duct cell cytology in a subset of patients after 12 months of statin administration in a subset of the trial population.","University of Vermont|Breast Cancer Research Foundation|Cancer and Leukemia Group B","Female","35 Years to 55 Years   (Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","V0407|CHRMS#: 05-059","January 2005","December 2010",,"June 4, 2009",,"February 11, 2010","University of California, San Francisco, San Francisco, California, United States|Delaware Christiana Care CCOP, Helen F. Graham Cancer Center, Newark, Delaware, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Duke University, Durham, North Carolina, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Vermont Cancer Center, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT00914017"
847,"NCT01412034","Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects","MODE","Completed","No Results Available","Homozygous Familial Hypercholesterolemia","Drug: CER-001","Percent change from baseline to follow-up in carotid mean vessel wall area|Change in carotid vessel wall volume","Cerenis Therapeutics, SA","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","23","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CER-001-CLIN-003","November 2011","October 2013","August 2014","August 8, 2011",,"August 18, 2015","Clinical Research Facility, Hartford, Connecticut, United States|Clinical Research Facility, N. Massapequa, New York, United States|Clinical Research Facility, Chicoutimi, Quebec, Canada|Clinical Research Facility, Quebec, Canada|Clinical Research Facility, Rome, Italy|Clinical Research Facility, Amsterdam, Netherlands|Clinical Research Facility, Maastricht, Netherlands|Clinical Research Facility, Nijmegen, Netherlands|Clinical Research Facility, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01412034"
848,"NCT03933631","Pilocarpine Use After Kahook Goniotomy","PAACK","Enrolling by invitation","No Results Available","Glaucoma","Drug: Pilocarpine|Drug: Prednisolone|Drug: Ofloxacin","Percentage of patients with lowering of intraocular pressure (IOP)|Proportion of patients whose regimen was reduced by 1 medication or more|Rate of progression towards further glaucoma surgeries","Montefiore Medical Center","All","30 Years to 100 Years   (Adult, Older Adult)","Phase 3","142","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-9829","May 1, 2019","December 2022","December 2022","May 1, 2019",,"November 25, 2019","Montefiore Wakefield Campus, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT03933631"
849,"NCT03273257","Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)",,"Recruiting","No Results Available","Chronic Thromboembolic Pulmonary Hypertension|CTEPH","Drug: Riociguat|Drug: Placebo|Procedure: Pulmonary endarterectomy","Change from baseline in pulmonary vascular resistance (PVR) to immediately before pulmonary endarterectomy (pre-PEA)|Change from baseline in pulmonary vascular resistance (PVR) to 6 months post pulmonary endarterectomy (PEA)|Number of patients with either all-cause death, PH-related hospitalisation, need for PAH-targeted therapy or WHO functional class unchanged or worse between randomisation and 6 months post pulmonary endarterectomy (composite endpoint)|Intraoperative circulatory arrest time|Frequency of intraoperative surgery-related complications (composite endpoint)|Surgical evaluation of specimen: ease of dissection plane|Surgical evaluation of specimen: completeness of disease clearance|Surgical evaluation of specimen: appearance of clot and vessel wall|Frequency of all-cause death|Frequency of withdrawal during randomised treatment phase","International CTEPH Association","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PEA Bridging Study","August 17, 2018","July 2020","July 2020","September 6, 2017",,"January 27, 2020","UC San Diego, La Jolla, California, United States|Hopital de Bicêtre, Paris, France|Kerckhoff-Klinik GmbH, Bad Nauheim, Germany|Papworth Hospital, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03273257"
850,"NCT03450629","Evaluation of Safety and Efficacy of Brimonidine Tartrate Ophthalmic Suspension",,"Recruiting","No Results Available","Open Angle Glaucoma|Ocular Hypertension","Drug: Brimonidine Tartrate Ophthalmic Suspension|Drug: Brimonidine Tartrate Ophthalmic Solution","Change from baseline in mean intraocular pressure","Sun Pharma Advanced Research Company Limited","All","2 Years and older   (Child, Adult, Older Adult)","Phase 3","666","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","CLR_16_33","September 13, 2018","April 2020","April 2020","March 1, 2018",,"February 10, 2020","SPARC Site 4, Chandler, Arizona, United States|SPARC Site 5, Prescott, Arizona, United States|SPARC Site 3, Sun City, Arizona, United States|SPARC Site 38, Burbank, California, United States|SPARC Site 44, Glendale, California, United States|SPARC Site 45, Glendale, California, United States|SPARC Site 43, Mission Hills, California, United States|SPARC Site 1, Newport Beach, California, United States|SPARC Site 14, Santa Barbara, California, United States|SPARC Site 47, Torrance, California, United States|SPARC Site 7, Colorado Springs, Colorado, United States|SPARC Site 11, Coral Springs, Florida, United States|SPARC Site 29, Deerfield Beach, Florida, United States|SPARC Site 34, Fort Myers, Florida, United States|SPARC Site 46, Hollywood, Florida, United States|SPARC Site 21, Jacksonville, Florida, United States|SPARC Site 35, Miami, Florida, United States|SPARC Site 27, Miami, Florida, United States|SPARC Site 10, Miami, Florida, United States|SPARC Site 16, Miami, Florida, United States|SPARC Site 19, Miami, Florida, United States|SPARC Site 25, Miami, Florida, United States|SPARC Site 41, Pompano Beach, Florida, United States|SPARC Site 18, Tampa, Florida, United States|SPARC Site 42, Atlanta, Georgia, United States|SPARC Site 2, Morrow, Georgia, United States|SPARC Site 22, Roswell, Georgia, United States|SPARC Site 12, Chicago, Illinois, United States|SPARC Site 23, Paducah, Kentucky, United States|SPARC Site 40, Bowie, Maryland, United States|SPARC Site 28, Kansas City, Missouri, United States|SPARC Site 48, Kansas City, Missouri, United States|SPARC Site 31, Saint Louis, Missouri, United States|SPARC Site 6, Henderson, Nevada, United States|SPARC Site 15, Poughkeepsie, New York, United States|SPARC Site 36, Rochester, New York, United States|SPARC Site 30, Gastonia, North Carolina, United States|SPARC Site 9, High Point, North Carolina, United States|SPARC Site 17, Winston-Salem, North Carolina, United States|SPARC Site 33, Fargo, North Dakota, United States|SPARC Site 37, Cincinnati, Ohio, United States|SPARC Site 8, Cleveland, Ohio, United States|SPARC Site 24, Cranberry Township, Pennsylvania, United States|SPARC Site 32, Memphis, Tennessee, United States|SPARC Site 39, Houston, Texas, United States|SPARC Site 13, Mission, Texas, United States|SPARC Site 20, San Antonio, Texas, United States|SPARC Site 26, Saint Albans, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT03450629"
851,"NCT01602367","Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients",,"Terminated","No Results Available","Hypertension","Drug: BMS-823778|Drug: Placebo matching with BMS-823778","The dose-dependent trend among doses of BMS-823778 and placebo by assessing the change from baseline in 24-hour ambulatory diastolic blood pressure following 12 weeks of double-blind treatment|Change in 24-hour ambulatory systolic blood pressure (SBP)(evaluation of the dose-dependent trend)|Change in 24-hour ambulatory diastolic blood pressure (DBP)|Change in 24-hour ambulatory SBP|Change in ambulatory daytime and nighttime DBP|Change in ambulatory daytime and nighttime SBP|Change in seated DBP|Change in seated SBP","Bristol-Myers Squibb","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MB121-008|2012‐000509‐54","July 2012","November 2012","November 2012","May 21, 2012",,"October 12, 2015","Nea Baptist Clinic, Jonesboro, Arkansas, United States|Local Institution, Los Angeles, California, United States|Desert Medical Group Inc., Palm Springs, California, United States|Local Institution, Coral Gables, Florida, United States|Local Institution, Atlanta, Georgia, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Local Institution, New Orleans, Louisiana, United States|Anderson And Collins Clinical Research, Inc., Edison, New Jersey, United States|Premier Research, Trenton, New Jersey, United States|Syracuse Preventive Cardiology, Syracuse, New York, United States|Metrolina Internal Medicine, Charlotte, North Carolina, United States|Pharmquest, Llc, Greensboro, North Carolina, United States|Pmg Research Of Salisbury, Salisbury, North Carolina, United States|Local Institution, Shelby, North Carolina, United States|Local Institution, Shelby, North Carolina, United States|Local Institution, Winston-salem, North Carolina, United States|Sterling Research Grp, Ltd., Cincinnati, Ohio, United States|Local Institution, Greenville, South Carolina, United States|Local Institution, Layton, Utah, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|National Clinical Research - Norfolk, Inc., Norfolk, Virginia, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States|Local Institution, Barranquilla, Colombia|Local Institution, Bucaramanga, Colombia|Local Institution, Cartagena, Colombia|Local Institution, Manizales, Colombia|Local Institution, Medellin, Colombia|Local Institution, Balatonfured, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Ponce, Puerto Rico|Local Institution, Odeshog, Sweden|Local Institution, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01602367"
852,"NCT01265888","Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.","PHiano","Completed","No Results Available","Pulmonary Arterial Hypertension|Idiopathic Pulmonary Fibrosis","Drug: Inhaled Nitric Oxide","Identify the minimally and maximum effective doses of inhaled nitric oxide generated by the GeNOsyl® System compared to placebo.|Assess the safety and tolerability of nitric oxide generated by the GeNOsyl® System in subjects with WHO Group 1 PAH and WHO Group 3 PH-IPF.|Evaluate the pharmacokinetics of total nitrates/nitrites and methemoglobin produced following inhalation of nitric oxide via the GeNOsyl® System.","Geno LLC","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","31","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Protocol # GeNO-P-2010-002|PHiano","March 2011","September 2016","September 2016","December 23, 2010",,"September 19, 2016","University of Alabama @ Birmingham, Birmingham, Alabama, United States|VA Greater LA Health Care System-UCLA, Los Angeles, California, United States|University of California- Davis Medical Center, Sacramento, California, United States|National Jewish Health, Denver, Colorado, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Washington University School of Medicine, St. Louis, Missouri, United States|University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States|Ohio State University, Martha Morehouse Medical Plaza, Columbus, Ohio, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01265888"
853,"NCT03624010","Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients",,"Active, not recruiting","No Results Available","Hypertension Pulmonary Secondary Heart Failure|Right Sided Heart Failure With Normal Ejection Fraction|Heart Failure With Normal Ejection Fraction","Drug: Levosimendan 2.5 mg/ml Injectable Solution","Clinical Safety measured by number of adverse events (AEs )|6-minute walk test (6MWT)|Patient global assessment|Physician's Assessment of Functional Class|Clinical Events: Death and hospitalizations","Tenax Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TNX-LVO-05","November 14, 2018","April 2022","April 2022","August 9, 2018",,"March 13, 2020","Stanford Healthcare, Stanford, California, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|North Shore University Hospital, Manhasset, New York, United States|New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, United States|Ichan School of Medicine at Mount Sinai, New York, New York, United States|Christ Hospital, Cincinnati, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|UW Health University Hospital, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03624010"
854,"NCT01644188","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Ezetimibe|Drug: Placebo (for ezetimibe)|Drug: Lipid Modifying Therapy (LMT)","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL--C at Week 24 - On--Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo-B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","720","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC11569|U1111-1121-4315|2011-004130-34","August 2012","May 2014","July 2015","July 18, 2012","November 6, 2015","August 4, 2016","Investigational Site Number 840980, Birmingham, Alabama, United States|Investigational Site Number 840918, Phoenix, Arizona, United States|Investigational Site Number 840925, Tucson, Arizona, United States|Investigational Site Number 840959, Anaheim, California, United States|Investigational Site Number 840301, Beverly Hills, California, United States|Investigational Site Number 840933, Chino, California, United States|Investigational Site Number 840991, Lincoln, California, United States|Investigational Site Number 840979, Los Angeles, California, United States|Investigational Site Number 840952, Palm Springs, California, United States|Investigational Site Number 840930, Thousand Oaks, California, United States|Investigational Site Number 840921, Vista, California, United States|Investigational Site Number 840962, Boynton Beach, Florida, United States|Investigational Site Number 840987, Bradenton, Florida, United States|Investigational Site Number 840302, Clearwater, Florida, United States|Investigational Site Number 840935, Jacksonville, Florida, United States|Investigational Site Number 840903, Miami, Florida, United States|Investigational Site Number 840920, Miami, Florida, United States|Investigational Site Number 840943, Ocala, Florida, United States|Investigational Site Number 840981, Oveido, Florida, United States|Investigational Site Number 840961, Port Orange, Florida, United States|Investigational Site Number 840303, Sarasota, Florida, United States|Investigational Site Number 840986, St. Petersburg, Florida, United States|Investigational Site Number 840988, St. Petersburg, Florida, United States|Investigational Site Number 840995, Meridian, Idaho, United States|Investigational Site Number 840902, Evansville, Indiana, United States|Investigational Site Number 840960, Topeka, Kansas, United States|Investigational Site Number 840940, Oxon Hill, Maryland, United States|Investigational Site Number 840966, Fall River, Massachusetts, United States|Investigational Site Number 840917, Kansas City, Missouri, United States|Investigational Site Number 840998, St. Louis, Missouri, United States|Investigational Site Number 840946, Butte, Montana, United States|Investigational Site Number 840914, Lincoln, Nebraska, United States|Investigational Site Number 840949, Albuquerque, New Mexico, United States|Investigational Site Number 840974, New Windsor, New York, United States|Investigational Site Number 840955, Greenville, North Carolina, United States|Investigational Site Number 840938, Lexington, North Carolina, United States|Investigational Site Number 840976, Smithfield, North Carolina, United States|Investigational Site Number 840985, Winston-Salem, North Carolina, United States|Investigational Site Number 840963, Cincinnati, Ohio, United States|Investigational Site Number 840970, Lyndhust, Ohio, United States|Investigational Site Number 840906, Marion, Ohio, United States|Investigational Site Number 840997, Marion, Ohio, United States|Investigational Site Number 840964, Perrysburg, Ohio, United States|Investigational Site Number 840913, Charleston, South Carolina, United States|Investigational Site Number 840912, Greer, South Carolina, United States|Investigational Site Number 840992, Summerville, South Carolina, United States|Investigational Site Number 840932, Bristol, Tennessee, United States|Investigational Site Number 840944, Nashville, Tennessee, United States|Investigational Site Number 840994, Fort Worth, Texas, United States|Investigational Site Number 840973, Houston, Texas, United States|Investigational Site Number 840939, Houston, Texas, United States|Investigational Site Number 840945, Sugar Land, Texas, United States|Investigational Site Number 840971, Tomball, Texas, United States|Investigational Site Number 840982, Orem, Utah, United States|Investigational Site Number 840931, Norfolk, Virginia, United States|Investigational Site Number 840984, Richmond, Virginia, United States|Investigational Site Number 840928, Renton, Washington, United States|Investigational Site Number 840990, Spokane, Washington, United States|Investigational Site Number 124902, Brampton, Canada|Investigational Site Number 124914, Mirabel, Canada|Investigational Site Number 124903, Montreal, Canada|Investigational Site Number 124918, Toronto, Canada|Investigational Site Number 208913, Esbjerg, Denmark|Investigational Site Number 208914, Glostrup, Denmark|Investigational Site Number 208905, Hellerup, Denmark|Investigational Site Number 208911, Herlev, Denmark|Investigational Site Number 208907, Hvidovre, Denmark|Investigational Site Number 208901, København S, Denmark|Investigational Site Number 208906, Køge, Denmark|Investigational Site Number 208908, Roskilde, Denmark|Investigational Site Number 208903, Silkeborg, Denmark|Investigational Site Number 250906, Dijon, France|Investigational Site Number 250907, Montpellier Cedex 5, France|Investigational Site Number 250903, Nantes, France|Investigational Site Number 250905, Nimes, France|Investigational Site Number 348908, Budapest, Hungary|Investigational Site Number 348901, Budapest, Hungary|Investigational Site Number 348903, Budapest, Hungary|Investigational Site Number 348905, Debrecen, Hungary|Investigational Site Number 348906, Szekesfehervar, Hungary|Investigational Site Number 376908, Holon, Israel|Investigational Site Number 376903, Kfar Saba, Israel|Investigational Site Number 376906, Ofakim, Israel|Investigational Site Number 376902, Petach Tikva, Israel|Investigational Site Number 376904, Rehovot, Israel|Investigational Site Number 376907, Safed, Israel|Investigational Site Number 376901, Tel Aviv, Israel|Investigational Site Number 410908, Anyang-Si, Korea, Republic of|Investigational Site Number 410920, Busan, Korea, Republic of|Investigational Site Number 410926, Daegu, Korea, Republic of|Investigational Site Number 410923, Gwangju, Korea, Republic of|Investigational Site Number 410909, Seoul, Korea, Republic of|Investigational Site Number 410922, Seoul, Korea, Republic of|Investigational Site Number 410921, Seoul, Korea, Republic of|Investigational Site Number 410905, Seoul, Korea, Republic of|Investigational Site Number 410901, Seoul, Korea, Republic of|Investigational Site Number 410914, Seoul, Korea, Republic of|Investigational Site Number 410924, Seoul, Korea, Republic of|Investigational Site Number 410915, Suwon, Korea, Republic of|Investigational Site Number 410913, Uijeongbu, Korea, Republic of|Investigational Site Number 410927, Wonju, Korea, Republic of|Investigational Site Number 643906, Barnaul, Russian Federation|Investigational Site Number 643903, Kemerovo, Russian Federation|Investigational Site Number 643927, Moscow, Russian Federation|Investigational Site Number 643928, Moscow, Russian Federation|Investigational Site Number 643931, Moscow, Russian Federation|Investigational Site Number 643924, Moscow, Russian Federation|Investigational Site Number 643932, Moscow, Russian Federation|Investigational Site Number 643908, Moscow, Russian Federation|Investigational Site Number 643904, Moscow, Russian Federation|Investigational Site Number 643911, Orenburg, Russian Federation|Investigational Site Number 643921, Ryazan, Russian Federation|Investigational Site Number 643925, Saint-Petersburg, Russian Federation|Investigational Site Number 643922, Saint-Petersburg, Russian Federation|Investigational Site Number 643929, Saratov, Russian Federation|Investigational Site Number 643914, St-Petersburg, Russian Federation|Investigational Site Number 710917, Alberton, South Africa|Investigational Site Number 710909, Bloemfontein, South Africa|Investigational Site Number 710914, Bloemfontein, South Africa|Investigational Site Number 710905, Cape Town, South Africa|Investigational Site Number 710904, Cape Town, South Africa|Investigational Site Number 710918, Middelburg, South Africa|Investigational Site Number 710913, Pretoria, South Africa|Investigational Site Number 710915, Somerset West, South Africa|Investigational Site Number 804905, Kiev, Ukraine|Investigational Site Number 804902, Uzhhorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT01644188"
855,"NCT01486433","The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects",,"Completed","No Results Available","Hypertriglyceridemia","Drug: Simvastatin|Drug: acetylsalicylic acid (ASA)|Drug: omefas","Area under the plasma concentration versus time curve (AUC0-tau)|Concentration at the end of a dosing interval (Cmax,ss) for simvastatin and beta- hydroxysimvastatin acid,","AstraZeneca","All","18 Years to 55 Years   (Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OM-EPA-007","November 2011","March 2012","March 2012","December 6, 2011",,"April 30, 2015","Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01486433"
856,"NCT00981435","Steroids After Laser Trabeculoplasty for Glaucoma","SALT","Completed","Has Results","Glaucoma","Drug: Prednisolone 1%|Drug: Ketorolac|Drug: Artificial Tears","Intraocular Pressure (IOP) Change|Intraocular Inflammation","Stanford University|Bascom Palmer Eye Institute|University of Pittsburgh Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","97","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20081142","September 2009","September 2015","September 2015","September 22, 2009","April 14, 2017","August 7, 2019","Bascom Palmer Eye Institute, Miami, Florida, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00981435"
857,"NCT00847899","Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance",,"Completed","No Results Available","Hypertension|Impaired Glucose Tolerance","Drug: AR9281|Drug: Placebo","Systolic and Diastolic blood pressure|Glucose dynamics and insulin sensitivity","Arete Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AR9281-CLN-003","January 2009","October 2009","November 2009","February 19, 2009",,"November 20, 2009","Arete Investigational site, Mobile, Alabama, United States|Arete Investigational site, Muscle Shoals, Alabama, United States|Arete Investigational site, Anaheim, California, United States|Arete Investigational site, Concord, California, United States|Arete Investigational site, Mission Hills, California, United States|Arete Investigational site, Bradenton, Florida, United States|Arete Investigational site, Deland, Florida, United States|Arete Investigational site, Jacksonville, Florida, United States|Arete Investigational site, Largo, Florida, United States|Arete Investigational site, Miami, Florida, United States|Arete Investigational site, New Port Richey, Florida, United States|Arete Investigational site, Pembroke Pines, Florida, United States|Arete Investigational site, Port Orange, Florida, United States|Arete Investigational site, Tampa, Florida, United States|Arete Investigational site, Marietta, Georgia, United States|Arete Investigational site, Addison, Illinois, United States|Arete Investigational site, Louisville, Kentucky, United States|Arete Investigational site, Brockton, Massachusetts, United States|Arete Investigational site, Paw Paw, Michigan, United States|Arete Investigational site, Las Vegas, Nevada, United States|Arete Investigational site, Cincinnati, Ohio, United States|Arete Investigational site, Cincinnati, Ohio, United States|Arete Investigational site, Marion, Ohio, United States|Arete investigational site, Mt. Gilead, Ohio, United States|Arete Investigational site, Oklahoma City, Oklahoma, United States|Arete Investigational site, Eugene, Oregon, United States|Arete Investigational site, Austin, Texas, United States|Arete Investigational site, Dallas, Texas, United States|Arete Investigational site, San Antonio, Texas, United States|Arete Investigational site, Orem, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00847899"
858,"NCT02652429","Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH",,"Active, not recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Inhaled Nitric Oxide","Incidence of Serious Adverse Events|Incidence of INOpulse device malfunction and/or device failure leading to an AE","Bellerophon Pulse Technologies|Bellerophon","All","Child, Adult, Older Adult","Phase 3","22","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PULSE-PAH-006","March 2016","December 2020","December 2020","January 11, 2016",,"January 18, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|West Los Angeles VA Healthcare Center, Los Angeles, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Cleveland Clinic Florida, Weston, Florida, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Mount Sinai Beth Israel, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|UC Health University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Wexner Medical Center, Columbus, Ohio, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Intermountain Medical Center, Murray, Utah, United States|Peter Lougheed Centre, Calgary, Alberta, Canada|University of Alberta Hospitals - MAHI, Edmonton, Alberta, Canada|Lawson Clinical Research Services, London, Ontario, Canada|University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02652429"
859,"NCT03293992","A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension",,"Completed","No Results Available","Glaucoma, Open-angle|Ocular Hypertension","Drug: 0.01% RO7058584|Drug: 0.1% RO7058584|Drug: 1% RO7058584|Drug: Matching Placebo|Drug: Latanoprost 0.005%","Incidence, Severity, and Causal Relationship of Ocular and Systemic Adverse Events (AEs)|Incidence of Abnormal Laboratory Findings|Incidence of Blood Pressure Abnormalities|Incidence of Pulse Rate Abnormalities|Incidence of Electrocardiogram (ECG) Findings|Change From Baseline in Mean Intraocular pressure (IOP) After 7 Days of Study Drug Administration|Change From Baseline in Mean Intraocular pressure (IOP) at Matched Clock-Times After 7 Days of Study Drug Administration|Cmax of RO7058584|Tmax of RO7058584|Ctrough of RO7058584|AUC0-24h of RO7058584","Hoffmann-La Roche","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BP39863","October 10, 2017","December 15, 2017","December 21, 2017","September 26, 2017",,"March 31, 2020","Arizona Eye Center, Chandler, Arizona, United States|Sall Research Medical Center, Artesia, California, United States|United Med Res Inst, Inglewood, California, United States|Eye research foundation, Newport Beach, California, United States|Rocky Mountain Lions Eye Inst, Aurora, Colorado, United States|Eye Care Centers Management, Inc. (Clayton Eye Center), Morrow, Georgia, United States|Coastal Research Associates, Roswell, Georgia, United States|Texan Eye/Keystone Research, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03293992"
860,"NCT02919917","Treatment of Post-SCI Hypotension",,"Recruiting","No Results Available","Spinal Cord Injury|Autonomic Dysreflexia|Orthostatic Hypotension|Baroreceptor Integrity|Sympathetic Integrity|Vagal Integrity|Hypotension|Cerebral Blood Flow|Blood Pressure|Venous Occlusion Plethysmography","Drug: Midodrine Hydrochloride","Rehabilitation|Systolic Blood Pressure|Orthostatic Hypotension and Autonomic Dysreflexia|Cerebral Blood Flow","James J. Peters Veterans Affairs Medical Center|Icahn School of Medicine at Mount Sinai","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 2|Phase 3","60","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","WEC-16-050","June 1, 2017","September 2021","September 2021","September 30, 2016",,"February 28, 2019","VA Medical Center, Bronx, Bronx, New York, United States|Mount Sinai School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02919917"
861,"NCT01323153","A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)",,"Completed","Has Results","Coronary Heart Disease","Drug: dalcetrapib|Drug: placebo","Percent Change From Baseline in High-density Lipoprotein C (HDL-C) Levels After 4 Weeks of Treatment|Similarity in Percent Change From Baseline in High-density Lipoprotein C (HDL-C) Levels After 4 Weeks of Treatment in Studies WC25501 and NC20971|Percent Change of High-density Lipoprotein C (HDL-C) Treatment Levels After 8, 12 and 20 Weeks of Treatment|Percent Change From Baseline in Blood Lipid Levels|Percent Change From Baseline in Lipoprotein Levels|Percent Change From Baseline in Apolipoprotein Levels|Safety: Incidence of Adverse Events","Hoffmann-La Roche","All","45 Years and older   (Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WC25501","March 2011","March 2012","March 2012","March 25, 2011","August 6, 2018","July 30, 2019","Pensacola, Florida, United States|Pensacola, Florida, United States|Saginaw, Michigan, United States|Saint Cloud, Minnesota, United States|Syracuse, New York, United States|Rapid City, South Dakota, United States|Ceske Budejovice, Czechia|Chrudim, Czechia|Hradec Kralove, Czechia|Jihlava, Czechia|Jindrichuv Hradec, Czechia|Praha, Czechia|Semily, Czechia|Teplice, Czechia|Zlin, Czechia|Znojmo, Czechia|Amsterdam, Netherlands|Arnhem, Netherlands|Beverwijk, Netherlands|Breda, Netherlands|Den Helder, Netherlands|Eindhoven, Netherlands|Gouda, Netherlands|Heerlen, Netherlands|Nieuwegein, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Sneek, Netherlands|Edinburgh, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|Stoke-on-Trent, United Kingdom|Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01323153"
862,"NCT02676830","Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312",,"Completed","No Results Available","Dyslipidemia","Drug: K-312 100 mg|Drug: K-312 100 ug C14 IV","Area under the plasma-concentration time curve to last measured time point|Oral bioavailability based on the ratio of AUC after oral dosing to the AUC after i.v. dosing","Kowa Research Institute, Inc.","Male","25 Years to 45 Years   (Adult)","Phase 1","13","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","K-312-1.03US","August 2014","February 2015","April 2015","February 8, 2016",,"February 18, 2016","Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02676830"
863,"NCT01547390","Early Prevention of Preeclampsia Study","EPAPP","Terminated","Has Results","Preeclampsia","Drug: Aspirin|Drug: placebo","Number of Participants With Preeclampsia|Number of Participants With IUGR, Early Preeclampsia, Severe Preeclampsia, Gestational Hypertension, Preterm Birth, Stillbirth, Placental Abruption, Antepartum Hemorrhage, Neonatal Death, NICU Admission, Miscarriage","Washington University School of Medicine","Female","Child, Adult, Older Adult","Not Applicable","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201112007","March 2012","July 20, 2015","July 20, 2015","March 7, 2012","May 14, 2018","June 29, 2018","Washington University, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01547390"
864,"NCT01148004","The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers",,"Completed","No Results Available","HIV|Fenofibrate|Protease Inhibitors|Hypertriglyceridemia|Glucuronosyltransferase","Drug: Fenofibrate|Drug: Ritonavir|Drug: Lopinavir/Ritonavir","Fenofibratae pharmacokinetic parameter values","National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","Phase 1","25","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","100124|10-CC-0124","May 13, 2010","July 29, 2013","July 29, 2013","June 22, 2010",,"December 9, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01148004"
865,"NCT01111682","Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure",,"Terminated","No Results Available","Traumatic Brain Injury|Elevated Intracranial Pressure","Drug: Mannitol|Drug: Hypertonic Saline","Proportion of time during which ICP is less than or equal to 20 mmHg during the first 120 hours following initiation of ICP monitoring. In the case where a patient is weaned from infusion, full ICP control will be assumed.|Therapy Intensity Level (TIL), reflecting the amount and duration of therapy required to control ICP. TIL incorporates, among others, variables such as degree of head elevation, level of sedation, volume of CSF drainage, and hypocapnia.|Long-term outcomes measured by Disability Rating Scale and Glasgow Outcome Scale-Extended|Incidence of pre-determined severe adverse events (SAEs): brain hypoxia, delayed decompression, pulmonary edema, renal failure, respiratory complications, seizures, systemic hypoxia, and uncontrollable ICP","University of Cincinnati|United States Department of Defense","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","5","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Shutter-2010-01","April 2010","November 2010","November 2010","April 27, 2010",,"March 5, 2013","University Hospital, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01111682"
866,"NCT01725594","A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003",,"Completed","No Results Available","Dyslipidemia","Drug: CAT 2003|Drug: Placebo","Frequency and severity of adverse events|AUCinf of CAT-2003|Cmax of CAT-1004|Changes from baseline for hematology, chemistry, coagulation and urinalysis|Changes from baseline for Physical exams|Changes from baseline for ECGs|Changes from baseline in vital signs|Assess the pharmacodynamic effects of multiple doses of CAT-2003 on triglycerides and other lipids (LDL-C, VLDL-C, VLDL-triglycerides, non-HDL-C, total cholesterol, HDL-C), apoB, lipoprotein(a), and PCSK9 in healthy subjects with mild dyslipidemia","Catabasis Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","CAT-2003-101","November 2012","May 2013","May 2013","November 14, 2012",,"July 11, 2013","Medpace CPU, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01725594"
867,"NCT01650090","Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma",,"Completed","No Results Available","Pulmonary Relapse of Osteosarcoma","Drug: Inhaled Lipid Cisplatin (ILC)","Observed Relapse Free Interval (RFI)|Median, 1, 2 and 5 year Overall Survival (OS)|Median, 1, 2 and 5 year Event Free Survival (EFS)","Eleison Pharmaceuticals LLC.","All","13 Years and older   (Child, Adult, Older Adult)","Phase 2","28","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","EP-ILC-201","August 2012","November 2018","November 2018","July 26, 2012",,"August 7, 2019","Children's Hospital Los Angeles, Los Angeles, California, United States|Stanford University Medical Center, Palo Alto, California, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|The Children's Hospital at Montefiore, Bronx, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01650090"
868,"NCT03868059","Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men",,"Completed","No Results Available","Hypogonadism, Male","Drug: LPCN 1021","Change in ambulatory blood pressure monitoring (ABPM)","Lipocine Inc.","Male","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","138","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LPCN 1021-18-001","April 30, 2018","February 19, 2019","February 21, 2019","March 8, 2019",,"March 8, 2019","Alabama Clinical Therapeutics, Birmingham, Alabama, United States|South Florida Medical Research, Aventura, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Neostart Corporation dba AGA Clinical Trials, Hialeah, Florida, United States|Jacksonville Impotence Treatment Center, Jacksonville, Florida, United States|Oviedo Medical Research, LLC, Oviedo, Florida, United States|Clinical Research Center of Florida, Pompano Beach, Florida, United States|Central Kentucky Research Associates, Inc., Lexington, Kentucky, United States|Regional Urology, Shreveport, Louisiana, United States|AccuMed Research Associates, Garden City, New York, United States|Manhattan Medical Research Practice PLLC, New York, New York, United States|Aventiv Research, Inc., Columbus, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|Clinical Research Associates, Inc., Nashville, Tennessee, United States|Granger Medical Clinic, West Valley City, Utah, United States|Rainier Clinical Research Center, Renton, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03868059"
869,"NCT03001817","Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function",,"Completed","No Results Available","Severe Hypertriglyceridemia","Drug: K-877|Drug: Fenofibrate|Drug: Placebo (for K-877)|Drug: Placebo (for Fenofibrate)","Percent change of Fasting Triglyceride(TG) Levels|Percent change of Fasting TG Levels|Percent Change of Other Lipid Parameters","Kowa Research Institute, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","551","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","K-877-301","November 28, 2016","June 24, 2019","June 24, 2019","December 23, 2016",,"May 1, 2020","Central Research Associates, Inc., Birmingham, Alabama, United States|Central Alabama Research, Birmingham, Alabama, United States|Cahaba Research, Inc., Birmingham, Alabama, United States|Boyett Health Services Inc, Hamilton, Alabama, United States|Longwood Research - Saadat Ansari, MD, LLC, Huntsville, Alabama, United States|Terence T. Hart, MD, Tuscumbia, Alabama, United States|Arrowhead Health Centers, Glendale, Arizona, United States|Phoenix Medical Research Institute, LLC, Peoria, Arizona, United States|Elite Clinical Studies, Phoenix, Arizona, United States|Clinical Research Institute of Arizona, LLC, Surprise, Arizona, United States|iResearch - Little Rock, Little Rock, Arkansas, United States|Lynn Institute of the Ozarks, Little Rock, Arkansas, United States|Advanced Research Center, Anaheim, California, United States|Torrance Clinical Research Institute Inc., Lomita, California, United States|Downtown L.A. Research Center, Inc., Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Lucita M. Cruz, MD., Inc., Norwalk, California, United States|Creekside Endocrine Associates, PC, Denver, Colorado, United States|Atlantic Clinical Research Collaborative, Boynton Beach, Florida, United States|ALL Medical Research, LLC, Cooper City, Florida, United States|S & W Clinical Research, Fort Lauderdale, Florida, United States|Indago Research and Health Center, Hialeah, Florida, United States|Jacksonville Impotence Treatment Center, Jacksonville, Florida, United States|AMPM Research Clinic, Miami Gardens, Florida, United States|Advanced Research Institute Inc, New Port Richey, Florida, United States|Ocala Cardiovascular Research, Ocala, Florida, United States|South Florida Research Solutions LLC. - Pembroke Pines, Pembroke Pines, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Cardiovascular Center of Sarasota, Sarasota, Florida, United States|Meridien Research - Tampa, Tampa, Florida, United States|Columbus Regional Health, Columbus, Georgia, United States|Physicians Research Associates, Inc, Lawrenceville, Georgia, United States|Georgia Institute for Clinical Research, Marietta, Georgia, United States|Meridian Clinical Research - Savannah, GA, Savannah, Georgia, United States|Solaris Clinical Research, Meridian, Idaho, United States|Apex Medical Research - Illinois, Chicago, Illinois, United States|Lemah Creek Clinical Research, Melrose Park, Illinois, United States|Koch Family Medicine, Morton, Illinois, United States|Community Hospital of Anderson and Madison County, Inc, Anderson, Indiana, United States|American Health Network - Avon Clinical Research Department, Avon, Indiana, United States|Medisphere Medical Research Center, Evansville, Indiana, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Buynak Clinical Research, P.C., Valparaiso, Indiana, United States|West Broadway Clinic, Council Bluffs, Iowa, United States|The Iowa Clinic - Cardiovascular Services, West Des Moines, Iowa, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|The Research Group of Lexington, LLC, Lexington, Kentucky, United States|Research Integrity LLC, Owensboro, Kentucky, United States|Clinical Trials Management, LLC - Northshore, Covington, Louisiana, United States|Clinical Trials Management LLC - Southshore, Metairie, Louisiana, United States|Clinical Trials of America, LLC - West Monroe, LA, West Monroe, Louisiana, United States|Maryland Cardiovascular Specialist, Baltimore, Maryland, United States|Aa Mrc, Llc, Flint, Michigan, United States|Oakland Medical Research Center, Troy, Michigan, United States|David M. Headley, MD P.A., Port Gibson, Mississippi, United States|Consult and Research Associates, Saint Louis, Missouri, United States|Advance Clinical Research, Inc, Saint Louis, Missouri, United States|Glacier View Research Institute, Kalispell, Montana, United States|Desert Endocrinology Clinical Research Center - Henderson, Henderson, Nevada, United States|Palm Research Center, Inc., Las Vegas, Nevada, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Lakeshore Primary Care Associate, Hamburg, New York, United States|Mid-Hudson Medical Research, PLLC - Hopewell Junction, New Windsor, New York, United States|Mid-Hudson Medical Research, PLLC - New Windsor, New Windsor, New York, United States|Orchard Park Family Practice, Orchard Park, New York, United States|Diabetes and Endocrinology Consultants, P.C., Morehead City, North Carolina, United States|Lillestol Research, LLC, Fargo, North Dakota, United States|Sterling Research Group, Ltd. - Auburn, Cincinnati, Ohio, United States|Aventiv Research, Inc., Columbus, Ohio, United States|Alpha Research Associates, LLC, Dayton, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|Ohio Clinical Research - Lyndhurst, Lyndhurst, Ohio, United States|Rama Research LLC, Marion, Ohio, United States|RAS Health Ltd, Marion, Ohio, United States|Summit Research Group, LLC, Munroe Falls, Ohio, United States|Ohio Clinical Research, LLC - Willoughby Hills, Willoughby Hills, Ohio, United States|South Oklahoma Heart Research, Oklahoma City, Oklahoma, United States|Clinical Research Associates of Central PA, LLC, Altoona, Pennsylvania, United States|Harleysville Medical Associates, Harleysville, Pennsylvania, United States|Richard M.Kastelic MD and Associates, Johnstown, Pennsylvania, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Center for Medical Research, LLC, Providence, Rhode Island, United States|DeGarmo Institute Of Medical Research, Greer, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|PMG Research of Bristol, LLC - State, Bristol, Tennessee, United States|New Phase Research & Development - Knoxville, Knoxville, Tennessee, United States|Clinical Research Solutions - Smyrna, TN, Smyrna, Tennessee, United States|Health Innovation Research Group, Arlington, Texas, United States|DCT-AACT, LLC, dba Discovery Clinical Trials, Austin, Texas, United States|Inquest Clinical Research, Baytown, Texas, United States|Protenium Clinical Research, LLC - Dallas, Dallas, Texas, United States|VA North Texas Health Care System - Dallas VA Medical Center (DVAMC), Dallas, Texas, United States|Academy of Diabetes, Thyroid and Endocrine, P.A., El Paso, Texas, United States|Juno Research, LLC - Northwest Site, Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Juno Research, LLC - Southwest Houston Site, Houston, Texas, United States|Pioneer Research Solutions Inc., Houston, Texas, United States|Grace Research, LLC - Huntsville, TX, Huntsville, Texas, United States|Protenium Clinical Research, LLC, Hurst, Texas, United States|Juno Research, LLC - Katy, Katy, Texas, United States|FMC Science, Lampasas, Texas, United States|DCT - McAllen Primary Care, LLC, McAllen, Texas, United States|San Antonio Premier Internal Medicine, San Antonio, Texas, United States|Physician PrimeCare Research Institute, PLLC dba Health Texas Research Institute, San Antonio, Texas, United States|Pinnacle Clinical Research, San Antonio, Texas, United States|Bandera Family HealthCare Research, LLC (BFHC), San Antonio, Texas, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|York Clinical Research LLC, Norfolk, Virginia, United States|Exemplar Research Inc. - Fairmont, WV, Morgantown, West Virginia, United States|Allegiance Research Specialists, LLC, Wauwatosa, Wisconsin, United States|Brest Regional Hospital, Brest, Belarus|Gomel Regional Clinical Center of Cardiology, Gomel, Belarus|Gomel Regional Clinical Hospital, Gomel, Belarus|Grodno University Hospital, Grodno, Belarus|City Clinical Hospital #10, Minsk, Belarus|City Clinical Hospital #1, Minsk, Belarus|Minsk Regional Clinical Hospital, Minsk, Belarus|Minsk Scientific and Practice Center of Surgery, Transplantology and Hematology, Minsk, Belarus|Mogilev Regional Medical and Diagnostic Center, Mogilev, Belarus|Vitebsk Regional Clinical Hospital, Vitebsk, Belarus|Medical Center Diamedical 2013 OOD, Dimitrovgrad, Bulgaria|University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski EAD- First Cardiology Clinic, Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski EAD- Second Cardiology Clinic, Pleven, Bulgaria|UMHAT Sveti Georgi - Clinic of Cardiology, Plovdiv, Bulgaria|MHAT Dr. Bratan Shukjerov, Smolyan, Bulgaria|Multiprofile Hospital For Active Treatment - Dr. Bratan Shukerov AD, Smolyan, Bulgaria|Fifth Multiprofile Hospital for Active Treatment - Sofia EAD - Department of Cardiology, Sofia, Bulgaria|Fifth Multiprofile Hospital for Active Treatment - Sofia EAD - Department of Endocrinology and Meteorism Diseases, Sofia, Bulgaria|Medical Center Orfey OOD, Stara Zagora, Bulgaria|Lipidova poradna, Bilina, Czechia|Medicus Services SRO, Brandýs nad Labem, Czechia|Fakultni nemocnice Hradec Kralove, Klinika gerontologicka a metabolicka, Hradec Kralove, Czechia|Ordinace pro choroby srdce a cev, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Onkologicka klinika 2. LF UK a FN Motol, Praha 5, Czechia|Oblastni nemocnice Trutnov, Oddeleni klinicke biochemie, Trutnov, Czechia|MUDr. Nina Zemkova s.r.o. Interni Ambulance, Uherské Hradište, Czechia|Unimed Ajara LLC, Batumi, Georgia|Clinic LJ Ltd, Kutaisi, Georgia|Aleksandre Aladashvili Clinic - LLC, Tbilisi, Georgia|Archangel St Michael Multiprofile Clinical Hospital Ltd, Tbilisi, Georgia|Emergency Cardiology Center by Academician G. Chapidze Ltd, Tbilisi, Georgia|Institute of Clinical Cardiology Ltd, Tbilisi, Georgia|Unimed Kakheti - Caraps Medline LLC, Tbilisi, Georgia|Unimed Kakheti - Telavi Referral Hospital LLC, Telavi, Georgia|DRC Gyogyszervizsgalo Kozpont Kft, Balatonfüred, Hungary|DRC Balatongyorok, Balatongyorok, Hungary|Dr Lakatos Ferenc Belgyogyaszati-Kardiologiai Maganrendelo, Bekescsaba, Hungary|Magyar Honvedseg Allami Egeszsegugyi Kozpont, II. sz Belgyogyaszat Osztaly, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|BKS Research Kft., Hatvan, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont I.sz. Belgyogyaszati Klinika, Pecs, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Szekesfehervar, Hungary|Indywidualna Specjalistyczna Praktyka Lekarska w Dziedzinie Kardiologii, lek. med. Krzysztof Cymerman, Gdynia, Poland|SALVIA Lekston i Madej s.j., Katowice, Poland|Malopolskie Centrum Alergii i Immunoterapii Allmedis SP Z O O, Krakow, Poland|AppleTreeClinics Sp. z o.o., Lodz, Poland|NZOZ All - Med Centrum Medyczne Specjalistyczne Gabinety Lekarskie Marcin Ogorek, Lodz, Poland|Nzoz Salusmed, Lodz, Poland|MEDICOME Sp. z o.o., Oswiecim, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Centrum Medyczne OMEGA SP Z O O, Plock, Poland|Centrum Zdrowia Metabolicznego Pawel Bogdanski, Poznan, Poland|Praktyka Lekarska Ewa Krzyzagorska, Poznan, Poland|Clinmedica Research Omc Sp z o.o. Sp, Skierniewice, Poland|Centrum Kardiologiczne Pro Corde Sp. z o. o., Wroclaw, Poland|City Clinical Hospital n.a. M.P. Konchalovskiy, Zelenograd, Moscow, Russian Federation|First City Clinical Hospital n.a. E.E.Volosevich, Arkhangelsk, Russian Federation|Northern Medical Clinical Center named after N.A. Semashko of the Federal Medical and Biological Agency, Arkhangelsk, Russian Federation|Altay Regional Cardiology Dispensary, Cardiology Department for Patients with Acute Myocardial Infarction, Barnaul, Russian Federation|Chita State Medical Academy, Chita, Russian Federation|Ural State Medical University based at Central City Clinical Hospital No.1 of Oktyabrskiy District, Ekaterinburg, Russian Federation|Interregional Clinical Diagnostic Center, Kazan, Russian Federation|Kazan State Medical University based at City Clinical Hospital #7, Kazan, Russian Federation|Federal State Budget Institution ""Scientific-Research Institute of Complex Problems of Cardiovascular Diseases"", Kemerovo, Russian Federation|Medical Center ""Alliance"", Kirovsk, Russian Federation|Krasnoyarsk State Medical University n.a. prof. V.F. Voino-Yasenetsky, Krasnoyarsk, Russian Federation|Central Clinical Hospital of Russian Academy of Sciences, Moscow, Russian Federation|City Clinical Hospital #15 n.a. O.M. Filatov, Moscow, Russian Federation|City Clinical Hospital n.a. M.E. Zhadkevich of Moscow Healthcare Department, Moscow, Russian Federation|Federal State Budget Institution ""Outpatient Clinic #3"" of Russian Federation President's Management Department, Moscow, Russian Federation|National Medical Research Center of Cardiology - Department of Atherosclerosis, Moscow, Russian Federation|National Medical Research Center of Cardiology, Moscow, Russian Federation|National Medical Research Center of Preventive Medicine, Moscow, Russian Federation|Non-governmental Private Healthcare Institution ""Scientific Clinical Centre of Open Joint-Stock Company Russian Railways"" (JSC ""RZD""), Moscow, Russian Federation|City Clinical Hospital No.2, Novosibirsk, Russian Federation|RC Medical LLC, Novosibirsk, Russian Federation|Research Institute of Physiology and Fundamental Medicine, Novosibirsk, Russian Federation|Orenburg State Medical University based at City Clinical Hospital #1, Orenburg, Russian Federation|Clinical-diagnostic center ""Zdorovye"", Rostov-on-Don, Russian Federation|Rostov-on-Don City Hospital of Emergency Care, Rostov-on-Don, Russian Federation|Almazov National Medical Research Centre, Scientific Laboratory of Electrocardiology, Saint Petersburg, Russian Federation|BioTechService LLC, Saint Petersburg, Russian Federation|Clinic Complex JSC, Saint Petersburg, Russian Federation|Limited Liability Company ""MedPomosch"", Saint Petersburg, Russian Federation|Medical Technologies LLC, Saint Petersburg, Russian Federation|North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russian Federation|City hospital #38 n.a. N.A. Semashko, Saint-Petersburg, Russian Federation|Regional Clinical Cardiology Dispensary, Saratov, Russian Federation|Saratov State Medical University n. a. V.I. Razumovsky, Saratov, Russian Federation|Saint-Petersburg State Budget Healthcare Institution ""City Pokrovskaya Hospital"", Cardiology Departmen, St-Petersburg, Russian Federation|Almazov National Medical Research Centre, St. Petersburg, Russian Federation|Clinical Hospital #122 n. a. L.G. Sokolov of the Federal Medical Biological Agency, St. Petersburg, Russian Federation|Consultative Diagnostic Center with Out-patient Clinic, St. Petersburg, Russian Federation|Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation|Autonomous Institution of healthcare of the Voronezh region ""Voronezh regional clinical consultative and diagnostic centre, Voronezh, Russian Federation|Yaroslavl Regional Clinical Hospital for War Veterans - International Center on the Problems of the Elderly ""Zdorovoe Dolgoletie"", Yaroslavl, Russian Federation|Ivano-Frankivsk Regional Clinical Cardiological Dispensary, Chronic Ischaemic Heart Disease Department, Ivano-Frankivsk, Ukraine|JSC ""Ukrainian Railways"" Kharkiv Railway Clinical Hospital#1 of Branch ""Healthcare Center"" of PJSC ""Ukrainian Railways"", Cardiology Depart #1, Kharkiv, Ukraine|JSC ""Ukrainian Railways"" Kharkiv Railway Clinical Hospital#1 of Branch ""Healthcare Center"" of PJSC ""Ukrainian Railways"", Cardiology Depart #2, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise ""City Clinical Emergency Hospital n.a. prof. O.I. Meshchaninov"" of Kharkiv City Council, Kharkiv, Ukraine|Municipal Noncommercial Enterprise ""City Clinical Hospital #27"" of Kharkiv City Council, Kharkiv, Ukraine|Municipal Noncommercial Enterprise ""City Outpatient Clinic #9"" of Kharkiv City Council, Kharkiv, Ukraine|Kyiv City Clinical Hospital #1, Urgent Cardiology Department, Kyiv, Ukraine|Limited Liability Company ""Treatment and Diagnostic Center ""Adonis Plus"""", Outpatient Department, Kyiv, Ukraine|SI ""Institute of Gerontology n.a. D.F.Chebotarev NAMS of Ukraine"", Cardiol. Un. of Clin. Physiology and Int. Organs Path. Dep-t., Gen. Ther.Unit, Kyiv, Ukraine|SI ""Institute of Gerontology n.a. D.F.Chebotarev NAMS of Ukraine"", Cardiol. Un. of Clin. Physiology and Int. Organs Path. Dep-t, Kyiv, Ukraine|Municipal Institution ""City Clinical Hospital #3 n.a. prof. L.J. Aleinikova"", Cardiology Intensive Therapy Department, Odesa, Ukraine|Small Private Enterprise, Medical Centre ""Puls"", Vinnytsya, Ukraine|Municipal Institution ""City Clinical Hospital #6"", Therapeutic Department, Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT03001817"
870,"NCT02524106","Bococizumab HIV Evaluation (B-HIVE) Study","B-HIVE","Terminated","Has Results","Dyslipidemia|Cardiovascular Disease","Drug: Bococizumab|Drug: Placebo","Change of LDL-C From Baseline to Week 12|Change in Lp(a) From Entry to Week 12","University of California, San Francisco|Pfizer|San Francisco General Hospital","All","40 Years and older   (Adult, Older Adult)","Phase 3","11","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WI204426","August 2016","November 2017","November 2017","August 14, 2015","June 19, 2019","June 19, 2019","San Francisco General Hospital, San Francisco, California, United States|Quest Clinical Research, San Francisco, California, United States|San Francisco Veteran's Affair Medical Center, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02524106/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02524106"
871,"NCT04200651","Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery","SUSTAIN","Suspended","No Results Available","Glaucoma|Cataract","Drug: Dexamethasone Ophthalmic Insert|Drug: Prednisolone Acetate 1% Oph Susp","Change in intraocular pressure (IOP) at 1 and 3 months|Change in best-corrected visual acuity (BCVA) at 1 and 3 months|Difference in adverse events between groups|Difference in number of glaucoma medications at 3 months|Percentage of patients requiring supplemental prednisolone acetate 1% eye drops|Incidence of cystoid macular edema (CME) at 3 months as seen on optical coherence tomography (OCT)|Difference in Ocular Comfort Index (OCI) score at 1 month|Difference in Ocular Comfort Index (OCI) score at 3 months|Self-reported patient preference at 3 months|Difference patients with absence of anterior chamber (AC) cells at 1 month","The New York Eye Surgery Center|Ocular Therapeutix, Inc.","All","21 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","146602","January 13, 2020","March 30, 2021","May 30, 2021","December 16, 2019",,"April 3, 2020","The New York Eye Surgery Center, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT04200651"
872,"NCT03678116","Effects of a Thermogenic Dietary Supplement on Metabolic, Hemodynamic, and Mood Responses",,"Completed","No Results Available","Energy Metabolism|Heart Rate|Blood Pressure|Mood","Drug: Sugar Pill (placebo)|Dietary Supplement: Caffeine (plus Teacrine and Cayenne)|Dietary Supplement: Caffeine (plus Teacrine)","Effects of Ingestion of a Commercially Available Thermogenic Dietary Supplement on Resting Energy Expenditure (REE)|Effects of Ingestion of a Commercially Available Thermogenic Dietary Supplement on Heart Rate|Effects of Ingestion of a Commercially Available Thermogenic Dietary Supplement on Blood Pressure|Effects of Ingestion of a Commercially Available Thermogenic Dietary Supplement on Mood Responses","University of Mary Hardin-Baylor|Dymatize Inc.","All","18 Years to 35 Years   (Adult)","Not Applicable","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","AMP-1","July 23, 2018","October 31, 2018","October 31, 2018","September 19, 2018",,"March 28, 2019","UMHB Human Performance Lab, Belton, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03678116"
873,"NCT00935766","Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries",,"Terminated","Has Results","Metabolic Diseases|Endocrine System Diseases|Heart Disease|Vascular Diseases|Diabetes|Cardiovascular Disease|Glucose Metabolism Disorders|Hypertension","Drug: Omega-3|Drug: Placebo","Change in Pulse Wave Velocity in Active vs. Placebo-treated Patients.|Change in Lipoprotein-associated Phospholipase A2 (LpPLA2)|Change in hsCRP","Denver Health and Hospital Authority|National Heart, Lung, and Blood Institute (NHLBI)|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","76","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","08-0722 LUCHAR AIM 4","September 2009","March 2012","March 2012","July 9, 2009","September 29, 2014","September 29, 2014","Denver Health and Hospital Authority, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT00935766"
874,"NCT01876368","Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan",,"Completed","Has Results","Hypertension","Drug: LCZ696|Drug: Olmesartan|Drug: Placebo of LCZ696|Drug: Placebo of Olmesartan","Change From Baseline in 24-hour Mean Ambulatory Systolic Blood Pressure (maSBP)|Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (maDBP)|Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)|Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)|Change From Baseline in Office Pulse Pressure|Number of Patients Achieving Successful Overall Blood Pressure Control|Number of Patients Achieving Successful Mean Sitting Systolic Blood Pressure (msSBP) Control|Number of Patients Achieving Successful Mean Sitting Diastolic Blood Pressure (msDBP) Control|Number of Patients Achieving Successful Mean Sitting Systolic Blood Pressure (msSBP) Response|Number of Patients Achieving Successful Mean Sitting Diastolic Blood Pressure (msDBP) Response|Number of Patients With Total Adverse Events, Serious Adverse Events and Death","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","376","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLCZ696A2318|2013-001783-36","September 2013","August 2014","August 2014","June 12, 2013","December 7, 2015","December 7, 2015","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Fair Oaks, California, United States|Novartis Investigative Site, Hawaiian Gardens, California, United States|Novartis Investigative Site, Long Beach, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Orangevale, California, United States|Novartis Investigative Site, Westlake Village, California, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Conyers, Georgia, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Edina, Minnesota, United States|Novartis Investigative Site, Belzoni, Mississippi, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Oregon City, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Varnville, South Carolina, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Bs As, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Bs As, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Capital Federal, Argentina|Novartis Investigative Site, Posadas, Misiones, Argentina|Novartis Investigative Site, Buenos aires, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Quezon City, Manila, Philippines|Novartis Investigative Site, Manila, Metro Manila, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Manati, Puerto Rico|Novartis Investigative Site, Ponce, Puerto Rico|Novartis Investigative Site, Ponce, Puerto Rico|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, St.- Petersburg, Russian Federation|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Centelles, Cataluña, Spain|Novartis Investigative Site, Hostalets de Balenya, Cataluña, Spain|Novartis Investigative Site, Alzira, Comunidad Valenciana, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01876368"
875,"NCT02487225","Pentoxifylline Treatment in Acute Pancreatitis (AP)","AP","Completed","Has Results","Acute Pancreatitis (AP)|Gallstone Pancreatitis|Alcoholic Pancreatitis|Trauma Acute Pancreatitis|Hypertriglyceridemia Acute Pancreatitis|Idiopathic (Unknown) Acute Pancreatitis|Medication Induced Acute Pancreatitis|Cancer Acute Pancreatitis|Miscellaneous (i.e. Acute on Chronic Pancreatitis)","Drug: Pentoxifylline|Drug: Placebo","Change in C-reactive Protein (C-RP) From Admission Baseline at One Week.|Change in Tumor Necrosis Factor-alpha (TNF-a) Levels From Admission Baseline at One Week.|Change in Interleukin-6 (IL-6) Levels From Admission Baseline at One Week.|Change in Interleukin-8 (IL-8) Levels From Admission Baseline at One Week.","Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","83","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15-001710|1R21DK101889-01A1","May 2015","April 30, 2017","October 31, 2017","July 1, 2015","January 23, 2019","January 23, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02487225/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02487225"
876,"NCT00970606","STIP: Statin Trial for Influenza Patients","STIP","Terminated","Has Results","Acute Respiratory Distress Syndrome|Influenza|H1N1 Influenza","Drug: Rosuvastatin (crestor)|Drug: Placebo","Hospital Mortality to Day 28 or if Mortality is Not Different Between Groups, Time to Achieve Resolution of Respiratory Failure (e.g., Time to Unassisted Breathing in Survivors (Including Patient's Never Requiring Mechanical Ventilation).","Gordon Bernard|Vanderbilt University Medical Center","All","13 Years and older   (Child, Adult, Older Adult)","Not Applicable","7","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STIP","October 2009","July 2011","July 2011","September 2, 2009","April 24, 2013","March 22, 2017","University of Arkansas, Little Rock, Alaska, United States|Maricopa Integrated Health System, Phoenix, Arizona, United States|Stanford, Stanford, California, United States|Northwestern University, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Johns Hopkins Hospital, Baltiomore, Maryland, United States|Boston University, Boston, Massachusetts, United States|Baystate Medical Center, Springfiled, Massachusetts, United States|Columbia University, New York, New York, United States|Mt Sinai, New York, New York, United States|Moses H. Cone Memorial Hospital, Greensboro, North Carolina, United States|Metro Health, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Oregon, Portland, Oregon, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Erlanger, Chattanooga, Tennessee, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas, San Antonio, Texas, United States|Intermountain, Murray, Utah, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00970606"
877,"NCT03617302","Inorganic Nitrate Supplementation on Cerebrovascular Aging and Arterial Stiffness Study","INCA","Recruiting","No Results Available","Aging|Arterial Stiffness|Endothelial Dysfunction|Hypertension|Cognitive Decline","Drug: Experimental: Nitrate-containing|Drug: Placebo: Nitrate-depleted","Acute change in carotid artery stiffness|Acute change in cerebral blood flow|Internal carotid artery endothelium-dependent dilation","Gary L. Pierce|University of Wisconsin, Madison|University of Iowa","All","50 Years to 79 Years   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","201805720","November 1, 2018","June 30, 2022","June 30, 2023","August 6, 2018",,"January 23, 2020","University of Iowa, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT03617302"
878,"NCT01677507","Glaucoma Biomarkers",,"Completed","Has Results","Glaucoma|Healthy","Drug: Variation in eye pressure response to timolol and latanoprost treatment","Variation in Eye Pressure Between Individuals.|Variation in Aqueous Flow Between Individuals.|Variation in Episcleral Venous Pressure.","University of Michigan|University of Nebraska|Mayo Clinic|National Eye Institute (NEI)","All","40 Years and older   (Adult, Older Adult)","Phase 4","135","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HUM00052276|R01EY022124","August 2012","August 30, 2016","August 30, 2016","September 3, 2012","September 13, 2017","September 13, 2017","University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01677507"
879,"NCT01525407","Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation",,"Completed","Has Results","Malignant Neoplasm","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Atorvastatin Calcium|Procedure: Peripheral Blood Stem Cell Transplantation","Grade 3-4 Acute GVHD|Chronic Extensive GVHD|Disease-free Survival|Grades II-IV Acute GVHD|Non-relapse Mortality|Overall Survival|Proportion of Donors Who Have to Discontinue Atorvastatin Because of Toxicity|Proportion of Patients Requiring Secondary Systemic Immunosuppressive Therapy|Recurrent or Progressive Malignancy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","83","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2545.00|NCI-2011-03827|P30CA015704|R01HL108307","May 2012","September 2015","February 2016","February 3, 2012","August 17, 2017","August 17, 2017","Stanford University Hospitals and Clinics, Stanford, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01525407"
880,"NCT01588496","Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities","TESLA","Completed","Has Results","Homozygous Familial Hypercholesterolemia","Biological: Evolocumab|Drug: Placebo","Part A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12|Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12|Part A: Change From Baseline in LDL-C at Week 12|Part A: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12|Part A: Percent Change From Baseline in Apolipoprotein B at Week 12|Part A: Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12|Part A: Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12|Part A: Percentage of Participants With 15% or Greater Reduction in LDL-C From Baseline at Week 12|Part A: Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) at Week 12|Part B: Percent Change From Baseline in LDL-C at the Mean of Weeks 6 and 12|Part B: Percent Change From Baseline in Apolipoprotein B at Week 12|Part B: Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 6 and 12|Part B: Percent Change From Baseline in Lipoprotein (a) at Week 12|Part B: Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 6 and 12","Amgen","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110233|2011-005399-40","April 5, 2012","January 31, 2014","January 31, 2014","May 1, 2012","October 2, 2015","November 29, 2018","Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Bruxelles, Belgium|Research Site, La Louvière, Belgium|Research Site, London, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Dijon, France|Research Site, Paris Cedex 13, France|Research Site, New Territories, Hong Kong|Research Site, Pisa, Italy|Research Site, Beirut, Lebanon|Research Site, Amsterdam, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Lugo, Galicia, Spain|Research Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01588496"
881,"NCT01112423","Safety Study of BMS-823778 in Subjects With Hypercholesterolemia",,"Completed","No Results Available","Dyslipidemia","Drug: BMS-823778|Drug: Placebo","Lowering of LDL-C|Pharmacokinetics (measuring trough concentrations)|Pharmacodynamic effects of BMS-823778 on Total cholesterol, HDL-C, Triglycerides, non-HDL-C, free fatty acids, Apolipoprotein fractions, HPA axis marker and free testosterone and sex hormone binding globulin (SHBG)","Bristol-Myers Squibb","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MB121-003","June 2010","December 2010","December 2010","April 28, 2010",,"October 12, 2015","Osborne Research Center, Little Rock, Arkansas, United States|Pra International, Lenexa, Kansas, United States|Sterling Research Grp, Ltd., Cincinnati, Ohio, United States|Cetero Research - San Antonio, San Antonio, Texas, United States|National Clinical Research - Norfolk, Inc., Norfolk, Virginia, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States|Local Institution, Brisbane, Queensland, Australia|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, Mount Pearl, Newfoundland and Labrador, Canada|Local Institution, London, Ontario, Canada|Local Institution, Drummondville, Quebec, Canada|Local Institution, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01112423"
882,"NCT03501966","Surgical Idiopathic Intracranial Hypertension Treatment Trial","SIGHT","Terminated","No Results Available","Idiopathic Intracranial Hypertension","Drug: Acetazolamide|Procedure: Optic Nerve Sheath Fenestration|Procedure: Ventriculoperitoneal CSF Shunting","Perimetric Mean Deviation (PMD)|Treatment Failure|Cerebrospinal Fluid (CSF) Opening Pressure|Papilledema Grade|OCT Retinal Nerve Fiber Layer Thickness|OCT Total retinal thickness|Visual Acuity (VA) using Early Treatment Diabetic Retinopathy Study (ETDRS) chart|Quality of Life (QoL) 36 Item Short Form Health Survey (SF-36v2)|Quality of Life (QoL) Visual Function Questionnaire (VFQ-25)|Quality of Life (QoL) 10-item neuro-ophthalmic supplement to the VFQ-25|Headaches","Jaeb Center for Health Research|National Eye Institute (NEI)|University of Iowa|Icahn School of Medicine at Mount Sinai","All","18 Years to 63 Years   (Adult)","Phase 3","16","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","SIGHT|1U10EY025990-01A1","February 6, 2019","August 28, 2019","August 28, 2019","April 18, 2018",,"February 11, 2020","University of Southern California, Los Angeles, California, United States|NeuroEyeOrbit Institute, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States|The Eye Care Group, Orange, Connecticut, United States|University of Miami, Miami, Florida, United States|Northwestern Medicine, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas School of Medicine, Prairie Village, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Bethesda Neurology, LLC, North Bethesda, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|State University of New York at Stony Brook, East Setauket, New York, United States|New York Eye & Ear Infirmary of Mount Sinai, New York, New York, United States|New York University School of Medicine, New York, New York, United States|University of Rochester, Rochester, New York, United States|Ohio Neuro-Ophthalmology, Orbital Disease and Oculoplastics, Columbus, Ohio, United States|Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Neuro-Eye Clinical Trials-Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Swedish Medical Center, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|University of Calgary, Calgary, Alberta, Canada|Sunnybrook Health Science Center, Toronto, Ontario, Canada|Rivera, Enrique J, Bayamón, Puerto Rico","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03501966/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03501966"
883,"NCT01431690","Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals",,"Completed","No Results Available","Hypertriglyceridemia","Drug: warfarin|Drug: omefas|Drug: omega-3-acid ethyl esters","Pharmacokinetics of R- and S- warfarin|Pharmacodynamics of R- and S- warfarin|Total EPA+DHA","AstraZeneca","All","18 Years to 55 Years   (Adult)","Phase 1","52","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OM-EPA-006","August 2011","October 2011","October 2011","September 9, 2011",,"April 24, 2015","Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01431690"
884,"NCT01065454","A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction","LEPHT","Active, not recruiting","Has Results","Hypertension, Pulmonary|Ventricular Dysfunction, Left","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo","Pulmonary Artery Mean Pressure (PAPmean) at Rest - Change From Baseline to Week 16|Venous Oxygen Saturation (SvO2) - Change From Baseline to Week 16|Pulmonary Vascular Resistance (PVR) - Change From Baseline to Week 16|Pulmonary Vascular Resistance Index (PVRi) - Change From Baseline to Week 16|Systemic Vascular Resistance (SVR) - Change From Baseline to Week 16|Systemic Vascular Resistance Index (SVRi) - Change From Baseline to Week 16|Transpulmonary Pressure Gradient (TPG) - Change From Baseline to Week 16|Pulmonary Capillary Wedge Pressure (PCWP) - Change From Baseline to Week 16|Tricuspid Annular Plane Systolic Excursion (TAPSE) - Change From Baseline to Week 16|Systolic Pulmonary Arterial Pressure (PAPsyst) - Change From Baseline to Week 16|Left Ventricular Ejection Fraction (LVEF) - Change From Baseline to Week 16|Left Ventricular End-systolic Volume (LVESV) - Change From Baseline to Week 16|Left Ventricular End-diastolic Volume (LVEDV) - Change From Baseline to Week 16|E-wave Deceleration Time - Change From Baseline to Week 16|Ratio of Mitral Peak Velocity of Early Filling to Mitral Peak Velocity of Late Filling (E/A) - Change From Baseline to Week 16|6-minute Walking Distance (6MWD) - Change From Baseline to Week 16|WHO (World Health Organization) Functional Class - Change From Baseline to Week 16|Percentage of Participants With Clinical Worsening|Borg CR 10 Scale - Change From Baseline to Week 16|EQ-5D Utility Score - Change From Baseline to Week 16|Minnesota Living With Heart Failure Questionnaire (MLHF) Score - Change From Baseline to Week 16|Cystatin C - Change From Baseline to Week 16|N-terminal Pro-brain Natriuretic Peptide (NT-pro BNP) - Change From Baseline to Week 16|Troponin T - Change From Baseline to Week 16|Asymmetric Dimethylarginine (ADMA) - Change From Baseline to Week 16|Osteopontin - Change From Baseline to Week 16","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","202","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14308|2009-015878-35","April 14, 2010","June 6, 2012","December 31, 2023","February 9, 2010","December 25, 2013","March 23, 2020","Fountain Valley, California, United States|Los Angeles, California, United States|San Diego, California, United States|Torrance, California, United States|Miami, Florida, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Cincinnati, Ohio, United States|Fairfield, Ohio, United States|Falls Church, Virginia, United States|Milwaukee, Wisconsin, United States|Darlinghurst, New South Wales, Australia|Chermside, Queensland, Australia|Prahran, Victoria, Australia|Innsbruck, Tirol, Austria|Wien, Austria|Aalst, Belgium|Bruxelles - Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Montreal, Quebec, Canada|Quebec, Canada|Beijing, China|Shanghai, China|Shanghai, China|Brno, Czechia|Olomouc, Czechia|Praha 2, Czechia|Praha 4, Czechia|Aarhus N, Denmark|Bron, France|Lille Cedex, France|Nantes, France|Pessac, France|Rouen, France|Toulouse, France|Heidelberg, Baden-Württemberg, Germany|Augsburg, Bayern, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Köln, Nordrhein-Westfalen, Germany|Erfurt, Thüringen, Germany|Napoli, Campania, Italy|Pavia, Lombardia, Italy|Nagoya, Aichi, Japan|Seto, Aichi, Japan|Ogaki, Gifu, Japan|Higashiibaraki, Ibaraki, Japan|Tsu, Mie, Japan|Sendai, Miyagi, Japan|Suita, Osaka, Japan|Kusatsu, Shiga, Japan|Sunto, Shizuoka, Japan|Arakawa-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Tanabe, Wakayama, Japan|Osaka, Japan|Osaka, Japan|Amsterdam, Netherlands|Amsterdam, Netherlands|Nijmegen, Netherlands|Bydgoszcz, Poland|Gdansk, Poland|Warszawa, Poland|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Majadahonda, Madrid, Spain|El Palmar, Murcia, Spain|Son Ferriol, Palma De Mallorca, Spain|A Coruña, Spain|Barcelona, Spain|Madrid, Spain|Valencia, Spain|Lugano, Ticino, Switzerland|Genève, Switzerland|Zürich, Switzerland|Cambridge, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01065454"
885,"NCT01105598","A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia",,"Completed","No Results Available","Mild Dyslipidemia","Drug: ETC-1002 or placebo","Assessment of safety and tolerability using adverse event reports, physical exams, vitals signs, ECGs, and clinical lab values|Characterization of pharmacokinetic parameters and percent change from baseline in pharmacodynamic endpoints","Esperion Therapeutics","All","18 Years to 55 Years   (Adult)","Phase 1","53","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ETC-1002-002","April 20, 2010","October 2, 2010","October 2, 2010","April 16, 2010",,"March 28, 2019","Jasper Clinic, Inc., Kalamazoo, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01105598"
886,"NCT02682511","Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension",,"Recruiting","No Results Available","Scleroderma, Diffuse|Scleroderma, Systemic|Scleroderma, Limited|Sclerosis, Progressive Systemic|Skin Diseases|Connective Tissue Diseases|Pathologic Processes|Autoimmune Diseases","Drug: Oral Ifetroban|Drug: Oral Placebo","Incidence of adverse events (AEs) and Serious AEs (SAEs)|Change from baseline in forced vital capacity (FVC)|Change from baseline in diffusion capacity for carbon monoxide (DLCO)|Change from baseline in the modified Rodnan skin score (mRSS)","Cumberland Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CPI-IFE-004","January 2017","December 2020","February 2021","February 15, 2016",,"August 15, 2019","UCLA, Los Angeles, California, United States|New Life Medical Research Center, Inc., Hialeah, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Hospital for Special Surgery, New York, New York, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor Research Institute, Dallas, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|KDH - Kokilaben Dhirubhai Ambani Hospital, Mumbai, Maharashtra, India|B. J. Government Medical College, Pune, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02682511"
887,"NCT01488409","Effects of Acipimox on Mitochondrial Function in Obesity",,"Completed","Has Results","Abdominal Obesity|Insulin Resistance|Hypertriglyceridemia","Drug: Acipimox|Drug: Placebo","Change From Baseline in Phosphocreatine Recovery (ViPCr) at 6-months|Change From Baseline in Insulin Sensitivity at 6-months|Change From Baseline in Mitochondrial Density at 6 Months|Change From Baseline in Intramyocellular Lipid Content at 6-months|Change From Baseline in Lipid Profile at 6-months","Massachusetts General Hospital|American Diabetes Association","All","18 Years to 55 Years   (Adult)","Phase 2","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2011-P-000175","May 2012","January 2015","January 2015","December 8, 2011","February 3, 2016","March 1, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01488409"
888,"NCT01329744","Effects of IGF-I in HIV Metabolic Disease",,"Terminated","No Results Available","HIV Lipodystrophy","Drug: mecasermin|Drug: Placebo control","Body composition|Glucose Homeostasis","University of Texas Southwestern Medical Center","All","18 Years to 60 Years   (Adult)","Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1K23DK080644-01A1","June 2011","June 2013","June 2013","April 6, 2011",,"March 23, 2016","University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01329744"
889,"NCT00885495","Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study",,"Unknown status","No Results Available","HIV Infections","Drug: darunavir, ritonavir, rosuvastatin|Drug: rosuvastatin, darunavir, ritonavir","To investigate the effect of darunavir/ritonavir on the pharmacokinetics of rosuvastatin.|To investigate the effect of rosuvastatin on the steady state pharmacokinetics of darunavir/ritonavir.|To compare the change in low-density lipoprotein (LDL) cholesterol with rosuvastatin therapy alone, darunavir/ritonavir therapy alone and with the co-administration of rosuvastatin and darunavir/ritonavir.","University of Cincinnati","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IDC 40","January 2009","June 2009","August 2009","April 22, 2009",,"April 22, 2009","University of Cincinnati AIDS Clinical Trials Unit, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00885495"
890,"NCT02096588","Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin",,"Active, not recruiting","Has Results","Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer","Drug: Simvastatin|Drug: Doxorubicin/cyclophosphamide","Change in Echocardiographic Global Longitudinal Strain (GLS)|Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Recurrence Free Survival (RFS) With Concurrent Simvastatin","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Avon Foundation","Female","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J13160|NA_00091900","May 20, 2014","April 25, 2017","March 1, 2022","March 26, 2014","June 26, 2019","June 26, 2019","Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital, Washington, District of Columbia, United States|Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02096588/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02096588"
891,"NCT01743001","Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome","MAESTRO","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Macitentan 10 mg|Drug: Placebo","Change From Baseline to Week 16 in Exercise Capacity, as Measured by 6-minute Walk Distance (6MWD)|Change From Baseline to Week 16 in WHO Functional Class|Change From Baseline to Week 16 in Dyspnea, Assessed by the Borg Dyspnea Index|Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire","Actelion","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","226","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-055-305","May 21, 2013","December 1, 2016","December 1, 2016","December 6, 2012","January 30, 2018","February 23, 2018","Ahmanson/UCLA Heart Disease Center, Los Angeles, California, United States|Stanford Hospital and Clinic, Palo Alto, California, United States|Emory University Hospital/the Emory Clinic, Atlanta, Georgia, United States|Barnes-Jewish Hosp/Wash Univ School of Med, Saint Louis, Missouri, United States|Children'S Heart Center Nevada, Las Vegas, Nevada, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Texas Children'S Hosp - Dept of Cardiology, Houston, Texas, United States|Gen Hosp Univ Vienna Dept Cardiology, Vienna, Austria|Mhat Nat Card Hosp - Cardiology Clinic, Sofia, Bulgaria|Mhat Nat Card Hosp - Pediatric Clin / Ped Card Dept, Sofia, Bulgaria|Mhat Sveta Anna Clin Card, Sofia, Bulgaria|Inst Nat Torax, Unidad Cardiopatia Congenitas Del Adulto, Providencia, Chile|Clinica Tabancura - Cardio Unit, Santiago, Chile|Guangdong General Hospital, Cardiology Dpt, Guangzhou, Guangdong, China|Wu Han Asia Heart Hosp, Wuhan, Hubei, China|The General Hosp of Shenyang Military Region, Shenyang, Liaoning, China|Beijing Anzhen Hospital, Cardiology Dpt, Beijing, China|Cardiovascular Institute&Fuwai Hospital, Beijing, China|Shanghai Pulmonary Hospital, Dept of Pulmonary Circulation, Shanghai, China|Hosp La Timone - Dept Pediatric Cardiology, Marseille Cedex 5, France|Hosp Laennec - Dept Cardiology, Nantes Cedex 1, France|Hosp Pompidou - Dept Congenital Cardiac Diseases, Paris Cedex 15, France|Hosp Cardiology Haut Leveque - Dept Congenital Diseases, Pessac, France|Herzzentrum Berlin, Ped Cardiology, Berlin, Germany|Universitätsklinikum Giessen - Pediatric Heart Center, Giessen, Germany|Uni Heidelberg - Kinderkardiologie, Heidelberg, Germany|Ahepa University General Hospital, Thessaloniki, Greece|Rabin Medical Centre - Pulmonology, Petach Tikvah, Israel|Institut Jantung Negara, Kuala Lumpur, Malaysia|Unidad de Investigacion Clin En Med, Sc (Udicem), Monterrey, Nuevo Leon, Mexico|Instituto Nacional de Cardiologia (Inc) Ignacio Chavez, Mexico City, Mexico|Instituto de Corazon de Querètaro, Querétaro, Mexico|PHC, MAB, Manila, Philippines|Cardiology Gdańsk Univ, Gdańsk, Poland|Cardiology Kraków Univ, Krakow, Poland|Cardiology Wrocław, Wrocław, Poland|Hosp Univ Coimbra - Dpt Cardiology, Coimbra, Portugal|Hosp Sta Marta - Dept Cardiology, Lisboa, Portugal|Er Inst For Cardvasc Dis ""Prof Dr Cc Iliescu"" - Card Ii, Bucuresti, Romania|Cardio Med Srl, Targu-Mures, Romania|Clin Hosp For Inf and Pulm Dis Victor Babes - Ii Pulm, Timisoara, Romania|Sci Institute Systemic Problems Cardio Diseases Kemerovo, Kemerovo, Russian Federation|Russian Cardiology Scientific and Production Complex, Moscow, Russian Federation|V. A. Almazov Institute of Cardiology, St Petersburg, Russian Federation|Dedinje Cardiovasc Inst - Cardiovasc Research Ctr, Belgrade, Serbia|Mother and Child Health Care Inst ""Dr Vukan Cupic"", Belgrade, Serbia|Clin Hosp Ctr Zemun - Cardiology Dept, Belgrade, Serbia|Hosp Univ Vall D'Hebron - Dpt Congenital Heart Disease Adult, Barcelona, Spain|Hosp Univ Virgen Macarena - Dpt Cardiology, Sevilla, Spain|Hosp Universitario La Fe Dpt Cardiology, Valencia, Spain|Omu Pediatry, Samsun, Turkey|Bristol Univ Hosp Congenital Heart Centre, Bristol, United Kingdom|Hanoi Medical University Hospital, Hanoi, Vietnam|Children's Hospital, Ho Chi Minh, Ho Chi Minh, Vietnam|Tam Duc Hospital, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT01743001"
892,"NCT01520454","Effect of Increased Free Fatty Acids on Leptin Function",,"Completed","Has Results","Obesity|Leptin Resistance","Drug: Saline|Drug: Intralipid|Dietary Supplement: Water|Dietary Supplement: oral fat|Drug: Heparin","Change in Circulating Glucagon-like Peptide-1 (GLP-1) Levels|Change in Circulating Gastric Inhibitory Polypeptide (GIP) Levels|Change in Circulating Ghrelin Levels|Change in Circulating Peptide Tyrosine Tyrosine (PYY) Levels|Change in Circulating Glucose Levels|Change in Circulating Insulin Levels|Change in Circulating Leptin Levels|Change in Circulating Adiponectin Levels|Phosphorylation of STAT3 Pathways Downstream of Leptin After Lipid Administration","Beth Israel Deaconess Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2009P000370","November 2011","December 2013","December 2016","January 30, 2012","April 26, 2017","May 11, 2018","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01520454"
893,"NCT01563978","Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis","Oskira ABPM","Completed","Has Results","Rheumatoid Arthritis","Drug: fostamatinib|Drug: placebo","Change From Baseline in 24-hour Mean Ambulatory SBP|Change From Baseline in 24-hour Mean Ambulatory DBP|Change From Baseline in Mean Daytime and Night-time SBP and DBP by Ambulatory Blood Pressure Monitoring|Change From Baseline in Mean Awake SBP and DBP by Ambulatory Blood Pressure Monitoring|Change From Baseline in Mean Sleeping SBP and DBP by Ambulatory Blood Pressure Monitoring|Mean Change From Baseline in Clinic SBP and DBP|Mean Change From Baseline in Morning Pre-dose Home SBP and DBP|Mean Change From Baseline in Evening Post-dose Home SBP and DBP|Mean Change From Completion/Discontinuation to Follow-up in Clinical Measurement of SBP and DBP|DAS28-CRP Improvement","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2","266","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4300C00033|2011-006070-73","April 2012","January 2013","January 2013","March 27, 2012","April 14, 2014","May 8, 2014","Research Site, Huntsville, Alabama, United States|Research Site, Huntington Beach, California, United States|Research Site, Santa Maria, California, United States|Research Site, Trumbull, Connecticut, United States|Research Site, Boca Raton, Florida, United States|Research Site, Brandon, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Venice, Florida, United States|Research Site, Decatur, Georgia, United States|Research Site, South Bend, Indiana, United States|Research Site, Cumberland, Maryland, United States|Research Site, Frederick, Maryland, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Florissant, Missouri, United States|Research Site, Richmond Heights, Missouri, United States|Research Site, Freehold, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Brooklyn, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Lake Oswego, Oregon, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Memphis, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, Nassau Bay, Texas, United States|Research Site, Tacoma, Washington, United States|Research Site, Sevlievo, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Brno, Czech Republic|Research Site, Hlucin, Czech Republic|Research Site, Hostivice, Czech Republic|Research Site, Kladno, Czech Republic|Research Site, Ostrava-Trebovice, Czech Republic|Research Site, Praha 11, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 4, Czech Republic|Research Site, Aachen, Germany|Research Site, Halle, Germany|Research Site, Gdynia, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Kalisz, Poland|Research Site, Katowice, Poland|Research Site, Poznan, Poland|Research Site, Sroda Wielkopolska, Poland|Research Site, Wroclaw, Poland|Research Site, Łódź, Poland|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Kempron Park, South Africa|Research Site, Donetsk, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporozhye, Ukraine",,"https://ClinicalTrials.gov/show/NCT01563978"
894,"NCT03011450","Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment",,"Completed","No Results Available","Severe Hypertriglyceridemia","Drug: K-877|Drug: Fenofibrate|Drug: Placebo (for K-877)","Percent change of fasting triglyceride(TG) levels|Percent change of fasting TG levels|Percent change of other lipid perimeter","Kowa Research Institute, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","471","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","K-877-303","November 26, 2016","July 5, 2019","July 5, 2019","January 5, 2017",,"May 1, 2020","Central Research Associates, Inc., Birmingham, Alabama, United States|Central Alabama Research, Birmingham, Alabama, United States|Cahaba Research, Inc., Birmingham, Alabama, United States|Boyett Health Services Inc, Hamilton, Alabama, United States|Longwood Research - Saadat Ansari, MD, LLC, Huntsville, Alabama, United States|Terence T. Hart, MD, Tuscumbia, Alabama, United States|Arrowhead Health Centers, Glendale, Arizona, United States|Phoenix Medical Research Institute, LLC, Peoria, Arizona, United States|Elite Clinical Studies, Phoenix, Arizona, United States|Clinical Research Institute of Arizona, LLC, Surprise, Arizona, United States|iResearch, Little Rock, Arkansas, United States|Lynn Institute of the Ozarks, Little Rock, Arkansas, United States|Advanced Research Center, Anaheim, California, United States|Torrance Clinical Research Institute Inc., Lomita, California, United States|Downtown L.A. Research Center, Inc., Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Pacific Coast Cardiology and Research, Newport Beach, California, United States|Lucita M. Cruz, MD., Inc., Norwalk, California, United States|Integrated Research Center, San Diego, California, United States|Optimus Medical Group, San Francisco, California, United States|Creekside Endocrine Associates, PC, Denver, Colorado, United States|Atlantic Clinical Research Collaborative, Boynton Beach, Florida, United States|ALL Medical Research, LLC, Cooper City, Florida, United States|S & W Clinical Research, Fort Lauderdale, Florida, United States|Indago Research and Health Center, Hialeah, Florida, United States|Jacksonville Impotence Treatment Center, Jacksonville, Florida, United States|AMPM Research Clinic, Miami Gardens, Florida, United States|Advanced Research Institute Inc, New Port Richey, Florida, United States|Ocala Cardiovascular Research, Ocala, Florida, United States|South Florida Research Solutions LLC., Pembroke Pines, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Cardiovascular Center of Sarasota, Sarasota, Florida, United States|Meridien Research - Tampa, Tampa, Florida, United States|Meridien Research, Tampa, Florida, United States|Columbus Regional Health, Columbus, Georgia, United States|iResearch, Decatur, Georgia, United States|Physicians Research Associates, Inc, Lawrenceville, Georgia, United States|Georgia Institute for Clinical Research, Marietta, Georgia, United States|Endocrine Research Solutions, Inc, Roswell, Georgia, United States|Meridian Clinical Research - Savannah, GA, Savannah, Georgia, United States|Solaris Clinical Research, Meridian, Idaho, United States|Lemah Creek Clinical Research, Burr Ridge, Illinois, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|Apex Medical Research, Chicago, Illinois, United States|Koch Family Medicine, Morton, Illinois, United States|Community Hospital of Anderson and Madison County, Inc, Anderson, Indiana, United States|American Health Network - Avon Clinical Research Department, Avon, Indiana, United States|Medisphere Medical Research Center, Evansville, Indiana, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Buynak Clinical Research, P.C., Valparaiso, Indiana, United States|West Broadway Clinic, Council Bluffs, Iowa, United States|The Iowa Clinic - Cardiovascular Services, West Des Moines, Iowa, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|The Research Group of Lexington, LLC, Lexington, Kentucky, United States|Research Integrity LLC, Owensboro, Kentucky, United States|Clinical Trials Management, LLC - Northshore, Covington, Louisiana, United States|Clinical Trials Management LLC - Southshore, Metairie, Louisiana, United States|Grace Research, LLC, Shreveport, Louisiana, United States|Clinical Trials of America, LLC, West Monroe, Louisiana, United States|Maryland Cardiovascular Specialists, Baltimore, Maryland, United States|Regeneris Medical, North Attleboro, Massachusetts, United States|Aa Mrc, Llc, Flint, Michigan, United States|Oakland Medical Research Center, Troy, Michigan, United States|David M. Headley, MD P.A., Port Gibson, Mississippi, United States|Consult and Research Associates, Saint Louis, Missouri, United States|Advance Clinical Research, Inc, Saint Louis, Missouri, United States|Glacier View Research Institute, Kalispell, Montana, United States|Desert Endocrinology Clinical Research Center, Henderson, Nevada, United States|Palm Research Center, Inc., Las Vegas, Nevada, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Lakeshore Primary Care Associate, Hamburg, New York, United States|Mid-Hudson Medical Research, PLLC - Hopewell Junction, New Windsor, New York, United States|Mid-Hudson Medical Research, PLLC - New Windsor, New Windsor, New York, United States|Orchard Park Family Practice, Orchard Park, New York, United States|Diabetes and Endocrinology Consultants, P.C., Morehead City, North Carolina, United States|Lillestol Research, LLC, Fargo, North Dakota, United States|Sterling Research Group, Ltd. - Auburn, Cincinnati, Ohio, United States|Aventiv Research, Inc., Columbus, Ohio, United States|Alpha Research Associates, LLC, Dayton, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|Ohio Clinical Research - Lyndhurst, Lyndhurst, Ohio, United States|Rama Research LLC, Marion, Ohio, United States|RAS Health Ltd, Marion, Ohio, United States|Summit Research Group, LLC, Munroe Falls, Ohio, United States|Ohio Clinical Research, LLC - Willoughby Hills, Willoughby Hills, Ohio, United States|COR Clinical Research, LLC., Oklahoma City, Oklahoma, United States|South Oklahoma Heart Research, Oklahoma City, Oklahoma, United States|Clinical Research Associates of Central PA, LLC, Altoona, Pennsylvania, United States|Harleysville Medical Associates, Harleysville, Pennsylvania, United States|Richard M.Kastelic MD and Associates, Johnstown, Pennsylvania, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Center for Medical Research, LLC, Providence, Rhode Island, United States|MD First Research, Anderson, South Carolina, United States|MDFirst Research - Anderson, Anderson, South Carolina, United States|DeGarmo Institute Of Medical Research, Greer, South Carolina, United States|MD First Research, Lancaster, South Carolina, United States|Family Medicine of SayeBrook, Myrtle Beach, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|PMG Research of Bristol, LLC - State, Bristol, Tennessee, United States|Chattanooga Research & Medicine, PLLC, Chattanooga, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|New Phase Research & Development, Knoxville, Tennessee, United States|Clinical Research Solutions - Smyrna, TN, Smyrna, Tennessee, United States|Health Innovation Research Group, Arlington, Texas, United States|DCT-AACT, LLC, dba Discovery Clinical Trials, Austin, Texas, United States|Inquest Clinical Research, Baytown, Texas, United States|Padre Coast Clinical Research, Corpus Christi, Texas, United States|Protenium Clinical Research, LLC - Dallas, Dallas, Texas, United States|VA North Texas Health Care System - Dallas VA Medical Center (DVAMC), Dallas, Texas, United States|Academy of Diabetes, Thyroid and Endocrine, P.A., El Paso, Texas, United States|Juno Research, LLC, Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Juno Research, LLC, Houston, Texas, United States|Pioneer Research Solutions Inc., Houston, Texas, United States|Grace Research, LLC, Huntsville, Texas, United States|Protenium Clinical Research, LLC, Hurst, Texas, United States|Juno Research, LLC, Katy, Texas, United States|FMC Science, Lampasas, Texas, United States|Pinnacle Clinical Research, Live Oak, Texas, United States|DCT - McAllen Primary Care, LLC, McAllen, Texas, United States|San Antonio Premier Internal Medicine, San Antonio, Texas, United States|Physician PrimeCare Research Institute, PLLC dba Health Texas Research Institute, San Antonio, Texas, United States|Bandera Family HealthCare Research, LLC (BFHC), San Antonio, Texas, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|York Clinical Research LLC, Norfolk, Virginia, United States|Cardiovascular Associates, Ltd, Virginia Beach, Virginia, United States|Exemplar Research Inc. - Fairmont, WV, Morgantown, West Virginia, United States|Allegiance Research Specialists, LLC, Wauwatosa, Wisconsin, United States|Brest Regional Hospital, Brest, Belarus|Gomel Regional Clinical Hospital, Gomel, Belarus|Gomel Regional Clinical Center of Cardiology, Gomel, Belarus|Grodno University Hospital, Grodno, Belarus|City Clinical Hospital #1, Minsk, Belarus|City Clinical Hospital #9, Minsk, Belarus|Minsk Scientific and Practice Center of Surgery, Transplantology and Hematology, Minsk, Belarus|City Clinical Hospital #10, Minsk, Belarus|Minsk Regional Clinical Hospital, Minsk, Belarus|Mogilev Regional Medical and Diagnostic Center, Mogilev, Belarus|Vitebsk Regional Clinical Hospital, Vitebsk, Belarus|Medical Center Diamedical 2013 OOD, Dimitrovgrad, Bulgaria|University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski EAD- First Cardiology Clinic, Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski EAD- Second Cardiology Clinic, Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment (UMHAT) Sveti Georgi, EAD - Clinic of Cardiology, Plovdiv, Bulgaria|MHAT Dr. Bratan Shukjerov, Smolyan, Bulgaria|Multiprofile Hospital For Active Treatment - Dr. Bratan Shukerov AD, Smolyan, Bulgaria|Fifth Multiprofile Hospital for Active Treatment - Sofia EAD - Department of Cardiology, Sofia, Bulgaria|Fifth Multiprofile Hospital for Active Treatment - Sofia EAD - Department of Endocrinology and Meteorism Diseases, Sofia, Bulgaria|Medical Center Orfey OOD, Stara Zagora, Bulgaria|Medicus Services SRO, Brandýs nad Labem, Czechia|Lipidova poradna, Bílina, Czechia|Fakultni nemocnice Hradec Kralove, Klinika gerontologicka a metabolicka, Hradec Králové, Czechia|Ordinace pro choroby srdce a cev, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Oblastni nemocnice Trutnov, Oddeleni klinicke biochemie, Trutnov, Czechia|MUDr. Nina Zemkova s.r.o. Interni Ambulance, Uherské Hradište, Czechia|Unimed Ajara LLC, Batumi, Georgia|Clinic LJ Ltd, Kutaisi, Georgia|Aleksandre Aladashvili Clinic - LLC, Tbilisi, Georgia|Archangel St Michael Multiprofile Clinical Hospital Ltd, Tbilisi, Georgia|Emergency Cardiology Center by Academician G. Chapidze Ltd, Tbilisi, Georgia|Institute of Clinical Cardiology Ltd, Tbilisi, Georgia|Unimed Kakheti - Caraps Medline LLC, Tbilisi, Georgia|Unimed Kakheti - Telavi Referral Hospital LLC, Telavi, Georgia|DRC Gyogyszervizsgalo Kozpont Kft, Balatonfüred, Hungary|DRC Balatongyorok, Balatongyörök, Hungary|Magyar Honvedseg Allami Egeszsegugyi Kozpont, II. sz Belgyogyaszat Osztaly, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Dr Lakatos Ferenc Belgyogyaszati-Kardiologiai Maganrendelo, Békéscsaba, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|BKS Research Kft., Hatvan, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont I.sz. Belgyogyaszati Klinika, Pécs, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Székesfehérvár, Hungary|Indywidualna Specjalistyczna Praktyka Lekarska w Dziedzinie Kardiologii, lek. med. Krzysztof Cymerman, Gdynia, Poland|SALVIA Lekston i Madej s.j., Katowice, Poland|Malopolskie Centrum Alergii i Immunoterapii Allmedis SP Z O O, Krakow, Poland|MEDICOME Sp. z o.o., Oświęcim, Poland|Centrum Zdrowia Metabolicznego Pawel Bogdanski, Poznań, Poland|Praktyka Lekarska Ewa Krzyzagorska, Poznań, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Centrum Medyczne OMEGA SP Z O O, Płock, Poland|Clinmedica Research Omc Sp z o.o. Sp, Skierniewice, Poland|Centrum Kardiologiczne Pro Corde Sp. z o. o., Wrocław, Poland|AppleTreeClinics Sp. z o.o., Łódź, Poland|Nzoz Salusmed, Łódź, Poland|NZOZ All - Med Centrum Medyczne Specjalistyczne Gabinety Lekarskie Marcin Ogorek, Łódź, Poland|Northern Medical Clinical Center named after N.A. Semashko of the Federal Medical and Biological Agency, Arkhangelsk, Russian Federation|First City Clinical Hospital n.a. E.E.Volosevich, Arkhangelsk, Russian Federation|Altay Regional Cardiology Dispensary, Cardiology Department for Patients with Acute Myocardial Infarction, Barnaul, Russian Federation|Chita State Medical Academy, Chita, Russian Federation|Ural State Medical University based at Central City Clinical Hospital No.1 of Oktyabrskiy District, Ekaterinburg, Russian Federation|Interregional Clinical Diagnostic Center, Kazan, Russian Federation|Kazan State Medical University based at City Clinical Hospital #7, Kazan, Russian Federation|Federal State Budget Institution ""Scientific-Research Institute of Complex Problems of Cardiovascular Diseases, Kemerovo, Russian Federation|Medical Center Alliance, Kirovsk, Russian Federation|Krasnoyarsk State Medical University n.a. prof. V.F. Voino-Yasenetsky, Krasnoyarsk, Russian Federation|National Medical Research Center of Preventive Medicine, Moscow, Russian Federation|City Clinical Hospital #15 n.a. O.M. Filatov, Moscow, Russian Federation|Central Clinical Hospital of Russian Academy of Sciences, Moscow, Russian Federation|City Clinical Hospital n.a. M.E. Zhadkevich of Moscow Healthcare Department, Moscow, Russian Federation|National Medical Research Center of Cardiology - Department of Atherosclerosis, Moscow, Russian Federation|National Medical Research Center of Cardiology, Moscow, Russian Federation|City Clinical Hospital n.a. M.P. Konchalovskiy, Moscow, Russian Federation|Non-governmental Private Healthcare Institution ""Scientific Clinical Centre of Open Joint-Stock Company Russian Railways"" (JSC ""RZD""), Moscow, Russian Federation|Federal State Budget Institution ""Outpatient Clinic #3"" of Russian Federation President's Management Department, Moscow, Russian Federation|City Clinical Hospital No.2, Novosibirsk, Russian Federation|RC Medical LLC, Novosibirsk, Russian Federation|Research Institute of Physiology and Fundamental Medicine, Novosibirsk, Russian Federation|Orenburg State Medical University based at City Clinical Hospital #1, Orenburg, Russian Federation|Clinical-diagnostic center Zdorovye, Rostov-on-Don, Russian Federation|Rostov-on-Don City Hospital of Emergency Care, Rostov-on-Don, Russian Federation|Clinic Complex JSC, Saint Petersburg, Russian Federation|North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russian Federation|Medical Technologies LLC, Saint Petersburg, Russian Federation|Limited Liability Company MedPomosch, Saint Petersburg, Russian Federation|City hospital #38 n.a. N.A. Semashko, Saint Petersburg, Russian Federation|BioTechService LLC, Saint Petersburg, Russian Federation|Consultative Diagnostic Center with Out-patient Clinic, Saint Petersburg, Russian Federation|Almazov National Medical Research Centre, Scientific Laboratory of Electrocardiology, Saint Petersburg, Russian Federation|Saint-Petersburg State Budget Healthcare Institution ""City Pokrovskaya Hospital"", Department of Cardiology N.3, Saint Petersburg, Russian Federation|Regional Clinical Cardiology Dispensary, Saratov, Russian Federation|Saratov State Medical University n. a. V.I. Razumovsky, Saratov, Russian Federation|Almazov National Medical Research Centre, St. Petersburg, Russian Federation|Clinical Hospital #122 n. a. L.G. Sokolov of the Federal Medical Biological Agency, St. Petersburg, Russian Federation|Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation|Autonomous Institution of healthcare of the Voronezh region ""Voronezh regional clinical consultative and diagnostic centre, Voronezh, Russian Federation|Yaroslavl Regional Clinical Hospital for War Veterans - International Center on the Problems of the Elderly ""Zdorovoe Dolgoletie"", Yaroslavl, Russian Federation|Ivano-Frankivsk Regional Clinical Cardiological Dispensary, Chronic Ischaemic Heart Disease Department, Ivano-Frankivs'k, Ukraine|Municipal Healthcare Institution Kharkiv City Clinical Hospital #27, Intensive Therapy Department, Kharkiv, Ukraine|Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine|Kharkiv Railway Clinic. Hosp.#1, Branch Office of ""Healthcare Center"" of PJSC ""Ukr. Railways"", Cardiology Depart #2, Kharkiv, Ukraine|Kharkiv Railway Clinic. Hosp.#1, Branch Office of Healthcare Center of PJSC Ukr. Railways, Cardiology Depart #1, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise ""City Clinical Emergency Hospital n.a. prof. O.I. Meshchaninov of Kharkiv City Council, Kharkiv, Ukraine|Municipal Healthcare Institution Kharkiv City Outpatient Clinic #9, General Practice and Family Medicine Department #1, Kharkiv, Ukraine|Limited Liability Company Treatment and Diagnostic Center Adonis Plus, Outpatient Department, Kyiv, Ukraine|Kyiv City Clinical Hospital #1, Urgent Cardiology Department, Kyiv, Ukraine|SI Institute of Gerontology n.a. D.F.Chebotarev NAMS of Ukraine, Cardiol. Un. of Clin. Physiology and Int. Organs Path. Dep-t., Gen. Ther.Unit, Kyiv, Ukraine|SI Institute of Gerontology n.a. D.F.Chebotarev NAMS of Ukraine, Cardiol. Un. of Clin. Physiology and Int. Organs Path. Dep-t, Kyiv, Ukraine|Municipal Institution City Clinical Hospital #3 n.a. prof. L.J. Aleinikova, Cardiology Intensive Therapy Department, Odesa, Ukraine|Small Private Enterprise, Medical Centre Puls, Vinnytsya, Ukraine|Municipal Institution City Clinical Hospital #6, Therapeutic Department, Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT03011450"
895,"NCT01474434","Efficacy of LCQ908 on Cardiovascular Risk",,"Terminated","Has Results","Coronary Artery Disease|Hypertriglyceridemia","Drug: pradigastat (LCQ908)|Drug: Placebo","Change From Baseline in Myocardial Perfusion Reserve Index (MPRi) Overall Mean (Part A, Cohort 1)|Change From Baseline in Total Exercise Duration (Part A, Cohort 1)|Time to Onset of Angina (Part A, Cohort 1)|Time to Onset of Exercise-induced Ischemia(Part A, Cohort 1)|Aortic Plaque Inflammation (Part B)|Number of Participants With Adverse Events (Part A, Cohort 1)|Number of Participants With Adverse Events (Part A, Cohort 2)|Postprandial Triglycerides (Part A, Cohort 1)|Postprandial Triglycerides (Part A, Cohort 2)|Pharmacokinetics of Pradigastat (LCQ908): Plasma Concentration (Part A)|Other Related Lipid Parameters (Part A)|Interleukin-6 (IL-6) Level (Part A)|C-reactive Protein (CRP) Level (Part A)|Adiponectin Level ( Part B)","Novartis Pharmaceuticals|Novartis","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLCQ908A2213","December 2011","June 2014","June 2014","November 18, 2011","April 14, 2016","April 14, 2016","Novartis Investigative Site, Pasadena, California, United States",,"https://ClinicalTrials.gov/show/NCT01474434"
896,"NCT02235909","An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension",,"Active, not recruiting","No Results Available","Hypertension","Drug: Azilsartan Medoxomil|Drug: Losartan|Drug: Placebo for Azilsartan Medoxomil|Drug: Placebo for Losartan","Change in Blood Pressure|Change in blood Pressure relative to the comparator","Arbor Pharmaceuticals, Inc.","All","6 Years to 18 Years   (Child, Adult)","Phase 3","215","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AR14.001","December 19, 2014","November 2019","April 2020","September 10, 2014",,"March 12, 2019","Advanced Research Center, INC, Anaheim, California, United States|Direct Helpers Research Center, Hialeah, Florida, United States|JDH Medical Group LLC, Miami, Florida, United States|University of Miami/Jackson Memorial Hospital, Miami, Florida, United States|Medical Research Center of Miami II, Inc., Miami, Florida, United States|Pioneer Clinical Research, North Miami, Florida, United States|Georgia Clinical Research, Snellville, Georgia, United States|Zoe Center for Pediatrics, Thomaston, Georgia, United States|University of Louisville, Louisville, Kentucky, United States|David M. Headley, MD PA, Port Gibson, Mississippi, United States|Mount Sinai PRIME, Lake Success, New York, United States|Medical University of South Carolina (MUSC), Charleston, South Carolina, United States|Memphis and Shelby County Pediatric Group, Memphis, Tennessee, United States|Southeast Texas Clinical Research Center, Beaumont, Texas, United States|Texas Children's Heart Center, Houston, Texas, United States|Ericksen Research & Development, LLC, Clinton, Utah, United States|Mid-Columbia Research, Richland, Washington, United States|Hospital Italiano, Ciudad Autonoma, Buenos Aires, Argentina|Hospital de Niños, Ciudad Autonoma, Buenos Aires, Argentina|Clinica de Nefrologia, Urologia y Enf. Cardiovasculares S A, Santa Fe, Argentina|Clínica Nefrokids Ltda, Curitiba, Brazil|Hospital São Lucas da PUCRS, Porto Alegre, Brazil|Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, Brazil|Fundação José Luiz Egydio Setúbal, São Paulo, Brazil|Hospital Samaritano, São Paulo, Brazil|Eurolatino Pesquisas Médicas Ltda., Uberlândia, Brazil|SHATPPD-Ruse EOOD, Ruse, Bulgaria|Fundacion Oftalmologica de Santander - FOSCAL, Bucaramanga, Colombia|Fundacion Valle del Lili, Cali, Colombia|Fundacion Hospitalaria San Vicente de Paul, Medellin, Colombia|Hospital Pablo Tobón Uribe, Medellin, Colombia|Institucion Prestadora de Servicios de Salud de la Universidad de Antioquia ""IPS UNIVERSITARIA"", Medellin, Colombia|Principal SMO Kft., Baja, Hungary|Svabhegy Plusz Gyermekegeszsegugyi Kozpont, Budapest, Hungary|Szent Lukacs Korhaz Dombovar, Dombovar, Hungary|Prehospital Med Kft., Miskolc, Hungary|Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin. Kozp., Szeged, Hungary|Ospedale Pediatrico Giovanni XXIII, Bari, Italy|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milano, Italy|A.R.N.A.S. Ospedale Civico e Benfratelli, G. Cristina e M.Ascoli, Palermo, Italy|Instituto de Investigaciones Aplicadas a la Neurociencia A.C., Durango, Mexico|Hospital General de Mexico, Mexico City, Mexico|Accelerium S. de R.L. de C.V., Monterrey, Mexico|Centro de Investigacion Clinica Chapultepec S.A. de C.V., Morelia, Mexico|SPZOZ Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa, Bialystok, Poland|Uniwersytecki Szpital Dziecięcy w Krakowie, Krakow, Poland|NZOZ TRI-medica, Lodz, Poland|Praktyka Lekarzy Rodzinnych R.Jadach, M.Domanski NZOZ, Wroclaw, Poland|LCS Clinical Research Unit, Johannesburg, Gauteng, South Africa|Soweto Clinical Trial Centre, Soweto, Gauteng, South Africa|Netcare St. Anne's Hospital, Pietermaritzburg, KwaZulu-Natal, South Africa|Groote Schuur Hospital E13 Renal Unit, Cape Town, Western Cape, South Africa|Clinical Projects Research SA (PTY) LTD, Worcester, Western Cape, South Africa|CRISMO Bertha Gxowa Research Centre, Germiston, South Africa|Cukurova University Medical Faculty, Adana, Turkey|Gazi University Medical Faculty, Ankara, Turkey|Istanbul University Istanbul Medical Faculty, Istanbul, Turkey|Dokuz Eylul University Medicine Faculty, Izmir, Turkey|Erciyes University Medical Faculty, Kayseri, Turkey|Celal Bayar University Medical Faculty, Manisa, Turkey|CMI Chernivtsi City Children Clinical Hospital, Chernivtsi, Ukraine|Regional Children CH Cardiology Department Kharkiv NMU, Kharkiv, Ukraine|SI National Research Center of Radiation Medicine of NAMSU, Kyiv, Ukraine|USPC of ES EO&T Transplantation of MHU, Kyiv, Ukraine|HSEI of Ukraine UMSA, Poltava, Ukraine|SSU Division MU Ch of pediatrics, Sumy, Ukraine|Vynnitsa Regional Children CH pediatric department № 1 M.I. Pyrogov NMU, Vinnytsia, Ukraine|CI Zaporizhzhia City Multibranch Children Hospital #5, Zaporizhzhia, Ukraine|CI Zaporizhzhia Regional Clinical Children Hospital of ZRC, Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT02235909"
897,"NCT01368536","Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes","VALENCIA","Terminated","Has Results","Hypertension|Stage 2 Hypertension|Diabetes","Drug: Valturna|Drug: Amlodipine|Drug: Chlorthalidone|Drug: Placebo of Valturna Tablet|Drug: Placebo Capsule","Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) After 12 Weeks of Treatment Ending With the Combination of Valturna and Amlodipine Versus Valturna Alone|Change From Baseline in MSSBP After 12 Weeks of Treatment Ending With Between the Valturna + Chlorthalidone Combination and Valturna Alone|Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) After 12 Weeks of Treatment|Percentage of Responders After Treatment|Percentage of Patients Achieving Blood Pressure Control After Treatment|Number of Patients With Adverse Events, Serious Adverse Events and Death to Assess Safety and Tolerability of Treatment With Valturna and Chlorthalidone or Valturna and Amlodipine Versus Valturna Alone","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 4","975","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CSPV100AUS05","May 2011","February 2012","February 2012","June 8, 2011","March 19, 2013","March 21, 2013","Novartis Investigative Site, Athens, Alabama, United States|Novartis Investigative Site, Florence, Alabama, United States|Novartis Investigative Site, Huntsville, Alabama, United States|Novartis Investigative Site, Montgomery, Alabama, United States|Novartis Investigative Site, Muscle Shoals, Alabama, United States|Novartis Investigative Site, Chandler, Arizona, United States|Novartis Investigative Site, Little Rock, Arkansas, United States|Novartis Investigative Site, Buena Park, California, United States|Novartis Investigative Site, Fair Oaks, California, United States|Novartis Investigative Site, Fresno, California, United States|Novartis Investigative Site, Healdsburg, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Orangevale, California, United States|Novartis Investigative Site, Riverside, California, United States|Novartis Investigative Site, Roseville, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, Santa Ana, California, United States|Novartis Investigative Site, West Covina, California, United States|Novartis Investigative Site, Shelton, Connecticut, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Ft. Lauderdale, Florida, United States|Novartis Investigative Site, Jupiter, Florida, United States|Novartis Investigative Site, Lauderdale Lakes, Florida, United States|Novartis Investigative Site, North Miami Beach, Florida, United States|Novartis Investigative Site, St. Petersburg, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, West Palm Beach, Florida, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Gurnee, Illinois, United States|Novartis Investigative Site, Lansing, Kansas, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Beltsville, Maine, United States|Novartis Investigative Site, Waltham, Massachusetts, United States|Novartis Investigative Site, Wellesley Hills, Massachusetts, United States|Novartis Investigative Site, Brooklyn Center, Minnesota, United States|Novartis Investigative Site, Belzoni, Mississippi, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Picayune, Mississippi, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Ozark, Missouri, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Henderson, Nevada, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Toms River, New Jersey, United States|Novartis Investigative Site, Toms River, New Jersey, United States|Novartis Investigative Site, Trenton, New Jersey, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Camillus, New York, United States|Novartis Investigative Site, Asheboro, North Carolina, United States|Novartis Investigative Site, Asheville, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Shelby, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Fargo, North Dakota, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Lyndhurst, Ohio, United States|Novartis Investigative Site, Zanesville, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Reading, Pennsylvania, United States|Novartis Investigative Site, Uniontown, Pennsylvania, United States|Novartis Investigative Site, Wallingford, Pennsylvania, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Easley, South Carolina, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, Mt. Pleasant, South Carolina, United States|Novartis Investigative Site, Summerville, South Carolina, United States|Novartis Investigative Site, Varnville, South Carolina, United States|Novartis Investigative Site, Fayetteville, Tennessee, United States|Novartis Investigative Site, Arlington, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Lake Jackson, Texas, United States|Novartis Investigative Site, Pasadena, Texas, United States|Novartis Investigative Site, Plano, Texas, United States|Novartis Investigative Site, Richardson, Texas, United States|Novartis Investigative Site, St. George, Utah, United States|Novartis Investigative Site, Arlington, Virginia, United States|Novartis Investigative Site, Carolina, Puerto Rico|Novartis Investigative Site, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01368536"
898,"NCT01392495","Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)",,"Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: Imatinib","Number of Patients With Adverse Events, Serious Adverse Events and Deaths|Change From Baseline in the Six Minute Walk Distance (6MWD)|Time to Clinical Worsening (TTCW) Endpoints|Medical Resource Utilization","Novartis Pharmaceuticals|Novartis","All","Child, Adult, Older Adult","Phase 3","17","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CQTI571A2102E1|2010-021960-14","June 2011","March 2014","March 2014","July 12, 2011","July 13, 2015","August 10, 2015","Novartis Investigative Site, Mineola, New York, United States|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01392495"
899,"NCT03482440","Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia",,"Recruiting","No Results Available","Preeclampsia","Drug: Salsalate Oral Tablet|Drug: Placebo Oral Tablet","change in endothelial function following salsalate treatment compared to placebo treatment|change in inflammatory response to ang II compared to baseline","University of Iowa|Penn State University","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","HL138133","August 26, 2018","August 2021","March 2023","March 29, 2018",,"September 17, 2019","University of Iowa, Iowa City, Iowa, United States|Pennsylvania State University, University Park, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03482440"
900,"NCT02984813","Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy",,"Unknown status","No Results Available","Open-angle Glaucoma|Diabetic Retinopathy","Drug: GlaucoHealth|Drug: GlaucoSelect|Drug: Placebo","Flavoprotein fluorescence index|Visual acuity|Humphrey visual field testing (24-2)","The New York Eye & Ear Infirmary","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","15.25","April 2016","January 2017","January 2017","December 7, 2016",,"December 7, 2016","New York Eye and Ear Infirmary of Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02984813"
901,"NCT01307098","Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency",,"Completed","Has Results","Cholesterol Ester Storage Disease(CESD)|Lysosomal Acid Lipase Deficiency|LAL-Deficiency","Drug: Sebelipase alfa 0.35 mg/kg|Drug: Sebelipase alfa 1 mg/kg|Drug: Sebelipase alfa 3 mg/kg","Number Of Participants Reporting TEAEs And Infusion-Related Reactions (IRRs)","Alexion Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LAL-CL01","April 25, 2011","January 6, 2012","January 6, 2012","March 2, 2011","December 11, 2018","December 11, 2018","Stanford, California, United States|New York, New York, United States|Pittsburgh, Pennsylvania, United States|Prague, Czechia|Paris, France|Cambridge, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01307098"
902,"NCT01047683","Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","MARINE","Completed","No Results Available","Hypertriglyceridemia","Drug: AMR101 (ethyl icosapentate)|Drug: Placebo","Difference between AMR101 (ethyl icosapentate) and placebo treatment groups in triglyceride lowering effect|Difference between AMR101 (ethyl icosapentate) and placebo treatment groups in other lipid and biomarker levels","Amarin Pharma Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","229","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AMR-01-01-0016","December 2009","October 2010","July 2011","January 13, 2010",,"January 17, 2014","Amarin Investigational Site, Sacramento, California, United States|Amarin Investigational Site, Golden, Colorado, United States|Amarin Investigational Site, Miami, Florida, United States|Amarin Investigational Site, Miami, Florida, United States|Amarin Investigational Site, Ocala, Florida, United States|Amarin Investigational Site, Addison, Illinois, United States|Amarin Investigational Site, Chicago, Illinois, United States|Amarin Investigational Site, Louisville, Kentucky, United States|Amarin Investigational Site, Butte, Montana, United States|Amarin Investigational Site, Raleigh, North Carolina, United States|Amarin Investigational Site, Winston-Salem, North Carolina, United States|Amarin Investigational Site, Cincinnati, Ohio, United States|Amarin Investigational Site, Cincinnati, Ohio, United States|Amarin Investigational Site, Lynhurst, Ohio, United States|Amarin Investigational Site, Tulsa, Oklahoma, United States|Amarin Investigational Site, Corpus Christi, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Richmond, Virginia, United States|Amarin Investigational Site, Aalborg, Denmark|Amarin Investigational Site, Herlev, Denmark|Amarin Investigational Site, Oulu, Finland|Amarin Investigational Site, Dresden, Germany|Amarin Investigational Site, Giessen, Germany|Amarin Investigational Site, Magdeburg, Germany|Amarin Investigational Site, Muenchen, Germany|Amarin Investigational Site, Muenchen, Germany|Amarin Investigational Site, Nuernberg, Germany|Amarin Investigational Site, Ahmedabad, India|Amarin Investigational Site, Bangalore, India|Amarin Investigational Site, Bangalore, India|Amarin Investigational Site, Bangalore, India|Amarin Investigational Site, Gopalapuram, India|Amarin Investigational Site, Indore, India|Amarin Investigational Site, Mysore, India|Amarin Investigational Site, Genova, Italy|Amarin Investigational Site, Palermo, Italy|Amarin Investigational Site, Guadalajara, Jalisco, Mexico|Amarin Investigational Site, Mexico City, Mexico|Amarin Investigational Site, Mexico City, Mexico|Amarin Investigational Site, Monterrey Nuevo Leon, Mexico|Amarin Investigational Site, Amsterdam, Netherlands|Amarin Investigational Site, Groningen, Netherlands|Amarin Investigational Site, Rotterdam, Netherlands|Amarin Investigational Site, Rotterdam, Netherlands|Amarin Investigational Site, Utrecht, Netherlands|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, St Petersburg, Russian Federation|Amarin Investigational Site, St. Petersburg, Russian Federation|Amarin Investigational Site, St. Petersburg, Russian Federation|Amarin Investigational Site, Bloemfontein, South Africa|Amarin Investigational Site, Cape Town, South Africa|Amarin Investigational Site, Johannesburg, South Africa|Amarin Investigational Site, Parktown, South Africa|Amarin Investigational Site, Pretoria, South Africa|Amarin Investigational Site, Somerset West, South Africa|Amarin Investigational Site, Ivano-Frankivsk, Ukraine|Amarin Investigational Site, Kiev, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Odessa, Ukraine",,"https://ClinicalTrials.gov/show/NCT01047683"
903,"NCT02722408","Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)",,"Completed","No Results Available","Hypercholesteremia","Drug: Gemcabene 300 mg|Drug: Gemcabene 600 mg|Drug: Gemcabene 900 mg","LDL-C|non-HDL-C|Total Cholesterol [TC]|Triglycerides [TG]|HDL-C|Very low-density lipoprotein [VLDL-C]|hsCRP|Fibrinogen|Lipoprotein(a)|Apolipoprotein B (ApoB)|Apolipoprotein A-1 (ApoA-1)|Apolipoprotein A-II (ApoA-II)|Apolipoprotein C-II (ApoC-II)|Apolipoprotein C-III (ApoC-III)|Apolipoprotein E(ApoE)|Adverse Events|Clinical Laboratory","NeuroBo Pharmaceuticals Inc.","All","17 Years and older   (Child, Adult, Older Adult)","Phase 2","8","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEM-201","May 2016","April 2017","August 2017","March 30, 2016",,"March 31, 2020","Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|Robarts Research Institute, London, Ontario, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Wolfson Medical Center Internal Medicine Dept., Holon, Israel|Center for Research, Prevention and Treatment of Atherosclerosis - Cardiology Department of Medicine Kiryat Hadassah, Jerusalem, Israel|Ziv Medical Center Internal Medicine Department, Safed, Israel",,"https://ClinicalTrials.gov/show/NCT02722408"
904,"NCT01520116","Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension",,"Unknown status","No Results Available","Primary Open Angle Glaucoma|Ocular Hypertension","Drug: Stage 1 - ATS907 - Dose 1|Drug: Stage 1 - ATS907 - Dose 2|Drug: Stage 1 - ATS907 - Dose 3|Drug: Stage 1 - ATS907 - Dose 4|Drug: Stage 1 - Vehicle|Drug: Stage 2 - ATS907 - Dose A - to be selected based on Stage 1|Drug: Stage 2 - ATS907 - Dose B - to be selected based on Stage 1|Drug: Timoptic","Mean Change in Intraocular Pressure from Baseline|Observed Intraocular Pressure and % change from Baseline IOP|Mean observed, mean change from Baseline and mean % change from Baseline for the mean diurnal IOP","Altheos, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","ATS907-201","January 2012","December 2012",,"January 27, 2012",,"November 1, 2012","Artesia, California, United States|Glendale, California, United States|St. Joseph, Michigan, United States|Cleveland, Ohio, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01520116"
905,"NCT01250535","Human Cytochrome P450 4F Enzymes and Drug Interactions",,"Completed","No Results Available","Healthy Volunteers|Drug Drug Interactions","Drug: Warfarin|Drug: Placebo|Drug: Lovastatin","Pharmacodynamics|Pharmacokinetics","University of North Carolina, Chapel Hill|National Institutes of Health (NIH)","All","18 Years to 60 Years   (Adult)","Phase 1","19","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","10-0576|1R01GM089994-01A1","December 2010","December 2011","December 2011","November 30, 2010",,"January 21, 2013","University of North Carolina, Clinical and Translational Research Center (CTRC), Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01250535"
906,"NCT01192412","The CHIPS Trial (Control of Hypertension In Pregnancy Study)",,"Completed","Has Results","Gestational Hypertension","Procedure: Intervention is blood pressure management approach|Procedure: Intervention is blood pressure management approach.","Pregnancy Loss or NICU Admission for Greater Than 48 Hours|Serious Maternal Complications Measured up to 6 Weeks Postpartum","University of British Columbia|Canadian Institutes of Health Research (CIHR)|Sunnybrook Research Institute","Female","Child, Adult, Older Adult","Not Applicable","987","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H08-00882|MCT-87522|07-3431","April 2009","February 2014","February 2014","September 1, 2010","January 11, 2017","January 11, 2017","Yale-New Haven Hospital, New Haven, Connecticut, United States|Norton Hospital Downtown, Louisville, Kentucky, United States|Norton Suburban Hospital, Louisville, Kentucky, United States|Beth Israel Deaconess, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Cooper University Hospital, Camden, New Jersey, United States|University of North Carolina, Chapel Hill, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Meriter Hospital, Madison, Wisconsin, United States|Hospital JR Vidal, Corrientes, Argentina|Hospital LC Lagomaggiore, Mendoza, Argentina|Hospital JM Cullen, Santa Fe, Argentina|Hospital Avellaneda, Tucuman, Argentina|Campbelltown Hospital, Campbelltown, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Women's and Children's Hospital, Adelaide, Australia|Ipswich Hospital, Ipswich, Australia|King Edward Memorial Hospital, Subiaco, Australia|St John of God Hospital, Subiaco, Australia|Hospital Materno Infantil, Goiania, Brazil|Hospital Universitario Antonio Pedro, Niteroi, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, Brazil|Maternidade Escola da UFRJ, Rio de Janeiro, Brazil|Clinica Perinatal Barra, Rio de Janerio, Brazil|Laranjeiras Clinica Perinatal, Rio de Janerio, Brazil|Maternidade Escola de Vila Nova Cachoeirinha, Sao Paulo, Brazil|Calgary Health Region - Foothills Hospital, Calgary, Alberta, Canada|Royal Alexandra Hospital, Edmonton, Alberta, Canada|Jim Pattison Outpatient Care and Surgery Centre, Surrey, British Columbia, Canada|University of British Columbia, Department of Obstetrics & Gynaecology, Vancouver, British Columbia, Canada|Children's & Women's Health Centre of BC, Vancouver, British Columbia, Canada|St Paul's Hospital, Vancouver, British Columbia, Canada|St Boniface General Hospital, Winnipeg, Manitoba, Canada|Women's Health Centre, St. John's, Newfoundland and Labrador, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|London Health Sciences Centre, London, Ontario, Canada|Ottawa Hospital Civic Division, Ottawa, Ontario, Canada|Ottawa Hospital General Division, Ottawa, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|St Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Toronto East General Hospital, Toronto, Ontario, Canada|Hopital Sainte-Justine, Montreal, Quebec, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|CHUS Fleurimont, Sherbrooke, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada|Regina General Hospital, Regina, Canada|Hospital Base Osorno, Osorno, Chile|Hospital Dr Sotero del Rio, Puente Alto, Chile|Clinica Materno Infantil Farallones, Cali, Colombia|Clinica Versalles, Cali, Colombia|Corporacion Conmfenalco Valle - Universidad Libre, Cali, Colombia|Tartu University Hospital-Women's Clinic, Tartu, Estonia|University of Debrecen, Debrecen, Hungary|Ma'ayney Hayeshua Medical Center, Bnei Brak, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Nazareth Hospital (EMMS), Nazareth, Israel|Islamic Hospital, Amman, Jordan|Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands|Flevo ziekenhuis, Almere, Netherlands|Meander Medisch Centrum, Amersfoort, Netherlands|Academic Medical Center, Amsterdam, Netherlands|OLVG, Amsterdam, Netherlands|VU Medical Center, Amsterdam, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|UMCG, Groningen, Netherlands|Kennemer Gasthuis Haarlem, Haarlem, Netherlands|Tergooiziekenhuizen, Hilversum, Netherlands|Spaarne Ziekenhuis, Hoofddorp, Netherlands|MUMC Maastricht, Maastricht, Netherlands|St Antonius Ziekenhuis, Nieuwegein, Netherlands|Ziekenhuis Bernhoven, Oss, Netherlands|Diakonessen Ziekenhuis, Utrecht, Netherlands|UMCU, Utrecht, Netherlands|Maxima Medical Centre, Veldhoven, Netherlands|Isala Klinieken Zwolle, Zwolle, Netherlands|Waitemata Health-North Shore Hospital, Auckland, New Zealand|Christchurch Women's Hospital, Christchurch, New Zealand|Medical University of Gdansk, Gdansk, Poland|Polish Mothers Memorial Hospital, Lodz, Poland|University School of Medical Sciences, Poznan, Poland|Basildon & Thurrock University Hospital, Basildon, United Kingdom|Birmingham Women's Hospital, Birmingham, United Kingdom|East Lancashire Hospitals NHS Trust, Blackburn, United Kingdom|Bradford Royal Infirmary, Bradford, United Kingdom|Chesterfield Royal Hospital, Chesterfield, United Kingdom|University Hospital Coventry and Warwickshire, Coventry, United Kingdom|The Royal Derby Hospital, Derby, United Kingdom|Calderdale Royal Hospital, Halifax, United Kingdom|Lancashire Teaching Hospitals NHS Foundation Trust, Lancashire, United Kingdom|Royal Lancaster Infirmary, Lancaster, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Liverpool Women's Hospital, Liverpool, United Kingdom|Guy's & St Thomas' Hospital, London, United Kingdom|Queen Elizabeth Hospital, London, United Kingdom|St Mary's Hospital, Manchester, United Kingdom|Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom|King's Mill Hospital, Nottinghamshire, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Queen's Medical Centre, Nottingham, United Kingdom|Southport & Ormskirk Hospital, Ormskirk, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom|Wexham Park Hospital, Slough, United Kingdom|City Hospitals Sunderland NHS Foundation Trust, Sunderland, United Kingdom|Singleton Hospital, Swansea, United Kingdom|South Warwickshire NHS Trust, Warwickshire, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom|York District Hospital, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01192412"
907,"NCT01739400","Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome","MAESTRO-OL","Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: Macitentan 10 mg tablet, once daily.","Change in Exercise Capacity as Measured by 6-minute Walking Distance (6MWD) Month 6 and 12|Change in WHO Functional Class (FC) at Month 6 and 12|Change in Borg Dyspnea Score at Month 6 and 12|Change in Peripheral Oxygen Saturation (SpO2) at Rest at Month 6 and 12","Actelion","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","217","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-055-308","September 10, 2013","January 12, 2018","January 12, 2018","December 3, 2012","April 16, 2019","April 16, 2019","Emory University Hospital/the Emory Clinic, Atlanta, Georgia, United States|Barnes-Jewish Hosp/Wash Univ School of Med, Saint Louis, Missouri, United States|Children'S Heart Center Nevada, Las Vegas, Nevada, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Texas Children'S Hosp - Dept of Cardiology, Houston, Texas, United States|Gen Hosp Univ Vienna Dept Cardiology, Vienna, Austria|Mhat Nat Card Hosp - Cardiology Clinic, Sofia, Bulgaria|Mhat Nat Card Hosp - Pediatric Clin / Ped Card Dept, Sofia, Bulgaria|Mhat Sveta Anna Clin Card, Sofia, Bulgaria|Instituto Nacional del Torax, Providencia, Santiago RCH, Chile|Clinica Tabancura - Cardio Unit, Santiago, Chile|Guangdong General Hospital, Cardiology Dpt, Guangzhou, Guangdong, China|Wu Han Asia Heart Hosp, Wuhan, Hubei, China|The General Hosp of Shenyang Military Region, Shenyang, Liaoning, China|Beijing Anzhen Hospital, Cardiology Dpt, Beijing, China|Cardiovascular Institute&Fuwai Hospital, Beijing, China|Shanghai Pulmonary Hospital, Dept of Pulmonary Circulation, Shanghai, China|Hosp La Timone - Dept Pediatric Cardiology, Marseille Cedex 5, France|Hosp Laennec - Dept Cardiology, Nantes Cedex 1, France|Hosp Pompidou - Dept Congenital Cardiac Diseases, Paris cedex 15, France|Hosp Cardiology Haut Leveque - Dept Congenital Diseases, Pessac, France|Herzzentrum Berlin, Ped Cardiology, Berlin, Germany|Universitätsklinikum Giessen - Pediatric Heart Center, Giessen, Germany|Uni Heidelberg - Kinderkardiologie, Heidelberg, Germany|Ahepa University General Hospital, Thessaloniki, Greece|Institut Jantung Negara, Kuala Lumpur, Malaysia|Unidad de Investigacion Clin En Med, Sc (Udicem), Monterrey, Nuevo Leon, Mexico|Instituto Nacional de Cardiologia (Inc) Ignacio Chavez, Mexico City, Mexico|Instituto de Corazon de Querètaro, Querétaro, Mexico|PHC, MAB, Manila, Philippines|Cardiology Gdańsk Univ, Gdańsk, Poland|Cardiology Kraków Univ, Krakow, Poland|Cardiology Wrocław, Wrocław, Poland|Hosp Univ Coimbra - Dpt Cardiology, Coimbra, Portugal|Hosp Sta Marta - Dept Cardiology, Lisboa, Portugal|Er Inst For Cardvasc Dis ""Prof Dr Cc Iliescu"" - Card Ii, Bucaresti, Romania|Cardio Med Srl, Targu-Mures, Romania|Clin Hosp For Inf and Pulm Dis Victor Babes - Ii Pulm, Timisoara, Romania|Sci Institute Systemic Poriblems Cardio Diseases Kemerovo, Kemerovo, Russian Federation|Russian Cardiology Scientific and Production Complex, Moscow, Russian Federation|V. A. Almazov Institute of Cardiology, St Petersburg, Russian Federation|Dedinje Cardiovasc Inst - Cardiovasc Research Ctr, Belgrade, Serbia|Mother and Child Health Care Institute Dr. Vukan Cupic, Belgrade, Serbia|Clin Hosp Ctr Zemun - Cardiology Dept, Belgrade, Serbia|Hosp Univ Vall D'Hebron - Dpt Congenital Heart Disease Adult, Barcelona, Spain|Hosp Univ Virgen Macarena - Dpt Cardiology, Sevilla, Spain|Hosp Universitario La Fe Dpt Cardiology, Valencia, Spain|Bristol Univ Hosp Congenital Heart Centre, Bristol, United Kingdom|Hanoi Medical University Hospital, Hanoi, Vietnam|Children'S Hospital, Ho Chi Minh, Ho Chi Minh, Vietnam|Tam Duc Hospital, Ho Chi Minh, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT01739400/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT01739400/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01739400"
908,"NCT01105975","A Study of LY2484595 in Patients With High LDL-C or Low HDL-C",,"Completed","Has Results","Dyslipidemia","Drug: LY2484595|Drug: Atorvastatin|Drug: Simvastatin|Drug: Rosuvastatin|Drug: Placebo for LY2484595|Drug: Placebo for Statins","Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin Monotherapy|Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin Monotherapy|Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 and Placebo|Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 and Placebo|Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Simvastatin or Rosuvastatin and Simvastatin/Rosuvastatin Monotherapy|Percent Change From Baseline to 12 Weeks Endpoint in Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Simvastatin or Rosuvastatin and Simvastatin/Rosuvastatin Monotherapy|Pharmacokinetics - LY2484595 Area Under the Concentration-Time Curve (AUC) at Steady-State|Percent Change From Baseline to 12 Weeks Endpoint in Plasma Cholesteryl Ester Transfer Protein (CETP) Activity|Percent Change From Baseline to 12 Weeks Endpoint in Plasma Cholesteryl Ester Transfer Protein (CETP) Mass|The Number of Episodes of Rashes at Any Time From Baseline Through Week 12|Change From Baseline to 12 Weeks Endpoint in Blood Pressure (BP)|Change From Baseline to 12 Weeks Endpoint in Serum Aldosterone|Change From Baseline to 12 Weeks Endpoint in Plasma Renin Activity|Change From Baseline to 12 Weeks Endpoint in Serum Potassium|Change From Baseline to 12 Weeks Endpoint in Serum Sodium|Change From Baseline to 12 Weeks Endpoint in Serum Bicarbonate|Change From Baseline to 18 Weeks Endpoint in EuroQoL Questionnaire - 5 Dimensions (EQ-5D) Score","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","398","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12468|I1V-MC-EIAF","April 2010","June 2011","June 2011","April 19, 2010","March 22, 2018","March 22, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fayetteville, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spring Valley, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vista, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Golden, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brandon, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Longwood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponte Vedra, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waterloo, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Auburn, Maine, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Picayune, Mississippi, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edison, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Endwell, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cary, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlotte, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greensboro, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hickory, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salisbury, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wilmington, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Red Lion, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yardley, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greer, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount Pleasant, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Simpsonville, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bristol, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kingsport, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tacoma, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oregon, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ballerup, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vejle, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bochum, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leipzig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Breda, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eindhoven, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Geleen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Groningen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leiderdorp, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zoetermeer, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdynia, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wroclaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Reading, Berkshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chorley, Lancashire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liverpool, Merseyside, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01105975"
909,"NCT03531905","Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C",,"Completed","Has Results","Diabetes|Diabetes Mellitus, Type 2|Cholesterolemia","Drug: Bempedoic acid + Ezetimibe FDC Oral Tablet|Drug: Ezetimibe 10 mg Oral Tablet|Drug: Placebo Oral Tablet|Drug: Placebo oral capsule","Percent Change From Baseline to Week 12/End of Study (EOS) in Low-density Lipoprotein Cholesterol (LDL-C)|Percent Change From Baseline to Week 12/EOS in LDL-C (Comparing Ezetimibe With Placebo)|Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)|Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)|Percent Change From Baseline to Week 12 in Total Cholesterol (TC)|Percent Change From Baseline to Week 12 in Apolipoprotein B (Apo B)|Percent Change From Baseline to Week 12 in Triglycerides (TGs)|Percent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C)|Number of Participants With LDL-C <70 Milligrams Per Deciliter (mg/dL) at Week 12|Secondary Outcome Measure: Number of Participants With an LDL-C Reduction of ≥50% From Baseline at Week 12|Change From Baseline to Week 12 in Hemoglobin A1C (HbA1c)|Percent Change From Baseline to Week 12 in HbA1c","Esperion Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","242","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1002FDC-058","May 9, 2018","June 18, 2019","June 18, 2019","May 22, 2018","April 8, 2020","April 9, 2020","Clinical Trials Research, Lincoln, California, United States|FInlay Medical Research, Miami, Florida, United States|L-MARC Research Center, Louisville, Kentucky, United States|Hampton Roads Center for Clinical Research, Suffolk, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03531905/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03531905/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03531905"
910,"NCT02990143","The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)",,"Unknown status","No Results Available","Glaucoma","Procedure: Ologen","The Effectiveness of ologen® Collagen Matrix in preventing intraocular pressure (IOP) spikes after Ahmed Glaucoma Valve Surgery (AGV-FP7)","The New York Eye & Ear Infirmary","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","13.33","January 2014","December 2017","December 2017","December 13, 2016",,"December 13, 2016","New York Eye and Ear Infirmary, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02990143"
911,"NCT03097107","Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL",,"Suspended","No Results Available","Dyslipidemias","Drug: Saroglitazar Magnesium 1 mg|Drug: Saroglitazar Magnesium 2 mg|Drug: Saroglitazar Magnesium 4 mg|Drug: Placebo","Percentage change in triglyceride cholesterol levels|Percentage change in TG-C|Percentage change in lipid profile.","Zydus Discovery DMCC","All","18 Years and older   (Adult, Older Adult)","Phase 2","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SARO.15.001.05","April 6, 2017","January 18, 2018","December 31, 2019","March 31, 2017",,"February 4, 2019","Medical Affiliated Research Center, Inc., Huntsville, Alabama, United States|Encompass Clinical Research, Encinitas, California, United States|Integrated Research Center, San Diego, California, United States|Ventura Clinical Trials, Ventura, California, United States|Colorado Springs Health Partners, Colorado Springs, Colorado, United States|Meridien Research - Bradenton, Bradenton, Florida, United States|Meridien Research - Lakeland, Lakeland, Florida, United States|Oviedo Medical Research, LLC, Oviedo, Florida, United States|Meridien Research - Tampa, Tampa, Florida, United States|River Birch Research Alliance LLC, Blue Ridge, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Herman Clinical Research, LLC, Suwanee, Georgia, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|Heartland Research Associates, LLC, Newton, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Centennial Medical Group, Elkridge, Maryland, United States|MD Medical Research, Oxon Hill, Maryland, United States|Mercury Street Medical, Butte, Montana, United States|Einstein Clinical Research, Charlotte, North Carolina, United States|Triad Clinical Trials LLC, Greensboro, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Wells Institute for Health Awareness, Kettering, Ohio, United States|Ohio Clinical Research - Lyndhurst, Lyndhurst, Ohio, United States|Awasty Research Network, LLC, Marion, Ohio, United States|Ohio Clinical Research, LLC - Willoughby Hills, Willoughby Hills, Ohio, United States|Columbia Research Group, Inc., Portland, Oregon, United States|PMG Research of Bristol, LLC, Bristol, Tennessee, United States|Jackson Clinic, Jackson, Tennessee, United States|Pioneer Research Solutions Inc., Houston, Texas, United States|National Clinical Research - Richmond, Inc, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03097107"
912,"NCT00848731","Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism",,"Completed","No Results Available","Pulmonary Embolism","Drug: nitric oxide","Borg score|vital signs","Atrium Health","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CMC_kline_iNO1.1","February 2009","May 2011","May 2011","February 20, 2009",,"June 27, 2011","Carolinas Medical Center, Charlotte, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00848731"
913,"NCT01654484","A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT",,"Completed","No Results Available","Glaucoma and Ocular Hypertension","Drug: DE-117|Drug: 0.0015% tafluprost|Drug: DE-117 and 0.0015% tafluprost|Drug: Placebo","Change from baseline in intraocular pressure (IOP) on Day 29 at each scheduled time point","Santen Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","33-001","July 2012","November 2012","November 2012","July 31, 2012",,"April 18, 2018","Santen Investigational Site, Newport Beach, California, United States|Santen Investigational Site, Deerfield Beach, Florida, United States|Santen Investigational Site, Largo, Florida, United States|Santen Investigational Site, Morrow, Georgia, United States|Santen Investigational Site, Roswell, Georgia, United States|Santen Investigational Site, Rochester, New York, United States|Santen Investigational Site, Cleveland, Ohio, United States|Santen Investigational Site, Austin, Texas, United States|Santen Investigational Site, Fort Worth, Texas, United States|Santen Investigational Site, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01654484"
914,"NCT02754596","Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution",,"Active, not recruiting","No Results Available","Glaucoma Open-angle","Drug: Travoprost Intraocular Implant, high elution|Drug: Travoprost Intraocular Implant, low elution|Drug: Timolol Maleate Ophthalmic Solution, 0.5%","Intraocular pressure (IOP) measured in mm Hg","Glaukos Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","GC-009","March 2016","September 2017","December 2020","April 28, 2016",,"March 8, 2019","John Berdahl, MD, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT02754596"
915,"NCT02859129","Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)","ECLIPSEIII","Completed","No Results Available","Hypertriglyceridemia","Drug: rosuvastatin 40 mg tablet|Drug: Epanova™ QD (2 x 1 g capsules)|Drug: Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose|Drug: Multiple (20) oral doses of 2 g Vascepa® every 12 hours","ln-transformed Cmax,ss of baseline-adjusted total EPA, total DHA, and total EPA+DHA|ln-transformed AUC0-tau of baseline-adjusted total EPA, total DHA, and total EPA+DHA|ln-transformed Cmax,ss of unadjusted total EPA, total DHA, and total EPA+DHA|dose proportionality of baseline-adjusted total EPA, total DHA, and total EPA+DHA systemic exposure will be assessed following multiple doses of Epanova™ 2 g and 4 g|ln-transformed AUC0-tau of unadjusted total EPA, total DHA, and total EPA+DHA","AstraZeneca","All","18 Years to 55 Years   (Adult)","Phase 1","114","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OM-EPA-009","September 2013","November 2013","November 2013","August 8, 2016",,"August 17, 2016","Celerion, Neptune, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02859129"
916,"NCT01692301","Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension",,"Completed","Has Results","Hypertension","Drug: LCZ696|Drug: Olmesartan|Drug: LCZ696 matching placebo|Drug: Olmesartan matching placebo|Drug: amlodipine|Drug: hydrochlorothiazide","Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 12 Weeks|Change From Baseline in Mean Central Pulse (CPP) Pressure|Change From Baseline in Mean Pulse Wave Velocity (PWV)|Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 52 Weeks|Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)|Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)|Change From Baseline in Mean Sitting Pulse Pressure (msPP)|Change From Baseline in Mean Arterial Pressure (MAP)|Change From Baseline in Mean 24-hour Systolic Blood Pressure (maSBP)|Change From Baseline in Mean 24-hour Diastolic Blood Pressure (maDBP)|Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure (maPP)","Novartis Pharmaceuticals|Novartis","All","60 Years and older   (Adult, Older Adult)","Phase 2","454","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLCZ696A2216|2012-002899-14","December 2012","April 2015","April 2015","September 25, 2012","May 4, 2016","May 4, 2016","Novartis Investigative Site, Clearwater, Florida, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Belzoni, Mississippi, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Lake Jackson, Texas, United States|Novartis Investigative Site, Pasadena, Texas, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Ramos Mejia, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Barranquilla, Atlantico, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Treviglio, BG, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, San Daniele Del Friuli, UD, Italy|Novartis Investigative Site, Shimotsuke-city, Tochigi, Japan|Novartis Investigative Site, Bucheon, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Jerez de La Frontera, Cadiz, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Terrassa, Catalunya, Spain|Novartis Investigative Site, Centelles, Cataluña, Spain|Novartis Investigative Site, Puerto de Sagunto, Comunidad Valenciana, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01692301"
917,"NCT01408303","[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL","ESPRIT","Completed","Has Results","Hypertriglyceridemia|Cardiovascular Disease","Drug: Olive oil, 4g|Drug: omega-3-carboxylic acids, 2g|Drug: omega-3-carboxylic acids, 4g","Serum Non-HDL Cholesterol","AstraZeneca|Omthera Pharmaceuticals, Inc|Medpace, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","646","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OM-EPA-004","August 2011","June 2012","June 2012","August 3, 2011","December 5, 2014","December 5, 2014","Muscle Shoals, Alabama, United States|Chandler, Arizona, United States|Phoenix, Arizona, United States|Little Rock, Arkansas, United States|Encinitas, California, United States|Lomita, California, United States|Los Angeles, California, United States|Sacramento, California, United States|San Diego, California, United States|Spring Valley, California, United States|Westlake Village, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Brandon, Florida, United States|Clearwater, Florida, United States|Coral Gables, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Melbourne, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Oviedo, Florida, United States|Ponte Vedra, Florida, United States|St. Petersburg, Florida, United States|Addison, Illinois, United States|Chicago, Illinois, United States|Oakbrook Terrace, Illinois, United States|Indianapolis, Indiana, United States|Newton, Kansas, United States|Wichita, Kansas, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Madisonville, Kentucky, United States|Auburn, Maine, United States|Oxon Hill, Maryland, United States|Troy, Michigan, United States|Edina, Minnesota, United States|Chesterfield, Missouri, United States|Kansas City, Missouri, United States|St. Louis, Missouri, United States|Butte, Montana, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Endwell, New York, United States|New Windsor, New York, United States|Rochester, New York, United States|Cary, North Carolina, United States|Charlotte, North Carolina, United States|Hickory, North Carolina, United States|High Point, North Carolina, United States|Raleigh, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Statesville, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Lyndhurst, Ohio, United States|Marion, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Eugene, Oregon, United States|Harleysville, Pennsylvania, United States|Jersey Shore, Pennsylvania, United States|Lansdale, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Mount Pleasant, South Carolina, United States|Mt Pleasant, South Carolina, United States|Rapid City, South Dakota, United States|Bristol, Tennessee, United States|Gray, Tennessee, United States|Kingsport, Tennessee, United States|Corpus Christi, Texas, United States|Houston, Texas, United States|Katy, Texas, United States|San Antonio, Texas, United States|Murray, Utah, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Olympia, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01408303"
918,"NCT01893515","The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects",,"Completed","No Results Available","Dyslipidemia","Drug: PRC-4016|Drug: Placebo","Percent change in triglycerides from baseline to week 12|Change in HDL-C from baseline to Week 12|Change in non-HDL-C from baseline to Week 12|Change in LDL-C from baseline to Week 12|Change in VLDL-C from baseline to Week 12|Change in total cholesterol from baseline to Week 12|Change in ApoA1 from baseline to Week 12|Change in Apo B from baseline to Week 12|Change in insulin from baseline to Week 12|Change in fasting plasma glucose from baseline to Week 12|Change in HbA1c from baseline to Week 12|Change in insulin resistance (HOMA) from baseline to Week 12|Change in Lp-PLA2 from baseline to Week 12|Change in hsCRP from baseline to Week 12|Change in red blood cell content of EPA and DHA from baseline to Week 12;","Pronova BioPharma","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","87","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTN 4016 13201","July 2013","July 2014","July 2014","July 9, 2013",,"October 30, 2015","Medical Affiliated Research Center, Inc., Huntsville, Alabama, United States|Terence Hart, MD, Muscle Shoals, Alabama, United States|Central Phoenix Medical Clinic, Phoenix, Arizona, United States|Pacific Oaks Medical Group, Beverly Hills, California, United States|National Research Institute - Wilshire, Los Angeles, California, United States|National Research Institute - East 118, Los Angeles, California, United States|Research Across America - Santa Ana, Santa Ana, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Colorado Springs Health Partners, Colorado Springs, Colorado, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Jacksonville Impotence Treatment Center, Jacksonville, Florida, United States|Compass Research East, LLC, Oviedo, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Meridien Research- Tampa, Tampa, Florida, United States|Evanston Premier Healthcare Research LLC, Evanston, Illinois, United States|Medisphere Medical Research Center, Evansville, Indiana, United States|Heartland Research Assoc., LLC, Newton, Kansas, United States|Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville, Kentucky, United States|Troy Internal Medicine, P.C., Troy, Michigan, United States|Radiant Research - Edina, Edina, Minnesota, United States|Mercury Street Medical, Butte, Montana, United States|Peters Medical Research, High Point, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Sterling Research Group, Ltd. - Auburn, Cincinnati, Ohio, United States|Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States|Columbus Clinical Research, Inc., Columbus, Ohio, United States|PSB Research/P. S. Bains, M.S., D.O., Marion, Ohio, United States|RAS Health Ltd, Marion, Ohio, United States|Lynn Health Science Institute - Oklahoma City, Oklahoma City, Oklahoma, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|UnitedResearch - Orangeburg, LLC, Orangeburg, South Carolina, United States|Padre Coast Clinical Research, Corpus Christi, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States|National Clinical Research - Norfolk, Inc., Norfolk, Virginia, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01893515"
919,"NCT01059864","Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550",,"Completed","Has Results","Rheumatoid Arthritis","Drug: CP-690,550|Drug: Atorvastatin|Drug: Atorvastatin Placebo","Percent Change From Baseline (Week 6) in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Week 12|Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12|12-Hours Fasting Lipid Profile|12-Hours Fasting Lipid Profile: Particle Size of Lipoproteins|12-Hours Fasting Lipid Profile: Level of Lipoprotein Particles|12-Hours Fasting Lipid Profile: Level of High Density Lipoprotein Cholesterol (HDL-C) Particles|Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])|Disease Activity Score Using 28-Joint Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])|Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])|Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])|Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response|Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response|Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response|Tender-Joint Count|Swollen-Joint Count|C-Reactive Protein (CRP)|Erythrocyte Sedimentation Rate (ESR)|Patient Assessment of Arthritis Pain|Physician's Global Assessment (PhysGA) of Arthritis Pain|Patient's Global Assessment (PtGA) of Arthritis Pain|Health Assessment Questionnaire Disability Index (HAQ-DI)","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","111","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A3921109","February 2010","November 2010","November 2010","February 1, 2010","December 13, 2012","December 13, 2012","Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Huntsville, Alabama, United States|Pfizer Investigational Site, Gilbert, Arizona, United States|Pfizer Investigational Site, Scottsdale, Arizona, United States|Pfizer Investigational Site, Upland, California, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Dayton, Ohio, United States|Pfizer Investigational Site, Mayfield Village, Ohio, United States|Pfizer Investigational Site, Greenville, South Carolina, United States|Pfizer Investigational Site, Allen, Texas, United States|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01059864"
920,"NCT03514420","Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With With Familial Partial Lipodystrophy (FPL)",,"Completed","No Results Available","Familial Partial Lipodystrophy","Drug: AKCEA-ANGPTL3-LRX","Reduction of fasting triglycerides (TG).|Effect of ISIS 703802 on mixed meal test (MMT).|Effect of ISIS 703802 on lipid parameters.|Effect of ISIS 703802 on glycosylated hemoglobin (HbA1c).|Effect of ISIS 703802 on hepatic fat fraction.|Effect of ISIS 703802 on fat distribution in various areas of the body.|The safety of ISIS 703802 by the incidence of treatment-emergent adverse events.","Akcea Therapeutics|Ionis Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISIS 703802-CS5","May 30, 2018","July 30, 2019","August 20, 2019","May 2, 2018",,"September 13, 2019","Clinical Site, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03514420"
921,"NCT03002168","Determining Lipid Content in Stool After Alpha-cyclodextrin","FMAT","Completed","No Results Available","Healthy Participants","Dietary Supplement: Alpha-cyclodextrin|Dietary Supplement: Placebo|Radiation: Triolein radiolabeled with 100 microcuries of 3^Hydrogen|Radiation: Tripalmitin radiolabeled with 20 microcuries of 14^Carbon","Change in lipid content in stool, measured using 3^H radiolabeled tracer|Change in lipid content in stool, measured using 14^C radiolabeled tracer|Change in blood triglyceride concentrations, measured using 3^H radiolabeled tracer|Change in blood triglyceride concentrations, measured using 14^C radiolabeled tracer|Change in blood glucose concentration","Mayo Clinic|SFI Research","All","18 Years to 60 Years   (Adult)","Not Applicable","8","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","16-005006","January 20, 2017","June 5, 2017","June 5, 2017","December 23, 2016",,"November 17, 2017","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03002168"
922,"NCT01133366","A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin",,"Completed","No Results Available","Healthy","Drug: warfarin sodium|Drug: mipomersen sodium; warfarin sodium","Area under the effect curve (AUC), for INR (international normalized ratio), PT (prothrombin time), and aPTT (activated partial thromboplastin time)|Maximal Value (MAX) for INR, PT and aPTT|Time of maximal effect (Tmax) for INR, PT, and aPTT|Warfarin Plasma Pharmacokinetic parameters (AUC 0-t, AUC 0-inf, Maximum Concentration (Cmax))|Mipomersen Plasma Pharmacokinetic parameters (AUC0-t, AUC0-inf, Cmax)|Incidence of treatment-emergent Adverse Events","Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.","All","18 Years to 45 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MIPO2900509","May 2010","May 2010","July 2010","May 28, 2010",,"August 3, 2016","PPD Development, LP, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01133366"
923,"NCT01925391","The Measurement of Intraocular Pressure in Normal Children Under General Anesthesia With and Without Nitrous Oxide and Anesthetic Eye Drops","IOP","Completed","No Results Available","Glaucoma|Intraocular Pressure|Anesthesia","Drug: Tono-pen XL Applanation tonometer + Ocu-film +","Measurement of intraocular pressure in nonglaucomatous children under Nitrous oxide/Oxygen/topical anesthesia and Nitrous oxide/Sevoflurane/oxygen/Topical anesthesia.","University of Miami","All","1 Year to 18 Years   (Child, Adult)","Early Phase 1","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","20120451","January 2013","May 2014","May 2014","August 19, 2013",,"June 16, 2014","University of Miami Bascom Palmer Eye Hospital, Miami, Florida, United States|Bascom Palmer Eye Hospital, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01925391"
924,"NCT01763866","LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","LAPLACE-2","Completed","Has Results","Hyperlipidemia","Biological: Evolocumab|Drug: Ezetimibe|Drug: Placebo to Evolocumab|Drug: Placebo to Ezetimibe|Drug: Atorvastatin|Drug: Rosuvastatin|Drug: Simvastatin","Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12|Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL|Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12|Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein(a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at Week 12|Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","2067","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110115|2012-001363-70","January 15, 2013","November 12, 2013","December 4, 2013","January 9, 2013","December 22, 2015","June 14, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Carmichael, California, United States|Research Site, Encino, California, United States|Research Site, Long Beach, California, United States|Research Site, Newport Beach, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Torrance, California, United States|Research Site, Tustin, California, United States|Research Site, Westlake Village, California, United States|Research Site, Littleton, Colorado, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Hammond, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Crestview Hills, Kentucky, United States|Research Site, Monroe, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Billings, Montana, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Manlius, New York, United States|Research Site, Rochester, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cadiz, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Mansfield, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Florence, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Suffolk, Virginia, United States|Research Site, Winchester, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Sydney, New South Wales, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Heidelberg Heights, Victoria, Australia|Research Site, Richmond, Victoria, Australia|Research Site, Blankenberge, Belgium|Research Site, ChÃªnÃ©e, Belgium|Research Site, Hasselt, Belgium|Research Site, Oostende, Belgium|Research Site, Tremelo, Belgium|Research Site, Vilvoorde, Belgium|Research Site, Burnaby, British Columbia, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Saint Johnâ€™s, Newfoundland and Labrador, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Brossard, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Kladno, Czechia|Research Site, Litomerice, Czechia|Research Site, Moravske Budejovice, Czechia|Research Site, Olomouc, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 3, Czechia|Research Site, Praha 4, Czechia|Research Site, Slany, Czechia|Research Site, Svitavy, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Brest Cedex 2, France|Research Site, Caen Cedex 9, France|Research Site, Dijon, France|Research Site, Le Creusot, France|Research Site, Montpellier cedex 05, France|Research Site, Nantes Cedex 1, France|Research Site, Paris cedex 12, France|Research Site, Paris, France|Research Site, Poitiers, France|Research Site, Strasbourg, France|Research Site, Bad Krozingen, Germany|Research Site, Berlin (Hellersdorf), Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Freiburg, Germany|Research Site, Heidelberg, Germany|Research Site, Homburg, Germany|Research Site, Leipzig, Germany|Research Site, Magdeburg, Germany|Research Site, Messkirch, Germany|Research Site, Witten, Germany|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Baja, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Dunaujvaros, Hungary|Research Site, Eger, Hungary|Research Site, Gyongyos, Hungary|Research Site, Hodmezovasarhely, Hungary|Research Site, Jaszbereny, Hungary|Research Site, Komarom, Hungary|Research Site, Marcali, Hungary|Research Site, Mosonmagyarovar, Hungary|Research Site, Pecs, Hungary|Research Site, Bologna, Italy|Research Site, Cagliari, Italy|Research Site, Chieti, Italy|Research Site, Ferrara, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Trieste, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Suwon, Korea, Republic of|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Leon, Guanajuato, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Monterrey, Nuevo LeÃ³n, Mexico|Research Site, San Luis Potosi, San Luis PotosÃ-, Mexico|Research Site, Tampico, Tamaulipas, Mexico|Research Site, Durango, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Den Helder, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Waalwijk, Netherlands|Research Site, Zwijndrecht, Netherlands|Research Site, Barnaul, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Alberton, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Lyttelton, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Kuils River, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Almeria, AndalucÃ-a, Spain|Research Site, AlmerÃ-a, AndalucÃ-a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, L'Hospitalet de Llobregat, CataluÃ±a, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Pozuelo de Alarcon, Madrid, Spain|Research Site, Pozuelo De AlarcÃ³n, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, GÃ¶teborg, Sweden|Research Site, Lund, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Uddevalla, Sweden|Research Site, Ã-rebro, Sweden|Research Site, Bellinzona, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Muensterlingen, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Zurich, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Birmingham, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, Doncaster, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harrow, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Scunthorpe, United Kingdom|Research Site, Wakefield, United Kingdom|Research Site, Whitby, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01763866"
925,"NCT03875911","Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy",,"Recruiting","No Results Available","Glaucoma Open-Angle Primary|Glaucoma|Open Angle Glaucoma|Glaucoma, Open-Angle","Drug: Mitomycin C","Intraocular Pressure Reduction","University of California, Los Angeles","All","20 Years to 85 Years   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-000432","March 30, 2019","December 31, 2020","December 31, 2022","March 15, 2019",,"September 26, 2019","Doheny Eye Center UCLA (Arcadia), Arcadia, California, United States|Doheny Eye Center UCLA (Fountain Valley), Fountain Valley, California, United States|Stein Eye Institute - UCLA (Westwood), Los Angeles, California, United States|Doheny Eye Center UCLA (Pasadena), Pasadena, California, United States",,"https://ClinicalTrials.gov/show/NCT03875911"
926,"NCT01263197","A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: albuterol|Drug: propranolol|Drug: placebo for LY2216684|Drug: placebo for albuterol|Drug: placebo for propranolol","Maximum, Minimum and Average Changes in Heart Rate|Maximum, Minimum and Average Changes in Systolic Blood Pressure|Maximum, Minimum and Average Changes in Diastolic Blood Pressure","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12598|H9P-EW-LNCI","December 2010","March 2011","March 2011","December 20, 2010","October 22, 2018","January 29, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01263197"
927,"NCT00835224","Safety and Efficacy of L-NAME and Midodrine to Increase MAP",,"Completed","Has Results","Orthostatic Hypotension|Spinal Cord Injury","Drug: L-NAME|Drug: Midodrine|Drug: Placebo","Blood Pressure","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","34","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A6161-W|VA Project #5481-08-017","May 2010","June 2013","August 2013","February 3, 2009","April 23, 2014","April 23, 2014","VA Medical Center, Bronx, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT00835224"
928,"NCT01058018","Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease","ASSERT","Completed","No Results Available","Atherosclerosis|Coronary Artery Disease","Drug: RVX000222|Drug: Placebo","The percent change in ApoA1 from baseline to 12 weeks post-randomization for each treatment arm compared to placebo.|Compare the dose and time response relationships for major lipids (ApoA1, total cholesterol, HDL-C, LDL-C, non-HDL-C, TG, ApoB, LDL, and HDL-subclasses) over 4, 8 and 12 weeks time course.","Resverlogix Corp","All","18 Years and older   (Adult, Older Adult)","Phase 2","299","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RVX222-CS-005","December 2009","June 2010",,"January 28, 2010",,"July 22, 2016","Orange County Research Center, Tustin, California, United States",,"https://ClinicalTrials.gov/show/NCT01058018"
929,"NCT01514682","Anti-Inflammatory Treatment of Schizophrenia",,"Completed","Has Results","Schizophrenia","Drug: Anti-inflammatory Combination Therapy|Drug: Placebo","Change in Persistent Positive Symptoms|Change in Neuropsychological Test Performance|Change in Depressive Symptoms|Change in Negative Symptoms|Change in Pro-inflammatory Cytokines|Change in C-Reactive Protein (CRP)","University of Maryland, Baltimore","All","18 Years to 60 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HP-00051603; 11T-002","June 2012","April 17, 2017","April 17, 2017","January 23, 2012","March 29, 2018","November 4, 2019","Maryland Psychiatric Research Center, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT01514682/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01514682"
930,"NCT03683186","A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension",,"Enrolling by invitation","No Results Available","PAH|Pulmonary Hypertension|Pulmonary Arterial Hypertension|Hypertension|Connective Tissue Diseases|Familial Primary Pulmonary Hypertension|Vascular Diseases|Cardiovascular Diseases|Hypertension, Pulmonary|Lung Diseases|Respiratory Tract Disease","Drug: Ralinepag","Number of subjects with treatment-emergent adverse events [Safety and Tolerability]","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","1000","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ROR-PH-303|APD811-303","September 23, 2019","September 2024","September 2024","September 25, 2018",,"May 1, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona, Tucson, Arizona, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|Santa Barbara Cottage Hospital, Santa Barbara, California, United States|Stanford University Medical Center, Stanford, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Central Florida Pulmonary Group, Orlando, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Piedmont Healthcare Pulmonary and Critical Care Research, Austell, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Kentuckiana Pulmonary Research Center, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Chest Medicine Associates, South Portland, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Boston University Medical Center, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|Winthrop Hospital, Mineola, New York, United States|NYU Langone Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Rochester, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati-Medical Science Building, Cincinnati, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|The Oregon Clinic, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|NewSTAT, PLLC, Knoxville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|The University of Vermont Medical Center, Burlington, Vermont, United States|University of Virginia Medical Center, Charlottesville, Virginia, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Hospital Italiano, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Sanatorio Parque S.A., Rosario, Santa Fe, Argentina|Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|Fundacion Favaloro, Ciudad Autonoma Buenos Aires, Argentina|Hospital Privado Centro Medico de Cordoba S.A, Cordoba, Argentina|Instituto de Cardiologia de Corrientes, Corrientes, Argentina|Hospital Italiano de Cordoba, Córdoba, Argentina|Instituto de Investigaciones Clinicas, Mar Del Plata, Argentina|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Macquarie University, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|Cliniques Universitaires de Bruxelles Hopital Erasme, Bruxelles, Belgium|UZ Leuven, UZ Leuven Campus Gasthuisberg, Herestraat 49, Leuven, Belgium|Instituto das Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa, Belo Horizonte, MG, Brazil|Hospital Sao Lucas da PUC-RS, Porto Alegre, R.S, Brazil|MHAT - ""National Heart Hospital"" EAD, 65, Konyovitza Str., Sofia, Bulgaria|Peter Lougheed Centre, Calgary, Alberta, Canada|LHSC - Victoria Hospital, London, Ontario, Canada|SMBD Jewish General Hospital d/b/a Jewish General Hospital, Montreal, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Québec, Quebec, Canada|Beijing Shijitan Hospital, Capital Medical University, Beijing, Beijing, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, China|Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China|Clinical Hospital Dubrava Zagreb, Avenija G.Šuška 6, Zagreb, Croatia|University Clinic for Pulmonary Diseases, Jordanovac 104, Zagreb, Croatia|Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark|Århus Universitetshospital, Århus, Denmark|CHU de Strasbourg - Nouvel Hôpital Civil, Ctre de competence Hypertension Arterielle Pulmona, 1 place de l Hopital, Strasbourg, Bas Rhin, France|CHU de Grenoble - Hôpital Albert Michallon, Clinique de Cardiologie, Boulevrad de la Chantourne, Grenoble, Isere, France|CHU de Saint-Etienne - Hopital Nord, Service de Medecine vasculaire et therapeutique, 81 Avenue A. Raimond, Saint-Étienne, Loire, France|CHU Nancy - Hôpital de Brabois Adultes, Pneumologie- Oncologie Médicale, Rue du Morvan, Vandoeuvre les Nancy, Meurthe Et Moselle, France|CHU Lyon - Hôpital Cardio-Vasculaire et Pneumologique Louis Pradel, Service de Pneumologie, 59 Boulevard Pinel, Bron cedex, Rhone, France|Groupement Hospitalier Sud - Hôpital Bicêtre, Service de Pneumologie, 78 Avenue du General Leclerc, Le Kremlin-Bicêtre, Val De Marne, France|University General Hospital Attikon, 1 Rimini Street, Chaidari, Athens, Greece|University General Hospital of Alexandroupolis, Alexandroupolis, Greece|""Onasseio"" Cardiosurgery Hospital, Hemodynamic Research and Interventional Cardiology Dept., 356, Syggrou Avenue, Athens, Greece|AHEPA General Hospital of Thessaloniki, A' Cardiology Clinic, 1 St. Kyriakidi Street, Thessaloniki, Greece|Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia, S.C. di Cardiologia, Viale Luigi Pinto, 1, Foggia, Italy|Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Gachon University Hospital Gil Medical Center, Incheon, Namdong-gu, Korea, Republic of|Krakowski Szpital Specjalistyczny im. Jana Pawla II, Oddział Kliniczny Chorób Serca i Naczyń z Pododdziałem Intensywnego Nadzoru Kardiologicznego, Pradnicka 80, Krakow, Poland|NZOZ Europejskie Centrum Zdrowia, ul. Borowa 14/18, Otwock, Poland|Premium Clinic Wrocław CM, Podwale 83/17, Wroclaw, Poland|Institutul de Urgenta pentru Boli Cardiovasculare ""Prof. Dr. C.C. Iliescu"", Sos. Fundeni nr. 258, Bucharest, Romania|Institutul de Pneumoftiziologie ""Marius Nasta"", Sos. Viilor nr. 90, Sector 5, Bucuresti, Romania|Institutul Inimii ""Niculae Stancioiu"" Cluj-Napoca, Cardiologie, Str. Motilor nr. 19-21, Cluj-Napoca, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie ""Dr. Victor Babes"" Timisoara, Str. Gheorghe Adam nr. 13, Timisoara, Romania|Hospital Universitari Vall d'Hebron, Respiratory Dept., Passeig Vall d'Hebron,119-129, Neumologia, Barcelona, Spain|Hospital Clinic de Barcelona, C/ Villarroel, 170, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|CE Dniprop RCC&C Center of Dniprop RC Dept of Card SI DMA of MOHU, Chair of Internal Medicine 3, 28, Knyazya Volodymyra Velykogo St., Dnipro, Ukraine|SI F.H.Yanovskyi National Institute of Phthisiology and Pulmonology of NAMSU, Clinical and Functional Dept, 10, Amosova St., Kyiv, Ukraine|Communal Noncommercial Enterprise of Lviv Regional Council Lviv Clinical Hospital, Dept of Cardiology, D.Halytskyi Lviv NMU, Ch of Internal Medicine #1, 7, Chernihivska str., Lviv, Ukraine|Golden Jubilee National Hospital, Glasgow, West Dunbartonshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03683186"
931,"NCT01592240","Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin",,"Completed","Has Results","Hypercholesterolemia","Drug: PBO|Drug: 200mg PF-04950615 (RN316)|Drug: 300mg PF-04950615 (RN316)|Drug: PF-04950615","Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12|Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24|Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 and 24|Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 and 24|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 and 24|Change From Baseline in Apolipoprotein B (ApoB) at Week 12 and 24|Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 12 and 24|Change From Baseline in Apolipoprotein A1 (ApoA1) at Week 12 and 24|Percent Change From Baseline in Apolipoprotein A1 (ApoA1) at Week 12 and 24|Change From Baseline in Apolipoprotein AII (ApoAII) at Week 12 and 24|Percent Change From Baseline in Apolipoprotein AII (ApoAII) at Week 12 and 24|Change From Baseline in Total Cholesterol at Week 12 and 24|Percent Change From Baseline in Total Cholesterol at Week 12 and 24|Change From Baseline in Lipoprotein (a) (Lp [a]) at Week 12 and 24|Percent Change From Baseline in Lipoprotein (a) (Lp [a]) at Week 12 and 24|Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol at Week 12 and 24|Percent Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol at Week 12 and 24|Change From Baseline in Triglycerides at Week 12 and 24|Percent Change From Baseline in Triglycerides at Week 12 and 24|Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 12 and 24|Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 12 and 24|Percentage of Participants With Positive Anti-drug (Anti-PF-04950615) Antibodies (ADA)|Percentage of Participants With Injection Site Adverse Events|Plasma Concentration of PF-04950615 at Week 12 and 24|Percentage of Participants With Low Density Lipoprotein-cholesterol Less Than (<) 100, <70, <40 and <25 Milligram Per Deciliter (mg/dL)","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","354","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B1481015|2012-001226-10","July 2012","April 2013","May 2013","May 7, 2012","December 5, 2017","December 5, 2017","Achieve Clinical Research, LLC, Birmingham, Alabama, United States|Medical Affiliated Research Center, Inc., Huntsville, Alabama, United States|The Office of James G. McMurray, MD, Huntsville, Alabama, United States|Southwest Heart Group, Tucson, Arizona, United States|Aureus Research Inc., Little Rock, Arkansas, United States|Universal Biopharma Research Institute Inc. - Alta Family Health Clinic, Dinuba, California, United States|Clinical Trials Research, Lincoln, California, United States|The Office of Lucita M. Cruz, MD, Inc., Norwalk, California, United States|Radiant Research, Santa Rosa, California, United States|St. Joseph's Medical Associates, Stockton, California, United States|Orange County Research Center, Tustin, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Zasa Clinical Research, Boynton Beach, Florida, United States|Florida Health Center, Davie, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Florida Research Network, LLC, Gainesville, Florida, United States|In Vivo Clinical Research, Inc., Hialeah, Florida, United States|Health Care Family Rehab and Research Center, Hialeah, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Community Research Foundation, Inc., Miami, Florida, United States|Kendall South Medical Center, Inc., Miami, Florida, United States|Omega Research Consultants, LLC, Orlando, Florida, United States|DMI Research, Pinellas Park, Florida, United States|St Johns Center for Clinical Research, Ponte Vedra, Florida, United States|The Office of Bridget Bellingar, DO, Seminole, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Radiant Research, Inc., Atlanta, Georgia, United States|North Georgia Clinical Research, Woodstock, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Northwest Clinical Trials, Boise, Idaho, United States|Fox Valley Clinical Research Center, LLC, Aurora, Illinois, United States|Radiant Research, Inc., Chicago, Illinois, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Midwest Heart & Vascular Specialists, Overland Park, Kansas, United States|L-MARC Research Center, Louisville, Kentucky, United States|Crescent City Clinical Research Center, Metairie, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Maine Research Associates, Lewiston, Maine, United States|ActivMed Practices and Research, Haverhill, Massachusetts, United States|Radiant Research, Inc., Edina, Minnesota, United States|Dybedal Clinical Research Center, Kansas City, Missouri, United States|Montana Medical Research, Inc., Missoula, Montana, United States|Meridian Clinical Research, Omaha, Nebraska, United States|New Mexico Clinical Research and Osteoporosis Center, Inc., Albuquerque, New Mexico, United States|Central New York Clinical Research, Manlius, New York, United States|Clinical Trials of America, Inc., Hickory, North Carolina, United States|North Carolina Clinical Research, Raleigh, North Carolina, United States|PMG Research of Raleigh, Raleigh, North Carolina, United States|Wake Internal Medicine Consultants, Raleigh, North Carolina, United States|PMG Research of Salisbury, Salisbury, North Carolina, United States|Ardmore Family Practice, Winston-Salem, North Carolina, United States|Clinical Trials of America, Inc., Winston-Salem, North Carolina, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Sentral Clinical Research Services, Cincinnati, Ohio, United States|Sterling Research Group, LTD., Cincinnati, Ohio, United States|Albert J. Weisbrot, M.D., Inc., Mason, Ohio, United States|Lynn Institute of Norman, Norman, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Upstate Pharmaceutical Research, Greenville, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Baylor College of Medicine - Center for Cardiovascular Disease Prevention, Houston, Texas, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Protenium Clinical Research, LLC, Hurst, Texas, United States|Paragon Research Center, LLC, San Antonio, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|National Clinical Research- Norfolk, Inc, Norfolk, Virginia, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States|Premier Clinical Research, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01592240"
932,"NCT02603809","Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension",,"Completed","Has Results","Essential Hypertension","Drug: Aprocitentan 5 mg|Drug: Aprocitentan 10 mg|Drug: Aprocitentan 25 mg|Drug: Aprocitentan 50 mg|Drug: Lisinopril 20 mg|Drug: Placebo","Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough|Change From Baseline to End of Double-blind Treatment in Sitting Systolic Blood Pressure at Trough|Control Rates at the End of the Double-blind Treatment Period Based on Trough Sitting Diastolic and Systolic Blood Pressure|Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Diastolic Blood Pressure|Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Systolic Blood Pressure|Change From Baseline to End of Double-blind Treatment in 24-hour Diastolic and Systolic Ambulatory Blood Pressure Monitoring (ABPM)|Ratio of Group Mean at Trough to Group Mean at Peak for Diastolic Blood Pressure Based on Ambulatory Blood Pressure Monitoring (ABPM)","Idorsia Pharmaceuticals Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","1659","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-080A201","December 14, 2015","February 28, 2017","April 7, 2017","November 13, 2015","April 13, 2020","April 27, 2020","Appalachian Cardiovascular Associates, Fort Payne, Alabama, United States|Radiant Research Inc, Chandler, Arizona, United States|Warner Family Practice / Radiant Research Inc, Chandler, Arizona, United States|Phoenix Medical Research Institute LLC, Peoria, Arizona, United States|Advanced Arizona Clinical Research, Tucson, Arizona, United States|Noble Clinical Research LLC, Tucson, Arizona, United States|Desert Sun Clinical Research LLc, Tucson, Arizona, United States|Advanced Research Center Inc, Anaheim, California, United States|Med Center, Carmichael, California, United States|John Muir Physician Network Clinical Research Center, Concord, California, United States|Clinical Trials Research, Lincoln, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|Entertainment Medical Group Inc, Los Angeles, California, United States|Artemis institute for Clinical Research, San Diego, California, United States|Memorial Research Medical Clinic / Orange County Research Center, Tustin, California, United States|Empire Clinical Research, Upland, California, United States|Clinical Research Consulting LLC, Milford, Connecticut, United States|Chase Medical Research LLC, Waterbury, Connecticut, United States|Alfieri Cardiology, Wilmington, Delaware, United States|ACRC - Cardiology, Atlantis, Florida, United States|Innovative Research of West Florida INC, Clearwater, Florida, United States|Avail Clinical Research LLC, DeLand, Florida, United States|Alan Graff, MD, PA, Fort Lauderdale, Florida, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|AGA Clinical Trials, Hialeah, Florida, United States|Canvas Clinical Research, LLC, Lake Worth, Florida, United States|LCC Medical Research Institute, Miami, Florida, United States|Allied Biomedical Research Institute, INC, Miami, Florida, United States|Southeast Regional Research Group, Savannah, Georgia, United States|Community Clin Res CTR, Anderson, Indiana, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Heartland Research Associated LLC, Newton, Kansas, United States|Heartland Research Associates LLC, Wichita, Kansas, United States|Heartland Research Associates LLC, Wichita, Kansas, United States|Avant Research Associates, LLC, Crowley, Louisiana, United States|Best Clinical Trials LLC, New Orleans, Louisiana, United States|New Orleans Center for Clinical Research - Nola, New Orleans, Louisiana, United States|Clinsite LLC, Ann Arbor, Michigan, United States|Primecare Research Associates, LLC, Florissant, Missouri, United States|Clinical Research Advantage, Inc. / Diagnostic Center Of Medicine - Durango, Las Vegas, Nevada, United States|Premier Research, Trenton, New Jersey, United States|Rochester Clinical Research Inc., Rochester, New York, United States|Metrolina Internal Medicine/Internal Medicine Research, Charlotte, North Carolina, United States|Pharmquest LLC, Greensboro, North Carolina, United States|Peters Medical Research, High Point, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Sterling Research Group Ltd., Cincinnati, Ohio, United States|Aventiv Research Inc., Columbus, Ohio, United States|Dayton Clinical Research, Dayton, Ohio, United States|Aventiv Research Inc., Dublin, Ohio, United States|Oklahoma City Clinic - Edmond / Radiant Research Inc, Edmond, Oklahoma, United States|Clinical Research Advantage, Inc. / Oklahoma City Clinic - Midwest City, Midwest City, Oklahoma, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Detweiler Family Medicine and Associates PC, Lansdale, Pennsylvania, United States|Suburban Research Center, Media, Pennsylvania, United States|Degarmo Institute of Medical Research, Greer, South Carolina, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Tekton Research Inc, Austin, Texas, United States|Texas Diabetes & Endocrinology, Austin, Texas, United States|Trinity Hypertension & Metabolic Research Institute, Carrollton, Texas, United States|Family Medicine Associates of Texas - ACRC Trials, Carrollton, Texas, United States|Coastal Bend Clinical Research, Corpus Christi, Texas, United States|TR - Global Medical Research, DeSoto, Texas, United States|Ventavia Research Group, LLC, Fort Worth, Texas, United States|Clinical Investigations of Texas, Plano, Texas, United States|Avant Research Associates LLC, Port Arthur, Texas, United States|Texas Diabetes & Endocrinology, Round Rock, Texas, United States|Radiant Research Inc, San Antonio, Texas, United States|Bandera Family Health Care, San Antonio, Texas, United States|Wasatch Clinical Research LLC, Salt Lake City, Utah, United States|Health Research of Hampton Roads, Newport News, Virginia, United States|National Clinical Research Inc, Richmond, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Manna Research - Vancouver, Vancouver, British Columbia, Canada|Canadian Phase Onwards Inc, Toronto, Ontario, Canada|Manna Research - Toronto, Toronto, Ontario, Canada|Manna Research - Levis, Levis, Quebec, Canada|Diex Recherche Montreal Inc, Montreal, Quebec, Canada|Diex Recherche Montreal Inc, Montréal, Quebec, Canada|Manna Research - Pointe Claire, Pointe-Claire, Quebec, Canada|Diex Reserach Sherbrooke Inc, Sherbrooke, Quebec, Canada|Cardiology Department Barzilai, Ashkelon, Israel|Soroka University Hospital - Hypertension Unit, Beer Sheva, Israel|The Hyper Unit, Edith Wolfson Medical Center, Holon, Israel|Hypertension Treatment Center, Internal Dep, Hadassah, Jerusalem, Israel|Hypertension And Nephrology Department, Meir Medical Center, Kefar Sava, Israel|Clinical Research Unit Kaplan Medical Center, Rehovot, Israel|Internal Med Department A, Ziv Medical Center, Safed, Israel|Advanced Medical Concepts, PSC, Cidra, Puerto Rico|Research & Cardiovascular Corp., Ponce, Puerto Rico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02603809/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02603809/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02603809"
933,"NCT00979732","The Effect of Grape Seed Extract on Blood Pressure in People With Pre-Hypertension","GSE","Unknown status","No Results Available","Hypertension","Dietary Supplement: grape seed extract|Dietary Supplement: grape seed extract placebo","Demonstrate the effectiveness of grape seed extract (GSE) in the lowering of systolic and diastolic blood pressure|Changes in markers of inflammation, oxidation and endothelial function in plasma.","Clinical Nutrition Research Center, Illinois Institute of Technology|Polyphenolics, Inc.","All","25 Years to 65 Years   (Adult, Older Adult)","Not Applicable","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSE 2009-050","November 15, 2009","October 15, 2019","October 15, 2019","September 18, 2009",,"March 16, 2018","Clinical Nutrition Research Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00979732"
934,"NCT02583672","Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)",,"Recruiting","No Results Available","Gaucher Disease Type 1","Drug: N-acetylcysteine","Change in subjects with Gaucher disease type 1, in concentration of glutathione in brain (μmol/g)|In healthy volunteers, determination of level of glutathione in brain (μmol/g)|Change in subjects with Gaucher disease type 1, in concentration of glutathione in blood (μmol/g)|Change in healthy volunteers, in concentration of glutathione in blood (μmol/g)|Change in subjects with Gaucher disease type 1, in concentration of myo-inositol in brain (μmol/g)|In healthy volunteers, determine the concentration of myo-inositol in brain (μmol/g)|Change in subjects with Gaucher disease type 1, in concentration of TNF-alpha in plasma (pg/mL)|Change in healthy volunteers, in concentration of TNF-alpha in plasma (pg/mL)|Change in subjects with Gaucher disease type 1, in concentration of N-acetylcysteine (NAC) in blood (µg/ml)","University of Minnesota|Rare Diseases Clinical Research Network|National Center for Advancing Translational Science (NCATS)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Neurological Disorders and Stroke (NINDS)|Lysosomal Disease Network","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LDN6722|U54NS065768","September 2015","July 31, 2020","July 31, 2021","October 22, 2015",,"July 30, 2019","University of Minnesota, Minneapolis, Minnesota, United States|New York University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02583672"
935,"NCT02422446","Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects",,"Terminated","Has Results","Type 2 Diabetes|Coronary Artery Disease","Drug: Icosapent ethyl","Change From Baseline in Endothelial Function at 12 Weeks Using Reactive Hyperemia Index (RHI)","Brigham and Women's Hospital","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 3","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","2013D003968","April 2015","March 1, 2017","March 1, 2017","April 21, 2015","June 6, 2018","June 6, 2018","Brigham and Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02422446/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02422446/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02422446"
936,"NCT03490916","Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography",,"Terminated","Has Results","High Altitude Pulmonary Edema","Drug: Acetazolamide|Drug: Placebo","Pulmonary Edema Before and After Taking Acetazolamide|Time to Completion of Ultrasound Exams","Vincent Kan|University of Massachusetts, Worcester","All","18 Years and older   (Adult, Older Adult)","Phase 4","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H00014860","March 23, 2018","April 4, 2018","April 4, 2018","April 6, 2018","May 10, 2019","May 10, 2019","UMass Medical School, Worcester, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03490916/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03490916"
937,"NCT01263717","Effects of Growth Hormone Releasing Hormone in HIV",,"Completed","Has Results","HIV|HIV Lipodystrophy","Drug: tesamorelin|Drug: placebo","Liver Fat|Visceral Adipose Tissue|Intramyocellular Lipid|Endogenous Growth Hormone Secretion|Insulin Sensitivity|HbA1c|Insulin Like Growth Factor 1 (IGF-I)|Lipid Panel|Carotid Intimal Medial Thickness (cIMT)|Glucose Tolerance|Adiponectin|Hemostatic Markers","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2007p-000638","December 2010","February 2014","February 2014","December 21, 2010","October 13, 2014","October 30, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01263717"
938,"NCT02083510","Apolipoprotein CIII Reduction Via Colchicine",,"Completed","No Results Available","Hypertriglyceridemia|Gout|Pericarditis","Drug: Colchicine","Reduction in ApoCIII levels|Reduction of triglycerides and very low density lipoprotein (VLDL) levels|Measurement of Apolipoprotein A and Apolipoprotein B via Vertical Auto Profile (VAP)","Scripps Translational Science Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13-6293|1UL1TR001114-01","February 2014","May 2014","May 2014","March 11, 2014",,"May 30, 2014","Scripps Translational Science Institute, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT02083510"
939,"NCT01242527","Epanova® for Lowering Very High Triglycerides","EVOLVE","Completed","Has Results","Severe Hypertriglyceridemia","Drug: placebo|Drug: omefas","Fasting Serum Triglycerides","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","399","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OM-EPA-003","January 2011","March 2012","April 2012","November 17, 2010","September 6, 2013","August 4, 2016","National City, California, United States|Sacramento, California, United States|Manchester, Connecticut, United States|Coral Gables, Florida, United States|Hialeah, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|St Petersburg, Florida, United States|Summerfield, Florida, United States|Atlanta, Georgia, United States|Addison, Illinois, United States|Chicago, Illinois, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Olive Branch, Mississippi, United States|High Point, North Carolina, United States|Salisbury, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Bristol, Tennessee, United States|Johnson City, Tennessee, United States|Kingsport, Tennessee, United States|San Antonio, Texas, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Olympia, Washington, United States|Copenhagen, Denmark|Gentofte, Denmark|Herlev, Denmark|Viborg, Denmark|Baja, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Debrecen, Hungary|Satoraljaujhely, Hungary|Szekesfehervar, Hungary|Szikszo, Hungary|Karnal, Haryana, India|Bangalore, Karnataka, India|Bangalore, Karnataka, India|Bangalore, Karnataka, India|Banswada, Karnataka, India|Indore, Madhya Pradesh, India|Pune, Maharashtra, India|Jaipur City, Rajasthan, India|Chennai, Tamil nadu, India|Surat, India|Amsterdam, Netherlands|Groningen, Netherlands|Rotterdam, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Moscow, Russian Federation|Novosibirsk, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01242527"
940,"NCT01320722","Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function","MODERATE","Completed","Has Results","Renal Function|Endothelial Function|Blood Pressure|Overweight|Obesity","Drug: Vitamin D ergocalciferol|Drug: Probenecid|Drug: Allopurinol|Drug: Placebo","Change in Renal Plasma Flow (RPF) in Response to Captopril in High Sodium Balance [Vitamin D]|Plasma Renin Activity (PRA) [Vitamin D]|Angiotensin II (ATII) Concentration [Vitamin D]|Change in Renal Plasma Flow (RPF) Response to Captopril in High Sodium Balance [Uric Acid]|Plasma Renin Activity (PRA) [Uric Acid]|Angiotensin II (ATII) Concentration [Uric Acid]|Change in Endothelium-Dependent Vasodilation (EDV)|Mean 24-Hour Ambulatory Blood Pressure (ABP)|Mean 24-Hour Ambulatory Blood Pressure (ABP) Nocturnal Dipping","Brigham and Women's Hospital|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","242","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2010-P-002049|1R01HL105440","March 2011","May 2015","June 2015","March 22, 2011","June 29, 2017","June 29, 2017","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01320722"
941,"NCT02250612","SYL040012, Treatment for Open Angle Glaucoma","SYLTAG","Completed","No Results Available","Open Angle Glaucoma|Ocular Hypertension","Drug: 1 drop of SYL040012 (bamosiran) Dose A|Drug: 1 drop of SYL040012 (bamosiran) Dose B|Drug: 1 drop of SYL040012 (bamosiran) Dose C|Drug: 1 drop of SYL040012 (bamosiran) Dose D|Drug: 1 drop of timolol maleate","Change from baseline in the mean diurnal IOP within each treatment arm|Mean diurnal IOP change of the different doses of SYL040012 eye drops versus Timolol maleate 0.5%|Change from baseline in the Glaucoma Quality of Life questionnaire (GQL-15) scores within each treatment arm|Change from baseline in vital signs and laboratory parameters as measurements of systemic tolerability|Assessment of Adverse Events Appearance","Sylentis, S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 2","184","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SYL040012_IV|2013-002947-27","October 2014","August 2015","January 2016","September 26, 2014",,"January 28, 2016","Sall Research Medical Center, Artesia, California, United States|North Bay Eye Associates, Petaluma, California, United States|Eye Care Centers Management, Inc (Clayton Eye Center), Morrow, Georgia, United States|Taustin Eye Center, Louisville, Kentucky, United States|East Tallin Central Hospital, Tallin, Estonia|Eye Clinic Dr. Krista Turman, Tallin, Estonia|Tartu University Hospital, Tartu, Estonia|Universitaetsklinikum Freiburg, Freiburg, Germany|University Clinic Magdeburg, Magdeburg, Germany|Klinikum der Universität München, München, Germany|Universitätsklinikum Münster, Münster, Germany|University Hospital Regensburg, Regensburg, Germany|Hospital de Torrevieja, Torrevieja, Alicante, Spain|Hospital de Jerez, Jerez de la Frontera, Cádiz, Spain|Clinica Universidad Navarra, Pamplona, Navarra, Spain|Hospital Clinic, Barcelona, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Clínico San Carlos, Madrid, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Instituto de Oftalmobiología Aplicada, Valladolid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT02250612"
942,"NCT01972178","Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia",,"Terminated","No Results Available","Dyslipidemia","Drug: PRC-4016|Drug: Placebo|Drug: Statins","Percent change in Non-HDL-C from baseline to Week 12|Change in triglycerides from baseline to Week 12|Change in HDL-C from baseline to Week 12|Change in LDL-C from baseline to Week 12|Change in VLDL-C from baseline to Week 12|Change in total cholesterol from baseline to Week 12|Change in ApoA1 from baseline to Week 12|Change in ApoB from baseline to Week 12|Change in insulin from baseline to Week 12|Change in fasting plasma glucose from baseline to Week 12|Change in HbA1c from baseline to Week 12|Change in Lp-PLA2 from baseline to Week 12|Change in hsCRP from baseline to Week 12|Change in red blood cell content of EPA and DHA from baseline to Week 12|Change in Insulin Resistance (HOMA) from baseline to Week 12","Pronova BioPharma","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","113","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CTN 4016 13202","November 2013","July 2014","August 2014","October 30, 2013",,"October 30, 2015","Medical Affiliated Research Center, Inc., Huntsville, Alabama, United States|Terence Hart, MD, Muscle Shoals, Alabama, United States|Pacific Oaks Medical Group, Beverly Hills, California, United States|National Research Institute - Wilshire, Los Angeles, California, United States|Research Across America - Santa Ana, Santa Ana, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Jacksonville Impotence Treatment Center, Jacksonville, Florida, United States|Compass Research East, LLC, Oviedo, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Meridien Research- Tampa, Tampa, Florida, United States|Evanston Premier Healthcare Research LLC, Evanston, Illinois, United States|Medisphere Medical Research Center, Evansville, Indiana, United States|Heartland Research Assoc., LLC, Newton, Kansas, United States|Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville, Kentucky, United States|Troy Internal Medicine, P.C., Troy, Michigan, United States|Radiant Research - Edina, Edina, Minnesota, United States|Peters Medical Research, High Point, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|Sterling Research Group, Ltd. - Auburn, Cincinnati, Ohio, United States|Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States|Columbus Clinical Research, Inc., Columbus, Ohio, United States|PSB Research/P. S. Bains, M.S., D.O., Marion, Ohio, United States|RAS Health Ltd, Marion, Ohio, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Padre Coast Clinical Research, Corpus Christi, Texas, United States|National Clinical Research - Norfolk, Inc., Norfolk, Virginia, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01972178"
943,"NCT01632358","Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients",,"Completed","No Results Available","Dyslipidaemia","Drug: TAP311 capsules|Drug: Placebo","Number of patients with adverse events|Pharmacokinetics of TAP311: The observed maximum plasma concentration following drug administration at steady state (Cmax,ss)|Pharmacokinetics of TAP311: The time to reach the maximum concentration after drug administration at steady state(Tmax, ss)|Pharmacokinetics of TAP311: The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)|Pharmacokinetics of TAP311: The Racc ratio from the plasma concentration-time data|Pharmacokinetics of TAP311: The AUCtau, from the plasma concentration-time data","Novartis Pharmaceuticals|Novartis","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","279","Industry","Interventional","Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTAP311X2201|2012-000857-29","June 2012","December 2012","December 2012","July 2, 2012",,"December 2, 2013","Novartis Investigative Site, Miramar, Florida, United States|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT01632358"
944,"NCT02959047","A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease",,"Recruiting","No Results Available","Peripheral Arterial Disease","Drug: Alirocumab|Drug: Matching placebo","Change in superficial femoral plaque volume (summed from both legs)|Change in calf muscle perfusion in the most symptomatic leg|Change in plaque characteristics|Change in 6-minute walk test|Change in LDL cholesterol|Change in high sensitivity c-reactive protein|Change in fibrinogen|Change in lipoprotein (a)","University of Virginia|Northwestern University","All","35 Years to 85 Years   (Adult, Older Adult)","Phase 4","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19404","July 17, 2017","July 17, 2020","July 17, 2021","November 8, 2016",,"October 11, 2018","Northwestern University, Chicago, Illinois, United States|University of Virginia Health System, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02959047"
945,"NCT01594333","Cardiovascular Inflammation Reduction Trial","CIRT","Completed","No Results Available","Cardiovascular Disease","Drug: Methotrexate|Drug: Placebo","Rate of major cardiovascular events|Rate of all-cause mortality|Rate of the primary endpoint plus coronary revascularization|Rate of hospitalization for congestive heart failure|Rate of primary endpoint plus all-cause mortality plus coronary revascularization plus congestive heart failure|Rate of new onset type 2 diabetes among those with metabolic syndrome but not diabetes at study entry","Brigham and Women's Hospital|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","4786","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2012P-000857|U01HL101422|U01HL101389","April 2013","December 2018","June 2019","May 9, 2012",,"July 12, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Appalachian Research Associates, Fort Payne, Alabama, United States|Avant Research Associates, LLC, Guntersville, Alabama, United States|Saadat Ansari MD LLC, Huntsville, Alabama, United States|University of South Alabama: Division of Clinical Research, Mobile, Alabama, United States|Heart Vascular of Northern Arizona, Cottonwood, Arizona, United States|CardioVascular Associates of Mesa, Mesa, Arizona, United States|Arizona Arthritis & Rheumatology Research, Phoenix, Arizona, United States|Scottsdale Medical Imaging, Scottsdale, Arizona, United States|The Heart Clinic, Scottsdale, Arizona, United States|Pima Heart, Tucson, Arizona, United States|Southern Arizona VA Health Care System, Tucson, Arizona, United States|Arkansas Cardiology, Little Rock, Arkansas, United States|Arkansas Heart Hospital, Little Rock, Arkansas, United States|Oracle Clinical Research, Inc., Anaheim, California, United States|Medical Group of Culver City, Culver City, California, United States|Touro University California- Solano County Affiliated Clinics, Fairfield, California, United States|University Of California San Francisco, Fresno, California, United States|VACCHCS, Fresno, California, United States|UCSD Sulpizio Cardiovascular Center, La Jolla, California, United States|University Of California San Diego, La Jolla, California, United States|Desert Medical Care & Wellness, La Quinta, California, United States|Kumar Medical Corporation, Lancaster, California, United States|Loma Linda University Health, Loma Linda, California, United States|VA Loma Linda Healthcare System, Loma Linda, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|Cardiovascular Innovation and Research, Long Beach, California, United States|Los Alamitos Cardiovascular, Los Alamitos, California, United States|Faye Montegrande Md. Clinical Research, Los Angeles, California, United States|Eastside Clinical Research Associates, Los Angeles, California, United States|Salman Khan A. Medical Corporation, Los Angeles, California, United States|University of Southern California, Los Angeles, California, United States|West LA VA Medical Center, Los Angeles, California, United States|VA Northern California Health Care, Mather, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|Orange County Heart Institute & Research, Orange, California, United States|University of CA Irvine Medical Center, Orange, California, United States|Diverse Research Solutions, Oxnard, California, United States|Huntington Memorial Hospital, Pasadena, California, United States|Central Coast Cardiology, Salinas, California, United States|Richard G. Friedman, MD, San Diego, California, United States|Ritchken and First MDs, San Diego, California, United States|Foundation for Cardiovascular Medicine, San Diego, California, United States|San Diego Cardiac Center, San Diego, California, United States|Veterans Affairs San Diego Healthcare System, San Diego, California, United States|UCSF at Zuckerberg SF General Hospital, San Francisco, California, United States|Coastal Heart Medical Group, Inc., Santa Ana, California, United States|Comprehensive Cardiovascular Care, Santa Maria, California, United States|Pacific Heart and Vascular Medical Group, Stockton, California, United States|Manoj D. Aswani M.D., Thousand Oaks, California, United States|Touro University California- Solano Public Health Affiliated Clinics, Vallejo, California, United States|Munni R. Selagamsetty, Md, Pc, Colorado Springs, Colorado, United States|Vijay - Aurora Denver Cardiology, Denver, Colorado, United States|Colorado Health Medical Group Heart Center of the Rockies, Fort Collins, Colorado, United States|Medical Center of the Rockies Research, Fort Collins, Colorado, United States|Unrein - Rocky Vista University Health Center, Parker, Colorado, United States|Connecticut Heart and Vascular Center, Bridgeport, Connecticut, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Cardiology Physicians/Red Clay Research, Newark, Delaware, United States|Boisey Barnes MD, PC, Washington, District of Columbia, United States|GWU Medical Faculty Associatin, Inc., Washington, District of Columbia, United States|Pianko - Aventura Research Center, LLC, Aventura, Florida, United States|North Ridge Heart Associates, Boca Raton, Florida, United States|St. Francis Medical Institute, Clearwater, Florida, United States|Gonzalez MD & Aswad MD Health Ser, Coral Gables, Florida, United States|American Research Institute, Inc., Cutler Bay, Florida, United States|Daytona Heart Group, Daytona Beach, Florida, United States|Daytona Heart Group, DeLand, Florida, United States|Seidman Clinical Trials, Delray Beach, Florida, United States|Steven Cohen MD, Delray Beach, Florida, United States|Infinite Clinical Research, Doral, Florida, United States|International Research Partners, LLC, Doral, Florida, United States|Medical Research Institute at Doral, Inc., Doral, Florida, United States|Lake Internal Medicine Assocaties, Eustis, Florida, United States|Invesclinic, Fort Lauderdale, Florida, United States|Primary Care Associates, Fort Myers, Florida, United States|Lee Physician Group, Fort Myers, Florida, United States|The Cardiac and Vascular Institute, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States|Qway Research, Hialeah, Florida, United States|State of the Art Research, Hialeah, Florida, United States|Healing Touch C&C Research, Hialeah, Florida, United States|Luzmed Clinical Research Institute, Hialeah, Florida, United States|Viviana Perez MD Research & Cosmetics, Hialeah, Florida, United States|Elite Cardiac Research Center LLC, Hialeah, Florida, United States|Nova Clinical Research Clinic, Hialeah, Florida, United States|Best Quality Research, Inc., Hialeah, Florida, United States|South Florida Research Solutions, LLC, Hollywood, Florida, United States|John Gutleber Medical Research Office, Homestead, Florida, United States|Cardiovascular Medical Associates of Palm Beach, Jupiter, Florida, United States|Hope Clinical Research, Kissimmee, Florida, United States|SIH Research, LLC, Kissimmee, Florida, United States|Lakes Research, LLC, Miami Lakes, Florida, United States|Veritas Research Corp., Miami Lakes, Florida, United States|Ocean Blue Medical Research Center, Miami Springs, Florida, United States|Medical Research Center of Florida, Miami, Florida, United States|LG Diagnostics, Inc., Miami, Florida, United States|St. Paul Medical Research Center, Inc., Miami, Florida, United States|Team Medical Research, Miami, Florida, United States|Paradise Clinical Research, LLC, Miami, Florida, United States|GAD Research Center, Miami, Florida, United States|Innovation Research Institute, Inc., Miami, Florida, United States|Sanitas Research, Miami, Florida, United States|Segui - Med Care Research, Miami, Florida, United States|South Florida Research Group, LLC, Miami, Florida, United States|Vista Health Research, LLC, Miami, Florida, United States|D De La Vega MD Research Group, Miami, Florida, United States|Southwest Florida Research, LLC, Naples, Florida, United States|Orlando Healthy Heart Institute, Orlando, Florida, United States|Palm Beach Gardens Research Center, LLC, Palm Beach Gardens, Florida, United States|Broward Research Center, Pembroke Pines, Florida, United States|Pioneer Clinical Research, Pembroke Pines, Florida, United States|Sandoval - Broward Research Center, Pembroke Pines, Florida, United States|Bay Area Heart Center: 49th Street, Saint Petersburg, Florida, United States|Bay Area Heart Center: 7th Avenue, Saint Petersburg, Florida, United States|Lenus Research & Medical Group, Sweetwater, Florida, United States|DBC Research, Tamarac, Florida, United States|Asclepes Research Centers, Weeki Wachee, Florida, United States|Gupta - Premier Heart and Vascular Center, Wesley Chapel, Florida, United States|Athens Regional Medical Center, Athens, Georgia, United States|Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, United States|Laureate Medical Group at Northside, Atlanta, Georgia, United States|Synergy Therapeutic Partners, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Atlanta Heart Specialists, LLC, Cumming, Georgia, United States|Heart and Rhythm Specialists, Dalton, Georgia, United States|Albert F. Johary MD, PC, Dunwoody, Georgia, United States|Infinite Clinical Trials, Riverdale, Georgia, United States|Atlanta Vanguard Medical Associates, Smyrna, Georgia, United States|Herman Clinical Research, LLC, Suwanee, Georgia, United States|Atlanta Heart Specialists, LLC, Tucker, Georgia, United States|Cardiology Associates of Vidalia, P.C., Vidalia, Georgia, United States|VA Pacific Islands Health Care System, Honolulu, Hawaii, United States|St. Luke's Idaho Cardiology Associates, Boise, Idaho, United States|Clinical Research Prime, Idaho Falls, Idaho, United States|Northwest Heart Clinical Research, Arlington Heights, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Advocate Med Group-Heart & Vascular Of Illinois, Chicago, Illinois, United States|Illinois Heart & Lung Research Center, SC, Normal, Illinois, United States|Captain James A. Lovell Federal Health, North Chicago, Illinois, United States|Specialty Physicians of Illinois, LLC, Olympia Fields, Illinois, United States|Advanced CardioVascular Consultants, Rock Island, Illinois, United States|Cardiospecialists, LTD, Dyer, Indiana, United States|Martin - Martin Family Practice and Research, Evansville, Indiana, United States|Krannert Institute Of Cardiology, Indianapolis, Indiana, United States|Community Hospital South, Indianapolis, Indiana, United States|Indiana Heart Physicians, Indianapolis, Indiana, United States|Medical Consultants, PC, Muncie, Indiana, United States|Iowa Heart Center, West Des Moines, Iowa, United States|Stahl - Midwest Heart & Vascular Specialists, Overland Park, Kansas, United States|Professional Research Network of KS, Wichita, Kansas, United States|Robert J. Dole VAMC, Wichita, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Robley Rex VAMC, Louisville, Kentucky, United States|Stoddard - University of Louisville, Louisville, Kentucky, United States|Bays - L-MARC Research Center, Louisville, Kentucky, United States|Research Integrity LLC, Owensboro, Kentucky, United States|Dorothy H. Banish, MD, APMC Study Group, Covington, Louisiana, United States|Avant Research Associates, LLC, Crowley, Louisiana, United States|North Oaks Cardiology, Hammond, Louisiana, United States|American Clinical Research, LLC, Marrero, Louisiana, United States|Otis Barnum D.O.P.C., Natchitoches, Louisiana, United States|Tulane University Office of Health Research, New Orleans, Louisiana, United States|Veterans Affairs Medical Center Shreveport, Shreveport, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Paul A. Shapero, M.D., Bangor, Maine, United States|Southern Maine Health Care, Biddeford, Maine, United States|InterMed, PA, Portland, Maine, United States|Maine Medical Partners Maine Health Cardiology, South Portland, Maine, United States|Maine Centers for Healthcare, Westbrook, Maine, United States|Sinai Center for Thrombosis Research, Baltimore, Maryland, United States|St. Mary's Medical Center, Charlotte Hall, Maryland, United States|Calvert Memorial Hospital, Clinton, Maryland, United States|Shah Associates, MD, LLC, Prince Frederick, Maryland, United States|Peninsula Cardiology Associates, Salisbury, Maryland, United States|IRC Clinics, Towson, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|St. Elizabeth's Medical Center, Boston, Massachusetts, United States|MGH Cardiology, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Massachusetts General Hospital - Chelsea Health Care Center, Chelsea, Massachusetts, United States|Pentucket Medical Associates, Inc., Haverhill, Massachusetts, United States|VA Central Western Massachusetts Healthca, Leeds, Massachusetts, United States|South Shore Internal Medicine, Milton, Massachusetts, United States|Lahey Medical Center, Peabody, Massachusetts, United States|North Shore Cardiovascular Associates, Salem, Massachusetts, United States|Reliant Medical Group, Worcester, Massachusetts, United States|Endeavor Medical Research, Alpena, Michigan, United States|John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan, United States|Trace Research Group at Wayne State University, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Flint Clinical Research, Flint, Michigan, United States|Apex Medical Research MI, Inc., Flint, Michigan, United States|Garden City Hospital, Garden City, Michigan, United States|Genesys Regional Medical Center, Grand Blanc, Michigan, United States|National Clinical LLC, Hamtramck, Michigan, United States|Academic Cardiology Associates PC, Rochester Hills, Michigan, United States|Beaumont Health Center, Royal Oak, Michigan, United States|Covenant Medical Center, Inc., Saginaw, Michigan, United States|Mid-Michigan Heart & Vascular Center, Saginaw, Michigan, United States|Centra Care Heart & Vascular Center at St. Cloud Hospital, Saint Cloud, Minnesota, United States|United Heart and Vascular Clinic, Saint Paul, Minnesota, United States|Gulfside Clinical Research, LLC, Gulfport, Mississippi, United States|University of MS Medical Center, Jackson, Mississippi, United States|David M. Headley M.D. PA Planters Clinic, Port Gibson, Mississippi, United States|Stern Cardiovascular Foundation, Inc., Southaven, Mississippi, United States|Center for Advanced Medicine and Research LLC, Bridgeton, Missouri, United States|Clinical Research Center University of Missouri, Columbia, Missouri, United States|Quantum Research LLC, Festus, Missouri, United States|Midwest Cardiology Associates, Independence, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|VA Medical Center Kansas City, Kansas City, Missouri, United States|Lake Regional Cardiovascular Institute, Osage Beach, Missouri, United States|VA St. Louis Health Care System (VASTLHCS), Saint Louis, Missouri, United States|SLUCare Cardiology, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Clinical Investigators LLC, Saint Louis, Missouri, United States|Consult and Research Associates, Saint Louis, Missouri, United States|Center for Advanced Medicine and Research, Saint Peters, Missouri, United States|CoxHealth: Wheeler Heart & Vascular Center, Springfield, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Great Falls Clinic Clinical Research Deptartment, Great Falls, Montana, United States|Cone - Montana Medical Research, Missoula, Montana, United States|Barrett Clinic, P.C., La Vista, Nebraska, United States|Heart Consultants, Omaha, Nebraska, United States|Alegent Creighton Health, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Internal Medicine Clinic, Las Vegas, Nevada, United States|Red Rock Clinical Research, LLC, Las Vegas, Nevada, United States|Sierra Nevada Health Care System, Reno, Nevada, United States|Renown Inst for Heart & Vasc Health, Reno, Nevada, United States|Lahey Cardiology, Nashua, New Hampshire, United States|Family Health at Mount Olive, Flanders, New Jersey, United States|Cardiocare, Hillsborough, New Jersey, United States|New Jersey Heart, Linden, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Cardiovascular Institute, New Brunswick, New Jersey, United States|Palisade Medical Center, North Bergen, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Mercer Bucks Cardiology, Robbinsville, New Jersey, United States|Cardio Metabolic Institute, Somerset, New Jersey, United States|Holy Name Medical Center, Inc., Teaneck, New Jersey, United States|Total Cardiology Care, LLC, Wayne, New Jersey, United States|Westwood Cardiology Associates, Westwood, New Jersey, United States|Presbyterian Heart Group, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|Albany Stratton VA Medical Center, Albany, New York, United States|Novel Research of New York, LLC, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Brown - SUNY Downstate Medical Center, Brooklyn, New York, United States|Buffalo Heart Group, Buffalo, New York, United States|Bassett Healthcare Network, Cooperstown, New York, United States|NYU Hudson Valley Cardiology, Cortlandt Manor, New York, United States|NYHQ, Flushing, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Long Island Heart Associates, Mineola, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|Queens Long Island Medical Group, New Hyde Park, New York, United States|Chinatown Cardiology, PC, New York, New York, United States|Weill Cornell Medical College and NY Presbyterian, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|DiGiovanna Institute for Medical Education and Research, North Massapequa, New York, United States|Champlain Valley Physician Hospital, Plattsburgh, New York, United States|Cardiology Associates of Schenectady, Schenectady, New York, United States|Clinical Study Center of Asheville, Asheville, North Carolina, United States|Metrolina Internal Medicine, Charlotte, North Carolina, United States|Gaffney Health Services, Charlotte, North Carolina, United States|Carolinas Research Center, Charlotte, North Carolina, United States|Eastern Carolina Cardiovascular, PA, Elizabeth City, North Carolina, United States|Eastern Cardiology, Greenville, North Carolina, United States|Northside Clinical Research, Lenoir, North Carolina, United States|Lake Shore Clinical Research, LLC., Mooresville, North Carolina, United States|Carteret Medical Group, Morehead City, North Carolina, United States|Cardiology Associates of Carolinas, PA, Morganton, North Carolina, United States|Eastern Nephrology Associates, PLLC, New Bern, North Carolina, United States|Boice Willis Clinic, Rocky Mount, North Carolina, United States|Sanford Cardiology, Sanford, North Carolina, United States|Natalie A. Doyle, MD, PA, Wilson, North Carolina, United States|Altru Health System Rehab Center, Grand Forks, North Dakota, United States|Akron General Medical Center, Akron, Ohio, United States|Ohio University Heritage College of Osteopathic Medicine, Athens, Ohio, United States|Diabetes and Endocrinology Associates of Stark Cit, Canton, Ohio, United States|The Lindner Research Center, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Optimed Research, LTD, Columbus, Ohio, United States|Dayton Heart Center, Dayton, Ohio, United States|Dayton Veteran Affairs Medical Center, Dayton, Ohio, United States|Colonnade Medical Group, Lancaster, Ohio, United States|Middletown Cardiovascular Associates, Middletown, Ohio, United States|Comprehensive Heart Care, Inc., Toledo, Ohio, United States|Mount Carmel Clinical Cardiovascular Care, Westerville, Ohio, United States|Premier Physicians, Westlake, Ohio, United States|Wooster Heart Group, Wooster, Ohio, United States|Unity Clinical Research, Lindsay, Oklahoma, United States|COR Clinical Research, LLC, Oklahoma City, Oklahoma, United States|Thadani - VA Medical Center Oklahoma City, OK, Oklahoma City, Oklahoma, United States|Today Clinical Research, Oklahoma City, Oklahoma, United States|Cardiovascular Health Clinic, Oklahoma City, Oklahoma, United States|Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, United States|Samaritan Health Services, Corvallis, Oregon, United States|Southern Oregon Cardiology, LLC, Medford, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Center for Clinical Res. Abington Health, Abington, Pennsylvania, United States|St. Luke's University Hospital, Bethlehem, Pennsylvania, United States|Renu-Ca Research Institute, Lower Bucks Hospital, Bristol, Pennsylvania, United States|Main Line Health Center, Broomall, Broomall, Pennsylvania, United States|Spirit Physician Services, Inc, Camp Hill, Pennsylvania, United States|The Chambersburg Hospital, Chambersburg, Pennsylvania, United States|Central Bucks Cardiology, Doylestown, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Heart Specialists of Lancaster County, Ephrata, Pennsylvania, United States|Saint Vincent Consultants in Cardiovascular Diseases, LLC, Erie, Pennsylvania, United States|Feasterville Family Healthcare Center, Feasterville, Pennsylvania, United States|Christiana Care Health System, Glen Mills, Pennsylvania, United States|Pinnacle Health Cardiovascular Institute, Harrisburg, Pennsylvania, United States|George Isajiw, MD, Lansdowne, Pennsylvania, United States|Bucks County Clinical Research, Morrisville, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Lehigh Valley Health Services, Sellersville, Pennsylvania, United States|Pish Medical Associates, Inc., Uniontown, Pennsylvania, United States|Lehigh Valley Family Practice, Whitehall, Pennsylvania, United States|Wilkes-Barre VA Medical Center, Wilkes-Barre, Pennsylvania, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|Ocean State Clinical Research Prtnr, Lincoln, Rhode Island, United States|Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Ocean State Research Institute, Inc, Providence, Rhode Island, United States|South Carolina Heart Center, Columbia, South Carolina, United States|Amistad Research Center, LLC, Columbia, South Carolina, United States|Charlotte Hearts, Indian Land, South Carolina, United States|Miller - SC Internal Medicine Associates.: Irmo, Irmo, South Carolina, United States|Inlet Cardiopulmonary & Associates, Pawleys Island, South Carolina, United States|Fusion Clinical Research of Spartanburg, Spartanburg, South Carolina, United States|Palmetto Research Center, LLC, Spartanburg, South Carolina, United States|New Phase Research & Development, Chattanooga, Tennessee, United States|Parkway Medical Group, Fayetteville, Tennessee, United States|Stern Cardiovascular Foundation, Inc., Germantown, Tennessee, United States|Kore Cardiovascular Research Institutue, Jackson, Tennessee, United States|New Phase Research & Development, Knoxville, Tennessee, United States|Cardiovascular Research of Knoxville, Knoxville, Tennessee, United States|Ramanathan - VAMC Memphis, Memphis, Tennessee, United States|Clinical Research Center Meharry Medical College, Nashville, Tennessee, United States|Avant Research Associates LLC, Austin, Texas, United States|Texas Heart and Vascular Research, LLC, Austin, Texas, United States|Southeast TX Clinical Research Center, Beaumont, Texas, United States|Cornerstone Family Medicine, Big Spring, Texas, United States|IMD Medical Center, Carrollton, Texas, United States|Texas Health Physicians Group, Carrollton, Texas, United States|Cardiovascular Research Institute of Dallas, Dallas, Texas, United States|North Texas Health Center, Dallas, Texas, United States|The Heart Center of Dallas, Dallas, Texas, United States|Global Medical Research, DeSoto, Texas, United States|The Medical Group of Texas, Fort Worth, Texas, United States|Texas Health Physicians Group, Fort Worth, Texas, United States|T&R Clinic, P.A., Haltom City, Texas, United States|Michele P. Sartori, MD, Houston, Texas, United States|Grand Medical Care, Katy, Texas, United States|Team Research Of Central Texas, Killeen, Texas, United States|Houston Heart and Vascular Associates, Kingwood, Texas, United States|Grace Research, LLC, Marshall, Texas, United States|Valley Heart Consultants, McAllen, Texas, United States|Heart Center, Palo Pinto General Hospital, Mineral Wells, Texas, United States|Valley Central Research Inc, Mission, Texas, United States|North Hills Medical Research, Inc, North Richland Hills, Texas, United States|Grace Research, LLC, Palestine, Texas, United States|Avant Research Associates, LLC, Port Arthur, Texas, United States|Santoscoy - Health Texas Research Institute, San Antonio, Texas, United States|Element Research Group, San Antonio, Texas, United States|Schnitzler Cardiovascular Consultants, San Antonio, Texas, United States|San Antonio Endovascular & Heart Institute, San Antonio, Texas, United States|Acacia Medical Research Institute, Sugar Land, Texas, United States|Health Plus Clinical Research, Sugar Land, Texas, United States|Lone Star Heart and Vascular Center, Tomball, Texas, United States|Northwest Houston Clinical Research, Tomball, Texas, United States|Hillcrest Family Health Center, Waco, Texas, United States|Utah Cardiology, P.C., Layton, Utah, United States|Utah Diabetes Center, Salt Lake City, Utah, United States|VA Medical Center, White River Junction, White River Junction, Vermont, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Seven Corners Medical Research Center, Falls Church, Virginia, United States|Hampton Family Practice Research, Hampton, Virginia, United States|Tidewater Physicians Multispecialty Group, Hampton, Virginia, United States|Virginia Cardiovascular Associates, Manassas, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Tucker Cardiology Associates, P.C., Mechanicsville, Virginia, United States|TPMG Clinical Research, Newport News, Virginia, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Roanoke Heart Institute PLC, Roanoke, Virginia, United States|Cardinal Internal Medicine Associates, Woodbridge, Virginia, United States|Tidewater Physicians Multispecialty Group, Yorktown, Virginia, United States|Frandsen Family Medicine DBA Sound Medi, Port Orchard, Washington, United States|Premier Clinical Research, Spokane, Washington, United States|Kootenai Heart Clinics, LLC, Spokane, Washington, United States|Northside Internal Medicine, Spokane, Washington, United States|Northwest Medical Associates, P.S., Vancouver, Washington, United States|Cardiology Associates of Bellin Health, Green Bay, Wisconsin, United States|Dean Foundation, Madison, Wisconsin, United States|University Of Wisconsin, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Columbia St. Mary's, Milwaukee, Wisconsin, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|The Medical Arts Health Research Group, North Vancouver, British Columbia, Canada|The Medical Arts Health Research Group, Penticton, British Columbia, Canada|Winnipeg Clinic, Winnipeg, Manitoba, Canada|Bramalea Medical Centre, Brampton, Ontario, Canada|Brampton Research Associates, Brampton, Ontario, Canada|Philippe R Beaudry Medicine Professional Corporation, Burlington, Ontario, Canada|Vizel Cardiac Research, Cambridge, Ontario, Canada|Dr. Linda Sinnaeve's Office, Chatham, Ontario, Canada|Scisco Clinical Research, Cornwall, Ontario, Canada|Dr. Peter Spadafora Health Center, Guelph, Ontario, Canada|John Stimac, MD, Hamilton, Ontario, Canada|KMH Cardiology & Diagnostics: Hamilton, Hamilton, Ontario, Canada|Dr. William Liang, Hamilton, Ontario, Canada|Source Unique Clinic, Hawkesbury, Ontario, Canada|Dr. Ronald Fowlis, Kitchener, Ontario, Canada|University Hospital, London, Ontario, Canada|Malton Medical Research, Mississauga, Ontario, Canada|KMH Cardiology & Diagnostics: Mississauga, Mississauga, Ontario, Canada|Sewa Ram Singal Medicine Professional Corporation, Mississauga, Ontario, Canada|Newmarket Cardiology Research Group, Newmarket, Ontario, Canada|Newmarket Cardiology Research Group, Newmarket, Ontario, Canada|Portage Medical Centre, Niagra Falls, Ontario, Canada|Humber River Regional Hospital, North York, Ontario, Canada|Bakbak Medicine Professional Corporation, Oshawa, Ontario, Canada|Dr. James Y. Cha, Oshawa, Ontario, Canada|University Of Ottawa Heart Institute, Ottawa, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|Steeple Hill Medical Centre, Pickering, Ontario, Canada|Sarnia Institute Of Clinical Research, Sarnia, Ontario, Canada|Scarborough Cardiology Research, Scarborough, Ontario, Canada|Scarborough General Hospital Cardiology Research Associates, Scarborough, Ontario, Canada|Milliken Medical Centre, Scarborough, Ontario, Canada|Canadian Centre for Research on Diabetes, Smith Falls, Ontario, Canada|Lake Shore Cardiology, St. Catharines, Ontario, Canada|Sardar Medical Clinic, St. Thomas, Ontario, Canada|G.S. Cardiac Lab Medicine Professional Corp, Sudbury, Ontario, Canada|Dr. R. Labonte Professional Med Corp, Sudbury, Ontario, Canada|Dr. G. Garrioch, Independent Practice, Sudbury, Ontario, Canada|Dr. Laurence Gibbs Medicine Professional Corp., Thedford, Ontario, Canada|Tillsonburg Medical Centre, Tillsonburg, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Weston Road Medical Clinic, Toronto, Ontario, Canada|Dr. Nigel Jagan Medicine Professional Corporation, Whitby, Ontario, Canada|Dr. Nwadiaro Medicine Professional Corp, Windsor, Ontario, Canada|Viacar Recherche Clinique Inc., Brossard, Quebec, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|Q&T Research Chicoutimi, Chicoutimi, Quebec, Canada|Viacar Recherche Clinique Inc., Greenfield Park, Quebec, Canada|CHUM Hotel-Dieu, Montreal, Quebec, Canada|Iucpq, Quebec City, Quebec, Canada|ALPHA Recherche Clinique, Québec, Quebec, Canada|CardioVasc HR, Saint-Jean-sur-Richelieu, Quebec, Canada|ViaCar Recherche Clinique Inc, Saint-Lambert, Quebec, Canada|Viacar Recherche Clinique, St. Lambert, Quebec, Canada|Hopital Pierre-Le Gardeur, Terrebonne, Quebec, Canada|Recherche Clinique Sigma, Inc., Quebec, Canada|Instituto Sanacoop, Bayamón, Puerto Rico|San Juan Bautista School of Medicine, Caguas, Puerto Rico|Norma S. Severino-Pacheco, MD, Canovanas, Puerto Rico|Cardiometabolic Research Center, Ponce, Puerto Rico|Miguel Sosa-Padilla, MD, San Juan, Puerto Rico|Yolanda Sierra Quinones, MD, Toa Baja, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01594333"
946,"NCT01303783","Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension","DISTINCT","Completed","No Results Available","Hypertension, Essential","Drug: Candesartan cilexetil (Atacand), 4 mg|Drug: Candesartan cilexetil (Atacand), 8 mg|Drug: Nifedipine GITS (Adalat, BAYA1040), 20 mg|Drug: Nifedipine GITS (Adalat, BAYA1040), 30 mg|Drug: Nifedipine GITS (Adalat, BAYA1040), 60 mg|Drug: Placebo|Drug: Candesartan cilexetil (Atacand), 16 mg|Drug: Candesartan cilexetil (Atacand), 32 mg","The primary efficacy variable is the change from baseline in mean seated diastolic blood pressure (MSDBP) at Week 8|Change in mean seated systolic blood pressure (MSSBP) at Week 8|Control rate at Week 8|Response rate at Week 8|Peripheral Edema|Time to achieve first BP control","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","1381","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14725|2009-017077-37","April 2011","May 2012","May 2012","February 25, 2011",,"April 18, 2017","Mobile, Alabama, United States|Los Angeles, California, United States|Coral Gables, Florida, United States|Deerfield Beach, Florida, United States|Deerfield Beach, Florida, United States|Ft. Lauderdale, Florida, United States|Jacksonville, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Valparaiso, Indiana, United States|Charlotte, North Carolina, United States|Harrisburg, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Cincinnati, Ohio, United States|Philadelphia, Pennsylvania, United States|Greenville, South Carolina, United States|Mt. Pleasant, South Carolina, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Kenosha, Wisconsin, United States|Bahía Blanca, Buenos Aires, Argentina|Quilmes, Buenos Aires, Argentina|Zárate, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Corrientes, Argentina|Córdoba, Argentina|Córdoba, Argentina|Santa Fe, Argentina|Wetteren, Oost-Vlaanderen, Belgium|De Pinte, Belgium|Deurne, Belgium|HAM, Belgium|Fortaleza, Ceará, Brazil|Brasília, Distrito Federal, Brazil|Goiania, Goiás, Brazil|Campinas, Sao Paulo, Brazil|Campinas, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Langley, British Columbia, Canada|St. John's, Newfoundland and Labrador, Canada|St. John's, Newfoundland and Labrador, Canada|Brampton, Ontario, Canada|Corunna, Ontario, Canada|Downsview, Ontario, Canada|Etobicoke, Ontario, Canada|London, Ontario, Canada|London, Ontario, Canada|Newmarket, Ontario, Canada|Sarnia, Ontario, Canada|Strathroy, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Chieti, Abruzzo, Italy|Bologna, Emilia-Romagna, Italy|Trieste, Friuli-Venezia Giulia, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Sassari, Sardegna, Italy|Pisa, Toscana, Italy|Perugia, Umbria, Italy|Mercato San Severino, Italy|Daejeon, Daejeon Gwang''yeogsi, Korea, Republic of|Wonju-si, Gang''weondo, Korea, Republic of|Anyang-si, Gyeonggido, Korea, Republic of|Goyang-Si, Gyeonggido, Korea, Republic of|Goyang-si, Gyeonggido, Korea, Republic of|Goyang-si, Gyeonggido, Korea, Republic of|Goyang-si, Gyeonggido, Korea, Republic of|Uijeongbu, Gyeonggido, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Chungchungbuk-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Alytus, Lithuania|Kaunas, Lithuania|Kaunas, Lithuania|Vilnius, Lithuania|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Port Elizabeth, Eastern Cape, South Africa|Johannesburg, Gauteng, South Africa|Petoria, Gauteng, South Africa|Roodepoort, Gauteng, South Africa|Durban, KwaZulu Natal, South Africa|Witbank, Mpumalanga, South Africa|Somerset West, Western Cape, South Africa|Stellenbosch, Western Cape, South Africa|Santiago de Compostela, A Coruña, Spain|Benidorm, Alicante, Spain|Petrer, Alicante, Spain|Oviedo, Asturias, Spain|Hostalets de Balenyà, Barcelona, Spain|Peralada, Girona, Spain|Barcelona, Spain|Granada, Spain|Huelva, Spain|Valencia, Spain|Dnipropetrovsk, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Vinnitsa, Ukraine|Zaporizhzhya, Ukraine|Zhytomyr, Ukraine|Bath, Avon, United Kingdom|Fowey, Cornwall, United Kingdom|Penzance, Cornwall, United Kingdom|Penzance, Cornwall, United Kingdom|St Austell, Cornwall, United Kingdom|Chesterfield, Derbyshire, United Kingdom|Glasgow, Glasgow City, United Kingdom|Glasgow, Glasgow City, United Kingdom|Blackpool, Lancashire, United Kingdom|Bath, Somerset, United Kingdom|Addlestone, Surrey, United Kingdom|Coventry, Warwickshire, United Kingdom|Leamington Spa, Warwickshire, United Kingdom|Chippenham, Wiltshire, United Kingdom|Trowbridge, Wiltshire, United Kingdom|Westbury, Wiltshire, United Kingdom|Bath, United Kingdom|Bath, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01303783"
947,"NCT00853112","A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension",,"Terminated","Has Results","Hypertension, Pulmonary","Drug: PF-00489791|Drug: placebo|Drug: sildenafil","Mean Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) Over 4 Hours Post Dose|Greatest Reduction From Baseline in Pulmonary Vascular Resistance Index (PVRI) and Systemic Vascular Resistance Index (SVRI) Over 4 Hours Post Dose|Mean Change From Baseline in Systemic Vascular Resistance Index (SVRI) Over 4 Hours Post Dose|Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Hour 1, 2, 3 and 4 Post Dose|Change From Baseline in Systemic Vascular Resistance Index (SVRI) at Hour 1, 2, 3 and 4 Post Dose|Change From Baseline in Cardiac Index (CI) at Hour 1, 2, 3 and 4 Post Dose|Change From Baseline in Mean Pulmonary Artery Pressure (mPAP), Systolic Pulmonary Artery Pressure (sPAP), Diastolic Pulmonary Artery Pressure (dPAP), Right Atrial Pressure (RAP) at Hour 1, 2, 3 and 4 Post Dose|Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP), Mean Systemic Arterial Pressure (SAP), Systolic Systemic Arterial Pressure (sSAP) and Diastolic Systemic Arterial Pressure (dSAP) at Hour 1, 2, 3 and 4 Post Dose|Mean Change From Baseline in Pulmonary Vascular Resistance (PVR) and Systemic Vascular Resistance (SVR) at Hour 1, 2, 3 and 4 Post Dose|Mean Change From Baseline in Heart Rate (HR) at Hour 1, 2, 3 and 4 Post Dose|Number of Participants With Clinically Significant Laboratory Values|Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Values|Change From Baseline in Mean Partial Pressure of Oxygen (PaO2) and Carbon Dioxide (PaCO2) at Hour 1 and 4 Post Dose|Plasma Concentration of PF-00489791 and Sildenafil","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A7331009|2008-003572-21","April 2009","July 2010","July 2010","March 2, 2009","October 24, 2017","October 24, 2017","Pulmonary Associates, PA, Phoenix, Arizona, United States|John C. Lincoln Hospital, North Mountain, Phoenix, Arizona, United States|Pulmonary Associates, PA, Phoenix, Arizona, United States|Shands at University of Florida, Gainesville, Florida, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center - Department of Internal Medicine Pulmonary, Dallas, Texas, United States|UT Southwestern St. Paul Hospital, Dallas, Texas, United States|Lawson Health Research Institute, London, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Sir Mortimer B. Davis, Jewish General Hospital, Montreal, Quebec, Canada|Thoraxklinik am Universitaetsklinikum, Heidelberg, Germany|Department Of Cardiology, MediCiti Hospital,, Hyderabad, Andhra Pardesh, India|Department Of Cardiology, Sri Venkateswara Institute Of Medical Sciences, Tirupati, Andhra Pardesh, India|Bankers Heart Institute, Vadodara, Gujarat, India|Omega Hospital, Mangalore, Karnataka, India|Moscow Healthcare Institution ""City Clinical Hospital No. 57"", Moscow, Russian Federation|Institute of Cardiosurgery n.a. V.I.Burakovsky, Moscow, Russian Federation|Hospital General Universitari Vall D´Hebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Universitetssjukhuset i Lund, Hjart- och Lungdivisionen, Lund, Sweden|Norrlands Universitetssjukhus, Kliniskt Forsknings Centrum, Umea, Sweden|Akademiska Sjukhuset, Kardiologen 50F/Forskningsenheten, Uppsala, Sweden|Universitaetsspittal Zuerich, Medizinische Klinik A, Zuerich, Switzerland",,"https://ClinicalTrials.gov/show/NCT00853112"
948,"NCT01060579","Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure",,"Completed","No Results Available","Glaucoma","Drug: AR-12286 0.5% ophthalmic solution|Drug: AR-12286 0.25% Ophthalmic solution|Drug: Latanoprost ophthalmic solution","The primary efficacy endpoint will be the mean intraocular pressure (IOP) across subjects within treatment group on each day at each post-treatment timepoint|Mean change from diurnally adjusted baseline IOP at each timepoint","Aerie Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","217","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AR-12286-CS202","February 2010","August 2010","August 2010","February 2, 2010",,"May 8, 2014","United Medical Research Institute, Inglewood, California, United States|North Bay Eye Associates, Petaluma, California, United States|Centre For Health Care, Poway, California, United States|East Florida Eye Institute, Stuart, Florida, United States|Marvin Greenberg, MD, Tamarac, Florida, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|Bradley Kwapiszeski, MD, Shawnee Mission, Kansas, United States|Taustine Eye Center, Louisville, Kentucky, United States|Comprehensive Eye Care, St Louis, Missouri, United States|Mount Sinai School Of Medicine, New York, New York, United States|Rochester Ophthalmology Group, Rochester, New York, United States|Glaucoma Consultants of the Capital Region, Slingerlands, New York, United States|Charlotte Eye Ear Nose and Throat, Charlotte, North Carolina, United States|The Eye Institute, Tulsa, Oklahoma, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Univ Eye Surgeons, Maryville Ctr., Maryville, Tennessee, United States|Texan Eye, Austin, Texas, United States|Medical Center Ophth. Associates, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01060579"
949,"NCT02410525","A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning",,"Completed","No Results Available","Healthy","Drug: [11C]PF-06427878|Drug: PF-06427878 10 mg|Drug: PF-06427878 600 mg","Percent injected radioactivity (per gram) over time in the liver|Percent injected radioactivity (per gram) over time in the plasma|Relative radioactivity in liver versus plasma|Time-course of total radioactivity as percentage of injected radioactivity (per gram) in the gall bladder, if this region is identifiable|% of parent in plasma over time|Plasma PK of PF-06427878: AUClast, as data permit|Plasma PK of PF-06427878: AUClast, as data permit.|Time-course of total radioactivity as percentage of injected radioactivity (per gram) in the biliary tree, if this region is identifiable|Time-course of total radioactivity as percentage of injected radioactivity (per gram) in the abdominal fat, if this region is identifiable|Time-course of total radioactivity as percentage of injected radioactivity (per gram) in the kidney, if this region is identifiable|Time-course of total radioactivity as percentage of injected radioactivity (per gram) in the urinary bladder, if this region is identifiable|Time-course of total radioactivity as percentage of injected radioactivity (per gram) in the thigh muscle, if this region is identifiable|Plasma PK of PF-06427878: AUCinf, as data permit|Plasma PK of PF-06427878: Cmax, as data permit|Plasma PK of PF-06427878: Tmax, as data permit|Plasma PK of PF-06427878: t½, as data permit|Plasma PK of PF-06427878: CL, as data permit|Plasma PK of PF-06427878: Vss, as data permit|Plasma PK of PF-06427878: Vss, as data permit.|Plasma PK of PF-06427878: AUCinf, as data permit.|Plasma PK of PF-06427878: Cmax, as data permit.|Plasma PK of PF-06427878: Tmax, as data permit.|Plasma PK of PF-06427878: t½, as data permit.|Plasma PK of PF-06427878: CL/F, as data permit.","Pfizer","Male","18 Years to 55 Years   (Adult)","Phase 1","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","B7871003","May 2015","September 2015","September 2015","April 7, 2015",,"October 29, 2015","New Haven Clinical Research Unit, New Haven, Connecticut, United States|Anylan Center, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02410525"
950,"NCT02219906","Resveratrol in Metabolic Syndrome: Effect on Platelet Hyper-reactivity and HDL Lipid Peroxidation",,"Completed","No Results Available","Metabolic Syndrome","Dietary Supplement: Resveratrol|Dietary Supplement: Placebo","Change in parameters of platelet activation|Change in parameter for platelet oxidative stress|Change in parameter for platelet oxidation levels|Serum Thromboxane measurments|Change in oxidative modifications of HDL|Change in plasma oxidative stress","Vanderbilt University|Vanderbilt University Medical Center","All","30 Years to 75 Years   (Adult, Older Adult)","Not Applicable","41","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","130996","May 2014","February 7, 2019","April 7, 2019","August 19, 2014",,"April 19, 2019","Vanderbilt University, Nashville, Tennessee, United States|Baylor University, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02219906"
951,"NCT01090661","A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects",,"Completed","No Results Available","Healthy","Drug: mipomersen sodium|Drug: moxifloxacin hydrochloride (Avelox®)|Drug: placebo","change from baseline in QTcF (corrected Frederica's CT interval)|ECG intervals (QTcB (corrected Bazett's QT interval), HR (heart rate, PR, QRS, and QT)|change in ECG morphological patterns|Correlation between delta delta QTc interval and plasma mipomersen concentrations|Incidence of treatment-emergent Adverse Events|mipomersen plasma pharmacokinetic (PK) parameters: Area Under the Curve (AUC 0-22.5h), Maximum Concentration (Cmax), Time to Maximum Concentration (Tmax)","Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.","All","18 Years to 45 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MIPO2800209","March 2010","May 2010","May 2010","March 22, 2010",,"August 3, 2016","PPD Development, LP, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01090661"
952,"NCT01342211","A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins",,"Completed","Has Results","Hypercholesterolemia|Dyslipidemia","Biological: Placebo|Drug: Statin|Biological: PF-04950615 (RN316)|Drug: Satin","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 85|Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 70 and <100 Milligram Per Deciliter (mg/dL)|Percentage of Participants Achieving at Least 30 Percent Decrease in Low-density Lipoprotein Cholesterol (LDL-C)|Change From Baseline in Lipid Parameters at Day 29, 57 and 85|Percent Change From Baseline in Lipid Parameters at Day 29, 57 and 85|Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Treatment-Emergent Adverse Events (TEAEs) by Severity|Number of Participants With Clinically Relevant Laboratory Abnormalities|Number of Participants With Clinically Significant Changes in Vital Signs and Electrocardiogram (ECG) Parameters|Number of Participants With Anti-drug Antibody (ADA)","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","93","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","B1481005","July 2011","February 2012","June 2012","April 27, 2011","October 11, 2017","October 11, 2017","Orange County Research Center, Tustin, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Innovative Research of West Florida, Inc., Clearwater, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|In Vivo Clinical Research, Inc., Doral, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Kendall South Medical Center, Miami, Florida, United States|North Georgia Clinical Research, Woodstock, Georgia, United States|North Georgia Internal Medicine, Woodstock, Georgia, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|L-MARC Research Center, Louisville, Kentucky, United States|Commonwealth Biomedical Research, LLC, Madisonville, Kentucky, United States|Maine Research Associates, Auburn, Maine, United States|Infinity Medical Research, North Dartmouth, Massachusetts, United States|Saint Luke's Hospital, Kansas City, Missouri, United States|Saint Luke's Lipid and Diabetes Research Center, Kansas City, Missouri, United States|The Center for Pharmaceutical Research, P.C., Kansas City, Missouri, United States|Medex Healthcare Research, Inc., Saint Louis, Missouri, United States|New Mexico Clinical Research & Osteoporosis Center, Incorporated, Albuquerque, New Mexico, United States|North Carolina Clinical Research, Raleigh, North Carolina, United States|PMG Research of Salisbury, Salisbury, North Carolina, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Oklahoma Cardiovascular Research Group (OCRG), Oklahoma City, Oklahoma, United States|Oklahoma Heart Hospital Physicians, Oklahoma City, Oklahoma, United States|Oklahoma Heart Hospital, Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Translational Research Center, Philadelphia, Pennsylvania, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Paragon Research Center, LLC, San Antonio, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|San Antonio Preventive & Diagnostic Medicine, PA, San Antonio, Texas, United States|National Clinical Research - Norfolk, Inc., Norfolk, Virginia, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States|The Medical Arts Health Research Group, Kelowna, British Columbia, Canada|Q & T Research Chicoutimi, Chicoutimi, Quebec, Canada|Centre de Recherche Clinique de Laval, Laval, Quebec, Canada|Diex Research Montreal Inc., Montreal, Quebec, Canada|Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Clinique des Maladies Lipidiques de Quebec Inc., Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01342211"
953,"NCT01275339","Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study","ASPEN","Terminated","Has Results","Aortic Stenosis|LV Remodeling, Hypertrophy","Drug: Tadalafil|Drug: Placebo","Diastolic Function as Measured by Tissue Doppler e'|Change in Myocardial Fibrosis (ECV) on MRI|Change in Other Echocardiographic Indices of Diastolic Function|Safety and Tolerability|Change in Indices of Systolic Function|Change in LV Hypertrophic Remodeling|Change in Novel Echocardiographic Indices of Diastolic Function|Change in 6 Minute Walk Distance|Change in Circulating Neurohormonal Markers|Change in Quality of Life|Change in Pulmonary Artery Pressure and Pulmonary Vascular Resistance as Assessed by Echo|Change in Systemic Blood Pressure|Change in RV Function|Change in AS Severity","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 4","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10-1334b","December 2012","April 14, 2017","April 14, 2017","January 12, 2011","April 17, 2019","April 17, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT01275339/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01275339"
954,"NCT01272388","Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study","ASPEN-AVR","Terminated","Has Results","Aortic Stenosis","Drug: Tadalafil|Drug: Placebo","Quality of Life as Assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ)|6 Minute Walk Distance","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 4","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10-1334a","January 2011","April 2011","April 2012","January 7, 2011","September 12, 2018","September 12, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01272388"
955,"NCT03542240","Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome",,"Active, not recruiting","No Results Available","Obesity|High Blood Pressure|High Cholesterol|Type2 Diabetes|Heart Diseases","Dietary Supplement: Curcumin","Change inintestinal permeability|Change in intestinal barrier function","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HM20012060","September 19, 2018","November 2020","November 2020","May 31, 2018",,"February 19, 2020","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03542240"
956,"NCT01514461","A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome",,"Completed","Has Results","Familial Chylomicronemia Syndrome (FCS)","Drug: LCQ908|Drug: Placebo","Percent Change in Fasting Triglycerides From Baseline to 12 Weeks|Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline or Final Fasting TG < 8.4 mmol/L (750 mg/dL)|Percentage of Patients Responding to Investigational Treatment by Achieving Final Fasting Triglycerides < 8.4 mmol/L (750 mg/dL)|Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline|Percentage of Patients Achieving Fasting Triglycerides (TG) Target Thresholds|Percent Change From Baseline in Fasting Triglycerides|Percent Change From Baseline for Postprandial Triglycerides Following the Standardized Meal Tolerance Test at Week 12|Pharmacokinetics of LCQ908 - Trough Concentration (Cmin) and Observed Maximum Blood Concentration (Cmax)|Pharmacokinetics of LCQ908- Area Under the Plasma Concentration Time Curve AUC (0-24hour)|Pharmacokinetics of LCQ908- Time to Reach Maximum Concentration Following Drug Administration Tmax (Hours)|Pharmacokinetics of LCQ908- Average Observed Blood Concentration (Cavg)|Number of Patients Reported With Any Adverse Event, Serious Adverse Event and Death","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLCQ908B2302|2011-005535-68","July 2012","May 2014","May 2014","January 23, 2012","June 3, 2015","June 3, 2015","Novartis Investigative Site, Seatlle, Washington, United States|Novartis Investigative Site, Chicoutimi, Quebec, Canada|Novartis Investigative Site, Ste-Foy, Quebec, Canada|Novartis Investigative Site, Ouest-Montreal, Canada|Novartis Investigative Site, Bron, France|Novartis Investigative Site, Nantes, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Köln, Germany|Novartis Investigative Site, Meibergdreef 9, Netherlands|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01514461"
957,"NCT03508687","Study of Gemcabene in Adults With FPLD",,"Completed","No Results Available","Familial Partial Lipodystrophy|Hypertriglyceridemia|Fatty Liver|NASH - Nonalcoholic Steatohepatitis","Drug: 300mg Gemcabene|Drug: 600mg Gemcabene","Change in fasting serum triglyceride (at 12 weeks)|Change in fasting serum triglycerides (through 24 weeks)|Percent change in fasting serum triglycerides (through 24 weeks)|Change in liver fat content as measured by MRI-PDFF|Percent change in liver fat content as measured by MRI-PDFF|Change in liver fibrosis|Percent change in liver fibrosis|Change in NAS (non-alcoholic steatohepatitis)|Percent change in NAS (non-alcoholic steatohepatitis)|Change in biomarkers of inflammation|Percent change in biomarkers of inflammation|Change in cholesterol|Percent change in cholesterol|Change in apolipoprotein|Percent change in apolipoprotein","Elif Oral|University of Michigan","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","5","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HUM00130803","March 13, 2018","July 31, 2019","July 31, 2019","April 26, 2018",,"August 6, 2019","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03508687"
958,"NCT01889368","Effect of a Grape Seed Extract (GSE) on Insulin Resistance",,"Completed","No Results Available","Metabolic Syndrome","Dietary Supplement: Grape Seed Extract|Dietary Supplement: Placebo","Changes in insulin resistance|Changes in oxidized LDL (oxLDL) concentrations|Changes in oxidative stress|Changes in vascular stress|Changes in insulin response","University of California, Davis|Illinois Institute of Technology","All","20 Years to 70 Years   (Adult, Older Adult)","Not Applicable","19","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","329493|329493-4","November 2012","March 2015","March 2015","June 28, 2013",,"June 27, 2017","VA Hospital, Mather, Mather, California, United States",,"https://ClinicalTrials.gov/show/NCT01889368"
959,"NCT03385239","Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)",,"Active, not recruiting","No Results Available","Hypertriglyceridemia|Cardiovascular Diseases","Drug: ISIS 678354|Drug: Placebo","Efficacy of different doses and dosing regimens of ISIS 678354 on the reduction in serum triglyceride (TG) levels from baseline at the primary analysis time point.|The safety of ISIS 678354 by the incidence of treatment-emergent adverse events.|Efficacy of different doses and dosing regimens of ISIS 678354 on serum triglyceride (TG) levels from baseline at the primary analysis time point.|To evaluate the efficacy of ISIS 678354 on serum levels of apolipoprotein C-III (apoC-III).|To evaluate the efficacy of ISIS 678354 on serum levels of cholesterol parameters.|To evaluate the efficacy of ISIS 678354 on serum levels of apolipoprotein B100 (apoB).|To evaluate the efficacy of ISIS 678354 on serum levels of apolipoprotein A-1 (apoA-I).|Plasma Cmax of ISIS 678354 across different doses and dose regimens.|Plasma Tmax of ISIS 678354 across different doses and dose regimens.|Plasma AUC values of ISIS 678354 across different doses and dose regimens.","Akcea Therapeutics|Ionis Pharmaceuticals, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","115","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ISIS 678354-CS2","January 5, 2018","November 25, 2019","February 28, 2020","December 28, 2017",,"February 17, 2020","Clinical Site, Cottonwood, Arizona, United States|Clinical Site, Little Rock, Arkansas, United States|Clinical Site, Carmichael, California, United States|Clinical Site, Fresno, California, United States|Clinical Site, La Jolla, California, United States|Clinical Site, Long Beach, California, United States|Clinical Site, Montclair, California, United States|Clinical Site, Wilmington, Delaware, United States|Clinical Site, Boca Raton, Florida, United States|Clinical Site, Jacksonville, Florida, United States|Clinical Site, New Port Richey, Florida, United States|Clinical Site, Munster, Indiana, United States|Clinical Site, Ames, Iowa, United States|Clinical Site, Kansas City, Kansas, United States|Clinical Site, Louisville, Kentucky, United States|Clinical Site, Fall River, Massachusetts, United States|Clinical Site, Cooperstown, New York, United States|Clinical Site, High Point, North Carolina, United States|Clinical Site, Portland, Oregon, United States|Clinical Site, Lansdale, Pennsylvania, United States|Clinical Site, Providence, Rhode Island, United States|Clinical Site, Greer, South Carolina, United States|Clinical Site, Houston, Texas, United States|Clinical Site, Milwaukee, Wisconsin, United States|Clinical Site, Cambridge, Ontario, Canada|Clinical Site, Sudbury, Ontario, Canada|Clinical Site, Brossard, Quebec, Canada|Clinical Site, Chicoutimi, Quebec, Canada|Clinical Site, Gatineau, Quebec, Canada|Clinical Site, Montréal, Quebec, Canada|Clinical Site, Québec, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03385239"
960,"NCT02110563","Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma",,"Terminated","No Results Available","Solid Tumors|Multiple Myeloma|Non-Hodgkins Lymphoma|Pancreatic Neuroendocrine Tumors|PNET|NHL","Drug: DCR-MYC","Number of patients with adverse events as a measure of safety and tolerability|DCR-MYC levels in blood|DCR-MYC biological activities|Preliminary antitumor activity","Dicerna Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCR-MYC-101","April 2014","October 5, 2016","November 3, 2016","April 10, 2014",,"December 15, 2017","Stanford Cancer Institute, Stanford, California, United States|University of Chicago, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|South Texas Accelerated Research Therapeutics (START)-Midwest, Grand Rapids, Michigan, United States|MD Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02110563"
961,"NCT01190358","Grape Seed Extract and Postprandial Oxidation and Inflammation","GSEMetS","Completed","No Results Available","Metabolic Syndrome","Dietary Supplement: Placebo|Dietary Supplement: Grape seed extract","Modification of the postprandial inflammatory response.|Metabolic response to a high fat meal.","University of California, Davis","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","200917488","August 2010","March 2011","September 2015","August 27, 2010",,"July 19, 2017","University of California Davis (Academic Surge, Ragle Human Nutrition Research Facility), Davis, California, United States|VA Hospital, Mather, Mather, California, United States",,"https://ClinicalTrials.gov/show/NCT01190358"
962,"NCT03258281","Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus After Elective Percutaneous Coronary Intervention","ISS-DMII","Terminated","No Results Available","Diabetes Mellitus, Type 2|Dyslipidemia Associated With Type II Diabetes Mellitus|Percutaneous Coronary Intervention","Drug: Evolocumab|Drug: Placebo","Absolute difference in ADP-stimulated P-selectin expression|Absolute differences in unstimulated and ADP-stimulated p-selectin and GPIIb/IIIa receptor expression and unstimulated CD36, and LOX-1|Absolute differences in lipid profile including LDL-C, oxLDL, fibrinogen|Prevalence of high on-clopidogrel platelet reactivity by the VerifyNow P2Y12 assa","Inova Health Care Services","All","Child, Adult, Older Adult","Phase 4","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","17-2639","May 1, 2018","September 1, 2019","September 1, 2019","August 23, 2017",,"October 10, 2019","Inova Fairfax Hospital, Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03258281"
963,"NCT02404896","Expanded Access Metreleptin Study",,"Active, not recruiting","No Results Available","Familial Partial Lipodystrophy","Drug: Metreleptin","Hypertriglyceridemia (Triglyceride level reduction)|HbA1c","University of Michigan","All","18 Years and older   (Adult, Older Adult)","Phase 2","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HUM00094843","January 2015","January 2025","January 2025","April 1, 2015",,"February 12, 2020","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02404896"
964,"NCT00891293","A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™",,"Completed","Has Results","Hypertriglyceridemia","Drug: Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)","Percent Change in Serum Triglycerides From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension).|Percent Change in Total Cholesterol From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study).|Percent Change in VLDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)|Percent Change in LDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)|Percent Change in HDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)|Percent Change in Ratio of Total-C:HDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Ext. Study)|Percent Change in Apo A-1 From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study|Percent Change in Apo B From LOV111859/OM5 (Double-blind [DB[ Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)|Percent Change in Non-HDL-C From LOV111859/OM5 (Double-blind [DB] Study) Baseline to Week 8 of LOV111860/OM5X (1st Open-label [OL] Extension Study) and From LOV111859/OM5 (DB Study) Baseline to Month 24 of LOV111821/OM5XX (2nd OL Extension Study)","GlaxoSmithKline","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 4","93","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","111821","March 2006","May 2008","May 2008","May 1, 2009","July 28, 2009","January 25, 2011","GSK Investigational Site, Spring Valley, California, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Coral Gables, Florida, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Longwood, Florida, United States|GSK Investigational Site, Pinellas Park, Florida, United States|GSK Investigational Site, Duhwoody, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Bloomington, Indiana, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Auburn, Maine, United States|GSK Investigational Site, Scarborough, Maine, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Wentzville, Minnesota, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Hickory, North Carolina, United States|GSK Investigational Site, Salisbury, North Carolina, United States|GSK Investigational Site, Statesville, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Cumberland, Rhode Island, United States|GSK Investigational Site, Mount Pleasant, South Carolina, United States|GSK Investigational Site, Bristol, Tennessee, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Winchester, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00891293"
965,"NCT01120769","Acetaminophen to Prevent Ischemic Oxidative Reperfusion Injury During Percutaneous Coronary Intervention for Acute Myocardial Infarction","APRIORI Pilot","Withdrawn","No Results Available","Acute Myocardial Infarction","Drug: Acetaminophen|Drug: Placebo","Plasma isoprostane level|Index of microcirculatory resistance","Vanderbilt University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","100001","July 2011","July 2012","July 2012","May 11, 2010",,"December 7, 2015","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01120769"
966,"NCT02314052","Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma",,"Terminated","Has Results","Hepatocellular Carcinoma","Drug: DCR-MYC","Phase 1b: Number of Patients With Adverse Events as a Measure of Safety and Tolerability|Phase 2: Patients With Adverse Events as a Measure of Safety and Tolerability|Phase 2: Preliminary Antitumor Activity|Cmax (ng/mL) - DCR-MYC Levels in Blood (Phase 1b Only): Dosing Day 1 and Day 8|DCR-MYC Biological Activities (Phase 1b Only)|Tmax (Hr) - DCR-MYC Levels in Blood (Phase 1b Only): Dosing Day 1 and Day 8|Cmax_D (kg*ng/mL/mg) - DCR-MYC Levels in Blood (Phase 1b Only): Dosing Day 1 and Day 8|AUClast_D (hr*kg*ng/mL/mg) - DCR-MYC Levels in Blood (Phase 1b Only): Dosing Day 1 and Day 8|AUClast (hr*ng/mL) - DCR-MYC Levels in Blood (Phase 1b Only): Dosing Day 1 and Day 8","Dicerna Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCR-MYC-102","January 27, 2015","October 11, 2016","October 11, 2016","December 10, 2014","September 4, 2018","September 4, 2018","Mayo Clinic, Scottsdale, Arizona, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|Asan Medical Center, Seoul, Korea, Republic of|National University Hospital of Singapore, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02314052"
967,"NCT02536911","A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate",,"Completed","No Results Available","Gaucher Disease","Drug: eliglustat","Assessment of PK parameter: Maximum plasma concentration observed (Cmax)|Assessment of PK parameter: Area under the plasma concentration (AUC)|Assessment of PK parameter: Area under the plasma concentration versus time curve (AUClast)|Assessment of PK parameter: Apparent total body clearance (CL/F)|Assessment of PK parameter: Apparent volume of distribution during the terminal phase (Vz/F)|Assessment of PK parameter: Predicted accumulation ratio (Rac,pred)|Assessment of PK parameter: Terminal half-life (t1/2z)|Change from baseline in ECG parameter|Number of adverse events","Genzyme, a Sanofi Company|Sanofi","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","POP13777|U1111-1170-3678","September 2015","December 2016","December 2016","September 1, 2015",,"February 10, 2017","Investigational Site Number 840002, Miami, Florida, United States|Investigational Site Number 840001, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02536911"
968,"NCT02211209","The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome",,"Completed","No Results Available","Familial Chylomicronemia Syndrome","Drug: Volanesorsen|Drug: Placebo","Efficacy of ISIS-APOCIIIRx as measured by the percent change in fasting triglycerides from baseline","Ionis Pharmaceuticals, Inc.|Akcea Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ISIS 304801-CS6|2014-002421-35","December 2014","December 19, 2016","March 28, 2017","August 7, 2014",,"December 20, 2019","IONIS Investigative Site, Encinitas, California, United States|IONIS Investigative Site, San Francisco, California, United States|IONIS Investigative Site, Kansas City, Kansas, United States|IONIS Investigative Site, Boston, Massachusetts, United States|IONIS Investigative Site, New York, New York, United States|IONIS Investigative Site, Oklahoma City, Oklahoma, United States|IONIS Investigative Site, Portland, Oregon, United States|IONIS Investigative Site, Philadelphia, Pennsylvania, United States|IONIS Investigative Site, Houston, Texas, United States|IONIS Investigative Site, Norfolk, Virginia, United States|IONIS Investigative Site, Seattle, Washington, United States|IONIS Investigative Site, Campinas, Brazil|IONIS Investigative Site, Sao Paulo, Brazil|IONIS Investigative Site, Sao Paulo, Brazil|IONIS Investigative Site, Vancouver, British Columbia, Canada|IONIS Investigative Site, Chicoutimi, Quebec, Canada|IONIS Investigative Site, Sainte-Foy, Quebec, Canada|IONIS Investigative Site, Marseille, France|IONIS Investigative Site, Nantes, France|IONIS Investigative Site, Paris, France|IONIS Investigative Site, Berlin, Germany|IONIS Investigative Site, Dresden, Germany|IONIS Investigative Site, Szikszo, Hungary|IONIS Investigative Site, Safed, Israel|IONIS Investigative Site, Milan, Italy|IONIS Investigative Site, Palermo, Italy|IONIS Investigative Site, Rome, Italy|IONIS Investigative Site, Amsterdam, Netherlands|IONIS Investigative Site, Rotterdam, Netherlands|IONIS Investigative Site, Cape Town, South Africa|IONIS Investigative Site, Zaragoza, Aragon, Spain|IONIS Investigative Site, La Coruna, Galicia, Spain|IONIS Investigative Site, Barcelona, Spain|IONIS Investigative Site, Madrid, Spain|IONIS Investigative Site, Malaga, Spain|IONIS Investigative Site, Sevilla, Spain|IONIS Investigative Site, Birmingham, United Kingdom|IONIS Investigative Site, Manchester, United Kingdom|IONIS Investigative Site, Manchester, United Kingdom|IONIS Investigative Site, Peterborough, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02211209"
969,"NCT01545830","Metabolic Syndrome and Insulin Resistance at Allina","MISURA","Completed","No Results Available","Metabolic Syndrome","Dietary Supplement: vitamin D3 (cholecalciferol)","insulin resistance score by NMR lipid fractionation|Reynolds Risk Score|Pre-diabetes stage|25-OH-vitamin D|fasting lipid profile|adiposity markers|TNF-alpha|weight|blood pressure|PROMIS-29|Perceived Stress Scale (PSS)|WPAI|PROMIS-GH|International Physical Activity Questionnaire (IPAQ)|IL-6|IL-8|HS-CRP|Lp-PLA2 (PLAC)|PAI-1|Fibrinogen","Allina Health System","All","18 Years and older   (Adult, Older Adult)","Phase 2","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SPA ID 3607","March 2012","February 2014","March 2014","March 7, 2012",,"September 1, 2016","Allina Health, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01545830"
970,"NCT01148836","Coenzyme Q-10 and Pulmonary Arterial Hypertension",,"Completed","Has Results","Pulmonary Arterial Hypertension","Dietary Supplement: Coenzyme Q-10 in Pulmonary Hypertension subjects|Dietary Supplement: Coenzyme Q-10 in Normal Control subjects","Left Ventricular End Diastolic Volume|Right Ventricular Outflow|Right Ventricle Myocardial Performance|Tricuspid Regurgitation Grade|Right Atrial Pressure|Red Blood Cells|Hemoglobin|Hematocrit|Mean Corpuscular Hemoglobin|Red Blood Cell Distribution Width","The Cleveland Clinic","All","18 Years to 55 Years   (Adult)","Not Applicable","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-497","January 2010","January 2014","January 2014","June 22, 2010","March 20, 2015","March 20, 2015","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01148836"
971,"NCT01058083","Safety Study of BMS-770767 in Subjects With Hypercholesterolemia",,"Completed","No Results Available","Dyslipidemia","Drug: BMS-770767|Drug: Placebo","Lowering of LDL-C|Pharmacokinetics (Blood Level) of BMS-770767|Pharmacodynamic effects of BMS-770767 on Total cholesterol, HDL-C, Triglycerides, non-HDL-C, non-esterified free fatty acids, Apolipoprotein fractions, HPA axis marker and free testosterone and sex hormone binding globulin (SHBG)","Bristol-Myers Squibb","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MB117-004|2009-014306-33","May 2010","March 2011","March 2011","January 28, 2010",,"April 19, 2012","Harrell, Robert, Little Rock, Arkansas, United States|Cetero Research - San Antonio, San Antonio, Texas, United States|Local Institution, Blacktown, New South Wales, Australia|Local Institution, Hornsby, New South Wales, Australia|Local Institution, Caboolture, Queensland, Australia|Local Institution, South Brisbane, Queensland, Australia|Local Institution, Daw Park, South Australia, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Bathurst, New Brunswick, Canada|Local Institution, Brampton, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Charlottetown, Prince Edward Island, Canada|Local Institution, Mirabel, Quebec, Canada|Local Institution, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01058083"
972,"NCT00903409","Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects",,"Completed","Has Results","Hypertriglyceridemia","Drug: Simvastatin + Lovaza® (omega-3-acid ethyl esters)","Median Percent Change of Non-HDL-C (High Density Lipoprotein-Cholesterol) in Switchers vs. Non-Switchers Subjects From LOV111858 End-of-Treatment (Week 8) to Month 4 of Extension Study (LOV111818)|Median Percent Change of Lipid Measurements From LOV111858 End-of-Treatment Week 8 to Months 4, 12, and 24 of the Open-Label Extension Study (LOV111818) in ""Switchers"" vs. Non-switchers|Median Percent Change of Lipid Measurements From LOV111858 End-of-Treatment Week 8 to LOV111818 Months 4, 12, and 24 of the Open-Label Extension Trial","GlaxoSmithKline","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 3","188","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment","111818|LOV111858","November 15, 2005","June 27, 2008","June 27, 2008","May 18, 2009","August 4, 2009","October 9, 2017","GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, Encinitas, California, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Greenbrae, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Thousand Oaks, California, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Pinellas Park, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Dunwoody, Georgia, United States|GSK Investigational Site, Suwanee, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Bloomington, Indiana, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Edina, Minnesota, United States|GSK Investigational Site, Wentzville, Minnesota, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Hickory, North Carolina, United States|GSK Investigational Site, Salisbury, North Carolina, United States|GSK Investigational Site, Statesville, North Carolina, United States|GSK Investigational Site, Wilmington, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Warwick, Rhode Island, United States|GSK Investigational Site, Bristol, Tennessee, United States|GSK Investigational Site, Plano, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Lakewood, Washington, United States|GSK Investigational Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00903409"
973,"NCT02944383","A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia","INDIGO-1","Completed","No Results Available","Severe Hypertriglyceridemia|Mixed Dyslipidemia","Drug: Gemcabene|Drug: Placebo Oral Tablet","Change in fasting triglycerides from Baseline (Day 1) to Week 12 (Day 84)","NeuroBo Pharmaceuticals Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","91","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GEM-401","December 2016","January 11, 2018","May 9, 2018","October 25, 2016",,"March 31, 2020","Appalachian Research Associates, Fort Payne, Alabama, United States|Del Sol Research Mangagement, LLC, Tucson, Arizona, United States|Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|Hope Clinical Research, Canoga Park, California, United States|SC Clinical Research, Garden Grove, California, United States|National Research Institute, Huntington Park, California, United States|National Research Institute, Los Angeles, California, United States|Paradigm Clinical Research, San Diego, California, United States|Paradigm Research, Wheat Ridge, Colorado, United States|Excel Medical Research, Boca Raton, Florida, United States|Meridien Research, Bradenton, Florida, United States|Direct Helpers Research Center, Hialeah, Florida, United States|Indago Research and Health Center, Hialeah, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Sunrise Medical Research, Lauderdale Lakes, Florida, United States|AR Developoment Solutions, Miami Lakes, Florida, United States|San Marcus Research Clinic, Inc., Miami, Florida, United States|Millenium Clinical Research, Inc., Miami, Florida, United States|Medcare Research, Miami, Florida, United States|Soma Medical Research, West Palm Beach, Florida, United States|Evanston Premier Clinical Research, Evanston, Illinois, United States|Midwest Institute for Clinical Research, Inc., Indianapolis, Indiana, United States|Richard Lochamy, M.D., Junction City, Kansas, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|L-MARC Research Center, Louisville, Kentucky, United States|Clinical Trials Management, LLC, Covington, Louisiana, United States|Clinical Trials Management, LLC, Metairie, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|University of Michigan Health Systems, Ann Arbor, Michigan, United States|Elite Clinical Research, Jackson, Mississippi, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|CHEAR Center, LLC, Bronx, New York, United States|Advantage Clinical Trials, Bronx, New York, United States|Eastern Carolina Medical Clinic, Benson, North Carolina, United States|Physicians East, NA, Farmville, North Carolina, United States|Physicians East, NA, Greenville, North Carolina, United States|Cary Medical Clinic, Morrisville, North Carolina, United States|Optimed Research, Columbus, Ohio, United States|PriMed Clinical Research, Dayton, Ohio, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|BTC of Lincoln, Lincoln, Rhode Island, United States|Carolinas Research Partners, LLC, Rock Hill, South Carolina, United States|Airline Complete Healthcare, Houston, Texas, United States|Sante Clinical Research, Kerrville, Texas, United States|FMC Science, Lampasas, Texas, United States|Clinical Investigations of Texas, Plano, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Clinical Investigation Specialists, Kenosha, Wisconsin, United States|Ecogene-21, Chicoutimi, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02944383"
974,"NCT01122108","Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale",,"Completed","Has Results","Healthy","Drug: Cholestyramine|Drug: Colesevelam HCl","Patient Acceptability of Colesevelam HCl Powder for Oral Suspension vs. Generic Cholestyramine Via the Bile Acid Sequestrant Acceptability (BASA) Scale, Based Upon an Anticipated Equivalent Cholesterol Lowering Doses of Each Comparator Drug.","Louisville Metabolic and Atherosclerosis Research Center|Provident Clinical Research|Daiichi Sankyo, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","42","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","002","April 2010","June 2010","June 2010","May 13, 2010","October 7, 2010","October 7, 2010","L-MARC Research Center, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT01122108"
975,"NCT02275156","Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab",,"Completed","Has Results","Hyperlipidemia|Mixed Dyslipidemia","Biological: Evolocumab","Maximum Observed Serum Concentration (Cmax) of Evolocumab|Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-last) for Evolocumab|Number of Participants With Adverse Events|Number of Participants With Clinically Relevant Vital Sign or Clinical Laboratory Changes|Number of Participants With Anti-evolocumab Antibodies|Area Under the Effect Curve From Baseline to Day 57 (AUECday1-57) for Low-density Lipoprotein Cholesterol (LDL-C)|Mean Percent Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140213","August 19, 2014","December 19, 2014","December 19, 2014","October 27, 2014","January 29, 2016","November 29, 2018","Research Site, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02275156"
976,"NCT02513823","Effectiveness of Vitamin D Supplementation",,"Terminated","Has Results","Elevated Blood Pressure|Endothelial Dysfunction","Dietary Supplement: 2,000 International Units (IU)of vitamin D3","Effectiveness of Vitamin D Supplementation on Reducing Blood Pressure|Effectiveness of Vitamin d Supplementation on Improving Endothelial Function","Texas Woman's University|The Methodist Hospital System","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","11089","December 1, 2015","August 1, 2016","October 14, 2016","August 3, 2015","October 4, 2019","October 4, 2019","Methodist Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02513823"
977,"NCT02422654","Taste Evaluation of Different Liquid Formulations With Eliglustat",,"Completed","No Results Available","Gaucher Disease","Drug: eliglustat","Measurement of palatability by 100 mm visual analogue scale (VAS) for overall acceptability|Subject's taste preference questionnaire from most preferred to least preferred of the 5 different liquid formulations","Genzyme, a Sanofi Company|Sanofi","All","18 Years to 55 Years   (Adult)","Phase 1","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ACC14373|U1111-1168-5133","April 2015","May 2015","May 2015","April 21, 2015",,"May 27, 2015","Investigational Site Number 840001, Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02422654"
978,"NCT00975689","Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine",,"Completed","Has Results","Niemann-Pick Disease, Type C","Drug: N-Acetyl Cysteine","Oxysterol Levels","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Oxford|Washington University School of Medicine|National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","All","12 Months and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","35","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","090185|09-CH-0185","August 2009","November 2010","November 2010","September 11, 2009","July 12, 2012","May 6, 2013","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00975689"
979,"NCT03105661","Use of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients",,"Recruiting","No Results Available","Obesity, Morbid|Preeclampsia","Drug: Labetalol Hydrochloride 200 mg|Drug: NIFEdipine 60 mg|Drug: Atenolol 25 mg","Rates of preeclampsia in morbidly obese pregnant women","University of Tennessee Graduate School of Medicine","Female","18 Years to 51 Years   (Adult)","Early Phase 1","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","4226","April 4, 2017","December 31, 2019","March 4, 2020","April 10, 2017",,"February 22, 2019","University of Tennessee Medical Center, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03105661"
980,"NCT01351025","Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells",,"Completed","Has Results","HIV-1 Infection","Drug: atorvastatin|Drug: placebo for atorvastin","Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in log10 IL-6|Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in CD4+ T-cell Activation Percent|Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in log10 D-dimer|Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in CD8+ T-cell Activation Percent|Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in MCP-1 (log10 Transformed)|Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in IP-10 (log10 Transformed)|Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in CD40L (log10 Transformed)|Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in sCD14 (log10 Transformed)|Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in P-selectin (log10 Transformed)|Difference Between [Change From Week 24 to Week 44] and Change From [Baseline to Week 20] in sCD163 (log10 Transformed)|Number of Participants With Safety Endpoints Before Study Treatment Cross-over (Baseline to Week 24)|Number of Participants With Safety Endpoints After Study Treatment Cross-over (Week 24 to Week 48)","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","98","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","ACTG A5275|1U01AI068636","April 2011","May 2014","May 2014","May 10, 2011","August 4, 2015","June 27, 2016","31788 Alabama CRS, Birmingham, Alabama, United States|UCLA CARE Center CRS (601), Los Angeles, California, United States|Ucsd, Avrc Crs (701), San Diego, California, United States|Harbor-UCLA Med. Ctr. CRS (603), Torrance, California, United States|University of Colorado Hospital CRS (6101), Aurora, Colorado, United States|Georgetown University CRS (GU CRS) (1008), Washington, District of Columbia, United States|Northwestern University CRS (2701), Chicago, Illinois, United States|Massachusetts General Hospital ACTG CRS (101), Boston, Massachusetts, United States|Brigham and Women's Hosp. ACTG CRS (107), Boston, Massachusetts, United States|Beth Israel Deaconess Med. Ctr., ACTG CRS (103), Boston, Massachusetts, United States|Wayne State Univ. CRS (31478), Detroit, Michigan, United States|Henry Ford Hosp. CRS (31472), Detroit, Michigan, United States|Washington U CRS (2101), St. Louis, Missouri, United States|Cooper Univ. Hosp. CRS (31476), Camden, New Jersey, United States|New Jersey Medical School-Adult Clinical Research Ctr. CRS (31486), Newark, New Jersey, United States|Cornell CRS (7804), New York, New York, United States|NY Univ. HIV/AIDS CRS (401), New York, New York, United States|AIDS Care CRS (1101), Rochester, New York, United States|University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787), Rochester, New York, United States|Unc Aids Crs (3201), Chapel Hill, North Carolina, United States|Duke Univ. Med. Ctr. Adult CRS (1601), Durham, North Carolina, United States|Univ. of Cincinnati CRS (2401), Cincinnati, Ohio, United States|Case CRS (2501), Cleveland, Ohio, United States|Metro Health CRS (2503), Cleveland, Ohio, United States|The Ohio State Univ. AIDS CRS (2301), Columbus, Ohio, United States|Hosp. of the Univ. of Pennsylvania CRS (6201), Philadelphia, Pennsylvania, United States|Pitt CRS (1001), Pittsburgh, Pennsylvania, United States|Houston AIDS Research Team CRS (31473), Houston, Texas, United States|Virginia Commonwealth Univ. Medical Ctr. CRS (31475), Richmond, Virginia, United States|University of Washington AIDS CRS (1401), Seattle, Washington, United States|Puerto Rico-AIDS CRS (5401), San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01351025"
981,"NCT01554800","Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease",,"Completed","No Results Available","Coronary Artery Disease|Atherosclerosis","Drug: ACP-501","Summary of Participants Experience with Safety and Tolerability|Pharmacokinetic profile|Change in High-Density Lipoprotein-Cholesterol (HDL-C) value following a single dose","MedImmune LLC|National Heart, Lung, and Blood Institute (NHLBI)","All","30 Years to 85 Years   (Adult, Older Adult)","Phase 1","16","Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACP 501-01|12-H-0092","March 2012","September 2012","September 2012","March 15, 2012",,"March 14, 2019","Cardiovascular and Pulmonary Branch (CPB) of NIH, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01554800"
982,"NCT02714569","A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia",,"Completed","No Results Available","Dyslipidemias","Drug: LY3202328|Drug: Placebo|Drug: Atorvastatin|Drug: Simvastatin","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Maximum Plasma Concentration (Cmax) of LY3202328|Area Under the Serum Concentration time Curve (AUC) from Zero to Infinity of LY3202328|Area Under the Serum Concentration-Time Curve (AUC tau) of LY3202328|Time to Maximum Concentration (Tmax) of LY3202328|Change from Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c)|Change from Baseline in Fasting Total Triglycerides|Change from Baseline in Fasting Total Cholesterol|Change from Baseline in Fasting Low-Density Lipoprotein Cholesterol (LDL-c)|Simvastatin Cmax in LY3202328 Co-administration|Atorvastatin Cmax in LY3202328 Co-administration|Simvastatin AUC 0-24 in LY3202328 Co-administration|Atorvastatin AUC 0-24 in LY3202328 Co-administration","Eli Lilly and Company","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","16417|I8Q-MC-GSEA","March 2016","February 2017","February 2017","March 21, 2016",,"March 14, 2017","Clinical Pharmacology of Miami, Inc., Miami, Florida, United States|PRA Health Sciences, Lenexa, Kansas, United States|PRA Health Sciences, Marlton, New Jersey, United States|PRA Health Sciences, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02714569"
983,"NCT02647853","Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers",,"Completed","No Results Available","Nasolabial Folds|Lipoatrophy|Lipodystrophy","Drug: TAT4 Gel concentration A|Drug: TAT4 Gel concentration B|Drug: Placebo","Adverse Event rates|Plasma pharmacokinetics (Cmax)|Plasma pharmacokinetics (Tmax)|Plasma pharmacokinetics (AUC0-24)","Topokine Therapeutics, Inc.","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAT4 A1","October 2014","December 2014","December 2014","January 6, 2016",,"January 6, 2016","Topokine Clinical Site, Cypress, California, United States",,"https://ClinicalTrials.gov/show/NCT02647853"
984,"NCT01051947","Impact of Nebivolol on Central Aortic Pressure",,"Withdrawn","No Results Available","Central Aortic Pressure","Drug: Nebivolol|Drug: Metoprolol","Stable blood pressure","Creighton University","All","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","08-15168","December 2009","May 2010","May 2010","January 20, 2010",,"August 1, 2011","The Cardiac Center at Creighton University, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01051947"
985,"NCT01566630","Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia",,"Terminated","Has Results","Pre-eclampsia","Drug: Placebo|Drug: RLX030","Number of Patients With Adverse Events, Serious Adverse and Death During Part 1 of the Study|Change From Baseline in Maternal Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in Part 1of the Study (Part 1)|Change From Baseline in Mean Maternal Arterial Pressure (Part 1)|Change From Baseline on Maternal Proteinuria (Part 1)|Decrease in Utero-placental Blood Flow (Part 1)|Change in Fetal Heart Rate (Part 1)|Improvement in Renal Function Assessed by Increase in Creatinine Clearance|Rate of Spontaneous Delivery and/or Mode of Delivery|Number of Patients With Absence of Anti-serelaxin Antibodies|Number of Patients With Abnormalities in Birth Weight, Gestational Age, Appearance, Pulse, Grimace, Activity, Respiration (APGAR) Score, Umbilical Cord Gases, and Days in Neonatal Intensive Care Unit (NICU)|Number of Patients With Abnormalities in Fetal Cardiotocography and Biophysical Profile|Pharmacokinetics of RLX030: Area Under the Blood Concentration-time Curve From Time Zero to Infinity (AUCinf)-Part 1|Pharmacokinetics of RLX030: Area Under the Blood Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)-Part 1|Pharmacokinetics of RLX030: Blood Concentration at 24 Hour (C 0-24h) After Administration- Part 1|Pharmacokinetics of RLX030: Terminal Elimination Half-life (T1/2)- Part 1|Pharmacokinetics of RLX030: Mean Residence Time (MRT)|Mean Number of Days Before Delivery","Novartis Pharmaceuticals|Novartis","Female","18 Years to 40 Years   (Adult)","Phase 2","3","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CRLX030A2205|2011-001617-14","May 2013","August 2014","August 2014","March 29, 2012","November 5, 2015","November 5, 2015","Novartis Investigative Site, Mobile, Alabama, United States|Novartis Investigative Site, Lexington, Kentucky, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Galveston, Texas, United States|Novartis Investigative Site, Modena, MO, Italy",,"https://ClinicalTrials.gov/show/NCT01566630"
986,"NCT03866382","Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors",,"Recruiting","No Results Available","Bladder Adenocarcinoma|Bladder Mixed Adenocarcinoma|Bladder Small Cell Carcinoma|Bladder Squamous Cell Carcinoma|Chromophobe Renal Cell Carcinoma|Infiltrating Bladder Lymphoepithelioma-Like Carcinoma|Infiltrating Bladder Urothelial Carcinoma|Infiltrating Bladder Urothelial Carcinoma With Giant Cells|Infiltrating Bladder Urothelial Carcinoma, Nested Variant|Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant|Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant|Kidney Medullary Carcinoma|Large Cell Neuroendocrine Carcinoma|Metastatic Bladder Carcinoma|Metastatic Bladder Large Cell Neuroendocrine Carcinoma|Metastatic Bladder Small Cell Carcinoma|Metastatic Bladder Squamous Cell Carcinoma|Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant|Metastatic Kidney Medullary Carcinoma|Metastatic Malignant Genitourinary System Neoplasm|Metastatic Penile Carcinoma|Metastatic Prostate Small Cell Carcinoma|Metastatic Sarcomatoid Renal Cell Carcinoma|Papillary Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Stage IV Bladder Cancer AJCC v8|Stage IV Penile Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IVA Bladder Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Bladder Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Testicular Leydig Cell Tumor|Testicular Sertoli Cell Tumor","Drug: Cabozantinib|Drug: Cabozantinib S-malate|Biological: Ipilimumab|Biological: Nivolumab","Objective response rate (ORR)|Duration of response|Progression-free survival (PFS)|Overall survival|Clinical benefit rate (CBR)|Incidence of adverse events (AE)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","186","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2019-01266|A031702|U10CA180821","April 12, 2019","February 28, 2023","February 28, 2023","March 7, 2019",,"May 1, 2020","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Kingman Regional Medical Center, Kingman, Arizona, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|PCR Oncology, Arroyo Grande, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Community Cancer Institute, Clovis, California, United States|University Oncology Associates, Clovis, California, United States|Epic Care-Dublin, Dublin, California, United States|Bay Area Breast Surgeons Inc, Emeryville, California, United States|Epic Care Partners in Cancer Care, Emeryville, California, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|Bay Area Tumor Institute, Oakland, California, United States|Epic Care Cyberknife Center, Walnut Creek, California, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|UF Cancer Center at Orlando Health, Orlando, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Emory Johns Creek Hospital, Johns Creek, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Loyola Center for Health at Burr Ridge, Burr Ridge, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Illinois CancerCare-Dixon, Dixon, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Marjorie Weinberg Cancer Center at Loyola-Gottlieb, Melrose Park, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|Loyola Center for Cancer Care and Research, Orland Park, Illinois, United States|University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Reid Health, Richmond, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|University of Kansas Clinical Research Center, Fairway, Kansas, United States|HaysMed University of Kansas Health System, Hays, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Olathe Health Cancer Center, Olathe, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Ascension Via Christi - Pittsburg, Pittsburg, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|University of Kansas Health System Saint Francis Campus, Topeka, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Hematology/Oncology Clinic PLLC, Baton Rouge, Louisiana, United States|Ochsner High Grove, Baton Rouge, Louisiana, United States|Ochsner Medical Center Kenner, Kenner, Louisiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|LSU Healthcare Network / Metairie Multi-Specialty Clinic, Metairie, Louisiana, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Mercy Medical Center, Springfield, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|Henry Ford Cancer Institute-Downriver, Brownstown, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States|Henry Ford Medical Center-Fairlane, Dearborn, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|Henry Ford Medical Center-Columbus, Novi, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Huron Medical Center PC, Port Huron, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Henry Ford Macomb Health Center - Shelby Township, Shelby, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Riverwood Healthcare Center, Aitkin, Minnesota, United States|Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Cambridge Medical Center, Cambridge, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health - Deer River Clinic, Deer River, Minnesota, United States|Essentia Health Saint Mary's - Detroit Lakes Clinic, Detroit Lakes, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Essentia Health - Fosston, Fosston, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Essentia Health Hibbing Clinic, Hibbing, Minnesota, United States|Fairview Maple Grove Medical Center, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Essentia Health - Park Rapids, Park Rapids, Minnesota, United States|Fairview Northland Medical Center, Princeton, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Essentia Health Sandstone, Sandstone, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Essentia Health Virginia Clinic, Virginia, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Parkland Health Center - Farmington, Farmington, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Truman Medical Centers, Kansas City, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital South, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Nebraska Medicine-Bellevue, Bellevue, Nebraska, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Nebraska Medicine-Village Pointe, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Las Vegas Urology - Green Valley, Henderson, Nevada, United States|Las Vegas Urology - Pebble, Henderson, Nevada, United States|Urology Specialists of Nevada - Green Valley, Henderson, Nevada, United States|Las Vegas Urology - Pecos, Las Vegas, Nevada, United States|Desert West Surgery, Las Vegas, Nevada, United States|OptumCare Cancer Care at Oakey, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Las Vegas Prostate Cancer Center, Las Vegas, Nevada, United States|Las Vegas Urology - Sunset, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Las Vegas Urology - Cathedral Rock, Las Vegas, Nevada, United States|Las Vegas Urology - Smoke Ranch, Las Vegas, Nevada, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Northwest, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Town Center, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Southwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|University Cancer Center, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Essentia Health Cancer Center-South University Clinic, Fargo, North Dakota, United States|Essentia Health - Jamestown Clinic, Jamestown, North Dakota, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Saint Elizabeth Boardman Hospital, Boardman, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physician LLC-Miami Valley Hospital North, Dayton, Ohio, United States|Miami Valley Hospital North, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Dublin Methodist Hospital, Dublin, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Mount Carmel Grove City Hospital, Grove City, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Saint Joseph Warren Hospital, Warren, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Saint Elizabeth Youngstown Hospital, Youngstown, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt-Ingram Cancer Center Cool Springs, Franklin, Tennessee, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas, United States|UT Southwestern Clinical Center at Richardson/Plano, Richardson, Texas, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Overlake Hospital Medical Center, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Valley Medical Center, Renton, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|Duluth Clinic Ashland, Ashland, Wisconsin, United States|Northwest Wisconsin Cancer Center, Ashland, Wisconsin, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, United States|Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",,"https://ClinicalTrials.gov/show/NCT03866382"
987,"NCT01773486","Effects of Hesperidin on Insulin Sensitivity","EHIS","Withdrawn","No Results Available","Obesity|Insulin Resistance","Drug: Hesperidin|Drug: Placebo","insulin sensitivity (determined by glucose clamp)|basal hepatic glucose production|endothelial function|blood pressure|Inflammatory markers","University of Maryland, Baltimore","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HP-00051658","June 2015","December 2015","December 2015","January 23, 2013",,"November 7, 2019","University of Maryland, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01773486"
988,"NCT03404180","Peripheral Nerve Blocks for Above-the-knee Amputations",,"Recruiting","No Results Available","Peripheral Vascular Diseases|Hyperglycaemia (Diabetic)|Hypertension|Coronary Artery Disease|Pulmonary Disease, Chronic Obstructive","Procedure: Peripheral nerve block|Drug: Intravenous Sedatives|Procedure: Lateral femoral cutaneous nerve blocks|Procedure: Obturator nerve blocks","Chi-squared tests of peripheral nerve block success as a primary anesthetic|Analysis of pain scores|Mortality","University of Florida|US Department of Veterans Affairs","All","18 Years and older   (Adult, Older Adult)","Phase 4","36","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB201702402|OCR18952","February 9, 2018","October 2020","October 2020","January 19, 2018",,"March 9, 2020","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03404180"
989,"NCT01414985","AAVRh.10 Administered to Children With Late Infantile Neuronal Ceroid Lipofuscinosis",,"Completed","No Results Available","Late Infantile Neuronal Ceroid Lipofuscinosis|Batten Disease","Biological: AAVrh.10CUCLN2","Change in CNS function, as measured by the Weill Cornell LINCL Scale|Safety, as measured by MRI|Change in Quality of Life, as measured by the Child Health Questionnaire (CHQ) or Infant Toddler Quality of Life (ITQoL) (depending on age)|Change in psychological development, as measured by the Mullen Scale","Weill Medical College of Cornell University","All","3 Years to 18 Years   (Child, Adult)","Phase 1|Phase 2","8","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1005011054|IND 13951","April 15, 2010","November 30, 2015","February 8, 2017","August 11, 2011",,"February 17, 2020","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01414985"
990,"NCT01161576","Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)",,"Active, not recruiting","No Results Available","Batten Disease|Late-Infantile Neuronal Ceroid Lipofuscinosis","Biological: AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies|Biological: AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies","Change in Weill-Cornell LINCL scale from Baseline to 18 months|Disease progression based on change in MRI imaging parameter (% grey matter volume) from Baseline to 18 Months|Disease progression based on change in MRI imaging parameter (% ventricular volume) from Baseline to 18 Months|Disease progression based on change in MRI imaging parameter cortical apparent diffusion coefficient) from Baseline to 18 Months|Change in Quality of Life Survey from Baseline to 18 Months|Mullen Scale (developmental assessment) from Baseline to 18 Months","Weill Medical College of Cornell University|National Institutes of Health (NIH)","All","2 Years to 18 Years   (Child, Adult)","Phase 1","25","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0810010013|UL1TR000457-06","August 2010","December 2020","August 2032","July 13, 2010",,"April 30, 2020","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01161576"
991,"NCT03393884","Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION 2)","OVATION 2","Active, not recruiting","No Results Available","Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer","Biological: GEN-1|Drug: Carboplatin|Drug: Paclitaxel","PFS","Celsion","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201-17-201","September 5, 2018","February 28, 2022","October 31, 2023","January 9, 2018",,"April 27, 2020","University of Alabama Birmingham, Birmingham, Alabama, United States|Mitchell Cancer Institute (University of South Alabama), Mobile, Alabama, United States|University of California - San Diego, La Jolla, California, United States|Gynecologic Oncology Associates (Hoag Hospital), Newport Beach, California, United States|Innovative Clinical Research, Whittier, California, United States|The Center for Gynecologic Oncology, Miramar, Florida, United States|Advent Health, Orlando, Florida, United States|Women's Care Florida, Saint Petersburg, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States|Billings Clinic, Billings, Montana, United States|Cooper Health (MD Anderson), Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Monter Cancer Center, Lake Success, New York, United States|NYU Langone, New York, New York, United States|Stephenson Cancer Center - Oklahoma University, Oklahoma City, Oklahoma, United States|West Penn Hospital of Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Sanford Health, Sioux Falls, South Dakota, United States|Chattanooga Women's Health, Chattanooga, Tennessee, United States|The West Clinic, Germantown, Tennessee, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03393884"
992,"NCT01714102","Resveratrol and the Metabolic Syndrome",,"Completed","No Results Available","Obesity|Insulin Resistance|Metabolic Syndrome","Dietary Supplement: Placebo|Dietary Supplement: Resveratrol","Reduction in Insulin resistance|Reduction in serum cytokines/chemokines|Reduction in blood pressure measurements|Reduction lipid values|Reduction in crown like structures and adipose tissue mass|Changes in HOMA-IR|Changes in gene expression in adipose tissue|Changes in gene expression in stool","Rockefeller University","Male","30 Years to 60 Years   (Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","JWA-0786","October 2012","August 2015","July 2018","October 25, 2012",,"October 24, 2018","The Rockefeller University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01714102"
993,"NCT02112994","Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency",,"Completed","Has Results","Lysosomal Acid Lipase Deficiency","Drug: Sebelipase Alfa","Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs)|Percent Change In Serum Lipids From Baseline To Week 144|Participants Testing Positive For Anti-drug Antibodies (ADAs)|Percent Change In Body Mass Index (BMI)-For-Age Percentile From Baseline To Week 144 In Pediatric Participants|Shift In Child-Pugh Status From Baseline To Week 144","Alexion Pharmaceuticals","All","8 Months and older   (Child, Adult, Older Adult)","Phase 2","31","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LAL-CL06|2011-004287-30","June 24, 2014","December 28, 2017","December 28, 2017","April 14, 2014","January 15, 2019","December 4, 2019","Chicago, Illinois, United States|Shreveport, Louisiana, United States|Cincinnati, Ohio, United States|Westmead, Australia|Brussels, Belgium|Sao Paulo, Brazil|Halifax, Nova Scotia, Canada|Zagreb, Croatia|Copenhagen, Denmark|Freiburg, Germany|Padova, Italy|Mexico City, Mexico|Amsterdam, Netherlands|Moscow, Russian Federation|A Coruna, Spain|Barcelona, Spain|Madrid, Spain|Balcali, Turkey|Birmingham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02112994/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02112994/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02112994"
994,"NCT00976495","Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Dapagliflozin|Drug: Placebo|Drug: Hydrochlorothiazide","Adjusted Percent Change From Baseline in Glomerular Filtration Rate (GFR) at Week 12 (Modified Last Observation Carried Forward [MLOCF])|Adjusted Mean Change From Baseline in 24-Hour Ambulatory Systolic Blood Pressure (ASBP) at Week 12 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Daytime (0900 to 2100 Hours) Ambulatory Systolic Blood Pressure (ASBP) at Week 12 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Nighttime (0100 to 0600 Hours) Ambulatory Systolic Blood Pressure (ASBP) at Week 12 (Last Observation Carried Forward [LOCF])","AstraZeneca|Astra Zeneca, Bristol-Myers Squibb","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","154","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science","MB102-035|EUDRACT #: 2009-010221-39","October 2009","November 2010","November 2010","September 14, 2009","March 8, 2017","March 8, 2017","Advanced Clinical Res Inst, Anaheim, California, United States|Torrance Clinical Research, Lomita, California, United States|Elite Research Institute, Miami, Florida, United States|Compass Research, Llc, Orlando, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States|University Of Michigan, Ann Arbor, Michigan, United States|Prism Research, St. Paul, Minnesota, United States|Memorial Hospital Of Rhode Island, Pawtucket, Rhode Island, United States|Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin, United States|Local Institution, Toronto, Ontario, Canada|Local Institution, Laval, Quebec, Canada|Local Institution, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT00976495"
995,"NCT02104336","Phase 2 Study of EPI-743 in Children With Pearson Syndrome",,"Terminated","No Results Available","Pearson Syndrome","Drug: EPI-743","Occurrence of episodes of sepsis, metabolic crisis or hepatic failure|Transfusion avoidance|Hematologic function|Neuromuscular function|Disease severity|Renal function|Hepatic function|Weight gain|Hospitalizations|Pancreatic function|Mortality","Edison Pharmaceuticals Inc","All","up to 18 Years   (Child, Adult)","Phase 2","2","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPI743-13-024","August 2014","November 2015","February 2016","April 4, 2014",,"July 26, 2018","Children's Hospital of Orange County, Orange, California, United States|Cleveland Clinic, Cleveland, Ohio, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02104336"
996,"NCT02187172","Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)","VIP-U","Completed","Has Results","Psoriasis|Cardiovascular Disease","Drug: Ustekinumab|Drug: Placebo","Change in Vascular Inflammation|Change in Inflammatory Biomarker Levels: Intercellular Adhesion Molecule-1 (ICAM-1)|Change in Inflammatory Biomarker Levels: Vascular Cell Adhesion Molecule-1 (VCAM-1)|Change in Inflammatory Biomarker Levels: C-reactive Protein (CRP)|Change in Inflammatory Biomarker Levels: Ferritin|Change in Inflammatory Biomarker Levels: Serum Amyloid A (SAA)|Change in Inflammatory Biomarker Levels: Interferon-gamma (INF-g)|Change in Inflammatory Biomarker Levels: Monocyte Chemoattractant Protein-1 (MCP-1)|Change in Inflammatory Biomarker Levels: Tumor Necrosis Factor-alpha (TNF-a)|Change in Inflammatory Biomarker Levels: GlycA|Change in Inflammatory Biomarker Levels: Interleukin (IL)-1b|Change in Inflammatory Biomarker Levels: IL-2ra|Change in Inflammatory Biomarker Levels: IL-12/23|Change in Inflammatory Biomarker Levels: IL-17a|Change in Inflammatory Biomarker Levels: IL-18|Change in Inflammatory Biomarker Levels: IL-6|Change in Inflammatory Biomarker Levels: IL-8|Change in Lipid Biomarker Levels: Triglycerides|Change in Lipid Biomarker Levels: Total Cholesterol|Change in Lipid Biomarker Levels: High-density Lipoprotein (HDL) Cholesterol|Change in Lipid Biomarker Levels: HDL Particle Number|Change in Lipid Biomarker Levels: HDL Particle Size|Change in Lipid Biomarker Levels: Large-HDL Particle Number|Change in Lipid Biomarker Levels: Small-HDL Particle Number|Change in Lipid Biomarker Levels: Medium-HDL Particle Number|Change in Lipid Biomarker Levels: Large Medium-HDL Particle Number|Change in Lipid Biomarker Levels: Low-density Lipoprotein (LDL) Cholesterol|Change in Lipid Biomarker Levels: LDL Particle Number|Change in Lipid Biomarker Levels: LDL Particle Size|Change in Lipid Biomarker Levels: Small-LDL Particle Number|Change in Lipid Biomarker Levels: Large-LDL Particle Number|Change in Lipid Biomarker Levels: Very Large-LDL Particle Number|Change in Lipid Biomarker Levels: Very Low-density Lipoprotein (VLDL) Particle Size|Change in Lipid Biomarker Levels: VLDL Particle Number|Change in Lipid Biomarker Levels: VLDL Triglycerides|Change in Lipid Biomarker Levels: Small-VLDL Particle Number|Change in Lipid Biomarker Levels: Medium-VLDL Particle Number|Change in Lipid Biomarker Levels: Large Medium-VLDL Particle Number|Change in Lipid Biomarker Levels: Large-VLDL Particle Number|Change in Lipid Biomarker Levels: Intermediate-density Lipoprotein (IDL) Particle Number|Change in Lipid Biomarker Levels: Cholesterol Efflux Capacity|Change in Lipid Biomarker Levels: Apolipoprotein-B|Change in Lipid Biomarker Levels: Fetuin-A|Change in Metabolic Biomarker Levels: Adiponectin|Change in Metabolic Biomarker Levels: Leptin|Change in Metabolic Biomarker Levels: Insulin|Change in Metabolic Biomarker Levels: Glucose|Change in Metabolic Biomarker Levels: Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)|Number of Participants Achieving PASI75 (75% or Greater Reduction in PASI Score)|Number of Participants Achieving PASI90 (90% or Greater Reduction in PASI Score)|Number of Participants Achieving Physician Global Assessment (PGA) Clear/Almost Clear|Change in Patient-Reported Outcomes: MEDFICTS|Change in Patient-reported Physical Activity Assessments: IPAQ","University of Pennsylvania|Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 4","43","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","820124","July 2014","September 11, 2018","September 11, 2018","July 10, 2014","August 15, 2019","August 15, 2019","University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT02187172/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02187172"
997,"NCT02620813","De Novo Lipogenesis of Sebaceous Glands in Acne",,"Completed","No Results Available","Acne Vulgaris","Drug: Tretinoin|Drug: Isotretinoin","Sebumeter measurement differences before and after treatment with isotretinoin|Change in the fractional contribution of DNL to the total sebum palmitate before and after treatment with isotretinoin at baseline and 3 months after treatment.|Change in the global acne grade score|Change in the investigator global assessment of acne|Change in the lesion counts of inflammatory and non-inflammatory lesions.|Difference in the fractional contribution of de novo lipogenesis (DNL) to the sebum total palmitate between those with and without acne|Difference in the fractional contribution of DNL to the sebum total palmitate before and after treatment with a topical retinoid (adapalene, tazarotene, or tretinoin).","University of California, Davis","All","15 Years to 45 Years   (Child, Adult)","Phase 4","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","725019","October 2015","October 12, 2017","October 12, 2017","December 3, 2015",,"June 12, 2019","Dermatology Research Area, Davis, California, United States|UC Davis Department of Dermatology, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT02620813"
998,"NCT04052594","A Study of LY3475766 in Healthy Participants",,"Suspended","No Results Available","Dyslipidemias","Drug: LY3475766 - IV|Drug: LY3475766 - SC|Drug: Placebo - IV|Drug: Placebo - SC","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3475766|PK: Maximum Observed Drug Concentration (Cmax) of LY3475766|PK: Time to Maximum Observed Drug Concentration (Tmax) of LY3475766|Pharmacodynamics (PD): Percent Change from Baseline in Triglycerides (TG)|PD: Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)|PD: Percent Change from Baseline in Apolipoprotein B (ApoB)","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","17394|J1T-MC-GZEA","September 3, 2019","November 2, 2020","November 2, 2020","August 12, 2019",,"April 22, 2020","WCCT Global, Cypress, California, United States|Covance Clinical Research Inc, Daytona Beach, Florida, United States|Covance, Dallas, Texas, United States|Covance Clinical Research Inc, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04052594"
999,"NCT03178396","Effects and Mechanisms of Melatonin on Blood Pressure, Insulin Resistance, and Platelets",,"Completed","No Results Available","Prehypertension|Healthy","Dietary Supplement: melatonin","Office Systolic Blood pressure change|Office Diastolic Blood pressure change|Ambulatory Systolic Blood pressure change|Ambulatory Diastolic Blood pressure change|HOMA: Homeostasis Model Assessment change|QUICKI: Quantitative insulin sensitivity check index change|Arachidonic acid stimulated aggregation change","Thomas Jefferson University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","31","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","15F.572|R01HL096593","December 7, 2015","August 9, 2016","August 9, 2016","June 6, 2017",,"June 8, 2017","Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03178396"
1000,"NCT02536937","A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate",,"Completed","No Results Available","Gaucher Disease","Drug: eliglustat","- Assessment of PK parameter: Maximum plasma concentration observed (Cmax)|- Assessment of PK parameter: Area under the plasma concentration (AUC)|Assessment of PK parameter: Area under the plasma concentration versus time curve (AUClast)|Assessment of PK parameter: Apparent total body clearance (CL/F)|Assessment of PK parameter: Apparent volume of distribution during the terminal phase (Vz/F)|Assessment of PK parameter: Predicted accumulation ratio (Rac,pred)|Assessment of PK parameter: Terminal half-life (t1/2z)|Number of adverse events","Sanofi","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","POP13778|U1111-1170-3686","September 2015","January 2017","January 2017","September 1, 2015",,"March 8, 2017","Investigational Site Number 840004, Miami, Florida, United States|Investigational Site Number 840002, St. Paul, Minnesota, United States|Investigational Site Number 840001, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02536937"
1001,"NCT03639623","Safety, Tolerability and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With NAFLD",,"Recruiting","No Results Available","Liver Transplant; Complications|NAFLD","Drug: Saroglitazar","Number of participants with adverse events assessed by CTCAE|Hepatic fat|Metabolic flexibility|Frequently sampled intravenous glucose tolerance test (Insulin resistance marker)|Glycosylated hemoglobin (Insulin resistance marker)|Fructosamine (Insulin resistance marker)|Serum liver enzymes|Serum lipids|Small dense low-density lipoprotein (Atherogenic lipoprotein)|LDL size and concentration (Atherogenic lipoprotein)|Very low-density lipoprotein (Atherogenic lipoprotein)|High-density lipoprotein (Atherogenic lipoprotein)|Quality of life (SF-36 Health Survey)|Peak plasma concentration [Cmax]|Time to reach peak plasma concentration [Tmax]|Area under plasma concentration vs. time curve till the last time point [AUC0-t]|Area under plasma concentration vs. time curve extrapolated to the infinity [AUC0-∞] after first dose|Area under plasma concentration vs. time curve in a 24 h dosing interval [AUCtau]|Elimination rate constant [λz]|Elimination half-life [t1/2]|Apparent volume of distribution [Vd/F]|Apparent clearance [CL/F]|Minimal or trough plasma concentration [Cmin] -for last dose only|Accumulation index calculated as a ratio of AUCtau (last dose)/AUCtau (first dose)|Fluctuation index","Zydus Discovery DMCC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SARO.17.010","February 25, 2019","April 2020","July 2020","August 21, 2018",,"November 19, 2019","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03639623"
1002,"NCT01062269","A Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study",,"Completed","Has Results","Healthy","Drug: Cholestyramine|Drug: Tang","Patient Acceptability of Orange-flavored Generic Questran (Cholestyramine) vs. Tang (a Commercial Powdered Orange Drink) Via 2 Versions of a Bile Acid Sequestrant Acceptability (BASA) Scale.|Weighted vs. Unweighted BASA Scale","Louisville Metabolic and Atherosclerosis Research Center|Provident Clinical Research|Daiichi Sankyo, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","42","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","OO1","January 2010","February 2010","April 2010","February 4, 2010","August 10, 2010","July 12, 2011","L-MARC Research Center, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT01062269"
1003,"NCT01060020","Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis",,"Completed","Has Results","Aortic Stenosis","Drug: Sildenafil","Percent Change in Mean Pulmonary Artery Pressure in the Whole Cohort.|Percent Change in Pulmonary Vascular Resistance in the Whole Cohort.|Percent Change in Cardiac Index.|Load Independent Index of Diastolic Filling.|Global Longitudinal Strain","Washington University School of Medicine|Barnes-Jewish Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-1780","January 2010","September 2011","October 2011","February 1, 2010","April 25, 2018","April 25, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01060020"
1004,"NCT02684591","Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy","ARRIVE","Completed","Has Results","Nonalcoholic Fatty Liver Disease|HIV","Drug: Aramchol|Drug: Placebo","Efficacy of Aramchol 600 mg vs. Placebo in Improving Hepatic Steatosis Assessed by Magnetic Resonance Imaging in Patients With HIV-associated NAFLD|Efficacy of Aramchol 600 mg Orally Daily Versus Placebo in Improving Serum Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels in Patients With HIV-associated NAFLD","University of California, San Diego","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ARRIVE","January 2016","February 2018","February 2018","February 18, 2016","August 21, 2019","August 21, 2019","University of California, San Diego, San Diego, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02684591/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02684591"
1005,"NCT03501433","Effects of Nicotinamide Riboside on Metabolism and Vascular Function",,"Unknown status","No Results Available","Aging|Lipemia","Dietary Supplement: Nicotinamide riboside chloride (Niagen)|Dietary Supplement: Placebo","NAD+|Vasodilatory responsiveness|Lipdemia|Oxidative stress and inflammation","Iowa State University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","17-603","February 1, 2018","December 2018","December 2018","April 18, 2018",,"April 18, 2018","Iowa State University, Ames, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT03501433"
1006,"NCT03342599","Effects of Alpha Lipoic Acid Supplementation on Metabolic Syndrome Markers in Young Overweight or Obese Males","ALA","Completed","No Results Available","Metabolic Syndrome|Obesity","Dietary Supplement: Alpha Lipoic Acid Supplement|Dietary Supplement: Placebo","Effects on whole blood fasting glucose|Effects on fasting plasma inflammatory biomarkers|Effects on body composition (body fat, muscle mass, body weight)|Effects on oxygen consumption and carbon dioxide production at rest|Effects on oxygen consumption and carbon dioxide production during exercise","University of La Verne","Male","18 Years to 35 Years   (Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","ULVALApilot-01|ULV2013-CASIRB-24","October 2013","September 2016","September 2016","November 17, 2017",,"November 17, 2017","University of La Verne Kinesiology Laboratory, La Verne, California, United States",,"https://ClinicalTrials.gov/show/NCT03342599"
1007,"NCT01720537","A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects",,"Completed","No Results Available","Hypercholesterolemia","Biological: PF-05335810 Dose A|Biological: PF-05335810 Dose B|Biological: Placebo|Biological: PF-04950615 Dose A|Biological: PF-05335810 Dose C|Biological: PF-04950615|Biological: PF-05335810 Dose D|Biological: PF-05335810 Dose E","Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Laboratory Test Values of Potential Clinical Importance|Change From Baseline in Heart Rate|Diastolic Blood Pressure|Change From Baseline in Electrocardiogram (ECG) Parameters|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Apparent Volume of Distribution (Vz/F)|Apparent Oral Clearance (CL/F)|Plasma Decay Half-Life (t1/2)|Absolute Bioavailability (%F)","Pfizer","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","133","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","B3091001","July 2012","October 2013","October 2013","November 2, 2012",,"December 4, 2018","Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, South Miami, Florida, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Kalamazoo, Michigan, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01720537"
1008,"NCT03626688","A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients",,"Recruiting","No Results Available","PAH|Pulmonary Hypertension|Pulmonary Arterial Hypertension|Hypertension|Connective Tissue Diseases|Familial Primary Pulmonary Hypertension|Vascular Diseases|Cardiovascular Diseases|Hypertension, Pulmonary|Lung Diseases|Respiratory Tract Disease","Drug: Ralinepag|Drug: Placebo","Time from randomization to the first adjudicated protocol-defined clinical worsening event|Change from Baseline in N-terminal pro-brain natriuretic peptide (NT-proBNP)|Change from Baseline in 6-minute walk distance (6MWD)|Change from Baseline in WHO/New York Heart Association (NYHA) Functional Class|Shift and proportion of subjects who attain all 3 of the following: NT-proBNP level <300 pg/mL, 6MWD >440 meters, and WHO/NYHA Functional Class I or II|Change from Baseline in health-related quality of life as measured by patient-reported outcomes.|Change from Baseline in heart rate recovery (HRR) following completion of the 6MWT|Time to all-cause nonelective hospitalization|Time to all-cause mortality|Safety and tolerability of ralinepag in subjects with PAH","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","700","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ROR-PH-301|APD811-301","August 30, 2018","December 2021","December 2021","August 13, 2018",,"May 1, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona, Tucson, Arizona, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|Santa Barbara Cottage Hospital, Santa Barbara, California, United States|Stanford University Medical Center, Stanford, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Central Florida Pulmonary Group, Orlando, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Piedmont Healthcare Pulmonary and Critical Care Research, Austell, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Kentuckiana Pulmonary Research Center, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Chest Medicine Associates, South Portland, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Boston University Medical Center, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|Winthrop Hospital, Mineola, New York, United States|NYU Langone Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Rochester, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati-Medical Science Building, Cincinnati, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|The Oregon Clinic, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|NewSTAT, PLLC, Knoxville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|The University of Vermont Medical Center, Burlington, Vermont, United States|University of Virginia Medical Center, Charlottesville, Virginia, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Hospital Italiano, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Sanatorio Parque S.A., Rosario, Santa Fe, Argentina|Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|Fundacion Respirar, Ciudad Autonoma Buenos Aires, Argentina|Fundacion Favaloro, Ciudad Autonoma Buenos Aires, Argentina|Hospital Italiano de Cordoba, Cordoba, Argentina|Hospital Privado Centro Medico de Cordoba S.A, Cordoba, Argentina|Instituto de Cardiologia de Corrientes, Corrientes, Argentina|Instituto de Investigaciones Clinicas, Mar Del Plata, Argentina|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Macquarie University, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|Cliniques Universitaires de Bruxelles Hopital Erasme, Bruxelles, Belgium|UZ Leuven, UZ Leuven Campus Gasthuisberg, Herestraat 49, Leuven, Belgium|Instituto das Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa, Belo Horizonte, MG, Brazil|Hospital Sao Lucas da PUC-RS, Porto Alegre, R.S, Brazil|MHAT - ""National Heart Hospital"" EAD, 65, Konyovitza Str., Sofia, Bulgaria|Peter Lougheed Centre, Calgary, Alberta, Canada|LHSC - Victoria Hospital, London, Ontario, Canada|SMBD Jewish General Hospital d/b/a Jewish General Hospital, Montreal, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Québec, Quebec, Canada|Beijing Shijitan Hospital, Capital Medical University, Beijing, Beijing, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, China|Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China|Clinical Hospital Dubrava Zagreb, Avenija G.Šuška 6, Zagreb, Croatia|University Clinic for Pulmonary Diseases, Jordanovac 104, Zagreb, Croatia|Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark|Århus Universitetshospital, Århus, Denmark|CHU de Strasbourg - Nouvel Hôpital Civil, Ctre de competence Hypertension Arterielle Pulmona, 1 place de l Hopital, Strasbourg, Bas Rhin, France|CHU de Grenoble - Hôpital Albert Michallon, Clinique de Cardiologie, Boulevrad de la Chantourne, Grenoble, Isere, France|CHU de Saint-Etienne - Hopital Nord, Service de Medecine vasculaire et therapeutique, 81 Avenue A. Raimond, Saint-Étienne, Loire, France|CHU Nancy - Hôpital de Brabois Adultes, Pneumologie- Oncologie Médicale, Rue du Morvan, Vandoeuvre les Nancy, Meurthe Et Moselle, France|CHU Lyon - Hôpital Cardio-Vasculaire et Pneumologique Louis Pradel, Service de Pneumologie, 59 Boulevard Pinel, Bron cedex, Rhone, France|Groupement Hospitalier Sud - Hôpital Bicêtre, Le Kremlin-Bicêtre, Val De Marne, France|University General Hospital Attikon, 1 Rimini Street, Chaidari, Athens, Greece|University General Hospital of Alexandroupolis, Alexandroupolis, Greece|""Onasseio"" Cardiosurgery Hospital, Hemodynamic Research and Interventional Cardiology Dept., 356, Syggrou Avenue, Athens, Greece|AHEPA General Hospital of Thessaloniki, A' Cardiology Clinic, 1 St. Kyriakidi Street, Thessaloniki, Greece|Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia, S.C. di Cardiologia, Viale Luigi Pinto, 1, Foggia, Italy|Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Gachon University Hospital Gil Medical Center, Incheon, Namdong-gu, Korea, Republic of|Krakowski Szpital Specjalistyczny im. Jana Pawla II, Oddział Kliniczny Chorób Serca i Naczyń z Pododdziałem Intensywnego Nadzoru Kardiologicznego, Pradnicka 80, Krakow, Poland|NZOZ Europejskie Centrum Zdrowia, ul. Borowa 14/18, Otwock, Poland|Premium Clinic Wrocław CM, Podwale 83/17, Wroclaw, Poland|Institutul de Urgenta pentru Boli Cardiovasculare ""Prof. Dr. C.C. Iliescu"", Sos. Fundeni nr. 258, Bucharest, Romania|Institutul de Pneumoftiziologie ""Marius Nasta"", Sos. Viilor nr. 90, Sector 5, Bucuresti, Romania|Institutul Inimii ""Niculae Stancioiu"" Cluj-Napoca, Cardiologie, Str. Motilor nr. 19-21, Cluj-Napoca, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie ""Dr. Victor Babes"" Timisoara, Str. Gheorghe Adam nr. 13, Timisoara, Romania|Hospital Universitari Vall d'Hebron, Respiratory Dept., Passeig Vall d'Hebron,119-129, Neumologia, Barcelona, Spain|Hospital Clinic de Barcelona, C/ Villarroel, 170, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Linköping Universitetssjukhuset, Linköping, Sweden|Norrlands Universitetssjukhus, Hjärtcentrum, Umeå, Sweden|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|CE Dniprop RCC&C Center of Dniprop RC Dept of Card SI DMA of MOHU, Chair of Internal Medicine 3, 28, Knyazya Volodymyra Velykogo St., Dnipro, Ukraine|SI F.H.Yanovskyi National Institute of Phthisiology and Pulmonology of NAMSU, Clinical and Functional Dept, 10, Amosova St., Kyiv, Ukraine|Communal Noncommercial Enterprise of Lviv Regional Council Lviv Clinical Hospital, Dept of Cardiology, D.Halytskyi Lviv NMU, Ch of Internal Medicine #1, 7, Chernihivska str., Lviv, Ukraine|Golden Jubilee National Hospital, Glasgow, West Dunbartonshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03626688"
1009,"NCT01370005","12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus",,"Completed","Has Results","Diabetes Mellitus, Type 2|Hypertension","Drug: Placebo|Drug: BI 10773","HbA1c Change From Baseline|Mean 24-hour Systolic Blood Pressure Change From Baseline|Mean 24-hour Diastolic Blood Pressure Change From Baseline|Proportion of Patients With HbA1c <7%|Fasting Plasma Glucose (FPG) Change From Baseline|Body Weight Change From Baseline|Daytime Mean Systolic Blood Pressure (SBP) Change From Baseline|Daytime Mean Diastolic Blood Pressure (DBP) Change From Baseline|Nighttime Mean Systolic Blood Pressure (SBP) Change From Baseline|Nighttime Mean Diastolic Blood Pressure (DBP) Change From Baseline|Trough Mean Seated Systolic Blood Pressure (SBP) Change From Baseline|Trough Mean Seated Diastolic Blood Pressure (DBP) Change From Baseline|Proportion of Patients Reaching Blood Pressure <130/80 mmHg|Composite Endpoint of Change From Baseline of HbA1c, Systolic Blood Pressure and Body Weight|Orthostatic Blood Pressure","Boehringer Ingelheim|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","825","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1245.48|2011-000347-25","June 2011","July 2012","July 2012","June 9, 2011","June 17, 2014","February 22, 2016","1245.48.10024 Boehringer Ingelheim Investigational Site, Huntsville, Alabama, United States|1245.48.10002 Boehringer Ingelheim Investigational Site, Phoenix, Arizona, United States|1245.48.10014 Boehringer Ingelheim Investigational Site, Lincoln, California, United States|1245.48.10030 Boehringer Ingelheim Investigational Site, Long Beach, California, United States|1245.48.10033 Boehringer Ingelheim Investigational Site, Long Beach, California, United States|1245.48.10027 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|1245.48.10041 Boehringer Ingelheim Investigational Site, Tustin, California, United States|1245.48.10039 Boehringer Ingelheim Investigational Site, West Hills, California, United States|1245.48.10008 Boehringer Ingelheim Investigational Site, Davie, Florida, United States|1245.48.10025 Boehringer Ingelheim Investigational Site, Edgewater, Florida, United States|1245.48.10001 Boehringer Ingelheim Investigational Site, Jacksonville, Florida, United States|1245.48.10016 Boehringer Ingelheim Investigational Site, Miami, Florida, United States|1245.48.10035 Boehringer Ingelheim Investigational Site, Palm Harbor, Florida, United States|1245.48.10018 Boehringer Ingelheim Investigational Site, Pensacola, Florida, United States|1245.48.10032 Boehringer Ingelheim Investigational Site, Pinellas Park, Florida, United States|1245.48.10012 Boehringer Ingelheim Investigational Site, Marietta, Georgia, United States|1245.48.10011 Boehringer Ingelheim Investigational Site, Addison, Illinois, United States|1245.48.10019 Boehringer Ingelheim Investigational Site, Arlington Heights, Illinois, United States|1245.48.10022 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States|1245.48.10017 Boehringer Ingelheim Investigational Site, Wichita, Kansas, United States|1245.48.10010 Boehringer Ingelheim Investigational Site, Albuquerque, New Mexico, United States|1245.48.10036 Boehringer Ingelheim Investigational Site, Charlotte, North Carolina, United States|1245.48.10005 Boehringer Ingelheim Investigational Site, Akron, Ohio, United States|1245.48.10004 Boehringer Ingelheim Investigational Site, Kettering, Ohio, United States|1245.48.10013 Boehringer Ingelheim Investigational Site, Erie, Pennsylvania, United States|1245.48.10020 Boehringer Ingelheim Investigational Site, Pittsburgh, Pennsylvania, United States|1245.48.10029 Boehringer Ingelheim Investigational Site, Knoxville, Tennessee, United States|1245.48.10015 Boehringer Ingelheim Investigational Site, Memphis, Tennessee, United States|1245.48.10034 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States|1245.48.10007 Boehringer Ingelheim Investigational Site, Houston, Texas, United States|1245.48.10009 Boehringer Ingelheim Investigational Site, Houston, Texas, United States|1245.48.10042 Boehringer Ingelheim Investigational Site, Houston, Texas, United States|1245.48.10026 Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|1245.48.10003 Boehringer Ingelheim Investigational Site, Orem, Utah, United States|1245.48.10023 Boehringer Ingelheim Investigational Site, Port Orchard, Washington, United States|1245.48.20002 Boehringer Ingelheim Investigational Site, Winnipeg, Manitoba, Canada|1245.48.20001 Boehringer Ingelheim Investigational Site, Halifax, Nova Scotia, Canada|1245.48.20004 Boehringer Ingelheim Investigational Site, Brampton, Ontario, Canada|1245.48.20006 Boehringer Ingelheim Investigational Site, Etobicoke, Ontario, Canada|1245.48.20007 Boehringer Ingelheim Investigational Site, Oakville, Ontario, Canada|1245.48.20005 Boehringer Ingelheim Investigational Site, Thornhill, Ontario, Canada|1245.48.20003 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|1245.48.42003 Boehringer Ingelheim Investigational Site, Benesov, Czech Republic|1245.48.42005 Boehringer Ingelheim Investigational Site, Brno, Czech Republic|1245.48.42002 Boehringer Ingelheim Investigational Site, Mlada Boleslav, Czech Republic|1245.48.42006 Boehringer Ingelheim Investigational Site, Neratovice, Czech Republic|1245.48.42008 Boehringer Ingelheim Investigational Site, Olomouc, Czech Republic|1245.48.42004 Boehringer Ingelheim Investigational Site, Opocno, Czech Republic|1245.48.42007 Boehringer Ingelheim Investigational Site, Pribram, Czech Republic|1245.48.42001 Boehringer Ingelheim Investigational Site, Slany, Czech Republic|1245.48.45006 Boehringer Ingelheim Investigational Site, Aalborg, Denmark|1245.48.45009 Boehringer Ingelheim Investigational Site, Aarhus C, Denmark|1245.48.45008 Boehringer Ingelheim Investigational Site, Hellerup, Denmark|1245.48.45002 Boehringer Ingelheim Investigational Site, Helsingør, Denmark|1245.48.45010 Boehringer Ingelheim Investigational Site, Hillerød, Denmark|1245.48.45003 Boehringer Ingelheim Investigational Site, København NV, Denmark|1245.48.45001 Boehringer Ingelheim Investigational Site, Rødovre, Denmark|1245.48.45004 Boehringer Ingelheim Investigational Site, Rødovre, Denmark|1245.48.45005 Boehringer Ingelheim Investigational Site, Vaerløse, Denmark|1245.48.45007 Boehringer Ingelheim Investigational Site, Vojens, Denmark|1245.48.37203 Boehringer Ingelheim Investigational Site, Pärnu, Estonia|1245.48.37201 Boehringer Ingelheim Investigational Site, Tallinn, Estonia|1245.48.37202 Boehringer Ingelheim Investigational Site, Tallinn, Estonia|1245.48.37204 Boehringer Ingelheim Investigational Site, Tallinn, Estonia|1245.48.35802 Boehringer Ingelheim Investigational Site, Helsinki, Finland|1245.48.35805 Boehringer Ingelheim Investigational Site, Joensuu, Finland|1245.48.35806 Boehringer Ingelheim Investigational Site, Kouvola, Finland|1245.48.35803 Boehringer Ingelheim Investigational Site, Oulu, Finland|1245.48.35804 Boehringer Ingelheim Investigational Site, Pori, Finland|1245.48.35801 Boehringer Ingelheim Investigational Site, Turku, Finland|1245.48.35807 Boehringer Ingelheim Investigational Site, Turku, Finland|1245.48.33004 Boehringer Ingelheim Investigational Site, Angers, France|1245.48.33008 Boehringer Ingelheim Investigational Site, Bourges, France|1245.48.33005 Boehringer Ingelheim Investigational Site, Mont de Marsan, France|1245.48.33001 Boehringer Ingelheim Investigational Site, Nantes Cedex 1, France|1245.48.33006 Boehringer Ingelheim Investigational Site, Orthez, France|1245.48.33003 Boehringer Ingelheim Investigational Site, Tierce, France|1245.48.33007 Boehringer Ingelheim Investigational Site, Tours, France|1245.48.49001 Boehringer Ingelheim Investigational Site, Berlin, Germany|1245.48.49008 Boehringer Ingelheim Investigational Site, Berlin, Germany|1245.48.49003 Boehringer Ingelheim Investigational Site, Dresden, Germany|1245.48.49004 Boehringer Ingelheim Investigational Site, Hannover, Germany|1245.48.49005 Boehringer Ingelheim Investigational Site, Lüneburg, Germany|1245.48.49002 Boehringer Ingelheim Investigational Site, Mainz, Germany|1245.48.49010 Boehringer Ingelheim Investigational Site, Nürnberg, Germany|1245.48.49009 Boehringer Ingelheim Investigational Site, Pirna, Germany|1245.48.49007 Boehringer Ingelheim Investigational Site, Schkeuditz, Germany|1245.48.49006 Boehringer Ingelheim Investigational Site, Teuchern, Germany|1245.48.96003 Boehringer Ingelheim Investigational Site, Baabda, Lebanon|1245.48.96001 Boehringer Ingelheim Investigational Site, Beirut, Lebanon|1245.48.96002 Boehringer Ingelheim Investigational Site, Lebanon, Lebanon|1245.48.31011 Boehringer Ingelheim Investigational Site, Breda, Netherlands|1245.48.31012 Boehringer Ingelheim Investigational Site, Eindhoven, Netherlands|1245.48.31009 Boehringer Ingelheim Investigational Site, Etten Leur, Netherlands|1245.48.31014 Boehringer Ingelheim Investigational Site, Groningen, Netherlands|1245.48.31013 Boehringer Ingelheim Investigational Site, Leiderdorp, Netherlands|1245.48.31003 Boehringer Ingelheim Investigational Site, Oude Pekela, Netherlands|1245.48.31016 Boehringer Ingelheim Investigational Site, Rotterdam, Netherlands|1245.48.31006 Boehringer Ingelheim Investigational Site, Soerendonk, Netherlands|1245.48.31008 Boehringer Ingelheim Investigational Site, Spijkenisse, Netherlands|1245.48.31002 Boehringer Ingelheim Investigational Site, Swifterbant, Netherlands|1245.48.31015 Boehringer Ingelheim Investigational Site, Velp, Netherlands|1245.48.31010 Boehringer Ingelheim Investigational Site, Woerden, Netherlands|1245.48.31019 Boehringer Ingelheim Investigational Site, Zijndrecht, Netherlands|1245.48.31017 Boehringer Ingelheim Investigational Site, Zoetermeer, Netherlands|1245.48.47008 Boehringer Ingelheim Investigational Site, Elverum, Norway|1245.48.47007 Boehringer Ingelheim Investigational Site, Hamar, Norway|1245.48.47002 Boehringer Ingelheim Investigational Site, Kløfta, Norway|1245.48.47001 Boehringer Ingelheim Investigational Site, Oslo, Norway|1245.48.47003 Boehringer Ingelheim Investigational Site, Oslo, Norway|1245.48.47004 Boehringer Ingelheim Investigational Site, Oslo, Norway|1245.48.47005 Boehringer Ingelheim Investigational Site, Oslo, Norway|1245.48.47006 Boehringer Ingelheim Investigational Site, Sørumsand, Norway|1245.48.47009 Boehringer Ingelheim Investigational Site, Ålesund, Norway|1245.48.46002 Boehringer Ingelheim Investigational Site, Härnösand, Sweden|1245.48.46004 Boehringer Ingelheim Investigational Site, Järfälla, Sweden|1245.48.46003 Boehringer Ingelheim Investigational Site, Lund, Sweden|1245.48.46007 Boehringer Ingelheim Investigational Site, Malmö, Sweden|1245.48.46006 Boehringer Ingelheim Investigational Site, Skene, Sweden|1245.48.46001 Boehringer Ingelheim Investigational Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01370005"
1010,"NCT03376555","Cheese Consumption and Human Microvascular Function",,"Recruiting","No Results Available","Microvascular Dysfunction","Drug: Acetylcholine (ACh) Dose Response|Drug: Local Heating (LH)|Drug: Flow Mediated Dilation with nitroglycerin","laser Doppler blood flow|Systolic Blood Pressure|Diastolic Blood Pressure|Flow Mediated Dilation","Lacy M. Alexander|National Dairy Council|Penn State University","All","55 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","STUDY4340|129552","March 2016","January 30, 2021","January 30, 2021","December 18, 2017",,"April 1, 2020","Pennsylvania State University, University Park, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03376555"
1011,"NCT02189252","An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis","ECLIPSEIV","Completed","Has Results","Severe Hypertriglyceridemia","Drug: Epanova|Drug: Lovaza","Baseline-adjusted AUC0-24 for Plasma Total EPA + Total DHA|Baseline-adjusted Cmax for Plasma Total EPA + Total DHA|Baseline-adjusted AUC0-24 for Plasma Total EPA|Baseline-adjusted Cmax for Plasma Total EPA|Baseline-adjusted AUC0-24 for Plasma Total DHA|Baseline-adjusted Cmax for Plasma Total DHA|Baseline-adjusted AUC0-24 for Plasma Total DPA|Baseline-adjusted Cmax for Plasma Total DPA","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5880C00003|OM-EPA-013","October 2014","July 2015","July 2015","July 14, 2014","June 20, 2016","June 20, 2016","Research Site, Kansas City, Kansas, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Chocoutimi, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02189252"
1012,"NCT01423812","DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects","DRIVESHAFT","Completed","Has Results","HIV","Drug: Twice-daily Darunavir and ritonavir|Drug: Once-daily Darunavir and ritonavir","Primary Efficacy Endpoint for Virologic Suppression in HIV-infected Subjects|Secondary Efficacy Endpoints|Safety Assessment|Immunologic Endpoints|Assessment of Virologic Failure|Medication Adherence Assessment","Ruth M. Rothstein CORE Center|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMC114HIV4063","January 2012","May 2014","April 2015","August 26, 2011","February 7, 2018","February 7, 2018","Ruth M. Rothstein CORE Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01423812"
1013,"NCT04076891","Treatment of Women With Lipedema Involving Substantial Fat Above the Knee or of Women and Men With Nodular Dercum's Disease",,"Completed","No Results Available","Dercum Disease|Lipedema","Drug: RZL-012","The incidence of any Grade 3 or greater event intolerable side effect experienced in a cohort","Raziel Therapeutics Ltd.","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RZL-012-FD-P2aUS-001.7","June 28, 2018","May 2, 2019","May 2, 2019","September 3, 2019",,"September 6, 2019","University of Arizona Clinical and Translational Science Research Center, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04076891"
1014,"NCT03492840","Evaluation of Safety and Efficacy of RZL-012 for the Treatment of Lipedema or of Nodular Dercum's Disease",,"Completed","No Results Available","Lipedema|Dercum Disease","Drug: RZL-012","The incidence of intolerable side effects (a related adverse event) as defined in the protocol.|For lipedema subjects - The reduction of fat above the knee in the injection site region|For Dercum's disease subjects - The reduction in local subcutaneous fat in the injection site region.|Extended duration of the fat reduction effect|Elucidation of the tissue changes|Improvement in local pain|Improvement in pain|Improvement in physical function in lipedema subjects|For lipedema subjects - The reduction in local subcutaneous fat in the injection site region","Raziel Therapeutics Ltd.|University of Arizona","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 2","12","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RZL-012-FD-P2aUS-001.2","May 1, 2018","May 6, 2019","May 6, 2019","April 10, 2018",,"May 14, 2019","University of Arizona Medical Center, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03492840"
1015,"NCT00997269","Benefit of CoQ-10 in Patients on Statins","CoQ-10","Completed","No Results Available","Pain|Soreness|Weakness|Fatigue","Dietary Supplement: Co-enzyme Q-10|Dietary Supplement: Placebo","Pain scores should be reduced","Stony Brook University","All","21 Years and older   (Adult, Older Adult)","Not Applicable","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2008-0436|AT004204","September 2009","July 2014","July 2014","October 19, 2009",,"May 2, 2016","Stony Brook University GCRC, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT00997269"
1016,"NCT02322203","Effects of Niacin Therapy on Lipoprotein Composition and Function",,"Completed","No Results Available","Cardiovascular Disease","Dietary Supplement: Niacin Extended Release","Changes in protein or lipid composition of any lipoprotein fraction and changes in vascular compliance as measured by CAVI","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","24","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","150042|15-H-0042","March 25, 2015","December 13, 2017","July 23, 2019","December 23, 2014",,"April 9, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02322203"
1017,"NCT04177680","Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia","ENHANCE-IT","Not yet recruiting","No Results Available","Hypertriglyceridemia","Drug: Omega 3 pentaenoic acid|Drug: icosapent ethyl","Percent change in plasma triglycerides|Percent change in plasma lipoproteins","Matinas BioPharma Nanotechnologies, Inc.|Matinas Biopharma, Inc|MB Clinical Research and Consulting LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MAT-002","April 2020","October 2020","November 2020","November 26, 2019",,"March 4, 2020","Matinas Investigational Site, Jacksonville, Florida, United States|Matinas Investigational site, Jupiter, Florida, United States|Matinas Investigational Site, Port Saint Lucie, Florida, United States|Matinas Investigational Site, Addison, Illinois, United States|Matinas Investigational Site, Chicago, Illinois, United States|Matinas Investigational site, Indianapolis, Indiana, United States|Matinas Investigational site, Louisville, Kentucky, United States|Matinas Investigational site, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04177680"
1018,"NCT01588314","Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease",,"Withdrawn","No Results Available","Fabry Disease|Neuropathic Pain","Drug: Gabapentin|Drug: placebo","average reduction in hydrocodone-acetaminophen use|Number and type of adverse events|Pain levels|Define therapeutic level for gabapentin","University of Minnesota|Genzyme, a Sanofi Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1112M07943","April 2012","June 2014","June 2014","April 30, 2012",,"May 29, 2019","University of Minnesota, Fariview, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01588314"
1019,"NCT02939547","Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)",,"Completed","No Results Available","Niemann-Pick Disease, Type C1","Drug: Hydroxypropyl-beta-cyclodextrin","Maximum Concentration ( C max) of Trappsol in plasma from patients with Niemann-Pick disease Type C1 by measurement of plasma levels|Time to Maximum Concentration (T max) of Trappsol in plasma from patients with Niemann-Pick disease Type C1 by measurement of plasma levels|Volume of Distribution of Trappsol in plasma from patients with Niemann-Pick disease Type C1 by measurement of plasma levels|Elimination half-life (T1/2) of Trappsol in plasma from patients with Niemann-Pick disease Type C1 by measurement of plasma levels|CSF levels of Trappsol|Potential blood biomarkers of NPC1|Potential CSF biomarkers of NPC1|Serum cholesterol precursors and metabolites|Fractionated cholesterol in hepatic tissue|Splenic morphology assessed by qualitative change in ultrasound compared with baseline, NIH total and individual domain severity scores|Hepatic morphology assessed by qualitative change in ultrasound compared with baseline, NIH total and individual domain severity scores|Number of patients with treatment-related adverse events as graded by CTCAE criteria ( Version 4.03)","CTD Holdings, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","CTD-TCNPC-101","October 11, 2017","October 22, 2019","October 22, 2019","October 20, 2016",,"November 6, 2019","UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02939547"
1020,"NCT02300233","The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia",,"Completed","No Results Available","Hypertriglyceridemia","Drug: volanesorsen|Drug: Placebo","The percent change in fasting triglycerides (TG) from baseline","Ionis Pharmaceuticals, Inc.|Akcea Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","114","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ISIS 304801-CS16|2014-003434-93","February 5, 2015","July 27, 2016","January 24, 2017","November 24, 2014",,"November 5, 2019","IONIS Investigative Site, Encinitas, California, United States|IONIS Investigative Site, San Francisco, California, United States|IONIS Investigative Site, Boca Raton, Florida, United States|IONIS Investigative Site, Miami, Florida, United States|IONIS Investigative Site, Sterling, Illinois, United States|IONIS Investigative Site, Kansas City, Kansas, United States|IONIS Investigative Site, Salisbury, Maryland, United States|IONIS Investigative Site, Towson, Maryland, United States|IONIS Investigative Site, Boston, Massachusetts, United States|IONIS Investigative Site, Grandville, Michigan, United States|IONIS Investigative Site, North Massapequa, New York, United States|IONIS Investigative Site, Benson, North Carolina, United States|IONIS Investigative Site, Chapel Hill, North Carolina, United States|IONIS Investigative Site, Farmville, North Carolina, United States|IONIS Investigative Site, Greenville, North Carolina, United States|IONIS Investigative Site, Morrisville, North Carolina, United States|IONIS Investigative Site, Raleigh, North Carolina, United States|IONIS Investigative Site, Wilson, North Carolina, United States|IONIS Investigative Site, Wilson, North Carolina, United States|IONIS Investigative Site, Cincinnati, Ohio, United States|IONIS Investigative Site, Kettering, Ohio, United States|IONIS Investigative Site, Marion, Ohio, United States|IONIS Investigative Site, Oklahoma City, Oklahoma, United States|IONIS Investigative Site, Portland, Oregon, United States|IONIS Investigative Site, Providence, Rhode Island, United States|IONIS Investigative Site, Houston, Texas, United States|IONIS Investigative Site, Salt Lake City, Utah, United States|IONIS Investigative Site, Norfolk, Virginia, United States|IONIS Investigative Site, Seattle, Washington, United States|IONIS Investigative Site, Vancouver, British Columbia, Canada|IONIS Investigative Site, London, Ontario, Canada|IONIS Investigative Site, Chicoutimi, Quebec, Canada|IONIS Investigative Site, Sainte-Foy, Quebec, Canada|IONIS Investigative Site, Dijon, France|IONIS Investigative Site, Marseille, France|IONIS Investigative Site, Paris, France|IONIS Investigative Site, Saint Herblain, France|IONIS Investigative Site, Koeln, North Rhine-Westphalia, Germany|IONIS Investigative Site, Berlin, Germany|IONIS Investigative Site, Dresden, Germany|IONIS Investigative Site, Amsterdam, North Holland, Netherlands|IONIS Investigative Site, Rotterdam, South Holland, Netherlands|IONIS Investigative Site, Utrecht, Netherlands|IONIS Investigative Site, Manchester, United Kingdom|IONIS Investigative Site, Peterborough, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02300233"
1021,"NCT00903617","Study to Test GSK256073 in Patients With Dyslipidemia",,"Completed","Has Results","Dyslipidaemias|Dyslipidemias","Drug: GSK256073|Drug: Placebo|Drug: Niaspan","The GSK256073 Area Under Concentration-time Curve (AUC) and High Density Lipoprotein Cholesterol (HDLc) Data to Evolve the Exposure-response Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship for Changes in HDLc Levels|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Electrocardiography (ECG) Findings|Change From Baseline in Vital Signs-Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Vital Signs-Heart Rate|Number of Participants With Abnormal Hematology Values|Number of Participants With Abnormal Clinical Chemistry Values|Number of Participants With Abnormal Urinalysis Results|Average Global Flushing Score|Number of Participants With Self Reported Assessment of Flushing|Average Number of Flushing Episodes|Average Time to Onset of Flushing|Participant's Average Duration of Flushing|Number of Participants Who Withdrew Due to Flushing|Mean Episode of Flushing as Measured by Visual Analogue Scale (VAS)|Percent Change From Baseline in Fasting Plasma HDLc and Apolipoprotein A-I (ApoA1) Concentrations Over Eight Weeks of Administration With GSK256073 or Placebo|Percent Change From Baseline in Fasting Levels of Total Cholesterol (TC), Triglyceride (TG), Glucose, Low Density Lipoprotein Cholesterol (LDLc), Apolipoprotein A2 (ApoAII), Apolipoprotein B (ApoB) Over 8 Weeks of Administration With GSK256073 or Placebo|Percent Change From Baseline in Insulin Over Eight Weeks of Administration With GSK256073 or Placebo|Percent Change From Baseline in Lipoprotein (a) (Lp[a]) Over Eight Weeks of Administration With GSK256073 or Placebo|Percent Change From Baseline in Non-esterified Fatty Acids (NEFA) Over Eight Weeks of Administration With GSK256073 or Placebo|Plasma PK- Maximum Observed Concentration (Cmax)|Plasma PK- Time of Occurrence of Cmax (Tmax)|Plasma PK- AUC(0-t)","GlaxoSmithKline","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","112795","June 15, 2009","February 16, 2010","February 16, 2010","May 18, 2009","September 21, 2017","December 5, 2019","GSK Investigational Site, Pembroke Pines, Florida, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Auburn, Maine, United States|GSK Investigational Site, Brooklyn Center, Minnesota, United States|GSK Investigational Site, Statesville, North Carolina, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Olympia, Washington, United States|GSK Investigational Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00903617"
1022,"NCT04155645","To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Type 2 Diabetes.",,"Active, not recruiting","No Results Available","Dyslipidemia|Type 2 Diabetes","Drug: AZD8233 subcutaneous injection|Drug: Placebo","Number of subjects with adverse events (AEs) due to AZD8233 SC multiple ascending dose treatment.|Vital sign: Systolic blood pressure (SBP)|Vital sign: Pulse rate|Vital sign: Oral body temperature|Number of patients with abnormal findings in resting 12-lead Electrocardiogram (ECG) and digital ECG (dECG).|Number of subject with abnormal findings in cardiac telemetry|Physical examination|Injection site reaction examinations|Laboratory assessments: Hematology - Blood cells count|Laboratory assessments: Hematology - Hemoglobin (Hb)|Laboratory assessments: Hematology - Hematocrit (HCT)|Laboratory assessments: Hematology - Mean corpuscular volume (MCV)|Laboratory assessments: Hematology - Mean corpuscular hemoglobin (MCH)|Laboratory assessments: Hematology - Mean corpuscular hemoglobin concentration (MCHC)|Laboratory assessments: Hematology - Differential WBC count|Laboratory assessments: Hematology - Platelet count and platelet function assessment.|Laboratory assessments: Hematology - Reticulocytes absolute count|Laboratory assessments: Serum clinical chemistry - Electrolytes|Laboratory assessments: Serum clinical chemistry - Blood urea nitrogen (BUN)|Laboratory assessments: Serum clinical chemistry - Creatinine|Laboratory assessments: Serum clinical chemistry - Glucose (fasting)|Laboratory assessments: Serum clinical chemistry - Creatine kinase|Laboratory assessments: Serum clinical chemistry - Direct bilirubin|Laboratory assessments: Serum clinical chemistry - Hemoglobin A1c (HbA1c)|Laboratory assessments: Serum clinical chemistry - Liver enzymes|Laboratory assessments: Serum clinical chemistry - Total bilirubin|Laboratory assessments: Serum clinical chemistry - Cell enzymes|Laboratory assessments: Serum clinical chemistry - Bicarbonate|Laboratory assessments: Serum clinical chemistry - Uric acid|Laboratory assessments: Coagulation|Renal safety biomarkers - Urine clusterin|Renal safety biomarkers - Urine cystatin-C|Renal safety biomarkers - Urine N-acetyl-beta-D-glucosaminidase (NAG)|Renal safety biomarkers - Urine albumin|Renal safety biomarkers - Urine creatinine|Renal safety biomarkers - Urine Kidney injury molecule1 (KIM-1)|Renal safety biomarkers - Urine Neutrophil gelatinase-associated lipocalin (NGAL)|Renal safety biomarkers - Urine Osteopontin|Renal safety biomarkers - Urine total protein|Immune Activation Response - High-sensitivity C-reactive protein (hs-CRP)|Complement Activation panel|Laboratory assessments: Clinical urinalysis|Plasma PK analysis: Time delay between drug administration and the first observed concentration in plasma (tlag).|Plasma PK analysis: Time to reach peak or maximum observed concentration or response following drug administration (tmax).|Plasma PK analysis: Observed maximum plasma concentration (Cmax).|Plasma PK analysis: Area under the plasma concentration-curve from time zero to time last value above the limit of quantification (AUC[0-last]).|Plasma PK analysis: Area under the concentration-time curve from time zero to 24 hours post-dose (AUC[0-24]).|Plasma PK analysis: Area under the concentration-time curve from time zero to 48 hours post-dose (AUC[0-48]).|Plasma PK analysis: Area under the concentration-time curve from time zero extrapolated to infinity (AUC).|Plasma PK analysis: Area under the plasma concentration-time curve from time during the dosing interval (AUCt).|Plasma PK analysis: Observed trough plasma drug concentration (Ctrough).|Plasma PK analysis: Apparent total body clearance of drug from plasma after extravascular administration (CL/F).|Plasma PK analysis: Apparent volume of distribution for parent drug at terminal phase (extravascular administration) (Vz/F).|Plasma PK analysis: Half-life associated with the terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2).|Plasma PK analysis: Mean Residence Time (MRT).|Urine PK analysis: Amount excreted in urine (Ae).|Urine PK analysis: Fraction excreted unchanged in urine (Fe).|Urine PK analysis: Renal clearance (CLR).|PD analysis: Levels of dyslipidemia related biomarkers.","AstraZeneca|Parexel","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","D7990C00002","November 21, 2019","March 3, 2021","March 3, 2021","November 7, 2019",,"April 24, 2020","Research Site, Glendale, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04155645"
1023,"NCT01196871","Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease",,"Completed","Has Results","Fabry Disease","Drug: Migalastat HCl|Biological: Agalsidase Beta|Biological: Agalsidase Alfa","Change In Area Under The Plasma Concentration Versus Time Curve (AUC) For Active α-Galactosidase A (α-Gal A) Levels After Administration Of Migalastat|Change In Maximum Observed Plasma Concentration (Cmax) For Active α-Gal A Levels After Administration Of Migalastat|Change In Time To Maximum Observed Plasma Concentration (Tmax) And Terminal Elimination Half-life (T1/2) For Active α-Gal A Levels After Administration Of Migalastat|Change In AUC For Total α-Gal A Protein Levels After Administration Of Migalastat|Change In Percentage Of AUCinfinity Extrapolated From The Last Time Point At Which Concentration Is Quantified To Infinity (AUCextrapolated %) For Total α-Gal A Protein Levels After Administration Of Migalastat|Change In Cmax For Total α-Gal A Protein Levels After Administration Of Migalastat|Change In Tmax And T1/2 For Total α-Gal A Protein Levels After Administration Of Migalastat|Change In AUC For Migalastat After Administration Of Agalsidase|Change In Cmax For Migalastat After Administration Of Agalsidase|Change In Tmax And T1/2 For Migalastat After Administration Of Agalsidase|Change From Baseline To Day 7 In Active α-Gal A In Skin Following Treatment With Agalsidase Alone And Co-administration With Migalastat","Amicus Therapeutics","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AT1001-013","February 2, 2011","October 9, 2012","October 9, 2012","September 9, 2010","November 1, 2018","December 19, 2018","Birmingham, Alabama, United States|Decatur, Georgia, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Springfield, Virginia, United States|Nedlands, Australia|Parkville, Australia|Edegem, Belgium|Montreal, Canada|Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01196871"
1024,"NCT01301066","A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects",,"Completed","Has Results","Dyslipidemia","Drug: Pitavastatin|Drug: Pravastatin","Change of Fasting Serum Low-density Lipoprotein Cholesterol (LDL-C) at 12 Weeks","Kowa Research Institute, Inc.|Kowa Pharmaceuticals America, Inc.|Eli Lilly and Company","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","252","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NK-104-4.05US","December 2010","March 2013","March 2013","February 23, 2011","April 29, 2014","April 29, 2014","Phoenix, Arizona, United States|Beverly Hills, California, United States|Costa Mesa, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|San Francisco, California, United States|Washington, District of Columbia, United States|Coral Gables, Florida, United States|Fort Lauderdale, Florida, United States|Fort Pierce, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Tampa, Florida, United States|Vero Beach, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Springfield, Massachusetts, United States|Berkley, Michigan, United States|St. Louis, Missouri, United States|Hillsborough, New Jersey, United States|Randolph, New Jersey, United States|New York, New York, United States|Rochester, New York, United States|Huntersville, North Carolina, United States|Addison, Texas, United States|Austin, Texas, United States|Corpus Christi, Texas, United States|Fort Worth, Texas, United States|Harlingen, Texas, United States|Houston, Texas, United States|Longview, Texas, United States|Annandale, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01301066"
1025,"NCT00902200","A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)",,"Completed","No Results Available","Elevated Intraocular Pressure","Drug: AR-12286|Drug: AR-12286 vehicle","The primary efficacy endpoint will be mean diurnal IOP on each day at which diurnal IOP is measured at each timepoint.","Aerie Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","89","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AR-12286-CS201","May 2009","September 2009","September 2009","May 15, 2009",,"April 21, 2014","Soilsh Practice, Pasadena, California, United States|Bacharach practice, Petaluma, California, United States|Hernando Eye Institute, Brooksville, Florida, United States|Taustine Eye Center, Louisville, Kentucky, United States|Mundorf Practice, Charlotte, North Carolina, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Texan Eye, Austin, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00902200"
1026,"NCT01417104","Aliskiren Effect on Aortic Plaque Progression","ALPINE","Terminated","Has Results","Atherosclerosis","Drug: Aliskiren|Drug: Placebo","Change in Normalized Total Aortic Wall Volume (TWV) Between the Trial Arms at the End of the Treatment|Change in the Percentage Wall Volume (PWV) Between Baseline and End of Treatment","Ohio State University|Novartis","All","45 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","71","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CSPP100AUS33T","October 2009","December 2011","January 2012","August 16, 2011","December 31, 2012","May 11, 2017","Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01417104"
1027,"NCT01965106","Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)",,"Completed","No Results Available","Glaucoma, Angle-closure, Primary, Acute","Drug: QPI-1007 Injection|Drug: (including placebo)","Safety and tolerability of a single intravitreal (IVT) dose of QPI-1007 as assessed by adverse events (AE)|Safety and tolerability of a single IVT dose of QPI-1007 as assessed by laboratory evaluations|Safety and tolerability of a single IVT dose of QPI-1007 as assessed by vital signs and weight|Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluations, Best Corrected Visual Acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (EDTRS) chart and slit lamp exams (anterior & posterior segment)|Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluations, Visual Field (VF) and Spectral Domain Optical Coherence Tomography (SD-OCT)|Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluation intraocular pressure (IOP)|Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluation, Fundus Photographs (FP)|Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluations optic nerve head stereo photographs and contrast sensitivity|Safety and tolerability of a single IVT dose of QPI-1007 as assessed by use of concomitant treatments|QPI-1007 pharmacokinetics (PK) parameters as assessed by the peak plasma concentration (Cmax)|QPI-1007 pharmacokinetics (PK) parameters as assessed by the time to peak plasma concentration (Tmax)|Difference between QPI-1007 and control group (sham) as assessed by the prevalence of the abnormal visual fields|Difference between QPI-1007 and control group (sham) as assessed by change in the mean deviation compared to baseline|Difference between QPI-1007 and control group (sham) as assessed by progression of the visual fields compared to baseline|Difference between QPI-1007 and control group (sham) as assessed by change in the mean BCVA using the EDTRS chart compared to baseline|Difference between QPI-1007 and control group (sham) as assessed by SD-OCT parameters|Difference between QPI-1007 and control group (sham) as assessed by change in the mean contrast sensitivity compared to baseline","Quark Pharmaceuticals","All","40 Years and older   (Adult, Older Adult)","Phase 2","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","QRK208","December 2013","June 2015","July 2015","October 18, 2013",,"April 7, 2017","The Gavin Herbert Eye Institute, UC Irvine, Orange, California, United States|Doheny Eye Center, UCLA, Pasadena, California, United States|Robert Cizik Eye Clinic - Clinical Trials Unit, Houston, Texas, United States|Dept. of Ophthalmology, University of Washington Medical Center, Seattle, Washington, United States|Singapore National Eye Centre, Singapore, Singapore|Hanoi Eye Hospital, Ha Noi, Vietnam|Vietnam National Institute of Ophthalmology, Ha Noi, Vietnam|Ho Chi Minh City Eye Hospital, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT01965106"
1028,"NCT01427517","Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease",,"Completed","Has Results","Parkinson's Disease|Gaucher's Disease","Drug: N-acetylcysteine","Brain GSH","University of Minnesota|Rare Diseases Clinical Research Network|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FWA00000312-2|U54NS065768","July 2011","December 2012","December 2012","September 1, 2011","August 2, 2013","November 1, 2019","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01427517"
1029,"NCT02027272","Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):","PRESIDEX","Terminated","Has Results","Eclampsia","Drug: Dexamethasone","Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES): Arandomized Clinical Trial Evaluating Corticosteroid Efficacy to Augment Standard Therapy and Shorten Recovery","University of Mississippi Medical Center","Female","18 Years to 45 Years   (Adult)","Not Applicable","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2011-0269","February 2012","December 2013","December 2013","January 6, 2014","May 26, 2016","May 26, 2016","University of Mississippi Medical Center, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT02027272"
1030,"NCT02009462","Artefill for the Treatment of HIV-associated Facial Lipoatrophy",,"Active, not recruiting","No Results Available","HIV-facial Lipoatrophy","Drug: Artefill dermal filler","Artefill for the Treatment of HIV-Associated Facial Lipoatrophy|Artefill for the Treatment of HIV-associated Facial Lipoatrophy","Gerald Pierone, Jr. M.D.|Suneva Medical, Inc.|AIDS Research and Treatment Center of the Treasure Coast","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARTCTC-01-001","December 2013","November 2019","November 2019","December 12, 2013",,"July 11, 2019","Whole Family Health Center, Vero Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02009462"
1031,"NCT01314586","Flax Lignans and Heart Health","ISULignan","Completed","No Results Available","Hypercholesterolemia","Dietary Supplement: secoisolariciresinol diglucoside-containing extract of flaxseed","Change in serum total cholesterol from baseline to 12 weeks after intervention treatments|Change in serum glucose from baseline to 12 weeks after intervention treatments|Change in blood pressure from baseline to end of treatment|Changes in serum clinical chemistry from baseline to end of treatment","Iowa State University|Archer Daniels Midland Co.","All","40 Years to 65 Years   (Adult, Older Adult)","Not Applicable","93","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","ADM Beneflax ISU-1","December 2007","July 2009","November 2009","March 14, 2011",,"March 14, 2011","Nutrition & Wellness Research Center, Ames, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT01314586"
1032,"NCT01612858","Metabolic Abnormalities in HIV-infected Persons",,"Completed","Has Results","Lipodystrophy|HIV Infection","Drug: Metformin|Drug: Pioglitazone","Change in Insulin Sensitivity From Baseline to Week 12 Post-treatment With Insulin Sensitizing Agent|Change in Hepatic Fat From Baseline to Week 12 Post-treatment With an Insulin Sensitizing Agent","Tufts Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","20","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLAMP-K23|1K23DK079789-01A2","June 2011","November 2014","November 2014","June 6, 2012","June 20, 2016","June 20, 2016","Tufts Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01612858"
1033,"NCT02124083","Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1",,"Completed","Has Results","Neimann-Pick Disease","Drug: Vorinostat","Number of Participants With Tolerabilty of 200 mg Vorinostat in Niemann-Pick Disease, Type C1|Number of Participants With Tolerabilty of 400 mg Vorinostat in Niemann-Pick Disease, Type C1|Biochemical Efficacy as Measured by Serum Cathepsin D|Biochemical Efficacy as Measured by Serum LGALS3","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Washington University School of Medicine|Weill Medical College of Cornell University|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","12","NIH|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","140102|14-CH-0102","April 25, 2014","December 13, 2016","December 13, 2016","April 28, 2014","February 22, 2018","February 22, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02124083"
1034,"NCT01937754","Study of the Effects of an Oral Nitric Oxide Supplement on Blood Pressure in Prehypertensive Adults",,"Unknown status","No Results Available","Prehypertension","Dietary Supplement: Nitric Oxide supplement|Dietary Supplement: Placebo","Reduction in Systolic and Diastolic Blood Pressure Readings|Improvement in Functional Capacity","Neogenis Laboratories","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Neo-4085","January 2013","September 2013",,"September 10, 2013",,"September 10, 2013","California Medical Institute, Beverly Hills, California, United States",,"https://ClinicalTrials.gov/show/NCT01937754"
1035,"NCT02452125","The Effects of Nicotine Chewing Gum in Parkinson's Disease","PD","Completed","No Results Available","Low Blood Pressure|Parkinsons Disease","Dietary Supplement: Nicotine gum","Blood Pressure|Heart Rate","New York Institute of Technology","All","Child, Adult, Older Adult","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BHS-1118","May 2015","June 1, 2017","June 1, 2017","May 22, 2015",,"July 28, 2017","New York Institute of Technology, Old Westbury, New York, United States",,"https://ClinicalTrials.gov/show/NCT02452125"
1036,"NCT03893071","Open‐Label Study of Long‐Term Safety and Efficacy of Intravenous Trappsol Cyclo (HPβCD) in Niemann‐Pick Disease Type C",,"Recruiting","No Results Available","Niemann-Pick Disease, Type C1","Drug: Hydroxypropyl-β-cyclodextrin","Adverse events (AEs): Frequency, severity, time to onset, duration, and relatedness to study product|Serious adverse events (SAEs): Frequency, severity, time to onset, duration and relatedness to study product|Number of discontinuations due to AEs: Patient Discontinuation, Study Treatment Discontinuation, Study and Site Discontinuation|Auditory capacity will be measured by behavioral auditory assessment|Change from baseline in total score as well as individual National Institute of Health (NIH) Niemann-Pick Disease Type C (NPC) Severity Scale (NCSS)","CTD Holdings, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTD‐TCNPC‐102","March 2019","March 2021","March 2021","March 28, 2019",,"March 28, 2019","UCSF Benioff Children's Hospital Oakland, Oakland, California, United States",,"https://ClinicalTrials.gov/show/NCT03893071"
1037,"NCT01702246","Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease",,"Completed","Has Results","Sickle Cell Disease","Drug: Simvastatin","Change in Frequency of Vaso-occlusive Pain Events, Before and After Treatment With Simvastatin|Change in Plasma High Sensitivity C-reactive Protein|Change From Baseline in Total Cholesterol Level After Treatment With Simvastatin","UCSF Benioff Children’s Hospital Oakland|University of California, Los Angeles","All","10 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DDCF-ICRA-2011","February 2012","May 2015","June 2015","October 8, 2012","December 19, 2016","December 19, 2016","Children's Hospital and Research Center Oakland, Oakland, California, United States",,"https://ClinicalTrials.gov/show/NCT01702246"
1038,"NCT01679197","Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy",,"Completed","Has Results","Fatty Liver Disease, Nonalcoholic|Nonalcoholic Steatohepatitis|Lipodystrophy","Drug: Metreleptin","Liver Histopathology|Liver Fat by MRI and MR Spectroscopy|Liver Function Tests|Fasting Lipids|Fasting Glucose|Body Weight","University of Michigan|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","5 Years and older   (Child, Adult, Older Adult)","Phase 2","23","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCRU 2834|R01DK088114-02","October 8, 2012","July 13, 2016","July 13, 2016","September 5, 2012","June 14, 2017","June 14, 2017","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01679197"
1039,"NCT01463215","Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease",,"Suspended","No Results Available","Type I Gaucher Disease","Drug: Ambroxol","Safety assessment based on potential changes in physical exam, vital signs, ECG, adverse event query, and clinical lab results, when compared to baseline values.|efficacy based on biomarker (glucocerebrosidase activities), lab results, as well as hepatic and splenic volumes from imaging scans.","Exsar Corporation","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CL-Ambroxol-002","December 2012","December 2014","August 2015","November 1, 2011",,"February 15, 2013","ExSAR Corporation, Monmouth Junction, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01463215"
1040,"NCT01930487","The Effects of an Antioxidant Formulation on Ocular Blood Flow",,"Completed","Has Results","Primary Open Angle Glaucoma","Dietary Supplement: dietary supplement with antioxidants|Dietary Supplement: Placebo","Change in Superior Retinal Capillary Blood Flow (% Zero Pixels)|Change in Inferior Retinal Capillary Blood Flow (% Zero Pixels)|Change in Ocular Perfusion Pressure|Change in Ophthalmic Artery Peak Systolic Blood Flow Velocity (cm/s)|Change in Central Retinal Artery Peak Systolic Blood Flow Velocity (cm/s)|Change in Nasal Posterior Ciliary Artery Peak Systolic Blood Flow Velocity (cm/s)|Change in Temporal Posterior Ciliary Artery Peak Systolic Blood Flow Velocity (cm/s)|Change in Ophthalmic Artery End Diastolic Blood Flow Velocity (cm/s)|Change in Central Retinal Artery End Diastolic Blood Flow Velocity (cm/s)|Change in Nasal Posterior Ciliary Artery End Diastolic Blood Flow Velocity (cm/s)|Change in Temporal Posterior Ciliary Artery End Diastolic Blood Flow Velocity (cm/s)|Change in Ophthalmic Artery Blood Flow - Vascular Resistance (Ratio)|Change in Central Retinal Artery Blood Flow - Vascular Resistance (Ratio)|Change in Nasal Posterior Ciliary Artery Blood Flow - Vascular Resistance (Ratio)|Change in Temporal Posterior Ciliary Artery Blood Flow - Vascular Resistance (Ratio)|Change in Ophthalmic Artery Peak Systolic Blood Flow Velocity (cm/s) - DM|Change in Ophthalmic Artery Peak Systolic Blood Flow Velocity (cm/s) - No DM|Change in Central Retinal Artery Peak Systolic Blood Flow Velocity (cm/s) - DM|Change in Central Retinal Artery Peak Systolic Blood Flow Velocity (cm/s) - No DM|Change in Nasal Posterior Ciliary Artery Peak Systolic Blood Flow Velocity (cm/s) - DM|Change in Nasal Posterior Ciliary Artery Peak Systolic Blood Flow Velocity (cm/s) - No DM|Change in Temporal Posterior Ciliary Artery Peak Systolic Blood Flow Velocity (cm/s) - DM|Change in Temporal Posterior Ciliary Artery Peak Systolic Blood Flow Velocity (cm/s) - No DM|Change in Ophthalmic Artery End Diastolic Blood Flow Velocity (cm/s) - DM|Change in Ophthalmic Artery End Diastolic Blood Flow Velocity (cm/s) - No DM|Change in Central Retinal Artery End Diastolic Blood Flow Velocity (cm/s) - DM|Change in Central Retinal Artery End Diastolic Blood Flow Velocity (cm/s) - No DM|Change in Nasal Posterior Ciliary Artery End Diastolic Blood Flow Velocity (cm/s) - DM|Change in Nasal Posterior Ciliary Artery End Diastolic Blood Flow Velocity (cm/s) - No DM|Change in Temporal Posterior Ciliary Artery End Diastolic Blood Flow Velocity (cm/s) - DM|Change in Temporal Posterior Ciliary Artery End Diastolic Blood Flow Velocity (cm/s) - No DM|Change in Ophthalmic Artery Blood Flow - Vascular Resistance (Ratio) - DM|Change in Ophthalmic Artery Blood Flow - Vascular Resistance (Ratio) - No DM|Change in Central Retinal Artery Blood Flow - Vascular Resistance (Ratio) - DM|Change in Central Retinal Artery Blood Flow - Vascular Resistance (Ratio) - No DM|Change in Nasal Posterior Artery Blood Flow - Vascular Resistance (Ratio) - DM|Change in Nasal Posterior Artery Blood Flow - Vascular Resistance (Ratio) - No DM|Change in Temporal Posterior Artery Blood Flow - Vascular Resistance (Ratio) - DM|Change in Temporal Posterior Artery Blood Flow - Vascular Resistance (Ratio) - No DM|Change in Ocular Perfusion Pressure - DM|Change in Ocular Perfusion Pressure - No DM|Change in Superior Retinal Capillary Blood Flow (% Zero Pixels) - DM|Change in Superior Retinal Capillary Blood Flow (% Zero Pixels) - No DM|Change in Inferior Retinal Capillary Blood Flow (% Zero Pixels) - DM|Change in Inferior Retinal Capillary Blood Flow (% Zero Pixels) - No DM","ScienceBased Health","All","30 Years to 70 Years   (Adult, Older Adult)","Not Applicable","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","007","August 2013","July 2015","August 2015","August 29, 2013","December 5, 2016","December 5, 2016","Glick Eye Institute, Ocular Vascular Research Center, Indiana University School of Medicine, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01930487"
1041,"NCT00991159","A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects",,"Completed","No Results Available","Healthy","Biological: RN316","Safety and tolerability of single, escalating, intravenous infusions of RN316 administered to healthy adult subjects|pharmacokinetics of RN316 in plasma after administration of single, escalating, intravenous infusions of RN316 to healthy adult subjects|pharmacodynamic effect (lipid-lowering) of single, escalating, intravenous doses of RN316 administered to healthy adult subjects|single dose immunogenicity","Pfizer","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","B1481001|RN316-101","November 2009","May 2010","May 2010","October 7, 2009",,"July 4, 2012","Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Miami Gardens, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00991159"
1042,"NCT03226821","Body Composition and Adipose Tissue in HIV",,"Recruiting","No Results Available","HIV Lipodystrophy Syndrome|Growth Hormone Deficiency|Body Composition","Drug: Tesamorelin","Change in Hepatic Lipid Content|Change in Visceral Adipose Tissue (VAT) mass|Change in Relative gene expression of CD68 gene|Change in Relative gene expression on TNF-alpha gene|Change in Resting Energy Expenditure (REE)","Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 68 Years   (Adult, Older Adult)","Phase 4","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAR2634|R01DK110771","February 7, 2018","April 30, 2021","April 30, 2021","July 24, 2017",,"April 11, 2018","Neuroendocrine Unit and Pituitary Center, Columbia University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03226821"
1043,"NCT03570632","Metformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1|Pregnancy in Diabetes","Drug: Metformin","Rate of hypertensive disorders of pregnancy|Home glucose levels throughout pregnancy|Birthweight|Neonatal morbidity","Maisa N. Feghali, MD|University of Pittsburgh","Female","18 Years to 50 Years   (Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRO18050459","July 8, 2019","December 2020","December 2020","June 27, 2018",,"July 10, 2019","Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03570632"
1044,"NCT01360476","Vitamin D Therapy to Reduce Cardiac Damage Among Vulnerable Hypertensive Patients","AdDReaCH","Completed","No Results Available","Hypertension|Left Ventricular Hypertrophy","Dietary Supplement: cholecalciferol (Vitamin D)|Dietary Supplement: Placebo","Change from Baseline in left ventricular hypertrophy at 1 year","Wayne State University|National Institute on Minority Health and Health Disparities (NIMHD)","All","30 Years to 74 Years   (Adult, Older Adult)","Not Applicable","354","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1R01MD005849-01A1","August 2011","November 2015","November 2015","May 25, 2011",,"December 9, 2015","Detroit Receiving Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01360476"
1045,"NCT01589237","Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.",,"Terminated","Has Results","Familial Chylomicronemia Syndrome (FCS) (HLP Type I)","Drug: LCQ908","Number of Patients With Any Adverse Events, Serious Adverse Events and Death|Changes From Baseline in Triglyceride Levels up to 52 Weeks|Changes From Baseline in Cholesterol Levels up to 52 Weeks|Changes From Baseline in HDL and Non HDL Cholesterol Levels up to 52 Weeks|Changes From Baseline in Glycerol Levels up to 52 Weeks|Changes From Baseline in Free Fatty Acid Levels up to 52 Weeks|Changes From Baseline in Apolipoprotein A1 Levels up to 52 Weeks|Changes From Baseline in Apolipoprotein B-48 Levels up to 52 Weeks|Changes From Baseline in Apolipoprotein B-100 Levels up to 52 Weeks","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","38","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLCQ908B2305|2012-000802-32","February 2013","July 2015","July 2015","May 1, 2012","November 15, 2016","November 15, 2016","Novartis Investigative Site, Seatlle, Washington, United States|Novartis Investigative Site, Chicoutimi, Quebec, Canada|Novartis Investigative Site, Ste-Foy, Quebec, Canada|Novartis Investigative Site, Ouest-Montreal, Canada|Novartis Investigative Site, Nantes, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Meibergdreef 9, Netherlands|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01589237"
1046,"NCT01375582","Objective Evaluation of Ocular Surface Lubricants in Two Environments",,"Completed","No Results Available","Dry Eye","Drug: B & L Soothe Lubricant Eye Drops|Drug: Liposic EDO|Drug: OcuFresh Eye Wash","Tear Film Properties","University of Rochester|Bausch & Lomb Incorporated","All","30 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","35809","June 2011","June 2012","June 2012","June 17, 2011",,"December 16, 2013","Flaum Eye Institute at the University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01375582"
1047,"NCT01803711","Omega 3 FA Supplements as Augmentation in the Treatment of Depression",,"Terminated","Has Results","Major Depression|Cancer|Diabetes|Cardiovascular Diseases","Drug: Desvenlafaxine|Dietary Supplement: Omega 3 Fatty acids|Drug: Placebo (for Omega 3 fatty acid supplement)","Hospital Anxiety and Depression Scale|Montgomery-Asberg Depression Rating Scale (MADRS)|Short Form Health Survey (SF-12)|Visual Analog Scale for Energy (VAS-E)|Visual Analog Scale for Pain (VAS-P)|Leeds Sleep Evaluation Questionnaire (LSEQ)","UConn Health","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OmegaDVS","February 2013","June 2016","June 2016","March 4, 2013","December 27, 2017","December 27, 2017","University of Connecticut Health Center, Farmington, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01803711"
1048,"NCT02221830","Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)","PHP3","Recruiting","No Results Available","Preeclampsia","Drug: Oxytocin|Drug: Placebo","Evaluation of Postpartum hematocrit|Primary postpartum hemorrhage|Estimated blood loss at delivery|Postpartum blood loss","University of Colorado, Denver","Female","13 Years to 45 Years   (Child, Adult)","Early Phase 1","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","13-2738|UL1TR001082","February 2015","December 2020","December 2020","August 20, 2014",,"January 18, 2020","University of Colorado Clinical and Translational Research Center, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02221830"
1049,"NCT03596099","Rice Vinegar as an Intervention to Lower Blood Pressure in Adults With Prehypertension and 10-year CVD Risk <10%","Rice-vinegar","Active, not recruiting","No Results Available","Prehypertension","Dietary Supplement: Mizkan rice vinegar with acetic acid|Dietary Supplement: Mizkan rice vinegar without acetic acid","Change in Systolic Blood Pressure|Changes in Diastolic Blood Pressure|Changes in Corresponding Blood Biomarkers|Changes in Vascular Reactivity via VENDYS®","Mizkan Holdings Co., Ltd.|ObvioHealth|Endothelix","All","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","130","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","OBVIO_MIZ_001","September 11, 2018","July 31, 2019","October 1, 2019","July 23, 2018",,"July 30, 2019","Primary Care Research Group, Atlanta, Georgia, United States|Endothelix Research Site c/o Bellaire Cardiology Associates, Bellaire, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03596099"
1050,"NCT03004001","Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome",,"Unknown status","No Results Available","Nephrotic Syndrome","Drug: Alirocumab|Drug: Alirocumab placebo|Drug: Atorvastatin","Levels of plasma lipoproteins|Levels of PCSK9|Triglyceride-rich lipoproteins (Remnants)|Lipidomics","Gloria Vega|Regeneron Pharmaceuticals|Aventis Pharmaceuticals|Dallas VA Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VA16-029","January 2017","December 2018","December 2018","December 28, 2016",,"March 13, 2017","DallasVAMC, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03004001"
1051,"NCT02248701","Testosterone Plus Finasteride Treatment After Spinal Cord Injury",,"Recruiting","No Results Available","Spinal Cord Injury|Spinal Cord Injuries|Trauma, Nervous System|Wounds and Injuries|Central Nervous System Diseases|Nervous System Diseases|Spinal Cord Diseases|Gonadal Disorders|Endocrine System Diseases|Hypogonadism|Genital Diseases, Male","Drug: testosterone enanthate, finasteride|Drug: placebo","Change in Hip Bone Mineral Density|Changes in Muscle Cross-Sectional Area|Change in Total Body Fat|Change in Walking Speed|Change in Neuromuscular Function|Change in Visceral Fat","VA Office of Research and Development|University of Florida","Male","18 Years and older   (Adult, Older Adult)","Phase 2","30","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","B1449-R|1I01RX001449-01A1|1IK1RX002327-01A1","January 16, 2017","May 31, 2021","June 1, 2021","September 25, 2014",,"March 25, 2020","North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02248701"
1052,"NCT00896298","Trial of Leptin Replacement Therapy in Patients With Lipodystrophy",,"Completed","Has Results","Hypoleptinemia|Generalized Lipodystrophy|Partial Lipodystrophy|Insulin Resistance","Drug: Leptin|Drug: Placebo","Fasting Serum Triglycerides|HbA1c|Fasting Serum Glucose|Body Weight","University of Texas Southwestern Medical Center","All","6 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","0502-294","April 2006","November 2014","November 2014","May 11, 2009","March 5, 2019","April 2, 2019","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00896298"
1053,"NCT01747135","Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease",,"Completed","No Results Available","Niemann-Pick Disease, Type C1","Drug: VTS-270","24-hydroxycholesterol Area under the curve|Hearing loss.","Vtesse, Inc., a Mallinckrodt Pharmaceuticals Company|Mallinckrodt","All","2 Years to 25 Years   (Child, Adult)","Phase 1","14","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","130001","January 2013","March 2017","March 2017","December 11, 2012",,"October 31, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01747135"
1054,"NCT03445650","RESET Trial - Part 1 (Followed by Reset Trial - Part 2) - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)",,"Suspended","No Results Available","Sjogren-Larsson Syndrome","Drug: ADX-102 1% Topical Dermal Cream (reproxalap)|Drug: Vehicle of ADX-102 Topical Dermal Cream","Visual Index Ichthyosis Severity (VIIS) Scaling severity score as assessed by the investigator.|(VIIS) Erythema severity score.|Pharmacokinetic profile.|Pharmacodynamic profile.","Aldeyra Therapeutics, Inc.","All","3 Years and older   (Child, Adult, Older Adult)","Phase 3","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ADX-102-SLS-006","July 19, 2018","December 2020","December 2020","February 26, 2018",,"March 19, 2020","Yale University, New Haven, Connecticut, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT03445650"
1055,"NCT03371355","Study of ISIS 703802 in Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease",,"Completed","No Results Available","NAFLD|Diabetes Mellitus, Type 2|Hypertriglyceridemia|Fatty Liver, Nonalcoholic","Drug: ISIS 703802|Drug: Placebo","Percent change in fasting TG level from Baseline at the primary analysis time point.|The safety of ISIS 703802 by the incidence of treatment-emergent adverse events|The effect of ISIS 703802 on changes from Baseline at End-of-Treatment on glucose metabolism|The effect of ISIS 703802 on changes from Baseline at End-of-Treatment lipid metabolism|The effect of ISIS 703802 on changes from Baseline at End-of-Treatment on liver fat|Plasma Cmax of ISIS 703802 across different doses and dose regimens|Plasma Tmax of ISIS 703802 across different doses and dose regimens|Plasma AUC values of ISIS 703802 across different doses and dose regimens|The effect of ISIS 703802 on changes from Baseline on biomarkers related to liver inflammation|The effect of ISIS 703802 on changes from Baseline on adipose tissue as related to body composition|The effect of ISIS 703802 on changes from Baseline on WHR (waist-to-hip ratio) as related to body composition.|The effect of ISIS 703802 on changes from Baseline on BMI (Body Mass Index) as related to body composition","Akcea Therapeutics|Ionis Pharmaceuticals, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ISIS 703802-CS2","December 18, 2017","November 21, 2019","February 24, 2020","December 13, 2017",,"March 13, 2020","Clinical Sites, Chandler, Arizona, United States|Clinical Site, Fountain Hills, Arizona, United States|Clinical Site, Glendale, Arizona, United States|Clinical Site, Mesa, Arizona, United States|Clinical Site, Mesa, Arizona, United States|Clinical Site, Phoenix, Arizona, United States|Clinical Site, Phoenix, Arizona, United States|Clinical Site, Phoenix, Arizona, United States|Clinical Site, Huntington Park, California, United States|Clinical Site, Los Angeles, California, United States|Clinical Site, Montclair, California, United States|Clinical Site, Panorama City, California, United States|Clinical Site, Poway, California, United States|Clinical Site, Boca Raton, Florida, United States|Clinical Site, Jupiter, Florida, United States|Clinical Site, Miami, Florida, United States|Clinical Site, Port Saint Lucie, Florida, United States|Clinical Site, Atlanta, Georgia, United States|Clinical Site, Chicago, Illinois, United States|Clinical Site, Indianapolis, Indiana, United States|Clinical Site, Louisville, Kentucky, United States|Clinical Site, Edina, Minnesota, United States|Clinical Site, Bridgeton, New Jersey, United States|Clinical Site, Princeton, New Jersey, United States|Clinical Site, Greensboro, North Carolina, United States|Clinical Site, High Point, North Carolina, United States|Clinical Site, Cincinnati, Ohio, United States|Clinical Site, Cincinnati, Ohio, United States|Clinical Site, Charleston, South Carolina, United States|Clinical Site, Austin, Texas, United States|Clinical Site, Carrollton, Texas, United States|Clinical Site, Dallas, Texas, United States|Clinical Site, Houston, Texas, United States|Clinical Site, Hurst, Texas, United States|Clinical Site, San Antonio, Texas, United States|Clinical Site, San Antonio, Texas, United States|Clinical Site, Layton, Utah, United States|Clinical Site, Hamilton, Ontario, Canada|Clinical Site, Toronto, Ontario, Canada|Clinical Site, Chicoutimi, Quebec, Canada|Clinical Site, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03371355"
1056,"NCT01399047","Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis","JUMP","Completed","Has Results","Juvenile Neuronal Ceroid Lipofuscinosis","Drug: Mycophenolate mofetil|Drug: Liquid Placebo","Tolerability - Number of Participants Who Completed Each Arm on Assigned Study Drug Dose|Unified Batten Disease Rating Scale Physical Subscale Change|Unified Batten Disease Rating Scale Seizure Subscale Change|Unified Batten Disease Rating Scale Behavior Subscale Change|Unified Batten Disease Rating Scale Capability Subscale Change","University of Rochester|Batten Disease Support and Research Assocation (BDSRA)","All","6 Years to 25 Years   (Child, Adult)","Phase 2","19","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3908","July 2011","November 2015","November 2015","July 21, 2011","January 23, 2017","May 21, 2019","University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01399047"
1057,"NCT03454893","Open-Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment -Naive Subjects With Classic Fabry Disease",,"Recruiting","No Results Available","Fabry Disease","Drug: AVR-RD-01","Incidence of Treatment-Emergent Adverse Events of AVR-RD-01 drug product|Change in the average number of Gb3 inclusions (ie, myelinosomes) per kidney peritubular capillary (PTC) per subject","AvroBio","Male","16 Years to 50 Years   (Child, Adult)","Phase 1|Phase 2","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVRO-RD-01-201","February 21, 2018","July 2021","November 2021","March 6, 2018",,"February 10, 2020","Hackensack University Medical Center, Hackensack, New Jersey, United States|Baylor University Medical Center, Houston, Texas, United States|Royal Melbourne Hospital, Melbourne, Parkville VIC, Australia|Royal Perth Hospital, Perth, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT03454893"
1058,"NCT01163851","Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin",,"Completed","Has Results","Hypercholesterolemia|Dyslipidemia","Biological: 4 mg/kg|Biological: 0.5 mg/kg","Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615|Maximum Observed Plasma Concentration (Cmax) of PF-04950615|Plasma Decay Half-Life (t1/2) of PF-04950615|Systemic Clearance (CL) of PF-04950615|Volume of Distribution at Steady State (Vss) of PF-04950615|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of PF-04950615|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Atorvastatin|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Atorvastatin|Maximum Observed Plasma Concentration (Cmax) of Atorvastatin|Plasma Decay Half-Life (t1/2) of Atorvastatin|Apparent Oral Clearance (CL/F) of Atorvastatin|Apparent Volume of Distribution (Vz/F) of Atorvastatin|Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64|Duration of Low Density Lipoprotein (LDL) Lowering Effects|Number of Participants With Toxicity or Intolerable Dose Criteria|Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Treatment-Emergent Adverse Events by Severity|Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Physical Examination|Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Vital Signs|Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Electrocardiogram (ECG) Parameters|Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters|Number of Participants With Positive Anti-drug Antibodies (ADA)","Pfizer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1481003","July 2010","February 2011","April 2011","July 16, 2010","May 7, 2015","March 1, 2018","Premier Research Group, Limited, Peoria, Arizona, United States|Dedicated Phase 1, Inc., Phoenix, Arizona, United States|Premier Research Group Limited, Phoenix, Arizona, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01163851"
1059,"NCT01504646","Effect of a Component of Fish Oil on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma",,"Completed","No Results Available","Asthma|Exercise-Induced Bronchoconstriction","Dietary Supplement: Lyprinol|Dietary Supplement: Placebo (Olive Oil)","Pulmonary Function (Percent Change in FEV1, measured in Liters)|Fraction of Exhaled Nitric Oxide","Indiana University|Pharmalink","All","18 Years to 30 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","1108006502","January 2012","August 2012","August 2012","January 5, 2012",,"October 23, 2018","Indiana University School of Health, Physical Education, and Recreation, Bloomington, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01504646"
1060,"NCT01722526","Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients",,"Completed","No Results Available","Human Acid Sphingomyelinase Deficiency","Drug: Recombinant human acid sphingomyelinase","Summary of Adverse Events (AEs)|Pharmacokinetics as measured by peak plasma concentration (Cmax), time to peak concentration (tmax), area under curve (AUC), half life (t1/2), drug clearance (CL), and volume of distribution (Vss)|Pharmacodynamics as measured by liver and skin biopsies, plasma, and dried blood spot","Genzyme, a Sanofi Company|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DFI13412|2012-003542-32|SPHINGO00812","March 2013","January 2014","January 2014","November 7, 2012",,"July 30, 2015","Mount Sinai School of Medicine, New York, New York, United States|St. Mary's Hospital, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01722526"
1061,"NCT00963664","Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma",,"Withdrawn","No Results Available","Melanoma|Malignant Melanoma","Drug: lovastatin|Drug: interferon alfa-2b","Overall survival|Time to progression of disease|Appearance of new distant metastases|Toleration of medication side effects and quality of life","NeoPlas Innovation","All","18 Years and older   (Adult, Older Adult)","Phase 2","250","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NI-MM-009","December 2009","December 2016","December 2016","August 21, 2009",,"September 9, 2009","NeoPlas Innovation, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00963664"
1062,"NCT00875160","A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101",,"Terminated","No Results Available","Type 1 Gaucher Disease","Drug: AT2101","To evaluate single-dose and multiple-dose pharmacokinetics of isofagomine following the oral administration of AT2101 in patients with type 1 Gaucher disease|To evaluate the safety and tolerability of oral AT2101 administered in patients with type 1 Gaucher disease|To evaluate the pharmacodynamic effect of WBC GCase of oral AT2101 administered in patients with type 1 Gaucher disease.","Amicus Therapeutics","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","1","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GAU-CL-104","April 2009","July 2009","July 2009","April 3, 2009",,"August 19, 2010","Comprehensive Phase One, Miramar, Florida, United States|Guy's Drug Research Unit, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00875160"
1063,"NCT01975389","The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects","SPIRE-2","Terminated","Has Results","Cardiovascular Disease","Drug: bococizumab (PF-04950615)|Drug: Placebo","Event Rate Per 100 Participant-years for First Occurrence of Major Cardiovascular (CV) Event|Event Rate Per 100 Participant-years for First Occurrence of Composite Endpoint of Cardiovascular (CV) Death, Non-fatal Myocardial Infraction (MI) or Non-fatal Stroke|Event Rate Per 100 Participant-years for First Occurrence of Composite Endpoint of All-cause Death, Non-fatal Myocardial Infraction (MI), Non-fatal Stroke or Hospitalization for Unstable Angina Needing Urgent Revascularization|Event Rate Per 100 Participant-years for First Occurrence of Composite Endpoint of All-cause Death, Non-fatal Myocardial Infarction (MI) or Non-fatal Stroke|Event Rate Per 100 Participant-years for First Occurrence of Hospitalization for Unstable Angina Needing Urgent Revascularization|Event Rate Per 100 Participant-years for First Occurrence of Composite Endpoint of Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), Non-fatal Stroke or Hospitalization for Unstable Angina|Event Rate Per 100 Participant-years for Cardiovascular (CV) Death|Event Rate Per 100 Participant-years for First Occurrence of Any Myocardial Infarction (Fatal or Non-fatal)|Event Rate Per 100 Participant-years for Fatal Myocardial Infarction (MI)|Event Rate Per 100 Participant-years for First Occurrence of Non-fatal Myocardial Infarction (MI)|Event Rate Per 100 Participant-years for First Occurrence of Any Stroke (Fatal or Non-fatal)|Event Rate Per 100 Participant-years for First Occurrence of Any Stroke (Fatal or Non-fatal), of Any Etiology|Event Rate Per 100 Participant-years for Fatal Stroke|Event Rate Per 100 Participant-years for First Occurrence of Non-fatal Stroke|Event Rate Per 100 Participant-years for First Occurrence of Hospitalization for Unstable Angina|Event Rate Per 100 Participant-years for First Occurrence of Hospitalization for Congestive Heart Failure (CHF)|Event Rate Per 100 Participant-years for First Occurrence of Coronary Revascularization|Event Rate Per 100 Participant-years for First Occurrence of Coronary Artery Bypass Graft Surgery (CABG)|Event Rate Per 100 Participant-years for First Occurrence of Percutaneous Coronary Intervention (PCI)|Event Rate Per 100 Participant-years for First Occurrence of Any Arterial Revascularizations|Event Rate Per 100 Participant-years for All-cause Death|Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 14|Nominal Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 14|Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Last Post-baseline Measurement|Percent Change From Baseline in Lipid Levels at Week 14|Percent Change From Baseline in Log-transformed Triglycerides and Lipoprotein (a) (Lp[a]) at Week 14|Percent Change From Baseline in Log-transformed High Sensitivity C-Reactive Protein (Hs-CRP) at Week 14","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","10564","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","B1481038|CV OUTCOMES 2|2013-002795-41","October 29, 2013","April 3, 2017","April 3, 2017","November 3, 2013","June 12, 2018","May 1, 2019","Ernest Hendrix, MD, PC, Athens, Alabama, United States|North Alabama Research Center, LLC, Athens, Alabama, United States|Central Alabama Research, Birmingham, Alabama, United States|Clinical Research Advantage, Inc./Simon Williamson Clinic, Birmingham, Alabama, United States|The Kirklin Clinic, Birmingham, Alabama, United States|Birmingham Heart Clinic, P.C., Birmingham, Alabama, United States|University of Alabama at Birmingham (Drug Shipment), Birmingham, Alabama, United States|Appalachian Cardiovascular Associates, Fort Payne, Alabama, United States|Fundamental Research, LLC, Gulf Shores, Alabama, United States|Avant Research Associates, LLC, Guntersville, Alabama, United States|Boyett Health Services, Hamilton, Alabama, United States|The Office of Saadat Ansari MD LLC, Huntsville, Alabama, United States|CB Flock Research Corporation, Mobile, Alabama, United States|Alaska Heart Institute, Anchorage, Alaska, United States|Phoenix Heart, PLLC, Glendale, Arizona, United States|Arrowhead Internal Medicine, Glendale, Arizona, United States|Clinical Research Advantage, Inc./Family Practice Specialists, Ltd., Phoenix, Arizona, United States|Cochise Clinical Research, Sierra Vista, Arizona, United States|Clinical Research Advantage, Inc. (Administrative Mailing Only), Tempe, Arizona, United States|Southwest Heart Group, Tucson, Arizona, United States|Arizona Endocrine and Rheumatology Associates, Tucson, Arizona, United States|Arkansas Heart Hospital Clinic, Little Rock, Arkansas, United States|Arkansas Site Management Services, LLC, Little Rock, Arkansas, United States|Cardiology Consultants of Orange County Medical Group, Inc., Anaheim, California, United States|Premier Valley Medical Group, Bakersfield, California, United States|Cardiovascular Research Foundation of Southern California, Beverly Hills, California, United States|Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|Southbay Pharma Research, Buena Park, California, United States|Pioneer Medical Group, Cerritos, California, United States|John Muir Physician Network Clinical Research Center, Concord, California, United States|Atlantic Ave Medical Clinic Inc., Cudahy, California, United States|Multani Medical Group, Downey, California, United States|Triwest Research Associates, LLC, El Cajon, California, United States|Diagnamics Inc., Encinitas, California, United States|T. Joseph Raoof, Md, Inc/Encino Research Center, Encino, California, United States|Aviva Research, Escondido, California, United States|Valley Research, Fresno, California, United States|St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton, California, United States|Omnibus Clinical Research, La Palma, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Prime Care Clinical Research Center, Laguna Hills, California, United States|Clinical Trials Research, Lincoln, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|American Institute of Research, Los Angeles, California, United States|Intermed Group, Los Angeles, California, United States|Academic Medical Research Institute, Los Angeles, California, United States|Eastside Clinical Research Associates, Los Angeles, California, United States|Richard S. Cherlin, MD, Los Gatos, California, United States|Facey Medical Foundation, Mission Hills, California, United States|California Medical Research Associates Inc., Northridge, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|Diabetes Associates Medical Group, Orange, California, United States|Saviers Medical Group, Port Hueneme, California, United States|California Research Foundation, San Diego, California, United States|San Diego Family Care dba Linda Vista Health Center, San Diego, California, United States|San Diego Family Care, San Diego, California, United States|Ritchken & First Md's, San Diego, California, United States|Wetlin Research Associates, Inc., San Diego, California, United States|West Coast Research LLC, San Ramon, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Coastal Biomedical Research, Inc., Santa Monica, California, United States|Encompass Clinical Research, Spring Valley, California, United States|St. Joseph's Medical Associates, Stockton, California, United States|Westlake Medical Research, Thousand Oaks, California, United States|Harbor-UCLA Medical Center - Torrance, Torrance, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|Bayview Research Group, Valley Village, California, United States|Coastal Metabolic Research Centre, Ventura, California, United States|Ventura Clinical Trials, Ventura, California, United States|Clinical Research Advantage, Inc. / Cassidy Medical Group - Vista, Vista, California, United States|Allianz Research Institute, Westminster, California, United States|American Institute of Research Studies, Whittier, California, United States|American Institute of Research, Whittier, California, United States|Elite Clinical Trials, Inc., Wildomar, California, United States|Elite Clinical Trials, Incorporated, Wildomar, California, United States|Colorado Springs Health Partners, Colorado Springs, Colorado, United States|Lynn Institute of the Rockies, Colorado Springs, Colorado, United States|Memorial Hospital: University of Colorado Health, Colorado Springs, Colorado, United States|Lynn Institute of Denver, Denver, Colorado, United States|Western Colorado Research, LLC, Glenwood Springs, Colorado, United States|South Denver Cardiology Associates, PC, Littleton, Colorado, United States|Connecticut Clinical Research, LLC, Bridgeport, Connecticut, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Cardiology Associates of Fairfield County, PC, Stamford, Connecticut, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|Christiana Care Health Services, Inc., Newark, Delaware, United States|Alfieri Cardiology, Wilmington, Delaware, United States|ACRC - Cardiology, Atlantis, Florida, United States|GulfCoast Endocrine and Diabetes Center, Clearwater, Florida, United States|Morton Plant Mease Health Care, Inc. Cardiovascular Research, Clearwater, Florida, United States|Team Medical Research, Coral Gables, Florida, United States|The Heart Group, PA, Daytona Beach, Florida, United States|Cardiology Associates Research Company, Daytona Beach, Florida, United States|The Cardiology Center, Delray Beach, Florida, United States|Continental Research Corp, Doral, Florida, United States|Care Research Center Inc, Doral, Florida, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Moonshine Research Center, Inc., Doral, Florida, United States|Invesclinic, LLC, Fort Lauderdale, Florida, United States|The Office of Dr. Alan Graff, MD, PA, Fort Lauderdale, Florida, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|The Office of Maxine E. Hamilton, MD, PA, Fort Lauderdale, Florida, United States|State Of The Art Research, LLC, Hialeah, Florida, United States|Direct Helpers Medical Center Inc, Hialeah, Florida, United States|Research Physicians Network Alliance, Hollywood, Florida, United States|Pines Clinical Research, Inc., Hollywood, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|River City Clinical Research, Jacksonville, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|East Coast Institute for Reserach, LLC, Jacksonville, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|The Office of Rachel Day, Jacksonville, Florida, United States|Baker-Gilmore Cardiovascular Institute, Jacksonville, Florida, United States|Solutions Through Advanced Research, Inc., Jacksonville, Florida, United States|Meridien Research, Lakeland, Florida, United States|The Heart Institute at Largo, Largo, Florida, United States|South Florida Clinical Research Institute, Margate, Florida, United States|Research Physicians Network Alliance, Miami Beach, Florida, United States|G & I Medical Research LLC, Miami Lakes, Florida, United States|Ocean Blue Medical Research Center, Inc., Miami Springs, Florida, United States|Future Clinical Research, Inc., Miami, Florida, United States|Advanced Clinical Research of Miami (ACROM) International, Miami, Florida, United States|Project4Research, Inc, Miami, Florida, United States|A & L Clinical Research, Miami, Florida, United States|Finlay Medical Research, Miami, Florida, United States|Pharmax Research Clinic, Inc., Miami, Florida, United States|Team Medical Research, Inc., Miami, Florida, United States|Team Medical Research, Miami, Florida, United States|South Florida Research Center, Inc., Miami, Florida, United States|Florida Medical Center & Research, Inc., Miami, Florida, United States|Medical Research Center, Miami, Florida, United States|Nuren Medical & Research Center, Miami, Florida, United States|Doctors Research Institute, Miami, Florida, United States|Advanced Pharma CR, LLC, Miami, Florida, United States|Coast Research Institute, Miami, Florida, United States|My Community Research Center, Inc., Miami, Florida, United States|Columbus Clinical Services LLC, Miami, Florida, United States|Cardiovascular Research Center of South Florida, Miami, Florida, United States|Research Institute of South Florida, Inc., Miami, Florida, United States|A & O Research Center, Inc., Miami, Florida, United States|BWell Research Center, Miami, Florida, United States|Pharmacology International Research, Inc., Miami, Florida, United States|Advanced Clinical Research, Miami, Florida, United States|South Florida Research Group, LLC, Miami, Florida, United States|International Research Associates, LLC, Miami, Florida, United States|Kendall South Medical Center, Inc., Miami, Florida, United States|Kendall South Medical Center, Inc, Miami, Florida, United States|M & M Medical Center, Inc, Miami, Florida, United States|Med Research Of Florida, LLC, Miami, Florida, United States|Southwest Florida Research, LLC, Naples, Florida, United States|BayCare Medical Group, New Port Richey, Florida, United States|The Heart & Vascular Institute of Florida, New Port Richey, Florida, United States|Bravo Health Care Center, North Bay Village, Florida, United States|Harmony Clinical Research, Inc., North Miami Beach, Florida, United States|Florida Hospital, Orlando, Florida, United States|Omega Research Consultants, LLC, Orlando, Florida, United States|Aba Family Medicine, LLC, Ormond Beach, Florida, United States|Millennium Research, Ormond Beach, Florida, United States|Ribo Research, LLC dba Peninsula Research, Ormond Beach, Florida, United States|A and R Research Group LLC, Pembroke Pines, Florida, United States|Research Physicians Network Alliance, Pembroke Pines, Florida, United States|South Broward Research, Pembroke Pines, Florida, United States|DBC Research USA, Pembroke Pines, Florida, United States|DBC Research, Pembroke Pines, Florida, United States|Cardiology Consultants, Pensacola, Florida, United States|DMI Research, Inc., Pinellas Park, Florida, United States|Clinical Research of Central Florida, Plant City, Florida, United States|Clinical Research of Florida, Plant City, Florida, United States|Jeffrey D Greff,MD, Plantation, Florida, United States|St. Johns Center for Clinical Research, Ponte Vedra, Florida, United States|Charlotte Heart Group Research Center, Port Charlotte, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Advance Medical Research, Saint Petersburg, Florida, United States|Intercoastal Medical Group, Sarasota, Florida, United States|Intercoastal Medical Group, Sarasota, Florida, United States|Cardiovascular Center Of Sarasota, Sarasota, Florida, United States|Heart & Vascular Center Research, Sarasota, Florida, United States|Intercoastal Medical Group (Drug Shipment Address and Administrative), Sarasota, Florida, United States|The Office of Bridget Bellingar, DO, Seminole, Florida, United States|Vita Health & Medical Center, Inc./Concept Clinical Trials, LLC, Tamarac, Florida, United States|Interventional Cardiac Consultants, Trinity, Florida, United States|Cardiology Partners Clinical Research Institute, Wellington, Florida, United States|Cleveland Clinic Cardiology Associates, West Palm Beach, Florida, United States|Metabolic Research Institute, Inc., West Palm Beach, Florida, United States|Clinical Research of Central Florida, Winter Haven, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Atlanta Center For Medical Research, Atlanta, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Rockdale Medical Research Associates, Conyers, Georgia, United States|Georgia Heart Specialists, LLC, Covington, Georgia, United States|Neurostudies.net, LLC, Decatur, Georgia, United States|Alta Pharmaceutical Research Center, Dunwoody, Georgia, United States|In-Quest Medical Research, LLC, Norcross, Georgia, United States|Atlanta Center for Clinical Research / Internal Medicine, Roswell, Georgia, United States|Dr. B. Abraham, P.C., Snellville, Georgia, United States|Georgia Clinical Research, LLC, Snellville, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Elite Clinial Trials, LLLP, Blackfoot, Idaho, United States|Elite Clinical Trials (Additional Administrative Room / Exam Rooms), Blackfoot, Idaho, United States|St. Luke's Idaho Cardiology Associates, Caldwell, Idaho, United States|Solaris Clinical Research, Meridian, Idaho, United States|Saltzer Medical Group, PA, Nampa, Idaho, United States|Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States|Clinical Research Advantage, Inc./Michigan Avenue Internists, Chicago, Illinois, United States|Apex Medical Research, AMR, Inc., Chicago, Illinois, United States|Clinical Research Advantage,Inc./Medical and Procedural Specilaists of Illinois, Chicago, Illinois, United States|Evanston Premier Healthcare Research, LLC, Evanston, Illinois, United States|Clinical Investigation Specialists, Inc, Gurnee, Illinois, United States|Heart Care Centers of Illinois, Mokena, Illinois, United States|Advanced CardioVascular Consultants, Rock Island, Illinois, United States|Investigators Research Group, LLC, Brownsburg, Indiana, United States|Investigative Clinical Research of Indiana, LLC, Elwood, Indiana, United States|Deaconess Clinic Downtown, Evansville, Indiana, United States|Clinical Research Advantage, Inc., Evansville, Indiana, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Clinical Research Advantage, Inc. / Family Medicine Associates, Evansville, Indiana, United States|Deaconess Clinic Mt. Pleasant, Evansville, Indiana, United States|American Health Network of Indiana LLC, Franklin, Indiana, United States|American Health Network of Indiana LLC, Greenfield, Indiana, United States|American Health Network of Indiana, LLC, Muncie, Indiana, United States|Cardiovascular Research of Northwest Indiana, LLC, Munster, Indiana, United States|Buynak Clinical Research, P.C., Valparaiso, Indiana, United States|West Broadway Clinic, Council Bluffs, Iowa, United States|Clinical Research Advantage, Inc., Council Bluffs, Iowa, United States|Midwest Cardiovascular Research Foundation, Davenport, Iowa, United States|University of Iowa-College of Public Health-Preventive Intervention Center, Iowa City, Iowa, United States|Northeast Iowa Medical Education Foundation, Waterloo, Iowa, United States|The Iowa Clinic, PC, West Des Moines, Iowa, United States|Hutchinson Clinic, P.A, Hutchinson, Kansas, United States|University Of Kansas Medical Center, Kansas City, Kansas, United States|Midwest Heart & Vascular Specialists, LLC, Overland Park, Kansas, United States|Women's & Family Care D.B.A. GTC Research, Shawnee Mission, Kansas, United States|Women's & Family Care, LLC D.B.A GTC Research, Shawnee Mission, Kansas, United States|Women's & Family Care, LLC D.B.A. GTC Research, Shawnee Mission, Kansas, United States|Central Cardiology Associates Research, Elizabethtown, Kentucky, United States|The Research Group of Lexington, LLC, Lexington, Kentucky, United States|L-MARC, Louisville, Kentucky, United States|Research Integrity, LLC., Owensboro, Kentucky, United States|Grace Research, LLC, Bossier City, Louisiana, United States|Avant Research Associates, LLC, Crowley, Louisiana, United States|Centex Studies, Lake Charles, Louisiana, United States|Imperial Health, LLP, Lake Charles, Louisiana, United States|American Clinical Research, LLC, Marrero, Louisiana, United States|West Jefferson Heart Clinic of Louisiana New Orleans Physician Services, Inc., Marrero, Louisiana, United States|Clinical Trials of America LA, Monroe, Louisiana, United States|KAMP Medical Research Inc., Natchitoches, Louisiana, United States|Clinical and Translation Research Center (CTRC) University Medical Center of New Orleans, Diagnostic, New Orleans, Louisiana, United States|Section of Nephrology and Hypertension, LSU Health Sciences Center-New Orleans, New Orleans, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Acadia Clinical Research, LLC, Bangor, Maine, United States|Acadia Clinical Research, Bangor, Maine, United States|Cranbrook Cardiology Research Associates, Cape Elizabeth, Maine, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|MedStar Cardiology Associates, Annapolis, Maryland, United States|MedStar Chesapeake CardioVascular Associates, Baltimore, Maryland, United States|MedStar Union Memorial Heart Specialists, Baltimore, Maryland, United States|Maryland Cardiovascular Specialists, Baltimore, Maryland, United States|Overlea Personal Physicians, Baltimore, Maryland, United States|Shahid Saeed, MD, PC, Baltimore, Maryland, United States|Maryland Heart Associates, LLC, Glen Burnie, Maryland, United States|Lutherville Personal Physicians, Lutherville, Maryland, United States|MD Medical Research, Oxon Hill, Maryland, United States|MetroWest Medical Center - Pharmacy Department, Framingham, Massachusetts, United States|MetroWest Medical Center Research Clinic, Framingham, Massachusetts, United States|MetroWest Medical Center, Framingham, Massachusetts, United States|ActivMed Practices and Research, Inc., Methuen, Massachusetts, United States|Charles River Medical Associates, Natick, Massachusetts, United States|Endeavor Medical Research, Alpena, Michigan, United States|St. Joseph Mercy Health System (Drug shipment Only), Ann Arbor, Michigan, United States|University of Michigan - Domino Farms, Ann Arbor, Michigan, United States|Quest Research Institute, Bingham Farms, Michigan, United States|IHA Chelsea Family & Internal Medicine, Chelsea, Michigan, United States|Healthy Heart Cardiology, Grandville, Michigan, United States|Westside Family Medical Center, Pc, Kalamazoo, Michigan, United States|Sparrow Clinical Research Institute, Lansing, Michigan, United States|Sparrow Thoracic & Cardiovascular Institute, Lansing, Michigan, United States|Detroit Clinical Research Center, PC, Livonia, Michigan, United States|MidMichigan Medical Center Midland, Midland, Michigan, United States|Michigan Cardio Vascular Institute, Saginaw, Michigan, United States|Tri-County Research, Inc., Sterling Heights, Michigan, United States|Medical Research Associates, Inc., Traverse City, Michigan, United States|Oakland Medical Research Center, Troy, Michigan, United States|Arcturus Healthcare, PLC, Troy Internal Medicine Research Division, Troy, Michigan, United States|Michigan Heart & Vascular Institute, Ypsilanti, Michigan, United States|Duluth Clinic, dba Essentia Health Duluth Clinic Investigational Drug Room, Duluth, Minnesota, United States|St. Mary's Medical Center dba Essentia Health St. Mary's Medical Center, Duluth, Minnesota, United States|St. Mary's Medical Center, Duluth, Minnesota, United States|The Duluth Clinic, Ltd., Duluth, Minnesota, United States|Radiant Research, Inc., Edina, Minnesota, United States|Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States|Allina Health System, dba Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Lillehei Clinical Research Unit, University of Minnesota, Minneapolis, Minnesota, United States|CentraCare Heart and Vascular Center, Saint Cloud, Minnesota, United States|HealthEast St. Joseph's Hospital inpatient Pharmacy, Saint Paul, Minnesota, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Cardiology Associates Research, LLC, Tupelo, Mississippi, United States|Missouri Cardiovascular Specialists, LLP, Columbia, Missouri, United States|Saint Luke's Lipid and Diabetes Research Center, Kansas City, Missouri, United States|Kansas City VA Medical Center, Kansas City, Missouri, United States|Mercy Research, Saint Louis, Missouri, United States|Glacier View Research Institute, Cardiology, Kalispell, Montana, United States|Montana Medical Research Inc., Missoula, Montana, United States|Bryan Heart, Lincoln, Nebraska, United States|Creighton Diabetes Research Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|AB Clinical Trials, Las Vegas, Nevada, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|Clinical Research Advantage, Inc., Las Vegas, Nevada, United States|John V. Bernard, MD dba Wellness and Research Center, Belvidere, New Jersey, United States|Advanced Heart Care LLC, Bridgewater, New Jersey, United States|Lourdes Cardiology Services, Cherry Hill, New Jersey, United States|USMA Clinical Research, Elizabeth, New Jersey, United States|Lourdes Cardiology Services, Hammonton, New Jersey, United States|NJ Heart, Linden, New Jersey, United States|Arysmed LLC, Lodi, New Jersey, United States|Amici Clinical Research, LLC, Martinsville, New Jersey, United States|Rutgers Biomedical and Health Sciences-Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Cardiac & Endovascular Associates, Ridgewood, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Cardio Metabolic Institute, Somerset, New Jersey, United States|TLB Research LLC, Trenton, New Jersey, United States|Lourdes Cardiology Services, Voorhees, New Jersey, United States|Westwood Cardiology Associates, P.A., Westwood, New Jersey, United States|Albuquerque Clinical Trials, Inc., Albuquerque, New Mexico, United States|Albany Medical College, Division of Community Endocrinology, Albany, New York, United States|Sorin Medical, P.C., Brooklyn, New York, United States|NY Total Medical Care, PC, Brooklyn, New York, United States|NY Scientific, Brooklyn, New York, United States|Buffalo Heart Group, Llp, Buffalo, New York, United States|NYU Hudson Valley Cardiology, Cortlandt Manor, New York, United States|Scott Research,Inc, Laurelton, New York, United States|SJH Cardiology Associates, Liverpool, New York, United States|Long Island Heart Associates, Mineola, New York, United States|Mid Hudson Medical Research, PLLC, New Windsor, New York, United States|Manhattan Medical Research Practice, New York, New York, United States|Peters Medical Research NY, LLC, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|DiGiovanna Institute for Medical Education And Research, North Massapequa, New York, United States|Hudson Valley Cardiovascular Practice, PC, Poughkeepsie, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Institute for Clinical Studies, Rosedale, New York, United States|Saratoga Clinical Research, LLC, Saratoga Springs, New York, United States|Central New York Cardiology, Utica, New York, United States|Great Lakes Medical Research, Westfield, New York, United States|Buffalo Medical Group, Williamsville, New York, United States|Novant Health Clinical Research, Charlotte, North Carolina, United States|Novant Health Heart and Vascular Institute, Charlotte, North Carolina, United States|Sensenbrenner Primary Care, Charlotte, North Carolina, United States|NC Heart and Vascular, Clayton, North Carolina, United States|LeBauer Cardiovascular Research Foundation, Greensboro, North Carolina, United States|Clinical Trials of America, Inc., Hickory, North Carolina, United States|Carolina Cardiology Cornerstone, High Point, North Carolina, United States|Clinical Trials of America- NC, LLC, Lenoir, North Carolina, United States|Research Institute of the Carolinas of Piedmont Healthcare, PA, Mooresville, North Carolina, United States|Burke Primary Care, Morganton, North Carolina, United States|Eastern Nephrology Associates, New Bern, North Carolina, United States|Boice Willis Clinic, Rocky Mount, North Carolina, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|NC Heart and Vascular Research, Smithfield, North Carolina, United States|Piedmont Healthcare/Research, Statesville, North Carolina, United States|Wake Forest University Health Sciences Institutional Review Board, Winston-Salem, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Radiant Research, Inc, Akron, Ohio, United States|The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, United States|Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States|Radiant Research, Inc., Columbus, Ohio, United States|Optimed Research, LTD, Columbus, Ohio, United States|Dayton Heart Center, Dayton, Ohio, United States|Premier Health Specialists, Inc. (dba Dayton Heart Center), Dayton, Ohio, United States|PriMed Clinical Research, Dayton, Ohio, United States|Delaware Research Group, LLC, Delaware, Ohio, United States|North Ohio Heart Center (Administrative Only), Elyria, Ohio, United States|North Ohio Heart Center, Elyria, Ohio, United States|North Ohio Heart Center, Lorain, Ohio, United States|SV Research LLC, Marion, Ohio, United States|Office of Daniel G. Williams, MD, Perrysburg, Ohio, United States|North Ohio Heart Center, Inc., Sandusky, Ohio, United States|ProMedica Northwest Ohio Cardiology Consultants, Toledo, Ohio, United States|Mercy Health Youngstown, LLC d/b/a St. Elizabeth Youngstown Hospital, Youngstown, Ohio, United States|LION Research, Norman, Oklahoma, United States|LION Research, Norman, Oklahoma, United States|COR Clinical Research LLC, Oklahoma City, Oklahoma, United States|Oklahoma Heart Hospital Physicians, Oklahoma City, Oklahoma, United States|Oklahoma Heart Hospital Research Foundation, Oklahoma City, Oklahoma, United States|South Oklahoma Heart Research, LLC, Oklahoma City, Oklahoma, United States|Integrated Medical Research PC, Ashland, Oregon, United States|Hillsboro Cardiology, PC, Hillsboro, Oregon, United States|Portland Preventive Cardiology LLC, Portland, Oregon, United States|Abington Hosptial, Abington, Pennsylvania, United States|Clinical Research Associates of Central PA, Altoona, Pennsylvania, United States|Brandywine Clinical Research, Downingtown, Pennsylvania, United States|Doylestown Cardiology Associates - VIAA, Doylestown, Pennsylvania, United States|Doylestown Health Cardiology, a division of Doylestown Health Physicians, Doylestown, Pennsylvania, United States|Amh/Feasterville Family Health Care Center, Feasterville-Trevose, Pennsylvania, United States|Greater Pittsburgh Vascular, Jefferson Hills, Pennsylvania, United States|Detweiler Family Medicine and Associates, PC, Lansdale, Pennsylvania, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Family Medical Associates, Levittown, Pennsylvania, United States|Mercer Bucks Cardiology, Newtown, Pennsylvania, United States|Philadelphia Health Associates-Adult Medicine, Philadelphia, Pennsylvania, United States|Allegheny Endocrinology Associates, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group, PC, Sayre, Pennsylvania, United States|SFM Clinical Trials, Inc., Scotland, Pennsylvania, United States|Fay-West Family Practice, Scottdale, Pennsylvania, United States|Grand View - Lehigh Valley Health Services, Buxmont Cardiology Division, Sellersville, Pennsylvania, United States|Montgomery Medical, Inc., Smithfield, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Berks Cardiologists, Ltd., Wyomissing, Pennsylvania, United States|Coastal Cardiology, Charleston, South Carolina, United States|Upstate Pharmaceutical Research, Greenville, South Carolina, United States|Mountain View Clinical Research, Inc., Greer, South Carolina, United States|The Diabetes Center, LLC, Murrells Inlet, South Carolina, United States|Black Hills Cardiovascular-Regional Health Research, Rapid City, South Dakota, United States|Mid-Cumberland Infectious Disease Consultants, PLC, Clarksville, Tennessee, United States|Collierville Medical Specialists, Collierville, Tennessee, United States|Stern Cardiovascular Foundation, Inc., Germantown, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|New Phase Research & Development, Knoxville, Tennessee, United States|PMG Research,Inc d/b/a PMG Research of Knoxville, Knoxville, Tennessee, United States|Cardiovascular Research of Knoxville, Knoxville, Tennessee, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Baptist Memorial Medical Group, Inc., Memphis, Tennessee, United States|The Green Clinic, PC, Memphis, Tennessee, United States|Southwind Medical Specialists, Memphis, Tennessee, United States|Tennessee Center for Clinical Trials, Tullahoma, Tennessee, United States|Trinity Clinical Research, LLC, Tullahoma, Tennessee, United States|PharmaTex Research, Amarillo, Texas, United States|Arlington Family Research Center, Inc., Arlington, Texas, United States|Texas Diabetes & Endocrinology, Austin, Texas, United States|Austin Heart, PLLC, Austin, Texas, United States|Aztec Medical Research, LLC, Channelview, Texas, United States|Corsicana Medical Research, PLLC, Corsicana, Texas, United States|Protenium Clinical Research, LLC, Dallas, Texas, United States|VA North Texas Health Care System - Dallas VAMC, Dallas, Texas, United States|Baylor Heart and Vascular Institute, Dallas, Texas, United States|Dallas Diabetes and Endocrine Center, Dallas, Texas, United States|Cardiovascular Research Institute of Dallas, Dallas, Texas, United States|Radiant Research, Inc., Dallas, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|Doctors Hospital At Renaissance, Edinburg, Texas, United States|Amir Malik Research, Fort Worth, Texas, United States|The Medical Group Of Texas, Fort Worth, Texas, United States|Rockwood Medical Clinic, Fort Worth, Texas, United States|San Gabriel Clinical Research, LLC, Georgetown, Texas, United States|East Texas Cardiology PA, Houston, Texas, United States|Spring Clinical Research, Houston, Texas, United States|Med Tech Research, LP, Houston, Texas, United States|Prime Care Medical Group, Houston, Texas, United States|Associates in Medicine, PA, Houston, Texas, United States|Alan S. Hoffman, M.D., Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Investigational Product Shipment Address TO: Investigational Drug Services (IDS),, Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Northwest Houston Cardiology, Houston, Texas, United States|Texas Center For Drug Development, Inc., Houston, Texas, United States|Private Practice Leadership, LLC, Houston, Texas, United States|Protenium Clinical Research, Hurst, Texas, United States|South Texas Cardiovascular Consultants, PLLC, Kerrville, Texas, United States|Caprock Cardiac Center Research Institute Inc., Lubbock, Texas, United States|Midland Clinical Research Center, Midland, Texas, United States|Hill Country Medical Associates, New Braunfels, Texas, United States|North Hills Medical Research, Inc., North Richland Hills, Texas, United States|Grace Research, LLC, Palestine, Texas, United States|Med-Olam Clinical Research, Pasadena, Texas, United States|Austin Institute for Clinical Research, Inc., Pflugerville, Texas, United States|Austin Institute for Clinical Research,Inc., Pflugerville, Texas, United States|Centex Studies, Inc, Pharr, Texas, United States|Legacy Heart Center, Plano, Texas, United States|South Texas Cardiovascular Consultants, PLLC, San Antonio, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Southwest Clinic, San Antonio, Texas, United States|Victorium Clinical Research, San Antonio, Texas, United States|Bandera Family Health Care, LLC, San Antonio, Texas, United States|Northeast Clinical Research of San Antonio, LLC (NECRSA, LLC), Schertz, Texas, United States|Acacia Medical Research Institute, LLC, Sugar Land, Texas, United States|IP + Dry ice deliveries Sugar Lakes Family Practice, Sugar Land, Texas, United States|Sugar Lakes Family Practice, Sugar Land, Texas, United States|Northwest Houston Heart Center, Tomball, Texas, United States|Admin & Storage only:Northwest Heart Center, Tomball, Texas, United States|Northwest Heart Center, Tomball, Texas, United States|Northwest Houston Clinical Research, PLLC, Tomball, Texas, United States|Victoria Heart and Vascular Center, PA, Victoria, Texas, United States|Utah Cardiology, PC, Bountiful, Utah, United States|Utah Cardiology, P.C., Layton, Utah, United States|Paramount Medical Care, Ogden, Utah, United States|Aspen Clinical Research LLC, Orem, Utah, United States|Revere Health, Provo, Utah, United States|Optimum Clinical Research, Inc., Salt Lake City, Utah, United States|Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States|Holladay Family Practice, Salt Lake City, Utah, United States|Heart Center at St. Mark's Hospital, Salt Lake City, Utah, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Clinical Research Institute of Northern Virginia, Burke, Virginia, United States|Virginia Heart, Falls Church, Virginia, United States|Seven Corners Medical Research Center, Falls Church, Virginia, United States|Heart Care Associates, P.C., Hopewell, Virginia, United States|Virginia Research Center, Midlothian, Virginia, United States|Chippenham and Johnston Willis Hospitals, Inc. dba CJW Medical Center, Richmond, Virginia, United States|Retreat Cardiology LLC, dba Cardiology Associates of Richmond, Richmond, Virginia, United States|Roanoke Heart Institute, Roanoke, Virginia, United States|Hampton Roads Center for Clinical Research, Suffolk, Virginia, United States|Office of Daniel W. Gottlieb, MD, PS, Burien, Washington, United States|Premier Clinical Research, Spokane, Washington, United States|Universal Research Group, LLC, Tacoma, Washington, United States|Walla Walla Clinic, Walla Walla, Washington, United States|Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States|Exemplar Research Inc, Fairmont, West Virginia, United States|Prevea Clinic, Inc., Green Bay, Wisconsin, United States|Clinical Investigation Specialists, Inc., Kenosha, Wisconsin, United States|Waukesha Heart Foundation, Waukesha, Wisconsin, United States|Instituto de Investigaciones Clinicas Bahia Blanca, Bahia Blanca, Buenos Aires, Argentina|Hospital Italiano Regional del Sur, Bahia Blanca, Buenos Aires, Argentina|CIPREC - Centro de Investigacion y Prevencion Cardiovascular S.A., C.a.b.a., Buenos Aires, Argentina|Hospital Britanico De Buenos Aires, Ciudad Autonoma de B. Aires, Buenos Aires, Argentina|Investigaciones Medicas IMOBA S.R.L., Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|CEDIC - Consultorios Medicos, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Clinica Coronel Suarez S.A., Coronel Suarez, Buenos Aires, Argentina|Framingham Centro Medico, La Plata, Buenos Aires, Argentina|CIMeL CHAHIN CHAHIN S.A., Lanus Este, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Mar del Plata, Mar del Plata, Buenos Aires, Argentina|DIM Clinica Privada, Ramos Mejia, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Zarate, Zarate, Buenos Aires, Argentina|Consultorios Asociados de Endocrinologia e Investigacion Clinica Aplicada, C.a.b.a, C.a.b.a., Argentina|STAT Research S.A., C.a.b.a, Caba, Argentina|Clinica Privada de Especialidades Medicas, Villa Maria, Cordoba, Argentina|CIPADI Centro Integral de Prevencion y Atencion en Diabetes, Godoy Cruz, Mendoza, Argentina|IMEP Instituto Medico Elsa Perez, Ciudadela, PCIA DE Buenos Aires, Argentina|Instituto Medico Aguero, Moron, PCIA DE Buenos Aires, Argentina|Cordis - Instituto del Corazon, Resistencia, PCIA DE Chaco, Argentina|Hospital de Alta Complejidad ""Pte. Juan Domingo Peron"", Formosa, PCIA DE Formosa, Argentina|Hospital Provincial Dr. Jose Maria Cullen, Santa Fe, PCIA DE Santa FE, Argentina|Centro De Investigaciones Clinicas Del Litoral S.R.L., Santa Fe, PCIA DE Santa FE, Argentina|Cedir S.A - Centro De Diagnostico Y Rehabilitacion S.A., Santa Fe, PCIA DE Santa FE, Argentina|Centro Modelo de Cardiologia, San Miguel De Tucuman, PCIA DE Tucuman, Argentina|Instituto de Hematologia y Medicina Clinica ""Dr. Ruben A. Davoli"", Rosario, Pcia. DE Santa FE, Argentina|Instituto Medico Ceniclar - Central De Investigaciones Clinicas Argentina - Sanatorio De La Mujer, Rosario, Provincia DE Santa FE, Argentina|Centro Medico CCBR Tucuman, San Miguel de Tucuman, Tucuman, Argentina|Cicemo - Consultorio de Investigaciones Clinicas E.M.O. S.R.L., Ciudad Autonoma De B. Aires, Argentina|Instituto Cardiovascular De Buenos Aires, Ciudad Autonoma de B. Aires, Argentina|Universidad Maimonides, Ciudad Autonoma De Buenos Aires, Argentina|Centro de Investigacion: AXISMED S.R.L., Ciudad Autonoma de Buenos Aires, Argentina|ILAIM Instituto Latinoamericano de Investigaciones Medicas, Cordoba, Argentina|Clinico Chutro SRL, Cordoba, Argentina|Centro de Investigaciones Clinicas ""Instituto del Corazon"", Cordoba, Argentina|Clinica Privada Colombo, Cordoba, Argentina|Instituto Medico DAMIC S.R.L., Cordoba, Argentina|Centro Medico Luquez, Cordoba, Argentina|IPAC Caraffa, Cordoba, Argentina|Instituto de Cardiologia de Corrientes ""Juana Fca. Cabral"", Corrientes, Argentina|Hospital Central de Mendoza, Mendoza, Argentina|Cordis S.A., Salta, Argentina|Centro Cardiovascular Salta, Salta, Argentina|Instituto Cardiovascular San Luis A.E., San Luis, Argentina|Boden Institute of Obesity, Nutrition, Exercise and Eating Disorders, Camperdown, New South Wales, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Central Coast Neurosciences Research, Erina, New South Wales, Australia|Central Coast Local Health District, Gosford Hospital, Gosford, New South Wales, Australia|Australian Clinical Research Network, Maroubra, New South Wales, Australia|Holy Spirit Northside Private Hospital Limited, Chermside, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Core Research Group Pty Ltd, Milton, Queensland, Australia|Redcliffe Hospital, Redcliffe, Queensland, Australia|Austrials Pty Ltd, Sherwood, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|Adelaide Medical Research, Ashford, South Australia, Australia|SA Heart, Ashford, South Australia, Australia|Southern Adelaide Diabetes and Endocrine Service, Daws Park, South Australia, Australia|Department of Cardiology, Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Heart and Vascular Research, Fullarton, South Australia, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Eastern Health - Box Hill Hospital, Box Hill, Victoria, Australia|The Northern Hospital, Epping, Victoria, Australia|Barwon Health-The Geelong Hospital, Geelong, Victoria, Australia|Austin Health - Heidelberg Repatriation Hospital, Heidelberg West, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Fremantle Hospital, Fremantle, Western Australia, Australia|HPS Pharmacies, Joondalup, Western Australia, Australia|Joondalup Cardiovascular Trials Foundation Inc., Joondalup, Western Australia, Australia|VZW Algemeen Ziekenhuis KLINA, Brasschaat, Antwerpen, Belgium|AZ Sint-Maarten, Mechelen, Antwerp, Belgium|Algemeen Stedelijk Ziekenhuis, Aalst, Oost-vlaanderen, Belgium|Az Sint Blasius, Dendermonde, Oost-vlaanderen, Belgium|AZ Sint Lucas Gent, Gent, Oost-vlaanderen, Belgium|Universitair Ziekenhuis Gent, Gent, Oost-vlaanderen, Belgium|Az Glorieux, Ronse, Oost-vlaanderen, Belgium|AZ Nikolaas, Campus Moerland, Sint-Niklaas, Oost-vlaanderen, Belgium|AZ Groeninge-Campus Loofstraat, Kortrijk, West-vlaanderen, Belgium|Az Damiaan, Oostende, West-vlaanderen, Belgium|ZNA Campus Middelheim, Antwerpen, Belgium|Imeldaziekenhuis Bonheiden, Bonheiden, Belgium|A.Z. St.Jan AV Brugge, Brugge, Belgium|University Hospital Brussels - Centrum voor hart- en vaatziekten, Brussels, Belgium|University Hospital Brussels- Diabeteskliniek, Brussels, Belgium|Private Practice 'Cardiovascular Detection Center', De Pinte, Belgium|ZOL Campus Sint-Jan, Genk, Belgium|AZ Maria Middelares, Gent, Belgium|Grand Hopital de Charleroi, Site St-Joseph, Gilly, Belgium|Hygeia, Hasselt, Belgium|Jessa Ziekenhuis, Hasselt, Belgium|Sint-Franciskusziekenhuis, Heusden-Zolder, Belgium|Centre Hospitalier Regional de Huy, Huy, Belgium|Jan Yperman Ziekenhuis, Cardiology, Ieper, Belgium|Centre Hospitalier De Jolimont - Lobbes, La Louviere (Haine-Saint-Paul), Belgium|Centre Hospitalier de Jolimont-Lobbes, La Louviere (Haine-Saint-Paul), Belgium|University hospitals Leuven - Neurology department, Leuven, Belgium|University hospitals Leuven, Leuven, Belgium|Centre Hospitalier Universitaire (CHU) de Liege, Liege, Belgium|Huisartsenpraktijk Medilink, Linkebeek, Belgium|Huisartsenpraktijk Luc Capiau, Massemen, Belgium|C.H.U. Ambroise Pare, Mons, Belgium|Mariaziekenhuis vzw, Overpelt, Belgium|Dr. Luc De Wolf - Private Practice, Tienen, Belgium|Fundacao Bahiana De Cardiologia, Salvador, BA, Brazil|HBA S/A ASSISTENCIA MEDICA E HOSPITALAR-Hospital da Bahia, Salvador, BA, Brazil|Centro de Pesquisas em Diabetes e Doencas Endocrino-Metabolicas Ltda, Fortaleza, CE, Brazil|Covance Central Laboratory Services, Indianapolis, Indiana, Brazil|CARDSEARCH/CARDRESEARCH - Cardiologia Assistencial e de Pesquisa LTDA, Belo Horizonte, Minas Gerais, Brazil|Nucleo de Pesquisa Clínica, Curitiba, Parana, Brazil|Universidade Federal do Para - Hospital Universitario Joao de Barros Barreto, Belem, PA, Brazil|Hospital Agamenon Magalhaes, Recife, Pernambuco, Brazil|Centro de Pesquisas Medicas Basica e Clinica LTDA, Recife, PE, Brazil|Sociedade Hospitalar Angelina Caron/Hospital e Maternidade Angelina Caron, Campina Grande do Sul, PR, Brazil|Hospital Santa Casa de Curitiba, Curitiba, PR, Brazil|Quanta Diagnostico e Terapia / Medicina Nuclear Alto da XV, Curitiba, PR, Brazil|Hospital Universitario - Associacao Educadora Sao Carlos - AESC, Canoas, RIO Grande DO SUL, Brazil|Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital Mae de Deus/Associacao Educadora Sao Carlos AESC / IMV - Instituto de Medicina Vascular, Porto Alegre, RIO Grande DO SUL, Brazil|Instituto de Cardiologia do Rio Grande do Sul / Fundacao Universitaria de Cardiologia, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital Mae de Deus - Instituto do Cancer, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital Mae de Deus-Associacao Educadora de Sao Carlos-AESC/IMV - Instituto de Medicina Vascular, Porto Alegre, RIO Grande DO SUL, Brazil|Mae de Deus - Centro de Oncologia Radioterapica (COR), Porto Alegre, RIO Grande DO SUL, Brazil|CCBR Brasil - Centro de Pesquisa e Analises Clinicas LTDA, Rio de Janeiro, RJ, Brazil|Hospital Santa Isabel, Blumenau, Santa Catarina, Brazil|Loema Medicina e Bem Estar- Centro Especializado em Cardiologia Ltda., Campinas, SAO Paulo, Brazil|IMC - Instituto de Molestias Cardiovasculares/Equipamentos Cardiovasculares Rio Preto Ltda, Sao Jose do Rio Preto, SAO Paulo, Brazil|CAEP - Centro Avançado de Estudos e Pesquisas Ltda., Campinas, SP, Brazil|Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HC-FMUSP), Sao Paulo, SP, Brazil|CARDSEARCH/CARDRESEARCH - Cardiologia Assistencial e de Pesquisa LTDA, Minas Gerais, Brazil|CPClin- Centro de Pesquisas Clinicas Ltda./Clinica Dr. Freddy Goldberg Eliaschewitz, Sao Paulo, Brazil|FGM-Clinica Paulista de Doencas Cardiovasculares, Sao Paulo, Brazil|CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda, Sao Paulo, Brazil|LMC Diabetes & Endocrinology (Calgary), Calgary, Alberta, Canada|Foothills Hospital/University of Calgary, Calgary, Alberta, Canada|Nanji Professional Corporation, Calgary, Alberta, Canada|The Medical Arts Health Research Group, Kelowna, British Columbia, Canada|Kelowna Cardiology Associates, Kelowna, British Columbia, Canada|Dr. Raymond Dong Inc., Surrey, British Columbia, Canada|Dr. Richard Bon Inc. & Dr. Adam Yeung Inc., Surrey, British Columbia, Canada|Dr. Stephen S. Cheung Inc., Surrey, British Columbia, Canada|SMH Cardiology Clinical Trials, Surrey, British Columbia, Canada|Dr. Dante E. Manyari Inc., Surrey, British Columbia, Canada|Dr. Stephanie Au, Inc., Surrey, British Columbia, Canada|Dr. Stephen Pearce Inc. & Dr. Peter K.H. Tan Inc., Surrey, British Columbia, Canada|SMH Cardiology Clinical Trials Inc, Surrey, British Columbia, Canada|Dr. Adam Yeung Inc., Surrey, British Columbia, Canada|Dr. Michael Kanakos Inc., Surrey, British Columbia, Canada|Dr. Stephen S. Cheung Inc., Surrey, British Columbia, Canada|Dr. Kapil M. Bhagirath Medical Services Corporation, Surrey, British Columbia, Canada|Victoria Heart Institute Foundation, Victoria, British Columbia, Canada|Discovery Clinical Services Ltd., Victoria, British Columbia, Canada|St. Boniface Hospital, Winnipeg, Manitoba, Canada|G.A. Research Associates Ltd., Moncton, New Brunswick, Canada|Cardiology Research Associates of New Brunswick, Saint John, New Brunswick, Canada|Health Sciences Centre, St. John's, NF, Canada|Health Science Centre, St. John's, NF, Canada|LMC Diabetes & Endocrinology (Brampton), Brampton, Ontario, Canada|Aviva Clinical Trial Group Inc., Burlington, Ontario, Canada|JBN Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Philippe R. Beaudry Medicine Professional Corporation, Burlington, Ontario, Canada|Cambridge Cardiac Care Centre, Cambridge, Ontario, Canada|Vizel Cardiac Research - Saul Vizel Professional Medicine Corporation, Cambridge, Ontario, Canada|Moran Medical Centre, Collingwood, Ontario, Canada|C & L Research, Fort Erie, Ontario, Canada|Parkdale Medical Centre, Hamilton, Ontario, Canada|Stroke Prevention & Atherosclerosis Research Centre (SPARC), London, Ontario, Canada|Western University - WCPHFM, London, Ontario, Canada|LMC Diabetes & Endocrinology (Markham), Markham, Ontario, Canada|Newmarket Cardiology Research Group, Newmarket, Ontario, Canada|LMC Clinical Research Inc. (Oakville), Oakville, Ontario, Canada|The Office of Dr. James Cha, Oshawa, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|London Road Diagnostic Clinic and Medical Centre, Sarnia, Ontario, Canada|Sarnia Institute of Clinical Research, Sarnia, Ontario, Canada|Scarborough Cardiology Research Associates Inc., Scarborough, Ontario, Canada|Canadian Centre for Research on Diabetes, Smiths Falls, Ontario, Canada|Brian Y.L. Wong Medicine Professional Corporation, Sudbury, Ontario, Canada|LMC Diabetes & Endocrinology (Thornhill), Thornhill, Ontario, Canada|JJ Dig Research LTD, Toronto, Ontario, Canada|Canadian Phase Onward, Inc., Toronto, Ontario, Canada|LMC Diabetes & Endocrinology (Bayview), Toronto, Ontario, Canada|Dr. Anil K. Gupta Medicine Professional Corporation, Toronto, Ontario, Canada|Dr. Mohan Babapulle Medicine Professional Cooperation, Waterloo, Ontario, Canada|Dr. Louis Yao, MD Office of, Weston, Ontario, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|Q & T Research Chicoutimi, Chicoutimi, Quebec, Canada|Q&T Recherche Outaouais Inc., Gatineau, Quebec, Canada|Omnispec Recherche Clinique Inc., Mirabel, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Diex Research Montreal, Inc., Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke - Hotel-Dieu, Sherbrooke, Quebec, Canada|Centre integre de sante et de services sociaux de Lanaudiere (CISSSL), St-Charles-Borromee, Quebec, Canada|Centre Integre de Sante et de services sociaux de Chaudiere-Appalaches (CISSA-CA) -, St-Georges, Beauce, Quebec, Canada|CISSS des Laurentides-Point de Service de St-Jerome- Comite d'ethique de la recherche, St-Jerome, Quebec, Canada|St-Jerome Medical Research Inc., St-Jerome, Quebec, Canada|C.I.C. Mauricie Inc., Trois-Rivieres, Quebec, Canada|LMC Clinical Research Inc. (Montreal), Ville Saint-Laurent, Quebec, Canada|Recherche Clinique Sigma inc, Quebec, Canada|Clinique des maladies lipidiques de Quebec, Quebec, Canada|Biomedica Research Group, Providencia Santiago, Metropolitana, Chile|CICAB, Santiago, Metropolitana, Chile|SMOLAM, Santiago, Metropolitana, Chile|Complejo Asitencial Dr. Sotero del Rio, Santiago, Metropolitana, Chile|Centro de Investigacion Clínica del Sur, Temuco, Region DE LA Araucania, Chile|Corporacion de Beneficencia Osorno, Osorno, Region DE LOS Lagos, Chile|Servicios Medicos Godoy, Santiago, Region Metropolitana, Chile|Quantum Research, Puerto Varas, Chile|Hospital y CRS El Pino, Santiago, Chile|Hospital Pablo Tobon Uribe, Medellin, Antioquia, Colombia|Rodrigo Botero S.A.S, Medellin, Antioquia, Colombia|Centro de Investigacion Clinica Avanzada y Multidisciplinaria CICLAM, Medellin, Antioquia, Colombia|Centro de Medicina del Ejercicio y Rehabilitacion Cardiaca S.A. CEMDE S.A., Medellin, Antioquia, Colombia|Clinica de la Costa LTDA, Barranquila, Atlantico, Colombia|Centro Cientifico Asistencial Jose Luis Accini S.A.S., Barranquilla, Atlantico, Colombia|Corazon Ips S.A.S., Barranquilla, Atlantico, Colombia|Corozan Ips Sas, Barranquilla, Atlantico, Colombia|Fundacion del Caribe para la Investigacion Biomedica - Fundacion BIOS, Barranquilla, Atlantico, Colombia|Centro de Diagnostico Cardiologico LTDA., Cartagena, Bolivar, Colombia|Asociacion IPS Medicos Internistas de Caldas, Manizales, Caldas, Colombia|MedPlus Medicina Prepagada S.A., Bogota D.C., Cundinamarca, Colombia|Solano & Terront Servicios Medicos Ltda-Establecimiento Comercial UNIENDO, Bogota D.C., Cundinamarca, Colombia|Dexadiab Servicios Medicos LTDA, Bogota D.C, Cundinamarca, Colombia|Caja de Compensacion Familiar CAFAM, Sede Centro de Atencion en Salud CAFAM FLORESTA, Bogota D.C, Cundinamarca, Colombia|Hospital Universitario San Ignacio, Bogota D.C, Cundinamarca, Colombia|Instituto de Investigacion Endocrinologia y Prevencion Metabolica - ENDOCARE LTDA., Bogota D.C, Cundinamarca, Colombia|Instituto del Corazon de Bucaramanga S.A., Bucaramanga, Santander, Colombia|Fundación Cardiovacular de Colombia - Instituto del Corazón de Floridablanca, Floridablanca, Santander, Colombia|Fundacion Reina Isabel, Cali, Valle DEL Cauca, Colombia|FREMLOVA APHOTECA s.r.o., Litovel, Czech Republic, Czechia|BENU Lekarna, Pardubice, Czech Republic, Czechia|Kardiologicka Ambulance, Brno, Jihomoravsky KRAJ, Czechia|EDUMED s.r.o., Broumov, Kralovehradecky KRAJ, Czechia|Edumed S.R.O., Jaromer, Kralovehradecky KRAJ, Czechia|Kardiologicka ambulance, Trutnov, Kralovehradecky KRAJ, Czechia|Lekarna na Poliklinice, Trutnov, Kralovehradecky KRAJ, Czechia|MUDr. Jan Vrkoc s.r.o., Ostrava, Moravskoslezsky KRAJ, Czechia|Pv-Kardiologie S.R.O., Pardubice, Pardubicky KRAJ, Czechia|CCBR Czech Brno, s.r.o., Brno, Czechia|DIKa centrum s.r.o., Kardiologicka a interni ambulance, Havirov, Czechia|Fakultni nemocnice Hradec Kralove, III. Interni gerontometabolicka klinika, Hradec Kralove, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Kardio interna s.r.o., Litovel, Czechia|Fakultni Nemocnice Olomouc, Olomouc, Czechia|Fakultni Nemocnice Olomouc, Olomouc, Czechia|CCBR Czech a.s., Pardubice, Czechia|Kardiologie Plzen s.r.o., Plzen, Czechia|Fakultni poliklinika Vseobecne fakultni nemocnice v Praze, Praha 2, Czechia|CCBR Czech Prague, s.r.o, Praha 3, Czechia|Kardiologie a interni lekarstvi, Praha 5, Czechia|NEFROMED, s.r.o., Praha 6, Czechia|Centrum kardiovaskularni prevence 1. LF UK a TN, Praha, Czechia|Interna a kardiologie s.r.o., Roznov pod Radhostem, Czechia|Nemocnice Pardubickeho kraje, a.s., Svitavska nemocnice, Svitavy, Czechia|Vseobecna kardiologicka ambulance s.r.o., Tabor, Czechia|Lekarna U Nemocnice, Tabor, Czechia|MUDr. Antonin Dufka, kardiologicka ambulance, Uherske Hradiste 1, Czechia|MUDr. Nina Zemkova s.r.o., Uherske Hradiste 1, Czechia|Lekarna Hradebni s.r.o., Uherske Hradiste, Czechia|KIGE s.r.o., Znojmo, Czechia|Sygehus Sonderjylland Aabenraa, Aabenraa, Denmark|Aalborg Universitetshospital, Lipidklinikken, Aalborg, Denmark|CCBR Aalborg, Aalborg, Denmark|Aarhus Universitetshospital, Aarhus N, Denmark|Aarhus Universitetshospital Skejby, Hjertesygdomme ¿ Klinisk Forskning, Aarhus, Denmark|CCBR Ballerup, Ballerup, Denmark|Bispebjerg og Frederiksberg Hospital, Copenhagen NV, Denmark|Rigshospitalet, Copenhagen Oe, Denmark|Sydvestjysk Sygehus, Esbjerg, Denmark|Frederiksberg Hospital, Frederiksberg, Denmark|Glostrup Hospital, Glostrup, Denmark|Herlev Universitetshospital, Kardiologisk afdeling S, Herlev, Denmark|Regionshospitalet Herning, Herning, Denmark|Hillerod Hospital, Hillerod, Denmark|Hvidovre Universitetshospital, Hjerte-lungemedicinsk afdeling, Hvidovre, Denmark|Amager Hospital, Kobenhavn S., Denmark|Region Sjaelland Sygehus Nord, Koge Sygehus, Koge, Denmark|Kolding Sygehus, Kolding, Denmark|Region Sjaelland Naestved Sygehus, Naestved, Denmark|Nykobing F. Sygehus-Medicinsk afdeling, Nykobing F., Denmark|Regionshospitalet Randers, Randers, Denmark|Regionshospitalet Silkeborg, Hjerte Projektkontor, Silkeborg, Denmark|Slagelse Sygehus, Slagelse, Denmark|Svendborg Sygehus, Svendborg, Denmark|CCBR Vejle, Vejle, Denmark|Hospitalsenheden Midt, Regionshospital Viborg, Viborg, Denmark|Linnan Klinikka Oy, Hameenlinna, Finland|Mehilainen Toolo, Helsinki, Finland|Helsinki University Central Hospital, Helsinki, Finland|Helsingin yliopistollinen keskussairaala, Sisaetaudit ja kuntoutus, Biomedicum 2U, Helsinki, Finland|Ita-Suomen laakarikeskus Oy, Joensuu, Finland|Studycor Oy, Jyvaskyla, Finland|Laeaekaerikeskus Aava Kerava, Kerava, Finland|Menoa oy, Kinkomaa, Finland|Kokkolan Keskussairaala, Kokkola, Finland|Mewell liikuntaklinikka, Kotka, Finland|Itae-Suomen Laeaekaeritalo Oy, Kuopio, Finland|Terveystalo Kuopio, Kuopio, Finland|Oulu Mentalcare Oy, Oulu, Finland|Terveystalo Oulu, Diapolis, Oulu, Finland|Oulu University Hospital, Oulu, Finland|Porin Laakaritalo Oy, Pori, Finland|Terveystalo Siilinjarvi, Siilinjarvi, Finland|FinnMedi Oy, Tampere, Finland|Terveystalo Pulssi, Turku, Finland|Turku University Hospital, Turku, Finland|Vantaan Tutkimuskeskus, Vantaa, Finland|CHU Jean Minjoz Cardiologie, Besancon, France|Centre Hospitalier De Bourg En Bresse - Hopital Fleyriat, Bourg En Bresse Cedex 10000, France|CHU de Caen, Caen cedex 9, France|Centre Hospitalier de Cannes- Service de Cardiologie, Cannes Cedex, France|Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France|Scp Cardiovasculaire De L'Est, Essey-Les-Nancy, France|Centre Hospitalier Louis Pasteur, Le Coudray, France|Hopital La Louviere, Lille, France|Centre Hospitalier Saint Philibert, Lomme, France|Hopital Cardiovasculaire Et Pneumologique Louis Pradel, Lyon Cedex 03, France|Hopital Arnaud de Villeneuve, Montpellier cedex 5, France|CHU de Nantes - Hopital Nord Laennec, Nantes, France|Nouvelles Cliniques Nantaises, Nantes, France|CHU Caremeau, Nimes cedex 9, France|CHU Caremeau, Nimes, France|Centre Hospitalier de PAU, PAU, France|Hopital Cardiologique, Pessac cedex, France|CHU de Poitiers, Poitiers cedex, France|CHU de Renes Hopital de Pontchaillou, Rennes Cedex 9, France|CHU de Toulouse, Toulouse cedex 9, France|Hopital Guy Chatiliez, Tourcoing, France|Hopital Trousseau, Tours Cedex 9, France|Centre Hospitalier (CH) de Valenciennes, Valenciennes, France|Polyclinique Vauban, Valenciennes, France|Universitaets Herzzentrum Freiburg Bad Krozingen, Bad Krozingen, Baden-wuerttemberg, Germany|Medizinische Universtatsklinik Heidelberg, Heidelberg, Baden-wurttemberg, Germany|Ze:ro Arztpraxen, Mannheim, Baden-wurttemberg, Germany|Gemeinschaftspraxis im Altstadt Carree, Fulda, Hessen, Germany|Klinische Forschung Schwerin GmbH, Schwerin, Mecklenburg-vorpommern, Germany|Zentrum Klinische Studien Neuwied (ZKSN), Neuwied, Rheinland Pfalz, Germany|Gemeinschaftspraxis Schwabenheim, Schwabenheim, Rhineland-palatinate, Germany|Klinikum Altenburger Land Gmbh, Altenburg, Germany|Zentralklinik Bad Berka GmbH, Bad Berka, Germany|Forschungszentrum Dr. med Irma Schoell, Bad Homburg, Germany|Institut fuer Klinische Forschung und Entwicklung(IKFE) Berlin GmbH, Berlin, Germany|Klinische Forschung Berlin-Mitte GmbH, Berlin, Germany|POLIKUM Institut GmbH, Berlin, Germany|DRK Kliniken Kopenick, Zentrum Klinische Forschung, Berlin, Germany|Berlin Research Centre-Synexus Clinical Research GmbH, Berlin, Germany|Synexus Clinical Research GmbH, Berlin, Germany|Deutsches Herzzentrum Berlin, Berlin, Germany|Medizinisches Versorgungszentrum am Bahnhof Spandau, Berlin, Germany|Klinikum Bielefeld, Bielefeld, Germany|Bochum Research Centre-Synexus Clinical Research GmbH, Bochum, Germany|MediClin Reha-Zentrum Spreewald, Burg-Spreewald, Germany|Klinikum Coburg, Coburg, Germany|HELIOS Amper-Klinikum Dachau, Dachau, Germany|Kardiologische Praxisgemeinschaft, Dortmund, Germany|St. Johannes-Hospital, Dortmund, Germany|Gemeinschaftspraxis fuer Kardiologie Dres. Med. Willgeroth/Wetzel, Dortmund, Germany|Klinsche Forschung Dresden GmbH, Dresden, Germany|Praxis Dr. med. Christoph Axthelm, Dresden, Germany|GWT-TUD GmbH, Studienzentrum Professor Hanefeld, Dresden, Germany|Gemeinschaftspraxis Dr. Hagemann/Breiderhoff/Durfeld, Essen, Germany|Medizentrum Essen Borbeck, Essen, Germany|Studienzentrum, Essen, Germany|Gemeinschaftspraxis Dres. Dirk Weber, Ulrich Weber, Heiner Saueressig, Birte Turner und Georg, Essen, Germany|Schwerpunktpraxis Dr. Luedemann fuer Diabetes Gefaess- und Ernaehrungsmedizin, Falkensee, Germany|IKF Institut fuer klinische Forschung Frankfurt, Frankfurt am Main, Germany|Clinphenomics Gmbh & Co Kg, Studienzentrum, Frankfurt, Germany|Synexus Clinical research GmbH, Frankfurt, Germany|Klinik und Poliklinik fuer Innere Medizin B-Kardiologie, Angiologie, Pulmologie, Internistische, Greifswald, Germany|Cardiologicum Hamburg, Hamburg, Germany|Praxis Dr. med Cornelia Brauer, Hamburg, Germany|Klinische Forschung Hannover-Mitte GmbH, Hannover, Germany|Universitatsklinikum des Saarlandes Klinik fur Innere Medizin III, Homburgsaar, Germany|Praxis Dr. Heister, Kamp-Lintfort, Germany|Studienzentrum Dr. Appel, Kassel, Germany|Zentrum fuer klinische Forschung, Koeln, Germany|Gemeinschaftspraxis Dr. Klein / Minnich, Kuenzing, Germany|Klinik fur Innere Medizin, Kardiologie und Angiologie MediClin Herzzentrum Lahr/Baden., Lahr, Germany|Synexus Clinical research GmbH, Leipzig, Germany|Synexus Leipzig Clinical Research Centre, Leipzig, Germany|Polikum Institut Leipzig GmbH, Leipzig, Germany|Gemeinschaftspraxis Dr. med. Heidrun Taeschner und Dr. med. Susanne Bonigut, Leipzig, Germany|Maerkische Kliniken GmbH, Klinikum Luedenscheid, Innere III, Luedenscheid, Germany|Klinikum Lunen, St. Marienhospital, Lunen, Germany|SMO.MD GmbH - Zentrum fÃ¼r klinische Studien, Magdeburg, Germany|SMO.MD GmbH, Zentrum fuer klinische Studien Site Management and Clinical Research Unit, Magdeburg, Germany|Pfuetzner Science & Health Institute-Gmbh, Mainz, Germany|Klinikum fuer Herz- & Kreislauferkrankungen, Muenchen, Germany|Klinikum Der Universitat Munchen, Munchen, Germany|Staedtisches Klinikum Muenchen GmbH, Munich, Germany|Kardiologische Praxis Northeim, Northeim, Germany|Gemeinschaftspraxis Drs Haggenmiller/Jeserich, Kardiologie, Angiologie, Innere Medizin, Nurnberg, Germany|Allgemeinmedizinisch-Internistische Praxisgemeinschaft, Offenbach, Germany|Praxis Dres. Med Naudts und Nowack, Rodgau, Germany|Klinik am See Rehabilitationszentrum fur Innere Medizin, Rudersdorf, Germany|Kardiologische Gemeinschaftspraxis Dres Med. Gerke/Burger, Soest, Germany|Praxisgemeinschaft Stuhr-Brinkum, Stuhr-Brinkum, Germany|Robert-Bosch-Krankenhaus, Stuttgart, Germany|Josephs-Hospital Warendorf Med. Klinik II, Kardiologie/Angiologie, Warendorf, Germany|Kardiologische Praxis, Wermsdorf, Germany|ForschungszentrumRuhr KliFoCenter GmbH, Witten, Germany|Bacs-Kiskun Megyei Korhaz, Kecskemet, Bacs-kiskun, Hungary|Pecsi Tudomanyegyetem AOK, II., Pecs, Baranya, Hungary|Szegedi Tudomanyegyetem AOK, I. sz Belgyogyaszati Klinika, Szeged, Csongrad, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Szekesfehervar, Fejer, Hungary|DRC Kft., Balatonfured, Hungary|DRC Kft., Balatongyorok, Hungary|Kardiologiai Maganrendelo, Bekescsaba, Hungary|Grof Tisza Istvan Korhaz Berettyoujfalu, Berettyoujfalu, Hungary|Budapesti Szent Ferenc Korhaz, Budapest, Hungary|Synexus Magyarorszag Kft, Budapest, Hungary|Szent Rokus Korhaz, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Gottsegen Gyorgy Orszagos Kardiologiai Intezet, Budapest, Hungary|Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary|Egyesitett Szent Istvan Korhaz es Szent Laszlo Korhaz, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak, III. Belgyogyaszat-Kardiologiai Osztaly, Budapest, Hungary|Debreceni Egyetem, Debrecen, Hungary|Synexus Magyarorszag Kft., Gyula, Hungary|Edes Szivunk Egeszsegkozpont Kft., Hajduszoboszlo, Hungary|BKS Research Kft., Albert Schweitzer Korhaz, Hatvan, Hungary|Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvar, Hungary|Jutrix Egeszsegugyi Kft, Kecskemet, Hungary|Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Josa Andras Oktatokorhaz, Nyiregyhaza, Hungary|Medifarma-98 Kft., Nyiregyhaza, Hungary|Pecsi Tudomanyegyetem AOK, I. Belgyogyaszati Klinika, Pecs, Hungary|Mentahaz Maganorvosi Kozpont, Szekesfehervar, Hungary|Hetenyi Geza Korhaz, Szolnok, Hungary|Markusovszky Egyetemi Oktatokarhaz, Szombathely, Hungary|Dr. Sydo es Tsa Kft., Veszprem, Hungary|Zala Megyei Korhaz, Diabetológiai Szakrendelés, Zalaegerszeg, Hungary|Zala Megyei Korhaz, Zalaegerszeg, Hungary|Dr. Jivraj Mehta Smarak Health Foundation, Bakeri Medical Research Centre, Ahmedabad, Gujarat, India|Apex Heart Institute (A Unit of TCVS Pvt. Ltd), Ahmedabad, Gujarat, India|SAL Hospital, Ahmedabad, Gujarat, India|Apple Hospital, Surat, Gujarat, India|Unicare Heart Institute & Research Center, Surat, Gujarat, India|BAPS - Pramukh Swami Hospital, Surat, Gujarat, India|Rhythm Heart Institute, Vadodara, Gujarat, India|Jehangir Clinical Development Centre Pvt. Ltd., Pune, Maharashtra, India|M.V. Hospital And Research Centre, Lucknow, Uttar Pradesh, India|Beaumont Hospital, Dublin, Leinster, Ireland|St James's Hospital, Dublin, Ireland|Tel Aviv Sourasky Medical Center, Tel Aviv, Tel-aviv, Israel|Barzilai Medical Center, Ashkelon, Israel|Ben Yair Community Clinic - Clalit Health Services, Beer Sheva, Israel|Heart Institute, Hillel Yaffe Medical Center, Hadera, Israel|Rambam Medical Center, Haifa, Israel|Cardiovascular Clinical Research Institute, Haifa, Israel|Edith Wolfson Medical Center, Holon, Israel|Hadassah Ein Kerem Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Sava, Israel|Meir Medical Center, Kfar-Saba, Israel|Galilee Medical Center, Cardiology Department, Nahariya, Israel|E.M.M.S Nazareth Hospital, Nazareth, Israel|Sha'aria Clinic, Clalit Health Services, Petach Tikva, Israel|Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel|Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel|Rabin Medical Center, Petah Tikva, Israel|Shuali Community Clinic, Clalit Health Services, Raanana, Israel|Department of Neurology & Sagol Neuroscience Center, Ramat Gan, Israel|Heart Institute, Kaplan Medical Center, Rehovot, Israel|Kaplan Medical Center Metabolism and Diabetes Clinic, Kaplan Medical Center, Rehovot, Israel|Internal Medicine A, Ziv Medical Center, Safed, Israel|Ziv Medical Center, Safed, Israel|Assuta Medical Center, Tel Aviv, Israel|The Chaim Sheba Medical Center, Tel Hashomer, Israel|Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel|A.O. Treviglio e Caravaggio, Treviglio (BG), Bergamo, Italy|AOU Policlinico ""Mater Domini"" UOC di Medicina Interna, Catanzaro, CZ, Italy|Covance Central Laboratory Services, Meyrin/Geneve, Geneve, Italy|Ospedale S. L. Mandic di Merate, Merate, Lecco, Italy|Dipartimento delle Patologie Emergenti, Unita di Medicina Interna e Dislipidemie Genetiche, Palermo, PA, Italy|Ospedale S. Maria della Misericordia -Dipartimento di Medicina, Medicina Interna,, Perugia, PG, Italy|Azienda Ospedaliera Della Provincia Di Lecco - Ospedale Manzoni, Lecco, Province OF Lecco, Italy|Dip Medicina Interna e Specialita Mediche, Policlinico Umberto I, Roma, RM, Italy|Policlinico Umberto I di Roma, Rome, RM, Italy|Azienda Ospedaliera S'Andrea di Roma - UOC Cardiologia, Rome, RM, Italy|Ospedale G. Fracastoro, San Bonifacio, Verona, Italy|AOUI di Verona - Ospedale Civile Maggiore Borgo Trento, Verona, VR, Italy|S. C. Cardiologia INRCA, Ancona, Italy|Ospedale Civile Regionale San Martino, Belluno, Belluno, Italy|Azienda Ospedaliera G. Brotzu, Cagliari, Italy|Unità Operativa Solventi e Unità Poliambulatorio, Milan, Italy|Department of Clinical Medicines and Cardiovascular Sciences, Universita ""Federico II"" di Napoli, Napoli, Italy|Divisione di Cardiologia con Utic ed Emodinamica - AOU Federico II di Napoli, Napoli, Italy|A.O. di Reggio Emilia Arcispedale ""S. Maria Nuova""/IRCCS, Reggio Emilia, Italy|AUSL Della Romagna-Ospedale Infermi, Rimini, Italy|Ospedale Santa Maria della Misericordia Azienda ULSS 18 of Rovigo, Rovigo, Italy|Azienda Ospedaliera Universitaria Santa Maria della Misericordia, Udine, Italy|Chungbuk National University Hospital, Cheongju-si, Chungcheonbuk-do, Korea, Republic of|Kangwon National University Hospital, Chuncheon-si, Gangwon-do, Korea, Republic of|Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju-Si, Gangwon-do, Korea, Republic of|Yonsei University Wonju Severance Christian Hospital, Wonju-si, Gangwon-do, Korea, Republic of|Donguk University Gyeongju Hospital, Gyeongju-si, Gyeongbuk, Korea, Republic of|Dongguk University Ilsan Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of|Inje University Ilsan Paik Hospital, Goyang-Si, Gyeonggi-do, Korea, Republic of|Myongji Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of|Uijeongbu St. Mary's Hospital-The Catholic University of Korea, Uijeongbu-si, Gyeonggi-do, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Daegu Catholic University Medical Center, Daegu, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|Hallym University Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|The Catholic University Of Korea Seoul St.Marys Hospital, Seoul, Korea, Republic of|Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Seoul, Korea, Republic of|Consultorio Dr. Leocadio Gerardo Munoz Beltran, Cd. Juarez, Chihuahua, Mexico|Centro Especializado en Diabetes Obesidad y Prevencion de Enfermedades Cardiovasculares, SC., Mexico, DF, Mexico|Consultorio de Endocrinologia y Nutriologia, Mexico, Distrito Federal, Mexico|Operadora de Hospitales Angeles S.A. de C.V. (Emergencies), Mexico, Distrito Federal, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion ""Salvador Zubiran"", Mexico, Distrito Federal, Mexico|Centro de Investigacion Clinica del Pacifico, S.A. de C.V., Acapulco de Juarez, Guerrero, Mexico|Hospital Del Pacifico,Centro De Investigacion Clinica Del Pacifico Cicpa,Torre Medica Del Pacifico, Acapulco, Guerrero, Mexico|Clinical Trials Mexico, S.A. de C.V., Pachuca de Soto, Hidalgo, Mexico|Investigacion Biomedica Aplicada de Hidalgo S.A. de C.V., Pachuca, Hidalgo, Mexico|Centro de Investigacion Medica Integral S.C., Guadalajara, Jalisco, Mexico|Icle S.C., Guadalajara, Jalisco, Mexico|Consultorio Privado del Dr. Gabriel Arturo Ramos Lopez, Guadalajara, Jalisco, Mexico|Unidad de Investigacion Clinica y Atencion Medica Hepa S.C., Guadalajara, Jalisco, Mexico|Instituto de Diabetes Obesidad y Nutricion, S.C., Cuernavaca, Morelos, Mexico|Hospital Inovamed Cuernavaca (Emergencies), Cuernavaca, Morelos, Mexico|Cardiolink Clin Trials, S.C., Monterrey, Nuevo LEON, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo LEON, Mexico|CRI Centro Regiomontano de Investigacion SC, Monterrey, Nuevo LEON, Mexico|Global Trial Research Center S.A. de C.V., Monterrey, Nuevo LEON, Mexico|Centro Integral Medico SJR S.C, San Juan del Rio, Queretaro, Mexico|Centro para el Desarrollo de la Medicina y de Asistencia Médica Especializada S.C., Culiacan, Sinaloa, Mexico|Hospital Angeles Culiacan, Culiacan, Sinaloa, Mexico|Centro de Estudios de Investigacion Metabolicos y Cardiovasculares S.C., Tampico, Tamaulipas, Mexico|Centro De Especialidades Medicas Del Estado De Veracruz, Xalapa, Veracruz, Mexico|Instituto Biomedico De Investigacion A.C., Aguascalientes, Mexico|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Unidad De Investigacion En Salud De Chihuahua S.C., Chihuahua, Mexico|Consultorio Medico de Especialidad Dr. Demetrio Kosturakis Garcia, Chihuahua, Mexico|Investigacion en Salud y Metabolismo S.C, Chihuahua, Mexico|Instituto Nacional de Ciencia Medicas y Nutricion Salvador Zubiran, Distrito Federal, Mexico|Lahoja Asociacion para la Investigacion y Farmacovigilancia S.C., Durango, Mexico|Centro Especializado en Diabetes, Obesidad y Prevencion de Enfermedades Cardiovasculares, S.C., Mexico, Mexico|Pharmacology and Clinical Research S.A. de C.V., Queretaro, Mexico|Cardioarritmias e Investigacion S.C., San Luis Potosi, Mexico|Hospital Lomas de San Luis lntemacional (Emergencies), San Luis Potosi, Mexico|Hospital Central ""Dr. Ignacio Morones Prieto"", San Luis Potosi, Mexico|Centro Especializado En Diabetes Y Metabolismo, Veracruz, Mexico|Tjongerschans Ziekenhuis, Heerenveen, Friesland, Netherlands|Zuyderland MC, Sittard-Geleen, Limburg, Netherlands|Isala, Zwolle, Overijssel, Netherlands|St. Franciscus Gasthuis, Rotterdam, Zuid-holland, Netherlands|Het Lange Land Ziekenhuis, Zoetermeer, Zuid-holland, Netherlands|Noordwest Ziekenhuisgroep, Alkmaar, Netherlands|EB Flevoresearch, Almere, Netherlands|Meander Medical Center, Amersfoort, Netherlands|Meander Medisch Centrum, Amersfoort, Netherlands|Amstelland Hospital, Amstelveen, Netherlands|Bovenij Ziekenhuis, Amsterdam, Netherlands|OLVG, locatie West, Amsterdam, Netherlands|VU University Medical Center, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Academic Medical Center, Amsterdam, Netherlands|Gelre Hospitals, Apeldoorn, Netherlands|Rode Kruis Ziekenhuis, Beverwijk, Netherlands|Tergooi Ziekenhuis, Blaricum, Netherlands|Andro Medical Research B.V., Breda, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Reinier de Graaf Ziekenhuis, Delft, Netherlands|Hedramed, Den Haag, Netherlands|Hagaziekenhuis, Den Haag, Netherlands|Bronovo Ziekenhuis, Den Haag, Netherlands|Deventer Ziekenhuis, Deventer, Netherlands|Van Weel Bethesda Hospital, Dirksland, Netherlands|Slingeland Ziekenhuis, Doetinchem, Netherlands|Albert Schweitzer Ziekenhuis-Albert Schweitzer Hospital, Dordrecht, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Netherlands|Andromed Eindhoven, Eindhoven, Netherlands|Heartcentre Catharina Hospital, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Beatrix Hospital, Gorinchem, Netherlands|Beatrix Ziekenhuis, Gorinchem, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Spaarne Gasthuis, Haarlem, Netherlands|Ropcke Zweers Hospital, Hardenberg, Netherlands|St. Jansdal Ziekenhuis, Harderwijk, Netherlands|Zuyderland Medisch Centrum, Heerlen, Netherlands|Zuyderland, Heerlen, Netherlands|Treant Zorggroep, location Bethesda, Hoogeveen, Netherlands|Vascular Research Centre, Hoorn, Netherlands|Quality Care Research, Kloosterhaar, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Alrijne Ziekenhuis, Leiden, Netherlands|Alrijne Ziekenhuis, Leiderdorp, Netherlands|GCM Maarssenbroek, Maarssen, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Isala Diaconessenhuis, Meppel, Netherlands|St Antonius Hospital, Nieuwegein, Netherlands|Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Waterland Hospital, Purmerend, Netherlands|Andro Medical Research B.V., Rotterdam, Netherlands|Hedramed, Rotterdam, Netherlands|Rotterdam Research Institute, Rotterdam, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands|D&A Research and Genetics, Sneek, Netherlands|Ziekenhuis Rivierenland, Tiel, Netherlands|Elisabeth-TweeSteden Ziekenhuis (previously named St. Elisabeth Ziekenhuis), Tilburg, Netherlands|St. Elisabeth Ziekenhuis, Tilburg, Netherlands|Elisabeth TweeSteden Ziekenhuis (ETZ), Tilburg, Netherlands|Bernhoven Ziekenhuis, Uden, Netherlands|EB Utrecht, Utrecht, Netherlands|Universitair Medisch Centrum (UMC) Utrecht - Locatie AZU, Utrecht, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Maxima Medisch Centrum, Veldhoven, Netherlands|VieCuri Medisch Centrum, Venlo, Netherlands|Twee Steden Ziekenhuis, Waalwijk, Netherlands|Klinisch Onderzoek Praktijk Zoetermeer, Zoetermeer, Netherlands|Albert Schweitzer Hospital, Zwijndrecht, Netherlands|Henderson Medical Centre, Henderson, Auckland, New Zealand|North Shore Hospital, Takapuna, Auckland, New Zealand|Hawke's Bay Hospital, Frimley, Hastings, New Zealand|North Shore Hospital, Laboratory, Auckland, New Zealand|North Shore Hospital- Inpatient Pharmacy, Auckland, New Zealand|Optimal Clinical Trials, Auckland, New Zealand|Auckland City Hospital, Auckland, New Zealand|Middlemore Clinical Trials, Auckland, New Zealand|Lipid and Diabetes Research Group, Christchurch, New Zealand|Southern Clinical Trials Shirley Ltd Don Beavan Medical Research Centre, Christchurch, New Zealand|Southern Clinical Trials Riccarton, Christchurch, New Zealand|Taranaki Base Hospital, New Plymouth, New Zealand|Papamoa Pines Medical Centre, Papamoa, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Clinical Horizons NZ Ltd, Tauranga, New Zealand|Clinical Trials Unit,Bay of Plenty(BOP) Clinical School, Tauranga, New Zealand|CCDHB, Wellington Hospital, Clinical Measurement Unit, Wellington, New Zealand|Wellington Hospital, Wellington, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Jeleniogorskie Centrum Chorob Serca, Przychodnia Kardiologiczna, Poradnia Kardiologiczna, Jelenia Gora, Dolnoslaskie, Poland|Synexus Polska Sp. z o.o. Oddzial we Wroclawiu, Wroclaw, Dolnoslaskie, Poland|Wojewodzki Szpital Specjalistyczny we Wroclawiu, Osrodek Badawczo-Rozwojowy, Wroclaw, Dolnoslaskie, Poland|Zdrowie s.c. Agnieszka i Donald Drozdz, Wroclaw, Dolnoslaskie, Poland|Halina Serafin NZOZ Centrum Medyczne SERAFIN-MED, Zarow, Dolnoslaskie, Poland|SPZOZ Uniwersytecki Szpital Kliniczny im. Wojskowej Akademii Medycznej Uniwersytetu Medycznego, Lodz, Iodzkie, Poland|NZOZ Vitamed, Bydgoszcz, Kujawsko-pomorskie, Poland|Nzoz Centrum Medyczne Kermed, Bydgoszcz, Kujawsko-pomorskie, Poland|Specjalistyczna Praktyka Lekarska Piotr Kubalski, Grudziadz, Kujawsko-pomorskie, Poland|Specjalistyczne Gabinety Lekarskie ""Medicor Plus"" - Jerzy Kopaczewski, Wloclawek, Kujawsko-pomorskie, Poland|Gabinet Lekarski Malgorzata Saryusz-Wolska, Lodz, Lodzkie, Poland|Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp. z o.o., Lodz, Lodzkie, Poland|""Prywatny Gabinet Kardiologiczny"" Dr N.Med. Maciej Kosmider, Lodz, Lodzkie, Poland|Prywatny Gabinet Lekarski Dr n. med. Michal Ogorek, Piotrkow Trybunalski, Lodzkie, Poland|Centrum Medyczne Ogrodowa Sp. z o.o., Skierniewice, Lodzkie, Poland|Clinical Best Solutions, Lublin, Lubelskie, Poland|Optimamed Specjalistyczne Gabinety Lekarskie, Lublin, Lubelskie, Poland|KO-MED Centra Kliniczne Lublin II, Lublin, Lubelskie, Poland|KO-MED Centra Kliniczne Pulawy, Pulawy, Lubelskie, Poland|KO-MED Centra Kliniczne Zamosc, Zamosc, Lubelskie, Poland|Landa Specjalistyczne Gabinety Lekarskie, Krakow, Malopolskie, Poland|Szpital Specjalistyczny im. J. Dietla w Krakowie, Oddzial Kardiologii, Krakow, Malopolskie, Poland|Krakowski Szpital Specjalistyczny im. Jana Pawla II, Oddzial Szybkiej Diagnostyki, Krakow, Malopolskie, Poland|Centrum Medyczne Zdrowa J. Trebacz, W. Zajdel Spolka Jawna, Krakow, Malopolskie, Poland|CENTRUM MEDYCZNE A-Z Clinic, Krakow, Malopolskie, Poland|Krakowskie Centrum Medyczne Sp. z o.o., Krakow, Malopolskie, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie,, Krakow, Malopolskie, Poland|NeuroCor Banaszkiewicz, Kulaga, Ostrowska, Tomaszewski lekarze spolka partnerska, Myslenice, Malopolskie, Poland|INTERCARD Sp. z. o. o. Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii w Nowym Targu, Nowy Targ, Malopolskie, Poland|Centrum Szybkiej Diagnostyki Kardiologicznej Kardiomed M. Zabowka E. Zabowka, Tarnow, Malopolskie, Poland|Specjalistyczny Gabinet Lekarski Internistyczno-Kardiologiczny Boguslaw Derlaga, Tarnow, Malopolskie, Poland|Synexus Polska Sp. z o.o. Oddzial w Katowicach, Katowice, Mazowieckie, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Specjalistyczna Przychodnia Lekarska ""MEDIKARD"", Plock, Mazowieckie, Poland|Centrum Medyczne Piaski Filia Nr 9, Warszawa, Mazowieckie, Poland|Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych w Warszawie, Warszawa, Mazowieckie, Poland|CSK MSW w Warszawie, Klinika Kardiologii Zachowawczej i Nadcisnienia Tetniczego, Warszawa, Mazowieckie, Poland|Wojskowy Instytut Medyczny, Klinika Kardiologii i Chorob Wewnetrznych, Centralny Szpital Kliniczny, Warszawa, Mazowieckie, Poland|Instytut Kardiologii im. Prymasa Tysiaclecia Stefana Kardynala Wyszynskiego, Warszawa, Mazowieckie, Poland|Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp. z o.o., Warszawa, Mazowieckie, Poland|Szpital Specjalistyczny w Brzozowie, Podkarpacki Osrodek Onkologiczny im. Ks. B. Markiewicza Oddzial, Brzozow, Podkarpackie, Poland|INTERCARD Sp. z o.o. Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii w Krosnie, Krosno, Podkarpackie, Poland|EMED Centrum Uslug Medycznych Ewa Smialek, Rzeszow, Podkarpackie, Poland|""""""OSTEO-MEDIC"""" s.c. Artur Racewicz, Jerzy Supronik"", Bialystok, Podlaskie, Poland|Podlaski Osrodek Kardiologii Janusz Korecki, Bialystok, Podlaskie, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdansku, Gdansk, Pomorskie, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Gdanskie Centrum Zdrowia, Poradnia Kardiologiczna, Gdansk, Pomorskie, Poland|Centrum Badan Klinicznych Pi-House, Poradnia Diabetologiczna, Gdansk, Pomorskie, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdyni, Gdynia, Pomorskie, Poland|NZOZ ""PRO CORDIS"" Sopockie Centrum Badan Kardiologicznych, Gdynia, Pomorskie, Poland|Gabinet Kardiologiczno - lnternistyczny, Gdynia, Pomorskie, Poland|Centrum Medyczne ""SOPMED"" Sp. z o.o., Sopot, Pomorskie, Poland|Indywidualna Specjalistyczna Praktyka Lekarska Malgorzata Biedrzycka, Starogard Gdanski, Pomorskie, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Wojewodzki Szpital Specjalistyczny Nr 4 w Bytomiu,, Bytom, Slaskie, Poland|Bogna Gabrylewicz Andrzej Ochala Unimed s.c., Katowice, Slaskie, Poland|Pro Familia Altera Poradnia Wielospecjalistyczna, Katowice, Slaskie, Poland|NZOZ Terapia Optima, Katowice, Slaskie, Poland|Przychodnia Specjalistyczna Samodzielny Publiczny ZOZ w Rudzie Slaskiej, Poradnie Specjalistyczne,, Ruda Slaska, Slaskie, Poland|NZOZ ""Medyk""Sp. z o. o., Wola, Slaskie, Poland|Prywatny Gabinet Lekarski Marianna Janion, Kielce, Swietokrzyskie, Poland|Wojewodzki Szpital Zespolony w Elblagu, Oddzial Kardiologiczny z Pododdzialem Kardiologii Inwazyjnej, Elblag, Warminsko-mazurskie, Poland|Synexus Polska Sp. z o.o Oddzial w Poznaniu, Poznan, Wielkopolskie, Poland|Nzoz ""Twoja Przychodnia"", Poznan, Wielkopolskie, Poland|""OSTEO-MEDIC"" s.c. Artur Racewicz, Jerzy Supronik, Bialystok, Poland|NZOZ Vitamed -Ga¿aj I Cichomski sp.j, Bydgoszcz, Poland|Medica Pro Familia Sp. z o.o. Spolka Komandytowo Akcyjna, Oddzial w Gdyni, Gdynia, Poland|Nzoz Gall-Med, Krakow, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie,, Krakow, Poland|SP ZOZ Szpital Uniwersytecki w Krakowie, Krakow, Poland|NZOZ Centrum Zdrowia i Profilaktyki Dabie Sp. z.o.o., Krakow, Poland|Specjalistyczny Osrodek Medycyny Wieku Dojrzalego, Lodz, Poland|""TWOJA PRZYCHODNIA"" Sp. Z o.o, Lublin, Poland|NeuroCor Banaszkiewicz, Kulaga, Ostrowska, Tomaszewski lekarze spolka partnerska, Myslenice, Poland|Medicus w Opolu Sp z o. o., Opole, Poland|Specjalistyczny Osrodek Leczniczo-Badawczy Zbigniew Zegota, Ostroda, Poland|Medicome Sp. z o.o., Oswiecim, Poland|Centrum Zdrowia Metabolicznego Pawel Bogdanski, Poznan, Poland|NZOZ Przychodnia Specjalistyczna Andrzej wittek Henryk Rudzki S.C., Ruda Slaska, Poland|KO-MED Centra Kliniczne Staszow, Staszow, Poland|Synexus Polska Sp. z o.o. Oddzial w Warszawie, Warszawa, Poland|Instytut Kardiologii, Ii Klinika Choroby WieCowej, Warszawa, Poland|Instytut Kardiologii im. Prymasa Tysiaclecia Stefana Kardynala Wyszynskiego, Warszawa, Poland|Instytut Kardiologii im. Prymasa Tysiaclecia Stefana Kardynala, Warszawa, Poland|Dobrostan Michal Bogacki, Wroclaw, Poland|The Office of Roberto J. Ayala-Rios, MD - Research Center and Private Practice (DMRA LLC), Anasco, Puerto Rico|Cardiometabolic Research Center, Inc., Ponce, Puerto Rico|Endocrine Lipid Diabetes Research Institute, Ponce, Puerto Rico|Pradnet Inc., San Juan, Puerto Rico|Altamira Family Medicine And Research Institute, San Juan, Puerto Rico|Miguel Sosa-Padilla, MD-Private Practice, San Juan, Puerto Rico|Centro de Diabetes para Puerto Rico, San Juan, Puerto Rico|Pitesti-Arges County Emergency Hospital, Pitesti, Arges, Romania|Medical Practice SRL, Oradea, Bihor, Romania|County Clinical Emergency Hospital Oradea, Oradea, Bihor, Romania|County Emergency Hospital Deva, Deva, Hunedoara, Romania|CMI Pop Calin Florin, Baia Mare, JUD Maramures, Romania|Centrul Medical Dr. Negrisanu SRL, Diabet Zaharat Nutritie si Boli Metabolice, Timisoara, Judet Timis, Romania|Dr. Pop Calin Florin - Cabinet Cardiologie, Baia Mare, Maramures, Romania|Podoleanu G. Cristian-Gheorghe-Calin - Cardiology Medical Practice, Targu Mures, Mures, Romania|Diabmed Dr. Popescu Alexandrina SRL, Diabet, Nutritie, Boli Metabolice, Ploiesti, Prahova, Romania|Dr. Busegeanu Mihaela Private Practice, Ploiesti, Prahova, Romania|Clinica Medicala Synexus Ltd., Bucharest, Sectorul 2, Romania|Institute of Cardiovascular Diseases Timisoara, Timisoara, Timis, Romania|Euromedica Hospital, Baia Mare, Romania|Spitalul Clinic Judetean De Urgenta Braila(Braila County Clincal Emergency Hospital), Braila, Romania|S.C. Polimed Dacia S.R.L., Brasov, Romania|Centrul Medical de Diagnostic si Tratament Ambulator Neomed SRL, Medicina Interna, Brasov, Romania|Data Plus Medical Clinic, Bucharest, Romania|""Prof. Dr. N.C. Paulescu"" National Institute of Diabetes, Nutrition and Metabolic Diseases,, Bucharest, Romania|Med Plus SRL (Med Plus Ltd.), Bucharest, Romania|S.C. Centrul Medical ""Sanatatea Ta"" S.R.L., Bucharest, Romania|Med Plus Srl, Bucharest, Romania|Spitalul Universitar De Urgenta Militar Central, Dr. Carol Davila, Bucuresti, Romania|Spitalul Clinic Colentina, Departament Cardiologie, Bucuresti, Romania|SC Centrul Medical Policlinico Di Monza SRL, Cardiologie, Bucuresti, Romania|SC Policlinica CCBR SRL, Bucuresti, Romania|Spitalul Clinic Judetean De Urgenta Cluj-Napoca, Diabet Zabarat, Cluj-Napoca, Romania|Spitalul Clinic Judetean de Urgenta Cluj-Napoca, Diabet Zaharat, Nutritie si Boli Metabolice, Cluj-Napoca, Romania|Dr. Mistodie Cristina Victoria MD, Office of, Galati, Romania|S.C. Diamed Obesity S.R.L., Galati, Romania|County Emergency Hospital Satu Mare Diabetes, Nutrition And Metabolic Diseases Department, Satu Mare, Romania|County Clinical Emergency Hospital Sibiu, Sibiu, Romania|Cardio Med SRL, Cardiologie, Tg. Mures, Romania|Centrul Medical Sf. Stefan, Timisoara, Romania|Institution Centrul Medical Sf. Stefan SRL, Diabet Nutritie si Boli Metabolice, Timisoara, Romania|State Budgetary Healthcare Institution ""Research Institution - Regional Clinical Hospital #1, Krasnodar, Krasnodar Region, Russian Federation|State Budgetary Healthcare Institution of Moscow Region ""Lubertsy Regional Hospital #2"", Lubertsy, Moscow Region, Russian Federation|Federal State Budgetary Institution of Healthcare Hospital of Russian Academy of Sciences, Troitsk, Moscow Region, Russian Federation|1st Pavlov State Medical University of St. Petersburg, St. Petersburg, Sankt-peterburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare, St. Petersburg, Sestroretsk, Russian Federation|FSBEI of HE Kazan State Medical University on the base of SBHI Clinical Hospital No.2, Kazan, Tatarstan Republic, Russian Federation|Municipal Budgetary State Healthcare Institution ""City Clinical Hospital #6"", Chelyabinsk, Russian Federation|Non-State Institution of Healthcare, Chelyabinsk, Russian Federation|State Budgetary Healthcare Institution ¿Region Clinical Hospital #3¿, Chelyabinsk, Russian Federation|Municipal Autonomous Institution ""City Clinical Hospital #14"", Ekaterinburg, Russian Federation|Regional Budgetary Healthcare Institution ""Cardiology Dispensary"", Ivanovo, Russian Federation|State Budgetary Institution of Healthcare of Kaluga Region ""Kaluga Regional Hospital"", Kaluga, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Kazan State Medical University"", Kazan, Russian Federation|State Autonomous Healthcare Institution ""Republic Clinical Hospital"", Kazan, Russian Federation|""SAHI of Kemerovo """"Regional Clinical Hospital of Emergency Medical Care n.a. M.A Podgorbunsky """""", Kemerovo, Russian Federation|Municipal Budgetary Institution of Healthcare Municipal Clinical Hospital #3 n.a. M.A. Podgorbunsky, Kemerovo, Russian Federation|FSBI ""Research institute of complex problems of cardio-vascular diseases"" of, Kemerovo, Russian Federation|FSHI ""Medical and Sanitary Unit of the Ministry of Internal Affairs of Russia across, Kemerovo, Russian Federation|Kirov Regional State Budgetary Healthcare Institution ""Kirov City Clinical Hospital #1"", Kirov, Russian Federation|Regional Budgetary Healthcare Institution ""Kursk City Clinical Emergency Hospital"", Kursk, Russian Federation|Non-State Institution of Healthcare ""Central Clinical Hospital #6 OAO ""RZhD"", Moscow, Russian Federation|SBHI Moscow city ""City Clinical Hospital #15 n.a. O.M. Filatova"" of Moscow Healthcare Department, Moscow, Russian Federation|Federal State Budgetary Institution ""Central Clinical Hospital with Polyclinic"", Moscow, Russian Federation|""Federal State Budgetary Institution ""Russian Cardiology Research And Production Complex"" Of, Moscow, Russian Federation|Moscow State Healthcare Institution ""City clinical hospital n.a. S.P.Botkin"", Moscow, Russian Federation|State Budget Institution of Healthcare (SBIH) of Moscow ""City Clinical Hospital #81, Moscow, Russian Federation|Federal State Budget Institution ""Out-patient Clinic #3"" of Russian Federation, President's, Moscow, Russian Federation|State Regional Budgetary Healthcare Institution, Murmansk, Russian Federation|State Budgetary Healthcare Institution of Nizhegorodskaya Region, Nizhniy Novgorod, Russian Federation|Federal State Budgetary Institution ""Research Institute of Therapy and Preventive Medicine"", Novosibirsk, Russian Federation|""Reafan"" LLC, Novosibirsk, Russian Federation|Municipal Budgetary Institution of Healthcare of Novosibirsk, Novosibirsk, Russian Federation|State Budgetary Institution of Healthcare of Novosibirsk region City Clinical Hospital of Emergency, Novosibirsk, Russian Federation|State Budgetary Healthcare Institution (SBHI) N.N. Burdenko Regional Clinical Hospital of Penza, Penza, Russian Federation|SBHI of Saint-Petersburg ""City Hospital # 38 n.a. N.A. Semashko"", Pushkin, Russian Federation|State Budgetary Educational Institution Of Higher Professional Education, Rostov-on-Don, Russian Federation|State Budgetary Educational Institution of Higher Professional Education, Rostov-on-Don, Russian Federation|State Budgetary Institution ""Ryazan Regional Clinical Hospital"", Ryazan, Russian Federation|Limited Liability Company ""Reavita"", Saint Petersburg, Russian Federation|LLC ""Institution of medical studies"", Saint Petersburg, Russian Federation|Federal State Budgetary Institution ""Federal Almazov Medical Research Centre"" of, Saint Petersburg, Russian Federation|Limited Liability Company International Medical Centre SOGAZ, Saint-Petersberg, Russian Federation|Saint-Petersburg State Budgetary Institution of Healthcare ""City Hospital #23"", Saint-Petersburg, Russian Federation|Saint-Petersburg State Budgetary Healthcare Institution ""City Alexandrovskaya Hospital"", Saint-Petersburg, Russian Federation|Saint-Petersburg State Budgetary Institution of Healthcare ""City Hospital #26"", Saint-Petersburg, Russian Federation|SBEI of HPE ""First Pavlov State Medical University of St. Petersburg"" of the MoH of the RF, Saint-Petersburg, Russian Federation|Federal State Budgetary Institution ""Advisory Diagnostic Center and Polyclinic"", Saint-Petersburg, Russian Federation|Saint-Petersburg State Budgetary Healthcare Institution ""City Hospital #15"", Saint-Petersburg, Russian Federation|State Budgetary Healthcare Institution ""Samara Regional Clinical Cardiology Dispensary"", Samara, Russian Federation|MHI ""City Clinical Hospital 12""of the Healthcare Committee of, Saratov, Russian Federation|State Institution of Healthcare ""Regional Clinical Hospital"", Saratov, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Academician I.P. Pavlov First, St. Petersburg, Russian Federation|Tyumen Cardiology Research Center-branch of the Tomsk NRMC, Tomsk, Russian Federation|State Budgetary Educational Institution of Highest Professional Education, Tomsk, Russian Federation|State Autonomous Healthcare Institution of Tyumen region ""Scientific-Practical Medical Center"", Tyumen, Russian Federation|""Tyumen Cardiology Center"" Affiliate of the FSBSI ""Scientific and Research Institution of Cardiology, Tyumen, Russian Federation|State Autonomous Healthcare Institution of Yaroslavl region Clinical Emergency Hospital n.a..N.V.So, Yaroslavl, Russian Federation|State Autonomous Healthcare Institution of Yaroslavl Region, Yaroslavl, Russian Federation|FSBEI of HE ""Yaroslavl State Medical University"" MH of the Russian Federation based on Clinical, Yaroslavl, Russian Federation|State Budgetary Healthcare Institution of Yaroslavl Region ""Clinical Hospital No. 10"", Yaroslavl, Russian Federation|State Healthcare Institution of Yaroslavl Region ""Clinical Hospital #8"", Yaroslavl, Russian Federation|Nemocnica Ruzinov-Univerzitna Nemocnica Bratislava (UNB), Bratislava, Bratislavsky, Slovakia|Stredoslovensky ustav srdcovych a cievnych chorob a.s., Banska Bystrica, Slovakia|Fakultna nemocnica F. D. Roosevelta, Banska Bystrica, Slovakia|Alian s.r.o., kardiologicka ambulancia, Bardejov, Slovakia|Metabol KLINIK s.r.o., Ambulancia pre diabetologiu, poruchy latkovej premeny a vyzivy, Bratislava, Slovakia|Univerzitna nemocnica Bmtislava, Nemocnica Stare Mesto, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Nemocnica Stare Mesto, l.interna klinika, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Nemocnica Stare Mesto, Bratislava, Slovakia|UN Bratislava, Nemocnica Ruzinov, V. interna klinika LFUK a UN Bratislava, Bratislava, Slovakia|Kardiovaskularne Centrum S.R.O., Bratislava, Slovakia|Metabolicke Centrum MUDr. Katariny Raslovej, S.R.O., Bratislava, Slovakia|Narodny ustav srdcovych a cievnych chorob, a.s., Bratislava, Slovakia|Univerzitna Nemocnica Bratislava, Bratislava, Slovakia|Narodny ustav srdcovych a cievnych chorob, a.s., Bratislava, Slovakia|KARDIO-SANUS spol.,s.r.o.,Kardiologicka, interna a sonograficka ambulancia, Bratislava, Slovakia|KARDIO-SANUS spol. s.r.o., Bratislava, Slovakia|VERIA, s.r.o. -Kardiologicka ambulancia, Bratislava, Slovakia|UN Bratislava Nemocnica Sv.Cyrila a Metoda, kardiologicka ambulancia 1, Bratislava, Slovakia|Endiamed s.r.o. Nestatna diabetologicka a endokrinologicka ambulancia, Dolny Kubin, Slovakia|JM-Interna s.r.o., interna ambulancia, Dolny Kubin, Slovakia|CARDIO D&R s.r.o., Kardiologicka ambulancia, Kosice, Slovakia|AGTO., spol. s r. o., Kosice, Slovakia|Cardio D&R spol.s.r.o., kardiologicka ambulancia, Kosice, Slovakia|Medicentrum Heart, Spol. S.R.O, Kralovsky Chlmec, Slovakia|CELL-B s.r.o. interna ambulancia, Levice, Slovakia|Liptovska nemocnica s poliklinikou MUDr.Ivana Stodolu Liptovsky Mikulas, Liptovsky Mikulas, Slovakia|Narodny Endokrinologicky A Diabetologicky Ustav N.O., Lubochna, Slovakia|KARDIO 1 s.r.o., Lucenec, Slovakia|Klinika hematologie a transfuziologie, Univerzitna nemocnica Martin, Martin, Slovakia|MEDI M&M s.r.o., Ambulancia vnutorneho lekarstva, Moldava nad Bodvou, Slovakia|MUDr. Kanderkova s.r.o., Diabetologicka ambulancia, Namestovo, Slovakia|Kardiocentrum Nitra s.r.o., kardiologicka ambulancia, Nitra, Slovakia|Fakultna nemocnica s poliklinikou Nove Zamky, I. interna klinika, Nove Zamky, Slovakia|Mediab s.r.o. Diabetologicka ambulancia, Pezinok, Slovakia|BENIMED s.r.o., Piestany, Slovakia|Medispol S.R.O., Presov, Slovakia|Medilex s.r.o. Interna ambulancia, Rimavska Sobota, Slovakia|Kardioamb S.R.O., Rimavska Sobota, Slovakia|DIAMEL, s.r.o., Diabetologicka ambulancia, Trencin, Slovakia|BV Medical, s.r.o. Diabetologicka ambulancia,, Trnava, Slovakia|Kardiologicka ambulancia, Trnava, Slovakia|Medivasa S.R.O., Diabetologicka Ambulancia, Zilina, Slovakia|IATROS International, Bloemfontein, FREE State, South Africa|JOSHA Research, Bloemfontein, FREE State, South Africa|Welkom Clinical Trial Centre, Welkom, FREE State, South Africa|Midrand Medical Centre, Halfway House, Gauteng, South Africa|Centre for Diabetes and Endocrinology, Houghton, Gauteng, South Africa|Sunninghill Hospital, Johannesburg, Gauteng, South Africa|I Engelbrecht Research (Pty) Ltd, Lyttelton, Gauteng, South Africa|Charlotte Maxeke Johannesburg Academic Hospital, Parktown, Gauteng, South Africa|Jongaie Research, Pretoria West, Gauteng, South Africa|Medipark Centre for Clinical Research, Pretoria, Gauteng, South Africa|Synexus Watermeyer Clinical Research Centre, Pretoria, Gauteng, South Africa|Roodepoort Medicross Clinical Research Centre, Roodepoort, Gauteng, South Africa|Wits Clinical Research-Chris Hani Baragwanath Hospital, Soweto, Gauteng, South Africa|Medi-Clinic Heart Hospital, Sunnyside, Gauteng, South Africa|Nash Ranjith Research Centre, Merebank, Durban, KWA ZULU Natal, South Africa|Suite 502, Durban, Kwazulu-natal, South Africa|Dr Ganesh c/o Dr NB Maharaj, Durban, Kwazulu-natal, South Africa|Limpopo Clinical Research Initiative, Thabazimbi, Limpopo, South Africa|Zinakekele Medical Centre, Moloto, Mpumalanga, South Africa|Drs Joynt Venter & Associates, Witbank (eMalahleni), Mpumalanga, South Africa|Dr JM Engelbrecht Trial Site-Vergelegen Mediclinic, Cape Town, Western CAPE, South Africa|Tiervlei Trial Centre, Cape Town, Western CAPE, South Africa|Synopsis Research cc, Cape Town, Western CAPE, South Africa|Helderberg Research Institute, Somerset West, Western CAPE, South Africa|Synexus Helderberg Clinical Research Centre, Somerset West, Western CAPE, South Africa|Vergelegen Mediclinic-Helderberg Research Institute, Somerset West, Western CAPE, South Africa|Unitas Hospital., Centurion, South Africa|Clinresco Centres (Pty) Ltd-Central Professional Suits, Gauteng, South Africa|Paarl Research Centre, Paarl, South Africa|TREAD Research cc, Parow, South Africa|Clinical Projects Research SA (Pty) Ltd, Worcester, South Africa|Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruna, Spain|Hospital Virgen De Los Lirios, Alcoy, Alicante, Spain|Hospital Regional Universitario de Malaga, Malaga, Andalucia, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Andalucia, Spain|Centro de Salud El Cristo, Oviedo, Asturias, Spain|Centro Salud Paulino Prieto, Oviedo, Asturias, Spain|Cap Florida, L'Hospitalet De Llobregat, Barcelona-cataluna, Spain|CAP Disset De Setembre (Sant Cosme I Sant Damia), El Prat De Llobregat, Barcelona/cataluna, Spain|Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|CAP La Mina, Sant Adria De Besos, Barcelona, Spain|EAP Vic, Vic, Barcelona, Spain|Hospital Universitario Marques De Valdecilla, Santander, Cantabria, Spain|Hospital Universitari de Tarragona Joan XXIII, Tarragona, Catalonia, Spain|Hospital Universitario San Juan de Alicante, Alicante, Comunidad Valenciana, Spain|Albera Salut, Peralada, Gerona, Spain|Hospital De Figueres, Figueres, Girona-catalonia, Spain|Hospital Santa Caterina, Salt, Girona, Girona, Spain|Hospital Comarcal d'Inca, Inca, Illes Balears, Spain|Hospital Arquitecto Marcide, El Ferrol, LA Coruna, Spain|Hospital Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Quiron Madrid, Pozuelo de Alarcon, Madrid, Spain|Hospital Universitario de Cruces, Barakaldo, PAIS Vasco, Spain|Hospital Universitario Sant Joan de Reus, Reus, Tarragona, Spain|Hospital General De Requena, Requena, Valencia, Spain|Gerencia de Gestion integrada de A Coruna, A Coruna, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General Universitario de Alicante; Servicio Cardiologia, Alicante, Spain|Hospital Virgen del Mar, Almeria, Spain|Parc de Salut mar ¿ Hospital del Mar, Barcelona, Spain|Parc de Salut Mar- Hospital del Mar, Barcelona, Spain|Centre Teknon, Barcelona, Spain|EAP Sardenya, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|CAP Centelles, Barcelona, Spain|CAP Amadeu Torner, Barcelona, Spain|Hospital Universitario de Bellvitge, Barcelona, Spain|Fundacio Hospital de I'Esperit Sant, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Complexo Hospitalario Universitario Arquitecto Marcide-Profesor Novoa Santos De Ferrol, Ferrol, Spain|Hospital Universitario San Cecilio, Granada, Spain|Hospital Universitario Virgen de las Nieves (HUVN), Granada, Spain|Hospital Universitari Arnau de Vilanova (HUAV), Lleida, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Pharmacy - Hospital Universitari Arnau de Vilanova (HUAV), Lleida, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Carlos III, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario La Paz; Unidad Metabolico-Vascular, Madrid, Spain|Hospital Universitario Infanta Sofía, Madrid, Spain|Carretera Alcala-Meco s/n, Madrid, Spain|H. U. Principe de Asturias, Madrid, Spain|Hospital Universitario Virgen de la Victoria. CE San Jose Obrero, Malaga, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Hospital Universitario Virgen De La Victoria, Malaga, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital Universitario Sant Joan de Reus, Reus (Tarragona), Spain|Clinica Nuevas Tecnologias En Diabetes Y Endocrinologia, Sevilla, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen de Valme, Sevilla, Spain|CAP Muralles, Tarragona, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Clinico Universitario Miguel Servet; Medicina Interna, Zaragoza, Spain|Karolinska universitetssjukhuset Huddinge, Stockholm, Huddinge, Sweden|Kasernens Läkarservice AB, Eksjö, Sweden|Sahlgrenska Universitetssjukhuset, Goteborg, Sweden|Pharmasite AB, Helsingborg, Sweden|Medicinklinikens forskningsenhet, Kristianstad, Sweden|Hjartmottagningen, Capio Citykliniken, Lund, Sweden|Probar E Lund AB, Lund, Sweden|Karlkliniken, Skanes Universitetssjukhus i Malmo, Malmo, Sweden|Pharmasite AB, Malmo, Sweden|Forskningsenheten, Medicinmottagningen Sahlgrenska Universitetssjukhuset/Molndal, Hus J, Molndal, Sweden|Ostersunds Sjukhus, Ostersund, Sweden|Dalecarlia Clinical Research Center, Rattvik, Sweden|Skelleftea Lasarett, Skelleftea, Sweden|A+Science City site, Stockholm, Sweden|Karolinska Universitetssjukhuset, Stockholm, Sweden|Hjartkliniken, Stockholm, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Vastmanlands Sjukhus Vasteras, Vasteras, Sweden|Universitatsspital, Basel, Basel Stadt, Switzerland|Diagene Laboratories Inc., Reinach, Basel, Switzerland|Hospitaux Universitaires de Geneve (HUG), Geneve, Geneva, Switzerland|Policlinique Medicale Universitaire, Lausanne, Vaud, Switzerland|Kantonsspital Winterthur, Winterthur, Zurich, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Cardiocentro Ticino, Lugano, Switzerland|Fondazione Diabete Lugano, Lugano, Switzerland|Luzerner Kantonsspital Luzern, Luzern 16, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|China Medical University Hospital, Taichung, Taiwan R O C, Taiwan|National Taiwan University Hospital, Taipei, Taiwan R O C, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital - New, Kaohsiung, Taiwan|Cardinal Tien Hospital, New Taipei City, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|National Cheng Kung University (NCKU) Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|MacKay Memorial Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Division of Cardiology, Department of Medicine, Faculty of Medicine, Siriraj Hospital,, Bangkoknoi, Bangkok, Thailand|Faculty of Medicine, Srinagarind Hospital, Khon Kaen University, Muang, Khon Kaen, Thailand|Heart Center, Songklanagarind Prince of Songkla University, Hat Yai, Songkla, Thailand|Cardiology Unit,Department of Medicine, Faculty of Medicine, Ramathibodi Hospital,, Bangkok, Thailand|Division Of cardiology,Department of Medicine,Faculty Of Medicine,Chulalongkorn University, Bangkok, Thailand|Baskent University, Adana Yuregir Training & Research Hospital, Adana, Turkey|A.karahisar Kocatepe Universitesi Hastanesi Ahmet Needet Sezer Uygulama ve, Afyonkarahisar, Turkey|Diskapi Yildirim Beyazit Egitim ve Arastirma Hastanesi, Ankara, Turkey|Ufuk University School of Medicine, Dr. Ridvan Ege Training & Research Hospital, Ankara, Turkey|Akdeniz Universitesi Tip Fakultesi, Antalya, Turkey|Antalya Training & Research Hospital, Antalya, Turkey|Adnan Menderes Universitesi Uygulama ve Arastirma Hastanesi, Aydin, Turkey|Bursa Yuksek Ihtisas Egitim ve Arastirma Hastanesi, Bursa, Turkey|Firat Universitesi, Elazig, Turkey|Gaziantep Universitesi Tip Fakultesi Sahinbey Egitim ve Arastirma Hastanesi, Gaziantep, Turkey|Bezmialem Vakif Universitesi Tip Fakultesi Kardiyoloji Bolurnu, Istanbul, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul, Turkey|Istanbul Universitesi Kardiyoloji Enstitusu, Istanbul, Turkey|Ege University, School of Medicine, Izmir, Turkey|Izmir Tepecik Egitim ve Arastirma Hastanesi, Izmir, Turkey|Dokuz Eylul Universitesi Tip Fakultesi Hastanesi, Izmir, Turkey|Dokuz Eylul Universitesi Tip Fakultesi, Izmir, Turkey|Kocaeli University School Of Medicine-Kocaeli Universitesi Tip Fakultesi, Kocaeli, Turkey|Mersin University, School of Medicine, Mersin, Turkey|Recep Tayyip Erdogan University School of Medicine, Training & Research Hospital, Rize, Turkey|Synexus Thames Valley Clinical Research Centre, Reading, Berkshire, United Kingdom|Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough, Cambridgeshire, United Kingdom|Brannel Surgery, St Austell, Cornwall, United Kingdom|Queens Hospital, Romford, Essex, United Kingdom|Synexus Manchester Clinical Research Centre-Manchester Science Park, Manchester, Greater Manchester, United Kingdom|Royal Oldham Hospital, Oldham, Greater Manchester, United Kingdom|Salford Royal NHS Foundation Trust, Salford, Greater Manchester, United Kingdom|Lister Hospital, Stevenage, Hertfordshire, United Kingdom|Queen Elizabeth II Hospital, East and North Hertfordshire NHS Trust, Welwyn Garden City, Hertfordshire, United Kingdom|Medway Maritime Hospital, Gillingham, Kent, United Kingdom|Synexus Scotland Clinical Research Centre, Glasgow, Lanarkshire, United Kingdom|Bolton NHS Foundation Trust, Bolton, Lancashire, United Kingdom|Synexus Lancashire Clinical Research Centre, Chorley, Lancashire, United Kingdom|Layton Medical Centre, Layton, Blackpool, Lancashire, United Kingdom|Synexus Merseyside Clinical Research Centre, Liverpool, Merseyside, United Kingdom|Whitby Group Practice, Whitby, North Yorkshire, United Kingdom|Albany House Medical Centre, Wellingborough, Northants, United Kingdom|Southern Health & Social Care Trust, Craigavon Area Hospital, Portadown, Northern Ireland, United Kingdom|Synexus North East Clinical Research Centre - Hexham General Hospital, Hexham, Northumberland, United Kingdom|South Axholme Practice, Doncaster, South Yorkshire, United Kingdom|Central Manchester University Hospitals NHS Foundation Trust, Manchester, South Yorkshire, United Kingdom|The Crouch Oak Family Practice, Addlestone, Surrey, United Kingdom|Ely Bridge Surgery, Cardiff, Wales, United Kingdom|Synexus Midlands Clinical Research Centre, Birmingham, WEST Midlands, United Kingdom|City Hospital, Birmingham, WEST Midlands, United Kingdom|Prince Philip Hospital, Llanelli, WEST Wales, United Kingdom|Royal Free London NHS Foundation Trust, Barnet, United Kingdom|Laurie Pike Health Centre, Birmingham, United Kingdom|Heart of England NHS Foundation Trust, Dept. of Clinical Biochemistry & Immunology, Birmingham, United Kingdom|Synexus Wales Clinical Research Centre, Cardiff, United Kingdom|Ashgate Medical Practice, Chesterfield, United Kingdom|Little Common Surgery, East Sussex, United Kingdom|Sea Road Surgery, East Sussex, United Kingdom|Staploe Medical Centre, Ely, United Kingdom|McGlone Practice - Ballieston Health Centre, Glasgow, United Kingdom|The Queen Elizabeth University Hospital- NHS Greater Glasgow and Clyde, Glosgow, United Kingdom|Burbage Surgery, Hinckley, United Kingdom|The Royal Liverpool and Broadgreen -University Hospitals NHS, Liverpool, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Peart-Rose Research Unit, Hammersmith Hospital, Imperial College NHS Trust, London, United Kingdom|The Red Porto cabin, The James Cook University Hospital, Middlesbrough, United Kingdom|St Mary's Hospital, Newport, United Kingdom|Wansford And Kings Cliffe Practice, Peterborough, United Kingdom|Rothwell and Desborough Healthcare Group, Rothwell, Northants, United Kingdom|Abertawe Bro Morgannwg University Local Health Board Joint, Swansea, United Kingdom|Western Sussex Hosptials NHS Trust, Worthing, United Kingdom|York Medical Group, York, United Kingdom|Strensall Healthcare Centre, York, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT01975389/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT01975389/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01975389"
1064,"NCT01975376","The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects","SPIRE-1","Terminated","Has Results","Cardiovascular Disease","Drug: bococizumab (PF-04950615)|Drug: Placebo","Event Rate Per 100 Participant-Years For First Occurrence of Major Cardiovascular (CV) Event|Event Rate Per 100 Participant-Years For First Occurrence of Composite Endpoint of Cardiovascular Death, Non-Fatal Myocardial Infraction, or Non-Fatal Stroke|Event Rate Per 100 Participant-Years For First Occurrence of Composite Endpoint of All-Cause Death, Non-Fatal Myocardial Infraction, Non-Fatal Stroke, or Hospitalization for Unstable Angina Needing Urgent Revascularization|Event Rate Per 100 Participant-Years For First Occurrence of Composite Endpoint of All-Cause Death, Non-Fatal Myocardial Infarction, or Non-Fatal Stroke|Event Rate Per 100 Participant-Years For First Occurrence of Hospitalization for Unstable Angina Needing Urgent Revascularization|Event Rate Per 100 Participant-Years For First Occurrence of Composite Endpoint of Cardiovascular Death, Non-Fatal Myocardial Infarction, Non-Fatal Stroke and Hospitalization for Unstable Angina|Event Rate Per 100 Participant-Years For Cardiovascular Death|Event Rate Per 100 Participant-Years For First Occurrence of Any Myocardial Infarction (Fatal or Non-Fatal)|Event Rate Per 100 Participant-Years For Fatal Myocardial Infarction|Event Rate Per 100 Participant-Years For First Occurrence of Non-Fatal Myocardial Infarction|Event Rate Per 100 Participant-Years For First Occurrence of Any Stroke (Fatal or Non-Fatal)|Event Rate Per 100 Participant-Years For First Occurrence of Any Stroke (Fatal or Non-Fatal), of Any Etiology|Event Rate Per 100 Participant-Years For Fatal Stroke|Event Rate Per 100 Participant-Years For First Occurrence of Non-Fatal Stroke|Event Rate Per 100 Participant-Years For First Occurrence of Hospitalization for Unstable Angina|Event Rate Per 100 Participant-Years For First Occurrence of Hospitalization for Congestive Heart Failure (CHF)|Event Rate Per 100 Participant-Years For First Occurrence of Coronary Revascularization|Event Rate Per 100 Participant-Years For First Occurrence of Coronary Artery Bypass Graft Surgery (CABG)|Event Rate Per 100 Participant-Years For First Occurrence of Percutaneous Coronary Intervention (PCI)|Event Rate Per 100 Participant-Years For First Occurrence of Any Arterial Revascularizations|Event Rate Per 100 Participant-Years For All-Cause Death|Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 14|Nominal Change From Baseline in Low Density Lipoprotein Cholesterol at Week 14|Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Last Post-Baseline Measurement|Percent Change From Baseline in Lipid Levels at Week 14|Percent Change From Baseline in Log-Transformed Lipoprotein (a) (Lp[a]) and Triglycerides at Week 14|Percent Change From Baseline in Log-Transformed High Sensitivity C-Reactive Protein (Hs-CRP) at Week 14","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","16784","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","B1481022|CV OUTCOMES 1|2013-002646-36|CV OUTCOMES 2","October 29, 2013","March 22, 2017","March 22, 2017","November 3, 2013","June 12, 2018","July 11, 2018","Ernest Hendrix, MD, PC, Athens, Alabama, United States|North Alabama Research Center LLC, Athens, Alabama, United States|Central Alabama Research, Birmingham, Alabama, United States|Clinical Research Advantage, Inc./Simon Williamson Clinic, Birmingham, Alabama, United States|Birmingham Heart Clinic, P.C., Birmingham, Alabama, United States|Cardiovascular Associates of the Southeast, LLC, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Appalachian Cardiovascular Associates, Fort Payne, Alabama, United States|Fundamental Research, LLC, Gulf Shores, Alabama, United States|Avant Research Associates, LLC, Guntersville, Alabama, United States|Boyett Health Services, Hamilton, Alabama, United States|Saadat Ansari Internal Medicine, Huntsville, Alabama, United States|CB Flock Research Corporation, Mobile, Alabama, United States|Alaska Heart Institute, Anchorage, Alaska, United States|Phoenix Heart, PLLC, Glendale, Arizona, United States|Arrowhead Internal Medicine, Glendale, Arizona, United States|Clinical Research Advantage, Inc./Family Practice Specialists, Ltd., Phoenix, Arizona, United States|Redpoint Research, Phoenix, Arizona, United States|Cochise Clinical Research, Sierra Vista, Arizona, United States|Clinical Research Advantage, Inc. (Administrative Mailing Only), Tempe, Arizona, United States|Southwest Heart Group, Tucson, Arizona, United States|University of Arizona Medical Center South Campus, Tucson, Arizona, United States|Arizona Endocrine and Rheumatology Associates, Tucson, Arizona, United States|Arkansas Heart Hospital Clinic, Little Rock, Arkansas, United States|Arkansas Site Management Services, LLC, Little Rock, Arkansas, United States|Cardiology Consultants of Orange County Medical Group Inc., Anaheim, California, United States|Premier Valley Medical Group, Bakersfield, California, United States|Cardiovascular Research Foundation of Southern California, Beverly Hills, California, United States|Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|Southbay Pharma Research, Buena Park, California, United States|Med Center, Carmichael, California, United States|Pioneer Medical Group, Cerritos, California, United States|John Muir Physician Network Clinical Research Center, Concord, California, United States|Atlantic Ave Medical Clinic Inc., Cudahy, California, United States|Multani Medical Group, Downey, California, United States|Triwest Research Associates, LLC, El Cajon, California, United States|Diagnamics, Inc., Encinitas, California, United States|T. Joseph Raoof, Md, Inc/Encino Research Center, Encino, California, United States|Aviva Research, Escondido, California, United States|Med Investigations, Inc., Fair Oaks, California, United States|Valley Research, Fresno, California, United States|St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton, California, United States|Omnibus Clinical Research, La Palma, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Prime Care Clinical Research Center, Laguna Hills, California, United States|Clinical Trials Research, Lincoln, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|American Institute of Research, Los Angeles, California, United States|Intermed Group, Los Angeles, California, United States|Academic Medical Research Institute, Los Angeles, California, United States|Eastside Clinical Research Associates, Los Angeles, California, United States|Richard S. Cherlin, MD, Los Gatos, California, United States|Facey Medical Foundation, Mission Hills, California, United States|California Medical Research Associates Inc., Northridge, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|Diabetes Associates Medical Group, Orange, California, United States|Saviers Medical Group, Port Hueneme, California, United States|Arch Health Partners, Poway, California, United States|A. R. I. Clinical Trials, Inc., Redondo Beach, California, United States|California Research Foundation, San Diego, California, United States|San Diego Family Care dba Linda Vista Health Center, San Diego, California, United States|San Diego Family Care, San Diego, California, United States|Ritchken & First Md's, San Diego, California, United States|Wetlin Research Associates, Inc., San Diego, California, United States|West Coast Research LLC, San Ramon, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Coastal Biomedical Research, Inc., Santa Monica, California, United States|Encompass Clinical Research, Spring Valley, California, United States|St. Joseph's Medical Associates, Stockton, California, United States|Westlake Medical Research, Thousand Oaks, California, United States|Los Angeles Biomedical Research Institute at Harbor - UCLA Medical Center, Torrance, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|Orange County Research Center, Tustin, California, United States|Bayview Research Group, Valley Village, California, United States|Coastal Metabolic Research Centre, Ventura, California, United States|Ventura Clinical Trials, Ventura, California, United States|Clinical Research Advantage, Inc. / Cassidy Medical Group - Vista, Vista, California, United States|Allianz Research Institute, Westminster, California, United States|American Institute of Research Studies, Whittier, California, United States|Elite Clinical Trials, Inc., Wildomar, California, United States|Elite Clinical Trials, Incorporated, Wildomar, California, United States|Colorado Springs Health Partners, Colorado Springs, Colorado, United States|ExpressCare Clinical Research, Colorado Springs, Colorado, United States|Lynn Institute of the Rockies, Colorado Springs, Colorado, United States|Memorial Hospital: University of Colorado Health, Colorado Springs, Colorado, United States|Lynn Institute of Denver, Denver, Colorado, United States|Western Colorado Research, LLC, Glenwood Springs, Colorado, United States|South Denver Cardiology Associates, PC, Littleton, Colorado, United States|Connecticut Clinical Research, LLC, Bridgeport, Connecticut, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Hartford Hospital, Hartford, Connecticut, United States|Cardiology Associates of Fairfield County, PC, Stamford, Connecticut, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|Christiana Care Health Services, Inc., Newark, Delaware, United States|Alfieri Cardiology, Wilmington, Delaware, United States|Capital Medical Associates, PC, Washington, District of Columbia, United States|ACRC - Cardiology, Atlantis, Florida, United States|Meridien Research, Brooksville, Florida, United States|Gulf Coast Endocrine and Diabetes Center, Clearwater, Florida, United States|Team Medical Research, Coral Gables, Florida, United States|The Heart Group, PA, Daytona Beach, Florida, United States|Cardiology Associates Research Company, Daytona Beach, Florida, United States|Seidman Clinical Trials, Delray Beach, Florida, United States|The Cardiology Center, Delray Beach, Florida, United States|Continental Research Corp, Doral, Florida, United States|Care Research Center Inc, Doral, Florida, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Moonshine Research Center, Inc., Doral, Florida, United States|Advanced Clinical Research of Miami (ACROM) International, Doral, Florida, United States|Invesclinic, LLC, Fort Lauderdale, Florida, United States|The Office of Alan Graff, MD, PA, Fort Lauderdale, Florida, United States|The Center for Diabetes and Endocrine Care, Fort Lauderdale, Florida, United States|Broward Health Medical Center (BHMC) (Broward General Medical Center (BGMC)), Fort Lauderdale, Florida, United States|The Office of Maxine E. Hamilton, MD, PA, Fort Lauderdale, Florida, United States|State Of The Art Research, LLC, Hialeah, Florida, United States|Direct Helpers Medical Center Inc, Hialeah, Florida, United States|Research Physicians Network Alliance, Hollywood, Florida, United States|Pines Clinical Research, Inc., Hollywood, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|River City Clinical Research, Jacksonville, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Baker-Gilmore Cardiovascular Institute, Jacksonville, Florida, United States|Solutions Through Advanced Research, Inc., Jacksonville, Florida, United States|Meridien Research, Lakeland, Florida, United States|The Heart Institute at Largo, Largo, Florida, United States|South Florida Clinical Research Institute, Margate, Florida, United States|Accelovance, Melbourne, Florida, United States|Research Physicians Network Alliance, Miami Beach, Florida, United States|G & I Medical Research LLC, Miami Lakes, Florida, United States|Future Clinical Research, Inc., Miami, Florida, United States|Advanced Clinical Research of Miami (ACROM) International, Miami, Florida, United States|Project4Research, Inc, Miami, Florida, United States|A & L Clinical Research, Miami, Florida, United States|Finlay Medical Research, Miami, Florida, United States|Pharmax Research Clinic, Inc., Miami, Florida, United States|South Florida Research Center, Inc., Miami, Florida, United States|Florida Medical Center & Research, Inc., Miami, Florida, United States|Medical Research Center, Miami, Florida, United States|Nuren Medical & Research Center, Miami, Florida, United States|Doctors Research Institute, Miami, Florida, United States|Advanced Pharma CR, LLC, Miami, Florida, United States|Coast Research Institute, Miami, Florida, United States|My Community Research Center, Inc., Miami, Florida, United States|Columbus Clinical Services LLC, Miami, Florida, United States|Cardiovascular Research Center of South Florida, Miami, Florida, United States|Research Institute of South Florida, Inc., Miami, Florida, United States|A & O Research Center, Inc., Miami, Florida, United States|BWell Research Center, Miami, Florida, United States|Pharmacology International Research, Inc., Miami, Florida, United States|Advanced Clinical Research, Miami, Florida, United States|South Florida Research Group, LLC, Miami, Florida, United States|International Research Associates, LLC, Miami, Florida, United States|Kendall South Medical Center, Inc., Miami, Florida, United States|M & M Medical Center, Inc, Miami, Florida, United States|Med Research Of Florida, LLC, Miami, Florida, United States|Southwest Florida Research, Naples, Florida, United States|BayCare Medical Group, New Port Richey, Florida, United States|The Heart & Vascular Institute of Florida, New Port Richey, Florida, United States|Bravo Health Care Center, North Bay Village, Florida, United States|Harmony Clincal Research, Inc., North Miami Beach, Florida, United States|Florida Hospital Cardiovascular Institute, Orlando, Florida, United States|Omega Research Consultants, LLC, Orlando, Florida, United States|Aba Family Medicine, LLC, Ormond Beach, Florida, United States|Millennium Research, Ormond Beach, Florida, United States|Ribo Research, LLC dba Peninsula Research, Ormond Beach, Florida, United States|A&R Research Group, LLC, Pembroke Pines, Florida, United States|Research Physicians Network Alliance, Pembroke Pines, Florida, United States|South Broward Research, Pembroke Pines, Florida, United States|DBC Research USA, Pembroke Pines, Florida, United States|DBC Research, Pembroke Pines, Florida, United States|Cardiology Consultants, Pensacola, Florida, United States|DMI Research, Inc., Pinellas Park, Florida, United States|Clincal Research of Florida, Plant City, Florida, United States|Clinical Research of Central Florida, Plant City, Florida, United States|Dr. Jeffrey Greiff MD, Office Of, Plantation, Florida, United States|Nova Clinical Research Collaborative, Plantation, Florida, United States|St. Johns Center for Clinical Research, Ponte Vedra, Florida, United States|Charlotte Heart Group Research Center, Port Charlotte, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Advance Medical Research, Saint Petersburg, Florida, United States|Intercoastal Medical Group, Sarasota, Florida, United States|Cardiovascular Center Of Sarasota, Sarasota, Florida, United States|Heart & Vascular Center Research, Sarasota, Florida, United States|Intercoastal Medical Group (Drug Shipment Address and Administrative), Sarasota, Florida, United States|The Office of Bridget Bellingar, DO, Seminole, Florida, United States|Vita Health & Medical Center, Inc./Concept Clinical Trials, LLC, Tamarac, Florida, United States|Interventional Cardiac Consultants, Trinity, Florida, United States|Cardiology Partners Clinical Research Institute, Wellington, Florida, United States|Cleveland Clinic Cardiology Associates, West Palm Beach, Florida, United States|Metabolic Research Institute, Inc., West Palm Beach, Florida, United States|Clinical Research of Central Florida, Winter Haven, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Atlanta Center For Medical Research, Atlanta, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Rockdale Medical Research Associates, Conyers, Georgia, United States|Georgia Heart Specialists, LLC, Covington, Georgia, United States|Neurostudies.Net, LLC, Decatur, Georgia, United States|Alta Pharmaceutical Research Center, Dunwoody, Georgia, United States|In-Quest Medical Research, LLC, Norcross, Georgia, United States|Atlanta Center for Clinical Research / Internal Medicine, Roswell, Georgia, United States|Dr. B. Abraham, P.C., Snellville, Georgia, United States|Georgia Clinical Research, LLC, Snellville, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Elite Clinial Trials, LLLP, Blackfoot, Idaho, United States|Elite Clinial Trials, Blackfoot, Idaho, United States|St. Luke's Idaho Cardiology Associates, Caldwell, Idaho, United States|Solaris Clinical Research, Meridian, Idaho, United States|Saltzer Medical Group, PA, Nampa, Idaho, United States|Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States|Clinical Research Advantage, Inc./Michigan Avenue Internists, Chicago, Illinois, United States|Apex Medical Research, AMR, Inc., Chicago, Illinois, United States|Clinical Research Advantage, Inc./Medical and Procedural Specialists of Illinois, Chicago, Illinois, United States|Evanston Premier Healthcare Research, LLC, Evanston, Illinois, United States|Clinical Investigation Specialists, Inc, Gurnee, Illinois, United States|Heart Care Centers of Illinois, Mokena, Illinois, United States|Advanced CardioVascular Consultants, Rock Island, Illinois, United States|Investigators Research Group, LLC, Brownsburg, Indiana, United States|Investigative Clinical Research of Indiana, LLC, Elwood, Indiana, United States|Deaconess Clinic Downtown, Evansville, Indiana, United States|Clinical Research Advantage, Inc. (IP Shipment and Research Site), Evansville, Indiana, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Clinical Research Advantage, Inc. / Family Medicine Associates, Evansville, Indiana, United States|Deaconess Clinic Mt. Pleasant, Evansville, Indiana, United States|American Health Network of Indiana LLC, Franklin, Indiana, United States|American Health Network of Indiana, LLC, Greenfield, Indiana, United States|American Health Network of Indiana, LLC, Muncie, Indiana, United States|Cardiovascular Research of Northwest Indiana, LLC, Munster, Indiana, United States|Buynak Clinical Research, P.C., Valparaiso, Indiana, United States|West Broadway Clinic, Council Bluffs, Iowa, United States|Clinical Research Advantage, Inc., Council Bluffs, Iowa, United States|Midwest Cardiovascular Research Foundation, Davenport, Iowa, United States|University of Iowa College of Public Health - Preventive Intervention Center, Iowa City, Iowa, United States|Northeast Iowa Medical Education Foundation, Waterloo, Iowa, United States|The Iowa Clinic, PC, West Des Moines, Iowa, United States|Hutchinson Clinic, P.A, Hutchinson, Kansas, United States|University Of Kansas Medical Center, Kansas City, Kansas, United States|Heartland Research Associates, LLC, Newton, Kansas, United States|Midwest Heart & Vascular Specialists, LLC, Overland Park, Kansas, United States|Women's & Family Care, LLC D.B.A GTC Research, Shawnee Mission, Kansas, United States|Central Cardiology Associates Research, Elizabethtown, Kentucky, United States|The Research Group of Lexington, LLC, Lexington, Kentucky, United States|L-MARC Research Center, Louisville, Kentucky, United States|Research Integrity, LLC., Owensboro, Kentucky, United States|Alexandria Cardiology Clinic, Alexandria, Louisiana, United States|Avant Research Associates, LLC, Crowley, Louisiana, United States|Centex Studies, Lake Charles, Louisiana, United States|Imperial Health, LLC, Lake Charles, Louisiana, United States|American Clinical Research, LLC, Marrero, Louisiana, United States|West Jefferson Heart Clinic of Louisiana New Orleans Physician Services, Inc., Marrero, Louisiana, United States|Clinical Trials of America LA, Monroe, Louisiana, United States|KAMP Medical Research Inc., Natchitoches, Louisiana, United States|Grace Research, LLC, Shreveport, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Acadia Clinical Research, LLC, Bangor, Maine, United States|Cranbrook Cardiology Research Associates, Westbrook, Maine, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|MedStar Cardiology Associates, Annapolis, Maryland, United States|MedStar Chesapeake CardioVascular Associates, Baltimore, Maryland, United States|MedStar Union Memorial Heart Specialists, Baltimore, Maryland, United States|Maryland Cardiovascular Specialists, Baltimore, Maryland, United States|Overlea Personal Physicians, Baltimore, Maryland, United States|Shahid Saeed, MD, PC, Baltimore, Maryland, United States|Maryland Heart Associates, LLC, Glen Burnie, Maryland, United States|Lutherville Personal Physicians, Lutherville, Maryland, United States|MD Medical Research, Oxon Hill, Maryland, United States|Metro West Medical Center Research Clinic, Framingham, Massachusetts, United States|Metro West Medical Center, Framingham, Massachusetts, United States|MetroWest Medical Center - Pharmacy Department, Framingham, Massachusetts, United States|Pentucket Medical Associates, LLC, Haverhill, Massachusetts, United States|ActivMed Practices and Research, Inc., Methuen, Massachusetts, United States|Charles River Medical Associates, Natick, Massachusetts, United States|Endeavor Medical Research, Alpena, Michigan, United States|St. Joseph Mercy Health System, Ann Arbor, Michigan, United States|University of Michigan - Domino Farms, Ann Arbor, Michigan, United States|IHA Chelsea Family & Internal Medicine, Chelsea, Michigan, United States|Healthy Heart Cardiology, Grandville, Michigan, United States|Westside Family Medical Center, Pc, Kalamazoo, Michigan, United States|Sparrow Clinical Research Institute, Lansing, Michigan, United States|Sparrow Thoracic & Cardiovascular Institute, Lansing, Michigan, United States|Detroit Clinical Research Center, PC, Livonia, Michigan, United States|MidMichigan Medical Center Midland, Midland, Michigan, United States|Michigan Cardio Vascular Institute, Saginaw, Michigan, United States|Tri-County Research, Inc., Sterling Heights, Michigan, United States|Medical Research Associates, Inc., Traverse City, Michigan, United States|Oakland Medical Research Center, Troy, Michigan, United States|Arcturus Healthcare, PLC, Troy Internal Medicine Research Division, Troy, Michigan, United States|Michigan Heart & Vascular Institute, Ypsilanti, Michigan, United States|Duluth Clinic, dba Essentia Health Duluth Clinic Investigational Drug Room, Duluth, Minnesota, United States|St. Mary's Medical Center (Primary Practice Site), Duluth, Minnesota, United States|Radiant Research, Inc., Edina, Minnesota, United States|Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States|Allina Health System, dba Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Lillehei Clinical Research Unit, University of Minnesota, Minneapolis, Minnesota, United States|CentraCare Heart and Vascular Center, Saint Cloud, Minnesota, United States|HealthEast Medical Research Institute, Saint Paul, Minnesota, United States|HealthEast St. Joseph's Hospital Pharmacy, Saint Paul, Minnesota, United States|Phillips Medical Services, PLLC, Jackson, Mississippi, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Cardiology Associates Research, LLC, Tupelo, Mississippi, United States|Missouri Cardiovascular Specialists, LLP, Columbia, Missouri, United States|Saint Luke's Lipid and Diabetes Research Center, Kansas City, Missouri, United States|Kansas City VA Medical Center, Kansas City, Missouri, United States|Mercy Research, Saint Louis, Missouri, United States|Glacier View Research Institute, Kalispell, Montana, United States|Glacier View Research Institute, Cardiology, Kalispell, Montana, United States|Montana Medical Research Inc., Missoula, Montana, United States|Clinical Research Advantage, Inc./Skyline Medical Center, PC, Elkhorn, Nebraska, United States|Bryan Heart, Lincoln, Nebraska, United States|Creighton Diabetes Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|AB Clinical Trials, Las Vegas, Nevada, United States|Clinical Research Of South Nevada, Las Vegas, Nevada, United States|Clinical Research Advantage, Inc., Las Vegas, Nevada, United States|John V. Bernard, MD dba Wellness and Research Center, Belvidere, New Jersey, United States|Advanced Heart Care LLC, Bridgewater, New Jersey, United States|Lourdes Cardiology Services, Cherry Hill, New Jersey, United States|USMA Clinical Research, Elizabeth, New Jersey, United States|Lourdes Cardiology Services, Hammonton, New Jersey, United States|NJ Heart, Linden, New Jersey, United States|Arysmed LLC, Lodi, New Jersey, United States|Amici Clinical Research, LLC, Martinsville, New Jersey, United States|Rutgers Biomedical and Health Sciences-Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Cardiac and Endovascular Associates, Ridgewood, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Cardio Metabolic Institute, Somerset, New Jersey, United States|TLB Research LLC, Trenton, New Jersey, United States|Lourdes Cardiology Services, Voorhees, New Jersey, United States|Westwood Cardiology Associates, Westwood, New Jersey, United States|Albuquerque Clinical Trials, Inc., Albuquerque, New Mexico, United States|Albany Medical College, Division of Community Endocrinology, Albany, New York, United States|Sorin Medical, P.C., Brooklyn, New York, United States|NY Total Medical Care, PC, Brooklyn, New York, United States|NY Scientific, Brooklyn, New York, United States|Buffalo Heart Group, Llp, Buffalo, New York, United States|NYU Hudson Valley Cardiology, Cortlandt Manor, New York, United States|Scott Research,Inc, Laurelton, New York, United States|SJH Cardiology Associates, Liverpool, New York, United States|Long Island Heart Associates, Mineola, New York, United States|Mid Hudson Medical Research, PLLC, New Windsor, New York, United States|Manhattan Medical Research Practice, New York, New York, United States|Peters Medical Research NY, LLC, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|DiGiovanna Institute for Medical Education And Research, North Massapequa, New York, United States|Hudson Valley Cardiovascular Practice, PC, Poughkeepsie, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Institute for Clinical Studies, Rosedale, New York, United States|Saratoga Clinical Research, LLC, Saratoga Springs, New York, United States|Central New York Cardiology, Utica, New York, United States|Great Lakes Medical Research, Westfield, New York, United States|Buffalo Medical Group - Research Department, Williamsville, New York, United States|Buffalo Medical Group, Williamsville, New York, United States|Kernodle Clinic, Department of the Private Diagnostic Clinic, PLLC, Burlington, North Carolina, United States|Novant Health Clinical Research, Charlotte, North Carolina, United States|Novant Health Heart and Vascular Institute, Charlotte, North Carolina, United States|PMG Research of Charlotte, Charlotte, North Carolina, United States|Sensenbrenner Primary Care, Charlotte, North Carolina, United States|NC Heart and Vascular, Clayton, North Carolina, United States|LeBauer Cardiovascular Research Foundation, Greensboro, North Carolina, United States|Clinical Trials of America, Inc., Hickory, North Carolina, United States|Carolina Cardiology Cornerstone, High Point, North Carolina, United States|Clinical Trials of America- NC, LLC, Lenoir, North Carolina, United States|Research Institute of the Carolinas of PiedmontHealthcare, PA, Mooresville, North Carolina, United States|Burke Primary Care, Morganton, North Carolina, United States|Eastern Nephrology Associates, New Bern, North Carolina, United States|Boice Willis Clinic, Rocky Mount, North Carolina, United States|PMG Research of Rock Mount, LLC - Patient Intake, Rocky Mount, North Carolina, United States|Piedmont Healthcare/Research, Statesville, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Radiant Research, Inc., Akron, Ohio, United States|The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, United States|Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States|Radiant Research, Inc., Columbus, Ohio, United States|Optimed Research, LTD, Columbus, Ohio, United States|Premier Health Specialists, Inc (dba Dayton Heart Center), Dayton, Ohio, United States|PriMed Clinical Research, Dayton, Ohio, United States|North Ohio Heart Center (Administrative Only), Elyria, Ohio, United States|North Ohio Heart Center, Elyria, Ohio, United States|North Ohio Heart Center, Lorain, Ohio, United States|SV Research, LLC, Marion, Ohio, United States|Daniel G. Williams, MD, Perrysburg, Ohio, United States|North Ohio Heart Center, Inc., Sandusky, Ohio, United States|North Ohio Heart Center, Sandusky, Ohio, United States|ProMedica Northwest Ohio Cardiology Consultants, Toledo, Ohio, United States|Mercy Health Youngstown, LLC d/b/a St. Elizabeth Youngstown Hospital, Youngstown, Ohio, United States|LION Research, Norman, Oklahoma, United States|COR Clinical Research LLC, Oklahoma City, Oklahoma, United States|Oklahoma Heart Hospital Physicians, Oklahoma City, Oklahoma, United States|Oklahoma Heart Hospital Research Foundation, Oklahoma City, Oklahoma, United States|Oklahoma Heart Hospital, Oklahoma City, Oklahoma, United States|South Oklahoma Heart Research, LLC, Oklahoma City, Oklahoma, United States|Integrated Medical Research PC, Ashland, Oregon, United States|Hillsboro Cardiology, P.C., Hillsboro, Oregon, United States|Portland Preventive Cardiology LLC, Portland, Oregon, United States|Abington Memorial Hospital (administrative only), Abington, Pennsylvania, United States|Clinical Research Associates of Central PA, Altoona, Pennsylvania, United States|Brandywine Clinical Research, Downingtown, Pennsylvania, United States|Doylestown Cardiology Associates - VIAA, Doylestown, Pennsylvania, United States|Doylestown Health Cardiology, a division of Doylestown Health Physicians, Doylestown, Pennsylvania, United States|AMH/Feasterville Family Health Care Center, Feasterville-Trevose, Pennsylvania, United States|Greater Pittsburgh Vascular, Jefferson Hills, Pennsylvania, United States|Detweiler Family Medicine & Associates, PC, Lansdale, Pennsylvania, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Family Medical Associates, Levittown, Pennsylvania, United States|Mercer Bucks Cardiology, Newtown, Pennsylvania, United States|Philadelphia Health Associates-Adult Medicine, Philadelphia, Pennsylvania, United States|Allegheny Endocrinology Associates, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group, PC, Sayre, Pennsylvania, United States|SFM Clinical Trials, Inc., Scotland, Pennsylvania, United States|Fay-West Family Practice, Scottdale, Pennsylvania, United States|Grand View - Lehigh Valley Health Services, Buxmont Cardiology Division, Sellersville, Pennsylvania, United States|Montgomery Medical, Inc., Smithfield, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Berks Cardiologists, Ltd., Wyomissing, Pennsylvania, United States|Coastal Cardiolgy, Charleston, South Carolina, United States|Upstate Pharmaceutical Research, Greenville, South Carolina, United States|Mountain View Clinical Research, Inc., Greer, South Carolina, United States|Black Hills Cardiovascular-Regional Health Research, Rapid City, South Dakota, United States|Mid-Cumberland Infectious Disease Consultants, PLC, Clarksville, Tennessee, United States|Collierville Medical Specialists, Collierville, Tennessee, United States|Stern Cardiovascular Foundation, Inc., Germantown, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|New Phase Research & Development, Knoxville, Tennessee, United States|PMG Research,Inc d/b/a PMG Research of Knoxville, Knoxville, Tennessee, United States|Cardiovascular Research of Knoxville, Knoxville, Tennessee, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Baptist Memorial Medical Group, Inc., Memphis, Tennessee, United States|The Green Clinic, PC, Memphis, Tennessee, United States|Southwind Medical Specialists, Memphis, Tennessee, United States|Tennessee Center for Clinical Trials, Tullahoma, Tennessee, United States|Trinity Clinical Research, LLC, Tullahoma, Tennessee, United States|PharmaTex Research, Amarillo, Texas, United States|Arlington Family Research Center, Inc., Arlington, Texas, United States|Texas Diabetes & Endocrinology, Austin, Texas, United States|Austin Heart, PLLC, Austin, Texas, United States|Southeast Texas Cardiology Associates II, L.L.P., Beaumont, Texas, United States|Southeast Texas Clinical Research Center, Beaumont, Texas, United States|Aztec Medical Research, LLC, Channelview, Texas, United States|Corsicana Medical Research, PLLC, Corsicana, Texas, United States|Baylor Research Institute IRB, Dallas, Texas, United States|Protenium Clinical Research, LLC, Dallas, Texas, United States|VA North Texas Health Care System - Dallas VAMC, Dallas, Texas, United States|Baylor Heart and Vascular Institute, Dallas, Texas, United States|Dallas Diabetes and Endocrine Center, Dallas, Texas, United States|Cardiovascular Research Institute of Dallas, Dallas, Texas, United States|Radiant Research, Inc., Dallas, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|Parkland Health and Hospital System, Dallas, Texas, United States|Baylor University Medical Center / Department of Pharmacy, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|(For IP storage only)The University of Texas Southwestern Medical Center, Dallas, Texas, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States|William P. Clements Jr. University Hospital, Dallas, Texas, United States|Doctors Hospital At Renaissance, Edinburg, Texas, United States|Amir Malik Research, Fort Worth, Texas, United States|The Medical Group of Texas, Fort Worth, Texas, United States|T & R Clinic, PA, Fort Worth, Texas, United States|Rockwood Medical Clinic, Fort Worth, Texas, United States|San Gabriel Clinical Research, LLC, Georgetown, Texas, United States|East Texas Cardiology PA, Houston, Texas, United States|Spring Clinical Research, Houston, Texas, United States|Med Tech Research, LP, Houston, Texas, United States|Prime Care Medical Group, Houston, Texas, United States|Associates in Medicine, PA, Houston, Texas, United States|Alan S. Hoffman, M.D., Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|ICTR/Baylor College of Medicine, Houston, Texas, United States|Investigational Drug Services, Houston, Texas, United States|Memorial Hermann Hospital, Texas Medical Center- UT Health Clinical Research Unit, Houston, Texas, United States|Memorial Hermann Hospital, Texas Medical Center, Houston, Texas, United States|The University of Texas Health Science Center at Houston- UT Physicians, Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Northwest Houston Cardiology, P.A., Houston, Texas, United States|Texas Center for Drug Development, Inc, Houston, Texas, United States|Private Practice Leadership, LLC, Houston, Texas, United States|Protenium Clinical Research LLC, Hurst, Texas, United States|South Texas Cardiovascular Consultants, PLLC, Kerrville, Texas, United States|DCOL Center for Clinical Research, Longview, Texas, United States|Caprock Cardiac Center Research Institute Inc., Lubbock, Texas, United States|Midland Clinical Research Center, Midland, Texas, United States|Hill Country Medical Associates, New Braunfels, Texas, United States|North Hills Medical Research, Inc., North Richland Hills, Texas, United States|Grace Research, LLC, Palestine, Texas, United States|Med-Olam Clinical Research, LLC., Pasadena, Texas, United States|Austin Institute for Clinicla Research,Inc., Pflugerville, Texas, United States|Centex Studies, Inc, Pharr, Texas, United States|South Texas Cardiovascular Consultants, PLLC, San Antonio, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Southwest Clinic, San Antonio, Texas, United States|FIRST Outpatient Research Unit, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Texas Health Science Center San Antonio, San Antonio, Texas, United States|University of Texas Health Sciences Center at San Antonio, San Antonio, Texas, United States|Victorium Clinical Research, San Antonio, Texas, United States|Bandera Family Health Care, LLC, San Antonio, Texas, United States|Northeast Clinical Research of San Antonio, LLC (NECRSA, LLC), Schertz, Texas, United States|Acacia Medical Research Institute, LLC/Royal Oaks Medcical Home and Wellness Clinics, Sugar Land, Texas, United States|IP + Dry ice deliveries Sugar Lakes Family Practice, Sugar Land, Texas, United States|Sugar Lakes Family Practice, Sugar Land, Texas, United States|Northwest Houston Heart Center, Tomball, Texas, United States|Admin & Storage only:Northwest Heart Center, Tomball, Texas, United States|Northwest Heart Center, Tomball, Texas, United States|Northwest Houston Clinical Research, PLLC, Tomball, Texas, United States|Victoria Heart & Vascular Center, PA, Victoria, Texas, United States|Victoria Heart and Vascular Center, PA, Victoria, Texas, United States|Utah Cardiology, PC, Bountiful, Utah, United States|Utah Cardiology, P.C., Layton, Utah, United States|Paramount Medical Care, Ogden, Utah, United States|Aspen Clinical Research LLC, Orem, Utah, United States|Revere Health, Provo, Utah, United States|Optimum Clinical Research, Inc, Salt Lake City, Utah, United States|Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States|Holladay Family Practice, Salt Lake City, Utah, United States|Heart Center at St. Mark's Hospital, Salt Lake City, Utah, United States|Clinical Research Institute of Northern Virginia, Burke, Virginia, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Virginia Heart, Falls Church, Virginia, United States|Seven Corners Medical Research Center, Falls Church, Virginia, United States|Heart Care Associates, P.C., Hopewell, Virginia, United States|Virginia Research Center, Midlothian, Virginia, United States|Chippenham and Johnston Willis Hospitals, Inc. dba CJW Medical Center, Richmond, Virginia, United States|Retreat Cardiology LLC, dba Cardiology Associates of Richmond, Richmond, Virginia, United States|Roanoke Heart Institute, Roanoke, Virginia, United States|Hampton Roads Center for Clinical Research, Suffolk, Virginia, United States|The Office of Daniel W. Gottlieb, MD, PS, Burien, Washington, United States|Premier Clinical Research, Spokane, Washington, United States|Universal Research Group, LLC, Tacoma, Washington, United States|Walla Walla Clinic, Walla Walla, Washington, United States|Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States|Fairmont General Hospital, Fairmont, West Virginia, United States|Prevea Clinic, Inc., Green Bay, Wisconsin, United States|Clinical Investigation Specialists, Inc., Kenosha, Wisconsin, United States|Waukesha Heart Foundation, Waukesha, Wisconsin, United States|Instituto de Investigaciones Clinicas Bahia Blanca, Bahia Blanca, Buenos Aires, Argentina|Hospital Italiano Regional del Sur, Bahia Blanca, Buenos Aires, Argentina|Hospital Britanico De Buenos Aires, Ciudad Autonoma de B. Aires, Buenos Aires, Argentina|CEDIC - Consultorios Medicos, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Framingham Centro Medico, La Plata, Buenos Aires, Argentina|CIMeL CHAHIN CHAHIN S.A., Lanus Este, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Mar del Plata, Mar del Plata, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Quilmes, Quilmes, Buenos Aires, Argentina|DIM Clinica Privada, Ramos Mejia, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Zarate, Zarate, Buenos Aires, Argentina|Consultorios Asociados de Endocrinologia e Investigacion Clinica Aplicada, C.a.b.a, C.a.b.a., Argentina|STAT Research S.A., C.a.b.a, Caba, Argentina|Clinica Privada de Especialidades Medicas, Villa Maria, Cordoba, Argentina|CIPADI Centro Integral de Prevencion y Atencion en Diabetes, Godoy Cruz, Mendoza, Argentina|Hospital Interzonal Gral. de Agudos Dr. Jose Penna, Bahia Blanca, PCIA DE Buenos Aires, Argentina|IMEP Instituto Medico Elsa Perez, Ciudadela, PCIA DE Buenos Aires, Argentina|Instituto Medico Aguero, Moron, PCIA DE Buenos Aires, Argentina|Corporacion Medica de San Martin, San Martin, PCIA DE Buenos Aires, Argentina|Cordis - Instituto del Corazon, Resistencia, PCIA DE Chaco, Argentina|Hospital de Alta Complejidad ""Pte. Juan Domingo Peron"", Formosa, PCIA DE Formosa, Argentina|Hospital Provincial Dr. Jose Maria Cullen, Santa Fe, PCIA DE Santa FE, Argentina|Centro De Investigaciones Clinicas Del Litoral S.R.L., Santa Fe, PCIA DE Santa FE, Argentina|Cedir S.A - Centro De Diagnostico Y Rehabilitacion S.A., Santa Fe, PCIA DE Santa FE, Argentina|Centro Modelo de Cardiologia, San Miguel De Tucuman, PCIA DE Tucuman, Argentina|Instituto de Hematologia y Medicina Clinica ""Dr. Ruben A. Davoli"", Rosario, Pcia. DE Santa FE, Argentina|Clinica Coronel Suarez S.A., Coronel Suarez, Provincia DE Buenos Aires, Argentina|Instituto Medico CENICLAR - Central de Investigaciones Clinicas Argentina -Sanatorio de la Mujer, Rosario, Provincia DE Santa FE, Argentina|Instituto de Investigaciones Clinicas Rosario, Rosario, Santa FE, Argentina|Centro Medico CCBR Tucuman, San Miguel de Tucuman, Tucuman, Argentina|CIPREC - Centro de Investigacion y Prevencion Cardiovascular S.A., C.a.b.a., Argentina|Instituto de Cardiologia y Cirugia Cardiovascular - Fundacion Favaloro, Ciudad Autonoma de B. Aires, Argentina|Cicemo - Consultorio de Investigaciones Clinicas E.M.O. S.R.L., Ciudad Autonoma De B. Aires, Argentina|Instituto Cardiovascular De Buenos Aires, Ciudad Autonoma de B. Aires, Argentina|Investigaciones Medicas IMOBA S.R.L., Ciudad Autonoma de Buenos Aires, Argentina|Universidad Maimonides, Ciudad Autonoma De Buenos Aires, Argentina|Centro de Investigacion: AXISMED S.R.L., Ciudad Autonoma de Buenos Aires, Argentina|ILAIM Instituto Latinoamericano de Investigaciones Medicas, Cordoba, Argentina|Clinico Chutro SRL, Cordoba, Argentina|Centro de Investigaciones Clinicas ""Instituto del Corazon"", Cordoba, Argentina|Clinica Privada Colombo, Cordoba, Argentina|Instituto Medico DAMIC S.R.L., Cordoba, Argentina|Centro Medico Luquez, Cordoba, Argentina|IPAC Caraffa, Cordoba, Argentina|Instituto de Cardiologia de Corrientes ""Juana Fca. Cabral"", Corrientes, Argentina|Hospital Central de Mendoza, Mendoza, Argentina|Cordis S.A., Salta, Argentina|Centro Cardiovascular Salta, Salta, Argentina|Instituto Cardiovascular San Luis A.E., San Luis, Argentina|Canberra Hospital, Garran, Australian Capital Territory, Australia|Boden Institute of Obesity, Nutrition, Exercise and Eating Disorders, Camperdown, New South Wales, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Central Coast Neurosciences Research, Erina, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Australian Clinical Research Network, Maroubra, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Holy Spirit Northside Private Hospital Limited, Chermside, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Core Research Group Pty Ltd, Milton, Queensland, Australia|Redcliffe Hospital, Redcliffe, Queensland, Australia|Austrials Pty Ltd, Sherwood, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|Adelaide Medical Research, Ashford, South Australia, Australia|SA Heart, Ashford, South Australia, Australia|Southern Adelaide Diabetes and Endocrine Service, Daws Park, South Australia, Australia|Department of Cardiology, Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Heart and Vascular Research, Fullarton, South Australia, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Eastern Health - Box Hill Hospital, Box Hill, Victoria, Australia|The Northern Hospital, Epping, Victoria, Australia|Barwon Health-The Geelong Hospital, Geelong, Victoria, Australia|Austin Health - Heidelberg Repatriation Hospital, Heidelberg West, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Fremantle Hospital, Fremantle, Western Australia, Australia|HPS Pharmacies, Joondalup, Western Australia, Australia|Joondalup Cardiovascular Trials Foundation Inc., Joondalup, Western Australia, Australia|Sir Charles Gairdner Hospital, Heart Research Institute, Nedlands, Western Australia, Australia|VZW Algemeen Ziekenhuis KLINA, Brasschaat, Antwerpen, Belgium|AZ Turnhout - campus St. Elisabeth, Turnhout, Antwerpen, Belgium|Hopital Erasme-Universite Libre de Bruxelles (ULB), Anderlecht, Brabant Flamand, Belgium|Centre hospitalier de Jolimont-Lobbes - Centre de Recherche Medicale de Jolimont, La Louviere, Haine Saint PAUL, Belgium|Algemeen Stedelijk Ziekenhuis, Aalst, Oost-vlaanderen, Belgium|Az Sint Blasius, Dendermonde, Oost-vlaanderen, Belgium|AZ Sint Lucas Gent-Campus Sint Lucas, Gent, Oost-vlaanderen, Belgium|Az Glorieux, Ronse, Oost-vlaanderen, Belgium|AZ Groeninge-Campus Loofstraat, Kortrijk, West-vlaanderen, Belgium|Az Damiaan, Oostende, West-vlaanderen, Belgium|A.Z. Sint-Augustinus Veurne, Veurne, West-vlaanderen, Belgium|ZNA Campus Middelheim, Antwerpen, Belgium|Imeldaziekenhuis Bonheiden, Bonheiden, Belgium|A.Z. St.Jan AV Brugge, Brugge, Belgium|University Hospital Brussels - Centrum voor hart- en vaatziekten, Brussels, Belgium|University Hospital Brussels- Diabeteskliniek, Brussels, Belgium|Private Practice 'Cardiovascular Detection Center', De Pinte, Belgium|ZOL Campus Sint-Jan, Genk, Belgium|AZ Maria Middelares, Gent, Belgium|Grand Hopital de Charleroi, Site St-Joseph, Gilly, Belgium|Hygeia, Hasselt, Belgium|Jessa Ziekenhuis, Hasselt, Belgium|Sint-Franciskusziekenhuis, Heusden-Zolder, Belgium|Centre Hospitalier Regional de Huy, Huy, Belgium|Jan Yperman Ziekenhuis, Cardiology, Ieper, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium|University hospitals Leuven - Cardiology department, Leuven, Belgium|Centre Hospitalier Chretien, Liege, Belgium|Centre Hospitalier Universitaire de Liege, Liege, Belgium|Huisartsenpraktijk Medilink, Linkebeek, Belgium|Huisartsenpraktijk Luc Capiau, Massemen, Belgium|AZ Sint-Maarten, Mechelen, Belgium|C.H.U. Ambroise Pare, Mons, Belgium|Mariaziekenhuis vzw, Overpelt, Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|Dr. Luc De Wolf - Private Practice, Tienen, Belgium|Instituto Cardiopulmonar da Bahia, Salvador, Bahia, Brazil|Fundacao Bahiana De Cardiologia, Salvador, BA, Brazil|HBA S/A ASSISTENCIA MEDICA E HOSPITALAR-Hospital da Bahia, Salvador, BA, Brazil|Hospital Universitario Walter Cantidio, Fortaleza, Ceara, Brazil|Hospital de Messejana Dr Carlos Alberto Studart Gomes, Fortaleza, Ceara, Brazil|Centro de Pesquisas em Diabetes e Doencas Endocrino-Metabolicas Ltda, Fortaleza, CE, Brazil|Instituto De Cardiologia Do Distrito Federal, Brasilia, Distrito Federal, Brazil|CEDOES - Centro de Diagnostico e Pesquisa da Osteoporose do Espirito Santo, Vitoria, Espirito Santo, Brazil|INGOH - Instituto Goiano de Oncologia e Hematologia, Goiania, Goias, Brazil|Via Medica - Clinica Medica Integrada Ltda - Barroso e Sebba Ltda, Goiania, GO, Brazil|Hospital Lifecenter / Lifecenter Sistema de Saude S.A, Belo Horizonte, MG, Brazil|Hospital Felicio Rocho, Belo Horizonte, MG, Brazil|Hospital Universitário Sao José / FELUMA - MG, Belo Horizonte, MG, Brazil|Liga Mineira de Ressuscitacao Cardiopulmonar, Belo Horizonte, Minas Gerais, Brazil|Hospital Vera Cruz, Belo Horizonte, Minas Gerais, Brazil|Hospital Universitario Ciencias Medicas / Fundacao Educacional Lucas Machado, Belo Horizonte, Minas Gerais, Brazil|Liga Mineira de Ressucitacao cardiopulmonar, Belo Horizonte, Minas Gerais, Brazil|CARDSEARCH/CARDRESEARCH - Cardiologia Assistencial e de Pesquisa LTDA, Belo Horizonte, Minas Gerais, Brazil|Universidade Federal de Uberlandia, Uberlandia, Minas Gerais, Brazil|Eurolatino Pesquisas Medicas LTDA, Uberlandia, Minas Gerais, Brazil|Hospital Santa Casa De Curitiba, Curitiba, Parana, Brazil|Nucleo de Pesquisa Clínica, Curitiba, Parana, Brazil|Hospital Parana - Parana Medical Research Center - MARIMED SERVICOS MEDICOS S.A., Maringa, Parana, Brazil|Universidade Federal do Para - Hospital Universitario Joao de Barros Barreto, Belem, PA, Brazil|Hospital Agamenon Magalhaes, Recife, Pernambuco, Brazil|Centro de Pesquisas Medicas Basica e Clinica LTDA, Recife, PE, Brazil|Sociedade Hospitalar Angelina Caron/Hospital e Maternidade Angelina Caron, Campina Grande do Sul, PR, Brazil|Irmandade da Santa Casa de Misericordia de Curitiba - Hospital Santa Casa de Misericordia, Curitiba, PR, Brazil|Quanta Diagnostico e Terapia / Medicina Nuclear Alto da XV, Curitiba, PR, Brazil|Hospital Universitario - Associacao Educadora Sao Carlos - AESC, Canoas, RIO Grande DO SUL, Brazil|Santa Casa De Misericordia De Pelotas, Pelotas, RIO Grande DO SUL, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital Mae de Deus/Associacao Educadora Sao Carlos AESC/IMV - Instituto de Medicina Vascular, Porto Alegre, RIO Grande DO SUL, Brazil|CCBR - Centro de Pesquisas e Analises Clinicas LTDA, Rio De Janeiro, RJ, Brazil|CCBR Brasil - Centro de Pesquisa e Analises Clinicas LTDA, Rio de Janeiro, RJ, Brazil|Hemocardio S/S Ltda, Natal, RN, Brazil|Associacao Hospitalar Beneficente Sao Vicente de Paulo - Hospital Sao Vicente de Paulo, Passo Fundo, RS, Brazil|Irmandade Da Santa Casa De Misericordia De Porto Alegre - ISCMPA, Porto Alegre, RS, Brazil|Uniao Brasileira de Educacao e Assistencia (UBEA) - Hospital Sao Lucas da PUCRS, Porto Alegre, RS, Brazil|Hospital Santa Isabel, Blumenau, Santa Catarina, Brazil|Insituto de Cardiologia de Santa Catarina, Sao Jose, Santa Catarina, Brazil|Loema Medicina e Bem Estar- Centro Especializado em Cardiologia Ltda, Campinas, SAO Paulo, Brazil|Scentryphar Pesquisa Clinica, Campinas, SAO Paulo, Brazil|Hospital E Maternidade Celso Pierro PUC - Campinas - Sociedade Campineira de Educacao e Instrucao, Campinas, SAO Paulo, Brazil|ICM - Instituto do Coracao de Marilia, Marilia, SAO Paulo, Brazil|Instituto Conceive, Paraiso, SAO Paulo, Brazil|Hospital Estadual Mario Covas, Santo Andre, SAO Paulo, Brazil|Instituto Domingo Braile _ Braile Hospital Dia LTDA, Sao Jose Do Rio Preto, SAO Paulo, Brazil|IMC - Instituto de Molestias Cardiovasculares/Equipamentos Cardiovasculares Rio Preto Ltda, Sao Jose do Rio Preto, SAO Paulo, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SAO Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, SAO Paulo, Brazil|CAEP - Centro Avançado de Estudos e Pesquisas Ltda., Campinas, SP, Brazil|CPQuali Pesquisa Clinica LTDA, Sao Paulo, SP, Brazil|Hospital Samaritano, Sao Paulo, SP, Brazil|Instituto de Conhecimento, Ensino e Pesquisa (Administrative local), Sao Paulo, SP, Brazil|Comed Care Empresa de Atendimento Clinico Geral - LTDA - Hospital Total Care, Sao Paulo, SP, Brazil|CCBR Sao Paulo, Sao Paulo, SP, Brazil|CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda., Sao Paulo, SP, Brazil|CPClin- Centro de Pesquisas Clinicas Ltda./Clinica Dr. Freddy Goldberg Eliaschewitz, Sao Paulo, Brazil|FGM-Clinica Paulista de Doencas Cardiovasculares, Sao Paulo, Brazil|SPDM Associacao Paulista para o Desenvolvimento da Medicina, Sao Paulo, Brazil|UNIFESP - Hospital Sao Paulo - Setor de Lipides, Aterosclerose e Biologia Vascular, Sao Paulo, Brazil|Instituto Jaqueline Scholz Issa e Mario Issa de Cardiologia LTDA, Sao Paulo, Brazil|LMC Diabetes & Endocrinology (Calgary), Calgary, Alberta, Canada|Foothills Hospital/University of Calgary, Calgary, Alberta, Canada|Nanji Professional Corporation, Calgary, Alberta, Canada|The Medical Arts Health Research Group, Kelowna, British Columbia, Canada|Dr Stephen Pearce Inc, Surrey, British Columbia, Canada|Dr. Adam Yeung Inc., Surrey, British Columbia, Canada|Dr. Micheal Kanakos Inc, Surrey, British Columbia, Canada|Dr. Raymond Dong Inc., Surrey, British Columbia, Canada|Dr. Richard Bon Inc., Surrey, British Columbia, Canada|Dr. Stephen S. Cheung Inc., Surrey, British Columbia, Canada|SMH Cardiology Clinical Trials, Surrey, British Columbia, Canada|Dr Peter K.H. Tan Inc, Surrey, British Columbia, Canada|Dr. Dante E. Manyari Inc., Surrey, British Columbia, Canada|Dr. Stephanie Au, Inc., Surrey, British Columbia, Canada|SMH Cardiology Clinical Trials Inc., Surrey, British Columbia, Canada|Dr. Kapil M. Bhagirath Medical Services Corporation, Surrey, British Columbia, Canada|Victoria Heart Institute Foundation, Victoria, British Columbia, Canada|Discovery Clinical Services Ltd., Victoria, British Columbia, Canada|St. Boniface Hospital, Winnipeg, Manitoba, Canada|Unicity Laboratory Services, Winnipeg, Manitoba, Canada|Rivergrove Medical Clinic, Winnipeg, Manitoba, Canada|G.A. Research Associates Ltd., Moncton, New Brunswick, Canada|Cardiology Research Associates of New Brunswick, Saint John, New Brunswick, Canada|Health Sciences Centre, St. John's, Newfoundland and Labrador, Canada|LMC Diabetes & Endocrinology (Brampton), Brampton, Ontario, Canada|Aviva Clinical Trial Group Inc., Burlington, Ontario, Canada|JBN Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Philippe R. Beaudry Medicine Professional Corporation, Burlington, Ontario, Canada|Cambridge Cardiac Care Centre, Cambridge, Ontario, Canada|Vizel Cardiac Research, Saul Vizel Professional Medicine Corporation, Cambridge, Ontario, Canada|Moran Medical Centre, Collingwood, Ontario, Canada|C & L Research, Fort Erie, Ontario, Canada|Parkdale Medical Centre, Hamilton, Ontario, Canada|Western University - WCPHFM, London, Ontario, Canada|Stroke Prevention & Atherosclerosis Research Centre (SPARC)-Siebens-Drake Research Institute, London, Ontario, Canada|LMC Diabetes & Endocrinology (Markham), Markham, Ontario, Canada|Newmarket Cardiology Research Group, Newmarket, Ontario, Canada|LMC Clinical Research Inc. (Oakville), Oakville, Ontario, Canada|LMC Oakville, Oakville, Ontario, Canada|The Office of Dr. James Cha, Oshawa, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|London Road Diagnostic Clinic and Medical Centre, Sarnia, Ontario, Canada|Sarnia Institute of Clinical Research, Sarnia, Ontario, Canada|Scarborough Cardiology Research Associates Inc., Scarborough, Ontario, Canada|Canadian Centre for Research on Diabetes, Smiths Falls, Ontario, Canada|Brian Y.L. Wong Medicine Professional Corporation, Sudbury, Ontario, Canada|LMC Diabetes & Endocrinology (Thornhill), Thornhill, Ontario, Canada|JJ Dig Research LTD, Toronto, Ontario, Canada|Canadian Phase Onward, Inc., Toronto, Ontario, Canada|LMC Diabetes & Endocrinology (Bayview), Toronto, Ontario, Canada|Dr. Anil K. Gupta Medicine Professional Corporation, Toronto, Ontario, Canada|Dr. Mohan Babapulle Medicine Professional Corporation, Waterloo, Ontario, Canada|Dr. Louis Yao, Weston, Ontario, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|Q & T Research Chicoutimi, Chicoutimi, Quebec, Canada|Q&T Recherche Outaouais Inc., Gatineau, Quebec, Canada|Centre de Recherche Clinique de Laval, Laval, Quebec, Canada|Omnispec clinical research inc, Mirabel, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Diex Research Montreal, Inc., Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke- Hotel-Dieu, Sherbrooke, Quebec, Canada|Centre integre de sante et de services sociaux de Lanaudiere (CISSSL), St Charles-Borromee, Quebec, Canada|Centre Integre de Sante et de services sociaux de Chaudiere-Appalaches (CISSS-CA), St-Georges, Beauce, Quebec, Canada|CISSS des Laurentides-Point de Service de St-Jerome- Comite d'ethique de la recherche, St-Jerome, Quebec, Canada|St-Jerome Medical Research Inc., St-Jerome, Quebec, Canada|LMC Diabetes & Endocrinology (Montreal), Ville Saint-Laurent, Quebec, Canada|Recherche Clinique Sigma Inc, Quebec, Canada|Clinique des maladies lipidiques de Quebec, Quebec, Canada|Biomedica Research Group, Providencia Santiago, Metropolitana, Chile|CICAB, Santiago, Metropolitana, Chile|SMOLAM, Santiago, Metropolitana, Chile|Hopsital y CRS El Pino, Santiago, Metropolitana, Chile|Complejo Asitencial Dr. Sotero del Rio, Santiago, Metropolitana, Chile|Centro de Investigacion Clínica del Sur, Temuco, Region DE LA Araucania, Chile|Corporacion de Beneficencia Osorno, Osorno, Region DE LOS Lagos, Chile|Hospital Clinico Magallanes, Punta Arenas, Region DE Magallanes, Chile|Servicios Medicos Godoy, Santiago, Region Metropolitana, Chile|Quantum Research, Puerto Varas, Chile|Guangdong General Hospital, Guangzhou, Guangdong, China|Haikou People's Hospital, Haikou, Hainan, China|The 2nd Affiliated Hospital Of Harbin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital of Habrin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital Of Harbin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital Of Zhengzhou University, Zhengzhou, Henan, China|The Central Hospital Of Wuhan, Wuhan, Hubei, China|Pu Ai Hospital of Wuhan City, Wuhan, Hubei, China|Changde First People's Hospital, Changde, Hunan, China|Changsha Central Hospital, Changsha, Hunan, China|Hunan Provincial People's Hospital, Changsha, Hunan, China|Xiangtan City Central Hospital, Xiangtan, Hunan, China|Zhuzhou Central Hospital, Zhuzhou, Hunan, China|Inner Mongolia Baogang Hospital, Baotou, Inner Mongolia, China|Inner Mongolia Autonomous Region People's Hospital, Hohhot, Inner Mongolia, China|Wuxi People's Hospital, Jiangsu, Jiangsu, China|Suzhou Kowloon Hospital Shanghai Jiaotong University School of Medicine, Suzhou, Jiangsu, China|The affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China|Jilin Province People`s Hospital, Changchun, Jilin, China|The First Hospital of Jilin University, Changchun, Jilin, China|China-Japan Union Hospital of Jilin University, Changchun, Jilin, China|General Hospital Of Ningxia Medical University, Yinchuan, Ningxia, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|The First Affiliated Hospital Of Xinjiang Medical University, Urumqi, Xinjiang, China|Ningbo First hospital, Ningbo, Zhejiang, China|Beijing Chao-yang Hospital, Beijing, China|FuWai Hospital, CAMS & PUMC, Beijing, China|Shanghai General Hospital, Shanghai, China|Tianjin Union Medical Center, Tianjin, China|Taizhou Hospital of Zhejiang Province, Zhejiang, China|Hospital Pablo Tobon Uribe, Medellin, Antioquia, Colombia|Centro de Investigacion Clinica Avanzada y Multidisciplinaria CICLAM, Medellin, Antioquia, Colombia|Centro de Medicina del Ejercicio y Rehabilitacion Cardiac - CEMDE S.A., Medellin, Antioquia, Colombia|Rodrigo Botero S.A.S., Medellin, Antioquia, Colombia|Clinica De La Costa Ltda, Barranquilla, Atlantico, Colombia|Centro Cientifico Asistencial Jose Luis Accini S.A.S., Barranquilla, Atlantico, Colombia|Corazon Ips Sas., Barranquilla, Atlantico, Colombia|Fundacion del Caribe Para La Investigacion Biomedica - Fundacion BIOS, Barranquilla, Atlantico, Colombia|Centro de Diagnostico Cardiologico LTDA., Cartagena, Bolivar, Colombia|Asociacion IPS Medicos Internistas de Caldas, Manizales, Caldas, Colombia|Hospital Universitario San Ignacio, Bogota D C, Cundinamarca, Colombia|MedPlus Medicina Prepagada S.A., Bogota D.C., Cundinamarca, Colombia|Instituto de Investigacion Endocrinologia y Prevencion Metabolica - ENDOCARE LTDA., Bogota D.C., Cundinamarca, Colombia|Simedics Ips Sas, Bogota D.C., Cundinamarca, Colombia|Solano & Terront Servicios Medicos Ltda-Establecimiento Comercial UNIENDO, Bogota D.C., Cundinamarca, Colombia|Dexadiab Servicios Medicos LTDA, Bogota D.C, Cundinamarca, Colombia|Caja de Compensacion Familiar CAFAM, Sede Centro de Atencion en Salud CAFAM FLORESTA, Bogota D.C, Cundinamarca, Colombia|Healthy Medical Center S.A.S, Zipaquira, Cundinamarca, Colombia|Fundacion Centro de Obesidad y Metabolismo COMETA, Pasto, Narino, Colombia|Instituto del Corazon de Bucaramanga S.A., Bucaramanga, Santander, Colombia|Fundacion Cardiovascular De Colombia - Instituto del Corazón Floridablanca, Floridablanca, Santander, Colombia|Fundacion Cardiovascular De Colombia - Instituto del Corazón Floridablanca, Floridablanca, Santander, Colombia|Fundacion Reina Isabel, Cali, Valle DEL Cauca, Colombia|Kardiologicka Ambulance, Brno, Jihomoravsky KRAJ, Czechia|Edumed S.R.O., Broumov, Kralovehradecky KRAJ, Czechia|EDUMED s.r.o., Jaromer, Kralovehradecky KRAJ, Czechia|Kardiologicka ambulance, Trutnov, Kralovehradecky KRAJ, Czechia|Lekarna na Poliklinice, Trutnov, Kralovehradecky KRAJ, Czechia|Mudr. Jan Vrkoc S.R.O., Ostrava, Moravskoslezsky KRAJ, Czechia|Pv-Kardiologie S.R.O., Pardubice, Pardubicky KRAJ, Czechia|CCBR Czech Brno, s.r.o., Brno, Czechia|DIKa centrum s.r.o., Kardiologicka a interni ambulance, Havirov, Czechia|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fremlova Apotheca s.r.o., Litovel, Czechia|Kardio interna s.r.o., Litovel, Czechia|Fakultni Nemocnice Olomouc, Olomouc, Czechia|CCBR Czech a.s., Pardubice, Czechia|Kardiologie Plzen s.r.o., Plzen, Czechia|Fakultni Nemocnice Kralovske Vinohrady, Praha 10, Czechia|Fakultni poliklinika Vseobecne fakultni nemocnice v Praze, Praha 2, Czechia|CCBR Czech Prague, s.r.o, Praha 3, Czechia|Kardiologie a interni lekarstvi, Praha 5, Czechia|NEFROMED, s.r.o., Praha 6, Czechia|Centrum kardiovaskularni prevence 1. LF UK a TN, Praha, Czechia|Interna a kardiologie s.r.o., Roznov pod Radhostem, Czechia|Nemocnice Pardubickeho kraje, a.s., Svitavska nemocnice, Svitavy, Czechia|Ordinace V Tabacce s.r.o., Tabor, Czechia|MUDr. Antonin Dufka, kardiologicka ambulance, Uherske Hradiste 1, Czechia|MUDr. Nina Zemkova s.r.o., Uherske Hradiste 1, Czechia|KIGE s.r.o., Znojmo, Czechia|Aabenraa Hospital Hjertemedicinsk klinik Kredslobscentret, SHS, Aabenraa, Denmark|Sygehus Sonderjylland Aabenraa, Aabenraa, Denmark|Aalborg Universitetshospital, Lipidklinikken, Aalborg, Denmark|CCBR Aalborg, Aalborg, Denmark|Aarhus Universitetshospital Skejby, Hjertesygdomme ¿ Klinisk Forskning, Aarhus, Denmark|CCBR Ballerup, Ballerup, Denmark|Bispebjerg og Frederiksberg Hospital, Copenhagen NV, Denmark|Sydvestjysk Sygehus, Hjertemedicinsk Projektgruppe, Esbjerg, Denmark|Frederiksberg Hospital, Frederiksberg, Denmark|Glostrup Hospital, Glostrup, Denmark|Herlev Universitetshospital, Herlev, Denmark|Regionshospitalet Herning, Herning, Denmark|Hillerod Hospital, Hillerod, Denmark|Hvidovre Universitetshospital, Hvidovre, Denmark|Karkirurgisk Klinisk, Kobenhavn O, Denmark|Amager Hospital, Kobenhavn S., Denmark|Region Sjaelland Sygehus Nord, Koge Sygehus, Koege, Denmark|Kolding Sygehus, Kolding, Denmark|Region Sjaelland Naestved Sygehus, Naestved, Denmark|Nykobing F. Sygehus-Medicinsk afdeling, Nykobing F., Denmark|Regionshospitalet Randers, Randers, Denmark|Regionshospitalet Silkeborg, Hjerte Projektkontor, Silkeborg, Denmark|Slagelse Sygehus, Slagelse, Denmark|Svendborg Sygehus, Svendborg, Denmark|CCBR Vejle, Vejle, Denmark|Hospitalsenheden Midt, Regionshospital Viborg, Viborg, Denmark|HYKS Jorvin sairaala, Espoo, Finland|Linnan Klinikka Oy, Hameenlinna, Finland|Geri-Med Oy, Helsinki, Finland|Helsinki University Central Hospital, Helsinki, Finland|Helsingin yliopistollinen keskussairaala, Sisaetaudit ja kuntoutus, Biomedicum 2U, Helsinki, Finland|Ita-Suomen laakarikeskus Oy, Joensuu, Finland|StudyCor Oy, Jyvaskyla, Finland|Laeaekaerikeskus Aava Kerava, Kerava, Finland|Menoa oy, Kinkomaa, Finland|Kokkolan Keskussairaala, Kokkola, Finland|Mewell liikuntaklinikka, Kotka, Finland|Itae-Suomen Laeaekaeritalo, Kuopio, Finland|Terveystalo Kuopio, Kuopio, Finland|Oulu Mentalcare Oy, Oulu, Finland|Terveystalo Oulu, Diapolis, Oulu, Finland|Oulu University Hospital, Oulu, Finland|Porin Laakaritalo Oy, Pori, Finland|Terveystalo Siilinjarvi, Siilinjarvi, Finland|FinnMedi Oy, Tampere, Finland|Terveystalo Pulssi, Turku, Finland|Turku University hospital, Turku, Finland|Vantaan Tutkimuskeskus, Vantaa, Finland|Ylitornion Terveyskeskus, Ylitornio, Finland|CHU Jean Minjoz Cardiologie, Besancon, France|Groupe Hospitalier de Pellegrin Hopital Pellegrin, Bordeaux, France|Centre Hospitalier De Bourg En Bresse - Hopital Fleyriat, Bourg En Bresse Cedex 10000, France|centre hospitalier Sub-Francilien, Corbeil-Essonnes, France|Scp Cardiovasculaire De L'Est, Essey-Les-Nancy, France|Centre Hospitalier Louis Pasteur, Le Coudray, France|Hopital La Louviere, Lille, France|Centre Hospitalier Saint Philibert, Lomme, France|Hopital Cardiovasculaire Et Pneumologique Louis Pradel, Lyon Cedex 03, France|Hopital Arnaud de Villeneuve - CHU Montpellier, Montpellier cedex 5, France|CHU de Nantes - Hopital Nord Laennec, Nantes, France|Nouvelles Cliniques Nantaises, Nantes, France|Chu De Nice - Hopital Pasteur, Nice Cedex 1, France|Hopital Cardiologique, Pessac cedex, France|CHU de Poitiers, Poitiers Cedex, France|CHU de Renes Hopital de Pontchaillou, Rennes Cedex 9, France|CHU de Toulouse, Toulouse cedex 9, France|Hospital Cuy Chatilliez, Tourcoing, France|Hopital Trousseau, Tours Cedex 9, France|Centre Hospitalier (GH) de Valenciennes, Valenciennes, France|Polyclinique Vauban, Valenciennes, France|Universitaets Herzzentrum Freiburg Bad Krozingen, Bad Krozingen, Baden-wuerttemberg, Germany|Medizinische Universitaetsklinik Heidelberg, Heidelberg, Baden-wurttemberg, Germany|Gemeinschaftspraxis im Altstadt Carree, Fulda, Hessen, Germany|Zentrum Klinische Studien Neuwied (ZKSN), Neuwied, Rheinland Pfalz, Germany|Gemeinschaftspraxis Schwabenheim, Schwabenheim, Rhineland-palatinate, Germany|Klinikum Altenburger Land Gmbh, Altenburg, Germany|Forschungszentrum Dr. med Irma Schoell, Bad Homburg, Germany|Institut fuer Klinische Forschung und Entwicklung(IKFE) Berlin GmbH, Berlin, Germany|Klinische Forschung Berlin- Mittte GmbH, Berlin, Germany|POLIKUM Institut GmbH, Polikum Berlin Friedenau, Berlin, Germany|DRK Kliniken Berlin Kopenick, Zentrum Klinische Forschung, Berlin, Germany|Synexus Clinical Research GmbH, Berlin, Germany|Deutsches Herzzentrum Berlin, Berlin, Germany|Medizinisches Versorgungszentrum am Bahnhof Spandau, Berlin, Germany|Staedtische Kliniken Bielefeld Gem. GmbH - Klinikum Mitte, Bielefeld, Germany|Bochum Research Centre-Synexus Clinical Research GmbH, Bochum, Germany|Synexus Clinical Research GmbH, Bochum, Germany|MediClin Reha-Zentrum Spreewald, Burg-Spreewald, Germany|Klinikum Coburg, Coburg, Germany|Kardiologische Praxisgemeinschaft, Dortmund, Germany|St. Johannes-Hospital, Dortmund, Germany|Gemeinschaftspraxis fuer Kardiologie Dres. Med. Willgeroth/Wetzel, Dortmund, Germany|Klinsche Forschung Dresden GmbH, Dresden, Germany|Praxis Dr. med. Christoph Axthelm, Dresden, Germany|GWT-TUD GmbH, Studienzentrum Professor Hanefeld, Dresden, Germany|Gemeinschaftspraxis Dr. Hagemann/Breiderhoff/Durfeld, Essen, Germany|Medizentrum Essen Borbeck, Essen, Germany|Studienzentrum, Essen, Germany|Gemeinschaftspraxis Dres. Dirk Weber, Ulrich Weber, Heiner Saueressig, Birte Turner und Georg, Essen, Germany|Schwerpunktpraxis Dr. Luedemann fuer Diabetes Gefaess- und Ernaehrungsmedizin, Falkensee, Germany|IKF Institut fuer klinische Forschung Frankfurt, Frankfurt am Main, Germany|Synexus Clinical Research GmbH, Frankfurt, Germany|Clinphenomics Gmbh & Co Kg, Studienzentrum, Frankfurt, Germany|Klinik und Poliklinik fuer Innere Medizin B - Kardiologie, Angiologie, Pulmologie, Greifswald, Germany|Cardiologicum Hamburg, Hamburg, Germany|Praxis Dr. med Cornelia Brauer, Hamburg, Germany|Klinische Forschung Hannover-Mitte GmbH, Hannover, Germany|Universitaetsklinikum des Saarlandes Klinik fuer Innere Medizin III, Homburg, Germany|Praxis Dr. Heister, Kamp-Lintfort, Germany|Studienzentrum Dr. Appel, Kassel, Germany|Zentrum fuer klinische Forschung, Koeln, Germany|Gemeinschaftspraxis Dr. Klein / Minnich, Kuenzing, Germany|Klinik fur Innere Medizin, Kardiologie und Angiologie MediClin Herzzentrum Lahr/Baden., Lahr, Germany|Synexus Leipzig Clinical Research Centre, Leipzig, Germany|SIBAmed Studienzentrum GmbH & Co. KGKG, Leipzig, Germany|Gemeinschaftspraxis Dr. med. Heidrun Taeschner und Dr. med. Susanne Bonigut, Leipzig, Germany|Klinikum Leverkusen GgmbH, Leverkusen, Germany|Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Germany|Maerkische Kliniken GmbH, Klinikum Luedenscheid, Innere III, Luedenscheid, Germany|Klinikum Lunen, St. Marienhospital, Lunen, Germany|SMO.MD GmbH, Zentrum fuer klinische Studien Site Management and Clinical Research Unit, Magdeburg, Germany|Pfuetzner Science & Health Institute-Gmbh, Mainz, Germany|Ze:ro Arztpraxen Dr. med. Salbach, Mannheim, Germany|Klinikum fuer Herz- & Kreislauferkrankungen, Muenchen, Germany|Klinikum Der Universitat Munchen, Munchen, Germany|Klinikum Fur Herz- & Kreislauferkrankungen, Munich, Germany|Staedtisches Klinikum Muenchen GmbH, Klinikum Neuperlach, Munich, Germany|Kardiologische Praxis Northeim, Northeim, Germany|Gemeinschaftspraxis Drs Haggenmiller/Jeserich, Kardiologie, Angiologie, Innere Medizin, Nurnberg, Germany|Allgemeinmedizinisch-Internistische Praxisgemeinschaft, Offenbach, Germany|Praxis Dres. Med Naudts und Nowack, Rodgau, Germany|Klinik Am See - Klinik Am See - Rehabilitationszentrum Fur Innere Medizin, Rudersdorf, Germany|Klinische Forschung Schwerin GmbH, Schwerin, Germany|Kardiologische Gemeinschaftspraxis Dres Med. Gerke/Buerger, Soest, Germany|Praxisgemeinschaft Stuhr-Brinkum, Stuhr-Brinkum, Germany|Robert-Bosch-Krankenhaus, Stuttgart, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Josephs-Hospital Warendorf Med. Klinik II, Kardiologie/Angiologie, Warendorf, Germany|Kardiologische Praxis, Wermsdorf, Germany|ForschungszentrumRuhr KliFoCenter GmbH, Witten, Germany|Bacs-Kiskun Megyei Korhaz, Kecskemet, Bacs-kiskun, Hungary|Pecsi Tudomanyegyetem AOK, II., Pecs, Baranya, Hungary|Szegedi Tudomanyegyetem AOK, I. sz Belgyogyaszati Klinika, Szeged, Csongrad, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Szekesfehervar, Fejer, Hungary|DRC Kft., Balatonfured, Hungary|DRC Kft., Balatongyorok, Hungary|Kardiologiai Maganrendelo, Bekescsaba, Hungary|Grof Tisza Istvan Korhaz Berettyoujfalu, Berettyoujfalu, Hungary|Budapesti Szent Ferenc Korhaz, Budapest, Hungary|Synexus Magyarorszag Kft, Budapest, Hungary|Szent Rokus Korhaz, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Gottsegen Gyorgy Orszagos Kardiologiai Intezet, Budapest, Hungary|Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary|Bajcsy-Zsilinszky Korhaz es Rendelointezet, Budapest, Hungary|Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak, III. Belgyogyaszat-Kardiologiai Osztaly, Budapest, Hungary|Debreceni Egyetem, I. sz. Belgyogyaszati Klinika, Debrecen, Hungary|Synexus Magyarorszag Egeszsegugyi Szolgaltato Kft., Debrecen, Hungary|Synexus Magyarorszag Kft., Gyula, Hungary|Edes Szivunk Egeszsegkozpont Kft., Hajduszoboszlo, Hungary|BKS Research Kft., Albert Schweitzer Korhaz, Hatvan, Hungary|Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvar, Hungary|Jutrix Egeszsegugyi Kft, Kecskemet, Hungary|Pest Megyei Flor ferenc Korhaz, Kistarcsa, Hungary|Josa Andras Oktatokorhaz, Nyiregyhaza, Hungary|Medifarma-98 Kft., Nyiregyhaza, Hungary|Pecsi Tudomanyegyetem AOK, I. Belgyogyaszati Klinika, Pecs, Hungary|Mentahaz Maganorvosi Kozpont, Szekesfehervar, Hungary|Hetenyi Geza Korhaz, Szolnok, Hungary|Markusovszky Egyetemi Oktatokarhaz, Szombathely, Hungary|Dr. Sydo es Tsa Kft, Veszprem, Hungary|Zala Megyei Korhaz, Zalaegerszeg, Hungary|Dr. Jivraj Mehta Smarak Health Foundation, Bakeri Medical Research Centre, Ahmedabad, Gujarat, India|Apex Heart Institute (A Unit of TCVS Pvt. Ltd), Ahmedabad, Gujarat, India|SAL Hospital, Ahmedabad, Gujarat, India|Apple Hospital, Surat, Gujarat, India|Unicare Heart Institute & Research Center, Surat, Gujarat, India|BAPS - Pramukh Swami Hospital, Surat, Gujarat, India|Rhythm Heart Institute, Vadodara, Gujarat, India|Aster Aadhar Hospital (Prerana Hospital Ltd.), Kolhapur, Maharashtra, India|Shri Krishna Hrudayalaya and Critical Care Centre, Nagpur, Maharashtra, India|Jehangir Clinical Development Centre Pvt. Ltd., Pune, Maharashtra, India|Mediciti Hospitals, Hyderabad, Telangana, India|M.V. Hospital And Research Centre, Lucknow, Uttar Pradesh, India|Beaumont Hospital, Dublin, Leinster, Ireland|The Adelaide & Meath Hospital-Dublin Incorporating The National Children's Hospital, Dublin, Ireland|Mater Misericordiae University Hospital, Dublin, Ireland|St. James's Hospital, Dublin, Ireland|Health Research Board, Galway, Ireland|Portiuncula Hospital, Galway, Ireland|Barzilai Medical Center, Ashkelon, Israel|Gefen Institute for Research and Cardiac Health, Bat Yam, Israel|The Soroka University Medical Center, Beer Sheva, Israel|Ben Yair Community Clinic - Clalit Health Services, Beer-Sheva, Israel|Heart Institute, Hillel Yaffe Medical Center, Hadera, Israel|Rambam Medical Center, Haifa, Israel|Cardiovascular Clinical Research Institute, Haifa, Israel|Edith Wolfson Medical Center, Holon, Israel|Heart Institute, Bikur Cholim Campus, Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Ein Kerem Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Meir Medical Center, Kfar-Saba, Israel|Galilee Medical Center, Cardiology Department, Nahariya, Israel|E.M.M.S Nazareth Hospital, Nazareth, Israel|Sha'aria Clinic, Clalit Health Services, Petach Tikva, Israel|Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel|Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel|Rabin Medical Center, Petah Tikva, Israel|Shuali Community Clinic, Clalit Health Services, Raanana, Israel|Department of Neurology & Sagol Neuroscience Center, Ramat Gan, Israel|Heart Institute, Kaplan Medical Center, Rehovot, Israel|Kaplan Medical Center, Rehovot, Israel|Internal Medicine A, Ziv Medical Center, Safed, Israel|Assuta Medical Center, Tel Aviv, Israel|The Chaim Sheba Medical Center, Tel HaShomer, Israel|Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel|A.O. Treviglio e Caravaggio, Treviglio (BG), Bergamo, Italy|AOU Policlinico ""Mater Domini"" UOC di Medicina interna, Catanzaro, CZ, Italy|Ospedale S. L. Mandic di Merate, Merate, Lecco, Italy|IRCCS Centro Cardiologico Fondazione Monzino, Milano, MI, Italy|Ospedale Civile Di Piove Di Sacco, Piove Di Sacco, Padova, Italy|AOU Policlinico ""P. Giaccone"" Dipartimento delle Patologie Emergenti, Unita di Medicina Interna, Palermo, PA, Italy|Ospedale S. Maria della Misericordia Dipartimento di Medicina, Medicina Interna,, Perugia, PG, Italy|Azienda Ospedaliera Della Provincia Di Lecco - Ospedale Manzoni, Lecco, Province OF Lecco, Italy|Dept.""Medicina lnterna e Specialita Mediche"" dell' Universita degli, Roma, RM, Italy|Policlinico Umberto I di Roma, Rome, RM, Italy|Azienda Ospedaliera S'Andrea di Roma - UOC Cardiologia, Rome, RM, Italy|Presidioospedaliero di san dona 'di PIAVE, San Dona Di Paive, Venezia, Italy|Ospedale G. Fracastoro, San Bonifacio, Verona, Italy|AOUI di Verona - Ospedale Civile Maggiore Borgo Trento, Verona, VR, Italy|I.N.R.C.A. di Ancona Ospedale Geriatrico, Ancona, Italy|Ospedale Civile Regionale San Martino, Belluno, Belluno, Italy|Azienda Ospedaliera G. Brotzu, Cagliari, Italy|Divisione di Cardiologia con UTIC ed Emodinamica, Naples, Italy|Department of Clinical Medicines and Cardiovascular Sciences, Universita ""Federico II"" di Napoli, Napoli, Italy|Divisione di Cardiologia con Utic ed Emodinamica - AOU Federico II di Napoli, Napoli, Italy|A.O. di Reggio Emilia Arcispedale ""S. Maria Nuova""/IRCCS, Reggio Emilia, Italy|AUSL Della Romagna-Ospedale Infermi, Rimini, Italy|Policlinico Umberto I di Roma - DAI Malattie Cardiovascolari e Respiratorie, Rome, Italy|Ospedale Santa Maria della Misericordia Azienda ULSS 18 of Rovigo, Rovigo, Italy|A.O.U. San Giovanni di Dio e Ruggi d'Aragona U.O.C. UTIC, Salerno, Italy|Azienda Ospedaliera Universitaria Santa Maria Della Misericordia, Udine, Italy|Chungbuk National University Hospital, Cheongju-si, Chungcheonbuk-do, Korea, Republic of|Kangwon National University Hospital, Chuncheon-si, Gangwon-do, Korea, Republic of|Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju-Si, Gangwon-do, Korea, Republic of|Dongguk University Ilsan Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of|Inje University Ilsan Paik Hospital, Goyang-Si, Gyeonggi-do, Korea, Republic of|MyongJi Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of|Uijeongbu St. Mary's Hospital-The Catholic University of Korea, Uijeongbu-si, Gyeonggi-do, Korea, Republic of|Inha University Hospital, Jung-gu, Incheon, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Daegu Catholic University Medical Center, Daegu, Korea, Republic of|Konyang University Hospital, Daejeon, Korea, Republic of|Daejeon St. Mary's Hospital-The Catholic University of Korea, Daejeon, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Hallym University Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Consultorio Dr. Leocadio Gerardo Munoz Beltran, Cd. Juarez, Chihuahua, Mexico|Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares, S.C., Mexico, D F, Mexico|Centro de Atencion e Investigacion en Factores de Riesgo Cardiovascular Omega S.C, Mexico, DF, Mexico|Consultorio de Endocrinologia y Nutriologia, Mexico, Distrito Federal, Mexico|Operadora de Hospitales Angeles S.A. de C.V.(Emergencies), Mexico, Distrito Federal, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion ""Salvador Zubiran"", Mexico, Distrito Federal, Mexico|Centro de Investigacion Clinica del Pacifico, S.A. de C.V., Acapulco de Juarez, Guerrero, Mexico|Investigacion Biomedica Aplicada de Hidalgo S.A. de C.V., Pachuca, Hidalgo, Mexico|Centro de Investigacion Medica Integral S.C., Guadalajara, Jalisco, Mexico|Instituto de Terapeutica Experimental y Clinica (INTEC) Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico|Hospital Mexico Americano S.C. (Emergencies), Guadalajara, Jalisco, Mexico|Consultorio Privado del Dr. Gabriel Arturo Ramos Lopez, Guadalajara, Jalisco, Mexico|CICEJ Centro de Investigacion Clinica Endocrinologica de Jalisco SC, Guadalajara, Jalisco, Mexico|Unidad de Investigacion Clinica y Atencion Medica HEPA S.C., Guadalajara, Jalisco, Mexico|Jardines Hospital de Especialidades S.A de C.V, Zapopan, Jalisco, Mexico|Instituto de Diabetes Obesidad y Nutricion, S.C., Cuernavaca, Morelos, Mexico|Hospital Inovamed Cuernavaca (Emergencies), Cuernavaca, Morelos, Mexico|Accelerium S. de R.L. de C.V., Monterrey, Nuevo LEON, Mexico|Hospital y Clinica OCA, S.A. de C.V., Monterrey, Nuevo LEON, Mexico|Monterrey International Research Center, Monterrey, Nuevo LEON, Mexico|Cardiolink Clin Trials, S.C., Monterrey, Nuevo LEON, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo LEON, Mexico|Hospital Universitario De Monterrey- ""Doctor Jose Eleuterio Gonzalez"", Monterrey, Nuevo LEON, Mexico|CRI Centro Regiomontano de Investigacion SC, Monterrey, Nuevo LEON, Mexico|Global Trial Research Center S.A. de C.V., Monterrey, Nuevo LEON, Mexico|Fundacion Santos y de la Garza Evia I.B.P. (Centro Medico Zambrano Hellion), San Pedro Garza Garcia, Nuevo LEON, Mexico|Centro Integral Medico SJR S.C, San Juan del Rio, Queretaro, Mexico|Centro para el Desarrollo de la Medicina y de Asistencia Médica Especializada S.C., Culiacan, Sinaloa, Mexico|Hospital Angeles Culiacan (Emergencies Only), Culiacan, Sinaloa, Mexico|Centro de Estudios de Investigacion Metabolicos y Cardiovasculares S.C., Tampico, Tamaulipas, Mexico|Centro de Especialidades Medicas del Estado de Veracruz, Xalapa, Veracruz, Mexico|Instituto Biomedico De Investigacion A.C., Aguascalientes, Mexico|Centro de Investigacion Cardiometabolica de Aguascalientes S.A. de C.V., Aguascalientes, Mexico|Centro Hospitalario Mac, S.A. de C.V. (Emergencies), Aguascalientes, Mexico|Hospital Cardiologica Aguescalientes, Aguascalientes, Mexico|Unidad de Investigacion en Salud de Chihuahua S.C., Chihuahua, Mexico|Investigacion en Salud y Metabolismo S.C., Chihuahua, Mexico|Consultorio Medico de Especialidad Dr. Demetrio Kosturakis Garcia, Chihuahua, Mexico|Investigacion en Salud y Metabolismo S.C, Chihuahua, Mexico|Instituto Nacional de Ciencia Medicas y Nutricion Salvador Zubiran, Distrito Federal, Mexico|Lahoja Asociacion para la Investigacion y Farmacovigilancia S.C., Durango, Mexico|Cardioprevent, S.C., Durango, Mexico|Pharmacology and Clinical Research S.A. de C.V., Queretaro, Mexico|Cardioarritmias e Investigacion S.C., San Luis Potosi, Mexico|Hospital Lomas de San Luis Intemacional (Emergencies), San Luis Potosi, Mexico|""Hospital Central """"Dr. Ignacio Morones Prieto"""""", San Luis Potosi, Mexico|Centro Especializado En Diabetes Y Metabolismo, Veracruz, Mexico|Tjongerschans Ziekenhuis, Heerenveen, Friesland, Netherlands|Zuyderland MC, Sittard-Geleen, Limburg, Netherlands|Isala, Zwolle, Overijssel, Netherlands|St. Franciscus Gasthuis, Rotterdam, Zuid-holland, Netherlands|Het Lange Land Ziekenhuis, Zoetermeer, Zuid-holland, Netherlands|Noordwest Ziekenhuisgroep, Alkmaar, Netherlands|EB Flevoresearch, Almere, Netherlands|Meander Medical Center, Amersfoort, Netherlands|Meander Medisch Centrum, Amersfoort, Netherlands|Amstelland Hospital, Amstelveen, Netherlands|Bovenij Ziekenhuis, Amsterdam, Netherlands|OLVG, locatie West, Amsterdam, Netherlands|VU University Medical Center, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Academic Medical Center, Amsterdam, Netherlands|Gelre Hospitals, Apeldoorn, Netherlands|Rode Kruis Ziekenhuis, Beverwijk, Netherlands|Tergooi Ziekenhuis, Blaricum, Netherlands|Andro Medical Research B.V., Breda, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Reinier de Graaf ziekenhuis, Delft, Netherlands|Hedramed, Den Haag, Netherlands|Hedramed, Den Haag, Netherlands|Hagaziekenhuis, Den Haag, Netherlands|HMC (Haaglanden Medisch Centrum) Bronovo, Den Haag, Netherlands|Deventer Ziekenhuis, Deventer, Netherlands|Van Weel Bethesda Hospital, Dirksland, Netherlands|Slingeland Ziekenhuis, Doetinchem, Netherlands|Albert Schweitzer Hospital, Dordrecht, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Netherlands|Andromed Eindhoven, Eindhoven, Netherlands|Heartcentre Catharina Hospital, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Beatrix Ziekenhuis, Gorinchem, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Spaarne Gasthuis, Haarlem, Netherlands|St. Jansdal Ziekenhuis, Harderwijk, Netherlands|Zuyderland Medisch Centrum, Heerlen, Netherlands|Zuyderland, Heerlen, Netherlands|Treant Zorggroep, location Bethesda, Hoogeveen, Netherlands|Vascular Research Centre, Hoorn, Netherlands|Quality Care Research, Kloosterhaar, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Alrijne Ziekenhuis, Leiden, Netherlands|Alrijne Ziekenhuis, Leiderdorp, Netherlands|GCM Maarssenbroek, Maarssen, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Isala Diaconessenhuis, Meppel, Netherlands|St Antonius Hospital, Nieuwegein, Netherlands|Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Waterland Hospital, Purmerend, Netherlands|Andro Medical Research B.V, Rotterdam, Netherlands|Rotterdam Research Institute, Rotterdam, Netherlands|St. Fransiscus Gasthuis, Rotterdam, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands|D&A Research and Genetics, Sneek, Netherlands|Ziekenhuis Rivierenland, Tiel, Netherlands|Elisabeth-TweeSteden Ziekenhuis (previously named St. Elisabeth Ziekenhuis), Tilburg, Netherlands|St. Elisabeth Ziekenhuis, Tilburg, Netherlands|Elisabeth TweeSteden Ziekenhuis (ETZ), Tilburg, Netherlands|Bernhoven Ziekenhuis, Uden, Netherlands|EB Utrecht, Utrecht, Netherlands|Universitair Medisch Centrum (UMC) Utrecht - Locatie AZU, Utrecht, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Maxima Medisch Centrum, Veldhoven, Netherlands|VieCuri Medisch Centrum, Venlo, Netherlands|Twee Steden Ziekenhuis, Waalwijk, Netherlands|Albert Schweitzer Hospital, Zwijndrecht, Netherlands|Optimal Clinical Trials, Grafton, Auckland, New Zealand|Henderson Medical Centre, Henderson, Auckland, New Zealand|Middlemore Hospital, Otahuhu, Auckland, New Zealand|North Shore Hospital, Takapuna, Auckland, New Zealand|Hawke's Bay Hospital, Frimley, Hastings, New Zealand|Auckland City Hospital, Auckland, New Zealand|Lipid and Diabetes Research Group, Christchurch, New Zealand|Southern Clinical Trials Shirley Ltd, Christchurch, New Zealand|Southern Clinical Trials Riccarton, Christchurch, New Zealand|RMC Medical Research Ltd., Dunedin, New Zealand|Taranaki Base Hospital, New Plymouth, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Clinical Horizons NZ Ltd., Tauranga, New Zealand|Clinical Trials Unit,Bay of Plenty(BOP) Clinicla School, Tauranga, New Zealand|Papamoa Pines Medical Centre, Tauranga, New Zealand|Clinical Horizons NZ Ltd, Tauranga, New Zealand|Wellington Hospital, Wellington, New Zealand|Jeleniogorskie Centrum Chorob Serca, Przychodnia Kardiologiczna, Poradnia Kardiologiczna, Jelenia Gora, Dolnoslaskie, Poland|Zdrowie s.c. Agnieszka i Donald Drozdz, Wroclaw, Dolnoslaskie, Poland|Halina Serafin NZOZ Centrum Medyczne SERAFIN-MED, Zarow, Dolnoslaskie, Poland|NZOZ Vitamed, Bydgoszcz, Kujawsko-pomorskie, Poland|Nzoz Centrum Medyczne Kermed, Bydgoszcz, Kujawsko-pomorskie, Poland|Specjalistyczna Praktyka Lekarska Piotr Kubalski, Grudziadz, Kujawsko-pomorskie, Poland|Specjalistyczne Gabinety Lekarskie ""Medicor Plus"" - Jerzy Kopaczewski, Wloclawek, Kujawsko-pomorskie, Poland|Gabinet Lekarski Malgorzata Saryusz-Wolska, Lodz, Lodzkie, Poland|Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp. z o.o. Jednostka 02, Lodz, Lodzkie, Poland|""Prywatny Gabinet Kardiologiczny"" Dr N.Med. Maciej Kosmider, Lodz, Lodzkie, Poland|Niepubliczny Zaklad Opieki Zdrowotnej CEREO-MED Sp. z o.o., Lodz, Lodzkie, Poland|Prywatny Gabinet Lekarski Dr n. med. Michal Ogorek, Piotrkow Trybunalski, Lodzkie, Poland|Centrum Medyczne Ogrodowa Sp. z o.o., Skierniewice, Lodzkie, Poland|Clinical Best Solutions, Lublin, Lubelskie, Poland|Optimamed Specjalistyczne Gabinety Lekarskie, Lublin, Lubelskie, Poland|KO-MED Centra Kliniczne Lublin II, Lublin, Lubelskie, Poland|KO-MED Centra Kliniczne Pulawy, Pulawy, Lubelskie, Poland|KO-MED Centra Kliniczne Zamosc, Zamosc, Lubelskie, Poland|Landa Specjalistyczne Gabinety Lekarskie, Krakow, Malopolskie, Poland|Krakowski Szpital Specjalistyczny im. Jana Pawla II, Krakow, Malopolskie, Poland|Szpital Specjalistyczny im. J. Dietla w Krakowie, Oddzial Kardiologii, Krakow, Malopolskie, Poland|Centrum Medyczne Zdrowa J. Trebacz, W. Zajdel Spolka jawna, Krakow, Malopolskie, Poland|CENTRUM MEDYCZNE A-Z Clinic, Krakow, Malopolskie, Poland|Krakowskie Centrum Medyczne Sp. z o.o., Krakow, Malopolskie, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie,, Krakow, Malopolskie, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie, Ambulatoria, Krakow, Malopolskie, Poland|NZOZ Centrum Zdrowia i Profilaktyki Dabie Sp. z.o.o., Krakow, Malopolskie, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Centrum Medyczne ProMiMed sp z o.o., sp.k., Krakow, Malopolskie, Poland|NeuroCor Banaszkiewicz, Kulaga, Ostrowska, Tomaszewski lekarze spolka partnerska, Myslenice, Malopolskie, Poland|INTERCARD Sp. z. o. o. Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii w Nowym Targu, Nowy Targ, Malopolskie, Poland|Medicome Sp. z o.o., Oswiecim, Malopolskie, Poland|Centrum Szybkiej Diagnostyki Kardiologicznej Kardiomed M. Zabowka E. Zabowka, Tarnow, Malopolskie, Poland|Specjalistyczny Gabinet Lekarski Internistyczno-Kardiologiczny Boguslaw Derlaga, Tarnow, Malopolskie, Poland|Synexus Polska Sp. z o.o. Oddzial w Katowicach, Katowice, Mazowieckie, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Specjalistyczna Przychodnia Lekarska ""MEDIKARD"", Plock, Mazowieckie, Poland|Centrum Medyczne Piaski Filia nr 9, Warszawa, Mazowieckie, Poland|Instytut Kardiologii im. Prymasa Tysiaclecia Stefana Kardynala Wyszynskiego, Warszawa, Mazowieckie, Poland|Wojskowy Instytut Medyczny,Centralny Szpital Kliniczny Ministerstwa Obronty Narodowej, Warszawa, Mazowieckie, Poland|Instytut Kardiologii im, Warszawa, Mazowieckie, Poland|Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp. z o.o., Warszawa, Mazowieckie, Poland|Szpital Specjalistyczny w Brzozowie, Podkarpacki Osrodek Onkologiczny im. Ks. B. Markiewicza Oddzial, Brzozow, Podkarpackie, Poland|INTERCARD Sp. z o.o. Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii w Krosnie, Krosno, Podkarpackie, Poland|EMED Centrum Uslug Medycznych Ewa Smialek, Rzeszow, Podkarpackie, Poland|""OSTEO-MEDIC"" s.c. Artur Racewicz, Jerzy Supronik, Bialystok, Podlaskie, Poland|Podlaski Osrodek Kardiologii Janusz Korecki, Bialystok, Podlaskie, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdansku, Gdansk, Pomorskie, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Gdanskie Centrum Zdrowia, Poradnia Kardiologiczna, Gdansk, Pomorskie, Poland|Centrum Badan Klinicznych Pi-House, Poradnia Diabetologiczna, Gdansk, Pomorskie, Poland|Medica Pro Familia Sp. z o.o. Spolka Komandytowo Akcyjna, Oddzial w Gdyni, Gdynia, Pomorskie, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdyni, Gdynia, Pomorskie, Poland|NZOZ ""PRO CORDIS"" Sopockie Centrum Badan Kardiologicznych, Gdynia, Pomorskie, Poland|Gabinet Kardiologiczno - lnternistyczny, Gdynia, Pomorskie, Poland|Centrum Medyczne ""SOPMED"" Sp. z o.o., Sopot, Pomorskie, Poland|Indywidualna Specjalistyczna Praktyka Lekarska Malgorzata Biedrzycka, Starogard Gdanski, Pomorskie, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Wojewodzki Szpital Specjalistyczny Nr 4 w Bytomiu, Bytom, Slaskie, Poland|Bogna Gabrylewicz Andrzej Ochala Unimed s.c., Katowice, Slaskie, Poland|Pro Familia Altera Poradnia Wielospecjalistyczna, Katowice, Slaskie, Poland|NZOZ Terapia Optima, Katowice, Slaskie, Poland|Przychodnia Specjalistyczna Samodzielny Publiczny ZOZ w Rudzie Slaskiej,, Ruda Slaska, Slaskie, Poland|NZOZ ""Medyk""Sp. z o. o., Wola, Slaskie, Poland|Prywatny Gabinet Lekarski Marianna Janion, Kielce, Swietokrzyskie, Poland|Wojewodzki Szpital Zespolony w Elblagu, Oddzial Kardiologiczny z Pododdzialem Kardiologii Inwazyjnej, Elblag, Warminsko-mazurskie, Poland|Specjalistyczny Osrodek Leczniczo-Badawczy Zbigniew Zegota, Ostroda, Warminsko-mazurskie, Poland|Synexus Polska Sp. z o.o Oddzial w Poznaniu, Poznan, Wielkopolskie, Poland|Nzoz ""Twoja Przychodnia"", Poznan, Wielkopolskie, Poland|Centrum Medyczne AMED, Warszawa, WOJ Mazowieckie, Poland|SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi 251 Pomorska, Lodz, Wojewodztwo Lodzkie, Poland|Marek Piepiorka Gabinet Kardiologiczno - lnternistyczny, Gdynia, Poland|Nzoz Gall-Med, Krakow, Poland|NZOZ Centrum Zdrowia i Profilaktyki Dabie Sp. z.o.o., Krakow, Poland|""TWOJA PRZYCHODNIA"" Sp. Z o.o, Lublin, Poland|Medicus w Opolu Sp z o. o., Opole, Poland|Centrum Zdrowia Metabolicznego Pawel Bogdanski, Poznan, Poland|NZOZ PRZYCHODNIA SPECJALISTYCZNA Andrzej Wittek Henryk Rudzki s.c., Ruda Slaska, Poland|KO-MED Centra Kliniczne Staszow, Staszow, Poland|Synexus Polska Sp. z o.o. Oddzial w Warszawie, Warszawa, Poland|Centrum Medyczne Warszawskiego Uniwersytetu Medycznego Sp. z o.o, Warszawa, Poland|Instytut Kardiologii im. Prymasa Tysiaclecia Stefana Kardynala Wyszynskiego Klinika Kardiologii, Warszawa, Poland|Synexus Polska Sp. z o.o. Oddzial we Wroclawiu, Wroclaw, Poland|Centrum Opieki Diabetologiczno-Endokrynologicznej i Ginekologiczno-Polozniczej, Wroclaw, Poland|Dobrostan Michal Bogacki, Wroclaw, Poland|The Office of Roberto J. Ayala-Rios, MD - Research Center and Private Practice (DMRA LLC), Anasco, Puerto Rico|Cardiometabolic Research Center, Inc., Ponce, Puerto Rico|Endocrine Lipid Diabetes Research Institute, Ponce, Puerto Rico|Consultorio Medico Figueroa, San Juan, Puerto Rico|Pradnet Inc., San Juan, Puerto Rico|Altamira Family Medicine And Research Institute, San Juan, Puerto Rico|Miguel Sosa-Padilla, MD-Private Practice, San Juan, Puerto Rico|Centro de Diabetes para Puerto Rico, San Juan, Puerto Rico|Pitesti-Arges County Emergency Hospital, Pitesti, Arges, Romania|Medical Practice SRL, Oradea, Bihor, Romania|County Clinical Emergency Hospital Oradea, Oradea, Bihor, Romania|County Emergency Hospital Deva, Deva, Hunedoara, Romania|Centrul Medical Sf. Stefan, Timisoara, JUD. Timis, Romania|Dr. Pop Calin Florin - Cabinet Cardiologie, Baia Mare, Maramures, Romania|Podoleanu G. Cristian-Gheorghe-Calin - Cardiology Medical Practice, Targu Mures, Mures, Romania|Diabmed Dr. Popescu Alexandrina SRL, Diabet, Nutritie, Boli Metabolice, Ploiesti, Prahova, Romania|Dr. Busegeanu Mihaela Private Practice, Ploiesti, Prahova, Romania|Institute of Cardiovascular Diseases Timisoara, Timisoara, Timis, Romania|Euromedica Hospital, Baia Mare, Romania|Spitalul Clinic Judetean De Urgenta Braila(Braila County Clincal Emergency Hospital), Braila, Romania|S.C. Polimed Dacia S.R.L., Brasov, Romania|Centrul Medical de Diagnostic si Tratament Ambulator Neomed, Brasov, Romania|Data Plus Medical Clinic, Bucharest, Romania|""Prof. Dr. N.C. Paulescu"" National Institute of Diabetes, Nutrition and Metabolic Diseases,, Bucharest, Romania|Med Plus SRL (Med Plus Ltd.), Bucharest, Romania|S.C. Centrul Medical ""Sanatatea Ta"" S.R.L., Bucharest, Romania|Spitalul Universitar De Urgenta Militar Central, Dr. Carol Davila, Bucuresti, Romania|Spitalul Clinic Colentina, Departament Cardiologie, Bucuresti, Romania|SC Clinica Medicala Synexus SRL, Medicina Interna, Bucuresti, Romania|SC Centrul Medical Policlinico Di Monza SRL, Cardiologie, Bucuresti, Romania|SC Policlinica CCBR SRL, Bucuresti, Romania|Spitalul Clinic Judetean de Urgenta Cluj-Napoca, Diabet Zaharat, Nutritie si Boli Metabolice, Cluj, Romania|Dr. Mistodie Cristina Victoria MD, Office of, Galati, Romania|S.C. Diamed Obesity S.R.L., Galati, Romania|County Emergency Hospital Satu Mare Diabetes, Nutrition And Metabolic Diseases Department, Satu Mare, Romania|County Clinical Emergency Hospital Sibiu, Sibiu, Romania|Cardio Med SRL, Targu Mures, Romania|Centrul Medical Dr. Negrisanu SRL, Diabet Zaharat, Nutritie si Boli Metabolice, Timisoara, Romania|State Budgetary Healthcare Institution ""Research Institution - Regional Clinical Hospital #1, Krasnodar, Krasnodar Region, Russian Federation|State Budgetary Healthcare Institution Of Moscow Region ""Lubertsy Regional Hospital #2"", Lubertsy, Moscow Region, Russian Federation|Federal State Budgetary Institution of Healthcare Hospital of Russian Academy of Sciences, Troitsk, Moscow Region, Russian Federation|State Budgetary Institution ""Ryazan Regional Clinical Hospital"", Ryazan, Ryazan Region, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare Municipal hospital, Saint-Petersburg, Sestroretsk, Russian Federation|FSBEI of HE Kazan State Medical University on the base of SBHI Clinical Hospital No.2, Kazan, Tatarstan Republic, Russian Federation|SBEI of HPE Kazan State Medical University on the base of SBHI Clinical Hospital No.2, Kazan, Tatarstan Republic, Russian Federation|Municipal Budgetary State Healthcare Institution ""City Clinical Hospital #6"", Chelyabinsk, Russian Federation|Non-State Institution of Healthcare ""Railway Clinical Hospital at station Chelyabinsk of open, Chelyabinsk, Russian Federation|State Budgetary Healthcare Institution ""Region Clinical Hospital #3"", Chelyabinsk, Russian Federation|Municipal Autonomous Institution ""City Clinical Hospital #14"", Ekaterinburg, Russian Federation|Regional Budgetary Healthcare Institution ""Cardiology Dispensary"", Ivanovo, Russian Federation|State Budgetary Institution of Healthcare of Kaluga Region ""Kaluga Regional Hospital"", Kaluga, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Kazan State Medical University"", Kazan, Russian Federation|State Autonomous Healthcare Institution, Kazan, Russian Federation|""SAHI of Kemerovo """"Regional Clinical Hospital of Emergency Medical Care n.a. M.A Podgorbunsky """""", Kemerovo, Russian Federation|Municipal Budgetary Institution of Healthcare, Kemerovo, Russian Federation|Federal state budgetary institution Research institute of complex problems, Kemerovo, Russian Federation|FSHI ""Medical and Sanitary Unit of the Ministry of Internal Affairs of Russia across Kemerovo region, Kemerovo, Russian Federation|Kirov Regional State Budgetary Healthcare Institution ""Kirov City Clinical Hospital #1"", Kirov, Russian Federation|Regional Budgetary Healthcare Institution ""Kursk City Clinical Emergency Hospital"", Kursk, Russian Federation|Non-State Institution of Healthcare ""Central Clinical Hospital #6 OAO ""RZhD"", Moscow, Russian Federation|Federal State Budgetary Institution ""State Research Center for Preventive Medicine"" of the Ministry, Moscow, Russian Federation|SBHI of Moscow city ""City Clinical Hospital #15 n.a. O.M. Filatova"", Moscow, Russian Federation|SBEI of HPE I. M. Sechenov First Moscow State Medical University, UKB #2, Moscow, Russian Federation|State Healthcare Institution ""City Clinical Hospital #51 of Healthcare Department of Moscow City"", Moscow, Russian Federation|Federal State Budgetary Institution ""Central Clinical Hospital with Polyclinic"", Moscow, Russian Federation|Federal State Budgetary Institution ""Russian Cardiology Research And Production Complex"" Of Ministry, Moscow, Russian Federation|Russian Cardiology Research And Production Complex of Ministry of Health of Russian Federation, Moscow, Russian Federation|Moscow State Healthcare Institution ""City clinical hospital n.a. S.P.Botkin"", Moscow, Russian Federation|SBIH ""City Clinical Hospital #81 Departments of Healthcare of Moscow"", Moscow, Russian Federation|Federal State Budget Institution ""Out-patient Clinic #3"" of Russian Federation,, Moscow, Russian Federation|State Regional Budgetary Healthcare Institution, Murmansk, Russian Federation|State Budgetary Healthcare Institution of Nizhegorodskaya Region, Nizhniy Novgorod, Russian Federation|Federal State Budgetary Institution ""Research Institute of Therapy and Preventive Medicine"" of, Novosibirsk, Russian Federation|SBRIHPE ""Novosibirsk State Medical University"" of MHSD of RF, Novosibirsk, Russian Federation|""Reafan"" LLC, Novosibirsk, Russian Federation|""SBHI of Novosibirsk """"City Clinical Hospital of Emergency Medical Care # 2"""""", Novosibirsk, Russian Federation|Municipal Budgetary Institution of Healthcare of Novosibirsk, Novosibirsk, Russian Federation|State Budgetary Institution of Healthcare of Novosibirsk region City Clinical Hospital of Emergency, Novosibirsk, Russian Federation|State Budgetary Institution of Healthcare""Penzenskaya Regional clinical hospital n.a N.N Burdenko"", Penza, Russian Federation|SBHI of Saint-Petersburg ""City Hospital # 38 n.a. N.A. Semashko"", Pushkin, Russian Federation|Federal State Budgetary Educational Institution of Higher Education, Rostov-on-Don, Russian Federation|State Budgetary Educational Institution Of Higher Professional Education, Rostov-on-Don, Russian Federation|State Budgetary Educational Institution of Higher Professional Education, Rostov-on-Don, Russian Federation|Federal State Budgetary Institution, Saint Petersburg, Russian Federation|Limited Liability Company International Medical Centre SOGAZ, Saint-Petersburg, Russian Federation|Saint-Petersburg State Budgetary Institution of Healthcare ""City Hospital #23"", Saint-Petersburg, Russian Federation|Saint-Petersburg State Budgetary Healthcare Institution ""City Alexandrovskaya Hospital"", Saint-Petersburg, Russian Federation|Federal state budget institution of healthcare Saint-Petersburg clinical hospital of Russian Academy, Saint-Petersburg, Russian Federation|Limited Liability Company ""Reavita"", Saint-Petersburg, Russian Federation|""Limited Liability Company """"Institute of Medical Research"""""", Saint-Petersburg, Russian Federation|Limited Liability Company ""Institute of Medical research"", Saint-Petersburg, Russian Federation|LLC ""Institution of medical studies"", Saint-Petersburg, Russian Federation|City Hospital # 38 n.a. Semashko, Saint-Petersburg, Russian Federation|SBEI of HPE ""First Pavlov State Medical University of St. Petersburg"" of the MOH of the RF, Saint-Petersburg, Russian Federation|Federal State Budgetary Institution ""Advisory Diagnostic Center and Polyclinic"", Saint-Petersburg, Russian Federation|Saint-Petersburg State Budgetary Healthcare Institution ""City Hospital #15"", Saint-Petersburg, Russian Federation|State Budgetary Healthcare Institution ""Samara Regional Clinical Cardiology Dispensary"", Samara, Russian Federation|MHI ""City Clinical Hospital #12"" of the Healthcare Committee, Saratov, Russian Federation|State Institution of Healthcare ""Regional Clinical Hospital"", Saratov, Russian Federation|State Budget Educational Institution of Higher Professional Education, Smolensk, Russian Federation|Federal State Budgetary Educational Institution of Higher Education, St. Petersburg, Russian Federation|Tyumen Cardiology Research Center-branch of the Tomsk NRMC, Tomsk, Russian Federation|GBOU VPO Siberian State Medical University Ministry of Healthcare of the Russian Federation, Tomsk, Russian Federation|State Budgetary Educational Institution of Highest Professional Education ""Siberian State Medical, Tomsk, Russian Federation|State Autonomous Institution of Healthcare of the Tyumen region Tyumen Institute of Therapy, Tyumen, Russian Federation|Affiliate of the Federal State Budgetary Institution Scientific Research Institute of Cardiology, Tyumen, Russian Federation|State Autonomous Healthcare Institution of Yaroslavl region, Yaroslavl, Russian Federation|FSBEI of HE ""Yaroslavl State Medical University"" MH of the Russian Federation, Yaroslavl, Russian Federation|State Budgetary Healthcare Institution of Yaroslavl Region ""Clinical Hospital No. 10"", Yaroslavl, Russian Federation|State Healthcare Institution of Yaroslavl Region ""Clinical Hospital #8"", Yaroslavl, Russian Federation|Nemocnica Ruzinov-Univerzitna Nemocnica Bratislava (UNB), Bratislava, Bratislavsky, Slovakia|Stredoslovensky Ustav Srdcovych A Cievnych Chorob A.S., Banska Bystrica, Slovakia|Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica, Banska Bystrica, Slovakia|Alian s.r.o., kardiologicka ambulancia, Bardejov, Slovakia|METABOL KLINIK s. r.o., Ambulancia pre diabetologiu, poruchy latkovej premeny a vyzivy, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Nemocnica Stare Mesto, l.intema klinika, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Nemocnica Stare Mesto, l.interna klinika, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Nemocnica Stare Mesto, Bratislava, Slovakia|UN Bratislava, Nemocnica Ruzinov, V. interna klinika LFUK a UN Bratislava, Bratislava, Slovakia|Kardiovaskularne centrum s.r.o., Bratislava, Slovakia|Metabolicke centrum MUDr. Katariny Raslovej, s.r.o., Bratislava, Slovakia|Narodny ustav srdcovych a cievnych chorob, a.s., Bratislava, Slovakia|Univerzitna Nemocnica Bratislava, Bratislava, Slovakia|Narodny ustav srdcovych a cievnych chorob, a.s., Bratislava, Slovakia|KARDIO-SANUS spol., s.r.o., Bratislava, Slovakia|UN Bratislava Nemocnica Sv. Cyrila a Metoda, kardiologicka ambulancia 1, Bratislava, Slovakia|VERIA, s.r.o. -Kardiologicka ambulancia, Bratislava, Slovakia|Endiamed s.r.o. Nestatna diabetologicka a endokrinologicka ambulancia, Dolny Kubin, Slovakia|JM-Interna s.r.o., interna ambulancia, Dolny Kubin, Slovakia|CARDIO D&R s.r.o. , Kardiologicka ambulancia, Kosice, Slovakia|AGTO., spol. s r. o., Kosice, Slovakia|Cardio D&R spol.s.r.o., Kardiologicka ambulancia, Kosice, Slovakia|Medicentrum Heart, Spol. S.R.O, Kralovsky Chlmec, Slovakia|CELL-B s.r.o. interna ambulancia, Levice, Slovakia|Liptovska nemocnica s poliklinikou MUDr.Ivana Stodolu Liptovsky Mikulas, Liptovsky Mikulas, Slovakia|KARDIO 1 s.r.o., Lucenec, Slovakia|Klinika hematologie a transfuziologie, Univerzitna nemocnica Martin, Martin, Slovakia|MEDI M&M s.r.o., Ambulancia vnutorneho lekarstva, Moldava nad Bodvou, Slovakia|MUDr. Kanderkova s.r.o., Diabetologicka ambulancia, Namestovo, Slovakia|Kardiocentrum Nitra s.r.o., kardiologicka ambulancia, Nitra, Slovakia|Fakultna Nemocnica s poliklinikou Nove Zamky, Nove Zamky, Slovakia|Mediab s.r.o. Diabetologicka ambulancia, Pezinok, Slovakia|BENIMED s.r.o., Piestany, Slovakia|Medispol S.R.O., Presov, Slovakia|Medilex s.r.o. Interna ambulancia, Rimavska Sobota, Slovakia|Kardioamb s.r.o., Rimavska Sobota, Slovakia|DIAMEL, s.r.o., Diabetologicka ambulancia, Trencin, Slovakia|BV Medical, s.r.o. Diabetologicka ambulancia,, Trnava, Slovakia|Kardiologicka ambulancia, Trnava, Slovakia|Medivasa, s.r.o., Zilina, Slovakia|Nash Ranjith Research Centre, Merebank, Durban, South Africa|IATROS International, Bloemfontein, FREE State, South Africa|JOSHA Research, Bloemfontein, FREE State, South Africa|Welkom Clinical trial Centre, Welkom, FREE State, South Africa|Midrand Medical Centre, Halfway House, Gauteng, South Africa|Sunward Park Hospital, Johannesburg, Gauteng, South Africa|Sunninghill Hospital, Johannesburg, Gauteng, South Africa|I Engelbrecht Research (Pty) Ltd, Lyttelton, Gauteng, South Africa|Charlotte Maxeke Johannesburg Academic Hospital, Parktown, Gauteng, South Africa|Jongaie Research, Pretoria West, Gauteng, South Africa|Medipark Centre for Clinical Research, Pretoria, Gauteng, South Africa|Synexus Watermeyer Clinical Research Centre, Pretoria, Gauteng, South Africa|Roodepoort Medicross Clinical Research Centre, Roodepoort, Gauteng, South Africa|Wits Clinical Research, Soweto, Gauteng, South Africa|Medi-Clinic Heart Hospital, Sunnyside, Gauteng, South Africa|Sunninghill Hospital, Sunninghill, Johannesburg, South Africa|Glastonbury Medical Research Centre, Durban, Kwazulu-natal, South Africa|Suite 502, Durban, Kwazulu-natal, South Africa|Dr Ganesh c/o Dr NB Maharaj, Durban, Kwazulu-natal, South Africa|Limpopo Clinical Research Initiative, Thabazimbi, Limpopo, South Africa|Zinakekele Medical centre, Moloto, Mpumalanga, South Africa|Drs Joynt Venter & Associates, Witbank (eMalahleni), Mpumalanga, South Africa|Dr JM Engelbrecht Trial Site-Vergelegen Mediclinic, Cape Town, Western CAPE, South Africa|Tiervlei Trial Centre, Cape Town, Western CAPE, South Africa|Synopsis Research cc, Cape Town, Western CAPE, South Africa|Helderberg Research Institute, Somerset West, Western CAPE, South Africa|Synexus Helderberg Clinical Research Centre, Somerset West, Western CAPE, South Africa|Global Clinical Trials (Pty) Ltd., Arcadia, Pretoria, South Africa|Unitas Hospital, Centurion, South Africa|Clinresco Centres (Pty) Ltd-Central Professional Suits, Gauteng, South Africa|Centre For Diabetes And Endocrinology, Johannesburg, South Africa|Paarl Research Centre, Paarl, South Africa|TREAD Research cc, Parow, South Africa|Clinical Projects Research SA (Pty) Ltd, Worcester, South Africa|Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruna, Spain|Hospital Universitario de Santiago de Compostela, Santiago de Compostela, A Coruna, Spain|Hospital Virgen De Los Lirios, Alcoy, Alicante, Spain|Hospital General Comarcal de Elda Virgen de la Salud, Elda, Alicante, Spain|Hospital Regional Universitario de Malaga, Malaga, Andalucia, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Andalucia, Spain|Centro de Salud El Cristo, Oviedo, Asturias, Spain|Centro Salud Paulino Prieto, Oviedo, Asturias, Spain|Cap Florida, L'Hospitalet De Llobregat, Barcelona-cataluna, Spain|Hospital General de Granollers, Granollers, Barcelona/cataluña, Spain|Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|CAP La Mina, Sant Adria De Besos, Barcelona, Spain|EAP Vic, Vic, Barcelona, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Institut Catala De La Salut - Hospital Universitari Arnau De Vilanova (Huav), Lleida, Catalonia, Spain|Hospital Universitari de Tarragona Joan XXIII, Tarragona, Catalonia, Spain|Hospital Universitario San Juan de Alicante, San Juan De Alicante (Alicante), Comunidad Valenciana, Spain|Albera Salut, Peralada, Gerona, Spain|Hospital De Figueres, Figueres, Girona-catalonia, Spain|Hospital Comarcal d'Inca, Inca, Illes Balears, Spain|Clinica Juaneda, Palma de Mallorca, Islas Baleares, Spain|Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, Spain|Hospital Arquitecto Marcide, El Ferrol, LA Coruna, Spain|H. U. Principe de Asturias, Alcala De Henares, Madrid, Spain|Hospital Principe de Asturias, Alcala De Henares, Madrid, Spain|Hospital Universitario Principe de Asturias, Alcala De Henares, Madrid, Spain|Hospital Universitario Fundacion Alcorcon, Alcorcon, Madrid, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Consultorio de Colloto, Colloto, Oviedo Asturias, Spain|Hospital Universitario de Cruces, Barakaldo, PAIS Vasco, Spain|Hospital Universitario Sant Joan de Reus, Reus, Tarragona, Spain|Hospital General de Requena, Requena, Valencia, Spain|Hospital Abente y Lago, A Coruna, Spain|Complejo Hospitalario Universitario A Coruna, A Coruna, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General Universitario de Alicante; Servicio Cardiologia, Alicante, Spain|Hospital Virgen del Mar, Almeria, Spain|Cap Disset De Setembre (Sant Cosme I Sant Damia), Barcelona/Cataluna, Spain|Hospital General De Granollers, Barcelona/Cataluña, Spain|Parc de Salut mar ¿ Hospital del Mar, Barcelona, Spain|Parc De Salut Mar-Hospital Del Mar, Barcelona, Spain|Centre Teknon, Barcelona, Spain|EAP Sardenya, Barcelona, Spain|Hospital de la Santa Creu i Sant pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|CAP Centelles, Barcelona, Spain|Fundacio Hospital de I'Esperit Sant, Barcelona, Spain|H. General Universitario de Ciudad Real, Ciudad Real, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Complexo Hospitalario Universitario Arquitecto Marcide-Profesor Novoa Santos De Ferrol, Ferrol, Spain|Hospital Universitario San Cecilio de Granada, Granada, Spain|Hospital Universitario Virgen de las Nieves (HUVN), Granada, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Carlos III, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario La Paz; Unidad Metabolico-Vascular, Madrid, Spain|Hospital Universitario Quiron Madrid, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Hospital Universitario Virgen De La Victoria, Malaga, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Clinica Nuevas Tecnologias en Diabetes y Endocrinologia, Sevilla, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitario Virgen de Valme, Sevilla, Spain|CAP Muralles, Tarragona, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Alvaro Cunqueiro (Hospital Meixoerio), Vigo, Spain|Hospital Clinico Universitario Miguel Servet; Medicina Interna, Zaragoza, Spain|Karolinska Universitetssjukhuset Huddinge, Stockholm, Huddinge, Sweden|Kasernens Läkarservice AB, Eksjö, Sweden|Clinical Trial Center (CTC)/Centrum foer klinisk proevning, Goteborg, Sweden|Sahlgrenska Universitetssjukhuset, Goteborg, Sweden|Centrum for klinisk provning-Sahlgrenska Universitetssjukhus, Gothenburg, Sweden|Pharmasite AB, Helsingborg, Sweden|Centralsjukhuset Karlstad, Karlstad, Sweden|Centralsjukhuset Kristianstad, Kristianstad, Sweden|Capio Citykliniken Hjartmottagning, Lund, Sweden|Probar E Lund AB, Lund, Sweden|Karlkliniken, Skanes Universitetssjukhus i Malmo, Malmo, Sweden|Pharmasite, Malmo, Sweden|Forskningsenheten, Medicinmottagningen Sahlgrenska Universitetssjukhuset/Molndal, Hus J, Molndal, Sweden|Ostersunds Sjukhus, Ostersund, Sweden|Dalecarlia Clinical Research Center, Rattvik, Sweden|Skelleftea Lasarett, Skelleftea, Sweden|Citydiabetes, Stockholm, Sweden|Karolinska Trial Alliance, KTA Prim, Stockholm, Sweden|Södersjukhuset Ab, Stockholm, Sweden|Karolinska Universitetssjukhuset, Stockholm, Sweden|Hjartkliniken, Stockholm, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Vastmanlands Sjukhus Vasteras, Vasteras, Sweden|Universitatsspital, Basel, Basel Stadt, Switzerland|Diagene Laboratories, Reinach, Basel Switzerland, Switzerland|Fondazione Diabete Lugano, Lugano, Ticino, Switzerland|Policlinique Medicale Universitaire, Lausanne, Vaud, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, VD, Switzerland|Kantonsspital Winterthur, Winterthur, Zurich, Switzerland|Hopitaux Universitaires de Geneve, Geneve, Switzerland|Cardiocentro Ticino, Lugano, Switzerland|Luzerner Kantonsspital Luzern, Luzern 16, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|China Medical University Hospital, Taichung, Taiwan R O C, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan ROC, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital - New, Kaohsiung, Taiwan|National Cheng Kung University (NCKU) Hospital, Tainan, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|MacKay Memorial Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Division of Cardiology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol, Bangkoknoi, Bangkok, Thailand|Clinical Research Center, Phramongkutklao Hospital, Rajathevee, Bangkok, Thailand|Endocrine Unit, Department of Medicine, Phramongkutklao Hospital, Rajathevee, Bangkok, Thailand|Cardiology Unit, Department of Medicine, Faculty of Medicine,Ramathibodi Hospital,Mahidol University, Ratchathewi, Bangkok, Thailand|Division of Cardiology, Department of medicine,Faculty of Medicine, Srinagarind Hospital, Khon Kaen, Muang, Khon Kaen, Thailand|Division of Cardiology, Department of Medicine, Faculty of Medicine, Songklanagarind Hospital,, Hat Yai, Songkhla, Thailand|Heart Center, Songklanagarind Prince of Songkla University, Hat Yai, Songkla, Thailand|Division Of cardiology,Department of Medicine,Faculty Of Medicine,Chulalongkorn University, Bangkok, Thailand|Dokuz Eylul Univesitesi Tip Fakultesi Hastanesi, Izmir, Ankara, Turkey|Baskent University, Adana Yuregir Training & Research Hospital, Adana, Turkey|A.karahisar Kocatepe Universitesi Hastanesi Ahmet Necdet Sezer Uygulama ve Arastirma Hastanesi, Afyonkarahisar, Turkey|Diskapi Yildirim Beyazit Egitim ve Arastirma Hastanesi, Ankara, Turkey|Akdeniz Universitesi Tip Fakultesi Hastanesi, Antalya, Turkey|Akdeniz Universitesi Tip Fakultesi, Antalya, Turkey|Antalya Training & Research Hospital, Antalya, Turkey|Bursa Yuksek Ihtisas Egitim ve Arastirma Hastanesi, Bursa, Turkey|Gaziantep Universitesi Tip Fakultesi Sahinbey Egitim ve Arastirma Hastanesi, Gaziantep, Turkey|Bezmialem Vakif Universitesi Tip Fakultesi Kardiyoloji Anabilim Dali, Istanbul, Turkey|Bezmialem Vakif Universitesi Tip Fakultesi Kardiyoloji Bolumu, Istanbul, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul, Turkey|Istanbul Universitesi Kardiyoloji Enstitusu, Istanbul, Turkey|Yeditepe University School of Medicine, Istanbul, Turkey|Ege University, School of Medicine, Izmir, Turkey|Dokuz Eylul Universitesi Tip Fakultesi, Izmir, Turkey|Kocaeli University School Of Medicine-Kocaeli Universitesi Tip Fakultesi, Kocaeli, Turkey|Dumlupinar Universitesi Kutahya Evliya Celebi EAH, Kutahya, Turkey|Mersin University, School of Medicine, Mersin, Turkey|Recep Tayyip Erdogan University School of Medicine, Training & Research Hospital, Rize, Turkey|Synexus Thames Valley Clinical Research Centre, Reading, Berkshire, United Kingdom|Westongrove Research Centre, Aylesbury, Buckinghamshire, United Kingdom|Peterborough City Hospital, Peterborough, Cambridgeshire, United Kingdom|Morrab Surgery, Penzance, Cornwall, United Kingdom|Brannel Surgery, St Austell, Cornwall, United Kingdom|The Michael White Centre for Diabetes & Endocrinology, Hull Royal Infirmary, Hull, EAST Yorkshire, United Kingdom|Queen's Hospital, Romford, Essex, United Kingdom|Synexus Manchester Clinical Research Centre-Manchester Science Park, Manchester, Greater Manchester, United Kingdom|Royal Oldham Hospital, Oldham, Greater Manchester, United Kingdom|St Francis Surgery, Chandlers Ford, Hampshire, United Kingdom|Lister Hospital, Stevenage, Hertfordshire, United Kingdom|East and North Hertfordshire NHS Trust, Welwyn Garden City, Hertfordshire, United Kingdom|Howlands Clinic - Queen Elizabeth II Hospital, Welwyn Garden City, Hertfordshire, United Kingdom|Synexus Scotland Clinical Research Centre, Glasgow, Lanarkshire, United Kingdom|Layton Medical Centre, Blackpool, Lancashire, United Kingdom|Synexus Lancashire Clinical Research Centre, Chorley, Lancashire, United Kingdom|Salford Royal NHS Foundation Trust - Dermatology Centre, Salford, M6 8hd, United Kingdom|Synexus Merseyside Clinical Research Centre, Liverpool, Merseyside, United Kingdom|The Royal Liverpool and Broadgreen -University Hospitals NHS Trust, Liverpool, Merseyside, United Kingdom|Whitby Group Practice, Whitby, North Yorkshire, United Kingdom|Albany House Medical Centre, Wellingborough, Northants, United Kingdom|Southern Health & Social Care Trust, Craigavon Area Hospital, Portadown, Northern Ireland, United Kingdom|Synexus North East Clinical Research Centre - Hexham General Hospital, Hexham, Northumberland, United Kingdom|South Axholme Practice, Doncaster, South Yorkshire, United Kingdom|Central Manchester University Hospitals NHS Foundation Trust, Manchester, South Yorkshire, United Kingdom|The Crouch Oak Family Practice, Addlestone, Surrey, United Kingdom|Ely Bridge Surgery, Cardiff, Wales, United Kingdom|Synexus Midlands Clinical Research Centre, Birmingham, WEST Midlands, United Kingdom|City Hospital, Birmingham, WEST Midlands, United Kingdom|Heart of England NHS Trust, Birmingham, West Mids, United Kingdom|Prince Philip Hospital, Llanelli, WEST Wales, United Kingdom|Royal Free London NHS Foundation Trust, Barnet, United Kingdom|Royal Victoria Hospital, Belfast, United Kingdom|Laurie Pike Health Centre, Birmingham, United Kingdom|Heart of England NHS Foundation Trust, Dept. of Clinical Biochemistry & Immunology, Birmingham, United Kingdom|Royal Bolton Hospital - Bolton Nhs Foundation Trust, Bolton, United Kingdom|Synexus Wales Clinical Research Centre, Cardiff, United Kingdom|Ashgate Medical Practice, Chesterfield, United Kingdom|Conquest Hospital - East Sussex Healthcare NHS Trust, East Sussex, United Kingdom|Little Common Surgery, East Sussex, United Kingdom|Sea Road Surgery, East Sussex, United Kingdom|Staploe Medical Centre, Ely, United Kingdom|The Queen Elizabeth University Hospital- NHS Greater Glasgow and Clyde, Glasgow, United Kingdom|McGlone Practice Baillieston Health Centre, Glasgow, United Kingdom|Burbage Surgery, Hinckley, United Kingdom|William Harvey Heart Centre (WHHC), London, United Kingdom|Royal Free Hospital, London, United Kingdom|Peart-Rose Research Unit, Hammersmith Hospital, Imperial College NHS Trust, London, United Kingdom|The Red Porto cabin, The James Cook University Hospital, Middlesbrough, United Kingdom|St Mary's Hospital, Newport, United Kingdom|Wansford And Kings Cliffe Practice, Peterborough, United Kingdom|Rothwell and Desborough Healthcare Group, Rothwell, Northants, United Kingdom|Abertawe Bro Morgannwg University Local Health Board, Swansea, United Kingdom|Western Sussex Hospitals NHS Trust, Worthing, United Kingdom|York Medical Group, York, United Kingdom|Strensall Healthcare Centre, York, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT01975376/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT01975376/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01975376"
1065,"NCT04159415","Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy",,"Recruiting","No Results Available","Generalized Lipodystrophy","Drug: Placebo|Drug: Low-Dose REGN4461|Drug: High-dose REGN4461","Absolute change from baseline hemoglobin A1c (HbA1c)|Absolute change from baseline fasting glucose|Absolute change from baseline weighted mean glucose (WMG)|Percent change from baseline fasting triglycerides (TG)|Absolute change in composite endpoint comprising absolute change in either HbA1c or percent change in fasting TG|Absolute change in HbA1c from baseline|Percent change in fasting TG from baseline over time|Absolute change from baseline in fasting glucose|Percent change from baseline in fasting TG|Absolute change from baseline in HbA1c over time|Absolute change from baseline in WMG over time|Change from baseline in glucose area under the concentration-time curve (AUC0-4) during a mixed meal tolerance test (MMTT)|Change from baseline in glucose AUC0-4 during a MMTT|Change from baseline in glucose infusion rate per kilogram body mass during hyperinsulinemia-euglycemic clamp (clamp study)|Change from baseline in glucose clearance rate (kITT) during insulin-tolerance test (ITT)|Incidence and severity of treatment-emergent adverse events (TEAEs)|Concentrations of total REGN4461 in serum over time|Incidence of anti-drug antibodies (ADA) to REGN4461 over time|Incidence of abnormal weight change|Incidence of vital sign abnormalities|Incidence of 12-lead electrocardiogram (ECG) abnormalities|Incidence of physical examination abnormalities|Incidence of laboratory abnormalities|Concentrations of total soluble leptin receptor (sLEPR) in serum over time","Regeneron Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R4461-GLD-1875|2019-000614-11","January 7, 2020","May 31, 2021","August 22, 2022","November 12, 2019",,"April 28, 2020","Regeneron Research Facility, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04159415"
1066,"NCT02458287","Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia","SPIRE-AI","Completed","Has Results","Hyperlipidemia","Biological: Bococizumab 150mg|Biological: Bococizumab 75mg|Biological: Bococizumab 150mg placebo|Biological: Bococizumab 75mg placebo","Percent Change From Baseline at Week 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) Level for Bococizumab 150 mg Dose Group and Matched Placebo|Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 0 (Day 1)|Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 2|Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 4|Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 6|Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 8|Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 150 mg Dose Group at Week 10|Percentage of Injections That Met the Definition for Successful Assessment Using the Participant Assessment Tool (PAT) for Bococizumab 75 mg Dose Group and Combined Bococizumab 150 mg and 75 mg Dose Group at Week 0 (Day 1), 2, 4, 6, 8 and 10|Percentage of Injections That Met the Definition for Successful Assessment Using the Observer Assessment Tool (OAT) for Bococizumab 150 mg Dose, Bococizumab 75 mg Dose Group and Combined Bococizumab 150 mg and 75 mg Dose Group at Week 0 (Day 1), 4 and 8|Percent Change From Baseline at Week 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) Level for Bococizumab 75 mg Dose Group and Matched Placebo|Percent Change From Baseline in Fasting Total Cholesterol (TC) at Week 12|Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 12|Percent Change From Baseline in Fasting Non- High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12|Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Percentage of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb)|Plasma Concentration of Bococizumab at Week 12|Plasma Concentration of Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) at Week 12","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","299","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B1481046|SPIRE-AI","June 2015","February 2016","February 2016","June 1, 2015","December 19, 2017","December 19, 2017","Radiant Research Incorporated, Chandler, Arizona, United States|Clinical Trial Research, Lincoln, California, United States|National Research Institute, Los Angeles, California, United States|California Medical Research Associates Inc., Northridge, California, United States|Northern California Research, Sacramento, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|ACRC - Cardiology, Atlantis, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Invesclinic, LLC, Fort Lauderdale, Florida, United States|Clinical Research of Miami, Inc., Miami, Florida, United States|Prestige Clinical Research Center, Inc., Miami, Florida, United States|A & R Research Group LLC, Pembroke Pines, Florida, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|North Georgia Clinical Research, Woodstock, Georgia, United States|North Georgia Internal Medicine, Woodstock, Georgia, United States|Solaris Clinical Research, Meridian, Idaho, United States|Evanston Premier Healthcare Research,LLC, Evanston, Illinois, United States|Midwest Institute For Clinical Research, Indianapolis, Indiana, United States|Buynak Clinical Research, P.C., Valparaiso, Indiana, United States|L-MARC Research Center, Louisville, Kentucky, United States|Omega Clinical Research Center, Metairie, Louisiana, United States|PharmQuest, Greensboro, North Carolina, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|PMG Research Of Charleston, Mount Pleasant, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Heart Care Associates, P.C., Hopewell, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|National Clinical Research-Richmond, Inc., Richmond, Virginia, United States|Rainier Clinical Research Center, Inc., Renton, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02458287"
1067,"NCT02471833","Health Evaluation in African Americans Using RAS Therapy","HEART","Recruiting","No Results Available","Alzheimer's Disease","Drug: Telmisartan 20mg|Drug: Telmisartan 40mg|Drug: Placebo","Change in concentration of cerebrospinal fluid angiotensin metabolites|Change in levels of plasma angiotensinogen|Change in levels of plasma renin|Change in levels of plasma angiotensin converting enzyme|Change in levels of plasma aldosterone|Change in levels of cerebrospinal fluid amyloid β42|Change in levels of cerebrospinal fluid T-tau|Change in levels of cerebrospinal fluid P-tau|Change in arterial function|Flanker Inhibitory Control and Attention Test|Set-shifting Test|Spatial 1-Back Test|Montreal Cognitive Assessment|Mini Mental State Examination (MMSE)|Wechsler Adult Intelligence Scale (WAIS)-Working Memory subtests|Wechsler Memory Scale-III Faces Test|Wechsler Memory Scale-Revised Logical Memory Test|Rey Auditory Verbal Learning Test|Arterial Spin Labeling-Magnetic Resonance Imaging|Structural Magnetic Resonance Imaging and White Matter Hyperintensities","Emory University","All","30 Years and older   (Adult, Older Adult)","Phase 1","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","IRB00080192","April 2015","June 30, 2020","June 30, 2020","June 15, 2015",,"June 3, 2019","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02471833"
1068,"NCT02654977","CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy",,"Active, not recruiting","No Results Available","Familial Partial Lipodystrophy|Nonalcoholic Steatohepatitis|NAFLD","Drug: Metreleptin","Improvement in Non alcoholic fatty liver disease|Improvement in triglyceride levels|Improvement in hemoglobin A1c values","University of Michigan","All","5 Years and older   (Child, Adult, Older Adult)","Phase 2","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HUM00093399","April 2015","February 2020","June 2020","January 13, 2016",,"October 23, 2019","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02654977"
1069,"NCT03887533","Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1",,"Recruiting","No Results Available","Niemann-Pick Disease, Type C1","Drug: VTS-270","Safety and Tolerabilty|plasma Cholestane-3B,5a,6B-triol","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","3 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","30","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","190028|19-CH-0028","January 6, 2020","January 1, 2022","January 1, 2022","March 25, 2019",,"January 31, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03887533"
1070,"NCT01722266","Liraglutide in the Treatment of Type 1 Diabetes Mellitus",,"Completed","Has Results","Type 1 Diabetes","Drug: Liraglutide|Drug: Placebo","Change in Mean Weekly Glucose Concentrations From Baseline at 12 Weeks|Change in HbA1c From Baseline at 12 Weeks|Change in Body Weight From Baseline at Week 12|Change in Total Insulin Dose From Baseline at 12 Weeks|Percent Time Spent in Hyperglycemia and Hypoglycemia|Reduction in the Area Under Curve(AUC) of Glucose Following the Meal|Serum Acetaminophen Concentrations Following Meal Challenge|Carbohydrate Intake|Insulin, C-peptide, Glucagon, GLP-1(Glucagon Like Peptide-1) and GIP(Gastric Inhibitory Polypeptide) Concentrations Following Meal Challenge.","Kaleida Health|Novo Nordisk A/S","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","72","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NN1962","November 2012","April 2014","April 2014","November 6, 2012","March 13, 2015","March 13, 2015","Diabetes-Endocrinology Center of Western NY, Williamsville, New York, United States",,"https://ClinicalTrials.gov/show/NCT01722266"
1071,"NCT02208284","A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects",,"Completed","No Results Available","Healthy","Drug: PF-06427878|Drug: Placebo","Assessment of adverse events (AEs).|Assessment of clinical laboratory tests.|Assessment of vital signs (including blood pressure and pulse rate).|Assessment of cardiac conduction intervals as assessed via 12-lead electrocardiogram (ECG).|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06427878|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - inf)] for PF-06427878|Maximum Observed Plasma Concentration (Cmax) for PF-06427878|Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06427878|Apparent Oral Clearance (CL/F) for PF-06427878|Apparent Volume of Distribution (Vz/F) for PF-06427878|Plasma Decay Half-Life (t1/2) for PF-06427878","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","B7871001","August 2014","December 2014","December 2014","August 5, 2014",,"March 4, 2015","New Haven Clinical Research Unit, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02208284"
1072,"NCT01068418","Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity",,"Completed","Has Results","Obesity|Vitamin D Deficiency|Hypertension","Dietary Supplement: Vitamin D (cholecalciferol)","The Change in the Mean Arterial Blood Pressure in Response to an Infusion of Angiotensin II|The Change in Renal Blood Flow in Response to an Infusion of Angiotensin II","Brigham and Women's Hospital","All","18 Years to 64 Years   (Adult)","Not Applicable","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2009p002062","February 2010","September 2011","September 2011","February 15, 2010","February 14, 2017","March 30, 2017","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01068418"
1073,"NCT02043301","Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm",,"Completed","Has Results","Hypercholesterolemia","Biological: Bococizumab (PF-04950615; RN316)","Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf)|Maximum Observed Plasma Concentration (Cmax)|Area Under the Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Apparent Clearance (CL/F)|Apparent Volume of Distribution (Vz/F)|Terminal Elimination Half-Life (t1/2)|Maximum Low-density Lipoprotein Cholesterol LDL-C Lowering Effect (Emax): Absolute Value|Emax: Change From Baseline|Emax: Percent Change From Baseline|Time to Reach Maximum LDL-C Lowering (Tmax, LDL-C)|Area Under the LDL-C Effect Curve (AUEC): Absolute Value|AUEC: Change From Baseline|AUEC: Percent Change From Baseline|Number of Participants With Injection Site Reactions (ISRs) by Severity|Number of Participants With Positive Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb)|Anti-Drug Antibody (ADA) Titer|Neutralizing Antibody (nAb) Titer","Pfizer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","B1481024","April 2014","November 2014","November 2014","January 23, 2014","May 31, 2019","May 31, 2019","Anaheim Clinical Trials, LLC, Anaheim, California, United States|Miami Research Associates, South Miami, Florida, United States|MRA Clinical Research, LLC, South Miami, Florida, United States|Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States|Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02043301"
1074,"NCT01757184","Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency","ARISE","Completed","Has Results","Lysosomal Acid Lipase Deficiency","Drug: Sebelipase Alfa|Drug: Placebo","Percentage Of Participants Achieving Alanine Aminotransferase Normalization|Percent Change From Baseline In Low-density Lipoprotein Cholesterol (LDL-C)|Percent Change From Baseline In Non-high Density Lipoprotein Cholesterol (Non-HDL-C)|Percentage Of Participants Achieving Aspartate Aminotransferase Normalization|Percent Change From Baseline In Triglycerides|Percent Change From Baseline In High-density Lipoprotein Cholesterol (HDL-C)|Percent Change From Baseline In Liver Fat Content|Participants With Improvement In Liver Histopathology (Decrease Of > 5% In Hepatic Steatosis Score)|Percent Change From Baseline In Liver Volume","Alexion Pharmaceuticals","All","4 Years and older   (Child, Adult, Older Adult)","Phase 3","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LAL-CL02","January 22, 2013","May 30, 2014","December 11, 2018","December 28, 2012","April 18, 2016","December 18, 2019","Tucson, Arizona, United States|Palo Alto, California, United States|San Francisco, California, United States|Wilmington, Delaware, United States|Chicago, Illinois, United States|Boston, Massachusetts, United States|Buffalo, New York, United States|Manhasset, New York, United States|New York, New York, United States|Cincinnati, Ohio, United States|Philadelphia, Pennsylvania, United States|Córdoba, Argentina|Brisbane, Australia|New Lambton, Australia|Parkville, Australia|Perth, Australia|Zagreb, Croatia|Olomouc, Czechia|Prague, Czechia|Paris, France|Vandoeuvre les Nancy, France|Freiburg, Germany|Mainz, Germany|Munich, Germany|Bergamo, Italy|Genoa, Italy|Padova, Italy|Tokyo, Japan|Tottori, Japan|Mexico City, Mexico|Warsaw, Poland|Moscow, Russian Federation|Elche, Spain|Madrid, Spain|Oviedo, Spain|Ankara, Turkey|Izmir, Turkey|Cambridge, United Kingdom|London, United Kingdom|Plymouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01757184"
1075,"NCT02402309","A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)",,"Completed","No Results Available","Sjögren-Larsson Syndrome","Drug: Active topical NS2 1% dermatologic cream|Drug: Vehicle placebo 0.0% NS2 dermatologic cream","Number of Participants with Adverse Events as a measure of Safety and Tolerability|Pharmacokinetics - Peak Plasma Concentration (Cmax)","Aldeyra Therapeutics, Inc.","All","6 Years and older   (Child, Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NS-003","March 2015","May 2016","June 2016","March 30, 2015",,"March 18, 2019","University of Nebraska Medical Center, Omaha, Nebraska, United States|Penn State Hershey Medical Center - Department of Dermatology, Hershey, Pennsylvania, United States|Pediatric and General Dermatology, Fairfax, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02402309"
1076,"NCT02585895","Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment",,"Completed","Has Results","Hypercholesterolemia","Biological: Evolocumab|Procedure: Low-density Lipoprotein Cholesterol (LDL-C) Apheresis","Percentage of Participants With Apheresis Avoidance at the End of Randomized Therapy|Percent Change From Baseline in Low-density Lipoprotein Cholesterol|Percent Change From Baseline in Non-high-density Lipoprotein-Cholesterol|Percent Change From Baseline in Total Cholesterol/High-density Lipoprotein Cholesterol Ratio","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140316|2015-001343-37","December 21, 2015","September 1, 2016","January 20, 2017","October 26, 2015","September 19, 2017","September 19, 2017","Research Site, Boca Raton, Florida, United States|Research Site, Kansas City, Kansas, United States|Research Site, Grandville, Michigan, United States|Research Site, Portland, Oregon, United States|Research Site, Heidelberg, Victoria, Australia|Research Site, Hradec Kralove, Czechia|Research Site, Bron, France|Research Site, Nantes Cedex 1, France|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Düsseldorf, Germany|Research Site, Flensburg, Germany|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Sevilla, Andalucía, Spain|Research Site, Harefield, United Kingdom|Research Site, Penarth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02585895"
1077,"NCT01489995","Migalastat Food Effect Study",,"Completed","No Results Available","Fabry Disease","Drug: A (migalastat)|Drug: B (migalastat)|Drug: C (migalastat)|Drug: D (migalastat)|Drug: E (migalastat)","Maximum observed plasma concentration of migalastat HCl after a single dose|Time of occurence of maximum observed plasma concentration of migalastat HCl after a single dose|Area under the plasma concentration-time curve of migalastat HCl after a single dose from time 0 (before dosing) to infinity|Terminal phase half life of migalastat HCl after a single dose|Apparent clearance following oral dosing of migalastat HCl after a single dose|Area under the plasma concentration-time curve of migalastat HCl after a single dose from time 0 (before dosing) to the time of the last quantifiable concentration|Adverse Events|Clinical Laboratory Tests|Vital Signs|ECGs|Physical Examination","Amicus Therapeutics","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","116050","October 2011","December 2011","December 2011","December 12, 2011",,"December 18, 2013","GSK Investigational Site, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01489995"
1078,"NCT03206060","Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma",,"Recruiting","No Results Available","Pheochromocytoma|Paraganglioma|Neuroendocrine Tumors|Neuroendocrine Neoplasms","Drug: Lu-177-DOTATATE|Drug: Ga-68-DOTATATE|Drug: F-18-FDG|Drug: Amino Acid solution","progression-free survival|safety and tolerability profile|Determine ability to decrease anti-hypertensive medication|Evaluate Quality of Life|Determine changes in plasma biochemical markers|Time to tumor progression|Objective response rate|Overall survival","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","170087|17-C-0087","October 10, 2017","January 1, 2023","January 1, 2025","July 2, 2017",,"April 16, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03206060"
1079,"NCT01413620","Vitamin E Supplementation in Burn Patients",,"Recruiting","No Results Available","Burn Injury","Drug: dl-alpha-tocopheryl acetate","Alpha-Tocopherol in Plasma, Adipose (also: Lung, Skin, Muscle, Liver in the case of Death)|Gamma-Tocopherol in Plasma, Adipose (also: Lung, Skin, Muscle, Liver in the case of Death)|Vitamin E Metabolites in Plasma, Urine|Malondialdehyde in Plasma, Urine (also: Lung, Skin, Muscle in the case of Death)|Isoprostanes in Plasma, Urine (also: Lung, Skin, Muscle in the case of Death)|Lipid Panel in Plasma and Triglyceride Concentration|Liver Ultrasound|Pulmonary Function Study Variables|Cardiopulmonary Stress Test|Open Body Surface Area and Wound Healing|Weight|Basal Metabolic Rate|Diet History and Food Intake|Fluid Balance|Incidence of Acute Respiratory Distress Syndrome (ARDS)|Incidence of Pneumonia|Incidence of Atelectasis|Ventilator Variables (Compliance, Resistance, Work of Breathing, Number of Days Ventilated)|Pulmonary Status Variables (Spirometry, Blood Gas, Diffusion Constant, Pulmonary Capillary Surface Area)","Shriners Hospitals for Children|University of Texas|Oregon State University","All","6 Months to 85 Years   (Child, Adult, Older Adult)","Phase 1","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","VitE2011","August 2011","August 2017","August 2021","August 10, 2011",,"August 19, 2016","Shriners Hospitals for Children, Galveston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01413620"
1080,"NCT01398943","Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)",,"Completed","Has Results","Pulmonary Disease, Chronic Obstructive","Drug: Tetrahydrobiopterin (BH4)|Dietary Supplement: Antioxidant Cocktail","Flow-Mediated Dilation (FMD)|Pulse Wave Velocity","Augusta University|American Heart Association","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","AHA00115CS","September 2010","June 2015","June 2015","July 21, 2011","July 25, 2017","December 11, 2017","Augusta University, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01398943"
1081,"NCT01243151","Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia",,"Completed","Has Results","Hypercholesterolemia|Dyslipidemia","Biological: PF-04950615 (RN316)","Number of Participants With Dose Limiting and Intolerable Treatment-Related Adverse Events (AEs)|Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Treatment-Related Adverse Events (AEs)|Number of Participants With Adverse Events (AEs) by Severity|Number of Participants With Laboratory Test Abnormalities|Number of Participants With Clinically Relevant Changes in Vital Signs|Number of Participants With Clinically Relevant Changes in Electrocardiogram (ECG) Parameters|Number of Participants With Anti-drug Antibodies (ADA)|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615|Maximum Observed Plasma Concentration (Cmax) of PF-04950615|Plasma Decay Half-Life (t1/2) of PF-04950615|Apparent Clearance (CL) of PF-04950615|Volume of Distribution at Steady State (Vss) of PF-04950615|Accumulation Ratio (Rac) of PF-04950615|Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Day 8, 15, 22, 29 and 78|Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Day 8, 15, 22, 29 and 78|Number of Participants Achieving LDL-C Less Than (<) 70 Milligram Per Deciliter (mg/dL)|Number of Participants Achieving LDL-C Less Than (<) 100 Milligram Per Deciliter (mg/dL)|Number of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in LDL-C From Baseline|Change From Baseline in Lipid Parameters: Apolipoprotein A1 (ApoA1) at Day 8, 15, 22, 29 and 78|Change From Baseline in Lipid Parameters: Apolipoprotein B (ApoB) at Day 8, 15, 22, 29 and 78|Change From Baseline in Lipid Parameters: Total Cholesterol at Day 8, 15, 22, 29 and 78|Change From Baseline in Lipid Parameters: High Density Lipoprotein Cholesterol (HDL-C) at Day 8, 15, 22, 29 and 78|Change From Baseline In Lipid Parameters: Non High Density Lipoprotein Cholesterol (Non HDL-C) at Day 8, 15, 22, 29 and 78|Change From Baseline In Lipid Parameters: Triglycerides (TG) at Day 8, 15, 22, 29 and 78|Percent Change From Baseline in Lipid Parameters: Apolipoprotein A1 (ApoA1) at Day 8, 15, 22, 29 and 78|Percent Change From Baseline In Lipid Parameters: Apolipoprotein B (ApoB) at Day 8, 15, 22, 29 and 78|Percent Change From Baseline In Lipid Parameters: Total Cholesterol at Day 8, 15, 22, 29 and 78|Percent Change From Baseline In Lipid Parameters: High Density Lipoprotein Cholesterol (HDL-C) at Day 8, 15, 22, 29 and 78|Percent Change From Baseline In Lipid Parameters: Non High Density Lipoprotein Cholesterol (Non HDL-C) at Day 8, 15, 22, 29 and 78|Percent Change From Baseline In Lipid Parameters: Triglycerides (TG) at Day 8, 15, 22, 29 and 78|Change From Baseline In Low Density Lipoprotein Cholesterol (LDL-C) Particle Size at Day 8, 15, 22, 36, 50, 64 and 78|Change From Baseline In Small Low Density Lipoprotein Cholesterol (LDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Change From Baseline In Medium Low Density Lipoprotein Cholesterol (LDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Change From Baseline In Large Low Density Lipoprotein Cholesterol (LDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Change From Baseline In Total Low Density Lipoprotein Cholesterol (LDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Levels at Baseline, Day 8, 15, 22, 36, 50, 64 and 78|C-Reactive Protein Levels at Day 8, 15, 21, 36, 57 and 78|Small High Density Lipoprotein-Cholesterol (HDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Medium High Density Lipoprotein-Cholesterol (HDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Large High Density Lipoprotein-Cholesterol (HDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Total High Density Lipoprotein-Cholesterol (HDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Small Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Medium Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Large Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|Total Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Levels at Day 8, 15, 22, 36, 50, 64 and 78|High Density Lipoprotein-Cholesterol (HDL-C) Particle Size at Day 8, 15, 22, 36, 50, 64 and 78|Very Low Density Lipoprotein-Cholesterol (VLDL-C) Particle Size at Day 8, 15, 22, 36, 50, 64 and 78","Pfizer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","B1481009","February 2011","October 2011","October 2011","November 18, 2010","January 22, 2019","January 22, 2019","California Clinical Trials Medical Group, Culver City, California, United States|Glendale Adventist Medical Center, Glendale, California, United States|SeaView Research, Inc., Miami, Florida, United States|SeaView Research, Inc., Miami, Florida, United States|Covance Clinical Research Unit, Inc., Honolulu, Hawaii, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|Prism Research, Saint Paul, Minnesota, United States|Healthcare Discoveries, LLC dba ICON Development Solutions, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01243151"
1082,"NCT03452228","Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis",,"Active, not recruiting","No Results Available","Severe Hypertriglyceridemia (sHTG)","Drug: evinacumab|Drug: Placebo","Percent lowering of TG levels from baseline following 12 weeks of repeated IV doses of evinacumab|Percent TG lowering from baseline following 2 to 24 weeks of repeated IV doses of evinacumab|Changes in patient reported abdominal and GI daily symptom questionnaire|Changes in patient reported daily dietary habits and impact questionnaire|Degree of pancreatic injury/inflammation through 18F-2-Fluoro-2-Deoxy-D glucose positron emission tomography (18F-FDG-PET) imaging at baseline as assessed by 18F-FDG standardized uptake values SUVmax and SUVmean|Change from baseline to degree of pancreatic injury/inflammation through 18F-FDG-PET imaging following 12 weeks of treatment with evinacumab as assessed by 18F-FDG standardized uptake values SUVmax and SUVmean|Degree of pancreatic injury/inflammation through Diffusion Weighted-Magnetic Resonance Imaging (DW-MRI) at baseline as assessed by ADC|Change from baseline to degree of pancreatic injury/inflammation through DW-MRI following 12 weeks of treatment with evinacumab as assessed by ADC|Change from baseline to degree of pancreatic injury/inflammation through DW-MRI following 24 weeks of treatment with evinacumab as assessed by ADC|Total evinacumab concentration in serum|Total ANGPTL3 concentrations|Incidence of anti-drug antibody (ADA)|Incidence of Treatment-emergent adverse events (TEAEs)|Incidence of serious adverse events (SAEs)|Incidence of laboratory abnormalities","Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1500-HTG-1522|2016-003307-62","June 7, 2018","December 17, 2019","August 3, 2020","March 2, 2018",,"January 31, 2020","Regeneron Research Facility, Boca Raton, Florida, United States|Regeneron Research Facility, Atlanta, Georgia, United States|Regeneron Research Facility, Kansas City, Kansas, United States|Regeneron Research Facility, New York, New York, United States|Regeneron Research Facility, Philadelphia, Pennsylvania, United States|Regeneron Research Facility, Pittsburgh, Pennsylvania, United States|Regeneron Research Facility, Dallas, Texas, United States|Regeneron Research Facility, Houston, Texas, United States|Regeneron Research Facility, Milwaukee, Wisconsin, United States|Regeneron Research Facility, Chicoutimi, Quebec, Canada|Regeneron Research Facility, Québec, Quebec, Canada|Regeneron Research Facility, Napoli, Campania, Italy|Regeneron Research Facility, Rome, Italy|Regeneron Research Facility, Birmingham, United Kingdom|Regeneron Research Facility, London, United Kingdom|Regeneron Research Facility, London, United Kingdom|Regeneron Research Facility, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03452228"
1083,"NCT01848340","An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects",,"Completed","No Results Available","HIV-associated Lipodystrophy Syndrome","Drug: GSK1265744B (sodium salt) containing 14C-GSK1265744B|Drug: 150 mg GSK1265744B|Drug: Placebo","Part A: Percent recovery of total radioactive [14C] GSK1265744 in urine and feces.|Part A: Composite of plasma GSK1265744 PK parameters to access total radioactivity in blood|Part B: Number of participants with the use of concurrent medication as a measure of safety and tolerability|Part B: Absolute values and changes over time of hematology as a measure of safety and tolerability.|Part B: Absolute values and changes over time of clinical chemistry as a measure of safety and tolerability.|Part B: Absolute values and changes over time of urinalysis as a measure of safety and tolerability.|Part B: Absolute values and changes over time of vital signs as a measure of safety and tolerability.|Part B: Absolute values and changes over time of ECG intervals and ECG rhythm as a measure of safety and tolerability.|Part B: Number of participants with adverse events as a measure of safety and tolerability|Part B: Composite of plasma GSK1265744 PK parameters|Part A: Blood: Plasma ratio of total drug-related material (radioactivity)|Part A: Percent of total radioactivity associated with red blood cells|Part A: Absolute values and changes over time of hematology as a measure of safety and tolerability.|Part A: Absolute values and changes over time of clinical chemistry as a measure of safety and tolerability.|Part A: Absolute values and changes over time of urinalysis as a measure of safety and tolerability.|Part A: Absolute values and changes over time of vital signs as a measure of safety and tolerability.|Part A: Absolute values and changes over time of ECG intervals and ECG rhythm as a measure of safety and tolerability.|Part A: Number of participants with adverse events as a measure of safety and tolerability","ViiV Healthcare|GlaxoSmithKline","All","18 Years to 60 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","117008","May 2013","July 2013","July 2013","May 7, 2013",,"November 4, 2013","GSK Investigational Site, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01848340"
1084,"NCT01435382","A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia",,"Completed","Has Results","Hypercholesterolemia|Dyslipidemias|Hyperlipidemias|Lipid Metabolism Disorders|Metabolic Diseases","Biological: PF-04950615 (RN316)","Maximum Observed Plasma Concentration (Cmax) of PF‑04950615|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615|Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of PF‑04950615|Area Under the Plasma Concentration-Time Curve From Time Zero To Infinity (AUCinf) of PF‑04950615|Apparent Clearance (CL/F) of PF-04950615 Subcutaneous Groups|Clearance (CL) of PF-04950615 Intravenous Group|Apparent Volume of Distribution (Vz/F) of PF-04950615 Subcutaneous Groups|Volume of Distribution at Steady State (Vss) of PF-04950615 Intravenous Group|Terminal Elimination Half-life (t1/2) of PF-04950615|Absolute Bioavailability of PF-04950615 Subcutaneous Groups|Absolute Value of Fasting Low-density Lipoprotein Cholesterol (LDL-C)|Percent Change From Baseline in Fasting Low-density Lipoprotein Cholesterol (LDL-C) at Day 2, 3, 4, 5, 6, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71 and 85|Duration of Fasting LDL-C Suppressed Below 70 mg/dL and 100 mg/dL","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","B1481006","October 2011","February 2012","April 2012","September 16, 2011","July 23, 2018","July 23, 2018","Profil Institute for Clinical Research, Inc., Chula Vista, California, United States|Elite Research Institute, Miami, Florida, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|PAREXEL International - Baltimore Early Phase Clinical Unit, Baltimore, Maryland, United States|Jasper Clinic, Inc., Kalamazoo, Michigan, United States|Prism Research, Saint Paul, Minnesota, United States|Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01435382"
1085,"NCT01730469","Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function",,"Completed","No Results Available","Fabry Disease","Drug: AT1001 150 mg","Number of subjects with adverse events to assess safety and tolerability|Clinical laboratory test values to assess safety and tolerability|Vital signs to assess safety and tolerability|Physician examination to assess safety and tolerability|Measure of ECG to assess safety and tolerability|Maximum observed concentration (Cmax) of AT1001|Time to achieve maximum concentration (Tmax) of AT1001|Apparent terminal elimination half life (t1/2 ) of AT1001|Area under the concentration-time curve from time zero to the last measurable concentration (AUC 0-t ) of AT1001|Area under the concentration-time curve extrapolated to infinity (AUC 0-inf) of AT1001|Apparent terminal elimination rate constant for AT1001|Oral clearance of AT1001|Oral volume of distribution of AT1001","Amicus Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","116431","August 2011","April 2012","April 2012","November 21, 2012",,"August 3, 2017","GSK Investigational Site, Costa Mesa, California, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01730469"
1086,"NCT04197479","A Phase 3 Study to Evaluate the Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease (NAFLD) Patients","MAESTRO-NAFLD1","Recruiting","No Results Available","Non-Alcoholic Fatty Liver Disease","Drug: Placebo|Drug: Resmetirom","The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the incidence of adverse events.|The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in low density lipoprotein C (LDL-C) from baseline to Week 24|The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in apolipoprotein B (ApoB) from baseline to Week 24|The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in hepatic fat fraction as determined by MRI-PDFF from baseline to Week 16.|The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in triglycerides (TGs) from baseline to Week 24 in patients with baseline TG > 150 mg/dL.|The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo after 52 weeks on N-terminal type III collagen propeptide (PRO-C3) in patients with baseline PRO-C3 ≥10 ng/mL.","Madrigal Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","700","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MGL-3196-14","December 16, 2019","December 2021","December 2021","December 13, 2019",,"March 4, 2020","Madrigal Clinical Site 0102, Marrero, Louisiana, United States|Madrigal Clinical Site 0104, Austin, Texas, United States|Madrigal Clinical Site 0101, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04197479"
1087,"NCT03888066","Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)","DIAMOND","Recruiting","No Results Available","Hyperkalemia","Drug: Patiromer|Drug: Placebos","Time to first occurrence of CV death or CV hospitalization (or equivalent in outpatient clinic)|Proportion of subjects on ≥ 50% of guideline-recommended target dose of RAASi medications|Total HF hospitalizations|Kansas City Cardiomyopathy Questionnaire (KCCQ)","Relypsa, Inc.|Vifor Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 3","2388","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Relypsa","April 25, 2019","December 31, 2021","March 31, 2022","March 25, 2019",,"April 20, 2020","Investigator Site 11-080, Alexander City, Alabama, United States|Investigator Site 11-041, Huntsville, Alabama, United States|Investigator Site 11-048, La Mesa, California, United States|Investigator Site 11-017, Long Beach, California, United States|Investigator Site 11-035, Pasadena, California, United States|Investigator Site 11-047, Thousand Oaks, California, United States|Investigator Site 11-058, West Hills, California, United States|Investigator Site 11-007, Littleton, Colorado, United States|Investigator Site 11-020, Bradenton, Florida, United States|Investigator Site 11-028, Brandon, Florida, United States|Investigator Site 11-011, Daytona Beach, Florida, United States|Investigator Site 11-003, Doral, Florida, United States|Investigator Site 11-014, Hialeah, Florida, United States|Investigator Site 11-078, Homestead, Florida, United States|Investigator Site 11-004, Jacksonville, Florida, United States|Research Site 11-001, Miami Lakes, Florida, United States|Research Site 11-002, Miami Lakes, Florida, United States|Investigator Site 11-006, Miami, Florida, United States|Investigator Site 11-005, Miami, Florida, United States|Investigator Site 11-032, North Miami Beach, Florida, United States|Investigator Site 11-039, Ocala, Florida, United States|Investigator Site 11-025, Orlando, Florida, United States|Investigator Site 11-015, Columbus, Georgia, United States|Investigator Site 11-031, Arlington Heights, Illinois, United States|Investigator Site 11-051, Hazel Crest, Illinois, United States|Investigator Site 11-063, Peoria, Illinois, United States|Investigator Site 11-069, Richmond, Indiana, United States|Investigator Site 11-061, Owensboro, Kentucky, United States|Investigator Site 11-026, Baton Rouge, Louisiana, United States|Investigator Site 11-022, West Monroe, Louisiana, United States|Investigator Site 11-027, Baltimore, Maryland, United States|Investigator Site 11-008, Saint Louis, Missouri, United States|Investigator Site 11-054, Linden, New Jersey, United States|Investigator Site 11-040, Manhasset, New York, United States|Investigator Site 11-053, Richmond Hill, New York, United States|Investigator Site 11-021, Stony Brook, New York, United States|Investigator Site 11-075, Charlotte, North Carolina, United States|Investigator Site 11-019, Fayetteville, North Carolina, United States|Investigator Site 11-064, Lorain, Ohio, United States|Investigator Site 11-042, Marion, Ohio, United States|Investigator Site 11-056, Hillsboro, Oregon, United States|Investigator Site 11-091, Jackson, Tennessee, United States|Investigator Site 11-092, Dallas, Texas, United States|Investigator Site 11-060, Fort Worth, Texas, United States|Investigator Site 11-072, Gonzales, Texas, United States|Investigator Site 11-009, Houston, Texas, United States|Investigator Site 11-016, Houston, Texas, United States|Investigator Site 11-033, Houston, Texas, United States|Investigator Site 11-079, Houston, Texas, United States|Investigator Site 11-034, Katy, Texas, United States|Investigator Site 11-029, Lampasas, Texas, United States|Investigator Site 11-010, McKinney, Texas, United States|Investigator Site 11-046, McKinney, Texas, United States|Investigator Site 11-045, Milwaukee, Wisconsin, United States|Investigator Site 61-002, Pleven, Bulgaria|Investigator Site 62-010, Mariánské Lázně, Czechia|Investigator Site 32-002, La Tronche, France|Investigator Site 32-005, Montpellier, France|Investigator Site 32-001, Nancy, France|Investigator Site 32-004, Paris, France|Investigator Site 32-003, Pau, France|Investigator Site 32-006, Toulon, France|Investigator Site 63-007, Tbilisi, Georgia|Investigator Site 63-011, Tbilisi, Georgia|Investigator Site 63-004, Tbilisi, Georgia|Investigator Site 63-002, Tbilisi, Georgia|Investigator Site 63-006, Tbilisi, Georgia|Investigator Site 63-008, Tbilisi, Georgia|Investigator Site 63-010, Tbilisi, Georgia|Investigator Site 63-003, Tbilisi, Georgia|Investigator Site 63-009, Tbilisi, Georgia|Investigator Site 63-001, Tbilisi, Georgia|Investigator Site 63-005, Tbilisi, Georgia|Investigator Site 64-002, Budapest, Hungary|Investigator Site 64-011, Budapest, Hungary|Investigator Site 64-005, Nyiregyhaza, Hungary|Investigator Site 65-014, Katowice, Poland|Investigator Site 65-016, Kraków, Poland|Investigator Site 65-002, Kraków, Poland|Investigator Site 65-012, Kędzierzyn-Koźle, Poland|Investigator Site 65-019, Olsztyn, Poland|Investigator Site 65-015, Ostrowiec Świętokrzyski, Poland|Investigator Site 65-013, Oława, Poland|Investigator Site 65-021, Pomorskie, Poland|Investigator Site 65-003, Poznań, Poland|Investigator Site 65-008, Rzeszów, Poland|Investigator Site 65-009, Tychy, Poland|Investigator Site 65-010, Wrocław, Poland|Investigator Site 65-005, Wrocław, Poland|Investigator Site 65-011, Zgierz, Poland|Investigator Site 65-001, Łódź, Poland|Investigator Site 37-007, Barcelona, Spain|Investigator Site 37-002, Barcelona, Spain|Investigator Site 37-008, Valencia, Spain|Investigator Site 39-006, Chesterfield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03888066"
1088,"NCT03098797","A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome","TAZPOWER","Active, not recruiting","No Results Available","Barth Syndrome","Drug: Elamipretide","Change in distance walked during the 6-minute walk test (6MWT)|Change in muscle strength as measured by handheld dynamometry|Change in five times sit-to-stand test|Change in 2-D and 3-D echocardiographic measurements|Change in accelerometry counts|Change in SWAY application balance assessments|Change in Patient Reported Outcomes|Change in Clinician Global Impression|Change in biomarkers|Number of participants with treatment related adverse events","Stealth BioTherapeutics Inc.","Male","12 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPIBA-201","May 1, 2017","April 2021","June 2021","April 4, 2017",,"April 14, 2020","McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03098797"
1089,"NCT01147068","Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults",,"Completed","Has Results","Influenza","Biological: 0.5mL Intramuscular Injection","Evaluation of Immunogenicity Measured by Seroconversion Rates of PanBlok With and Without Adjuvant Compared to Placebo in Healthy Adults 18-49 Years of Age.|Evaluation and Comparison of Immunogenicity From Geometric Mean Titers of PanBlok With and Without Adjuvant and Placebo in Healthy Adults 18-64 Years of Age.|Serologic Response Rates at Day 21 Using PanBlok With and Without Adjuvant and Placebo in Healthy Adults 18-64 Years of Age","Protein Sciences Corporation","All","18 Years to 49 Years   (Adult)","Phase 1|Phase 2","392","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PSC22 GLA-SE","June 2010","October 2011","October 2011","June 22, 2010","November 26, 2012","November 26, 2012","Vince and Associates Clinical Research, Overland Park, Kansas, United States|Meridian Clinical Research, Omaha, Nebraska, United States|University of Rochester, Rochester, New York, United States|Benchmark Research, Fort Worth, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01147068"
1090,"NCT00837616","Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism",,"Completed","Has Results","Turner Syndrome|Hypogonadism|Premature Ovarian Failure","Drug: 17 B estradiol orally|Drug: 17 B estradiol","Change in Weight From Baseline at 12 Months|Change in Body Mass Index From Baseline at 12 Months|Change in Percent Fat Mass From Baseline in 12 Months|Change in Fat Free Mass From Baseline at 12 Months|Characterize PK/PD and Relative Biological Potency of Different Oral vs TD Estrogen Preparations|Changes in Insulin Growth Factor-I From Baseline at 12 Months|Lipids Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months|Rates of Lipid Oxidation After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months|Serum 17B Estradiol Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months|Serum Estrone Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months|Serum Estrone Sulfate Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months","Nemours Children's Clinic|Genentech, Inc.","Female","13 Years to 20 Years   (Child, Adult)","Phase 4","41","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","908-M01","January 2009","June 2012","December 2012","February 5, 2009","February 10, 2014","March 27, 2014","Nemours Children's Clinic, Jacksonville, Florida, United States|Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Chile/Clinica las Condes, Santiago, Chile",,"https://ClinicalTrials.gov/show/NCT00837616"
1091,"NCT03720990","Smith-Lemli-Opitz Syndrome and Cholic Acid",,"Not yet recruiting","No Results Available","Smith-Lemli-Opitz Syndrome","Drug: Cholic Acid","Change in Serum Cholesterol and Cholesterol Metabolites","University of Nebraska|University of Colorado, Denver|Children's Hospital Medical Center, Cincinnati|University of Pittsburgh","All","2 Years to 25 Years   (Child, Adult)","Phase 1|Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB#464-18-FB","May 1, 2020","August 31, 2020","August 31, 2020","October 26, 2018",,"March 25, 2020","Colorado Children's Hospital, Aurora, Colorado, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03720990"
1092,"NCT01008384","The Effect of Vitamin D Repletion on Small Low Density Lipoprotein (LDL) Particle Number in Subjects at Elevated Cardiovascular Risk",,"Completed","No Results Available","Atherosclerosis","Dietary Supplement: Vitamin D3","Small LDL particle concentration","Rockefeller University","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)","MAP-0683","October 2009","October 2011","October 2011","November 5, 2009",,"June 1, 2012","The Rockefeller University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01008384"
1093,"NCT02527343","The BROADEN Study: A Study of Volanesorsen (Formerly ISIS-APOCIIIRx) in Patients With Familial Partial Lipodystrophy",,"Active, not recruiting","No Results Available","Familial Partial Lipodystrophy","Drug: volanesorsen|Drug: Placebo","Efficacy of volanesorsen (IONIS-APOCIIIRx) measured as the percent change in fasting triglycerides from baseline.|Change from Baseline in hepatic steatosis (as assessed by hepatic fat fraction using magnetic resonance imaging (MRI).|Change from Baseline in hemoglobin A1c (HbA1c)|A composite endpoint at Month 6 for percent of patients who achieve a. ≥ 40% reduction in fasting TG, and b. ≥ 30% reduction of hepatic fat fraction percent|Change in patient-reported outcomes (PRO)","Ionis Pharmaceuticals, Inc.|Akcea Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ISIS 304801-CS17","October 31, 2015","June 30, 2018","September 30, 2021","August 19, 2015",,"January 10, 2020","IONIS Investigative Site, Aurora, Colorado, United States|IONIS Investigative Site, Ann Arbor, Michigan, United States|IONIS Investigative Site, Rochester, Minnesota, United States|IONIS Investigative Site, Saint Louis, Missouri, United States|IONIS Investigative Site, Morehead City, North Carolina, United States|IONIS Investigative Site, Philadelphia, Pennsylvania, United States|IONIS Investigative Site, Dallas, Texas, United States|IONIS Investigative Site, Leuven, Belgium|IONIS Investigative Site, Brasilia, Brazil|IONIS Investigative Site, Rio de Janeiro, Brazil|IONIS Investigative Site, Sao Paulo, Brazil|IONIS Investigative Site, Halifax, Nova Scotia, Canada|IONIS Investigative Site, Berlin, Germany|IONIS Investigative Site, Koeln, Germany|IONIS Investigative Site, Muenster, Germany|IONIS Investigative Site, Athens, Greece|IONIS Investigative Site, Ioannina, Greece|IONIS Investigative Site, Haifa, Israel|IONIS Investigative Site, Bologna, Italy|IONIS Investigative Site, Catania, Italy|IONIS Investigative Site, Pisa, Italy|IONIS Investigative Site, Amsterdam-Zuidoost, Netherlands|IONIS Investigative Site, Porto, Portugal|IONIS Investigative Site, Moscow, Russian Federation|IONIS Investigative Site, Santiago de Compostela, Spain|IONIS Investigative Site, Sevilla, Spain|IONIS Investigative Site, Izmir, Turkey|IONIS Investigative Site, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02527343"
1094,"NCT03248882","Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)",,"Completed","Has Results","Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis","Drug: Placebo|Drug: PF-05221304","Percent Change From Baseline in Liver Fat by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI- PDFF) at Week 16|Percent Change From Baseline in Alanine Aminotransferase at Week 16|Number of Participants With Treatment-Emergent Adverse Events|Number of Participants With Laboratory Abnormalities|Number of Participants With Vital Signs Data Meeting Predefined Criteria|Number of Participants With 12-Lead Electrocardiogram (ECG) Data Meeting Predefined Criteria","Pfizer","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","305","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","C1171002|2017-001156-55","August 22, 2017","February 26, 2019","March 27, 2019","August 14, 2017","March 10, 2020","March 10, 2020","Franco Felizarta MD, Bakersfield, California, United States|eStudySite, Chula Vista, California, United States|San Diego Imaging Chula Vista, Chula Vista, California, United States|University of California, San Diego (Altman Clinical and Translational Research Institute), La Jolla, California, United States|University of California, San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|Clinical Trials Research, Lincoln, California, United States|National Research Institute, Los Angeles, California, United States|Stanford University Medical Center, Blake wilbur Building, Palo Alto, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Huntington Medical Research Institute, Pasadena, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|Precision Research Institute, San Diego, California, United States|Quest Clinical Research, San Francisco, California, United States|South Denver Gastroenterology, P.C., Englewood, Colorado, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|Ocean Blue Medical Research Center, Inc, Miami Springs, Florida, United States|Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States|Stand Up MRI of Miami, Miami, Florida, United States|Avail Clinical Research, LLC, Orange City, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Advanced Gastroenterology Associates, LLC, Palm Harbor, Florida, United States|Qps-Mra, Llc, South Miami, Florida, United States|Tampa General Medical Group, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|South Florida Center Of Gastroenterology, PA, Wellington, Florida, United States|Independent Imaging, Wellington, Florida, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Invision Imaging, Honolulu, Hawaii, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Ascension Via Christi Imaging at St. Francis, Wichita, Kansas, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Digestive Disease Associates, PA, Catonsville, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic- Main Campus, Rochester, Minnesota, United States|Gastrointestinal Associates, PA, Flowood, Mississippi, United States|Colonnades at Baptist, Jackson, Mississippi, United States|BioTelemetry Research, Rochester, New York, United States|Investigational Drug Service, University of North Carolina Hospitals, Chapel Hill, North Carolina, United States|The University of NC at Chapel Hill, Clinical and Translational Research Center (CTRC), Chapel Hill, North Carolina, United States|The University of North Carolina at Chapel Hill, Biomedical Research Imaging Center (MRI Facility), Chapel Hill, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|PMG Research, Inc., Winston-Salem, North Carolina, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Prime Imaging (Chattanooga Outpatient Center), Chattanooga, Tennessee, United States|ClinSearch, Chattanooga, Tennessee, United States|Touchstone, Austin, Texas, United States|Baylor College of Medicine - Advanced Liver Therapies, Houston, Texas, United States|Pinnacle Clinical Research, Rollingwood, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Pinnacle Clinical Research, PLLC, San Antonio, Texas, United States|Clinical Research Advantage, Inc./Wasatch Peak Family Practice, Layton, Utah, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Australian Clinical Research Network, Maroubra, New South Wales, Australia|Spectrum Medical Imaging, Randwick, New South Wales, Australia|Castlereagh Imaging, Westmead, New South Wales, Australia|Storr Liver Centre, Westmead Hospital, Westmead, New South Wales, Australia|Dr. Jones & Partners Medical Imaging, Adelaide, South Australia, Australia|Royal Adelaide Hospital, Department of Gastroenterology and Hepatology, Adelaide, South Australia, Australia|Flinders Medical Centre/Department of Gastroenterology & Hepatology, Adelaide, South Australia, Australia|Radiology SA, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Dr TG Elliott Inc - BC Diabetes, Vancouver, British Columbia, Canada|False Creek Healthcare Centre, Vancouver, British Columbia, Canada|False Creek Healthcare, Vancouver, British Columbia, Canada|LAIR Centre, Vancouver, British Columbia, Canada|Discovery Clinical Services Ltd., Victoria, British Columbia, Canada|West Coast Medical Imaging, Victoria, British Columbia, Canada|Nova Scotia Health Authority, QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Nova Scotia Health Authority, QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Nova Scotia Health Authority - QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Aggarwal and Associates Limited, Brampton, Ontario, Canada|St. Joseph's Health Care London, London, Ontario, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Oxford Medical Imaging, Mississauga, Ontario, Canada|LMC Clinical Research Inc. (Bayview), Toronto, Ontario, Canada|St. Michael's Hospital - MRI Research Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|University Health Network (UHN) - Toronto General Hospital - Toronto Centre for Liver Disease (TCLD), Toronto, Ontario, Canada|University of Toronto - Toronto General Hospital, Toronto, Ontario, Canada|University Health Network (UHN), Toronto, Ontario, Canada|Toronto Liver Centre - Liver Care Centre Corporation, Toronto, Ontario, Canada|Resonance Magnetique du Saguenay-Lac-Saint-Jean, Chicoutimi, Quebec, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|Medpharmgene Inc, Montreal, Quebec, Canada|Clinique de Medecine Urbaine du Quartier Latin, Montreal, Quebec, Canada|Centre de recherche du CHUM, Montreal, Quebec, Canada|Cedar Cancer Center - McGill University Health Centre, Montreal, Quebec, Canada|Chronic Viral Illness Service - Royal Victoria Hospital - McGill University Health Centre (MUHC), Montreal, Quebec, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Research Institute of the MUHC, Montreal, Quebec, Canada|Radiologie Varad, Montreal, Quebec, Canada|Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l'Estrie, Sherbrooke, Quebec, Canada|Recherche Medicale St-Jerome Inc, St-Jerome, Quebec, Canada|IRM Quebec, Quebec, Canada|IRM Quebec, Quebec, Canada|CHU de Quebec - Universite Laval - site Centre Hospitalier de l'Universite Laval (CHUL), Quebec, Canada|Centre de recherche de l'Institut Universitaire de Cardiologie et de pneumologie de Quebec, Quebec, Canada|Centre de recherche Saint-Louis, Quebec, Canada|IRM Québec - Clinique St-Louis, Quebec, Canada|Alpha Recherche Clinique, Quebec, Canada|Clinix, Quebec, Canada|Hillel Yaffe Medical Center, Hadera, Israel|Rambam Health Care Campus, Haifa, Israel|Lady Davis Carmel Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Hebrew University Medical Center - Ein Kerem, Jerusalem, Israel|Galilee Medical Center, Nahariya, Israel|Holy Family Hospital, Nazareth, Israel|Rabin Medical Center, Petah Tikva, Israel|The Chaim Sheba Medical Center, Ramat-Gan, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|ClinicMed Badurski i wspolnicy Spolka Jawna, Bialystok, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdansku, Gdansk, Poland|Centrum Badan Klinicznych PI-House Sp. z o.o., Gdansk, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdyni, Gdynia, Poland|Osrodek Badan Klinicznych, Jaworze, Poland|Synexus Polska Sp. z o.o. Oddzial w Katowicach, Katowice, Poland|Silmedic Sp. z o.o. Oddzial w Katowicach, Katowice, Poland|Centrum Medyczne A-Z Clinic, Krakow, Poland|Krakowskie Centrum Medyczne sp. z o.o., Krakow, Poland|Gabinet Lekarski Malgorzata Saryusz-Wolska, Lodz, Poland|Synexus Polska Sp. z o.o Oddzial w Poznaniu, Poznan, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|Synexus Polska Sp. z o. o. Oddzial w Warszawie, Warszawa, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Centrum Badan Klinicznych, Wroclaw, Poland|Synexus Polska Sp. z o.o. Oddzial we Wroclawiu, Wroclaw, Poland|DOBROSTAN - Gabinety Lekarskie, Wroclaw, Poland|Changhua Christian Hospital, Changhua city, Changhua County, Taiwan|Chung-Ho Memorial Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan|National Cheng-Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03248882/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03248882/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03248882"
1095,"NCT04095793","Extension Study of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure",,"Recruiting","No Results Available","Symptomatic Neurogenic Orthostatic Hypotension","Drug: ampreloxetine","Physical examination|Neurological Examination|Vital Signs|ECGs|Clinical Laboratory Tests|Concomitant Medications|Adverse Events (AEs)|Subject compliance to study treatment|Incidence of Falls|Changes from baseline in Columbia Suicide Severity Rating Scale (C-SSRS)","Theravance Biopharma","All","30 Years and older   (Adult, Older Adult)","Phase 3","80","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0171","September 19, 2019","February 2022","March 2025","September 19, 2019",,"April 7, 2020","Neurostudies, Inc., Port Charlotte, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Inland Northwest Research, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04095793"
1096,"NCT02304484","Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab",,"Completed","Has Results","Hypercholesterolemia","Biological: Evolocumab","Number of Participants With Adverse Events|Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)","Amgen","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","770","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140128|2014-001524-30","November 24, 2014","March 9, 2018","March 9, 2018","December 2, 2014","March 19, 2019","March 19, 2019","Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Long Beach, California, United States|Research Site, San Diego, California, United States|Research Site, Torrance, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Munster, Indiana, United States|Research Site, Lexington, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Bay City, Michigan, United States|Research Site, Midland, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Columbia, Missouri, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, Fargo, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Córdoba, Argentina|Research Site, Córdoba, Argentina|Research Site, Liverpool, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Chermside, Queensland, Australia|Research Site, Herston, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Epping, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Antwerpen, Belgium|Research Site, Edegem, Belgium|Research Site, Genk, Belgium|Research Site, Hasselt, Belgium|Research Site, Lodelinsart, Belgium|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Québec, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Praha 2, Czechia|Research Site, Zlin, Czechia|Research Site, Besancon cedex, France|Research Site, Chambray les Tours, France|Research Site, Marseille cedex 5, France|Research Site, Paris, France|Research Site, Pessac Cedex, France|Research Site, Essen, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Szeged, Hungary|Research Site, Reykjavik, Iceland|Research Site, Galway, Ireland|Research Site, Hadera, Israel|Research Site, Jerusalem, Israel|Research Site, Novara, Italy|Research Site, Rozzano MI, Italy|Research Site, Sesto San Giovanni (MI), Italy|Research Site, Torino, Italy|Research Site, Daejeon, Korea, Republic of|Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kuantan, Pahang, Malaysia|Research Site, Penang, Malaysia|Research Site, Guadalajara, Jalisco, Mexico|Research Site, San Luis Potosi, San Luis Potosí, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Aguascalientes, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Oslo, Norway|Research Site, Chrzanow, Poland|Research Site, Kedzierzyn Kozle, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Centurion, Gauteng, South Africa|Research Site, Sunninghill, Gauteng, South Africa|Research Site, Kuils River, Western Cape, South Africa|Research Site, Malaga, Andalucía, Spain|Research Site, Gijon, Asturias, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, L Hospitalet De Llobregat, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Göteborg, Sweden|Research Site, Stockholm, Sweden|Research Site, Geneva 14, Switzerland|Research Site, New Taipei, Taiwan|Research Site, Newcastle Upon Tyne, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02304484/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02304484/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02304484"
1097,"NCT02579265","Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants",,"Recruiting","No Results Available","Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days","Drug: Smoflipid 20% (investigational lipid for parenteral nutrition)|Drug: Intralipid® 20%","The number of patients in each treatment group with conjugated bilirubin levels > 2 mg/dL during the first 28 days of study treatment, confirmed by a second sample collected 7 days after the first sample|Body weight (change from Baseline)|Body length (change from Baseline)|Head circumference (change from Baseline)|Time to full enteral or oral feeds|Fatty acids in plasma and red blood cell membranes (change from Baseline)|Length of stay in hospital|Ratio of number of independent bloodstream infections to number of days on study medication|Ratio of the number of patients with 1 or more bloodstream infections to number of patients on study medication|Number of patients who complete PN treatment without lipid minimization|Number of patients needing to be withdrawn from the study due to elevated conjugated bilirubin levels|Cumulative number of days of conjugated bilirubin levels > 1.5 mg/dL|Area under the curve for time period in which conjugated bilirubin levels are > 1.5 mg/dL in patients who are not withdrawn from the study|Cumulative number of days patients are administered a lipid dose without lipid minimization|Time to conjugated bilirubin > 2 mg/dL (confirmed by a second sample collected 7 days after the first|Collection of AE data|Blood sampling for safety analysis|Blood sampling for special analysis (sterols including phytosterols, α-tocopherol)|Holman index","Fresenius Kabi","All","Child, Adult, Older Adult","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","SMOF-018-CP3","December 2015","July 2020","October 2020","October 19, 2015",,"January 28, 2020","Lucile Packard Children's Hospital, Palo Alto, California, United States|UC San Diego Medical Center, San Diego, California, United States|Rady Children's Hospital San Diego, San Diego, California, United States|Yale - New Haven Children's Hospital, New Haven, Connecticut, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Mount Sinai Hospital, New York, New York, United States|Steven & Alexandra Cohen Children's Medical Center of NY, New York, New York, United States|The Children's Hospital at OU Medical Center, Oklahoma City, Oklahoma, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02579265"
1098,"NCT02004691","Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency","ASCEND","Active, not recruiting","No Results Available","Sphingomyelin Lipidosis","Drug: placebo (saline)|Drug: GZ402665","Percentage change in spleen volume (combined with change in SRS in the US only, and referred to as ""combination spleen endpoint"")|Percentage change in diffusing capacity of the lung for carbon monoxide|Percentage change in liver volume|Percentage change in platelet count|Change in fatigue severity as measured by item 3 of the Brief Fatigue Inventory scale|Change in pain severity as measured by item 3 of the Brief Pain Inventory scale|Change in dyspnea severity as measured by the Functional Assessment of Chronic Illness Therapy dyspnea tool|Change in SRS (except US, where it is part of the primary ""combination spleen endpoint"")|Number of adverse events","Genzyme, a Sanofi Company|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DFI12712|2015‐000371‐26|U1111-1142-5963","December 18, 2015","October 17, 2019","October 2023","December 9, 2013",,"December 3, 2019","Investigational Site Number 840005, San Francisco, California, United States|Investigational Site Number 840003, Decatur, Georgia, United States|Investigational Site Number 840006, Bronx, New York, United States|Investigational Site Number 032001, Córdoba, Argentina|Investigational Site Number 036001, Westmead, Australia|Investigational Site Number 076001, Porto Alegre, Brazil|Investigational Site Number 100001, Sofia, Bulgaria|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 250001, Paris, France|Investigational Site Number 276001, Mainz, Germany|Investigational Site Number 380002, Napoli, Italy|Investigational Site Number 380001, Udine, Italy|Investigational Site Number 392001, Fukushima-Shi, Japan|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 620002, Porto, Portugal|Investigational Site Number 724001, Madrid, Spain|Investigational Site Number 788001, Tunis, Tunisia|Investigational Site Number 792002, Ankara, Turkey|Investigational Site Number 792003, Istanbul, Turkey|Investigational Site Number 792001, Izmir, Turkey|Investigational Site Number 826002, Birmingham, United Kingdom|Investigational Site Number 826001, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02004691"
1099,"NCT01624142","Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders","TAUSSIG","Completed","Has Results","Severe Familial Hypercholesterolemia","Biological: Evolocumab","Number of Participants With Adverse Events|Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)|Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)|Percent Change From Baseline in Lipoprotein (a)|Percent Change From Baseline in Apolipoprotein B|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio|Percentage of Participants With a 15% or Greater Reduction in LDL-C","Amgen","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","300","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20110271|2011-005400-15","June 1, 2012","May 11, 2018","May 11, 2018","June 20, 2012","January 28, 2019","January 28, 2019","Research Site, Los Angeles, California, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Hobart, Tasmania, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Bruxelles, Belgium|Research Site, La Louvière, Belgium|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, London, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 2, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Dijon, France|Research Site, Paris Cedex 13, France|Research Site, Athens, Greece|Research Site, New Territories, Hong Kong|Research Site, Ramat Gan, Israel|Research Site, Cinisello Balsamo (MI), Italy|Research Site, Napoli, Italy|Research Site, Pisa, Italy|Research Site, Kanazawa, Ishikawa, Japan|Research Site, Suita, Osaka, Japan|Research Site, Beirut, Lebanon|Research Site, Amsterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Lugo, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT01624142/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT01624142/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01624142"
1100,"NCT03039491","Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults",,"Recruiting","No Results Available","HIV Lipodystrophy|Aging","Biological: Pneumococcal polysaccharide vaccine 23 valent|Biological: 13 valent conjugated pneumococcal vaccine","Antibody response|opsonophagocytic antibody activity|PPS-specific B cell phenotype|Expression of TACI on PPS-specific B cells|Expression of BAFFR on PPS-specific B cells|Expression of BCMA on PPS-specific B cells|Expression of CD40 on PPS-specific B cells|Expression of cluster of differentiation 21 (CD21) on PPS-specific B cells|Expression of CD21 on PPS-specific B cells|Serum interleukin-6 (IL-6)|Serum BAFF|Serum APRIL|Serum IL-10|Serum IL-1(RA)|Serum IL-1(B)|Serum IL-8|Serum TNFalpha","Medical University of South Carolina","All","21 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MUSC vaccine study","September 1, 2015","March 30, 2020","March 30, 2020","February 1, 2017",,"April 17, 2019","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03039491"
1101,"NCT01879319","Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen",,"Completed","Has Results","Primary Hypercholesterolemia|Mixed Dyslipidemia","Biological: Evolocumab AMD|Biological: Evolocumab AI/pen","Percentage of Participants With Full Administration of Evolocumab at Both Weeks 4 and 8|Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120356","July 2013","December 2013","December 2013","June 17, 2013","December 23, 2015","December 23, 2015","Research Site, Phoenix, Arizona, United States|Research Site, Encino, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Tustin, California, United States|Research Site, Ventura, California, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Saint Augustine, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Lexington, Kentucky, United States|Research Site, Lewiston, Maine, United States|Research Site, Ayer, Massachusetts, United States|Research Site, Manlius, New York, United States|Research Site, Cadiz, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Lansdale, Pennsylvania, United States|Research Site, Jackson, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Burnaby, British Columbia, Canada|Research Site, London, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Pointe-Claire, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01879319"
1102,"NCT01849497","Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen",,"Completed","Has Results","Primary Hypercholesterolemia|Mixed Dyslipidemia","Biological: Evolocumab Pre-filled Syringe|Biological: Evolocumab AI/pen","Percentage of Participants With Full Administration of Evolocumab at Both Weeks 2 and 4|Percent Change From Baseline in LDL-C at Week 6","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","149","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120348","April 18, 2013","September 2, 2013",,"May 8, 2013","October 9, 2015","November 29, 2018","Research Site, Encino, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Ventura, California, United States|Research Site, Westlake Village, California, United States|Research Site, Miami, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Hammond, Indiana, United States|Research Site, Auburn, Maine, United States|Research Site, Manlius, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Cadiz, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Lansdale, Pennsylvania, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Pointe-Claire, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01849497"
1103,"NCT02489344","Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease",,"Completed","Has Results","Fabry Disease","Drug: GZ/SAR402671","Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Urinalysis|Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities|Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities|Change From Baseline in Plasma Globotriaosylceramide (GL-3) Concentration at Weeks 26, 52, 104, and 156|Change From Baseline in Plasma Lyso Globotriaosylceramide (Lyso GL-3) Concentration at Weeks 26, 52, 104, and 156|Change From Baseline in Plasma Glucosylceramide (GL-1) Concentration At Weeks 26, 52, 104, and 156|Change From Baseline in Plasma Monosialodihexosylganglioside (GM3) Concentration At Weeks 26, 52, 104, and 156|Change From Baseline in Urine GL-3 Concentration At Weeks 26, 52, 104, and 156|Change From Baseline in High Sensitivity Cardiac Troponin T At Weeks 26, 52, 104, and 156|Change From Baseline in Podocyturia Counts (Per Milligram of Creatinine) At Weeks 12, 26, and 156|Summary of Shifts From Baseline in Skin GL-3 Score in Superficial Capillary Endothelial Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score|Summary of Shifts From Baseline in Skin GL-3 Score in Deep Vessels Endothelial Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score|Summary of Shifts From Baseline in Skin GL-3 Score in Deep Vessels Smooth Muscle Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score|Summary of Shifts From Baseline in Skin GL-3 Score in Perineurium Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score|Change From Baseline in Mental Component Summary and Physical Component Summary of the Short Form-36 (SF-36) Health Survey at Weeks 26, 52, 104 and 156|Gastrointestinal (GI) Symptoms: Number of Participants With Abdominal Pain at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Abdominal Pain Severity Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Number of Days With Abdominal Pain Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Number of Participants With Abdominal Distension at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Abdominal Distension Severity Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, and 156|Gastrointestinal Symptoms: Number of Participants in Categories of Response Regarding Eating Less Due to Abdominal Pain/Bloating at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Satisfaction Over Bowel Habits at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Frequency of Bowel Movements - Most Number of Times Bowel Movement Per Day at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Frequency of Bowel Movements - Least Number of Times Bowel Movement Per Day at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Influence of GI Symptoms of Fabry Disease on Life at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Number of Participants With Stool Consistency Assessment by Bristol Stool Scale Scoring at Baseline and Weeks 26, 52, 104, and 156|Change From Baseline in Beck Depression Inventory (BDI) Total Score at Weeks 26, 104, and 156|Change From Baseline in Albumin/Creatinine Ratio (ACR) and Protein/Creatinine Ratio (PCR) at Weeks 26, 52, 104, and 156|Number of Participants in Categories of Echocardiogram (ECHO) Results at Baseline and at Weeks 26, 52, 104, and 156|Number of Participants in Categories of Brain Magnetic Resonance Imaging (MRI) Results at Baseline and Weeks 26, and 156|Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Weeks 26, 52, 104, and 156","Genzyme, a Sanofi Company|Sanofi","Male","18 Years and older   (Adult, Older Adult)","Phase 2","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS14116|2014-004995-49|U1111-1165-9049","July 7, 2015","November 20, 2018","November 20, 2018","July 3, 2015","December 9, 2019","December 9, 2019","Investigational Site Number 840002, Atlanta, Georgia, United States|Investigational Site Number 840003, Cincinnati, Ohio, United States|Investigational Site Number 840001, Fairfax, Virginia, United States|Investigational Site Number 250001, Garches, France|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 826002, Cambridge, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02489344/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02489344/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02489344"
1104,"NCT03739931","Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies",,"Recruiting","No Results Available","Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma|Dose Expansion: Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non-Hodgkin Lymphoma, and Urothelial Cancer","Biological: mRNA-2752|Biological: mRNA-2752 + durvalumab","Percentage of subjects with dose limiting toxicities (DLTs)|Percentage of subjects with adverse events (AEs)|Overall response rate (ORR)|Protein expression of IL-23, IL-36γ and OX40L in tumors|Concentrations of mRNA-2752 in blood and non-compartmental PK parameters","ModernaTX, Inc.|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 1","126","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","mRNA-2752-P101","November 27, 2018","June 2020","July 2021","November 14, 2018",,"April 24, 2020","University of Colorado Aurora, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Sarah Cannon Research Institute at Florida Cancer Specialists, Sarasota, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Cancer Center at Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Rabin Medical Center, Petah Tikva, Israel",,"https://ClinicalTrials.gov/show/NCT03739931"
1105,"NCT03323398","Dose Escalation and Efficacy Study of mRNA 2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Patients With Advanced Malignancies",,"Recruiting","No Results Available","Relapsed/Refractory Solid Tumor Malignancies or Lymphoma|Ovarian Cancer","Biological: mRNA-2416|Biological: Durvalumab","Percentage of subjects with dose limiting toxicities (DLTs) with mRNA-2416 alone|Percentage of subjects with dose limiting toxicities (DLTs) with mRNA-2416 in combination with durvalumab|Percentage of subjects with adverse events (AEs) for mRNA-2416 alone|Percentage of subjects with adverse events (AEs) for mRNA-2416 in combination with durvalumab|In Phase II dose expansion: objective response rate (ORR) of mRNA-2416 alone and in combination with durvalumab in patients with ovarian cancer based on RECIST v1.1|Percentage of subjects with anti-OX40L antibodies|Maximum Observed Serum Concentration (Cmax) of mRNA-2416|Maximum Observed Serum Concentration (Cmax) of mRNA-2416 alone|Area under the serum concentration-time curve (AUC) of mRNA-2416 alone|Area under the serum concentration-time curve (AUC) of mRNA-2416 in combination with durvalumab|In Phase I only: ORR based on RECIST v1.1 or Cheson 2014 criteria (lymphomas)|In Phase I only: duration of response based on RECIST v1.1 or Cheson 2014 criteria (lymphomas)|In Phase I only: progression-free survival based on RECIST v1.1 or Cheson 2014 criteria (lymphomas)|Disease control rate in patients with ovarian cancer (RECIST v1.1)|In Phase II: disease control rate in patients with ovarian cancer (RECIST v1.1)|In Phase II: duration of response in patients with ovarian cancer (RECIST v1.1)","ModernaTX, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","117","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","mRNA-2416-P101","August 9, 2017","September 2021","March 2022","October 27, 2017",,"March 23, 2020","University of Colorado Hospital, Aurora, Colorado, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03323398"
1106,"NCT02344290","Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults","REPRIEVE","Active, not recruiting","No Results Available","HIV Infections|Cardiovascular Diseases","Drug: Pitavastatin|Drug: Placebo","Time to the first event of a composite of major cardiovascular events|Time to the first of each individual component of the primary endpoint|Time to death (all-cause mortality)|Time to death (all-cause mortality) and/or major adverse cardiovascular events (MACE)|Time to any (composite) or each (individual) of the following clinical diagnoses (including recurrent diagnoses as appropriate)|Calculated fasting low-density lipoprotein (LDL) and non-high-density lipoprotein (HDL) cholesterol level|Time to any of the following adverse events (including recurrent events as appropriate)|For substudy: evidence of non-calcified coronary atherosclerotic plaque (NCP)|For substudy: volume of NCP at study entry and change in NCP over 2 years|For substudy: progression of NCP|For substudy: number of high risk plaque features|For substudy: changes in inflammatory markers|For substudy: changes in markers of glucose homeostasis","National Institute of Allergy and Infectious Diseases (NIAID)|National Heart, Lung, and Blood Institute (NHLBI)|Kowa Pharmaceuticals America, Inc.|Gilead Sciences|Massachusetts General Hospital (MGH)|NEAT ID","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 3","7770","NIH|Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","A5332|11960|1U01HL123339-01|1U01HL123336-01|EU5332","March 26, 2015","March 24, 2023","March 26, 2023","January 22, 2015",,"February 6, 2020","Alabama CRS, Birmingham, Alabama, United States|University of Arizona CRS, Tucson, Arizona, United States|University of Southern California CRS, Los Angeles, California, United States|UCLA CARE Center CRS, Los Angeles, California, United States|Mills Clinical Research CRS, Los Angeles, California, United States|VA West Los Angeles Medical Center CRS, Los Angeles, California, United States|Los Angeles LGBT Center CRS, Los Angeles, California, United States|Eisenhower Health Center at Rimrock CRS, Palm Springs, California, United States|Stanford AIDS Clinical Trials Unit CRS, Palo Alto, California, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Ucsf Hiv/Aids Crs, San Francisco, California, United States|Harbor-UCLA CRS, Torrance, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|Denver Public Health CRS, Denver, Colorado, United States|Yale University CRS, New Haven, Connecticut, United States|VA Connecticut Healthcare System CRS, West Haven, Connecticut, United States|Whitman-Walker Health CRS, Washington, District of Columbia, United States|Georgetown University CRS (GU CRS), Washington, District of Columbia, United States|Capital Medical Associates, PC CRS, Washington, District of Columbia, United States|Infectious Diseases Clinic, Washington DC Veterans Affairs Medical Center CRS, Washington, District of Columbia, United States|Malcom Randall VA Medical Center CRS, Gainesville, Florida, United States|AHF-The Kinder Medical Group CRS, Miami, Florida, United States|The University of Miami AIDS Clinical Research Unit (ACRU) CRS, Miami, Florida, United States|University of Miami Infectious Disease Research Unit at Jackson Memorial Hospital CRS, Miami, Florida, United States|AHF - South Beach CRS, Miami, Florida, United States|Orlando Immunology Center CRS, Orlando, Florida, United States|Community AIDS Network/Comprehensive Care Clinic CRS, Sarasota, Florida, United States|Florida Department of Health - Hillsborough County, Tampa, Florida, United States|AIDS Research and Treatment Center of the Treasure Coast CRS, Vero Beach, Florida, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|Augusta University Research Institute, Inc. CRS, Augusta, Georgia, United States|Northwestern University CRS, Chicago, Illinois, United States|Rush University CRS, Chicago, Illinois, United States|UIC Project WISH CRS, Chicago, Illinois, United States|Indiana University Infectious Diseases Research CRS, Indianapolis, Indiana, United States|Department of Internal Medicine, University of Iowa Hospitals & Clinics CRS, Iowa City, Iowa, United States|Bluegrass Care Clinic/University of Kentucky Research Foundation CRS, Lexington, Kentucky, United States|550 Clinic -University of Louisville CRS, Louisville, Kentucky, United States|Tulane - Louisiana Community AIDS Research Program (T-LaCARP) CRS, New Orleans, Louisiana, United States|Johns Hopkins University CRS, Baltimore, Maryland, United States|Tufts Medical Center CRS, Boston, Massachusetts, United States|Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States|Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS, Boston, Massachusetts, United States|Boston Medical Center CRS, Boston, Massachusetts, United States|Baystate Infectious Diseases Clinical Research CRS, Springfield, Massachusetts, United States|Henry Ford Hosp. CRS, Detroit, Michigan, United States|St. John Newland Medical Associates CRS, Southfield, Michigan, United States|Abbott Northwestern Hospital CRS, Minneapolis, Minnesota, United States|University of Mississippi Medical Center CRS, Jackson, Mississippi, United States|Washington University Therapeutics (WT) CRS, Saint Louis, Missouri, United States|Specialty Care Center CRS, Omaha, Nebraska, United States|Cooper Univ. Hosp. CRS, Camden, New Jersey, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|James J Peters VA Medical Center CRS, Bronx, New York, United States|Mount Sinai Beth Israel CRS, New York, New York, United States|VA New York Harbor Healthcare System (NYHHS), NY Campus CRS, New York, New York, United States|Weill Cornell Chelsea CRS, New York, New York, United States|Mount Sinai Downtown CRS, New York, New York, United States|Mount Sinai West Samuels CRS, New York, New York, United States|Mount Sinai St. Luke's Morningside CRS, New York, New York, United States|Infectious Disease Clinical and Translational Research Center (CTRC) CRS, New York, New York, United States|Columbia P&S CRS, New York, New York, United States|Weill Cornell Uptown CRS, New York, New York, United States|University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Duke University Medical Center CRS, Durham, North Carolina, United States|Greensboro CRS, Greensboro, North Carolina, United States|Wake Forest Baptist Medical Center CRS, Winston-Salem, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|Case Clinical Research Site, Cleveland, Ohio, United States|Ohio State University CRS, Columbus, Ohio, United States|University of Toledo Medical Center CRS, Toledo, Ohio, United States|Oklahoma State University Center for Health Sciences CRS, Tulsa, Oklahoma, United States|Division of Infectious Diseases Clinical Research Center- Drexel University CRS, Philadelphia, Pennsylvania, United States|Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States|Center of Translational AIDS Research, Lewis Katz School of Medicine at Temple University CRS, Philadelphia, Pennsylvania, United States|Positive Health Clinic CRS, Pittsburgh, Pennsylvania, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence, Rhode Island, United States|Medical University of South Carolina: Division of Infectious Diseases CRS, Charleston, South Carolina, United States|Palmetto Health Clinical Trial Department CRS, Columbia, South Carolina, United States|Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, United States|Trinity Health and Wellness Center CRS, Dallas, Texas, United States|Dallas VA Medical Center CRS, Dallas, Texas, United States|UT Southwestern HIV/ID Clinical Trials Unit CRS, Dallas, Texas, United States|Houston AIDS Research Team CRS, Houston, Texas, United States|Michael E. DeBakey VAMC REPRIEVE CRS, Houston, Texas, United States|Inova Heart and Vascular Institute CRS, Falls Church, Virginia, United States|Virginia Commonwealth University CRS, Richmond, Virginia, United States|University of Washington AIDS CRS, Seattle, Washington, United States|Medical College of Wisconsin, Inc. CRS, Milwaukee, Wisconsin, United States|Gaborone CRS, Gaborone, South-East District, Botswana|Tropical Medicine Foundation Dr. Heitor Vieira Dourado CRS, Manaus, Amazonas, Brazil|School of Medicine, Federal University of Minas Gerais CRS, Belo Horizonte, Minas Gerais, Brazil|HGNI HIV Family Care Clinic - HHFCC CRS, Nova Iguacu, Rio De Janeiro, Brazil|Hospital Nossa Senhora da Conceicao CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Referencia e Treinamento DST/AIDS CRS, Sao Paulo, São Paulo, Brazil|Projeto Praça Onze Pesquisa em Saúde CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado CRS, Rio de Janeiro, Brazil|Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro, Brazil|Instituto de Infectologia Emilio Ribas CRS, Sao Paulo, Brazil|Centro de Pesquisas Clínicas IC-HCFMUSP CRS, Sao Paulo, Brazil|Vancouver ID Research & Care Centre Society CRS, Vancouver, British Columbia, Canada|Hamilton Health Sciences - Special Immunology Services Clinic CRS, Hamilton, Ontario, Canada|Maple Leaf Research CRS, Toronto, Ontario, Canada|Toronto General Hospital CRS, Toronto, Ontario, Canada|Chronic Viral Illness Service CRS, Montreal, Quebec, Canada|Centre hospitalier de l'Université Laval CRS, Quebec City, Quebec, Canada|GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS, Port-au-Prince, Haiti|Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti|Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, Maharashtra, India|Chennai Antiviral Research and Treatment (CART) CRS, Chennai, Tamil Nadu, India|Barranco CRS, Lima, Peru|San Miguel CRS, Lima, Peru|Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico|Soweto ACTG CRS, Johannesburg, Gauteng, South Africa|Wits Helen Joseph Hospital CRS (Wits HJH CRS), Johannesburg, Gauteng, South Africa|Durban International Clinical Research Site CRS, Durban, Kwa Zulu Natal, South Africa|University of Cape Town Lung Institute (UCTLI) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Universitario Valle d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario de Bellvitge, Barcelona, Spain|Hospital Universitario de Basurto de Basurto, Bilbao, Spain|Hospital General Universitario De Elche, Elche, Spain|Hospital Gregorio Universitario Maranon, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Thai Red Cross AIDS Research Centre (TRC-ARC) CRS, Bangkok, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Joint Clinical Research Centre (JCRC)/Kampala Clinical Research Site, Kampala, Uganda|Milton Park CRS, Harare, Zimbabwe","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02344290/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02344290"
1107,"NCT02228460","Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease",,"Completed","Has Results","Fabry Disease","Drug: GZ/SAR402671","Change From Baseline at Week 26 in Skin Globotriaosylceramide (GL-3) Score in Superficial Skin Capillary Endothelium: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26|Mean Change From Baseline at Week 26 in Skin GL-3 Score in Superficial Skin Capillary Endothelium|Change From Baseline in Plasma GL-3 Concentration at Week 26|Change From Baseline in Plasma Lyso Globotriaosylceramide (Lyso-GL-3) Concentration at Week 26|Change From Baseline in Plasma Glucosylceramide (GL-1) Concentration at Week 26|Change From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Endothelial Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26|Change From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Smooth Muscle Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26|Change From Baseline at Week 26 in Skin GL-3 Score in Perineurium Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26|Change From Baseline in Urine Globotriaosylceramide (GL-3) Concentration at Week 26|Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Pharmacokinetics (PK): Maximum Plasma Drug Concentration (Cmax) of GZ/SAR402671|PK: Plasma Trough Concentration (Ctrough) of GZ/SAR402671|PK: Time to Reach Maximum Plasma Drug Concentration (Tmax) of GZ/SAR402671|PK: Area Under Plasma Concentration Versus Time Curve From 0 to 24 Hours (AUC0-24) of GZ/SAR402671|PK: Terminal Half-life (t1/2z) of GZ/SAR402671|PK: Apparent Total Body Clearance of GZ/SAR402671 at Steady State (CLss/F)|PK: Apparent Volume of Distribution of GZ/SAR402671 (Vss/F) at Steady State|PK: Cumulated Amount of GZ/SAR402671 Excreted in Urine From 0 to 24 Hours (Ae0-24)|PK: Percentage of Dose of GZ/SAR402671 Excreted in Urine From 0 to 24 Hours (fe0-24)|PK: Renal Clearance (CLR) of GZ/SAR402671 From 0 to 24 Hours","Genzyme, a Sanofi Company|Sanofi","Male","18 Years to 49 Years   (Adult)","Phase 2","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACT13739|2013-005324-41|U1111-1152-1456","November 2014","September 2016","September 2016","August 29, 2014","December 17, 2019","December 17, 2019","Investigational Site Number 840002, Atlanta, Georgia, United States|Investigational Site Number 840003, Cincinnati, Ohio, United States|Investigational Site Number 840001, Fairfax, Virginia, United States|Investigational Site Number 250001, Garches, France|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 826003, Birmingham, United Kingdom|Investigational Site Number 826002, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02228460"
1108,"NCT01043640","Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders",,"Completed","Has Results","Mucopolysaccharidosis|Hurler Syndrome|Hunter Syndrome|Maroteaux-Lamy Syndrome|Sly Syndrome|Alpha Mannosidosis|Fucosidosis|Aspartylglucosaminuria|Adrenoleukodystrophy (ALD)|Krabbe Disease|Metachromatic Leukodystrophy (MLD)|Sphingolipidoses|Peroxisomal Disorders","Drug: Campath-1H|Drug: Cyclophosphamide|Drug: Busulfan|Procedure: Allogeneic stem cell transplantation|Drug: Cyclosporine A|Drug: Mycophenolate Mofetil","Number of Patients With Donor Derived Engraftment|Number of Patients With Grade 0 Graft-Versus-Host Disease (GVHD)|Number of Patients With Grade 1 Graft-Versus-Host Disease (GVHD)|Number of Patients With Grade 2 Graft-Versus-Host Disease (GVHD)|Number of Patients With Grade 3 Graft-Versus-Host Disease (GVHD)|Number of Patients With Grade 4 Graft-Versus-Host Disease (GVHD)|Number of Patients Who Died Peri-Transplant|Donor Cell Chimerism Following Transplant","Masonic Cancer Center, University of Minnesota","All","up to 21 Years   (Child, Adult)","Phase 2","46","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009LS088|MT2009-19","December 2009","June 2015","June 2017","January 7, 2010","May 12, 2017","February 5, 2018","Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01043640"
1109,"NCT01529424","Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia",,"Completed","No Results Available","Hypertriglyceridemia","Drug: ISIS apoC-III Rx|Drug: Placebo","VLDL apoC-III","Ionis Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","89","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ISIS 304801-CS2","February 2012","January 2014","January 2014","February 8, 2012",,"June 16, 2016","Farmville Internal Medicine, Farmville, North Carolina, United States|Mark R. Cervi, Greenville, North Carolina, United States|Physicians East, Quadrangle Medical Specialists, Greenville, North Carolina, United States|Carolina East Family Medicine, Greenville, North Carolina, United States|Eastern Carolina Physicians, Kinston, North Carolina, United States|Natalie A Doyle, MD PA, Wilson, North Carolina, United States|Isis Investigational site, Chicoutimi, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01529424"
1110,"NCT03872401","Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke","VESALIUS-CV","Recruiting","No Results Available","Coronary Heart Disease (CHD)","Drug: Evolocumab|Drug: Placebo","Time to Coronary Heart Disease Death, Myocardial Infarction, or Ischemic Stroke|Time to Coronary Heart Disease Death, Myocardial Infarction, Ischemic Stroke, or Any Ischemia-driven Arterial Sroke|Time to MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization|Time to CHD Death, MI, or Any Ischemia-driven Arterial Revascularization|Time to Cardiovascular Death, MI, or Stroke|Time to Myocardial Infarction|Time to Any Ischemia-driven Arterial Revascularization|Time to CHD Death|Time to Cardiovascular Death|Time to All Cause of Death|Time to Ischemic Stroke","Amgen","All","50 Years to 79 Years   (Adult, Older Adult)","Phase 3","12000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20170625|2018-004565-14","June 11, 2019","May 29, 2024","May 29, 2024","March 13, 2019",,"April 7, 2020","Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Beverly Hills, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Riverside, California, United States|Research Site, Roseville, California, United States|Research Site, Sacramento, California, United States|Research Site, Torrance, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Golden, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Boca Raton, Florida, United States|Research Site, Brandon, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Delray Beach, Florida, United States|Research Site, Green Cove Springs, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Cumming, Georgia, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Davenport, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Covington, Kentucky, United States|Research Site, Eunice, Louisiana, United States|Research Site, Hammond, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Great Barrington, Massachusetts, United States|Research Site, Natick, Massachusetts, United States|Research Site, Flint, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Kingston, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New York, New York, United States|Research Site, Southampton, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Jersey Shore, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, East Greenwich, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Little River, South Carolina, United States|Research Site, Murrells Inlet, South Carolina, United States|Research Site, Summerville, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Mesquite, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Farmington, Utah, United States|Research Site, Suffolk, Virginia, United States|Research Site, Winchester, Virginia, United States|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Moron, Buenos Aires, Argentina|Research Site, San Nicolas, Buenos Aires, Argentina|Research Site, Zarate, Buenos Aires, Argentina|Research Site, Santa Rosa, La Pampa, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Corrientes, Argentina|Research Site, Salta, Argentina|Research Site, San Juan, Argentina|Research Site, San Luis, Argentina|Research Site, Garran, Australian Capital Territory, Australia|Research Site, Camperdown, New South Wales, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Bundaberg, Queensland, Australia|Research Site, Milton, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Leabrook, South Australia, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Epping, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Joondalup, Western Australia, Australia|Research Site, Woolloongabba, Australia|Research Site, Haskovo, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Concord, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Markham, Ontario, Canada|Research Site, Nepean, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St Jerome, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Beroun, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Broumov, Czechia|Research Site, Havirov - Mesto, Czechia|Research Site, Hodonin, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Klatovy IV, Czechia|Research Site, Louny, Czechia|Research Site, Ostrava, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 3, Czechia|Research Site, Praha 5 - Smichov, Czechia|Research Site, Rychnov nad Kneznou, Czechia|Research Site, Svitavy, Czechia|Research Site, Trinec, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Znojmo, Czechia|Research Site, Aalborg, Denmark|Research Site, Aarhus N, Denmark|Research Site, Ballerup, Denmark|Research Site, Esbjerg, Denmark|Research Site, Gentofte, Denmark|Research Site, Herlev, Denmark|Research Site, Herning, Denmark|Research Site, Hillerod, Denmark|Research Site, Kobenhavn O, Denmark|Research Site, Kobenhavn S, Denmark|Research Site, Kolding, Denmark|Research Site, Silkeborg, Denmark|Research Site, Svendborg, Denmark|Research Site, Vejle, Denmark|Research Site, Viborg, Denmark|Research Site, Bron, France|Research Site, Grenoble, France|Research Site, Le Coudray, France|Research Site, Marseille Cedex 08, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Rennes, France|Research Site, Rouen, France|Research Site, Toulouse Cedex 9, France|Research Site, Bad Krozingen, Germany|Research Site, Bad Neuheim, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Fulda, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Kassel, Germany|Research Site, Leipzig, Germany|Research Site, Magdeburg, Germany|Research Site, Mannheim, Germany|Research Site, Markleeberg, Germany|Research Site, Papenburg, Germany|Research Site, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Balatonkeresztur, Hungary|Research Site, Bekescsaba, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyongyos, Hungary|Research Site, Gyula, Hungary|Research Site, Hatvan, Hungary|Research Site, Miskolc, Hungary|Research Site, Pecs, Hungary|Research Site, Sopron, Hungary|Research Site, Szeged, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Szentes, Hungary|Research Site, Szolnok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Bergamo, Italy|Research Site, Catanzaro, Italy|Research Site, Chieti, Italy|Research Site, Massa, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Roma, Italy|Research Site, San Donato Milanese, Italy|Research Site, Torino, Italy|Research Site, Udine, Italy|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Gyeonggi-do, Korea, Republic of|Research Site, Alkmaar, Netherlands|Research Site, Almelo, Netherlands|Research Site, Almere, Netherlands|Research Site, Amersfoort, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Apeldoorn, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Beverwijk, Netherlands|Research Site, Breda, Netherlands|Research Site, Delft, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Dirksland, Netherlands|Research Site, Dordrecht, Netherlands|Research Site, Ede, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Emmen, Netherlands|Research Site, Enschede, Netherlands|Research Site, Goes, Netherlands|Research Site, Gouda, Netherlands|Research Site, Groningen, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Helmond, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Leiden, Netherlands|Research Site, Meppel, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Schiedam, Netherlands|Research Site, Sneek, Netherlands|Research Site, The Hague, Netherlands|Research Site, Tiel, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Uden, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Venlo, Netherlands|Research Site, Zaandam, Netherlands|Research Site, Zwijndrecht, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Kielce, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krosno, Poland|Research Site, Leczna, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lubin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Miechow, Poland|Research Site, Plock, Poland|Research Site, Poznan, Poland|Research Site, Pulawy, Poland|Research Site, Ruda Slaska, Poland|Research Site, Siedlce, Poland|Research Site, Skierniewice, Poland|Research Site, Staszow, Poland|Research Site, Swidnik, Poland|Research Site, Szczecin, Poland|Research Site, Tarnow, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wegrow, Poland|Research Site, Wloclawek, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Zamosc, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kirov, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Sait-Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tyumen, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Almeria, Andalucía, Spain|Research Site, Cordoba, Andalucía, Spain|Research Site, Granada, Andalucía, Spain|Research Site, Malaga, Andalucía, Spain|Research Site, Sevilla, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Valladolid, Castilla León, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Vigo, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Falun, Sweden|Research Site, Goteborg, Sweden|Research Site, Harnosand, Sweden|Research Site, Jonkoping, Sweden|Research Site, Lidkoping, Sweden|Research Site, Malmo, Sweden|Research Site, Ostersund, Sweden|Research Site, Stockholm, Sweden|Research Site, Umea, Sweden|Research Site, Hualien, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Aberdeen, United Kingdom|Research Site, Barnsley, United Kingdom|Research Site, Bath, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Bollington, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Burton-on-Trent, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Cleveleys, United Kingdom|Research Site, Corby, United Kingdom|Research Site, Corby, United Kingdom|Research Site, Crawley, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Kenilworth, United Kingdom|Research Site, Leamington Spa, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newport, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Nuneaton, United Kingdom|Research Site, Penzance, United Kingdom|Research Site, Poole, United Kingdom|Research Site, Romford, United Kingdom|Research Site, Sandbach, United Kingdom|Research Site, Scunthorpe, United Kingdom|Research Site, Shipley, United Kingdom|Research Site, Sidcup, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Thetford, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, Wakefield, United Kingdom|Research Site, Watford, United Kingdom|Research Site, West Bromwich, United Kingdom|Research Site, Whitby, United Kingdom|Research Site, Wokingham, United Kingdom|Research Site, Worcester, United Kingdom|Research Site, Yeovil, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03872401"
1111,"NCT01154985","Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)",,"Completed","Has Results","Steatohepatitis","Drug: Placebo capsule|Drug: EPA-E 300 mg capsule","Histological Response Defined by Change From Baseline in Standardized Scoring of Liver Biopsies|Alanine Transaminase (ALT) Levels","Mochida Pharmaceutical Company, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","243","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MCH-02-001","June 2010","October 2012","October 2012","July 1, 2010","November 20, 2014","November 20, 2014","Mochida Investigative Site, Dothan, Alabama, United States|Mochida Investigative Site, Tucson, Arizona, United States|Mochida Investigative Site, Anaheim, California, United States|Mochida Investigative Site, Coronado, California, United States|Mochida Investigative Site, LaJolla, California, United States|Mochida Investigative Site, Los Angeles, California, United States|Mochida Investigative Site, San Diego, California, United States|Mochida Investigative Site, San Diego, California, United States|Mochida Investigative Site, Littleton, Colorado, United States|Mochida Investigative Site, Hialeah, Florida, United States|Mochida Investigative Site, Chicago, Illinois, United States|Mochida Investigative Site, Lexington, Kentucky, United States|Mochida Investigative Site, New Orleans, Louisiana, United States|Mochida Investigative Site, Chevy Chase, Maryland, United States|Mochida Investigative Site, Detroit, Michigan, United States|Mochida Investigative Site, Plymouth, Minnesota, United States|Mochida Investigative Site, Jackson, Mississippi, United States|Mochida Investigative Site, Tupelo, Mississippi, United States|Mochida Investigative Site, Plainview, New York, United States|Mochida Investigative Site, Asheville, North Carolina, United States|Mochida Investigative Site, Durham, North Carolina, United States|Mochida Investigative Site, Cincinnati, Ohio, United States|Mochida Investigative Site, Cincinnati, Ohio, United States|Mochida Investigative Site, Cleveland, Ohio, United States|Mochida Investigative Site, Providence, Rhode Island, United States|Mochida Investigative Site (2 sites), Germantown, Tennessee, United States|Mochida Investigative Site, Nashville, Tennessee, United States|Mochida Investigative Site, Houston, Texas, United States|Mochida Investigative Site (2 sites), Houston, Texas, United States|Mochida Investigative Site, San Antonio, Texas, United States|Mochida Investigative Site, Newport News, Virginia, United States|Mochida Investigative Site, Richmond, Virginia, United States|Mochida Investigative Site, Seattle, Washington, United States|Mochida Investigative Site, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01154985"
1112,"NCT03675412","Caffeine Consumption in Glaucoma Patients and Healthy Subjects",,"Recruiting","No Results Available","Glaucoma, Primary Open Angle","Dietary Supplement: Caffeine tablet","Blood flow change in back of eye before and after caffeine","Wills Eye","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB#18-729","December 30, 2018","December 30, 2020","June 30, 2021","September 18, 2018",,"February 5, 2020","Wills Eye Glaucoma Service, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03675412"
1113,"NCT01811472","Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients",,"Completed","Has Results","Non-alcoholic Fatty Liver Disease (NAFLD)","Drug: LCQ908|Drug: placebo","Change From Baseline in Percentage of Fat in the Liver as Assessed Using MRI at Week 24|Change From Baseline in Percentage of Fat in the Liver as Assessed Using MRI at Week 12|Percentage of Responders at Week 12|Percentage of Responders at Week 24|Change From Baseline Values for Alanine Aminotransferase (ALT) , Aspartate Aminotransferase (AST) and Gamma-glutamyl Transpeptidase (GGT) to Week 6|Change From Baseline Values for Alanine Aminotransferase (ALT) , Aspartate Aminotransferase (AST) and Gamma-glutamyl Transpeptidase (GGT) to Week 12|Change From Baseline Values for Alanine Aminotransferase (ALT) , Aspartate Aminotransferase (AST) and Gamma-glutamyl Transpeptidase (GGT) to Week 24|Percentage of Patients With Normalized Liver Enzymes|Percent Change From Baseline in Fasting Triglycerides|Post-prandial Peak Triglycerides Over 0 - 8 Hours|Change From Baseline in Body Weight|Change From Baseline in Waist Circumference|Number of Patients With Adverse Events, Serious Adverse Events (SAEs) and Death as Assessment of Safety and Tolerability","Novartis Pharmaceuticals|Novartis","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 2","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLCQ908A2216|2013-000049-38","June 2013","September 2014","September 2014","March 14, 2013","February 4, 2016","February 4, 2016","Novartis Investigative Site, Mobile, Alabama, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Tamarac, Florida, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Tupelo, Mississippi, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Plano, Texas, United States|Novartis Investigative Site, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01811472"
1114,"NCT01609140","A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease",,"Completed","No Results Available","Coronary Heart Disease","Drug: MPSK3169A|Drug: Placebo","Absolute change from baseline in LDL-c concentration|Absolute change from baseline in LDL-c concentration for each arm at the nadir for that arm|Average value over time of the change in LDL-c (absolute and percent change) for each arm, up to Day 169, weighted by the number of weeks between consecutive LDL-c measurements|Percent change from baseline in LDL-c concentration at Day 169 and at the nadir for each arm|Percent and absolute change from baseline in LDL-c concentration at all other designated timepoints|Percent and absolute change from baseline in total cholesterol, non-HDL-c, and apolipoprotein B (ApoB) at Day 169 and at the nadir for each arm","Genentech, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","248","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GC28210","May 2012","May 2013","July 2013","May 31, 2012",,"November 2, 2016","Goodyear, Arizona, United States|Carmichael, California, United States|Spring Valley, California, United States|Walnut Creek, California, United States|Wildomar, California, United States|Jacksonville, Florida, United States|Ponte Verde, Florida, United States|Boise, Idaho, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Auburn, Maine, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|St. Louis, Missouri, United States|Rochester, New York, United States|Wilmington, North Carolina, United States|Fargo, North Dakota, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Springdale, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Greer, South Carolina, United States|Mount Pleasant, South Carolina, United States|Spartanburg, South Carolina, United States|Rapid City, South Dakota, United States|Bristol, Tennessee, United States|Knoxville, Tennessee, United States|Boerne, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Richmond, Virginia, United States|Wenatchee, Washington, United States|Mount Pearl, Newfoundland and Labrador, Canada|St. John's, Newfoundland and Labrador, Canada|Sarnia, Ontario, Canada|Toronto, Ontario, Canada|Woodstock, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Sainte-foy, Quebec, Canada|St-jerome, Quebec, Canada|Trois-Rivières, Quebec, Canada|Hodonin, Czech Republic|Jičícin, Czech Republic|Marianske Lazne, Czech Republic|Ostrava - Poruba, Czech Republic|Rakovník, Czech Republic|Berlin, Germany|Köln, Germany|Komarom, Hungary|Nagykanizsa, Hungary|Nyíregyháza, Hungary|Sopron, Hungary|Auckland, New Zealand|Auckland, New Zealand|Christchurch, New Zealand|Nelson, New Zealand|Tauranga, New Zealand|Elverum, Norway|Hamar, Norway|Oslo, Norway|Oslo, Norway|Sandnes, Norway|Bardejov, Slovakia|Bratislava, Slovakia|Presov, Slovakia|Rimavska Sobota, Slovakia|Cape Town, South Africa|Cape Town, South Africa|Centurion, South Africa|Pretoria, South Africa",,"https://ClinicalTrials.gov/show/NCT01609140"
1115,"NCT03425539","Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease","MODIFY","Recruiting","No Results Available","Fabry Disease","Drug: Lucerastat|Drug: Placebo","Response to study treatment on neuropathic pain defined as a reduction from baseline to Month 6 of at least 30% in the ""modified"" Brief Pain Inventory-Short Form 3 (BPI-SF3) score of ""neuropathic pain at its worst in the last 24 hours""|Change from baseline to Month 6 in the average daily 11-point Numerical Rating Scale (NRS-11) score of ""abdominal pain at its worst in the last 24 hours"" in subjects with GI symptoms at baseline.|Change from baseline to Month 6 in the number of days with at least one stool of a Bristol Stool Scale (BSS) consistency Type 6 or 7 in subjects with GI symptoms at baseline.|Change from baseline to Month 6 in plasma globotriaosylceramide (Gb3).","Idorsia Pharmaceuticals Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","108","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ID-069A301","June 21, 2018","May 15, 2021","June 15, 2021","February 7, 2018",,"April 29, 2020","University of Alabama at Birmingham - Nephrology Research Clinic, Birmingham, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|University of Arizona Center for Applied Genetics & Genomics Medicine, Tucson, Arizona, United States|University of California Irvine, Irvine, California, United States|University of California - Los Angeles, Los Angeles, California, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|University of Florida College of Medicine - Division of Nephrology, Hypertension & Renal Transplantation, Gainesville, Florida, United States|Emory University School of Medicine; Department of Human Genetics, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa Stead Family Children's Hospital - Division of Medical Genetics, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Infusion Associates, Grand Rapids, Michigan, United States|University of Minnesota - Pediatric Gene Therapy, Minneapolis, Minnesota, United States|St. Peter's University Hospital Genetics & Genomic Medicine, New Brunswick, New Jersey, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center - Human Genetics Dept., Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh (UPMC), Pittsburgh, Pennsylvania, United States|Greenwood Genetic Center, Greenville, South Carolina, United States|Research Baylor Institute of Metabolic Disease, Dallas, Texas, United States|University of Utah - Division of Medical Genetics, Salt Lake City, Utah, United States|Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, Virginia, United States|Royal Melbourne Hospital - Department of Nephrology, Parkville, Australia|Royal Perth Hospital, Department of Nephrology, Perth, Australia|Allgemeines Krankenhaus der Stadt Wien - Universitätsklinik für Innere Medizin III - Klinische Abteilung für Nephrologie und Dialyse, Vienna, Austria|University Hospital Ghent, Ghent, Belgium|University Hospital Leuven, Leuven, Belgium|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|M.A.G.I.C Clinic Ltd, Calgary, Canada|Queen Elizabeth II Health Sciences Center - Halifax Infirmary - Division of Nephrology, Halifax, Canada|Research Center, Hôpital Du Sacré-Coeur de Montréal, Montréal, Canada|Vancouver Hospital & Health Sciences - Vancouver General Hospital, Vancouver, Canada|Health Sciences Center Winnipeg, Winnipeg, Canada|Charite Campus Virchow-Klinikum - Nephrologie und Internistische Intensivmedizin, Berlin, Germany|SphinCS GmbH, Hochheim, Germany|Fachinternistische Gemeinschaftspraxis Markgräferland, Mühlheim, Germany|Medizinische Klinik und Poliklinik I der Universität - Schwerpunkt Nephrologie, Würzburg, Germany|Hosp Alma Mater Studiorum, Dublin, Ireland|AOU CAREGGI - NEPHROLOGY and CARDIOMIOPATIE, Florence, Italy|ASST Monza, Hospital San Gerardo, Nephrology, Monza, Italy|University of Naples Federico II (Nephrology), Naples, Italy|Hospital Academisch Medisch Centrum - Department of Internal Medicine Div. Endrocrinology and Metabolism, Amsterdam, Netherlands|Haukeland University Hospital Helse Bergen HF, Bergen, Norway|University Hospital in Cracow - Dep. of of Allergies and Immunology, Krakow, Poland|Cardinal Wyszynski Institute of Cardiology, Warsaw, Poland|Department of Pediatric Nutrition and Metabolic Diseases; The Children's Memorial Health Institute, Warsaw, Poland|Hospital Universitari Vall d'Hebrón, Barcelona, Spain|Hospital Universitari de Bellvitge; Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Ramon y Cajal. Servicio de Medicina Interna, Madrid, Spain|Hospital Quironsalud Zaragoza, Zaragoza, Spain|Universität Zürich Psychiatrische Universitätsklinik, Zurich, Switzerland|University Hospital Birmingham NHS Foundation Trust - Center for Rare Diseases, Birmingham, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Lysosomal Storage Disorders Unit, Department of Hematology - Royal Free London NHS Foundation Trust, London, United Kingdom|The Royal Free Hospital, Department of Haematology Royal Free London NHS Foundation Trust, London, United Kingdom|National Hospital for Neurology and Neurosurgery, London, United Kingdom|Salford Royal (Hope) Hospital, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03425539"
1116,"NCT03750552","Clinical Effect of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure (Sequoia Study)",,"Recruiting","No Results Available","Symptomatic Neurogenic Orthostatic Hypotension","Drug: ampreloxetine|Drug: Placebo","Change from baseline in OHSA#1 at Week 4|Change from baseline in OHSA composite score in Weeks 1 to 4|Change from baseline in OHDAS composite score in Weeks 1 to 4|PGI-C at Week 4|Incidence of falls","Theravance Biopharma","All","30 Years and older   (Adult, Older Adult)","Phase 3","188","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0169|2018-003289-15","January 24, 2019","September 2020","September 2020","November 23, 2018",,"April 7, 2020","St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|North County Neurology Associates, Carlsbad, California, United States|Collaborative Neuroscience Network, LLC, Long Beach, California, United States|Stanford Neuroscience Health Center, Palo Alto, California, United States|University of Colorado Clinical Translational Research Center, Aurora, Colorado, United States|Colorado Springs Neurological Associates, PC, Colorado Springs, Colorado, United States|Boca Raton Regional Hospital, Marcus Neuroscience Institute, Boca Raton, Florida, United States|Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida, United States|Neurostudies, Inc, Port Charlotte, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|NorthShore University Health System, Glenview, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Struthers Parkinson Center, Golden Valley, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|New York University Langone Health, New York, New York, United States|Wake Forest University Baptist Health Sciences, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Booth Gardner Parkinson's Care Center, Kirkland, Washington, United States|Inland Northwest Research, Spokane, Washington, United States|Concord Hopsital, Concord, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|The Royal Melbourne Hospital, Parkville, Victoria, Australia|""Medizinische Universitat Innsbruck Abteilung Fur Neurologie"", Innsbruck, Austria|UMHAT ""Sveti Georgi"" EAD Clinic of Neurological Diseases, Plovdiv, Bulgaria|MHATNP ""Sv.Naum"", EAD, Sofia, Bulgaria|UMHAT ""Alexandrovska"""" EAD Clinic of Neurological Diseases"", Sofia, Bulgaria|University of Calgary, Calgary, Alberta, Canada|London Health Sciences Centre-CCIT, London, Ontario, Canada|University Health Network - Toronto Western Hospital Movement Disorders Clinic, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Bispebjerg og Frederiksberg Hospital, Copenhagen, Denmark|Odense Universitetshospital, Odense, Denmark|East Tallinn Central Hospital, Tallinn, Estonia|Astra Team Clinic, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Roger Salengro - CHU Lille, Lille Cedex, Nord, France|CHU Caremeau, Nîmes, France|Hospital Pierre Paul Rquet, CHU Purpan, Toulouse, France|Clinexpert Kft., Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Pecsi Tudomanyegyetem, Neurologiai Klinika, Pécs, Hungary|Szent Borbala Korhaz, Tatabanya, Hungary|Rabin Medical Center, Petah Tikva, Israel|Kaplan Medical Center, Rehovot, Israel|Ziv Medical Center, Safed, Israel|Tel Aviv Medical Center, Tel Aviv, Israel|Chaim Sheba Medical Center, Tel HaShomer, Israel|Fondazione Istituto G.Giglio di Cefalù, Cefalù, Palermo, Italy|Azienda Ospedaliero Universitaria ""Ospedali Riuniti Ancona Umberto I - G.M. Lancisi - G. Salesi"""", SOD Clinica di Neuroriabilitazione"", Ancona, Italy|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milano, Italy|A.O. Santa Maria, Terni, Italy|New Zealand Brain Research Institute, Christchurch, New Zealand|Specjalistyczna Praktyka Lekarska prof.Grzegorz Opala, Katowice, Poland|Specjalistyczne Gabinety sp. z o.o., Krakow, Poland|PRATIA MCM Kraków, Kraków, Poland|Krakowska Akademia Neurologii Sp z o.o. Centrum Neurologii Klinicznej, Kraków, Poland|Instytut Zdrowia dr Boczarska-Jedynak, Oświęcim, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|ETG Warszawa, Warszawa, Poland|State Autonomous Institution of Healthcare ""Republican Clinical Hospital of the Ministry of Healthcare of Republic Tatarstan, Kazan, Tatarstan, Russian Federation|Federal State Budgetary Institution ""Federal Sibirian Scientific and Clinical Center of Federal Medico-Biological Agency"""""", Krasnoyarsk, Russian Federation|NHI ""Central Clinical Hospital #2 of JSC ""Russian Railways"" n.a. N.A. Semashko"", Moscow, Russian Federation|City Neurological Center Sibneiromed, Novosibirsk, Russian Federation|SBEIHPE Novosibirsk State Medical University, Novosibirsk, Russian Federation|Federal State Budgetary Institution ""National Medical Research Centre of psychiatry and neurology named after V.M. Bekhterev"""" of the Ministry of Healthcare of the Russian Federation"", Saint Petersburg, Russian Federation|Human Brain Institute RAMS, Saint Petersburg, Russian Federation|Saint Petersburg State Budgetary Institution of Healthcare ""City Hospital # 40 of Kurortnyi region"", Saint Petersburg, Russian Federation|Regional State Budgetary Institution of Healthcare ""Smolensk Regional Clinical Hospital"", Smolensk, Russian Federation|Hospital Universitario Donostia, San Sebastián, Guipuzcoa, Spain|Navarrabiomed Fundacion Miguel Servet, Pamplona, Navarra, Spain|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Mutua de Terrasa, Barcelona, Spain|Hospital Universitario Puerta del Mar, Cadiz, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Communal Institution Dnipropetrovsk I.I.Mechnikov RCH, Dnipro, Ukraine|Communal Noncommercial Enterprise ""City Policlinic #9"" of Kharkiv City Council, Kharkiv, Ukraine|""Communal Noncommercial Enterprise of Lviv Regional Council """"Lviv Regional Clinical Hospital"""" Dept of Neurology"", Lviv, Ukraine|Communal Institution Acad. O.I. Yuschenko VRPsH Vinnytsia M.I. Pyrogov NMU Ch of ND with the Course of Neurosurgery, Vinnytsia, Ukraine|Communal Institution City Clinical Hospital #6, Zaporizhzhia, Ukraine|Royal Devon and Exeter Hospital, Exeter, Devon, United Kingdom|Re:Cognition Health, Plymouth, Devon, United Kingdom|Barts Hospital, London, Greater London, United Kingdom|Re:Cognition Health, London, Greater London, United Kingdom|The National Hospital for Neurology & Neurosurgery, London, Greater London, United Kingdom|Re:Cognition Health Ltd, Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03750552"
1117,"NCT03829657","Clinical Effect Durability of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure (Redwood Study)",,"Recruiting","No Results Available","Symptomatic Neurogenic Orthostatic Hypotension","Drug: ampreloxetine|Drug: Placebo","Change (worsening) from baseline in OHSA#1 score of 1.0 point and worsening of disease severity as assessed by a 1 point change in PGI-S|Change from baseline in OHSA#1 at Week 6 post randomization at Week 6 post randomization.|Change from baseline in OHSA composite score at Week 6 post randomization|Change from baseline in OHDAS composite score at Week 6 post randomization|Change from baseline in PGI-S at Week 6 post randomization|Change from baseline in percent of time spent in standing position as measured by a wearable device at Week 6 post randomization|Change from baseline in average number of steps taken as measured by a wearable device at Week 6 post randomization","Theravance Biopharma","All","30 Years and older   (Adult, Older Adult)","Phase 3","258","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0170|2018-003941-41","February 22, 2019","May 2021","May 2021","February 4, 2019",,"April 7, 2020","Banner Sun Health Research Institute, Sun City, Arizona, United States|Colorado Springs Neurological Associates, PC, Colorado Springs, Colorado, United States|Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida, United States|Neurostudies, Inc, Port Charlotte, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|NorthShore University Health System, Glenview, Illinois, United States|University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States|Henry Ford Medical Center - West Bloomfield, West Bloomfield, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|New York University Langone Health, New York, New York, United States|Wake Forest University Baptist Health Sciences, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center (UCGNI), Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Inland Northwest Research, Spokane, Washington, United States|""University of Calgary Teaching Research and Wellness Building"", Calgary, Alberta, Canada|Bispebjerg Hospital, Copenhagen, Denmark|Odense Universitetshospital, Odense, Denmark|Astra Team Clinic, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milano, Italy|PRATIA MCM Kraków, Kraków, Poland|Instytut Zdrowia dr Boczarska-Jedynak, Oswiecim, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|Federal State Budgetary Institution ""Federal Sibirian Scientific and Clinical Center of Federal Medico-Biological Agency"", Krasnoyarsk, Russian Federation|City Neurological Center Sibneiromed, LLC, Novosibirsk, Russian Federation|Hospital del Mar, Barcelona, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Communal Noncommercial Enterprise ""City Policlinic #9"" of Kharkiv City Council, Kharkiv, Ukraine|""Communal Noncommercial Enterprise of Lviv Regional Council """"Lviv Regional Clinical Hospital, Lviv, Ukraine|Communal Institution Acad. O.I. Yuschenko VRPsH Vinnytsia M.I. Pyrogov NMU Ch of ND with the Course of Neurosurgery, Vinnytsia, Ukraine|Royal Devon and Exeter Hospital NHS Trust, Exeter, Devon, United Kingdom|Re:Cognition Health Ltd, London, Greater London, United Kingdom|The National Hospital for Neurology & Neurosurgery, London, Greater London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03829657"
1118,"NCT03737214","A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease",,"Recruiting","No Results Available","Fabry Disease","Drug: Lucerastat","Treatment-emergent adverse events (AEs)","Idorsia Pharmaceuticals Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","108","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID-069A302|2018-002210-12","December 18, 2018","May 22, 2022","May 22, 2022","November 9, 2018",,"March 26, 2020","University of Alabama at Birmingham - Nephrology Research Clinic, Birmingham, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|University of Arizona Center for Applied Genetics & Genomics Medicine, Tucson, Arizona, United States|University of California Irvine, Irvine, California, United States|University of California - Los Angeles, Los Angeles, California, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|University of Florida College of Medicine - Division of Nephrology, Hypertension & Renal Transplantation, Gainesville, Florida, United States|Emory University School of Medicine; Department of Human Genetics, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa Stead Family Children's Hospital - Division of Medical Genetics, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Infusion Associates, Grand Rapids, Michigan, United States|University of Minnesota - Pediatric Gene Therapy, Minneapolis, Minnesota, United States|St. Peter's University Hospital Genetics & Genomic Medicine, New Brunswick, New Jersey, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center - Human Genetics Dept., Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh (UPMC), Pittsburgh, Pennsylvania, United States|Greenwood Genetic Center, Greenville, South Carolina, United States|Research Baylor Institute of Metabolic Disease, Dallas, Texas, United States|University of Utah - Division of Medical Genetics, Salt Lake City, Utah, United States|Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, Virginia, United States|Royal Melbourne Hospital, Department of Respiratory Medicine, Parkville, Australia|Royal Perth Hospital Unit - The University of Western Australia, Perth, Australia|Allgemeines Krankenhaus der Stadt Wien - Universitätsklinik für Innere Medizin III - Klinische Abteilung für Nephrologie und Dialyse, Vienna, Austria|University Hospital Ghent, Ghent, Belgium|University Hospital Leuven, Leuven, Belgium|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|M.A.G.I.C Clinic Ltd, Calgary, Canada|Queen Elizabeth II Health Sciences Center - Halifax Infirmary - Division of Nephrology, Halifax, Canada|Research Center, Hôpital Du Sacré-Coeur de Montréal, Montréal, Canada|Vancouver Hospital & Health Sciences - Vancouver General Hospital, Vancouver, Canada|Health Sciences Center Winnipeg, Winnipeg, Canada|Charité-Virchow Klinikum - Nephrologie und Internistische Intensivmedizin, Berlin, Germany|SphinCS GmbH, Hochheim, Germany|Fachinternistische Gemeinschaftspraxis Markgräferland, Mühlheim, Germany|Medizinische Klinik und Poliklinik I der Universität - Schwerpunkt Nephrologie, Würzburg, Germany|Hosp Alma Mater Studiorum, Dublin, Ireland|AOU CAREGGI - NEPHROLOGY and CARDIOMIOPATIE, Florence, Italy|ASST Monza, Hospital San Gerardo, Nephrology, Monza, Italy|University of Naples Federico II (Nephrology), Naples, Italy|Hospital Academisch Medisch Centrum - Department of Internal Medicine Div. Endrocrinology and Metabolism, Amsterdam, Netherlands|Haukeland University Hospital Helse Bergen HF, Bergen, Norway|Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland|University Hospital in Cracow - Dep. of of Allergies and Immunology, Krakow, Poland|Cardinal Wyszynski Institute of Cardiology, Warsaw, Poland|Hospital Universitari Vall d'Hebrón, Barcelona, Spain|Hospital Universitari de Bellvitge; Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Ramon y Cajal. Servicio de Medicina Interna, Madrid, Spain|Hospital Quironsalud Zaragoza, Zaragoza, Spain|Universität Zürich Psychiatrische Universitätsklinik, Zurich, Switzerland|University Hospital Birmingham NHS Foundation Trust - Center for Rare Diseases, Birmingham, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|The Royal Free Hospital, Department of Haematology Royal Free London NHS Foundation Trust, London, United Kingdom|National Hospital for Neurology and Neurosurgery, London, United Kingdom|Salford Royal (Hope) Hospital, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03737214"
1119,"NCT01678898","Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients",,"Completed","Has Results","Fabry Disease","Drug: PRX-102","Adverse Events","Protalix","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PB-102-F01 & PB-102-F02","October 2012","March 6, 2016","March 6, 2016","September 5, 2012","January 27, 2020","January 27, 2020","UC Davis Medical Center, MIND Institute Department of Pediatrics, Section of Genetics, Sacramento, California, United States|Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States|University of Iowa Health Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Duke University Medical Center, Durham, North Carolina, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Research Baylor Institute of Metabolic Disease, Dallas, Texas, United States|O & O Alpan LLC, Fairfax, Virginia, United States|Royal Melbourne Hospital, Victoria Park, Australia|Hematology and Clinical Research Private Institute, Asuncion, Paraguay|Clinical Center of Serbia, Belgrade, Serbia|Hospital de Dia Quiron Zaragoza, Zaragoza, Spain|The Royal Free Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01678898"
1120,"NCT03624517","Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices","LOVARB","Recruiting","No Results Available","Esophageal Varices|Liver Cirrhoses|Bleeding Esophageal Varices|Upper Gastrointestinal Bleeding","Drug: Octreotide","Esophageal varices rebleed within 72-hours after control of initial bleed|Esophageal varices rebleed at 7 days and 30 days after control of initial bleed|Survival at 7 days and 30 days after control of initial bleed","Medical University of South Carolina|Ohio State University|University of Texas Southwestern Medical Center|University of Florida Health","All","18 Years and older   (Adult, Older Adult)","Phase 4","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Pro00027015","September 19, 2018","December 2020","December 2021","August 10, 2018",,"February 12, 2020","University of Florida Health, Jacksonville, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|The Ohio state University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|The University of Texas at Austin, Austin, Texas, United States|Texas Tech University Health Sciences Center, El Paso, Texas, United States|Brooke Army Medical Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03624517"
1121,"NCT01074944","A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)",,"Completed","Has Results","Gaucher Disease","Drug: Eliglustat tartrate","PAP: Percentage of Participants Who Remained Stable for 52 Weeks During the PAP|PAP: Mean Hemoglobin (Hb) Level at Baseline, Weeks 26 and 52|PAP: Mean Platelet Count at Baseline, Weeks 26, 52|PAP: Mean Spleen Volume at Baseline, Weeks 26, 52|PAP: Mean Liver Volume at Baseline, Weeks 26, 52|PAP: Mean Biomarker (Chitotriosidase) Value at Baseline, Weeks 26 and Week 52|PAP: Mean Biomarker (GL-1 on DBS) Value at Baseline, Week 26 and Week 52|PAP: Mean Biomarker Macrophage Inflammatory Protein-1 Beta (MIP1-beta) Value at Baseline, Weeks 26, 52|PAP: Bone Mineral Density (BMD) at Baseline and Week 52|PAP: Total T-Scores for BMD at Baseline and Week 52|PAP: Total Z-scores for BMD at Baseline and Week 52|PAP: Number of Participants With Mobility Status Asessments (MS) at Baseline, Weeks 26, and 52.|PAP: Number of Participants With Bone Crises at Baseline, Weeks 26 and 52|PAP: Number of Participants With Bone Pain Levels During the Past 4 Weeks at Baseline, Weeks 26 and 52|PAP: Total Bone Marrow Burden Score (BMB) at Baseline and Week 52|LIP: Mean Hemoglobin (Hb) Level at Baseline, Weeks 26, 52 and 78|LIP: Mean Platelet Count at Baseline, Weeks 26, 52 and 78|LIP: Mean Liver Volume at Baseline, Weeks 26, 52 and 78|LIP: Mean Spleen Volume at Baseline, Weeks 26, 52 and 78|LIP: Mean Biomarker (Chitotriosidase) Value at Baseline, Weeks 26, 52, and 78|LIP: Mean Biomarker (GL-1 on DBS) Value at Baseline, Week 26, Week 52, and Week 78|LIP: Mean Biomarker (MIP1-beta) Value at Baseline, Week 78|LIP: Number of Participants With Mobility Status (MS) at Baseline, Weeks 26, 52 and 78|LIP: Number of Participants With Bone Crises Assessment at Baseline, Weeks 26, 52 and 78|LIP: Number of Participants With Bone Pain Levels During the Past 4 Weeks at Baseline, Weeks 26, 52 and 78|LTTP: Percentage of Participants Who Maintained a Stable Bone Criterion ,Hemoglobin Level, Platelet Count, Liver Volume and Spleen Volume at 1 Year and 2 Years|LTTP: Number of Participants With Mobility Status (MS) at Baseline, 1 Year and 2 Years|LTTP: Number of Participants With Bone Crises Assessment at Baseline, 1 Year and 2 Years|LTTP: Number of Participants With Bone Pain Levels During the Past 4 Weeks at Baseline, 1 Year, and 2 Years|LTTP: Bone Mineral Density (BMD) at Baseline, 1 Year, and 2 Years|LTTP: Total T-Scores for BMD at Baseline, 1 Year, and 2 Years|LTTP: Total Z-scores for BMD at Baseline, 1 Year, and 2 Years|LTTP: Total Bone Marrow Burden Score (BMB) at Baseline, 1 Year, and 2 Years|LTTP: Mean Biomarker (Chitotriosidase) Value at Baseline, 1 Year, and 2 Years|LTTP: Mean Biomarker (GL-1 on DBS) Value at Baseline, 1 Year, and 2 Years|LTTP: Mean Biomarker (MIP1-beta) Value at Baseline, 1 Year, and 2 Years","Genzyme, a Sanofi Company|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","170","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GZGD03109|2009-015811-42|EFC12818","June 2010","October 2015","October 2015","February 24, 2010","December 2, 2016","February 6, 2017","University of California, San Diego Medical Center, San Diego, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Emory University Medical Center, Decatur, Georgia, United States|Children's Memorial Hospital, Chicago, Illinois, United States|Mount Sinai Medical Center, New York, New York, United States|New York University School of Medicine, New York, New York, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States|O and O Alpan LLC, Springfield, Virginia, United States|Royal Prince Alfred Hospital, Camperdown, Australia|Monash Medical Centre, Clayton, VIC, Australia|Royal Perth Hospital, Perth, WA, Australia|Medical University Vienna, Vienna, Austria|Hospital das Clinicas da UFMG, Belo Horizonte, Brazil|Cettro - Centro de Tratamento de Oncologia e Hematologia, Brasília, Brazil|Hemocentro - UNICAMP, Campinas, Brazil|Instituto Tropical de Medicina Reprodutiva e Menopausa - INTRO, Cuiaba, Brazil|Hospital Universitario Walter Cantidio - HUWC, Fortaleza, Brazil|Hemocentro de Ribeirão Preto Núcleo de Hemoterapia de Franca, Franca, Brazil|Hemorio, Rio de Janeiro, Brazil|Hospital de Clínicas da Universidade Federal do Parana, Sao Paulo, Brazil|IGEIM - Institute of Genetic and Inborn Erros of Metabolism, Sao Paulo, Brazil|Mount Sinai Hospital, Toronto, Canada|Peking Union Medical College Hospital, Beijing, China|Peking University People's Hospital, Beijing, China|Shanghai Xinhua Hospital Shanghai Xinhua Hospital, Shanghai, China|Tianjin Hematonosis Hospital, Tianjin, China|University Hospital Centre Zagreb, Zagreb, Croatia|Hôpital Haut Lévêque, Bordeaux, France|Hôpital Femme Mère Enfant Centre de référence des maladies Héréditaires du métabolisme, Bron, France|General Hospital of Athens ""G. Gennimatas"", Athens, Greece|King Edward Memorial (KEM) Hospital, Mumbai, India|Hiroshima University Hospital, Hiroshima, Japan|Jikei University Hospital, Tokyo, Japan|Juntendo University Hospital, Tokyo, Japan|Mie Chuou Medical Center, Tsu, Mie, Japan|Academic Medical Center, Amsterdam, Netherlands|Hospital de Santa Maria, Lisboa, Portugal|Hospital do Divíno Espírito Santo, Ponta Delgada - São Miguel - Açores, Portugal|Spitaulu Clinic de Urgenta, Cluj-Napoca, Romania|State Medical and Prophylactic Healthcare Institution; Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russian Federation|Hematology Research Center of Russian Academy of Medical Sciences, Moscow, Russian Federation|St. Petersburg State Medical Pavlov University, St. Petersburg, Russian Federation|Clinical Centre of Serbia, Belgrade, Serbia|University Hospital Lund, Lund, Sweden",,"https://ClinicalTrials.gov/show/NCT01074944"
1122,"NCT03604198","Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome",,"Enrolling by invitation","No Results Available","Cushing Syndrome","Drug: relacorilant","Long-term safety of relacorilant","Corcept Therapeutics","All","Child, Adult, Older Adult","Phase 2","75","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CORT125134-452","May 7, 2018","July 2021","July 2021","July 27, 2018",,"March 18, 2020","Site 033, Indianapolis, Indiana, United States|Site 061, Metairie, Louisiana, United States|Site 047, Saint Louis, Missouri, United States|Site 072, El Paso, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03604198"
1123,"NCT03797469","Nutritional Supplements and Performance During Visual Field Testing (B3 Vitamin)",,"Recruiting","No Results Available","Visual Field Defect, Peripheral|Glaucoma, Open-Angle","Dietary Supplement: Vitamin B3|Dietary Supplement: Pyruvate|Dietary Supplement: Placebo","Change in 24-2 visual field test|Change in Montreal Cognitive Assessment (MoCA) scores","Columbia University","All","40 Years to 80 Years   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","AAAR8208","April 15, 2019","March 31, 2020","March 31, 2020","January 9, 2019",,"January 27, 2020","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03797469"
1124,"NCT00913081","Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH)","ANTI-FLUSH","Completed","Has Results","Flushing","Dietary Supplement: Quercetin|Dietary Supplement: Placebo","Whether Quercetin Dose-dependently Reduces Laser Doppler Flux Index Primary Peak Following Immediate-release Niacin","University of Pennsylvania|Abbott","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 4","17","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","IRB #808911","February 2009","August 2009","December 2009","June 3, 2009","March 5, 2015","March 5, 2015","CTRC Univ. of Penn - Andrew Mutch Bldg., 4th floor, Phila, Pennsylvania, United States|University of Pennsylvania, Phila, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00913081"
1125,"NCT01068860","To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies",,"Completed","Has Results","Type 2 Diabetes Mellitus|Impaired Glucose Tolerance","Drug: Canakinumab 150 mg|Drug: Placebo to Canakinumab","Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 0-2 Hours, From Baseline to 4 Weeks.|Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 2-4 Hours, From Baseline to 4 Weeks|Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 0-4 Hours, From Baseline to 4 Weeks.|Mean Change in Fasting Plasma Glucose, From Baseline to 4 Weeks|Mean Change in Fructosamine, From Baseline to 4 Weeks|Mean Change in Fasting Plasma Insulin, From Baseline to 4 Weeks|Mean Change in Quantitative Insulin Sensitivity Check Index (QUICKI) Score, From Baseline to 4 Weeks|Mean Change in Fasting Glucose Disposition Index(GDI)1 and Index 2, From Baseline to 4 Weeks|Mean Change in Absolute Glucose Level at 2 Hours, From Baseline to 4 Weeks|Mean Change in Insulin Area Under the Curve (AUC) 0-4 Hours, From Baseline to 4 Weeks|Mean Change in C-peptide Area Under the Curve (AUC), 0-4 Hours, From Baseline to 4 Weeks|Mean Change in Post-prandial Glucose Area Under the Curve (AUC)0-4 Hours, From Baseline to 4 Weeks|Mean Change in Peak Plasma Glucose, From Baseline to 4 Weeks|Mean Change in Peak Plasma Insulin, From Baseline to 4 Weeks|Mean Change in Peak Plasma C-peptide Level, From Baseline to 4 Weeks|Number of Participants Reporting Death, Serious Adverse Events (SAEs) and Adverse Events (AEs) Above 5% Frequency, From Baseline to 4 Weeks","Novartis","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 2","246","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CACZ885I2207","February 2010","August 2010","August 2010","February 15, 2010","September 5, 2011","September 5, 2011","National Research Institute, Los Angeles, California, United States|Crest Clinical Trials, Santa Ana, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Commonwealth Biomedical Research LLC, Madisonville, Kentucky, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|VA Medical Center, Omaha, Nebraska, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Dallas Diabetes and Endocrine Center, Dallas, Texas, United States|Texas Center for Drug Development P.A., Houston, Texas, United States|Utah Clinical Trials, Salt Lake City, Utah, United States|Barwon Health - Geelong Hospital, Geelong, Victoria, Australia|Austin Health - Heidelberg Repatriation Hospital, Heidelberg Heights, Victoria, Australia|Melbourne Health - Royal Melbourne Hospital, Melbourne, Victoria, Australia|Lifestyle Metabolism Centre (Etobicoke), Etobicoke, Ontario, Canada|LMC Endocrinology Centres (Markham) Ltd, Markham, Ontario, Canada|LMC Endocrinology Centres (Thornhill) Ltd, Thornhill, Ontario, Canada|Centre de recherche clinique de Laval, Laval, Quebec, Canada|Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Lihavuustutkimusyksikkö, Helsinki, Finland|Lääkärikeskus Mehiläinen Töölö, Helsinki, Finland|ODL Terveys Oy, Oulu, Finland|Clintrial Berlin Praxis fuer medizinische Studien, Berlin, Germany|Klinische Forschung Berlin-Buch Dr. Andrei Khariouzov, Berlin, Germany|""Sana Krankenhaus Gerresheim, Duesseldorf, Germany|Gemeinschaftspraxis Dr. Ingo Zeissig, Duisburg, Germany|Praxis Dr. Thorsten Rau, Essen, Germany|Praxis Dr. med. Joerg Luedemann, Falkensee, Germany|Dr. Helmut Anderten Gemeinschaftspraxis Dres. Anderten und Krok, Hildesheim, Germany|Praxis Dr. Julia Chevts, Karlsruhe, Germany|Pro Scientia Med, Luebeck, Germany|Praxis Dr. Winfried Keuthage, Muenster, Germany|Praxis Dr. Uwe Boeckmann, Neumuenster, Germany|Dr. Klaus Funke IkFE Studiencenter Potsdam GMBH I.G., Potsdam, Germany|Praxis Dr. Gerhard Steinmaier, Viernheim, Germany|Praxis Dr. Reinhold U. Schneider, Wetzlar-Naunheim, Germany|Visakha Diabetes & Endocrine Centre, Visakhapatnam, AP, India|Jnana Sanjeevini Medical Center, Bangalore, Kar, India|Bangalore Diabetes Hospital,, Banglore, KAR, India|Health & Research Centre, Trivandrum, Ker, India|Indrayani Speciality Hospital,, Nagpur, Maharastra, India|Sahyadri Hospital Bibewewadi Centre of Excellence for Diabetics, Pune, Mah, India|Diabetes Thyroid Hormone Research Institute Pvt .Ltd., Indore, MP, India|Madras Diabetes Research Foundation, Chennai, TN, India|Azienda Ospedaliera-Ospedali Riuniti di BergamoU, Bergamo, BG, Italy|Az. Ospedaliera Universit. S.Martino-Universita degli Studi, Genova, GE, Italy|Azienda Ospedaliera S. Paolo-Polo Universitario, Milano, MI, Italy|Fondazione Centro San Raffaele del Monte Tabor-IRCCSUnità, Milano, Mi, Italy|Az. Ospedaliera Della Prov.di Pavia, Casorate Primo, PV, Italy|A.O.Universitaria Senese, Universita degli Studi di Siena, Siena, SI, Italy|S.C.D.U. Endocrinologia e Malattie del Metabolismo, Torino, To, Italy|Policlinico A.Gemelli - Univ.Cattolica del Sacro Cuore, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT01068860"
1126,"NCT02004704","A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency",,"Active, not recruiting","No Results Available","Sphingomyelin Lipidosis","Drug: GZ402665","Adverse events (AEs)/treatment-emergent adverse events (TEAEs), including infusion-associated reactions and adverse events of special interest (AESIs).|Complete physical examinations including extended neurologic and abbreviated physical exams.|Vital signs, echocardiograms and electrocardiograms.|Clinical laboratory tests.|Safety biomarkers.|Liver biopsy (patients previously enrolled in DFI13412).|Liver ultrasound/Doppler (patients previously enrolled in DFI13803).|Immune response assessments|Spleen and liver volume|Pulmonary imaging|Pulmonary function test|Hematology|Lipid profile|Health outcome questionnaires (adults and pediatric)|Hand X ray for bone age and bone maturation (pediatric patients)|Linear patient growth by height Z -score (pediatric patients)","Genzyme, a Sanofi Company|Sanofi","All","Child, Adult, Older Adult","Phase 2","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS13632|2013-000051-40|U1111-1141-65868","December 17, 2012","December 2023","December 2023","December 9, 2013",,"April 22, 2020","Investigational Site Number 840001, New York, New York, United States|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 076001, Porto Alegre, Brazil|Investigational Site Number 250002, Bron Cedex, France|Investigational Site Number 276002, Hochheim Am Main, Germany|Investigational Site Number 380002, Sassari, Italy|Investigational Site Number 380001, Udine, Italy|Investigational Site Number 826001, London, United Kingdom|Investigational Site Number 826002, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02004704"
1127,"NCT00891202","A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)",,"Completed","Has Results","Gaucher Disease, Type 1","Drug: Eliglustat tartrate|Drug: Placebo","PAP: Percent Change From Baseline in Spleen Volume (in Multiples of Normal [MN]) at Week 39 of the Primary Analysis Period With Eliglustat Tartrate Treatment as Compared to Placebo|PAP: Hemoglobin Level|PAP: Absolute Change From Baseline in Hemoglobin Level at Week 39|PAP: Percent Change From Baseline in Liver Volume (in MN) at Week 39|PAP: Percent Change From Baseline in Platelet Counts at Week 39|LTTP: Percent Change From Baseline in Spleen Volume (in MN) at Week 234|LTTP: Absolute Change From Baseline in Hemoglobin Level at Week 234|LTTP: Percent Change From Baseline in Liver Volume (in MN) at Week 234|LTTP: Percent Change From Baseline in Platelet Counts at Week 234","Genzyme, a Sanofi Company|Sanofi","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GZGD02507|2008-005222-37|EFC12813","November 2009","July 2012","January 2016","May 1, 2009","September 3, 2014","March 3, 2017","UCSF MS Center, San Francisco, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Emory University Medical Genetics, Decatur, Georgia, United States|University of Kansas Medical Center, Division of Hematology/Oncology, Dept. of Medicine, Westwood, Kansas, United States|New York University School of Medicine, Neurology Department, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University hospital ""Alexandrovska"" Sofia, Sofia, Bulgaria|Sir Mortimer B. Davis - Jewish General Hospital, Montreal, Quebec, Canada|Mount Sinai Hospital and the Samuel Lunenfeld Research Institute, Toronto Ontario, Canada|Hospital de San Jose, Bogota, Colombia|Christian Medical College Hospital, Vellore, India|Rabin Medical Center, Beilinson Hospital, Petach Tikvah, Israel|Hôtel-Dieu de France University Hospital, Beirut, Lebanon|OCA Hospital, Monterrey, Nuevo Leon, Mexico|Hematology Research Center of Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation|Institut za endokrinologiju, Belgrade, Serbia|Hopital La-Rabta, Tunis, TN, Tunisia|Royal Free Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00891202"
1128,"NCT02843035","GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3","LEAP","Recruiting","No Results Available","Gaucher Disease Type 1-Gaucher Disease Type 3","Drug: GZ402671","Number of patients with adverse events|Assessment of pharmacodynamic (PD) parameter: Lyso-glucosylceramide (lyso-GL1) and glucosylceramide (GL-1) in cerebrospinal fluid (CSF)|Assessment of pharmacodynamic (PD) parameter: Lyso-glucosylceramide (lyso-GL1) and glucosylceramide (GL-1) in plasma|Assessment of pharmacokinetic parameter: Plasma maximum concentration (Cmax)|Assessment of pharmacokinetic parameter: Time at Cmax (Tmax)|Assessment of pharmacokinetic parameter: Area under the curve (AUC)|Assessment of pharmacokinetic parameter: plasma trough concentration (Ctrough)|Assessment of pharmacokinetic parameter: CSF maximum concentration (Cmax)|Assessment of pharmacokinetic parameter: CSF time at Cmax (Tmax)|Assessment of pharmacokinetic parameter: CSF area under the curve (AUC)|Immunogenicity testing as needed for IAR (Cerezyme)","Genzyme, a Sanofi Company|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PDY13949|2014-002550-39|U1111-1156-4278","January 2017","May 2024","May 2024","July 25, 2016",,"March 19, 2020","Investigational Site Number 840002, New Haven, Connecticut, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 276001, Mainz, Germany|Investigational Site Number 392001, Minato-Ku, Japan|Investigational Site Number 826003, Cambridge, United Kingdom|Investigational Site Number 826001, London, United Kingdom|Investigational Site Number 826002, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02843035"
1129,"NCT04026178","Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy",,"Recruiting","No Results Available","Generalized Lipodystrophy","Drug: Metreleptin","Percentage of participants who develop anti-metreleptin/leptin antibodies at any timepoint after treatment with metreleptin|Percentage of participants who develop anti-metreleptin/leptin antibodies with neutralizing activity at any timepoint after treatment with metreleptin|Percentage of participants with SAEs, AESIs or adverse events leading to discontinuation|Percentage of participants with neutralizing or non-neutralizing antibodies who also show one or several of: a. Significant change of HbA1c b. Significant change of triglycerides c. Concomitant SAEs, AESIs or AEs leading to discontinuation","Aegerion Pharmaceuticals, Inc.","All","1 Year and older   (Child, Adult, Older Adult)","Phase 4","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AEGR-734-401","November 14, 2018","January 2022","January 2022","July 19, 2019",,"December 18, 2019","Ochsner Clinic, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Endocrinology Research Associates, Columbus, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University Texas Southwestern INT, Dallas, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04026178"
1130,"NCT01885559","HALT Progression of Polycystic Kidney Disease Study B","HALT PKD B","Completed","Has Results","Kidney, Polycystic","Drug: Lisinopril|Drug: Telmisartan|Drug: Placebo","Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death.|Albuminuria|Aldosterone|Hospitalizations|Cardiovascular Hospitalizations|Quality of Life Physical Component Summary|Quality of Life Mental Component Summary|Back or Flank Pain","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Boehringer Ingelheim|Merck Sharp & Dohme Corp.|Polycystic Kidney Disease Foundation|University of Pittsburgh|Washington University School of Medicine","All","15 Years to 64 Years   (Child, Adult)","Phase 3","486","NIH|Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HALT PKD B|U01DK062401|U01DK082230","January 2006","June 2014","June 2014","June 25, 2013","March 10, 2015","April 22, 2020","University of Colorado Health Sciences Center, Aurora, Colorado, United States|Emory University School of Medicine, Atlanta, Georgia, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Tufts University-New England Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01885559"
1131,"NCT02925195","Individualized Response to Vitamin D Treatment Study","INVITE","Enrolling by invitation","No Results Available","Characteristics That Modify the Response to Cholecalciferol Treatment","Dietary Supplement: Vitamin D3|Drug: Placebo","Change in serum 1,25(OH)2D concentration|Change in serum PTH concentration|Change in blood pressure|Change in urine calcium concentrations|Change in serum calcium concentrations","University of Washington|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","682","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STUDY00001485|R01HL096875","January 11, 2017","June 2019","June 2019","October 5, 2016",,"April 17, 2019","University of California, Los Angeles, Los Angeles, California, United States|Northwestern University, Evanston, Illinois, United States|John Hopkins University, Baltimore, Maryland, United States|Columbia Univeristy, New York, New York, United States|Wake Forest University, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02925195"
1132,"NCT03643562","Adrabetadex for Patients With Nerve Symptoms of Niemann-Pick Type C Disease (NPC)",,"Recruiting","No Results Available","Niemann-Pick Type C Disease","Drug: Adrabetadex","Clinician Global Impression of Change (Clinician-CGIC)|Composite Niemann Pick Type C Severity Scale (NPC-SS)","Vtesse, Inc., a Mallinckrodt Pharmaceuticals Company|Mallinckrodt","All","4 Years and older   (Child, Adult, Older Adult)","Phase 3","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VTS-270-001","June 18, 2018","May 22, 2021","July 31, 2021","August 23, 2018",,"February 17, 2020","University of Arkansas System, Little Rock, Arkansas, United States|Loma Linda University Health System, Loma Linda, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Hospital, Washington, District of Columbia, United States|Rare Disease Research, LLC, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States|Children's Specialty Center of Nevada, Las Vegas, Nevada, United States|NYU Langone Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|The Children's Hospital at TriStar Centennial, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Carilion Medical Center, Carilion Clinic, Roanoke, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03643562"
1133,"NCT01458119","Open-Label Phase 3 Long-Term Safety Study of Migalastat","AT1001-041","Terminated","Has Results","Fabry Disease","Drug: migalastat hydrochloride","Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)|Annualized Rate Of Change In The Estimated Glomerular Filtration Rate (eGFR)","Amicus Therapeutics","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","85","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AT1001-041|2011-004800-40","October 14, 2011","February 17, 2016","February 17, 2016","October 24, 2011","October 2, 2018","October 2, 2018","Atlanta, Georgia, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|Boston, Massachusetts, United States|Grand Rapids, Michigan, United States|New York, New York, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Dallas, Texas, United States|Fairfax, Virginia, United States|Seattle, Washington, United States|Pilar, Argentina|Adelaide, Australia|Parkville, Australia|Edegem, Belgium|Porto Alegre, Brazil|Montreal, Canada|Copenhagen, Denmark|Cairo, Egypt|Garches, France|Roma, Italy|Barcelona, Spain|Ankara, Turkey|London, United Kingdom|Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01458119"
1134,"NCT02867813","Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension","FOURIER OLE","Active, not recruiting","No Results Available","Dyslipidemia","Biological: Evolocumab","Subject incidence of adverse events|Percent change of LDL-C from baseline at each scheduled visit|Achieve an LDL-C < 40 mg/dL (1.03 mmol/L) at each scheduled visit","Amgen","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 3","5037","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20130295|2015-004780-36","September 2, 2016","September 29, 2021","September 29, 2021","August 16, 2016",,"October 18, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Banning, California, United States|Research Site, Long Beach, California, United States|Research Site, Oceanside, California, United States|Research Site, Oxnard, California, United States|Research Site, Palm Springs, California, United States|Research Site, Roseville, California, United States|Research Site, San Diego, California, United States|Research Site, San Pedro, California, United States|Research Site, Tarzana, California, United States|Research Site, Torrance, California, United States|Research Site, Valley Village, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Ponte Vedra Beach, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Dunwoody, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Suwanee, Georgia, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Meridian, Idaho, United States|Research Site, Addison, Illinois, United States|Research Site, Belleville, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Jerseyville, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Waterloo, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Hammond, Louisiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Natchitoches, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Newton, Massachusetts, United States|Research Site, Grandville, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Muskegon, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Kalispell, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, West Seneca, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Calabash, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Willoughby, Ohio, United States|Research Site, Pryor, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Chambersburg, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Indian Land, South Carolina, United States|Research Site, Moncks Corner, South Carolina, United States|Research Site, North Myrtle Beach, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Germantown, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Kerrville, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Layton, Utah, United States|Research Site, West Jordan, Utah, United States|Research Site, Burke, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Suffolk, Virginia, United States|Research Site, Federal Way, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Jihlava, Czechia|Research Site, Liberec, Czechia|Research Site, Mohelnice, Czechia|Research Site, Ostrava-Dubina, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha 2, Czechia|Research Site, Prerov, Czechia|Research Site, Pribram VIII, Czechia|Research Site, Znojmo, Czechia|Research Site, Bekescsaba, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Bielsko-Biala, Poland|Research Site, Bydgoszcz, Poland|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Gizycko, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Nysa, Poland|Research Site, Olsztyn, Poland|Research Site, Plock, Poland|Research Site, Poznan, Poland|Research Site, Pszczyna, Poland|Research Site, Pulawy, Poland|Research Site, Ruda Slaska, Poland|Research Site, Skierniewice, Poland|Research Site, Staszow, Poland|Research Site, Swidnik, Poland|Research Site, Tarnow, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wloclawek, Poland|Research Site, Wroclaw, Poland|Research Site, Zamosc, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Kosice, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT02867813"
1135,"NCT04020055","A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variants and Severe Renal Impairment",,"Not yet recruiting","No Results Available","Fabry Disease","Drug: migalastat HCl 150 mg","Maximum observed concentration (Cmax)|Concentration at the end of a dosing interval at steady state (Ctrough)|Average plasma migalastat concentration over the dosing interval (Cavg)|Time to maximum concentration (tmax)|Apparent terminal elimination half-life (t½)|Area under the concentration time curve at steady state during the dosing interval (AUC0-τ)|Plasma clearance (CL/F)|peak and trough plasma migalastat concentrations|Change in Amount excreted urine|Change in Fraction of the dose recovered in urine|adverse events (AEs)|Number of subjects with abnormal clinical chemistry laboratory test results|Number of subjects with abnormal hematology laboratory test results|Number of subjects with abnormal urinalysis laboratory test results|Number of subjects with abnormal electrocardiogram (ECG) findings as a measure of safety and tolerability|change from baseline in estimated glomerular filtration rate (eGFR) based on the Modification of Diet in Renal Disease equation (eGFR MDRD)|change from baseline eGFR based on the Chronic Kidney Disease Epidemiology Collaboration equation (eGFRCKD-EPI)|change from baseline in plasma globotriaosylsphingosine (lyso-Gb3)|Number of subjects with abnormal echocardiogram (ECHO) results","Amicus Therapeutics","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AT1001-025","March 30, 2021","December 31, 2021","December 31, 2021","July 15, 2019",,"December 5, 2019","Emory SOM, Atlanta, Georgia, United States|NYU School of Medicine, New York, New York, United States|UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Antwerp University Hospital, Edegem, Belgium|Internal Medicine Unit Croix Saint Simon Hospital, Paris, France|Azienda Ospedalira Universitaria CAREGGI S.O.D.c. Nefrologia Dialisi Trapianto, Florence, Italy|S.C. Nefrologia - Clinica Nefrologica, Monza, Italy|Hospital Universitario Virgen del Rocio, Sevilla, C.p., Spain|Hospital General Universitario de Elda, Elda, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Royal Free London NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04020055"
1136,"NCT03759665","N-Acetyl-L-Leucine for GM2 Gangliosdisosis (Tay-Sachs and Sandhoff Disease)",,"Recruiting","No Results Available","GM2 Gangliosidosis|Tay-Sachs Disease|Sandhoff Disease","Drug: IB1001","Clinical Impression of Change in Severity (CI-CS)|Spinocerebellar Ataxia Functional Index (SCAFI)|Scale for Assessment and Rating of Ataxia (SARA) score|EuroQuol - 5 Dimension (EQ-5D) Quality of Life Scale|Modified Disability Rating Scale (mDRS)|Investigator's Clinical Global Impressions (CGI)|Parent/Caregiver's Clinical Global Impressions (CGI)|Patient's Clinical Global Impressions (CGI) if able","IntraBio Inc","All","6 Years and older   (Child, Adult, Older Adult)","Phase 2","39","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IB1001-202","June 7, 2019","April 1, 2020","July 1, 2020","November 30, 2018",,"October 22, 2019","University of California - Los Angeles, Los Angeles, California, United States|Mayo Clinic, Rochester, Minnesota, United States|NYU Langone School of Medicine, New York, New York, United States|University of Giessen, Gießen, Germany|Ludwig Maximilian University of Munich, München, Germany|Bellvitge University Hospital, Barcelona, Spain|Salford Trust, Salford, Greater Manchester, United Kingdom|Royal Manchester Children's Hospital, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03759665"
1137,"NCT01061671","Simvastatin Therapy for Moderate and Severe COPD","STATCOPE","Terminated","Has Results","Pulmonary Disease, Chronic Obstructive","Drug: simvastatin|Drug: Placebo","Rates of COPD Exacerbations|Time to First COPD Exacerbation|Change in FEV1 (% Pred) From Baseline to Last Measure|Acute Exacerbation COPD Hospitalization Rates (Events/Patient Year)","University of Minnesota|National Heart, Lung, and Blood Institute (NHLBI)|Canadian Institutes of Health Research (CIHR)|Ottawa Hospital Research Institute","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 3","885","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","689|U10HL074424","March 2010","January 2014","January 2014","February 3, 2010","March 26, 2015","January 2, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|Veteran's Administration Medical Center, Birmingham, Alabama, United States|LA BioMed at Harbor-UCLA Medical Center, Los Angeles, California, United States|University of California at San Francisco, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|Malcom Randall VA Medical Center, Gainesville, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Illinois Health System, Chicago, Illinois, United States|LSU Health, New Orleans, Louisiana, United States|University of Maryland Baltimore, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Veteran's Administration Medical Center, Boston, Massachusetts, United States|Reliant Medical Group, Worcester, Massachusetts, United States|Veteran's Administration Medical Center, Ann Arbor, Michigan, United States|University of Michigan, Ann Arbor, Michigan, United States|Veteran's Administration Medical Center, Minneapolis, Minnesota, United States|HealthPartners Research Foundation, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Lovelace Respiratory Research Institute, Albuquerque, New Mexico, United States|Western New York Veterans Administration Healthcare System, Buffalo, New York, United States|Duke University, Durham, North Carolina, United States|Cincinnati VAMC, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke's Hospital and Health Network, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Institute for Respiratory and Sleep, Langhorne, Pennsylvania, United States|Temple University Lung Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Pittsburgh VA Medical Center, Pittsburgh, Pennsylvania, United States|Respiratory Specialists, Wyomissing, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|University of Calgary, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Royal Columbian Hospital, New Westminster, British Columbia, Canada|Surrey Memorial Hospital, Surrey, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|Lion's Gate Hospital, Vancouver, British Columbia, Canada|St. Boniface Hospital, Winnipeg, Manitoba, Canada|Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Ottawa Civic Hospital, Ottawa, Ontario, Canada|Inspiration Research Limited, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec (Laval Hospital), Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01061671"
1138,"NCT02697136","CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases","TANGO","Terminated","No Results Available","Familial Hypoalphalipoproteinemia","Drug: CER-001|Drug: Placebo","Change in mmean vessel wall area (MVWA) of the carotid artery|Change in mean vessel wall area (MVWA) of the carotid artery|Change in Target to Background Ratio (TBR) of the carotid artery","Cerenis Therapeutics, SA","All","18 Years and older   (Adult, Older Adult)","Phase 3","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CER-001-CLIN-009","December 2015","October 2018","December 21, 2018","March 3, 2016",,"February 11, 2019","Investigative Site, Salt Lake City, Utah, United States|Investigative Site, La Louvière, Belgium|Investigative Site, Vancouver, British Columbia, Canada|Investigative Site, Halifax, Nova Scotia, Canada|Investigative Site, London, Ontario, Canada|Investigative Site, Chicoutimi, Quebec, Canada|Investigative Site, Montreal, Quebec, Canada|Investigative Site, Lille, France|Investigative Site, Montpellier, France|Investigative Site, Rouen, France|Investigative Site, Toulouse, France|Investigative Site, Jerusalem, Israel|Investigative Site, Tel Aviv, Israel|Investigative Site, Genoa, Italy|Investigative Site, Milan, Italy|Investigative Site, Pisa, Italy|Investigative Site, Rome, Italy|Investigative Site, Amsterdam, Netherlands|Investigative Site, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT02697136"
1139,"NCT02612129","Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C",,"Active, not recruiting","No Results Available","Niemann-Pick Disease, Type C","Drug: arimoclomol|Drug: Placebo","Change in NPC disease severity score|Change in the Niemann Pick type C Clinical Database (NPC-cdb) score|Change in NPCCSS score|Change in NPCCSS score (individual domains)|Change in Quality of Life (EQ5DY)|Change in the SARA score|Change in the 9HPT (9 Hole Peg Test)|Adverse events (AEs);|Change in CGI-S and CGI-I Score (Clinical Global Impression-Severity/Improvement)","Orphazyme","All","2 Years to 18 Years   (Child, Adult)","Phase 2|Phase 3","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CT-ORZY-NPC-002","June 14, 2016","June 20, 2018","October 2020","November 23, 2015",,"February 24, 2020","UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|Mayo Clinic Children's Center, Rochester, Minnesota, United States|University Hospital Copenhagen (Rigshospitalet), Copenhagen, Denmark|CHU de Montpellier, Montpellier, France|Hôpital Trousseau, Paris, France|Villa Metabolica Mainz, Mainz, Germany|Dr. von Haunersches Kinderspital der Universität München, Munich, Germany|Ospedale Pediatrico Bambino Gesù, Rome, Italy|Azienda Ospedaliero-Universitaria ""Santa Maria della Misericordia"" di Udin, Udine, Italy|The Children´s Memorial Istitute Warsaw, Warsaw, Poland|Hospital Vall D'Hebron, Barcelona, Spain|INSELSPITAL University Hospital Bern, Bern, Switzerland|Birmingham Children's Hospital, Birmingham, United Kingdom|Great Ormond Street Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02612129"
1140,"NCT01218659","Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease",,"Completed","Has Results","Fabry Disease","Drug: migalastat hydrochloride|Biological: agalsidase","Annualized Rate Of Change From Baseline To Month 18 In Measured Glomerular Filtration Rate|Annualized Rate Of Change From Baseline To Month 18 In eGFR|Annualized Rate Of Change From Baseline To Month 18 In eGFR By The Modification Of Diet In Renal Disease Equation","Amicus Therapeutics","All","16 Years to 74 Years   (Child, Adult, Older Adult)","Phase 3","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AT1001-012|ATTRACT|2010-022636-37","September 8, 2011","May 27, 2014","May 28, 2015","October 11, 2010","November 1, 2018","November 1, 2018","Los Angeles, California, United States|Aurora, Colorado, United States|Decatur, Georgia, United States|Grand Rapids, Michigan, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Fairfax, Virginia, United States|Milwaukee, Wisconsin, United States|Parkville, Victoria, Australia|Perth, West Australia, Australia|Vienna, Austria|Edegem, Belgium|Sao Paulo, Brazil|Copenhagen, Denmark|Garches, France|Lille, France|Firenze, Italy|Niigata, Japan|Osaka, Japan|Osaka, Japan|Tokyo, Japan|Cambridge, United Kingdom|London, United Kingdom|London, United Kingdom|Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01218659"
1141,"NCT03152552","A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure",,"Terminated","Has Results","Diabetes Mellitus and Heart Failure","Drug: LIK066|Drug: Placebo|Drug: Empagliflozin","Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 12|Change From Baseline in Glycated Hemoglobin (HbA1c) at Weeks 12 and 36|Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 12 and 36|Change From Baseline in Body Weight at Weeks 12 and 36|Change From Baseline in Body Composition Assessed by Bio-impedance (Total Body Fat Mass) at Weeks 12 and 36|Change From Baseline in Body Composition Assessed by Bio-impedance (Visceral Fat Level) at Weeks 12 and 36|Change From Baseline in Body Composition Assessed by Bio-impedance (Lean Body Mass) at Weeks 12 and 36|Change From Baseline in Body Composition Assessed by DXA (Total Body Fat Mass) at Weeks 12 and 36|Change From Baseline in Body Composition Assessed by DXA (Visceral Fat Mass) at Weeks 12 and 36|Change From Baseline in Body Composition Assessed by DXA (Lean Body Mass) at Weeks 12 and 36|Change From Baseline in Body Composition Assessed by DXA (Total Body Water) at Weeks 12 and 36|Change From Baseline in Sitting Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 12 and 36|Change From Baseline in Fasting Lipid Profile (Triglycerides (TG)) at Weeks 12 and 36|Change From Baseline in Fasting Lipid Profile (Lipoproteins) at Weeks 12 and 36|Change From Baseline in Fasting Lipid Profile (Total Cholesterol) at Weeks 12 and 36|Change From Baseline in High Sensitive C-reactive Protein (hsCRP) at Weeks 12 and 36|Change From Baseline in 24 Hour Urinary Glucose Excretion (UGE) at Weeks 12 and 36|Change From Baseline in 24 Hour Sodium Excretion at Weeks 12 and 36|Change From Baseline in Left Atrial Size at Weeks 12 and 36|Change From Baseline in Left Atrial Volume at Weeks 12 and 36|Number of Participants With New York Heart Association (NYHA) Class I, II, II or IV|Number of Participants With Change From Baseline in New York Heart Association (NYHA) Class at Week 12 and 36|Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 36|Change From Baseline in 24 Hour Urinary Calcium Excretion at Weeks 12 and 36|24 Hour Urinary Phosphate Excretion at Weeks 12 and 36|Change From Baseline in Bone Mineral Density (BMD) at Weeks 12 and 36","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CLIK066B2204|2016-003084-19","July 25, 2017","June 6, 2018","June 6, 2018","May 15, 2017","August 28, 2019","August 28, 2019","Novartis Investigative Site, Huntsville, Alabama, United States|Novartis Investigative Site, Carmichael, California, United States|Novartis Investigative Site, Concord, California, United States|Novartis Investigative Site, Long Beach, California, United States|Novartis Investigative Site, Northridge, California, United States|Novartis Investigative Site, Stockton, California, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Bradenton, Florida, United States|Novartis Investigative Site, Clearwater, Florida, United States|Novartis Investigative Site, Delray Beach, Florida, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Gurnee, Illinois, United States|Novartis Investigative Site, Bogalusa, Louisiana, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Columbia, South Carolina, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Sugar Land, Texas, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Capital Federal, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Lennik, Brussels, Belgium|Novartis Investigative Site, Aalst, Belgium|Novartis Investigative Site, Bonheiden, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sainte Foy, Quebec, Canada|Novartis Investigative Site, St-Jerome, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Krapinske toplice, Croatia|Novartis Investigative Site, Rijeka, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Brandys nad Labem, Czech Republic, Czechia|Novartis Investigative Site, Svitavy, Czech Republic, Czechia|Novartis Investigative Site, Trebic, Czech Republic, Czechia|Novartis Investigative Site, Karvina, Czechia|Novartis Investigative Site, Kolin, Czechia|Novartis Investigative Site, Prague 5, Czechia|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Prerov, Czechia|Novartis Investigative Site, Hellerup, Denmark|Novartis Investigative Site, Svendborg, Denmark|Novartis Investigative Site, Bad Oeynhausen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Halle, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Budapest, HUN, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szekszard, Hungary|Novartis Investigative Site, Wilton, Cork, Ireland|Novartis Investigative Site, County Limerick, Ireland|Novartis Investigative Site, Dublin 4, Ireland|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, San Donato Milanese, MI, Italy|Novartis Investigative Site, Milano, Italy|Novartis Investigative Site, Rimini, Italy|Novartis Investigative Site, Cheongju si, Chungcheongbuk Do, Korea, Republic of|Novartis Investigative Site, Wonju, Gangwon-Do, Korea, Republic of|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Durango, Mexico|Novartis Investigative Site, Alkmaar, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Venlo, Netherlands|Novartis Investigative Site, Loerenskog, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Trondheim, Norway|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Ponce, Puerto Rico|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bloemfontein, Free State, South Africa|Novartis Investigative Site, Paarl, Western Cape, South Africa|Novartis Investigative Site, Worcester, South Africa|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Villamartin, Cadiz, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Caceres, Extremadura, Spain|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Chelmsford, Essex, United Kingdom|Novartis Investigative Site, London, GBR, United Kingdom|Novartis Investigative Site, Sunderland, Tyne And Wear, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03152552/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03152552/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03152552"
1142,"NCT03694275","A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Participants With 15Q Duplication Syndrome or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)",,"Recruiting","No Results Available","15q Duplication Syndrome|CDKL5 Deficiency Disease","Drug: TAK-935","Percent Change from Baseline in Motor Seizure Frequency During the Maintenance Period|Percentage of Participants Considered as Treatment Responders During the Maintenance Period|Percent Change from Baseline in Motor Seizure Frequency During the Treatment Period|Change from Baseline in Clinician's Global Impression of Severity and Change (CGI-S/C) Responses of Investigator|Correlation of plasma 24S-hydroxycholesterol (24HC) Levels and change in motor seizures|Change from Baseline in Care Clinical Global Impression of Change (CGI-C) Responses of Parent/Family","Takeda|Ovid Therapeutics Inc.","All","2 Years to 55 Years   (Child, Adult)","Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAK-935-18-002 (OV935)|U1111-1219-5787","September 10, 2018","August 14, 2020","September 11, 2020","October 3, 2018",,"February 12, 2020","UCLA, Los Angeles, California, United States|Research Institute Children's Hospital Colorado, Aurora, Colorado, United States|Center for Rare Neurological Diseases, Norcross, Georgia, United States|Center for Rare Neurological Diseases (CRND)--Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Children's Hospital Translational Neuroscience Center, Boston, Massachusetts, United States|Minnesota Epilepsy Group, P.A., Saint Paul, Minnesota, United States|New York University (NYU), New York, New York, United States|Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03694275"
1143,"NCT02048059","ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases",,"Completed","No Results Available","Breast Cancer|Brain Metastases","Drug: ANG1005","Intracranial objective response rate (iORR)|Duration of intracranial objective response|Median intracranial progression-free survival (PFS)|Intracranial PFS rates at 3, 6 and 12 months|6-month overall survival (OS) rate|Extracranial objective response rate (eORR) and duration of response|Number of Patients with adverse events|Plasma pharmacokinetics of ANG1005|Intracranial ORR by modified Response Assessment in Neuro-Oncology (RANO) criteria|Intracranial clinical benefit rate (iCBR) at 3 and 6 months|Potential immunogenicity of ANG1005","Angiochem Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","72","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANG1005-CLN-04","April 2014","March 2016","September 2017","January 29, 2014",,"February 25, 2020","University of Arizona Cancer Center, Tucson, Arizona, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|University of California - LAC Medical Center, Los Angeles, California, United States|University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, United States|UC - Irvine Chao Family Comprehensive Cancer Center, Orange, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|GRU Cancer Center - Georgia Regents University, Augusta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Maryland - Greenebaum Cancer Center, Baltimore, Maryland, United States|National Cancer Institute, Bethesda, Maryland, United States|Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|The Long Islan Brain Tumor Center at Neurological Surgery P.C., Commack, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Univeristy of Texas Health Science Center in San Antonio, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02048059"
1144,"NCT02804750","Study to Evaluate CORT125134 in Participants With Cushing's Syndrome",,"Completed","Has Results","Cushing's Syndrome","Drug: CORT125134","Percentage of Participants With One or More Adverse Events|Percentage of Participants With One or More Severe (≥Grade 3) Adverse Events|Percentage of Participants With Hypertension Who Experience Improvement in Blood Pressure Following Treatment With CORT125134|Percentage of Participants With IGT / T2DM Who Experienced a ≥25% Reduction in AUCglucose Following Treatment With CORT125134","Corcept Therapeutics","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CORT125134-451","June 2016","September 2018","September 2018","June 17, 2016","September 25, 2019","October 15, 2019","Laguna Hills, California, United States|Aurora, Colorado, United States|Fort Lauderdale, Florida, United States|Miami, Florida, United States|Indianapolis, Indiana, United States|Covington, Kentucky, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|New York, New York, United States|Cleveland, Ohio, United States|Pittsburgh, Pennsylvania, United States|Richmond, Virginia, United States|Budapest, Hungary|Pecs, Hungary|Cuneo, Italy|Messina, Italy|Milano, Italy|Naples, Italy|Orbassano, Italy|Roma, Italy|Siena, Italy|Torino, Italy|Leiden, Netherlands|Rotterdam, Netherlands|Salford, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02804750/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02804750/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02804750"
1145,"NCT00952627","Effects of Pycnogenol on Cardiac Fibrosis and Diastolic Dysfunction in Aged Hypertensive Subjects",,"Terminated","No Results Available","Cardiac Fibrosis|Diastolic Dysfunction","Dietary Supplement: Pycnogenol|Dietary Supplement: Placebo","cardiac fibrosis (by measuring the serum markers of myocardial fibrosis and collagen turnover) and diastolic dysfunction (by transthoracic echocardiogram)|liver and kidney function tests|Immunological measurements including the cytokine profile in serum (interleukin (IL)-4, IL-10, interferon-gamma, C-reactive protein).","University of Arizona|Horphag Research","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 2","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","UofAFRS 439130","July 2009","July 2011","July 2011","August 6, 2009",,"December 17, 2013","University of Arizona, Sarver Heart Center, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00952627"
1146,"NCT03759639","N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)",,"Active, not recruiting","No Results Available","Niemann-Pick Disease, Type C","Drug: IB1001","Clinical Impression of Change in Severity (CI-CS)|Spinocerebellar Ataxia Functional Index (SCAFI)|Scale for Assessment and Rating of Ataxia (SARA) score|EuroQuol- 5 Dimension (EQ-5D) Quality of Life Scale|Modified Disability Rating Scale (mDRS)|Investigator's Clinical Global Impressions (CGI)|Parent/Caregiver's Clinical Global Impressions (CGI)|Patient's Clinical Global Impressions (CGI) if able","IntraBio Inc","All","6 Years and older   (Child, Adult, Older Adult)","Phase 2","34","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IB1001-201","September 4, 2019","April 1, 2020","July 1, 2020","November 30, 2018",,"February 7, 2020","Mayo Clinic, Rochester, Minnesota, United States|University of Giessen, Gießen, Germany|Ludwig Maximilian University of Munich, München, Germany|Comenius University in Bratislva, Bratislava, Slovakia|Bellvitge University Hospital, Barcelona, Spain|Salford Trust, Salford, Greater Manchester, United Kingdom|Great Ormond Street Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|Royal Manchester Children's Hospital, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03759639"
1147,"NCT02593305","Dietary Nitrate and Physiological Aging",,"Completed","Has Results","Aging","Dietary Supplement: Super Beets|Dietary Supplement: Super Beets Placebo","Change in Carotid Chemosensitivity Following 4 Weeks of Dietary Nitrate Supplementation and Placebo in Older Adults|Change in Systolic Blood Pressure During Metaboreflex Testing Following 4 Weeks of Dietary Nitrate Supplementation and Placebo in Older Adults.","Darren P Casey|Neogenis Laboratories|University of Iowa","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","201507735","October 2015","April 28, 2017","April 28, 2017","November 1, 2015","October 14, 2019","October 14, 2019","University of Iowa, Iowa City, Iowa, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02593305/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02593305/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02593305"
1148,"NCT01152580","Melatonin Osteoporosis Prevention Study","MOPS","Completed","Has Results","Osteoporosis|Osteopenia","Dietary Supplement: melatonin|Dietary Supplement: sugar pill","The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Osteocalcin (OC) Levels in Women After 6 Months, as Compared to Baseline|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Type-1 Collagen Cross-linked N-telopeptide (NTX) Levels in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Bone Density in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Menopause-Specific Quality of Life (MENQOL) Physical Domain Scores in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Menopause-Specific Quality of Life (MENQOL) Vasomotor Domain Scores in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Menopause-Specific Quality of Life (MENQOL) Psychosocial Domain Scores in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Menopause-Specific Quality of Life (MENQOL) Sexual Domain Scores in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in the Pittsburgh Sleep Quality Index (PSQI) in Women After 6 Months, as Compared to Baseline.","Duquesne University","Female","45 Years to 54 Years   (Adult)","Phase 1","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","07-88","September 2008","July 2010","July 2010","June 29, 2010","March 12, 2012","March 13, 2012","Duquesne University School of Pharmacy Center for Pharmacy Care, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01152580"
1149,"NCT01797302","Vitamin D and Vascular Health in Children",,"Completed","No Results Available","Obesity|Vitamin D Deficiency","Dietary Supplement: Vitamin D3","brachial artery flow-mediated dilation (FMD)|pulse-wave velocity (PWV)|fasting glucose/fasting insulin ratio","University of Pittsburgh|National Heart, Lung, and Blood Institute (NHLBI)|Office of Dietary Supplements (ODS)","All","10 Years to 18 Years   (Child, Adult)","Not Applicable","225","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO12100034|R01HL112985|5R01HL112985-05","August 2013","August 13, 2018","August 13, 2018","February 22, 2013",,"December 5, 2019","Primary Care Center, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT01797302/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01797302"
1150,"NCT01141192","The Effect of Vitamin D Supplementation on Glucose Metabolism in Non-Diabetic African American Adults","AVIS","Completed","No Results Available","Type 2 Diabetes","Dietary Supplement: vitamin D3, cholecalciferol|Dietary Supplement: Inactive comparator","Fasting glucose level before, mid-way through, and after the vitamin D3 supplement or placebo trial.|Serum 25-OH D levels in response to vitamin D3 supplement or placebo across a range of adiposity","Augusta University","All","19 Years to 60 Years   (Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","0910091","January 2010","May 2010","May 2010","June 10, 2010",,"June 10, 2010","Medical College of Georgia, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01141192"
